PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	JOHNSON, VG; NICHOLLS, PJ				JOHNSON, VG; NICHOLLS, PJ			HISTIDINE-21 DOES NOT PLAY A MAJOR ROLE IN DIPHTHERIA-TOXIN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE ACTIVITY; AERUGINOSA EXOTOXIN-A; NAD BINDING-SITE; ESCHERICHIA-COLI; ASPARTIC-ACID; FULL-LENGTH; MUTANT; FRAGMENT; TRANSLATION; EXPRESSION	It has been proposed that the histidine at position 21 (H21) of the diphtheria toxin A subunit (DTA) plays an important role in the ADP-ribosyltransferase (ADPRT) activity of the toxin. The region of DT encompassing H21 demonstrates sequence similarity with other toxins exhibiting ADPRT activity, is located along the catalytic cleft of DTA, and when H21 is chemically modified, ADPRT activity is abolished. H21 was mutagenized by a polymerase chain reaction-based system whereby all alternative amino acids were substituted in place of the histidine. The majority of the substitutions virtually abolished enzymatic activity, the exception being a mutant in which H21 was replaced with asparagine (DTA-H21N). This mutant demonstrated only a slight increase in K-m and relatively small decreases in both reaction rate (k(cat)) and catalytic efficiency (k(cat)/K-m). Asparagine is a sterically conserved substitution, but its side-chain is unable to replace the imidazole group of histidine in general acid-base mechanisms or to participate in electrostatic interactions. This suggests that H21 is important in maintaining a steric conformation required for catalysis rather than in participating in an electrostatic or acid-base type of exchange.	NIDR,MICROBIAL ECOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	JOHNSON, VG (corresponding author), US FDA,CBER,DIV BACTERIAL PROD,BACTERIAL TOXINS LAB,BLDG 29,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BLANKE S, 1992, ZBL BAKT S, V23, P349; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1988, MOL MICROBIOL, V2, P293, DOI 10.1111/j.1365-2958.1988.tb00031.x; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; EMERICK A, 1985, DNA-J MOLEC CELL BIO, V4, P78; GILL DM, 1988, BACTERIAL PROTEIN TO, P315; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HONJO T, 1968, J BIOL CHEM, V243, P3553; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; JOHNSON VG, 1993, J BIOL CHEM, V268, P3514; KANDEL J, 1974, J BIOL CHEM, V249, P2088; KASLOW HR, 1989, J BIOL CHEM, V264, P6386; KILLEEN KP, 1992, P NATL ACAD SCI USA, V89, P6207, DOI 10.1073/pnas.89.13.6207; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILES EW, 1989, J BIOL CHEM, V264, P6280; NICHOLLS PJ, 1993, J BIOL CHEM, V268, P5302; NICOLLS PJ, 1992, GENETICALLY ENG TOXI, P339; OKEEFE DO, 1992, ARCH BIOCHEM BIOPHYS, V296, P678, DOI 10.1016/0003-9861(92)90626-8; PAPINI E, 1987, FEBS LETT, V215, P73, DOI 10.1016/0014-5793(87)80116-3; PAPINI E, 1989, J BIOL CHEM, V264, P12385; PAPINI E, 1990, TOXICON, V28, P631, DOI 10.1016/0041-0101(90)90251-2; PORATH J, 1992, PROTEIN EXP PURIF, V2, P95; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TWETEN RK, 1985, J BIOL CHEM, V260, P392; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021; WILSON BA, 1992, CURR TOP MICROBIOL, V175, P27; 1986, FED REGISTER, V51, P16971; 1986, FED REG 3, V51, P16961	35	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4349	4354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308004				2022-12-25	WOS:A1994MW98900071
J	KAPLAN, DL; BORON, WF				KAPLAN, DL; BORON, WF			LONG-TERM EXPRESSION OF C-H-RAS STIMULATES NA-H AND NA+-DEPENDENT CL-HCO3 EXCHANGE IN NIH-3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; INTRACELLULAR-PH; CYTOPLASMIC-PH; GROWTH-FACTORS; 3T3 CELLS; EXTRACELLULAR PH; PROXIMAL TUBULE; ANGIOTENSIN-II; ACID-EXTRUSION; ALKALINIZATION	In a study of intracellular pH (pH(i)) regulation, we compared c-H-ras-transformed fibroblasts (FT9s) with parental NIH 3T3 cells. Cells were grown on a coverslip and placed in a flow-through cuvette; pH(i) was monitored using a fluorescent dye. Whether cells were in a CO2-free or CO2-containing solution, steady-state pH(i) was similar to 0.5 higher in FT9s than in 3T3s. Rates of pH(i) recovery from acid loads in the presence of CO2 indicate that total net acid extrusion (J(total)) was far greater in FT9s than 3T3s in the pH(i) range 6.3-7.4. In both FT9s and 3T3s, pH(i) recovery was blocked by removing Na+. In FT9s, most of (J)(total), was blocked by ethyl isopropyl amiloride (EIPA) and was probably due to Na-H exchange. A smaller component was inhibited by 4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS) and required Cl- and was probably due to Na+-dependent Cl-HCO3 exchange. In 3T3s, the DIDS-sensitive and Cl--dependent components of (J)(total), were very small. The dominant acid extruder in 3T3s appears to be a Na-H exchanger insensitive to 50 mu M EIPA. We determined the flux-pH(i) relationships for both the Na-H and Na+-dependent Cl-HCO3 exchangers in both FT9s and 3T3s. p21(ras) alkaline shifts the pH(i) profile of each transporter by similar to 0.7, without affecting the V-max. These shifts in the flux-pH(i) relationships provide a mechanism for the large increase in steady-state pH(i) produced by long-term expression of p21(ras).			KAPLAN, DL (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287; Kaplan, Daniel/0000-0003-2760-7745	NIDDK NIH HHS [DK17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER S, 1965, J CLIN INVEST, V44, P21, DOI 10.1172/JCI105123; ADLER S, 1965, J CLIN INVEST, V44, P8, DOI 10.1172/JCI105129; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIERMAN AJ, 1988, J BIOL CHEM, V263, P15253; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BORON WF, 1992, J GEN PHYSIOL, V99, P817, DOI 10.1085/jgp.99.5.817; BORON WF, 1979, AM J PHYSIOL, V237, pC185, DOI 10.1152/ajpcell.1979.237.3.C185; BOS JL, 1989, CANCER RES, V49, P4682; BOYARSKY G, 1990, P NATL ACAD SCI USA, V87, P5921, DOI 10.1073/pnas.87.15.5921; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; CASSEL D, 1983, P NATL ACAD SCI-BIOL, V80, P6224, DOI 10.1073/pnas.80.20.6224; CHEN LK, 1991, THESIS YALE U; DEUTSCH C, 1984, J CELL BIOL, V98, P885, DOI 10.1083/jcb.98.3.885; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; GANZ MB, 1990, AM J PHYSIOL, V259, pF269, DOI 10.1152/ajprenal.1990.259.2.F269; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GANZ MB, 1988, AM J PHYSIOL, V254, pF787, DOI 10.1152/ajprenal.1988.254.6.F787; GEIBEL J, 1990, P NATL ACAD SCI USA, V87, P7917, DOI 10.1073/pnas.87.20.7917; GILLIES RJ, 1991, J BIOL CHEM, V266, P1551; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; GRINSTEIN S, 1985, P NATL ACAD SCI USA, V82, P1429, DOI 10.1073/pnas.82.5.1429; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; JOHNSON JD, 1976, NATURE, V262, P661, DOI 10.1038/262661a0; KAPLAN DL, 1992, FASEB J, V6, pA1639; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; NAKHOUL NL, 1994, IN PRESS J GEN PHYSL; OLSNES S, 1986, J CELL BIOL, V102, P967, DOI 10.1083/jcb.102.3.967; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; POUYSSEGUR J, 1985, FEBS LETT, V190, P115, DOI 10.1016/0014-5793(85)80439-7; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHULDINER S, 1982, P NATL ACAD SCI-BIOL, V79, P7778, DOI 10.1073/pnas.79.24.7778; SCHWARTZ GJ, 1985, J CLIN INVEST, V75, P1638, DOI 10.1172/JCI111871; SZWERGOLD BS, 1989, J CELL PHYSIOL, V138, P227, DOI 10.1002/jcp.1041380203; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VAUPEL P, 1989, CANCER RES, V49, P6449; YAMADA H, 1990, MOL CELL BIOL, V10, P1822, DOI 10.1128/MCB.10.4.1822	44	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4116	4124						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307971				2022-12-25	WOS:A1994MW98900036
J	OGIERDENIS, E; BLAIS, A; HOURI, JJ; VOISIN, T; TRUGNAN, G; CODOGNO, P				OGIERDENIS, E; BLAIS, A; HOURI, JJ; VOISIN, T; TRUGNAN, G; CODOGNO, P			THE EMERGENCE OF A BASOLATERAL 1-DEOXYMANNOJIRIMYCIN-SENSITIVE MANNOSE CARRIER IS A FUNCTION OF INTESTINAL EPITHELIAL-CELL DIFFERENTIATION - EVIDENCE FOR A NEW INHIBITORY EFFECT OF 1-DEOXYMANNOJIRIMYCIN ON FACILITATIVE MANNOSE TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; VILLUS-CRYPT AXIS; LIVER GOLGI MEMBRANES; RAT-LIVER; CACO-2 CELLS; ENDOPLASMIC-RETICULUM; ALPHA-MANNOSIDASE; MESSENGER-RNA; PEPTIDE-YY; GLUCOSE TRANSPORTERS	We have previously reported that 1-deoxymannojiri-mycin (dMM), a specific cy-mannosidase I inhibitor interfered with the uptake of D-[2-H-3]mannose in differentiated HT-29 cells (a cell line derived from a human colon adenocarcinoma) (Ogier Denis, E., Trugnan, G., Sapin, C., Aubery, M., and Codogno, P. (1990) J. Biol. Chem. 265, 5366-5369). In the present work, we have used another cell line derived from a human colon adenocarcinoma, Caco-2 cells, which has the capacity to grow and to dif ferentiate on porous filters. We have determined that mannose could enter the cells by two distinct transporters. One sensitive to dMM, present at the basolateral membrane of differentiated Caco-2 cells, and one insensitive to the drug localized at the brush border membrane of these cells. The basolateral mannose uptake is mediated by a Na+-independent transporter whereas the apical entry of mannose is under the dependence of Na+. We have focused our studies on the basolateral dMM-sensitive mannose carrier. Kinetic studies indicated that this facilitative mannose transporter has a K-m and a V-max of 55 +/- 8 mu m and 0.144 +/- 0.005 mu mol/mg of protein/ min, respectively. This basolateral transporter is clearly distinct from facilitative glucose transporters. Moreover, this dMM-sensitive mannose transport accurately follows the differentiation process of intestinal epithelial cells as well in vitro as shown using Caco-2 cells as in vivo when experiments were done on crypt cells and villus cells isolated from rat jejunum.	INSERM, U239, UNITE RECH BIOL & PHYSIOPATHOL CELLULES DIGEST, F-75018 PARIS, FRANCE; FAC PHARM CHATENAY MALABRY, DIPARTIMENTO MICROBIOL, F-92296 CHATENAY MALABRY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay			voisin, thierry/R-1241-2017; Ogier-Denis, Eric/E-5030-2016; Codogno, Patrice/G-1384-2013	voisin, thierry/0000-0002-4320-5183; Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593				ALVAREZHERNANDE.X, 1991, BIOCHIM BIOPHYS ACTA, V1070, P2205; BELL GI, 1993, J BIOL CHEM, V268, P19161; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; BLAIS A, 1987, J MEMBRANE BIOL, V99, P113, DOI 10.1007/BF01871231; BOLLER K, 1988, DIFFERENTIATION, V39, P51, DOI 10.1111/j.1432-0436.1988.tb00080.x; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURANT CF, 1992, J BIOL CHEM, V267, P14523; BURNHAM DB, 1989, AM J PHYSIOL, V256, pG808, DOI 10.1152/ajpgi.1989.256.4.G808; BURTON PS, 1993, BIOCHEM BIOPH RES CO, V190, P760, DOI 10.1006/bbrc.1993.1114; CHANDRASENA G, 1992, CELL MOL BIOL, V38, P243; DARMOUL D, 1991, AM J PHYSIOL, V261, pG763, DOI 10.1152/ajpgi.1991.261.5.G763; DAVIDSON NO, 1992, AM J PHYSIOL, V262, pC795, DOI 10.1152/ajpcell.1992.262.3.C795; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELLWOOD KC, 1993, P SOC EXP BIOL MED, V202, P440, DOI 10.3181/00379727-202-43556; ELSAS LJ, 1992, ANNU REV MED, V43, P377, DOI 10.1146/annurev.me.43.020192.002113; FORSEE WT, 1989, J BIOL CHEM, V264, P3869; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; HARRIS DS, 1992, P NATL ACAD SCI USA, V89, P7556, DOI 10.1073/pnas.89.16.7556; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUGHES TE, 1988, J BIOL CHEM, V263, P3425; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LABURTHE M, 1988, AM J PHYSIOL, V254, pG457, DOI 10.1152/ajpgi.1988.254.3.G457; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; MAHRAOUI L, 1992, AM J PHYSIOL, V263, pG312, DOI 10.1152/ajpgi.1992.263.3.G312; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MENDELSSOHN DC, 1989, AM J PHYSIOL, V257, pF1100, DOI 10.1152/ajprenal.1989.257.6.F1100; NEEFJES JJ, 1989, J BIOL CHEM, V264, P10271; OGIERDENIS E, 1990, J BIOL CHEM, V265, P5366; PINTO M, 1983, BIOL CELL, V47, P323; RAND EB, 1993, AM J PHYSIOL, V264, pG1169, DOI 10.1152/ajpgi.1993.264.6.G1169; RINDLER MJ, 1988, J CELL BIOL, V107, P471, DOI 10.1083/jcb.107.2.471; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; SIMON PM, 1979, BIOCHEM J, V178, P407, DOI 10.1042/bj1780407; TABAS I, 1979, J BIOL CHEM, V254, P1655; THORENS B, 1990, AM J PHYSIOL, V259, pC279; THWAITES DT, 1993, J BIOL CHEM, V268, P7640; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; VOISIN T, 1990, AM J PHYSIOL, V258, pG753, DOI 10.1152/ajpgi.1990.258.5.G753; VOISIN T, 1990, ANN NY ACAD SCI, V611, P343; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	50	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4285	4290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307994				2022-12-25	WOS:A1994MW98900061
J	GEROLD, P; DIECKMANNSCHUPPERT, A; SCHWARZ, RT				GEROLD, P; DIECKMANNSCHUPPERT, A; SCHWARZ, RT			GLYCOSYLPHOSPHATIDYLINOSITOLS SYNTHESIZED BY ASEXUAL ERYTHROCYTIC STAGES OF THE MALARIAL PARASITE, PLASMODIUM-FALCIPARUM - CANDIDATES FOR PLASMODIAL GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHOR PRECURSORS AND PATHOGENICITY FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; DEVELOPMENTAL VARIATION; GLYCOLIPID PRECURSORS; MAMMALIAN-CELLS; BIOSYNTHESIS; IDENTIFICATION; MEROZOITES; ACYLATION	Plasmodium falciparum is the causative agent of malaria tropica in man. Biochemical studies were focused on the asexual, intraerythrocytic stages of P. falciparum, because of their role in the clinical phase of the disease and the possibility of propagation in a cell culture system. In this report, we describe the in-culture labeling of malarial glycolipids and the analysis of their hydrophilic moieties. They were identified as glycosylphosphatidylinositols (GPIs) by: 1) labeling with [H-3]mannose, [H-3]glucosamine, and [H-3]ethanolamine and 2) sensitivity toward glycosylphosphatidylinositol-specific phospholipase D, phospholipase A2, and nitrous acid. Malarial GPIs are shown to be unaffected by treatment with phosphatidylinositol-specific phospholipase C, regardless of prior treatment with mild base commonly used for inositol deacylation. Two candidates for putative GPI-anchor precursors to malarial membrane proteins with the structures ethanolamine-phosphate-6(Manalpha1-2)Manalpha1-2Manalpha1-6Manalpha1-4GlcN-PI (Pf(gl) alpha) and ethanolamine-phosphate-6Manalpha1-2Manalpha1-6Manalpha1-4-GlcN-PI (Pf(gl); beta) were identified.			GEROLD, P (corresponding author), PHILIPPS UNIV,ZENTRUM HYG & MED MIKROBIOL,ROBERT KOCH STR 17,D-35037 MARBURG,GERMANY.							BRAUNBRETON C, 1988, NATURE, V332, P457, DOI 10.1038/332457a0; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DIECKMANNSCHUPPERT A, 1992, EUR J BIOCHEM, V205, P815, DOI 10.1111/j.1432-1033.1992.tb16846.x; DIECKMANNSCHUPPERT A, 1992, PARASITOL RES, V78, P416, DOI 10.1007/BF00931698; DOERING TL, 1990, J BIOL CHEM, V265, P611; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; GEROLD P, 1992, Biochemical Society Transactions, V20, p297S; Gerold P., 1992, Biological Chemistry Hoppe-Seyler, V373, P844; GOMAN M, 1982, MOL BIOCHEM PARASIT, V5, P391, DOI 10.1016/0166-6851(82)90012-3; HALDAR K, 1985, J BIOL CHEM, V260, P4969; HALDAR K, 1986, P NATL ACAD SCI USA, V83, P8565, DOI 10.1073/pnas.83.22.8565; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LOCKYER MJ, 1989, VACCINATION STRATEGI, P124; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCDOWELL W, 1988, POSTTRANSLATIONAL MO; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROSENFELD L, 1974, CARBOHYD RES, V32, P287, DOI 10.1016/S0008-6215(00)82106-0; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SCHWARZ RT, 1993, RES IMMUNOL, V144, P24, DOI 10.1016/S0923-2494(05)80092-6; SCHWARZ RT, 1986, MOL CELL BIOL, V6, P964, DOI 10.1128/MCB.6.3.964; SCHWARZ RT, 1989, BIOCHEM SOC T, V7, pS746; SCHWARZ RT, 1987, HOST PARASITIC CELLU, P275; SHARMA CB, 1974, EUR J BIOCHEM, V46, P35, DOI 10.1111/j.1432-1033.1974.tb03594.x; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5195, DOI 10.1073/pnas.85.14.5195; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; TOMAVO S, 1992, J BIOL CHEM, V267, P21446; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; WALTER EI, 1990, J IMMUNOL, V144, P1030; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	49	142	144	0	92	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2597	2606						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300589				2022-12-25	WOS:A1994MV43200039
J	LEE, SW; ELLIS, V; DICHEK, DA				LEE, SW; ELLIS, V; DICHEK, DA			CHARACTERIZATION OF PLASMINOGEN ACTIVATION BY GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED UROKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; RECEPTOR-BOUND UROKINASE; HUMAN-ENDOTHELIAL-CELLS; PRO-UROKINASE; GLYCOSYL-PHOSPHATIDYLINOSITOL; ENZYMATIC-ACTIVITY; MEMBRANE; BINDING; MONOCYTES; KINETICS	The characteristics of plasminogen activation by glycosylphosphatidylinositol (GPI)-anchored urokinase were evaluated and compared with those reported previously for receptor-bound urokinase. When expressed in cultured bovine aortic endothelial cells, GPI anchoring of single-chain urokinase plasminogen activator (scu-PA) potentiated plasmin generation as compared with GPI-anchored scu-PA that had been released into solution from the cell surface by enzymatic cleavage of the GPI anchor (''released'' scu-PA). The potentiation of plasmin generation by GPI-anchored scu-PA was inhibited in a dose-dependent manner by 6-aminohexanoic acid, a lysine analog, suggesting that the augmentation of plasmin generation by GPI-anchored scu-PA was dependent on simultaneous binding of plasminogen to the cell surface. GPI-anchored two-chain urokinase (tcu)-PA cleaved a peptide substrate at a rate equivalent to that of released urokinase. However, at a plasminogen concentration of 0.5 muM, GPI-anchored tcu-PA activated plasminogen less rapidly than did released urokinase. Modeling of kinetics of individual reactions revealed that cell-associated plasminogen activation by GPI-anchored tcu-PA was characterized by a K(m) of approximately 0.15 muM. This value of K(m) was 70-fold below that for activation of solution plasminogen by GPI-anchored urokinase. There was a concomitant decrease in V(max) for plasminogen activation by anchored tcu-PA. These alterations in kinetic parameters are similar to those reported previously for the activation of plasminogen by receptor-bound tcu-PA. In addition, GPI-anchored tcu-PA exhibited a modest resistance to plasminogen activator inhibitor 1 inactivation. The enzymatic characteristics of GPI-anchored urokinase reported here resemble closely those reported previously for receptor-bound urokinase. These data suggest that the urokinase receptor may regulate plasmin generation through a relatively nonspecific localization of urokinase to the cell Surface rather than through any intrinsic property of the urokinase receptor.	NHLBI, MOLEC HEMATOL BRANCH, BLDG 10, RM 7D-18, BETHESDA, MD 20892 USA; RIGSHOSP, FINSEN LAB, DK-2100 COPENHAGEN, DENMARK	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Rigshospitalet; University of Copenhagen			Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X; Dichek, David/0000-0002-5224-2736				BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DICHEK DA, 1993, THROMB HAEMOSTASIS, V70, P198; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1993, METHOD ENZYMOL, V223, P223; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; LEE SW, 1992, J BIOL CHEM, V267, P13020; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LONGSTAFF C, 1992, J BIOL CHEM, V267, P173; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MILES LA, 1985, J BIOL CHEM, V260, P4303; NACHMAN RL, 1991, ANN NY ACAD SCI, V614, P240, DOI 10.1111/j.1749-6632.1991.tb43706.x; OSWALD RE, 1989, NATURE, V337, P579, DOI 10.1038/337579a0; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1985, BIOCHEM J, V225, P149, DOI 10.1042/bj2250149; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1991, THROMB HAEMOSTASIS, V66, P32; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; SCULLY MF, 1989, ARCH BIOCHEM BIOPHYS, V268, P438, DOI 10.1016/0003-9861(89)90311-1; SOBERANO ME, 1976, BIOCHIM BIOPHYS ACTA, V445, P763, DOI 10.1016/0005-2744(76)90126-1; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; THORSEN S, 1974, SCAND J CLIN LAB INV, V34, P167, DOI 10.3109/00365517409050831; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86	31	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2411	2418						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300567				2022-12-25	WOS:A1994MV43200014
J	LUO, MJ; SMELAND, TE; SHOUKRY, K; SCHULZ, H				LUO, MJ; SMELAND, TE; SHOUKRY, K; SCHULZ, H			DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE FROM RAT-LIVER MITOCHONDRIA - PURIFICATION AND CHARACTERIZATION OF A NEW ENZYME INVOLVED IN THE BETA-OXIDATION OF UNSATURATED FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXYACYL-COA DEHYDROGENASE; REVISED PATHWAY; HYDRATASE; PROTEIN	Mitochondrial DELTA3,5,DELTA2,4-dienoyl-CoA isomerase, which catalyzes the conversion of 3,5-octadienoyl-CoA to 2,4-octadienoyl-CoA, was purified from rat liver 370-fold at almost 30% yield by a six-step purification procedure. The final preparation appeared to be homogeneous as judged by gel electrophoresis. The molecular weights of the native enzyme and its subunit(s) were estimated to be 126,000 and 32,000, respectively. The purification of DELTA3,5,DELTA2,4-dienoyl-CoA isomerase completes the characterization of the enzymes functioning in the NADPH-dependent pathway for the beta-oxidation of unsaturated fatty acids with double bonds extending from odd-numbered carbon atoms. This novel pathway may not be operative in peroxisomes because DELTA3,5,DELTA2,4-dienoyl-CoA isomerase was only detected in mitochondria. Substrates of this pathway are 2,5-dienoyl-CoAs formed from 5-enoyl-CoAs by acyl-CoA dehydrogenase. Two sequential isomerization reactions catalyzed by DELTA3,DELTA2-enoyl-CoAs isomerase and DELTA3,5,DELTA2,4-dienoyl-CoA isomerase, respectively, convert 2,5-dienoyl-CoAs to 2,4-dienoyl-CoAs, which are reduced by NADPH-dependent 2,4-dienoyl-CoA reductase (EC 1.3.1.34) before reentering the beta-oxidation spiral.	CUNY CITY COLL, DEPT CHEM, NEW YORK, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY)					NCRR NIH HHS [RR 03060] Funding Source: Medline; NHLBI NIH HHS [HL 18089, HL 30847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018089, R01HL030847] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELMANS F, 1955, BIOCHEM J, V59, P438, DOI 10.1042/bj0590438; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUPLESSIS LM, 1980, LIPIDS, V14, P943; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HASHIMOTO T, 1990, PROG CLIN BIOL RES, V321, P137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NADA MA, 1992, ANAL BIOCHEM, V201, P62, DOI 10.1016/0003-2697(92)90174-6; OCHOA S, 1955, METHOD ENZYMOL, V1, P735, DOI 10.1016/0076-6879(55)01128-2; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; Schulz H, 1981, Methods Enzymol, V71 Pt C, P398; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6674; TEINMAN H, 1965, METHOD ENZYMOL, V35, P136; THOMASON SC, 1968, J CHEM EDUC, V45, P546, DOI 10.1021/ed045p546; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; YANG SY, 1986, J BIOL CHEM, V261, P5390	22	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2384	2388						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300563				2022-12-25	WOS:A1994MV43200010
J	HARA, E; YAMAGUCHI, T; NOJIMA, H; IDE, T; CAMPISI, J; OKAYAMA, H; ODA, K				HARA, E; YAMAGUCHI, T; NOJIMA, H; IDE, T; CAMPISI, J; OKAYAMA, H; ODA, K			ID-RELATED GENES ENCODING HELIX-LOOP-HELIX PROTEINS ARE REQUIRED FOR G(1) PROGRESSION AND ARE REPRESSED IN SENESCENT HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE; DNA-BINDING; C-FOS; RETINOBLASTOMA PROTEIN; MAMMALIAN-CELLS; 3T3 CELLS; EXPRESSION; GROWTH; PRODUCT	Three complete cDNA clones encoding Id-related helix-loop-helix (HLH) proteins lacking a basic region were isolated from a pcD2 cDNA expression library prepared from TIG-3 human diploid fibroblasts (HDF). Of these cDNAs (Id-1H, Id-1H', and Id-2H), two (Id-IH and Id-1H') appeared to be derived by alternative RNA splicing. Id-1H and Id-2H seem to be human homologues of mouse Id-1 and Id-2, respectively, and have potential to encode 154 and 135 amino acid proteins. The Id-1H and Id-2H mRNAs were barely detectable in quiescent early passage HDF; serum coordinately induced both mRNAs, with two peaks of expression, in early and late in G1. Antisense oligomers complementary to Id-1H and Id-2H mRNA prevented early passage HDF from entering the S phase of the cell cycle. The treatment of serum-stimulated early passage cells with the antisense Id-1H oligomer completely abolished Id-1H. In senescent cells, serum barely induced the Id-1H and Id-2H mRNAs, although the levels of c-myc expression induced were similar in early passage and senescent cells. The expression levels of these Id genes vary among immortal human cell lines. Both genes were overexpressed in VA4 SV40-transformed lung fibroblasts and EJ-1 bladder carcinoma cells, while these genes were expressed at a very low level in SVts8 cells derived from SV40 tsA-transformed TIG-3 cells. SVts8 cells may acquire some function redundant to Id proteins. HT1080 fibrosarcoma cells expressed the Id-1H gene but not the Id-2H gene, suggesting these Id genes may subserve redundant functions.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,TOYONAKA,OSAKA 560,JAPAN; HIROSHIMA UNIV,DEPT CELLULAR & MOLEC BIOL,HIROSHIMA 734,JAPAN; LAWRENCE BERKELEY LAB,DEPT CELL & MOLEC BIOL,BERKELEY,CA 94720	Tokyo University of Science; Tokyo University of Science; Osaka University; Hiroshima University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NATIONAL INSTITUTE ON AGING [R37AG009909, R01AG009909, R56AG009909] Funding Source: NIH RePORTER; NIA NIH HHS [AG09909] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; McCormick A, 1991, CURR OPIN CELL BIOL, V3, P230, DOI 10.1016/0955-0674(91)90144-N; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; RICHTER KH, 1991, CANCER RES, V51, P6010; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; STEIN CA, 1988, CANCER RES, V52, P428; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	50	279	288	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2139	2145						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294468				2022-12-25	WOS:A1994MR98800089
J	MULLIS, KG; HUYNH, M; KORNFELD, RH				MULLIS, KG; HUYNH, M; KORNFELD, RH			PURIFICATION AND KINETIC-PARAMETERS OF BOVINE LIVER N-ACETYLGLUCOSAMINE-1-PHOSPHODIESTER ALPHA-N-ACETYLGLUCOSAMINIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; RAT-LIVER; PHOSPHORYLATION; PHOSPHODIESTERASE; OLIGOSACCHARIDES; RECOGNITION; RESIDUES; PROTEINS	The enzyme N-acetyl-glucosamine phosphodiester alpha-N-acetylglucosaminidase (phosphodiester alpha-GlcNAcase) catalyzes the second step in the formation of the mannose 6-phosphate targeting signal on lysosomal enzyme oligosaccharides by removing GlcNAc residues from GlcNAc-alpha-P-mannose moieties, which are formed in the first step by UDP-N-acetyl-glucosamine:glycoprotein N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase). Phosphodiester alpha-GlcNAcase, a membrane-bound enzyme, has been purified about 3,000-fold from bovine liver to apparent homogeneity using detergent solubilization, fractionation on DEAE-cellulose, affinity chromatography on lectin-Sepharose columns, gel filtration, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The enzyme migrated as 129- and 121-kDa species on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Since both bands had the same amino-terminal sequence, the smaller species is presumed to be derived from the larger by proteolysis. Kinetic analysis of bovine phosphodiester alpha-GlcNAcase with enzymatically synthesized artificial and biological substrates indicates that phosphodiester alpha-GlcNAcase requires GlcNAc-alpha-P R for substrate and that when R contains the Manalpha1,2Man linkage the substrate binding is most effective. Unlike GlcNAc-phosphotransferase, bovine phosphodiester alpha-GlcNAcase does not require a protein recognition determinant on lysosomal enzyme substrates.	WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NCI NIH HHS [CA08759] Funding Source: Medline; NHLBI NIH HHS [T32-HL07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDIAK B, 1987, J BIOL CHEM, V262, P5775; COUSO R, 1986, J BIOL CHEM, V261, P6326; HARLOW E, 1988, ANTIBODIES LABORATOR; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRYSTAL G, 1987, ANAL BIOCHEM, V167, P86, DOI 10.1016/0003-2697(87)90136-9; LACKS SA, 1980, J BIOL CHEM, V255, P7467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MULLIS KC, 1993, J BIOL CHEM, V269, P1727; MULLIS KG, 1992, ANAL BIOCHEM, V205, P200, DOI 10.1016/0003-2697(92)90424-6; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; SCHLOSNAGLE DC, 1974, J BIOL CHEM, V249, P7574; TABAS I, 1980, J BIOL CHEM, V255, P6633; VARKI A, 1981, J BIOL CHEM, V256, P9937; VARKI A, 1983, ARCH BIOCHEM BIOPHYS, V222, P145, DOI 10.1016/0003-9861(83)90511-8; WAHEED A, 1981, J BIOL CHEM, V256, P5717	18	9	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1718	1726						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294420				2022-12-25	WOS:A1994MR98800030
J	MILTENBERGER, RJ; CORTNER, J; FARNHAM, PJ				MILTENBERGER, RJ; CORTNER, J; FARNHAM, PJ			AN INHIBITORY RAF-1 MUTANT SUPPRESSES EXPRESSION OF A SUBSET OF V-RAF-ACTIVATED GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; PROTEIN-KINASE; C-FOS; MAP KINASE; SIGNAL TRANSDUCTION; MOUSE FIBROBLASTS; EGR-1 PROMOTER; BINDING-SITE; 3T3 CELLS	The Proto-oncogene Raf-1 is a cytoplasmic serine/threonine kinase implicated in the signaling process in cell proliferation. To determine if Raf-1 is sufficient and necessary to transmit mitogenic signals to growth-responsive genes, we examined the effect of constitutively activated (v-raf) or inhibitory (Raf-C4) Raf-1 proteins on reporter gene activation in transient expression assays of NIH 3T3 cells. In serum-starved cells, v-raf strongly activated transcription from the promoters of the immediate-early genes c-fos and egr-2, as well as the proximal or B promoter of the late growth response gene rep-3 (rep-3b). Two other late response gene promoters, cad and dhfr, were only modestly activated by v-raf, however. An individual serum response element from the c-fos or egr-2 promoter conferred both serum-inducibility and v-raf-responsiveness to a heterologous promoter. Consistent with the degree to which antisense c-raf-1 RNA and dominant-negative Raf-1 proteins interfere with NIH 3T3 cell proliferation, Raf-C4 reduced serum-induced transcription from the egr-2 and rep-3b promoters in a dose-dependent manner by 50%. In contrast, Raf-C4 did not significantly reduce transcription from the c-fos or cad promoters or the serum response element-driven heterologous promoters. We conclude that Raf-1 is both sufficient and necessary to activate a subset of early and late growth response genes.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [T32CA009135, P30CA007175, P01CA023076] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA23076, CA09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CORTNER J, 1990, MOL CELL BIOL, V10, P3788, DOI 10.1128/MCB.10.7.3788; CORTNER J, 1991, THESIS U WISCONSIN M; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANNINK M, 1990, ONCOGENE, V5, P1843; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIAO WSL, 1986, J BIOL CHEM, V261, P5577; LIM K, 1989, BIOTECHNIQUES, V7, P576; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MAMON H, 1991, COLD SPRING HARB SYM, V56, P251; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAO GN, 1988, EXP CELL RES, V178, P449, DOI 10.1016/0014-4827(88)90413-2; RIM M, 1992, ONCOGENE, V7, P2065; RIVERA V M, 1990, New Biologist, V2, P751; Sambrook J, 1989, MOL CLONING LABORATO; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	50	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15674	15680						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340392				2022-12-25	WOS:A1993LN30500054
J	UNNO, M; YONEKURA, H; NAKAGAWARA, K; WATANABE, T; MIYASHITA, H; MORIIZUMI, S; OKAMOTO, H; ITOH, T; TERAOKA, H				UNNO, M; YONEKURA, H; NAKAGAWARA, K; WATANABE, T; MIYASHITA, H; MORIIZUMI, S; OKAMOTO, H; ITOH, T; TERAOKA, H			STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION OF MOUSE REG GENES, REG-I AND REG-II - A NOVEL TYPE OF REG GENE, REG-II, EXISTS IN THE MOUSE GENOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC STONE PROTEIN; MESSENGER-RNA; REGENERATING ISLETS; NUCLEOTIDE-SEQUENCE; RAT; CELLS; ENHANCER; INSULIN; ACID; PITUITARY	We previously identified a gene, reg (i.e. regenerating gene), in the screening of a regenerating islet-derived cDNA library of rat (Terazono, K., Yamamoto, H., Takasawa, S., Shiga, K., Yonemura, Y., Tochino, Y., and Okamoto, H. (1988) J. Biol. Chem. 263, 2111-2114), and isolated a human reg cDNA and gene (Watanabe, T., Yonekura, H., Terazono, K., Yamamoto, H., and Okamoto, H. (1990) J. Biol. Chem. 265, 7432-7439); the rat and human cDNAs encode 165- and 166- amino acid proteins, respectively. Until now, it was thought that there is a single locus for Reg protein in the mammalian genome. In this study, we isolated two distinct cDNAs and genes, one of which was a mouse homologue to rat and human reg gene, the other a novel type of reg gene. We designated them reg I and reg II, respectively. The two proteins encoded by these genes share 76% amino acid sequence identity with each other. Both genes span about 3 kilobase pairs, and the genomic organization of six exons and five introns is conserved between them. Chromosomal mapping studies indicate that the reg I gene is localized on mouse chromosome 12, whereas the reg II gene is localized on chromosome 3. By Northern blot analysis, both reg I and reg II mRNAs are detected in the normal pancreas and hyperplastic islets of aurothioglucose-treated mice, but not in the normal islets. It is remarkable that in the gallbladder reg I is expressed, but reg II is not.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,2-1 SEIRYO MACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN; SHIONOGI & CO LTD,SHIONOGI RES LAB,FUKUSHIMA KU,OSAKA 553,JAPAN	Tohoku University; Shionogi & Company Limited			Unno, Michiaki/AAX-5246-2020; Unno, Michiaki/A-8633-2010	Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416				BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECARO AM, 1989, BIOCHIM BIOPHYS ACTA, V994, P281, DOI 10.1016/0167-4838(89)90305-1; DECARO AM, 1987, EUR J BIOCHEM, V168, P201; DELAMONTE SM, 1990, J CLIN INVEST, V86, P1004, DOI 10.1172/JCI114762; DRICKAMER K, 1987, J BIOL CHEM, V262, P2582; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FODOR E, 1991, BIOCHEMISTRY-US, V30, P8102, DOI 10.1021/bi00247a002; FRANCIS PJ, 1992, DIABETOLOGIA, V35, P238, DOI 10.1007/BF00400923; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GROSS J, 1985, J CLIN INVEST, V76, P2115, DOI 10.1172/JCI112216; HAGENBUCHLE O, 1980, CELL, V21, P179, DOI 10.1016/0092-8674(80)90125-7; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; KAWAGUCHI N, 1991, DEV BIOL, V144, P86, DOI 10.1016/0012-1606(91)90481-H; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LASSERRE C, 1992, CANCER RES, V52, P5089; Maniatis T, 1989, DECONTAMINATION DILU; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MIYAURA C, 1991, MOL ENDOCRINOL, V5, P226, DOI 10.1210/mend-5-2-226; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; Okamoto H., 2008, MOL BIOL ISLETS LANG, P209; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; ROSENBERG L, 1983, J SURG RES, V35, P63, DOI 10.1016/0022-4804(83)90127-0; ROUQUIER S, 1991, J BIOL CHEM, V266, P786; SHARON N, 1989, LECTINS; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; TACHIBANA K, 1988, MOL ENDOCRINOL, V2, P973, DOI 10.1210/mend-2-10-973; TAKASAWA S, 1992, FEBS LETT, V307, P318, DOI 10.1016/0014-5793(92)80704-K; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; Terazono K., 2008, MOL BIOL ISLETS LANG, P301; TOCHINO Y, 1983, DIABETES MICROANGIOP, P423; TRASK BJ, 1992, METHOD CELL BIOL, V35, P3; UNNO M, 1992, PANCREATIC ISLET CEL, P61; WATANABE T, 1990, J BIOL CHEM, V265, P7432; YAMAMOTO T, 1992, J HISTOCHEM CYTOCHEM, V40, P221, DOI 10.1177/40.2.1348066; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J; YONEKURA H, 1988, J BIOL CHEM, V263, P2990; YONEMURA Y, 1984, DIABETES, V33, P401, DOI 10.2337/diabetes.33.4.401	45	128	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15974	15982						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340418				2022-12-25	WOS:A1993LN30500092
J	GEE, SH; BLACHER, RW; DOUVILLE, PJ; PROVOST, PR; YURCHENCO, PD; CARBONETTO, S				GEE, SH; BLACHER, RW; DOUVILLE, PJ; PROVOST, PR; YURCHENCO, PD; CARBONETTO, S			LAMININ-BINDING PROTEIN-120 FROM BRAIN IS CLOSELY-RELATED TO THE DYSTROPHIN-ASSOCIATED GLYCOPROTEIN, DYSTROGLYCAN, AND BINDS WITH HIGH-AFFINITY TO THE MAJOR HEPARIN-BINDING DOMAIN OF LAMININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE PROTEOGLYCAN; COMPLETE SEQUENCE; CELL-MEMBRANES; RECEPTOR; COMPONENTS; NEURONS; MUSCLE; CHAIN; FORM	When brain proteins separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose are probed with I-125-labeled laminin, a single broad band of approximately 120 kDa binds laminin specifically. We show here by two-dimensional electrophoresis and protein microsequencing that this band consists of two distinct laminin-binding proteins. One of these is the amyloid precursor protein. The other, laminin-binding protein (LBP) 120, is closely related to the dystrophin-associated glycoprotein, dystroglycan (156 kDa); 5 peptides from purified bovine brain LBP120, ranging in size from 7 to 19 residues, are up to 100% identical to the predicted amino acid sequence of muscle dystroglycan (Ibraghimov-Beskrovnaya, O., Ervasti, J. M., Leveille, C. J., Slaughter, C. A., Sernett, S. W., and Campbell, K. P. (1992) Nature 355, 696-702). These protein microsequence data support the data of Ibraghimov-Beskrovnaya et al., which suggest that the dystroglycan precursor is processed into 120/156- and 43-kDa proteins. Moreover, the data suggest a revision in the position of the proposed cleavage site of the precursor. The glycosylation and extracellular localization of LBP120/dystroglycan are consistent with it being a cell surface laminin receptor. LBP120/dystroglycan, either as a native protein, or following SDS-PAGE and transfer to nitrocellulose, binds with high affinity (K(d) = 90 nM) to a proteolytic fragment of laminin (E3) containing the major heparin binding domain. This binding is Ca2+-dependent and inhibited by low concentrations of heparin. Thus, LBP120/dystroglycan is a major non-integrin laminin receptor whose high affinity interaction with laminin may reflect a structural role in brain and muscle.	MCGILL UNIV,MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA; ATHENA NEUROSCI,S SAN FRANCISCO,CA 94080; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854	McGill University; Rutgers State University New Brunswick; Rutgers State University Medical Center				Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036425, R01DK036425] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36425] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FRENETTE GP, 1989, J BIOL CHEM, V264, P3078; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; HARLOW E, 1988, ANTIBODIES LABORATOR, P494; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V85, P1282, DOI 10.1073/pnas.85.4.1282; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIESI P, 1985, EMBO J, V4, P1163, DOI 10.1002/j.1460-2075.1985.tb03755.x; LINDENBAUM MH, 1993, CURR BIOL, V3, P109, DOI 10.1016/0960-9822(93)90167-M; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; POMERANZ HD, 1991, J COMP NEUROL, V313, P625, DOI 10.1002/cne.903130408; RAO CN, 1983, BIOCHEM BIOPH RES CO, V111, P804; RUNYAN RB, 1986, J CELL BIOL, V102, P432, DOI 10.1083/jcb.102.2.432; RUPP F, 1992, J NEUROSCI, V12, P3535; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; TIMPL R, 1982, METHOD ENZYMOL, V82, P831; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WARD LD, 1990, CURRENT RES PROTEIN, P179; WOO HJ, 1990, J BIOL CHEM, V265, P7097; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981	46	272	272	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14972	14980						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325873				2022-12-25	WOS:A1993LL75900066
J	JUNG, G; FUKUI, Y; MARTIN, B; HAMMER, JA				JUNG, G; FUKUI, Y; MARTIN, B; HAMMER, JA			SEQUENCE, EXPRESSION PATTERN, INTRACELLULAR-LOCALIZATION, AND TARGETED DISRUPTION OF THE DICTYOSTELIUM MYOSIN ID HEAVY-CHAIN ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA-CASTELLANII; HOMOLOGOUS RECOMBINATION; CELL MOTILITY; GENE; DISCOIDEUM; CHEMOTAXIS; CLONING; ACTIN; IA; IB	The complete sequence of the Dictyostelium myosin ID (DMID) heavy chain isoform has been determined from cDNA and genomic clones. Like the DMIB isoform characterized previously, the DMID isoform is up-regulated during starvation-induced chemotatic aggregation, and its 124-kDa heavy chain contains the tail domain sequences that correspond to both the membrane and second actin-binding sites. An antibody that is specific for the DMID isoform was found to stain the actin-rich pseudopods at the leading edge of migrating cells. Protein microsequencing data reveals that the myosin I isoform localized to leading edge pseudopods in a previous study (Fukui, Y., Lynch, T. J., Brzeska, H., and Korn, E. D. (1989) Nature 341, 328-33 1) was DMIB, indicating that DMID and DMIB also colocalize and that both should influence the dynamics of actin-rich cortical structures. This and other data indicate that the DMID and DMIB isoforms are closely related and are distinct from the DMIA and DMIE isoforms, which possess truncated tail domains and are not up-regulated during chemotactic aggregation. Cells in which the DMID gene was rendered nonfunctional by targeted gene disruption do not show obvious behavioral defects, suggesting that another myosin I isoform(s) (possibly DMIB) might compensate for DMID. Finally, Southern blot data indicate that Dictyostelium may contain as many as nine myosin I isoforms.	NHLBI, CELL BIOL LAB, 9000 ROCKVILLE PIKE, 3-B1-22, BETHESDA, MD 20892 USA; NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, CHICAGO, IL 60611 USA; NIMH, CLIN NEUROSCI BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ADAMS RJ, 1989, CELL MOTIL CYTOSKEL, V14, P178, DOI 10.1002/cm.970140203; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; COTE GP, 1985, J BIOL CHEM, V260, P4543; DELOZANNE A, 1987, METHOD CELL BIOL, V28, P489; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DELOZANNE A, 1985, P NATL ACAD SCI USA, V82, P6807, DOI 10.1073/pnas.82.20.6807; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FUJISAKI H, 1985, J BIOL CHEM, V260, P1183; FUKUI Y, 1987, METHOD CELL BIOL, V28, P347; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HAMMER JA, 1983, J BIOL CHEM, V258, P168; HOROWITZ JA, 1990, J BIOL CHEM, V265, P20646; Janmey PA, 1991, CURR OPIN CELL BIOL, V3, P4, DOI 10.1016/0955-0674(91)90159-V; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KORN ED, 1988, J CELL BIOCHEM, V36, P37, DOI 10.1002/jcb.240360105; LYNCH T J, 1988, Journal of Cell Biology, V107, p7A; LYNCH TJ, 1990, BIOPHYS J, V57, pA536; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NELLEN W, 1988, BIOCHEM BIOPH RES CO, V154, P54, DOI 10.1016/0006-291X(88)90648-1; OSTER GF, 1987, J CELL SCI, P35; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RUBINO S, 1987, PROTOPLASMA, V136, P63, DOI 10.1007/BF01276319; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPUDICH JA, 1989, CELL REGUL, V1, P1; TITUS M A, 1990, Journal of Cell Biology, V111, p168A; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; URRUTIA RA, 1993, IN PRESS BIOCH BIOPH; VARNUM B, 1986, DEV BIOL, V113, P218, DOI 10.1016/0012-1606(86)90124-7; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	48	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14981	14990						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325874				2022-12-25	WOS:A1993LL75900067
J	WANG, CK; LIAO, RL; CHEUNG, HC				WANG, CK; LIAO, RL; CHEUNG, HC			ROTATIONAL-DYNAMICS OF SKELETAL-MUSCLE TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTANCE DISTRIBUTIONS; ENERGY-TRANSFER; FLUORESCENCE; CALCIUM; COMPLEX; RESOLUTION; CALMODULIN; BINDING; DOMAIN; SITES	Upon excitation by 280 nm, the intensity decay of the 2 tyrosine residues (residues 10 and 109) of rabbit skeletal muscle troponin C is resolved into three components. The anisotropy decay in the absence of divalent cation is biphasic with a short correlation time of 0.67 ns and a long correlation time of 9.23 ns. The limiting anisotropy is 0.225, considerably lower than the value expected for immobilized tyrosine. Upon excitation by 290 nm, the anisotropy decay is also biphasic, and the limiting anisotropy increases to 0.274. The recovery of anisotropy by excitation at a wavelength near the red edge of the tyrosine absorption spectrum is evidence of fluorescence resonance energy transfer between the two tyrosines. For energy transfer to occur, the average separation between the 2 tyrosines is unlikely much larger than the Forster distance R(o), congruent-to 10 angstrom, and this close proximity of the residues would require a highly distorted dumbbell shape of troponin C in solution. These results are consistent with a flexible central helix, which either has a segmental flexibility with large amplitude or results in a spectrum of conformations including those in which the two globular domains are in a very close proximity.	UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025193] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR25193] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; CHEUNG HC, 1982, BIOCHEMISTRY-US, V21, P5135, DOI 10.1021/bi00264a005; CHEUNG HC, 1987, BIOCHEMISTRY-US, V26, P5904, DOI 10.1021/bi00392a049; GAUDUCHON P, 1978, BIOPHYS CHEM, V8, P87, DOI 10.1016/0301-4622(78)85026-1; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GRYCZYNSKI I, 1988, BIOPHYS CHEM, V30, P49, DOI 10.1016/0301-4622(88)85003-8; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KASPRZAK A, 1982, BIOCHEMISTRY-US, V21, P5924, DOI 10.1021/bi00266a030; KINOSITA K, 1977, BIOPHYS J, V20, P289, DOI 10.1016/S0006-3495(77)85550-1; LAKOWICZ JR, 1988, BIOCHEMISTRY-US, V27, P9149, DOI 10.1021/bi00426a012; LEAVIS PC, 1978, ARCH BIOCHEM BIOPHYS, V187, P243, DOI 10.1016/0003-9861(78)90030-9; LIAO RL, 1992, BIOPHYS J, V63, P986, DOI 10.1016/S0006-3495(92)81685-5; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LUDESCHER RD, 1987, BIOPHYS CHEM, V28, P59, DOI 10.1016/0301-4622(87)80075-3; PERRY SV, 1974, BIOCHEM J, V141, P733, DOI 10.1042/bj1410733; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RUGGIERO A, 1989, BIOPHYS J, V55, P1111, DOI 10.1016/S0006-3495(89)82908-X; SMALL EW, 1984, REV SCI INSTRUM, V55, P879, DOI 10.1063/1.1137850; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TOROK K, 1992, BIOCHEMISTRY-US, V31, P3452, DOI 10.1021/bi00128a020; WANG CK, 1985, BIOPHYS J, V48, P727, DOI 10.1016/S0006-3495(85)83831-5; WANG CK, 1986, J MOL BIOL, V191, P509, DOI 10.1016/0022-2836(86)90145-2; WANG CK, 1989, PROTEINS, V6, P424, DOI 10.1002/prot.340060409; WANG CK, 1988, BIOPHYS J, V53, pA73; WANG CLA, 1983, J BIOL CHEM, V258, P9175; WEBER G, 1970, P NATL ACAD SCI USA, V65, P823, DOI 10.1073/pnas.65.4.823	32	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14671	14677						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325844				2022-12-25	WOS:A1993LL75900024
J	FIELDS, CG; MICKELSON, DJ; DRAKE, SL; MCCARTHY, JB; FIELDS, GB				FIELDS, CG; MICKELSON, DJ; DRAKE, SL; MCCARTHY, JB; FIELDS, GB			MELANOMA CELL-ADHESION AND SPREADING ACTIVITIES OF A SYNTHETIC 124-RESIDUE TRIPLE-HELICAL MINI-COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PEPTIDE-SYNTHESIS; IV-COLLAGEN; BINDING-SITE; POLYTRIPEPTIDES; ATTACHMENT; SEQUENCE; MULTIPLE; HYDROXYPYROLINE; IDENTIFICATION; STABILIZATION	A great variety of cells, such as melanoma cells, fibroblasts, platelets, keratinocytes, and epithelial cells, adhere to and migrate on specific regions within the triple-helical domains of types I, III, and IV collagen. The relative importance of collagen primary, secondary, and tertiary structures on these cellular activities has not been ascertained, as no general synthetic methodology exists to allow for the study of peptides incorporating biologically active sequences in triple-helical conformation. We have thus developed a novel, generally applicable solid-phase branching methodology for the synthesis of aligned, triple-helical collagen-model polypeptides (i.e. ''mini-collagens''). Three nascent peptide chains are carboxyl-terminally linked through one N(alpha)-amino and two N(epsilon)-amino groups of Lys, while repeating Gly-Pro-Hyp triplets induce triple helicity. A homotrimeric triple-helical polypeptide (THP) of 124 amino acids, incorporating residues 1263-1277 of alpha1(IV) collagen, was synthesized. Highly metastatic mouse melanoma cells showed a profound preference for adhesion to this THP as compared with a single-stranded peptide (SSP) incorporating the same type IV collagen sequence or a branched peptide containing eight repeats of Gly-Pro-Hyp (designated GPP*). Specifically, 50% cell adhesion occurred at a THP concentration of 1.12 muM, while comparable levels of adhesion required [SSP] = 170 muM or [GPP*] > 100 muM. Melanoma cells also spread on the THP to a greater extent than on the SSP or GPP*. These results are the first direct demonstrations of the significance of triple helicity for cell adhesion to and spreading on a specific collagen sequence and support earlier conclusions of conformational dependency for cell adhesion to and migration on types I and IV collagen. In addition, the melanoma cell THP activities support the concept that tumor cell adhesion and spreading on type IV collagen involves multiple, distinct domains in triple-helical conformation. The triple-helical peptide synthetic protocol developed here will allow eventually for the study of both structure and biological activity of specific, glycosylated collagen sequences in homotrimeric and heterotrimeric forms.	UNIV MINNESOTA,DEPT LAB MED & PATHOL,BOX 107,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR BIOMED ENGN,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [R01CA043924, R55CA054263] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54263, CA 43924] Funding Source: Medline; PHS HHS [KD 44494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON JG, 1992, ANAL BIOCHEM, V202, P210; ANDREEVA NS, 1963, ASPECTS PROTEIN STRU, P137; AUMAILLEY M, 1986, J CELL BIOL, V103, P1569, DOI 10.1083/jcb.103.4.1569; BABEL W, 1984, EUR J BIOCHEM, V143, P545, DOI 10.1111/j.1432-1033.1984.tb08404.x; BABIARZ B, 1992, EXP CELL RES, V203, P276, DOI 10.1016/0014-4827(92)90065-G; BARANY G, 1977, J AM CHEM SOC, V99, P7363, DOI 10.1021/ja00464a050; BARANY G, 1985, J AM CHEM SOC, V107, P4936, DOI 10.1021/ja00303a019; BLANKEMEYERMENGE B, 1988, TETRAHEDRON LETT, V29, P5871, DOI 10.1016/S0040-4039(00)82212-1; BRODSKY B, 1992, BIOPOLYMERS, V32, P447, DOI 10.1002/bip.360320423; CAMERON JD, 1991, INVEST OPHTH VIS SCI, V32, P2766; CHELBERG MK, 1989, CANCER RES, V49, P4796; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FIELDS C G, 1991, Peptide Research, V4, P95; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS CG, 1989, INT J PEPT PROT RES, V33, P298; FIELDS CG, 1992, ANAL BIOCHEM, V203, P245, DOI 10.1016/0003-2697(92)90309-U; Fields G. B., 1992, SYNTHETIC PEPTIDES U, P77; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FIELDS GB, 1992, J PHYS CHEM-US, V96, P3974, DOI 10.1021/j100189a013; FIELDS GB, 1991, J AM CHEM SOC, V113, P4202, DOI 10.1021/ja00011a023; GOLDMAN R, 1992, EUR J IMMUNOL, V22, P1109, DOI 10.1002/eji.1830220502; GUIBE F, 1989, TETRAHEDRON LETT, V30, P2641, DOI 10.1016/S0040-4039(00)99087-7; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; KLEINMAN HK, 1978, J BIOL CHEM, V253, P5642; KUNZ H, 1988, ANGEW CHEM INT EDIT, V27, P711, DOI 10.1002/anie.198807111; KUNZ H, 1989, PEPTIDES 1988, P154; LEGRAND YJ, 1980, BIOCHEM BIOPH RES CO, V96, P1579, DOI 10.1016/0006-291X(80)91354-6; LLOYDWILLIAMS P, 1991, TETRAHEDRON LETT, V32, P4207, DOI 10.1016/S0040-4039(00)79906-0; LONG CG, 1992, J MOL BIOL, V225, P1, DOI 10.1016/0022-2836(92)91020-P; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; MILLIONOVA MI, 1963, BIOPHYS-USSR, V8, P478; MUTTER M, 1992, J AM CHEM SOC, V114, P1463, DOI 10.1021/ja00030a049; NEMETHY G, 1986, BIOCHEMISTRY-US, V25, P3184, DOI 10.1021/bi00359a016; OLSEN BR, 1971, J MOL BIOL, V57, P589, DOI 10.1016/0022-2836(71)90111-2; RAMACHAN.GN, 1973, BIOCHIM BIOPHYS ACTA, V322, P166, DOI 10.1016/0005-2795(73)90187-6; ROTH W, 1979, MAKROMOL CHEM, V180, P905; RUBIN K, 1981, CELL, V24, P463, DOI 10.1016/0092-8674(81)90337-8; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHARFFETTERKOCHANEK K, 1992, J INVEST DERMATOL, V98, P3, DOI 10.1111/1523-1747.ep12493266; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; WADE J D, 1991, Peptide Research, V4, P194; WILKE MS, 1990, J INVEST DERMATOL, V95, P264, DOI 10.1111/1523-1747.ep12484883; ZIJENAH LS, 1990, THROMB RES, V59, P553, DOI 10.1016/0049-3848(90)90415-9	50	108	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14153	14160						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314781				2022-12-25	WOS:A1993LJ82500056
J	ALBERTA, JA; RUNDELL, K; STILES, CD				ALBERTA, JA; RUNDELL, K; STILES, CD			IDENTIFICATION OF AN ACTIVITY THAT INTERACTS WITH THE 3'-UNTRANSLATED REGION OF C-MYC MESSENGER-RNA AND THE ROLE OF ITS TARGET SEQUENCE IN MEDIATING RAPID MESSENGER-RNA DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; CELL-FREE SYSTEM; RICH SEQUENCES; NUCLEOTIDE-SEQUENCE; STABILITY INVITRO; GENE-EXPRESSION; CODING REGION; 1ST STEP	Single or multiple copies of the pentameric motif, AUUUA, are found in the 3'-untranslated domain of most immediate early mRNAs. A broad body of data links this 5-base element to the selective degradation of these mRNAs. However, AUUUA motifs are neither always necessary nor always sufficient to tag an mRNA for rapid degradation. Here, we describe a cytoplasmic, protease-sensitive factor in Balb/c3T3 cells that interacts with the 3'-untranslated region of c-myc mRNA. The factor recognizes a 39-base uridine-rich domain adjacent to, but distinct from, the c-mye AUUUA motif. In chimeric mRNA constructs, the 39-base binding element cooperates with adjacent sequence material to destabilize beta-globin mRNA.	DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM CELL & DEV BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Northwestern University					NATIONAL CANCER INSTITUTE [R01CA022042] Funding Source: NIH RePORTER; NCI NIH HHS [CA22042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BONNIEU A, 1990, ONCOGENE, V5, P1585; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GRAHAM FL, 1973, J VIROL, V52, P455; GREENBERG JR, 1972, NATURE, V242, P102; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LIEBERMAN AP, 1990, J EXP MED, V172, P989, DOI 10.1084/jem.172.3.989; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PERRY RP, 1973, J MOL BIOL, V79, P681, DOI 10.1016/0022-2836(73)90071-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAYMOND V, 1989, ONCOGENE RES, V5, P1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SINGER RH, 1973, J MOL BIOL, V78, P321, DOI 10.1016/0022-2836(73)90119-8; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	48	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4532	4538						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308023				2022-12-25	WOS:A1994MW98900095
J	MASON, GGF; WITTE, AM; WHITELAW, ML; ANTONSSON, C; MCGUIRE, J; WILHELMSSON, A; POELLINGER, L; GUSTAFSSON, JA				MASON, GGF; WITTE, AM; WHITELAW, ML; ANTONSSON, C; MCGUIRE, J; WILHELMSSON, A; POELLINGER, L; GUSTAFSSON, JA			PURIFICATION OF THE DNA-BINDING FORM OF DIOXIN RECEPTOR - ROLE OF THE ARNT COFACTOR IN REGULATION OF DIOXIN RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOBIOTIC RESPONSIVE ELEMENTS; HEAT-SHOCK PROTEIN; AH-RECEPTOR; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN-ENHANCER; NUCLEAR RECEPTORS; RETINOIC ACID; P-450C GENE; IDENTIFICATION; CLONING	The basic region/helix-loop-helix dioxin receptor mediates signal transduction by dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin). Upon ligand binding the dioxin receptor is converted from a latent, non-DNA binding form to a form that directly interacts with target genes by binding to dioxin-responsive transcriptional control elements. We have purified by conventional and DNA affinity chromatographic procedures the ligand-activated, DNA binding form of dioxin receptor to examine its architecture and functional properties. We observed that the DNA binding activity of the receptor was labile. Most notably, this activity was lost following DNA affinity purification. In complementation experiments we have identified an auxiliary factor(s) that exhibited very poor, if any, intrinsic affinity for the DNA target sequence in vitro but strongly increased the DNA binding activity of the purified receptor-containing material identified by immunoblot analysis. In a similar fashion the in vitro expressed basic region/helix-loop-helix factor Arnt (that has been postulated to modulate the nuclear translocation function of the receptor) reconstituted the DNA binding function of the purified receptor, and the purified auxiliary factor reconstituted receptor activity upon addition to an extract from mutant, Arnt-deficient hepatoma cells. Conversely, purified dioxin receptor reconstituted DNA binding activity in extracts from receptor deficient hepatoma cells which express bona fide levels of Arnt. Interestingly, UV cross-linking studies using a BrdU-substituted DNA target sequence indicated that primarily the receptor protein was bound to DNA. Moreover, we demonstrate that purified receptor or Arnt exhibited virtually no detectable affinity for the target sequence individually but, in the presence of one another, showed a strong synergy in DNA binding activity in vitro. Importantly, simultaneous expression of the receptor and Arnt resulted in synergistic induction of gene expression in vivo. These data demonstrate that Arnt plays a central role in control of dioxin receptor function by cooperatively modulating the DNA binding activity of the receptor in vitro and dioxin-dependent transactivation in vivo.	KAROLINSKA INST,HUDDINGE HOSP,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet								ANDERSSON S, 1991, J BIOL CHEM, V264, P10078; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bailar J C 3rd, 1991, N Engl J Med, V324, P260, DOI 10.1056/NEJM199101243240409; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BLANAR MA, 1992, SCIENCE, V251, P1211; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CUTHILL S, 1991, MOL CELL BIOL, V11, P412; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HANKINSON O, 1983, SOMATIC CELL GENET, V9, P97; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HAPGOOD J, 1991, MOL CELL BIOL, V11, P4314, DOI 10.1128/MCB.11.9.4314; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P1382; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POELLINGER L, 1985, ANAL BIOCHEM, V144, P371, DOI 10.1016/0003-2697(85)90130-7; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1991, MOL PHARMACOL, V39, P20; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V261, P6352; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG X, 1991, ARCH BIOCHEM BIOPHYS, V287, P186, DOI 10.1016/0003-9861(91)90405-8; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	54	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4438	4449						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308014				2022-12-25	WOS:A1994MW98900084
J	METZLER, WJ; BELL, AJ; ERNST, E; LAVOIE, TB; MUELLER, L				METZLER, WJ; BELL, AJ; ERNST, E; LAVOIE, TB; MUELLER, L			IDENTIFICATION OF THE POLY-L-PROLINE-BINDING SITE ON HUMAN PROFILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; N-15-LABELED PROTEINS; NUCLEOTIDE-SEQUENCE; ACTIN; GENE; CLONING; DOMAIN; CDNA; RECEPTOR	Profilin is a ubiquitous protein that has been implicated in the signaling pathway leading to cytoskeletal rearrangement in cells. An unusual property of profilin is its high binding affinity for poly-L-proline (PLP). This binding property is conserved in the profilins from diverse species with little sequence homology. We have monitored the binding of PLP to profilin by fluorescence and nuclear magnetic resonance spectroscopies. NMR spectroscopy has identified several residues whose amide nitrogen and amide hydrogen chemical shifts are significantly perturbed by binding of PLP. The affected residues are located at various locations throughout profilin's primary structure; however, mapping the location of the affected residues onto the recently determined three dimensional solution structure of human profilin indicates that the effects of PLP binding are highly localized. Poly-L-proline binds profilin at the hydrophobic interface between profilin's NH2- and COOH-terminal helices and the upper face of its antiparallel beta-sheet. In contrast, residues located on the opposite side of the profilin structure are unaffected. The extent of the potential interaction surface of the PLP-profilin complex suggests that as few as 6 contiguous prolines would be sufficient for binding profilin. Examination of sequence data bases indicates that stretches of prolines of this length and longer occur in numerous regulatory proteins, suggesting that the ability of profilin to bind polyproline may be an important component of its signaling capabilities.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC BIOCHEM,PRINCETON,NJ 08543	Bristol-Myers Squibb	METZLER, WJ (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC NMR,POB 4000,PRINCETON,NJ 08543, USA.							AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BABCOCK G, 1989, CELL MOTIL CYTOSKEL, V14, P230, DOI 10.1002/cm.970140209; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BLAKE TJ, 1991, ONCOGENE, V6, P653; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CHAMPE MA, 1989, NUCLEIC ACIDS RES, V17, P3304, DOI 10.1093/nar/17.8.3304; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1990, CELL MOTIL CYTOSKEL, V17, P71, DOI 10.1002/cm.970170202; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KATAKAMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1122, P123, DOI 10.1016/0167-4838(92)90314-4; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; METZLER WJ, 1993, IN PRESS BIOCHEMISTR, V32; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MUELLER L, 1992, J MAGN RESON, V96, P408, DOI 10.1016/0022-2364(92)90096-P; MUELLER L, 1979, MOL PHYS, V38, P963; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11383, DOI 10.1093/nar/16.23.11383; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	40	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4620	4625						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308034				2022-12-25	WOS:A1994MW98900106
J	NICULESCU, F; RUS, H; SHINO, ML				NICULESCU, F; RUS, H; SHINO, ML			RECEPTOR-INDEPENDENT ACTIVATION OF GUANINE-NUCLEOTIDE-BINDING REGULATORY PROTEINS BY TERMINAL COMPLEMENT COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CATALYZED ADP-RIBOSYLATION; GTP-BINDING; SIGNAL TRANSDUCTION; HUMAN-ERYTHROCYTES; PLASMA-MEMBRANES; NUCLEATED CELLS; PHOSPHOLIPASE-C; MASTOPARAN; ATTACK	Activation of heterotrimeric guanine nucleotide-binding proteins (G proteins) by terminal complement complexes (TCC) was investigated on human lymphoblastoid B-cell line JY25 and its mutant JY5 deficient in glycosylphosphatidylinositol-anchored proteins. TCC assembly achieved by antibody dependent activation of C7-deficient serum reconstituted with C7 increased specific guanosine-5'-(gamma-thio)triphosphate (GTP gamma S) binding, 4- and 8-fold, in JY25 and JY5 membranes, respectively, between 2 and 10 min, over the level without C7. TCC also increased GTPase activity 5- and 4-fold in JY25 and JY5, respectively, between 5 and 10 min. Increased GTPase activity was noted first with C5b-7 assembly, which increased further with C5b-8 and C5b-9. The presence of G proteins in anti TCC immunoprecipitates of cell lysates was investigated by demonstration of Ga subunit that can be ADP-ribosylated by pertussis toxin (PTX). Immunoprecipitated TCC complexes contained a PTX-sensitive 41-kDa Gi alpha/Go alpha subunit, as shown by SDS PAGE and Western blotting. These complexes were functionally active as determined by GTP gamma S binding. We have further shown that enhanced TCC elimination from the plasma membrane induced by TCC-generated signals was inhibited by PTX. In conclusion the biological activities induced by TCC in nucleated cells may be mediated in part by activation of PTX-sensitive G proteins.	UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Rus, Horea/AAF-2583-2020		FIC NIH HHS [FO5 TWO 4624] Funding Source: Medline; NIAID NIH HHS [R01-AI19622] Funding Source: Medline; NINDS NIH HHS [R01-NS15662] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004624] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015662] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTONNY B, 1992, J BIOL CHEM, V267, P6710; BHAKDI S, 1983, BIOCHIM BIOPHYS ACTA, V737, P343, DOI 10.1016/0304-4157(83)90006-0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMMAKANTI RK, 1992, J BIOL CHEM, V267, P7576; CARNEY DF, 1990, J IMMUNOL, V145, P623; CARNEY DF, 1986, J IMMUNOL, V137, P263; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418; HANSCH GM, 1992, IMMUNOPHARMACOLOGY, V24, P107, DOI 10.1016/0162-3109(92)90017-7; HANSCH MG, 1981, P NATL ACAD SCI USA, V78, P5112; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOLLANDER N, 1989, J IMMUNOL, V142, P3913; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; KOSKI CL, 1987, J CLIN INVEST, V80, P1492, DOI 10.1172/JCI113231; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LILLIE THW, 1992, BIOCHEM J, V288, P181, DOI 10.1042/bj2880181; MORGAN BP, 1989, BIOCHEM J, V264, P1; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; NICULESCU F, 1992, AM J PATHOL, V140, P1039; NICULESCU F, 1993, J IMMUNOL, V150, P214; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; RAMM LE, 1983, BIOL RESPONSE MEDIAT, P117; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; RUS HG, 1987, IMMUNOL LETT, V16, P15, DOI 10.1016/0165-2478(87)90054-X; SANDERS ME, 1986, J RHEUMATOL, V13, P1028; SCHEPERS TM, 1993, BIOCHEM J, V289, P469, DOI 10.1042/bj2890469; SCHONERMARK S, 1986, J IMMUNOL, V136, P1772; SEEGER W, 1986, J IMMUNOL, V137, P1286; SHIN ML, 1988, PROG ALLERGY, V40, P44; SICILIANO SJ, 1990, J BIOL CHEM, V265, P16873; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; TSCHOPP J, 1988, CYTOLYTIC LYMPHOCYTE, V1, P185; VANGURI P, 1988, J BIOL CHEM, V263, P7228; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WIEDMER T, 1987, J BIOL CHEM, V262, P13674; WU DQ, 1992, J BIOL CHEM, V267, P1811; YANAGA F, 1992, J BIOL CHEM, V267, P5114; YANG LJ, 1993, J BIOL CHEM, V268, P3739; YATANI A, 1991, J BIOL CHEM, V266, P22872	49	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4417	4423						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308012				2022-12-25	WOS:A1994MW98900081
J	BISSIG, M; HAGENBUCH, B; STIEGER, B; KOLLER, T; MEIER, PJ				BISSIG, M; HAGENBUCH, B; STIEGER, B; KOLLER, T; MEIER, PJ			FUNCTIONAL EXPRESSION CLONING OF THE CANALICULAR SULFATE TRANSPORT-SYSTEM OF RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; EXCHANGE	We have cloned a single cDNA encoding the canalicular sulfate transporter of rat liver using Xenopus laevis oocytes as a functional expression system. The cloned cDNA sulfate anion transporter-1 (sat-1) expresses saturable Na+-independent sulfate uptake (K(m) approximately 0.14 mM) that can be inhibited by, 4,4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS, IC50 = 28 muM) and oxalate, but not by succinate or cholate. These properties are very similar to sulfate uptake expressed in oocytes injected with total rat liver mRNA and to the bicarbonate/sulfate exchange system previously characterized in canalicular rat liver plasma membrane vesicles. The cloned sat-1 cDNA has a total length of 3726 base pairs (bp) with an open reading frame encompassing 2109 bp, a 5'-untranslated region of 367 bp, and a 3'-untranslated region of 1250 bp. The coding region predicts a protein of 703 amino acids with a calculated molecular mass of 75.4 kDa. Computer-based hydrophobicity analysis suggests the presence of 12 putative transmembrane spanning domains. Furthermore, three potential glycosylation sites are detected (Asn-158, Asn-163, Asn-587). Northern blot analysis indicates that similar sulfate anion transporters are also present in the kidney, muscle, and brain of rat and in the liver of the mouse. Using antisense oligonucleotides the mRNA-species of the sat-1 analogue in rat kidney has been characterized by hybrid depletion experiments (Markovich, D., Bissig, M., Sorribas, V., Hagenbuch, B., Meier, P. J., and Murer, H. (1994) J. Biol. Chem. 269, 3022-3026).	UNIV HOSP ZURICH,DEPT MED,DIV CLIN PHARMACOL & TOXICOL,CH-8091 ZURICH,SWITZERLAND; SWISS FED INST TECHNOL,INST CELL BIOL,CH-8092 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich			Stieger, Bruno/U-6323-2017; Hagenbuch, Bruno/M-5294-2016	Stieger, Bruno/0000-0002-7190-5785; Hagenbuch, Bruno/0000-0002-2938-8630				COLMAN A, 1986, TRANSCRIPTION TRANSL, P271; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HUGENTOBLER G, 1986, AM J PHYSIOL, V251, pG656, DOI 10.1152/ajpgi.1986.251.5.G656; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MARKOVICH D, 1994, J BIOL CHEM, V269, P3022; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; Meier Peter J., 1993, P587; MEIER PJ, 1987, AM J PHYSIOL, V253, pG461, DOI 10.1152/ajpgi.1987.253.4.G461; PALACIN M, 1990, J BIOL CHEM, V265, P7142; Sambrook J, 1989, MOL CLONING LABORATO; Stremmel Wolfgang, 1993, P225; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	14	168	174	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3017	3021						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300633				2022-12-25	WOS:A1994MV43200093
J	BOYER, JL; GRABER, SG; WALDO, GL; HARDEN, TK; GARRISON, JC				BOYER, JL; GRABER, SG; WALDO, GL; HARDEN, TK; GARRISON, JC			SELECTIVE ACTIVATION OF PHOSPHOLIPASE-C BY RECOMBINANT G-PROTEIN ALPHA-SUBUNIT AND BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; PERTUSSIS TOXIN; RECEPTOR; PURIFICATION; CELLS; STIMULATION; MEMBRANES; CALCIUM; ISOZYME	Receptor activation of phospholipase C (PLC) via G-proteins occurs by pertussis toxin-sensitive and toxin-insensitive signaling pathways. The alpha-subunits of the G(q) family are presumed to mediate the toxin-insensitive pathway, but the nature of the G-proteins mediating the toxin-sensitive pathway is not established. Recently, PLC-beta has been shown to be activated by G-protein beta subunits of mixed or undefined composition. The relative activities of G-protein subunits that might activate PLC-beta were examined using defined recombinant alpha- and betagamma-subunits obtained from the baculovirus expression system by reconstituting the purified subunits with purified bovine brain PLC-beta1 or turkey erythrocyte PLC-beta in unilamellar phospholipid vesicles. Turkey erythrocyte Galpha11 and recombinant Galpha11 and Galpha(q) obtained after expression in Sf9 cells activated both bovine brain PLC-beta1 and turkey erythrocyte PLC-beta. In contrast, under the same assay conditions, recombinant Galpha(i1), Galpha(i2), Galpha(i3), and Galpha(o) were without effect on either type of PLC. All types of betagamma-subunits tested (rbeta1gamma2, rbeta1gamma3, rbeta2gamma2, rbeta2gamma3, bovine brain betagamma or turkey erythrocyte betagamma) inhibited Galpha11-mediated activation of PLC, presumably by promotion of formation of inactive heterotrimeric G-protein. All types of betagamma-subunits also markedly stimulated the activity of turkey erythrocyte PLC-beta but did not activate bovine brain PLC-beta1. Of the four different betagamma complexes of defined composition, three stimulated PLC with similar activities whereas beta2gamma3 was less effective. The data suggest that pertussis toxin-sensitive activation of PLC is mediated by the betagamma-subunits of G-proteins acting on specific phospholipase C isoenzymes.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CB 7365,FAC LAB OFF BLDG,CHAPEL HILL,NC 27599; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Virginia					NIDDK NIH HHS [DK-19952] Funding Source: Medline; NIGMS NIH HHS [GM-38213, GM-29536] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM029536, R01GM038213] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1993, FASEB J, V7, P499; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MARTIN TFJ, 1989, INOSITOL LIPIDS CELL, P81; MAURICE DH, 1993, BIOCHEM J, V290, P765, DOI 10.1042/bj2900765; MEISENHELDER J, 1989, CELL, V57, P1099; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; SHAYMAN JA, 1987, J BIOL CHEM, V262, P17083; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; VERGHESE MW, 1985, BIOCHEM BIOPH RES CO, V127, P450, DOI 10.1016/S0006-291X(85)80181-9; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALDO GL, 1991, MOL PHARMACOL, V40, P480; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WU DQ, 1992, J BIOL CHEM, V267, P1811	43	109	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2814	2819						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300614				2022-12-25	WOS:A1994MV43200068
J	XING, MZ; WILKINS, PL; MCCONNELL, BK; MATTERA, R				XING, MZ; WILKINS, PL; MCCONNELL, BK; MATTERA, R			REGULATION OF PHOSPHOLIPASE-A(2) ACTIVITY IN UNDIFFERENTIATED AND NEUTROPHIL-LIKE HL-60 CELLS - LINKAGE BETWEEN IMPAIRED RESPONSES TO AGONISTS AND ABSENCE OF PROTEIN-KINASE C-DEPENDENT PHOSPHORYLATION OF CYTOSOLIC PHOSPHOLIPASE-A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; PROMYELOCYTIC LEUKEMIA-CELLS; ARACHIDONIC-ACID RELEASE; DIMETHYL-SULFOXIDE; HL-60 CELLS; SIGNAL TRANSDUCTION; DIFFERENTIATION; RECEPTORS; PURIFICATION; CULTURE	We compared the regulation of cytosolic phospholipase A2 (cPLA2) activity in undifferentiated and neutrophil-like HL60 cells. Although Ca2+-mobilizing P2-purinergic receptors are expressed in both cell types, arachidonic acid (AA) release stimulated by P2-purinergic agonists was 5-7-fold higher in the differentiated cells. Similarly, the stimulation of AA release by AlF4- in intact cells or by ATP and guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) in electropermeabilized cells was significantly higher in the differentiated cells. Treatment with phorbol 12-myristate 13-acetate (PMA) enhanced A23187-stimulated AA release in intact HL60 granulocytes with minimal effects in the undifferentiated cells. Immunoblotting experiments showed similar levels of cPLA2 and of agonist-mediated activation of mitogen-activated protein kinase in both cell types. Experiments measuring stimulation of AA release by either melittin, using endogenously labeled intact cells, or Ca2+, using homogenates and exogenous substrate, indicated that undifferentiated cells do not lack an activatable PLA2. The stimulatory effects of GTPgammaS and Ca2+ on AA release in homogenates from endogenously labeled cells suggested that undifferentiated cells display G protein-cPLA2 coupling. Basal and PMA-stimulated phosphorylation of cPLA2 was detected in differentiated, but not in undifferentiated cells. However, the two cell types displayed only subtle differences in the time courses of phosphorylation of mitogen-activated protein kinase triggered by agonists and PMA. The observed defect in cPLA2 phosphorylation may represent the alteration preventing agonist-mediated stimulation of AA release in undifferentiated HL60 cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University					NIGMS NIH HHS [GM 46552-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM046552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BILLAH MM, 1986, J BIOL CHEM, V261, P5824; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONSER RW, 1981, BIOCHEM BIOPH RES CO, V98, P614, DOI 10.1016/0006-291X(81)91158-X; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COCKCROFT S, 1991, BIOCHEM SOC T, V19, P333, DOI 10.1042/bst0190333; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COWEN DS, 1989, J CLIN INVEST, V83, P1651, DOI 10.1172/JCI114064; COWEN DS, 1990, BIOCHIM BIOPHYS ACTA, V1053, P195, DOI 10.1016/0167-4889(90)90014-5; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; FURTH EE, 1989, J BIOL CHEM, V264, P18494; GAO G, 1990, J BIOL CHEM, V265, P2431; GARCIA MD, 1991, BIOCHEM J, V273, P573, DOI 10.1042/bj2730573; GODSON C, 1990, J BIOL CHEM, V265, P8369; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HO AK, 1987, J BIOL CHEM, V262, P11764; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HONG SL, 1976, P NATL ACAD SCI USA, V73, P1730, DOI 10.1073/pnas.73.5.1730; INSEL PA, 1991, BIOCHEM SOC T, V19, P329, DOI 10.1042/bst0190329; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MOLLAY C, 1974, FEBS LETT, V46, P141, DOI 10.1016/0014-5793(74)80354-6; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; STEINER MR, 1993, BIOCHIM BIOPHYS ACTA, V1166, P124, DOI 10.1016/0005-2760(93)90292-H; SUGA K, 1990, J BIOL CHEM, V265, P12363; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P83; WINKLER JD, 1993, BIOCHEM J, V291, P825, DOI 10.1042/bj2910825; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; XING MZ, 1992, J BIOL CHEM, V267, P25966; XING MZ, 1992, J BIOL CHEM, V267, P6602; YORIO T, 1978, NATURE, V271, P79, DOI 10.1038/271079a0	55	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3117	3124						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300648				2022-12-25	WOS:A1994MV43200109
J	HORITA, DA; HAJDUK, PJ; GOETINCK, PF; LERNER, LE				HORITA, DA; HAJDUK, PJ; GOETINCK, PF; LERNER, LE			NMR-STUDIES OF PEPTIDES DERIVED FROM THE PUTATIVE BINDING REGIONS OF CARTILAGE PROTEINS - NO EVIDENCE FOR BINDING TO HYALURONAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINK PROTEIN; PROTEOGLYCANS; DOMAINS; ACID	Previous work has implicated sequences within the tandem repeats of cartilage link protein in the interaction of link protein with hyaluronan. This conclusion was based on competitive inhibition experiments using synthetic peptides (Goetinck, P. F., Stirpe, N. S., Tsonis, P. A., and Carlone, D. (1987) J. Cell Biol. 105, 2403-2407). Further investigation of this system using high resolution nuclear magnetic resonance, circular dichroism, and competitive inhibition with other peptides indicates that the previously observed inhibition of link protein-hyaluronan binding was not caused by peptide-hyaluronan interactions. Instead, nonspecific aggregation of the peptides with link protein is proposed to account for all of the experimental data. Consequently, there is no direct experimental evidence to support the conclusion that these sequences in the tandem repeats of link protein are responsible for the link protein-hyaluronan interaction. If these peptides do represent the hyaluronan binding regions of link protein, these results imply a highly structure-dependent interaction between link protein and hyaluronan. Conformational analysis of the peptides using two-dimensional nuclear Overhauser spectroscopy indicates that the linear peptides do not adopt any stable secondary structure. However, several residues in the disulfide-looped peptides exhibit connectivities, suggesting a relatively long-lived extended chain conformation, consistent with predictions of secondary structure based on sequence analysis.	UNIV WISCONSIN,DEPT CHEM,1101 UNIV AVE,MADISON,WI 53706; MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Massachusetts General Hospital				Horita, David/0000-0002-9563-107X	NCRR NIH HHS [SIO RRO 4981] Funding Source: Medline; NIAMS NIH HHS [R29 AR39801] Funding Source: Medline; NICHD NIH HHS [HD 22016] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022016] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039801] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HASCALL VC, 1977, J SUPRAMOL STR CELL, V7, P101, DOI 10.1002/jss.400070110; LEE KK, 1991, HPLC PEPTIDES PROTEI, P389; LYON M, 1986, BIOCHIM BIOPHYS ACTA, V881, P22, DOI 10.1016/0304-4165(86)90092-9; Maroudas A, 1986, ARTICULAR CARTILAGE, P311; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; PERIN JP, 1987, J BIOL CHEM, V262, P13269; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TANG LH, 1979, J BIOL CHEM, V254, P523; VOLD RL, 1968, J CHEM PHYS, V48, P3831, DOI 10.1063/1.1669699; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117	16	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1699	1704						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294417				2022-12-25	WOS:A1994MR98800027
J	PERLMAN, JH; THAW, CN; LAAKKONEN, L; BOWERS, CY; OSMAN, R; GERSHENGORN, MC				PERLMAN, JH; THAW, CN; LAAKKONEN, L; BOWERS, CY; OSMAN, R; GERSHENGORN, MC			HYDROGEN-BONDING INTERACTION OF THYROTROPIN-RELEASING-HORMONE (TRH) WITH TRANSMEMBRANE TYROSINE-106 OF THE TRH RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCARINIC CHOLINERGIC RECEPTORS; PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; RAT PITUITARY-CELLS; MOLECULAR-BIOLOGY; NEUROKININ-1 RECEPTOR; ADRENERGIC-RECEPTORS; EXTRACELLULAR DOMAIN; ANTAGONIST BINDING; HIGH-AFFINITY	Thyrotropin-releasing hormone (TRH, pyroglutamic acid-histidine-proline-amide) binds to a seven-transmembrane-spanning, G protein-coupled receptor. We tested the hypothesis that Tyr106 of the third transmembrane helix of the TRH receptor (TRH-R) binds pyroglutamyl of TRH by mutating Tyr106 to Phe and replacing the ring carbonyl of the TRH pyroglutamyl moiety with a methylene group ([Pro1]TRH). Compared to the affinity of wild-type TRH-R for TRH, the affinities of [Phe106]TRH-R for TRH and of wild-type TRH-R for [Pro1]TRH were 100,000- and 110,000-fold lower, respectively. The affinity of [Phe106]TRH-R for [Pro1]TRH was only 16-fold lower than that for TRH, demonstrating a lack of additivity of the effects of these changes in the receptor and ligand. These data provide compelling evidence that the hydroxyl group of Tyr106 of the TRH-R binds the TRH pyroglutamyl carbonyl group. To our knowledge, this represents the highest affinity, non-covalent bond yet observed between single functional groups of a GPCR and ligand and is the first delineation of a direct binding interaction between a residue in the transmembrane core of a GPCR and a specific moiety of a peptide agonist.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV MOLEC MED,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021; CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; TULANE UNIV,MED CTR,DEPT MED,ENDOCRINE SECT,NEW ORLEANS,LA 70112	Cornell University; Cornell University; NewYork-Presbyterian Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tulane University					NIDDK NIH HHS [DK 43036, DK 02101] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043036, K11DK002101] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; DELAPENA P, 1992, BIOCHEM J, V284, P891, DOI 10.1042/bj2840891; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; DRUMMOND AH, 1985, BIOCHEM BIOPH RES CO, V127, P63, DOI 10.1016/S0006-291X(85)80126-1; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GERSHENGORN MC, 1986, ENDOCRINOLOGY, V119, P833, DOI 10.1210/endo-119-2-833; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GOREN HJ, 1977, MOL PHARMACOL, V13, P606; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; IMAI A, 1987, METHOD ENZYMOL, V141, P100; IMAI A, 1985, J BIOL CHEM, V260, P536; KAMIYA K, 1980, J CHEM SOC CHEM COMM, V10, P438; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; METCALF G, 1989, THYROTROPIN RELEASIN; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; QUINTANA J, 1993, MOL ENDOCRINOL, V7, P767, DOI 10.1210/me.7.6.767; RAMSDELL JS, 1985, MOL CELL ENDOCRINOL, V43, P173, DOI 10.1016/0303-7207(85)90081-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Strader C D, 1991, Adv Exp Med Biol, V287, P209; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; VENTER JC, 1989, BIOCHEM PHARMACOL, V38, P1197, DOI 10.1016/0006-2952(89)90325-0; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; XIE YB, 1990, J BIOL CHEM, V265, P21411; YAMADA M, 1992, BIOCHEM BIOPH RES CO, V184, P367, DOI 10.1016/0006-291X(92)91202-2; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; ZHAO DY, 1992, ENDOCRINOLOGY, V130, P3529, DOI 10.1210/en.130.6.3529; ZHU GC, 1992, J CELL BIOCHEM, V50, P159	44	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1610	1613						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294406				2022-12-25	WOS:A1994MR98800012
J	FELIX, CA; BROWN, DL; MITSUDOMI, T; IKAGAKI, N; WONG, A; WASSERMAN, R; WOMER, RB; BIEGEL, JA				FELIX, CA; BROWN, DL; MITSUDOMI, T; IKAGAKI, N; WONG, A; WASSERMAN, R; WOMER, RB; BIEGEL, JA			POLYMORPHISM AT CODON-36 OF THE P53 GENE	ONCOGENE			English	Note							CELL LUNG-CANCER; TP53; MUTATIONS; P53-GENE; REGION	A polymorphism at codon 36 in exon 4 of the p53 gene was identified by single strand conformation polymorphism (SSCP) analysis and direct sequencing of genomic DNA PCR products. The polymorphic allele, present in the heterozygous state in genomic DNAs of four of 100 individuals (4%), changes the codon 36 CCG to CCA, eliminates a FinI restriction site and creates a BccI site. Including this polymorphism there are four known polymorphisms in the p53 coding sequence.	CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV GENET,PHILADELPHIA,PA 19104; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT SURG 2,KITAKYUSHU,FUKUOKA 807,JAPAN; THOMAS JEFFERSON UNIV,CANC RES CTR,PHILADELPHIA,PA 19107	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Occupational & Environmental Health - Japan; Jefferson University	FELIX, CA (corresponding author), CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV ONCOL,PHILADELPHIA,PA 19104, USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505	NATIONAL CANCER INSTITUTE [R01CA046274, P01CA047983] Funding Source: NIH RePORTER; NCI NIH HHS [P0-1 CA 47983, CA 46274] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA HG, 1990, ONCOGENE, V5, P1409; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; CARBONE D, 1991, ONCOGENE, V6, P1691; CHIBA I, 1990, ONCOGENE, V5, P1603; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P6969, DOI 10.1093/nar/19.24.6969-a; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELACALLE O, 1990, NUCLEIC ACIDS RES, V18, P206, DOI 10.1093/nar/18.1.206-a; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; FELIX CA, 1993, ONCOGENE, V8, P1203; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; FELIX CA, 1992, CANCER RES, V52, P2243; FELIX CA, 1992, J CLIN INVEST, V89, P649; MAZARS GR, 1992, ONCOGENE, V7, P781; MITSUDOMI T, 1992, ONCOGENE, V7, P171; PERILONGO G, 1993, LEUKEMIA, V7, P912; PROSSER J, 1991, NUCLEIC ACIDS RES, V19, P4799, DOI 10.1093/nar/19.17.4799-a; WILLEMS PMW, 1992, NUCLEIC ACIDS RES, V20, P1172, DOI 10.1093/nar/20.5.1172-a	17	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					327	328						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302598				2022-12-25	WOS:A1994MW24700041
J	LEFRANCOISMARTINEZ, AM; DIAZGUERRA, MJM; VALLET, V; KAHN, A; ANTOINE, B				LEFRANCOISMARTINEZ, AM; DIAZGUERRA, MJM; VALLET, V; KAHN, A; ANTOINE, B			GLUCOSE-DEPENDENT REGULATION OF THE L-PYRUVATE KINASE GENE IN A HEPATOMA-CELL LINE IS INDEPENDENT OF INSULIN AND CYCLIC-AMP	FASEB JOURNAL			English	Note						GLUCOSE SIGNALING PATHWAY; TRANSCRIPTION; HIGH GLUCOSE DIET; HEPATOCYTE-LIKE CELL LINES; GLYCOLYTIC ENZYME	POST-TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; RAT-LIVER; GLUCOKINASE GENE; EXPRESSION; TISSUE; HEPATOCYTES; ELEMENTS; PROMOTER; FRUCTOSE	Hepatocyte-like mhAT3F cells have been derived from the hepatoma of a transgenic mouse expressing the SV40 large T antigen under the control of the antithrombin III gene regulatory region (Antoine, B., Levrat, F., Vallet, V., Berbar, T., Cartier, N., Dubois, N., Briand, P., and Kahn, A. (1992) Gene expression in hepatocyte-like lines established by targeted carcinogenesis in transgenic mice. Exp. Cell. Res. 200, 175-185; F. Levrat et al., unpublished results). In these cells, the L-PK gene is transcriptionally activated by glucose, as it is in vivo and in cultured hepatocytes. However, in contrast to the L-PK gene regulation in the liver and isolated hepatocytes, the glucose responsiveness does not require insulin and is not blocked by cyclic AMP. In mhAT3F cells, the insensitivity to insulin might be due to the replacement of insulin-dependent glucokinase by insulin-independent hexokinases able to phosphorylate glucose in the absence of the hormone. The glucose-dependent activation of the L-PK gene is delayed, requires ongoing protein synthesis, and is mediated by the same glucose response element as in vivo and in isolated hepatocytes. These results suggest that the glucose-dependent signaling pathway responsible for the transcriptional activation of glycolytic and lipogenic genes requires glucose phosphorylation, a phenomenon that is insulin-dependent in the liver but insulin-independent in cultured hepatoma cells. Nevertheless, the action of glucose 6-phosphate is most likely indirect.			LEFRANCOISMARTINEZ, AM (corresponding author), INSERM,U129,INST COCHIN GENET MOLEC,RECH GENET & PATHOL MOLEC LAB,F-75014 PARIS,FRANCE.		Díaz-Guerra, María José M/M-2855-2014	Díaz-Guerra, María José M/0000-0003-3843-3912				ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGNET M, 1991, J BIOL CHEM, V266, P7368; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; HAYZER DJ, 1990, BIOCHEM J, V270, P261, DOI 10.1042/bj2700261; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JENKINS AB, 1986, INT J BIOCHEM, V18, P311, DOI 10.1016/0020-711X(86)90036-4; LEVRAT F, 1993, IN PRESS EXP CELL RE; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MAGNUSON MA, 1992, J CELL BIOCHEM, V48, P115, DOI 10.1002/jcb.240480202; MARIE S, 1993, IN PRESS J BIOL CHEM; MATSUDA T, 1990, J BIOCHEM-TOKYO, V108, P778, DOI 10.1093/oxfordjournals.jbchem.a123280; MEIENHOFER MC, 1987, EUR J BIOCHEM, V169, P237, DOI 10.1111/j.1432-1033.1987.tb13603.x; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NOUSPIKEL T, 1992, EUR J BIOCHEM, V210, P365, DOI 10.1111/j.1432-1033.1992.tb17430.x; Schapira F, 1973, Adv Cancer Res, V18, P77, DOI 10.1016/S0065-230X(08)60751-4; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TREMP GL, 1989, J BIOL CHEM, V264, P19904; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P178; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; Weinhouse S, 1976, CURRENT TOPICS CELLU, P1; YAMADA K, 1990, J BIOL CHEM, V265, P19885	28	70	71	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					89	96		10.1096/fasebj.8.1.8299894	http://dx.doi.org/10.1096/fasebj.8.1.8299894			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299894				2022-12-25	WOS:A1994MV28200013
J	SHAUGHNESSY, J; WIENER, F; HUPPI, K; MUSHINSKI, JF; POTTER, M				SHAUGHNESSY, J; WIENER, F; HUPPI, K; MUSHINSKI, JF; POTTER, M			A NOVEL C-MYC-ACTIVATING RECIPROCAL T(1215) CHROMOSOMAL TRANSLOCATION JUXTAPOSES S-ALPHA TO PVT-1 IN A MOUSE PLASMACYTOMA	ONCOGENE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; DNA FRAGMENTS; NEOPLASTIC DEVELOPMENT; ATAXIA-TELANGIECTASIA; MURINE PLASMACYTOMAS; AGAROSE GELS; CELL-LINES; LOCUS; SEQUENCES; ONCOGENE	Oil-induced murine plasmacytomas typically carry c-myc-activating non-random reciprocal chromosomal translocations that take the form of either a T(12;15) that fuses the c-myc proto-oncogene to an immunoglobulin heavy chain switch region or a T(6;15) that juxtaposes the Pvt-l locus, located 220 kb 3' of c-myc, to the immunoglobulin light china locus, C-kappa. In this report we show that the plasmacytoma ABPC 60 harbors a novel c-myc-activating T(12;15) in which the chromosome 15 breakpoint occurs in the Pvt-1 region, resulting in the head-to-tail juxtaposition of the Pvt-1 major breakpoint cluster to the IgA switch region. Restriction mapping and nucleotide sequencing of this atypical translocation indicate that a paracentric inversion in chromosome 12 must have preceeded the translocation. This is the first example of a T(12;15) with a break 3' of the c-myc gene. The rearrangement places the 3' C alpha enhancer (3'alpha E) greater than 200 kb downstream of the c-myc promoters, however c-myc mRNA levels are similar to those observed in plasmacytomas with typical T(12;15)s that translocate 3'alpha E much closer (15-25 kb) and upstream of c-myc. The up regulation of c-myc that results from this rearrangement is thought to be brought about by the interaction of the c-myc promoters with the IgA enhancer element that has been strategically relocated into the Pvt-1 region.	NCI,GENET LAB,BETHESDA,MD 20892; KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM,SWEDEN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet								AXELSON H, 1991, ONCOGENE, V6, P2263; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CALVO CF, 1991, J IMMUNOL, V146, P1353; CITRI Y, 1987, J EXP MED, V165, P1188, DOI 10.1084/jem.165.4.1188; CLURMAN BE, 1988, CELLULAR ONCOGENE AC, P55; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; DENNY CT, 1986, NATURE, V320, P549, DOI 10.1038/320549a0; EARLY PW, 1979, P NATL ACAD SCI USA, V76, P857, DOI 10.1073/pnas.76.2.857; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HUPPI K, 1993, INT J CANCER, V53, P493, DOI 10.1002/ijc.2910530323; HUPPI K, 1990, P NATL ACAD SCI USA, V87, P6964, DOI 10.1073/pnas.87.18.6964; HUPPI K, 1992, IMMUNOGENETICS, V37, P288; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MOUNTZ JD, 1984, SCIENCE, V226, P1087, DOI 10.1126/science.6494925; MUSHINSKI JF, 1988, CELLULAR ONCOGENE AC, P181; NESBITT MN, 1973, CHROMOSOMA, V41, P145, DOI 10.1007/BF00319691; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MA, 1987, MOL CELL BIOL, V7, P4130, DOI 10.1128/MCB.7.11.4130; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STERN MH, 1989, BLOOD, V74, P2076; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANNESS BG, 1983, NATURE, V301, P425, DOI 10.1038/301425a0; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; WILLIAMS BG, 1980, GENETIC ENG, P201; 1972, J HERED, V63, P69	49	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					247	253						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302586				2022-12-25	WOS:A1994MW24700030
J	TSUCHIYA, H; FUJII, M; TANAKA, Y; TOZAWA, H; SEIKI, M				TSUCHIYA, H; FUJII, M; TANAKA, Y; TOZAWA, H; SEIKI, M			2 DISTINCT REGIONS FORM A FUNCTIONAL ACTIVATION DOMAIN OF THE HTLV-1 TRANSACTIVATOR TAX1	ONCOGENE			English	Note							VIRUS TYPE-I; TRANSCRIPTIONAL ACTIVATION; ADENOVIRUS-E1A PROTEIN; BINDING; EXPRESSION; GENES; PROMOTERS; MECHANISM; SEQUENCES; ENHANCER	Taxi of human T-cell leukemia virus type 1 (HTLV-1) is an enigmatic viral transactivator that regulates expression of the viral gene and also several cellular genes normally controlled by various mitogenic signals. However, previous studies have failed to define the functional domains of Taxi for enhancer specificities and for transcriptional activation (95% of the protein portion was indispensable for the activation function). This complexity has hampered understanding of the molecular basis of Taxi action. In this study, we analysed the activation function of a Taxi fused to the heterologous DNA-binding domain of the yeast transcription factor GAL4 and dissected the domain required for the activation function by using derivatives of a Taxi mutant with an insertion between amino acids (a.a.) 170 and 171. Analysis of the derivatives of the mutant fusion protein having various partial overlaps encompassing the interrupted site suggested that two contiguous stretches, AD-I (2-255 a.a.) and AD-II (227-337 a.a.), should be both intact for the activation function of Taxi and that they form a functional activation domain.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC VIROL & ONCOL,KANAZAWA,ISHIKAWA 920,JAPAN; KITASATO UNIV,SCH HYG SCI,DEPT IMMUNOL,SAGAMIHARA,KANAGAWA 228,JAPAN	Kanazawa University; Kitasato University			Seiki, Motoharu/K-9443-2015					ALEXANDRE C, 1991, ONCOGENE, V6, P1851; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P2349; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HIRAI H, 1992, ONCOGENE, V7, P1737; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; KELLY K, 1992, ONCOGENE, V7, P1463; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	34	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					337	340						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302601				2022-12-25	WOS:A1994MW24700043
J	HAMELIN, R; JEGO, N; LAURENTPUIG, P; VIDAUD, M; THOMAS, G				HAMELIN, R; JEGO, N; LAURENTPUIG, P; VIDAUD, M; THOMAS, G			EFFICIENT SCREENING OF P53 MUTATIONS BY DENATURING GRADIENT GEL-ELECTROPHORESIS IN COLORECTAL TUMORS	ONCOGENE			English	Article							SINGLE BASE SUBSTITUTIONS; POLYMERASE CHAIN-REACTION; CANCER CELL-LINES; SUPPRESSOR GENE; BREAST-CANCER; DNA FRAGMENTS; LUNG-CANCER; GC-CLAMP; POINT MUTATIONS; KI-RAS	Alterations in exons 5-8 of the p53 gene have been found in the vast majority of human tumors. Although some specific codons have been revealed as preferential mutational sites in defined tumor types, mutations are generally so scattered within this region that various screening methods for their detection have been widely used. However, the capacity of these techniques to detect exhaustively all mutations has not been evaluated. In this report, conditions for analysing exons 5-8 of the p53 gene by denaturing gradient gel electrophoresis (DGGE) have been elaborated using the Melt87 and SQHTX computer programs. The procedure requires five different amplifications. The screening of 90 colorectal tumors revealed 56 amplification products demonstrating abnormal DGGE behavior. Direct sequencing of these amplification products after asymmetric polymerase chain reaction (PCR) showed, besides polymorphism, 49 somatically mutated DNA samples (54.4%) corresponding to 38 different p53 variants. Moreover, 25 additional p53 variants identified in other tumor types were also detectable with our conditions. Thus, altogether the procedure has been successfully used in the detection of 63 different p53 variants. The experimental differences in migration between the wild-type homoduplex DNA molecule and the heteroduplex(es) containing one mismatch were systematically compared with those calculated by the SQHTX program. The computer program was found to be reliably predictive. This DGGE procedure appears thus to be effective and reliable for detecting mutations in exons 5-8 of the p53 gene.	INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75231 PARIS 05,FRANCE; FAC SCI PHARMACEUT & BIOL PARIS,BIOL MOLEC LAB,F-75006 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite			laurent-puig, pierre/B-2226-2013; Vidaud, Michel/O-7346-2017; Laurent-Puig, Pierre/K-3641-2019	laurent-puig, pierre/0000-0001-8475-5459; Laurent-Puig, Pierre/0000-0001-8475-5459				ABRAMS ES, 1990, GENOMICS, V7, P463, DOI 10.1016/0888-7543(90)90188-Z; BAKER SJ, 1990, CANCER RES, V50, P7717; BARTEK J, 1990, ONCOGENE, V5, P893; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CARBONE D, 1991, ONCOGENE, V6, P1691; CHIBA I, 1990, ONCOGENE, V5, P1603; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DAMICO D, 1992, ONCOGENE, V7, P339; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISHIOKA C, 1991, BIOCHEM BIOPH RES CO, V177, P901, DOI 10.1016/0006-291X(91)90623-F; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JEGO N, 1993, ONCOGENE, V8, P209; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KRAWCZAK M, 1991, HUM GENET, V86, P425; LAW JC, 1991, CANCER RES, V51, P6385; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAZARS GR, 1992, ONCOGENE, V7, P781; MAZARS GR, 1992, ONCOGENE, V7, P1015; MAZARS R, 1992, CANCER RES, V52, P3918; MAZARS R, 1991, ONCOGENE, V6, P1685; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PORTIER M, 1992, ONCOGENE, V7, P2539; PROSSER J, 1990, ONCOGENE, V5, P1573; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J., 1989, MOL CLONING LABORATO, P31; SHAW P, 1991, ONCOGENE, V6, P2121; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; TOMNAGA O, 1993, IN PRESS ONCOGENE; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575	47	95	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2213	2220						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336944				2022-12-25	WOS:A1993LP17100022
J	RAO, VN; OHNO, T; PRASAD, DDK; BHATTACHARYA, G; REDDY, ESP				RAO, VN; OHNO, T; PRASAD, DDK; BHATTACHARYA, G; REDDY, ESP			ANALYSIS OF THE DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION FUNCTIONS OF HUMAN FLI-1 PROTEIN	ONCOGENE			English	Article							ETS-RELATED PROTEIN; PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; C-FOS; C-ETS-1 PROTOONCOGENE; DOMAIN PROTEIN; GENE FAMILY; ERG GENE; V-ETS	Three of the ets oncogene superfamily members v-ets, Spi-1/PU.1 and Fli-1, have been shown to he directly involved in retroviral-mediated acute erythroleukemias. The Fli-1 gene was found to be rearranged in 75% of the erythroleukemias induced by Friend murine leukemia virus (F-MuLV), suggesting that it could play a key role in cellular transformation. We have previously isolated and characterized the human Fli-1 gene and have found it to be highly homologous (80%) to the human erg-2 gene. Human Fli-1 was also shown to be rearranged in Ewing's sarcoma cases, in which the amino-terminal region of the Fli-1 gene was replaced with a novel coding region of a putative RNA-binding protein, EWS. In this report, we show that the recombinant Fli-1 protein expressed in bacteria binds to DNA in a sequence-specific manner. It appears that Fli-1 and erg proteins fall into the category of ets proteins that recognize limited ets target sequences, unlike c-ets-1, ets-2 and Elk-1. The Fli-1 gene was found to activate the transcription of the reporter gene that was linked to Fli-1 target sequences, suggesting that Fli-1 is a sequence-specific transcriptional activator. Deletion analysis revealed the presence of two autonomous transcriptional activation domains, one at the amino-terminal region (amino-terminal transcriptional activation domain, ATA) and the other at the carboxy-terminal region (carboxy-terminal transcriptional activation domain, CTA). Secondary structural analysis of ATA and CTA domains revealed the presence of helix-loop-helix (H-L-H) and/or turn-loop-turn (T-L-T) regions. From these results it appears that a portion of the Fli-1 ATA domain (H-L-H region) was replaced by the amino-terminal domain of EWS gene in Ewing's sarcoma cases. Therefore alteration in the transcriptional activation function of Fli-1 may be responsible for human malignancies such as sarcomas, leukemias and lymphomas in which this gene is rearranged.	JEFFERSON CANC INST,BLUMLE LIFE SCI BLDG,233 S 10 ST,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA 51083, CA 57157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057157, P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PRASAD DDK, 1992, CANCER RES, V52, P5833; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1992, ONCOGENE, V11, P2335; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1992, GUIDE BOOK ONCOGENES; REDDY ESP, 1990, CANCER RES, V50, P5013; ROBERTSON M, 1988, NATURE, V336, P522, DOI 10.1038/336522a0; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SELLERI L, 1991, P NATL ACAD SCI USA, V88, P887, DOI 10.1073/pnas.88.3.887; SIDDIQUE H, 1993, ONCOGENE, V8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TREIZENBERG SJ, 1988, GENE DEV, V2, P718; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; [No title captured]	59	107	107	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2167	2173						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336942				2022-12-25	WOS:A1993LP17100017
J	MURPHY, G; SEGAIN, JP; OSHEA, M; COCKETT, M; IOANNOU, C; LEFEBVRE, O; CHAMBON, P; BASSET, P				MURPHY, G; SEGAIN, JP; OSHEA, M; COCKETT, M; IOANNOU, C; LEFEBVRE, O; CHAMBON, P; BASSET, P			THE 28-KDA N-TERMINAL DOMAIN OF MOUSE STROMELYSIN-3 HAS THE GENERAL-PROPERTIES OF A WEAK METALLOPROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; TISSUE INHIBITOR; ACTIVATION; PURIFICATION; COLLAGENASE; MECHANISMS; IV; PROCOLLAGENASE; RECOMBINANT; EXPRESSION	The putative matrix metalloproteinase mouse stromelysin-3 was expressed from Escherichia coli and from a mouse myeloma cell line. In the former case a single major protein of 58-kDa was detectable by immunoblotting, but no proteolytic activity could be elicited by zymography or trypsin or organomercurial treatment as would be expected for a typical matrix metalloproteinase. In the latter case immunodetectable proteins of 55-58 and 27-28-kDa were produced. The effect of trypsin or organomercurial treatment of the 55-58-kDa forms was to generate a 51-kDa form and lower molecular mass fragments. Upon zymographic analysis only the 27-28-kDa forms showed caseinolytic activity. N-terminal sequencing and immunoblotting analysis with antibodies specific to distinct domains of stromelysin-3 indicated that the 27-28-Da stromelysin-3 forms had lost the predicted propeptide and the majority of the C-terminal domain. The purified 28-kDa form of stromelysin-3 could weakly degrade a number of extracellular matrix proteins and was inhibited by TIMP. However, the evidence that mature full-length stromelysin-3 is a metalloproteinase could not be substantiated and the precise role of this protein in vivo remains to be elucidated. By partial analogy with interstitial collagenase, one hypothesis is that stromelysin-3 with an intact C-terminal domain has specific properties for an as yet undefined substrate.	CELLTECH LTD, SLOUGH SL1 4EN, ENGLAND; FAC MED STRASBOURG, INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS, UA 184,INSERM, F-67085 STRASBOURG, FRANCE	Celltech Group Ltd; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	MURPHY, G (corresponding author), STRANGEWAYS RES LAB, WORTS CAUSEWAY, CAMBRIDGE CB1 4RN, ENGLAND.		Lefebvre, Olivier/I-2388-2016; Lefebvre, Olivier/S-6436-2019	Lefebvre, Olivier/0000-0001-9130-9174; Lefebvre, Olivier/0000-0001-9130-9174	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASSET P, 1993, BREAST CANCER RES TR, V24, P185, DOI 10.1007/BF01833259; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEVY A, 1992, GENOMICS, V13, P881, DOI 10.1016/0888-7543(92)90175-R; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MULLER D, 1993, CANCER RES, V53, P165; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846	38	119	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15435	15441						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340372				2022-12-25	WOS:A1993LN30500021
J	ZHU, LQ; MCKAY, RR; SHORTRIDGE, RD				ZHU, LQ; MCKAY, RR; SHORTRIDGE, RD			TISSUE-SPECIFIC EXPRESSION OF PHOSPHOLIPASE-C ENCODED BY THE NORPA GENE OF DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL TRANSDUCTION; NERVOUS-SYSTEM; RECEPTOR; PURIFICATION; PROTEINS; SEQUENCE; ISOZYMES; CALCIUM; CLONING	Mutations in the norpA gene of Drosophila melanogaster severely affect the light-evoked photoreceptor potential with strong mutations rendering the fly blind. Molecular cloning of the norpA gene revealed that it encodes phosphatidylinositol-specific phospholipase C, which enzymes play a pivotal role in one of the largest classes of signaling pathways known. We have used Northern analysis, Western blots, phospholipase C activity assays, and immunohistochemical staining of tissues to examine the tissue-specific expression of the norpA gene and found that it is expressed in a variety of tissues besides the eye. Hybridization of norpA cRNA probe to blots of poly(A+) RNA reveals that the gene encodes at least four transcripts: a 7.5-kilobase (kb) transcript that is expressed in eye and 6.5-, 5.5-, and 5.0-kb transcripts that are expressed in adult body or early stages of development. Antiserum generated against the major gene product of norpA recognizes a 130-kDa protein that is abundant in eyes but severely reduced or absent in norpA mutants, a result which is consistent with previous conclusions that the norpA gene encodes an essential component of the visual system. However, the norpA antiserum also recognizes a 130-kDa protein in adult legs, thorax, and male abdomen, but not female abdomen. These localizations are supported by results of phospholipase C activity assays which show that the norpA mutation reduces phospholipase C activity in each of the tissues in which norpA protein can be detected. Furthermore, immunohistochemical staining of tissue sections with the norpA antiserum demonstrates that the norpA protein is abundant in the retina and ocelli and is present to a lesser extent in the brain and thoracic nervous system. Since some of the above mentioned tissues that express norpA (such as thorax, legs, and abdomen) have no known photoreceptor tissue, we conclude that the norpA gene product is also likely to have a role in signaling pathways other than phototransduction.	SUNY Buffalo, DEPT BIOL SCI, COOKE HALL, RM 109, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; COLLINGRIDGE G, 1987, NATURE, V330, P604, DOI 10.1038/330604a0; DUERR JS, 1982, P NATL ACAD SCI-BIOL, V79, P3646, DOI 10.1073/pnas.79.11.3646; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; HU KG, 1978, J COMP PHYSIOL, V126, P15, DOI 10.1007/BF01342646; INOUE H, 1988, J BIOCHEM-TOKYO, V103, P91, DOI 10.1093/oxfordjournals.jbchem.a122246; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARKOW TA, 1980, BEHAV NEURAL BIOL, V29, P276, DOI 10.1016/S0163-1047(80)90612-3; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MICHELL RH, 1989, BIOCHEM SOC T, V17, P1; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PANDIELLA A, 1989, TRENDS PHARMACOL SCI, V10, P411; PUTNEY JW, 1988, J EXP BIOL, V139, P135; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SCHNEUWLY S, 1991, J BIOL CHEM, V266, P24314; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SLACK BE, 1986, AM J PHYSIOL, V250, pC340, DOI 10.1152/ajpcell.1986.250.2.C340; STULL JT, 1988, AM J MED SCI, V296, P241, DOI 10.1016/S0002-9629(15)40865-1; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUZUKI E, 1992, NEUROSCI RES, V13, P155, DOI 10.1016/0168-0102(92)90096-U; Sved J, 1986, DROSOPH INF SERV, V63, P169; TOMPKINS L, 1982, BEHAV GENET, V12, P295, DOI 10.1007/BF01067849; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; VOLPE P, 1986, FEBS LETT, V197, P1, DOI 10.1016/0014-5793(86)80285-X; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171	37	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15994	16001						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340420				2022-12-25	WOS:A1993LN30500094
J	GARRICK, MD; GNIECKO, K; LIU, YH; COHAN, DS; GARRICK, LM				GARRICK, MD; GNIECKO, K; LIU, YH; COHAN, DS; GARRICK, LM			TRANSFERRIN AND THE TRANSFERRIN CYCLE IN BELGRADE RAT RETICULOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON UPTAKE; RABBIT RETICULOCYTES; RECEPTOR; BINDING; RELEASE; ANEMIA; CELLS	Belgrade rats have an autosomal recessive anemia with hypochromia and microcytosis. Iron uptake into reticulocytes is approximately 20% of normal, but transferrin uptake is unimpaired. We have systematically compared the transferrin cycle in Belgrade versus normal reticulocytes to locate the defect more precisely. Belgrade transferrin was functionally normal as purified transferrin or whole plasma. Transferrin affinity of Belgrade receptors was indistinguishable from normal, but Belgrade reticulocytes had twice as many receptors. Belgrade transferrin endocytosis was 1.5 times faster than normal, whereas exocytosis is about twice as fast. Initially Belgrade reticulocytes internalize iron at an unimpaired rate, but they lag behind normal by 5 min. During reincubation, they release 25-33% of iron taken up during a 30-min preincubation, whereas normal cells do not lose a detectable fraction. Unexpectedly, transferrin cycle time was unchanged. Hence another kinetic step of the cycle is slower, compensating for increases in Belgrade endocytosis and exocytosis. After one cycle, Belgrade reticulocytes retain only half of the iron that entered, but over 90% of iron entering normal cells remains within. Iron unloading is ineffective inside the Belgrade vesicle; 85% of iron that entered on transferrin returned to the medium after exocytosis, whereas only 45% of iron entering normal reticulocytes exits. Ineffective utilization of iron in or near Belgrade endosomes accounts for the Belgrade defect.	SUNY Buffalo, DEPT PEDIAT, BUFFALO, NY 14214 USA; SUNY Buffalo, DEPT MED, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	GARRICK, MD (corresponding author), SUNY Buffalo, DEPT BIOCHEM, 140 FARBER HALL, 3435 MAIN ST, BUFFALO, NY 14214 USA.			Garrick, Michael/0000-0001-7342-6983				BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BOWEN BJ, 1987, BLOOD, V70, P38; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; EDWARDS J, 1986, BLOOD, V67, P623; EDWARDS JA, 1978, BLOOD, V51, P347; FARCICH EA, 1992, AM J HEMATOL, V39, P9, DOI 10.1002/ajh.2830390104; GARRICK L, 1988, BLOOD, V72, pA41; GARRICK L M, 1990, Experimental Hematology (Charlottesville), V18, P573; GARRICK LM, 1975, BIOCHEM J, V149, P245, DOI 10.1042/bj1490245; GARRICK LM, 1991, J CELL PHYSIOL, V146, P460, DOI 10.1002/jcp.1041460317; GARRICK LM, 1993, IN PRESS BLOOD; GARRICK M, 1990, Experimental Hematology (Charlottesville), V18, P573; GARRICK M, 1988, BLOOD, V72, pA42; GARRICK M D, 1990, Journal of Cell Biology, V111, p82A; GARRICK MD, 1990, BLOOD, V76, pA8; GARRICK MD, 1990, BLOOD, V111, pA8; GARRICK MD, 1990, BLOOD, V111, pA82; HRADILEK A, 1987, J CELL PHYSIOL, V133, P192, DOI 10.1002/jcp.1041330126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NUNEZ MT, 1983, J BIOL CHEM, V258, P9676; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OKADA S, 1979, J LAB CLIN MED, V93, P189; PAVLOVICKENTERA V, 1989, EXP HEMATOL, V17, P812; RAPOPORT SM, 1986, RETICULOCYTE, P145; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELIGMAN PA, 1983, PROG HEMATOL, V13, P131; SIPE DM, 1991, J BIOL CHEM, V266, P8002; SLADICSIMIC D, 1969, ANN NY ACAD SCI, V165, P93, DOI 10.1111/j.1749-6632.1969.tb27779.x; SLADICSIMIC D, 1966, GENETICS, V53, P1079; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505	33	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14867	14874						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325865				2022-12-25	WOS:A1993LL75900052
J	KIM, SK; NORDEN, B; TAKAHASHI, M				KIM, SK; NORDEN, B; TAKAHASHI, M			ROLE OF DNA INTERCALATORS IN THE BINDING OF RECA TO DOUBLE-STRANDED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR DICHROISM SPECTROSCOPY; FLOW-ORIENTED SOLUTION; ESCHERICHIA-COLI; PROTEIN-BINDING; DUPLEX DNA; ELECTRON-MICROSCOPY; NEUTRON-SCATTERING; COMPLEXES; STOICHIOMETRY; RECOMBINATION	RecA protein can bind to double-stranded DNA even without the cofactor ATP if a DNA intercalator such as ethidium bromide is present (Thresher R. J., and Griffith, J. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5056-5060). We have studied the structure and association kinetics of the ethidium-promoted DNA-RecA complex in order to understand the role of this intercalator in the DNA-RecA association process, information that could provide insight about the binding mechanism of RecA to DNA. Both linear dichroism and fluorescence measurements show that ethidium remains intercalated between the DNA bases in the RecA-DNA complex in the absence of ATP. Even in the presence of the ATP analog, adenosine 5'-O-(3-thiotriphosphate) (ATPgammaS), ethidium bromide shows some stimulating effect on the binding of RecA to DNA. The results indicate that the destacking of DNA bases is an important limiting step in the association of RecA to DNA (DNA is stretched in the ATPgammaS-RecA-DNA complex). In the presence of ATPgammaS, however, ethidium was extruded from DNA upon the binding of RecA. This result suggests that the binding mechanism of RecA to DNA may involve intercalation of one or more amino acid residues of RecA between the DNA bases. Such an intercalation would also be consistent with the stretching of DNA and the observation that the DNA bases remain in a (virtually stacked) perpendicular geometry (Takahashi, M., Kubista, M., and Norden, B. (1991) Biochemie (Paris) 73, 219-226; Norden, B., Elvingson, C., Kubista, M., Sjoberg, B., Ryberg, H., Ryberg, M., Mortensen, K., and Takahashi, M. (1992b) J. Mol. Biol. 226, 1175-1191).	UNIV PARIS 11,INST CURIE,CNRS,URA 1342,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	KIM, SK (corresponding author), CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN.		Norden, Bengt/ABE-3675-2020	Norden, Bengt/0000-0002-7946-200X				CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; CHRYSOGELOS S, 1983, J BIOL CHEM, V258, P2624; DICAPUA E, 1989, BIOCHEMISTRY-US, V28, P3287, DOI 10.1021/bi00434a025; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DOMBROSKI DF, 1983, NUCLEIC ACIDS RES, V11, P7487, DOI 10.1093/nar/11.21.7487; ERIKSSON S, 1993, J BIOL CHEM, V268, P1805; ERIKSSON S, 1993, J BIOL CHEM, V268, P1811; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HAGMAR P, 1992, J MOL BIOL, V226, P1193, DOI 10.1016/0022-2836(92)91061-S; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; NORDEN B, 1990, J MOL BIOL, V216, P223, DOI 10.1016/S0022-2836(05)80311-0; NORDEN B, 1985, APPL SPECTROSC, V39, P647, DOI 10.1366/0003702854250356; NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; TAKAHASHI M, 1989, J BIOL CHEM, V264, P8568; TAKAHASHI M, 1991, FEBS LETT, V279, P270, DOI 10.1016/0014-5793(91)80165-Y; TAKAHASHI M, 1987, J BIOL CHEM, V262, P8109; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; WADA A, 1964, J POLYM SCI PART A, V2, P853, DOI 10.1002/pol.1964.100020222; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9	33	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14799	14804						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325858				2022-12-25	WOS:A1993LL75900043
J	SHAKARJIAN, MP; EISEMAN, E; PENHALLOW, RC; BOLEN, JB				SHAKARJIAN, MP; EISEMAN, E; PENHALLOW, RC; BOLEN, JB			3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE INHIBITION IN A RAT MAST-CELL LINE - IMPAIRMENT OF TYROSINE KINASE-DEPENDENT SIGNAL-TRANSDUCTION AND THE SUBSEQUENT DEGRANULATION RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; HIGH-AFFINITY; RECEPTOR; IGE; PHOSPHORYLATION; PROTEINS; RBL-2H3	IgE molecules bind mast cells via a heterotetrameric receptor termed Fc(epsilon)RI. Cross-linking of bound IgE by specific allergen (Ag) initiates a signal transduction cascade resulting in a degranulation response. Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in isoprenoid and sterol biosynthesis, by the cholesterol-lowering drug, lovastatin, blocks Fc(epsilon)RI-dependent [H-3] serotonin ([H-3]5HT) release from the mast cell line, RBL-2H3. We studied the mode and locus of action of lovastatin in these cells. Lovastatin inhibited Ag-stimulated degranulation, as well as that evoked by ionomycin or by phorbol 12-myristate 13-acetate and ionomycin, stimuli which bypass early receptor events. Inhibition was concentration-dependent, occurred at levels which reduce lipid synthesis, and was reversible by addition of mevalonic acid, the product of the reductase reaction. The effects of lovastatin were not mimicked by treatment with the sterol demethylase inhibitor, econazole, suggesting that nonsterol isoprenoid synthesis is required for the degranulation response. Conversely, tyrosine kinase inhibitors from three disparate chemical classes reduced stimulus-evoked [H-3]5HT release in a manner similar to lovastatin, suggesting that these agents share similar loci of action. Accordingly, lovastatin altered the phosphorylation pattern in unstimulated RBL-2H3, and reduced the phosphorylation response to IgE cross-linking. By analogy to 5HT release, this effect was concentration-dependent and mevalonic acid-reversible. The tyrosine kinase inhibitor, geldanamycin, also reduced the phosphorylation response to Ag. Lyn, a Src-related tyrosine kinase activated upon IgE cross-linking, was little influenced by either lovastatin or geldanamycin. Thus, lipid synthesis inhibition by lovastatin results in impaired tyrosine phosphorylation in RBL-2H3. This impairment is reflected in the subsequent exocytotic response. While lovastatin may inhibit tyrosine phosphorylation via an indirect mechanism, our results with tyrosine kinase inhibitors support the concept that multiple tyrosine kinases participate in the Fc(epsilon)RI-dependent signal transduction process.			SHAKARJIAN, MP (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA.							ALBER G, 1991, J BIOL CHEM, V266, P22613; ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; COLIGAN JE, 1983, METHOD ENZYMOL, V91, P413; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DEANIN GG, 1991, J IMMUNOL, V146, P3528; DEANIN GG, 1991, CELL REGUL, V2, P627, DOI 10.1091/mbc.2.8.627; EISEMAN E, 1992, NATURE, V355, P78; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SCHNEIDER H, 1992, INT IMMUNOL, V4, P447, DOI 10.1093/intimm/4.4.447; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WHITE KN, 1988, J IMMUNOL, V141, P942; YU KT, 1991, J BIOL CHEM, V266, P22564	29	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15252	15259						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325896				2022-12-25	WOS:A1993LL75900102
J	WALKER, RK; KRISHNASWAMY, S				WALKER, RK; KRISHNASWAMY, S			THE INFLUENCE OF FACTOR VA ON THE ACTIVE-SITE OF FACTOR-XA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE CHLOROMETHYL KETONE; COAGULATION FACTOR-XA; PROTHROMBINASE COMPLEX; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; PROTEIN-C; ANALYTICAL ULTRACENTRIFUGATION; CONFORMATIONAL SENSITIVITY; CATALYZED ACTIVATION; COFACTOR DEPENDENCE	The interaction of factor Xa with factor Va on the membrane surface results in a 3,000-fold increase in the k(cat) for the activation of prothrombin catalyzed by factor Xa. The reaction between the transition state irreversible inhibitor dansylglutamyl-glycyl-arginyl chloromethyl ketone (DEGRck) and factor Xa was characterized and employed to evaluate changes in the active site of factor Xa resulting from its interaction with factor Va, which may account for the increased catalytic efficiency of the enzyme complex. Inhibition studies indicated a two-step inhibition reaction involving a reversible binding step (K(i) = 1.13 muM) and an irreversible alkylation step (k(i) = 0.65 s-1). The interaction between factors Va and Xa in solution or on membranes resulted in a small decrease in the overall second-order rate constant (k(i)/K(i)) for the inhibition reaction. The incorporation of DEGRck into the active site of factor Xa results in a large change in the fluorescence intensity of the dansyl moiety. The fluorescence change was employed to study the reaction between enzyme and inhibitor directly by stopped-flow fluorescence measurements. The fluorescence traces were biphasic, indicating that the association of DEGRck with factor Xa and the subsequent covalent modification of the active site could be resolved because of differences in fluorescence intensities of the intermediate and product. This interpretation was verified by rapid chemical quench experiments. The reaction between DEGRck and factor Xa was characterized by a second-order association rate constant of 8.38 +/- 0.28 x 10(5) M-1.s-1 and an intrinsic rate constant for the alkylation step of 1.67 +/- 0.25 s-1. The rate constant for the alkylation step was unchanged in the presence of factor Va and membranes, whereas the association rate constant was modestly decreased by approximately 50%. The decrease in the association rate constant did not result from the partitioning of factor Xa to the membrane surface and could therefore be ascribed to an effect of factor Va on the protease. The data suggest that the interaction between factors Va and Xa on the membrane surface does not detectably alter the catalytic residues but may result in changes in the binding or accessibility of substrate to extended macromolecular recognition sites on the protease.	EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,DRAWER AR,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL-47465, HL-38337] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R29HL038337] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; Bevington PR, 1969, DATA REDUCTION ERROR; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P177; ESMON CT, 1974, J BIOL CHEM, V249, P7798; ESMON CT, 1974, J BIOL CHEM, V249, P7791; FERSHT A, 1977, ENZYME STRUCTURE MEC, P111; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; Gomori G, 1942, J LAB CLIN MED, V27, P955; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P571; Jesty J, 1976, Methods Enzymol, V45, P95; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KETTNER C, 1981, THROMB RES, V22, P645, DOI 10.1016/0049-3848(81)90062-1; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LEE J, 1989, BIOPHYS CHEM, V33, P99, DOI 10.1016/0301-4622(89)80012-2; LEE J, 1989, BIOCHEMISTRY-US, V28, P4263, DOI 10.1021/bi00436a022; LEYTUS SP, 1984, BIOCHIM BIOPHYS ACTA, V788, P74, DOI 10.1016/0167-4838(84)90299-1; LIU W, 1986, BIOCHIM BIOPHYS ACTA, V870, P185, DOI 10.1016/0167-4838(86)90220-7; LU RL, 1989, J BIOL CHEM, V264, P12956; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; MOORE JW, 1981, KINETICS MECHANISM, P290; NEISHEIM ME, 1979, J BIOL CHEM, V254, P10952; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; POULOS TL, 1976, J BIOL CHEM, V251, P1097; Powers J C, 1977, Methods Enzymol, V46, P197; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; ROSING J, 1980, J BIOL CHEM, V255, P274; RUF W, 1991, J BIOL CHEM, V266, P2158; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Segel IH, 1975, ENZYME KINETICS, P113; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; TSOU CL, 1988, ADV ENZYMOL RAMB, V61, P381; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WALKER RK, 1992, CIRCULATION, V86, P466; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1992, J BIOL CHEM, V267, P11023	64	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13920	13929						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314758				2022-12-25	WOS:A1993LJ82500025
J	DAVIS, LH; BENNETT, V				DAVIS, LH; BENNETT, V			IDENTIFICATION OF 2 REGIONS OF BETA(G) SPECTRIN THAT BIND TO DISTINCT SITES IN BRAIN MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SPECTRIN; ANKYRIN; CYTOSKELETON; ASSOCIATION; PROTEINS; ISOFORM; PURIFICATION; CALMODULIN; ANALOGS; CELLS	This study analyzed the complex interactions of intact spectrin with bovine brain membranes by evaluating membrane associations of defined regions of beta(G) spectrin, the subunit responsible for high affinity membrane binding. Two regions of beta(G) spectrin were expressed in bacteria and demonstrated to contain fully functional binding site(s) for a subset of spectrin-binding sites in brain membranes depleted of peripheral proteins. One region, located near the NH2 terminus, was comprised of 106-residue repeats and required repeats 2-7 for full activity. The other binding domain was located at the COOH terminus, which is the most variable between beta(G) and beta(R) spectrins, is distinct from the 106-residue repeats, and contains a pleckstrin homology domain. NH2-terminal beta spectrin polypeptides interacted with a membrane site(s) that recognized both brain and erythrocyte isoforms of spectrin, was inhibited by calcium/calmodulin, and was not blocked by the COOH-terminal polypeptide. The COOH-terminal region associated with a membrane site(s) that was specific for brain spectrin, was not inhibited by calcium/calmodulin, and was not blocked by the NH2-terminal polypeptide. These observations demonstrate membrane association of spectrin with at least two independent sites, which differ with regard to regulation by calcium/calmodulin and in selectivity for spectrin isoforms.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	DAVIS, LH (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA.							BENNETT V, 1981, P NATL ACAD SCI-BIOL, V78, P7550, DOI 10.1073/pnas.78.12.7550; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS JQ, 1986, J BIOL CHEM, V261, P6198; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DUBREUIL RR, 1990, J CELL BIOL, V111, P1849, DOI 10.1083/jcb.111.5.1849; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1991, J BIOL CHEM, V266, P18200; LAMBERT S, 1993, J NEUROSCI, V13, P3725; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; Sambrook J, 1989, MOL CLONING LABORATO; STEINER JP, 1988, J BIOL CHEM, V263, P14417; STEINER JP, 1989, J BIOL CHEM, V264, P2783; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788	26	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4409	4416						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308011				2022-12-25	WOS:A1994MW98900080
J	FISCHER, WH; BEHAN, DP; PARK, MY; POTTER, E; LOWRY, PJ; VALE, W				FISCHER, WH; BEHAN, DP; PARK, MY; POTTER, E; LOWRY, PJ; VALE, W			ASSIGNMENT OF DISULFIDE BONDS IN CORTICOTROPIN-RELEASING FACTOR-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA; PREGNANCY; HORMONE; SECRETION	We have previously isolated, cloned, and characterized a protein that specifically binds and inactivates the peptide corticotropin-releasing factor. The integrity of the disulfide bonds in the binding protein is essential for this activity as reduction abolishes the protein's ability to bind corticotropin-releasing factor. The disulfide arrangement of the 10 cysteines present in the mature protein was established by analysis of proteolytically cleaved protein and sequence analysis of cystine containing fragments. A pattern is observed where each cysteine is connected to the next one in a sequential manner. Inspection of the genomic DNA encoding for this protein reveals that four of the domains defined by disulfide linkage coincide with four different exons.	UNIV READING,DEPT BIOCHEM & PHYSIOL,READING RG6 2AJ,BERKS,ENGLAND	University of Reading	FISCHER, WH (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037, USA.				NICHD NIH HHS [HD 13527] Funding Source: Medline; NIDDK NIH HHS [DK 26741] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHAN DP, 1993, GENOMICS, V16, P63, DOI 10.1006/geno.1993.1141; BEHAN DP, 1993, ANN NY ACAD SCI, V697, P1, DOI 10.1111/j.1749-6632.1993.tb49918.x; BEHAN DP, 1989, J ENDOCRINOL, V122, P28; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CAMPBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054, DOI 10.1210/jcem-64-5-1054; FISCHER WH, 1993, RAPID COMMUN MASS SP, V7, P225, DOI 10.1002/rcm.1290070312; GOLAND RS, 1986, J CLIN ENDOCR METAB, V63, P1199, DOI 10.1210/jcem-63-5-1199; LINTON EA, 1987, J CLIN ENDOCR METAB, V64, P1047, DOI 10.1210/jcem-64-5-1047; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; POTTER E, 1991, NATURE, V349, P423, DOI 10.1038/349423a0; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; SASAKI A, 1984, J CLIN ENDOCR METAB, V59, P812; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8	14	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4313	4316						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307998				2022-12-25	WOS:A1994MW98900065
J	JEFFERIES, HBJ; THOMAS, G; THOMAS, G				JEFFERIES, HBJ; THOMAS, G; THOMAS, G			ELONGATION FACTOR-1-ALPHA MESSENGER-RNA IS SELECTIVELY TRANSLATED FOLLOWING MITOGENIC STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIA CELLS; S-ADENOSYLMETHIONINE DECARBOXYLASE; MESSENGER-RNA; PROTEIN-SYNTHESIS; FACTOR-TU; NUCLEOTIDE-SEQUENCE; RIBOSOMAL-SUBUNITS; FACTOR 1-ALPHA; ACTIN GENES; MOUSE	Stimulation of quiescent Swiss 3T3 cells to proliferate leads to a selective 6-fold increase in the rate of translation of protein synthesis elongation factor eEF-1 alpha. Northern blot and solution hybridization protection studies show that levels of eEF-1 alpha mRNA remain constant following serum stimulation, demonstrating that eEF-1 alpha transcripts are not degraded following mitogenic stimulation and that the increase in eEF-1 alpha synthesis is accounted for by pre-existing mRNA. Localization of these transcripts in resting cells shows that they are largely distributed equally between stored mRNA protein particles and monosomes/disomes. Following serum addition, eEF-1 alpha transcripts present in mRNA protein particles redistribute to large polysomes rather than to monosomes and disomes as would be expected. The same is true for those transcripts present in monosomes and disomes. Salt shift and translational runoff studies indicate that eEF-1 alpha transcripts sedimenting with monosomes and disomes in quiescent cells are associated with actively translating ribosomes. The results suggest that a specific transcript can move within polysome profile as a function of the affinity of translational apparatus for that transcript.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; VOLLUM INST, PORTLAND, OR 97201 USA	Friedrich Miescher Institute for Biomedical Research								AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAG J, 1991, TRANSLATION EUKARYOT, V3, P71; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BANDMAN E, 1975, EXP CELL RES, V90, P159, DOI 10.1016/0014-4827(75)90369-9; BERGMANN JE, 1979, J BIOL CHEM, V254, P1927; BOHM H, 1989, BIOCHEM INT, V19, P277; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COLOMBO B, 1968, P NATL ACAD SCI USA, V61, P651, DOI 10.1073/pnas.61.2.651; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FALVEY AK, 1970, J MOL BIOL, V53, P21, DOI 10.1016/0022-2836(70)90043-4; FALVEY AK, 1970, J MOL BIOL, V53, P1, DOI 10.1016/0022-2836(70)90042-2; HAMMOND ML, 1988, J BIOL CHEM, V263, P17785; HERRERA F, 1991, EUR J BIOCHEM, V200, P321, DOI 10.1111/j.1432-1033.1991.tb16188.x; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HERSHKO A, 1971, NATURE-NEW BIOL, V232, P206, DOI 10.1038/newbio232206a0; JOHNSON LF, 1974, CELL, V1, P95, DOI 10.1016/0092-8674(74)90068-3; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MACH M, 1986, J BIOL CHEM, V261, P1697; MARIOTTINI P, 1990, MOL CELL BIOL, V10, P816, DOI 10.1128/MCB.10.2.816; MARKS PA, 1965, P NATL ACAD SCI USA, V53, P1437, DOI 10.1073/pnas.53.6.1437; MATTAJ IW, 1987, EMBO J, V6, P2409, DOI 10.1002/j.1460-2075.1987.tb02519.x; MORLEY SJ, 1990, BIOCHIMIE, V72, P259, DOI 10.1016/0300-9084(90)90081-Q; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RAO TR, 1987, MOL CELL BIOL, V7, P687, DOI 10.1128/MCB.7.2.687; RAO TR, 1988, MOL CELL BIOL, V8, P1085, DOI 10.1128/MCB.8.3.1085; ROTH WW, 1987, MOL CELL BIOL, V7, P3929, DOI 10.1128/MCB.7.11.3929; RUDLAND PS, 1974, P NATL ACAD SCI USA, V71, P750, DOI 10.1073/pnas.71.3.750; RUDLAND PS, 1975, J MOL BIOL, V96, P745, DOI 10.1016/0022-2836(75)90150-3; Sambrook J, 1989, MOL CLONING LABORATO; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SPIRIN AS, 1985, TRENDS BIOCHEM SCI, V10, P162, DOI 10.1016/0968-0004(85)90158-6; STAEHELIN T, 1971, METHOD ENZYMOL, V20, P433; SUNITHA I, 1987, BIOCHEM BIOPH RES CO, V144, P560, DOI 10.1016/S0006-291X(87)80003-7; TAMM I, 1978, ADV VIRUS RES, V22, P188; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VAZQUEZ D, 1979, MOL BIOL BIOCH BIOPH, V30, P34; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; XIANG L, 1989, NUCLEIC ACIDS RES, V17, P442; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YENOFSKY R, 1983, MOL CELL BIOL, V3, P1197, DOI 10.1128/MCB.3.7.1197	59	101	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4367	4372						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308006				2022-12-25	WOS:A1994MW98900074
J	KAMADA, S; TOYOSHIMA, K; AKIYAMA, T				KAMADA, S; TOYOSHIMA, K; AKIYAMA, T			SERUM-INDEPENDENT PHOSPHORYLATION OF C-JUN AND ALTERATIONS IN AP-1 COMPONENTS BY TRANSFORMATION WITH VARIOUS ONCOGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC INHIBITOR; DNA-BINDING ACTIVITY; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; MOUSE FIBROBLASTS; LEUCINE ZIPPER; GENE FAMILY; V-JUN; FOS; GROWTH	To understand the mechanisms regulating the trans activating activity of Jun/AP-1, we analyzed alterations in c-Jun induced by growth stimulation and cell transformation. Serum stimulation of quiescent NIH3T3 cells induced a marked increase in phosphorylation of c-Jun in its amino-terminal activation domain. On the other hand, this domain was highly phosphorylated, in a se rum-independent manner, in cells transformed with various oncogenes, including active c-raf-1, v-src, active Ha ras, and active erbB-2. There were no obvious differences in the phosphorylation states of c-Jun in exponentially growing normal and transformed cells. However, in the exponentially growing state, the TRECAT activity in transformed cells was markedly higher than that in normal cells. Gel retardation analysis indicated that the AP-1 components in transformed cells were significantly different from those in normal cells. These results suggest that some other alterations besides phosphorylation of c-Jun are involved in enhancement of AP-1 activity in exponentially growing transformed cells.	OSAKA UNIV, MICROBIAL DIS RES INST, DEPT ONCOGENE RES, SUITA, OSAKA 565, JAPAN	Osaka University								ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJIMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P724, DOI 10.1016/0006-291X(91)90168-7; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	52	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4565	4570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308027				2022-12-25	WOS:A1994MW98900099
J	MAKEH, I; THOMAS, M; HARDELIN, JP; BRIAND, P; KAHN, A; SKALA, H				MAKEH, I; THOMAS, M; HARDELIN, JP; BRIAND, P; KAHN, A; SKALA, H			ANALYSIS OF A BRAIN-SPECIFIC ISOZYME - EXPRESSION AND CHROMATIN STRUCTURE OF THE RAT ALDOLASE-C GENE AND TRANSGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; HYPERSENSITIVE SITES; MOLECULAR-CLONING; MESSENGER-RNAS; PROMOTER; DOMAIN; CELLS; TRANSCRIPTION; PHOSPHORYLASE; ISOENZYME	Aldolase C mRNA is detected by Northern blot in all fetal tissues in rat; it is very abundant in the adult brain and undetectable in the other adult tissues. However, reverse transcriptase polymerase chain reaction amplification indicates that this gene is not totally repressed in these tissues. A DNase-I hypersensitivity site located in a 115-base pair proximal promoter fragment is detectable in the brain as well as in other adult tissues. Two MspI/HpaII restriction sites located at -3800 and -450 base pairs are demethylated in the brain and totally or partially methylated in other tissues. In transgenic mice, a 12.5-kilobase genomic fragment is strongly and tissue specifically expressed in different lines, with conservation of a methylation pattern similar to that of the endogenous gene. A chloramphenicol acetyltransferase gene directed by either 800 or 115 base pairs of aldolase C 5'-flanking sequences is tissue specifically expressed in transgenic mice, but the level of expression is very low. This level is greatly increased when the transgene consists of a chloramphenicol acetyltransferase hybrid gene directed by 5.5 kilobases of aldolase C 5'-flanking sequences. We propose therefore that the chromatin structure around the aldolase C promoter is accessible in fetal tissues, then remains open in the adult brain, where the gene is very active, as well as in tissues in which it is practically inactive. The specificity of expression in the brain is conferred by a short 115-base pair proximal promoter fragment that needs more upstream sequences to be fully active.	INST COCHIN GENET MOLEC, INSERM, U129, RECH GENET & PATHOL MOLEC LAB, F-75014 PARIS, FRANCE; INST COCHIN GENET MOLEC, INSERM, U380, RECH GENET & PATHOL EXPTL LAB, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Thomas, Muriel/D-9164-2015	Thomas, Muriel/0000-0002-7608-3274				BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; DELAIN D, 1973, Differentiation, V1, P349, DOI 10.1111/j.1432-0436.1973.tb00131.x; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; GAZDAR AF, 1981, CANCER RES, V41, P2773; GODBOUT R, 1988, GENE DEV, V2, P949, DOI 10.1101/gad.2.8.949; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; KAHN A, 1981, EUR J BIOCHEM, V116, P7, DOI 10.1111/j.1432-1033.1981.tb05293.x; KAHN A, 1980, PEDIATR RES, V14, P1162, DOI 10.1203/00006450-198011000-00003; KEYSER YD, 1985, J CLIN INVEST, V76, P1892; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; MEEHAN R, 1992, J CELL SCI, P9; MIQUEROL L, 1994, IN PRESS J BIOL CHEM; MUKAI T, 1991, BIOCHEM BIOPH RES CO, V174, P1035, DOI 10.1016/0006-291X(91)91523-F; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; NUMAZAKI M, 1984, EUR J BIOCHEM, V142, P165, DOI 10.1111/j.1432-1033.1984.tb08265.x; OPDECAMP K, 1992, NUCLEIC ACIDS RES, V20, P171, DOI 10.1093/nar/20.2.171; PEEK R, 1991, NUCLEIC ACIDS RES, V19, P77, DOI 10.1093/nar/19.1.77; PENHOET E, 1966, P NATL ACAD SCI USA, V56, P1275, DOI 10.1073/pnas.56.4.1275; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; POPOVICI T, 1990, FEBS LETT, V268, P189, DOI 10.1016/0014-5793(90)81005-9; SATO K, 1972, SCIENCE, V178, P879, DOI 10.1126/science.178.4063.879; SCHAPIRA F, 1970, BIOCHEM BIOPH RES CO, V40, P321, DOI 10.1016/0006-291X(70)91012-0; SKALA H, 1987, EUR J BIOCHEM, V163, P513, DOI 10.1111/j.1432-1033.1987.tb10898.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; SUSOR WA, 1971, ANAL BIOCHEM, V43, P147, DOI 10.1016/0003-2697(71)90119-9; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; TAKASHI M, 1990, AM J CLIN PATHOL, V93, P631, DOI 10.1093/ajcp/93.5.631; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THOMAS M, 1993, IN PRESS EUR J BIOCH; THOMPSON RJ, 1982, BRAIN RES, V232, P489, DOI 10.1016/0006-8993(82)90294-3; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TSUTSUMI K, 1985, J MOL BIOL, V181, P153, DOI 10.1016/0022-2836(85)90081-6; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; VILLEPONTEAU B, 1984, CELL, V39, P469, DOI 10.1016/0092-8674(84)90454-9; ZENNO S, 1990, J BIOCHEM, V107, P810, DOI 10.1093/oxfordjournals.jbchem.a123130	42	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4194	4200						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307981				2022-12-25	WOS:A1994MW98900047
J	AMSTAD, P; MORET, R; CERUTTI, P				AMSTAD, P; MORET, R; CERUTTI, P			GLUTATHIONE-PEROXIDASE COMPENSATES FOR THE HYPERSENSITIVITY OF CU,ZN-SUPEROXIDE DISMUTASE OVERPRODUCERS TO OXIDANT STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MANGANESE-SUPEROXIDE-DISMUTASE; MOUSE EPIDERMAL-CELLS; HYDROGEN-PEROXIDE; CYTO-TOXICITY; MAMMALIAN-CELLS; EXPRESSION; GENE; DNA; ENHANCEMENT; RESISTANCE	The balance between several components of the antioxidant defenses appears to be important for the cellular resistance to oxidative stress. While Cu,Zn-superoxide dismutase (SOD) transfectants of mouse epidermal cells JB6 clone 41 were sensitized to oxidants produced by xanthine/xanthine oxidase (X/XO) consecutive transfection with catalase corrected their hypersensitivity (Amstad, P., Peskin, A., Shah, G., Mirault, M. E., Moret, R., Zbinden, I., and Cerutti, P. (1991) Biochemistry 30, 9305-9313). We studied the effect of the transfection of bovine selenoglutathione peroxidase (GPx) on the sensitivity of JB6 clone 41 and its SOD transfectants. Sensitivity to DNA strand breakage and killing by X/XO was reversely related to the activity ratios GPx over SOD. A GPx-transfectant of JB6 clone 41 cells with a GPx/SOD ratio of 3.8 was very strongly protected. The hypersensitivity of the SOD clones with GPx/SOD ratios of 0.4 was corrected or overcorrected by secondary transfection with bovine Se-GPx resulting in increased activity ratios GPx/SOD of 1 to 2.4. Our results indicate that small deviations from the physiological activity ratios of GPx/SOD have a dramatic effect on the resistance of cells to oxidant-induced damage to the genome and cell killing.			AMSTAD, P (corresponding author), SWISS INST EXPTL CANC RES,DEPT CARCINOGENESIS,CH BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.				NCI NIH HHS [R01CA52310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Battey, 1986, BASIC METHODS MOL BI; BLOCH CA, 1986, J BACTERIOL, V168, P795, DOI 10.1128/jb.168.2.795-798.1986; CANTONI O, 1989, EUR J BIOCHEM, V182, P209, DOI 10.1111/j.1432-1033.1989.tb14819.x; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CERUTTI P, OXYRADICALS MOL BIOL; CERUTTI P, 1983, GENES PROTEINS ONCOG, P55; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; GRONER Y, 1990, PROG CLIN BIOL RES, V360, P233; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; KEDZIORA J, 1988, FREE RADICAL BIO MED, V4, P317, DOI 10.1016/0891-5849(88)90052-4; KELNER M, 1990, BIOL REACT INTERMED, V4, P305; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LINK EM, 1988, BIOCHEM J, V249, P391, DOI 10.1042/bj2490391; MAO GD, 1993, J BIOL CHEM, V268, P416; Mello Filho AC, 1984, BIOCHEM J, V218, P273; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; MUEHLEMATTER D, 1988, CARCINOGENESIS, V9, P239, DOI 10.1093/carcin/9.2.239; MULLENBACH GT, 1988, OXYRADICALS MOL BIOL, P313; OCHI T, 1987, P NATL ACAD SCI USA, V84, P990, DOI 10.1073/pnas.84.4.990; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SINET PM, 1979, LIFE SCI, V24, P29, DOI 10.1016/0024-3205(79)90276-5; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5	29	187	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1606	1609						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294405				2022-12-25	WOS:A1994MR98800011
J	YAN, XQ; BRADY, G; ISCOVE, NN				YAN, XQ; BRADY, G; ISCOVE, NN			OVEREXPRESSION OF PDGF-B IN MURINE HEMATOPOIETIC-CELLS INDUCES A LETHAL MYELOPROLIFERATIVE SYNDROME IN-VIVO	ONCOGENE			English	Article							V-SIS GENE; COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR; RETROVIRUS VECTORS; GM-CSF; EXPRESSION; INTERLEUKIN-1; INVIVO; MICE	Although PDGF is not a primary hematopoietic cytokine, effects in hematopoietic cell cultures have been reported. We recently described responses of multilineage hematopoietic precursors to PDGF. The effects were shown to be neutralized by antibody to LL-1 beta and mediated by marrow macrophages that expressed PDGF receptor RNA and responded to PDGF by upregulation of IL-1 RNA. The present study was performed to determine whether constitutive expression of PDGF by hematopoietic cells would have hematopoetic consequences in vivo. Retroviral vectors containing a PDGF-B gene were constructed and infected into normal marrow cells. Irradiated mice reconstituted with infected cells consistently developed a lethal myeloproliferative syndrome with anemia, neutrophilia and monocytosis, declining hematopoiesis in marrow with shift to the spleen, and extensive infiltration of immature hematopoietic cells into the parenchymal organs and connective tissues. In addition to PDGF, the retroviral constructs expressed a nea resistance marker. Phenotypic expression patterns in fibroblasts and in hematopoietic colony-forming cells in vitro were consistent with a significant degree of interaction between the two expressed inserts. Moreover, selection of infected cells for G418 resistance significantly reduced not only the number of infected reconstituting cells but also the intensity of the evoked syndrome in vivo. The observations have important implications for projected gene therapy protocols, and identify a novel potential pathway to myeloproliferative disease.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO M4X 1K9, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto								BANCROFT JD, 1984, MANUAL HISTOLOGICAL, P52; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BOWENPOPE DF, 1984, BLOOD, V64, P458; BOWTELL DDL, 1988, J VIROL, V62, P2464, DOI 10.1128/JVI.62.7.2464-2473.1988; BRACH MA, 1990, BLOOD, V76, P1972; BRADY G, 1988, ONCOGENE, V3, P687; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CHANG JM, 1989, J CLIN INVEST, V84, P1488, DOI 10.1172/JCI114324; CHANG JM, 1989, BLOOD, V73, P1487; DAINIAK N, 1983, J CLIN INVEST, V71, P1206, DOI 10.1172/JCI110869; DELWICHE F, 1985, J CLIN INVEST, V76, P137, DOI 10.1172/JCI111936; DICK JE, 1991, BLOOD, V78, P624, DOI 10.1182/blood.V78.3.624.bloodjournal783624; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ELIAS JA, 1990, J IMMUNOL, V145, P161; EMERMAN M, 1986, NUCLEIC ACIDS RES, V14, P9381, DOI 10.1093/nar/14.23.9381; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; FIBBE WE, 1988, BLOOD, V72, P860; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; HANNINK M, 1986, MOL CELL BIOL, V6, P1304, DOI 10.1128/MCB.6.4.1304; HARIHARAN IK, 1989, CURR TOP MICROBIOL, V149, P99; HARRISON DE, 1991, BLOOD, V78, P1237; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; ISCOVE NN, 1989, J IMMUNOL, V142, P2332; ISCOVE NN, 1990, J IMMUNOL, V145, P190; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JOHNSSON A, 1986, EMBO J, V5, P1535, DOI 10.1002/j.1460-2075.1986.tb04394.x; JOHNSSON A, 1985, P NATL ACAD SCI USA, V82, P1721, DOI 10.1073/pnas.82.6.1721; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF D, 1989, LEUKEMIA, V3, P847; MICHALEVICZ R, 1986, BRIT J HAEMATOL, V63, P591, DOI 10.1111/j.1365-2141.1986.tb07537.x; PAIGE CJ, 1986, J IMMUNOL METHODS, V93, P37, DOI 10.1016/0022-1759(86)90430-8; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; QUESNIAUX VFJ, 1993, BLOOD, V81, P1497; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; Sambrook J, 1989, MOL CLONING; SIEFF CA, 1987, J CLIN INVEST, V79, P48, DOI 10.1172/JCI112806; VAUX DL, 1990, INT IMMUNOL, V2, P965, DOI 10.1093/intimm/2.10.965; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; YAN XQ, 1993, J IMMUNOL, V150, P2440; ZSEBO KM, 1988, BLOOD, V71, P99; [No title captured]	46	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					163	173						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302575				2022-12-25	WOS:A1994MW24700020
J	DAVODEAU, F; HOUDE, I; BOULOT, G; ROMAGNE, F; NECKER, A; CANAVO, N; PEYRAT, MA; HALLET, MM; VIE, H; JACQUES, Y; MARIUZZA, R; BONNEVILLE, M				DAVODEAU, F; HOUDE, I; BOULOT, G; ROMAGNE, F; NECKER, A; CANAVO, N; PEYRAT, MA; HALLET, MM; VIE, H; JACQUES, Y; MARIUZZA, R; BONNEVILLE, M			SECRETION OF DISULFIDE-LINKED HUMAN T-CELL RECEPTOR-GAMMA-DELTA HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; MOLECULAR-GENETICS; CHIMERIC PROTEIN; EXPRESSION; TCR	The availability of soluble forms of T-cell antigen receptors (sTCR) should be of great use in the detailed characterization of their interactions with ligands, for the generation of anti-TCR monoclonal antibodies (mAb), and for the eventual determination of their three-dimensional structures by x-ray crystallography. Here, we show that efficient secretion of nonchimeric disulfide-linked human gammadelta TCR could be achieved by simply introducing translational termination codons upstream from the sequences encoding TCR chain transmembrane regions. This recombinant protein appeared to be correctly folded, as judged by its reactivity with a panel of anti-gamma and anti-delta mAbs, and proved to be a powerful immunogen, allowing generation of mAb that are able to recognize both soluble- and membrane-bound gammadelta TCR. While variable and constant domains of gammadelta sTCR seem to be folded into compact conformations, the extreme sensitivity of its interchain disulfide bridge to digestion with papain suggests that sTCR C-terminal portions are in a more extended configuration than the corresponding region in immunoglobulins. Finally, the gammadelta heterodimer remains stable even after removal of the interchain disulfide link, suggesting the existence of strong noncovalent forces holding the two chains together.	INST BIOL NANTES,INSERM,U211,9 QUAI MONCOUSU,F-44035 NANTES 01,FRANCE; INST PASTEUR,F-75024 PARIS,FRANCE; IMMUNOTECH SA,F-13276 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Davodeau, Francois/M-1888-2015; Vie, Henri/L-2651-2015	Davodeau, Francois/0000-0001-8181-0192				BASI GS, 1992, J IMMUNOL METHODS, V155, P175, DOI 10.1016/0022-1759(92)90284-Z; BISMUTH G, 1990, MOL IMMUNOL, V27, P1127, DOI 10.1016/0161-5890(90)90101-5; COUSIN MA, 1985, LYMPHOKINE RES, V4, P319; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DAVODEAU F, 1993, EUR J IMMUNOL, V23, P804, DOI 10.1002/eji.1830230405; DEVAUX B, 1991, EUR J IMMUNOL, V21, P2111, DOI 10.1002/eji.1830210920; EILAT D, 1992, P NATL ACAD SCI USA, V89, P6871, DOI 10.1073/pnas.89.15.6871; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GASCOIGNE NRJ, 1987, P NATL ACAD SCI USA, V84, P2936, DOI 10.1073/pnas.84.9.2936; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HARLOW E, 1988, ANTIBODIES LABORATOR, P580; HATA S, 1987, SCIENCE, V238, P678, DOI 10.1126/science.3499667; JAMESON SC, 1990, J IMMUNOL, V145, P1324; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LEFRANC MP, 1986, P NATL ACAD SCI USA, V83, P9596, DOI 10.1073/pnas.83.24.9596; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MALISSEN M, 1992, IMMUNOL TODAY, V13, P49; MARIUZZA RA, 1989, J BIOL CHEM, V264, P7310; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIOSSEC C, 1990, J EXP MED, V171, P1171, DOI 10.1084/jem.171.4.1171; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WEBER S, 1992, NATURE, V356, P93; WIGLERR M, 1979, CELL, V16, P177	29	26	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15455	15460						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340374				2022-12-25	WOS:A1993LN30500023
J	DRAKE, SL; VARNUM, J; MAYO, KH; LETOURNEAU, PC; FURCHT, LT; MCCARTHY, JB				DRAKE, SL; VARNUM, J; MAYO, KH; LETOURNEAU, PC; FURCHT, LT; MCCARTHY, JB			STRUCTURAL FEATURES OF FIBRONECTIN SYNTHETIC PEPTIDE FN-C/H II, RESPONSIBLE FOR CELL-ADHESION, NEURITE EXTENSION, AND HEPARAN-SULFATE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; SURFACE RECEPTORS; PLATELET FACTOR-4; CYTOCHROME-C; IV COLLAGEN; N-CAM; PROTEIN; PROTEOGLYCAN; DOMAIN; IDENTIFICATION	FN-C/H II (KNNQKSEPLIGRKKT), a heparin-binding peptide derived from the COOH-terminal heparin-binding domain of fibronectin, mediates cell adhesion for a variety of cell types and promotes neurite out-growth. By systematic amino acid substitution of synthetic peptide analogues of FN-C/H II, the basic structural features necessary for activity have been identified in the COOH-terminal residues LIGRKK. This biologically ''active'' sequence has been located in several other heparin/heparan sulfate-binding proteins and may represent a potential binding motif for sulfated polyanions. NMR structural studies indicate that the COOH-terminal segment of FN-C/H II displays significant multiple-turn or helix-like character suggesting that the RKK sequence may lie on the same surface of the protein, as opposed to alternating in an extended chain motif.	UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR BIOMED ENGN,MINNEAPOLIS,MN 55455; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Jefferson University; Jefferson University			Letourneau, Paul C/A-6764-2009		NATIONAL CANCER INSTITUTE [R55CA054263, R01CA043924] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043194, K99HL143194] Funding Source: NIH RePORTER; NCI NIH HHS [CA43924, CA54263] Funding Source: Medline; NHLBI NIH HHS [HL-43194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKALOW FJ, 1991, J BIOL CHEM, V12, P7812; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COLE GJ, 1989, EXP CELL RES, V182, P44, DOI 10.1016/0014-4827(89)90278-4; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HAUGEN PK, 1992, J NEUROSCI, V12, P2034; HAUGEN PK, 1992, J NEUROSCI, V12, P2597; HAUGEN PK, 1990, J CELL BIOL, V111, P2733, DOI 10.1083/jcb.111.6.2733; HEIMER R, 1987, ANAL BIOCHEM, V165, P448, DOI 10.1016/0003-2697(87)90295-8; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; JEERNER J, 1979, J CHEM PHYS, V71, P4546; JULIANO RL, 1987, BIOCHIM BIOPHYS ACTA, V907, P261, DOI 10.1016/0304-419X(87)90009-6; KLEIN DJ, 1989, DEV BIOL, V133, P515, DOI 10.1016/0012-1606(89)90054-7; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P925, DOI 10.1021/bi00218a007; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MERENMIES J, 1990, J BIOL CHEM, V265, P16271; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; OEGEMA TR, 1979, J BIOL CHEM, V254, P1312; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; SAMPSON PM, 1985, ANAL BIOCHEM, V151, P304, DOI 10.1016/0003-2697(85)90180-0; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WAGNER R, 1988, BIOCHEMISTRY-US, V27, P7167; WILKE MS, 1991, J INVEST DERMATOL, V97, P573, DOI 10.1111/1523-1747.ep12481915; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260	60	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15859	15867						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340411				2022-12-25	WOS:A1993LN30500078
J	RUTENBER, E; FAUMAN, EB; KEENAN, RJ; FONG, S; FURTH, PS; DEMONTELLANO, PRO; MENG, E; KUNTZ, ID; DECAMP, DL; SALTO, R; ROSE, JR; CRAIK, CS; STROUD, RM				RUTENBER, E; FAUMAN, EB; KEENAN, RJ; FONG, S; FURTH, PS; DEMONTELLANO, PRO; MENG, E; KUNTZ, ID; DECAMP, DL; SALTO, R; ROSE, JR; CRAIK, CS; STROUD, RM			STRUCTURE OF A NONPEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE - DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN IMMUNODEFICIENCY VIRUS-1; MULTIWIRE AREA DETECTOR; 3-DIMENSIONAL STRUCTURE; TYPE-1 PROTEASE; RESOLUTION; PROTEINASE; RETRIEVAL	A stable, non-peptide inhibitor of the protease from type 1 human immunodeficiency virus has been developed, and the stereochemistry of binding defined through crystallographic three-dimensional structure determination. The initial compound, haloperidol, was discovered through computational screening of the Cambridge Structural Database using a shape complementarity algorithm. The subsequent modification is a non-peptidic lateral lead, which belongs to a family of compounds with well characterized pharmacological properties. This thioketal derivative of haloperidol and a halide counterion are bound within the enzyme active site in a mode distinct from that observed for peptide-based inhibitors. A variant of the protease cocrystallized with this inhibitor shows binding in the manner predicted during the initial computer-based search. The structures provide the context for subsequent synthetic modifications of the inhibitor.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Salto, Rafael/A-6486-2011; Fauman, Eric/AAC-8275-2020	Salto, Rafael/0000-0002-7044-3611; Fauman, Eric/0000-0002-9739-0249; Keenan, Robert/0000-0003-1466-0889	NIGMS NIH HHS [GM 39552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN FH, 1973, J CHEM DOC, V13, P119, DOI 10.1021/c160050a006; ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BLUNDELL TL, 1990, TRENDS BIOCHEM SCI, V15, P425, DOI 10.1016/0968-0004(90)90280-O; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11297, DOI 10.1021/bi00161a006; DATTA N, 1979, ACTA CRYSTALLOGR B, V35, P1486, DOI 10.1107/S0567740879006828; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; FISANICK W, 1990, J CHEM INF COMP SCI, V30, P145, DOI 10.1021/ci00066a008; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; FURGUSON G, 1991, ACTA CRYSTALLOGR B, V47, P479; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; PREUTZ M, 1992, PROTEIN STRUCTURE NE; ROSE JR, 1993, J BIOL CHEM, V268, P11939; RUSINKO A, 1989, J CHEM INF COMP SCI, V29, P251, DOI 10.1021/ci00064a004; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; TILTON RF, 1986, J MOL BIOL, V192, P443, DOI 10.1016/0022-2836(86)90374-8; VERHOEF JC, 1990, EUR J DRUG METAB PH, V15, P83, DOI 10.1007/BF03190191; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	30	127	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15343	15346						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340363				2022-12-25	WOS:A1993LN30500006
J	BULET, P; DIMARCQ, JL; HETRU, C; LAGUEUX, M; CHARLET, M; HEGY, G; VANDORSSELAER, A; HOFFMANN, JA				BULET, P; DIMARCQ, JL; HETRU, C; LAGUEUX, M; CHARLET, M; HEGY, G; VANDORSSELAER, A; HOFFMANN, JA			A NOVEL INDUCIBLE ANTIBACTERIAL PEPTIDE OF DROSOPHILA CARRIES AN O-GLYCOSYLATED SUBSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT IMMUNITY; ANTIMICROBIAL PEPTIDES; PROTEINS; CDNA; SEQUENCE; CECROPIA; CLONING; FAMILY; MEMBER; CELLS	One of the facets of the host defense of higher insects is the rapid and transient synthesis, following bacterial challenge or trauma, of a battery of potent antibacterial peptides (Steiner, H., Hultmark, D., Engstrom, A., Bennich, H., and Boman, H. G. (1981) Nature 292, 246-248). The best characterized of these peptides are the cecropins (ibid.), 4-kDa peptides devoid of cysteines, and the insect defensins (Hoffmann, J. A., and Hetru, C. (1992) Immunol. Today 13, 411-415), 4-kDa peptides with three intramolecular disulfide bridges. Several other inducible antibacterial peptides have been characterized only at the level of their amino acid sequences (Hoffmann, J. A., Dimarcq, J. L., and Bulet, P. (1992) Medecine & Sciences 8, 432-439). We report here the isolation of a novel 19-residue proline-rich inducible antibacterial peptide from Drosophila. In contrast to all previous reports on antibacterial peptides, this molecule carries a substitution as evidenced by molecular mass determinations; our data show that this reflects the O-glycosylation of a Thr residue by an N-acetylgalactosamine plus a galactose. A synthetic nonsubstituted peptide of identical amino acid sequence has an activity several times lower (5-10) than the native compound. Our data suggest that this substitution represents a post-translational modification essential for the full biological activity of this novel peptide.	UNIV STRASBOURG 1,BIOL GEN LAB,CNRS,F-67070 STRASBOURG,FRANCE; UNIV STRASBOURG 1,SPECTROMETRIE MASSE BIOORGAN,CNRS,URA CHIM ORGAN SUBST NAT 31,F-67008 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; ANDO K, 1988, BIOCHEMISTRY-US, V27, P1715, DOI 10.1021/bi00405a050; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BULET P, 1991, J BIOL CHEM, V266, P24520; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CORCES V, 1981, P NATL ACAD SCI-BIOL, V78, P7038, DOI 10.1073/pnas.78.11.7038; DIMARCQ JL, 1988, EUR J BIOCHEM, V171, P17, DOI 10.1111/j.1432-1033.1988.tb13752.x; HAN JH, 1987, NUCLEIC ACIDS RES, V15, P6304, DOI 10.1093/nar/15.15.6304; HOFFMANN JA, 1992, M S-MED SCI, V8, P432, DOI 10.4267/10608/3159; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; KOCKUM K, 1984, EMBO J, V3, P2071, DOI 10.1002/j.1460-2075.1984.tb02093.x; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; Mason PJ, 1985, NUCLEIC ACID HYBRIDI, P113; MOORE KS, 1991, J BIOL CHEM, V266, P19851; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; SAMAKOVLIS C, 1990, EMBO J, V9, P2969, DOI 10.1002/j.1460-2075.1990.tb07489.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER MP, 1983, ANAL BIOCHEM, V128, P66, DOI 10.1016/0003-2697(83)90345-7; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDORSSELAER A, 1990, BIOMED ENVIRON MASS, V19, P692, DOI 10.1002/bms.1200191108; WICKER C, 1990, J BIOL CHEM, V265, P22493; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YANNISCHPERRON C, 1985, GENE, V33, P103; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	28	322	349	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14893	14897						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325867				2022-12-25	WOS:A1993LL75900056
J	MARKLUND, U; BRATTSAND, G; SHINGLER, V; GULLBERG, M				MARKLUND, U; BRATTSAND, G; SHINGLER, V; GULLBERG, M			SERINE-25 OF ONCOPROTEIN-18 IS A MAJOR CYTOSOLIC TARGET FOR THE MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTES-T; PHOSPHORYLATION SITE; MAP KINASES; C-MYC; SUBSTRATE; GENE; PHOSPHOPROTEIN; STATHMIN; BRAIN; IDENTIFICATION	Oncoprotein 18 (Op18) is an 18-19-kDa cytoplasmic phosphoprotein, of unknown function, that is frequently up-regulated in transformed cells. Stimulation of various cell-surface receptors results in extensive phosphorylation of Op18 and this protein has, therefore, previously been implicated in intracellular signaling. In the present study, by expression of specific Op18 cDNA mutant constructs and phosphopeptide mapping, we have identified in vivo phosphorylation sites. In conjunction with in vitro phosphorylation experiments, using purified wild-type and mutant Op18 proteins in combination with a series of kinases, these results have identified two distinct proline-directed kinase families that phosphorylate Op 1 8 with overlapping but distinct site preference. These two kinase families, mitogen activated protein (MAP) kinases and cyclin dependent cdc2 kinases, are involved in receptor and cell cycle-regulated phosphorylation events, respectively. Therefore, Op18 may reside at a junction where receptor and cell cycle-regulated kinase families interact with the same substrate. The present study shows that the MAP kinase has a 20-fold preference for Ser25 as opposed to Ser38 of Op18, while cdc2 kinases have a 5-fold preference for the Ser38 residue. Only a minor fraction of the 4.5 x 10(6)Op18 molecules/cell in a leukemic T-cell line are normally in their Ser25 phosphorylated form. However, antigen receptor stimulation of this cell line is shown to result in a rapid conversion of 35-45% of all Op18 molecules to the Ser25 phosphorylated form. These results suggest that Ser25 of Op18 may be a major cytoplasmic target for the MAP kinase in cells with high expression of Op18.	UMEA UNIV, DEPT CELL & MOLEC BIOL, S-90187 UMEA, SWEDEN	Umea University				Shingler, Victoria/0000-0002-7349-1678; Gullberg, Martin/0000-0002-3984-4572				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1989, SCAND J IMMUNOL, V30, P233, DOI 10.1111/j.1365-3083.1989.tb01206.x; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FRIEDRICH B, 1988, IMMUNOBIOLOGY, V176, P465, DOI 10.1016/S0171-2985(88)80027-5; FRIEDRICH B, 1989, EUR J IMMUNOL, V19, P17, DOI 10.1002/eji.1830190104; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Maniatis T, 1989, MOL CLONING; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NEL AE, 1990, J IMMUNOL, V144, P2683; PILON M, 1991, J IMMUNOL, V146, P1047; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SETH A, 1991, J BIOL CHEM, V266, P23521; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHU XX, 1989, J BIOL CHEM, V264, P14556	49	129	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15039	15049						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325880				2022-12-25	WOS:A1993LL75900074
J	PAVLIAK, V; BRISSON, JR; MICHON, F; UHRIN, D; JENNINGS, HJ				PAVLIAK, V; BRISSON, JR; MICHON, F; UHRIN, D; JENNINGS, HJ			STRUCTURE OF THE SIALYLATED L3 LIPOPOLYSACCHARIDE OF NEISSERIA-MENINGITIDIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE; MAGNETIC-RESONANCE; ANTIGENS; OLIGOSACCHARIDES; SPECTROSCOPY; LIPOOLIGOSACCHARIDES; GLYCOPROTEINS; GLYCOLIPIDS; INHIBITION; COMPONENTS	The L3 immunotype lipopolysaccharide (LPS) of Neisseria meningitidis was subjected to degradation procedures, which produced a number of different oligosaccharide fragments. The high resolution H-1 and C-13 NMR spectroscopic analyses of these oligosaccharides yielded structural information on a number of different regions of the LPS. For example, from one oligosaccharide, it was found that the endogenous sialylation of the meningococcal LPS occurs at O-3 of the terminal beta-D-galactopyranosyl residue of its lacto-N-neotetraose antenna in the alpha-D-configuration. From another, it was also established that the dominant structural feature responsible for L3 epitope specificity is the presence of a phosphorylethanolamine substituent at O-3 of the penultimate heptopyranosyl residue of its other antenna. In addition from information obtained with another oligosaccharide the structure of the 3-deoxy-D-manno-octulosonic acid disaccharide region of the L3 LPS was also elucidated. From all the above cumulative data plus some published data, it was then possible to reconstruct the complete structure of the entire native L3 LPS.	NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA K1A 0R6, ONTARIO, CANADA; SLOVAK ACAD SCI, INST CHEM, CS-84238 BRATISLAVA, CZECHOSLOVAKIA	National Research Council Canada; Slovak Academy of Sciences								ALTMAN E, 1987, EUR J BIOCHEM, V170, P185, DOI 10.1111/j.1432-1033.1987.tb13685.x; ALTMAN E, 1992, EUR J BIOCHEM, V204, P225, DOI 10.1111/j.1432-1033.1992.tb16628.x; BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BHATTACHARJEE AK, 1978, BIOCHEMISTRY-US, V17, P645, DOI 10.1021/bi00597a013; BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; DIFABIO JL, 1989, BIOCHEM CELL BIOL, V67, P78; DIFABIO JL, 1990, CAN J CHEM, V68, P1029, DOI 10.1139/v90-160; FEIZI T, 1985, TRENDS BIOCHEM SCI, V10, P24, DOI 10.1016/0968-0004(85)90012-X; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; GAMIAN A, 1992, J BIOL CHEM, V267, P922; GU XX, 1991, ANAL BIOCHEM, V196, P311, DOI 10.1016/0003-2697(91)90472-6; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HOLST O, 1991, J BACTERIOL, V173, P1862, DOI 10.1128/jb.173.6.1862-1866.1991; INAGAKI F, 1989, J MAGN RESON, V81, P186, DOI 10.1016/0022-2364(89)90278-3; JANSSON PE, 1989, CARBOHYD RES, V188, P169, DOI 10.1016/0008-6215(89)84069-8; JENNINGS HJ, 1984, INFECT IMMUN, V43, P407, DOI 10.1128/IAI.43.1.407-412.1984; JENNINGS HJ, 1983, CARBOHYD RES, V121, P233, DOI 10.1016/0008-6215(83)84020-8; JENNINGS HJ, 1987, A VAN LEEUW J MICROB, V53, P519, DOI 10.1007/BF00415511; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KESSLER H, 1989, J MAGN RESON, V85, P1, DOI 10.1016/0022-2364(89)90314-4; KNIREL YA, 1988, BIOORG KHIM+, V14, P77; KOSMA P, 1987, CARBOHYD RES, V167, P39, DOI 10.1016/0008-6215(87)80266-5; KRASIKOVA IN, 1982, EUR J BIOCHEM, V126, P349; KULSHIN VA, 1992, J BACTERIOL, V174, P1793, DOI 10.1128/jb.174.6.1793-1800.1992; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MANDRELL RE, 1991, J BACTERIOL, V173, P2823, DOI 10.1128/JB.173.9.2823-2832.1991; MANDRELL RE, 1977, INFECT IMMUN, V16, P471, DOI 10.1128/IAI.16.2.471-475.1977; MICHON F, 1990, J BIOL CHEM, V265, P7243; POZSGAY V, 1991, BIOORG MED CHEM LETT, V1, P391, DOI 10.1016/S0960-894X(00)80262-0; SABESAN S, 1986, J AM CHEM SOC, V108, P2068, DOI 10.1021/ja00268a056; TSAI CM, 1991, INFECT IMMUN, V59, P3604, DOI 10.1128/IAI.59.10.3604-3609.1991; ZOLLINGER WD, 1980, INFECT IMMUN, V28, P451; ZOLLINGER WD, 1977, INFECT IMMUN, V18, P424, DOI 10.1128/IAI.18.2.424-433.1977	33	87	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14146	14152						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314780				2022-12-25	WOS:A1993LJ82500055
J	SUN, Y; DONG, ZG; NAKAMURA, K; COLBURN, NH				SUN, Y; DONG, ZG; NAKAMURA, K; COLBURN, NH			DOSAGE-DEPENDENT DOMINANCE OVER WILD-TYPE P53 OF A MUTANT P53 ISOLATED FROM NASOPHARYNGEAL CARCINOMA	FASEB JOURNAL			English	Note						P53; TUMOR SUPPRESSOR GENE; NASOPHARYNGEAL CARCINOMA; HETEROZYGOUS MUTATION; DOMINANT NEGATIVE	TUMOR SUPPRESSOR GENE; TATA-BINDING PROTEIN; CANCER CELLS; SV40-TRANSFORMED CELLS; LUNG-CANCER; MUTATIONS; ANTIGEN; TRANSFORMATION; GROWTH; EXPRESSION	Mutational inactivation of p53, a tumor suppressor gene, is the most common genetic alteration found in human cancer. Most mutated p53s either lose tumor suppressor function or gain oncogenic activity. We recently reported the detection of a heterozygous point mutation of p53 at codon 280 in nasopharyngeal carcinoma (NPC) (1), a high-incidence malignancy in southern China and southeast Asia. Given its heterozygous state, in which both wild-type and mutated p53 gene were expressed, p53-thr280 should function dominantly in the presence of the wild-type form if it is to play a role in nasopharynx carcinogenesis. We tested this dominance hypothesis in the cells of two model systems: 1) human Saos-2 cells lacking endogenous p53, and 2) mouse JB6 tumor promotion-resistant cells (P-) expressing endogenous wild-type p53. The results showed dosage-dependent dominance of p53-thr280 in controlling WT p53-driven transcriptional activity; in governing cell growth; and in progressing P- phenotype to tumor promotion-sensitive (P+) phenotype. This dominant negative effect was seen at a 1:1 (WT:MU) ratio and was more striking at a ratio of 1:3. A model is proposed to explain the dominant negative effect of mutant p53. We conclude from this study that p53-thr280 is likely to be dominant in the heterozygous state found in NPC and that this dominant-negative mutated p53 may contribute to the genesis of NPC or of other carcinomas in which both mutant and wild-type p53 are expressed.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BCDP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SUN, Y (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,CELL BIOL SECT,FREDERICK,MD 21702, USA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7712; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIBA I, 1990, ONCOGENE, V5, P1603; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HEINTZ N, 1991, HORMONAL CONTROL REG, P3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; ISAACS WB, 1991, CANCER RES, V51, P4716; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LATCHMAN DS, 1991, EUKARYOTIC TRANSCRIP, P87; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAZARS R, 1991, ONCOGENE, V6, P1685; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1993, IN PRESS MOL CARCINO; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG W, 1993, IN PRESS ONCOGENE	54	58	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					944	950		10.1096/fasebj.7.10.8344492	http://dx.doi.org/10.1096/fasebj.7.10.8344492			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344492				2022-12-25	WOS:A1993LQ33700019
J	HISCOCK, DRR; YANAGISHITA, M; HASCALL, VC				HISCOCK, DRR; YANAGISHITA, M; HASCALL, VC			NUCLEAR-LOCALIZATION OF GLYCOSAMINOGLYCANS IN RAT OVARIAN GRANULOSA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; INTRACELLULAR DEGRADATIVE PATHWAYS; BINDING; LIVER; IDENTIFICATION; TRANSCRIPTION; HEPATOCYTES; METABOLISM; RECEPTOR	In rat ovarian granulosa cell cultures, internalized cell surface heparan sulfate is processed by either a fast lysosome-mediated pathway or by a slow pathway which generates glycosaminoglycan fragments. Cell-associated dermatan sulfate proteoglycans also undergo processing through analogous pathways, although the slow pathway does not involve endoglycosidic cleavage of the dermatan sulfate chains. In the present study we tested whether intracellular glycosaminoglycan fragments in rat ovarian granulosa cells were transient residents of the nuclei. A technique for isolating nuclei was devised in which cells were lysed with a hypo-osmotic extraction buffer containing detergent. Nuclei were then purified by conventional methods, and final preparations gave excellent recovery of the starting DNA (similar to 90%). The technique was used to isolate glycosaminoglycans from nuclei after cells were metabolically radiolabeled with [S-35]sulfate. The results indicated the possible presence of dermatan sulfate, but not heparan sulfate, glycosaminoglycans at this location. Failure to remove cell surface proteoglycans with trypsin before preparation of nuclei resulted in nuclear contamination with significant amounts of intact dermatan sulfate proteoglycans. Nuclei preparations obtained using traditional homogenization steps from cells either treated without or with trypsin gave identical results except that recoveries of DNA were much lower (similar to 30%). The results demonstrate the difficulty in isolating pure nuclei and therefore also of firm conclusions pertaining to the nuclear association of glycosaminoglycans.			HISCOCK, DRR (corresponding author), NIDR,BONE RES BRANCH,PROTEOGLYCAN CHEM SECT,BETHESDA,MD 20892, USA.							BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CAREY DJ, 1987, J BIOL CHEM, V262, P3376; CARLSON DM, 1968, J BIOL CHEM, V243, P616; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FURUKAWA K, 1983, BIOCHIM BIOPHYS ACTA, V740, P466, DOI 10.1016/0167-4781(83)90096-9; FURUKAWA K, 1977, BIOCHIM BIOPHYS ACTA, V499, P278, DOI 10.1016/0304-4165(77)90010-1; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; GRAHAM JM, 1990, ANAL BIOCHEM, V187, P318, DOI 10.1016/0003-2697(90)90463-J; HEUSER JE, 1980, J CELL BIOL, V86, P212, DOI 10.1083/jcb.86.1.212; ISHIHARA M, 1989, J CELL PHYSIOL, V138, P467, DOI 10.1002/jcp.1041380305; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; WESTERGRENTHORSSON G, 1991, J CELL PHYSIOL, V147, P523, DOI 10.1002/jcp.1041470319; YANAGISHITA M, 1989, J BIOL CHEM, V264, P17551; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANAGISHITA M, 1979, J BIOL CHEM, V254, P2355; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1987, BIOL PROTEOGLYCANS, P105; YANAGISHITA M, 1984, J BIOL CHEM, V259, P1260; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	30	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4539	4546						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308024				2022-12-25	WOS:A1994MW98900096
J	CONNOR, J; PAK, CC; SCHROIT, AJ				CONNOR, J; PAK, CC; SCHROIT, AJ			EXPOSURE OF PHOSPHATIDYLSERINE IN THE OUTER LEAFLET OF HUMAN RED-BLOOD-CELLS - RELATIONSHIP TO CELL-DENSITY, CELL AGE, AND CLEARANCE BY MONONUCLEAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCCURRING ANTI-BAND-3 ANTIBODIES; HUMAN-ERYTHROCYTES; TRANSBILAYER MOVEMENT; SICKLE ERYTHROCYTES; PLASMA-MEMBRANES; INVIVO; SURFACE; RECOGNITION; MACROPHAGES; PHOSPHOLIPIDS	Human red blood cells (RBC) were separated by density on self-forming Percoll gradients into five distinct populations. The transbilayer movement and equilibrium distribution of 1-oleoyl-2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminocaproyl)phosphatidylserine (NBD-PS) was slower in dense cells and equilibrated in the inner leaflet of these cells to a lesser degree than in light cells. Conversely, the outward movement of the lipid was slower in light cells. Assessment of endogenous PS in the cells' outer leaflet by the prothrombinase activity of externalized PS revealed an increase in its presence at the cell surface with increasing cell density. The presence of PS on the cell surface directly correlated with the propensity of the RBC to be bound by autologous monocytes. To determine whether increased cell density is associated with increased cell age, the in vivo clearance of density-separated murine RBC was monitored in syngeneic mice. The T1/2 of circulation of light cells was about twice that of dense cells. The majority of the cleared cells localized in the spleen. Studies carried out in antibody-deficient SCID mice indicated that RBC were cleared via a mechanism that was independent of antibody. These data suggest that cell age is related to cell density and that cells of increasing age and density display higher amounts of PS in their outer leaflet.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CELL BIOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NIDDK NIH HHS [DK 41714] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041714] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN D, 1982, NATURE, V295, P612, DOI 10.1038/295612a0; ALLEN TM, 1988, P NATL ACAD SCI USA, V85, P8067, DOI 10.1073/pnas.85.21.8067; AMINOFF D, 1988, BLOOD CELLS, V14, P229; BARTOSZ G, 1981, BIOCHIM BIOPHYS ACTA, V644, P69, DOI 10.1016/0005-2736(81)90059-6; BARTOSZ G, 1991, GERONTOLOGY, V37, P33, DOI 10.1159/000213251; BARTOSZ G, 1984, MECH AGEING DEV, V24, P1, DOI 10.1016/0047-6374(84)90172-6; BARTOSZ G, 1990, BLOOD CELL BIOCH, V1, P45; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BLUMENFELD N, 1991, BLOOD, V77, P849; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; COMFURIUS P, 1990, J LIPID RES, V31, P1719; CONNOR J, 1992, J BIOL CHEM, V267, P19412; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; CONNOR J, 1989, P NATL ACAD SCI USA, V86, P3184, DOI 10.1073/pnas.86.9.3184; DALE GL, 1990, BIOCHIM BIOPHYS ACTA, V1036, P183, DOI 10.1016/0304-4165(90)90032-R; DHERMY D, 1987, BIOCHIM BIOPHYS ACTA, V904, P201, DOI 10.1016/0005-2736(87)90369-5; DUMASWALA UJ, 1984, TRANSFUSION, V24, P490, DOI 10.1046/j.1537-2995.1984.24685066807.x; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; GALILI U, 1986, J CLIN INVEST, V77, P27, DOI 10.1172/JCI112286; GREENWALT TJ, 1988, BRIT J HAEMATOL, V68, P465, DOI 10.1111/j.1365-2141.1988.tb04237.x; HENTSCHEL WM, 1986, CLIN CHIM ACTA, V157, P33, DOI 10.1016/0009-8981(86)90315-3; HERRMANN A, 1990, BIOCHIM BIOPHYS ACTA, V1027, P41, DOI 10.1016/0005-2736(90)90045-P; JAIN SK, 1983, BRIT J HAEMATOL, V53, P247, DOI 10.1111/j.1365-2141.1983.tb02018.x; JAIN SK, 1988, BIOCHIM BIOPHYS ACTA, V937, P205, DOI 10.1016/0005-2736(88)90242-8; KAY MMB, 1983, P NATL ACAD SCI-BIOL, V80, P1631, DOI 10.1073/pnas.80.6.1631; KAY MMB, 1978, J SUPRAMOL STR CELL, V9, P555, DOI 10.1002/jss.400090409; LINDERKAMP O, 1982, BLOOD, V59, P1121; LUTZ HU, 1988, BLOOD CELLS, V14, P175; LUTZ HU, 1992, BIOCHIM BIOPHYS ACTA, V1116, P1, DOI 10.1016/0304-4165(92)90120-J; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; Lutz HU, 1990, BLOOD CELL BIOCH, V1, P81; MORRISON M, 1983, BIOMED BIOCHIM ACTA, V42, pS107; MUELLER TJ, 1987, J CLIN INVEST, V79, P492, DOI 10.1172/JCI112839; NASH GB, 1980, BIORHEOLOGY, V17, P479; NASH GB, 1983, BIOPHYS J, V43, P63, DOI 10.1016/S0006-3495(83)84324-0; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; PIOMELLI S, 1993, AM J HEMATOL, V42, P46, DOI 10.1002/ajh.2830420110; RIFKIND JM, 1983, ARCH BIOCHEM BIOPHYS, V222, P582, DOI 10.1016/0003-9861(83)90556-8; SCHLEPPERSCHAFER J, 1983, BIOCHEM BIOPH RES CO, V115, P551, DOI 10.1016/S0006-291X(83)80180-6; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131; SCHWARTZ RS, 1985, J CLIN INVEST, V75, P1965, DOI 10.1172/JCI111913; UTSUGI T, 1991, CANCER RES, V51, P3062; VANOSS CJ, 1982, BIORHEOLOGY, V19, P725; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; ZWAAL RFA, 1989, MOL CELL BIOCHEM, V91, P23, DOI 10.1007/BF00228075	48	262	269	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2399	2404						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300565				2022-12-25	WOS:A1994MV43200012
J	KRATZ, F; HARTMANN, M; KEPPLER, B; MESSORI, L				KRATZ, F; HARTMANN, M; KEPPLER, B; MESSORI, L			THE BINDING-PROPERTIES OF 2 ANTITUMOR RUTHENIUM(III) COMPLEXES TO APOTRANSFERRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-METABOLISM; PERSPECTIVES; TRANSFERRINS; CISPLATIN	The interaction of two ruthenium(III) complexes exhibiting high anticancer activity, namely trans-indazolium(bisindazole)tetrachlororuthenate(III) (ruind) and trans-imidazolium(bisimidazole)tetrachlororuthenate(III) (ru-im), with human serum apotransferrin has been investigated through spectroscopic and chromatographic techniques with the ultimate goal of preparing adducts with good selectivity for cancer cells. Whereas the binding of ru-im to human serum apotransferrin takes several hours, ru-ind, the less toxic complex, gives rise to a well defined 2:1 complex within a few minutes. We have ascertained that ru-ind binding occurs around the iron binding sites; binding does not occur in the absence of bicarbonate, and this anion dictates the kinetic and mechanistic characteristics of protein binding of ru-ind. The two ruthenium(III) complexes do not behave as iron(III) complexes, eg. FE(EDTA) or Fe(nitrilotriacetate), which lose their respective ligands when binding apotransferrin, but the N-heterocycles remain attached to the metal in the protein-bound species. Reversion of binding is obtained by acidification in the presence of chelators such as citrate or ATP. In comparison with cisplatin and its deactivation by serum proteins, our results indicate that other metal complexes such as ruind could use transferrin as a drug delivery system. Furthermore, the rapid protein binding of ru-ind seems to be related to a lower toxicity while still exhibiting high antitumor activity.	UNIV FLORENCE,DEPT CHEM,INORGAN & BIOINORGAN CHEM LAB,I-50121 FLORENCE,ITALY	University of Florence	KRATZ, F (corresponding author), UNIV HEIDELBERG,INST ANORGAN CHEM,NEUENHEIMER FELD 270,D-69120 HEIDELBERG,GERMANY.			messori, luigi/0000-0002-9490-8014; Keppler, Bernhard/0000-0003-0877-1822				ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BATES GW, 1975, J BIOL CHEM, V250, P2177; CAZZOLA M, 1990, BLOOD, V75, P1903; COLE WC, 1980, CHEM-BIOL INTERACT, V30, P223, DOI 10.1016/0009-2797(80)90128-3; CRICHTON RR, 1992, BIOCHEMISTRY-US, V31, P11255, DOI 10.1021/bi00161a001; DALEYYATES PT, 1985, BIOCH MECHANISMS PLA, P121; Faulk W.P., 1990, OXIDOREDUCTION PLASM, V1, P205; HAGEN WR, 1993, IN PRESS J CHEM S DA; Keppler BK, 1989, PROGR CLIN BIOCH MED, V10, P41; KRATZ F, 1993, J INORG BIOCHEM, V49, P79, DOI 10.1016/0162-0134(93)85017-3; KRATZ F, 1992, METAL IONS BIOL MED, V2, P69; Kratz F., 1993, METAL COMPLEXES CANC, P391; KROGHJESPERSEN K, 1984, INORG CHEM, V23, P4390, DOI 10.1021/ic00193a060; Lipponer K.-G., 1992, THESIS U HEIDELBERG; MANOHARAN PT, 1973, INORG CHEM, V12, P2753, DOI 10.1021/ic50130a003; MASON SF, 1982, MOL OPTICAL ACTIVITY; PIZZO SV, 1988, J INORG BIOCHEM, V33, P67, DOI 10.1016/0162-0134(88)80035-7; TAKAHASHI K, 1985, JPN J CANCER RES, V76, P68; Trowbridge I S, 1991, BIOTECHNOLOGY PLASMA, V58, P139; Ward S. G., 1988, METAL BASED ANTITUMO, P1; WELLHONER HH, 1991, J BIOL CHEM, V266, P4309	22	198	205	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2581	2588						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300587				2022-12-25	WOS:A1994MV43200037
J	QUEST, AFG; BARDES, ESG; BELL, RM				QUEST, AFG; BARDES, ESG; BELL, RM			A PHORBOL ESTER BINDING DOMAIN OF PROTEIN KINASE-C-GAMMA - HIGH-AFFINITY BINDING TO A GLUTATHIONE-S-TRANSFERASE/CYS2 FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-100 MIXED MICELLES; REGULATORY DOMAIN; 2ND MESSENGERS; DILUTE-SOLUTION; LIPID-BINDING; N-CHIMAERIN; ACTIVATION; DIACYLGLYCEROL; PHOSPHATIDYLSERINE; CALCIUM	Cysteine-rich regions of protein kinase C (PKC) are implicated in diacylglycerol-dependent regulation of kinase activity. The second cysteine-rich region (residues 92-173) of PKCgamma was expressed as a fusion protein with glutathione-S-transferase in Escherichia coli and purified to homogeneity by affinity chromatography. This fusion protein displayed high affinity phorbol dibutyrate (PDBu) binding (K(d) 23 nM). The phosphatidylserine dependence of PDBu binding was highly cooperative with Hill numbers (near 4.5) similar to those previously reported for PKCgamma (Burns, D. J., and Bell, R. M. (1991) J. Biol. Chem. 266,18330-18338). The fusion protein specifically bound 4beta-hydroxy-PDBu but not the 4alpha-stereoisomer. Furthermore, sn-1,2-dioctanoylglycerol (diC8) stereoselectively competed for PDBu binding. The cysteine-rich region was sufficient for association of the fusion protein to liposome preparations containing phosphatidylserine and phosphatidylcholine. Association was significantly enhanced in a stereospecific manner by the presence of PDBu as well as diC8. These results establish that a single cysteine-rich domain (residues 92-173) of PKCgamma contains regions necessary and sufficient for lipid-dependent stereospecific interactions with PDBu and diC8. Furthermore, the region is sufficient to confer translocation of a fusion protein to liposomes in a PDBu- and diC8-dependent fashion. Thus, a single cysteine-rich region of PKCgamma displays many of the properties characteristic of PKC.	DUKE UNIV, MED CTR, CELL GROWTH REGULAT & ONCOGENESIS SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Duke University					NIGMS NIH HHS [GM 38737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BELL RM, 1991, J BIOL CHEM, V266, P4661; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BONI LT, 1985, J BIOL CHEM, V260, P819; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; BURNS DJ, 1992, PROTEIN KINASE C CUR, P25; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANNUN YA, 1987, METHOD ENZYMOL, V141, P287; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HUBBARD SR, 1991, SCIENCE, V254, P1776; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1986, J BIOL CHEM, V261, P4867; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MICHELL RH, 1992, TRENDS BIOCHEM SCI, V17, P274, DOI 10.1016/0968-0004(92)90433-A; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PREISS J, 1986, J BIOL CHEM, V261, P8597; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RANDO RR, 1988, FASEB J, V2, P2348, DOI 10.1096/fasebj.2.8.3282960; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; SOSSIN WS, 1992, J NEUROSCI, V12, P1160; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; White DA, 1973, FORM FUNCTION PHOSPH, P441; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0	62	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2953	2960						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300627				2022-12-25	WOS:A1994MV43200086
J	CHNG, JLC; IBRAHIM, B				CHNG, JLC; IBRAHIM, B			TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL MECHANISMS MODULATE CREATINE-KINASE EXPRESSION DURING DIFFERENTIATION OF OSTEOBLASTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT OSTEO-SARCOMA; RNA POLYMERASE-II; MESSENGER-RNA; REGULATORY ELEMENTS; GROWTH CARTILAGE; PROMOTER REGION; ROS 17/2.8; BRAIN; SEQUENCES; GENE	Enhancement of energy metabolism is fundamental to the developmental programs of many cell types. This work examines the molecular mechanisms that mediate changes in energy metabolism during differentiation of osteoblastic cells. When the rat osteoblastic cell line, ROS 17/2.8, is induced to differentiate with 1,25-dihydroxyvitamin D3, expression of creatine kinase-b (ck-b), a pivotal enzyme in energy metabolism, is enhanced. Maximum enhancement occurs at 48 h of induction with 10 nM 1,25-dihydroxyvitamin D3 when creatine kinase activity is 2.1-fold over uninduced cells. This, is associated with a 2-fold increase in transcription rate and the formation of a second protein-DNA complex on the ck-b gene promoter that is supplementary to the one present in undifferentiated cells. In addition, the contribution of posttranscriptional regulatory mechanisms is suggested by (1) the increase in ck-b mRNA abundance exceeds that of transcription rate, indicating an increase in message stability, (2) the increase in ck-b mRNA precedes and exceeds that of protein activity, indicating translational modulation, and (3) RNA mobility-shift assays indicate that a cytosolic factor in ROS 17/2.8 cells interacts specifically with the highly conserved 3'-untranslated region of the ck-b mRNA. We have previously reported that such an interaction mediates translational control (Ch'ng, J. L. C., Shoemaker, D. L., Schimmel, P., and Holmes, E. W. (1990) Science 248,1003-1006). The physiological roles of these regulatory mechanisms during osteoblast differentiation are discussed.	VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044490] Funding Source: NIH RePORTER; NIDDK NIH HHS [1RO1 DK44490] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBLE FM, 1991, CURRENT PROTOCOLS MO; BENFIELD PA, 1988, GENE, V63, P227, DOI 10.1016/0378-1119(88)90527-6; BESSMAN SP, 1985, ANN REV BIOCH, V54, P8314; BILLADELLO JJ, 1986, BIOCHEM BIOPH RES CO, V138, P392, DOI 10.1016/0006-291X(86)90294-9; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; DAOUK GH, 1988, J BIOL CHEM, V263, P2442; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKERT BS, 1980, J CELL BIOL, V86, P1, DOI 10.1083/jcb.86.1.1; FRIEDMAN DL, 1992, J BIOL CHEM, V267, P4270; FUNANAGE VL, 1992, BONE MINER, V17, P228, DOI 10.1016/0169-6009(92)90742-V; GRONOWICZ G, 1986, J BONE MINER RES, V1, P441; HAMES BD, 1984, TRANSCRIPTION TRANSL; HARRISON JR, 1989, ENDOCRINOLOGY, V125, P327, DOI 10.1210/endo-125-1-327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; KADDURAHDAOUK R, 1990, MOL CELL BIOL, V10, P1476, DOI 10.1128/MCB.10.4.1476; KATOH R, 1991, CLIN ORTHOPAEDICS, V271, P283; KELLER TCS, 1991, CELL MOTIL CYTOSKEL, V19, P169, DOI 10.1002/cm.970190305; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEECH AR, 1978, ANAL BIOCHEM, V90, P561, DOI 10.1016/0003-2697(78)90150-1; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MARIMAN E, 1991, GENE, V102, P205, DOI 10.1016/0378-1119(91)90079-Q; MITCHELL MT, 1990, J BIOL CHEM, V265, P8259; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; RIGS BL, 1988, OSTEOPORSIS; RITCHIE ME, 1991, NUCLEIC ACIDS RES, V19, P6231, DOI 10.1093/nar/19.22.6231; SHAPIRO IM, 1992, J BONE MINER RES, V7, P493; SOMJEN D, 1989, P NATL ACAD SCI USA, V86, P3361, DOI 10.1073/pnas.86.9.3361; SOMJEN D, 1989, ENDOCRINOLOGY, V125, P1870; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; WALLIMANN T, 1990, PROG CLIN BIOL RES, V344, P877; YI TM, 1991, NUCLEIC ACIDS RES, V19, P3027, DOI 10.1093/nar/19.11.3027	36	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2336	2341						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294491				2022-12-25	WOS:A1994MR98800115
J	POSSMAYER, FE; GRABER, P				POSSMAYER, FE; GRABER, P			THE PH(IN) AND PH(OUT) DEPENDENCE OF THE RATE OF ATP SYNTHESIS CATALYZED BY THE CHLOROPLAST H+-ATPASE, CF0F1, IN PROTEOLIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-PH; COUPLING FACTOR; EXTERNAL PH; SPINACH-CHLOROPLASTS; SYNTHESIS HYDROLYSIS; ACTIVATION; TRANSPORT; SYNTHASE; MEMBRANE; PHOTOPHOSPHORYLATION	The H+-ATPase from chloroplasts was isolated, purified, and reconstituted into liposomes from phosphatidylcholine/phosphatidic acid. The rate of ATP synthesis was measured after energization of the proteoliposomes by an acid-base transition as a function pH(out) and pH(in). At any given pH(out), the rate increased sigmoidally with increasing internal H+ concentration with half-maximal rates at about pH(in) 5.3 for all pH(out) values between 9.3 and 7.2. At any given pH(in), the rate decreased sigmoidally with increasing external H+ concentration with half-maximal rates at about pH(out) 7.8. The dependence on internal H+ concentration was attributed to the protonation of three monovalent groups with the same pK(in), and the dependence on external proton concentration to the deprotonation of two groups with the same pK(out). The following scheme is proposed. The first step of the reaction is the binding of three (or four) protons from the inside of the F0 part, followed by ADP and P(i) binding at the F1 part. Then, the enzyme conformation is changed, and the proton binding sites are exposed to the outside, followed by proton release from F0 and ATP release from F1. The reaction cycle is closed by changing the enzyme conformation to the form where protons can bind from the inside.	UNIV STUTTGART, INST BIOL, PFAFFENWALDRING 57, D-70550 STUTTGART, GERMANY	University of Stuttgart								ALLGYER TT, 1979, BIOCHEMISTRY-US, V18, P5348, DOI 10.1021/bi00591a014; ALTHOFF G, 1989, J MEMBRANE BIOL, V108, P263, DOI 10.1007/BF01871741; BIAUDET P, 1987, BIOCHIM BIOPHYS ACTA, V893, P544, DOI 10.1016/0005-2728(87)90106-X; BIZOUARN T, 1991, BIOCHEMISTRY-US, V30, P6847, DOI 10.1021/bi00242a007; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DAVENPORT JW, 1986, BIOCHIM BIOPHYS ACTA, V851, P136, DOI 10.1016/0005-2728(86)90256-2; DEWEY TG, 1981, J BIOL CHEM, V256, P8941; FROMME P, 1987, Z NATURFORSCH C, V42, P1239; Gr_ aber P., 1980, PHOTOSYNTHESIS, VII; GRABER P, 1992, J BIOENERG BIOMEMBR, V24, P493, DOI 10.1007/BF00762367; GRABER P, 1977, BIOCHIM BIOPHYS ACTA, V461, P426, DOI 10.1016/0005-2728(77)90231-6; GRABER P, 1984, BER BUNSEN PHYS CHEM, V88, P599, DOI 10.1002/bbpc.19840880706; GRABER P, 1976, BIOCHIM BIOPHYS ACTA, V423, P141, DOI 10.1016/0005-2728(76)90174-2; Graber P, 1987, PROGR PHOTOSYNTHESIS, V3, P177; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRZESIEK S, 1988, BIOCHIM BIOPHYS ACTA, V938, P411, DOI 10.1016/0005-2736(88)90139-3; JAGENDORF AT, 1966, P NATL ACAD SCI USA, V55, P170, DOI 10.1073/pnas.55.1.170; JENCKS WP, 1989, METHOD ENZYMOL, V171, P145; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; KOTHEN G, 1992, RES PHOTOSYNTHESIS, V2, P645; KRAMER DM, 1990, PHOTOSYNTH RES, V26, P213, DOI 10.1007/BF00033134; KRAMER DM, 1989, BIOCHIM BIOPHYS ACTA, V976, P28, DOI 10.1016/S0005-2728(89)80186-0; LABAHN A, 1992, FEBS LETT, V313, P177, DOI 10.1016/0014-5793(92)81439-S; Lauger P., 1991, ELECTROGENIC ION PUM; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILLS JD, 1984, BIOCHIM BIOPHYS ACTA, V764, P93, DOI 10.1016/0005-2728(84)90145-2; MILLS JD, 1982, PHOTOSYNTHESIS, V2, P839; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGLE JF, 1983, J MEMBRANE BIOL, V74, P1, DOI 10.1007/BF01870590; NISHIMURA M, 1962, BIOCHIM BIOPHYS ACTA, V59, P177; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PICK U, 1974, FEBS LETT, V48, P32, DOI 10.1016/0014-5793(74)81055-0; PICK U, 1979, J BIOL CHEM, V254, P2793; PORTIS AR, 1976, J BIOL CHEM, V251, P1610; RAVIZZINI RA, 1980, BIOCHIM BIOPHYS ACTA, V591, P135, DOI 10.1016/0005-2728(80)90227-3; RICHARD P, 1990, EUR J BIOCHEM, V193, P921, DOI 10.1111/j.1432-1033.1990.tb19418.x; RUMBERG B, 1980, BER BUNSEN PHYS CHEM, V84, P1055, DOI 10.1002/bbpc.19800841025; RUMBERG B, 1990, CURRENT RES PHOTOSYN, V3, P125; SCHMIDT G, 1985, BIOCHIM BIOPHYS ACTA, V808, P46, DOI 10.1016/0005-2728(85)90026-X; SCHOLL DW, 1982, MAR GEOL, V4, P105; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; Stein W., 2012, TRANSPORT DIFFUSION; STRELOW F, 1993, FEBS LETT, V323, P19, DOI 10.1016/0014-5793(93)81439-7; VONWALRAVEN HS, 1990, BIOCHIM BIOPHYS ACTA, V1015, P425	48	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1896	1904						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294439				2022-12-25	WOS:A1994MR98800054
J	WALZ, T; SMITH, BL; ZEIDEL, ML; ENGEL, A; AGRE, P				WALZ, T; SMITH, BL; ZEIDEL, ML; ENGEL, A; AGRE, P			BIOLOGICALLY-ACTIVE 2-DIMENSIONAL CRYSTALS OF AQUAPORIN CHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; WATER CHANNELS; RECONSTITUTION; FAMILY; CDNA; MIP	Plasma membranes of several mammalian tissues are highly permeable to water due to the presence of CHIP, the 28-kDa channel-forming integral protein which is the archetypal member of the aquaporin family of water channel proteins. To define its native structure, purified red cell CHIP protein was reconstituted into lipid bilayers at a high protein-to-lipid ratio, and the resulting 3-mum diameter membrane vesicles were examined by high resolution electron microscopy. The reconstituted membranes contained highly ordered two-dimensional crystalline lattices of p422(1) symmetry in which each CHIP tetramer contained a central depression extending from the outer and inner surfaces of the membrane into the transbilayer domain of the molecule. The reconstituted membranes also exhibited extremely high osmotic water permeability, P(f) = 0.472 cm/s, corresponding to the sum of activities of all incorporated CHIP molecules. These studies report the first two-dimensional crystallization of a biologically active water channel and provide direct evidence of the structure responsible for its pore-like behavior.	UNIV BASEL, BIOCTR, ME MULLER INST HIGH RESOLUT ELECTRON MICROSCOPY, CH-4056 BASEL, SWITZERLAND; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; UNIV PITTSBURGH, SCH MED, DIV RENAL ELECTROLYTE, PITTSBURGH, PA 15213 USA	University of Basel; Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Walz, Thomas/0000-0003-2606-2835	NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline; NIDDK NIH HHS [DK43955] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; AMBUDKAR SV, 1986, METHOD ENZYMOL, V125, P558; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Finkelstein A., 1987, WATER MOVEMENT LIPID; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HORWITZ J, 1987, BIOCHEMISTRY-US, V26, P8092, DOI 10.1021/bi00399a012; JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZEIDEL ML, 1994, IN PRESS BIOCHEMISTR	25	179	183	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1583	1586						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294400				2022-12-25	WOS:A1994MR98800005
J	YIM, MB; CHAE, HZ; RHEE, SG; CHOCK, PB; STADTMAN, ER				YIM, MB; CHAE, HZ; RHEE, SG; CHOCK, PB; STADTMAN, ER			ON THE PROTECTIVE MECHANISM OF THE THIOL-SPECIFIC ANTIOXIDANT ENZYME AGAINST THE OXIDATIVE DAMAGE OF BIOMACROMOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN RESONANCE; PULSE-RADIOLYSIS; THIYL RADICALS; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; MOLECULAR-OXYGEN; AQUEOUS-SOLUTION; GLUTATHIONE; DITHIOTHREITOL; INACTIVATION	A thiol-specific antioxidant enzyme (TSA), which provides protection against the inactivation of other enzymes by the thiol/Fe(III)/oxygen system, was previously isolated and cloned. We investigated the mechanism by which TSA protects biomolecules from oxidative damage caused by the thiol-containing oxidation system using the spin trapping method with 5,5-dimethyl-1-pyrroline N-oxide (DMPO). Thiyl radicals from dithiothreitol (.DTT) were produced by horseradish peroxidase/H2O2 under aerobic and anaerobic conditions and by the Fe(III)/oxygen system. The formation of DMPO-.DTT radical adducts were inhibited by TSA regardless of the thiyl radical-generating conditions used. The active mutant C170S also quenched the signals of the radical adduct, whereas the inactive mutant C47S did not exert any effect. It was also found that C170S has a higher rate at the initial stage of the reaction than that of the native enzyme, although C170S failed to remove DMPO-.DTT radical adducts completely. These results indicate that only active TSA can catalyze the removal of thiyl radicals, and cysteine 47 is required for this activity. In addition, thiyl radicals react with oxygen to generate unidentified thiylperoxy species. Fe.EDTA reacts with this species to generate a reactive radical that can abstract hydrogen atom from ethanol to produce a hydroxyethyl radical. This reactive thiyl-oxygen radical is believed to be responsible for causing deleterious effects on biomolecules. Together, our data indicate that TSA protects biomolecules from oxidative damage by catalyzing the removal of thiyl radicals before they generate more reactive radicals. However, presently we cannot rule out the possibility that TSA can also use other thiol-containing species as substrates.			YIM, MB (corresponding author), NHLBI,BIOCHEM LAB,BLDG 3,RM 202,BETHESDA,MD 20892, USA.							AKHLAQ MS, 1987, INT J RADIAT BIOL, V51, P91, DOI 10.1080/09553008714550531; ASMUS KD, 1992, OXIDATIVE DAMAGE REP, P226; BAKER MZ, 1982, INT J RADIAT BIOL, V41, P595, DOI 10.1080/09553008214550691; BECKER D, 1988, INT J RADIAT BIOL, V53, P767, DOI 10.1080/09553008814551121; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAN PC, 1973, J AM CHEM SOC, V95, P5504, DOI 10.1021/ja00798a012; CHATGILIALOGLU C, 1990, NATO ADV SCI I A-LIF, V197, P31; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; DAVIES MJ, 1987, CHEM-BIOL INTERACT, V61, P177, DOI 10.1016/0009-2797(87)90038-X; GILBERT BC, 1990, NATO ADV SCI I A-LIF, V197, P135; GLATT H, 1983, SCIENCE, V220, P961, DOI 10.1126/science.6342137; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; ITO O, 1984, B CHEM SOC JPN, V57, P1745, DOI 10.1246/bcsj.57.1745; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; JAYSON GG, 1971, INT J RADIAT BIOL RE, V19, P143, DOI 10.1080/09553007114550191; JOSEPHY PD, 1984, TETRAHEDRON LETT, V25, P1685, DOI 10.1016/S0040-4039(01)81144-8; KENNEDY CH, 1986, BIOCHEM BIOPH RES CO, V141, P1123, DOI 10.1016/S0006-291X(86)80160-7; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM K, 1985, J BIOL CHEM, V260, P5394; KIM KW, 1988, J BIOL CHEM, V263, P4704; LAI CS, 1977, BIOCHEM BIOPH RES CO, V78, P51, DOI 10.1016/0006-291X(77)91220-7; Mason RP, 1982, FREE RADICALS BIOL, V5, P161; MISRA HP, 1974, J BIOL CHEM, V249, P2151; PRUTZ WA, 1987, INT J RADIAT BIOL, V52, P677, DOI 10.1080/09553008714552191; PUNEKAR NS, 1987, J BIOL CHEM, V262, P6714; PURDIE JW, 1973, CAN J CHEM, V51, P3132, DOI 10.1139/v73-466; QUINTILIANI M, 1986, INT J RADIAT BIOL, V50, P573, DOI 10.1080/09553008614550981; REYNOLDS CH, 1980, BIOCHEM J, V185, P451, DOI 10.1042/bj1850451; ROSS D, 1985, J BIOL CHEM, V260, P5028; SCHONEICH C, 1989, BIOCHEM BIOPH RES CO, V161, P113, DOI 10.1016/0006-291X(89)91568-4; SCHONEICH C, 1990, NATO ADV SCI I A-LIF, V197, P367; SCHONEICH C, 1989, FREE RADICAL RES COM, V6, P393, DOI 10.3109/10715768909087923; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; SCHULTEFROHLINDE D, 1989, FREE RADICAL RES COM, V6, P181, DOI 10.3109/10715768909073465; SEVILLA MD, 1987, BIOCHEM BIOPH RES CO, V144, P1037, DOI 10.1016/S0006-291X(87)80068-2; SEVILLA MD, 1990, INT J RADIAT BIOL, V57, P65, DOI 10.1080/09553009014550351; SIMIC M, 1970, J AM CHEM SOC, V92, P6096, DOI 10.1021/ja00723a067; SWARTS SG, 1989, J PHYS CHEM-US, V93, P155, DOI 10.1021/j100338a034; TAMBA M, 1986, INT J RADIAT BIOL, V50, P595, DOI 10.1080/09553008614550991; TROTTA PP, 1974, J BIOL CHEM, V249, P1915; von Sonntag C., 1987, CHEM BASIS RAD BIOL, P353; Wardman P, 1988, GLUTATHIONE CONJUGAT, P43; WELLNER VP, 1984, P NATL ACAD SCI-BIOL, V81, P4732, DOI 10.1073/pnas.81.15.4732; YAMAZAKI I, 1977, FREE RADICALS BIOL, V3, P183; ZHANG N, 1991, J PHYS CHEM-US, V95, P4718, DOI 10.1021/j100165a024	46	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1621	1626						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294408				2022-12-25	WOS:A1994MR98800015
J	FAVIER, D; GONDA, TJ				FAVIER, D; GONDA, TJ			DETECTION OF PROTEINS THAT BIND TO THE LEUCINE-ZIPPER MOTIF OF C-MYB	ONCOGENE			English	Note							PROTO-ONCOGENE PRODUCT; LEUKEMIA-CELL LINE; HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA; HOMEOBOX GENE; DNA-BINDING; V-MYB; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; EXPRESSION	The product of the c-myb proto-oncogene, c-Myb, binds DNA and can enhance transcription of genes bearing copies of the DNA sequence it recognises. Deletion or disruption of a negative regulatory domain (NRD) in the carboxyl portion of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform haemopoietic cells. Since mutational analysis has shown that one critical element within the NRD is a leucine zipper motif, we have sought to identify cellular proteins that can interact with the c-Myb leucine zipper. Using fusion proteins containing this region as an affinity reagent, we have identified two nuclear proteins, p67 and p160, that bind to the wildtype, but not to a mutated c-Myb leucine zipper. These two proteins were shown to be related by comparison of peptides generated by partial digestion. While p160 was found to be ubiquitous amongst different murine haemopoietic cell lines, and was also present in NIH3T3 fibroblasts, p67 was detected in a restricted set of immature myeloid cells. Intriguingly p160, but not p67, could also bind to the c-Jun leucine zipper.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia								ALEXANDER B, 1992, GENE CHROMOSOME CANC, V5, P286, DOI 10.1002/gcc.2870050404; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAUERLE PA, 1988, SCIENCE, V242, P540; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COOPER PC, 1982, LEUKEMIA RES, V6, P313, DOI 10.1016/0145-2126(82)90093-5; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GONDA TJ, 1991, SEMINARS VIROLOGY, V2, P351; GONDA TJ, 1993, IN PRESS BLOOD; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P308; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDO T, 1992, ONCOGENE, V7, P1999; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; ZOBEL A, 1991, ONCOGENE, V6, P1397	44	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					305	311						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302594				2022-12-25	WOS:A1994MW24700037
J	PEREZ, JL; SHEN, XY; FINKERNAGEL, S; SCIORRA, L; JENKINS, NA; GILBERT, DJ; COPELAND, NG; WONG, TW				PEREZ, JL; SHEN, XY; FINKERNAGEL, S; SCIORRA, L; JENKINS, NA; GILBERT, DJ; COPELAND, NG; WONG, TW			IDENTIFICATION AND CHROMOSOMAL MAPPING OF A RECEPTOR TYROSINE KINASE WITH A PUTATIVE PHOSPHOLIPID-BINDING SEQUENCE IN ITS ECTODOMAIN	ONCOGENE			English	Article							FACTOR-VIII; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; GENETIC-LINKAGE; DNA-SEQUENCES; FACTOR-V; C-KIT; FAMILY; MOUSE; ACID	We have cloned a novel receptor tyrosine kinase that has an unusual ectodomain. The extracellular sequence consists of 416 amino acids and has none of the structural motifs that have been found in other receptor tyrosine kinases. The 150 amino acids in the amino terminus of the receptor is homologous to a putative phospholipid-binding sequence that is found also in other cell adhesion molecules such as the neuronal A5 antigen and coagulation factors V and VIII. The kinase domain has a short cytoplasmic tail and contains a short insert between subdomains I and II. The structure of this receptor kinase suggests that it belongs to a new family of receptors involved in cell-cell interactions. The cell adhesion kinase (Cak) is expressed at low levels in most adult tissues and expression is highest in the brain and lung. Using fluorescence in situ hybridization and interspecific backcross mapping, the Cak gene was localized to human chromosome 6 and mouse chromosome 17.	ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854; ROBERT WOOD JOHNSON MED SCH,DEPT PEDIAT,PISCATAWAY,NJ 08854; NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; GOODWIN RH, UNPUB; Green EL, 1981, GENETICS PROBABILITY, P77; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JABS EW, 1987, AM J HUM GENET, V41, P374; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANE WH, 1988, BLOOD, V71, P539; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MUNOZDORADO J, 1991, CELL, V67, P995, DOI 10.1016/0092-8674(91)90372-6; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PAWSON T, 1990, TRENDS GENET, V6, P110; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RESCIGNO J, 1991, ONCOGENE, V6, P1909; ROSNET O, 1991, ONCOGENE, V6, P1641; RYDER LP, 1981, ANNU REV GENET, V15, P169, DOI 10.1146/annurev.ge.15.120181.001125; SHIER P, 1989, J BIOL CHEM, V264, P14605; SIRACUSA LD, 1991, GENETICS, V127, P169; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; ZHU H, 1993, APP CYTOGENET, V19, P33; ZIEGLER SF, 1993, ONCOGENE, V8, P663	43	41	45	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					211	219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302582				2022-12-25	WOS:A1994MW24700026
J	CUPP, C; TAYLOR, JP; KHALILI, K; AMINI, S				CUPP, C; TAYLOR, JP; KHALILI, K; AMINI, S			EVIDENCE FOR STIMULATION OF THE TRANSFORMING GROWTH-FACTOR-BETA-1 PROMOTER BY HIV-1 TAT IN CELLS DERIVED FROM CNS	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY-SYNDROME; NECROSIS-FACTOR-ALPHA; LONG-TERMINAL REPEAT; MONONUCLEAR PHAGOCYTES; AIDS PATIENTS; INDEPENDENT ACTIVATION; KAPOSIS-SARCOMA; BRAIN CULTURES; GLIAL-CELLS	Infection by human immunodeficiency virus type 1 (HIV-1), the etiologic agent of the acquired immunodeficiency syndrome (AIDS), is often complicated with a high incidence of neurologic disorders. It is believed that HIV-1, in addition to infecting both macroglial and microglial cells, may influence the expression of several strategic genes of uninfected neighboring or latently infected brain cells. It is suspected that the viral-encoded transregulatory protein, Tat, facilitates cross-communications between these cells. In support of this concept, earlier studies demonstrated that Tat is released from the infected cells, and has the capacity to be taken up by the uninfected cells and exert its biological activity on the responsive gene. Recent studies in several laboratories suggest the involvement of Tat in altering the expression of a limited number of cellular regulatory factors which, in turn, may mediate the altered physiology of the cells. In this communication, we demonstrate the ability of the HIV-1 Tat protein to increase expression of transforming growth factor beta1 (TGF-beta1), a cytokine with potent immunosuppressive activity, in human astrocytic glial cells. Implications of the Tat-mediated induction of TGF-beta1 expression and cytokine involvement in the regulation of immune response and central nervous system (CNS) pathology are discussed.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,JEFFERSON INST MOLEC MED,MOLEC NEUROVIROL SECT,PHILADELPHIA,PA 19107	Jefferson University			Taylor, J. Paul/N-2482-2018	Taylor, J. Paul/0000-0002-5794-0349				BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BREEN EC, 1990, J IMMUNOL, V144, P480; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CHOWDHURY M, 1993, ONCOGENE, V8, P887; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; JEYAPAUL J, 1991, ONCOGENE, V6, P1507; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KEKOW J, 1990, P NATL ACAD SCI USA, V87, P8321, DOI 10.1073/pnas.87.21.8321; KHALILI K, 1986, J VIROL, V60, P935, DOI 10.1128/JVI.60.3.935-942.1986; KIM SJ, 1989, J BIOL CHEM, V264, P402; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LAZDINS JK, 1991, J IMMUNOL, V147, P1201; LAZDINS JK, 1991, RES VIROLOGY, V142, P239, DOI 10.1016/0923-2516(91)90063-9; LEPEZUNIGA JL, 1987, J CLIN MICROBIOL, V25, P1695, DOI 10.1128/JCM.25.9.1695-1700.1987; LOTZ M, 1990, FASEB J, V4, P1861; MARCUZZI A, 1992, J VIROL, V66, P4228, DOI 10.1128/JVI.66.7.4228-4232.1992; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAHL SM, 1991, J EXP MED, V173, P981, DOI 10.1084/jem.173.4.981; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WRIGHT SC, 1988, J IMMUNOL, V141, P99	44	104	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2231	2236						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336945				2022-12-25	WOS:A1993LP17100024
J	AGARWAL, A; SALEM, P; ROBBINS, KC				AGARWAL, A; SALEM, P; ROBBINS, KC			INVOLVEMENT OF P72(SYK), A PROTEIN-TYROSINE KINASE, IN FC-GAMMA RECEPTOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; T-CELL; CROSS-LINKING; ZETA-CHAIN; MONOCLONAL-ANTIBODIES; HUMAN-MONOCYTES; SRC FAMILY; U937 CELLS; PHOSPHORYLATION; ACTIVATION	Previous studies have demonstrated that multichain immune recognition receptors, such as the T-cell receptor, signal their occupancy by inducing tyrosine phosphorylation of cellular protein substrates. Type I and II receptors for the Fc portion of IgG are single-chain immune recognition receptors having external, trans-membrane, and cytoplasmic domains. In the present study, we have investigated the possibility that, upon engagement, Fcgamma receptors induce protein-tyrosine phosphorylation. Our findings reveal increased phosphorylation of a number of proteins on tyrosine residues after cross-linking of either high (FcgammaRI) or low (FcgammaRII) affinity receptors expressed on HL60 cells. Engagement of FcgammaRII induced rapid tyrosine phosphorylation that decayed to basal levels by 40 min. In contrast, phosphorylation induced by FcgammaRI cross-linking was more delayed, peaking at 5-10 min, and returning to basal levels by 60 min. Kinase assays of cellular proteins immunoprecipitated from lysates of activated cells by antibody to phosphotyrosine revealed phosphorylation of a 72-kDa molecule that was not present in lysates of resting cells. This phosphoprotein was identified as p72syk by immunoprecipitation with antibodies directed against two different regions of the syk gene product. Immunoprecipitation with antibodies against p72syk followed by immunoblotting with anti-phosphotyrosine antibodies revealed an activation-dependent tyrosine phosphorylation of p72syk. Thus, our present findings demonstrate induction of protein-tyrosine phosphorylation following engagement of monomeric immune recognition receptors and identify p72syk as a tyrosine kinase substrate involved in signaling by FcgammaRI and FcgammaRII.	NIDR, CELLULAR DEV & ONCOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; EINSPAHR KJ, 1991, P NATL ACAD SCI USA, V88, P6279, DOI 10.1073/pnas.88.14.6279; EISEMAN E, 1992, NATURE, V355, P78; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; GUYRE PM, 1989, J IMMUNOL, V143, P1650; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LOONEY RJ, 1986, J IMMUNOL, V136, P1641; MACINTYRE EA, 1989, J IMMUNOL, V142, P2377; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; RANKIN BM, 1993, J IMMUNOL, V150, P605; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VANDEWINKEL JGJ, 1990, SCAND J IMMUNOL, V31, P315; VIVIER E, 1991, J IMMUNOL, V146, P206; WANGE RL, 1992, J BIOL CHEM, V267, P11685; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	37	138	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15900	15905						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340414				2022-12-25	WOS:A1993LN30500082
J	MUNCHPETERSEN, B; TYRSTED, G; CLOOS, L				MUNCHPETERSEN, B; TYRSTED, G; CLOOS, L			REVERSIBLE ATP-DEPENDENT TRANSITION BETWEEN 2 FORMS OF HUMAN CYTOSOLIC THYMIDINE KINASE WITH DIFFERENT ENZYMATIC-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-LYMPHOCYTES; HUMAN DEOXYTHYMIDINE KINASE; ACUTE MYELOCYTIC-LEUKEMIA; CELL-CYCLE; SUBSTRATE-SPECIFICITY; MESSENGER-RNA; DNA-SYNTHESIS; BLAST CELLS; PURIFICATION; PLACENTA	Human cytosolic thymidine kinase, subunit molecular mass about 24 kDa, is a tetramer in the presence of ATP but a dimer in the presence of thymidine or without substrates. The pure, substrate-free enzyme showed complex, non-hyperbolic thymidine substrate kinetics with an apparent K(m) of 15 muM. Incubation with ATP at 4-degrees-C induced a time-dependent transition to an enzyme form with hyperbolic kinetics and a 20-fold lower K(m) value for thymidine (0.7 muM) but the same maximal velocity as for cytosolic thymidine kinase (TK1) without ATP. Removal of the ATP by carboxymethyl chromatography reestablished the non-hyperbolic kinetics with the low affinity for thymidine (K(m(app)) = 12 muM), and this enzyme form could be reversed once more by ATP incubation to the high affinity enzyme form. Similar shifts could not be induced by thymidine. The activating effect of ATP depended on the concentration of enzyme protein in a linear manner. These results indicate that ATP is a positive effector of cytosolic thymidine kinase, controlling a kinetically slow transition between two molecular forms of the enzyme. A hypothetical reaction mechanism is presented to explain the complex kinetic behavior.	UNIV COPENHAGEN,PANUM INST,DEPT MED BIOCHEM & GENET BIOCHEM LAB C,DK-2200 COPENHAGEN,DENMARK	University of Copenhagen	MUNCHPETERSEN, B (corresponding author), ROSKILDE UNIV CTR,DEPT BIOL & CHEM 1,BOX 260,DK-4000 ROSKILDE,DENMARK.							COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; ELLIMS PH, 1982, MOL CELL BIOCHEM, V45, P113; FERRARO P, 1992, EXP CELL RES, V199, P349, DOI 10.1016/0014-4827(92)90444-D; GAN TE, 1983, J BIOL CHEM, V258, P7000; HOLDEN L, 1980, EUR J CANCER, V16, P115, DOI 10.1016/0014-2964(80)90116-4; ITO M, 1990, J BIOL CHEM, V265, P6954; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KAUFFMAN MG, 1991, ONCOGENE, V6, P1427; KIT S, 1976, MOL CELL BIOCHEM, V11, P161, DOI 10.1007/BF01744997; KOFOED ML, 1986, PHOTODERMATOLOGY, V3, P158; LEE LS, 1976, J BIOL CHEM, V251, P2600; LEE LS, 1976, BIOCHEMISTRY-US, V15, P3686, DOI 10.1021/bi00662a007; MUNCHPETERSEN B, 1984, MOL CELL BIOCHEM, V64, P173; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; MUNCHPETERSEN B, 1977, BIOCHIM BIOPHYS ACTA, V478, P364, DOI 10.1016/0005-2787(77)90152-6; MUNCHPETERSEN B, 1990, LEUKEMIA RES, V14, P39, DOI 10.1016/0145-2126(90)90144-X; PIPER AA, 1980, BIOCHIM BIOPHYS ACTA, V633, P400, DOI 10.1016/0304-4165(80)90198-1; Plagemann P.G.W., 1980, CURR TOP MEMBR TRANS, P225; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; TAMIYA N, 1989, BIOCHIM BIOPHYS ACTA, V995, P28, DOI 10.1016/0167-4838(89)90229-X; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025	22	70	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15621	15625						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340387				2022-12-25	WOS:A1993LN30500046
J	VASU, SK; KEDERSHA, NL; ROME, LH				VASU, SK; KEDERSHA, NL; ROME, LH			CDNA CLONING AND DISRUPTION OF THE MAJOR VAULT PROTEIN-ALPHA GENE (MVPA) IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN GENE; TRANSFORMATION; EXPRESSION; SEQUENCE; GENERATION; NUMBER; CELLS; RNA	Vaults are large cytoplasmic ribonucleoprotein particles found in nearly all eukaryotic cells. Dictyostelium vaults contain two major proteins, MVPalpha (94.2 kDa) and MVPbeta (approximately 92 kDa). Using an anti-rat vault antibody, we screened a Dictyostelium cDNA expression library and isolated a 2.8-kilobase pair clone that contained a single full-length reading frame. The identity of the clone was established by the presence of a predicted 20-amino acid sequence identical to that found in a peptide sequenced from purified MVPalpha. We have disrupted the single copy gene using homologous recombination and have demonstrated a loss of MVPalpha. Although the cells still produce MVPbeta, they do not contain characteristic vault particles, suggesting that MVPalpha is required for normal vault structure. These cells should be a valuable tool for elucidating the function of vaults.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, 33-257 CHS, LOS ANGELES, CA 90024 USA; IMMUNOGEN INC, CAMBRIDGE, MA 02139 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; ImmunoGen, Inc.			Rome, Leonard H/E-8786-2016	Rome, Leonard H/0000-0002-1236-2063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038097] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHUGANI D C, 1991, Journal of Cell Biology, V115, p458A; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORING V, 1991, J BIOL CHEM, V266, P17509; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KNECHT DA, 1990, DEV GENET, V11, P403, DOI 10.1002/dvg.1020110513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; NELLEN W, 1985, GENE, V39, P155, DOI 10.1016/0378-1119(85)90309-9; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPUDICH JA, 1987, METHOD CELL BIOL, V28, P9; VIERA J, 1987, METHOD ENZYMOL, V153, P3	24	42	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15356	15360						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340365				2022-12-25	WOS:A1993LN30500009
J	HSU, LC; HU, MC; CHENG, HC; LU, JC; CHUNG, BC				HSU, LC; HU, MC; CHENG, HC; LU, JC; CHUNG, BC			THE N-TERMINAL HYDROPHOBIC DOMAIN OF P450C21 IS REQUIRED FOR MEMBRANE INSERTION AND ENZYME STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE DEFICIENCY; ESCHERICHIA-COLI; AMINO-ACIDS; CYTOCHROME-P-450; EXPRESSION; PROTEINS; SIGNAL; MUTATION; ORIENTATION; SEQUENCE	Microsomal cytochromes P-450 are known to be integrated into smooth endoplasmic reticulum through their hydrophobic sequences located at the N termini. The length requirement of the membrane insertion signal was determined by the generation of six plasmids encoding mutant P450c21 that lacked various portions of the N-terminal hydrophobic domains. When they were transcribed and translated in vitro in the presence of endoplasmic reticulum membranes, mutant protein lacking more than a third of the first hydrophobic domain gradually lost the ability to insert into the membrane and stayed mostly in the soluble fraction when the first N-terminal hydrophobic domain was removed. The steady-state amount of the truncated proteins was progressively reduced in parallel to the extent of their N-terminal deletions, due to their fast degradation. This process was accompanied by a decrease in the enzymatic activity. Therefore, the first hydrophobic domain of P450c21 not only serves as a membrane targeting and anchoring domain, but it is also important for the in vivo protein stability.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan				Chung, Bon-chu/0000-0002-8612-0219; HU, MENG-CHUN/0000-0002-2783-5687; Hsu, Li-Chung/0000-0001-7206-5231; Cheng, Hsu-Chen/0000-0002-6586-6425				AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; BARNES HJ, 1992, J BASIC CLIN PHYSL S, V3, P13; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CHIOU SH, 1990, J BIOL CHEM, V265, P3549; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; DASMAHAPATRA B, 1987, NUCLEIC ACIDS RES, V15, P3933, DOI 10.1093/nar/15.9.3933; ELIASSON E, 1992, J BIOL CHEM, V267, P15765; FALETTO MB, 1992, J BIOL CHEM, V267, P2032; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; HU MC, 1990, MOL ENDOCRINOL, V4, P893, DOI 10.1210/mend-4-6-893; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LI YC, 1991, J BIOL CHEM, V266, P19186; MILLER WL, 1989, ANNU REV GENET, V23, P371, DOI 10.1146/annurev.ge.23.120189.002103; MILLER WL, 1987, J PEDIATR-US, V111, P1, DOI 10.1016/S0022-3476(87)80334-7; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NELSON DR, 1988, J BIOL CHEM, V263, P6038; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RICKETTS MH, 1992, BIOCHEM BIOPH RES CO, V186, P426, DOI 10.1016/S0006-291X(05)80825-3; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SPEISER PW, 1992, J CLIN INVEST, V90, P584, DOI 10.1172/JCI115897; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TUSIELUNA MT, 1991, MOL ENDOCRINOL, V5, P685, DOI 10.1210/mend-5-5-685; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WEDELL A, 1992, P NATL ACAD SCI USA, V89, P7232, DOI 10.1073/pnas.89.15.7232; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WU DA, 1991, J CLIN INVEST, V88, P519, DOI 10.1172/JCI115334	31	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14682	14686						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325846				2022-12-25	WOS:A1993LL75900026
J	HARDUINLEPERS, A; SHAPER, JH; SHAPER, NL				HARDUINLEPERS, A; SHAPER, JH; SHAPER, NL			CHARACTERIZATION OF 2 CIS-REGULATORY REGIONS IN THE MURINE BETA-1,4-GALACTOSYLTRANSFERASE GENE - EVIDENCE FOR A NEGATIVE REGULATORY ELEMENT THAT CONTROLS INITIATION AT THE PROXIMAL SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; GENOMIC STRUCTURE; MESSENGER-RNAS; MAMMARY-GLAND; EXPRESSION; PROTEIN; PROMOTER; BINDING; MOUSE; HORMONE	The beta1,4-galactosyltransferase (beta1,4-GT) gene is unusual in that it specifies, two mRNAs in somatic cells of 3.9 and 4.1 kilobases (kb). These two transcripts arise as a consequence of initiation at two different sets of start sites that are separated by approximately 200 base pairs. Translation of each mRNA results in the predicted synthesis of two related protein isoforms that differ only in the length of their NH2-terminal cytoplasmic domain (Russo, R. N., Shaper, N. L., and Shaper, J. H. (1990) J. Biol. Chem. 265, 3324-3331). In this study we show that the cellular requirement for beta1,4-GT correlate with the transcriptional start site used. In cells and tissues that express low transcript levels, the 4.1-kb transcriptional start site is apparently used exclusively. Increased transcription from the 4.1-kb start site plus low levels of transcription from the 3.9-kb start site result in the intermediate, beta1,4-GT transcript levels that are found in almost all somatic cell types. However, in mid- to late pregnant and lactating mammary glands very high transcript levels are observed, which correlate with the predominant use of the 3.9-kb transcriptional start site. To identify the cis-acting elements that regulate the use of the two transcriptional start sites, we constructed a series of beta1,4-GT/CAT hybrids and carried out transient transfection assays using mouse L cells and Drosophila SL2 cells. These studies have delineated both a distal and proximal regulatory region just upstream of the 4.1- and 3.9-kb transcriptional start sites, respectively. In addition, a negative cis-acting regulatory region was identified that represses transcription from the proximal site. These results suggest a model of transcriptional regulation in which the distal region functions as a housekeeping promoter while the proximal region functions as a mammary cell-specific promoter. Differential initiation from the two promoters is a mechanism for regulation of beta1,4-GT enzyme levels. The predictions from this model are consistent with the conclusion that both protein isoforms are functionally equivalent resident trans-Golgi membrane-bound enzymes.	JOHNS HOPKINS UNIV,CTR ONCOL,SCH MED,CELL STRUCT & FUNCT LAB,RM 1-127,600 N WOLFE ST,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University			Harduin-Lepers, Anne/O-7503-2017	Harduin-Lepers, Anne/0000-0002-1233-3799	NCI NIH HHS [CA45799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BEYER TA, 1982, GLYCOCONJUGATES, V3, P25; Brew K, 1970, Essays Biochem, V6, P93; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; BURDON T, 1991, J BIOL CHEM, V266, P6909; CATO ACB, 1992, PROG NUCLEIC ACID RE, V43, P1, DOI 10.1016/S0079-6603(08)61042-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DOPPLER W, 1991, MOL ENDOCRINOL, V5, P1624, DOI 10.1210/mend-5-11-1624; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HARDUINLEPERS A, 1992, GLYCOBIOLOGY, V2, P361, DOI 10.1093/glycob/2.4.361; HATHAWAY HJ, 1992, J CELL BIOL, V117, P369, DOI 10.1083/jcb.117.2.369; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hill R L, 1968, Brookhaven Symp Biol, V21, P139; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LUBON H, 1988, BIOCHEM J, V256, P391, DOI 10.1042/bj2560391; MASIBAY AS, 1989, P NATL ACAD SCI USA, V86, P5733, DOI 10.1073/pnas.86.15.5733; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MUNOZ B, 1989, MOL CELL ENDOCRINOL, V62, P23, DOI 10.1016/0303-7207(89)90109-3; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; PIAGGIO G, 1990, FOCUS, V12, P83; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHAPER NL, 1990, CYTOGENET CELL GENET, V54, P172, DOI 10.1159/000132987; SHUR B D, 1991, Glycobiology, V1, P563, DOI 10.1093/glycob/1.6.563; STRANGE R, 1991, CELL GROWTH DIFFER, V2, P549; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TURKINGTON RW, 1968, J BIOL CHEM, V243, P3382; VILOTTE JL, 1992, GENE, V119, P287, DOI 10.1016/0378-1119(92)90285-W; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; Zhou Ming-Dong, 1992, Gene Expression, V2, P127; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	63	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14348	14359						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314795				2022-12-25	WOS:A1993LJ82500082
J	CARR, FE; WONG, NCW				CARR, FE; WONG, NCW			CHARACTERISTICS OF A NEGATIVE THYROID-HORMONE RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT GENE; RETINOIC ACID RECEPTORS; AUXILIARY PROTEIN; NUCLEAR RECEPTORS; PROMOTER ACTIVITY; T3 RECEPTOR; X-RECEPTOR; HALF-SITE; TATA BOX; BINDING	Thyroid hormones may stimulate or repress transcriptional activity depending upon the specific gene. Whereas, a palindromic DNA sequence, TREpal, mediates positive regulation by thyroid hormone, the negative response element (nT(3)RE) remains undefined. Therefore, we have examined the DNA sequences that mediate the inhibitory effects of thyroid hormone on the transcription of the beta-subunit gene of rat thyrotropin (rTSH beta). In rat pituitary tumor cells (GH(3)), transient expression of plasmid constructs containing the putative nT(3)RE of rTSH beta mediated negative regulation by L-triiodothyronine (T-3). Since this nT(3)RE contained sequences which resembled a half-site motif of the consensus T(3)RE and the idealized palindrome (TREpal), we tested a construct containing this half-site motif in the same cells. T-3 decreased the activity of this plasmid. Cotransfection studies in T-3-receptor (T(3)R)-deficient cells indicated that either alpha or beta isoforms of T(3)R were required for the inhibitory effects of the hormone. Both T(3)R isomers bind to DNA sequences containing the nT(3)RE from rTSH beta DNA or the half-site motif of TREpal. In summary, our results show that the repressive properties of T-3 are mediated by a nT(3)RE from rTSH beta. Unexpectedly, this motif resembles a half-site component of TREpal which enhances promoter activity in response to T-3.	UNIV CALGARY,DEPT MED & MED BIOCHEM,CALGARY T2N 4N1,AB,CANADA	University of Calgary	CARR, FE (corresponding author), WALTER REED ARMY MED CTR,DEPT CLIN INVEST,RES LABS,KYLE METAB UNIT,6800 GEORGIA AVE,WASHINGTON,DC 20307, USA.							BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1992, J BIOL CHEM, V267, P18689; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHIN WW, 1993, RECENT PROG HORM RES, V48, P393; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ROSEN ED, 1991, MOL CELL ENDOCRINOL, V78, pC83, DOI 10.1016/0303-7207(91)90175-R; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG M, 1992, 74TH ANN M END SOC S; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	33	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4175	4179						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307979				2022-12-25	WOS:A1994MW98900044
J	DERUITER, GA; VANBRUGGENVANDERLUGT, AW; MISCHNICK, P; SMID, P; VANBOOM, JH; NOTERMANS, SHW; ROMBOUTS, FM				DERUITER, GA; VANBRUGGENVANDERLUGT, AW; MISCHNICK, P; SMID, P; VANBOOM, JH; NOTERMANS, SHW; ROMBOUTS, FM			2-O-METHYL-D-MANNOSE RESIDUES ARE IMMUNODOMINANT IN EXTRACELLULAR POLYSACCHARIDES OF MUCOR RACEMOSUS AND RELATED MOLDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE CHROMATOGRAPHY; LINKED IMMUNOSORBENT-ASSAY; ABSIDIA-CYLINDROSPORA; LIQUID-CHROMATOGRAPHY; CARBOHYDRATE ANALYSIS; LIPOPOLYSACCHARIDES; PURIFICATION; STRAINS; LINKAGE; ELISA	In this study, the structure of the immunodominant carbohydrate epitope of the extracellular polysaccharides from mold species belonging to the order Mucorales reactive with rabbit IgG antibodies was elucidated. An exo-alpha-D-mannanase which was able to abolish the antigenicity of these polysaccharides completely was purified and characterized, and the activity was compared with that of an alpha-D-mannosidase. Analysis of the monomeric reaction products after enzymatic treatment revealed the presence of 2-O-methyl D-mannose residues. This compound is a constituent of the polysaccharides from the mold genera Mucor, Rhizopus, Rhizomucor, Absidia, Syncephalastrum, and Thamnidium, and its occurrence in fungi has not been reported until now. Two mannan fractions which are highly reactive with rabbit IgG were isolated from the extracellular polysaccharides of Mucor racemosus and characterized with ethylation analysis. The role of the newly found 2-O-methyl-D-mannose residues in the immunoreactivity was assessed by specific degradation of these mannans with the exo-alpha-D-mannanase and subsequent ethylation analysis. It was concluded that the immunodominant carbo hydrates reactive with rabbit IgG are chains composed of a single terminal non-reducing 2-O-methyl-D-mannose residue, alpha(1-2)-linked to a short sequence of alpha(1-2)linked D-mannose residues.	AGR UNIV WAGENINGEN,DEPT FOOD SCI,6703 HD WAGENINGEN,NETHERLANDS; UNIV HAMBURG,DEPT ORGAN CHEM,D-20146 HAMBURG,GERMANY; GORLAEUS LABS,DEPT ORGAN CHEM,2300 RA LEIDEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,WATER & FOOD MICROBIOL LAB,3720 BA BILTHOVEN,NETHERLANDS	Wageningen University & Research; University of Hamburg; Netherlands National Institute for Public Health & the Environment			Rombouts, Frans/F-9882-2011					BARTNICKI-GARCIA S, 1972, Carbohydrate Research, V23, P75, DOI 10.1016/S0008-6215(00)81579-7; BOWIE JU, 1984, CARBOHYD RES, V125, P301, DOI 10.1016/0008-6215(84)85165-4; CLAMP JR, 1965, BIOCHEM J, V94, P17, DOI 10.1042/bj0940017; Cole G. T., 1991, The fungal spore and disease initiation in plants and animals., P403; DERUITER GA, 1992, CARBOHYD POLYM, V18, P1, DOI 10.1016/0144-8617(92)90181-O; DERUITER GA, 1993, MYCOL RES, V97, P690, DOI 10.1016/S0953-7562(09)80149-4; DERUITER GA, 1993, TRENDS FOOD SCI TECH, V4, P91, DOI 10.1016/0924-2244(93)90089-S; DERUITER GA, 1992, ANAL BIOCHEM, V207, P176, DOI 10.1016/0003-2697(92)90520-H; DERUITER GA, 1993, J GEN MICROBIOL, V139, P1557, DOI 10.1099/00221287-139-7-1557; DERUITER GA, 1991, CARBOHYD RES, V215, P47, DOI 10.1016/0008-6215(91)84006-Z; DERUITER GA, 1992, ANTON LEEUW INT J G, V62, P189, DOI 10.1007/BF00582579; DERUITER GA, 1991, NATO ASI SERIES H, V53, P169; ENGLYST HN, 1984, ANALYST, V109, P937, DOI 10.1039/an9840900937; HAYASHI O, 1978, J GEN MICROBIOL, V108, P345, DOI 10.1099/00221287-108-2-345; HAYASHI O, 1978, J GEN MICROBIOL, V106, P289, DOI 10.1099/00221287-106-2-289; HEARN VM, 1980, MOL IMMUNOL, V17, P1097, DOI 10.1016/0161-5890(80)90106-6; JANSSON PE, 1976, PRACTICAL GUIDE METH, V8; KAUFMAN L, 1989, J CLIN MICROBIOL, V27, P1979, DOI 10.1128/JCM.27.9.1979-1982.1989; KEMPER MS, 1988, THESIS U MINNESOTA M; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; LINDBERG B, 1990, ADV CARBOHYD CHEM BI, V48, P279, DOI 10.1016/S0065-2318(08)60033-5; MIYAZAKI T, 1979, J GEN MICROBIOL, V111, P417, DOI 10.1099/00221287-111-2-417; MIYAZAKI T, 1977, Kitasato Archives of Experimental Medicine, V50, P1; MIYAZAKI T, 1971, CHEM PHARM BULL, V19, P1450; MIYAZAKI T, 1972, CHEM PHARM BULL, V20, P330; MIYAZAKI T, 1980, ACS SYM SER, V126, P81; MORT A, 1983, CAN J MICROBIOL, V29, P993, DOI 10.1139/m83-156; NOTERMANS S, 1985, INT J FOOD MICROBIOL, V2, P247, DOI 10.1016/0168-1605(85)90015-7; OGNER G, 1980, SOIL SCI, V129, P1, DOI 10.1097/00010694-198001000-00001; Pitt J.I., 1985, FUNGI FOOD SPOILAGE, P143; SCHMIDT W, 1980, ARCH MICROBIOL, V127, P217, DOI 10.1007/BF00427196; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SMID P, 1993, THESIS STATE U LEIDE, P35; SNAITH SM, 1973, ADV CARBOHYD CHEM BI, V28, P401; SUGAR AM, 1992, CLIN INFECT DIS, V14, pS126, DOI 10.1093/clinids/14.Supplement_1.S126; VANBRUGGENVANDERLUGT AW, 1992, J BACTERIOL, V174, P6096; VANLANGENHOVE A, 1985, CARBOHYD RES, V143, P1, DOI 10.1016/S0008-6215(00)90691-8; WECKESSER J, 1979, ANNU REV MICROBIOL, V33, P215, DOI 10.1146/annurev.mi.33.100179.001243; YAMADA H, 1982, CHEM PHARM BULL, V30, P1784; YAMADA H, 1982, J GEN MICROBIOL, V128, P189; YAMADA H, 1982, CARBOHYD RES, V110, P113, DOI 10.1016/0008-6215(82)85030-1	41	9	9	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4299	4306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307996				2022-12-25	WOS:A1994MW98900063
J	GORDON, JA; HELLER, SK; KADUCE, TL; SPECTOR, AA				GORDON, JA; HELLER, SK; KADUCE, TL; SPECTOR, AA			FORMATION AND RELEASE OF A PEROXISOME-DEPENDENT ARACHIDONIC-ACID METABOLITE BY HUMAN SKIN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; TUBULAR EPITHELIAL-CELLS; RAT-LIVER PEROXISOMES; SMOOTH-MUSCLE CELLS; BETA-OXIDATION; 12-HYDROXYEICOSATETRAENOIC ACID; ENDOTHELIAL-CELLS; PATHWAY; IDENTIFICATION; REDUCTASE	Human skin fibroblasts labeled with [5,6,8,9,11,12,14,15-H-3]arachidonic acid produce a radioactive metabolite that has a shorter retention time on reverse-phase high-performance liquid chromatography than arachidonic acid. This product is not retained in the cells; it is released entirely into the extracellular fluid in a time dependent manner. The metabolite does not cochromatograph with any of the eicosanoid standards, and its formation is not prevented by the addition of cyclooxygenase, lipoxygenase, or cytochrome P-450 inhibitors. The compound is not produced by fibroblasts labeled with [1-C-14]arachidonic acid, suggesting that it is formed through an oxidative process. Chemical analyses indicated that the metabolite is 4,7,10-hexadecatrienoic acid (16:3). Peroxisome-deficient human skin fibroblasts did not produce 16:3, indicating that it probably is formed through peroxisomal beta-oxidation. Human umbilical vein endothelial cells and porcine pulmonary artery smooth muscle cells also release radioactive 16:3 following labeling with [H-3]arachidonic acid. Therefore, the production of this metabolite is not limited only to fibroblasts. The fact that 16:3 is released into the extracellular fluid suggests that it may be a new type of lipid mediator derived from arachidonic acid, formed through a peroxisome-dependent oxidative process.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa	GORDON, JA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,E 300 G GH,200 HAWKINS DR,IOWA CITY,IA 52242, USA.		Spector, Arthur/AAG-9860-2020		NHLBI NIH HHS [HL 49264] Funding Source: Medline; NIDDK NIH HHS [DK 28516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOMMES V, 1981, J BIOL CHEM, V256, P8259; FALES HM, 1973, ANAL CHEM, V45, P2302, DOI 10.1021/ac60335a020; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; GORDON JA, 1989, J LIPID RES, V30, P731; GORDON JA, 1987, AM J PHYSIOL, V253, pC277, DOI 10.1152/ajpcell.1987.253.2.C277; GORDON JA, 1990, J CLIN INVEST, V85, P1173, DOI 10.1172/JCI114550; GORDON JA, 1993, J CLIN INVEST, V92, P169, DOI 10.1172/JCI116545; GORDON JA, 1991, BIOCHIM BIOPHYS ACTA, V1085, P21, DOI 10.1016/0005-2760(91)90227-9; HADJIAGAPIOU C, 1987, PROSTAG OTH LIPID M, V34, P579, DOI 10.1016/0090-6980(87)90100-6; HADJIAGAPIOU C, 1990, J BIOL CHEM, V265, P4369; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ISAACS WB, 1989, J BIOL CHEM, V264, P17953; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MAAS RL, 1982, J BIOL CHEM, V257, P7055; MATHUR SN, 1990, J BIOL CHEM, V265, P21048; MOORE SA, 1988, J CELL PHYSIOL, V137, P75, DOI 10.1002/jcp.1041370109; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OSMUNDSEN H, 1985, BIOCHEM J, V230, P329, DOI 10.1042/bj2300329; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; SCHEPERS L, 1988, J BIOL CHEM, V263, P2724; SCHULZ H, 1987, LIFE SCI, V40, P1443, DOI 10.1016/0024-3205(87)90375-4; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SHEN XY, 1988, BIOCHEMISTRY-US, V27, P996, DOI 10.1021/bi00403a024; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; STOLL LL, 1989, J CELL PHYSIOL, V139, P253, DOI 10.1002/jcp.1041390206; VANROLLINS M, 1985, BIOCHIM BIOPHYS ACTA, V833, P272, DOI 10.1016/0005-2760(85)90199-7; WANG LX, 1990, J LIPID RES, V31, P2265; WIGREN J, 1993, J LIPID RES, V34, P625	36	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4103	4109						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307970				2022-12-25	WOS:A1994MW98900034
J	GREENWOOD, JA; SCOTT, CW; SPREEN, RC; CAPUTO, CB; JOHNSON, GVW				GREENWOOD, JA; SCOTT, CW; SPREEN, RC; CAPUTO, CB; JOHNSON, GVW			CASEIN KINASE-II PREFERENTIALLY PHOSPHORYLATES HUMAN TAU ISOFORMS CONTAINING AN AMINO-TERMINAL INSERT - IDENTIFICATION OF THREONINE-39 AS THE PRIMARY PHOSPHATE ACCEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; EPIDERMAL GROWTH-FACTOR; HEAT-SHOCK PROTEIN; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; BINDING DOMAIN; TUBULIN; NEUROFILAMENTS; CALMODULIN	The in vitro phosphorylation of the microtubule-associated protein tau by casein kinase II was studied. Purified human brain tau was phosphorylated by casein kinase II to a stoichiometry of 0.7 mol of P-32/mol of tau. Individual recombinant human tau isoforms were phosphorylated to stoichiometries ranging from 0.2 to 0.8 mol of P-32/mol of tau. Casein kinase II catalyzed a 4-fold greater incorporation of phosphate into the tau isoform containing a 58-amino acid insert near its amino terminus (T4L) than the isoforms without the 58-amino acid insert (T3 and T4). Phosphopeptide mapping of casein kinase II phosphorylated human tau and recombinant tau isoforms suggested that the isoforms containing an amino-terminal insert constitute the major substrates for casein kinase II within the tau family. The sites of phosphorylation on T4L were identified by digesting phosphorylated T4L with the protease Asp-N, separating the peptides by reversed phase high performance liquid chromatography, and analyzing the isolated peptides by liquid-secondary ion mass spectrometry and solid-phase amino-terminal sequencing. Thr(39) was identified as the predominant phosphorylation site, which is located 5 residues from the amino-terminal insert in T4L. Phosphopeptide mapping of tau isolated from LA-N-5 neuroblastoma cells indicates that Thr(39) is phosphorylated in situ. To our knowledge, this is the first demonstration of a differential phosphorylation of the human tau isoforms, with the isoforms containing the acidic aminoterminal insert being the preferred substrates of casein kinase II.	UNIV ALABAMA, DEPT PSYCHIAT & BEHAV NEUROBIOL, BIRMINGHAM, AL 35294 USA; ICI AMER INC, ICI PHARMACEUT GRP, WILMINGTON, DE 19897 USA	University of Alabama System; University of Alabama Birmingham			Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404; Greenwood, Juliet/0000-0001-6438-964X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027538, R29NS027538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER; NIA NIH HHS [AG06569] Funding Source: Medline; NINDS NIH HHS [NS27538] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AAMODT EJ, 1984, BIOCHEMISTRY-US, V23, P6023, DOI 10.1021/bi00320a019; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BAUM L, 1992, BRAIN RES, V573, P126, DOI 10.1016/0006-8993(92)90121-O; BINART N, 1989, BIOCHEM BIOPH RES CO, V159, P140, DOI 10.1016/0006-291X(89)92415-7; CAPUTO CB, 1989, BIOCHIM BIOPHYS ACTA, V1012, P299, DOI 10.1016/0167-4889(89)90112-2; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CRUTE BE, 1992, J NEUROCHEM, V59, P2017; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; DIAZNIDO J, 1988, MOL CELL BIOCHEM, V79, P73, DOI 10.1007/BF00229400; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; FLAMENT S, 1990, BRAIN RES, V516, P15, DOI 10.1016/0006-8993(90)90891-E; FUJITAYAMAGUCHI Y, 1989, P NATL ACAD SCI USA, V86, P7306, DOI 10.1073/pnas.86.19.7306; GATICA M, 1987, P NATL ACAD SCI USA, V84, P324, DOI 10.1073/pnas.84.2.324; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HEIMANN R, 1985, J BIOL CHEM, V260, P2160; IIMOTO DS, 1990, BRAIN RES, V507, P273, DOI 10.1016/0006-8993(90)90282-G; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KHILKO S, 1992, PROTEIN EXPRES PURIF, V3, P355, DOI 10.1016/S1046-5928(05)80035-X; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASLIAH E, 1992, AM J PATHOL, V140, P263; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MIYATA Y, 1986, J BIOL CHEM, V261, P3026; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POLLARD TD, 1984, J CELL BIOL, V99, pS33, DOI 10.1083/jcb.99.1.33s; RUNGE MS, 1981, P NATL ACAD SCI-BIOL, V78, P1431, DOI 10.1073/pnas.78.3.1431; SACKS DB, 1988, J BIOL CHEM, V263, P2377; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SCOTT CW, 1991, J NEUROSCI RES, V30, P154, DOI 10.1002/jnr.490300116; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040	58	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4373	4380						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308007				2022-12-25	WOS:A1994MW98900075
J	MUSTAFI, D; MAKINEN, MW				MUSTAFI, D; MAKINEN, MW			CATALYTIC CONFORMATION OF CARBOXYPEPTIDASE-A - STRUCTURE OF A TRUE ENZYME REACTION INTERMEDIATE DETERMINED BY ELECTRON-NUCLEAR DOUBLE-RESONANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LABELED AMINO-ACIDS; METAL-ION; COMPUTER-GRAPHICS; CRYSTAL-STRUCTURE; ESTER HYDROLYSIS; ACTIVE-SITE; MECHANISM; BINDING; SPECTROSCOPY; ENVIRONMENT	The structure of a catalytically competent reaction intermediate of carboxypeptidase A (CPA) formed with the specific spin-label ester substrate O-[3-(2,2,5,5-tetramethyl-1-oxypyrrolinyl)propen-2-oyl]- -L-beta-phenyllactate through application of cryoenzymological methods has been determined by electron nuclear double resonance (ENDOR) and molecular modeling. It is shown that the reaction intermediate is best identified as a mixed anhydride acylenzyme derivative in which the side chain of Glu-270 is acylated by the spin-label substrate, in agreement with previous cryoenzymological and spectroscopic studies from this laboratory. From the observed proton ENDOR shifts corresponding to principal hyperfine coupling components and assigned by selective deuteration, the dipolar hyperfine coupling components were calculated to estimate electron-proton distances. With these ENDOR-determined distances as constraints, the conformation of the substrate free in solution and in the active site of CPA has been determined on the basis of torsion angle search calculations. With a catalytically active, acetylated form of CPA, we have also assigned the position of the side chain of Tyr-198 with respect to the nitroxyl group. The positional assignments of both substrate and active-site residues in a true reaction intermediate provide important constraints in defining the structural basis of action of CPA.	UNIV CHICAGO,CUMMINGS LIFE SCI CTR,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021900] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21900] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOWITZ N, 1967, BIOCHEM BIOPH RES CO, V29, P862, DOI 10.1016/0006-291X(67)90299-9; BERLINER L J, 1976, P592; BRESLOW R, 1977, P NATL ACAD SCI USA, V74, P1303, DOI 10.1073/pnas.74.4.1303; BYERS LD, 1973, BIOCHEMISTRY-US, V12, P2070, DOI 10.1021/bi00735a008; CAPIOMONT A, 1974, J CHEM PHYS, V60, P2530, DOI 10.1063/1.1681393; CARTWRIGHT SJ, 1981, CRC CRIT REV BIOCH, V11, P145; CESARIO M, 1975, CRYST STRUCT COMMUN, V4, P245; CHIARI G, 1981, ACTA CRYSTALLOGR B, V37, P1623, DOI 10.1107/S0567740881006729; CHRISTIANSON DW, 1986, P NATL ACAD SCI USA, V83, P7568, DOI 10.1073/pnas.83.20.7568; COX DJ, 1964, BIOCHEMISTRY-US, V3, P44, DOI 10.1021/bi00889a008; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; DESLONGCHAMPS P, 1975, TETRAHEDRON, V31, P2463, DOI 10.1016/0040-4020(75)80257-2; Deslongchamps P, 1983, STEREOELECTRONIC EFF, P54; DOUZOU P, 1977, CRYOBIOCHEMISTRY, P286; GALDES A, 1983, BIOCHEMISTRY-US, V22, P1888, DOI 10.1021/bi00277a023; GARDELL SJ, 1987, J BIOL CHEM, V262, P576; GEOGHEGAN KF, 1983, BIOCHEMISTRY-US, V22, P2255, DOI 10.1021/bi00278a031; GLOVSKY J, 1972, BIOCHEM BIOPH RES CO, V47, P244, DOI 10.1016/S0006-291X(72)80034-2; GRIFFITH OH, 1965, J CHEM PHYS, V43, P2909, DOI 10.1063/1.1697233; IIJIMA H, 1987, PROTEINS, V2, P330, DOI 10.1002/prot.340020408; JOELA H, 1991, J PHYS CHEM-US, V95, P9135, DOI 10.1021/j100176a021; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOCH TR, 1979, J BIOL CHEM, V254, P2310; KUO LC, 1985, J AM CHEM SOC, V107, P5255, DOI 10.1021/ja00304a036; KUO LC, 1982, J BIOL CHEM, V257, P24; KUO LC, 1983, J MOL BIOL, V163, P63, DOI 10.1016/0022-2836(83)90030-X; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIPSCOMB WN, 1974, TETRAHEDRON, V30, P1725, DOI 10.1016/S0040-4020(01)97306-5; LUMRY R, 1951, J AM CHEM SOC, V73, P4330, DOI 10.1021/ja01153a090; Makinen M W, 1984, Adv Inorg Biochem, V6, P1; MAKINEN MW, 1979, J BIOL CHEM, V254, P356; MAKINEN MW, 1989, J MOL BIOL, V207, P201, DOI 10.1016/0022-2836(89)90451-8; MAKINEN MW, 1982, J AM CHEM SOC, V104, P2667, DOI 10.1021/ja00373a070; MAKINEN MW, 1977, ANNU REV BIOPHYS BIO, V6, P301, DOI 10.1146/annurev.bb.06.060177.001505; MOCK WL, 1976, BIOORG CHEM, V5, P403, DOI 10.1016/0045-2068(76)90025-0; MUSTAFI D, 1990, J AM CHEM SOC, V112, P2558, DOI 10.1021/ja00163a012; MUSTAFI D, 1990, BIOPOLYMERS, V29, P45, DOI 10.1002/bip.360290108; MUSTAFI D, 1991, J MAGN RESON, V91, P497, DOI 10.1016/0022-2364(91)90376-5; MUSTAFI D, 1993, J AM CHEM SOC, V115, P3674, DOI 10.1021/ja00062a037; NARUTO S, 1985, J AM CHEM SOC, V107, P5262, DOI 10.1021/ja00304a037; Quiocho F A, 1971, Adv Protein Chem, V25, P1, DOI 10.1016/S0065-3233(08)60278-8; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P5455, DOI 10.1073/pnas.78.9.5455; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P3408, DOI 10.1073/pnas.78.6.3408; RIORDAN JF, 1963, BIOCHEMISTRY-US, V2, P1460, DOI 10.1021/bi00906a045; Rozantsev E.G., 1970, FREE NITROXYL RADICA, P203; SANDER ME, 1985, BIOCHEM BIOPH RES CO, V132, P681, DOI 10.1016/0006-291X(85)91186-6; SANDER ME, 1986, ZINC ENZYMES, P207; SCHECHTE.I, 1970, EUR J BIOCHEM, V14, P516, DOI 10.1111/j.1432-1033.1970.tb00318.x; SIMPSON RT, 1963, BIOCHEMISTRY-US, V2, P616, DOI 10.1021/bi00903a039; SUH J, 1976, J AM CHEM SOC, V98, P1940, DOI 10.1021/ja00423a048; TURLEY JW, 1972, ACTA CRYSTALL B-STRU, VB 28, P1641, DOI 10.1107/S0567740872004765; VALLEE BL, 1984, ADV ENZYMOL, V56, P284; WELLS GB, 1994, J BIOL CHEM, V269, P4577; WELLS GB, 1988, J AM CHEM SOC, V110, P6343, DOI 10.1021/ja00227a012; WELLS GB, 1990, J AM CHEM SOC, V112, P2566, DOI 10.1021/ja00163a013	56	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4587	4595						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308030				2022-12-25	WOS:A1994MW98900102
J	UEDA, N; INIGUEZLLUHI, JA; LEE, E; SMRCKA, AV; ROBISHAW, JD; GILMAN, AG				UEDA, N; INIGUEZLLUHI, JA; LEE, E; SMRCKA, AV; ROBISHAW, JD; GILMAN, AG			G-PROTEIN BETA-GAMMA-SUBUNITS - SIMPLIFIED PURIFICATION AND PROPERTIES OF NOVEL ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; MUSCARINIC K+-CHANNEL; GTP-BINDING; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; MOLECULAR-CLONING; ALPHA-SUBUNITS; EXPRESSION; CDNA; TRANSDUCIN	The beta and gamma subunits of heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) form tightly associated complexes. To examine functional differences among the large number of possible combinations of unique beta and gamma subunits, we have synthesized and characterized beta gamma complexes containing gamma(5) and gamma(7), two widely distributed gamma subunits. When either gamma(5) or gamma(7) is expressed concurrently with beta 1 or beta(2) subunits in a baculovirus/Sf9 cell system, all four subunit complexes support pertussis toxin-catalyzed ADP-ribosylation of rG(i alpha 1) (where ''r'' indicates recombinant), indicating formation of functional complexes. Each of the complexes was purified by subunit exchange chromatography, using the G203A mutant of rG(i alpha 1) as the immobilized ligand. The purified preparations were compared with other recombinant beta gamma subunits, including beta(1) gamma(1) and beta(1) gamma(2), for their ability to modulate type I and II adenylyl cyclase activities; stimulate phosphoinositide-specific phospholipase C beta; support pertussis toxin-catalyzed ADP-ribosylation of rG(i alpha 1) and G(o alpha); and inhibit steady-state GTP hydrolysis catalyzed by G(s alpha), G(o alpha), and myristoylated rG(i alpha 2) The results emphasize the unique properties of beta(1) gamma(1). The properties of the complexes containing gamma(5) or gamma(7) were similar to each other and to those of beta(1) gamma(2).	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Geisinger Medical Center				Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NIGMS NIH HHS [GM31954, GM34497, GM39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R01GM039867, R01GM031954, R29GM039867, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BRANDT DR, 1985, J BIOL CHEM, V260, P266; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GAO B, 1987, J BIOL CHEM, V262, P17254; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRAF R, 1992, J BIOL CHEM, V267, P24307; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAGA K, 1992, J BIOL CHEM, V267, P2222; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; ITOH H, 1991, J BIOL CHEM, V266, P16226; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEE E, 1992, J BIOL CHEM, V267, P1212; LEE E, 1993, IN PRESS METHODS ENZ; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	62	169	172	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4388	4395						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308009				2022-12-25	WOS:A1994MW98900077
J	SOLLENBERGER, KG; KAO, TL; TAPAROWSKY, EJ				SOLLENBERGER, KG; KAO, TL; TAPAROWSKY, EJ			STRUCTURAL-ANALYSIS OF THE CHICKEN MAX GENE	ONCOGENE			English	Note							DNA-BINDING; C-MYC; RAS COTRANSFORMATION; ENHANCERS; PROTEIN; DOMAINS; FORMS	The recent identification of Max, a nuclear phosphoprotein that dimerizes with members of the Myc protein family, has provided an additional tool to examine the role of the Myc oncoprotein as a sequence-specific DNA binding protein and a potential regulator of gene transcription. Here we report the nucleotide sequence of an avian max gene isolated from a lambda EMBL3 genomic library prepared from size-selected chicken embryo fibroblast DNA. The complete transcription unit encoding chicken Max is contained on a 5.7kbp BglII DNA fragment which expresses an appropriately sized max mRNA of 1.5 kb following transfection of C3H10T1/2 mouse fibroblasts. The coding region of the chicken max gene is organized into five exons and the overall identity between the human and chicken max coding sequences is 85% at the nucleotide level and 96% at the amino acid level. The basic helix - loop - helix/leucine zipper region, the casein kinase II phosphorylation sites and the nuclear localization signal sequence are 100% conserved in all vertebrate Max proteins characterized to date. DNA sequence analysis of the 5' flanking region of the chicken max coding sequence reveals the absence of consensus TATA or CAAT motifs, but the presence of numerous GC-rich sequences that are typical in eukaryotic genes which are expressed constitutively in different tissues and under different growth conditions.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA42835] Funding Source: Medline; NIDDK NIH HHS [DK07532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA042835, R01CA042835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P381; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MIN SY, 1992, ONCOGENE, V7, P1531; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; VAIDYA TB, 1992, GENE, V116, P223, DOI 10.1016/0378-1119(92)90519-U; VASTRIK I, 1993, ONCOGENE, V8, P503	22	17	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					661	664						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290277				2022-12-25	WOS:A1994MW24800035
J	JACOB, R; BREWER, C; FRANSEN, JAM; NAIM, HY				JACOB, R; BREWER, C; FRANSEN, JAM; NAIM, HY			TRANSPORT, FUNCTION, AND SORTING OF LACTASE-PHLORHIZIN HYDROLASE IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; PLASMA-MEMBRANE GLYCOPROTEIN; MDCK CELLS; INTRACELLULAR-TRANSPORT; PHLORHIZIN HYDROLASE; LACTOSE-INTOLERANCE; POLARIZED DELIVERY; O-GLYCOSYLATION; APICAL SURFACE	Lactase-phlorizin hydrolase (LPH), a small intestinal brush-border glycoprotein, is synthesized as a single chain precursor (pro-LPH, M(r) = 215,000-230,000) that undergoes cleavage to the final mature form (LPHm, M(r) = 160,000 in the human). In the human and pig small intestine as well as in the colon carcinoma cell line Caco-2, this cleavage takes place intracellularly prior to insertion into the brush-border membrane. To assess the role of proteolytic cleavage on the transport, function, and sorting of LPH a stable Madin-Darby canine kidney cell line was generated which expresses LPH (denoted as MDCK-ML). Biosynthetic labeling experiments demonstrated that the transport kinetics and posttranslational processing pattern of LPH in this cell line are similar to those in intestinal cells. Moreover, the enzymatic activity was found to be indistinguishable from that of brush-border LPH (LPHm). The sorting of LPH was studied by biosynthetic labeling of cells grown on filters followed by cell surface immunoprecipitation. Here, we could demonstrate that the cleaved LPHm molecule was predominantly found at the apical membrane, whereas complex glycosylated uncleaved pro-LPH (pro-LPHc) was targeted to both domains, the apical as well as the basolateral. In pulse-chase experiments at 20-degrees-C pro-LPH was arrested in the trans-Golgi network, and cleavage to LPHm did not take place. By contrast, when the chase temperature was raised to 37-degrees-C transport of pro-LPHc resumed, and cleavage to LPHm occurred. We conclude that the proteolytic cleavage of pro-LPHc to LPHm is a post-trans-Golgi network event and is most likely not implicated in the sorting of LPH by exposition of otherwise masked sorting elements.	HEINRICH HEINE UNIV,INST MICROBIOL,PROT SECRET GRP,UNIV STR 1,D-40225 DUSSELDORF,GERMANY; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS	Heinrich Heine University Dusseldorf; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Radboud University Nijmegen			Fransen, Jack/E-8924-2010; Jacob, Ralf/B-8163-2011	Fransen, Jack/0000-0002-0571-7639; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BULLER HA, 1987, J BIOL CHEM, V262, P17206; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; FRANSEN JAM, 1985, EUR J CELL BIOL, V38, P6; FREUND JN, 1989, FEBS LETT, V248, P39, DOI 10.1016/0014-5793(89)80427-2; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; KLUMPERMAN J, 1991, J CELL SCI, V100, P339; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LOW SH, 1991, J BIOL CHEM, V266, P13391; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATTER K, 1989, J BIOL CHEM, V264, P13131; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1992, J BIOL CHEM, V267, P25494; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1992, BIOCHEM J, V285, P13, DOI 10.1042/bj2850013; NAIM HY, 1993, DYN NUTR R, V3, P102; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; QUAN R, 1990, J BIOL CHEM, V265, P15882; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; RODRIGUEZBOULAN E, 1984, J CELL BIOL, V98, P308, DOI 10.1083/jcb.98.1.308; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; Sambrook J, 1989, MOL CLONING LABORATO; SEBASTIO G, 1989, AM J HUM GENET, V45, P489; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; WITTE J, 1990, J CLIN INVEST, V86, P1338, DOI 10.1172/JCI114843; YEH KY, 1991, GASTROENTEROLOGY, V101, P312, DOI 10.1016/0016-5085(91)90005-6	39	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2712	2721						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300602				2022-12-25	WOS:A1994MV43200055
J	CHESNEAU, V; PIEROTTI, AR; BARRE, N; CREMINON, C; TOUGARD, C; COHEN, P				CHESNEAU, V; PIEROTTI, AR; BARRE, N; CREMINON, C; TOUGARD, C; COHEN, P			ISOLATION AND CHARACTERIZATION OF A DIBASIC SELECTIVE METALLOENDOPEPTIDASE FROM RAT TESTES THAT CLEAVES AT THE AMINO-TERMINUS OF ARGININE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCESSING ENZYME; SOMATOSTATIN-28 CONVERTASE; AMINOPEPTIDASE-B; MAMMALIAN TESTIS; MESSENGER-RNA; GENE ENCODES; BRAIN CORTEX; YEAST KEX2; EXPRESSION; CELLS	A metalloendopeptidase that selectively cleaves doublets of basic amino acids on the amino-terminal side of arginine residues was purified to homogeneity from rat testes and analyzed further. Two catalytically active forms with apparent relative molecular masses of 110,000 and 140,000 Da, respectively, were present in the purified preparation of the enzyme. Antibodies raised against the purified testis endopeptidase revealed by immunoblot both the 110- and 140-kDa forms in both rat testis and brain cortex extracts. The isolated enzyme was inhibited by metal chelators and divalent cations. Its activity, lost after preincubation with EDTA, was restored by low concentrations of Zn2+ and Mn2+, thus demonstrating the metallopeptidase nature of the enzyme. This endopeptidase also exhibited a high sensitivity to amastatin (100% inhibition at 20 muM), an aminopeptidase inhibitor. A substrate specificity study using physiologically important or synthetic peptides containing a processing dibasic site indicated that cleavage occurred selectively at the amino-terminal side of an arginine residue, independent of the nature of the basic doublet. The enzyme produced such a cleavage at the Arg-Lys doublet of somatostatin 28 (K(m) = 43 muM), at the Arg-Arg doublet of dynorphin A (K(m) = 6.45 muM) and atrial natriuretic factor (K(m) = 6.25 muM), and at the Lys-Arg doublet of preproneurotensin-(154-170) (K(m) = 17.3 muM). Moreover, cleavage efficiency was found to be higher for the larger substrates. The distinctive properties of this endopeptidase imply that this protein is a member of a novel class of proteolytic enzymes that may be involved in the endoproteolytic maturation of hormonal precursors.	UNIV PARIS 06, BIOCHEM SIGNAUX REGULATEURS CELLULAIRES & MOLEC LA, CNRS, URA 1682, F-75006 PARIS, FRANCE; CTR ETUD SACLAY, DEPT RECH IMAGERIE PHARMACOL & PHYSIOL, SERV PHARMACOL & IMMUNOL, F-91191 GIF SUR YVETTE, FRANCE; COLL FRANCE, BIOL CELLULE NEUROENDOCRINE GRP, URA 1115, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; College de France								AOYAGI T, 1978, J ANTIBIOT, V31, P636, DOI 10.7164/antibiotics.31.636; BOURDAIS J, 1990, BIOCHEM BIOPH RES CO, V170, P1263, DOI 10.1016/0006-291X(90)90530-Z; BRAKCH N, 1993, BIOCHEMISTRY-US, V32, P4925, DOI 10.1021/bi00069a029; BRAKCH N, 1993, EUR J BIOCHEM, V216, P39, DOI 10.1111/j.1432-1033.1993.tb18114.x; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHEN CLC, 1984, P NATL ACAD SCI-BIOL, V81, P5672, DOI 10.1073/pnas.81.18.5672; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOUGLASS J, 1987, ENDOCRINOLOGY, V120, P707, DOI 10.1210/endo-120-2-707; ERDOS EG, 1985, LAB INVEST, V52, P437; Frobert Y, 1992, Methods Mol Biol, V80, P65, DOI 10.1385/0-89603-204-3:65; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GERMAIN D, 1992, EUR J BIOCHEM, V204, P121, DOI 10.1111/j.1432-1033.1992.tb16613.x; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; GLUSCHANKOF P, 1987, NEUROCHEM RES, V12, P951, DOI 10.1007/BF00966318; GLUSCHANKOF P, 1987, J BIOL CHEM, V262, P9615; GOMEZ S, 1988, P NATL ACAD SCI USA, V85, P5468, DOI 10.1073/pnas.85.15.5468; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KEW D, 1990, P NATL ACAD SCI USA, V87, P9143, DOI 10.1073/pnas.87.23.9143; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; KILPATRICK DL, 1985, P NATL ACAD SCI USA, V82, P7467, DOI 10.1073/pnas.82.21.7467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NISHINO N, 1979, BIOCHEMISTRY-US, V18, P4340, DOI 10.1021/bi00587a012; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PANDEY KN, 1991, BIOCHEM BIOPH RES CO, V180, P437, DOI 10.1016/S0006-291X(05)81312-9; PEKARY AE, 1984, LIFE SCI, V34, P939, DOI 10.1016/0024-3205(84)90298-4; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P988, DOI 10.1210/jcem-33-6-988; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	41	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2056	2061						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294457				2022-12-25	WOS:A1994MR98800077
J	DEV, IK; DALLAS, WS; FERONE, R; HANLON, M; MCKEE, DD; YATES, BB				DEV, IK; DALLAS, WS; FERONE, R; HANLON, M; MCKEE, DD; YATES, BB			MODE OF BINDING OF FOLATE ANALOGS TO THYMIDYLATE SYNTHASE - EVIDENCE FOR 2 ASYMMETRIC BUT INTERACTIVE SUBSTRATE-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOBACILLUS-CASEI; DIHYDROFOLATE-REDUCTASE; QUINAZOLINE ANTIFOLATE; CRYSTAL-STRUCTURE; SYNTHETASE; INHIBITORS; EXPRESSION; ENZYME; AFFINITY	Human thymidylate synthase is a polymeric protein composed of two subunits with identical primary structures. In this study we determined the binding affinities of 5,10-methylene tetrahydropteroyltetraglutamate (folate substrate) and a group of close structural folate analog inhibitors. Thymidylate synthase bound both mono and polyglutamylated folate substrates and analogs more tightly in the presence of deoxyuridylate. These results and product inhibition studies confirmed that the orders of substrate addition and product release from thymidylate synthase were similar for mono and polyglutamylated substrates. Equilibrium dialysis studies showed that the folate substrate in a ternary complex with deoxyuridylate bound to one of the subunits (site A) with a K(d) of 720 nm. The binding of the substrate to the second subunit (site B) was much weaker, and the K(d) could not be determined by this method. However, dissociation constants for each subunit could be measured for the folate analog inhibitors, and, depending on the inhibitor, the relative K(d) value for each subunit varied substantially. For example, formyl-5,8-dideazafolate and tetraglutamylated 10-propargyl-5,8-dideazafolate bound to both sites with similar K(d) values, whereas D1694Glu4 bound to subunit A with a higher affinity (K(d) = 1.0 nM) than to subunit B (K(d) = 30 nM). In contrast, 1843U89 (mono or diglutamylated form) had a much higher affinity for subunit B (K(d) approximately 1 nM) compared with subunit A (K(d) approximately 400 nM). Enzyme inhibition kinetic analyses showed that the K(i) values of 1843U89 were quite low (0.1 nM) and that the inhibition was noncompetitive. In contrast, the other folate analogs inhibited the enzyme via mixed inhibition (i.e. both the K(m) for the folate substrate and the V(max) were altered). We conclude that the two subunits of thymidylate synthase bind folate substrates and analogs differently and that the asymmetric binding of the ligands is the major factor that determines the inhibition kinetics of each folate analog inhibitor.			DEV, IK (corresponding author), BURROUGHS WELLCOME CO, DIV MOLEC GENET & MICROBIOL, RES TRIANGLE PK, NC 27709 USA.							AULL JL, 1974, J BIOL CHEM, V249, P1167; AULL JL, 1974, MICROCHEM J, V19, P210, DOI 10.1016/0026-265X(74)90076-9; BAPAT AR, 1983, J BIOL CHEM, V258, P4130; BEAUDETTE NV, 1977, ARCH BIOCHEM BIOPHYS, V179, P272, DOI 10.1016/0003-9861(77)90112-6; BEAUDETTE NV, 1980, ARCH BIOCHEM BIOPHYS, V200, P410, DOI 10.1016/0003-9861(80)90371-9; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; BOYER PD, 1977, STRUCTURE FUNCTION E, P261; CANTWELL BMJ, 1988, EUR J CANCER CLIN ON, V24, P733, DOI 10.1016/0277-5379(88)90307-0; CHENG YC, 1985, CANCER RES, V45, P598; CISNEROS R J, 1988, Drugs of the Future, V13, P859; DALLAS WS, 1992, J BACTERIOL, V174, P5961, DOI 10.1128/jb.174.18.5961-5970.1992; DANENBERG KD, 1979, J BIOL CHEM, V254, P4345; DANENBERG PV, 1978, BIOCHEMISTRY-US, V17, P4018, DOI 10.1021/bi00612a022; DARON HH, 1978, J BIOL CHEM, V253, P940; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; DEV IK, 1984, J BIOL CHEM, V259, P1114; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; DEV IK, 1989, J BIOL CHEM, V264, P19132; DOLNICK BJ, 1978, J BIOL CHEM, V253, P3563; DUCH DS, 1993, CANCER RES, V53, P810; FERONE R, 1986, J BIOL CHEM, V261, P6363; GALIVAN JH, 1976, BIOCHEMISTRY-US, V15, P356, DOI 10.1021/bi00647a018; GALIVAN JH, 1976, BIOCHEM BIOPH RES CO, V71, P527, DOI 10.1016/0006-291X(76)90819-6; GARVEY EP, 1987, J BIOL CHEM, V262, P9068; GHOSE C, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P860; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HENDERSON PJ, 1973, BIOCHEM J, V135, P101, DOI 10.1042/bj1350101; HUANG CY, 1982, ANNU REV BIOCHEM, V51, P935, DOI 10.1146/annurev.bi.51.070182.004443; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; JACKMAN AL, 1991, CANCER RES, V51, P5579; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KAMB A, 1992, BIOCHEMISTRY-US, V31, P12876, DOI 10.1021/bi00166a024; KEYOMARSI K, 1990, J BIOL CHEM, V265, P19163; LANGENBACH R, 1976, BIOCHIM BIOPHYS ACTA, V422, P295, DOI 10.1016/0005-2744(76)90140-6; LAPATPOLASKO L, 1990, BIOCHEMISTRY-US, V29, P9561, DOI 10.1021/bi00493a010; LAZDUNSKI M, 1972, CURRENT TOPICS CELLU, V6, P267; LEARY RP, 1975, J BIOL CHEM, V250, P4864; LOCKSHIN A, 1979, J BIOL CHEM, V254, P2285; LOCKSHIN A, 1981, BIOCHEM PHARMACOL, V30, P247, DOI 10.1016/0006-2952(81)90085-X; LORENSON MY, 1967, J BIOL CHEM, V242, P3332; LU YZ, 1984, BIOCHEMISTRY-US, V23, P6870, DOI 10.1021/bi00321a091; Maniatis T, 1982, MOL CLONING LABORATO, P312; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MILLER SM, 1991, BIOCHEMISTRY-US, V30, P2600, DOI 10.1021/bi00224a006; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MOORE MA, 1986, J BIOL CHEM, V261, P2745; NAKAGAWA TY, 1986, P NATL ACAD SCI USA, V83, P2007, DOI 10.1073/pnas.83.7.2007; PATTISHALL KH, 1976, J BIOL CHEM, V251, P7011; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; RADPARVAR S, 1988, ARCH BIOCHEM BIOPHYS, V260, P342, DOI 10.1016/0003-9861(88)90458-4; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; RODE W, 1979, J BIOL CHEM, V254, P1538; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTI DV, 1984, FOLATES PTERINS, P345; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT RL, 1956, RECL TRAV CHIM PAY B, V75, P787, DOI 10.1002/recl.19560750711; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPECTOR T, 1981, ANAL BIOCHEM, V115, P403, DOI 10.1016/0003-2697(81)90025-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKEISHI K, 1985, NUCLEIC ACIDS RES, V13, P2035, DOI 10.1093/nar/13.6.2035; VARNEY MD, 1992, J MED CHEM, V35, P663, DOI 10.1021/jm00082a006; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11; WARD WHJ, 1992, BIOCHEM PHARMACOL, V43, P2029, DOI 10.1016/0006-2952(92)90646-Z; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	65	68	69	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1873	1882						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294436				2022-12-25	WOS:A1994MR98800051
J	DROLET, M; BI, X; LIU, LF				DROLET, M; BI, X; LIU, LF			HYPERNEGATIVE SUPERCOILING OF THE DNA-TEMPLATE DURING TRANSCRIPTION ELONGATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-I MUTANTS; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; GYRASE INHIBITORS; RIBOSOMAL-RNA; PLASMID DNA; PBR322 DNA; REPLICATION; SPECIFICITY; INITIATION	Supercoiled plasmid DNAs with negative superhelicity several times higher than normal have been isolated from Escherichia coli topA mutants. The formation of these hypernegatively supercoiled plasmid DNAs is apparently induced by transcription. We show that hypernegatively supercoiled plasmid DNAs isolated from topA mutants contain R-loop(s). To study the mechanism of formation of hypernegatively supercoiled plasmid DNA, we have been able to reproduce hypernegatively supercoiled DNA in vitro using purified RNA polymerase and DNA gyrase. The formation of hypernegatively supercoiled plasmid DNA template in vitro is shown to require transcription elongation and is tightly linked to R-loop formation. We propose that one of the roles of topoisomerase I is to suppress R-loop formation during transcription elongation.			LIU, LF (corresponding author), UMDNJ,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,675 HOES LANE,PISCATAWAY,NJ 08854, USA.		Drolet, Marc/M-1328-2019	Liu, Leroy/0000-0001-9396-763X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27731] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; CHAMPOUX JJ, 1975, BIOCHEMISTRY-US, V14, P307, DOI 10.1021/bi00673a017; COOK DN, 1992, P NATL ACAD SCI USA, V89, P10603, DOI 10.1073/pnas.89.22.10603; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; FRANCO RJ, 1989, J BACTERIOL, V171, P6573, DOI 10.1128/jb.171.12.6573-6579.1989; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GELLERT M, 1982, COLD SPRING HARB SYM, V47, P763; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GILMOUR DS, 1986, CELL, V44, P1401; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; KAGUNI JM, 1984, J BIOL CHEM, V259, P8578; KOO HS, 1990, J BIOL CHEM, V265, P12300; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; LODGE JK, 1989, J BACTERIOL, V171, P2181, DOI 10.1128/jb.171.4.2181-2187.1989; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; PARADA CA, 1989, J BIOL CHEM, V264, P15120; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; RICHARDSON JP, 1975, J MOL BIOL, V98, P565, DOI 10.1016/S0022-2836(75)80087-8; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU HY, 1991, J MOL BIOL, V219, P615, DOI 10.1016/0022-2836(91)90658-S; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	34	110	111	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2068	2074						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294458				2022-12-25	WOS:A1994MR98800079
J	FENG, LL; XIA, YY; WILSON, CB				FENG, LL; XIA, YY; WILSON, CB			ALTERNATIVE SPLICING OF THE NC1 DOMAIN OF THE HUMAN-ALPHA-3(IV) COLLAGEN GENE - DIFFERENTIAL EXPRESSION OF MESSENGER-RNA TRANSCRIPTS THAT PREDICT 3 PROTEIN VARIANTS WITH DISTINCT CARBOXYL REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; IV COLLAGEN; ALPORT SYNDROME; GOODPASTURE ANTIGEN; HEREDITARY NEPHRITIS; ALPHA-3(IV) CHAIN; SEQUENCE-ANALYSIS; IDENTIFICATION; LOCALIZATION; CLONING	Three clones of NC1 of alpha3(IV) collagen, named Q1, L5, and V, were isolated from human kidney; these predict three variant alpha3(IV) NC1 domains of 232-, 60-, and 199-amino acid residues, respectively, with unique COOH-termini. The human collagen IV gene (COL4A3) was isolated and characterized, and it was shown that the cDNA variants arose from alternative splicing by deletion of exon 4 in L5 and deletion of exon 2 in V. The mRNA transcripts were differentially expressed in fetal-and adult human kidney with Ql the major species. Exon 4L5 lacked 183 residues from the carboxyl terminus with a frameshift producing a unique 11-amino acid terminal peptide. In exon 2- V a frameshift resulted in a unique V carboxyl terminus of 53 novel peptides with a new glycosylation site. The size of recombinant proteins indicated the frameshifts and new stop codons were as predicted. The multiple forms of the alpha3(IV) NC1 region may contribute to autoimmune glomerular disease and hereditary nephritis, in which this portion of the collagen IV molecule is thought to play an important role.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020043, R01DK020043] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIDDK NIH HHS [DK20043] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN GP, 1988, J VIROL, V62, P2850, DOI 10.1128/JVI.62.8.2850-2858.1988; ANAND SK, 1978, J PEDIATR-US, V92, P952, DOI 10.1016/S0022-3476(78)80372-2; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BRINKER JM, 1985, P NATL ACAD SCI USA, V82, P3649, DOI 10.1073/pnas.82.11.3649; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1990, J LAB CLIN MED, V115, P365; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROUZET J, 1990, J BACTERIOL, V172, P5980, DOI 10.1128/jb.172.10.5980-5990.1990; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; Feng Lili, 1992, Journal of the American Society of Nephrology, V3, P629; Fujinami R S, 1988, Ann N Y Acad Sci, V540, P210, DOI 10.1111/j.1749-6632.1988.tb27063.x; GARBE T, 1990, J BACTERIOL, V172, P6774, DOI 10.1128/jb.172.12.6774-6782.1990; GARY GL, 1984, P NATL ACAD SCI USA, V81, P2645; Goebel S.J., 1990, VIROLOGY, V179, P517; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HORSFALL AC, 1992, MOL BIOL REP, V16, P139, DOI 10.1007/BF00464701; HOSTIKKA SL, 1987, FEBS LETT, V224, P297, DOI 10.1016/0014-5793(87)80473-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUEY B, 1993, KIDNEY INT, V44, P307, DOI 10.1038/ki.1993.245; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KEFALIDES NA, 1993, KIDNEY INT, V43, P85, DOI 10.1038/ki.1993.15; KEFALIDES NA, 1993, KIDNEY INT, V43, P94, DOI 10.1038/ki.1993.16; KIDA H, 1988, VIROLOGY, V162, P160, DOI 10.1016/0042-6822(88)90405-9; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; KLEPPEL MM, 1992, KIDNEY INT, V41, P1629, DOI 10.1038/ki.1992.235; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MCCOY RC, 1982, KIDNEY INT, V21, P642, DOI 10.1038/ki.1982.72; MCCOY RC, 1976, LAB INVEST, V34, P325; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; NUNN D, 1990, J BACTERIOL, V172, P2991; QUINONES S, 1992, J BIOL CHEM, V267, P19780; REES AJ, 1978, LANCET, V1, P966; SAITO A, 1991, Journal of the American Society of Nephrology, V2, P560; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SPEAR GS, 1984, CLIN NEPHROL, V21, P3; TAYLOR TK, 1992, INT J SYST BACTERIOL, V42, P593, DOI 10.1099/00207713-42-4-593; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRYGGVASON K, 1990, ANN NY ACAD SCI, V580, P97, DOI 10.1111/j.1749-6632.1990.tb17922.x; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; WILSON CB, 1972, ANN INTERN MED, V76, P91, DOI 10.7326/0003-4819-76-1-91; XIA YY, 1993, AM J PHYSIOL, V264, pF774, DOI 10.1152/ajprenal.1993.264.5.F774; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1991, GENOMICS, V9, P1, DOI 10.1016/0888-7543(91)90214-Y	51	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2342	2348						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294492				2022-12-25	WOS:A1994MR98800116
J	JUMINAGA, D; ALBAUGH, SA; STEINER, RF				JUMINAGA, D; ALBAUGH, SA; STEINER, RF			THE INTERACTION OF CALMODULIN WITH REGULATORY PEPTIDES OF PHOSPHORYLASE-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; TROPONIN-C; MELITTIN; SUBUNIT; DOMAINS	The regulatory peptides Phk13 (301-327) and Phk5 (342-367) have been synthesized and their interaction with calmodulin studied. In the case of Phk13 modified forms were also synthesized in which a tryptophan group was placed at position 4 or 21, as well as a form with tryptophan at position 4 and nitrotyrosine at position 21. From tryptic digestion, circular dichroism, and radiationless energy transfer measurements, it appears that Phk13 forms an elongated complex with calmodulin in which the peptide is in a non-helical conformation, probably bent into a hairpin-shaped structure, the connecting strand of calmodulin is extended and exposed to the action of proteolytic enzymes, and the peptide makes contact with both the N- and C-terminal half-molecules of calmodulin. In contrast, the Phk5 peptide has an alpha-helical conformation in the complex, which is relatively compact in shape.			JUMINAGA, D (corresponding author), UNIV MARYLAND,DEPT CHEM & BIOCHEM,CATONSVILLE,MD 21228, USA.							BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; CADAY CG, 1986, BIOCHEM BIOPH RES CO, V135, P419, DOI 10.1016/0006-291X(86)90011-2; CHEUNG HC, 1991, TOPICS FLUORESCENCE, V2, P128; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GARONE L, 1990, ARCH BIOCHEM BIOPHYS, V276, P12, DOI 10.1016/0003-9861(90)90003-H; GARONE L, 1988, BIOPHYS CHEM, V32, P231; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; LINSE S, 1986, FEBS LETT, V199, P28, DOI 10.1016/0014-5793(86)81217-0; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RICHMAN PG, 1978, BIOCHEMISTRY-US, V17, P928, DOI 10.1021/bi00598a029; Steiner R. F., 1991, TOPICS FLUORESCENCE, V2, P1, DOI DOI 10.1007/0-306-47058-6_; STEINER RF, 1986, ARCH BIOCHEM BIOPHYS, V246, P286, DOI 10.1016/0003-9861(86)90474-1; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; WATTERSON DM, 1980, J BIOL CHEM, V255, P962	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1660	1667						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294413				2022-12-25	WOS:A1994MR98800021
J	LINDBERG, FP; LUBLIN, DM; TELEN, MJ; VEILE, RA; MILLER, YE; DONISKELLER, H; BROWN, EJ				LINDBERG, FP; LUBLIN, DM; TELEN, MJ; VEILE, RA; MILLER, YE; DONISKELLER, H; BROWN, EJ			RH-RELATED ANTIGEN CD47 IS THE SIGNAL-TRANSDUCER INTEGRIN-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RED-CELL MEMBRANE; HUMAN-CHROMOSOMES; VACCINIA VIRUS; IDENTIFICATION; PHAGOCYTOSIS; SEQUENCE	Integrin-associated protein (LAP) is a 50-kDa membrane protein with an amino-terminal immunoglobulin domain and a carboxyl-terminal multiply membrane-spanning region. It is physically and funcitonally associated with the integrin alpha(v)beta3 vitronectin receptor and is involved in the increase in intracellular calcium concentration, which occurs upon cell adhesion to extracellular matrix. Oxidative burst in neutrophils can be induced or inhibited via LAP. Surprisingly, LAP is also expression erythrocytes, which have no known integrins. IAP has been shown to be identical to OA3, an ovarian carcinoma antigen. We now show that IAP expression is reduced on Rh(null)erythrocytes. The IAP structural gene is mapped to q13.1-2 on human chromosome 3, within a region known to contain a gene encoding the Rh-associated 1D8 antigen. By expression studies on human erythrocytes and IAP transfectants, IAP is shown to be identical to the 1D8 antigen and to CD47, a cell surface protein with broad tissue distribution, reduced in expression on Rh(null) erythrocytes. Two CD47 antibodies recognize the immunoglobulin domain of IAP, as does antibody 1D8. These studies suggest the possibility that IAP and the Rh polypeptides may share a pathway for membrane expression on erythrocytes. Furthermore, decreased expression of IAP on Rh(null) cells may contribute to the these cells' abnormal cation permeabilities. These studies demonstrate an unexpected link between integrin signal transduction and erythrocyte membrane structure.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT LAB MED,ST LOUIS,MO 63110; DUKE UNIV,MED CTR,DIV HEMATOL ONCOL,DURHAM,NC 27710; COLORADO HLTH SCI CTR,DEPT MED,DENVER,CO 80220	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Duke University; University of Colorado System; University of Colorado Anschutz Medical Campus				Telen, Marilyn/0000-0003-3809-1780	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00304] Funding Source: Medline; NIGMS NIH HHS [GM38330] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agre P, 1991, Baillieres Clin Haematol, V4, P793, DOI 10.1016/S0950-3536(06)80031-4; AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BALLAS SK, 1984, BLOOD, V63, P1046; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CAMPBELL IG, 1992, CANCER RES, V52, P5416; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GRESHAM H, 1990, CLIN RES, V38, pA480; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; MILLER YE, 1987, AM J HUM GENET, V4, P1061; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P221; POELS LG, 1986, JNCI-J NATL CANCER I, V76, P781; POSS MT, 1993, VOX SANG, V64, P231, DOI 10.1111/j.1423-0410.1993.tb03061.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; SPRING FA, 1989, LEUKOCYTE TYPING, V4, P660; STURGEON P, 1970, BLOOD-J HEMATOL, V36, P310, DOI 10.1182/blood.V36.3.310.310; TELEN MJ, 1986, HUM IMMUNOL, V17, P311, DOI 10.1016/0198-8859(86)90283-1; YUNIS JJ, 1976, SCIENCE, V191, P1268, DOI 10.1126/science.1257746; ZAHAR BC, 1993, BLOOD, V82, P656; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	28	129	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1567	1570						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294396				2022-12-25	WOS:A1994MR98800001
J	VERMA, AK; ENYEDI, A; FILOTEO, AG; PENNISTON, JT				VERMA, AK; ENYEDI, A; FILOTEO, AG; PENNISTON, JT			REGULATORY REGION OF PLASMA-MEMBRANE CA2+ PUMP - 28 RESIDUES SUFFICE TO BIND CALMODULIN BUT MORE ARE NEEDED FOR FULL AUTO-INHIBITION OF THE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; TRYPSIN PROTEOLYSIS; FUNCTIONAL DOMAINS; HUMAN-ERYTHROCYTES; CA-2+-ATPASE; CA2+-ATPASE; CLEAVAGE; PROTEINS	The Ca2+-pumping activity of constructs containing various portions of the putative 28-residue calmodulin-binding domain (C domain) of hPMCA4b were compared. As the length of the C domain in the pump increased, the pump's activity decreased and the ability of calmodulin to stimulate the activity increased. Study of the calmodulin dependence of activity showed that the construct containing all 28 residues of the C domain had a K1/2 for calmodulin equal to that of the complete molecule; the constructs containing less of the C domain interacted less strongly with calmodulin. On the other hand, incorporation of all 28 residues of the C domain did not decrease the activity of the pump (in the absence of calmodulin) as low as the activity of the complete molecule. This indicates that other segments of the molecule, further toward the COOH terminus, are also required for the degree of inhibition seen in the complete molecule.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,GUGGENHEIM 1642C,200 1ST ST SW,ROCHESTER,MN 55905	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; BENAIM G, 1984, J BIOL CHEM, V259, P8471; CARAFOLI E, 1987, CALCIUM BINDING PROT, P78; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	19	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1687	1691						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294415				2022-12-25	WOS:A1994MR98800025
J	PARK, DJ; WILCZYNSKI, SP; PAQUETTE, RL; MILLER, CW; KOEFFLER, HP				PARK, DJ; WILCZYNSKI, SP; PAQUETTE, RL; MILLER, CW; KOEFFLER, HP			P53 MUTATIONS IN HPV-NEGATIVE CERVICAL-CARCINOMA	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; POLYMERASE CHAIN-REACTION; TUMOR SUPPRESSOR GENE; CELL LUNG-CANCER; DNA; ASSOCIATION; EXPRESSION; SEQUENCE; LINES; TRANSCRIPTION	Human papillomavirus (HPV) infection has been strongly linked to the development of cervical carcinoma. Two viral oncoproteins, E6 and E7, produced by HPV, have been shown to immortalize primary human genital epithelial cells by interacting with the protein products of cellular tumor suppressor genes p53 and Rb, respectively. E6 binds to the cellular p53 protein promoting p53 degradation and inactivity. This mechanism has been suggested to contribute to the oncogenesis of HPV-positive anogential cancers. In HPV-negative cervical carcinoma, p53 mutation is thought to be the possible mechanism of oncogenesis. We have studied 257 cervical carcinoma specimens for HPV infection by Southern blot analysis and polymerase chain reaction (PCR). Of 257 samples, 39 were HPV-negative. We have further studied 21 HPV-negative specimens for p53 mutations utilizing PCR amplification of genomic DNA followed by single-stranded conformation polymorphism (SSCP) analysis and DNA sequencing. We found only two missense point mutations of p53 gene. In summary, although inactivation of p53 mediated either by E6 or by mutations may be an important key step in the development of cervical carcinoma, our study suggests that other mechanisms may also be involved in development of cervical cancer.	CITY HOPE NATL MED CTR, DEPT PATHOL, DUARTE, CA 91010 USA	City of Hope	PARK, DJ (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI MED CTR, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90048 USA.				NCI NIH HHS [CA42710, CA32737] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710, P30CA042710, P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKIN NB, 1989, CANCER GENET CYTOGEN, V37, P229, DOI 10.1016/0165-4608(89)90053-8; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLOSS JD, 1991, HUM PATHOL, V22, P711, DOI 10.1016/0046-8177(91)90294-Y; BORRESEN AL, 1992, LANCET, V339, P1350; BUSBYEARLE RMC, 1992, LANCET, V339, P1350, DOI 10.1016/0140-6736(92)91993-I; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, ONCOGENE, V6, P873; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUJITA M, 1992, CANCER RES, V52, P5323; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hayashi K, 1991, PCR Methods Appl, V1, P34; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLY EA, 1986, J NATL CANCER I, V76, P983; Hoskins WJ, 1989, CANC PRINCIPLES PRAC, P1099; HOWLEY PM, 1991, CANCER RES, V51, pS5019; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MANOS MM, 1989, CANCER CEL, V7, P209; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER CW, 1992, CANCER RES, V52, P1695; MUNGER K, 1989, J VIROL, V63, P4417; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAQUETTE RL, 1993, CANCER-AM CANCER SOC, V72, P1272, DOI 10.1002/1097-0142(19930815)72:4<1272::AID-CNCR2820720420>3.0.CO;2-Q; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WERNESS BA, 1991, IMPORTANT ADV ONCOLO, P2; WILCZYNSKI SP, 1988, HUM PATHOL, V19, P697, DOI 10.1016/S0046-8177(88)80176-X; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	49	82	82	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					205	210						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302581				2022-12-25	WOS:A1994MW24700025
J	AZIZ, N; WU, J; DUBENDORFF, JW; LIPSICK, JS; STURGILL, TW; BENDER, TP				AZIZ, N; WU, J; DUBENDORFF, JW; LIPSICK, JS; STURGILL, TW; BENDER, TP			C-MYB AND V-MYB ARE DIFFERENTIALLY PHOSPHORYLATED BY P42MAPK IN-VITRO	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; AVIAN-MYELOBLASTOSIS VIRUS; COLONY-STIMULATING FACTOR; SERINE-THREONINE KINASE; LONG TERMINAL REPEAT; MYELIN BASIC-PROTEIN; DNA-BINDING ACTIVITY; MAP KINASE	The product of the c-myb proto-oncogene is a highly conserved transcription factor that has been shown to function as both a transactivator and repressor. The v-myb oncogenes of E26 leukemia virus and avian myeloblastosis virus (AMV) encode proteins truncated at both the amino and carboxy termini, deleting portions of the DNA-binding and negative regulatory domains present in c-Myb. Similar truncations of c-Myb alter its function, suggesting that the viral proteins lack important regulatory sequences. Interestingly, eight potential sites of phosphorylation by proline-directed protein kinases conserved between the avian, murine and human Myb proteins are clustered in or near the negative regulatory domain of c-Myb. The majority of these sites are deleted in both the E26 and AMV viral proteins. In this paper we show that one proline-directed protein kinase, p42mapk, phosphorylates bacterially synthesized avian and murine c-Myb but not AMV v-Myb in vitro. We find that p42mapk phosphorylates c-Myb on serine and threonine, but not on tyrosine. Furthermore, deletion analysis indicates that the sites of phosphorylation map to the C-terminal negative regulatory domain. We speculate that the inability of v-Myb to be phosphorylated by p42mapk may contribute to its oncogenic properties.	SUNY, DEPT MICROBIOL, STONY BROOK, NY 11794 USA; UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; University of Virginia; University of Virginia			Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606; Aziz, Natasha/0000-0001-8195-1446	NCI NIH HHS [CA 40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ADDISON C, 1990, ONCOGENE, V5, P423; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BADING H, 1989, ONCOGENE, V4, P33; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOSSELUT R, 1992, VIROLOGY, V186, P764, DOI 10.1016/0042-6822(92)90044-P; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DASGUPTA P, 1992, J VIROL, V66, P270, DOI 10.1128/JVI.66.1.270-276.1992; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NEL AE, 1990, J IMMUNOL, V144, P2683; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKUDA K, 1992, BLOOD, V79, P2880; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAO H, 1990, J BIOL CHEM, V265, P15471; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	84	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2259	2265						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336948				2022-12-25	WOS:A1993LP17100028
J	TAMURA, K; KANAOKA, Y; JINNO, S; NAGATA, A; OGISO, Y; SHIMIZU, K; HAYAKAWA, T; NOJIMA, H; OKAYAMA, H				TAMURA, K; KANAOKA, Y; JINNO, S; NAGATA, A; OGISO, Y; SHIMIZU, K; HAYAKAWA, T; NOJIMA, H; OKAYAMA, H			CYCLIN-G - A NEW MAMMALIAN CYCLIN WITH HOMOLOGY TO FISSION YEAST CIG1	ONCOGENE			English	Article							CELL-CYCLE; DNA-REPLICATION; IDENTIFICATION; EUKARYOTES; ACTIVATION; PROTEINS; FAMILY; PHASE; SWI4	A new gene encoding a cyclin-like protein has been isolated from a rat fibroblast cDNA library by cross-hybridization with a mixutre of c-src family proto-oncogene kinase domains as a probe. This putative cyclin, called cyclin G, contains a typical cyclin box at the N-terminus but no apparent 'destruction box' or 'PEST' sequence. Interestingly, in its C-terminus region, it has a sequence homologous with a tyrosine phosphorylation site of the epidermal growth factor receptor. Although this cyclin is phylogenetically related to HCS26 of Saccharomyces cerevisiae, it most resembles Cig1, a B-type cyclin, of Schizosaccharomyces pombe, which has been suggested to act at the G1/S phase of the cell cycle. Cyclin G mRNA is induced within 3h after growth stimulation and remains elevated with no apparent cell cycle dependency, indicating its close association with growth stimuli but not with the cell cycle.	OSAKA UNIV, DEPT MOLEC GENET, MICROBIAL DIS RES INST, SUITA, OSAKA 565, JAPAN; RES DEV CORP JAPAN, OKAYAMA CELL SWITCHING PROJECT, KYOTO 606, JAPAN; OSAKA UNIV, DEPT NEUROSURG, OSAKA 553, JAPAN	Osaka University; Japan Science & Technology Agency (JST); Osaka University								BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINSHULL J, 1989, J CELL SCI, P77; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STUDIER JA, 1988, MOL BIOL EVOL, V5, P729; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	28	146	159	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2113	2118						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336937				2022-12-25	WOS:A1993LP17100011
J	WU, FYH; CHANG, NT; CHEN, WJ; JUAN, CC				WU, FYH; CHANG, NT; CHEN, WJ; JUAN, CC			VITAMIN-K3-INDUCED CELL-CYCLE ARREST AND APOPTOTIC CELL-DEATH ARE ACCOMPANIED BY ALTERED EXPRESSION OF C-FOS AND C-MYC IN NASOPHARYNGEAL CARCINOMA-CELLS	ONCOGENE			English	Article							OXIDATIVE STRESS; GROWTH-FACTOR; DNA DAMAGE; ACTIVATION; LINE; INDUCTION; MENADIONE; ONCOGENE; PROTEIN; INVITRO	Vitamin K3 is known to inhibit the growth of various rodent and human tumor cells. However, the molecular mechanism of its action is still elusive. We have found that vitamin K3 induces cell cycle arrest and apoptotic cell death in nasopharyngeal carcinoma (NPC) cells, as evaluated by flow cytometry and DNA gel electrophoresis. Involvement of c-fos and c-myc proto-oncogenes and expression of their proto-oncoproteins in VK3-induced cell cycle arrest and apoptosis were also investigated. Northern blot analysis of NPC cells treated with 50 mum VK3 showed that c-fos was transiently induced for 60 min after treatment, while c-myc was persistently induced for 1-9 h after drug treatment. Western blot analysis also showed that c-Fos was induced at 4-6 h and at 1-4 h after treatment with 50 mum and 200 mum VK3 respectively, while c-Myc was induced at 1-6 h and at 4-6 h, respectively, after such treatments. These results suggest that the expression of c-fos and c-myc may play an important role in the signaling mechanism of VK3-induced growth arrest and apoptotic cell death.			WU, FYH (corresponding author), ACAD SINICA, INST BIOMED SCI, CANC RES GRP, TAIPEI 11529, TAIWAN.							AGARWAL ML, 1991, CANCER RES, V51, P5993; AKMAN SA, 1988, P AN M AM SOC CLIN, V7, P76; AKMAN SA, 1984, P ASCO, V3, P37; ASKEW DS, 1991, ONCOGENE, V6, P1915; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHANG YS, 1989, CANCER RES, V49, P6752; CHLEBOWSKI RT, 1985, CANCER TREAT REP, V69, P527; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLOTTA F, 1990, BIOCHEM BIOPH RES CO, V168, P1013, DOI 10.1016/0006-291X(90)91130-K; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; GOLD J, 1986, CANCER TREAT REP, V70, P1433; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; JUAN CC, 1993, BIOCHEM BIOPH RES CO, V190, P907, DOI 10.1006/bbrc.1993.1135; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; MALORNI W, 1991, CHEM-BIOL INTERACT, V80, P217, DOI 10.1016/0009-2797(91)90026-4; MARKS DI, 1991, BIOCHEM PHARMACOL, V42, P1859, DOI 10.1016/0006-2952(91)90582-P; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; MITCHELL JS, 1965, ACTA RADIOL THER PHY, V3, P329, DOI 10.3109/02841866509133108; MITCHELL JS, 1974, BRIT J CANCER, V29, P373, DOI 10.1038/bjc.1974.85; MITCHELL JS, 1983, INT J RADIAT ONCOL, V9, P57, DOI 10.1016/0360-3016(83)90209-2; NAGOURNEY R, 1987, P AN M AM SOC CLIN, V6, P359; NGO EO, 1991, BIOCHEM PHARMACOL, V42, P1961, DOI 10.1016/0006-2952(91)90596-W; NOTO V, 1989, CANCER, V63, P901, DOI 10.1002/1097-0142(19890301)63:5<901::AID-CNCR2820630518>3.0.CO;2-G; NUTTER LM, 1991, BIOCHEM PHARMACOL, V41, P1283, DOI 10.1016/0006-2952(91)90099-Q; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SU W-C, 1991, Kaohsiung Journal of Medical Sciences, V7, P454; WICKSTROM EL, 1989, IN VITRO CELL DEV B, V25, P297; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WU FYH, 1991, P AM ASSOC CANC RES, V32, P396; WU FYH, 1993, IN PRESS LIFE SCI; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1987, ARCH TOXICOL, P3; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUH YS, 1989, J BIOL CHEM, V264, P10904; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	45	93	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2237	2244						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336946				2022-12-25	WOS:A1993LP17100025
J	CAMPBELL, CG; SPRAY, DC; WOLKOFF, AW				CAMPBELL, CG; SPRAY, DC; WOLKOFF, AW			EXTRACELLULAR ATP(4-) MODULATES ORGANIC ANION TRANSPORT BY RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANE; ECTO-ATPASE; CONJUGATED HYPERBILIRUBINEMIA; MOUSE MACROPHAGES; CELL; SULFOBROMOPHTHALEIN; FIBROBLASTS; BILIRUBIN; RESPONSES; RECEPTORS	The hepatocyte has an organic anion transport system that recognizes compounds such as bilirubin and sulfobromophthalein. These anions circulate bound tightly to albumin from which they are extracted rapidly by hepatocytes by an electroneutral process that requires extracellular inorganic anions such as Cl- for activity. Transport activity is reduced by depletion of intracellular ATP, but whether ATP interacts directly with this transporter is not known. In this study, the influence of extracellular ATP on the hepatocyte organic anion transport mechanism has been characterized. In the presence of 2.5 mM Ca2+ and 2 mM Mg2+, initial uptake of [S-35]sulfobromophthalein was reduced by 50% at 1 mM ATP. In the absence of divalent cations sensitivity to ATP was 10-fold greater. Other nucleotides including UTP, CTP, GTP, ADP, AMP, and AMP-PCP (adenosine 5'-(beta,gamma-methylene)triphosphate) were inactive. Decreased transport activity was rapidly reversible, was non-competitive with respect to ATP, did not require ATP hydrolysis, and did not correlate with P2y purinergic receptor activity. Differential activity of ATP on sulfobromophthalein transport in the presence and absence of divalent cations was not due to ecto-ATPase activity but rather to alteration in [ATP4-]. Although an ATP4- receptor in macrophages mediates increased cellular permeability, reduced organic anion permeability is seen in hepatocytes. This effect is not seen in the hepatoma cell line HepG2. Modulation of activity of the organic anion transporter by extracellular ATP may have important pathophysiological consequences in conditions resulting in liver cell injury.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,LIVER RES CTR,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Spray, David/0000-0001-8368-5073	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK023026] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-23026, DK-41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTY RA, 1968, J BIOL CHEM, V243, P1337; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; CAO CX, 1992, J INFECT DIS, V165, P322, DOI 10.1093/infdis/165.2.322; CHAREST R, 1985, J BIOL CHEM, V260, P5789; CHE MX, 1992, J BIOL CHEM, V267, P9684; CHRIST GJ, 1992, AM J PHYSIOL, V263, pC373, DOI 10.1152/ajpcell.1992.263.2.C373; COCKCROFT S, 1980, BIOCHEM J, V188, P789, DOI 10.1042/bj1880789; DAHLQUIST R, 1974, ACTA PHARMACOL TOX, V34, P368, DOI 10.1111/j.1600-0773.1974.tb03533.x; DIXON CJ, 1990, BIOCHEM J, V269, P499, DOI 10.1042/bj2690499; DUBYAK GR, 1990, ANN NY ACAD SCI, V603; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; GARTNER U, 1982, GASTROENTEROLOGY, V83, P1163; GONZALEZ FA, 1989, BIOCHEM BIOPH RES CO, V164, P706, DOI 10.1016/0006-291X(89)91517-9; GONZALEZ FA, 1989, J CELL PHYSL, V139, P105; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HAUSSINGER D, 1987, EUR J BIOCHEM, V167, P65; HAUSSINGER D, 1988, EUR J BIOCHEM, V178, P249, DOI 10.1111/j.1432-1033.1988.tb14450.x; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KITAMURA T, 1991, HEPATOLOGY, V14, P640, DOI 10.1016/0270-9139(91)90051-V; KURISU H, 1989, ANAL BIOCHEM, V179, P72, DOI 10.1016/0003-2697(89)90202-9; LIN SH, 1988, J BIOL CHEM, V263, P12253; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; LIN SH, 1989, J BIOL CHEM, V264, P14403; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MIN AD, 1991, HEPATOLOGY, V14, P1217, DOI 10.1002/hep.1840140642; MIN AD, 1991, J CLIN INVEST, V87, P1496, DOI 10.1172/JCI115159; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; WEISMAN GA, 1989, J CELL PHYSIOL, V138, P375, DOI 10.1002/jcp.1041380221; WOLKOFF AW, 1985, J CLIN INVEST, V76, P454, DOI 10.1172/JCI111993; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; ZIMNIAK P, 1992, ARCH BIOCHEM BIOPHYS, V292, P534, DOI 10.1016/0003-9861(92)90027-T	41	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15399	15404						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340370				2022-12-25	WOS:A1993LN30500016
J	HAMEL, CP; TSILOU, E; PFEFFER, BA; HOOKS, JJ; DETRICK, B; REDMOND, TM				HAMEL, CP; TSILOU, E; PFEFFER, BA; HOOKS, JJ; DETRICK, B; REDMOND, TM			MOLECULAR-CLONING AND EXPRESSION OF RPE65, A NOVEL RETINAL-PIGMENT EPITHELIUM-SPECIFIC MICROSOMAL PROTEIN THAT IS POSTTRANSCRIPTIONALLY REGULATED IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; SEQUENCE-ANALYSIS; BOVINE RETINA; CELLS; IDENTIFICATION; DIFFERENTIATION; 11-CIS-RETINYL; NITROCELLULOSE; PURIFICATION; TRANSLATION	Studies reported previously from this laboratory have shown that microsomal membranes of the vertebrate retinal pigment epithelium (RPE) contain an RPE-specific 65-kDa protein, RPE65, which bears the determinant recognized by the strictly tissue-specific monoclonal antibody RPE9, and which is developmentally regulated (Hamel, C. P., Tsilou, E., Harris, E., Pfeffer, B. A., Hooks, J. J., Detrick, B., and Redmond, T. M. (1993) J. Neurosci. Res. 34, 414-425). Microsequencing of 17 tryptic and chymotryptic peptides obtained from the in situ digestion of the RPE65 blotted on nitrocellulose yielded primary sequences that were used to generate oligonucleotide probes. An 84-nucleotide guessmer was used to isolate two clones from a bovine RPE lambdaZap II cDNA library. Rapid amplification of cDNA ends was used to complete the 5' and 3' ends, resulting in a 3,115-base pair composite cDNA. The open reading frame encodes a novel protein of 533 amino acid residues with a computed molecular weight of 60,940. This protein does not match any other sequence in the data bases. The 231 amino acids obtained from peptide sequencing match 43% of the amino acid sequence deduced from the cDNA. The protein has a calculated pI of 6.41 and is not predicted to have any transmembrane segments. The open reading frame expressed in Escherichia coli has an apparent molecular weight identical to that of the native protein and is recognized by the monoclonal antibody RPE9, further corroborating its validity. Northern blot analysis detected a major mRNA species of 3.15 kilobases for RPE65, as well as shorter species, only in RPE and not in other tissues (including other ocular tissues). Cultured RPE cells (7 weeks in primary culture) contained RPE65 mRNA in amounts equivalent to fresh RPE. Such cells, however, contained no immunodetectable RPE65. The possible structure of this RPE-specific protein and hypotheses for the absence of translation in vitro are discussed.	NEI, RETINAL CELL & MOLEC BIOL LAB,BLDG 6,RM 339, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA; NEI, IMMUNOL & VIROL LAB, BETHESDA, MD 20892 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT PATHOL, WASHINGTON, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); George Washington University				Redmond, T. Michael/0000-0002-1813-5291				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BERMAN ER, 1991, BIOCH EYE, P380; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BLANER WS, 1987, J BIOL CHEM, V262, P53; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENT A, 1990, P NATL ACAD SCI USA, V87, P318, DOI 10.1073/pnas.87.1.318; CRABB JW, 1988, J BIOL CHEM, V263, P18678; CRABB JW, 1988, J BIOL CHEM, V263, P18688; DAS A, 1990, METHOD ENZYMOL, V182, P93; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIESER L, 1992, GENOMICS, V13, P873, DOI 10.1016/0888-7543(92)90173-P; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOOKS JJ, 1989, INVEST OPHTH VIS SCI, V30, P2106; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; JOSEPH DP, 1991, J PHYSIOL-LONDON, V435, P439, DOI 10.1113/jphysiol.1991.sp018518; KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEIGHTON J, 1969, SCIENCE, V163, P472, DOI 10.1126/science.163.3866.472; MATA NL, 1992, J BIOL CHEM, V267, P9794; MAYERSON PL, 1986, J CELL BIOL, V103, P299, DOI 10.1083/jcb.103.1.299; MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pfeffer BA, 1991, PROG RETINAL RES, V10, P251; PIDGEON C, 1991, ANAL BIOCHEM, V194, P163, DOI 10.1016/0003-2697(91)90164-O; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1982, J BIOL CHEM, V257, P13329; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHALLAL A, 1988, EYE, V2, pS180, DOI 10.1038/eye.1988.143; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SPOERRI PE, 1988, EUR J CELL BIOL, V46, P362; STRAMM LE, 1990, EXP EYE RES, V50, P521, DOI 10.1016/0014-4835(90)90041-R; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG N, 1992, CURR EYE RES, V11, P783, DOI 10.3109/02713689209000751; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392	49	270	292	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15751	15757						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340400				2022-12-25	WOS:A1993LN30500064
J	MATHAI, JC; SAUNA, ZE; JOHN, O; SITARAMAM, V				MATHAI, JC; SAUNA, ZE; JOHN, O; SITARAMAM, V			RATE-LIMITING STEP IN ELECTRON-TRANSPORT - OSMOTICALLY SENSITIVE DIFFUSION OF QUINONES THROUGH VOIDS IN THE BILAYER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; LATERAL DIFFUSION; OXIDATIVE-PHOSPHORYLATION; PHOTOSYNTHETIC ACTIVITY; PHOSPHOLIPID-VESICLES; BIOLOGICAL-MEMBRANES; VARIABLE POROSITY; FLUORESCENCE; UBIQUINONE; PERMEABILITY	Respiration in mitochondria and photosynthesis in chloroplasts varied with the osmotic stretch of the membrane such that these processes were uniformly inhibited at higher osmolalities. A systematic evaluation of segmental electron transport in these intact particles showed that no individual complex exhibited osmotic sensitivity, whereas osmotic sensitivity appeared wherever the assay involved crossing over the corresponding quinone in the electron transport chain. The evidence was consistent with the rate-limiting step in electron transport being the availability of voids for quinone migration rather than any of the components of electron transport chain per se. Evidence based on quinone reconstitution in mitochondria depleted of quinone by acetone treatment clearly distinguished the kinetic control in the hypotonic domain and diffusive control via availability of voids in the hypertonic domain. Influence as well as the presence of voids was further confirmed in quinone-depleted mitochondria reconstituted with quinone as well as cholesterol. Decrease in lateral diffusion of the fluorescent probe, 12-(9-anthroyl)stearic acid, on osmotic compression of the bilayer is consistent with a change in void size distribution on osmotic compression of the bilayer. A direct correlation between succinate cytochrome c oxidoreductase activity and diffusivity of fluorescent probe 12-(9-anthroyl)stearic acid confirmed the availability of voids as the rate-limiting step in electron transport.			MATHAI, JC (corresponding author), UNIV POONA,DEPT ZOOL,POONA 411007,MAHARASHTRA,INDIA.		Sauna, Zuben E./AAA-7149-2019					AMENTA JS, 1964, J LIPID RES, V5, P270; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BEAVIS AD, 1986, EUR J BIOCHEM, V158, P315, DOI 10.1111/j.1432-1033.1986.tb09753.x; BLUME A, 1983, BIOCHEMISTRY-US, V22, P5436, DOI 10.1021/bi00292a027; BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001; BREHM P, 1984, J PHYSIOL-LONDON, V350, P631, DOI 10.1113/jphysiol.1984.sp015222; CHALPIN DB, 1983, BIOCHIM BIOPHYS ACTA, V731, P465, DOI 10.1016/0005-2736(83)90042-1; CHAZOTTE B, 1989, J BIOL CHEM, V264, P4978; CHONG PLG, 1985, J BIOL CHEM, V260, P4484; COHEN MH, 1959, J CHEM PHYS, V31, P1164, DOI 10.1063/1.1730566; Crofts A. R., 1978, CURR TOP BIOENERG, V7, P175; DEAMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P165, DOI 10.1073/pnas.80.1.165; FATO R, 1986, BIOCHEMISTRY-US, V25, P3378, DOI 10.1021/bi00359a043; GALLA HJ, 1979, J MEMBRANE BIOL, V48, P215, DOI 10.1007/BF01872892; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GOULD JM, 1975, BIOCHIM BIOPHYS ACTA, V387, P135; GOULD JM, 1973, EUR J BIOCHEM, V37, P185, DOI 10.1111/j.1432-1033.1973.tb02974.x; GRAHAM JM, 1970, EUR J BIOCHEM, V12, P58, DOI 10.1111/j.1432-1033.1970.tb00820.x; GRIENSTEIN S, 1985, AM J PHYSIOL, V246, pC204; GUTMAN M, 1980, BIOCHIM BIOPHYS ACTA, V594, P53, DOI 10.1016/0304-4173(80)90013-0; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; HATEFI Y, 1979, METHOD ENZYMOL, V55, P35; HERON C, 1978, BIOCHEM J, V179, P791; IZAWA S, 1974, BIOCHIM BIOPHYS ACTA, V357, P127, DOI 10.1016/0005-2728(74)90118-2; Izawa S., 1980, METHODS ENZYMOL    C, P413; KAISER WM, 1982, PLANTA, V154, P538, DOI 10.1007/BF00402997; KAISER WM, 1981, PLANTA, V1151, P375; KRAUSE GH, 1982, BIOCHIM BIOPHYS ACTA, V679, P116, DOI 10.1016/0005-2728(82)90262-6; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; KROGER A, 1973, EUR J BIOCHEM, V39, P313, DOI 10.1111/j.1432-1033.1973.tb03129.x; LAVERGNE J, 1991, TRENDS BIOCHEM SCI, V16, P129, DOI 10.1016/0968-0004(91)90054-Y; LAWFORD AG, 1973, BIOCHEM J, V136, P711; LENAZ G, 1986, J BIOENERG BIOMEMBR, V18, P369, DOI 10.1007/BF00743011; LESTER RL, 1961, BIOCHIM BIOPHYS ACTA, V47, P358, DOI 10.1016/0006-3002(61)90297-9; LI W, 1986, BIOCHEMISTRY-US, V25, P8220, DOI 10.1021/bi00373a015; LILLEY RM, 1975, NEW PHYTOL, V75, P1, DOI 10.1111/j.1469-8137.1975.tb01365.x; MARSH D, 1974, BIOCHIM BIOPHYS ACTA, V363, P373, DOI 10.1016/0005-2736(74)90076-5; MATHAI JC, 1989, BIOCHIM BIOPHYS ACTA, V976, P214, DOI 10.1016/S0005-2728(89)80233-6; MAYER H, 1971, METHODS ENZYMOL C, V18, P182; MCGRATH AE, 1976, BIOCHIM BIOPHYS ACTA, V426, P173, DOI 10.1016/0005-2736(76)90330-8; OLEARY TJ, 1987, P NATL ACAD SCI USA, V84, P429, DOI 10.1073/pnas.84.2.429; PETERS R, 1983, P NATL ACAD SCI-BIOL, V80, P7183, DOI 10.1073/pnas.80.23.7183; PU LC, 1967, METHOD ENZYMOL, V10, P33; PUMPHREY AM, 1960, BIOCHEM J, V76, P61, DOI 10.1042/bj0760061; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; SAMBASIVARAO D, 1983, BIOCHIM BIOPHYS ACTA, V722, P256, DOI 10.1016/0005-2728(83)90072-5; SAMBASIVARAO D, 1986, BIOCHIM BIOPHYS ACTA, V857, P48, DOI 10.1016/0005-2736(86)90097-0; SAMBASIVARAO D, 1988, BIOCHIM BIOPHYS ACTA, V933, P200, DOI 10.1016/0005-2728(88)90071-0; SAMBASIVARAO D, 1985, BIOCHIM BIOPHYS ACTA, V806, P195, DOI 10.1016/0005-2728(85)90097-0; SITARAMAM V, 1981, P NATL ACAD SCI-BIOL, V78, P3441, DOI 10.1073/pnas.78.6.3441; SITARAMAM V, 1989, BIOCHIM BIOPHYS ACTA, V975, P252, DOI 10.1016/S0005-2728(89)80256-7; SITARAMAM V, 1989, MOL CELL BIOCHEM, V91, P91, DOI 10.1007/BF00228083; SITARAMAM V, 1991, INDIAN J BIOCH BIOPH, V29, P103; SITARAMAM V, 1991, MEMBRANE STRUCTURE F, P123; SITARAMAM V, 1984, EBEC REP, V3, P555; SITARAMAM V, 1988, INDIAN J BIOCH BIOPH, V47, P395; SOZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194; TAKANAKA K, 1975, ARCH BIOCHEM BIOPHYS, V169, P420; Trebst A, 1972, Methods Enzymol, V24, P146; ULRICH EL, 1985, BIOCHEMISTRY-US, V24, P2501, DOI 10.1021/bi00331a016; WALKER DA, 1981, PLANTA, V153, P273, DOI 10.1007/BF00383899; WALKER DA, 1980, METHOD ENZYMOL, V69, P94, DOI DOI 10.1016/S0076-6879(80)69011-9; WELCH G R, 1982, Progress in Biophysics and Molecular Biology, V39, P109; WILLIAMSON P, 1983, BIOCHIM BIOPHYS ACTA, V732, P387, DOI 10.1016/0005-2736(83)90055-X; YOCUM CF, 1980, METHOD ENZYMOL, V69, P576	66	33	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15442	15454						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340373				2022-12-25	WOS:A1993LN30500022
J	ROMANI, A; MARFELLA, C; SCARPA, A				ROMANI, A; MARFELLA, C; SCARPA, A			HORMONAL-STIMULATION OF MG(2+) UPTAKE IN HEPATOCYTES - REGULATION BY PLASMA-MEMBRANE AND INTRACELLULAR ORGANELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE MAGNESIUM; PROTEIN-KINASE-C; RAT-LIVER; MG-2+ EFFLUX; INOSITOL TRISPHOSPHATE; ISOLATED-MITOCHONDRIA; ANION TRANSPORT; 2ND MESSENGERS; CELLS; CALCIUM	Collagenase dispersed rat liver hepatocytes release Mg2+ when stimulated with norepinephrine or accumulate Mg2+ when stimulated with vasopressin, respectively. Mg2+ fluxes in either direction account for a net loss or gain of approximately 10% of total cell magnesium and are rapidly reversible. Both stimulated Mg2+ efflux and Mg2+ influx require physiological concentration of extracellular NaCl and Ca2+. In the absence of extracellular Na+, Mg2+ efflux, but not influx, can be observed in the presence of extracellular Cl-. Under these conditions, the efflux is inhibited by the Cl-/HCO3- exchanger inhibitor 4,4'-dinitrostilbene-2,2'-disulfonic acid. In hepatocytes, Mg2+ influx, but not efflux, is completely inhibited by thapsigargin, a specific inhibitor of the endoplasmic reticulum Ca2+ ATPase. Several lines of evidence, such as measurements of cytosolic Ca2+ or of cytosolic Ca2+ buffering, indicate that the effect of thapsigargin in inhibiting Mg2+ influx could not be explained by an increase in cytosolic Ca2+. Instead, the inhibition of hepatocyte Mg2+ influx was found to be the result of the depletion of the Ca2+ stored within the endoplasmic reticulum.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University				Romani, Andrea/0000-0001-9864-4848	NHLBI NIH HHS [HL 18708] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018708] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APRILLE JR, 1988, FASEB J, V2, P2547, DOI 10.1096/fasebj.2.10.3290024; ARIAS IM, 1988, LIVER BIOL PATHOBIOL, P9; BAUMANN O, 1991, P NATL ACAD SCI USA, V88, P741, DOI 10.1073/pnas.88.3.741; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BLACKMORE PF, 1982, J BIOL CHEM, V257, P190; BOND M, 1987, J BIOL CHEM, V262, P15630; BOYNTON AL, 1983, BIOCHEM BIOPH RES CO, V115, P383, DOI 10.1016/0006-291X(83)91015-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAYDEN DJ, 1989, BRIT J PHARMACOL, V98, P809, DOI 10.1111/j.1476-5381.1989.tb14609.x; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CSERMELY P, 1987, CARCINOGENESIS, V8, P1663, DOI 10.1093/carcin/8.11.1663; DEYOUNG MB, 1989, AM J PHYSIOL, V257, pC750, DOI 10.1152/ajpcell.1989.257.4.C750; DIPOLO R, 1988, BIOCHIM BIOPHYS ACTA, V946, P424, DOI 10.1016/0005-2736(88)90418-X; DRANSFIELD DT, 1991, J CELL BIOL, V115, P300; FLATMAN PW, 1984, J MEMBRANE BIOL, V80, P1, DOI 10.1007/BF01868686; GARFINKEL L, 1986, J MOL CELL CARDIOL, V18, P1003, DOI 10.1016/S0022-2828(86)80289-9; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GUNTHER T, 1991, MAGNESIUM-B, V13, P122; GUNTHER T, 1984, BIOCHEM BIOPH RES CO, V119, P124, DOI 10.1016/0006-291X(84)91627-9; GUNTHER T, 1985, BIOCHEM BIOPH RES CO, V130, P540, DOI 10.1016/0006-291X(85)90450-4; GUNTHER T, 1992, FEBS LETT, V297, P132, DOI 10.1016/0014-5793(92)80343-F; HARMAN AW, 1990, BIOCHEM BIOPH RES CO, V170, P477, DOI 10.1016/0006-291X(90)92116-H; JAKOB A, 1989, FEBS LETT, V246, P127, DOI 10.1016/0014-5793(89)80267-4; JELICKS LA, 1990, J BIOL CHEM, V265, P1394; JENNINGS ML, 1985, ANNU REV PHYSIOL, V47, P519; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KRAUSFRIEDMANN N, 1986, P NATL ACAD SCI USA, V83, P8943, DOI 10.1073/pnas.83.23.8943; MURPHY E, 1989, J BIOL CHEM, V264, P5622; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOSEK MT, 1990, J BIOL CHEM, V265, P8444; OTTO DA, 1983, ISOLATION CHARACTERI, P41; ROMANI A, 1992, FEBS LETT, V296, P135, DOI 10.1016/0014-5793(92)80364-M; ROMANI A, 1991, J BIOL CHEM, V266, P24376; ROMANI A, 1990, NATURE, V346, P841, DOI 10.1038/346841a0; ROMANI A, 1990, FEBS LETT, V269, P37, DOI 10.1016/0014-5793(90)81113-3; ROTEVATN S, 1989, AM J PHYSIOL, V257, pC141, DOI 10.1152/ajpcell.1989.257.1.C141; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SIMCHOWITZ L, 1990, ANNU REV PHYSIOL, V52, P381; SOMLYO AV, 1985, J BIOL CHEM, V260, P6801; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; VORMANN J, 1987, MAGNESIUM, V6, P220; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4	46	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15489	15495						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340377				2022-12-25	WOS:A1993LN30500028
J	SHOREIBAH, M; PERNG, GS; ADLER, B; WEINSTEIN, J; BASU, R; CUPPLES, R; WEN, DZ; BROWNE, JK; BUCKHAULTS, P; FREGIEN, N; PIERCE, M				SHOREIBAH, M; PERNG, GS; ADLER, B; WEINSTEIN, J; BASU, R; CUPPLES, R; WEN, DZ; BROWNE, JK; BUCKHAULTS, P; FREGIEN, N; PIERCE, M			ISOLATION, CHARACTERIZATION, AND EXPRESSION OF A CDNA-ENCODING N-ACETYLGLUCOSAMINYLTRANSFERASE-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; ASN-LINKED OLIGOSACCHARIDES; HAMSTER-KIDNEY CELLS; NIH 3T3; TRANSFORMATION; GLYCOSYLATION; SURFACE; GLYCOSYLTRANSFERASES; PHYTOHEMAGGLUTININ; GLYCOPEPTIDES	A cDNA clone for the complete coding sequence for alpha-1,3(6)-mannosylglycoprotein beta-1,6-N-acetylglucosaminyltransferase V (GlcNAc-T V, EC 2.4.1.155) was isolated and expressed in COS-7 cells. Degenerate oligonucleotide primers for polymerase chain reaction were synthesized based on the amino acid sequence of three tryptic peptides isolated from affinity-purified GlcNAc-T V. Polymerase chain reaction amplimers were isolated from rat and mouse mRNA. A cDNA-encoding full-length enzyme was isolated from a rat 1 cell (EJ-ras-transformed) library and sequenced. Transient expression of this clone in COS-7 cells, followed by enzymatic activity assays, demonstrated that this cDNA sequence encodes GlcNAc-T V. Northern analysis of rat kidney mRNA revealed a single band corresponding to a length of about 7 kilobases. Sequence analysis of the cDNA clone demonstrated an open reading frame that encoded a type II membrane protein of 740 amino acids.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR COMPLEX CARBOHYDRATE RES,ATHENS,GA 30602; AMGEN INC,THOUSAND OAKS,CA 91320; UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Amgen; University of Miami					NCI NIH HHS [CA 49926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; CRAWLEY SC, 1990, ANAL BIOCHEM, V185, P112, DOI 10.1016/0003-2697(90)90264-A; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EASTON EW, 1991, J BIOL CHEM, V266, P21674; GLICK MC, 1974, J VIROL, V13, P967, DOI 10.1128/JVI.13.5.967-974.1974; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; NISKIKAWA A, 1992, J BIOL CHEM, V267, P18199; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PIERCE M, 1987, BIOCHEM BIOPH RES CO, V146, P679, DOI 10.1016/0006-291X(87)90582-1; PIERCE M, 1986, J BIOL CHEM, V261, P772; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Sambrook J, 1989, MOL CLONING LABORATO; SANTER UV, 1984, CANCER RES, V44, P3730; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Shur BD, 1989, CURR OPIN CELL BIOL, V1, P905, DOI 10.1016/0955-0674(89)90057-4; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; WARREN L, 1978, BIOCHIM BIOPHYS ACTA, V516, P97, DOI 10.1016/0304-419X(78)90005-7; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; ZHOU Q, 1991, CELL SURFACE CARBOHY, P99	28	117	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15381	15385						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340368				2022-12-25	WOS:A1993LN30500013
J	CASTELLO, A; CADEFAU, J; CUSSO, R; TESTAR, X; HESKETH, JE; PALACIN, M; ZORZANO, A				CASTELLO, A; CADEFAU, J; CUSSO, R; TESTAR, X; HESKETH, JE; PALACIN, M; ZORZANO, A			GLUT-4 AND GLUT-1 GLUCOSE-TRANSPORTER EXPRESSION IS DIFFERENTIALLY REGULATED BY CONTRACTILE ACTIVITY IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC RATS; PRETRANSLATIONAL SUPPRESSION; INSULIN RESISTANCE; GENE-EXPRESSION; SOLEUS MUSCLE; DNA-BINDING; PROTEIN; DENERVATION; STIMULATION; INVIVO	Mammalian skeletal muscle expresses GLUT-4 and GLUT-1 glucose transporters. Here, we have investigated whether GLUT- 1 and GLUT-4 expression is regulated in muscle by contractile activity. GLUT-1 mRNA levels were high in skeletal muscle at days 16 and 17 of fetal life and decreased markedly by days 19 and 21. In contrast, GLUT-4 mRNA levels were clearly detectable at day 21 of fetal life, and they increased progressively during postnatal life. The timing data for GLUT-4 induction and GLUT- 1 repression suggest that these processes are related to skeletal muscle innervation. GLUT-4 mRNA decreased markedly in adult rat and rabbit tibialis anterior muscle after severage of peroneal nerve. In contrast, GLUT-1 mRNA levels showed a 9-fold increase in rat muscle 3 days after denervation. Direct stimulation of rabbit tibialis anterior muscle with extracellular electrodes protected GLUT-4 mRNA levels against the effect of denervation. This indicates that the repression of GLUT-4 mRNA associated with denervation is due, at least in part, to electrical activity. Increased contractile activity induced for 24 h by indirect electrical stimulation at low frequency caused a marked and specific increase in GLUT-1 mRNA levels in rabbit tibialis anterior muscle. Our results indicate that (a) innervation-dependent basal contractile activity regulates in an inverse manner the expression of GLUT-1 and GLUT-4 in skeletal muscle, and (b) enhanced contractile activity stimulates GLUT-1 expression in the absence of modifications to GLUT-4 expression. This suggests the existence of different factors which depend on contractile activity and which control GLUT-1 and GLUT-4 glucose transporter expression in skeletal muscle.	UNIV BARCELONA, FAC BIOL, DEPT BIOQUIM & FISIOL, AVE DIAGONAL 645, E-08028 BARCELONA, SPAIN; UNIV BARCELONA, FAC MED, DEPT CIENCIES FISIOL HUMANES & NUTR, E-08028 BARCELONA, SPAIN; ROWETT RES INST, DEPT BIOCHEM SCI, BUCKSBURN AB2 9SB, ABERDEEN, SCOTLAND	University of Barcelona; University of Barcelona; University of Aberdeen			Farré, Anna Castelló/K-9637-2015; Cadefau, Joan Aureli/G-2906-2016; Cadefau, Joan AurelI/M-7934-2018; Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015	Farré, Anna Castelló/0000-0001-8497-6251; Cadefau, Joan Aureli/0000-0001-6020-189X; Cadefau, Joan AurelI/0000-0001-6020-189X; Palacin, Manuel/0000-0002-8670-293X				AUGERT G, 1985, DIABETOLOGIA, V28, P295, DOI 10.1007/BF00271689; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; BUONANNO A, 1992, NUCLEIC ACIDS RES, V20, P539, DOI 10.1093/nar/20.3.539; BURANT CF, 1984, AM J PHYSIOL, V247, pE657, DOI 10.1152/ajpendo.1984.247.5.E657; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODERRE L, 1992, ENDOCRINOLOGY, V131, P1821, DOI 10.1210/en.131.4.1821; CONDON K, 1990, DEV BIOL, V138, P256, DOI 10.1016/0012-1606(90)90196-P; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; EVANS S, 1987, J BIOL CHEM, V262, P4911; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; FURLER SM, 1991, AM J PHYSIOL, V261, pE337, DOI 10.1152/ajpendo.1991.261.3.E337; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GREEN HJ, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P617; HABER RS, 1992, DIABETES, V41, P728, DOI 10.2337/diabetes.41.6.728; HANDBERG A, 1992, AM J PHYSIOL, V262, pE721, DOI 10.1152/ajpendo.1992.262.5.E721; HARRIS AJ, 1989, DEVELOPMENT, V107, P751; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOOD DA, 1989, EUR J BIOCHEM, V179, P275, DOI 10.1111/j.1432-1033.1989.tb14551.x; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; ONTELL M, 1988, AM J ANAT, V181, P279, DOI 10.1002/aja.1001810306; PETTE D, 1992, AM J PHYSIOL, V262, pR333, DOI 10.1152/ajpregu.1992.262.3.R333; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; Rosen K., 1990, FOCUS, V12, P23; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SCHWARZ G, 1983, PFLUG ARCH EUR J PHY, V398, P130, DOI 10.1007/BF00581060; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SLOT JW, 1990, NATURE, V346, P369, DOI 10.1038/346369a0; SMITH RL, 1984, J BIOL CHEM, V259, P2201; STROUT HV, 1990, ENDOCRINOLOGY, V126, P2728, DOI 10.1210/endo-126-5-2728; TSAY HJ, 1989, J CELL BIOL, V108, P1523, DOI 10.1083/jcb.108.4.1523; WALLACE S, 1992, FEBS LETT, V301, P69, DOI 10.1016/0014-5793(92)80212-Y; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WHITELAW PF, 1992, BIOCHEM J, V281, P143, DOI 10.1042/bj2810143; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764	58	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14998	15003						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325875				2022-12-25	WOS:A1993LL75900069
J	CRECHET, JB; POULLET, P; BERNARDI, A; FASANO, O; PARMEGGIANI, A				CRECHET, JB; POULLET, P; BERNARDI, A; FASANO, O; PARMEGGIANI, A			PROPERTIES OF THE SDC25 C-DOMAIN, A GDP TO GTP EXCHANGE FACTOR OF RAS PROTEINS AND IN-VITRO MODULATION OF ADENYLYL-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVATING PROTEIN; CDC25 GENE; ELONGATION-FACTORS; KINETIC-PROPERTIES; CALF BRAIN; YEAST; KIRROMYCIN; PRODUCT; MUTANTS	The SDC25 C-domain, the product encoded by the 3'-terminal part of the Saccharomyces cerevisiae SDC25 gene, acts as a GDP dissociation stimulator on RAS proteins (Crechet, J. B., Poullet, P., Mistou, M. Y., Parmeggiani, A., Camonis, J., Boy-Marcotte, E., Damak, F., and Jacquet, M. (1990b) Science 248, 866-868). To define further its role in the RAS-adenylyl cyclase pathway, an in vitro system was used, which utilized cell membranes from yeast strains with appropriate genotypes carrying alterations in the positive regulators of adenylyl cyclase activity. The SDC25 C-domain was able to stimulate the adenylyl cyclase activity of membranes from RAS2 cdc25 strains. Our results indicate that the SDC25 C-domain activates adenylyl cyclase by rapidly recycling the active RAS2. or RAS1.GTP complex from the respective GDP complex. This is also supported by the observation that the stimulation of adenylyl cyclase activity by RAS2T152I, a mutant characterized by a constitutively fast GDP to GTP exchange, was insensitive to the action of the SDC25 C-domain. No direct influence of this GDP dissociation stimulator on adenylyl cyclase was detected. Biochemical evidence was obtained, showing that in the presence of the functional target of RAS, the adenylyl cyclase, the effects of SDC25 C-domain and the catalytic domain of GTPase-activating protein are antagonistic. This in vitro system allowed a quantitative evaluation of the effects of positive and negative effectors of RAS on adenylyl cyclase and the biochemical analysis of conditions inducing a phenotype of permanently activated adenylyl cyclase.	UNIV PALERMO,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-90123 PALERMO,ITALY; CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE	University of Palermo; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	CRECHET, JB (corresponding author), ECOLE POLYTECH,BIOCHIM LAB,CNRS,SDI 61840,F-91128 PALAISEAU,FRANCE.							BARONI MD, 1989, MOL CELL BIOL, V9, P2715, DOI 10.1128/MCB.9.6.2715; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BREVIARIO D, 1988, EMBO J, V7, P1805, DOI 10.1002/j.1460-2075.1988.tb03012.x; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CRECHET JB, 1986, EUR J BIOCHEM, V161, P647, DOI 10.1111/j.1432-1033.1986.tb10489.x; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; CRECHET JB, 1986, EUR J BIOCHEM, V161, P655, DOI 10.1111/j.1432-1033.1986.tb10490.x; DAMAK F, 1991, MOL CELL BIOL, V11, P202, DOI 10.1128/MCB.11.1.202; DANIEL J, 1987, MOL CELL BIOL, V7, P3857, DOI 10.1128/MCB.7.10.3857; DEVENDITTIS E, 1986, EMBO J, V5, P3657, DOI 10.1002/j.1460-2075.1986.tb04696.x; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ENGELBERG D, 1990, EMBO J, V9, P641, DOI 10.1002/j.1460-2075.1990.tb08156.x; FASANO O, 1978, EUR J BIOCHEM, V89, P557, DOI 10.1111/j.1432-1033.1978.tb12560.x; FEGER G, 1991, EMBO J, V10, P349, DOI 10.1002/j.1460-2075.1991.tb07956.x; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1991, J BIOL CHEM, V266, P2962; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JONES S, 1984, CELL, V37, P437; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; REY I, 1991, ONCOGENE, V6, P347; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624	39	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14836	14841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325863				2022-12-25	WOS:A1993LL75900048
J	FAUCHER, C; CAPDEVIELLE, J; CANAL, I; FERRARA, P; MAZARGUIL, H; MCGUIRE, WL; DARBON, JM				FAUCHER, C; CAPDEVIELLE, J; CANAL, I; FERRARA, P; MAZARGUIL, H; MCGUIRE, WL; DARBON, JM			THE 28-KDA PROTEIN WHOSE PHOSPHORYLATION IS INDUCED BY PROTEIN-KINASE-C ACTIVATORS IN MCF-7 CELLS BELONGS TO THE FAMILY OF LOW-MOLECULAR-MASS HEAT-SHOCK PROTEINS AND IS THE ESTROGEN-REGULATED 24-KDA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CANCER-CELLS; STRESS PROTEINS; PHOSPHOLIPASE-C; PHORBOL ESTERS; GROWTH; RECEPTOR; ELECTROPHORESIS; INHIBITION; COMPONENT	We have previously reported the presence of a 28-kDa protein in human mammary adenocarcinoma MCF-7 cells, whose phosphorylation by phorbol ester 12-O-tetradecanoylphorbol-13-acetate(TPA) and permeant diacylglycerol 1,2-dioctanoyl-sn-glycerol was correlated to growth arrest induced by the protein kinase C (PKC) activators. We now investigate the possible identity of this protein with the estrogen-regulated ''24-kDa'' protein shown as related to the mammalian heat shock protein 27 (Fuqua, S. A. W., Blum-Salingaros, M., and McGuire, W. L. (1989) Cancer Res 49, 4126-4129). P-32-Labeled 28-kDa protein from TPA-treated MCF-7 cells was immunoprecipitated with a 24-kDa-specific monoclonal antibody. Immunoblots from cell extracts fractionated by two-dimensional isoelectric focusing/SDS-polyacrylamide gel electrophoresis demonstrated that TPA induced the conversion of a 28-kDa isoform ''a'' (pI 6.7) to a more acidic isoform ''b'' (pI 6.2). Two-dimensional gel analysis of [H-3]leucine-labeled MCF-7 cell extracts demonstrated that conversely to TPA, which induced only phosphorylation of 28-kDa protein, heat shock induced both synthesis (increase of isoform a) and phosphorylation (conversion of isoforms a to b) of the protein. P-32 labeling of MCF-7 cells allowed demonstration of the presence of an extra phosphoisoform ''c'' (pI 5.9) upon TPA as well as heat shock treatment. When cells were pretreated with the bisindolylmaleimide GF109203X, a selective inhibitor of PKC, the heat shock-induced phosphorylation was unchanged, while the TPA effect was almost abolished, suggesting that the heat shock-activated protein kinase was very likely different from PKC. However, peptide mapping of the 28-kDa phosphoprotein suggested identical sites of phosphorylation upon TPA and heat shock stimulation. Partial amino acid sequencing of the 28-kDa protein revealed identity with both the 24-kDa protein and the mammalian HSP27. The fact that estrogens and PKC, respectively, regulate expression and phosphorylation of this 24/28-kDa protein strongly argues for its key role in MCF-7 cell proliferation and differentiation.	FAC MED TOULOUSE,INSERM,U133,F-31062 TOULOUSE,FRANCE; SANOFI ELF BIORECH,F-31328 LABEGE,FRANCE; CNRS,PHARMACOL & TOXICOL MOLEC LAB,F-31077 TOULOUSE,FRANCE; UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV ONCOL,SAN ANTONIO,TX 78284	Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis; Centre National de la Recherche Scientifique (CNRS); University of Texas System; University of Texas Health San Antonio								ANG D, 1991, J BIOL CHEM, V266, P24233; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHRETIEN P, 1988, J CELL PHYSIOL, V137, P157, DOI 10.1002/jcp.1041370119; CIOCCA DR, 1991, BREAST CANCER RES TR, V20, P33, DOI 10.1007/BF01833355; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COFFER AI, 1985, CANCER RES, V45, P3686; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; EDWARDS DP, 1980, BIOCHEM BIOPH RES CO, V93, P804, DOI 10.1016/0006-291X(80)91148-1; FUQUA SAW, 1989, CANCER RES, V49, P4126; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; ISSANDOU M, 1986, FEBS LETT, V200, P337, DOI 10.1016/0014-5793(86)81164-4; ISSANDOU M, 1988, CANCER RES, V48, P6943; ISSANDOU M, 1991, J BIOL CHEM, V266, P21037; JOZAN S, 1985, BIOCHEM BIOPH RES CO, V107, P1566; KAGEYAMA M, 1991, J PHARMACOL EXP THER, V259, P1019; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LEE YJ, 1990, BIOCHEM BIOPH RES CO, V172, P119, DOI 10.1016/S0006-291X(05)80181-0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WELCH WJ, 1985, J BIOL CHEM, V260, P3058	30	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15168	15173						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325890				2022-12-25	WOS:A1993LL75900090
J	GEMMELL, CH; SEFTON, MV; YEO, EL				GEMMELL, CH; SEFTON, MV; YEO, EL			PLATELET-DERIVED MICROPARTICLE FORMATION INVOLVES GLYCOPROTEIN-IIB-IIIA - INHIBITION BY RGDS AND A GLANZMANN THROMBASTHENIA DEFECT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVATED PLATELETS; PLASMA-MEMBRANE; PROCOAGULANT ACTIVITY; FIBRINOGEN BINDING; WHOLE-BLOOD; FACTOR-VA; COMPLEX; VESICULATION; VESICLES; RECEPTOR	While the physiologic role of platelet microparticles may include a stable, physical dispersion of concentrated surface procoagulant activity the mechanism(s) of platelet vesiculation remains unknown. We demonstrate using flow cytometric methods a central role for the beta3 integrin glycoprotein (GP) IIb-IIIa complex and its ligand tetrapeptide Arg-Gly-Asp-Ser (RGDS) binding site in platelet vesiculation. Time- and calcium-dependent vesiculation of platelets in response to ADP, collagen, thrombin, phorbol myristate acetate, and the thrombin peptide SFLLRN were dramatically inhibited, in a concentration-dependent manner, by monoclonal antibodies to GPIIb-IIIa (A2A9, 7E3, PAC1) and RGDS. Complete inhibition with A2A9 and RGDS occurred at 7.5 mug/ml and 75 muM, respectively, while control antibodies and a mock peptide had no effect. Platelet vesiculation requires intact GPIIb-IIIa and is fully supported by the intracellular pool of GPIIb-IIIa alone since de-complexing of this heterodimer by calcium chelation completely abolished microparticle formation in response to collagen (no alpha-granule release) but not to thrombin or SFLLRN. A central role for GPIIb-IIIa is supported by the near total inability of Glanzmann's thrombasthenic (type I) platelets to vesiculate in response to thrombin, ADP, collagen, and phorbol 12-myristate 13-acetate. This extends the biologic roles of GPIIb-IIIa to include platelet vesiculation and suggests that one or all of its binding ligands play a role.	UNIV TORONTO, DEPT MED, TORONTO M5S 1A4, ONTARIO, CANADA; UNIV TORONTO, DEPT CHEM ENGN & APPL CHEM, TORONTO M5S 1A4, ONTARIO, CANADA	University of Toronto; University of Toronto								ABRAMS CS, 1990, BLOOD, V75, P128; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BERMAN CL, 1989, METHOD ENZYMOL, V169, P311; BEVERS EM, 1986, BRIT J HAEMATOL, V63, P335; BODE AP, 1991, BLOOD, V77, P887; COLLER BS, 1989, J CLIN INVEST, V7, P101; COMFURIUS P, 1985, BIOCHIM BIOPHYS ACTA, V815, P143, DOI 10.1016/0005-2736(85)90485-7; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; HOFFMAN M, 1992, THROMB HAEMOSTASIS, V68, P74; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; JY W, 1991, CLIN RES, V39, pA268; LEE Y, 1992, CLIN RES, V40, pA358; MONTGOMERY RR, 1983, J CLIN INVEST, V71, P385, DOI 10.1172/JCI110780; NURDEN AT, 1989, PLATELET IMMUNOBIOLO, P63; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1988, BLOOD, V71, P831; PIDARD D, 1986, BLOOD, V67, P604; PLOW EF, 1987, BLOOD, V70, P110; PLOW EF, 1992, J LAB CLIN MED, V120, P198; POLASEK J, 1982, THROMB RES, V28, P433, DOI 10.1016/0049-3848(82)90125-6; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROSING J, 1985, BLOOD, V65, P1557, DOI 10.1182/blood.V65.6.1557.bloodjournal6561557; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHATTIL S, 1991, CURR STUD HEMATOL BL, V58, P26, DOI DOI 10.1159/000419332; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SKAER RJ, 1981, PLATELETS BIOL PATHO, V2, P321; SUTHERLAND DR, 1991, BLOOD, V77, P84; TANS G, 1991, BLOOD, V77, P2641; THIAGARAJAN P, 1991, J BIOL CHEM, V266, P24302; WARREN BA, 1972, BRIT J EXP PATHOL, V53, P206; WARREN BA, 1972, MICROVASC RES, V4, P159, DOI 10.1016/0026-2862(72)90062-3; WEISS HJ, 1979, AM J MED, V67, P206, DOI 10.1016/0002-9343(79)90392-9; WENCELDRAKE JD, 1986, AM J PATHOL, V124, P324; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; WIEDMER T, 1991, BLOOD, V78, P2880	39	118	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14586	14589						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325838				2022-12-25	WOS:A1993LL75900010
J	HEMRIC, ME; LU, FWM; SHRAGER, R; CAREY, J; CHALOVICH, JM				HEMRIC, ME; LU, FWM; SHRAGER, R; CAREY, J; CHALOVICH, JM			REVERSAL OF CALDESMON BINDING TO MYOSIN WITH CALCIUM-CALMODULIN OR BY PHOSPHORYLATING CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; PROTEIN-KINASE-C; CHICKEN GIZZARD CALDESMON; INTACT HUMAN-PLATELETS; LIGHT-CHAIN KINASE; ATPASE ACTIVITY; HEAVY-MEROMYOSIN; SKELETAL-MUSCLE; CROSS-LINKING; F-ACTIN	Caldesmon, an actin-binding protein from smooth muscle and non-muscle cells, has previously been shown to bind stoichiometrically to smooth muscle myosin in an ATP-dependent manner. We now show quantitatively the effects of Ca2+-calmodulin and phosphorylation on the binding of caldesmon to myosin. Ca2+-calmodulin reduces the binding of caldesmon to myosin with the same effectiveness as it does the binding of caldesmon to actin. However, Ca2+-calmodulin is ineffective in antagonizing the binding of the purified myosin-binding region of caldesmon to myosin. These and other results suggest that Ca2+-calmodulin binding to the COOH-terminal region of caldesmon is responsible for reversal of binding to myosin. Phosphorylation of the NH2-terminal region of caldesmon by the co-purifying kinase, calmodulin-dependent protein kinase II, weakens but does not eliminate the binding of caldesmon to smooth muscle myosin. Finally, phosphorylation of smooth muscle myosin by smooth muscle myosin light chain kinase has no effect on the binding of caldesmon to myosin. Since Ca2+-calmodulin and phosphorylation of caldesmon weaken the binding of caldesmon to both actin and myosin, these events may be coordinately regulated.	E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858; NIH,BETHESDA,MD 20892	University of North Carolina; East Carolina University; National Institutes of Health (NIH) - USA				Chalovich, Joseph/0000-0002-1243-4055	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035216] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR035216, AR35216] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABOUGOU JC, 1989, FEBS LETT, V257, P408, DOI 10.1016/0014-5793(89)81583-2; ADAM L P, 1991, Biophysical Journal, V59, p56A; ADAM L P, 1992, Biophysical Journal, V61, pA7; ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; BARANY M, 1991, FEBS LETT, V279, P65, DOI 10.1016/0014-5793(91)80252-X; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P5739, DOI 10.1073/pnas.88.13.5739; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; CHALOVICH JM, 1991, J MUSCLE RES CELL M, V12, P503, DOI 10.1007/BF01738438; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FUJII T, 1987, J BIOL CHEM, V262, P2757; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEGMANN TE, 1991, CELL MOTIL CYTOSKEL, V20, P109, DOI 10.1002/cm.970200204; HEMRIC M E, 1991, Biophysical Journal, V59, p57A; HEMRIC M E, 1992, Biophysical Journal, V61, pA6; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HETTASCH JM, 1991, J BIOL CHEM, V266, P11876; IKEBE M, 1991, ARCH BIOCHEM BIOPHYS, V288, P538, DOI 10.1016/0003-9861(91)90232-8; IKEBE M, 1988, J BIOL CHEM, V263, P3055; IKEBE M, 1990, J BIOL CHEM, V265, P17607; KATAYAMA E, 1989, Biophysical Journal, V55, p232A; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LIN JJC, 1991, CELL MOTIL CYTOSKEL, V20, P95, DOI 10.1002/cm.970200203; LITCHFIELD DW, 1987, J BIOL CHEM, V262, P8056; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU FWM, 1993, BIOPHYS J, V64, pA29; LYNCH WP, 1987, J BIOL CHEM, V262, P7429; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON SB, 1986, BIOCHEM J, V237, P605, DOI 10.1042/bj2370605; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; NGAI PK, 1985, BIOCHEM J, V230, P695, DOI 10.1042/bj2300695; PERSECHINI A, 1983, BIOCHEMISTRY-US, V22, P470, DOI 10.1021/bi00271a033; PFITZER G, 1992, Biophysical Journal, V61, pA7; REDWOOD CS, 1990, FEBS LETT, V270, P53, DOI 10.1016/0014-5793(90)81233-E; SCOTTWOO GC, 1990, BIOCHEM J, V268, P367, DOI 10.1042/bj2680367; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WALKER G, 1989, J BIOL CHEM, V264, P496; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WANG CLA, 1991, J BIOL CHEM, V266, P13956; WAWRZYNOW A, 1991, FEBS LETT, V289, P213, DOI 10.1016/0014-5793(91)81072-G; WELLS C, 1984, J MUSCLE RES CELL M, V5, P97, DOI 10.1007/BF00713154; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	62	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15305	15311						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325900				2022-12-25	WOS:A1993LL75900109
J	HENDERSON, LA; QURESHI, MN				HENDERSON, LA; QURESHI, MN			A PEPTIDE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION BINDS TO NOVEL HUMAN CELL-SURFACE POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL-MYRISTATE ACETATE; ENVELOPE GLYCOPROTEIN; SOLUBLE CD4; SYNTHETIC PEPTIDE; HIV-INFECTION; TRANSMEMBRANE PROTEIN; CYTOPLASMIC DOMAIN; SEQUENCE IDENTITY; AIDS RETROVIRUS; T4 ANTIGEN	Putative cell surface human immunodeficiency virus (HIV) gp41 receptor proteins of 45 and 80 kDa (p45 and p80, respectively) were identified on human cells using a 17-amino acid peptide, referred to as CS3. In contrast, murine P815 cells expressed a peptide binding protein of 80 kDa only. A segment of 8 amino acids within CS3 contains the minimum sequence able to inhibit binding of radiolabeled CS3 to p80 and p45, as shown by competitive binding studies. Human p45 was purified from CD4+ RH9 cells by CS3 peptide affinity chromatography. Human p80 was partially purified from RH9 cell lysates by size exclusion chromatography followed by SDS-polyacrylamide gel electrophoresis; a rabbit polyclonal antibody was raised against this preparation. Anti-p80 antibody inhibited HIV infection in a dose-dependent manner. The CS3 region of gp41 has been been shown previously to be exposed on viral particles and envelope-expressing cells predominately after conformational changes in the HIV envelope occur due to the interaction of CD4 with gp120. These results, together with those from previous studies, suggest that following the interaction of gp120 with CD4, there may be a second receptor interaction necessary for virus entry/fusion.	BETH ISRAEL MED CTR,DEPT PATHOL & LAB MED,NEW YORK,NY 10003	Harvard University; Beth Israel Deaconess Medical Center	HENDERSON, LA (corresponding author), GUTHRIE RES INST,SAYRE,PA 18840, USA.							ACRES RB, 1986, J BIOL CHEM, V261, P6210; BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; CELADA F, 1990, J EXP MED, V172, P1143, DOI 10.1084/jem.172.4.1143; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; CIANCIOLO GJ, 1988, IMMUNOL LETT, V19, P7, DOI 10.1016/0165-2478(88)90112-5; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DIAMOND DC, 1990, P NATL ACAD SCI USA, V87, P5001, DOI 10.1073/pnas.87.13.5001; DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; HOXIE JA, 1988, J IMMUNOL, V140, P786; HOXIE JA, 1986, J IMMUNOL, V137, P1194; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; LEVY JA, 1986, SCIENCE, V232, P998, DOI 10.1126/science.3010461; LORES P, 1992, AIDS RES HUM RETROV, V8, P2063, DOI 10.1089/aid.1992.8.2063; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; MOORE JP, 1991, SCIENCE, V56, P1133; MULLIGAN MJ, 1992, J VIROL, V66, P3971, DOI 10.1128/JVI.66.6.3971-3975.1992; NGO TT, 1981, J BIOL CHEM, V256, P1313; OBRIEN WA, 1992, J VIROL, V66, P3125, DOI 10.1128/JVI.66.5.3125-3130.1992; QURESHI NM, 1990, AIDS, V4, P553, DOI 10.1097/00002030-199006000-00009; RICHARDSON NE, 1986, P NATL ACAD SCI USA, V85, P6102; RUEGG CL, 1989, J VIROL, V63, P3257, DOI 10.1128/JVI.63.8.3257-3260.1989; RUEGG CL, 1990, J IMMUNOL, V144, P3928; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SLECKMAN BP, 1989, J IMMUNOL, V142, P1457; SOLBACH W, 1982, J EXP MED, V1156, P1250; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; TURNER S, 1992, P NATL ACAD SCI USA, V89, P1335, DOI 10.1073/pnas.89.4.1335; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; WILSON C, 1990, J VIROL, V64, P3240, DOI 10.1128/JVI.64.7.3240-3248.1990	46	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15291	15297						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325899				2022-12-25	WOS:A1993LL75900107
J	KANG, HA; SCHWELBERGER, HG; HERSHEY, JWB				KANG, HA; SCHWELBERGER, HG; HERSHEY, JWB			TRANSLATION INITIATION FACTOR-EIF-5A, THE HYPUSINE-CONTAINING PROTEIN, IS PHOSPHORYLATED ON SERINE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EIF-4D; FACTOR 4D; PURIFICATION; BIOSYNTHESIS; RIBOSOMES; YEAST; CELLS	Translation initiation factor eIF-5A (formerly called eIF-4D) is a small, highly conserved protein in eukaryotic cells that undergoes a unique modification at one of its lysine residues to form hypusine. eIF-5A stimulates in vitro the synthesis of methionyl-puromycin, a model reaction for formation of the first peptide bond. In Saccharomyces cerevisiae eIF-5A is encoded by two highly homologous genes, TIF51A and TIF51B, and each gene gives rise to two hypusinated isoelectric variants, eIF-5Aa (more acidic) and eIF-5Ab (more basic). In order to study the structural and functional differences between the two isoforms, both isoelectric forms were purified from a yeast strain overexpressing TIF51A and were shown to stimulate identically the synthesis of methionyl-puromycin in a heterologous mammalian assay system. Pulse-chase labeling of yeast cells with [S-35]methionine showed that the basic form, eIF-5Ab, is a precursor form of the acidic form, eIF-5Aa. Immunoprecipitation of P-32-labeled cell lysates with rabbit antibodies specific for yeast eIF-5A, phosphoprotein phosphatase treatment of eIF-5Aa, and phosphoamino acid analysis demonstrated that eIF-5Aa is generated by phosphorylation of eIF-5Ab on serine. Therefore eIF-5A undergoes two post-translational modifications, hypusination and phosphorylation, where the activity of the factor is dependent on the first but is not influenced in vitro by the second.			KANG, HA (corresponding author), UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA.				NIGMS NIH HHS [GM22135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTIG D, 1992, EUR J BIOCHEM, V204, P751, DOI 10.1111/j.1432-1033.1992.tb16690.x; BENNE R, 1978, J BIOL CHEM, V253, P3070; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CHAMOT D, 1992, NUCLEIC ACIDS RES, V20, P665, DOI 10.1093/nar/20.4.665; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; DUNCAN RF, 1986, J BIOL CHEM, V261, P2903; GORDON ED, 1987, J BIOL CHEM, V262, P16590; GORDON ED, 1987, J BIOL CHEM, V262, P16585; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KANG HA, 1992, MOL GEN GENET, V233, P487, DOI 10.1007/BF00265449; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MEHTA KD, 1990, J BIOL CHEM, V265, P8802; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARK MH, 1984, J BIOL CHEM, V259, P2123; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1987, J BIOL CHEM, V262, P12730; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; Sherman F., 1986, METHODS YEAST GENETI; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; THOMAS A, 1979, EUR J BIOCHEM, V98, P329, DOI 10.1111/j.1432-1033.1979.tb13192.x; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WOLFF EC, 1992, J BIOL CHEM, V267, P6107	28	38	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14750	14756						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325852				2022-12-25	WOS:A1993LL75900035
J	SEVERINOV, K; SOUSHKO, M; GOLDFARB, A; NIKIFOROV, V				SEVERINOV, K; SOUSHKO, M; GOLDFARB, A; NIKIFOROV, V			RIFAMPICIN REGION REVISITED - NEW RIFAMPICIN-RESISTANT AND STREPTOLYDIGIN-RESISTANT MUTANTS IN THE BETA-SUBUNIT OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RPOB GENE; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION; DNA; TERMINATION; MUTATION; PROTEIN; ORGANIZATION; PHENOTYPES; OPERON	Mutations to rifampicin resistance (Rif(R)) in Escherichia coli alter the beta subunit of RNA polymerase (RNAP). A series of new point Rif(R) mutations was isolated with the aid of random polymerase chain reaction-mediated mutagenesis followed by selection on rifampicin (Rif). All of the new Rif(R) mutants, including changes in two novel positions, fell into the two principal clusters previously identified in the middle section of beta. Disruption of the spacer between the two clusters with deletions and insertions led to RNAP that was functional and sensitive to Rif in vitro, indicating that the spacer is not directly involved in Rif binding. However, most of the spacer mutants were strongly resistant to streptolydigin, suggesting that this area is involved in the binding of streptolydigin. An insertion of six consecutive histidines into the spacer was constructed that could be used to anchor RNAP on a Ni-chelate matrix without the loss of enzymatic activity, indicating that this region is looped out of the RNAP molecule.	PUBL HLTH RES INST CITY NEW YORK INC, 455 1ST AVE, NEW YORK, NY 10016 USA; RUSSIAN ACAD SCI, INST MOLEC GENET, MOSCOW 123182, RUSSIA	Russian Academy of Sciences			Severinov, Konstantin/C-8545-2016		NIGMS NIH HHS [GM-30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIKHANIAN SI, 1970, 2ND P LEP C, P28; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BRIAT JF, 1979, EUR J BIOCHEM, V98, P285, DOI 10.1111/j.1432-1033.1979.tb13187.x; CASSANI G, 1971, NATURE-NEW BIOL, V230, P197, DOI 10.1038/newbio230197a0; CLARK MA, 1992, CURR MICROBIOL, V25, P283, DOI 10.1007/BF01575863; DAS A, 1978, P NATL ACAD SCI USA, V75, P4828, DOI 10.1073/pnas.75.10.4828; ENGEL JN, 1990, J BACTERIOL, V172, P5732, DOI 10.1128/jb.172.10.5732-5741.1990; GARDNER MJ, 1991, MOL BIOCHEM PARASIT, V44, P115, DOI 10.1016/0166-6851(91)90227-W; GUARENTE LP, 1978, P NATL ACAD SCI USA, V75, P294, DOI 10.1073/pnas.75.1.294; HARTMANN G, 1967, BIOCHIM BIOPHYS ACTA, V145, P843, DOI 10.1016/0005-2787(67)90147-5; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; IGLOI GL, 1990, MOL GEN GENET, V221, P379, DOI 10.1007/BF00259403; IWAKURA Y, 1973, MOL GEN GENET, V121, P181, DOI 10.1007/BF00277531; JIN DJ, 1989, J BACTERIOL, V171, P5229, DOI 10.1128/jb.171.9.5229-5231.1989; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JOHNSTON DE, 1976, RNA POLYM, P101; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV M, 1993, IN PRESS GENE AMST; KIDD GH, 1980, BIOCHIM BIOPHYS ACTA, V609, P14, DOI 10.1016/0005-2787(80)90197-5; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LISITSYN NA, 1984, MOL GEN GENET, V196, P173, DOI 10.1007/BF00334112; LISITSYN NA, 1985, BIOORG KHIM+, V11, P132; LISITSYN NA, 1988, EUR J BIOCHEM, V177, P363, DOI 10.1111/j.1432-1033.1988.tb14385.x; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MINDLIN SZ, 1972, MOL GEN GENET, V115, P115, DOI 10.1007/BF00277290; MORROW TO, 1979, J BACTERIOL, V137, P374, DOI 10.1128/JB.137.1.374-383.1979; NENE V, 1982, MOL GEN GENET, V188, P399, DOI 10.1007/BF00330040; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1981, MOL GEN GENET, V184, P536, DOI 10.1007/BF00352535; OVCHINNIKOV YA, 1983, MOL GEN GENET, V190, P344, DOI 10.1007/BF00330662; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEIF R, 1969, NATURE, V223, P1068, DOI 10.1038/2231068a0; SCHULTZ W, 1981, NUCLEIC ACIDS RES, V24, P6889; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; STENDER W, 1977, EUR J BIOCHEM, V76, P591, DOI 10.1111/j.1432-1033.1977.tb11629.x; SZYBALSKI W, 1952, SCIENCE, V116, P46; VONDERHELM K, 1972, NATURE-NEW BIOL, V235, P82, DOI 10.1038/newbio235082a0; WEHRLI W, 1968, P NATL ACAD SCI USA, V61, P667, DOI 10.1073/pnas.61.2.667; YEPIZPLASCENCIA GM, 1990, NUCLEIC ACIDS RES, V18, P1869, DOI 10.1093/nar/18.7.1869; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052; ZILLIG W, 1970, COLD SPRING HARB SYM, V35, P47, DOI 10.1101/SQB.1970.035.01.010	45	176	183	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14820	14825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325861				2022-12-25	WOS:A1993LL75900046
J	VANDAM, M; MULLBERG, J; SCHOOLTINK, H; STOYAN, T; BRAKENHOFF, JPJ; GRAEVE, L; HEINRICH, PC; ROSEJOHN, S				VANDAM, M; MULLBERG, J; SCHOOLTINK, H; STOYAN, T; BRAKENHOFF, JPJ; GRAEVE, L; HEINRICH, PC; ROSEJOHN, S			STRUCTURE-FUNCTION ANALYSIS OF INTERLEUKIN-6 UTILIZING HUMAN MURINE CHIMERIC MOLECULES - INVOLVEMENT OF 2 SEPARATE DOMAINS IN RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; AMINO-ACIDS; HUMAN IL-6; BIOLOGIC ACTIVITIES; INTERNAL DELETIONS; SIGNAL TRANSDUCER; ESCHERICHIA-COLI; HIGH-AFFINITY; EXPRESSION; CYTOKINES	As an approach to understanding the interaction of interleukin-6 (IL-6) and its 80-kDa receptor (gp80), we have constructed chimeric human/murine IL-6-molecules, which were expressed in Escherichia coli and analyzed for biological activity and receptor binding. This experimental strategy was based on the observation that human IL-6 acts on human and murine cells, whereas murine IL-6 stimulates only murine cells. The regions to be exchanged were chosen according to the four antiparallel helix model of the hematopoietic cytokine family. All 14 chimeras constructed showed biological activity on murine cells. From the differential biological activities on human cells we deduced that three out of four domains of IL-6 are involved in species specificity, whereas only two domains are necessary for specific recognition by the gp80 IL-6-receptor protein.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CLB, CENT LAB, 1066 CX AMSTERDAM, NETHERLANDS		VANDAM, M (corresponding author), RHEIN WESTFAL TH AACHEN KLINIKUM, INST BIOCHEM, PAUWELSSTR 30, W-5100 AACHEN, GERMANY.		Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; ARCONE R, 1991, FEBS LETT, V288, P197, DOI 10.1016/0014-5793(91)81033-5; BAUER J, 1991, ANN HEMATOL, V62, P203, DOI 10.1007/BF01729833; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FIORILLO MT, 1992, EUR J IMMUNOL, V22, P799, DOI 10.1002/eji.1830220325; FONTAINE V, 1991, GENE, V104, P227, DOI 10.1016/0378-1119(91)90254-9; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; IDA N, 1989, BIOCHEM BIOPH RES CO, V165, P728, DOI 10.1016/S0006-291X(89)80027-0; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LAURELL CB, 1972, SCAND J CLIN LAB INV, V29, P21, DOI 10.3109/00365517209102748; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LUTTICKEN C, 1991, FEBS LETT, V282, P265, DOI 10.1016/0014-5793(91)80491-K; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MACKIEWICZ A, 1990, P NATL ACAD SCI USA, V87, P1491, DOI 10.1073/pnas.87.4.1491; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SAITO M, 1992, J IMMUNOL, V148, P4066; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SNOUWAERT JN, 1991, J IMMUNOL, V146, P585; STUDIER FW, 1990, METHOD ENZYMOL, V185, P517; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAL M, 1985, J BIOL CHEM, V260, P9976; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XG, 1990, BLOOD, V76, P2599; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	46	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15285	15290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325898				2022-12-25	WOS:A1993LL75900106
J	DIAMOND, AM; CHOI, IS; CRAIN, PF; HASHIZUME, T; POMERANTZ, SC; CRUZ, R; STEER, CJ; HILL, KE; BURK, RF; MCCLOSKEY, JA; HATFIELD, DL				DIAMOND, AM; CHOI, IS; CRAIN, PF; HASHIZUME, T; POMERANTZ, SC; CRUZ, R; STEER, CJ; HILL, KE; BURK, RF; MCCLOSKEY, JA; HATFIELD, DL			DIETARY SELENIUM AFFECTS METHYLATION OF THE WOBBLE NUCLEOSIDE IN THE ANTICODON OF SELENOCYSTEINE TRANSFER RNA[SER]SEC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; TRANSFER-RNA; ESCHERICHIA-COLI; MAMMALIAN-CELLS; INSERTS SELENOCYSTEINE; RIBOSE METHYLATION; SEQUENCE-ANALYSIS; AMINO-ACID; GENE; UGA	We reported previously that the presence of selenium in culture media of mammalian cells influences both the steady-state levels and distributions of two tRNA isoacceptors involved in the insertion of selenocysteine into protein in response to certain UGA codons. In this study, we demonstrate an increase in the levels of these isoacceptors in rats fed a selenium-adequate diet compared to animals fed a selenium-deficient diet, as well as a shift in the relative distribution toward the tRNA which elutes later from an RPC-5 column. These effects were found to occur in a tissue-specific manner. Both selenocysteine tRNAs were isolated from rat liver, sequenced, analyzed by mass spectrometry, and shown to differ only by ribose 2'-O-methylation of 5-methylcarboxymethyluridine that occurs in the wobble position of the anticodon. This modified nucleoside has been documented previously only in yeast tRNA while the corresponding 2'-O-methylribose derivative has not been observed. The structure of these nucleosides was established by mass spectrometry and confirmed by chemical synthesis. Although the role of methylation of the wobble nucleotide is not known, the differences in elution properties from RPC-5 columns are consistent with other experimental observations indicating that a change in tRNA conformation accompanies this methylation.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,NASHVILLE,TN 37232; UNIV MINNESOTA,MED CTR,DEPT MED,MINNEAPOLIS,MN 55455; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112	Vanderbilt University; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; Utah System of Higher Education; University of Utah	DIAMOND, AM (corresponding author), UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637, USA.			Pomerantz, Steven/0000-0003-2173-7442	NATIONAL CANCER INSTITUTE [R01CA054364] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA54364] Funding Source: Medline; NIEHS NIH HHS [R01 ES02497] Funding Source: Medline; NIGMS NIH HHS [R01 GM29812] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BROWN DG, 1973, J NUTR, V103, P102, DOI 10.1093/jn/103.1.102; BURK RF, 1972, J NUTR, V102, P1049, DOI 10.1093/jn/102.8.1049; BURK RF, 1987, METHOD ENZYMOL, V143, P307; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; DIAMOND A, 1981, CELL, V25, P497, DOI 10.1016/0092-8674(81)90068-4; DIAMOND A, 1983, METHOD ENZYMOL, V100, P431; DIAMOND AM, 1990, NUCLEIC ACIDS RES, V18, P6727, DOI 10.1093/nar/18.22.6727; EDMONDS CG, 1988, ANAL CHEM, V60, P2314, DOI 10.1021/ac00171a034; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; GARCIA GE, 1991, J BACTERIOL, V173, P2093, DOI 10.1128/jb.173.6.2093-2098.1991; GEHRKE CW, 1990, CHROMATOGRAPHY MOD A, pA3; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; HATFIELD D, 1982, P NATL ACAD SCI-BIOL, V79, P6215, DOI 10.1073/pnas.79.20.6215; HATFIELD D, 1970, P NATL ACAD SCI USA, V67, P1200, DOI 10.1073/pnas.67.3.1200; HATFIELD D, 1991, NUCLEIC ACIDS RES, V19, P939, DOI 10.1093/nar/19.4.939; HATFIELD D, 1992, BIOCHEM BIOPH RES CO, V184, P254, DOI 10.1016/0006-291X(92)91186-T; HATFIELD D, 1992, TRANSFER RNA PROTEIN, P269; HATFIELD D, 1972, P NATL ACAD SCI USA, V67, P3014; HATFIELD DL, 1990, CRIT REV BIOCHEM MOL, V25, P71, DOI 10.3109/10409239009090606; HATFIELD DL, 1991, MOL MICROBIOL, V5, P1183, DOI 10.1111/j.1365-2958.1991.tb01891.x; HEIDER J, 1989, NUCLEIC ACIDS RES, V17, P2529, DOI 10.1093/nar/17.7.2529; HILL KE, 1991, J BIOL CHEM, V266, P10050; KATO N, 1983, BIOCH INT, V5, P835; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KELMERS AD, 1971, ANAL BIOCHEM, V44, P486, DOI 10.1016/0003-2697(71)90236-3; KUMAGAI I, 1982, J BIOL CHEM, V257, P7388; KUNTZEL B, 1975, BIOCHIMIE, V57, P61, DOI 10.1016/S0300-9084(75)80110-6; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; Maxam A M, 1980, Methods Enzymol, V65, P499; McCloskey J. A., 1974, BASIC PRINCIPLES NUC, V1, P209; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; RANDERATH E, 1981, CANCER RES, V41, P2863; ROE BA, 1974, NUCLEIC ACIDS RES, V2, P21; ROGG H, 1977, P NATL ACAD SCI USA, V74, P4243, DOI 10.1073/pnas.74.10.4243; Silberklang M, 1979, Methods Enzymol, V59, P58; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STADTMAN TC, 1991, BIOFACTORS, V3, P21; TUMAITIS T D, 1970, Biochimica et Biophysica Acta, V224, P391, DOI 10.1016/0005-2787(70)90572-1	45	121	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14215	14223						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314785				2022-12-25	WOS:A1993LJ82500064
J	BARKER, CW; FAGAN, JB; PASCO, DS				BARKER, CW; FAGAN, JB; PASCO, DS			DOWN-REGULATION OF P4501A1 AND P4501A2 MESSENGER-RNA EXPRESSION IN ISOLATED HEPATOCYTES BY OXIDATIVE STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR KAPPA-B; HYDROGEN-PEROXIDE; TRANSCRIPTIONAL REGULATION; N-ACETYLCYSTEINE; RECEPTOR KINASE; MESSENGER-RNAS; RAT ADIPOCYTES; INTACT-CELLS; AH RECEPTOR; ACTIVATION	We have previously shown that the inflammatory mediator interleukin-1 suppressed transcription of CYP1A1 and CYP1A2 mRNAs (Barker, C. W., Fagan, J. B., and Pasco, D. S. (1992) J. Biol. Chem. 267, 8050-8055). Since many of the actions of inflammatory mediators are mimicked by oxidative stress, we treated isolated hepatocytes with 0.25-1.0 mM H2O2 to determine whether expression of these genes is also modulated by oxidative stress. Inducer dependent accumulation of CYP1A1 and CYP1A2 mRNAs were maximally reduced approximately 50 and 70%, respectively, by 1.0 mM H2O2. Run-on transcription analysis suggested that the effect of H2O2 was mediated transcriptionally. The reduction in CYP1A mRNA levels was not due to a reduction in the levels of all mRNAs due to some general toxic effect since H2O2 did not reduce glyceraldehyde-3-phosphate dehydrogenase, alpha-tubulin, beta-fibrinogen, or albumin mRNA levels, and did not increase lactate dehydrogenase released into the medium. Insulin-mimicked H2O2 action, reducing the expression of both mRNAs, and N-acetylcysteine, which increases intracellular glutathione levels, completely reversed the insulin effect on both mRNAs and the H2O2 effect on CYP1A1 mRNA, but only partially reversed the H2O2 effect on CYP1A2 mRNA. This study indicates that the CYP1A1 and CYP1A2 genes are responsive to oxidative stress and that the majority of this responsiveness can be modified by cellular redox potential.	MAHARISHI INT UNIV,MOLEC BIOL LAB,FAIRFIELD,IA 52557						NCI NIH HHS [R01-CA55228] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055228] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P4790, DOI 10.1073/pnas.87.12.4790; BARKER CW, 1992, J BIOL CHEM, V267, P8050; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696; BUTLER MA, 1989, CANCER RES, V49, P25; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FAGAN JB, 1986, ARCH BIOCHEM BIOPHYS, V244, P261, DOI 10.1016/0003-9861(86)90116-5; FALETTO MB, 1988, J BIOL CHEM, V263, P12187; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GATTI S, 1993, CLIN EXP IMMUNOL, V91, P456; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HANKINSON O, 1993, ARCH BIOCHEM BIOPHYS, V300, P1, DOI 10.1006/abbi.1993.1001; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KOJ A, 1985, ACUTE PHASE RESPONSE, pR22; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KUKIELKA E, 1991, DRUG METAB DISPOS, V19, P1108; KURIEKA E, 1990, ARCH BIOCHEM BIOPHYS, V283, P326; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LITTLE SA, 1990, J BIOL CHEM, V255, P10888; LIU PT, 1993, TOXICOLOGY, V80, P37, DOI 10.1016/0300-483X(93)90075-4; LU AYH, 1980, PHARMACOL REV, V31, P277; MANNERING GJ, 1986, ANNU REV PHARMACOL, V26, P455, DOI 10.1146/annurev.pa.26.040186.002323; MAY JM, 1979, J BIOL CHEM, V254, P9017; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PASCO DS, 1993, J BIOL CHEM, V268, P1053; PELKONEN O, 1982, PHARMACOL REV, V34, P190; PERISTERIS P, 1992, CELL IMMUNOL, V140, P390, DOI 10.1016/0008-8749(92)90205-4; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SANTHANAM K, 1989, CANCER LETT, V45, P129, DOI 10.1016/0304-3835(89)90147-X; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; SHIMM DS, 1992, RADIAT RES, V129, P149, DOI 10.2307/3578151; STARKE PE, 1985, J BIOL CHEM, V260, P86; SUGAWA K, 1985, J BIOL CHEM, V280, P5026; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	59	103	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3985	3990						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307954				2022-12-25	WOS:A1994MW98900016
J	HUG, P; SLEIGHT, RG				HUG, P; SLEIGHT, RG			FUSOGENIC VIROSOMES PREPARED BY PARTITIONING OF VESICULAR STOMATITIS-VIRUS G-PROTEIN INTO PREFORMED VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-SENSITIVE LIPOSOMES; MEMBRANE-FUSION; UNILAMELLAR VESICLES; INTRACELLULAR FATE; DEPENDENT FUSION; ENCAPSULATED DNA; COATED VESICLES; CELLS; RECONSTITUTION; FLUORESCENCE	Virosomes were prepared by the insertion of vesicular stomatitis virus glycoprotein, a pH-sensitive fusion protein, into preformed liposomes. The fusogenic activity of these virosomes was characterized in cell-free fusion assays using liposomal targets. Fusion was monitored by concentration-dependent changes in the efficiency of resonance energy transfer between N-(lissamine rhodamine B sulfonyl)-phosphatidylethanolamine and N-(4-nitrobenzo-2-oxa-1,3-diazol)-phosphatidylethanolamine and by electron microscopy. The fusogenic activity was dependent on the presence of vesicular stomatitis virus glycoprotein, was pH-sensitive, and had a pH threshold of activation similar to that of the native virus. The ex tent of fusion was dependent upon the lipid composition of the vesicles. This technique will allow vesicles prepared by any method to be made fusogenic.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati					NIGMS NIH HHS [GM-39035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUMENTHAL R, 1988, CELL BIOPHYS, V12, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNS M, 1984, VIROLOGY, V137, P49, DOI 10.1016/0042-6822(84)90007-2; COLLINS D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P234, DOI 10.1016/0005-2736(90)90102-T; COLLINS D, 1987, CANCER RES, V47, P735; CONNOR J, 1984, P NATL ACAD SCI-BIOL, V81, P1715, DOI 10.1073/pnas.81.6.1715; CUDD A, 1985, BIOCHIM BIOPHYS ACTA, V845, P477, DOI 10.1016/0167-4889(85)90214-9; EIDELMAN O, 1984, J BIOL CHEM, V259, P4622; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GOULDFOGERITE S, 1985, ANAL BIOCHEM, V148, P15, DOI 10.1016/0003-2697(85)90622-0; GUY HR, 1992, BIOPHYS J, V62, P113; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG L, 1983, METHOD ENZYMOL, V149, P88; HUG P, 1991, BIOCHIM BIOPHYS ACTA, V1097, P1, DOI 10.1016/0925-4439(91)90016-3; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIDOT M, 1989, BIOCHIM BIOPHYS ACTA, V980, P281, DOI 10.1016/0005-2736(89)90314-3; LIU D, 1989, BIOCHEM BIOPH RES CO, V163, P326; LIU DX, 1990, BIOCHIM BIOPHYS ACTA, V1022, P348, DOI 10.1016/0005-2736(90)90284-U; MAGEE WE, 1974, J CELL BIOL, V63, P492, DOI 10.1083/jcb.63.2.492; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; METSIKKO K, 1986, EMBO J, V5, P3429, DOI 10.1002/j.1460-2075.1986.tb04665.x; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORGAN DO, 1988, IMMUNOL TODAY, V9, P84, DOI 10.1016/0167-5699(88)91270-4; NANDI PK, 1986, J BIOL CHEM, V261, P6722; PATERNOSTRE MT, 1989, FEBS LETT, V243, P251, DOI 10.1016/0014-5793(89)80139-5; PETRI WA, 1979, J BIOL CHEM, V254, P4313; PETRI WA, 1980, VIROLOGY, V107, P543, DOI 10.1016/0042-6822(80)90323-2; POLLARD HB, 1992, BIOPHYS J, V62, P15, DOI 10.1016/S0006-3495(92)81764-2; ROSIER RN, 1979, ANAL BIOCHEM, V96, P384, DOI 10.1016/0003-2697(79)90596-7; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHEULE RK, 1987, BIOCHIM BIOPHYS ACTA, V899, P185, DOI 10.1016/0005-2736(87)90399-3; SCHLEGEL R, 1983, CELL, V32, P639, DOI 10.1016/0092-8674(83)90483-X; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; STRAUBINGER RM, 1983, METHOD ENZYMOL, V101, P512; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; THOMAS D, 1985, J VIROL, V54, P598, DOI 10.1128/JVI.54.2.598-607.1985; VAINSTEIN A, 1983, METHOD ENZYMOL, V101, P492; WALTER A, 1993, BIOCHEMISTRY-US, V32, P3271, DOI 10.1021/bi00064a009; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE JM, 1992, J CELL BIOCH C SJ, V16, P111; WILLIAMS MC, 1991, AM J RESP CELL MOL, V5, P41, DOI 10.1165/ajrcmb/5.1.41; YATVIN MB, 1980, SCIENCE, V210, P1253, DOI 10.1126/science.7434025; ZAKIM D, 1989, METHOD ENZYMOL, V171, P253; ZON G, 1988, PHARM RES-DORDR, V5, P539, DOI 10.1023/A:1015985728434	48	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4050	4056						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307962				2022-12-25	WOS:A1994MW98900026
J	BURMA, S; MUKHERJEE, B; JAIN, A; HABIB, S; HASNAIN, SE				BURMA, S; MUKHERJEE, B; JAIN, A; HABIB, S; HASNAIN, SE			AN UNUSUAL 30-KDA PROTEIN-BINDING TO THE POLYHEDRON GENE PROMOTER OF AUTOGRAPHA-CALIFORNICA NUCLEAR POLYHEDROSIS-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION VECTORS; RNA-POLYMERASE; TRANSCRIPTION; PHOSPHORYLATION; INITIATION; ACTIVATION; SITES; CELLS	Gel retardation assays-using nuclear extracts from the Autographa californica nuclear polyhedrosis virus-infected Sf21 (Spodoptera frugiperda) insect cell line revealed a host factor (polyhedrin promoter-binding protein or PPBP) that binds to the polyhedrin gene promoter. A hexanucleotide sequence (AATAAA) within the promoter is important for binding in association with neighboring elements, some of which are contributed by the sequence TAAGTATT present at the transcription start point. PPBP was affinity purified and appears to be an unusual DNA-binding protein with respect to its stability (binding was obtained at NaCl concentrations and temperatures ranging from 0.2 to 2 m and 0 to 65-degrees-C, respectively), high binding affinity (binding even in the absence of nonspecific DNA) with an apparent dissociation constant of approximately 3.7 x 10(-12) M, and high specificity (binding was unaffected in the presence of a 50,000 times excess of nonspecific DNA). From UV cross-linking and Southwestern analyses the molecular mass of PPBP was estimated to be approximately 30 kDa. PPBP is phosphorylated and may have a regulatory function because dephosphorylation abolished DNA binding activity. Differences in PPBP characteristics between nuclear extracts from Sf21 and from Bm5 (Bombyx mori) cell line suggested that additional factors may be involved in the interaction of PPBP with the polyhedrin promoter.			BURMA, S (corresponding author), NATL INST IMMUNOL,EUKARYOT GENE EXPRESS LAB,ARUNA ASAF ALI MARG,NEW DELHI 110067,INDIA.		HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791				BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARACAMO J, 1990, GENE DEV, V4, P1611; CHODOSH L, 1988, CURRENT PROTOCOLS MO, V2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HUH NE, 1990, J GEN VIROL, V71, P195, DOI 10.1099/0022-1317-71-1-195; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MARZLUFF WF, 1990, METHOD ENZYMOL, V181, P30; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MILLER LK, 1989, BIOESSAYS, V11, P91, DOI 10.1002/bies.950110404; NAKHAI B, 1991, FEBS LETT, V283, P104, DOI 10.1016/0014-5793(91)80564-J; OOI BG, 1989, J MOL BIOL, V210, P721, DOI 10.1016/0022-2836(89)90105-8; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PASSARELLI AL, 1993, J VIROL, V67, P2149, DOI 10.1128/JVI.67.4.2149-2158.1993; PASSARELLI AL, 1993, J VIROL, V67, P3481, DOI 10.1128/JVI.67.6.3481-3488.1993; POSSEE R, 1991, VIROLOGY, V185, P299; POSSEE RD, 1987, NUCLEIC ACIDS RES, V15, P10233, DOI 10.1093/nar/15.24.10233; PUGH BF, 1992, J BIOL CHEM, V267, P679; RANKIN C, 1988, GENE, V70, P39, DOI 10.1016/0378-1119(88)90102-3; RAO MV, 1990, J BIOL CHEM, V265, P5617; RICE WC, 1986, VIRUS RES, V6, P155, DOI 10.1016/0168-1702(86)90047-X; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROELVINK PW, 1992, J GEN VIROL, V73, P1481, DOI 10.1099/0022-1317-73-6-1481; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P1815, DOI 10.1093/nar/20.7.1815; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SRIDHAR P, 1993, FEBS LETT, V315, P282, DOI 10.1016/0014-5793(93)81179-4; SRIDHAR P, 1993, IN PRESS GENE AMST; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WILSON ME, 1987, J VIROL, V61, P661, DOI 10.1128/JVI.61.3.661-666.1987; YANG CL, 1991, VIRUS RES, V20, P251, DOI 10.1016/0168-1702(91)90079-B; YOUNG LS, 1991, SCIENCE, V252, P542, DOI 10.1126/science.1708526	41	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2750	2757						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300607				2022-12-25	WOS:A1994MV43200060
J	FRANKE, TF; TARTOF, KD; TSICHLIS, PN				FRANKE, TF; TARTOF, KD; TSICHLIS, PN			THE SH2-LIKE AKT HOMOLOGY (AH) DOMAIN OF C-AKT IS PRESENT IN MULTIPLE COPIES IN THE GENOME OF VERTEBRATE AND INVERTEBRATE EUKARYOTES - CLONING AND CHARACTERIZATION OF THE DROSOPHILA-MELANOGASTER C-AKT HOMOLOG DAKT1	ONCOGENE			English	Article							PROTEIN-KINASE-C; SEQUENCE-ANALYSIS; GENE; DNA; CHROMOSOME; ONCOGENE	The Akf proto-oncogene encodes a serine-threonine protein kinase whose carboxyterminal catalytic domain is closely related to the catalytic domains of all the known members of the protein kinase C (PKC) family. Akt, however, differs from PKC in its N-terminal region which contains a domain related distantly to the SH2 domain of cytoplasmic tyrosine kinases and other signalling proteins, which we have named Akt homology (AH) domain. Low stringency hybridization of a c-akt AH probe to a panel of genomic DNAs from vertebrate and invertebrate eucaryotes detected multiple DNA bands (perhaps multiple genes) in all tested species. Drosophila DNA contains at least three hybridizing DNA bands. One of them was cloned, and found by sequence analysis, to define an Akt related gene (Dakt1). Comparison between the coding regions of c-akt and Dakt1 revealed 64.6% identity at the nucleotide level and 76.5% similarity at the amino acid level. The highest degree of homology was detected in the AH domain (68.3% similarity at the amino acid level) and the catalytic domain (83.3% similarity). Additional sequence comparisons revealed that the amino acid similarity between the catalytic domains of Dakt1 and the three known members of the Drosophila protein kinase C (PKC) family, Dpkc1, Dpkc2 and Dpkc3, is 68%, 63.6% and 67.1%, respectively. Dakt1 was mapped to Drosophila chromosome 3R 89BC. Its expression is subject to developmental regulation with the highest levels detected within the fourth hour of embryonic development. These results confirm that the AH domain of Akt defines new protein families in both vertebrate and invertebrate eucaryotes. The high degree of homology between the catalytic domains of Dakt1 and the three known members of the Drosophila PKC family suggests an evolutionarily conserved functional relationship between the members of the two families.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-06927, CA-38047] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BEDIAN V, 1991, DEV GENET, V12, P188, DOI 10.1002/dvg.1020120303; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGELS WR, 1986, FOCUS, V8, P6; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HICKS JL, 1992, J CELL SCI, V101, P247; Jowett T., 1986, DROSOPHILA, P275; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAWRENCE PA, 1992, MAKING FLY, P13; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NELSON CR, 1992, MOL GEN GENET, V235, P11, DOI 10.1007/BF00286176; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; VASLET CA, 1980, NATURE, V285, P674, DOI 10.1038/285674a0; Wieschaus E., 1986, P199	32	36	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					141	148						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302573				2022-12-25	WOS:A1994MW24700017
J	SKERKA, C; ZIPFEL, PF; SIEBENLIST, U				SKERKA, C; ZIPFEL, PF; SIEBENLIST, U			2 REGULATORY DOMAINS ARE REQUIRED FOR DOWN-REGULATION OF C-MYC TRANSCRIPTION IN DIFFERENTIATING U937 CELLS	ONCOGENE			English	Article							BURKITT-LYMPHOMA; TRANS-ACTIVATION; DNA-REPLICATION; PROTEIN-BINDING; HL60 CELLS; EXPRESSION; GENE; ONCOGENE; PROMOTER; INITIATION	In many differentiating cells, a reduction of c-myc proto-oncogene expression is a prerequisite for terminal differentiation. The downmodulation of c-myc in differentiating cells is due to at least two different mechanisms: (i) an elongation block to c-myc transcription activated during an early phase of differentiation and (ii) an inhibition of transcription initiation activated during a later phase. In order to determine cis-acting target structures of the c-myc gene required for the late-phase downregulation of transcriptional initiation, we permanently transfected U937 cells with constructs containing the bacterial chloramphenicol acetyl transferase (CAT) gene driven by a 2.8 kb c-myc promoter region or deletions thereof. We determined two distinct domains in the c-myc promoter region both of which are essential for efficient terminal downregulation: a proximal domain and a distal domain which are located between base pairs - 606 to - 101, and between - 2392 to - 1396, respectively, relative to P1. The identification of two distinct regulatory elements suggests the requirement and cooperation of two regulatory factors as an essential event for mediating differentiation-induced downregulation of c-myc in monocytic cells. The implications of these results for deregulation of the translocated c-myc allele in Burkitt's lymphoma are discussed.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	SKERKA, C (corresponding author), BERNHARD NOCHT INST TROP MED,BERNARD NOCHT STR 74,W-2000 HAMBURG 36,GERMANY.							ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Battey, 1986, BASIC METHODS MOL BI; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Dimitrovsky E., 1986, NATURE, V322, P748; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GIDLUND M, 1981, NATURE, V292, P848, DOI 10.1038/292848a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KELLY K, 1985, J CLIN IMMUNOL, V5, P65, DOI 10.1007/BF00915003; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; PELLICI PG, 1986, P NATL ACAD SCI USA, V83, P2984; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; SAKELSA K, 1991, ONCOGENE RES, V6, P73; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SLUNGAARD A, 1987, J CLIN INVEST, V79, P1542, DOI 10.1172/JCI112987; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527	37	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2135	2143						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336940				2022-12-25	WOS:A1993LP17100014
J	HOLMES, DF; WATSON, RB; STEINMANN, B; KADLER, KE				HOLMES, DF; WATSON, RB; STEINMANN, B; KADLER, KE			EHLERS-DANLOS SYNDROME TYPE-VIIB - MORPHOLOGY OF TYPE-I COLLAGEN FIBRILS FORMED IN-VIVO AND IN-VITRO IS DETERMINED BY THE CONFORMATION OF THE RETAINED N-PROPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; CHICK-EMBRYO TENDONS; LENGTH CDNA CLONE; PRO-ALPHA-2(I) CHAIN; CONNECTIVE-TISSUE; STAINING PATTERN; PC-COLLAGEN; PROCOLLAGEN; PROTEINASE; GENE	Previously we showed that fibrils generated from collagen and pNcollagen(-ex6) from fibroblasts of an individual with Ehlers-Danlos syndrome (EDS) type VIIB were hieroglyphic in cross-section and all N-propeptides were located at the fibril surface. Hieroglyphs were resolved to near-cylindrical fibrils (that were similar in appearance to the fibrils seen in the. tissues of individuals with EDS type VIIB) by treatment with N-proteinase which cleaved the pNalpha1(I) chains but not the pNalpha2(I)-ex6 chains (Watson, R. B., Wallis, G. A., Holmes, D. F., Viljoen, D., Byers, P. H., and Kadler, K. E. (1992) J. Biol. Chem. 267, 9093-9100). Here, quantitative scanning transmission electron microscopy (STEM) showed that N-propeptides in hieroglyphs were in a ''bent-back'' conformation and thus located exclusively in the overlap zone of the fibril D-period (D = 67 nm). In contrast, STEM of fibrils from the dermis of an individual with EDS type VIIB showed that partially cleaved N-propeptides (in which cleaved pNalpha1(I) remained in noncovalent association with pNalpha2(I)-ex6 chains) were distributed equally between the gap and overlap zones of the fibrils. Comparison of experimental data with theoretical mass distributions of the fibril based on amino acid sequence data gave a consistent value of 33 nm for the total axial extent for the N-propeptides in hieroglyphic and tissue fibrils irrespective of the location of N-propeptides to the gap or overlap zone. These data exclude the possibility that N-propeptides adopt a random configuration, but rather, that they locate to specific sites in the gap and overlap zones. The results demonstrated that cleavage of pNalpha1(I) chains in vivo releases the N-propeptides from the constraints of the bent-back conformation. Co-distribution of partially cleaved N-propeptides between gap and overlap zones allows a higher surface packing density of N-propeptides and explains how circularity of large diameter fibrils can be achieved despite the retention of N-propeptides in tissues of individuals with EDS type VIIB.	UNIV MANCHESTER,SCH BIOL SCI,DEPT BIOCHEM & MOLEC BIOL,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND; UNIV MANCHESTER,SCH BIOL SCI,DEPT MED BIOPHYS,MANCHESTER M13 9PT,LANCS,ENGLAND; UNIV ZURICH,CHILDRENS HOSP,DEPT PEDIAT,DIV METAB,CH-8032 ZURICH,SWITZERLAND	University of Manchester; University of Manchester; University Children's Hospital Zurich; University of Zurich			KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BYERS PH, 1989, METABOLIC BASIS INHE, P2805; CAPALDI MJ, 1982, BIOPOLYMERS, V21, P2291, DOI 10.1002/bip.360211115; CHAPMAN JA, 1974, CONNECT TISSUE RES, V2, P151, DOI 10.3109/03008207409152100; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P2201, DOI 10.1002/bip.360281212; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; COUNTS DF, 1980, J INVEST DERMATOL, V74, P96, DOI 10.1111/1523-1747.ep12519991; DALESSIO M, 1988, GENE, V67, P105, DOI 10.1016/0378-1119(88)90013-3; DEWET W, 1987, J BIOL CHEM, V262, P16032; ENGEL A, 1982, MICRON, V13, P425, DOI 10.1016/0047-7206(82)90094-2; ENGEL A, 1978, ULTRAMICROSCOPY, V3, P273, DOI 10.1016/S0304-3991(78)80037-0; ENGEL A, 1981, ULTRAMICROSCOPY, V7, P45, DOI 10.1016/0304-3991(81)90022-X; ENGEL A, 1984, J ULTRA MOL STRUCT R, V88, P105, DOI 10.1016/S0022-5320(84)80003-9; ENGEL J, 1977, BIOCHEMISTRY-US, V16, P4026, DOI 10.1021/bi00637a014; EYRE DR, 1985, J BIOL CHEM, V260, P1322; FIEDLERNAGY C, 1981, ARCH BIOCHEM BIOPHYS, V212, P668, DOI 10.1016/0003-9861(81)90411-2; FJOLSTAD M, 1974, J PATHOL, V112, P183, DOI 10.1002/path.1711120309; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLBROOK KA, 1980, J INVEST DERMATOL, V74, P100, DOI 10.1111/1523-1747.ep12520000; HOLMES DF, 1991, J MOL BIOL, V220, P111, DOI 10.1016/0022-2836(91)90385-J; HOLMES DF, 1991, BIOCHEM SOC T, V19, P808, DOI 10.1042/bst0190808; HOLMES DF, 1991, J MOL BIOL, V19, P808; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; MEEK KM, 1979, J BIOL CHEM, V254, P710; MOULD AP, 1987, J MOL BIOL, V197, P543; NUSGENS BV, 1992, NAT GENET, V1, P214, DOI 10.1038/ng0692-214; PELTONEN L, 1980, P NATL ACAD SCI USA, V71, P6179; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; SMITH LT, 1992, AM J HUM GENET, V51, P235; STEINMANN B, 1985, ANN NY ACAD SCI, V460, P506, DOI 10.1111/j.1749-6632.1985.tb51224.x; STEINMANN B, 1980, J BIOL CHEM, V255, P8887; Steinmann Beat, 1993, P351; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; VASAN NS, 1991, AM J HUM GENET, V48, P305; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WATSON RB, 1992, J BIOL CHEM, V267, P9093; WIRTZ MK, 1990, J BIOL CHEM, V265, P6312; WIRTZ MK, 1987, J BIOL CHEM, V262, P16376; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	46	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15758	15765						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340401				2022-12-25	WOS:A1993LN30500065
J	KUMAR, GB; BLACK, PN				KUMAR, GB; BLACK, PN			BACTERIAL LONG-CHAIN FATTY-ACID TRANSPORT - IDENTIFICATION OF AMINO-ACID-RESIDUES WITHIN THE OUTER-MEMBRANE PROTEIN FADL REQUIRED FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; BINDING; PURIFICATION; DEGRADATION; MUTATIONS; MUTANTS; CLONING; SYSTEM	The outer membrane protein FadL (product of the fadL gene) of Escherichia coli is required for the specific binding and transport of exogenous long-chain fatty acids prior to metabolic utilization. The carboxyl end of FadL has been proposed to play a crucial role by facilitating the transport of long-chain fatty acids. In an attempt to define specific amino acid residues within carboxyl region of FadL essential for activity, a series of deletion and point mutations within the 3' end of the fadL+ gene have been constructed and characterized. These fadL mutants were classified into three categories based on functional properties attributable to the altered FadL proteins: (i) those that had essentially wild-type levels of long-chain fatty acid binding and transport, (ii) those that had wild-type levels of long-chain fatty acid binding but were defective in transport, and (iii) those that were defective for both long-chain fatty acid binding and transport. These findings demonstrate that amino acid residues Phe448, Pro428, Val410, and Ser397 are required for optimal levels of long-chain fatty acid transport and that amino acid residues Pro428 and Val410 are essential for long-chain fatty acid binding.	UNIV TENNESSEE, CTR HLTH SCI,COLL MED,DEPT BIOCHEM,SUITE G01, MOLEC SCI BLDG,858 MADISON AVE, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center				Black, Paul/0000-0002-6272-6881				BLACK PN, 1987, J BIOL CHEM, V262, P1412; BLACK PN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P97, DOI 10.1016/0005-2760(90)90099-J; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BLACK PN, 1988, J BACTERIOL, V170, P2850, DOI 10.1128/jb.170.6.2850-2854.1988; BLACK PN, 1985, J BIOL CHEM, V260, P1780; BLUNDELL T, 1986, SCIENCE, V234, P1005, DOI 10.1126/science.3775369; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; GINSBURGH CL, 1984, J BIOL CHEM, V259, P8437; ISACKSON PJ, 1985, P NATL ACAD SCI USA, V82, P6226, DOI 10.1073/pnas.82.18.6226; KAMEDA K, 1987, BIOCHEM INT, V14, P227; KAMEDA K, 1986, BIOCHEM INT, V13, P343; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MANGROO D, 1992, J BIOL CHEM, V267, P17095; Maniatis T., 1982, MOL CLONING; Miller J. H., 1972, EXPT MOL GENETICS, P433; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NUNN WD, 1978, P NATL ACAD SCI USA, V75, P3377, DOI 10.1073/pnas.75.7.3377; NUNN WD, 1986, J BIOL CHEM, V261, P167; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; RICHARDSON JS, 1989, PREDICTION PROTEIN S, P2; ROCK CO, 1985, J BIOL CHEM, V260, P2720; SALEMME FR, 1983, PROG BIOPHYS MOL BIO, V42, P95, DOI 10.1016/0079-6107(83)90005-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F	31	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15469	15476						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340375				2022-12-25	WOS:A1993LN30500025
J	BARKER, PA; LOMENHOERTH, C; GENSCH, EM; MEAKIN, SO; GLASS, DJ; SHOOTER, EM				BARKER, PA; LOMENHOERTH, C; GENSCH, EM; MEAKIN, SO; GLASS, DJ; SHOOTER, EM			TISSUE-SPECIFIC ALTERNATIVE SPLICING GENERATES 2 ISOFORMS OF THE TRKA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; NEUROTROPHIC FACTOR; PROTOONCOGENE PRODUCT; MOLECULAR-CLONING; MELANOMA-CELLS; GENE-TRANSFER; EXPRESSION; BRAIN	The trkA receptor functions as a signal transducing receptor for nerve growth factor. In this report, we show that alternative splicing results in the production of two distinct trkA isoforms in both rats and humans. These isoforms differ by virtue of a 6-amino acid insertion in their extracellular domain, the placement of which corresponds exactly with the breakpoint found in several human trkA oncogenes. When tested in fibroblasts, the presence (trkAII) or absence (trkAI) of the 6-amino acid insert does not affect the receptor's ligand binding specificity or its ability to transduce functional signals in response to nerve growth factor. In rats and humans, trkAII is the only isoform expressed within neuronal tissues at appreciable levels whereas trkAI, the form of trkA originally cloned, appears to be expressed mainly in non-neuronal tissues.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Stanford University; Regeneron			Meakin, Susan/K-8823-2013; Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Meakin, Susan/0000-0003-2469-6615; Glass, David/0000-0001-6187-4164	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS04270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; AYERLELIEVE C, 1988, P NATL ACAD SCI USA, V88, P2628; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1115; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARKER PA, 1991, J BIOL CHEM, V266, P19113; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BUXSER SE, 1983, J CELL BIOCHEM, V22, P219, DOI 10.1002/jcb.240220404; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DIAMOND J, 1992, J NEUROSCI, V12, P1454; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARANO N, 1987, J NEUROCHEM, V48, P225, DOI 10.1111/j.1471-4159.1987.tb13151.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MILLER FD, 1991, J CELL BIOL, V112, P303, DOI 10.1083/jcb.112.2.303; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; PARVINEN M, 1992, J CELL BIOL, V117, P629, DOI 10.1083/jcb.117.3.629; PIAETTA E, 1992, J BIOL CHEM, V267, P11078; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	61	180	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15150	15157						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325889				2022-12-25	WOS:A1993LL75900088
J	KRUDE, T; KNIPPERS, R				KRUDE, T; KNIPPERS, R			NUCLEOSOME ASSEMBLY DURING COMPLEMENTARY-DNA STRAND SYNTHESIS IN EXTRACTS FROM MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; SIMIAN VIRUS 40; REPLICATION INVITRO; POLYACRYLAMIDE GELS; CHROMATIN; PROTEIN; HISTONES; INITIATION; MINICHROMOSOMES; PURIFICATION	Circular single-stranded phage M13 DNA is used as a template for complementary strand synthesis in cytosolic extracts from proliferating HeLa cells. DNA synthesis is initiated by one or maximally two priming events and typically leads to covalently closed double-stranded reaction products. When carried out in the presence of the nuclear chromatin assembly factor CAF-1, complementary strand synthesis is accompanied by nucleosome assembly. This novel system is very useful for the study of basic biochemical aspects concerning the assembly of nucleosomes. The activity of CAF-1 completely depends on complementary strand synthesis and acts stoichiometrically to promote the assembly of nucleosomes in a noncooperative manner. Apparently, CAF-1 activity is coupled to DNA synthesis via a structural feature of replicating DNA, most likely its partial single strandedness.	UNIV CONSTANCE,FAK BIOL,W-7750 CONSTANCE,GERMANY	University of Konstanz				Krude, Torsten/0000-0002-1842-1933				ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; BANERJEE S, 1990, MOL CELL BIOL, P2863; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; CUSICK ME, 1984, J MOL BIOL, V178, P249, DOI 10.1016/0022-2836(84)90143-8; DILWORTH SM, 1988, BIOESSAYS, V9, P44, DOI 10.1002/bies.950090203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1991, EMBO J, V10, P3043, DOI 10.1002/j.1460-2075.1991.tb07855.x; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; KRUDE T, 1993, MOL CELL BIOL, V13, P1059, DOI 10.1128/MCB.13.2.1059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LASSLE M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P1, DOI 10.1016/0167-4781(92)90045-2; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; NELSON T, 1981, BIOCHEMISTRY-US, V20, P2594, DOI 10.1021/bi00512a035; OUDET P, 1975, CELL, V4, P281, DOI 10.1016/0092-8674(75)90149-X; OUDET P, 1977, COLD SPRING HARB SYM, V47, P287; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SENSHU T, 1978, J BIOCHEM-TOKYO, V84, P985, DOI 10.1093/oxfordjournals.jbchem.a132213; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; van Holde K.E., 1988, CHROMATIN; VOLLENWEIDER HJ, 1975, P NATL ACAD SCI USA, V72, P83, DOI 10.1073/pnas.72.1.83; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WESSEL R, 1992, VIROLOGY, V189, P293, DOI 10.1016/0042-6822(92)90705-T; WOLFFE A, 1992, CHROMATIN STRUCTURE; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	53	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14432	14442						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314801				2022-12-25	WOS:A1993LJ82500093
J	JAKUBOWSKI, M; ROBERTS, JL				JAKUBOWSKI, M; ROBERTS, JL			PROCESSING OF GONADOTROPIN-RELEASING-HORMONE GENE TRANSCRIPTS IN THE RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; MESSENGER-RNA; ESTROUS-CYCLE; PROESTROUS SURGE; ANTISENSE RNA; FEMALE RAT; EXPRESSION; NEURONS; PROTEIN; CDNA	The precursor of gonadotropin-releasing hormone (GnRH) and the 56-amino acid GnRH-associated peptide is encoded in an mRNA of about 560 bases in length. This mRNA derives from an similar to-4300-base pair-long gene consisting of four relatively short exons (denoted 1, 2, 3, and 4) and three large introns (A,B, and C). In this study, we characterized the order by which the three introns are spliced from the primary transcript and processing intermediates to give rise to a mature mRNA and evaluated the potential role of gene transcription and pre-mRNA processing in the control of proGnRH mRNA levels in vivo. Nuclear and cytoplasmic RNA fractions isolated from rat preoptic area anterior hypothalamus (POA-AH) and basal olfactory area (located rostral to the POA) were analyzed by 1) solution hybridization-RNase protection mapping using several RNA probes directed at various regions of the proGnRH gene and 2) reverse transcription-polymerase chain reaction using several oligonucleotide primers. Both types of analysis showed that proGnRH pre-mRNA processing begins with the splicing of intron B from the primary gene transcript. Hence, intron B is the ideal target for studying proGnRH primary transcript by in situ hybridization. Subsequent splicing of introns A and C appeared to take place in two alternative, although not equally prevalent pathways. Quantitative analysis indicated that the proGnRH hnRNA species constituted, ore a mole basis, about 20% of the total gene transcripts in the POA-AH. The primary transcript alone constituted about 10% of the total gene transcripts in the POA-AH and as much as 20% in the basal olfactory area. The prospect of blockade of proGnRH hnRNA processing by means of hybridization with endogenous antisense RNAs (transcribed from the SH gene on the opposite strand of the same DNA locus) did not prove to be likely, as the SH transcripts were present at very low levels compared to any of the proGnRH RNA species. We conclude that the relatively large pool of proGnRH hnRNA may reflect a high rate of gene transcription and/or slow RNA processing.	CUNY MT SINAI SCH MED,DR ARTHUR M FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIDDK NIH HHS [DK 39029] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039029] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN JP, 1986, P NATL ACAD SCI USA, V83, P179, DOI 10.1073/pnas.83.1.179; ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; BINHAM PM, 1988, TRENDS GENET, V5, P134; BOND CT, 1989, MOL ENDOCRINOL, V3, P1257, DOI 10.1210/mend-3-8-1257; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FREMEAU RT, 1989, MOL BRAIN RES, V6, P197, DOI 10.1016/0169-328X(89)90054-5; GOUBAU S, 1992, ENDOCRINOLOGY, V130, P3098, DOI 10.1210/en.130.5.3098; HIATT ES, 1992, ENDOCRINOLOGY, V130, P1030, DOI 10.1210/en.130.2.1030; HOFFMAN GE, 1990, ENDOCRINOLOGY, V126, P1736, DOI 10.1210/endo-126-3-1736; JAKUBOWSKI M, 1992, J NEUROENDOCRINOL, V4, P79, DOI 10.1111/j.1365-2826.1992.tb00349.x; KING JC, 1987, PEPTIDES, V8, P721, DOI 10.1016/0196-9781(87)90049-0; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LEE WS, 1992, ENDOCRINOLOGY, V130, P3101, DOI 10.1210/en.130.5.3101; LEE WS, 1990, P NATL ACAD SCI USA, V87, P5163, DOI 10.1073/pnas.87.13.5163; LEVIN N, 1991, FRONT NEUROENDOCRIN, V12, P1; LEVIN N, 1991, 73RD ANN M END SOC, P42; MALIK KF, 1991, ANAT REC, V231, P457, DOI 10.1002/ar.1092310408; MERCHENTHALER I, 1988, BRAIN RES BULL, V20, P713, DOI 10.1016/0361-9230(88)90082-2; MUNROE SH, 1988, EMBO J, V7, P2523, DOI 10.1002/j.1460-2075.1988.tb03100.x; PAGESY P, 1992, MOL ENDOCRINOL, V6, P523, DOI 10.1210/me.6.4.523; Palkovits M., 1988, MAPS GUIDE MICRODISS; PARK OK, 1990, ENDOCRINOLOGY, V127, P365, DOI 10.1210/endo-127-1-365; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; RONNEKLEIV OK, 1986, NEUROENDOCRINOLOGY, V43, P564, DOI 10.1159/000124583; SEEBURG PH, 1984, NATURE, V311, P666, DOI 10.1038/311666a0; SHIVERS BD, 1983, NEUROENDOCRINOLOGY, V36, P1, DOI 10.1159/000123522; TOSIC M, 1990, EMBO J, V9, P401, DOI 10.1002/j.1460-2075.1990.tb08124.x	27	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4078	4083						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307966				2022-12-25	WOS:A1994MW98900030
J	DITTMANN, J; WENGER, RM; KLEINKAUF, H; LAWEN, A				DITTMANN, J; WENGER, RM; KLEINKAUF, H; LAWEN, A			MECHANISM OF CYCLOSPORINE-A BIOSYNTHESIS - EVIDENCE FOR SYNTHESIS VIA A SINGLE LINEAR UNDECAPEPTIDE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIENZYME POLYPEPTIDE; TOLYPOCLADIUM-INFLATUM; MULTIFUNCTIONAL ENZYME; SYNTHETASE	Cyclosporin A is synthesized by cyclosporin synthetase, a multienzyme polypeptide. This enzyme catalyzes at least 40 reaction steps in an assembly belt-like mechanism. It activates all constituent amino acids of cyclosporin A to thioesters via amino acyladenylates and carries out specific N-methylation reactions. During elongation, the activated amino acids are linked by peptide bonds leading to enzyme-bound nascent peptide chains. Some of the linear peptides of the growing cyclosporin A chain were isolated and their N-terminal amino acid was determined. D-Alanine at position 8 of the cyclosporin A molecule was found to be a starting amino acid in the biosynthetic process of cyclosporin A formation. Four intermediate peptides of the growing peptide chain of cyclosporin A could be isolated and identified. All of them represent partial sequences of cyclosporin A starting with D-alanine. That these intermediate peptides were bound by thioester linkage to cyclosporin synthetase could be demonstrated by liberation of the peptides with performic acid. The peptides strongly suggest the stepwise synthesis of a single linear peptide precursor of cyclosporin A.	TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,FRANKLINSTR 29,D-10587 BERLIN,GERMANY; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Technical University of Berlin; Novartis; Sandoz			Lawen, Alfons/A-6598-2008	Lawen, Alfons/0000-0001-6553-9945				BERG P, 1958, J BIOL CHEM, V233, P608; BOREL JF, 1986, PROG ALLERGY, V38, P9; DITTMANN J, 1990, BIOL CHEM H-S, V371, P829, DOI 10.1515/bchm3.1990.371.2.829; GEVERS W, 1968, P NATL ACAD SCI USA, V60, P269, DOI 10.1073/pnas.60.1.269; Gray W R, 1972, Methods Enzymol, V25, P121, DOI 10.1016/S0076-6879(72)25010-8; KAHAN BD, 1984, CYCLOSPORIN BIOL ACT; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; LAWEN A, 1991, J BIOL CHEM, V266, P15567; LAWEN A, 1989, J ANTIBIOT, V42, P1283, DOI 10.7164/antibiotics.42.1283; LAWEN A, 1990, J BIOL CHEM, V265, P11355; LAWEN A, 1993, J BIOL CHEM, V268, P20452; LIPMANN F, 1971, SCIENCE, V173, P875, DOI 10.1126/science.173.4000.875; ROSKOSKI R, 1970, BIOCHEMISTRY-US, V9, P4846; SCHINDLER R, 1985, CYCLOSPORIN AUTOIMMU; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCHMIDT B, 1992, FEBS LETT, V307, P355, DOI 10.1016/0014-5793(92)80712-P; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VANLIEMPT H, 1989, J BIOL CHEM, V264, P3680; WENGER RM, 1984, HELV CHIM ACTA, V67, P502, DOI 10.1002/hlca.19840670220; WENGER RM, 1983, HELV CHIM ACTA, V66, P2672, DOI 10.1002/hlca.19830660836; ZOCHER R, 1986, BIOCHEMISTRY-US, V25, P550, DOI 10.1021/bi00351a005; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P43, DOI 10.1021/bi00530a008	22	62	62	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2841	2846						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300618				2022-12-25	WOS:A1994MV43200072
J	FANTOZZI, DA; HAROOTUNIAN, AT; WEN, W; TAYLOR, SS; FERAMISCO, JR; TSIEN, RY; MEINKOTH, JL				FANTOZZI, DA; HAROOTUNIAN, AT; WEN, W; TAYLOR, SS; FERAMISCO, JR; TSIEN, RY; MEINKOTH, JL			THERMOSTABLE INHIBITOR OF CAMP-DEPENDENT PROTEIN-KINASE ENHANCES THE RATE OF EXPORT OF THE KINASE CATALYTIC SUBUNIT FROM THE NUCLEUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; REGULATORY SUBUNIT; HEPATOMA-CELLS; PROGESTERONE-RECEPTOR; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; SKELETAL-MUSCLE; PORE COMPLEX; SITE-A; LOCALIZATION	The catalytic (C) subunit of cAMP-dependent protein kinase is inhibited by the regulatory (R) subunit and by a thermostable inhibitor (PKI). Both inhibitors also affect the intracellular distribution of the C subunit. Whether injected into the cytoplasm or into the nucleus, free C subunit can enter and exit the nucleus freely. After 30 min its distribution is identical and is independent of the initial site of injection. In contrast, when C is injected into the cytoplasm complexed with R or PKI, the complexes are restricted to the cytoplasm (1-3). However, unlike the R subunit, which is restricted to the cytoplasm like the holoenzyme, free PKI enters the nucleus rapidly following its injection into the cytoplasm. When holoenzyme is injected directly into the nucleus, it cannot exit and return to the cytoplasm. In contrast, nuclear injection of a C.PKI complex results in the rapid exit of the C subunit from the nucleus. In equilibrated cells previously injected with the C subunit, subsequent cytoplasmic injection of either PKI or type 1 R depletes the nucleus of C although PKI does so faster, consistent with its ability to enter the nucleus. Both inhibitors block the cAMP response element-regulated gene expression. Hence PKI may serve as a nuclear scavenger of C providing a mechanism not only for inhibition but also for subcellular localization in the presence of cAMP by restricting the access of the C subunit to the nucleus.	UNIV CALIF SAN DIEGO,DEPT MED,0613-K,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego			Meinkoth, Judy L/G-2900-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALABDALY FA, 1989, ENDOCRINOLOGY, V124, P2901, DOI 10.1210/endo-124-6-2901; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BROWNE CL, 1980, J CELL BIOL, V87, P336, DOI 10.1083/jcb.87.2.336; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; BYUS CV, 1982, J CELL BIOL, V93, P727, DOI 10.1083/jcb.93.3.727; CHANDRAN UR, 1992, MOL ENDOCRINOL, V6, P837, DOI 10.1210/me.6.5.837; CLAIR T, 1987, FEBS LETT, V224, P377, DOI 10.1016/0014-5793(87)80488-X; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; EINCK L, 1984, J CELL BIOL, V98, P205, DOI 10.1083/jcb.98.1.205; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FLETCHER WH, 1986, J BIOL CHEM, V261, P5504; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; HERBERG FW, 1993, IN PRESS PROTEIN ENG; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; JUNGMANN RA, 1988, METHOD ENZYMOL, V159, P225; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KREBS EG, 1986, ENZYMES, P3; KUETTEL MR, 1984, CELL BIOL INT REP, V8, P949, DOI 10.1016/0309-1651(84)90193-0; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LOHMANN SM, 1980, J BIOL CHEM, V255, P9985; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MEIER UT, 1992, CELL, V70, P127; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; SARASWAT LD, 1988, METHOD ENZYMOL, P325; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STACEY DW, 1984, EXP CELL RES, V154, P283, DOI 10.1016/0014-4827(84)90687-6; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS J, 1991, J BIOL CHEM, V266, P10906; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0; ZOLLER MJ, 1979, J BIOL CHEM, V254, P2408	51	81	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2676	2686						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300597				2022-12-25	WOS:A1994MV43200050
J	WAKIM, BT; ASWAD, GD				WAKIM, BT; ASWAD, GD			CA2+-CALMODULIN-DEPENDENT PHOSPHORYLATION OF ARGININE IN HISTONE-3 BY A NUCLEAR KINASE FROM MOUSE LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PHOSPHORYLATION; TREATED HELA-CELLS; PROTEIN-KINASE; CHROMATIN STRUCTURE; PURIFICATION; CALMODULIN; ACID; MITOSIS; CYCLE; DNA	A Ca2+-calmodulin dependent histone 3 kinase was partially purified from a low salt (150 mm NaCl) nuclear extract of mouse leukemia cells by calmodulin-Sepharose affinity chromatography. In vitro, the kinase activity transferred gamma-phosphate from ATP to histone 3 to form an acid-labile and alkaline-stable linkage. Under the assay conditions 1.8 mol of phosphate are incorporated per mol of histone 3. Upon modification of arginine residues with phenylglyoxal prior to phosphorylation, a considerable decrease in the amount of phosphate transferred to histone 3 was observed. Amino acid analysis revealed that H3 was phosphorylated on arginine residues. To identify the phosphorylated peptide(s), histone 3 was cleaved with cyanogen bromide prior to phosphorylation. The phosphorylated mixture was then separated by gel filtration high-performance liquid chromatography under denaturing conditions. Fragments I (N-terminal 10.3-kDa peptide) and III (C-terminal 1.7-kDa peptide) were both phosphorylated. Amino acid sequencing further revealed that the molar yields of 3 of the 4 arginines present in the phosphorylated cyanogen bromide fragment III were reduced by a factor of about 10 compared with the corresponding arginines from the unphosphorylated fragment. In the case of fragment I, 25 cycles of Edman degradation revealed that the recovery of only arginine 2 was reduced by a factor of 20. The putative phosphorylation sites are arginines 2, 128, 129, and 131. The sequence information offered an indirect evidence that these arginines were the sites of phosphorylation. The kinase described in this report represents a first member of a potentially important new class of kinases which are Ca2+-calmodulin dependent and which phosphorylate arginine.	LOYOLA UNIV,STRITCH SCH MED,DEPT MICROBIOL & IMMUNOL,MAYWOOD,IL 60153	Loyola University Chicago	WAKIM, BT (corresponding author), LOYOLA UNIV,STRITCH SCH MED,MACROMOLEC LAB,MAYWOOD,IL 60153, USA.							BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; Bonner J, 1968, METHODS ENZYMOL, V12, P3; BRADBURY EM, 1983, CIBA F SYMP, V93, P246; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GURLEY LR, 1974, J CELL BIOL, V60, P356, DOI 10.1083/jcb.60.2.356; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HUANG JM, 1991, J BIOL CHEM, V266, P9023; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KEITH CH, 1985, NATURE, V316, P848, DOI 10.1038/316848a0; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; LEVYFAVATIER F, 1987, EUR J BIOCHEM, V166, P617, DOI 10.1111/j.1432-1033.1987.tb13558.x; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARKS DB, 1973, J BIOL CHEM, V248, P5660; MATTHEWS HR, 1978, EXP CELL RES, V111, P343, DOI 10.1016/0014-4827(78)90179-9; MATTHEWS HR, 1984, MOL CELL BIOCHEM, V59, P81; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NYGARD O, 1991, J BIOL CHEM, V266, P16425; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; SHOEMAKER CB, 1980, J BIOL CHEM, V255, P1048; SHOEMAKER CB, 1978, J BIOL CHEM, V253, P5802; SIMPSON RT, 1978, NUCLEIC ACIDS RES, V5, P1109, DOI 10.1093/nar/5.4.1109; STEINER AW, 1980, J CHROMATOGR, V202, P263, DOI 10.1016/S0021-9673(00)81735-5; WAKIM BT, 1990, BIOCHEM BIOPH RES CO, V171, P84, DOI 10.1016/0006-291X(90)91359-Z; WEI YF, 1990, ANAL BIOCHEM, V190, P188, DOI 10.1016/0003-2697(90)90179-D; WEI YF, 1990, METHOD ENZYMOL, V200, P388; WHITLOCK JP, 1980, NATURE, V287, P74, DOI 10.1038/287074a0; WHITLOCK JP, 1983, J BIOL CHEM, V258, P1299	34	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2722	2727						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300603				2022-12-25	WOS:A1994MV43200056
J	HEIDENREICH, O; BENSELER, F; FAHRENHOLZ, A; ECKSTEIN, F				HEIDENREICH, O; BENSELER, F; FAHRENHOLZ, A; ECKSTEIN, F			HIGH-ACTIVITY AND STABILITY OF HAMMERHEAD RIBOZYMES CONTAINING 2'-MODIFIED PYRIMIDINE NUCLEOSIDES AND PHOSPHOROTHIOATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTI-HIV-1 THERAPEUTIC AGENTS; SELF-CLEAVAGE REACTION; MESSENGER-RNA; CATALYTIC ACTIVITY; HIV-1 REPLICATION; MEDIATED CLEAVAGE; GENE-EXPRESSION; INVIVO; CELLS	The influence of chemical modifications on the catalytic activity and stability of a hammerhead ribozyme directed against the long terminal repeat RNA of the human immunodeficiency virus 1 was examined. Previous studies had shown that substitution of all pyrimidine nucleosides by their 2'-fluoro analogs led to an 8-fold decrease in catalytic efficiency in the cleavage reaction compared to the unmodified ribozyme (Heidenreich, O., and Eckstein, F. (1992) J. Biol. Chem. 267,1904-1909). It is shown here that replacement of the 2'-fluoro-2'-deoxyuridines in the conserved region of this ribozyme, positions 4 and 7, by 2'-amino-2'-deoxyuridines fully restores catalytic activity of the ribozyme. Ribozymes containing these 2'-modifications show an increased stability against RNases present in fetal calf serum and in cell culture supernatant. The stability is increased further by the incorporation of four terminal phosphorothioates as protection against 3'-exonucleases, the degree of which depends on the secondary structure of the ribozyme. Such ribozymes are stable in undiluted fetal calf serum for at least 24 h. The results clearly demonstrate the potential to design stable ribozymes without any loss of catalytic activity.	MAX PLANCK INST EXPTL MED, HERMANN REIN STR 3, D-37075 GOTTINGEN, GERMANY	Max Planck Society			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483				BENSELER F, 1992, NUCLEOS NUCLEOT, V11, P1333, DOI 10.1080/07328319208021177; BRUENING G, 1989, METHOD ENZYMOL, V180, P546; BUZAYAN JM, 1990, NUCLEIC ACIDS RES, V18, P4447, DOI 10.1093/nar/18.15.4447; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CHEN CJ, 1992, NUCLEIC ACIDS RES, V20, P4581, DOI 10.1093/nar/20.17.4581; CODINGTON JF, 1964, J ORG CHEM, V29, P558, DOI 10.1021/jo01026a009; CONNOLLY BA, 1991, OLIGONUCLEOTIDES ANA, P155; COTTEN M, 1990, TRENDS BIOTECHNOL, V8, P174, DOI 10.1016/0167-7799(90)90168-W; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROPULIC B, 1992, J VIROL, V66, P1432; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Eder P S, 1991, Antisense Res Dev, V1, P141; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; Fersht A., 1985, ENZYME STRUCTURE MEC; FOX JJ, 1963, J ORG CHEM, V28, P936, DOI 10.1021/jo01039a014; GOODCHILD J, 1992, NUCLEIC ACIDS RES, V20, P4607, DOI 10.1093/nar/20.17.4607; HAMPTON A, 1966, BIOCHEMISTRY-US, V5, P2076, DOI 10.1021/bi00870a040; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HEIDENREICH O, 1993, FASEB J, V7, P90, DOI 10.1096/fasebj.7.1.7678566; HENDRY P, 1992, NUCLEIC ACIDS RES, V20, P5737, DOI 10.1093/nar/20.21.5737; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HOMANN M, 1993, NUCLEIC ACIDS RES, V21, P2809, DOI 10.1093/nar/21.12.2809; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; KOIZUMI M, 1992, GENE, V117, P179, DOI 10.1016/0378-1119(92)90727-7; KRUG A, 1989, NUCLEOS NUCLEOT, V8, P1473, DOI 10.1080/07328318908048855; LANGE W, 1993, IN PRESS LEUKEMIA; LHUILLIER PJ, 1992, EMBO J, V11, P4411, DOI 10.1002/j.1460-2075.1992.tb05541.x; LI BFL, 1987, BIOCHEMISTRY-US, V26, P1086, DOI 10.1021/bi00378a015; LO KMS, 1992, VIROLOGY, V190, P176, DOI 10.1016/0042-6822(92)91203-7; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; OLSEN DB, 1991, BIOCHEMISTRY-US, V30, P9735, DOI 10.1021/bi00104a024; Ortigao J F, 1992, Antisense Res Dev, V2, P129; PAOLELLA G, 1992, EMBO J, V11, P1913, DOI 10.1002/j.1460-2075.1992.tb05244.x; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; ROSSI JJ, 1990, TRENDS BIOTECHNOL, V8, P179, DOI 10.1016/0167-7799(90)90169-X; ROSSI JJ, 1992, AIDS RES HUM RETROV, V8, P183, DOI 10.1089/aid.1992.8.183; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SHIBAHARA S, 1989, NUCLEIC ACIDS RES, V17, P239, DOI 10.1093/nar/17.1.239; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SIOUD M, 1992, J MOL BIOL, V223, P831, DOI 10.1016/0022-2836(92)90244-E; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; STEINECKE P, 1992, EMBO J, V11, P1525, DOI 10.1002/j.1460-2075.1992.tb05197.x; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TANG JY, 1993, NUCLEIC ACIDS RES, V21, P2729, DOI 10.1093/nar/21.11.2729; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; TSUCHL T, 1993, P NATL ACAD SCI USA, V90, P6991; TSUJI H, 1992, EUR J CLIN CHEM CLIN, V30, P339; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; WILLIAMS DM, 1991, BIOCHEMISTRY-US, V30, P4001, DOI 10.1021/bi00230a027; WILLIAMS DM, 1992, BIOCHEMISTRY-US, V89, P918; WOISARD A, 1992, J AM CHEM SOC, V114, P10072, DOI 10.1021/ja00051a056; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; ZHENG X, 1993, J VIROL, V67, P1840, DOI 10.1128/JVI.67.4.1840-1847.1993; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	65	147	195	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2131	2138						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294467				2022-12-25	WOS:A1994MR98800088
J	BAI, WL; ARLINGHAUS, RB; SINGH, B				BAI, WL; ARLINGHAUS, RB; SINGH, B			ASSOCIATION OF V-MOS WITH SOLUBLE VIMENTIN IN-VITRO AND IN TRANSFORMED-CELLS	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; CELLULAR-TRANSFORMATION; INTERMEDIATE FILAMENTS; MEIOTIC MATURATION; OOCYTE MATURATION; PRODUCT; ONCOGENE; PHOSPHORYLATION; P34CDC2	Our previous studies have shown that vimentin can serve as a substrate for the v-Mos protein kinase in vitro. Furthermore, the amount of vimentin molecules in Moloney murine sarcoma virus (Mo-MuSV) transformed cells is decreased relative to uninfected cells and a lower molecular weight form is observed in these v-mos transformed cells (Singh & Arlinghaus, Virology 173: 144-156, 1989). Vimentin filaments are hyperphosphorylated and disassemble when cells enter mitosis. Here, we show that vimentin was coprecipitated with p85gag-mos from mitotic cell extracts by two different anti-Mos antibodies that do not crossreact with vimentin. However, we were unable to detect vimentin/v-Mos complexes in interphase extracts, possibly due to lack of soluble vimentin. p37env-mos was also found to associate with purified bovine lens vimentin in vitro. The significance of these findings with regard to v-mos-induced cellular transformation is discussed.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC PATHOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA45125, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARLINGHAUS RB, 1985, J GEN VIROL, V66, P1845, DOI 10.1099/0022-1317-66-9-1845; BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1991, ONCOGENE, V6, P1715; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BENZEEV A, 1984, BIOCHIM BIOPHYS ACTA, V780, P197, DOI 10.1016/0304-419X(85)90003-4; BIA W, 1992, ONCOGENE, V7, P1757; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; BROWN RL, 1981, P NATL ACAD SCI-BIOL, V78, P5593, DOI 10.1073/pnas.78.9.5593; CARLEY WW, 1981, J CELL BIOL, V90, P797, DOI 10.1083/jcb.90.3.797; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHAN D, 1989, P NATL ACAD SCI USA, V86, P2747, DOI 10.1073/pnas.86.8.2747; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4769, DOI 10.1073/pnas.77.8.4769; GREUENS G, 1983, ALL BIOL INT REP, V7, P35; HERZOG NK, 1988, ONCOGENE, V3, P225; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LIU JX, 1990, ONCOGENE, V5, P171; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1986, P NATL ACAD SCI USA, V83, P3629, DOI 10.1073/pnas.83.11.3629; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1989, VIROLOGY, V173, P144, DOI 10.1016/0042-6822(89)90230-4; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; VIKSTROM KL, 1989, P NATL ACAD SCI USA, V86, P549, DOI 10.1073/pnas.86.2.549; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, ONCOGENE, V355, P649; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	40	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2207	2212						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336943				2022-12-25	WOS:A1993LP17100021
J	INOUE, J; TAKAHARA, T; AKIZAWA, T; HINO, O				INOUE, J; TAKAHARA, T; AKIZAWA, T; HINO, O			BCL-3, A MEMBER OF THE I-KAPPA-B PROTEINS, HAS DISTINCT SPECIFICITY TOWARDS THE REL FAMILY OF PROTEINS	ONCOGENE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ENHANCER-BINDING-PROTEIN; CELL-CYCLE CONTROL; DNA-BINDING; TRANSCRIPTION FACTOR; PROTOONCOGENE BCL-3; MAMMALIAN-CELLS; P65 SUBUNIT; ACTIVATION; INHIBITION	Expression of the bcl-3 gene is demonstrated to be elevated in some B-cell chronic lymphocytic leukemias with a chromosomal translocation, t(14;19)(q32;q13.1). Bcl-3 protein has seven tandem ankyrin repeats that are also found in IkappaB proteins, inhibitors of Rel/NFkappaB transcription factors. In this paper, we demonstrate that Bcl-3 is a member of IkappaB family of proteins with a novel specificity. Bcl-3 preferentially associates with the p50 of NFkappaB, and the nuclear localization signal of p50 is required for this association. Bcl-3 inhibits the DNA-binding activity of p50 homodimers but not that of p50-p65 heterodimers. Transient transfection experiments revealed that appropriate expression of Bcl-3 results in inhibition of the function of p50 homodimers but not that of p50-p65 heterodimers, whereas pp40 and IkappaBgamma inhibit the function of both p50 homodimers and p50-p65 heterodimers. These studies suggest that Bcl-3 could modulate the transcription in a way different from pp40 and IkappaBgamma.	JAPANESE FDN CANC RES,INST CANC,DEPT EXPTL PATHOL,TOSHIMA KU,TOKYO 170,JAPAN; SETSUNAN UNIV,DEPT ANALYT CHEM,HIRAKATA,OSAKA 573,JAPAN	Japanese Foundation for Cancer Research; Setsunan University	INOUE, J (corresponding author), UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JOHANNESS A, 1991, CELL, V65, P1281; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHUTZE S, 1992, CELL, V71, P765; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WULZYN FG, 1992, NATURE, V358, P597; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	40	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2067	2073						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336935				2022-12-25	WOS:A1993LP17100006
J	GEISER, T; DEWALD, B; EHRENGRUBER, MU; CLARKLEWIS, I; BAGGIOLINI, M				GEISER, T; DEWALD, B; EHRENGRUBER, MU; CLARKLEWIS, I; BAGGIOLINI, M			THE INTERLEUKIN-8-RELATED CHEMOTACTIC CYTOKINES GRO-ALPHA, GRO-BETA, AND GRO-GAMMA ACTIVATE HUMAN NEUTROPHIL AND BASOPHIL LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY ACTIVITY; RESPIRATORY BURST; PEPTIDE-1 INTERLEUKIN-8; RECEPTOR-BINDING; HUMAN MONOCYTES; HIGH-AFFINITY; EXPRESSION; PROTEIN; CELLS; PURIFICATION	GROalpha, a protein structurally related to interleukin-8 (IL-8) and originally described as a melanoma growth stimulatory factor, possesses potent neutrophil-stimulating activity. Recently, two closely related genes, grobeta and grogamma, were identified. In the present work, the three GRO proteins were chemically synthesized, and their biological activities on human neutrophils and other leukocytes were compared. GROalpha, GRObeta, and GROgamma, like IL-8, induced chemotaxis, shape change, a rise in intracellular free calcium levels, exocytosis, and the respiratory burst in neutrophils. The GRO proteins were also active toward basophils as shown by chemotaxis and intracellular calcium concentration changes. The order of potency in neutrophils and basophils was IL-8 > GROalpha greater-than-or-equal-to GROgamma > GRObeta. Of the two IL-8 receptors expressed on human neutrophils, one binds GROalpha with high and the other with low affinity. Competition binding experiments using radiolabeled IL-8 and GROalpha revealed the same characteristics for GRObeta and GROgamma. Similarly, cross-desensitization, as assessed by the stimulus-dependent changes in intracellular calcium concentration, indicated that all three GRO proteins interact with common receptors. From these results, it can be concluded that GROalpha, GRObeta, and GROgamma have the same pattern of activity toward human granulocytes and that the differences in amino acid sequence among these proteins have only minor effects on biological activity.	UNIV BRITISH COLUMBIA,CTR BIOMED RES,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia	GEISER, T (corresponding author), UNIV BERN,THEODOR KOCHER INST,POB 99,CH-3000 BERN 9,SWITZERLAND.							ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; GOLDS EE, 1989, BIOCHEM J, V259, P585, DOI 10.1042/bj2590585; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; IIDA N, 1990, MOL CELL BIOL, V10, P5596, DOI 10.1128/MCB.10.10.5596; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; KRIEGER M, 1992, J IMMUNOL, V149, P2662; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; Sager R, 1992, Cytokines, V4, P96; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THOMAS HG, 1988, MOL CELL ENDOCRINOL, V57, P69, DOI 10.1016/0303-7207(88)90033-0; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; WYMANN MP, 1987, J BIOL CHEM, V262, P12048; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; WYMANN MP, 1987, BIOCHEM BIOPH RES CO, V147, P361, DOI 10.1016/S0006-291X(87)80130-4	34	249	253	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15419	15424						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340371				2022-12-25	WOS:A1993LN30500019
J	HAIMOVICH, B; LIPFERT, L; BRUGGE, JS; SHATTIL, SJ				HAIMOVICH, B; LIPFERT, L; BRUGGE, JS; SHATTIL, SJ			TYROSINE PHOSPHORYLATION AND CYTOSKELETAL REORGANIZATION IN PLATELETS ARE TRIGGERED BY INTERACTION OF INTEGRIN RECEPTORS WITH THEIR IMMOBILIZED LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; CELL-ADHESION; SIGNAL TRANSDUCTION; CYTOCHALASIN-D; EXTRACELLULAR-MATRIX; STIMULATED PLATELETS; LYMPHOCYTE ADHESION; ACTIVATED PLATELETS; DEPENDENT ADHESION; THROMBUS FORMATION	Agonist-induced platelet activation causes fibrinogen binding to integrin alpha(IIb)beta3 (glycoprotein (GP) IIb-IIIa) and platelet aggregation. This is associated with the phosphorylation of specific platelet proteins on tyrosine residues. Since fibrinogen immobilized on a solid matrix can bind platelet GP IIb-IIIa without the need for exogenous agonists, we examined whether platelet adhesion to a fibrinogen matrix induces tyrosine phosphorylation. Platelets adhered to fibrinogen in a GP IIb-IIIa-dependent manner and assumed a spread morphology. This change in cell shape was associated with tyrosine phosphorylation of multiple proteins, most prominently two unidentified proteins (101 and 105 kDa) and pp125FAK, a focal adhesion protein-tyrosine kinase. Pretreatment of platelets with prostaglandin I2 to increase cAMP, with cytochalasin D to inhibit actin polymerization, or with ADP scavengers to remove ADP did not affect initial adhesion, but inhibited both platelet spreading and tyrosine phosphorylation of pp125FAK and the 101- and 105-kDa proteins. This suggested that adhesion to fibrinogen caused cytoskeletal reorganization and the local release of ADP from platelet-dense granules, which potentiated the biochemical and morphological responses of the platelets to fibrinogen. Platelet adhesion to a collagen matrix also led to the induction of tyrosine phosphorylation of the 101- and 105-kDa proteins and pp125FAK. In this case, tyrosine phosphorylation was dependent on the interaction of collagen with integrin alpha2beta1 (GP Ia-IIa), and it was independent of both GP IIb-IIIa and ADP. These results indicate that platelet adhesion to fibrinogen or collagen induces signal transduction that is initiated through integrins GP IIb-IIIa and alpha2beta1, respectively. In both cases, tyrosine phosphorylation is accompanied by cytoskeletal reorganization and changes in cell shape. However, different regulatory components may be interposed between each of these integrins and the enzymes that control the level of protein tyrosine phosphorylation.	UNIV PENN, SCH MED, HOWARD HUGHES MED INST, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NCI NIH HHS [CA47572] Funding Source: Medline; NHLBI NIH HHS [HL40387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARROLL RC, 1982, CELL, V30, P385, DOI 10.1016/0092-8674(82)90236-7; CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205; COLLER BS, 1989, BLOOD, V74, P182; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DHAR A, 1991, J BIOL CHEM, V266, P18797; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAIMOVICH B, 1991, CELL REGUL, V2, P271, DOI 10.1091/mbc.2.4.271; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; Huang E. M., 1986, BIOCH PLATELETS, P1; HUANG MM, 1993, IN PRESS J CELL BIOL; JEN CJ, 1987, AM J PHYSIOL, V253, pH745, DOI 10.1152/ajpheart.1987.253.4.H745; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; NACHMIAS VT, 1991, CELL MOTIL CYTOSKEL, V20, P190, DOI 10.1002/cm.970200303; OLORUNDARE OE, 1992, BLOOD, V79, P99, DOI 10.1182/blood.V79.1.99.bloodjournal79199; PEERSCHKE EIB, 1985, AM J PHYSIOL, V248, pC466, DOI 10.1152/ajpcell.1985.248.5.C466; PEERSCHKE EIB, 1984, P SOC EXP BIOL MED, V175, P109; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1989, BLOOD, V73, P150; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TANGEN O, 1971, THROMB DIATH HAEMOST, V25, P268; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1986, BLOOD, V67, P322; WEISS HJ, 1978, BLOOD, V51, P267; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	56	260	263	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15868	15877						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340412				2022-12-25	WOS:A1993LN30500079
J	HOCKENSMITH, JW; KUBASEK, WL; EVERTSZ, EM; MESNER, LD; VONHIPPEL, PH				HOCKENSMITH, JW; KUBASEK, WL; EVERTSZ, EM; MESNER, LD; VONHIPPEL, PH			LASER CROSS-LINKING OF PROTEINS TO NUCLEIC-ACIDS .2. INTERACTIONS OF THE BACTERIOPHAGE-T4 DNA-REPLICATION POLYMERASE ACCESSORY PROTEINS COMPLEX WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMER-TEMPLATE JUNCTION; ATP HYDROLYSIS; III HOLOENZYME; 45 PROTEINS; T4; SYSTEM; STIMULATION; GENE-44	In this paper we examine the interactions of the polymerase accessory proteins subassembly of the bacteriophage T4 DNA replication complex, using single-pulse ultraviolet laser excitation to induce protein-nucleic acid cross-links. The laser-induced cross-linking permits effective ''freezing'' of the instantaneous equilibrium state of the complex and thus provides a mechanism to dissect the individual protein-nucleic acid interactions involved in complex assembly. We find that the binding of the gene 44, 62, and 45 proteins is dependent not only on the presence of each of the other proteins, but also on the presence of adenine nucleotide cofactors. We find that the nonhydrolyzable analogs of ATP often behave more like ADP than ATP in these experiments. Gene 45 protein is able to induce an increase in cross-linking of the gp44/62 complex to nucleic acids, and this increased cross-linking correlates with changes in the apparent K(m) of the gp44/62 complex for polynucleotides and with changes in V(max) during ATP hydrolysis. Our results suggest that the enhanced DNA binding is predominately through the gene 62 protein and not the ATPase catalytic subunit (gene 44 protein). Thus the gene 62 protein seems to play an integral role in gp45-mediated enhancement of the ATP hydrolytic activity of gp44. These results are summarized and integrated in the form of a model for the multiple interactions of the accessory proteins with DNA and one another in the presence of mononucleotide cofactors and substrates.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon; University of Oregon; University of Oregon	HOCKENSMITH, JW (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,BOX 440,CHARLOTTESVILLE,VA 22908, USA.			von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-29158, GM-43569, GM-15792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R37GM015792, R01GM029158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, V3, P241; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15712; HOCKENSMITH JW, 1987, UCLA S MOL CELL BIOL, V47, P111; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUBASEK WL, 1988, THESIS U OREGON; KUBASEK WL, 1993, IN PRESS PHOTOCHEM P; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MESNER LD, 1992, P NATL ACAD SCI USA, V89, P2521, DOI 10.1073/pnas.89.7.2521; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MUNN MM, 1991, J BIOL CHEM, V266, P20034; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NOSSAL NG, 1979, J BIOL CHEM, V254, P6032; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; RUSH J, 1989, J BIOL CHEM, V264, P10943; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	28	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15721	15730						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340396				2022-12-25	WOS:A1993LN30500060
J	HERREN, B; ROONEY, B; WEYER, KA; IBERG, N; SCHMID, G; PECH, M				HERREN, B; ROONEY, B; WEYER, KA; IBERG, N; SCHMID, G; PECH, M			DIMERIZATION OF EXTRACELLULAR DOMAINS OF PLATELET-DERIVED GROWTH-FACTOR RECEPTORS - A REVISED MODEL OF RECEPTOR-LIGAND INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PDGF RECEPTORS; SIMIAN SARCOMA-VIRUS; B-CHAIN; BETA-RECEPTOR; V-SIS; MONOCLONAL-ANTIBODY; KINASE ACTIVATION; CDNA CLONING; BINDING; EXPRESSION	The alpha- and beta-subunits of the receptor for platelet-derived growth factor (PDGFR) were found to be autophosphorylated in the absence of ligands at high expression levels which suggests a propensity of PDGFRs to dimerize spontaneously. When the extracellular domains (ED) of both receptors were expressed and purified to homogeneity, they could be dimerized specifically by the different PDGF isoforms. PDGF-BB-induced dimerization was dependent on uncleaved loop I sequences present on both chains. Whereas, in solution, the EDs were weak competitors for PDGF binding to cellular PDGFRs, they formed high and low affinity complexes upon immobilization on solid phase. Cross-competition experiments defined two distinct binding sites on PDGFRalpha-ED. PDGF-AB bound only to the low affinity form of immobilized PDGFRbeta-ED and could not dimerize PDGFRbeta-ED. Cross-linking studies, however, revealed that both chains of PDGF-AB can interact with a PDGFRbeta-ED monomer. Cross-linking of PDGF homodimers with EDs also yielded complexes which contained more than two ligand chains. These results led to a revised model of receptor-ligand interaction and indicate that monomeric PDGF should be able to dimerize PDGF receptors.	F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,GRENZACHERSTR 124,CH-4002 BASEL,SWITZERLAND	Roche Holding				Rooney, Barrie/0000-0002-5540-9431				ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; COOK AL, 1992, BIOCHEM J, V281, P57, DOI 10.1042/bj2810057; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1987, J BIOL CHEM, V262, P10780; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JAUMANN M, 1992, FEBS LETT, V302, P265, DOI 10.1016/0014-5793(92)80456-Q; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KELLY JD, 1985, EMBO J, V4, P3399, DOI 10.1002/j.1460-2075.1985.tb04096.x; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MAIORELLA B, 1988, BIO-TECHNOL, V6, P1406, DOI 10.1038/nbt1288-1406; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PECH M, 1989, P NATL ACAD SCI USA, V86, P2693, DOI 10.1073/pnas.86.8.2693; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RUBIN K, 1988, LANCET, V1, P1353; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; Summers MD, 1987, TEXAS AGR EXPT STATI; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	51	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15088	15095						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325884				2022-12-25	WOS:A1993LL75900080
J	INCE, BA; ZHUANG, Y; WRENN, CK; SHAPIRO, DJ; KATZENELLENBOGEN, BS				INCE, BA; ZHUANG, Y; WRENN, CK; SHAPIRO, DJ; KATZENELLENBOGEN, BS			POWERFUL DOMINANT-NEGATIVE MUTANTS OF THE HUMAN ESTROGEN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; V-ERBA; GENE; DNA; EXPRESSION; PROMOTER; ELEMENT	We have identified and characterized three human estrogen receptor (ER) mutants, which, at low concentrations, are capable of blocking the intracellular activity of wild type ER. The mutants, a truncated ER (ER1-530), a point mutant (L540Q), and a frameshift (S554fs), were generated by random chemical mutagenesis of the ER hormone binding domain and screened first for low activity in a yeast selection system. In transient co-transfection assays using ER-deficient Chinese hamster ovary cells, all three mutants exhibited less than 10% of the transcription activation activity of wild type ER, and when co-expressed with wild type ER, each of the mutants effectively suppressed the ability of wild type ER to activate transcription of an estrogen-regulated reporter plasmid. When equal amounts of plasmid encoding the ER mutants and wild type ER were used, S554fs, ER1-530, and L540Q suppressed the activity of wild type ER by 80, 55, and 75%, respectively. At a ratio of 1 part S554fs to 10 parts wild type ER, transcription was still inhibited by 40%. Western blot analysis showed that all three mutants were expressed at approximately the same level as wild type ER. Suppression of transcription was specific for ER, since the mutants did not inhibit progesterone receptor-mediated transcription. Not all mutations leading to inactive ER confer the dominant negative phenotype, as five ER mutants rendered transcriptionally inactive by point mutations between residues 516 and 524 of the ER hormone binding domain were poor inhibitors of wild type ER activity. Binding studies showed that the L540Q and S554fs dominant negative mutants bound 17beta-estradiol with wild type affinity (K(d) = 0.3-0.5 nM), whereas ER1-530 exhibited a 15-fold reduction in affinity for estradiol. The three dominant negative ERs showed significant ability to interact with the estrogen response element (ERE) in promoter interference assays, but ER1-530 and S554fs displayed little or no binding to the ERE in gel mobility shift assays where higher affinity for the DNA may be required for the receptor-ERE complex to remain associated during the electrophoresis. These data support the idea that, in all three mutants, it is loss of function of the COOH-terminal transactivation domain which leads to the dominant negative phenotype. S554fs, a powerful dominant negative mutant, is a good candidate for further studies aimed at suppressing the estrogen-dependent growth of human breast cancer cells.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,524 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NCI NIH HHS [CA18119] Funding Source: Medline; NICHD NIH HHS [HD16720] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA018119, R37CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHANG TC, 1990, J BIOL CHEM, V265, P8176; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FUQUA SAW, 1992, CANCER RES, V52, P483; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; GREENE GL, 1984, BIOCHEM ACTION HORM, V11, P207; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; ING NH, 1992, J BIOL CHEM, V267, P17617; KATZENELLENBOGEN BS, 1987, BIOCHEMISTRY-US, V26, P2364, DOI 10.1021/bi00382a043; KATZENELLENBOGEN BS, 1991, J NATL CANCER I, V83, P1434, DOI 10.1093/jnci/83.20.1434; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; READ LD, 1991, GENES ONCOGENES HORM, P277; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; REESE JC, 1992, J BIOL CHEM, V267, P9868; REESE JC, 1991, J BIOL CHEM, V266, P10880; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELMI S, 1991, J BIOL CHEM, V266, P11589; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WANG Y, 1991, MOL ENDOCRINOL, V11, P1707; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	54	114	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14026	14032						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314770				2022-12-25	WOS:A1993LJ82500039
J	WANG, XD; BRIGGS, MR; HUA, XX; YOKOYAMA, C; GOLDSTEIN, JL; BROWN, MS				WANG, XD; BRIGGS, MR; HUA, XX; YOKOYAMA, C; GOLDSTEIN, JL; BROWN, MS			NUCLEAR-PROTEIN THAT BINDS STEROL REGULATORY ELEMENT OF LOW-DENSITY-LIPOPROTEIN RECEPTOR PROMOTER .2. PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; TRANSCRIPTION FACTOR; SEQUENCE; IDENTIFICATION; REPRESSION; PATHWAY; GENE	This paper describes the purification and characterization of a sterol regulatory element binding protein (SREBP) that recognizes the SRE-1 sequence in the 5' flanking region of the gene for the low density lipoprotein (LDL) receptor. The protein was purified more than 38,000-fold from nuclear extracts of human HeLa cells by ion exchange, gel filtration, and DNA-affinity chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified preparation revealed a cluster of bands at 59-68 kDa, each of which bound to the SRE-1 element as revealed by cross-linking experiments. Binding of SREBP correlated perfectly with transcriptional activity in a series of 16 sterol regulatory elements with point mutations. In the LDL receptor promoter, the 10-base pair SRE-1 is embedded in a 16-base pair sequence designated Repeat 2, which is adjacent to Repeat 3, a binding site for nuclear factor Sp1. Oligonucleotides containing Repeat 2 + 3 bound SREBP and Sp1 as revealed by mobility shift assays. SREBP produced a DNase I footprint over the SRE-1 sequence, which was immediately adjacent to the footprint produced by Sp1. The current data are consistent with the concept that SREBP acts in concert with Sp1 to achieve high level, sterol-suppressible transcription of the gene for the LDL receptor.			WANG, XD (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.				NHLBI NIH HHS [5F32HL07833, HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, F32HL007833] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEHTA KD, 1991, J BIOL CHEM, V266, P10415; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STARK HC, 1992, P NATL ACAD SCI USA, V89, P2180, DOI 10.1073/pnas.89.6.2180; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773	19	264	271	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14497	14504						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314806				2022-12-25	WOS:A1993LJ82500101
J	AKITA, Y; OHNO, S; YAJIMA, Y; KONNO, Y; SAIDO, TC; MIZUNO, K; CHIDA, K; OSADA, S; KUROKI, T; KAWASHIMA, S; SUZUKI, K				AKITA, Y; OHNO, S; YAJIMA, Y; KONNO, Y; SAIDO, TC; MIZUNO, K; CHIDA, K; OSADA, S; KUROKI, T; KAWASHIMA, S; SUZUKI, K			OVERPRODUCTION OF A CA2+-INDEPENDENT PROTEIN-KINASE-C ISOZYME, NPKC-EPSILON, INCREASES THE SECRETION OF PROLACTIN FROM THYROTROPIN-RELEASING HORMONE-STIMULATED RAT PITUITARY GH(4)C(1) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GH4C1 CELLS; GH3 CELLS; DIFFERENTIAL REGULATION; DOWN-REGULATION; RECEPTOR; TRH; BINDING; FAMILY; EXPRESSION; BRAIN	Rat pituitary GH(4)C(1) cells express protein kinase C (PKC) transcripts for cPKC alpha, cPKC beta II, nPKC delta, nPKC epsilon, nPKC eta, and aPKC xi, but not for cPKC gamma or nPKC theta. Of the transcripts produced, the nPKC epsilon isoform is the most abundant. Transfection of GH(4)C(1) cells with an expression plasmid containing nPKC epsilon cDNA leads to the transient overexpression of cellular nPKC epsilon and confers enhanced phorbol ester binding activity. Transient expression of an inactive point mutant (nPKC epsilon(K-->R)) Of nPKC epsilon, where Lys(436) at the putative ATP-binding site is replaced with Arg, also confers elevated binding activity. However, only overproduction of the wild type in transfected cells increases the basal levels and stimulates the secretion of prolactin (PRL) by 12-O-tetradecanoylphorbol-13-acetate or thyrotropin-releasing hormone (TRH). In stable clones overexpressing nPKC epsilon, immunocytofluorescence and immunoblot experiments indicated that TRH causes the rapid translocation and down-regulation of an appreciable fraction of nPKC epsilon. Both the basal and TRH-stimulated levels of PRL secretion are clearly correlated with the expression level of nPKC epsilon but not with the TRH receptor densities in these clones. The dose dependence of TRH-stimulated secretion were similar in all cells overexpressing cPKC alpha, cPKC beta II, nPKC epsilon, and nPKC delta, but the enhancement of PRL secretion was specific for the overproduction of nPKC epsilon; no effect was found when other isozymes were overproduced. These findings clearly demonstrate that the expression level of nPKC epsilon in GH(4)C(1) cells is rate-limiting for basal and TRH-stimulated PRL secretion, and they provide the first direct evidence that nPKC epsilon plays a key role in hormonal secretory processes.	YOKOHAMA CITY UNIV,SCH MED,DEPT MOLEC BIOL,KANAZAWA KU,YOKOHAMA 236,JAPAN; UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	Yokohama City University; University of Tokyo; University of Tokyo	AKITA, Y (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.		Saido, Takaomi C/N-5472-2015; Kuroki, Toshio/A-9500-2011; Sado, Takaomi/AAN-2759-2021; Ohno, Shigeo/B-1768-2010	Saido, Takaomi C/0000-0003-1970-6903; Kuroki, Toshio/0000-0001-6369-4351; Sado, Takaomi/0000-0003-1970-6903; Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; AKITA Y, 1990, J BIOL CHEM, V265, P354; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CASTILLO ARD, 1992, J CELL BIOL, V119, P797; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; FUJIMOTO J, 1991, MOL ENDOCRINOL, V5, P1527, DOI 10.1210/mend-5-10-1527; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GUADAGNO SN, 1992, J BIOL CHEM, V267, P2697; HA KS, 1993, J BIOL CHEM, V268, P10534; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KILEY SC, 1992, MOL ENDOCRINOL, V6, P120, DOI 10.1210/me.6.1.120; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P1477; LOPEZBARNEO J, 1990, P NATL ACAD SCI USA, V87, P8150, DOI 10.1073/pnas.87.20.8150; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MIZUNO K, 1993, FEBS LETT, V330, P114, DOI 10.1016/0014-5793(93)80254-R; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; OZAWA K, 1993, J BIOL CHEM, V268, P2280; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RAMSDELL JS, 1986, J BIOL CHEM, V261, P5301; RAMSDELL JS, 1986, J BIOL CHEM, V261, P7073; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SUZUKI K, 1993, RECENT ADV MOL BIOCH; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; VANDEMOORTELE S, 1991, J CELL SCI, V99, P79; YAJIMA Y, 1982, IN VITRO CELL DEV B, V18, P1009, DOI 10.1007/BF02796376; YAJIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P571, DOI 10.1016/S0006-291X(05)80073-7; YAJIMA Y, 1988, MOL PHARMACOL, V33, P592	44	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4653	4660						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308036				2022-12-25	WOS:A1994MW98900111
J	SCHWEIZER, A; CLAUSEN, H; VAN MEER, G; HAURI, HP				SCHWEIZER, A; CLAUSEN, H; VAN MEER, G; HAURI, HP			LOCALIZATION OF O-GLYCAN INITIATION, SPHINGOMYELIN SYNTHESIS, AND GLUCOSYLCERAMIDE SYNTHESIS IN VERO CELLS WITH RESPECT TO THE ENDOPLASMIC RETICULUM-GOLGI INTERMEDIATE COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY-GLANDS; UDPGLUCOSE-CERAMIDE GLUCOSYLTRANSFERASE; TERMINAL N-ACETYLGALACTOSAMINE; TN-ANTIGEN; SUBCELLULAR-LOCALIZATION; INTRACELLULAR-TRANSPORT; MONOCLONAL-ANTIBODY; RECYCLING PATHWAY; PLASMA-MEMBRANE; BREFELDIN-A	The identification of an endoplasmic reticulum-Golgi intermediate compartment (ERGIC), defined by the 53-kDa transmembrane marker protein ERGIC-53, has added to the complexity of the exocytic pathway of higher eukaryotic cells. Recently, a subcellular fractionation procedure was established for the isolation of the ERGIC from Vero cells (Schweizer, A., Matter, K., Ketcham, C. M., and Hauri, H.-P. (1991) J. Cell Biol, 113, 45-54) which provides a means to study more precisely the compartmentalization of the various enzymic functions along the early secretory pathway. Here, we have investigated if O-glycan initiation and sphingomyelin synthesis are associated with the ERGIC by analyzing both the responsible enzyme activities and their corresponding products. Moreover, the synthesis of glucosylceramide, the precursor of most glycosphingolipids, was also analyzed. In the purified ERGIC fraction UDP. GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc transferase) was only minimally enriched, sphingomyelin synthase was not enriched, and UDP-glucose:ceramide glucosyl transferase specific activity was lower than in the homogenate. On Percoll gradients all three enzymes cofractionated with Golgi markers rather than ERGIC-53. Accordingly, sphingomyelin concentrations were extremely low in the ERGIC fraction. Double immunofluorescence localization of core N-acetylgalactosamine, the product of GalNAc transferase, by monoclonal antibodies against GalNAc-Ser/Thr (Tn antigen) revealed only little apparent overlap with ERGIC-53. This was particularly evident in brefeldin A-treated cells which showed entirely different patterns of Tn antigens and ERGIC-53. The results suggest that in the secretory pathway of Vero cells O-glycan initiation and sphingomyelin as well as glucosylceramide synthesis mainly occur beyond the ERGIC in the Golgi apparatus.	UNIV BASEL, BIOZENTRUM, DEPT PHARMACOL, CH-4056 BASEL, SWITZERLAND; FAC HLTH SCI COPENHAGEN, SCH DENT, DK-2200 COPENHAGEN, DENMARK; UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	University of Basel; Utrecht University			van Meer, Gerrit/AAH-1560-2021; clausen, henrik/AAD-8016-2021	van Meer, Gerrit/0000-0002-5976-6436				Balch WE, 1990, CURR OPIN CELL BIOL, V2, P634, DOI 10.1016/0955-0674(90)90104-M; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BERNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99, DOI 10.1016/0005-2760(81)90095-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COLLINS RN, 1992, J BIOL CHEM, V267, P24906; COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DAHR W, 1974, VOX SANG, V27, P29, DOI 10.1111/j.1423-0410.1974.tb02386.x; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; DURIEUX I, 1990, BIOCHIM BIOPHYS ACTA, V1024, P263, DOI 10.1016/0005-2736(90)90352-O; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELLINGER A, 1992, J HISTOCHEM CYTOCHEM, V40, P919, DOI 10.1177/40.7.1607641; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HIROHASHI S, 1985, P NATL ACAD SCI USA, V82, P7039, DOI 10.1073/pnas.82.20.7039; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HOMA FL, 1993, J BIOL CHEM, V268, P12609; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KJELDSEN T, 1988, CANCER RES, V48, P2214; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MARGGRAF WD, 1981, BIOCHIM BIOPHYS ACTA, V664, P61, DOI 10.1016/0005-2760(81)90028-X; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOREAU P, 1993, BIOCHIM BIOPHYS ACTA, V1146, P9, DOI 10.1016/0005-2736(93)90332-T; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PILLER V, 1990, J BIOL CHEM, V265, P9264; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STIEGER B, 1988, J CELL BIOL, V106, P1853, DOI 10.1083/jcb.106.6.1853; TAKAHASHI HK, 1988, CANCER RES, V48, P4361; THURNHER M, 1993, IN PRESS IMMUNOL LET; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VAN MEER G, 1993, J CELL SCI, V104, P833; Van Meer Gerrit, 1992, Trends in Cell Biology, V2, P332; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; VANHELVOORT A, 1994, IN PRESS J BIOL CHEM; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WANG YC, 1992, J BIOL CHEM, V267, P2728; ZAMBRANO F, 1975, BIOCHIM BIOPHYS ACTA, V380, P357, DOI 10.1016/0005-2760(75)90104-6	61	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4035	4041						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307959				2022-12-25	WOS:A1994MW98900023
J	MALMBERG, RL; CELLINO, ML				MALMBERG, RL; CELLINO, ML			ARGININE DECARBOXYLASE OF OATS IS ACTIVATED BY ENZYMATIC CLEAVAGE INTO 2 POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE	Oat arginine decarboxylase is synthesized as a 66-kDa proenzyme, but the soluble enzyme is found in oats as a complex of 42- and 24-kDa polypeptide fragments, both derived from the 66-kDa precursor. We report here that this proteolytic cleavage is the result of a processing enzyme, distinct from arginine decarboxylase itself, that leads to activation of the arginine decarboxylase. The proteolysis is resistant to a standard set of protease inhibitors, but is inhibited by high concentrations of Zn2+, as is the activation of arginine decarboxylase. Agmatine, putrescine, spermidine, and spermine, as well as the arginine decarboxylase inhibitor difluoromethylarginine, each had no effect on the reaction. Oat arginine decarboxylase is thus similar to some other amino acid decarboxylases in requiring a proteolytic cleavage for activation; however, it differs in that the other examples are auto-catalytic self-processing.			MALMBERG, RL (corresponding author), UNIV GEORGIA,DEPT BOT,ATHENS,GA 30602, USA.			Malmberg, Russell/0000-0002-7448-5034				BELL E, 1990, MOL GEN GENET, V224, P431, DOI 10.1007/BF00262438; BITONTI AJ, 1987, BIOCHEM J, V242, P69, DOI 10.1042/bj2420069; Brandford M.M., 1976, ANAL BIOCHEM, V72, P248; COHN MS, 1977, J BIOL CHEM, V252, P8212; HIATT AC, 1986, J BIOL CHEM, V261, P1293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY R, 1980, METHOD ENZYMOL, V65, P367; MALMBERG RL, 1992, PLANT PHYSIOL, V100, P146, DOI 10.1104/pp.100.1.146; PIKE CS, 1972, PLANT PHYSIOL, V49, P521, DOI 10.1104/pp.49.4.521; RECSEI PA, 1993, P NATL ACAD SCI USA, V80, P973; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STOREY RD, 1986, PHYTOCHEMISTRY, V25, P2701; TIBURCIO AF, 1986, PLANT PHYSIOL, V82, P375, DOI 10.1104/pp.82.2.375; VIERSTRA RD, 1984, PLANTA, V160, P521, DOI 10.1007/BF00411140; YOUNG ND, 1984, PLANT PHYSIOL, V76, P331, DOI 10.1104/pp.76.2.331	15	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2703	2706						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300600				2022-12-25	WOS:A1994MV43200053
J	CREPALDI, T; PRAT, M; GIORDANO, S; MEDICO, E; COMOGLIO, PM				CREPALDI, T; PRAT, M; GIORDANO, S; MEDICO, E; COMOGLIO, PM			GENERATION OF A TRUNCATED HEPATOCYTE GROWTH-FACTOR RECEPTOR IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PRE-GOLGI DEGRADATION; MET PROTO-ONCOGENE; C-MET; SCATTER FACTOR; BREFELDIN-A; EPITHELIAL-CELLS; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PEST HYPOTHESIS	The hepatocyte growth factor (HGF) receptor (p190MET) is a tyrosine kinase composed of two disulfide-linked chains, alpha of 50 kDa and beta of 145 kDa. We have previously described an isoform (p140MET) containing a beta chain of 85 kDa, lacking the cytoplasmic kinase domain. The two receptor variants originate by post-translational processing of a common single-chain precursor of 170 kDa (Pr170). In the endoplasmic reticulum a fraction of Pr170 is cleaved at the cytosolic side generating an intermediate product of 120 kDa (Pr120). This molecule 1) is already detectable after 15 min of pulse labeling, 2) contains high mannose-branched oligosaccharides, and 3) accumulates upon treatments inhibiting the export from the endoplasmic reticulum. A second cleavage, occurring after 30 min of chase in the trans-Golgi network, converts the single-chain precursors Pr170 and Pr120 into the mature heterodimers p190MET and p140MET This process is inhibited by brefeldin A treatment. Conditions leading to Pr170 accumulation in the endoplasmic reticulum, such as receptor overexpression, induce kinase activation and overproduction of Pr120. Conversely, cells expressing a kinase-defective HGF receptor lack the truncated isoform. The proteolytic cleavage of the cytoplasmic domain may thus represent a safety mechanism aimed at preventing ligand-independent intracellular activation of the HGF receptor kinase.			CREPALDI, T (corresponding author), UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,C M DAZEGLIO 52,I-10126 TURIN,ITALY.		Giordano, Silvia/J-9858-2018; crepaldi, tiziana/AAY-7207-2020; Medico, Enzo/K-8497-2018	Giordano, Silvia/0000-0003-1854-1086; crepaldi, tiziana/0000-0003-3410-947X; Medico, Enzo/0000-0002-3917-2438; Comoglio, Paolo/0000-0002-7056-5328				AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BARDELLI A, 1992, ONCOGENE, V7, P1973; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FURLONG RA, 1991, J CELL SCI, V100, P173; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; LONGATI P, 1993, IN PRESS ONCOGENE, V8; MARK MR, 1993, IN PRESS J BIOL CHEM, V268; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1990, INVAS METAST, V10, P49; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	63	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1750	1755						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294424				2022-12-25	WOS:A1994MR98800034
J	FAYOS, BE; BARTLES, JR				FAYOS, BE; BARTLES, JR			REGULATION OF HEPATOCYTIC GLYCOPROTEIN SIALYLATION AND SIALYLTRANSFERASES BY PEROXISOME PROLIFERATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; PLASMA-MEMBRANE PROTEINS; GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; RAT-LIVER; TRANSCRIPTIONAL REGULATION; LINKED OLIGOSACCHARIDES; SIALIC-ACID; EXPRESSION; GENE; GLYCOSYLATION	Short-term dietary exposure of rats to a representative member of each of the three classes of peroxisome proliferators was found to elicit: (i) 71-80 and 66-75% reductions in the specific activities of the hepatic beta-galactoside alpha2,6- and alpha2,3-sialyltransferases, respectively; (ii) a 67-69% reduction in the level of hepatic beta-galactoside alpha2,6-sialyltransferase protein; and (iii) 41-46 and 6-28% reductions in the levels of the hepatic beta-galactoside alpha2,6- and alpha2,3-sialyltransferase mRNAs, respectively. These changes were found to correlate with a reduction in the sialylation of the N-linked glycans of a prototypical hepatocytic sialoglycoconjugate, the integral plasma membrane glycoprotein CE9, as was evident through: (i) a decrease in apparent molecular mass, (ii) a conversion to a more basic distribution of isoelectric points, and (iii) 56-72 and 33-44% decreases in the ability to bind lectins specific for sialic acid in alpha2,3- and alpha2,6-linkage, respectively. When assessed by labeling semithin frozen sections of liver tissue with a fluorescent lectin specific for alpha2,6-linked sialic acid, the reduced sialylation observed for CE9 was found to extend to other hepatocytic glycoconjugates in the livers of peroxisome proliferator-treated rats.	NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,WARD BLDG,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University				Bartles, James/0000-0002-7056-3875	NCI NIH HHS [CA53997] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053997] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARTLES JR, 1985, J CELL BIOL, V100, P1126, DOI 10.1083/jcb.100.4.1126; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BARTLES JR, 1991, DEV BIOL, V143, P258, DOI 10.1016/0012-1606(91)90076-F; BARTLES JR, 1990, CANCER RES, V50, P669; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDLUND C, 1986, CHEM-BIOL INTERACT, V57, P255, DOI 10.1016/0009-2797(86)90001-3; GROLLMAN EF, 1993, J BIOL CHEM, V268, P3604; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130; HUBBARD AL, 1985, J CELL BIOL, V100, P1115, DOI 10.1083/jcb.100.4.1115; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NEHME CL, 1993, J CELL BIOL, V120, P6587; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SHAH S, 1992, J BIOL CHEM, V267, P10652; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WANG WC, 1988, J BIOL CHEM, V263, P4576; WANG XC, 1990, J BIOL CHEM, V265, P17849; WANG XC, 1989, J BIOL CHEM, V264, P1854; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WEN DX, 1992, J BIOL CHEM, V267, P21011	36	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2151	2157						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294470				2022-12-25	WOS:A1994MR98800091
J	VOLKMANN, M; HOFMANN, WJ; MULLER, M; RATH, U; OTTO, G; ZENTGRAF, H; GALLE, PR				VOLKMANN, M; HOFMANN, WJ; MULLER, M; RATH, U; OTTO, G; ZENTGRAF, H; GALLE, PR			P53 OVEREXPRESSION IS FREQUENT IN EUROPEAN HEPATOCELLULAR-CARCINOMA AND LARGELY INDEPENDENT OF THE CODON-249 HOT-SPOT MUTATION	ONCOGENE			English	Article							HEPATITIS-B VIRUS; CELL-LINE; GENE; EXPRESSION; CONFORMATION; AFLATOXIN; ETIOLOGY	Mutations in the p53 tumour suppressor gene have been recently described in hepatocellular carcinomas (HCC) from high risk areas such as China and South Africa. Our study was designed to assess the importance of p53 aberrations in HCCs from Europe, where the major risk factors in hepatocarcinogenesis, aflatoxin exposure and chronic hepatitis B virus (HBV) infection, do not play a dominant role. We investigated 22 HCCs and, as controls, their corresponding tumour-free liver tissues, seven livers with primary biliary cirrhosis and four morphologically normal livers. p53 overexpression, which is usually associated with point mutations of the p53 gene, was detected in 10 of the 22 HCCs by immunoblotting and immunohistochemistry. p53 expression was restricted to the nucleus in the positive cells, while all cells in the control tissues were negative. There was no obvious etiological preference in the p53 positive tumours. Particularly, underlying chronic HBV infection did not appear to be associated with an increased rate of p53 overexpression in European HCCs. SSCP and sequence analysis of exons 5-8 of the p53 gene revealed point mutations in six out of eight tumours with increased steady state levels of p53. In conclusion, our study demonstrates increased p53 levels due to point mutations in a significant proportion of European HCCs. The codon 249 mutation, which was detected in one of the cases, is not predominant in these tumours.	UNIV HEIDELBERG,DEPT INTERNAL MED,GASTROENTEROL ABT,D-69115 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,ANGEW TUMORVIROL,D-69115 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT PATHOL,D-69115 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT SURG,D-69115 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg			Galle, Peter/ABE-2872-2021; Galle, Peter R/T-5292-2018; Martina, Mueller-Schilling/R-4162-2016	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992; 				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; CARBONE D, 1991, ONCOGENE, V6, P1691; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; FUSUN Y, 1986, ADV CANCER RES, V47, P297; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN MC, 1993, INT J CANCER, V53, P51, DOI 10.1002/ijc.2910530111; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JOHNSON PJ, 1987, J HEPATOL, V4, P140, DOI 10.1016/S0168-8278(87)80021-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI DZ, 1993, CARCINOGENESIS, V14, P169, DOI 10.1093/carcin/14.2.169; MACNAB GM, 1976, BRIT J CANCER, V34, P509, DOI 10.1038/bjc.1976.205; MURAKAMI Y, 1991, CANCER RES, V51, P552; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIDA N, 1993, CANCER RES, V53, P368; ODA T, 1992, CANCER RES, V52, P6358; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PUISIEUX A, 1991, CANCER RES, V51, P6185; RAJAGOPALAN MS, 1986, LIFE SCI, V39, P1287, DOI 10.1016/0024-3205(86)90190-6; SCORSONE KA, 1992, CANCER RES, V52, P1635; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X	31	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					195	204						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302580				2022-12-25	WOS:A1994MW24700024
J	CACACE, AM; GUADAGNO, SN; KRAUSS, RS; FABBRO, D; WEINSTEIN, IB				CACACE, AM; GUADAGNO, SN; KRAUSS, RS; FABBRO, D; WEINSTEIN, IB			THE EPSILON ISOFORM OF PROTEIN-KINASE-C IS AN ONCOGENE WHEN OVEREXPRESSED IN RAT FIBROBLASTS	ONCOGENE			English	Article							CELL-LINE; GROWTH-CONTROL; PHORBOL ESTER; PKC-EPSILON; EXPRESSION; FAMILY; TRANSFORMATION; GENE; CONSTRUCTION; PURIFICATION	We have overproduced the Ca2+-independent protein kinase C isoform, nPKCepsilon, in Rat 6 embryo fibroblasts, and examined the effects of this novel isoform on cell growth and transformation. As compared to vector control cell lines expressing only the hygromycin resistance gene, the nPKCepsilon overproducing cell lines exhibited a 7-13-fold increase in Ca2+-independent enzyme activity. Detailed analysis of seven individual nPKCepsilon over-producing clones indicated that those clones that expressed very high activity displayed a number of disorders in growth control, including: formation of dense foci in monolayer culture, decreased doubling time, increased saturation density, decreased serum requirement, growth in soft agar, and tumor formation in nude mice. These findings are in contrast to previous studies from our laboratory indicating that stable expression of high levels of cPKCbeta1 produced only a partially transformed phenotype (Housey et al., 1988). Taken together, these results provide the first direct evidence that distinct isoforms of PKC can exert different effects on growth control and malignant transformation in the same cell type.	COLUMBIA UNIV, DEPT PHARMACOL, 701 W 168 ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10027 USA; COLUMBIA UNIV, CTR CANC, NEW YORK, NY 10027 USA; CIBA GEIGY AG, CH-4002 BASEL, SWITZERLAND; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10027 USA	Columbia University; Columbia University; Columbia University; Novartis; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University								BAXTER G, 1992, J BIOL CHEM, V267, P1910; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRAUSS RS, 1989, ONCOGENE, V4, P991; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SOSSIN W, 1992, NEUROSCIENCE, V12, P1160; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEINSTEIN, 1991, COLD SPRING HARBOR S	33	261	262	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2095	2104						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336936				2022-12-25	WOS:A1993LP17100009
J	NAUMANN, M; NIETERS, A; HATADA, EN; SCHEIDEREIT, C				NAUMANN, M; NIETERS, A; HATADA, EN; SCHEIDEREIT, C			NF-KAPPA-B PRECURSOR P100 INHIBITS NUCLEAR TRANSLOCATION AND DNA-BINDING OF NF-KAPPA-B/REL-FACTORS	ONCOGENE			English	Article							CANDIDATE PROTOONCOGENE BCL-3; PROTO-ONCOGENE; P50 PRECURSOR; CYTOPLASMIC RETENTION; TRANSCRIPTION FACTOR; REL ONCOGENE; V-REL; C-REL; SUBUNIT; CLONING	The NF-kappaB precursor p100 (lyt-10, p97, p98) generates after proteolytic processing a 52 kDa subunit, which can bind to kappaB-motifs. A deregulated form of the p100 gene, which is structurally altered by a t(10;14) translocation, has a potential oncogenic role in certain human B cell lymphomas. In this study p100 was analysed for its ability to interact with its own processing product p52, with p50, the product of the NF-kappaB precursor p105, and with other NF-kappaB/rel-proteins. As demonstrated by a combination of Western blot analysis, band shift analysis and indirect immunofluorescence labelling of transfected cells, p100 itself was localized in the cytoplasm and indiscriminately retained each co-expressed NF-kappaB subunit. Thereby it simultaneously inhibited their DNA binding activities. Thus, a major function of p100 is, like p105, to associate with subunits of the rel multigene family in the cytoplasm in an IkappaB-like fashion. The similarity between p100 and p105 is also reflected by equivalent protein interactions of their processing products: like NF-kappaB-p50, also NF-kappaB-p52 heteromerised promiscuously with all rel-factors tested. Moreover, p52 efficiently interacts with the candidate oncogene product Bcl-3 and also binds to the basic-leucine zipper protein NF-IL6.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,IHNESTR 73,D-14195 DAHLEM,GERMANY	Max Planck Society			Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, EMBO J, V17, P135; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STORMS RW, 1992, VIROLOGY, V188, P765, DOI 10.1016/0042-6822(92)90531-S; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	42	80	80	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2275	2281						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336950				2022-12-25	WOS:A1993LP17100030
J	LEE, FJS; MOSS, J				LEE, FJS; MOSS, J			AN RNA-BINDING PROTEIN GENE (RBP1) OF SACCHAROMYCES-CEREVISIAE ENCODES A PUTATIVE GLUCOSE-REPRESSIBLE PROTEIN CONTAINING 2 RNA RECOGNITION MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; NUCLEOTIDE-SEQUENCE; CONSENSUS SEQUENCE; PARTICLE CONTAINS; SNRNP PROTEIN; SEX-LETHAL; DROSOPHILA; YEAST; EXPRESSION; DOMAIN	A gene, termed RNA-binding protein (RBP1), was cloned from Saccharomyces cerevisiae. RBP1 contains an open reading frame of 2016 nucleotides that encodes a 672-amino acid protein with a calculated M(r) of approximately 75,000. Southern blots of genomic DNA from wild-type and RBP1-disrupted strains were consistent with the presence of homologous genes. RNA blots revealed a major 2.7-kb RNA band and two minor bands of 1.5 and 1.1 kb. The sequence of the putative RBP1 protein contains two copies of an RNA recognition motif, two glutamine stretches, an asparagine-rich region, a methionine-rich region, and two long potential alpha-helixes. In addition, recombinant RBP1 fusion protein can bind to RNA and single-stranded DNA but not double-stranded DNA. RBP1 is a glucose-repressible gene. Disruption of RBP1 increased cell growth rate in the early log phase. Overexpression of RBP1 or reduction in its translation by expression of antisense RNA decreased or increased the cell growth rate, respectively. From these observations, we infer that RBP1 may be involved in growth regulation, possibly through its participation in RNA metabolism.			LEE, FJS (corresponding author), NHLBI, CELLULAR METAB LAB, ROOM 5N-307, BLDG 10, BETHESDA, MD 20892 USA.			LEE, FANG-JEN/0000-0002-2167-2426				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BRUHN L, 1992, MOL CELL BIOL, V12, P3563, DOI 10.1128/MCB.12.8.3563; CHEREST H, 1990, NUCLEIC ACIDS RES, V18, P659, DOI 10.1093/nar/18.3.659; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HUDSPETH MES, 1982, CELL, V30, P617, DOI 10.1016/0092-8674(82)90258-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KUMA K, 1990, FEBS LETT, V260, P67, DOI 10.1016/0014-5793(90)80067-S; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1992, BIOTECHNIQUES, V12, P677; LEE FJS, 1992, BIOTECHNIQUES, V13, P844; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Maniatis T., 1982, MOL CLONING; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PINKHAM JL, 1987, MOL CELL BIOL, V7, P578, DOI 10.1128/MCB.7.2.578; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SACHS AB, 1986, CELL, V45, P527; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPP M, 1986, NUCLEIC ACIDS RES, V14, P6803, DOI 10.1093/nar/14.17.6803; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; SHERMAN F, 1986, METHODS YEAST GENETI, P79; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WAHLGREN M, 1986, P NATL ACAD SCI USA, V83, P2677, DOI 10.1073/pnas.83.8.2677; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	60	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15080	15087						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325883				2022-12-25	WOS:A1993LL75900079
J	ADACHI, Y; COPELAND, TD; HATANAKA, M; OROSZLAN, S				ADACHI, Y; COPELAND, TD; HATANAKA, M; OROSZLAN, S			NUCLEOLAR TARGETING SIGNAL OF REX PROTEIN OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I SPECIFICALLY BINDS TO NUCLEOLAR SHUTTLE PROTEIN-B-23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MESSENGER-RNA; HTLV-I; TRANS-ACTIVATION; GENE-EXPRESSION; SEQUENCES; IDENTIFICATION; P40X; PHOSPHORYLATION; LOCALIZATION	Rex protein, the post-transcriptional regulator of human T-cell leukemia virus type I, is located predominantly in the cell nucleolus and is associated with the cytoplasmic accumulation of unspliced and singly spliced viral mRNAs. The N-terminal 19-amino acid segment of Rex has been identified as the nucleolar targeting signal (NOS) and shown to be important for Rex function. To study the molecular interaction between the NOS region of Rex and its binding host protein(s) in the nucleolus, we chemically synthesized a functional NOS peptide (wild type) and mutant NOS peptides. Fluorescein isothiocyanate-conjugated functional NOS peptide was rapidly taken up by human cells and was transported to the nucleolus. Using affinity chromatography, we identified nucleolar protein B-23 as the major protein that binds to NOS. We also identified two highly acidic regions of B-23 (amino acids 120-132 and 161-188) as acceptor regions for NOS. Previous experiments have suggested that B-23 functions as a shuttle protein for the nucleolar transport of ribosomal components. Our results suggest that B-23 may also serve as a shuttle for the import of Rex from the cytoplasm to the nucleolus coupled to the export of viral mRNAs containing the Rex-responsive element.	NCI,FREDERICK CANC RES & DEV CTR,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,PROT STRUCT GRP,FREDERICK,MD 21702; KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 606,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Kyoto University					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1990, J CHROMATOGR-BIOMED, V530, P39, DOI 10.1016/S0378-4347(00)82300-2; ADACHI Y, 1992, J BIOL CHEM, V267, P21977; ADACHI Y, 1990, BIOCHEM BIOPH RES CO, V169, P469, DOI 10.1016/0006-291X(90)90355-Q; ADACHI Y, 1992, J BIOL CHEM, V267, P19373; ADACHI Y, 1991, J BIOL CHEM, V266, P3968; ADACHI Y, 1990, BIOL MED SIGNAL TRAN, P478; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURGEOIS CA, 1988, INT REV CYTOL, V111, P1, DOI 10.1016/S0074-7696(08)61730-1; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHANG JH, 1988, J BIOL CHEM, V263, P12824; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GESSAIN A, 1985, LANCET, V2, P407; GEY GO, 1952, CANCER RES, V12, P264; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; Hadjiolov AA, 1985, NUCLEOLUS RIBOSOME B; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; NAGASHIMA K, 1986, J VIROL, V60, P394, DOI 10.1128/JVI.60.2.394-399.1986; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; OHE Y, 1989, J BIOCHEM-TOKYO, V106, P844, DOI 10.1093/oxfordjournals.jbchem.a122941; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RHIM JS, 1975, INT J CANCER, V15, P23, DOI 10.1002/ijc.2910150104; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIRAKAWA H, 1992, J BIOL CHEM, V267, P6641; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; WACHSMAN W, 1984, SCIENCE, V226, P177, DOI 10.1126/science.6091270; ZHANG XT, 1989, BIOCHEM BIOPH RES CO, V164, P176, DOI 10.1016/0006-291X(89)91699-9	47	112	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13930	13934						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314759				2022-12-25	WOS:A1993LJ82500026
J	CHAPPELL, DA; FRY, GL; WAKNITZ, MA; MUHONEN, LE; PLADET, MW; IVERIUS, PH; STRICKLAND, DK				CHAPPELL, DA; FRY, GL; WAKNITZ, MA; MUHONEN, LE; PLADET, MW; IVERIUS, PH; STRICKLAND, DK			LIPOPROTEIN-LIPASE INDUCES CATABOLISM OF NORMAL TRIGLYCERIDE-RICH LIPOPROTEINS VIA THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN/ALPHA-2-MACROGLOBULIN RECEPTOR IN-VITRO - A PROCESS FACILITATED BY CELL-SURFACE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN C-II; ALPHA-2-MACROGLOBULIN RECEPTOR; MONOCLONAL-ANTIBODIES; CHYLOMICRON REMNANTS; HIGH-AFFINITY; PLASMA-LIPOPROTEINS; HEYMANN NEPHRITIS; LDL-RECEPTOR; BOVINE-MILK; PROTEIN	Bovine milk lipoprotein lipase (LPL) induced binding, uptake, and degradation of I-125-labeled normal human triglyceride-rich lipoproteins by cultured mutant fibroblasts lacking LDL receptors. The induction was dose-dependent and occurred whether LPL and I-125-lipoproteins were added to incubation media simultaneously or LPL was allowed to bind to cell surfaces, and unbound LPL was removed by washing prior to the assay. Lipolytic modification of lipoproteins did not appear to be necessary for increased catabolism because the effect of LPL was not prevented by inhibitors of LPL's enzymatic activity, p-nitrophenyl N-dodecylcarbamate or phenylmethylsulfonyl fluoride. However, the effect was abolished by boiling LPL prior to the assay suggesting that major structural features of LPL were required. Also, LPL-induced binding to cells was blocked by an anti-LPL monoclonal antibody but not by antibodies that are known to block apolipoprotein E- or B-100-mediated binding to low density lipoprotein (LDL) receptors. This indicates that LPL itself mediated I-125-lipoprotein binding to cells. Cellular degradation of I-125-lipoproteins was partially or completely blocked by two previously described ligands for the LDL receptor-related protein/alpha2-macroglobulin receptor (LRP): activated alpha2-macroglobulin (alpha2M*), and the 39-kDa receptor-associated protein. These data implicated LRP as mediating LPL-induced lipoprotein degradation and were confirmed by showing that LPL's effects were prevented by an immunoaffinity-isolated polyclonal antibody against LRP. Furthermore, LPL promoted binding of I-125-lipoproteins to highly purified LRP in a solid-phase assay. Heparin or heparinase treatment of cells markedly decreased LPL-induced binding, uptake, and degradation of lipoproteins, but had no effect on catabolism of alpha2M*. Thus, cell-surface proteoglycans were obligatory participants in the effects of LPL but were not required for LRP-mediated catabolism of alpha2M*. Taken together, these in vitro findings establish that through interaction with cell-surface proteoglycans, LPL induces catabolism of normal human triglyceride-rich lipoproteins via LRP.	UNIV UTAH,VET AFFAIRS MED CTR,DEPT INTERNAL MED,SALT LAKE CITY,UT 84148; AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; American Red Cross	CHAPPELL, DA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,E318 GH,IOWA CITY,IA 52242, USA.				NHLBI NIH HHS [HL49264, T32 HLO7413] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264, T32HL007413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1989, J CLIN INVEST, V84, P1906, DOI 10.1172/JCI114378; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; Iverius P H, 1986, Methods Enzymol, V129, P691; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; MILNE RW, 1982, FEBS LETT, V146, P97, DOI 10.1016/0014-5793(82)80712-6; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MUSLINER TA, 1979, BIOCHIM BIOPHYS ACTA, V575, P277, DOI 10.1016/0005-2760(79)90029-8; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OSTLUNDLINDQVIST AM, 1983, ARTERIOSCLEROSIS, V3, P433, DOI 10.1161/01.ATV.3.5.433; PACKARD CJ, 1984, J CLIN INVEST, V74, P2178, DOI 10.1172/JCI111644; PETERSON J, 1985, BIOCHIM BIOPHYS ACTA, V837, P262, DOI 10.1016/0005-2760(85)90049-9; QUINN DM, 1982, BIOCHEMISTRY-US, V21, P6872, DOI 10.1021/bi00269a038; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SHIN HC, 1992, BIOCHEMISTRY-US, V31, P811, DOI 10.1021/bi00118a025; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VILARO S, 1988, BIOCHIM BIOPHYS ACTA, V959, P106, DOI 10.1016/0005-2760(88)90021-5; VILARO S, 1986, BIOCHEM J, V236, P273, DOI 10.1042/bj2360273; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4; WEISGRABER KH, 1978, J BIOL CHEM, V253, P6281; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	55	187	189	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14168	14175						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314783				2022-12-25	WOS:A1993LJ82500058
J	ROTROSEN, D; YEUNG, CL; KATKIN, JP				ROTROSEN, D; YEUNG, CL; KATKIN, JP			PRODUCTION OF RECOMBINANT CYTOCHROME-B558 ALLOWS RECONSTITUTION OF THE PHAGOCYTE NADPH OXIDASE SOLELY FROM RECOMBINANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; EXPRESSION; COMPONENT; BACULOVIRUS; ACTIVATION; CLONING; SUBUNIT	Phagocytic white blood cells contain a multicomponent oxidase that generates microbicidal products by catalyzing electron transfer from NADPH to molecular oxygen. Activation of this oxidase requires interactions of a unique membrane flavocytochrome with the cytosolic proteins p47phox, p67phox, and p21Rac. This flavocytochrome, designated cytochrome b558, is a heteromer comprising a 22-kDa alpha-subunit (p22phox) and a glycosylated almost-equal-to 91-kDa beta-subunit (gp91phox). Cytochrome b558 was expressed in Sf9 insect cells coinfected with recombinant baculoviruses carrying cDNAs for p22phox and gp91phox. Membranes of these cells contained a b-type cytochrome with a dithionite-reduced minus oxidized difference spectrum similar to that of neutrophil cytochrome b558. The recombinant cytochrome b558 beta-subunit was heterogeneously N-glycosylated as demonstrated by its susceptibility to cleavage with endoglycosidases F and H. In contrast to the neutrophil cytochrome b558, a portion of the N-linked oligosaccharide was of the high mannose type. Recombinant cytochrome b558 supported superoxide production in a cell-free assay containing recombinant p47phox, p67phox, and p21Rac. The enzymatic turnover of the partially purified recombinant cytochrome b558 and neutrophil cytochrome b558 were similar (almost-equal-to 100-160 mol of superoxide generated/s/mol of cytochrome heme, range of two experiments) and the native and recombinant cytochromes showed similar requirements for NADPH and exogenous FAD. These studies represent the first reconstitution of the NADPH oxidase solely from recombinant proteins and define a model system to explore the structure and function of cytochrome b558.			ROTROSEN, D (corresponding author), NIAID,HOST DEF LAB,BLDG 10,RM 11N112,BETHESDA,MD 20892, USA.							ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CARILLO N, 1992, J BIOL CHEM, V267, P15537; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HARPER AM, 1985, BIOCHEM J, V227, P783, DOI 10.1042/bj2270783; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; ISOGAI Y, 1993, J BIOL CHEM, V268, P4025; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KATKIN JP, 1992, INFLAMMATION, V16, P393, DOI 10.1007/BF00917630; KLEINBERG ME, 1989, J IMMUNOL, V143, P4152; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KWONG CH, 1993, IN PRESS BIOCHEMISTR; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALY FE, 1988, J IMMUNOL, V140, P2334; NAKAMURA M, 1988, BLOOD, V72, P1550; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P221; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROTROSEN D, 1992, INFLAMMATION BASIC P, P589; Sambrook J, 1989, MOL CLONING LABORATO; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V326, P88; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195	36	78	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14256	14260						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314788				2022-12-25	WOS:A1993LJ82500070
J	HALLBERG, B; RAYTER, SI; DOWNWARD, J				HALLBERG, B; RAYTER, SI; DOWNWARD, J			INTERACTION OF RAS AND RAF IN INTACT MAMMALIAN-CELLS UPON EXTRACELLULAR STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C	It has recently been shown that Ras proteins interact directly with Raf serine/threonine kinases in vitro and in the yeast two-hybrid system, leading to speculation that Raf proteins function as effecters for Res. Here it is demonstrated that the endogenous Raf-1 protein co-immunoprecipitates with Ras from mammalian cells when the non-neutralizing anti-Ras monoclonal antibody Y13-238 is used. The formation of a Ras-Raf complex is absolutely dependent on prior treatment of the cells with a stimulus that activates Ras: phorbol ester or anti-T cell receptor antibody in the case of human peripheral blood T lymphoblasts, or epidermal growth factor in the case of Rat-1 fibroblasts. Up to 3% of cellular Raf-1 can be found in association with Ras. The association is not competed by addition of exogenous GST-Raf to the cell lysates and is therefore unlikely to be due to Ras-Raf binding after cell lysis. Specific interaction of Ras and Raf therefore occurs in intact mammalian cells in response to stimuli that cause Res to become GTP-bound.			HALLBERG, B (corresponding author), IMPERIAL CANC RES FUND,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Downward, Julian/0000-0002-2331-4729				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HARLOW E, 1988, ANTIBODIES LABORATOR; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; RAPP UR, 1991, ONCOGENE, V6, P495; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	25	179	182	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3913	3916						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307946				2022-12-25	WOS:A1994MW98900003
J	LEBART, MC; MEJEAN, C; CASANOVA, D; AUDEMARD, E; DERANCOURT, J; ROUSTAN, C; BENYAMIN, Y				LEBART, MC; MEJEAN, C; CASANOVA, D; AUDEMARD, E; DERANCOURT, J; ROUSTAN, C; BENYAMIN, Y			CHARACTERIZATION OF THE ACTIN-BINDING SITE ON SMOOTH-MUSCLE FILAMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL REGION; ALPHA-ACTININ; SKELETAL-MUSCLE; SEQUENCE; PROTEIN; DOMAIN; DYSTROPHIN; IDENTIFICATION; CALMODULIN; SPECTRIN	We have isolated an NH2-terminal fragment of filamin (M(r) = 70,000) after digestion with Staphylococus aureus V8 protease. This fragment was shown to interact with filamentous actin in cosedimentation assays. Using cross-reactive anti-peptides antibodies directed against the strongly conserved 27-mer sequence of alpha-actinin, already implicated as an actin binding site (Kuhlman, P. A., Hemmings, L., and Critchley, D, R. (1992) FEBS Lett. 304, 201-206), we obtained evidence suggesting that the homologous sequence of filamin (121-147 sequence) is the major element in the interaction with actin. In particular, we used enzyme-linked immunosorbent assay experiments, in conjunction with a synthetic peptide approach, and found that the hydrophobic part of the 27-mer peptide (141-147 sequence) is largely involved in actin binding. Thus, the filamin sequence 121-147 (or the alpha-actinin sequence 108-134) and the actin counterpart composed of residues 112-125 and 360-372 (we have already implicated) could constitute the main interface between actin and these cytoskeletal proteins. However, the divergent behavior of filamin and alpha-actinin toward conformational changes of actin argues in favor of distinctive interfaces. Finally, the ionic strength dependence of the filamin-actin interaction, in contrast to that with alpha-actinin, strongly suggests that, besides hydrophobic interactions conferred by the 27-mer sequence, more hydrophilic region(s) of filamin participate(s) in the binding.	UNIV MONTPELLIER 1,ECOLE PRAT HAUTES ETUD,RECH MOTIL CELLULAIRE LAB,CNRS,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier								BARON MD, 1987, J BIOL CHEM, V262, P17623; BENYAMIN Y, 1986, J IMMUNOL METHODS, V86, P21, DOI 10.1016/0022-1759(86)90260-7; BETTACHE N, 1989, P NATL ACAD SCI USA, V86, P6028, DOI 10.1073/pnas.86.16.6028; BRESNICK AR, 1990, J BIOL CHEM, V265, P9236; BRESNICKAR, 1991, J BIOL CHEM, V266, P12989; Bretscher A, 1991, CURR OPIN STRUC BIOL, V1, P281, DOI 10.1016/0959-440X(91)90074-4; BULINSKI JC, 1983, P NATL ACAD SCI-BIOL, V80, P1506, DOI 10.1073/pnas.80.6.1506; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; DABROWSKA R, 1985, J MUSCLE RES CELL M, V6, P29, DOI 10.1007/BF00712309; DAVIES P, 1977, FEBS LETT, V77, P228, DOI 10.1016/0014-5793(77)80240-8; DAVIES PJA, 1978, J BIOL CHEM, V253, P4036; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; Engvall E, 1980, Methods Enzymol, V70, P419; FRIEDEN C, 1982, J BIOL CHEM, V257, P2882; GORLIN J, 1989, Journal of Cell Biology, V109, p272A; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HAMMONDS RG, 1987, CELL, V51, P1, DOI 10.1016/0092-8674(87)90002-X; HANIN V, 1989, Peptide Research, V2, P367; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOCK RS, 1990, BIOCHEMISTRY-US, V29, P9441, DOI 10.1021/bi00492a019; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOUMEIDA A, 1991, BIOCHEM J, V274, P753, DOI 10.1042/bj2740753; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBART MC, 1990, BIOCHEM BIOPH RES CO, V173, P120, DOI 10.1016/S0006-291X(05)81030-7; LEBART MC, 1993, J BIOL CHEM, V268, P5642; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; MALHOTRA A, 1986, BIOCHIM BIOPHYS ACTA, V874, P347, DOI 10.1016/0167-4838(86)90034-8; MARUYAMA K, 1985, J BIOCHEM-TOKYO, V97, P1517, DOI 10.1093/oxfordjournals.jbchem.a135207; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MEJEAN C, 1992, EUR J BIOCHEM, V209, P555, DOI 10.1111/j.1432-1033.1992.tb17320.x; MEJEAN C, 1988, BIOCHEM BIOPH RES CO, V152, P368, DOI 10.1016/S0006-291X(88)80723-X; MIMURA N, 1986, J BIOL CHEM, V261, P680; MONTGELARD C, 1990, EXPERIENTIA, V46, P303, DOI 10.1007/BF01951773; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; PACAUD M, 1993, BIOCHEMISTRY-US, V32, P363, DOI 10.1021/bi00052a045; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866	42	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4279	4284						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307993				2022-12-25	WOS:A1994MW98900060
J	PIETRINI, G; SUH, YJ; EDELMANN, L; RUDNICK, G; CAPLAN, MJ				PIETRINI, G; SUH, YJ; EDELMANN, L; RUDNICK, G; CAPLAN, MJ			THE AXONAL GAMMA-AMINOBUTYRIC-ACID TRANSPORTER GAT-1 IS SORTED TO THE APICAL MEMBRANES OF POLARIZED EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN ALTERS; HIPPOCAMPAL-NEURONS; RAT-BRAIN; GABA TRANSPORTER; IMMUNOCYTOCHEMICAL LOCALIZATION; MDCK CELLS; EXPRESSION; PROTEINS; CULTURE; CLONING	Recent studies suggest that epithelial cells and neu neurons employ similar mechanisms to target proteins to the distinct subdomains of their polarized cell surface membranes. We have examined the sorting behavior of the neuronal gamma-aminobutyric acid (GABA) transporter CAT-1 expressed by transfection in the polarized epithelial Madin-Darby canine kidney (MDCK) cell line. We find that the GABA transporters endogenously expressed by polarized hippocampal neurons in culture are restricted to axonal plasma membranes. In transfected MDCK cells, the GABA transporter is found to be localized primarily to the apical cell surface when examined by immunocytochemistry, cell surface biotinylation, and transport assay. MDCK cells exposed to hyperosmotic stress express a close relative of GAT-1, the betaine transporter (BGT-1). We find that BGT-1 expressed by transfection in MDCK cells accumulates predominantly at the basolateral cell surface. These observations suggest that the sorting information required for axonal targeting may be similar to that which mediates apical localization in epithelia. Furthermore, it would appear that despite their high degree of homology, the BGT-1 and GAT-1 transporters manifest sorting signals which specify their targeting to distinct cell surface domains.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; CNR,CTR CYTOPHARMACOL,I-20129 MILAN,ITALY; UNIV MILAN,DEPT PHARMACOL,I-20129 MILAN,ITALY	Yale University; Yale University; Consiglio Nazionale delle Ricerche (CNR); University of Milan				Caplan, Michael/0000-0001-5768-4405	NIGMS NIH HHS [GM-42136] Funding Source: Medline; PHS HHS [7259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BLACK MM, 1989, TRENDS NEUROSCI, V12, P211, DOI 10.1016/0166-2236(89)90124-0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CACERES A, 1986, J NEUROSCI, V6, P714; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Goslin K., 1991, CULTURING NERVE CELL, P251; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KUMINOTO M, 1991, J CELL BIOL, V115, P1319; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LIU QR, 1993, J BIOL CHEM, V268, P2106; MABJEESH NJ, 1992, FEBS LETT, V299, P99, DOI 10.1016/0014-5793(92)80109-T; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; Mugnaini E., 1985, HDB CHEM NEUROANAT 1, V4; NAKANISHI T, 1990, AM J PHYSIOL, V258, pF1061, DOI 10.1152/ajprenal.1990.258.4.F1061; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PFALLER W, 1990, J CELL PHYSIOL, V142, P247, DOI 10.1002/jcp.1041420205; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RADIAN R, 1990, J NEUROSCI, V10, P1319; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SIEMERS KA, 1993, SCIENCE, V260, P552; SIMONS K, 1985, ANN REV CELL BIOL, V1, P295; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197; ZURZOLO C, 1993, SCIENCE, V260, P550, DOI 10.1126/science.8386394	39	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4668	4674						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308038				2022-12-25	WOS:A1994MW98900113
J	RAVICHANDRAN, KS; BURAKOFF, SJ				RAVICHANDRAN, KS; BURAKOFF, SJ			THE ADAPTER PROTEIN SHC INTERACTS WITH THE INTERLEUKIN-2 (IL-2) RECEPTOR UPON IL-2 STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; TYROSINE KINASES; BETA-SUBUNIT; ACTIVATION; REGION; CHAIN; IDENTIFICATION; ASSOCIATION; BINDING; DOMAIN	Binding of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) stimulates Src family kinases, tyrosine phosphorylation of several proteins, conversion of Ras to its active GTP-bound form, and eventually c-fos, c-jun, and c-myc induction. The IL-2Rbeta chain plays a crucial role in IL-2R signaling. Within the cytoplasmic domain of the beta chain, a region essential for mitogenesis and another involved in binding the Src family kinase Lck have been defined. The beta chain itself is tyrosine-phosphorylated upon IL-2 stimulation. Since the adapter protein Shc acts upstream of Ras and is involved in T cell receptor-mediated Ras activation, we examined the role of Shc in IL-2 signaling. Shc was found to be tyrosine-phosphorylated upon IL-2 stimulation in CTLL-20 cells. After its phosphorylation, Shc interacted with another adapter protein, Grb2, and, via Grb2, with the Ras GTP/GDP exchange factor mSOS. After IL-2 stimulation, Shc also associated with the IL-2Rbeta chain. Thus, during IL-2 signaling, the interaction of Shc with the IL-2Rbeta chain and its simultaneous association with Grb2 and mSOS may couple IL-2R stimulation to Ras signaling.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL, 44 BINNEY ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Ravichandran, Kattur Soundarapandian/AAG-7319-2019	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FUNG MR, 1991, J IMMUNOL, V147, P1253; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SATOH T, 1992, J BIOL CHEM, V267, P25423; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	23	133	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1599	1602						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294403				2022-12-25	WOS:A1994MR98800009
J	BAIERBITTERLICH, G; RAPPAPORT, J; BAIER, G; LOONEY, D; WONGSTAAL, F				BAIERBITTERLICH, G; RAPPAPORT, J; BAIER, G; LOONEY, D; WONGSTAAL, F			TRANSCELLULAR ACTIVATION OF THE HTLV PROMOTER BY HUMAN HEMATOPOIETIC-CELLS	ONCOGENE			English	Note							LEUKEMIA-LYMPHOMA VIRUS; T-CELL; INTERLEUKIN-2; EXPRESSION; RETROVIRUS; GENE; LYMPHOCYTES; INFECTION; SEQUENCES; DISTINCT	We examined the ability of hematopoietic cells to transactivate the HTLV promoter by a transcellular mechanism. HeLa cells containing a CAT reporter gene driven by the HTLV-2 promoter were cocultivated with hematopoietic cells of the B-(Raji), T-(HuT78, Jurkat) and monocyte/promyelocytic (THP-1, U937 and HL60) lineages. Cocultivation with U937 and HuT78 cells constitutively and significantly transactivated the HTLV-2 promoter, while no effect was observed with the other lines. However, activation of other T-cell lines (CEM, Jurkat, Molt-3 and MT-4) with a combination of phorbolester and phytohemagglutinin also resulted in potent transactivation. Supernatant from HuT78 cells exhibited detectable transactivating activity, suggesting that the activation is mediated by a secreted factor(s). This factor also transactivates the HTLV-1 promoter. We used a panel of HTLV-1 LTR deletion mutants to map the responsive elements to this factor(s). Unlike the response element to the HTLV transactivator protein, Tax, which can be mapped to a small region in the enhancer, maximal transactivation by the cellular factor(s) required the complete U3 sequence. Transcellular activation of the HTLV promoter by activated T-cells may play a role in the development of leukemia in HTLV infected individuals.	UNIV CALIF SAN DIEGO,SAN DIEGO,CA; NIH,BETHESDA,MD; SAN DIEGO VA MED CTR,SAN DIEGO,CA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA	BAIERBITTERLICH, G (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA, USA.		Baier, Gottfried/E-8755-2012	Baier, Gottfried/0000-0002-2085-8325				BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BOEHNLEIN E, 1988, CONTROL HUMAN RETROV, P191; CHEN ISY, 1982, J VIROL, V41, P183, DOI 10.1128/JVI.41.1.183-191.1982; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DAEFLER S, 1991, MOL F ONCOLOGY, P229; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; MANZARI V, 1983, P NATL ACAD SCI-BIOL, V80, P1574, DOI 10.1073/pnas.80.6.1574; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MERL S, 1984, BLOOD, V64, P967; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PAVLAKIS GN, 1988, CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, P281; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; ROSENBLATT JD, 1988, BLOOD, V71, P363; SAXON A, 1978, ANN INTERN MED, V88, P323, DOI 10.7326/0003-4819-88-3-323; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TEMIN HM, 1974, J VIROL, V13, P291, DOI 10.1128/JVI.13.2.291-297.1974; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	28	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					319	322						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302596				2022-12-25	WOS:A1994MW24700039
J	MURPHY, C; KRETSCHMER, C; BIESINGER, B; BECKERS, J; JUNG, J; DESROSIERS, RC; MULLERHERMELINK, HK; FLECKENSTEIN, BW; RUTHER, U				MURPHY, C; KRETSCHMER, C; BIESINGER, B; BECKERS, J; JUNG, J; DESROSIERS, RC; MULLERHERMELINK, HK; FLECKENSTEIN, BW; RUTHER, U			EPITHELIAL TUMORS INDUCED BY A HERPESVIRUS ONCOGENE IN TRANSGENIC MICE	ONCOGENE			English	Article							SAIMIRI STRAINS; SMALL RNAS; EXPRESSION; REGION; GENE; TRANSFORMATION; IDENTIFICATION; CONSEQUENCES; STP-C488; GENOME	To investigate the role of herpesviral genes in tumourigenesis, transgenic mice were generated expressing STP-C, a transformation associated protein of the lymphoma inducing herpesvirus saimiri. Epithelial tumours developed in the salivary gland, pancreas, thymus and liver of transgenic mice within the first weeks of life. Thus, the target cells for tumour formation in the transgenic mice were surprisingly different from those of the herpesvirus from which the oncogene was derived. Our results identify STP-C as a herpesvirus oncogene sufficient for tumour induction without the cooperation of other viral gene products. Furthermore, the results demonstrate pleiotropic transforming capabilities of the STP-C oncogene and suggest that the specificity of lymphoma induction by the virus is determined by factors other than the oncogene itself.	EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV WURZBURG, INST PATHOL, D-97080 WURZBURG, GERMANY; UNIV ERLANGEN NURNBERG, INST KLIN & MOLEK VIROL, D-91054 ERLANGEN, GERMANY; HARVARD UNIV, SCH MED, NEW ENGLAND REG PRIMATE RES CTR, SOUTHBOROUGH, MA 01772 USA	European Molecular Biology Laboratory (EMBL); University of Wurzburg; University of Erlangen Nuremberg; Harvard University			Beckers, Johannes/K-7237-2012	Beckers, Johannes/0000-0001-7874-3822				ALBRECHT JC, 1992, NUCLEIC ACIDS RES, V20, P1810; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; AZEN EA, 1984, SCIENCE, V226, P967, DOI 10.1126/science.6095444; BIESINGER B, 1990, VIROLOGY, V176, P505, DOI 10.1016/0042-6822(90)90020-R; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BODEMER W, 1986, J VIROL, V60, P114, DOI 10.1128/JVI.60.1.114-123.1986; CASTLE AM, 1992, J BIOL CHEM, V267, P13093; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FIELDS BN, 1990, FIELDS VIROLOGY, P1373; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P253; GODDARD MJ, 1991, J CLIN PATHOL, V44, P660, DOI 10.1136/jcp.44.8.660; HOGAN B, 1986, MANIPULATING MOUSE E, P230; JUNG JU, 1991, J VIROL, V65, P6953, DOI 10.1128/JVI.65.12.6953-6960.1991; JUNG JU, 1992, J VIROL, V66, P1777, DOI 10.1128/JVI.66.3.1777-1780.1992; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDES C, 1990, EXP PATHOL-JENA, V40, P239, DOI 10.1016/S0232-1513(11)80308-7; MEDVECZKY MM, 1989, J VIROL, V63, P3601, DOI 10.1128/JVI.63.9.3601-3611.1989; MEDVECZKY P, 1984, J VIROL, V52, P938, DOI 10.1128/JVI.52.3.938-944.1984; MELENDEZ LV, 1968, LAB ANIM CARE, V18, P374; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MURTHY S, 1986, EMBO J, V5, P1625, DOI 10.1002/j.1460-2075.1986.tb04405.x; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; RUTHER U, 1989, PROG NUCLEIC ACID RE, V36, P235; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SIMMER B, 1991, J GEN VIROL, V72, P1953, DOI 10.1099/0022-1317-72-8-1953; TRIMBLE JJ, 1988, SCIENCE, V239, P1145, DOI 10.1126/science.2830673; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587	30	51	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					221	226						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302583				2022-12-25	WOS:A1994MW24700027
J	NISHIO, Y; AIELLO, LP; KING, GL				NISHIO, Y; AIELLO, LP; KING, GL			GLUCOSE-INDUCED GENES IN BOVINE AORTIC SMOOTH-MUSCLE CELLS IDENTIFIED BY MESSENGER-RNA DIFFERENTIAL DISPLAY	FASEB JOURNAL			English	Note						GENE REGULATION; ELONGATION FACTOR	PROTEIN-KINASE-C; ELONGATION FACTOR-II; HUMAN-BREAST-CANCER; GLYCEMIC CONTROL; DIABETIC RATS; CLONING; CDNA; EXPRESSION; MORTALITY; SEQUENCE	Hyperglycemia is postulated to cause chronic changes in the vasculature of diabetic patients, suggesting structural or genetic alterations. We have characterized the glucose induced alterations of gene expression in cultured bovine aortic smooth muscle cells using the recently developed mRNA differential display method. After five days of incubation with either 5.5 or 22 mM glucose, RNA preparations were isolated from confluent cells and probed with 10 candidate clones identified after screening up to 3000 mRNA species. Among these, three clones (2A, 2C, 3) showed significant changes in expression by Northern blot analysis. Elevated glucose levels decreased the mRNA expression of clones 2A and 3 to 51 +/- 7% (P < .01) and 59 +/- 10% (P < .05) (mean% of control +/- SEM), respectively. Expression of clone 2C was increased in 22 mM glucose condition to 221 +/- 23% (P < .05). Nucleotide sequence analysis showed that clone 3 had 77% homology to the 3'-noncoding region of human elongation factor 2, a member of the GTPase family which is essential for polypeptide synthesis. Clones 2A and 2C do show no homology to known nucleotide sequences. These results indicate that physiologically attainable high glucose conditions can significantly effect gene expression in aortic smooth muscle cells. Furthermore, mRNA differential display can be used in metabolic studies to identify new genes regulated by nutrients such as glucose.	HARVARD UNIV,SCH MED,JOSLIN DIABETES CTR,DIV RES,1 JOSLIN PL,BOSTON,MA 02115; HARVARD UNIV,JOSLIN DIABET CTR,BEETHAM EYE INST,CAMBRIDGE,MA 02138; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NEI NIH HHS [EY05110] Funding Source: Medline; NIDDK NIH HHS [DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1993, DIABETES, V42, pA88; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAGLIERO E, 1988, J CLIN INVEST, V82, P735, DOI 10.1172/JCI113655; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DWORKIN MB, 1980, DEV BIOL, V76, P449, DOI 10.1016/0012-1606(80)90393-0; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GAWLER D, 1986, NATURE, V323, P182; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; KESSLER II, 1971, AM J MED, V51, P715, DOI 10.1016/0002-9343(71)90299-3; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MNIATIS T, 1982, MOL CLONING, P197; MUONA P, 1991, DIABETES, V40, P605, DOI 10.2337/diabetes.40.5.605; NISHIO Y, 1988, DIABETES, V37, P1181, DOI 10.2337/diabetes.37.9.1181; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAPP G, 1988, BIOL CHEM H-S, V369, P247, DOI 10.1515/bchm3.1988.369.1.247; REYNET C, 1993, DIABETES, V42, pA94; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; WEISSBACH H, 1976, ANNU REV BIOCHEM, V45, P191, DOI 10.1146/annurev.bi.45.070176.001203; WILLIAMS B, 1992, DIABETES, V41, P1464, DOI 10.2337/diabetes.41.11.1464; WILLIAMS JG, 1979, J MOL BIOL, V129, P19, DOI 10.1016/0022-2836(79)90056-1; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; ZIYADEH FN, 1990, AM J PHYSIOL, V259, pF704, DOI 10.1152/ajprenal.1990.259.4.F704	29	88	90	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					103	106		10.1096/fasebj.8.1.8299882	http://dx.doi.org/10.1096/fasebj.8.1.8299882			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299882				2022-12-25	WOS:A1994MV28200015
J	ROONEY, TA; HAGER, R; STUBBS, CD; THOMAS, AP				ROONEY, TA; HAGER, R; STUBBS, CD; THOMAS, AP			HALOTHANE REGULATES G-PROTEIN-DEPENDENT PHOSPHOLIPASE-C ACTIVITY IN TURKEY ERYTHROCYTE-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; GH3 PITUITARY-CELLS; ADENYLATE-CYCLASE; GUANINE-NUCLEOTIDES; ADRENERGIC-RECEPTOR; GENERAL-ANESTHESIA; CALCIUM CURRENT; MUSCLE-CELLS; RAT-HEART; ACTIVATION	The ability of halothane to stimulate phospholipase C (PLC) was examined in turkey erythrocyte membranes prepared from [H-3]inositol-labeled turkey erythrocytes by measuring [H-3]inositol phosphate formation ([H-3]InsP) in the presence and absence of G-protein activation. In the presence of guanosine 5'-3-O-(thio)triphosphate) (GTPgammaS), halothane (0.5-10 mM) caused a dose-dependent activation of PLC. The EC50 value for halothane-induced PLC activation was 2.8 +/- 0.3 mM. Halothane (0.1-30 mM) had no effect on PLC activity in the absence of G-protein activation and did not affect Ca2+-dependent PLC activity. The activation of PLC by GTPgammaS occurred after an initial lag period of 60 s which was followed by a linear increase in [H-3]InsP. Halothane dose-dependently decreased the lag period for GTPgammaS-induced PLC activation (minimal value 15 s) and increased the rate of [H-3]InsP formation at all time points following this lag. As a result, halothane shifted the EC50 value for GTPgammaS-induced PLC activation to the left (4-fold) and increased its maximal response. Halothane also caused a dose-dependent activation of PLC in the presence of AlF4-. Half-maximal stimulation of AlF4--activated PLC occurred with an EC50 value of 2.9 +/- 0.4 mM halothane, which is similar to the halothane dose giving half-maximal stimulation of PLC in the presence of GTPgammaS. At low doses (0.1-0.3 mM) halothane inhibited both isoproterenol- and adenosine 5'-O-(2-thiodiphosphate) (ADPbetaS)-induced [H-3]InsP formation, whereas at higher concentrations it stimulated PLC independent of the presence of these agonists. At concentrations chosen to reflect their different membrane/buffer partition coefficients, both hexanol (5 mM) and benzyl alcohol (20 mM) fluidized turkey erythrocyte membranes to the same degree as halothane (5 mM). However, these agents had no effect on GTPgammaS- or AlF4-induced PLC activity, indicating that halothane-induced PLC activation was not secondary to changes in bulk lipid fluidity properties. Halothane also stimulated [H-3]inositol bisphosphate and [H-3]inositol trisphosphate formation in intact erythrocytes. These data demonstrate that the anesthetic halothane can stimulate G-protein-dependent PLC activity and modify the responsiveness of this signaling system to activation by receptor-linked agonists.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,RM 271 JAH,1020 LOCUST ST,PHILADELPHIA,PA 19107	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA07215, AA08022] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA008022, R01AA008022] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BEAN BP, 1981, J GEN PHYSIOL, V77, P233, DOI 10.1085/jgp.77.3.233; BEECHEM JM, 1989, CHEM PHYS LIPIDS, V50, P237, DOI 10.1016/0009-3084(89)90052-2; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOSNJAK ZJ, 1991, ANESTHESIOLOGY, V74, P340, DOI 10.1097/00000542-199102000-00022; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1989, J BIOL CHEM, V264, P13917; BOYER JL, 1989, J BIOL CHEM, V264, P884; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; DANIELL LC, 1988, J PHARMACOL EXP THER, V245, P1; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FRANKS NP, 1987, TRENDS PHARMACOL SCI, V8, P169, DOI 10.1016/0165-6147(87)90160-X; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; HARDEN TK, 1987, J BIOL CHEM, V262, P9057; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HAYDON DA, 1983, J PHYSIOL-LONDON, V341, P429, DOI 10.1113/jphysiol.1983.sp014814; HERRINGTON J, 1991, J NEUROSCI, V11, P2226; IAIZZO PA, 1990, CELL CALCIUM, V11, P515, DOI 10.1016/0143-4160(90)90027-R; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLIP A, 1990, J PHARMACOL EXP THER, V254, P552; LAKOWICZ JR, 1985, BIOPHYS CHEM, V21, P61, DOI 10.1016/0301-4622(85)85007-9; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; NAKAHIRO M, 1989, FASEB J, V3, P1850, DOI 10.1096/fasebj.3.7.2541038; NARAYANAN TK, 1988, BIOCHEM PHARMACOL, V37, P1219, DOI 10.1016/0006-2952(88)90774-5; NICOLL RA, 1982, SCIENCE, V217, P1055, DOI 10.1126/science.7112112; PUIL E, 1990, J PHARMACOL EXP THER, V255, P955; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; ROONEY TA, 1989, J BIOL CHEM, V264, P6817; SCHRAMM M, 1975, J BIOL CHEM, V250, P2232; SEEMAN P, 1972, PHARMACOL REV, V24, P583; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SILL JC, 1991, MOL PHARMACOL, V40, P1006; STERN RC, 1991, J NEUROSCI, V11, P2217; STUBBS CD, 1980, BIOCHEMISTRY-US, V19, P2756, DOI 10.1021/bi00553a034; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V775, P374, DOI 10.1016/0005-2736(84)90193-7; STUBBS CD, 1983, ESSAYS BIOCHEM, V19, P1; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WHEELER DM, 1988, ANESTHESIOLOGY, V69, P578, DOI 10.1097/00000542-198810000-00019	46	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15550	15556						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340382				2022-12-25	WOS:A1993LN30500037
J	HURLBURT, BK; YANOFSKY, C				HURLBURT, BK; YANOFSKY, C			ANALYSIS OF HETERODIMER FORMATION BY THE ESCHERICHIA-COLI TRP REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL GENE; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; BINDING; APOREPRESSOR; DNA; PURIFICATION; RESOLUTION; EXPRESSION; K-12	The trp repressor of Escherichia coli is a dimeric DNA-binding protein that regulates transcription of several operons concerned with tryptophan metabolism. Although heterodimer formation between mutant and wild type subunits occurs readily in vivo, comparable heterodimers could be formed in vitro only under extreme conditions. To explain this difference we analyzed trp repressor dimer formation and dissociation using an in vitro transcription/translation system. Nascent wild type or mutant repressor polypeptides, synthesized in the presence of an excess of a second repressor, were invariably incorporated into heterodimers. In contrast, previously synthesized and assembled wild type dimers appeared to be refractory to dissociation, since they did not form heterodimers. However, previously synthesized mutant dimeric repressors that were defective in tryptophan binding readily dissociated and formed heterodimers. We noted that the ability of a dimeric repressor to dissociate under our conditions correlated inversely with its affinity for tryptophan. Consistent with this conclusion, we found that dissociation of the wild type aporepressor (no added tryptophan) was appreciably more rapid than dissociation of the tryptophan-saturated wild type repressor.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011980] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM11980] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH C, 1991, EUR J BIOCHEM, V202, P53, DOI 10.1111/j.1432-1033.1991.tb16344.x; ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; CAREY J, 1989, J BIOL CHEM, V264, P1941; GRADDIS TJ, 1988, PROTEINS, V4, P173, DOI 10.1002/prot.340040304; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HURLBURT BK, 1992, NUCLEIC ACIDS RES, V20, P337, DOI 10.1093/nar/20.2.337; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KLIG LS, 1988, J MOL BIOL, V202, P769, DOI 10.1016/0022-2836(88)90557-8; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SIGLER PB, 1992, TRANSCRIPTIONAL REGU, P475; SQUIRES CL, 1975, J MOL BIOL, V92, P93, DOI 10.1016/0022-2836(75)90093-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZUBAY G, 1970, LACTOSE OPERON, P375; ZURAWSKI G, 1981, J MOL BIOL, V145, P47, DOI 10.1016/0022-2836(81)90334-X	22	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14794	14798						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325857				2022-12-25	WOS:A1993LL75900042
J	JANKOWSKI, JA; SCHROEDER, TJ; CIOLKOWSKI, EL; WIGHTMAN, RM				JANKOWSKI, JA; SCHROEDER, TJ; CIOLKOWSKI, EL; WIGHTMAN, RM			TEMPORAL CHARACTERISTICS OF QUANTAL SECRETION OF CATECHOLAMINES FROM ADRENAL-MEDULLARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL CHROMAFFIN CELLS; EXOCYTOTIC FUSION PORE; SEA-URCHIN EGGS; GRANULE MATRIX; CHROMOGRANIN-A; CONFORMATIONAL CHANGE; MEMBRANE-FUSION; AGGREGATION; PROTEIN; BINDING	Exocytotic release of vesicular catecholamine from individual bovine adrenal medullary cells was detected with carbon fiber microelectrodes. Release was elicited from cells permeabilized with 20 muM digitonin in extracellular solutions of pH 5.5, 7.4, or 8.2, and with 100 muM nicotine at pH 7.4. Release detected amperometrically with a 6-mum radius electrode and 1-mum cell-electrode spacing was qualitatively similar for each pH and stimulus. However, amperometric detection with smaller electrodes (radius = 1 mum), cyclic voltammetry, or increased cell-electrode spacing with the larger electrode all resulted in a severe reduction in size and frequency of spikes detected at pH 5.5. Thus, the existence of a steep catecholamine concentration gradient at the cell surface is necessary to cause dissociation of the vesicular matrix at low extracellular pH. At an extracellular pH of 7.4, the distribution of amperometric spike widths measured with a 1-mum cell-electrode spacing was found to be inconsistent with that predicted for diffusional dispersion during transport from the cell surface to the electrode. Both of these results agree with the hypotheses that the chromaffin vesicle matrix normally exists in an aggregated state that can be dissociated by a chemical driving force. Some of the spikes exhibit a pre-spike feature. These were present more often following permeabilization in acidic pH as opposed to more alkaline solutions, and were most prevalent following exposure to nicotine at pH 7.4. The variability in the occurrence of the pre-spike feature suggests it originates from free catecholamine within the vesicle, since the molar fraction bound by the vesicular matrix is regulated by the pH-dependent conformation and Ca2+-dependent binding affinity of chromogranin A, a major protein in the vesicle.	UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill								ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; CASEY RP, 1977, BIOCHEMISTRY-US, V16, P972, DOI 10.1021/bi00624a025; CHANDLER DE, 1989, J CELL BIOL, V109, P1269, DOI 10.1083/jcb.109.3.1269; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CIOLKOWSKI EL, 1992, J AM CHEM SOC, V114, P2815, DOI 10.1021/ja00034a009; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DUNN LA, 1983, J BIOL CHEM, V258, P4989; ENGSTROM RC, 1987, ANAL CHEM, V59, P2005, DOI 10.1021/ac00142a024; GERHARDT G, 1982, ANAL CHEM, V54, P2618, DOI 10.1021/ac00251a054; GORR SU, 1988, BONE MINER, V4, P17; HELLE KB, 1973, BIOCHIM BIOPHYS ACTA, V318, P181, DOI 10.1016/0005-2736(73)90112-0; HOLZ RW, 1983, J BIOL CHEM, V258, P7506; JANKOWSKI JA, 1992, J BIOL CHEM, V267, P18329; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; KAWAGOE KT, 1991, ANAL CHEM, V63, P1589, DOI 10.1021/ac00015a017; KNIGHT DE, 1985, J MEMBRANE BIOL, V83, P147, DOI 10.1007/BF01868746; KOPELL WN, 1982, J BIOL CHEM, V257, P5707; KUIJPERS GAJ, 1989, J BIOL CHEM, V264, P698; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; MERKLE CJ, 1991, DEV BIOL, V148, P429, DOI 10.1016/0012-1606(91)90262-2; MONCK JR, 1991, BIOPHYS J, V59, P39, DOI 10.1016/S0006-3495(91)82196-8; MONCK JR, 1992, J CELL BIOL, V119, P1395, DOI 10.1083/jcb.119.6.1395; MONCK JR, 1990, P NATL ACAD SCI USA, V87, P7804, DOI 10.1073/pnas.87.20.7804; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OCONNOR DT, 1991, BRAIN RES, V567, P188, DOI 10.1016/0006-8993(91)90795-W; PLETSCHE.A, 1973, BRAIN RES, V62, P317, DOI 10.1016/0006-8993(73)90692-6; SCHAFER T, 1987, BIOSCIENCE REP, V7, P269, DOI 10.1007/BF01121448; SCHMIDT W, 1983, EUR J CELL BIOL, V32, P31; SCHROEDER TJ, 1992, ANAL CHEM, V64, P3077, DOI 10.1021/ac00048a003; SEN R, 1979, BIOCHIM BIOPHYS ACTA, V587, P75, DOI 10.1016/0304-4165(79)90222-8; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STREIN TG, 1992, ANAL CHEM, V64, P1368, DOI 10.1021/ac00037a012; TERAKAWA S, 1991, NEUROSCI LETT, V123, P82, DOI 10.1016/0304-3940(91)90163-N; UNVAS B, 1977, ACTA PHYSL SCAND, V99, P476; UNVAS B, 1980, ACTA PHYSL SCAND, V109, P345; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; VIVEROS OH, 1969, SCIENCE, V165, P911, DOI 10.1126/science.165.3896.911; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WILSON SP, 1983, J BIOL CHEM, V258, P4994; WINKLER H, 1977, NEUROSCIENCE, V2, P657, DOI 10.1016/0306-4522(77)90022-7; WINKLER H, 1976, NEUROSCIENCE, V1, P65, DOI 10.1016/0306-4522(76)90001-4; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1991, J BIOL CHEM, V266, P7740; ZIMMERBERG J, 1987, BIOSCIENCE REP, V7, P251, DOI 10.1007/BF01121447; [No title captured]	53	123	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14694	14700						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325848				2022-12-25	WOS:A1993LL75900028
J	NAKAYAMA, M; YAZAKI, K; KUSANO, A; NAGATA, K; HANAI, N; ISHIHAMA, A				NAKAYAMA, M; YAZAKI, K; KUSANO, A; NAGATA, K; HANAI, N; ISHIHAMA, A			STRUCTURE OF MOUSE MX1 PROTEIN - MOLECULAR ASSEMBLY AND GTP-DEPENDENT CONFORMATIONAL CHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS; GENE; RESISTANCE; CELLS; SEQUENCE; CLONING; NUCLEI; FAMILY	Mouse Mx1 protein is an interferon-inducible nuclear protein and confers resistance to influenza virus infection. The Mx1 protein purified from interferon-induced A2G mouse liver exhibited GTPase activity as did the Mx1 protein purified from the Mx1 cDNA-expressing Escherichia coli (Nakayama, M., Nagata, K., Kato, A., and Ishihama, A. (1991) J. Biol. Chem. 266, 21404-21408; Nakayama, M., Nagata, K., and Ishihama, A. (1992) Virus Res. 22, 227-234). The Mx1 protein purified from both mouse liver and Mx1-cDNA expressing E. coli was found to exist as assembled polymeric states judged from gel filtration pattern. By making a set of deletion derivatives of the Mx1 cDNA, the main motif for self-assembly of the Mx1 protein was mapped between amino acid residues 51-99. This motif is highly conserved not only in the Mx family of proteins but also in Mx-related proteins. The polymeric form of Mx1 from E. coli was observed as ''horseshoe''-like structure by negative staining microscopy. When the Mx1 protein was incubated with GTP, this horseshoe structure was transformed to larger and tightly stacked helical forms. Electron microscopic analysis of immunostained liver of the interferon-induced mice indicated that the Mx1 protein exists in nuclei, forming giant complexes of about half the size of nucleoli.	NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN; NAGOYA UNIV,FAC SCI,DEPT BIOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,TOKYO 113,JAPAN; TOKYO RES LABS,DIV IMMUNOL,TOKYO 194,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Nagoya University; Tokyo Metropolitan Institute of Medical Science								AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; ARNHEITER H, 1988, EMBO J, V7, P1315, DOI 10.1002/j.1460-2075.1988.tb02946.x; ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; BRONI B, 1990, J VIROL, V64, P6335, DOI 10.1128/JVI.64.12.6335-6340.1990; Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; DREIDING P, 1985, VIROLOGY, V140, P192, DOI 10.1016/0042-6822(85)90460-X; HORISBERGER MA, 1990, J VIROL, V64, P1171, DOI 10.1128/JVI.64.3.1171-1181.1990; JONES BA, 1992, GENE DEV, V6, P386; KOLB E, 1992, J VIROL, V66, P1709, DOI 10.1128/JVI.66.3.1709-1716.1992; KRUG RM, 1985, J VIROL, V56, P201, DOI 10.1128/JVI.56.1.201-206.1985; MEIER E, 1988, J VIROL, V62, P2386, DOI 10.1128/JVI.62.7.2386-2393.1988; MEIER E, 1990, J VIROL, V64, P6263, DOI 10.1128/JVI.64.12.6263-6269.1990; MELEN K, 1992, J BIOL CHEM, V267, P25898; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1992, VIRUS RES, V22, P227, DOI 10.1016/0168-1702(92)90054-D; NOTEBORN M, 1987, J INTERFERON RES, V7, P657, DOI 10.1089/jir.1987.7.657; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAVLOVIC J, 1990, J VIROL, V64, P3379; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; STAEHELI P, 1989, MOL CELL BIOL, V9, P3117, DOI 10.1128/MCB.9.7.3117; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STAEHELI P, 1988, MOL CELL BIOL, V8, P4524, DOI 10.1128/MCB.8.10.4524; STAEHELI P, 1990, ADV VIRUS RES, V38, P140; WEITZ G, 1989, J INTERFERON RES, V9, P679, DOI 10.1089/jir.1989.9.679; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	25	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15033	15038						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325879				2022-12-25	WOS:A1993LL75900073
J	SHINITZKY, M; FRIEDMAN, P; HAIMOVITZ, R				SHINITZKY, M; FRIEDMAN, P; HAIMOVITZ, R			FORMATION OF 1,3-CYCLIC GLYCEROPHOSPHATE BY THE ACTION OF PHOSPHOLIPASE-C ON PHOSPHATIDYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS; PHOSPHATIDYLINOSITOL; PURIFICATION; PHOSPHATE; MESSENGER	The action of phospholipase C (PLC) from Bacillus cereus on phosphatidylglycerol (PG), derived from egg yolk phosphatidylcholine (PC), was examined in an ether-water mixture. The PLC cleavage of PG and PC followed a Michaelis-Menten kinetics with apparent V(max) values per 1 mug enzyme of 0.26 and 0.91 mumol.min-1 and K(m) values of 10 and 12 mM, respectively. When the same enzymic reaction was carried out in minimally buffered aqueous solution of 1% Triton X-100, the decrease in pH with respect to phospholipid cleavage was as expected with PC but much less pronounced with PG. This could be accounted for by the formation of a cyclic glycerophosphate, rather than alpha-glycerophosphate, in the PLC hydrolysis of PG. Examination of the chemical nature of the water-soluble product of PG by phosphorus nuclear magnetic resonance (P-31 NMR) revealed a single band at 2.31 ppm, while the bands of alpha-glycerophosphate and beta-glycerophosphate appeared at 5.12 and 4.57 ppm, respectively. Basic hydrolysis of the phospholipase cleavage product of PG (0.1 M NaOH for 1 min at 80-degrees-C) followed by neutralization shifted its P-31 NMR band to 5.18 ppm, which practically coincided with that of alpha-glycerophosphate. Analogous experiments were carried out with PG labeled with H-3 at the carbon 2 of the glycerol headgroup ([H-3]PG). Autoradiography of thin layer chromatography (TLC) of the [H-3]PG enzymic hydrolyzate displayed a single H-3-labeled compound, which could be converted to alpha-glycerophosphate by basic hydrolysis. These results strongly suggest that the phosphate headgroup of PG is cleaved off by PLC as 1,3-cyclic glycerophosphate. A series of PLC experiments with phosphatidyl dihydroxyacetone and phosphatidyl 1,3-propanediol as model substrates supported this assignment. Two-dimensional homonuclear H-1 NMR correlated spectra as well as infrared spectra carried out on the isolated sodium salt of this product could further confirm such a structure. The unique structure and chemical nature of 1,3-cyclic glycerophosphate may bear a distinct physiological function.			SHINITZKY, M (corresponding author), WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL.							BAILLY O, 1922, B SOC CHIM FR, V31, P848; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACKBUR.GM, 1971, TETRAHEDRON, V27, P2903, DOI 10.1016/S0040-4020(01)98082-2; BOLCKINO SB, 1985, J BIOL CHEM, V260, P14201; DAWSON RMC, 1971, BIOCHEM J, V122, P605, DOI 10.1042/bj1220605; Dennis EA, 1983, ENZYMES, P307; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; Eibl H, 1981, Methods Enzymol, V72, P632; EXTON JH, 1990, J BIOL CHEM, V265, P1; FRIEDMAN P, 1992, THESIS WEIZMANN I RE; GALLAGHER G, 1987, METHODS STEREOCHEMIC, V8, P297; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HAVERKATE F, 1965, BIOCHIM BIOPHYS ACTA, V106, P78; IKEZAWA H, 1978, BIOCHIM BIOPHYS ACTA, V528, P247; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; KHORANA HG, 1957, J AM CHEM SOC, V79, P430, DOI 10.1021/ja01559a054; KHORANA HG, 1961, SOME RECENT DEV CHEM, P44; KUMAMOTO J, 1956, J AM CHEM SOC, V78, P4858, DOI 10.1021/ja01600a012; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Little C., 1981, METHOD ENZYMOL, V71, P725; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; OTNAESS AB, 1977, EUR J BIOCHEM, V79, P459, DOI 10.1111/j.1432-1033.1977.tb11828.x; OTTOLENGHI AC, 1969, METHOD ENZYMOL, V14, P188; ROBERTS MF, 1978, J BIOL CHEM, V253, P1252; ROSS TS, 1986, J BIOL CHEM, V261, P1119; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; VOLWERK JJ, 1989, J CELL BIOCHEM, V39, P315, DOI 10.1002/jcb.240390311; WILSON DB, 1985, J BIOL CHEM, V260, P3496; Zwaal R F, 1974, Methods Enzymol, V32, P154	29	22	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14109	14115						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314778				2022-12-25	WOS:A1993LJ82500050
J	STRONGIN, AY; MARMER, BL; GRANT, GA; GOLDBERG, GI				STRONGIN, AY; MARMER, BL; GRANT, GA; GOLDBERG, GI			PLASMA MEMBRANE-DEPENDENT ACTIVATION OF THE 72-KDA TYPE-IV COLLAGENASE IS PREVENTED BY COMPLEX-FORMATION WITH TIMP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-3 STROMELYSIN; SKIN FIBROBLAST PROCOLLAGENASE; 72 KDA PROGELATINASE; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; SEQUENCE IDENTIFICATION; PURIFICATION; EXPRESSION; MECHANISMS; CELLS	Human 72-kDa type IV collagenase (72T4Cl) is secreted as a proenzyme that can form a specific stoichiometric complex with the tissue inhibitor of metalloproteases TIMP-2 via interaction with the carboxyl-terminal domain of the enzyme. Both complexed an free enzymes can be activated by treatment with organomercurials. The mechanism of the 72T4Cl activation under physiological conditions is not known. Here we describe a ''plasma membrane-dependent'' activation of inhibitor-free 72T4Cl and identify the first conversion intermediate as a 64-kDa species resulting from cleavage of the Asn37-Leu peptide bond in the presence of plasma membranes from 12-O-tetradecanoylphorbol-13-acetate-induced HT1080 cells. This reaction is specific for 72T4Cl in that a closely related proenzyme (92-kDa type IV collagenase) is resistant to activation under the same conditions. Formation of the 72T4Cl.TIMP-2 complex inhibits activation at the level of the initial Asn37-Leu cleavage. Addition of TIMP-1 has no effect on this reaction, but blocks the autocatalytic conversion of the Leu38 intermediate into a 62-kDa active enzyme with an amino-terminal Tyr81. Membrane-dependent activation of 72T4Cl is competitively inhibited in the presence of a 26-kDa peptide derived from the carboxyl-terminal domain of the enzyme. The results suggest that interaction of the carboxyl-terminal domain of the enzyme with a membrane-associated component(s) causes initiation of enzyme activation through an autoproteolytic mechanism.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	STRONGIN, AY (corresponding author), WASHINGTON UNIV,SCH MED,DIV DERMATOL,ST LOUIS,MO 63110, USA.		Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NIAMS NIH HHS [T32 AR07284, R01 AR39472, R01 AR40618] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039472, R01AR040618, T32AR007284] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROWN PD, 1990, CANCER RES, V50, P6184; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRISCH SM, 1990, ONCOGENE, V5, P75; Goldberg G I, 1992, Matrix Suppl, V1, P25; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GOLDBERG GI, 1991, REGULATORY MECHANISM, P421; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KESKIOJA J, 1992, EXP CELL RES, V202, P471, DOI 10.1016/0014-4827(92)90101-D; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	34	319	332	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14033	14039						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314771				2022-12-25	WOS:A1993LJ82500040
J	WANG, L; LIN, XH; CUI, DF; WANG, ZY; CHI, CW				WANG, L; LIN, XH; CUI, DF; WANG, ZY; CHI, CW			ASSIGNMENT OF THE BINDING-SITE FOR TISSUE-PLASMINOGEN ACTIVATOR ON HUMAN FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-INSOLUBLE GLOBULIN; CROSS-LINKING; COLLAGEN; FRAGMENTS; PROTEIN; FIBRIN; INVITRO; PLASMA; CHAIN; CELLS	The tissue-type plasminogen activator (t-PA) has been found to bind reversibly to human fibronectin (Fn). To locate the binding site on Fn for t-PA, the Fn was de graded with N-tosyl-L-phenylalanyl chloromethyl ketone treated trypsin, and the resulting fragments were monitored by the enzyme-linked immunosorbent assay method for t-PA binding activities. A 20-kDa fragment with t-PA binding activity was identified, separated, and purified. It was subjected to further degradation with Staphylococcus aureus proteinase V8. An active 10-kDa fragment was finally purified by reverse-phase high pressure liquid chromatography on a C-3 column. The dissociation constants of the binding of Fn and the 10-kDa fragment to t-PA were estimated by Scatchard plot to be 1.13 x 10(-8) and 2.08 x 10(-8) M, respectively. The 10- kDa fragment was sequenced and proved to be located at the 8-9th domains of type I homology of Fn. Based on the structural analysis of the 8-9th domains, a heptadecapeptide corresponding to the sequence Thr(535)-Gly(551) Of Fn, which resided at the large disulfide loop of domain (I-9), was designed and synthesized. Both the 10-kDa fragment and the synthetic peptide could com petitively inhibit the binding of Fn to t-PA. The synthetic peptide showed about one-tenth of the binding activity of Fn to BPA with a dissociation constant of 1.35 x 10(-7) M and was proved to be the binding region of Fn for t-PA. In addition, like the intact Fn, both the 10-kDa fragment and the synthetic peptide could remarkably enhance the amidolytic activity of t-PA in a dose-dependent manner,as shown by using S-2288 as a chromogenic substrate.	ACAD SINICA, SHANGHAI INST BIOCHEM, SHANGHAI 200031, PEOPLES R CHINA; SHANGHAI MED UNIV 2, SHANGHAI INST HEMATOL, SHANGHAI 200025, PEOPLES R CHINA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University								BANYAI L, 1983, FEBS LETT, V163, P37, DOI 10.1016/0014-5793(83)81157-0; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DODD I, 1986, THROMB HAEMOSTASIS, V55, P94; EMMERLING MR, 1981, BIOCHEMISTRY-US, V20, P3242, DOI 10.1021/bi00514a040; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GILBOA N, 1985, THROMB HAEMOSTASIS, V54, P639; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HYNES RO, 1976, BIOCHIM BIOPHYS ACTA, V458, P73, DOI 10.1016/0304-419X(76)90015-9; HYNES RO, 1990, FIBRONECTIN, P5; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; INGHAM KC, 1988, J BIOL CHEM, V263, P4624; KESKIOJA J, 1980, J CELL BIOL, V85, P527, DOI 10.1083/jcb.85.3.527; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; LITVINOVICH SV, 1991, J MOL BIOL, V217, P563, DOI 10.1016/0022-2836(91)90758-X; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; MENZEL EJ, 1981, FEBS LETT, V129, P188, DOI 10.1016/0014-5793(81)80787-9; MOSESSON MW, 1975, BIOCHIM BIOPHYS ACTA, V386, P509, DOI 10.1016/0005-2795(75)90294-9; MOSHER DF, 1986, ANN NY ACAD SCI, V485, P264, DOI 10.1111/j.1749-6632.1986.tb34588.x; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; NIEUWENHUIZEN W, 1988, EUR J BIOCHEM, V174, P163, DOI 10.1111/j.1432-1033.1988.tb14077.x; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SEKIGUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P2661, DOI 10.1073/pnas.77.5.2661; STEMBERGER A, 1976, H-S Z PHYSIOL CHEM, V357, P1003; VARTIO T, 1982, EUR J BIOCHEM, V123, P223, DOI 10.1111/j.1432-1033.1982.tb19757.x; VERHEIJEN JH, 1985, THROMB RES, V39, P281, DOI 10.1016/0049-3848(85)90223-3; XUE JC, 1991, ACTA BIOCH BIOPH SIN, V22, P281; ZARDI L, 1979, CELL, V18, P649, DOI 10.1016/0092-8674(79)90120-X	32	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4332	4336						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308001				2022-12-25	WOS:A1994MW98900068
J	YADAV, SP; BREW, K; MAJERCIK, MH; PUETT, D				YADAV, SP; BREW, K; MAJERCIK, MH; PUETT, D			A LABEL SELECTION APPROACH TO ASSESS THE ROLE OF INDIVIDUAL AMINO-GROUPS IN HUMAN CHORIOGONADOTROPIN RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LEYDIG TUMOR-CELLS; SITE-DIRECTED MUTAGENESIS; BETA-SUBUNIT; ALPHA-SUBUNIT; GLYCOPROTEIN HORMONES; BIOLOGICAL-ACTIVITY; HUMAN CHORIOTROPIN; TERMINAL REGION; LUTROPIN	Human choriogonadotropin (hCG) was trace-labeled with [H-3]acetic anhydride and then incubated with transformed murine Leydig cells (MA-10). The bound hormone was recovered, subunits (alpha and beta) were separated and then cleaved, and the peptides were purified by high performance liquid chromatography. Analysis of the labeling patterns of peptides from the initial preparation and the bound hCG fraction enabled us to determine the protection factor of several amino groups, which is a measure of the effects of acetylation on receptor binding. The largest protection factors, indicating lower labeling in the bound fraction, were found on beta and involved the alpha-amino group/Lys(2) (analyzed together) and Lys(104), which exhibited 6 fold and 5-fold selections against binding, respectively. Thus, acetylation at either of these amino groups does not prevent binding but results in selection against hormone association with receptor. Other amino groups were analyzed (e.g. Lys(122) on beta; the alpha-amino group and lysines 44/45 (analyzed as a pair), 51, and 75 on alpha), and the selection factors indicated either no change or only modest changes (2-fold) in selection for or against binding. These results indicate that the alpha-amino group/Lys(2) and Lys(104) of the hormone-specific beta subunit participate, either directly or indirectly, in receptor binding.	UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOLEC BIOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, REPROD SCI & ENDOCRINOL LABS, MIAMI, FL 33101 USA	University System of Georgia; University of Georgia; University of Miami; University of Miami			Brew, Keith/W-1643-2019; Brew, Keith/A-6746-2009	Brew, Keith/0000-0003-1306-1032	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033973] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07129] Funding Source: Medline; NIDDK NIH HHS [DK33973] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1974, BIOCHIM BIOPHYS ACTA, V371, P203, DOI 10.1016/0005-2795(74)90169-X; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; AZUMA C, 1990, J MOL ENDOCRINOL, V5, P97, DOI 10.1677/jme.0.0050097; BIRKEN S, 1987, ENDOCRINOLOGY, V121, P657, DOI 10.1210/endo-121-2-657; BIRKEN S, 1986, J BIOL CHEM, V261, P719; Bosshard H R, 1979, Methods Biochem Anal, V25, P273, DOI 10.1002/9780470110454.ch4; BOUSFIELD GR, 1988, J BIOL CHEM, V263, P12602; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHARLESWORTH MC, 1987, J BIOL CHEM, V262, P13409; CHEN F, 1991, J BIOL CHEM, V266, P19357; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN F, 1991, BIOCHEMISTRY-US, V30, P10171, DOI 10.1021/bi00106a014; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHEN WY, 1991, J BIOL CHEM, V266, P6246; CHENG KW, 1973, J BIOL CHEM, V248, P7930; CHIN D, 1989, J BIOL CHEM, V264, P15367; COMBARNOUS Y, 1992, ENDOCR REV, V13, P670, DOI 10.1210/edrv-13-4-670; ELDEIRY S, 1989, MOL ENDOCRINOL, V3, P1523, DOI 10.1210/mend-3-10-1523; ERICKSON LD, 1990, ENDOCRINOLOGY, V126, P2555, DOI 10.1210/endo-126-5-2555; Gordon WL, 1985, LUTEINIZING HORMONE, P173; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HUANG JN, 1993, MOL CELL ENDOCRINOL, V90, P211, DOI 10.1016/0303-7207(93)90154-C; HUANG JN, 1993, J BIOL CHEM, V268, P9311; JACKSON AE, 1987, PROTEINS, V2, P202, DOI 10.1002/prot.340020305; KAPLAN H, 1971, BIOCHEM J, V124, P289, DOI 10.1042/bj1240289; KEUTMANN HT, 1988, BIOCHEMISTRY-US, V27, P8939, DOI 10.1021/bi00425a010; KEUTMANN HT, 1992, MOL CELL ENDOCRINOL, V86, pC1, DOI 10.1016/0303-7207(92)90168-6; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KEUTMANN HT, 1992, PEPTIDES CHEM BIOL, P74; LLOSA PDL, 1974, BIOCHIM BIOPHYS ACTA, V342, P97, DOI 10.1016/0005-2795(74)90110-X; LUSTBADER JW, 1993, ENDOCR REV, V14, P291, DOI 10.1210/er.14.3.291; MAJERCIK MH, 1989, STEROIDS, V54, P627, DOI 10.1016/0039-128X(89)90085-8; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MERZ WE, 1984, SECRETION ACTION GON, P59; PARSONS TF, 1984, ENDOCRINOLOGY, V114, P2223, DOI 10.1210/endo-114-6-2223; PUETT D, 1989, J PROTEIN CHEM, V8, P779, DOI 10.1007/BF01024902; REED DK, 1991, J BIOL CHEM, V266, P14251; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SALESSE R, 1990, MOL CELL ENDOCRINOL, V68, P113, DOI 10.1016/0303-7207(90)90183-9; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; XIA H, 1993, J MOL ENDOCRINOL, V10, P337, DOI 10.1677/jme.0.0100337; XIA HY, 1993, MOL CELL ENDOCRINOL, V92, pR1, DOI 10.1016/0303-7207(93)90086-Y; YADAV S, 1990, J BIOL CHEM, V265, P14163; YADAV SP, 1991, J BIOL CHEM, V266, P698; YADAV SP, 1991, FASEB J, V5, pA1521; YOO J, 1991, J BIOL CHEM, V266, P17741; YOO JK, 1993, J BIOL CHEM, V268, P13034	48	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3991	3998						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307955				2022-12-25	WOS:A1994MW98900017
J	LI, BY; RAMAKRISHNAN, S				LI, BY; RAMAKRISHNAN, S			RECOMBINANT HYBRID TOXIN WITH DUAL ENZYMATIC-ACTIVITIES - POTENTIAL USE IN PREPARING HIGHLY EFFECTIVE IMMUNOTOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; DIPHTHERIA-TOXIN; PSEUDOMONAS EXOTOXIN; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; PROTEIN-SYNTHESIS; FRAGMENT-A; DOMAIN-II; EXPRESSION; CELLS	Bacterial toxins and ribosomal inhibitory proteins isolated from plants are used to prepare tumor-specific cytotoxic conjugates. The ability of these conjugates to kill tumor cells depends on binding, internalization, translocation to cytoplasm, and translation inhibition. Modulation of any one of these processes can improve cytotoxicity. Since bacterial and plant toxins act at a distinct step in translation, a combination of their activities could be more effective. Therefore, a chimeric protein was prepared by genetically fusing the coding region of the ricin A chain (RTA) and the fragment A of diphtheria toxin (DTA). The hybrid protein (RTA-DTA) expressed in bacteria retained the N-glycosidase activity of the RTA and ADP-ribosylation activity of the DTA. The hybrid toxin was more potent than the ricin A chain (11-fold) and the diphtheria toxin (50-fold) in inhibiting cell-free translation. Immunotoxin made with the hybrid toxin was about 100- and 1000-fold more effective than RTA or DTA conjugate, respectively, in inhibiting tumor cell growth in vitro. These results indicate that the hybrid toxin with dual activities could be useful in preparing potent immunotoxins with better anti-tumor cell activity.	UNIV MINNESOTA, DEPT PHARMACOL, 3-249 MILLARD HALL, 435 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [CA 48068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BJORN MJ, 1985, CANCER RES, V45, P1214; BLUM JS, 1991, J BIOL CHEM, V266, P22091; CASELLAS P, 1984, J BIOL CHEM, V259, P9359; CHAUDHARY VK, 1988, P NATL ACAD SCI USA, V85, P2939, DOI 10.1073/pnas.85.9.2939; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB PW, 1992, SEMIN HEMATOL, V29, P6; ENDO Y, 1987, J BIOL CHEM, V262, P8128; FRANKEL A, 1989, MOL CELL BIOL, V9, P415, DOI 10.1128/MCB.9.2.415; GILL DM, 1971, J BIOL CHEM, V246, P1492; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; GRIFFIN TW, 1992, J IMMUNOTHER, V11, P12, DOI 10.1097/00002371-199201000-00002; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JANSEN B, 1993, LEUKEMIA, V7, P290; JOHNSON VG, 1991, INTRACELLULAR TRAFFI; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; LEWIN B, 1990, GENES, V4, P156; LI BY, 1992, PROTEIN EXPRES PURIF, V3, P386, DOI 10.1016/S1046-5928(05)80040-3; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MURPHY JR, 1985, CURR TOP MICROBIOL, V118, P235; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NICHOLLS PJ, 1992, GENETICALLY ENG TOXI, P339; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PEARSON JW, 1989, CANCER RES, V49, P3562; PIRKER R, 1989, CANCER RES, V49, P4791; PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001; RAMAKRISHNAN S, 1992, ANNU REV PHARMACOL, V32, P579; RAMAKRISHNAN S, 1984, SCIENCE, V223, P58, DOI 10.1126/science.6318313; RAMAKRISHNAN S, 1989, CANCER RES, V49, P613; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; STROM TB, 1991, ANN NY ACAD SCI, V636, P233, DOI 10.1111/j.1749-6632.1991.tb33455.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG C, 1991, J BIOL CHEM, V266, P14159; UCHIDA T, 1973, J BIOL CHEM, V248, P3845; UCKUN FM, 1993, LEUKEMIA, V7, P341; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VANOOSTERHOUT YVJM, 1992, CANCER RES, V52, P5921; VITETTA ES, 1986, J IMMUNOL, V136, P1880; VIVETTA ES, 1990, J CLIN IMMUNOL, V1, pS15; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; YAMAIZUMI M, 1982, P NATL ACAD SCI-BIOL, V79, P461, DOI 10.1073/pnas.79.2.461	45	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2652	2658						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300596				2022-12-25	WOS:A1994MV43200047
J	JOSHI, B; YAN, RQ; RHOADS, RE				JOSHI, B; YAN, RQ; RHOADS, RE			IN-VITRO SYNTHESIS OF HUMAN PROTEIN-SYNTHESIS INITIATION FACTOR-4-GAMMA AND ITS LOCALIZATION ON 43-S AND 48-S INITIATION-COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA TRANSLATION; AMINO-ACID-SEQUENCE; WHEAT-GERM; KINASE-C; PHOSPHORYLATION; EIF-4F; IDENTIFICATION; INVOLVEMENT; RECOGNITION	The rate of protein synthesis is controlled in a large number of physiological situations at the stage of 48 S initiation complex formation, a phase that involves the recruitment of mRNA to the 40 S ribosomal subunit. This process is mediated by the eukaryotic initiation factor-4 (eIF-4) group of translation initiation factors consisting of eIF-4E, eIF-4A, eIF-4B, and eIF-4gamma. In order to develop a new tool to study this process, we have produced radiolabeled eIF-4gamma by in vitro transcription and translation. Despite the fact that eIF-4gamma is predicted from the cDNA sequence to be 154 kDa, the major synthetic product migrated on SDS-polyacrylamide gel electrophoresis at 205 kDa. Although this is similar to the migration of the fastest polypeptide of authentic eIF-4gamma (approximately 206 kDa), no products were found to co-migrate with the slowest forms of authentic eIF-4gamma (210-220 kDa), suggesting that these forms derive from extensive modification of the initial polypeptide. The in -vitro product also formed a complex with eIF-4E, as judged by its ability to bind to m7GTP-Sepharose. Sucrose gradient sedimentation studies demonstrated that eIF-4gamma was present on both 43 and 48 S initiation complexes but not 80 S complexes. This supports a model in which free eIF-4E binds to mRNA followed by binding of the eIF-4E-mRNA complex to a 43 S initiation complex already containing eIF-4gamma.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 1501 KINGS HIGHWAY, SHREVEPORT, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport				Yan, Riqiang/0000-0001-7195-7617	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; CLEMENS M, 1987, TRANSLATION TRANSCRI, P277; COLE JA, 1988, J CELL BIOL, V107, pA547; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GRASSER FA, 1991, J VIROL, V65, P3779; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; JACKSON RJ, 1991, NATURE, V353, P14, DOI 10.1038/353014a0; JOSHI B, 1991, BIOCHEM SOC T, V19, P282; JOSHI B, 1992, THESIS U SUSSEX BRIG; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LICHTENBERGKRAAG B, 1990, J STRUCT BIOL, V105, P46, DOI 10.1016/1047-8477(90)90097-V; MCMULLIN EL, 1988, BIOCHEM BIOPH RES CO, V153, P925; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; SAFER B, 1978, J BIOL CHEM, V253, P3384; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WEBB NR, 1984, BIOCHEMISTRY-US, V23, P177, DOI 10.1021/bi00297a001; YAN RQ, 1992, J BIOL CHEM, V267, P23226	43	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2048	2055						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294456				2022-12-25	WOS:A1994MR98800076
J	LEUNG, KY; BETTS, JC; XU, L; NABEL, GJ				LEUNG, KY; BETTS, JC; XU, L; NABEL, GJ			THE CYTOPLASMIC DOMAIN OF THE INTERLEUKIN-1 RECEPTOR IS REQUIRED FOR NUCLEAR FACTOR-KAPPA-B SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN IMMUNODEFICIENCY VIRUS; NECROSIS-FACTOR-ALPHA; IL-1 RECEPTOR; T-CELLS; EXPRESSION; CLONING; ACTIVATION; PROTEIN	Interleukin-1 (IL-1) plays a central role in mediating immune and inflammatory responses. Binding of IL-1 to the type I 80-kDa receptor results in generation of intracellular signals and activation of the transcription factor NF-kappaB. However, the nature of the signals required to generate NF-kappaB binding activity remains unclear. In this paper, we show that NF-kappaB1 (p50) and RelA (p65) were specifically translocated to the nucleus following activation of intact type I IL-1 receptor (IL-1R). The C-terminal region of the type I IL-1R is required for this effect, and deletion of its cytoplasmic domain abrogates the activation of NF-kappaB by IL-1. These results provide evidence that IL-1 modulates the activity of NF-kappaB through the type I IL-1 receptor and identifies a domain required for signal transduction to this specific transcription factor.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT INTERNAL MED,1150 W MED CTR DR,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029179] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; FREIMUTH WW, 1989, J IMMUNOL, V143, P3064; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GUIDA S, 1992, GENE, V111, P239, DOI 10.1016/0378-1119(92)90693-J; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; Sambrook J., 1989, MOL CLONING LABORATO, P31; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLACK J, 1993, J BIOL CHEM, V268, P2513; ZHANG L, 1994, IN PRESS CYTOKINE	23	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1579	1582						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294399				2022-12-25	WOS:A1994MR98800004
J	BATES, S; BONETTA, L; MACALLAN, D; PARRY, D; HOLDER, A; DICKSON, C; PETERS, G				BATES, S; BONETTA, L; MACALLAN, D; PARRY, D; HOLDER, A; DICKSON, C; PETERS, G			CDK6 (PLSTIRE) AND CDK4 (PSK-J3) ARE A DISTINCT SUBSET OF THE CYCLIN-DEPENDENT KINASES THAT ASSOCIATE WITH CYCLIN D1	ONCOGENE			English	Article							PROTEIN-KINASE; CELL-CYCLE; CANDIDATE ONCOGENE; CHROMOSOME 11Q13; BCL-1 GENE; G1 PHASE; EXPRESSION; FAMILY; IDENTIFICATION; ACTIVATION	Deregulated expression of cyclin D1 is a feature of several neoplastic and proliferative disorders, but its normal role in the cell cycle remains unclear. Here we show that in a squamous carcinoma cell line with ii-fold amplification of the CCND1 gene, cyclin D1 associates specifically with p33(cdk4) (PSK-J3) and p38(cdk6) (PLSTIRE), two closely related members of the cyclin-dependent kinase (CDK) family. In these tumour cells, there is little evidence for an association between cyclin D1 and other CDKs, but in diploid human fibroblasts both CDK2 and CDK5 can be co-precipitated with cyclin D1, as well as CDK4. The data suggest that D-type cyclins participate in multiple interactions with CDKs but that the nature or stoichiometry of these associations may differ in different types of cell.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; DOU QP, 1993, CANCER RES, V53, P1493; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FAUST JB, 1992, CANCER RES, V52, P2460; GOLDFARB M, 1991, ONCOGENE, V6, P65; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HALL FL, 1993, ONCOGENE, V8, P1377; Hancock D C, 1992, Methods Mol Biol, V80, P33, DOI 10.1385/0-89603-204-3:33; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nei M., 1987, MOL EVOLUTIONARY GEN, P287; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKUDA T, 1992, ONCOGENE, V7, P2249; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	45	284	296	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					71	79						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302605				2022-12-25	WOS:A1994MW24700009
J	KYRIAKIS, JM; FORCE, TL; RAPP, UR; BONVENTRE, JV; AVRUCH, J				KYRIAKIS, JM; FORCE, TL; RAPP, UR; BONVENTRE, JV; AVRUCH, J			MITOGEN REGULATION OF C-RAF-1 PROTEIN-KINASE ACTIVITY TOWARD MITOGEN-ACTIVATED PROTEIN KINASE-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; THREONINE TYROSINE KINASE; ERK-1 GENE-PRODUCT; MAP KINASE; SIGNAL TRANSDUCTION; RAF-1 KINASE; S6 KINASE; PHOSPHORYLATION; INSULIN; SERINE	The c-raf-1 protooncogene encodes a Ser/Thr protein kinase. A mitogen-activated protein kinase-kinase (MAPKK) purified from bovine brain is phosphorylated and activated 4-9-fold in vitro by c-Raf-1 from mitogen-treated cells. c-Raf-1 protein kinase activity, measured by the phosphorylation of brain MAPKK substrate, is detectably activated within 1 min after addition of platelet-derived growth factor (PDGF) to 3T3 cells, increasing more rapidly than the endogenous NIH 3T3 cell MAPKK activity. c-Raf-1 activation is also induced by insulin, phorbol ester, thrombin, and endothelin. PDGF-, epidermal groth factor-, and insulin-stimulated P-32-c-Raf-1 yield very similar, complex tryptic P-32-peptide maps, wherein only 2 of 10 P-32-peptides appear entirely de novo after growth factor addition. Mitogen-activated protein kinase/extracellular signal-regulated kinase-2 can phosphorylate c-Raf-1 in vitro on 4-6 tryptic P-32-peptides, all of which comigrate with tryptic P-32-peptides derived from c-Raf-1 labeled in situ. Mitogen-activated protein kinase phosphorylation of c-Raf-1 in vitro, however, does not 1) generate P-32-peptides that comigrate with those that appear de novo after PDGF or insulin treatment in situ; 2) does not convert c-Raf-1 polypeptides to a slower mobility on SDS-polyacrylamide gel electrophoresis as is seen after PDGF or insulin; 3) does not alter c-Raf-1 kinase activity toward MAPKK. Thus, based on overlapping site specificity, Erk-2 is a viable candidate to be among the PDGF-stimulated c-Raf-1 kinases. Although PDGF/insulin-stimulated c-Raf-1 Ser/Thr phosphorylation may be necessary to sustain the active state, a role for mitogen-activated protein kinase/extracellular signal-regulated kinase-2 phosphorylation in the initiation of c-Raf-1 activation is unlikely.	MASSACHUSETTS GEN HOSP, DIABET UNIT, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, MED SERV, CARDIOL UNIT, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Force, Thomas/0000-0002-0450-8659	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001986, P01DK038452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046577, R01GM046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38452, DK01986] Funding Source: Medline; NIGMS NIH HHS [GM46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSI ED, 1989, J BIOL CHEM, V264, P10836; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1990, BIOCHIM BIOPHYS ACTA, V1054, P73, DOI 10.1016/0167-4889(90)90207-T; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1988, HDB ONCOGENES, P213; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173	40	100	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16009	16019						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340422				2022-12-25	WOS:A1993LN30500096
J	ARCIERO, DM; HOOPER, AB				ARCIERO, DM; HOOPER, AB			HYDROXYLAMINE OXIDOREDUCTASE FROM NITROSOMONAS-EUROPAEA IS A MULTIMER OF AN OCTA-HEME SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; RESONANCE SPECTROSCOPY; REDOX POTENTIOMETRY; CYTOCHROME-C; RESOLUTION; REDUCTION; CLEAVAGE; P460	A fully active form of hydroxylamine oxidoreductase from Nitrosomonas has been purified with high recovery and shown by reverse-phase high performance liquid chromatography and N-terminal analysis to contain only a 63-kDa subunit and to lack the 11-kDa protein previously thought to be a second subunit. Based on the previously published values of molecular weight in solution, hydroxylamine oxidoreductase probably has an alpha2 or alpha3 oligomeric structure. The enzyme was digested separately with trypsin and chymotrypsin and peptides which contained covalently bound heme were separated by high performance liquid chromatography and their amino acid sequences determined. A total of seven heme-containing peptides of unique amino acid sequence were obtained. Six of these heme-containing peptides clearly contained a single c-heme with optical properties indistinguishable from the tryptic heme-containing peptide from horse heart cytochrome c. No noncovalently bound heme was observed. One of the seven heme-containing peptides (T7) was unusual in that it released 2 amino acid residues after each cycle of the Edman degradation due to a nondisulfide cross-link and exhibited a Soret band that was broadened in both the ferric form at neutral pH and the pyridine ferrohemochrome. Subdigestion of peptide T7 with nonspecific proteases (Pronase, bromelain, or pepsin) resulted in the isolation of two smaller heme-containing peptides of unique sequences. One of these was spectrally identical to the other c-heme containing peptides, whereas the second was still apparently cross-linked, again releasing 2 amino acid residues after each Edman cycle. This second peptide possessed a heme-like chromophore with absorption bands (Soret, alpha and beta) red-shifted about 6 nm relative to the spectrum of c-heme-containing peptides. Thus, hydroxylamine oxidoreductase contains a total of eight covalently bound hemes per subunit, seven of which are c-hemes. The eighth, which is attached to a cross-linked peptide, is probably the unusual P460 heme which is unique to hydroxylamine oxidoreductase and thought to be at the active site.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities								AMBLER RP, 1969, FEBS LETT, V5, P115, DOI 10.1016/0014-5793(69)80308-X; AMBLER RP, 1968, BIOCHEM J, V109, pP47; ANDERSSON KK, 1991, BIOCHEM BIOPH RES CO, V174, P358, DOI 10.1016/0006-291X(91)90528-F; ANDERSSON KK, 1984, J BIOL CHEM, V259, P6833; ANDERSSON KK, 1983, FEBS LETT, V164, P236, DOI 10.1016/0014-5793(83)80292-0; ARCIERO DM, 1991, BIOCHEMISTRY-US, V30, P11466, DOI 10.1021/bi00112a014; ARCIERO DM, 1989, J CELL BIOL, V107, pA619; DISPIRITO AA, 1986, J BIOL CHEM, V261, P7048; ERICKSON RH, 1972, BIOCHIM BIOPHYS ACTA, V275, P231, DOI 10.1016/0005-2728(72)90044-8; FONTANA A, 1973, FEBS LETT, V32, P135, DOI 10.1016/0014-5793(73)80756-2; Fuhrhop J.H., 1975, LABORATORY METHODS P, P48; HILL GC, 1975, EUR J BIOCHEM, V57, P265, DOI 10.1111/j.1432-1033.1975.tb02298.x; HOOPER AB, 1978, BIOCHEMISTRY-US, V17, P2984, DOI 10.1021/bi00608a007; HOOPER AB, 1984, EUR J BIOCHEM, V141, P565, DOI 10.1111/j.1432-1033.1984.tb08230.x; HOOPER AB, 1965, J BIOL CHEM, V240, P4044; HOOPER AB, 1989, AUTOTROPHIC BACTERIA, P239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN D K, 1973, Nature (London), V241, P533, DOI 10.1038/241533a0; LIPSCOMB JD, 1982, BIOCHEMISTRY-US, V21, P3965, DOI 10.1021/bi00260a010; LIPSCOMB JD, 1982, BIOCHEMISTRY-US, V21, P3973, DOI 10.1021/bi00260a011; LOGAN MSP, 1991, THESIS U MINNESOTA S; MASSON P, 1990, ELECTROPHORESIS, V11, P128, DOI 10.1002/elps.1150110205; NASRI H, 1987, J AM CHEM SOC, V109, P2549, DOI 10.1021/ja00242a069; PETTIGRE.GW, 1972, FEBS LETT, V22, P64, DOI 10.1016/0014-5793(72)80220-5; PETTIGREW GW, 1973, NATURE, V241, P531, DOI 10.1038/241531a0; PRINCE RC, 1987, BIOCHEMISTRY-US, V26, P970, DOI 10.1021/bi00377a043; PRINCE RC, 1983, FEBS LETT, V163, P25, DOI 10.1016/0014-5793(83)81154-5; REES MK, 1968, BIOCHEMISTRY-US, V7, P366, DOI 10.1021/bi00841a046; TERRY KR, 1981, BIOCHEMISTRY-US, V20, P7026, DOI 10.1021/bi00527a039; VICKERY LE, 1981, BIOCHIM BIOPHYS ACTA, V670, P291, DOI 10.1016/0005-2795(81)90022-2; YAMANAKA T, 1979, J BIOCHEM, V86, P1101, DOI 10.1093/oxfordjournals.jbchem.a132604; YAMANAKA T, 1974, J BIOCHEM-TOKYO, V75, P1265, DOI 10.1093/oxfordjournals.jbchem.a130510	32	78	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14645	14654						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325841				2022-12-25	WOS:A1993LL75900021
J	ZHAO, GP; SOMERVILLE, RL				ZHAO, GP; SOMERVILLE, RL			AN AMINO-ACID SWITCH (GLY(281)ASTERISK-ARG) WITHIN THE HINGE REGION OF THE TRYPTOPHAN SYNTHASE BETA-SUBUNIT CREATES A NOVEL CLEAVAGE SITE FOR THE OMPT PROTEASE AND SELECTIVITY DIMINISHES AFFINITY TOWARD A SPECIFIC MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PROTEOLYTIC CLEAVAGE; BINDING; GENE; BETA-2-SUBUNIT; PURIFICATION; DOMAINS; INVITRO; PEPTIDE	The in vitro susceptibility to endogenous proteases of the beta subunit of Escherichia coli tryptophan synthase was studied immunochemically. Whereas the wild-type beta subunit was apparently very stable, the missense mutant beta(BS), carrying an amino acid switch from Gly to Arg at residue 281, underwent specific proteolytic cleavage. Polyclonal chicken antibodies and monoclonal antibodies specific for the N terminus (monoclonal antibody (mAb) 15-1), the C terminus (mAb 93-6), and the ''hinge'' region (mAb 164-2) were used to study the hydrolysis of the beta(B8) polypeptide. Cleavage products of 30 kDa, from the N terminus, and 13 kDa, from the C terminus, were observed. These two polypeptides correspond to the well characterized F1 (N-terminal) and F2 (C-terminal) fragments that are generated during the limited tryptic proteolysis of the wild-type beta subunit. The outer membrane-associated protease OmpT was shown to be responsible for the cleavage of the beta(B8) mutant protein. Proteolytic cleavage, observed only under neutral non-denaturing conditions, was specific for the peptide bond between Arg281 and Met282. The Arg-Met peptide bond has not previously been reported to be susceptible to cleavage by the OmpT protease. The beta(B8) polypeptide had dramatically reduced affinity for mAb 164-2. This antibody interacted more strongly with the OmpT-generated F1-like fragment than with the intact beta(B8) protein. These results strongly suggest that the G281R mutation alters the conformation of the hinge region of the mutant beta subunit, particularly the beta-turn around Gly281. The implications with respect to the epitope recognized by mAb 164-2 are discussed.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [GM22131] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022131] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED SA, 1986, BIOCHEMISTRY-US, V25, P3118, DOI 10.1021/bi00359a008; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; ALEXANDER L, 1975, BIOCHEM BIOPH RES CO, V67, P1055, DOI 10.1016/0006-291X(75)90781-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAWFORD IP, 1964, GENETICS, V49, P267; CRAWFORD IP, 1963, GENETICS, V48, P725; CRAWFORD IP, 1978, BIOCHEM BIOPH RES CO, V85, P309, DOI 10.1016/S0006-291X(78)80044-8; CREIGHTON TE, 1970, METHODS ENZYMOLOGY A, V17, P365, DOI DOI 10.1021/ACS.BIOCHEM.8B00167; DELEPIERRE M, 1991, EUR J BIOCHEM, V201, P681, DOI 10.1111/j.1432-1033.1991.tb16329.x; DJAVADIOHANIANCE L, 1986, BIOCHEMISTRY-US, V25, P2502, DOI 10.1021/bi00357a033; DJAVADIOHANIANCE L, 1984, BIOCHEMISTRY-US, V23, P97, DOI 10.1021/bi00296a016; Friedrich P., 1984, SUPRAMOLECULAR ENZYM; FRIGUET B, 1989, RES IMMUNOL, V140, P355, DOI 10.1016/0923-2494(89)90142-9; GENTRY D R, 1990, Protein Expression and Purification, V1, P81, DOI 10.1016/1046-5928(90)90050-9; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GRODBERG J, 1988, NUCLEIC ACIDS RES, V16, P1209, DOI 10.1093/nar/16.3.1209; HARLOW E, 1988, ANTIBODIES LABORATOR; HATZFELD M, 1992, FEBS LETT, V302, P239, DOI 10.1016/0014-5793(92)80450-U; HOGBERGRAIBAUD A, 1977, P NATL ACAD SCI USA, V74, P442, DOI 10.1073/pnas.74.2.442; HYDE CC, 1988, J BIOL CHEM, V263, P17857; LARVOR MP, 1991, MOL IMMUNOL, V28, P523, DOI 10.1016/0161-5890(91)90167-I; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1985, PYRIDOXAL PHOSPHATE, P253; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEDGWICK B, 1989, J BACTERIOL, V171, P2249, DOI 10.1128/jb.171.4.2249-2251.1989; SONG CS, 1985, J IMMUNOL, V135, P3354; SUGIMURA K, 1988, J BACTERIOL, V170, P5625, DOI 10.1128/jb.170.12.5625-5632.1988; SUGIMURA K, 1988, J BACTERIOL, V170, P3650, DOI 10.1128/jb.170.8.3650-3654.1988; SUGIMURA K, 1988, BIOCHEM BIOPH RES CO, V153, P753, DOI 10.1016/S0006-291X(88)81159-8; YANOFSKY C, 1956, J BIOL CHEM, V223, P171; YANOFSKY C, 1972, ENZYMES, V7, P1; ZHAO GP, 1993, J BIOL CHEM, V268, P14921; ZHAO GP, 1992, J BIOL CHEM, V267, P526	35	11	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14912	14920						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325868				2022-12-25	WOS:A1993LL75900059
J	RAJAGOPALAN, K; CHAVAN, AJ; HALEY, BE; WATT, DS				RAJAGOPALAN, K; CHAVAN, AJ; HALEY, BE; WATT, DS			SYNTHESIS AND APPLICATION OF BIDENTATE PHOTOAFFINITY CROSS-LINKING REAGENTS - NUCLEOTIDE PHOTOAFFINITY PROBES WITH 2 PHOTOACTIVE GROUPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; GLUTAMATE-DEHYDROGENASE; 5'-TRIPHOSPHATE; GLYCOSYLATION; PURIFICATION; TRIPHOSPHATE; PROTEINS; CHAIN	Two ''targeted bidentate'' photoaffinity cross-linking reagents, the monoanhydride of 8-N3ADP with N-(4-(benzoyl)phenylmethyl)phosphoramide ([gamma-P-32]8-N3ATPgammaBP) and the monoanhydride of 8-N3GDP with N-(4-(benzoyl)phenylmethyl)-phosphoramide ([gamma-P-32] 8-N3GTPgammaBP), were developed for studying the inter- and intramolecular interactions of nucleotide-binding proteins. Experiments using these bidentate reagents with two photoactive groups led to specific cross-linking: [gamma-P-32]8-N3GTPgammaBP and [gamma-P-32]8-N3ATPgammaBP showed intersubunit cross-linking of glutamate dehydrogenase and [gamma-P-32]8-N3GTPgammaBP appeared to cross-link the alpha- and beta-subunits of tubulin. The non-azido ''monodentate'' versions of these reagents, the monoanhydride of ADP with N-(4-(benzoyl)phenylmethyl)-phosphoramide ([gamma-P-32]ATPgammaBP) and the monoanhydride of GDP with N-(4-(benzoyl)phenylmethyl)-phosphoramide ([gamma-P-32]GTPgammaBP), were also synthesized and characterized. The ability of these monodentate reagents with one photoactive group to serve as photoaffinity probes was established by photolabeling specifically the exchangeable GTP-binding domain of tubulin with [gamma-P-32[GTPgammaBP and the ATP-binding domain of purified adenylate kinase and several nucleotide-binding proteins in human brain homogenate with [gamma-P-32]ATPgammaBP.	UNIV KENTUCKY, DEPT CHEM, LEXINGTON, KY 40506 USA; UNIV KENTUCKY, COLL PHARM, LUCILLE P MARKEY CANC CTR, DIV MED CHEM & PHARMACEUT, LEXINGTON, KY 40506 USA	University of Kentucky; University of Kentucky					NIGMS NIH HHS [GM 35766, GM 47427] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766, R01GM047427] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABKINA GT, 1975, BIOORG KHIM+, V1, P611; BAYLEY H, 1983, PHOTOGENERATED REAGE, P114; Boyer P.D, 1973, ENZYMES, P279; CALVERT JG, 1966, PHOTOCHEMISTRY, P300; CAMPBELL S, 1990, P NATL ACAD SCI USA, V87, P1243, DOI 10.1073/pnas.87.3.1243; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; Chavan AJ, 1990, BIOCONJUGATE CHEM, V1, P337, DOI 10.1021/bc00005a007; CHIBA S, 1990, J BIOL CHEM, V265, P19777; CROCKER PJ, 1991, BIOCONJUGATE CHEM, V2, P419; Czarnecki J, 1979, Methods Enzymol, V56, P642; DALZIEL K, 1972, BIOCHEM J, V126, P975, DOI 10.1042/bj1260975; DOUKAS MA, 1992, BIOCONJUGATE CHEM, V3, P484, DOI 10.1021/bc00018a004; GALARDY RE, 1973, NATURE-NEW BIOL, V242, P127, DOI 10.1038/newbio242127a0; GEAHLEN RL, 1977, P NATL ACAD SCI USA, V74, P4375, DOI 10.1073/pnas.74.10.4375; Girshovich A S, 1977, Methods Enzymol, V46, P656; GLONEK T, 1974, SCIENCE, V185, P352, DOI 10.1126/science.185.4148.352; GOLDIN BF, 1972, CURRENT TOPICS CELLU, V4, P77; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; Imai N, 1990, BIOCONJUGATE CHEM, V1, P138, DOI 10.1021/bc00002a008; KHATOON S, 1989, ANN NEUROL, V26, P210, DOI 10.1002/ana.410260205; KIM H, 1987, FASEB J, V46, P2229; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KING SM, 1991, METHOD ENZYMOL, V196, P449; KNORRE DG, 1976, FEBS LETT, V70, P105, DOI 10.1016/0014-5793(76)80736-3; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEVYA E, 1991, PHOTOCHEM PHOTOBIOL, V54, P329; MAHMOOD R, 1987, J BIOL CHEM, V262, P14479; PAL PK, 1979, BIOCHEMISTRY-US, V18, P838, DOI 10.1021/bi00572a016; PANTALONI D, 1969, EUR J BIOCHEM, V11, P510, DOI 10.1111/j.1432-1033.1969.tb00803.x; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SALVUCCI ME, 1993, J BIOL CHEM, V268, P14239; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; TAKAHITO I, 1990, MACROMOLECULES, V23, P4879; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; THALMANN E, 1991, BIOCHIM BIOPHYS ACTA, V1088, P301, DOI 10.1016/0167-4781(91)90067-V; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; YAN HG, 1991, BIOCHEMISTRY-US, V30, P5539, DOI 10.1021/bi00236a029	39	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14230	14238						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314786				2022-12-25	WOS:A1993LJ82500066
J	WANG, YK; LIAO, PC; ALLISON, J; GAGE, DA; ANDREWS, PC; LUBMAN, DM; HANASH, SM; STRAHLER, JR				WANG, YK; LIAO, PC; ALLISON, J; GAGE, DA; ANDREWS, PC; LUBMAN, DM; HANASH, SM; STRAHLER, JR			PHORBOL 12-MYRISTATE 13-ACETATE-INDUCED PHOSPHORYLATION OF OP18 IN JURKAT T-CELLS - IDENTIFICATION OF PHOSPHORYLATION SITES BY MATRIX-ASSISTED LASER-DESORPTION IONIZATION MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-ENRICHED PHOSPHOPROTEIN; 2 CYTOSOLIC PROTEINS; ACTIVATION; STATHMIN; KINASE; GENE; ELECTROPHORESIS; PROLIFERATION; DIGESTION; LEUKEMIA	Op18 is a widely expressed, cell cycle-regulated, phosphoprotein involved in signal transduction of a variety of stimuli. In actively proliferating Jurkat T cells which express Op18 at high level, phorbol 12-myristate 13-acetate (PMA) treatment induces a rapid increase in the level of several Op18 phosphorylated forms. To determine phosphorylation sites involved in the PMA effect, the major Op18 phosphorylated forms were resolved in Jurkat T cells, before and after treatment with PMA, using preparative immobilized pH gradient-based two-dimensional polyacrylamide gel electrophoresis. Tryptic fragments of phosphorylated Op18 were analyzed by two-dimensional thin layer peptide mapping and were resolved by reverse-phase high performance liquid chromatography prior to analysis by matrix-assisted laser desorption ionization mass spectrometry. Phosphorylation sites were identified by further treatment of the proteolytic fragments with different enzymes and determination of the mass shifts by matrix-assisted laser desorption ionization mass spectrometry. Two major phosphorylation sites were identified. Low constitutive levels of phosphorylation at Ser25 and Ser38 in Op18a and Op18b was demonstrated. Treatment with PMA resulted in enhanced phosphorylation of Ser25 in Op18a and of both Ser25 and Ser38 in Op18b. Taken together with prior studies of Op18 phosphorylation, the data suggest that Op18 phosphorylation occurs at identical sites in different tissues and organisms.	UNIV MICHIGAN,SCH MED,DEPT PEDIAT,R4451 KRESGE I,BOX 0510,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOCHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT CHEM,ANN ARBOR,MI 48109; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan State University; Michigan State University				Andrews, Philip/0000-0001-6843-5420	NCI NIH HHS [CA32146] Funding Source: Medline; NCRR NIH HHS [RR0480-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHAIT BT, 1992, 40TH P ASMS C MASS S, P1939; COOPER HL, 1990, J IMMUNOL, V145, P1205; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1991, P NATL ACAD SCI USA, V88, P5709, DOI 10.1073/pnas.88.13.5709; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KARAS M, 1991, MASS SPECTROM REV, V10, P335, DOI 10.1002/mas.1280100503; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LEGOUVELLO S, 1991, FEBS LETT, V287, P80, DOI 10.1016/0014-5793(91)80020-4; MARY D, 1989, J BIOL CHEM, V264, P14498; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; PEYRON JF, 1989, BIOCHEM J, V258, P505, DOI 10.1042/bj2580505; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SCHAR M, 1991, RAPID COMMUN MASS SP, V5, P319, DOI 10.1002/rcm.1290050705; SCHAR M, 1991, CHIMIA, V45, P123; SCHUBART UK, 1982, J BIOL CHEM, V257, P2231; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; STRAHLER J R, 1991, Methods (Orlando), V3, P109, DOI 10.1016/S1046-2023(05)80202-6; STRAHLER JR, 1992, J IMMUNOL, V149, P1191; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; ZHU XX, 1989, J BIOL CHEM, V264, P14556	30	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14269	14277						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314790				2022-12-25	WOS:A1993LJ82500072
J	FOOD, MR; ROTHENBERGER, S; GABATHULER, R; HAIDL, ID; REID, G; JEFFERIES, WA				FOOD, MR; ROTHENBERGER, S; GABATHULER, R; HAIDL, ID; REID, G; JEFFERIES, WA			TRANSPORT AND EXPRESSION IN HUMAN MELANOMAS OF A TRANSFERRIN-LIKE GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; SURFACE PROTEIN; PHOSPHOLIPASE-D; ANTIGEN P97; PHOSPHATIDYLINOSITOL; RECEPTOR; IRON; ANTIBODY; SYSTEM; CELLS	Melanotransferrin, also called p97, is a cell surface glycoprotein which was first described as a marker antigen, for human melanoma cells. Although p97 has a striking structural similarity to human serum transferrin and lactoferrin, its function has not yet between determined. One feature that distinguishes p97 from the other members of the transferrin family is the presence of a stretch of 24 hydrophobic amino acids at the C terminus, previously assumed to form a proteinacious transmembrane domain. In this study, sensitivity to bacterial phosphatidylinositol-specific phospholipase C, biosynthetic labeling with [H-3]ethanolamine, and partitioning in Triton X-114 are used to establish that p97 is expressed at the cell surface as a glycosylphosphatidylinositol-anchored protein. In addition, to gain insight into the intracellular transport of p97, biosynthetic transport studies were performed on a melanoma cell line. These studies resulted in the identification of an additional form of p97 which is found in the medium and which likely does not originate from an alternatively spliced form of the p97 mRNA. These findings, together with our recent observation of the co-localization of p97 and the transferrin receptor in brain capillary endothelium (W. A. Jefferies, M. R. Food, R. Gabathuler, S. Rothenberger, T. Yamada, and P. L. McGeer, manuscript submitted) raise important questions about the function of the two forms of p97 detected and the possible involvement of this protein in a cellular iron uptake mechanism that is independent from the transferrin/transferrin receptor system.	UNIV BRITISH COLUMBIA, BIOTECHNOL LAB,RM 237,WESTBROOK BLDG, 6174 UNIV BLVD, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT ZOOL, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia			Reid, Gregor/F-6260-2011	Reid, Gregor/0000-0002-7567-3424; Rothenberger, Sylvia/0000-0001-8633-2994				BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BASSET P, 1986, CANCER RES, V46, P1644; BAZIL V, 1991, J IMMUNOL, V147, P1567; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN JP, 1982, NATURE, V296, P171, DOI 10.1038/296171a0; BROWN JP, 1981, P NATL ACAD SCI-BIOL, V78, P539, DOI 10.1073/pnas.78.1.539; DOERING TL, 1990, J BIOL CHEM, V265, P611; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; HELLSTROM I, 1983, INT J CANCER, V31, P553, DOI 10.1002/ijc.2910310505; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; KAHN M, 1991, J IMMUNOL, V146, P3235; LIAO SK, 1985, J CELL BIOCHEM, V27, P303, DOI 10.1002/jcb.240270311; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; METZ CN, 1991, J BIOL CHEM, V266, P17733; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; PLOWMAN GD, 1983, NATURE, V303, P70, DOI 10.1038/303070a0; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TAKAMI N, 1992, J BIOL CHEM, V267, P1042; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; VONBOXBERG Y, 1990, EUR J BIOCHEM, V190, P249; WOODBURY RG, 1981, INT J CANCER, V27, P145, DOI 10.1002/ijc.2910270204; WOODBURY RG, 1980, P NATL ACAD SCI-BIOL, V77, P2183, DOI 10.1073/pnas.77.4.2183	30	87	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3034	3040						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300636				2022-12-25	WOS:A1994MV43200096
J	LEE, JS; FAVRE, B; HEMMINGS, BA; KIEFER, B; NAGAMINE, Y				LEE, JS; FAVRE, B; HEMMINGS, BA; KIEFER, B; NAGAMINE, Y			OKADAIC ACID-DEPENDENT INDUCTION OF THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENE ASSOCIATED WITH STABILIZATION AND AUTOREGULATION OF C-JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACTIN-BINDING-PROTEIN; DNA-BINDING; MESSENGER-RNA; MOLECULAR-CLONING; CATALYTIC SUBUNIT; PHORBOL-ESTER; KIDNEY-CELLS; V-JUN; PHOSPHORYLATION	We have previously shown that the tumor promoter okadaic acid (OA), an inhibitor of protein phosphatases 1 and 2A, transcriptionally induces the urokinase-type plasminogen activator (uPA) gene in LLC-PK1 cells. This induction occurs independently of the protein kinase C-and cAMP-dependent signaling pathways. Here we show that a sequence located 2.0 kilobases upstream of the uPA gene, which resembles an AP-1-recognition sequence, mediates the action of OA. DNA-protein interaction studies, together with mRNA and protein analyses, indicate that c-Jun, but not c-Fos, is involved in OA-dependent uPA gene induction. The appearance of high levels of uPA mRNA and DNA binding activity of c-Jun to the AP-1-like site correspond to the appearance of c-Jun accumulation, suggesting that c-Jun accumulation is a critical event in OA-dependent uPA gene induction. c-Jun protein levels increase significantly between 100 and 160 min following OA treatment, whereas c-Jun translation increases only slightly in this time frame, suggesting that post-translation mechanisms are also involved in c-Jun accumulation. Pulse-chase analyses shows that OA specifically stabilizes c-Jun. We discuss our results with respect to the possibility that protein phosphatase 2A maintains c-Jun in its down-regulated state in LLC-PK1 cells.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDRUS L, 1988, J BIOL CHEM, V263, P6183; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHEN M, 1989, J BIOL CHEM, V264, P14282; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1991, MOL ASPECTS CELLULAR, V6, P295; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DUFFY MJ, 1990, CANCER RES, V50, P6827; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOODE N, 1992, J BIOL CHEM, V267, P16878; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MENOUD PA, 1993, NUCLEIC ACIDS RES, V21, P1845, DOI 10.1093/nar/21.8.1845; MILLMAN G, 1981, SOMAT CELL GENET, V7, P161; NAGAMINE Y, 1983, CELL, V32, P1181, DOI 10.1016/0092-8674(83)90301-X; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; NAGAMINE Y, 1992, FIBRINOLYSIS, V6, P121; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PONTREMOLI S, 1987, P NATL ACAD SCI USA, V84, P398, DOI 10.1073/pnas.84.2.398; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; VONDERAHE D, 1990, NUCLEIC ACIDS RES, V18, P1991, DOI 10.1093/nar/18.8.1991; YU H, 1990, CANCER RES, V50, P7623; ZHANG Z, 1988, BIOCHEM BIOPH RES CO, V151, P355, DOI 10.1016/0006-291X(88)90601-8; ZIEGLER A, 1991, J BIOL CHEM, V266, P21067	66	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2887	2894						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300623				2022-12-25	WOS:A1994MV43200078
J	MERLIE, JP; MUDD, J; CHENG, TC; OLSON, EN				MERLIE, JP; MUDD, J; CHENG, TC; OLSON, EN			MYOGENIN AND ACETYLCHOLINE-RECEPTOR ALPHA-GENE PROMOTERS MEDIATE TRANSCRIPTIONAL REGULATION IN RESPONSE TO MOTOR INNERVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-SUBUNIT GENE; MUSCLE-SPECIFIC ENHANCER; LIGHT CHAIN ENHANCER; MESSENGER-RNA LEVELS; PROTEIN-KINASE-C; SKELETAL-MUSCLE; ELECTRICAL-ACTIVITY; GAMMA-SUBUNIT; 5'-FLANKING REGION; UPSTREAM SEQUENCE	Several genes expressed in skeletal muscle are transcriptionally repressed by electrical activity arising from motor innervation and are rapidly induced following denervation. Among these are genes encoding the subunits of the nicotinic acetylcholine receptor (AChR) and the myogenic helix-loop-helix protein myogenin, which activates muscle-specific genes. To understand how electrical activity arising from motor innervation is converted into a transcriptional response, we have attempted to localize cis-acting sequences in the AChR alpha subunit and myogenin genes sufficient to direct activity-dependent transcription. Here we show that an 111-base pair and a 335-base pair region from the promoters of the AChR alpha subunit and myogenin genes, respectively, can confer activity-dependent regulation to a linked reporter gene in transgenic mice. The presence of binding sites for myogenic helix-loop-helix proteins in both of these regulatory regions is consistent with the hypothesis that these myogenic regulators serve as nuclear targets for the signaling cascade through which motor innervation leads to changes in gene transcription in skeletal muscle.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center								BALDWIN TJ, 1988, J CELL BIOL, V107, P2271, DOI 10.1083/jcb.107.6.2271; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUONANNO A, 1988, NATO ASI SER H, V32, P541; CANGIANO A, 1993, NEUROREGENERATION; Cannon WB, 1949, SUPERSENSITIVITY DEN; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; DUTTON EK, 1993, P NATL ACAD SCI USA, V90, P2040, DOI 10.1073/pnas.90.5.2040; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EDMONDSON DG, 1992, MOL CELL BIOL, V21, P1; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUNDERSEN K, 1993, BIOTECHNIQUES, V14, P412; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; JIA HT, 1992, CELL MOL NEUROBIOL, V12, P241, DOI 10.1007/BF00712929; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KLARSFELD A, 1987, MOL CELL BIOL, V7, P951, DOI 10.1128/MCB.7.2.951; Langley JN, 1916, J PHYSIOL-LONDON, V50, P335; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; NEVILLE CM, 1992, CELL MOL NEUROBIOL, V12, P511, DOI 10.1007/BF00711232; NUMBERGER M, 1991, EMBO J, V10, P2957, DOI 10.1002/j.1460-2075.1991.tb07846.x; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PIETTE J, 1989, EMBO J, V8, P687, DOI 10.1002/j.1460-2075.1989.tb03427.x; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1991, J BIOL CHEM, V266, P22588; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SALMON AM, 1992, NEUROREPORT, V3, P973, DOI 10.1097/00001756-199211000-00006; SANES JR, 1991, DEVELOPMENT, V113, P1181; SCHMALBRUCK H, 1985, HDB MIKROSK ANAT, V11, P1; SIMON AM, 1992, DEVELOPMENT, V114, P545; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TSAY HJ, 1989, J CELL BIOL, V108, P1523, DOI 10.1083/jcb.108.4.1523; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WANG XM, 1990, EMBO J, V9, P783, DOI 10.1002/j.1460-2075.1990.tb08174.x; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WITZEMANN V, 1989, FEBS LETT, V242, P419, DOI 10.1016/0014-5793(89)80514-9; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	68	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2461	2467						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300573				2022-12-25	WOS:A1994MV43200021
J	SIPPEL, CJ; MCCOLLUM, MJ; PERLMUTTER, DH				SIPPEL, CJ; MCCOLLUM, MJ; PERLMUTTER, DH			BILE-ACID TRANSPORT BY THE RAT-LIVER CANALICULAR BILE-ACID TRANSPORT ECTO-ATPASE PROTEIN IS DEPENDENT ON ATP BUT NOT ON ITS OWN ECTO-ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; RESISTANCE P-GLYCOPROTEIN; NUCLEOTIDE-BINDING SITE; CELL-ADHESION MOLECULE; MULTIDRUG-RESISTANCE; CYSTIC-FIBROSIS; TAUROCHOLATE TRANSPORT; MEMBRANE-VESICLES; CHLORIDE CHANNELS; EXPRESSION	We have shown that bile acid efflux and ecto-ATPase activities are two distinct properties of a single rat liver hepatocyte canalicular membrane protein (Sippel, C. J., Suchy, F. J., Ananthanarayanan, M., and Perlmutter, D. H. (1993) J. Biol. Chem. 268, 2083-2091). Bile acid efflux in COS cells transfected with this rat hepatocyte canalicular bile acid transport/ecto-ATPase cDNA is stimulated by ATP and inhibited by nonhydrolyzable ATP analogs. In this study, we depleted transfected COS cells of ATP to examine whether bile acid efflux mediated by this transporter was dependent on ATP or just stimulated by ATP. We also used mutagenesis of an ATPase consensus sequence in the ectoplasmic domain to examine the relationship of ATPase activity to bile acid efflux mediated by the same polypeptide. The results indicate that bile acid transport is abrogated by ATP depletion and reconstituted by exogenous ATP in a concentration-dependent and saturable manner. Introduction of mutations at amino acids Gly97 and Arg98 in the ATPase consensus sequence abrogated ATPase activity but did not affect synthesis or cell surface delivery of the transporter and did not affect its bile acid transport activity. Taken together, the data indicate that bile acid efflux mediated by the rat hepatocyte canalicular bile acid transport/ecto-ATPase protein is dependent on ATP but not on its own ATPase activity. The data, therefore, imply that 1) ATP affects its bile acid transport activity through an entirely distinct mechanism; and 2) if there is any functional relationship between the ecto-ATPase and bile acid transport properties, it is mediated indirectly through regulation of net ATP concentrations in the canalicular space by the ecto-ATPase.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	SIPPEL, CJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.				NICHD NIH HHS [K08 HD00954-01, T32 HDO7409] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409, K08HD000954] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAHAM EH, 1992, P NATL ACAD SCI USA, V90, P312; ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLITZER B, 1982, AM J PHYSIOL, V6, pG48; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; CULLEN BR, 1987, METHOD ENZYMOL, V152, P562; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAST C, 1992, HEPATOLOGY, V16, pA148; KAUR P, 1992, J BIOL CHEM, V267, P19272; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; NISHIDA T, 1992, HEPATOLOGY, V16, pA149; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; RUETZ S, 1987, J BIOL CHEM, V262, P11324; SHNEIDER BL, 1993, J BIOL CHEM, V268, P6985; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SMITH DJ, 1992, HEPATOLOGY, V15, P969, DOI 10.1002/hep.1840150535; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WINE JJ, 1992, NATURE, V360, P18, DOI 10.1038/360018a0; YIH LH, 1991, CELL BIOL INT REP, V15, P253, DOI 10.1016/0309-1651(91)90157-E; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226	42	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2820	2826						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300615				2022-12-25	WOS:A1994MV43200069
J	PAK, M; WILLIS, IM; SCHULMAN, LH				PAK, M; WILLIS, IM; SCHULMAN, LH			ANALYSIS OF ACCEPTOR STEM BASE-PAIRING ON TRANSFER RNA(TRP) AMINOACYLATION AND FUNCTION IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATOR TRANSFER-RNA; ELONGATION-FACTOR-TU; FORMYLMETHIONINE TRANSFER-RNA; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; RECOGNITION; TRYPTOPHAN; IDENTITY; MUTANTS; SYNTHETASE	The role of acceptor stem base pairs in determining the identity of Escherichia coli tRNA(Trp) was examined by complementation of an E. coli strain containing a temperature-sensitive tRNA(Trp) gene (trpT(ts)) and by monitoring aminoacylation levels in vivo. All derivatives of tRNA(Trp) containing substitutions at the first 3 base pairs in the acceptor stem complemented the trpT(ts) mutation at the nonpermissive temperature (42-degrees-C). However, three acceptor stem derivatives (tRNA(Trp)/C1.G72, tRNA(Trp)/C2.G71, and tRNA(TrP)/A3 . U70) required overexpression for growth at 42-degrees-C. Northern analysis of these derivatives following acid/urea gel electrophoresis showed no defects in tRNA aminoacylation at the nonpermissive temperature. Instead, these tRNAs appear to be defective in translation. This was suggested by the weak opal suppressor activities of the corresponding tRNA(UCA)Trp derivatives. These results demonstrate that the three terminal acceptor stem base pairs do not contribute to the identity of tRNA(Trp). Substitution of the C1.A72 base pair in a methionine initiator tRNA containing the tryptophan anticodon and discriminator base (tRNA(CCA)fMet/G73) with A1.U72, the base pair found in tRNA(Trp), or G1.C72 resulted in the conversion of these tRNAs into tryptophan-inserting elongator tRNAs in vivo. However, changes to U1.A72 or C1.G72 in tRNA(CCA)fMet/G73 resulted in misaminoacylation and/or defects in translation. Our data indicate that the A1.U72 base pair is a context-dependent, negative identity element of tRNA(Trp).	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV & MOLEC BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Willis, Ian/0000-0001-6599-2395	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07128] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUTORIN AS, 1981, J MOL BIOL, V152, P593, DOI 10.1016/0022-2836(81)90271-0; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; EISENBERG SP, 1979, J BIOL CHEM, V254, P5562; EISENBERG SP, 1980, J BIOL CHEM, V255, P1128; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1991, NUCLEIC ACIDS RES, V19, P6379, DOI 10.1093/nar/19.23.6379; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; JEKOWSKY E, 1977, J MOL BIOL, V114, P451, DOI 10.1016/0022-2836(77)90262-5; LEE CP, 1991, J BIOL CHEM, V266, P18012; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; PALLANCK L, 1992, TRANSFER RNA PROTEIN, P279; ROGERS MJ, 1992, P NATL ACAD SCI USA, V89, P3463, DOI 10.1073/pnas.89.8.3463; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHOFIEL.P, 1968, BIOCHIM BIOPHYS ACTA, V155, P410, DOI 10.1016/0005-2787(68)90185-8; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SMITH D, 1989, J MOL BIOL, V206, P503, DOI 10.1016/0022-2836(89)90497-X; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; WIKMAN FP, 1987, NUCLEIC ACIDS RES, V15, P5787, DOI 10.1093/nar/15.14.5787; YANOFSKY C, 1977, J MOL BIOL, V113, P663, DOI 10.1016/0022-2836(77)90229-7	33	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2277	2282						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294486				2022-12-25	WOS:A1994MR98800108
J	RAMCHANDRAN, R; SEN, GC; MISONO, K; SEN, I				RAMCHANDRAN, R; SEN, GC; MISONO, K; SEN, I			REGULATED CLEAVAGE-SECRETION OF THE MEMBRANE-BOUND ANGIOTENSIN-CONVERTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-ALPHA; MESSENGER-RNAS; DIPEPTIDYL CARBOXYPEPTIDASE; EXPRESSION; RAT; TRANSCRIPTION; ISOENZYMES; MECHANISMS; PROTEINS; SEQUENCE	Angiotensin-converting enzyme (ACE) is an ectoprotein anchored in the plasma membrane through a hydrophobic domain near its carboxyl-terminal region. Mouse epithelial cells transfected with rabbit testicular ACE cDNA, synthesize, glycosylate, and secrete ACE by cleavage processing of its membrane-anchoring carboxyl-terminal region. Because the cleavage-secretion process is slow, the enzyme accumulates on the cell surface. We show that this process can be enhanced by treatment of cells with tumor-promoting phorbol esters leading to depletion of the cell surface enzyme. The cleavage processing occurs only after the protein has reached the cell surface and is not affected by disruption of the Golgi apparatus or the lysosomal compartments. The exact peptide bond cleaved has been identified by sequencing the amino-terminal residues of the purified COOH-terminal tail left in the cells after ACE is secreted and the carboxyl-terminal residues of secreted ACE. The cleavage occurs at a monobasic site between Arg-663 and Ser-664 generating the soluble enzyme and leaving a cell-bound protein of 74 residues. These results demonstrate the existence of cellular mechanisms that regulate the conversion of cell-bound ACE to a soluble enzyme.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48258] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERG T, 1986, J HISTOCHEM CYTOCHEM, V34, P753, DOI 10.1177/34.6.3009604; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; CUSHMAN DW, 1980, PROG MED CHEM, V17, P42; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELDORRY HA, 1982, P NATL ACAD SCI-BIOL, V79, P4295, DOI 10.1073/pnas.79.14.4295; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; ERDOS E. G., 1967, LIFE SCI, V6, P569, DOI 10.1016/0024-3205(67)90090-2; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; Hayashi R, 1977, Methods Enzymol, V47, P84; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUANG EJ, 1990, CELL, V3, P349; HUBERT C, 1991, J BIOL CHEM, V266, P21985; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LU HS, 1991, J BIOL CHEM, V266, P8102; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SEN I, 1993, J BIOL CHEM, V268, P25748; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; WEI L, 1991, J BIOL CHEM, V266, P5540	32	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2125	2130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294466				2022-12-25	WOS:A1994MR98800087
J	SHEPARD, AR; ZHANG, WG; EBERHARDT, NL				SHEPARD, AR; ZHANG, WG; EBERHARDT, NL			2 CGTCA MOTIFS AND A GHF1/PIT1 BINDING-SITE MEDIATE CAMP-DEPENDENT PROTEIN KINASE-A REGULATION OF HUMAN GROWTH-HORMONE GENE-EXPRESSION IN RAT ANTERIOR-PITUITARY GC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; TRANS-ACTING FACTOR; CYCLIC-AMP; RESPONSIVE ELEMENT; THYROID-HORMONE; TRANSCRIPTION FACTOR; TUMOR-CELLS; 5'-FLANKING REGION; PROLACTIN GENE; DNA	We established the cis-acting elements which mediate cAMP responsiveness of the human growth hormone (hGH) gene in transiently transfected rat anterior pituitary tumor GC cells. Analysis of the intact hGH gene or hGH 5'-flanking DNA (5'-FR) coupled to the hGH cDNA or chloramphenicol acetyltransferase or luciferase genes, indicated that cAMP primarily stimulated hGH promoter activity. Cotransfection of a protein kinase A inhibitory protein cDNA demonstrated that the cAMP response was mediated by protein kinase A. Mutational analysis of the hGH promoter identified two core cAMP response element motifs (CGTCA) located at nucleotides -187/-183 (distal cAMP response element; dCRE) and -99/-95 (proximal cAMP response element; pCRE) and a pituitary-specific transcription factor (GHF1/Pit1) binding site at nucleotides -123/-112 (dGHF1) which were required for cAMP responsiveness. GHF1 was not a limiting factor, since overexpression of GHF1 in cotransfections increased basal but not forskolin induction levels. Gel shift analyses indicated that similar, ubiquitous, thermostable protein(s) specifically bound the pCRE and dCRE motifs. The CGTCA motif-binding factors were cAMP response element binding protein (CREB)/activating transcription factor-1 (ATF-1)-related, since the DNA-protein complex was competed by unlabeled CREB consensus oligonucleotide, specifically super-shifted by antisera to CREB and ATF-1 but not ATF-2, and was bound by purified CREB with the same relative binding affinity (pCRE < dCRE < CREB) and mobility as the GC nuclear extract. UV cross-linking and Southwestern blot analyses revealed multiple DNA-protein interactions of which almost-equal-to 100- and almost-equal-to 45-kDa proteins were predominant; the almost-equal-to 45-kDa protein may represent CREB. These results indicate that CREB/ATF-1-related factors act coordinately with the cell-specific factor GHF1 to mediate cAMP-dependent regulation of hGH-1 gene transcription in anterior pituitary somatotrophs.	MAYO CLIN & MAYO FDN,DEPT MED & BIOCHEM,ENDOCRINE RES UNIT,4-407 ALFRED,SMH,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MOLEC BIOL,ROCHESTER,MN 55905; UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143	Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRISANI O, 1990, J BIOL CHEM, V265, P3212; BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; BARINAGA M, 1983, NATURE, V306, P84, DOI 10.1038/306084a0; BEIMLING P, 1992, ONCOGENE, V7, P257; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BRENT GA, 1988, MOL ENDOCRINOL, V2, P792, DOI 10.1210/mend-2-9-792; CATTINI PA, 1986, J BIOL CHEM, V261, P3367; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEWIT JR, 1987, MOL CELL BIOL, V7, P725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; EASTMAN A, 1987, BIOTECHNIQUES, V5, P731; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GROVE JR, 1987, SCIENCE, V238, P530; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KEECH CA, 1992, MOL ENDOCRINOL, V6, P2059, DOI 10.1210/me.6.12.2059; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; LEE TC, 1992, NUCLEIC ACIDS RES, V20, P140, DOI 10.1093/nar/20.1.140; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LIU F, 1993, J BIOL CHEM, V268, P6714; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICKEL BE, 1991, MOL CELL BIOCHEM, V106, P181; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; ZHANG WG, 1992, J BIOL CHEM, V267, P15056; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	61	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1804	1814						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294429				2022-12-25	WOS:A1994MR98800041
J	JACOBS, SM; GORSE, KM; WESTIN, EH				JACOBS, SM; GORSE, KM; WESTIN, EH			IDENTIFICATION OF A 2ND PROMOTER IN THE HUMAN C-MYB PROTOONCOGENE	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; CYCLE-RELATED GENES; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; MAMMALIAN-CELLS; V-MYB; DNA; ACTIVATION; SEQUENCES; BINDING	We have previously described an alternatively spliced cDNA clone of the human c-myb proto-oncogene which has been shown to enhance the differentiation of Friend murine erythroleukemia cells. This clone, pMbm-2, contains unique 5' sequences which replace exon 1. The human c-myb intron 1 was sequenced to determine the exact position of this unique sequence and to further characterize the role of intron 1 in the regulation of the human c-myb gene. Here we report that intron 1 of c-myb is highly conserved between human and mouse throughout the intron, while only those sequences directly adjacent to exons 1 and 2 are conserved between human and chicken. The unique sequence of pMbm-2 was located directly adjacent to exon 2, suggesting that it arose as a product of alternative transcription initiation within intron 1. RNAase protection analysis was used to map a cluster of transcription start sites at the 5' end of exon 2. Levels of messages utilizing these start sites are proportional to those arising from the primary promoter. Functional characterization of this region revealed that this region can function as a promoter. Deletion studies have revealed the presence of negative and positive regulatory elements within this region which are utilized with different efficiencies in different cell lines. These studies suggest that cis or trans factors acting in this region may serve a dual function in both attenuation and transcription initiation.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MICROBIOL IMMUNOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, DIV HEMATOL ONCOL, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University								ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BOISE LH, 1992, CELL GROWTH DIFFER, V3, P53; BOISE LH, 1992, ONCOGENE, V7, P1817; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DVORAK M, 1989, NUCLEIC ACIDS RES, V17, P5651; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HRUBY DE, 1990, BIOTECHNIQUES, V8, P170; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LI WH, 1985, MOL BIOL EVOL, V2, P150; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maniatis T, 1989, MOL CLONING; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OHYASHIKI K, 1988, CANCER GENET CYTOGEN, V33, P83, DOI 10.1016/0165-4608(88)90053-2; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; ROSSON D, 1990, VIROLOGY, V175, P562, DOI 10.1016/0042-6822(90)90441-S; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; TORELLI U, 1986, LEUKEMIA RES, V10, P1249, DOI 10.1016/0145-2126(86)90244-4; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	56	30	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					227	235						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302584				2022-12-25	WOS:A1994MW24700028
J	SHEMESH, J; EHRLICH, R				SHEMESH, J; EHRLICH, R			ABERRANT BIOSYNTHESIS AND TRANSPORT OF CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES IN CELLS TRANSFORMED WITH HIGHLY ONCOGENIC HUMAN ADENOVIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; INTRACELLULAR-TRANSPORT; SURFACE EXPRESSION; MONOCLONAL-ANTIBODIES; INTERFERON-GAMMA; MESSENGER-RNA; TRANSLATIONAL REPRESSION; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; ANTIGEN RECEPTOR	The expression of class I major histocompatibility complex antigens on the surface of cells transformed by adenovirus 12 (Ad12) is generally very low. The absence of class I antigens correlates with the high oncogenicity of this virus. In primary embryonal fibroblasts from transgenic mice that express both endogenous H-2 genes and a miniature swine class I gene (PD1), Ad12-mediated transformation results in complete suppression of cell surface expression of class I antigens, but only 50% of the cell lines tested demonstrated decreased steady state levels of class I mRNA. The complete absence of cell surface class I antigens is accompanied by decreased levels of newly synthesized class I molecules. Those molecules that are immunoprecipitated by class I-specific antibodies are assembled with beta2-microglobulin, but their transport through the Golgi is inefficient. The biosynthesis of both the endogenous H-2K, H-2D, and the transgene product, PD1, is similarly altered in the transformed cells. The results suggest that Ad12 transformation is associated with both reduced synthesis rate and inefficient transport of class I molecules to the cell surface. This might be a general mechanism by which virus-infected or -transformed cells escape immune surveillance.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								ACKRILL AM, 1988, ONCOGENE, V3, P483; AHRINGER J, 1991, NATURE, V349, P347; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; ANDERSSON M, 1987, J IMMUNOL, V138, P3960; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BOS JL, 1983, EMBO J, V2, P73, DOI 10.1002/j.1460-2075.1983.tb01383.x; BOUILLOT M, 1989, NATURE, V339, P443; BRAUN RE, 1991, ENZYME, V44, P120; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; CERUNDOLO V, 1990, NATURE, V345, P349; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; COPLELAND CS, 1988, CELL, V53, P197; DAVIS WC, 1987, VET IMMUNOL IMMUNOP, V15, P337, DOI 10.1016/0165-2427(87)90005-5; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FELLOUS M, 1977, IMMUNOGENETICS, V5, P423, DOI 10.1007/BF01570501; FOHRING B, 1983, VIROLOGY, V131, P463, DOI 10.1016/0042-6822(83)90512-3; FRELS WI, 1985, SCIENCE, V228, P577, DOI 10.1126/science.3885396; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GOODENOW RS, 1985, SCIENCE, V230, P777, DOI 10.1126/science.2997918; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GRAHAM FL, 1984, ADENOVIRUSES, P339; HAMMERLING GJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P245, DOI 10.1016/0304-419X(87)90008-4; HO MK, 1982, J IMMUNOL, V128, P1221; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; HYMAN R, 1977, IMMUNOGENETICS, V4, P171, DOI 10.1007/BF01575656; JACOBY WB, 1979, METHOD ENZYMOL, V58, P110; JEFFERIES WA, 1988, EMBO J, V7, P3423, DOI 10.1002/j.1460-2075.1988.tb03216.x; JEFFERIES WA, 1990, J EXP MED, V172, P1653, DOI 10.1084/jem.172.6.1653; JUTILA MA, 1988, EUR J IMMUNOL, V18, P1819, DOI 10.1002/eji.1830181125; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KATOH S, 1990, EMBO J, V9, P127, DOI 10.1002/j.1460-2075.1990.tb08088.x; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOPPELMAN B, 1990, J IMMUNOL, V145, P2730; KRUYS V, 1990, ENZYME, V44, P193, DOI 10.1159/000468757; LALANNE JL, 1983, NUCLEIC ACIDS RES, V11, P1567, DOI 10.1093/nar/11.5.1567; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MAGUIRE K, 1991, ONCOGENE, V6, P1417; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MEIJER I, 1989, J VIROL, V9, P4039; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OZATO K, 1981, J IMMUNOL, V126, P317; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; Sambrook J., 1989, MOL CLONING LAB MANU; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHEMESH J, 1991, J VIROL, V65, P5544, DOI 10.1128/JVI.65.10.5544-5548.1991; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STANDART N, 1990, ENZYME, V44, P106, DOI 10.1159/000468751; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; VITELLO A, 1990, SCIENCE, P1423; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725; WILLIAMS DB, 1988, J BIOL CHEM, V263, P4549; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; ZHOU DFH, 1989, J IMMUNOL, V143, P3390; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL R, 1979, ADV IMMUNOL, V22, P51	78	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15704	15711						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340394				2022-12-25	WOS:A1993LN30500058
J	HISANAGA, S; ISHIGURO, K; UCHIDA, T; OKUMURA, E; OKANO, T; KISHIMOTO, T				HISANAGA, S; ISHIGURO, K; UCHIDA, T; OKUMURA, E; OKANO, T; KISHIMOTO, T			TAU-PROTEIN KINASE-II HAS A SIMILAR CHARACTERISTIC TO CDC2 KINASE FOR PHOSPHORYLATING NEUROFILAMENT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; SUBUNIT NF-H; NEUROFIBRILLARY TANGLES; POSTTRANSLATIONAL MODIFICATION; RAT; ANTIBODIES; NEURONS; POLYPEPTIDES; DEPHOSPHORYLATION; IDENTIFICATION	Tau protein kinase II purified from a bovine brain tau protein fraction (Ishiguro, K., Takamatsu, M., Tomizawa, K., Omori, A., Takahashi, M., Arioka, M., Uchida, T., and Imahori, K. (1992) J. Biol. Chem. 267, 10897-10901) was shown to have a similar substrate specificity to cdc2 kinase in that both phosphorylate neurofilament (NF) proteins. Tau protein kinase II recognized the dephosphorylated form of the heavy subunit of NF (NF-H) as a predominant substrate. The substrate was phosphorylated to the same extent with tau protein kinase II as with cdc2 kinase. Upon phosphorylation, the electrophoretic mobility of the NF-H on SDS-polyacrylamide gel electrophoresis changed to the position of the phosphorylated form. A synthetic peptide containing a KSPXK sequence was by far a better substrate for tau protein kinase II than that containing a KSPXX sequence, as was also observed with cdc2 kinase. NF-H lost its microtubule-associating ability upon phosphorylation with tau protein kinase II as well as with cdc2 kinase. Although anti-PSTAIR antibody (PSTAIR is an amino acid sequence commonly found in cdc2 and several cdc2-related kinases) failed to react with tau protein kinase II, tau protein kinase II bound to p13suc1-Sepharose beads (p13suc1 is a yeast protein known to bind to cdc2 kinase).	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN		HISANAGA, S (corresponding author), TOKYO INST TECHNOL,FAC BIOSCI,CELL & DEV BIOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN.							ANDERTON BH, 1982, NATURE, V298, P84, DOI 10.1038/298084a0; AUTILIOGAMBETTI L, 1983, BANBURY REPORT, V15, P117; BAILLY E, 1992, J CELL SCI, V101, P529; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BLACK MM, 1988, J NEUROSCI, V8, P3296; BREEN KC, 1988, FEBS LETT, V241, P213, DOI 10.1016/0014-5793(88)81064-0; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CORK LC, 1986, J NEUROPATH EXP NEUR, V45, P56, DOI 10.1097/00005072-198601000-00005; DAUTIGNY A, 1988, BIOCHEM BIOPH RES CO, V154, P1099, DOI 10.1016/0006-291X(88)90254-9; DOSEMECI A, 1990, CELL MOL NEUROBIOL, V10, P369, DOI 10.1007/BF00711181; DRAETTA G, 1988, ONCOGENE, V2, P553; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GLICKSMAN MA, 1987, J NEUROBIOL, V18, P167, DOI 10.1002/neu.480180205; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; HAYES TE, 1991, NEW BIOL, V3, P259; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HISANAGA S, 1990, CELL REGUL, V1, P237, DOI 10.1091/mbc.1.2.237; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1989, J NEUROSCI, V9, P959; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, BIOCHIM BIOPHYS ACTA, V755, P25, DOI 10.1016/0304-4165(83)90268-4; KISHIMOTO T, 1988, DEV GROWTH DIFFER, V30, P105; KOSIK KS, 1987, J NEUROSCI, V7, P3142; KSIEZAKREDING H, 1987, P NATL ACAD SCI USA, V84, P3410, DOI 10.1073/pnas.84.10.3410; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEW J, 1992, J BIOL CHEM, V267, P13383; LIEBERBURG I, 1989, P NATL ACAD SCI USA, V86, P2463, DOI 10.1073/pnas.86.7.2463; MEYERSON M, 1991, COLD SPRING HARB SYM, V56, P177; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NIXON RA, 1987, J NEUROSCI, V7, P1145; NUKINA N, 1987, P NATL ACAD SCI USA, V84, P3415, DOI 10.1073/pnas.84.10.3415; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PANT HC, 1986, J BIOL CHEM, V261, P2968; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; RODER HM, 1991, J NEUROSCI, V11, P3325; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TORUDELBAUFFE D, 1986, BIOCHEM J, V235, P283, DOI 10.1042/bj2350283; WIBLE BA, 1989, P NATL ACAD SCI USA, V86, P720, DOI 10.1073/pnas.86.2.720	53	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15056	15060						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325881				2022-12-25	WOS:A1993LL75900076
J	PHILIPS, A; CHALBOS, D; ROCHEFORT, H				PHILIPS, A; CHALBOS, D; ROCHEFORT, H			ESTRADIOL INCREASES AND ANTIESTROGENS ANTAGONIZE THE GROWTH FACTOR-INDUCED ACTIVATOR PROTEIN-1 ACTIVITY IN MCF7 BREAST-CANCER CELLS WITHOUT AFFECTING C-FOS AND C-JUN SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; LEUCINE ZIPPER; CDNA SEQUENCES; MESSENGER-RNA; ANTIESTROGENS; STIMULATION; CULTURE; INSULIN; BINDING	In estrogen receptor positive human breast cancer cells, anti-estrogens inhibit the mitogenic effect of growth factors in the absence of estrogens. As activator protein-1 (AP-1) activity is one of the first nuclear events following growth factor receptor activation, we studied the effects of estrogens and anti-estrogens on growth factor-induced AP-1 activity using transient transfection of the AP-1-responsive gene (AP-1)4-TK-CAT into MCF7 cells. The growth factor-induced AP-1 response was increased by estradiol and inhibited by anti-estrogens in conditions where growth factor-induced c-fos and c-jun mRNA levels were unchanged by hormone and anti-hormone treatments. The same regulations were obtained when the AP-1 response was directly induced by co-transfection of c-fos and c-jun expression vectors. Co-transfection of the wild-type estrogen receptor HEGO amplified both effects. Inhibition of AP-1 activity by anti-estrogens was unlikely to be explained by the presence of residual estrogens in MCF7 cells. (i) anti-estrogens inhibited AP-1 activity in conditions where they had no effect on basal ERE-mediated activity levels, whereas estradiol was as efficient in stimulating both activities. (ii) The relative efficacy of the two anti-estrogens, OH-tamoxifen and ICI 164,384 in inhibiting these two activities was different; OH-tamoxifen was more efficient in inhibiting ERE-mediated activity, whereas ICI 164,384 was more efficient in trans-repressing AP-1-mediated activity. We conclude that in conditions where c-fos and c-jun syntheses were not affected, the estrogen receptor cooperated with growth factors to stimulate the AP-1 response when activated by estrogens but inhibited AP-1-mediated transcription when occupied by anti-estrogens.	UNIV MONTPELLIER, 60 RUE NAVACELLES, F-34090 MONTPELLIER, FRANCE; INSERM, U148, HORMONES & CANC UNIT, F-34090 MONTPELLIER, FRANCE	Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			PHILIPS, Alexandre/AAB-6047-2020					AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BERTHOIS Y, 1989, BIOCHEM BIOPH RES CO, V159, P126, DOI 10.1016/0006-291X(89)92413-3; CAPONY F, 1978, MOL CELL ENDOCRINOL, V11, P181, DOI 10.1016/0303-7207(78)90006-0; CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276, DOI 10.1210/jcem-55-2-276; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; COEZY E, 1982, CANCER RES, V42, P317; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DARBRE P, 1983, CANCER RES, V43, P349; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FREISS G, 1990, J STEROID BIOCHEM, V37, P777, DOI 10.1016/0960-0760(90)90419-L; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LIPPMAN M, 1976, CANCER RES, V36, P4595; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; ROCHEFORT H, 1987, TRENDS PHARMACOL SCI, V8, P126, DOI 10.1016/0165-6147(87)90180-5; ROCHEFORT H, 1980, HORMONES CANCER, V14, P21; ROUX P, 1991, ONCOGENE, V6, P2155; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAMBROOK J, 1989, MOL CLONING LABORATO, P1630; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIRBASKU DA, 1979, HORMONES CELL CULTUR, V6, P477; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; SUMIDA C, 1989, ENDOCRINOLOGY, V124, P591, DOI 10.1210/endo-124-2-591; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; VANDERBURG B, 1990, MOL ENDOCRINOL, V4, P1720, DOI 10.1210/mend-4-11-1720; VIC P, 1987, BIOCHEM BIOPH RES CO, V146, P1502; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	44	148	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14103	14108						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314777				2022-12-25	WOS:A1993LJ82500049
J	ALI, AA; MARCUS, JN; HARVEY, JP; ROLL, R; HODGSON, CP; WILDRICK, DM; CHAKRABORTY, A; BOMAN, BM				ALI, AA; MARCUS, JN; HARVEY, JP; ROLL, R; HODGSON, CP; WILDRICK, DM; CHAKRABORTY, A; BOMAN, BM			RB1 PROTEIN IN NORMAL AND MALIGNANT HUMAN COLORECTAL TISSUE AND COLON-CANCER CELL-LINES	FASEB JOURNAL			English	Note						RETINOBLASTOMA PROTEIN; IMMUNOSTAINING; COLORECTAL CANCER; CELL LINES; RB1 GENE	RETINOBLASTOMA SUSCEPTIBILITY GENE; CARCINOMA-CELLS; ALTERED EXPRESSION; TUMOR SUPPRESSOR; OSTEO-SARCOMA; C-MYC; PRODUCT; GROWTH; PHOSPHORYLATION; INACTIVATION	The pattern of human retinoblastoma (RB1) gene protein expression was directly examined in normal and malignant human colorectal tissues and in seven colorectal carcinoma cell lines by immunohistochemistry using the mouse monoclonal antibody (RB-MAb-1) directed against the retinoblastoma protein (RB). This is the first demonstration of RB immunostaining in adult human colonic epithelium and colorectal carcinomas. Specificity using RB-MAb-1 was confirmed by western blot analysis, which showed bands of 110-116 kDa corresponding to the sizes of unphosphorylated and phosphosrylated RB. RB staining of normal adult colonic epithelium was confined to the nucleus and was most intense in the transitional zone of the crypt, whereas lumenal cells (fully differentiated) were RB negative. Primary colorectal carcinomas and all the colon cancer cell lines stained positively for nuclear RB, but the expression was heterogeneous with varying fractions of RB negative cells present. Because we and others have previously shown that loss or inactivation of the RB1 gene is infrequent in colorectal carcinomas, reduced RB expression in such cells is probably due to a cellular regulatory mechanism. For example, RB negative cells may be those in early-G1 phase (known to have reduced RB levels) or growth-arrested cells that have differentiated. The ability to directly detect RB in primary colorectal carcinomas will permit assessment of whether heterogeneous expression of the RB1 gene product has prognostic significance for survival of patients with this cancer.	CREIGHTON UNIV, SCH MED, CREIGHTON CANC CTR, CALIF & 24TH STS, OMAHA, NE 68178 USA; CREIGHTON UNIV, SCH MED, DEPT PATHOL, OMAHA, NE 68178 USA; TRITON LABS, ALAMEDA, CA 94501 USA	Creighton University; Creighton University								ALI AA, 1992, INT CONGR SER, V990, P29; BOMAN BM, 1988, GENETIC EPIDEMIOLOGY, P343; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUSET M, 1987, IN VITRO CELL DEV B, V23, P403; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GOPE R, 1990, HEREDITARY COLORECTA, P489; GOPE R, 1990, J NATL CANCER I, V82, P340; HAM AW, 1969, HISTOLOGY, P679; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1993, 1993 P AM ASS CANC R, P3; KORNBLAU SM, 1992, CANCER RES, V52, P4587; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; MELING GI, 1991, BRIT J CANCER, V64, P475, DOI 10.1038/bjc.1991.334; Moyer M. P., 1990, COLON CANCER CELLS, P85; MULERIS M, 1987, CANCER GENET CYTOGEN, V29, P289, DOI 10.1016/0165-4608(87)90239-1; Oi V.T., 1980, SELECTED METHODS CEL, P351; OLIVE M, 1993, IN VITRO CELL DEV-AN, V29A, P239; PASCAL RR, 1968, GASTROENTEROLOGY, V54, P835; PATTEN BM, 1968, HUMAN EMBRYOLOGY, P383; REICHMANN A, 1981, INT J CANCER, V28, P431, DOI 10.1002/ijc.2910280407; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SPARKS RL, 1990, CELL TISSUE KINET, V23, P71, DOI 10.1111/j.1365-2184.1990.tb01334.x; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; XU HJ, 1989, ONCOGENE, V4, P807; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; YAN ZF, 1992, ONCOGENE, V7, P801; YOKOTA J, 1988, ONCOGENE, V3, P471	46	38	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1993	7	10					931	937		10.1096/fasebj.7.10.8344490	http://dx.doi.org/10.1096/fasebj.7.10.8344490			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344490				2022-12-25	WOS:A1993LQ33700017
J	COSKUNARI, FF; SKOKOTAS, A; MOE, GR; HILL, TM				COSKUNARI, FF; SKOKOTAS, A; MOE, GR; HILL, TM			BIOPHYSICAL CHARACTERISTICS OF TUS, THE REPLICATION ARREST PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS CHROMOSOME; DNA-BINDING PROTEIN; TERMINATOR PROTEIN; SECONDARY-STRUCTURE; CIRCULAR-DICHROISM; ANTIGEN HELICASE; SEQUENCE; IDENTIFICATION; REGION; GENE	Tus, a DNA-binding protein, mediates arrest of DNA replication in Escherichia coli. Tus binds to DNA sequences called Ter sites, located in the terminus region of the chromosome, and forms replication-arrest complexes that block movement of DNA replication forks in a polar fashion. We have analyzed Tus to determine some of its physical parameters and biochemical characteristics. Native Tus had an 8(20,w) of 3.2, a Stokes' radius of 23 Angstrom, an axial ratio of 2, and a molar absorption coefficient of 39,700 M(-1) cm(-1). The data also indicated that Tus existed as a monomeric protein in solution and when complexed with its cognate DNA binding site. Secondary structure estimated from the circular dichroism spectrum suggested that Tus consisted of 40% alpha-helix, 0% beta-sheet, 15% turn, and 45% aperiodic structure. The isoeletric point of native Tus (pH 7.5) was significantly different than that calculated from its amino acid sequence (pH 10.1), possibly because the tertiary structure of Tus perturbs the ionization of several residues. In addition, partial proteolytic digests of free Tus protein did not produce a subfragment of Tus that retained DNA binding activity, but did demonstrate that Tus was resistant to proteolysis when complexed with a Ter site.	DREXEL UNIV,DEPT BIOSCI & BIOTECHNOL,PHILADELPHIA,PA 19104; UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	Drexel University; University of Delaware					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043193, R01GM043193] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43193] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRIGAN CM, 1987, NUCLEIC ACIDS RES, V15, P8501, DOI 10.1093/nar/15.20.8501; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; FREIFELDER D, 1982, PHYSICAL BIOCH, P466; GARNER MM, 1982, BIOCHEMISTRY-US, V21, P6032, DOI 10.1021/bi00267a001; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1989, J BIOL CHEM, V264, P21031; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HO YS, 1982, J BIOL CHEM, V257, P9128; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1989, EMBO J, V8, P2435, DOI 10.1002/j.1460-2075.1989.tb08374.x; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NATARAJAN S, 1991, P NATL ACAD SCI USA, V88, P3867, DOI 10.1073/pnas.88.9.3867; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; ROECKLEIN B, 1991, RES MICROBIOL, V142, P169, DOI 10.1016/0923-2508(91)90026-7; SALAMAN MR, 1971, BIOCHEM J, V122, P93, DOI 10.1042/bj1220093; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SHARMA B, 1992, J BACTERIOL, V174, P7854, DOI 10.1128/JB.174.23.7854-7858.1992; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SISTA P, 1990, GENE DEV, V5, P74; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; SOBER HA, 1970, HDB BIOCH, pC10; TOMBS MP, 1959, BIOCHEM J, V73, P167, DOI 10.1042/bj0730167; VANIERSEL J, 1985, ANAL BIOCHEM, V151, P196, DOI 10.1016/0003-2697(85)90072-7; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; YANG JT, 1986, METHOD ENZYMOL, V130, P208	46	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4027	4034						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307958				2022-12-25	WOS:A1994MW98900022
J	KRECK, ML; UHLINGER, DJ; TYAGI, SR; INGE, KL; LAMBETH, JD				KRECK, ML; UHLINGER, DJ; TYAGI, SR; INGE, KL; LAMBETH, JD			PARTICIPATION OF THE SMALL MOLECULAR-WEIGHT GTP-BINDING PROTEIN RAC1 IN CELL-FREE ACTIVATION AND ASSEMBLY OF THE RESPIRATORY BURST OXIDASE - INHIBITION BY A CARBOXYL-TERMINAL RAC PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL NADPH OXIDASE; ADENINE-DINUCLEOTIDE PHOSPHATE; FREE SYSTEM; PLASMA-MEMBRANE; CYTOSOLIC COMPONENTS; RECOMBINANT P47-PHOX; ANIONIC AMPHIPHILE; EXCHANGE PROTEINS; CYTOCHROME-B558; RECONSTITUTION	NADPH-dependent superoxide generation was activated by anionic amphiphiles plus GTP gamma S in a cell-free system consisting of plasma membranes plus recombinant p47-phox, p67-phox, and the small GTP-binding protein Rac1. Rac1 was expressed in Escherichia coli both as the native form and as a mutant form (Rac1(C189S)) lacking the prenylation site. When preloaded with GTP gamma S, both Rac proteins supported activity to a level comparable to that seen using cytosol. A peptide corresponding to the carboxyl-terminal region of Rad was used to investigate oxidase assembly and activation. Rac1(178-188), but not several control peptides, inhibited activity. The peptide inhibited competitively (K-i = 15 mu M) with respect to Rac1(C189S), while inhibition was noncompetitive or mixed with respect to p47-phox and p67-phox. This indicated specific inhibition of the interaction of the Rac protein with its target, possibly cytochrome b(558) The peptide was effective only when added prior to activation with arachidonic acid, suggesting that it affects assembly rather than activity. Consistent with this possibility the peptide prevented translocation of p47-phox and p67-phox to the plasma membrane. Thus, Rac plays a central role in the assembly of the neutrophil NADPH oxidase.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University					NCI NIH HHS [CA 46508] Funding Source: Medline; NIAID NIH HHS [AI22809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; ANDO S, 1992, J BIOL CHEM, V267, P25709; BABIOR BM, 1987, TRENDS BIOCHEM SCI, V12, P241, DOI 10.1016/0968-0004(87)90118-6; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FUJIMOTO S, 1989, J BIOL CHEM, V264, P21629; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MIKI T, 1992, J BIOL CHEM, V267, P18695; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; PARK JW, 1992, J BIOL CHEM, V267, P17327; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PEVERI P, 1990, BLOOD, V76, P751; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEIFERT R, 1988, EUR J BIOCHEM, V175, P51, DOI 10.1111/j.1432-1033.1988.tb14165.x; SMITH RM, 1991, BLOOD, V77, P673; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2	41	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4161	4168						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307977				2022-12-25	WOS:A1994MW98900042
J	ACHARYA, AS; BOBELIS, DJ; WHITE, SP				ACHARYA, AS; BOBELIS, DJ; WHITE, SP			ELECTROSTATIC MODIFICATION AT THE AMINO TERMINI OF HEMOGLOBIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-PROPERTIES; GLYCERALDEHYDE; CYANATE	The structural perturbations of the amino-terminal domains of hemoglobin A resulting from the carbamino adduct formation (a reversible in vivo electrostatic modification reaction) at Val-1(alpha) and Val-1(beta) is expected to be mimicked in the derivatives of HbA reductively alkylated at its alpha-amino terminus with aldehydes containing a negatively charged functional group at their distal end (double-headed reagents). Derivatives of HbA with galacturonic acid linked through alkylamino linkage either to Val-1(alpha) or Val-1(beta) (disubstituted derivatives) as well as to both Val-1(alpha) and Val-1(beta) (tetrasubsituted derivative) have been now prepared. All the three derivatives exhibit normal cooperativity but reduced O2 affinities. The functional consequence of the modification of HbA at its amino termini with D-galacuronic acid has been compared with that of the carboxymethylation of HbA at the same sites. This comparative study suggests that the stereochemistry of the carboxylate ion introduced into beta-cleft of Hb dictates the level of reduction in the O2 affinity of the molecule seen on derivatization. However such a unique stereochemistry of the carboxylate ion of the reagent does not appear to be crucial to lower oxygen affinity when the modification is at the amino terminus of the alpha-chain. The molecular modeling studies demonstrate that the carboxylate ion of the carbamino adduct at the amino terminus of the beta-chain as well as the carboxylate of carboxymethyl group at the same site are in a geometrical orientation that favors the formation of an intrachain ionic interaction with the epsilon-amino group of Lys-82(beta). On the other hand the stereochemistry of a carboxylate ion of galacuronic acid on Val-1(beta) appears to be appropriate to form either an intrachian salt bridge with epsilon-amino group of Ly2-82(beta) of the same chain (intrachain) or alternatively an interchain salt bridge involving the epsilon-amino group of Lys-82(beta) of the trans chain. We speculate that the latter, i.e. trans configuration is favored as a result of the potential of D-galacturonic acid bound to Val-1(beta) to form an additional hydrogen bond with trans His-143(beta).	DNX CORP, PRINCETON FORRESTAL CTR, PRINCETON, NJ 08540 USA	Princeton University	ACHARYA, AS (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, DIV HEMATOL, BRONX, NY 10461 USA.				NHLBI NIH HHS [HL-38665] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABOLA EE, 1987, PROTEIN DATA BANK CR, P107; ACHARYA AS, 1983, INT J PEPT PROT RES, V22, P78; ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; ACHARYA AS, 1983, J BIOL CHEM, V258, P3761; ACHARYA AS, 1984, J BIOL CHEM, V259, P4372; ACHARYA AS, 1980, J BIOL CHEM, V255, P1406; ACHARYA AS, 1982, FED PROC, V41, P1174; ACHARYA AS, 1985, J BIOL CHEM, V260, P6039; Benesch R E, 1974, Adv Protein Chem, V28, P211, DOI 10.1016/S0065-3233(08)60231-4; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BUCCI E, 1965, J BIOL CHEM, V240, pP551; BUCCI E, 1989, J BIOL CHEM, V264, P6191; BUCCI E, 1981, METHOD ENZYMOL, V76, P527; CERAMI A, 1971, P NATL ACAD SCI USA, V68, P1180, DOI 10.1073/pnas.68.6.1180; DIDONATO A, 1983, J BIOL CHEM, V258, P1890; FANELLI AR, 1964, ADV PROTEIN CHEM, V19, P73, DOI 10.1016/S0065-3233(08)60189-8; FANTL WJ, 1987, J BIOL CHEM, V262, P12700; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; KILMARTIN JV, 1973, PHYSIOL REV, V53, P836, DOI 10.1152/physrev.1973.53.4.836; KILMARTIN JV, 1969, NATURE, V222, P1243, DOI 10.1038/2221243a0; MANNING JM, 1991, ADV ENZYMOL RAMB, V64, P55; NIGEN AM, 1974, J BIOL CHEM, V249, P6611; PERUTZ MF, 1978, SCI AM, V239, P92, DOI 10.1038/scientificamerican1278-92; SEETHARAM R, 1986, J CELL BIOCHEM, V30, P87, DOI 10.1002/jcb.240300110; TENEYCK LF, 1976, J MOL BIOL, V100, P3, DOI 10.1016/S0022-2836(76)80029-0; [No title captured]	26	3	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2796	2804						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300612				2022-12-25	WOS:A1994MV43200066
J	UCHIDA, K; KAWAKISHI, S				UCHIDA, K; KAWAKISHI, S			IDENTIFICATION OF OXIDIZED HISTIDINE GENERATED AT THE ACTIVE-SITE OF CU,ZN-SUPEROXIDE DISMUTASE EXPOSED TO H2O2 - SELECTIVE GENERATION OF 2-OXO-HISTIDINE AT THE HISTIDINE-118	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUPEROXIDE-DISMUTASE; METAL-CATALYZED OXIDATION; HYDROGEN-PEROXIDE; FREE-RADICALS; DNA; INACTIVATION; PROTEINS; COPPER; FRAGMENTATION; CONVERSION	Inactivation of CuZn-superoxide dismutase (Cu,Zn-SOD) by its own reaction product H2O2 is a well-known phenomenon. Generation of the hydroxyl radical has been a matter of great concern, and the target molecule has been regarded as its own active site histidine residues, whose oxidized forms have not yet been identified (Hodgson, E.K., and Fridovich, I. (1975) Biochemistry 14, 5294-5299). Here we report on the identification of oxidized histidines generated at the active site of Cu,Zn-SOD by reaction with H2O2. When bovine erythrocyte Cu,Zn-SOD (0.5 mg/ml) was treated with 5 mm H2O2 in 50 mm sodium phosphate buffer (pH 7.2), histidine was significantly lost; however, except for a significant increase in aspartate and glutamate, nothing new appeared in the amino acid analysis of oxidized Cu,Zn-SOD. On the other hand, the hydrolysates of oxidized Cu,Zn-SOD involved an unknown product that was detectable by reverse-phase high performance liquid chromatography with electrochemical detection. The product was found to be identical to 2-oxo-histidine that had been discovered as the major oxidation product of histidine and its peptides treated with a copper/ascorbate-free radical generating system. The main product present in the hydrolysate of H2O2-treated Cu,Zn-SOD was 2-oxo-histidine. Approximately 0.66 mol/mol subunit was formed when Cu,Zn-SOD was treated with 5 mM H2O2 for 30 min. Both metal chelators and the hydroxyl radical scavengers only slightly inhibited the 2-oxo-histidine formation (10-39%), suggesting that the active species were produced mainly inside the ligands of the Cu2+ in the enzyme. Trypsin digestion of H2O2-treated Cu,Zn-SOD showed selective reactions at the sequences of Gly24-Lys67 and Thr114-Arg126, in that histidine residues locate at the active center. Two new products derived from those peptides appeared in the tryptic map. Amino acid analysis of both products demonstrated the loss of only histidine. One of them derived from Thr114-Arg126 contained an equimolar amount of 2-oxo-histidine, indicating that His-118 was converted selectively to 2-oxo-histidine; however, another product derived from Gly24-Lys67 contained only 0.085 mol of 2-oxo-histidine/mol of peptide, suggesting that the product is a mixture consisting of unidentified forms of oxidized histidine. Taken together, the present study provided direct evidence that 2-oxo-histidine was generated in the Cu,Zn-SOD exposed to H2O2 and that its generation was selective at histidine 118 of the active site of the enzyme.			UCHIDA, K (corresponding author), NAGOYA UNIV,SCH AGR,FOOD & BIODYNAM LAB,NAGOYA 46401,JAPAN.			Uchida, Koji/0000-0003-3894-5299				AMICI A, 1989, J BIOL CHEM, V264, P3341; BLECH DM, 1983, ARCH BIOCHEM BIOPHYS, V224, P579, DOI 10.1016/0003-9861(83)90245-X; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; Floyd R A, 1986, Free Radic Res Commun, V1, P163, DOI 10.3109/10715768609083148; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASAI H, 1987, CARCINOGENESIS, V8, P1959, DOI 10.1093/carcin/8.12.1959; KASAI H, 1986, ENVIRON HEALTH PERSP, V67, P111, DOI 10.2307/3430324; KATO Y, 1992, J BIOL CHEM, V267, P23646; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SALO DC, 1990, J BIOL CHEM, V265, P11919; SATO K, 1992, J BIOL CHEM, V267, P25371; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STEINMAN HM, 1974, J BIOL CHEM, V249, P7326; STEWART LC, 1987, BIOCHEMISTRY-US, V26, P5302, DOI 10.1021/bi00391a013; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; UCHIDA K, 1990, BIOCHEM BIOPH RES CO, V169, P265, DOI 10.1016/0006-291X(90)91463-3; UCHIDA K, 1990, ARCH BIOCHEM BIOPHYS, V283, P20, DOI 10.1016/0003-9861(90)90606-Y; UCHIDA K, 1986, BIOCHEM BIOPH RES CO, V138, P659, DOI 10.1016/S0006-291X(86)80547-2; UCHIDA K, 1989, BIOORG CHEM, V17, P334; YIM MB, 1993, J BIOL CHEM, V268, P4099	33	198	203	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2405	2410						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300566				2022-12-25	WOS:A1994MV43200013
J	ZHANG, JS; MACRAE, TH				ZHANG, JS; MACRAE, TH			NUCLEOTIDE DEPENDENCE AND CYTOPLASMIC LOCALIZATION OF A 49-KDA MICROTUBULE CROSS-LINKING PROTEIN FROM THE BRINE SHRIMP, ARTEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN HEAVY-CHAIN; ACTIVATED ATPASE; MITOTIC SPINDLE; MECHANOCHEMICAL ENZYME; MONOCLONAL-ANTIBODIES; CHICKEN ERYTHROCYTES; TRYPANOSOMA-BRUCEI; GROWTH CONES; DYNEIN; IDENTIFICATION	Many different proteins associate with microtubules, influencing their spatial organization and function. These include proteins of a structural nature, which link microtubules to one another or to other cellular organelles and which may stimulate tubulin assembly. The second group, the so-called dynamic microtubule-associated proteins, move subcellular components along microtubules through nucleotidase action. In this report the effects of nucleotides on a 49-kDa protein which appears to associate with ordered arrays of microtubules within Artemia are described, revealing a protein with novel characteristics. Efficient removal of the 49-kDa protein from microtubules assembled in cell-free extracts of Artemia occurred with GTP and some analogues of ATP, nonhydrolyzable or otherwise, but not with ATP itself. The latter nucleotide had a greater impact on cross-linking when microtubules were assembled from purified tubulin. The 49-kDa protein possessed a low level of nucleotidase activity, preferring either ATP or GTP as substrate. Unlike other microtubule-associated proteins, the enzymatic activity of the 49-kDa protein was not stimulated by microtubules, at least under assay conditions in which cross-linking was disrupted by nucleotides. Immunofluorescent staining of Artemia larvae by affinity-purified antibodies indicated that the 49-kDa protein is located in mitotic spindles, midbodies, and setal cells, all regions containing organized microtubules. The 49-kDa microtubule cross-linking protein from Artemia, through its unusual response to nucleotides and its cytoplasmic location, has a unique position within the heterogeneous family of microtubule-associated proteins described to date.	DALHOUSIE UNIV,DEPT BIOL,HALIFAX B3H 4J1,NS,CANADA	Dalhousie University								AAMODT EJ, 1986, J CELL BIOL, V103, P23, DOI 10.1083/jcb.103.1.23; AMOS LA, 1989, J CELL SCI, V93, P19; BALABAN N, 1989, CELL MOTIL CYTOSKEL, V14, P393, DOI 10.1002/cm.970140309; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRAMBLETT GT, 1989, CELL MOTIL CYTOSKEL, V13, P145, DOI 10.1002/cm.970130303; CAMPBELL EJ, 1989, J CELL SCI, V93, P29; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; COHN SA, 1989, J BIOL CHEM, V264, P4290; FEICK P, 1991, J CELL BIOL, V112, P689, DOI 10.1083/jcb.112.4.689; GARD DL, 1991, DEV BIOL, V143, P346, DOI 10.1016/0012-1606(91)90085-H; GOLDSTEIN LSB, 1993, J CELL BIOL, V120, P1, DOI 10.1083/jcb.120.1.1; GRISSOM PM, 1992, CELL MOTIL CYTOSKEL, V21, P281, DOI 10.1002/cm.970210404; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HARLOW E, 1988, ANTIBODIES LAB MANUA, P498; HATSUMI M, 1992, J CELL SCI, V103, P1013; HIROKAWA N, 1985, J CELL BIOL, V101, P1858, DOI 10.1083/jcb.101.5.1858; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HOLLENBECK PJ, 1986, J CELL BIOL, V103, P1539, DOI 10.1083/jcb.103.4.1539; HOLLENBECK PJ, 1984, J CELL BIOL, V99, P1251, DOI 10.1083/jcb.99.4.1251; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; JENSEN CG, 1991, EUR J CELL BIOL, V54, P121; JENSEN CG, 1991, PROTOPLASMA, V161, P137, DOI 10.1007/BF01322726; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KALLAJOKI M, 1992, J CELL SCI, V102, P91; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; MACRAE TH, 1991, CELL MOTIL CYTOSKEL, V18, P189, DOI 10.1002/cm.970180305; MACRAE TH, 1992, BIOCHIM BIOPHYS ACTA, V1160, P145, DOI 10.1016/0167-4838(92)90001-T; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MANDELKOW EM, 1992, CELL MOTIL CYTOSKEL, V22, P235, DOI 10.1002/cm.970220403; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITHIEUX G, 1988, BIOCHIM BIOPHYS ACTA, V971, P29; MITHIEUX G, 1989, J BIOL CHEM, V264, P4664; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OCONNELL MJ, 1993, J CELL BIOL, V120, P153, DOI 10.1083/jcb.120.1.153; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PRESCOTT AR, 1992, J CELL SCI, V102, P103; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; SANCHEZ I, 1990, EUR J CELL BIOL, V52, P349; SAWIN KE, 1992, J CELL SCI, V101, P303; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHROEDER CC, 1990, J CELL BIOL, V111, P2553, DOI 10.1083/jcb.111.6.2553; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; TABLIN F, 1991, EUR J CELL BIOL, V56, P415; TAKEMURA R, 1992, J CELL SCI, V103, P953; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; UMEYAMA T, 1993, J CELL BIOL, V120, P451, DOI 10.1083/jcb.120.2.451; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P6259, DOI 10.1073/pnas.80.20.6259; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VONMASSOW A, 1989, CELL MOTIL CYTOSKEL, V14, P562, DOI 10.1002/cm.970140413; WINCKLER B, 1991, P NATL ACAD SCI USA, V88, P6033, DOI 10.1073/pnas.88.14.6033; WOODS A, 1989, J CELL SCI, V93, P491; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; ZHANG JS, 1992, BIOCHEM CELL BIOL, V70, P1055, DOI 10.1139/o92-150	72	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3053	3062						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300639				2022-12-25	WOS:A1994MV43200099
J	CASEY, WM; GIBSON, KJ; PARKS, LW				CASEY, WM; GIBSON, KJ; PARKS, LW			COVALENT ATTACHMENT OF PALMITOLEIC ACID (C16-1 DELTA(9)) TO PROTEINS IN SACCHAROMYCES-CEREVISIAE - EVIDENCE FOR A 3RD CLASS OF ACYLATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; ALPHA-SUBUNIT; TERMINUS; CELLS	Saccharomyces cerevisiae was used as a model system to characterize the covalent attachment of palmitoleic acid to proteins. Chemically synthesized cis-[9,10-H-3]hexadecenoic acid (palmitoleic acid) was used to demonstrate the attachment of this lipid species to at least six proteins (m = 122, 58, 45, 41, 31, and 17 kDa). The majority of the labeled proteins are distinct from those labeled with [H-3]palmitic acid (16:0). Based on the lability of the bond in the presence of methanolic KOH or hydroxylamine (pH 8), we propose that [H-3] palmitoleic acid is attached to proteins via a thioester linkage. The identity of the palmitoleic acid was established by C-18 reverse phase high performance thin layer chromatography and argentation thin layer chromatography analysis after the fatty acid was liberated from the proteins by either transesterification or saponification. Incorporation of [H-3]palmitoleic acid into proteins was only slightly inhibited (relative to [H-3] myristic acid) by the presence of cycloheximide, indicating that the attachment of [H-3]palmitoleic acid occurs post-translationally. This report is the first description of multiprotein acylation by a long chain unsaturated fatty acid.	DUPONT CO INC,EXPTL STN,WILMINGTON,DE 19880	DuPont	CASEY, WM (corresponding author), N CAROLINA STATE UNIV,DEPT MICROBIOL,RALEIGH,NC 27695, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037222] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37222] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES DE, 1963, J CHEM SOC, P775, DOI 10.1039/jr9630000775; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASABIELL X, 1991, BIOCHEM J, V278, P679, DOI 10.1042/bj2780679; CASEY WM, 1993, BIOCHEM BIOPH RES CO, V193, P1297, DOI 10.1006/bbrc.1993.1766; CASEY WM, 1992, J BACTERIOL, V174, P7283, DOI 10.1128/jb.174.22.7283-7288.1992; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JENIS DM, 1987, LEUKEMIA RES, V11, P935, DOI 10.1016/0145-2126(87)90139-1; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDER ME, 1991, J BIOL CHEM, V266, P4654; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MORRIS LJ, 1962, CHEM IND-LONDON, P1238; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; STRAUCH MA, 1992, MOL MICROBIOL, V6, P2909, DOI 10.1111/j.1365-2958.1992.tb01750.x; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; TOWLER DA, 1988, ANN REV BIOCH, V57, P5382; VINCENZINI MT, 1983, INT J BIOCHEM, V15, P1283, DOI 10.1016/0020-711X(83)90220-3; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	23	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2082	2085						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294460				2022-12-25	WOS:A1994MR98800081
J	IZZO, NJ; TULENKO, TN; COLUCCI, WS				IZZO, NJ; TULENKO, TN; COLUCCI, WS			PHORBOL ESTERS AND NOREPINEPHRINE DESTABILIZE ALPHA(1B)-ADRENERGIC RECEPTOR MESSENGER-RNA IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ALPHA-ADRENERGIC RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; GENE-EXPRESSION; CALCIUM EFFLUX; STIMULATION; INCREASES; CA-2+; MECHANISMS; ACTIVATION	The mechanism by which norepinephrine (NE) down-regulates alpha1B-adrenergic receptor (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells. NE, phorbol esters, and bradykinin each decreased alpha-AR mRNA levels by 70-80%. The protein kinase C inhibitor (+)-1-5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%. Neither ryanodine nor EGTA inhibited down-regulation of alpha-AR mRNA by NE. Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level. Both NE and phorbol esters increased the rate of alpha-AR mRNA degradation. In NE-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of alpha-AR mRNA. The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MED COLL PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19129 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Drexel University				Izzo, Nicholas/0000-0002-0196-2055; Colucci, Wilson/0000-0002-0576-9420	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008324, R01HL030496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08324, HL425309, HL30496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLAES N, 1983, J CELL PHYSIOL, V116, P167, DOI 10.1002/jcp.1041160207; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLUCCI WS, 1986, P NATL ACAD SCI USA, V83, P1743, DOI 10.1073/pnas.83.6.1743; COLUCCI WS, 1981, CIRC RES, V48, P104, DOI 10.1161/01.RES.48.1.104; COLUCCI WS, 1986, CIRC RES, V58, P393, DOI 10.1161/01.RES.58.3.393; COLUCCI WS, 1985, MOL PHARMACOL, V27, P517; COLUCCI WS, 1988, BIOCHEM BIOPH RES CO, V156, P924, DOI 10.1016/S0006-291X(88)80932-X; COLUCCI WS, 1908, CLIN RES, V36, pA269; COTECCHIA S, 1985, LIFE SCI, V37, P2389, DOI 10.1016/0024-3205(85)90106-7; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HISAYAMA T, 1990, BRIT J PHARMACOL, V100, P677, DOI 10.1111/j.1476-5381.1990.tb14075.x; HU ZW, 1993, J BIOL CHEM, V268, P3610; HWANG KS, 1987, PFLUG ARCH EUR J PHY, V408, P343, DOI 10.1007/BF00581127; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; MAJESKY MW, 1990, J BIOL CHEM, V265, P1082; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; NAKAKI T, 1990, MOL PHARMACOL, V37, P30; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; SEI CA, 1991, J BIOL CHEM, V266, P15910; TSUJIMOTO G, 1987, CIRC RES, V61, P86, DOI 10.1161/01.RES.61.1.86; WIKBERG JES, 1983, LIFE SCI, V33, P1409, DOI 10.1016/0024-3205(83)90824-X	30	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1705	1710						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294418				2022-12-25	WOS:A1994MR98800028
J	MANO, H; MORI, R; OZAWA, T; TAKEYAMA, K; YOSHIZAWA, Y; KOJIMA, R; ARAO, Y; MASUSHIGE, S; KATO, S				MANO, H; MORI, R; OZAWA, T; TAKEYAMA, K; YOSHIZAWA, Y; KOJIMA, R; ARAO, Y; MASUSHIGE, S; KATO, S			POSITIVE AND NEGATIVE REGULATION OF RETINOID X-RECEPTOR GENE-EXPRESSION BY THYROID-HORMONE IN THE RAT - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL CONTROLS BY THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESTROGEN RESPONSE ELEMENT; MESSENGER-RNA; ACID RECEPTORS; BETA; SUPERFAMILY; STABILITY; CLONING; MEDIATE; LIGAND; ALPHA	The 9-cis-retinoic acid receptors (RXRs), belonging to the members of the steroid/thyroid hormone receptor superfamily, act as auxiliary proteins, heterodimerizing with other nuclear receptors such as retinoic acid receptors (RARs), vitamin D receptor, thyroid hormone receptors, and peroxisome-proliferator activated receptor, thereby transactivating target genes in a ligand-dependent manner. We have previously reported that in the rat, thyroid hormone (TH) positively and negatively regulates the hepatic mRNA levels of RXRbeta and RXRgamma, respectively. In the present study, we have tried to elucidate the level at which TH regulates the gene expression of RXRbeta and RXRgamma in the rat. A RNA synthesis inhibitor (actinomycin D), but not a protein synthesis inhibitor (cycloheximide), blocked the induction of RXRbeta mRNA by TH. On the other hand, none of these drugs inhibited the decrease of RXRgamma mRNA levels caused by TH. Nuclear run-on assays showed that the transcription rate of the RXRbeta gene was positively regulated by TH, whereas the transcription of RXRgamma gene was not controlled by TH. Taken together, these results indicate that the gene expression of RXRbeta is positively regulated by TH at transcriptional level, while the negative regulation of the RXRgamma gene expression by TH may occur at a post-transcriptional level in intact rat. Thus, the RXR-mediated signal transductions may be modulated in part through TH control of the levels of RXRbeta and RXRgamma.	TOKYO UNIV AGR, FAC AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN	Tokyo University of Agriculture			Arao, Yukitomo/AAL-1665-2021	Arao, Yukitomo/0000-0003-1560-351X				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BELLARD M, 1989, METHOD ENZYMOL, V170, P317; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KRANE IM, 1991, MOL ENDOCRINOL, V5, P469, DOI 10.1210/mend-5-4-469; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANO H, 1993, BIOCHEM BIOPH RES CO, V191, P943, DOI 10.1006/bbrc.1993.1308; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; NINOMIYA Y, 1992, BIOCHEM BIOPH RES CO, V187, P1374, DOI 10.1016/0006-291X(92)90454-S; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; RIEGEL AT, 1987, MOL ENDOCRINOL, V1, P160, DOI 10.1210/mend-1-2-160; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	28	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1591	1594						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294402				2022-12-25	WOS:A1994MR98800007
J	TILLOTSON, LG; WANG, TC; BRAND, SJ				TILLOTSON, LG; WANG, TC; BRAND, SJ			ACTIVATION OF GASTRIN TRANSCRIPTION IN PANCREATIC INSULINOMA CELLS BY A CACC PROMOTER ELEMENT AND A 70-KDA SEQUENCE-SPECIFIC DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GENE-TRANSCRIPTION; ISLET CELL; ENHANCER-BINDING; CONTROL REGION; GLUCAGON GENE; EXPRESSION; UPSTREAM; IDENTIFICATION; DOMAINS	Gastrin gene expression in the pancreatic islets is developmentally regulated and occurs largely during fetal life. Deletional analysis of transiently transfected rat insulinoma cells with gastrin 5'-flanking sequences in luciferase reporter genes demonstrated that the gastrin promoter sequence proximal to -111 base pairs (bp) contains the cis-regulatory elements necessary for maximal transcription. Mutational analysis identified the sequence CCCCACCCCA (-109 to -100 bp) as a positive cis-regulatory element (CACC) located 5' to a previously described negative element (-100 to -90 bp) and E-box positive element at -82 bp. Multimers of the CACC element in a heterologous promoter activated transcription independent of the other cis-regulatory elements. CACC binding proteins were purified from insulinoma cell nuclear extracts by cation exchange and affinity chromatography. Southwestern blot of nuclear extracts identified a 70-kDa CACC-binding protein. Mutational analysis of the CACC element showed a close correlation between DNA binding of this protein and transcriptional activation. Transcriptional activation by multimers of the CACC element in a heterologous promoter was detected in a variety of cell lines but was strongest in those of islet lineage. Likewise, the presence of the 70-kDa CACC-binding protein was found in many cell lines but was most abundant in the insulinoma cells. The CACC-binding protein has not been previously identified among the known pancreatic regulatory factors and may have an important role in the developmental expression of gastrin.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	TILLOTSON, LG (corresponding author), MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, JACKSON 7, BOSTON, MA 02114 USA.				NIDDK NIH HHS [DK42147] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042147] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BACHWICH D, 1992, MOL ENDOCRINOL, V6, P1175, DOI 10.1210/me.6.8.1175; BARDRAM L, 1990, P NATL ACAD SCI USA, V87, P298, DOI 10.1073/pnas.87.1.298; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND SJ, 1984, NATURE, V309, P456, DOI 10.1038/309456a0; BRAND SJ, 1988, J BIOL CHEM, V263, P5341; BRAND SJ, 1988, J BIOL CHEM, V263, P16597; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DEMEDIUK BH, 1992, GASTROENTEROLOGY, V102, P728; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DONG JL, 1991, MOL ENDOCRINOL, V5, P1633, DOI 10.1210/mend-5-11-1633; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GODLEY JM, 1989, P NATL ACAD SCI USA, V86, P3036, DOI 10.1073/pnas.86.9.3036; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HEITZ PU, 1977, DIABETES, V26, P632, DOI 10.2337/diabetes.26.7.632; ITO R, 1984, P NATL ACAD SCI-BIOL, V81, P4662, DOI 10.1073/pnas.81.15.4662; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KLEINERT H, 1990, EMBO J, V9, P711, DOI 10.1002/j.1460-2075.1990.tb08164.x; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; LARSSON LI, 1976, NATURE, V262, P609, DOI 10.1038/262609a0; LEE SL, 1988, J BIOL CHEM, V263, P16604; LEVANKIM C, 1989, J BIOL CHEM, V264, P20407; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MERCHANT JL, 1993, GASTROENTEROLOGY, V104, P283; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONSOLINGE WW, 1993, GASTROENTEROLOGY, V104, P1099; WANG TC, 1990, J BIOL CHEM, V265, P8908; WANG TC, 1993, J CLIN INVEST, V92, P1349, DOI 10.1172/JCI116708; WHEELER MB, 1992, MOL CELL BIOL, V12, P3531, DOI 10.1128/MCB.12.8.3531; WIBORG O, 1984, P NATL ACAD SCI-BIOL, V81, P1067, DOI 10.1073/pnas.81.4.1067; YU CY, 1991, J BIOL CHEM, V266, P8907	58	22	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2234	2240						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294480				2022-12-25	WOS:A1994MR98800101
J	WEI, SQ; STADER, J				WEI, SQ; STADER, J			2 DISTINCT REGIONS OF THE LAMB SIGNAL SEQUENCE FUNCTION IN DIFFERENT STEPS IN EXPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI; SECB; MUTATIONS; TRANSLOCATION; COMPETENCE; STABILITY; PROMOTES; PEPTIDE; INVIVO	The hydrophobic core of the Escherichia coli LamB signal sequence contains two structurally distinct regions. One region forms a helix in nonpolar environments, and the other is less structured. These regions seem to be of special importance for export, as judged by the magnitude of the defect caused by their mutational inactivation. To gain insight into the mechanistic importance of these two regions, we examined the ability of precursors to pass partially through the export pathway when each region is mutated. The results demonstrate that mutations in the helical and unstructured regions of the signal sequence block different steps in the export pathway.	UNIV MISSOURI,SCH BIOL SCI,KANSAS CITY,MO 64110	University of Missouri System; University of Missouri Kansas City					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043514] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN E, 1990, J BIOL CHEM, V265, P18154; BANKAITIS VA, 1984, J BIOL CHEM, V259, P2193; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; BRUCH MD, 1989, BIOCHEMISTRY-US, V28, P8554, DOI 10.1021/bi00447a043; CLARK D, 1980, J BIOL CHEM, V255, P714; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; DECOCK H, 1992, MOL MICROBIOL, V6, P599; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FIKES JD, 1987, J BACTERIOL, V169, P2345, DOI 10.1128/jb.169.6.2345-2351.1987; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOTTESMAN S, 1990, METHOD ENZYMOL, V185, P119; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; RYAN JP, 1985, J BIOL CHEM, V260, P4832; STADER J, 1988, J BACTERIOL, V170, P1973, DOI 10.1128/jb.170.4.1973-1974.1988; STADER J, 1986, J BIOL CHEM, V261, P5075; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TRUN NJ, 1988, J BACTERIOL, V170, P5928, DOI 10.1128/jb.170.12.5928-5930.1988; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978	24	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1648	1653						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294411				2022-12-25	WOS:A1994MR98800019
J	SMARDA, J; LIPSICK, JS				SMARDA, J; LIPSICK, JS			C-MYB PREVENTS TPA-INDUCED DIFFERENTIATION AND CELL-DEATH IN V-MYB TRANSFORMED MONOBLASTS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; NORMAL HUMAN-LYMPHOCYTES; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; LEUKEMIA-VIRUS; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; TRANS-ACTIVATION; E26; INVITRO	Myelomonocytic cells transformed by v-Myb or altered forms of c-Myb do not contain the full-length c-Myb protein found in most immature hematopoietic cells. To determine if c-Myb was a dominant inhibitor of v-Myb, we have induced the synthesis of full-length c-Myb in monoblasts transformed by v-Myb. We found that although some morphological changes occurred, the presence of both c-Myb and v-Myb was compatible with cell growth. However, the response to phorbol ester (TPA) was significantly altered by c-Myb. Monoblasts transformed by v-Myb can be induced to differentiate into macrophages by treatment with TPA. This process is accompanied by a significant amount of cell death. However, when c-Myb was made TPA-inducible in these cells, TPA-induced differentiation into macrophages was blocked and cell death was prevented. These results demonstrate a significant difference in the biological effects of v-Myb and c-Myb in transformed myelomonocytic cells.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [R01-CA43592, K04 CA01457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001457, R01CA043592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATRON KM, 1992, J IMMUNOL, V148, P934; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LIU JL, 1992, VIROLOGY, V189, P583, DOI 10.1016/0042-6822(92)90581-9; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOSCOVICI C, 1985, RETROVIRUSES HUMAN P, P177; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P325; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PESSANO S, 1979, MICROBIOLOGICA, V2, P379; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SAMBROOK J, 1989, MOL COLONING LABORAT; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SMARDA J, 1993, IN PRESS GENE; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	59	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					237	245						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302585				2022-12-25	WOS:A1994MW24700029
J	BOISSEL, JP; LEE, WR; PRESNELL, SR; COHEN, FE; BUNN, HF				BOISSEL, JP; LEE, WR; PRESNELL, SR; COHEN, FE; BUNN, HF			ERYTHROPOIETIN STRUCTURE-FUNCTION-RELATIONSHIPS - MUTANT PROTEINS THAT TEST A MODEL OF TERTIARY STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ERYTHROPOIETIN; COLONY-STIMULATING FACTOR; HAMSTER OVARY CELLS; CYTOKINE RECEPTOR SUPERFAMILY; HUMAN GROWTH-HORMONE; 3-DIMENSIONAL STRUCTURE; HUMAN INTERLEUKIN-4; SECONDARY STRUCTURE; EXTRACELLULAR DOMAIN; GLOBULAR PROTEINS	On the basis of its primary sequence and the location of its disulfide bonds, we propose a structural model of the erythropoietic hormone erythropoietin (Epo) which predicts a four alpha-helical bundle motif, in common with other cytokines. In order to test this model, site-directed mutants were prepared by high level transient expression in Cos7 cells and analyzed by a radioimmuno assay and by bioassays utilizing mouse and human Epo-dependent cell lines. Deletions of 5 to 8 residues within predicted alpha-helices resulted in the failure of export of the mutant protein from the cell. In contrast, deletions at the NH2 terminus (DELTA2-5), the COOH terminus (DELTA163-166), or in predicted interhelical loops (AB: DELTA32-36, DELTA53-57; BC: DELTA78-82; CD: DELTA111-119) resulted in the export of immunologically detectable Epo muteins that were biologically active. The mutein DELTA48-52 could be readily detected by radio-immunoassay but had markedly decreased biological activity. However, replacement of each of these deleted residues by serine resulted in Epo muteins with full biological activity. Replacement of Cys29 and Cys33 by tyrosine residues also resulted in the export of fully active Epo. Therefore, this small disulfide loop is not critical to Epo's stability or function. The properties of the muteins that we tested are consistent with our proposed model of tertiary structure.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BOISSEL, JP (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA.			Lee, W Robert/0000-0002-3545-0170	NHLBI NIH HHS [R01-HL42949] Funding Source: Medline; NIGMS NIH HHS [R01-GM 39900] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ANDRES DA, 1991, J BIOL CHEM, V266, P14277; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Carnot P, 1906, CR HEBD ACAD SCI, V143, P432; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COHEN FE, 1986, BIOCHEMISTRY-US, V25, P266, DOI 10.1021/bi00349a037; COHEN FE, 1986, SCIENCE, V234, P349, DOI 10.1126/science.3489989; COHEN FE, 1979, J MOL BIOL, V132, P275, DOI 10.1016/0022-2836(79)90260-2; COHEN FE, 1987, PROTEINS, V2, P162, DOI 10.1002/prot.340020209; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CURTIS BM, 1991, PROTEINS, V11, P111, DOI 10.1002/prot.340110204; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P2633, DOI 10.1021/bi00383a034; DELORME E, 1992, BIOCHEMISTRY-US, V31, P9871, DOI 10.1021/bi00156a003; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DUBE S, 1988, J BIOL CHEM, V263, P17516; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; ERSLEV A, 1953, BLOOD, V8, P349, DOI 10.1182/blood.V8.4.349.349; FAQUIN WC, 1992, BLOOD, V79, P1987; FAQUIN WC, 1993, IN PRESS EXP HEMATOL, V21; FUKUDA MN, 1989, BLOOD, V73, P84; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; HANKINS WD, 1987, BLOOD, V70, pA173; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; KINGSTON RE, 1991, CURRENT PROTOCOLS MO, V1; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Krumdieck N, 1943, P SOC EXP BIOL MED, V54, P14, DOI 10.3181/00379727-54-14283; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI PH, 1986, J BIOL CHEM, V261, P3116; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LIN FK, 1987, NATO ASI SER H, V8, P23; MANAVALAN P, 1992, J PROTEIN CHEM, V11, P321, DOI 10.1007/BF01024870; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; NARHI LO, 1991, J BIOL CHEM, V266, P23022; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; Parry D A, 1988, J Mol Recognit, V1, P107, DOI 10.1002/jmr.300010302; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; PRESNELL SR, 1992, BIOCHEMISTRY-US, V31, P983, DOI 10.1021/bi00119a006; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; REISSMANN KR, 1950, BLOOD, V5, P372, DOI 10.1182/blood.V5.4.372.372; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; SPIVAK JL, 1989, BLOOD, V73, P90; STERNBERG MJE, 1982, INT J BIOL MACROMOL, V4, P137, DOI 10.1016/0141-8130(82)90042-3; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; TSUDA E, 1990, EUR J BIOCHEM, V188, P405, DOI 10.1111/j.1432-1033.1990.tb15417.x; WANG FF, 1985, ENDOCRINOLOGY, V116, P2286, DOI 10.1210/endo-116-6-2286; WASLEY LC, 1991, BLOOD, V77, P2624; WEN D, 1993, IN PRESS BLOOD; YAMAGUCHI K, 1991, J BIOL CHEM, V266, P20434; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	69	107	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15983	15993						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340419				2022-12-25	WOS:A1993LN30500093
J	CHEN, CS; POENIE, M				CHEN, CS; POENIE, M			NEW FLUORESCENT-PROBES FOR PROTEIN-KINASE-C - SYNTHESIS, CHARACTERIZATION, AND APPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOCYTOCHEMICAL EVIDENCE; MALEIC ANHYDRIDES; RAT FIBROBLASTS; PHORBOL ESTERS; LIVING CELLS; LOCALIZATION; CALCIUM; SELECTIVITY; ACTIVATION; INHIBITORS	Fluorescent derivatives of the bisindolylmaleimide inhibitors of protein kinase C (PKC) were synthesized and tested with respect to their inhibitory potency, specificity, and usefulness as fluorescent cytological stains for PKC. Several of the fluorescent bisindolylmaleimide derivatives (fim-1, fim-2, and rim-1) acted as ATP-competitive catalytic site inhibitors and retained much of the potency and specificity of the parental compound. The R6-C1 and the PKCbeta1-overexpressing R6-PKC3 cell lines were used for testing fim-1 and rim-1 as cytological stains for PKC. Comparisons showed that the R6-PKC3 cells stained much more brightly than R6-C1 cells. When R6-PKC3 cells were treated with the phorbol ester phorbol 12-myristate 13-acetate (PMA) for 30 min, staining with fim-1 or anti-PKCbeta1 revealed a dramatic translocation of PKC to the cell periphery. When R6-PKC3 cells were exposed to PMA for 24 h to down-regulate PKC, cytoplasmic staining was drastically reduced. Staining patterns obtained with an antibody specific for PKCbeta1 and with fim-1 were remarkably similar except for mitochondrial staining, which was only seen with fim-1. A closer examination of the mitochondrial staining showed that mitochondria convert from filamentous to punctate shapes and cluster around the nucleus when cells are treated with PMA. This punctate morphology, perinuclear clustering, and staining with fim-1 persists when PKC is down-regulated. Overall, these results indicate that fim-1 and rim-1 can serve as useful fluorescent probes for PKC. The mitochondrial staining may be due to a PKC isoform resistant to down-regulation.	UNIV TEXAS,DEPT ZOOL,141 PATTERSON LABS,AUSTIN,TX 78712	University of Texas System; University of Texas Austin			Poenie, Martin/A-7428-2009	Poenie, Martin/0000-0003-2524-4039	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAZS M, 1991, J CELL BIOCHEM, V46, P266, DOI 10.1002/jcb.240460311; BORNER C, 1992, J BIOL CHEM, V267, P12892; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DAVIS PD, 1990, TETRAHEDRON LETT, V31, P2353; DAVIS PD, 1990, TETRAHEDRON LETT, V31, P5201, DOI 10.1016/S0040-4039(00)97842-0; GAPSKI GR, 1975, J MED CHEM, V18, P526, DOI 10.1021/jm00239a020; GARCIABORRON JC, 1990, J PROTEIN CHEM, V9, P683, DOI 10.1007/BF01024763; GIRARD PR, 1987, CANCER RES, V47, P2892; GREGORIO C, 1992, P NATL ACAD SCI USA, V77, P990; GUADAGNO SN, 1992, J BIOL CHEM, V267, P2697; HAGIWARA M, 1988, PHARMACOLOGY, V36, P365, DOI 10.1159/000138324; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HO AK, 1988, J BIOL CHEM, V263, P9292; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUANG KP, 1986, J BIOL CHEM, V261, P4781; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; ITO T, 1988, J CELL BIOL, V107, P929, DOI 10.1083/jcb.107.3.929; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; JOLY F, 1990, BIOCHEM J, V271, P501, DOI 10.1042/bj2710501; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LAWSON D, 1978, J CELL BIOL, V79, P394, DOI 10.1083/jcb.79.2.394; LISKAMP RMJ, 1985, BIOCHEM BIOPH RES CO, V131, P920, DOI 10.1016/0006-291X(85)91327-0; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TRAN PL, 1984, NOUV J CHIM, V8, P751; TRAN PL, 1985, CARCINOGENESIS, V6, P433, DOI 10.1093/carcin/6.3.433; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	35	70	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15812	15822						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340406				2022-12-25	WOS:A1993LN30500072
J	DELISSER, HM; YAN, HC; NEWMAN, PJ; MULLER, WA; BUCK, CA; ALBELDA, SM				DELISSER, HM; YAN, HC; NEWMAN, PJ; MULLER, WA; BUCK, CA; ALBELDA, SM			PLATELET ENDOTHELIAL-CELL ADHESION MOLECULE-1 (CD31)-MEDIATED CELLULAR AGGREGATION INVOLVES CELL-SURFACE GLYCOSAMINOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HEPARIN-BINDING; N-CAM; HETEROPHILIC ADHESION; MEDIATED ADHESION; PROTEIN; CD31; IDENTIFICATION; PECAM-1; FIBRONECTIN	Platelet/endothelial cell adhesion molecule-I (PECAM-1, CD31) is a 130-kDa integral membrane glycoprotein expressed on endothelial cells, platelets, and leukocytes. Experiments analyzing the aggregation of mouse L-cells stably transfected with full-length PECAM-1 cDNA have demonstrated that PECAM-1 is capable of mediating calcium-dependent heterophilic aggregation. In this report the ligand interactions involved in the aggregation process were studied. This aggregation was inhibited by heparin and chondroitin sulfate, but not by other glycosaminoglycans. Enzymatic removal of cell surface glycosaminoglycans confirmed a PECAM-1-glycosaminoglycan interaction and suggested that this interaction involved glycosaminoglycans on adjacent cells. PECAM-1 contains a glycosaminoglycan consensus binding sequence in the second immunoglobulin-like domain of the molecule's extracellular domain. A comparable region in the related adhesion protein N-CAM has been shown to mediate the adhesive properties of N-CAM. Cells expressing mutant PECAM-1 protein missing the second domain failed to aggregate. Synthetic peptides mimicking the consensus glycosaminoglycan binding sequence, L-K-R-E-K-N, inhibited aggregation. These results demonstrate that PECAM-1-mediated aggregation is dependent on the binding of PECAM-1 to specific glycosaminoglycans on adjacent cells via a glycosaminoglycan consensus binding sequence in the second immunoglobulin-like homology domain.	UNIV PENN,SCH MED,DEPT MED,DIV PULM,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; BLOOD CTR SOUTHEASTERN WISCONSIN,INST BLOOD RES,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT CELLULAR BIOL,MILWAUKEE,WI 53207; ROCKEFELLER UNIV,NEW YORK,NY 10021	University of Pennsylvania; The Wistar Institute; Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Rockefeller University			DeLisser, Horace/AFM-1942-2022		NHLBI NIH HHS [HL43002-02, HL-01587, HL-39023] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039023, R01HL043002, K11HL001587] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALDWIN HS, 1992, CIRCULATION, V86, P1203; BERMAN ME, 1992, FASEB J, V6, pA1888; BRENAN M, 1986, EUR J IMMUNOL, V16, P423, DOI 10.1002/eji.1830160419; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; CABANAS C, 1989, EUR J IMMUNOL, V19, P1373, DOI 10.1002/eji.1830190804; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; GENG JG, 1991, J BIOL CHEM, V266, P22313; GILL PJ, 1986, BIOCHEMISTRY-US, V25, P405, DOI 10.1021/bi00350a020; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HORNE MK, 1989, BLOOD, V74, P238; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KELTON JG, 1986, HAEMOSTASIS, V16, P173; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LOW SH, 1991, J BIOL CHEM, V266, P13391; MASSIA SP, 1992, J BIOL CHEM, V267, P10133; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; MUNAIM SI, 1991, DEV BIOL, V143, P297, DOI 10.1016/0012-1606(91)90080-M; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; NADER HB, 1991, J BIOL CHEM, V266, P10518; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OHTO H, 1985, BLOOD, V66, P873; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PARISH CR, 1988, J IMMUNOL, V141, P3498; PROBSTMEIER R, 1989, J NEUROCHEM, V53, P1794, DOI 10.1111/j.1471-4159.1989.tb09245.x; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; SIEBER F, 1981, J CELL BIOL, V90, P55, DOI 10.1083/jcb.90.1.55; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; VANMOURIK JA, 1985, J BIOL CHEM, V260, P1300; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105	50	173	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16037	16046						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340425				2022-12-25	WOS:A1993LN30500099
J	STERNEMARR, R; GUREVICH, VV; GOLDSMITH, P; BODINE, RC; SANDERS, C; DONOSO, LA; BENOVIC, JL				STERNEMARR, R; GUREVICH, VV; GOLDSMITH, P; BODINE, RC; SANDERS, C; DONOSO, LA; BENOVIC, JL			POLYPEPTIDE VARIANTS OF BETA-ARRESTIN AND ARRESTIN3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; GTP-BINDING PROTEIN; S-ANTIGEN; PINEAL-GLAND; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; SEQUENCE-ANALYSIS; ADENYLYL CYCLASE; CDNA CLONES; RHODOPSIN	Retinal arrestin (S-antigen) inactivates the photo-transduction cascade by binding to light-activated phosphorylated rhodopsin and thereby ''arresting'' coupling to the G protein transducin. Beta-arrestin (betaarr), a ubiquitous arrestin homolog, acts analogously to desensitize the beta2-adrenergic receptor by disrupting G(s) receptor interaction. In an attempt to identify additional ''arrestins'' which might regulate the multitude of G protein-coupled receptors, we have isolated two bovine brain cDNAs which encode polypeptide variants of an arrestin homolog which we have designated arrestin3 (arr3). The open reading frames of these two cDNAs are identical except that the long form, arr3L, contains an 11-amino-acid insert between residues 361 and 362. Arr3 is more closely related to bovine betaarr (78% identity) than to bovine visual arrestin (56% identity). Polymerase chain reaction amplification of RNA and immunoblotting of lysates with an arr3-specific antibody suggest that the short form, arr3S, is the major form of arr3 in all bovine tissues and that it is most abundant in the spleen. Furthermore, polymerase chain reaction amplification of betaarr mRNA indicates that in several tissues (lung, liver, spleen, and pituitary), the major form of betaarr lacks 8 amino acids which are present in brain betaarr. Immunoblotting with an antibody which recognizes betaarr and arr3 with equal sensitivity demonstrates that betaarr (either the long or the short polypeptide) is the major arrestin in all (non-photoreceptor bearing) tissues examined. These observations suggest that in some tissues, as many as four arrestin homolog variants may play a role in the regulation of G protein-coupled receptors.	JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; WILLS EYE HOSP & RES INST, DIV RES, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA; NIDDKD, MOLEC PATHOPHYSIOL BRANCH, BETHESDA, MD 20892 USA	Jefferson University; Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY5095] Funding Source: Medline; NHLBI NIH HHS [HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERTRAND P, 1990, J BIOL CHEM, V265, P18576; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BROEKHUYSE RM, 1985, CURR EYE RES, V4, P613, DOI 10.3109/02713688508999993; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DONOSO LA, 1985, INVEST OPHTH VIS SCI, V26, P561; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; Innis MA, 1990, PCR PROTOCOLS GUIDE; KIM CM, 1993, IN PRESS RECEPTOR; KNOPSE V, 1988, CURR EYE RES, V7, P1137; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KUNAPULI P, 1993, IN PRESS P NATL ACAD; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEURING U, 1990, FEBS LETT, V276, P192, DOI 10.1016/0014-5793(90)80540-Y; SHINOHARA T, 1987, JPN J OPHTHALMOL, V31, P197; SHINOHARA T, 1989, PROGR RETINAL RES, V8, P51; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SOMERS RL, 1984, SCIENCE, V226, P182, DOI 10.1126/science.6091271; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; VANTOL HHM, 1992, NATURE, V358, P149; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; YAMAKI K, 1990, J BIOL CHEM, V265, P20757; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453	57	136	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15640	15648						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340388				2022-12-25	WOS:A1993LN30500049
J	WESTERLUND, JA; WEISGRABER, KH				WESTERLUND, JA; WEISGRABER, KH			DISCRETE CARBOXYL-TERMINAL SEGMENTS OF APOLIPOPROTEIN-E MEDIATE LIPOPROTEIN ASSOCIATION AND PROTEIN OLIGOMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; SEDIMENTATION EQUILIBRIUM; III HYPERLIPOPROTEINEMIA; DENSITY LIPOPROTEINS; PLASMA-LIPOPROTEINS; AMPHIPATHIC HELIX; AQUEOUS-SOLUTION; LIPID PARTICLE; A-IV; CHOLESTEROL	The carboxyl terminus of apolipoprotein (apo) E is required for lipoprotein association and for tetramer formation. To correlate these roles with specific regions within the carboxyl terminus, a series of apoE3 variants with carboxyl-terminal truncations at residues 266, 244, 223, and 191 were expressed in Escherichia coli. As determined by gel permeation and sedimentation equilibrium centrifugation, the four truncated variants were monomeric in solution. Compared to native apoE3 (299 residues), all had reduced affinity for lipoproteins, as assessed by incubation of I-125-labeled proteins with plasma followed by fractionation of lipoprotein classes by gel filtration. The 266-residue variant associated with very low density lipoproteins and high density lipoproteins, but was partly non-lipoprotein-bound (25% of total). Shorter variants, with 244 or fewer residues, did not associate with very low density lipoproteins and only associated slightly (approximately 20%) with high density lipoproteins, with the major portion non-lipoprotein-bound (65-73%). After these proteins were injected into rabbits, the clearance rate was proportional to the plasma level of non-lipoprotein-bound protein. These results indicate lipoprotein association modulates the clearance of apoE, residues within the segment 267-299 are critical for apoE tetramerization and facilitate lipoprotein association, and residues within the segment 245-266 also contribute to lipoprotein association.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,DEPT PATHOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BELCHER JD, 1991, J LIPID RES, V32, P359; BOTHWELL MA, 1978, J BIOL CHEM, V253, P2073; CHAN L, 1991, CURR OPIN LIPIDOL, V2, P96; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DAVIS RW, 1991, J LIPID RES, V32, P1013; DAYHOFF MO, 1952, J AM CHEM SOC, V74, P2515, DOI 10.1021/ja01130a018; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; HORIE Y, 1992, J BIOL CHEM, V267, P1962; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; LOHSE P, 1992, J LIPID RES, V33, P1583; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MANTULIN WW, 1980, J BIOL CHEM, V255, P8185; POLLET RJ, 1979, J BIOL CHEM, V254, P30; RALL SC, 1986, METHOD ENZYMOL, V128, P273; REIJNGOUD DJ, 1982, BIOCHEMISTRY-US, V21, P2969, DOI 10.1021/bi00541a026; REYNOLDS JA, 1976, J BIOL CHEM, V251, P6013; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; Sparrow J T, 1980, Ann N Y Acad Sci, V348, P187, DOI 10.1111/j.1749-6632.1980.tb21300.x; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; SVEDBERG T, 1940, ULTRACENTRIFUGE, P55; TAJIMA S, 1983, J BIOL CHEM, V258, P73; TALL AR, 1976, J BIOL CHEM, V251, P3749; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WU YV, 1962, BIOCHEMISTRY-US, V1, P698, DOI 10.1021/bi00910a025; YOKOYAMA S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P99, DOI 10.1016/0005-2760(90)90266-Z; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	37	148	151	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15745	15750						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340399				2022-12-25	WOS:A1993LN30500063
J	RAJAN, AS; AGUILARBRYAN, L; NELSON, DA; NICHOLS, CG; WECHSLER, SW; LECHAGO, J; BRYAN, J				RAJAN, AS; AGUILARBRYAN, L; NELSON, DA; NICHOLS, CG; WECHSLER, SW; LECHAGO, J; BRYAN, J			SULFONYLUREA RECEPTORS AND ATP-SENSITIVE K+ CHANNELS IN CLONAL PANCREATIC ALPHA-CELLS - EVIDENCE FOR 2 HIGH-AFFINITY SULFONYLUREA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; LIGAND-BINDING SYSTEMS; POTASSIUM CHANNELS; H-3 GLIBENCLAMIDE; MEMBRANE PATCHES; SKELETAL-MUSCLE; SECRETION; PROTEIN; PURIFICATION; SOMATOSTATIN	We tested for the presence of sulfonylurea receptors in pancreatic alpha cells. Two high affinity sulfonylurea receptors were identified in clonal pancreatic alpha cells (alphaTC-6): a 140-kDa species observed previously in clonal pancreatic beta cells (HIT) and a second 150-kDa protein. The dissociation constant (K(d)) for both receptors is approximately 3.5 nM for an iodinated glyburide analog, 5-iodo-2-hydroxyglyburide. The estimated number of receptors (B(max)) increases approximately 2-fold, from 3.1 to 6.8 pmol/mg of membrane protein as the pH of the binding buffer is reduced from 7.5 to 6. Consistent with the notion that high affinity sulfonylurea receptors are integral components of the A-P-sensitive K+ channel, we demonstrated the presence of ATP-sensitive K+ channels in inside-out patches of alphaTC-6 cells. Whole cell K+ currents that activated with time showed inward rectification at positive potentials (above 0 mV) and were almost completely suppressed by 5 nM glyburide. Likewise, glyburide blocked Rb-86+ efflux from ATP-depleted alphaTC-6 cells, an effect that was reversed by 400 muM diazoxide. The presence of sulfonylurea receptors provides a mechanism by which sulfonylureas can directly modulate alpha cell function. The properties of the 150-kDa receptor and the role of ATP-sensitive K+ channels in alpha cells remain to be elucidated, but as in beta cells, ATP-sensitive K+ channels may be involved in metabolic regulation of alpha cells by glucose.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Baylor College of Medicine; Baylor College of Medicine; Washington University (WUSTL)	RAJAN, AS (corresponding author), BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030, USA.		Nichols, Colin/D-6336-2012		NCRR NIH HHS [RR-04525] Funding Source: Medline; NHLBI NIH HHS [HL45742] Funding Source: Medline; NIDDK NIH HHS [DK41898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041898] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Ashford M. L. J, 1990, POTASSIUM CHANNELS S, P300; BELLES B, 1987, PFLUG ARCH EUR J PHY, V409, P582, DOI 10.1007/BF00584657; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; DAVIES NW, 1990, NATURE, V343, P375, DOI 10.1038/343375a0; DEWEILLE JR, 1989, PFLUEGERS ARCH, V414, P580; EFENDIC S, 1980, ACTA PHYSIOL SCAND, V108, P231, DOI 10.1111/j.1748-1716.1980.tb06527.x; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FINDLAY I, 1992, J PHARMACOL EXP THER, V262, P71; FOSSET M, 1988, FEBS LETT, V242, P94, DOI 10.1016/0014-5793(88)80992-X; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GRODSKY GM, 1977, FED PROC, V36, P2714; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LOUBATIERES A, 1957, ANN NY ACAD SCI, V71, P192, DOI 10.1111/j.1749-6632.1957.tb54591.x; LUYCKX AS, 1983, HDB EXPT PHARM, V66, P175; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSON DA, 1992, J BIOL CHEM, V267, P14928; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; OSTENSON CG, 1986, DIABETOLOGIA, V29, P861, DOI 10.1007/BF00870141; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PETERSSON B, 1962, Z ZELLFORSCH MIK ANA, V57, P559, DOI 10.1007/BF00339882; PETERSSON B, 1966, ACTA ENDOCRINOL-COP, V53, P480, DOI 10.1530/acta.0.0530480; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; QIN D, 1988, AM J PHYSIOL, V255, pH980, DOI 10.1152/ajpheart.1988.255.4.H980; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RONNER P, 1991, DIABETES S1, V40, pA155; RORSMAN P, 1988, J GEN PHYSIOL, V91, P223, DOI 10.1085/jgp.91.2.223; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SHOBACK DM, 1984, P NATL ACAD SCI-BIOL, V81, P3113, DOI 10.1073/pnas.81.10.3113; SPRUCE AE, 1987, J PHYSIOL-LONDON, V382, P213, DOI 10.1113/jphysiol.1987.sp016364; STURGESS NC, 1985, LANCET, V2, P474; ZUNKLER BJ, 1989, N-S ARCH PHARMACOL, V340, P328	40	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15221	15228						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325894				2022-12-25	WOS:A1993LL75900098
J	TUKEY, RH; PENDURTHI, UR; NGUYEN, NT; GREEN, MD; TEPHLY, TR				TUKEY, RH; PENDURTHI, UR; NGUYEN, NT; GREEN, MD; TEPHLY, TR			CLONING AND CHARACTERIZATION OF RABBIT LIVER UDP-GLUCURONOSYLTRANSFERASE CDNAS - DEVELOPMENTAL AND INDUCIBLE EXPRESSION OF 4-HYDROXYBIPHENYL UGT2B13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; RAT-LIVER; DIGITOXIGENIN-MONODIGITOXOSIDE; DEPENDENT EXPRESSION; GENE; CYTOCHROME-P-450; INDUCTION; PURIFICATION; SEQUENCE; ACID	A polyclonal antibody generated against rabbit liver p-nitrophenol UDP-glucuronosyltransferase (UGT) was used to screen a rabbit liver cDNA expression library constructed in lambdagt11. A 500-base pair cDNA clone, termed pPNP, generated a fusion protein that was antigenic with the antibody. Clone pPNP encoded the 3' region of a UGT. To identify larger recombinants, clone pPNP was used as a probe to screen a second cDNA library constructed in lambdaZAP. Two different cDNA clones were identified by DNA sequence analysis. Based upon their predicted amino acid sequence analysis, the clones encode transferases belonging to the UGT2 subfamily, and have been identified as UGT2B13 and UGT2B14. The predicted N-terminal sequence of UGT2B13 is identical to that determined for the purified rabbit liver estrone UGT. However, expression of the UGT2B13 cDNA in COS-1 cells displayed no activity in the presence of estrone but efficiently conjugated 4-hydroxybiphenyl. Results of Southern blot analysis using the 5' divergent region of the UGT2B13 cDNA that encodes exon 1 demonstrates that multiple genes share sequence homology to UGT2B13, an observation which indicates that the estrone UGT and UGT2B 1 3 genes are encoded by separate alleles. When the 5' variable. regions of the cDNAs where used in Northern blot analysis, the expression of UGT2B 13 and UGT2B 14 were shown to be expressed primarily in adult rabbits. However, when neonatal rabbits were treated with either dexamethasone or rifampicin, UGT2B13 mRNA levels were induced. The neonatal induction of UGT2B13 mRNA corresponded with similar increases in 4-hydroxybiphenyl UGT activity. The expression and induction of UGT2B13 paralleled that of the developmentally regulated rabbit liver progesterone 6beta-hydroxylase P4503A6.	UNIV CALIF SAN DIEGO,CTR CANC,DEPT MED,LA JOLLA,CA 92093; UNIV IOWA,DEPT PHARMACOL,IOWA CITY,IA 52242	University of California System; University of California San Diego; University of Iowa	TUKEY, RH (corresponding author), UNIV CALIF SAN DIEGO,CTR CANC,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [R01CA037139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026221] Funding Source: NIH RePORTER; NCI NIH HHS [CA37139] Funding Source: Medline; NIGMS NIH HHS [GM26221, GM36590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTIN C, 1992, BIOCHEM PHARMACOL, V44, P836, DOI 10.1016/0006-2952(92)90426-J; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANSAL SK, 1980, ANAL BIOCHEM, V109, P321, DOI 10.1016/0003-2697(80)90655-7; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; CARLSON J, 1984, J BIOTECHNOL, V1, P253, DOI 10.1016/0168-1656(84)90017-8; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; Dutton G.F., 1980, GLUCURONIDATION DRUG; FALANY CN, 1983, DRUG METAB DISPOS, V11, P426; GASSER R, 1989, MOL PHARMACOL, V35, P617; GASSER R, 1988, MOL PHARMACOL, V32, P22; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GOVIND S, 1986, DNA-J MOLEC CELL BIO, V5, P371, DOI 10.1089/dna.1986.5.371; GREEN MD, 1989, ARCH BIOCHEM BIOPHYS, V273, P72, DOI 10.1016/0003-9861(89)90163-X; GREEN MD, 1988, ARCH BIOCHEM BIOPHYS, V262, P367, DOI 10.1016/0003-9861(88)90200-7; HAQUE SJ, 1991, DNA CELL BIOL, V10, P515, DOI 10.1089/dna.1991.10.515; JOHNSON EF, 1987, J BIOL CHEM, V262, P5918; KHANI SC, 1987, P NATL ACAD SCI USA, V84, P638, DOI 10.1073/pnas.84.3.638; LEIGHTON JK, 1984, J BIOL CHEM, V259, P1165; LEIGHTON JK, 1984, BIOCHEMISTRY-US, V23, P204, DOI 10.1021/bi00297a005; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; MCMANUS ME, 1990, CANCER RES, V50, P3367; OKINO ST, 1985, P NATL ACAD SCI USA, V82, P5310, DOI 10.1073/pnas.82.16.5310; PENDURTHI UR, 1990, J BIOL CHEM, V265, P14662; PORTER TD, 1989, MOL PHARMACOL, V36, P61; POTENZA CL, 1989, J BIOL CHEM, V264, P16222; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Sambrook J, 1989, MOL CLONING LAB MANU, P83; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHUETZ EG, 1986, J BIOL CHEM, V261, P8270; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; STYCZYNSKI P, 1991, MOL PHARMACOL, V40, P80; TEPHLY T, 1988, XENOBIOTICA, V18, P1201, DOI 10.3109/00498258809042244; TEPHLY TR, 1990, CHEM RES TOXICOL, V3, P509, DOI 10.1021/tx00018a004; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TUKEY R H, 1990, P423; TUKEY RH, 1982, DRUG METAB DISPOS, V10, P97; TUKEY RH, 1978, BIOCHEM J, V171, P659, DOI 10.1042/bj1710659; TUKEY RH, 1985, J BIOL CHEM, V260, P3347; TUKEY RH, 1981, ARCH BIOCHEM BIOPHYS, V209, P565, DOI 10.1016/0003-9861(81)90314-3; VONMEYERINCK L, 1985, DRUG METAB DISPOS, V13, P700; WATKINS JB, 1982, TOXICOL APPL PHARM, V64, P439, DOI 10.1016/0041-008X(82)90240-X; WATKINS JB, 1985, DRUG METAB DISPOS, V13, P186; YUAN PM, 1983, P NATL ACAD SCI-BIOL, V80, P1169, DOI 10.1073/pnas.80.5.1169; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074	48	33	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15260	15266						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325897				2022-12-25	WOS:A1993LL75900103
J	ARTIGUES, A; FARRANT, H; SCHIRCH, V				ARTIGUES, A; FARRANT, H; SCHIRCH, V			CYTOSOLIC SERINE HYDROXYMETHYLTRANSFERASE - DEAMIDATION OF ASPARAGINYL RESIDUES AND DEGRADATION IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; HUMAN-ERYTHROCYTES; METHYLATION; PEPTIDES; ASPARTYL; ISOASPARTATE; PURIFICATION; SPECIFICITY; MECHANISM; SITE	Rabbit liver cytosolic serine hydroxymethyltransferase exists as a set of subforms which exhibit different isoelectric points. Previous studies have shown that deamidation of an asparagine residue at position 5 of the amino acid sequence accounted for some of the charge heterogeneity (Artigues, A., Birkett, A., and Schirch, V. (1990) J. Biol. Chem. 265, 4853-4858). The present study has also identified asparagine 220 as being partially deamidated. An estimated 25-30% of the purified enzyme contains an isoaspartyl residue at position 220. This suggests that deamidation of asparagine 220 occurs by the beta-aspartyl shift mechanism. Western blot analysis of purified cytosolic serine hydroxymethyltransferase, after isoelectric focusing under reducing and denaturing conditions, showed four subforms of the individual subunits with respect to isoelectric point. Extracts from 3-day- and 3.5-year-old rabbit livers showed the presence of these same four subunit subforms. Purified cytosolic serine hydroxymethyltransferase was found to be degraded in 24 h after mechanical injection into Xenopus laevis oocytes. However, when the first 14 amino acid residues are removed from the enzyme by digestion with chymotrypsin, leaving a fully catalytically active enzyme, the rate and extent of degradation of the truncated enzyme in oocytes were significantly reduced. One of the deamidated asparagine residues is at position 5, suggesting that this deamidation site may be a signal for degradation of the enzyme.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTIGUES A, 1990, J BIOL CHEM, V265, P4853; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1984, J BIOL CHEM, V259, P714; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BYRNE PC, 1992, BIOCHEM J, V286, P117, DOI 10.1042/bj2860117; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; DESROSIERS RR, 1990, J BIOL CHEM, V265, P21368; DILIBERTO EJ, 1976, J NEUROCHEM, V26, P1159, DOI 10.1111/j.1471-4159.1976.tb07001.x; GALLETTI P, 1989, INT J PEPT PROT RES, V33, P397; GAVILANES F, 1982, J BIOL CHEM, V257, P1431; GEORGENASCIMENT.C, 1990, BIOCHEMISTRY-US, V29, P9586; GIULIAN GG, 1984, ANAL BIOCHEM, V142, P421, DOI 10.1016/0003-2697(84)90486-X; HITCHCOCK MJM, 1987, METHOD ENZYMOL, V152, P276; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; KIM S, 1983, J BIOCHEM BIOPH METH, V8, P9, DOI 10.1016/0165-022X(83)90016-7; LADINO CA, 1990, MECH AGEING DEV, V55, P123, DOI 10.1016/0047-6374(90)90020-G; LOWENSON J, 1988, BLOOD CELLS, V14, P103; LOWENSON JD, 1990, J BIOL CHEM, V265, P3106; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; LURA R, 1988, BIOCHEMISTRY-US, V27, P7671, DOI 10.1021/bi00420a015; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MURRAY ED, 1984, J BIOL CHEM, V259, P722; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; SCHIRCH L, 1968, J BIOL CHEM, V243, P5651; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH LVG, 1963, J BIOL CHEM, V238, P1032; SCHIRCH V, 1986, EUR J BIOCHEM, V161, P45, DOI 10.1111/j.1432-1033.1986.tb10122.x; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; TESHIMA G, 1991, BIOCHEMISTRY-US, V30, P3916, DOI 10.1021/bi00230a016; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; YUKSEL KU, 1986, ARCH BIOCHEM BIOPHYS, V248, P452, DOI 10.1016/0003-9861(86)90498-4	37	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13784	13790						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314747				2022-12-25	WOS:A1993LJ82500006
J	CUIF, MH; PORTEU, A; KAHN, A; VAULONT, S				CUIF, MH; PORTEU, A; KAHN, A; VAULONT, S			EXPLORATION OF A LIVER-SPECIFIC, GLUCOSE/INSULIN-RESPONSIVE PROMOTER IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PYRUVATE-KINASE GENE; RAT-LIVER; EXPRESSION; CELLS; TRANSCRIPTION; BINDING	The functional role of the different sites binding transcriptional factors on the tissue-specific, glucose-responsive promoter of the L type pyruvate kinase gene (L-PK) has been investigated in transgenic mice. These sites are able to bind, from 3' to 5', HNF1, NF1, HNF4, and MLTF/USF, respectively. We have compared the level of chloramphenicol acetyltransferase reporter transgene expression when driven by a L-PK promoter fragment of either -96 base pairs (bp) (containing only the HNF1 binding site) or -150 bp (lacking the MLTF/USF binding site) or driven by a -183-bp L-PK promoter fragment with or without the NF1 binding site. Our results demonstrate that: 1) HNF1 alone is not sufficient to promote an efficient L-PK gene transcription in vivo; 2) with only binding sites for HNF1, NF1, and HNF4, though the tissue-specific pattern of expression is respected, the level of the gene transcription is low and the hormonal control is lost; 3) the MLTF/USF binding site is the, target of the hormonal control, required for both positive response to carbohydrates and negative response to glucagon; 4) the role of NF1 in the promoter activity could be to negatively modulate the L-PK gene expression in the different tissues, without interfering with the glucose and hormone responsiveness.	INST COCHIN GENET MOLEC,INSERM,U129,RECH GENET & PATHOL MOLEC LAB,24 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Vaulont, Sophie/O-6732-2017					BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BOQUET D, 1992, EUR J BIOCHEM, V207, P13, DOI 10.1111/j.1432-1033.1992.tb17013.x; COGNET M, 1991, J BIOL CHEM, V266, P7368; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IMMAMURA K, 1982, METHOD ENZYMOL, V90, P150; JUMP DB, 1990, J BIOL CHEM, V265, P3474; NOGUCHI T, 1993, FEBS LETT, V318, P269, DOI 10.1016/0014-5793(93)80526-Z; PUZENAT N, 1992, BIOCHEM BIOPH RES CO, V189, P1119, DOI 10.1016/0006-291X(92)92320-W; SHIH HM, 1992, J BIOL CHEM, V267, P13222; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TREMP GL, 1989, J BIOL CHEM, V264, P19904; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; WEBER A, 1984, J BIOL CHEM, V259, P1798	17	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13769	13772						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314745				2022-12-25	WOS:A1993LJ82500002
J	CARTER, RS; AVADHANI, NG				CARTER, RS; AVADHANI, NG			COOPERATIVE BINDING OF GA-BINDING PROTEIN TRANSCRIPTION FACTORS TO DUPLICATED TRANSCRIPTION INITIATION REGION REPEATS OF THE CYTOCHROME-C-OXIDASE SUBUNIT-IV GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; AFFINITY DNA-BINDING; TFIID COMPLEX; NUCLEAR FACTOR; LESS PROMOTER; SEQUENCE; ELEMENTS; SITE; TATA; ACTIVATION	Transcriptional activity of the TATA-less cytochrome c oxidase subunit IV (COXIV) gene promoter depends upon two tandemly repeated sequence elements, each mapping immediately downstream of major loci of transcriptional initiation. In this paper, we demonstrate that binding of the GA-binding protein (GABP) to ets sequence motifs within each repeated unit is required for transcriptional activation of the COXIV promoter. High affinity binding of GABP to the COXIV promoter required both the DNA-binding GABP alpha subunit and the non-DNA-binding GABP beta subunit. Binding of the heteromeric GABP complex to sequences containing two GABP binding sites was shown to have a 10-20 fold greater affinity than to DNA sequences with a single site. GABP binding was necessary for promoter function of a 33-base pair fragment of the COXIV initiation region in transfected 3T3 or COS cells. Binding of GABP to the COXIV initiation region was also required for maximal transcriptional stimulation by an upstream Sp1 binding site. The initiation region was demonstrated to direct accurate transcriptional initiation in vitro, and mutations to the GABP binding sites affected not only transcriptional activity but also initiation site selection. These results indicate that the initiation region repeats of the COXIV promoter may function as GABP-dependent initiator motifs that position mRNA start sites in the absence of a TATA box or other promoter elements.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,BIOCHEM LAB,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R37CA022762, R01CA022762] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; BASU A, 1993, J BIOL CHEM, V268, P4188; BASU A, 1991, J BIOL CHEM, V266, P15450; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BHAT KS, 1989, BIOCHEMISTRY-US, V28, P763, DOI 10.1021/bi00428a052; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HONG D, 1993, EMBO J, V12, P501; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFER B, 1991, J BIOL CHEM, V266, P10989; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON CC, 1991, SCIENCE, V253, P789; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VARBASIUS JV, 1993, GENE DEV, V7, P380; VARBASIUS JV, 1991, MOL CELL BIOL, V11, P5631; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YOGANATHAN T, 1992, BIOCHEM J, V287, P349, DOI 10.1042/bj2870349; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	49	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4381	4387						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308008				2022-12-25	WOS:A1994MW98900076
J	HARGROVE, MS; SINGLETON, EW; QUILLIN, ML; ORTIZ, LA; PHILLIPS, GN; OLSON, JS; MATHEWS, AJ				HARGROVE, MS; SINGLETON, EW; QUILLIN, ML; ORTIZ, LA; PHILLIPS, GN; OLSON, JS; MATHEWS, AJ			HIS(64)(E7)-]TYR APOMYOGLOBIN AS A REAGENT FOR MEASURING RATES OF HEMIN DISSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; HUMAN HEMOGLOBIN; SYNTHETIC GENE; BINDING; MECHANISM; DISORDER; RESIDUE	To develop an assay for hemin dissociation, His(64)(E7) was replaced by Tyr in sperm whale myoglobin producing a holoprotein with a distinct green color due to an intense absorption band at 600 nm. Val(6)8(E11) was replaced by Phe in the same protein to increase its stability. When excess Tyr(64)-Val(68) apoglobin is mixed with either metmyoglobin or methemoglobin, the solution turns from brown to green, and the absorbance changes can be used to measure complete time courses for hemin dissociation from either holoprotein. This assay has been used to measure rates of hemin dissociation from native metmyoglobin, four myoglobin mutants (Ala(64)(E7), Ala(68)(E11), Phe(68)(E11), and Glu(45)(CD3)), native methemoglobin, valence hybrid hemoglobins, and two mutant hemoglobins ((alpha(Gly-E7)beta(native))(2), and (alpha(native)beta(Gly-E7))(2)). Two kinetic phases were observed for hemin dissociation from native human hemo-globin at pH 7.0 and 37 degrees C. Valence and mutant hybrid hemoglobins were used to assign the faster phase (k = 7.8 +/- 2.0 h(-1)) to hemin dissociation from ferric beta subunits and the slower (k = 0.6 +/- 0.15 h(-1)) to dissociation from (alpha subunits. The corresponding rate for wild-type metmyoglobin 0.007 +/- 0.004 h(-1).	RICE UNIV, WM KECK CTR COMP BIOL, HOUSTON, TX 77251 USA; SOMATOGEN INC, BOULDER, CO 80301 USA	Rice University	HARGROVE, MS (corresponding author), RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA.		ortiz, luis a/H-9851-2013	ortiz, luis a/0000-0003-4510-7066; Olson, John/0000-0002-0760-5403	NIAMS NIH HHS [AR 40252] Funding Source: Medline; NIGMS NIH HHS [GM-08280, GM-35649] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649, T32GM008280] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOJULA HS, 1986, BIOCHEM J, V237, P613, DOI 10.1042/bj2370613; Ascoli F, 1981, Methods Enzymol, V76, P72; BANERJEE R, 1962, BIOCHIM BIOPHYS ACTA, V64, P368, DOI 10.1016/0006-3002(62)90746-1; BANERJEE R, 1962, BIOCHIM BIOPHYS ACTA, V64, P385, DOI 10.1016/0006-3002(62)90747-3; BANERJEE R, 1962, BIOCHEM BIOPH RES CO, V8, P114, DOI 10.1016/0006-291X(62)90247-4; BELLELLI A, 1993, J BIOL CHEM, V268, P4742; BELLELLI A, 1990, J BIOL CHEM, V265, P18898; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUNN HF, 1968, J BIOL CHEM, V243, P465; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P634; CARVER TE, 1992, J BIOL CHEM, V267, P14443; COLETTA M, 1985, J BIOL CHEM, V260, P4151; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; GIACOMETTI GM, 1977, J BIOL CHEM, V252, P7447; GIBSON QH, 1963, J BIOL CHEM, V238, P1384; GIBSON QH, 1960, BIOCHEM J, V77, P328, DOI 10.1042/bj0770328; LAMAR GN, 1984, J AM CHEM SOC, V106, P6395, DOI 10.1021/ja00333a050; LIGHT WR, 1987, J BIOL CHEM, V262, P46; LIGHT WR, 1987, THESIS WM RICE U; MATHEWS AJ, 1991, J BIOL CHEM, V266, P21631; MURPHY MRN, 1985, STRUCTURE BEEF LIVER; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Riggs A., 1981, Methods in Enzymology, V76, P5; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; SMITH ML, 1984, FEBS LETT, V169, P147, DOI 10.1016/0014-5793(84)80307-5; SMITH ML, 1991, P NATL ACAD SCI USA, V88, P882, DOI 10.1073/pnas.88.3.882; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; TOMODA A, 1978, J BIOL CHEM, V253, P7415; Vandegriff K D, 1992, Biotechnol Genet Eng Rev, V10, P403; WINTERBOURN CC, 1977, BIOCHEM J, V165, P141, DOI 10.1042/bj1650141	36	205	209	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4207	4214						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307983				2022-12-25	WOS:A1994MW98900049
J	SPALDING, TA; BIRDSALL, NJM; CURTIS, CAM; HULME, EC				SPALDING, TA; BIRDSALL, NJM; CURTIS, CAM; HULME, EC			ACETYLCHOLINE MUSTARD LABELS THE BINDING-SITE ASPARTATE IN MUSCARINIC ACETYLCHOLINE-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLETHYLCHOLINE MUSTARD; IRREVERSIBLE BINDING; ANTAGONIST BINDING; GUINEA-PIG; MEMBRANES; CELLS	Acetylcholine mustard (AChM) is an analogue of acetylcholine (ACh) in which the onium headgroup is replaced by a chemically reactive aziridinium moiety. AChM aziridinium has agonist activity, but, having bound, reacts with and blocks the muscarinic receptor (mAChR) binding site. Purified mAChRs from rat forebrain have been specifically labeled with [H-3]AChM. The linkage formed is cleaved by hydroxylamine, is found within cyanogen bromide (CNBr) peptides with molecular masses of approximately 2.4 and 3.9 kDa, and is close to a disulfide bonded cysteine. Edman degradation reveals a site of label attachment 26 residues C-terminal to a CNBr cleavage site. As in the case of the alkylating antagonist analogue [H-3]propylbenzilylcholine mustard, these findings indicate that a conserved aspartic acid residue in transmembrane helix 3 of the mAChRs, corresponding to Asp-105 (m1 sequence), is the site of label attachment.	MRC,NATL INST MED RES,DIV PHYS BIOCHEM,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research								BAKER SP, 1986, MOL PHARMACOL, V30, P411; BARLOW RB, 1964, INTRODUCTION CHEMICA, P185; BOLDEN CP, 1990, J PHARMACOL EXP THER, V254, P136; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HULME EC, 1990, BIOCHEM SOC T, V18, P440, DOI 10.1042/bst0180440; JACKSON CH, 1972, J MED CHEM, V15, P1183, DOI 10.1021/jm00281a026; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAZARENO S, 1993, LIFE SCI, V52, P449, DOI 10.1016/0024-3205(93)90301-I; MEYER EM, 1987, J NEUROCHEM, V48, P477, DOI 10.1111/j.1471-4159.1987.tb04117.x; Page K. M., 1993, Life Sciences, V52, P560, DOI 10.1016/0024-3205(93)90336-2; ROBINSON DA, 1975, BRIT J PHARMACOL, V53, P363, DOI 10.1111/j.1476-5381.1975.tb07372.x; SPALDING TA, 1993, LIFE SCI, V52, P561; UCHIYAMA H, 1990, J NEUROCHEM, V54, P1870, DOI 10.1111/j.1471-4159.1990.tb04885.x; WHEATLEY M, 1987, CELLULAR MOL BASIS C, P91; WONG SKF, 1988, J BIOL CHEM, V263, P7925	18	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4092	4097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307968				2022-12-25	WOS:A1994MW98900032
J	KLEINBERGERDORON, N; KANNER, BI				KLEINBERGERDORON, N; KANNER, BI			IDENTIFICATION OF TRYPTOPHAN RESIDUES CRITICAL FOR THE FUNCTION AND TARGETING OF THE GAMMA-AMINOBUTYRIC-ACID TRANSPORTER (SUBTYPE-A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; DOPAMINE TRANSPORTER; GLYCINE TRANSPORTER; GABA TRANSPORTER; MOUSE-BRAIN; NEUROTRANSMITTER TRANSPORTERS; PLASMA-MEMBRANE; XENOPUS OOCYTES; BETA-ALANINE; CLONING	The gamma-aminobutyric acid transporter is localized in nerve terminals. It catalyzes coupled electrogenic translocation of the neurotransmitter with two or three sodium ions and one chloride ion. The transporter contains 599 amino acids and 12 putative membrane spanning alpha-helices. It is the first described member of a neurotransmitter transporter superfamily. Using site-directed mutagenesis we have investigated the role of all 10 tryptophan residues predicted to reside in these helices. All 10 have been changed to serine as well as to leucine residues. Expression of mutant cDNAs in which the tryptophans, located in positions 68, 222, and 230, are replaced by either of these two amino acids reveals that they are severely impaired in gamma-aminobutyric acid transport. Mutants in which a phenylalanine or a tyrosine residue is introduced, at either position 68 or 230, are active. On the other hand, at the 222 position replacement of the tryptophan by the aromatic amino acids results in inactive transport. After prelabeling of the proteins with [S-35]methionine, immunoprecipitation of mutant transporters indicates that their expression levels are similar to those of the wild type. Reconstitution experiments, aimed to reveal the activity of transporter molecules not apparent in the plasma membrane, indicate that the lack of activity of the W230S transporter in intact cells is by and large due to its inefficient targeting to the plasma membrane. Tryptophan residues 68 and 222 appear to be required for the intrinsic activity of the transporter. Based on several observations, including one that tryptophan residue 222 is conserved in all amino acid transporter members of the superfamily, but not in those transporting biogenic amines, we hypothesize that the pi electrons of this tryptophan could be involved in the binding of the amino group of these neurotransmitters.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,POB 1172,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem					NINDS NIH HHS [NS 16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENNETT JP, 1974, LIFE SCI, V15, P1046; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREMEAU RT, 1992, NEURON, V89, P7189; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1989, BIOCHEMISTRY-US, V28, P3722, DOI 10.1021/bi00435a015; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; LOEWENTHAL R, 1991, BIOCHEMISTRY-US, V30, P6775, DOI 10.1021/bi00241a021; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RADIAN R, 1990, J NEUROSCI, V10, P1319; RADIAN R, 1985, J BIOL CHEM, V260, P1859; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	45	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3063	3067						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300640				2022-12-25	WOS:A1994MV43200100
J	WINKLER, E; KLINGENBERG, M				WINKLER, E; KLINGENBERG, M			EFFECT OF FATTY-ACIDS ON H+ TRANSPORT ACTIVITY OF THE RECONSTITUTED UNCOUPLING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; NUCLEOTIDE-BINDING; PURINE NUCLEOTIDES; MITOCHONDRIA; MECHANISM; CONDUCTANCE; ACTIVATION; SITE	A detailed study on the activation of H+ transport by reconstituted uncoupling proteins from brown adipose tissue is given, including the influence of chain lengths and of other structural modifications, concentration dependence, and the influence of nucleotides. Uncoupling protein was reconstituted with phosphatidylcholine in such a way as to keep H+ transport with endogenous fatty acids at a minimum. Using excess of polystyrene beads on reconstitution avoided the complications arising from the use of albumin. Both DELTApsi-driven H+ uptake and H+ efflux systems are used by changing the polarity. Fatty acids stimulate H+ uptake up to 6-fold and H+ efflux more than 10-fold. There is no competition between the inhibition by nucleotides (GTP) and fatty acids. Also, the binding of GTP and ATP is not affected. Only fatty acids starting from Cs activate, reaching a maximum at C-14. However, unsaturated homologous of C18 (oleic, linoleic, etc.) are fully active. Hydrophilic substitutions by hydroxyl, CO2H, bromo, doxyl groups also permit good activation, probably due to improved uptake into the lipid phase. The hydrophobic moiety exhibits a low specificity. Blockage of carboxyl by esterification abolishes the activation. Maximum activation requires high total concentrations of 200-300 muM. The distribution of fatty acids between proteoliposomes and solution was determined. The activation mode of fatty acids is discussed either as regulatory activators or as cofactors in H+ translocation involving their carboxyl groups. Two alternatives are considered, namely that the fatty acids carboxyl group is at the translocation center or in the channel facilitating H+ transfer to the constituent H+-translocating carboxyl groups.	UNIV MUNICH,INST PHYS BIOCHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY	University of Munich								Bernardi G, 1971, METHOD ENZYMOL, V22, P325; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; GOODMAN DS, 1958, J AM CHEM SOC, V80, P3892, DOI 10.1021/ja01548a024; GUTKNECHT J, 1987, P NATL ACAD SCI USA, V84, P6443, DOI 10.1073/pnas.84.18.6443; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HEATON GM, 1978, EUR J BIOCHEM, V82, P515, DOI 10.1111/j.1432-1033.1978.tb12045.x; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1990, J LIPID MED, V2, P89; KATIYAR SS, 1991, BIOCHEM BIOPH RES CO, V175, P1104, DOI 10.1016/0006-291X(91)91679-7; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; KLINGENBERG M, 1986, METHOD ENZYMOL, V126, P498; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KOPECKY J, 1987, EUR J BIOCHEM, V164, P687, DOI 10.1111/j.1432-1033.1987.tb11181.x; LIN CS, 1982, BIOCHEMISTRY-US, V21, P2950, DOI 10.1021/bi00541a023; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; LOCKE RM, 1982, EUR J BIOCHEM, V129, P381, DOI 10.1111/j.1432-1033.1982.tb07061.x; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; ROONEY EK, 1983, BIOCHIM BIOPHYS ACTA, V728, P159, DOI 10.1016/0005-2736(83)90467-4; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SMITH R, 1973, P NATL ACAD SCI USA, V70, P289, DOI 10.1073/pnas.70.2.289; SOBER HA, 1970, HDB CHEM, pE13; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; WELLS MA, 1969, METHOD ENZYMOL, V14, P178; WINKLER E, 1992, EUR J BIOCHEM, V203, P295, DOI 10.1111/j.1432-1033.1992.tb19859.x; WINKLER E, 1992, EUR J BIOCHEM, V207, P135, DOI 10.1111/j.1432-1033.1992.tb17030.x	28	162	164	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2508	2515						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300577				2022-12-25	WOS:A1994MV43200027
J	BORST, DW; BETLEY, MJ				BORST, DW; BETLEY, MJ			PROMOTER ANALYSIS OF THE STAPHYLOCOCCAL ENTEROTOXIN-A GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; MESSENGER-RNA; AUREUS; TRANSCRIPTION; SEQUENCES; TOXIN; INITIATION; PLASMIDS	The promoter region of the staphylococcal enterotoxin A (SEA) gene (sea) of Staphylococcus aureus was localized by primer extension analysis in conjunction with in vitro mutagenesis. The 5'-end of sea mRNA was located 86 base pairs upstream of the translational initiation codon. A DNA region with good agreement with canonical promoter sequences was observed beginning 8 base pairs upstream of the apparent transcriptional start site. Analysis of a series of progressive deletions of upstream DNA revealed that no DNA upstream of the putative -35 region was required for transcription of sea (determined by primer extension analysis) or for SEA production as detected by Western immunoblot analysis. Deletion mutants extending into the -35 region or mutants containing nucleotide substitutions in the -10 region both showed dramatic reductions in SEA production and transcription of sea. Analysis of a deletion mutant in which 59 base pairs between the transcriptional and translational start sites were deleted revealed slightly increased levels of SEA production.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL JG, 1987, CURRENT PROTOCOLS MO; BAYLES KW, 1989, J BACTERIOL, V171, P4799, DOI 10.1128/jb.171.9.4799-4806.1989; Bergdoll M.S., 1983, STAPHYLOCOCCI STAPHY, V2, P559; BETLEY MJ, 1985, SCIENCE, V229, P185, DOI 10.1126/science.3160112; BETLEY MJ, 1988, J BACTERIOL, V170, P34, DOI 10.1128/jb.170.1.34-41.1988; BETLEY MJ, 1992, CHEM IMMUNOL, V55, P1; Betley MJ, 1990, MOL BIOL STAPHYLOCOC, P327; BORST DW, 1994, IN PRESS INFECT IMMU, V64; CZOP JK, 1974, INFECT IMMUN, V9, P229, DOI 10.1128/IAI.9.2.229-235.1974; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GASKILL ME, 1988, J BIOL CHEM, V263, P6276; GRAVES MC, 1986, J BIOL CHEM, V261, P1409; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HOLMBERG SD, 1984, JAMA-J AM MED ASSOC, V251, P487, DOI 10.1001/jama.251.4.487; HUFNAGLE WO, 1991, INFECT IMMUN, V59, P2126, DOI 10.1128/IAI.59.6.2126-2134.1991; IORDANESCU S, 1975, J BACTERIOL, V124, P597; KARLS R, 1989, NUCLEIC ACIDS RES, V17, P3927, DOI 10.1093/nar/17.10.3927; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; MAHMOOD R, 1990, J BIOL CHEM, V265, P4652; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; NOLETO AL, 1982, J FOOD PROTECT, V45, P1096, DOI 10.4315/0362-028X-45.12.1096; NOVICK RP, 1972, J MOL BIOL, V68, P285, DOI 10.1016/0022-2836(72)90214-8; NOVICK RP, 1963, J GEN MICROBIOL, V33, P121, DOI 10.1099/00221287-33-1-121; NOVICK RP, 1979, PLASMID, V2, P109, DOI 10.1016/0147-619X(79)90010-6; OTERO A, 1990, APPL ENVIRON MICROB, V56, P555, DOI 10.1128/AEM.56.2.555-559.1990; REGASSA LB, 1991, INFECT IMMUN, V59, P955, DOI 10.1128/IAI.59.3.955-962.1991; SANDLER P, 1988, J MOL BIOL, V203, P905, DOI 10.1016/0022-2836(88)90116-7; TREMAINE MT, 1993, INFECT IMMUN, V61, P356, DOI 10.1128/IAI.61.1.356-359.1993	30	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1883	1888						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294437				2022-12-25	WOS:A1994MR98800052
J	PACIFICI, RE; THOMASON, AR				PACIFICI, RE; THOMASON, AR			HYBRID TYROSINE KINASE CYTOKINE RECEPTORS TRANSMIT MITOGENIC SIGNALS IN RESPONSE TO LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; MURINE ERYTHROPOIETIN RECEPTOR; CELL-SURFACE RECEPTORS; EGF RECEPTOR; EXTRACELLULAR DOMAIN; EXPRESSION CLONING; PROTEINS; TRANSDUCTION; SUPERFAMILY; COMPLEX	While much is known about the mechanisms by which members of the receptor tyrosine kinase family effect mitogenic signal transduction, much less is known about such mechanisms for members of the hematopoietic cytokine receptor family. In an effort to determine the extent to which the signal transduction mechanisms of these two receptor families may be related, we constructed and tested interfamily hybrid receptors. Two hybrid receptors consisting of the ligand-binding domain of the epidermal growth factor receptor (EGFR) fused to the transmembrane and cytoplasmic domains of the erythropoietin receptor (EPOR), as well as the parental EPOR or EGFR, were introduced into interleukin-3-dependent 32D cells. Part of the EPOR extracellular region containing a conserved WSXWS amino acid motif was present in one of the hybrid receptors but not in the other. Cells expressing EGFR grew only poorly in response to EGF, whereas cells expressing either of the EGFR/EPOR hybrid receptors or EPOR grew robustly in epidermal growth factor or erythropoietin, respectively. This is the first demonstration of a chimera between these two unrelated receptor families that responds to ligand stimulation. The results indicate that the mechanisms by which receptor tyrosine kinases and cytokine receptors propagate mitogenic signals are sufficiently similar to allow interchange of their ligand binding domains and that generation of an efficient mitogenic signal by a cytokine receptor depends primarily on its cytoplasmic and/or transmembrane regions.	AMGEN INC, DEPT MOLEC BIOL, AMGEN CTR, 14-1-B-220, THOUSAND OAKS, CA 91320 USA	Amgen								BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNARD O, 1987, P NATL ACAD SCI USA, V84, P2125, DOI 10.1073/pnas.84.8.2125; CHAN KY, 1991, INVEST OPHTH VIS SCI, V32, P3209; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DUAN DSR, 1991, J BIOL CHEM, V266, P413; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; HIGUCHI R, 1989, PCR PROTOCOLS GUIDE, P177; Hsuan J J, 1989, Prog Growth Factor Res, V1, P23, DOI 10.1016/0955-2235(89)90039-2; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; IHLE JN, 1981, J IMMUNOL, V126, P2184; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1991, METHOD ENZYMOL, V198, P225; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; NEUMANN D, 1993, J BIOL CHEM, V268, P13639; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; QUELLE DE, 1992, MOL CELL BIOL, V12, P4533; SAWYER ST, 1989, J BIOL CHEM, V264, P13343; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TARTARE S, 1991, J BIOL CHEM, V266, P9900; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; ZIDOVETZKI R, 1981, P NATL ACAD SCI-BIOL, V78, P6981, DOI 10.1073/pnas.78.11.6981	41	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1571	1574						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294397				2022-12-25	WOS:A1994MR98800002
J	ROBERTS, JD; IZUTA, S; THOMAS, DC; KUNKEL, TA				ROBERTS, JD; IZUTA, S; THOMAS, DC; KUNKEL, TA			MISPAIR-SPECIFIC, SITE-SPECIFIC, AND STRAND-SPECIFIC ERROR RATES DURING SIMIAN VIRUS-40 ORIGIN-DEPENDENT REPLICATION IN-VITRO WITH EXCESS DEOXYTHYMIDINE TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 DNA-REPLICATION; INITIATION; FIDELITY; EXTRACTS; REPAIR	We have measured the fidelity of leading and lagging strand DNA replication in HeLa cell extracts. Providing an excess of one dNTP in reactions induces replication errors consistent with misincorporation of that dNTP. With excess dTTP, both substitutions and single-nucleotide frameshifts are induced. Error distribution is nonrandom; reproducible hot spots for a substitution and a frameshift error are observed. Measurements with two vectors having the origin of replication on opposite sides of the mutational target demonstrate that error rates for G.dTTP and C.dTTP mispairs depend on whether the strand is replicated as the leading or lagging strand. Also, the two hot spots are only observed in one origin-target orientation. Replication reactions reconstituted from two fractions derived from extracts are 3-fold less accurate, but the error specificity with excess dTTP is similar to that with extracts. This suggests that the processes responsible for the nonrandom error rates are not lost as a result of fractionation. Furthermore, the reconstituted system is devoid of mismatch repair activity. Thus, mismatch repair is not responsible for the mispair-, site-, and strand-specific differences observed.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; HALLIDAY JA, 1990, ENVIRON MOL MUTAGEN, V16, P143, DOI 10.1002/em.2850160303; HAUSER J, 1988, MOL CELL BIOL, V8, P3267, DOI 10.1128/MCB.8.8.3267; HAY RT, 1982, CELL, V28, P767, DOI 10.1016/0092-8674(82)90056-3; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; Kornberg A., 1992, DNA REPLICATION; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; MILLER JK, 1986, P NATL ACAD SCI USA, V83, P1026, DOI 10.1073/pnas.83.4.1026; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, CANCER CELL, V6, P133	23	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1711	1717						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294419				2022-12-25	WOS:A1994MR98800029
J	VAN HELVOORT, A; VANT HOF, W; RITSEMA, T; SANDRA, A; VAN MEER, G				VAN HELVOORT, A; VANT HOF, W; RITSEMA, T; SANDRA, A; VAN MEER, G			CONVERSION OF DIACYLGLYCEROL TO PHOSPHATIDYLCHOLINE ON THE BASOLATERAL SURFACE OF EPITHELIAL (MADIN-DARBY CANINE KIDNEY) CELLS - EVIDENCE FOR THE REVERSE ACTION OF A SPHINGOMYELIN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CULTURED FIBROBLASTS; INTRACELLULAR-TRANSPORT; PLASMA-MEMBRANE; GOLGI-APPARATUS; PHOSPHATIDIC-ACID; RAT-LIVER; METABOLISM; SPHINGOLIPIDS; CERAMIDE	When N-6[7-nitro-2,1,3-benzoxadiazol-4-yl]aminohexanoyl-phosphatidic acid (C6-NBD-PA) is inserted into the plasma membrane of fibroblasts, it is metabolized by the cells to C6-NBD-diacylglycerol (DG), -triacylglycerol, -phosphatidylcholine (PC), and -phosphatidylethanolamine (PE) (Pagano, R. E., Longmuir, K. J., and Martin, O. C. (1983) J. Biol. Chem. 258, 2034-2040). In Madin-Darby canine kidney (MDCK) cells incubated at 10-degrees-C with C6-NBD-PA, up to 70% of the newly synthesized C6-NBD-PC but no Co-NBD-PE could be depleted from the basolateral cell surface by the addition of bovine serum albumin to the medium. Preincubation of the cells with [H-3]choline for 2 h at 37-degrees-C prior to C6-NBD-PA addition at 10-degrees-C labeled non-depletable C6-NBD-PC with a specific activity of >10 times that of the depletable C6-NBD-PC on the basolateral cell surface, indicating that the latter had not been synthesized by the CDP-choline pathway. C6-NBD-DG could substitute for C6-NBD-PA as substrate for both intracellular and surface C6-NBD-PC synthesis. In addition, C6-NBD-PC synthesis on the cell surface was independent of the location of the C6-NBD-chain on the 1- or 2-position, indicating that the reaction occurred by transfer of phosphorylcholine. Using C6-NBD-ceramide, C6-NBD-sphingomyelin (SM) synthesis also was discovered on the basolateral but not on the apical cell surface. The conversion of PC plus ceramide to DG and SM on the basolateral MDCK cell surface suggests that,the synthesis of C6-NBD-PC on this surface occurred via the reverse reaction of a SM synthase. Indeed, the surface C6-NBD-PC synthesis was reduced to 40-50% by addition of C6-NBD-ceramide or hydrolysis of cell surface SM by exogenous neutral sphingomyelinase. Since DG activates protein kinase C and ceramide indirectly inhibits,this kinase but activates other kinase(s) and phosphatase(s), the phosphocholine transferase at the cell surface may have a regulatory role in signal transduction.	UNIV UTRECHT, SCH MED,DEPT CELL BIOL,AZU H02314, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS; UNIV IOWA, COLL MED, DEPT ANAT, IOWA CITY, IA 52242 USA	Utrecht University; University of Iowa			van Meer, Gerrit/AAH-1560-2021; van Helvoort, Ardy/U-7549-2019	van Helvoort, Ardy/0000-0002-3585-0676; van Meer, Gerrit/0000-0002-5976-6436	FOGARTY INTERNATIONAL CENTER [F06TW001534] Funding Source: NIH RePORTER; FIC NIH HHS [F06 TW 01534] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		DAO HNT, 1991, ANAL BIOCHEM, V196, P46; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FRIES E, 1986, BIOCHEM J, V237, P33, DOI 10.1042/bj2370033; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALLEN KJ, 1993, BIOCHIM BIOPHYS ACTA, V1166, P305, DOI 10.1016/0005-2760(93)90111-L; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KOLSENICK R, 1992, TRENDS CELL BIOL, V2, P232; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; KUDOH T, 1983, BIOCHIM BIOPHYS ACTA, V754, P82, DOI 10.1016/0005-2760(83)90084-X; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; MALGAT M, 1986, J LIPID RES, V27, P251; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MARTIN OC, 1986, ANAL BIOCHEM, V159, P101, DOI 10.1016/0003-2697(86)90313-1; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PAGANO RE, 1981, J CELL BIOL, V91, P872, DOI 10.1083/jcb.91.3.872; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; SPENCE MW, 1983, J BIOL CHEM, V258, P8595; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANTHOF W, 1990, J CELL BIOL, V111, P977, DOI 10.1083/jcb.111.3.977; VANTHOF W, 1992, BIOCHEM J, V283, P913, DOI 10.1042/bj2830913; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73	36	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1763	1769						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294425				2022-12-25	WOS:A1994MR98800036
J	ANDERSON, PJ				ANDERSON, PJ			THE MODIFICATION OF HEMOGLOBIN BY CITRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYHEMOGLOBIN-S; ALPHA-CHAINS; IDENTIFICATION; BINDING; SITE	Citrate, when activated by a water-soluble carbodiimide, covalently modifies hemoglobin. At pH values near neutrality, complete modification of the N-terminal valine residues of alpha- and beta-globin chains can be accomplished with a high degree of specificity. These groups react at a much more rapid rate than a slower reacting set of functional groups. Modification of hemoglobin with citrate alters the oxygen affinity of the protein. Although the p50 is not changed, the cooperative nature of oxygen binding is greatly decreased. Hemoglobin S modified with citrate is more soluble than unmodified hemoglobin S. The time taken for deoxygenated hemoglobin S to come out of solution in concentrated phosphate solutions is increased by citrate modification.			ANDERSON, PJ (corresponding author), UNIV OTTAWA,DEPT BIOCHEM,OTTAWA K1H 8M5,ONTARIO,CANADA.							ADACHI K, 1987, J BIOL CHEM, V262, P10470; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ANDERSON PJ, 1970, BIOCHEM J, V117, P292; BENESCH RE, 1988, BIOCHEM BIOPH RES CO, V156, P9, DOI 10.1016/S0006-291X(88)80798-8; BERBERS GAM, 1991, J LAB CLIN MED, V117, P157; Carraway K L, 1972, Methods Enzymol, V25, P616, DOI 10.1016/S0076-6879(72)25060-1; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; FANTL WJ, 1987, BIOCHEMISTRY-US, V26, P5755, DOI 10.1021/bi00392a026; FREEDMAN RB, 1968, BIOCHEM J, V108, P383, DOI 10.1042/bj1080383; GILLES MA, 1990, ANAL BIOCHEM, V184, P244, DOI 10.1016/0003-2697(90)90675-Y; HOARE DG, 1967, J BIOL CHEM, V242, P2447; KAVANAUGH MP, 1988, BIOCHEMISTRY-US, V27, P1804, DOI 10.1021/bi00405a062; KLOTZ IM, 1981, SCIENCE, V213, P724, DOI 10.1126/science.7256275; KLOTZ IM, 1985, J BIOL CHEM, V260, P6215; LANG ME, 1990, OXYGEN TRANSPORT TIS, V12, P225; MEJILLANO MR, 1991, J BIOL CHEM, V266, P657; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; SHIMIZU K, 1974, BIOCHEMISTRY-US, V13, P809, DOI 10.1021/bi00701a026; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P2697; VERBURG JG, 1992, J BIOL CHEM, V267, P3886	21	3	3	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15504	15509						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340379				2022-12-25	WOS:A1993LN30500030
J	POON, D; WEIL, PA				POON, D; WEIL, PA			IMMUNOPURIFICATION OF YEAST TATA-BINDING PROTEIN AND ASSOCIATED FACTORS - PRESENCE OF TRANSCRIPTION FACTOR-IIIB TRANSCRIPTIONAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; POLYMERASE-III; FACTOR-TFIIIB; PURIFICATION; COACTIVATORS; ACTIVATION; ANTIBODIES; HOMOLOGY; ENCODES; COMPLEX	The TATA-binding proteins (TBP) from both human and Drosophila have been shown to exist in various distinct multiprotein complexes that are required, respectively, for transcription by all three RNA polymerases. In contrast, in vitro biochemical analyses have suggested that yeast TBP exists as a monomeric 27-kDa protein free in solution. We have examined the oligomerization state of yeast TBP and report here that yeast TBP, like human and Drosophila TBPs, is also stably associated with other proteins in vitro. Using anti-TBP antibodies we have immunopurified yeast TBP and associated factors (TBP-associated factors or TAFs). When this fraction was analyzed by SDS-polyacrylamide gel electrophoresis, polypeptides of approximate relative molecular size ranging from 170 to 60 kDa are prominently represented. Immunoblot analysis revealed that one of these TAFs, TAF70, corresponds to BRF1/TDS4/PCF4, a subunit of transcription factor (TF) IIIB. Furthermore, this highly purified TAF fraction can reconstitute polymerase III transcription when supplemented with purified RNA polymerase III and TFIIIC. Our data indicate that our TAF fraction contains TFIIIB transcription factor activity and that all the subunits of yeast TFIIIB are stably complexed with TBP.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V69, P685; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HUET J, 1985, J BIOL CHEM, V260, P5304; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; POON D, 1993, J BIOL CHEM, V268, P5005; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGGART AKP, 1992, CELL, V71; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	32	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15325	15328						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340360				2022-12-25	WOS:A1993LN30500001
J	WASHKO, PW; WANG, YH; LEVINE, M				WASHKO, PW; WANG, YH; LEVINE, M			ASCORBIC-ACID RECYCLING IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COULOMETRIC ELECTROCHEMICAL DETECTION; PERFORMANCE LIQUID-CHROMATOGRAPHY; DEHYDROASCORBIC ACID; DIABETES-MELLITUS; HYDROGEN-PEROXIDE; FREE-RADICALS; PLASMA; LEUKOCYTES; PROTECTION; SUPEROXIDE	Ascorbic acid (vitamin C) accumulation in activated human neutrophils is increased as much as 10-fold above the mM concentrations present in normal neutrophils. Internal concentrations as high as 14 mM are achieved when external vitamin is at physiologic concentration. The mechanism is by oxidation of external vitamin to dehydroascorbic acid, preferential transmembrane translocation of dehydroascorbic acid, and intracellular reduction to ascorbic acid within minutes. These data indicate that vitamin C accumulation is enhanced in activated human neutrophils and that human neutrophils utilize and recycle oxidized external vitamin C under physiologic conditions.	NIDDKD,CELL BIOL & BIOCHEM SECT,CELL BIOL & GENET LAB,BLDG 8,RM 415,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BABIOR BM, 1984, BLOOD, V64, P959; BAEHNER RL, 1977, BLOOD, V50, P327; BANERJEE A, 1982, ANN CLIN BIOCHEM, V19, P65, DOI 10.1177/000456328201900201; BERGSTEN P, 1990, J BIOL CHEM, V265, P2584; BIGLEY RH, 1974, J EXP MED, V139, P1084, DOI 10.1084/jem.139.5.1084; BLAKE DR, 1981, CLIN SCI, V61, P483, DOI 10.1042/cs0610483; COX BD, 1975, BIOCHEM MED METAB B, V12, P183, DOI 10.1016/0006-2944(75)90110-6; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DHARIWAL KR, 1990, ANAL BIOCHEM, V189, P18, DOI 10.1016/0003-2697(90)90037-A; DRATH DB, 1974, INFECT IMMUN, V10, P1077, DOI 10.1128/IAI.10.5.1077-1083.1974; FANTONE JC, 1982, AM J PATHOL, V107, P397; HENDRY JM, 1964, CLIN CHIM ACTA, V9, P498, DOI 10.1016/0009-8981(64)90089-0; HORNIG D, 1971, CLIN CHIM ACTA, V32, P33, DOI 10.1016/0009-8981(71)90460-8; IRWIN MI, 1976, J NUTR, V106, P823; JENNINGS PE, 1987, DIABETES RES CLIN EX, V6, P151; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P438; LIU TZ, 1982, CLIN CHEM, V28, P2225; Lunec J, 1985, Free Radic Res Commun, V1, P31, DOI 10.3109/10715768509056534; MILLER TE, 1969, J BACTERIOL, V98, P949, DOI 10.1128/JB.98.3.949-955.1969; MRTENSSON J, 1991, P NATL ACAD SCI USA, V88, P4656, DOI 10.1073/pnas.88.11.4656; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; OHNO Y, 1985, J BIOL CHEM, V260, P8438; OKAMURA M, 1980, CLIN CHIM ACTA, V103, P259; Ralli EP, 1938, J CLIN INVEST, V17, P765, DOI 10.1172/JCI101006; ROOS D, 1980, AGENTS ACTIONS, V10, P528, DOI 10.1007/BF02024158; SALIN ML, 1975, J CLIN INVEST, V56, P1319, DOI 10.1172/JCI108208; SAUBERLICH HE, 1975, ANN NY ACAD SCI, V258, P438, DOI 10.1111/j.1749-6632.1975.tb29302.x; SHILOTRI PG, 1977, J NUTR, V107, P1513, DOI 10.1093/jn/107.8.1513; SHILOTRI PG, 1977, AM J CLIN NUTR, V30, P1077, DOI 10.1093/ajcn/30.7.1077; SKLAR LA, 1985, J BIOL CHEM, V260, P1461; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANKOVA L, 1975, INFECT IMMUN, V12, P252, DOI 10.1128/IAI.12.2.252-256.1975; STANKOVA L, 1984, METABOLISM, V33, P347, DOI 10.1016/0026-0495(84)90197-5; STEWART CP, 1953, BIOCHEM J, V53, P254, DOI 10.1042/bj0530254; WASHKO P, 1992, J BIOL CHEM, V267, P23568; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WASHKO PW, 1992, ANAL BIOCHEM, V204, P1, DOI 10.1016/0003-2697(92)90131-P; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WINTERBOURN CC, 1983, BIOCHIM BIOPHYS ACTA, V763, P175, DOI 10.1016/0167-4889(83)90041-1	40	232	235	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15531	15535						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340380				2022-12-25	WOS:A1993LN30500034
J	LU, WY; ZHANG, WL; MOLLOY, SS; THOMAS, G; RYAN, K; CHIANG, YW; ANDERSON, S; LASKOWSKI, M				LU, WY; ZHANG, WL; MOLLOY, SS; THOMAS, G; RYAN, K; CHIANG, YW; ANDERSON, S; LASKOWSKI, M			ARG(15)-LYS(17)-ARG(18) TURKEY OVOMUCOID 3RD DOMAIN INHIBITS HUMAN FURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEINASES; SEQUENCES; CLEAVAGE; ENZYMES	Turkey ovomucoid third domain with Leu18 in its reactive site is a potent inhibitor of many serine proteinases: subtilisins, chymotrypsins, and elastases. Previous studies showed that an L18K mutation made it a moderately strong inhibitor of trypsin, while an L18E mutation made it a strong inhibitor of Glu-specific Streptomyces griseus proteinase (GluSGP). For human furin substrates the consensus optimal sequence is RXKR down. Therefore the A15R, T17K, and L18R mutations were made in turkey ovomucoid third domain. The mutant inhibits human furin with a K(a) of 1.1 x 10(7) M-1. As human furin catalyzes an obligatory step in human immunodeficiency virus proliferation, this inhibitor, along with the others already available, deserves further study.	PURDUE UNIV, DEPT CHEM, BROWN CHEM BLDG, W LAFAYETTE, IN 47907 USA; OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; RUTGERS UNIV, DEPT CHEM, PISCATAWAY, NJ 08854 USA; RUTGERS UNIV, DEPT MOLEC BIOL & BIOCHEM, PISCATAWAY, NJ 08854 USA; RUTGERS UNIV, CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08854 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Oregon Health & Science University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick			Lu, Wuyuan/J-8452-2017; Lu, Wuyuan/B-2268-2010	Lu, Wuyuan/0000-0003-1318-9968; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010462] Funding Source: NIH RePORTER; NIA NIH HHS [AG 10462] Funding Source: Medline; NIDDK NIH HHS [DK 44629] Funding Source: Medline; NIGMS NIH HHS [GM 10831] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APOSTOL I, 1993, IN PRESS J PROTEIN C, V12; BRESNAHAN PA, 1993, MECHANISMS INTRACELL, P225; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; CREIGHTON TE, 1989, TRENDS BIOCHEM SCI, V14, P319, DOI 10.1016/0968-0004(89)90159-X; EMPIE MW, 1982, BIOCHEMISTRY-US, V21, P2274, DOI 10.1021/bi00539a002; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HIRONO S, 1979, J MOL BIOL, V131, P855, DOI 10.1016/0022-2836(79)90205-5; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KOMIYAMA T, 1991, J BIOL CHEM, V266, P10727; LASKOWSKI M, 1987, COLD SPRING HARB SYM, V52, P545, DOI 10.1101/SQB.1987.052.01.062; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI M, 1987, BIOCHEMISTRY-US, V26, P202, DOI 10.1021/bi00375a028; LU W, 1992, 6TH S PROT SOC SAN D, P79; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OTLEWSKI J, 1987, BIOL CHEM H-S, V368, P1505; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOTT MJ, 1987, J BIOL CHEM, V262, P5899; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; WIECZOREK M, 1987, BIOCHEM BIOPH RES CO, V144, P499, DOI 10.1016/S0006-291X(87)80537-5; YOSHIDA N, 1988, J BIOCHEM, V104, P451, DOI 10.1093/oxfordjournals.jbchem.a122488	25	56	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14583	14585						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325837				2022-12-25	WOS:A1993LL75900009
J	HAREL, R; FUTERMAN, AH				HAREL, R; FUTERMAN, AH			INHIBITION OF SPHINGOLIPID SYNTHESIS AFFECTS AXONAL OUTGROWTH IN CULTURED HIPPOCAMPAL-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; CELLS; CERAMIDE	Neuronal growth is regulated by both extracellular and cellular determinants and is believed to proceed by the addition of new membrane material at the growth cone. To determine whether lipid synthesis is necessary to maintain neuronal growth, we have examined the effect of Fumonisin B1, an inhibitor of ceramide synthesis, on the development of cultured hippocampal neurons. Fumonisin B1 inhibits ceramide synthesis in hippocampal neurons both in vivo and in vitro. Ganglioside synthesis and content was reduced after Fumonisin B1 treatment, and ganglioside GD1b was not detectable at the cell surface by immunofluorescence. Inhibition of sphingolipid synthesis by Fumonisin B1 had a significant effect on axonal growth. Between days 2-3 in culture, mean axon length increased from 170 to 240 mum, but in Fumonisin-treated cells, no increase in axon length was observed. Addition of a fluorescent derivative of ceramide together with Fumonisin B1 reversed this effect, confirming that Fumonisin B1 acts via inhibition of ceramide synthase. Further, ceramide by itself caused a significant increase in axon length. We discuss three possible mechanisms by which inhibition of sphingolipid synthesis could disrupt axonal growth, among them the possibility that ongoing sphingolipid synthesis is necessary to provide new membrane material to the growing axon.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Futerman, Anthony/0000-0003-0013-0115				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPENOT RB, 1991, J NEUROSCI, V11, P1126; COLLINS RN, 1992, J BIOL CHEM, V267, P24906; Craig A M, 1992, Curr Opin Neurobiol, V2, P602, DOI 10.1016/0959-4388(92)90025-G; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; FUTERMAN AH, 1993, IN PRESS CURR TOP ME; Goslin K., 1991, CULTURING NERVE CELL, P251; HAKAMORI S, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTH S, 1978, ANAL BIOCHEM, V86, P543, DOI 10.1016/0003-2697(78)90781-9; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; MANDON EC, 1992, J BIOL CHEM, V267, P11144; NORRED WP, 1992, MYCOPATHOLOGIA, V117, P73, DOI 10.1007/BF00497281; ORTEGA E, 1990, MOL IMMUNOL, V27, P1269, DOI 10.1016/0161-5890(90)90031-T; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, 1990, BIOCHEM SOC T, V18, P361, DOI 10.1042/bst0180361; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; SAITO M, 1985, BIOCHEM BIOPH RES CO, V127, P1, DOI 10.1016/S0006-291X(85)80117-0; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; TRINCHERA M, 1991, J BIOL CHEM, V266, P9093; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; WANG E, 1991, J BIOL CHEM, V266, P14486; WU GS, 1991, J NEUROCHEM, V56, P95, DOI 10.1111/j.1471-4159.1991.tb02567.x; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F	34	173	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14476	14481						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314804				2022-12-25	WOS:A1993LJ82500098
J	ROLDAN, ERS; FRAGIO, C				ROLDAN, ERS; FRAGIO, C			PHOSPHOLIPASE-A2 ACTIVATION AND SUBSEQUENT EXOCYTOSIS IN THE CA2+/IONOPHORE-INDUCED ACROSOME REACTION OF RAM SPERMATOZOA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG SPERMATOZOA; PROTEIN-KINASE-C; UNSATURATED FATTY-ACIDS; SEA-URCHIN SPERM; HUMAN-NEUTROPHILS; MAMMALIAN SPERMATOZOA; POSSIBLE INVOLVEMENT; DIFFERENTIAL ACTIONS; 2ND MESSENGERS; CA-2+ INFLUX	In ram spermatozoa treatment with Ca2+ and A23187 or ionomycin stimulated the release of arachidonic acid (20:4) and exocytosis of the acrosome in a time- and concentration-dependent manner. Diacylglycerol did not appear to be the source of 20:4. On the other hand, generation of 20:4 was significantly correlated with breakdown of phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine under a variety of conditions, thus indicating that 20:4 release was due to phospholipase A2 activity. Generation of 20:4 preceded acrosomal exocytosis. Moreover, it was significantly correlated with exocytosis when spermatozoa were stimulated with Ca2+ and A23187 or ionomycin for different periods of time or with different ionophore concentrations. Treatment with Ro 31-4493, a compound that has been found to inhibit sperm phospholipase A2 activity in vitro, considerably reduced both the release of 20:4 and exocytosis; addition of exogenous 20:4 or lysophosphatidylcholine overcame the inhibitory effect of Ro 31-4493. Spermatozoa preincubated with several unsaturated fatty acids, including 20:4, underwent exocytosis much more rapidly when treated with Ca2+/A23187. Exogenous lysophosphatidylcholine also enhanced acrosomal exocytosis and this effect was mimicked by an alkyl-containing analogue (1-O-alkyl-glycerophosphorylcholine = lyso-platelet activating factor). These results indicate that phospholipase A2 plays a fundamental role in the exocytosis of the acrosome elicited by Ca2+ and ionophore stimulation. Therefore, it is possible that activation of this enzyme constitutes an essential Ca2+-dependent event underlying exocytosis in response to physiological stimuli.			ROLDAN, ERS (corresponding author), AFRC, BABRAHAM INST, DEPT DEV & SIGNALLING, CELL RECOGNIT & SIGNALLING LAB, CAMBRIDGE CB2 4AT, ENGLAND.		Roldan, Eduardo R.S./M-7947-2014	Roldan, Eduardo R.S./0000-0002-7545-4248				ALVAREZ JG, 1989, J ANDROL, V10, pP43; ANDERSON RA, 1990, MOL REPROD DEV, V27, P305, DOI 10.1002/mrd.1080270405; ANTAKI P, 1988, GAMETE RES, V19, P305, DOI 10.1002/mrd.1120190309; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; BASS DA, 1987, J BIOL CHEM, V262, P6643; BAULDRY SA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P178; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BENNET PJ, 1987, BIOCHIM BIOPHYS ACTA, V919, P255, DOI 10.1016/0005-2760(87)90265-7; BILLAH MM, 1987, BIOCHEM BIOPH RES CO, V144, P683, DOI 10.1016/S0006-291X(87)80019-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BURCH RM, 1988, FEBS LETT, V234, P283, DOI 10.1016/0014-5793(88)80099-1; COLLADOESCOBAR D, 1990, J IMMUNOL, V144, P244; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; DAVIS PD, 1988, BIOCHEM SOC T, V16, P816, DOI 10.1042/bst0160816; DEGEORGE JJ, 1987, J BIOL CHEM, V262, P9979; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOMINO SE, 1989, BIOL REPROD, V41, P133, DOI 10.1095/biolreprod41.1.133; FLEMING AD, 1981, GAMETE RES, V4, P253, DOI 10.1002/mrd.1120040402; FLEMING AD, 1984, J EXP ZOOL, V229, P485, DOI 10.1002/jez.1402290317; GOPPELTSTRUEBE M, 1989, BRIT J PHARMACOL, V98, P1287, DOI 10.1111/j.1476-5381.1989.tb12676.x; GUERETTE P, 1988, GAMETE RES, V19, P203, DOI 10.1002/mrd.1120190210; HARRISON RAP, 1982, J EXP ZOOL, V222, P81, DOI 10.1002/jez.1402220111; HARRISON RAP, 1990, J REPROD FERTIL, P51; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; HINKOVSKA VT, 1987, INT J BIOCHEM, V19, P569, DOI 10.1016/0020-711X(87)90143-1; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; IMAI A, 1990, COMP BIOCHEM PHYS B, V95, P635, DOI 10.1016/0305-0491(90)90033-P; JONES R, 1976, PROC R SOC SER B-BIO, V193, P317, DOI 10.1098/rspb.1976.0050; JONES R, 1979, FERTIL STERIL, V31, P531; KRAMER RM, 1987, BIOCHEM J, V248, P779, DOI 10.1042/bj2480779; LANGLAIS J, 1992, BIOCHEM BIOPH RES CO, V182, P208, DOI 10.1016/S0006-291X(05)80132-9; LAX Y, 1990, BIOCHIM BIOPHYS ACTA, V1043, P12, DOI 10.1016/0005-2760(90)90104-6; LLANOS MN, 1982, J EXP ZOOL, V221, P107, DOI 10.1002/jez.1402210114; Lucy J.A., 1970, NATURE, V227, P814, DOI 10.1038/227815a0; LUI CW, 1979, J EXP ZOOL, V207, P173, DOI 10.1002/jez.1402070202; MAJERUS PW, 1984, CELL, V37, P701, DOI 10.1016/0092-8674(84)90405-7; MATSUMURA K, 1991, DEV GROWTH DIFFER, V33, P365; MEIZEL S, 1984, J EXP ZOOL, V231, P283, DOI 10.1002/jez.1402310213; MEIZEL S, 1983, FEBS LETT, V161, P315, DOI 10.1016/0014-5793(83)81032-1; MILLS SC, 1969, J REPROD FERTIL, V18, P367, DOI 10.1530/jrf.0.0180367; MITCHELL KT, 1986, ANAL BIOCHEM, V158, P447, DOI 10.1016/0003-2697(86)90574-9; NEILL AR, 1972, BIOCHEM J, V127, P375, DOI 10.1042/bj1270375; NEILL AR, 1973, J REPROD FERTIL, V34, P279, DOI 10.1530/jrf.0.0340279; OHZU E, 1982, J EXP ZOOL, V224, P259, DOI 10.1002/jez.1402240216; ONO K, 1982, DEV GROWTH DIFFER, V24, P305; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PILTCH A, 1989, BIOCHEM J, V261, P395, DOI 10.1042/bj2610395; POLLARD HB, 1988, J EXP BIOL, V139, P267; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RIFFO M, 1992, HISTOCHEMISTRY, V97, P25, DOI 10.1007/BF00271278; Roldan E.R.S., 1990, P179; ROLDAN ERS, 1989, BIOCHEM J, V259, P397, DOI 10.1042/bj2590397; ROLDAN ERS, 1992, BIOCHEM J, V281, P767, DOI 10.1042/bj2810767; ROLDAN ERS, 1990, BIOCHEM BIOPH RES CO, V172, P8, DOI 10.1016/S0006-291X(05)80165-2; ROLDAN ERS, 1988, BIOCHEM BIOPH RES CO, V155, P901, DOI 10.1016/S0006-291X(88)80581-3; ROLDAN ERS, 1991, BIOCHEM BIOPH RES CO, V176, P294, DOI 10.1016/0006-291X(91)90923-U; RONKKO S, 1992, INT J BIOCHEM, V24, P869, DOI 10.1016/0020-711X(92)90091-E; Scott T W, 1973, J Reprod Fertil Suppl, V18, P65; SCOTT TW, 1967, BIOCHEM J, V102, P456, DOI 10.1042/bj1020456; SELIVONCHICK DP, 1980, BIOCHIM BIOPHYS ACTA, V618, P242, DOI 10.1016/0005-2760(80)90030-2; SHAMSBORHAN G, 1981, GAMETE RES, V4, P407, DOI 10.1002/mrd.1120040506; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; THAKKAR JK, 1983, BIOCHIM BIOPHYS ACTA, V754, P44, DOI 10.1016/0005-2760(83)90080-2; THAKKAR JK, 1984, BIOL REPROD, V30, P679, DOI 10.1095/biolreprod30.3.679; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; WEINMAN S, 1986, J HISTOCHEM CYTOCHEM, V34, P1171, DOI 10.1177/34.9.2426345; ZANEVELD LJD, 1992, COMP SPERMATOLOGY 20, P277	69	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13962	13970						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314762				2022-12-25	WOS:A1993LJ82500031
J	WIKSTROM, L; LODISH, HF				WIKSTROM, L; LODISH, HF			UNFOLDED H2B ASIALOGLYCOPROTEIN RECEPTOR SUBUNIT POLYPEPTIDES ARE SELECTIVELY DEGRADED WITHIN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; VIRUS GLYCOPROTEIN; SECRETORY PROTEINS; CELL-SURFACE; PRE-GOLGI; TRANSPORT; CALCIUM; RETENTION; THAPSIGARGIN; TRANSFERRIN	When expressed alone in fibroblasts, approximately 80% of newly made H2b subunits of the human asialoglycoprotein receptor are retained and degraded in the endoplasmic reticulum (ER), whereas about 20% reaches the plasma membrane (1). Thapsigargin, an inhibitor of the ER Ca2+ ATPase, blocks ER folding of the H1 (2) as well as of the H2b subunit, prevents maturation of H2b, and accelerates ER degradation of newly made H2b. The secretory pathway is normal in thapsigargin-treated cells, as monitored by maturation of the vesicular stomatitis virus G protein. The protease inhibitors TLCK and TPCK block the first step in ER degradation of H2, an endoproteolytic cleavage just exoplasmic to the membrane-spanning domain. In protease inhibitor-treated cells, the approximately 80% of H2b that would normally be degraded remains in the ER; as judged by migration on nonreducing SDS-polyacrylamide gel electrophoresis this H2b is improperly folded. Thus, incorrectly folded H2b is normally subjected to ER degradation. In the presence of thapsigargin H2b cannot fold properly and is degraded within the ER. The preferential ER degradation of misfolded or unfolded membrane proteins demonstrated here, functions as a step in ER quality control.	WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; LUDWIG INST CANC RES,S-10401 STOCKHOLM,SWEDEN	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research					NIGMS NIH HHS [GM 35012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUE S, 1992, J BIOL CHEM, V267, P9080; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1983, VIROLOGY, V125, P335, DOI 10.1016/0042-6822(83)90206-4; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STROUS GJAM, 1983, J CELL BIOL, V97, P1815, DOI 10.1083/jcb.97.6.1815; TANIYAMA Y, 1991, J BIOL CHEM, V266, P6456; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZILBERSTEIN A, 1980, CELL, V21, P417, DOI 10.1016/0092-8674(80)90478-X	39	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14412	14416						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314799				2022-12-25	WOS:A1993LJ82500090
J	DOKTER, WHA; DIJKSTRA, AJ; KOOPMANS, SB; STULP, BK; KECK, W; HALIE, MR; VELLENGA, E				DOKTER, WHA; DIJKSTRA, AJ; KOOPMANS, SB; STULP, BK; KECK, W; HALIE, MR; VELLENGA, E			G(ANH)MTETRA, A NATURAL BACTERIAL-CELL WALL BREAKDOWN PRODUCT, INDUCES INTERLEUKIN-1-BETA AND INTERLEUKIN-6 EXPRESSION IN HUMAN MONOCYTES - A STUDY OF THE MOLECULAR MECHANISMS INVOLVED IN INFLAMMATORY CYTOKINE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCCURRING MURAMYL PEPTIDES; SLOW-WAVE SLEEP; NF-KAPPA-B; ESCHERICHIA-COLI; HUMAN PROINTERLEUKIN-1-BETA; TRANSCRIPTION FACTOR; MUREIN HYDROLASES; GENE-EXPRESSION; HUMAN-URINE; PEPTIDOGLYCAN	It is believed that induction of cytokine expression by bacterial cell wall components plays a role in the development and course of sepsis. However, most attention has been focused on lipopolysaccharide (LPS). We studied the ability of N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-isoglutamyl-m-diaminopimelyl-D-alanine (G(Anh)MTetra), a naturally occurring breakdown product of peptidoglycan that is produced by soluble lytic transglycosylase of Escherichia coli, to induce cytokine expression in human monocytes. G(Anh)MTetra was found to strongly induce interleukin (IL)-1 beta and IL-6 mRNA expression after 2 h and IL-1 beta and IL-6 protein secretion after 48 h of activation. The increase in mRNA accumulation was at least partly due to an increase in the transcription rates of the respective genes and was accompanied by a strong induction of nuclear factor-kappa B and activator protein-1 transcription factor expression. Experiments using inhibitors of protein kinase C, protein kinase A, and tyrosine kinase-dependent pathways revealed that G(Anh)MTetra-induced IL-1 beta and IL-6 mRNA expression involves activation of an H7-inhibitable pathway. By using the protein synthesis inhibitor cycloheximide, it was shown that G(Anh)MTetra-induced IL-6 mRNA expression depends on the synthesis of new protein, whereas G(Anh)MTetra-induced IL-1 beta mRNA accumulation does not. When responses to G(Anh)MTetra were compared with those to LPS and muramyldipeptide (MDP), it was found that the optimal response to G(Anh)MTetra induction was similar to that of LPS but significantly higher than the response to MDP. Furthermore, maximal G(Anh)MTetra-induced IL-1 beta and IL-6 mRNA expression could be enhanced by co stimulation with LPS or MDP, suggesting that different receptors and/or transduction pathways were involved. These results indicate that G(Anh)MTetra induces IL-1 beta and IL-6 expression in human monocytes suggesting a possible role for G(Anh)MTetra in the release of cytokines during sepsis.	UNIV GRONINGEN,DEPT MED,DIV HEMATOL,9713 EZ GRONINGEN,NETHERLANDS; HOFFMAN LA ROCHE LTD,DEPT PHARMA RES,CH-4002 BASEL,SWITZERLAND	University of Groningen; Roche Holding								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AZUMA I, 1992, INT J IMMUNOPHARMACO, V14, P487; BAUERLE PA, 1988, CELL, V53, P211; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; BRAKENHOFF JPJ, 1987, J IMMUNOL, V139, P4116; CHAUHAN D, 1993, BLOOD, V81, P1540; CLARK BD, 1986, NUCLEIC ACIDS RES, V14, P7897, DOI 10.1093/nar/14.20.7897; COOKSON BT, 1989, BIOCHEMISTRY-US, V28, P1744, DOI 10.1021/bi00430a048; DEWIT H, 1993, EXP HEMATOL, V21, P785; DINARELLO CA, 1986, FASEB J, V45, P2545; DINARELLO CA, 1991, BLOOD, V77, P1627; DOFFERHOFF ASM, 1993, J ANTIMICROB CHEMOTH, V31, P373, DOI 10.1093/jac/31.3.373; DOKTER WHA, 1993, BLOOD, V81, P35; DOKTERWHA, 1993, BLOOD, V81, P337; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; ELONZ F, 1974, BIOCHEM BIOPH RES CO, V59, P1317; ENGEL H, 1992, J BACTERIOL, V174, P6394, DOI 10.1128/JB.174.20.6394-6403.1992; ENGEL H, 1992, APPL MICROBIOL BIOT, V37, P772, DOI 10.1007/BF00174845; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FENTON MJ, 1987, J IMMUNOL, V138, P3972; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLD MR, 1985, INFECT IMMUN, V49, P731, DOI 10.1128/IAI.49.3.731-741.1985; GRUSS HJ, 1992, BLOOD, V80, P2563; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HELLE M, 1991, J IMMUNOL METHODS, V138, P47, DOI 10.1016/0022-1759(91)90063-L; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOVACS EJ, 1989, J IMMUNOL, V143, P3532; KRUEGER JM, 1984, J BIOL CHEM, V259, P2659; KRUEGER JM, 1987, BRAIN RES, V403, P249, DOI 10.1016/0006-8993(87)90062-X; KRUEGER JM, 1982, J BIOL CHEM, V257, P1664; LECONTEL C, 1993, J IMMUNOL, V150, P4541; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; MARTIN SA, 1984, J BIOL CHEM, V259, P2652; MARTIN SA, 1987, J BIOL CHEM, V262, P7514; MCCABE WR, 1981, CURRENT CLIN TOPICS, V2, P121; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; POLANSKI M, 1989, J IMMUNOL, V143, P2706; RIESENFELDORN I, 1989, INFECT IMMUN, V57, P1890, DOI 10.1128/IAI.57.7.1890-1893.1989; Sambrook J, 1989, MOL CLONING LABORATO; SCHLINDER R, 1990, J BIOL CHEM, V265, P10232; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SINHA RK, 1980, INFECT IMMUN, V29, P914; Tufano M A, 1991, Eur Cytokine Netw, V2, P361; TUOMANEN E, 1985, J INFECT DIS, V151, P535, DOI 10.1093/infdis/151.3.535; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; TUOMANEN E, 1987, AM REV RESPIR DIS, V135, P869, DOI 10.1164/arrd.1987.135.4.869; TURNER M, 1989, J IMMUNOL, V143, P3556; VELLENGA E, 1988, BLOOD, V71, P1529; VERMEULEN MW, 1984, INFECT IMMUN, V46, P476, DOI 10.1128/IAI.46.2.476-483.1984	57	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4201	4206						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307982				2022-12-25	WOS:A1994MW98900048
J	HAZUDA, DJ; WOLFE, AL; HASTINGS, JC; ROBBINS, HL; GRAHAM, PL; LAFEMINA, RL; EMINI, EA				HAZUDA, DJ; WOLFE, AL; HASTINGS, JC; ROBBINS, HL; GRAHAM, PL; LAFEMINA, RL; EMINI, EA			VIRAL LONG TERMINAL REPEAT SUBSTRATE-BINDING CHARACTERISTICS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INTEGRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; RETROVIRAL DNA INTEGRATION; PROTEIN INVITRO; SEQUENCES; RECOGNITION; IDENTIFICATION; RECOMBINATION; ENDONUCLEASE; CLEAVAGE; REQUIRES	A DNA binding assay was developed for the human immunodeficiency virus type 1 (HIV-1) integrase. The assay was capable of defining discrete complexes between the enzyme and the viral long terminal repeat (LTR) substrate. DNA binding reflected the sequence requirements previously demonstrated for the enzyme's 3'-end processing activity. Binding exhibited a nonlinear dependence on integrase concentration, suggesting that the enzyme functions as a multimer. The oligomeric state was investigated by UV-photo-cross-linking of integrase-LTR oligonucleotide complexes using DNA substrates substituted with 5-bromo-2'-deoxycytidine within the integrase recognition sequence. In the absence of divalent cation, integrase cross-linked to the LTR oligonucleotide as a single species whose mobility by SDS-polyacrylamide gel electrophoresis was consistent with the formation of tetramers. Using these techniques, analysis of the binding properties of integrase mutants demonstrated that the catalytic and sequence-specific DNA binding activities of the enzyme are distinct, involving residues within the conserved ''DD(35)E'' and zinc finger motifs, respectively.			HAZUDA, DJ (corresponding author), MERCK RES LABS,W POINT,PA 19486, USA.		Graham, Petra/V-8136-2019	Graham, Petra/0000-0003-2890-2447				BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HANAS JS, 1983, J BIOL CHEM, V258, P4120; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JONES KS, 1992, J BIOL CHEM, V267, P16037; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1991, P NATL ACAD SCI USA, V88, P4695, DOI 10.1073/pnas.88.11.4695; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KROGSTAD PA, 1990, J VIROL, V64, P2796, DOI 10.1128/JVI.64.6.2796-2801.1990; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; ROTH MJ, 1990, J VIROL, V64, P4709, DOI 10.1128/JVI.64.10.4709-4717.1990; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; STRUHL K, 1990, PROTEINS FORM FUNCTI; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1991, NUCLEIC ACIDS RES, V19, P3821, DOI 10.1093/nar/19.14.3821; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991	33	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3999	4004						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307956				2022-12-25	WOS:A1994MW98900018
J	SATO, S; HUGHES, RC				SATO, S; HUGHES, RC			REGULATION OF SECRETION AND SURFACE EXPRESSION OF MAC-2, A GALACTOSIDE-BINDING PROTEIN OF MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRIFFONIA-SIMPLICIFOLIA I-B4; MONOCLONAL-ANTIBODIES; PERITONEAL-MACROPHAGES; MEMBRANE-GLYCOPROTEINS; LECTIN BINDING; CELLS; LAMININ; ACTIVATION; IGE; CHAINS	Mac-2, a 30-35-kDa galactoside-binding protein, is synthesized at similar levels in murine peritoneal exudate macrophages whether recruited in response to an intraperitoneal pathogen Mycobacterium microti, to sterile inflammatory stimuli such as thioglycollate broth, or to concanavalin A. In elicited or activated macrophages up to 30% of Mac-2 is constitutively secreted, and secretion is stimulated markedly by calcium ionophore A23187. Only thioglycollate elicited macrophages express cell surface Mac-2, and binding is mostly (>80%) a result of affinity for cell surface carbohydrate structures. Mac-2 surface expression is markedly reduced upon further activation of thioglycollate elicited macrophages with bacterial lipopolysaccharide in vitro. Polylactosamine structures are present on all macrophage populations examined as determined by binding of Lycopersicon esculentum lectin, whereas alpha-galactosyl residues detected by Griffonia simplicifolia isolectin B4 are expressed only on the thioglycollate elicited macrophages, indicating that these residues are the major determinants responsible for Mac-2 surface expression. Chemical crosslinking experiments have identified binding of endogenous cell-surface Mac-2 to three glycoproteins of molecular masses of 92, 125, and 180 kDa containing alpha-galactosyl and polylactosamine structures on thioglycollate-elicited macrophages. The restricted cell surface distribution of Mac-2 on thioglycollate-elicited peritoneal macrophages, a population of recently recruited monocytes, suggests a role(s) in early events of macrophage infiltration and tissue fixation such as extravasion and cell-matrix interactions.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research								ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; ARNAOUT MA, 1990, BLOOD, V75, P1037; BAUVOIS B, 1992, J IMMUNOL, V148, P3912; Bayer E A, 1979, Methods Enzymol, V62, P308; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; FODDY L, 1990, J CELL SCI, V97, P139; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GALILI U, 1988, J BIOL CHEM, V263, P17755; HAINES KA, 1983, P NATL ACAD SCI-BIOL, V80, P3448, DOI 10.1073/pnas.80.11.3448; HO MK, 1982, J IMMUNOL, V128, P1221; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUGHES RC, 1992, BIOCHEM SOC T, V20, P279, DOI 10.1042/bst0200279; IRIMURA T, 1987, EUR J IMMUNOL, V17, P73, DOI 10.1002/eji.1830170113; KAWASHIMA H, 1990, GLYCOCONJUGATE J, V7, P323, DOI 10.1007/BF01073376; KOTHS K, 1993, J BIOL CHEM, V268, P14245; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LINSLEY PS, 1986, BIOCHEMISTRY-US, V25, P2978, DOI 10.1021/bi00358a037; MADDOX DE, 1982, CELL IMMUNOL, V71, P202, DOI 10.1016/0008-8749(82)90509-3; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MERCURIO AM, 1985, J IMMUNOL, V135, P1305; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MUNRO JM, 1992, AM J PATHOL, V141, P1397; Murphy L A, 1978, Methods Enzymol, V50, P345; NABARRA B, 1988, LAB INVEST, V58, P524; NACHBAR MS, 1982, METHOD ENZYMOL, V83, P363; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; PETRYNIAK J, 1992, EUR J BIOCHEM, V206, P197, DOI 10.1111/j.1432-1033.1992.tb16917.x; PETRYNIAK J, 1986, ARCH BIOCHEM BIOPHYS, V244, P57, DOI 10.1016/0003-9861(86)90094-9; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; RAZ A, 1988, CANCER RES, V48, P645; RAZ A, 1986, CANCER RES, V46, P3667; RAZ A, 1981, CANCER RES, V41, P3642; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; SATO S, 1992, J BIOL CHEM, V267, P6983; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SATO S, 1991, J BIOL CHEM, V266, P11485; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHAW LM, 1989, J EXP MED, V169, P303, DOI 10.1084/jem.169.1.303; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SOROKIN SP, 1992, ANAT REC, V232, P520, DOI 10.1002/ar.1092320409; TABOR DR, 1992, J CELL PHYSIOL, V152, P500, DOI 10.1002/jcp.1041520309; TABOR DR, 1989, J LEUKOCYTE BIOL, V45, P452, DOI 10.1002/jlb.45.5.452; TAKACS B, 1987, J IMMUNOL, V138, P1999; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WARFEL AH, 1992, J LEUKOCYTE BIOL, V52, P80, DOI 10.1002/jlb.52.1.80; WARFEL AH, 1991, J CELL PHYSIOL, V147, P265, DOI 10.1002/jcp.1041470211; WOO HJ, 1990, J BIOL CHEM, V265, P7097	55	231	237	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4424	4430						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308013				2022-12-25	WOS:A1994MW98900082
J	YAMASAKI, K; DAIHO, T; KANAZAWA, T				YAMASAKI, K; DAIHO, T; KANAZAWA, T			3'-O-(5-FLUORO-2,4-DINITROPHENYL)-ATP EXCLUSIVELY LABELS LYS-492 AT THE ACTIVE-SITE OF THE SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; ADENOSINE-TRIPHOSPHATASE; FLUORESCEIN ISOTHIOCYANATE; CA-2+-TRANSPORTING ATPASE; TRIPHOSPHOPYRIDOXAL; IDENTIFICATION; VESICLES; PEPTIDE; CALCIUM; PROTEIN	Sarcoplasmic reticulum vesicles were labeled with 40 mu M 3'-O-(5-fluoro-2,4-dinitrophenyl)-ATP (FDNP-ATP) at 25 degrees C and pH 7.0 for 4 h. The Ca-2+-ATPase was inhibited strongly. The enzyme was almost completely protected either by 20 mM Mg.ATP or by 50 mM acetyl phosphate against this inhibition. P-i gave no protection. There was a linear relationship between the extent of this inhibition and the Mg.ATP-sensitive part of the content of bound FDNP-ATP. Extrapolation showed that the enzyme is completely inhibited by Mg.ATP sensitive binding of 3.6 nmol of FDNP-ATP/mg of the vesicle protein. This value is in good agreement with the content of the phosphorylation site (3.3 nmol/mg of the vesicle protein) in the vesicles used. These findings indicate that binding of 1 mol of FDNP-ATP per mol of the active sites leads to a complete inhibition of the enzyme. The acetylphosphatase activity and phosphorylation with ATP were also strongly inhibited by this labeling, whereas phosphorylation with P-i was not inhibited. The labeled vesicles were solubilized in SDS, and the Ca2+-ATPase was purified by size exclusion high performance liquid chromatography. Mapping the labeled peptides in the tryptic digest by reversed-phase high performance liquid chromatography and sequencing showed that Lys-492 was exclusively labeled with FDNP-ATP These results show that Lys-492 is located in or near the ATP binding site and apart from the phosphorylation site and P-i binding site. Molecular modeling of FDNP-ATP suggests that this Lys-492 residue is situated on the 3'-OH side of the ribose moiety of bound ATP and is close to the alpha-phosphoryl group.	ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA 078,JAPAN	Asahikawa Medical College								AHKOW G, 1980, J ORG CHEM, V45, P4399, DOI 10.1021/jo01310a027; ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; AZEGAMI M, 1975, J BIOCHEM-TOKYO, V78, P409, DOI 10.1093/oxfordjournals.jbchem.a130921; AZEGAMI M, 1964, J BIOCHEM-TOKYO, V55, P346, DOI 10.1093/oxfordjournals.jbchem.a127892; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHUAN H, 1988, J BIOL CHEM, V263, P13003; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DYALL LK, 1960, J CHEM SOC, P5160, DOI 10.1039/jr9600005160; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FRAENKEL-CONRAT H, 1955, Methods Biochem Anal, V2, P359, DOI 10.1002/9780470110188.ch12; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; KANAZAWA T, 1971, J BIOCHEM-TOKYO, V70, P95, DOI 10.1093/oxfordjournals.jbchem.a129631; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MAROUX S, 1966, BIOCHIM BIOPHYS ACTA, V122, P147, DOI 10.1016/0926-6593(66)90098-1; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MAYINGER P, 1992, BIOCHEMISTRY-US, V31, P10536, DOI 10.1021/bi00158a017; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; NEIL GL, 1966, NATURE, V210, P903, DOI 10.1038/210903a0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PUCELL A, 1971, J BIOL CHEM, V246, P3389; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; WU JC, 1989, BIOCHEMISTRY-US, V28, P8905, DOI 10.1021/bi00448a033; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706	38	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4129	4134						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307973				2022-12-25	WOS:A1994MW98900038
J	LI, L; WYSK, M; GONZALEZ, FA; DAVIS, RJ				LI, L; WYSK, M; GONZALEZ, FA; DAVIS, RJ			GENOMIC LOCI OF HUMAN MITOGEN-ACTIVATED PROTEIN-KINASES	ONCOGENE			English	Note							INSULIN; RAF	Mitogen-activated protein (MAP) kinases [also known as Erks] have been established to function as important mediators of signal transduction by growth factor receptors. Several components of the MAP kinase signal transduction pathway have been demonstrated to be oncogenically activated in malignant tumors. These include growth factor receptors, the GTP-binding protein Ras, and the protein kinase Raf. The genes that encode MAP kinases therefore represent potential targets of carcinogenic insults. Here, we report the genomic loci of three MAP kinase genes are widely distributed within the human genome: p41(mapk) (Erk2) at 22q11.2; p44(mapk) (Euk1) at 16p11.2; and p63(mapk) (Erk3-related) at 18q12-21.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA58396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILE H, 1992, NATURE, V358, P414; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HEIM S, 1987, CANCER CYTOGENETICS; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SETH A, 1992, J BIOL CHEM, V267, P24796; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VERMA RS, 1989, HUMAN CHROMOSOMES; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; 1993, GENOME DATA BASE	33	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					647	649						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290275				2022-12-25	WOS:A1994MW24800033
J	OLIVIER, AR; PARKER, PJ				OLIVIER, AR; PARKER, PJ			BOMBESIN, PLATELET-DERIVED GROWTH-FACTOR, AND DIACYLGLYCEROL INDUCE SELECTIVE-MEMBRANE ASSOCIATION AND DOWN-REGULATION OF PROTEIN-KINASE-C ISOTYPES IN SWISS 3T3-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; 3T3 CELLS; SIGNAL TRANSDUCTION; PHORBOL ESTERS; PHOSPHATIDYLCHOLINE HYDROLYSIS; RAT FIBROBLASTS; DNA-SYNTHESIS; GH4C1 CELLS; ACTIVATION; EPSILON	Swiss 3T3 cells contain protein kinase C (PKC) isotypes alpha, delta, epsilon and zeta (Olivier, A. R., and Parker, P. J. (1992) J. Cell. Physiol. 152, 240-244). Acute stimulation of quiescent cells with the neuropeptide bombesin decreases the mobility of PKC-delta and PKC-epsilon on SDS-polyacrylamide gels. These slower migrating forms of PKC-delta and PKC-epsilon rapidly (within 1 s) and selectively are found associated with the Triton X-100-soluble membrane fraction. No change in the mobility or distribution of PKC-alpha or PKC-zeta is detected. Long-term treatment of cells with bombesin induces selective membrane association and down-regulation of PKC-delta and PKC-epsilon (decreasing 70 and 65%, respectively). No change in the long-term distribution of PKC-alpha and PKC-zeta was detected. Bombesin did, however, increase PKC-alpha protein levels by 60% compared to control cells. PKC-zeta levels remained unchanged. Both the shift in mobility and down-regulation of PKC-delta and PKC-epsilon were only induced by mitogenic doses of bombesin. The potent mitogen platelet-derived growth factor induced similar effects on the PKC isotypes delta and epsilon. PKC-alpha and PKC-zeta levels were unaffected. Repeated doses of the synthetic diglyceride 1-oleoyl-2-acetyl-sn-glycerol induced PKC-delta and PKC-epsilon down-regulation and stimulated the cells to divide. Again PKC-alpha and PKC-zeta levels were unaffected. These results show a correlation between the membrane association and down-regulation of PKC-delta and PKC-epsilon and the entry of cells into S phase.			OLIVIER, AR (corresponding author), IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933				AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1992, J BIOL CHEM, V267, P12892; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; COOK SJ, 1991, CELL SIGNAL, V3, P273, DOI 10.1016/0898-6568(91)90055-Y; HA KS, 1993, J BIOL CHEM, V268, P10534; ISSANDOU M, 1989, BIOCHEM BIOPH RES CO, V163, P201, DOI 10.1016/0006-291X(89)92121-9; KILEY S, 1990, J BIOL CHEM, V265, P15704; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; MARAIS RM, 1991, METHOD ENZYMOL, V200, P234; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OLIVIER AR, 1992, BIOCHEM SOC T, V20, P603, DOI 10.1042/bst0200603; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; ORMEROD MG, 1990, FLOW CYTOMETRY; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETTITT TR, 1993, BIOCHEM J, V289, P487, DOI 10.1042/bj2890487; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	40	101	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2758	2763						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300608				2022-12-25	WOS:A1994MV43200061
J	FRICK, DN; WEBER, DJ; GILLESPIE, JR; BESSMAN, MJ; MILDVAN, AS				FRICK, DN; WEBER, DJ; GILLESPIE, JR; BESSMAN, MJ; MILDVAN, AS			DUAL DIVALENT-CATION REQUIREMENT OF THE MUTT DGTPASE - KINETIC AND MAGNETIC-RESONANCE STUDIES OF THE METAL AND SUBSTRATE COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE; NUCLEOSIDE TRIPHOSPHATASE; MUTATOR GENE; NMR; IDENTIFICATION; PURIFICATION; PROTEINS; EXCHANGE; ENZYME	Kinetic analyses of both the Mn2+- and Mg2+-activated hydrolysis of dGTP by MutT show the requirement for two divalent cations. Whereas Mn2+ supports a 20-fold lower k(cat) (0.19 s-1) than Mg2+ (4.0 s-1), the K(m) of Mn2+.dGTP (6.3 mum) is 45-fold lower than that of Me2+.dGTP (284 mum). Adenosine 5'-(alpha,beta-methylenetriphosphate) (AMPCPP) is a linear competitive inhibitor with respect to dGTP with a K(i) for Mn2+.AMPCPP (42 muM) which is 57-fold lower than the K(i) of Mg2+.AMPCPP (2.4 mm). Such tightening suggests that a metal-bridge E.M2+.NTP.M2+ complex is the catalytically active species. The 12 dissociation constants describing the quaternary MutT.M2+.AMPCPP.M2+ complex were evaluated for both Mn2+ and Mg2+, using EPR and NMR methods. MutT binds a single Mn2+ with a K(d) of 130 +/- 40 muM in reasonable agreement with the kinetically determined activator constant of Mn2+ of 230 +/- 72 muM. The MutT.AMPCPP complex binds two Mn2+ ions, the weaker of which has a K(d) of 16 +/- 2 muM in agreement with the kinetically determined K(m)Mn2+ of 26 +/- 10 muM. MutT.Mn2+ binds Mn2+.AMPCPP with K(d) of 16 +/- 4 muM, whereas MutT alone binds Mn2+.AMPCPP with a K(d) of 135 +/- 30 muM. The 17-fold enhanced paramagnetic effect of Mn2+ on the longitudinal relaxation rate of water protons found with the binary MutT.Mn2+ complex decreases to 4.7-fold upon binding of AMPCPP and to 8.7-fold upon binding of Mn2+.AMPCPP, further supporting a metal-bridge MutT.M2+.NTP.M2+ complex. By competition with Mn2+ MutT binds Mg2+ at one site with a K(d) of 7.5 mM, and MutT.AMPCPP binds Mg2+ at two sites, the weaker of which has a K(d) of 0.9 mm. These values are comparable to the kinetically determined K(a)Mg of 15 +/- 7 mM and K(m)Mg of 1.7 +/- 0.7 mM, respectively. Studies with the racemic, substitution-inert beta,gamma-bidentate tetraamminecobalt (III)-beta,gamma-phosphate-ATP (Co3+(NH3)4ATP) complex show that MutT slowly hydrolyzes only the A stereoisomer but requires Mg2+ or Mn2+ to do so, confirming a dual metal ion requirement.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University			Weber, David J/B-5349-2011; Gillespie, Joel/GXW-0158-2022	Weber, David J/0000-0002-8824-1110; Gillespie, Joel/0000-0002-5075-1609; Frick, David/0000-0002-2434-7223	NIDDK NIH HHS [DK 28616] Funding Source: Medline; NIGMS NIH HHS [GM18649, 5-T32-GM07231] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028616, R01DK028616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007231] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1993, 1993 ENC C ST LOUIS, P94; ADAMS H, 1965, METHOD ENZYMAT AN, P575; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; ARMSTRONG RN, 1979, BIOCHEMISTRY-US, V18, P1230, DOI 10.1021/bi00574a018; BERMAN KM, 1970, J BIOL CHEM, V245, P5309; BHATNAGAR SK, 1990, J BACTERIOL, V172, P2802, DOI 10.1128/jb.172.5.2802-2803.1990; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BULLIONIS LC, 1993, THESIS J HOPKINS U B; CARR HY, 1954, PHYS REV, V94, P630, DOI 10.1103/PhysRev.94.630; CLELAND WW, 1979, ADV INORG BIOCHEM, P163; COHN M, 1954, NATURE, V173, P1090, DOI 10.1038/1731090b0; CORNELIUS RD, 1978, BIOCHEMISTRY-US, V17, P3279, DOI 10.1021/bi00609a016; CORNELIUS RD, 1988, INORG CHEM, V16, P2799; DAWSON RMC, 1986, DATA BIOCH RES, P413; DIXON M, 1964, ENZYMES, P438; FOWLER RG, 1992, MUTAT RES, V284, P307, DOI 10.1016/0027-5107(92)90015-T; FRICK DN, 1993, FASEB J, V7, pA1064; GRANOT J, 1980, J BIOL CHEM, V255, P931; GRANOT J, 1979, FEBS LETT, V103, P265, DOI 10.1016/0014-5793(79)81342-3; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAZIRO Y, 1959, J BIOCHEM-TOKYO, V46, P1523, DOI 10.1093/oxfordjournals.jbchem.a126949; KOFRON JL, 1988, BIOCHEMISTRY-US, V27, P4781, DOI 10.1021/bi00413a030; LI TM, 1978, J BIOL CHEM, V253, P3918; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MERRITT EA, 1978, BIOCHEMISTRY-US, V17, P3274, DOI 10.1021/bi00609a015; MICHAELS G, 1978, J BIOL CHEM, V253, P7656; Mildvan A S, 1972, Methods Enzymol, V26, P654; MILDVAN AS, 1963, BIOCHEMISTRY-US, V2, P910, DOI 10.1021/bi00905a003; MILDVAN AS, 1966, J BIOL CHEM, V241, P1178; MILDVAN AS, 1970, ENZYMES, V2, P446; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; SHIOTA T, 1969, BIOCHEMISTRY-US, V8, P5022, DOI 10.1021/bi00840a052; SWITZER RL, 1971, J BIOL CHEM, V246, P2447; SY J, 1973, P NATL ACAD SCI USA, V70, P306, DOI 10.1073/pnas.70.2.306; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; WEBER DJ, 1993, FASEB J, V7, pA1289; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	40	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1794	1803						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294428				2022-12-25	WOS:A1994MR98800040
J	NGAI, SM; SONNICHSEN, FD; HODGES, RS				NGAI, SM; SONNICHSEN, FD; HODGES, RS			PHOTOCHEMICAL CROSS-LINKING BETWEEN NATIVE RABBIT SKELETAL TROPONIN-C AND BENZOYLBENZOYL-TROPONIN-I INHIBITORY PEPTIDE, RESIDUES 104-115	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEAR-MAGNETIC-RESONANCE; MUSCLE-CONTRACTION; BIOLOGICAL-ACTIVITY; SYNTHETIC PEPTIDES; REGULATORY DOMAIN; CRYSTAL-STRUCTURE; CALCIUM-BINDING; REGION; TROPOMYOSIN	The troponin I (TnI) inhibitory region (residues 104-115) was synthesized with alpha-C-14-labeled Gly-104 and a covalently linked benzoylbenzoyl (BB) moiety at the N terminus to yield a photoactivatable radioactive peptide (BBIp). BBIp was cross-linked to rabbit skeletal muscle troponin C (TnC) to locate the binding site on TnC. The TnC/BBIp mixture was subjected to photolysis in aqueous buffer at pH 7.5 in the presence or absence of Ca2+. A covalent (1:1) cross-linked protein-peptide complex (TnC.BBIp) was isolated in both cases. The cross-linked complex was digested with trypsin, and the peptide fragments were separated by reversed-phase high performance liquid chromatography. The radioactive cross-linked peptide was isolated and further characterized by peptide sequencing and mass spectrometry before and after cyanogen bromide cleavage. The results indicated that Met-155 of TnC was cross-linked to the BB moiety of BBIp in either the presence or absence of Ca2+. The biological activity of both the BBIp peptide and the cross-linked TnC.BBIp complex was studied and a model of the TnC-inhibitory peptide complex was derived using molecular dynamic and energy minimization calculations.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV ALBERTA, MRC CANADA, PROT STRUCT & FUNCT GRP, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV ALBERTA, PROT ENGN NETWORK CTR EXCELLENCE, EDMONTON T6G 2H7, ALBERTA, CANADA	University of Alberta; University of Alberta; University of Alberta			Sönnichsen, Frank D/D-8408-2011; Ngai, Sai Ming/S-4898-2018	Sönnichsen, Frank D/0000-0002-4539-3755; Ngai, Sai Ming/0000-0002-4484-2483				BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; BURKE TWL, 1991, HIGH PERFORMANCE LIQ, P643; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CACHIA PJ, 1985, CALMODULIN ANTAGONIS, P63; Campbell A P, 1989, Adv Exp Med Biol, V255, P195; CAMPBELL AP, 1991, BIOCHEM CELL BIOL, V69, P674, DOI 10.1139/o91-101; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; CHONG PCS, 1982, J BIOL CHEM, V257, P1667; CHONG PCS, 1981, J BIOL CHEM, V256, P5071; CHONG PCS, 1983, FEBS LETT, V153, P372, DOI 10.1016/0014-5793(83)80646-2; CHONG PCS, 1982, J BIOL CHEM, V257, P2549; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DRABIKOWSKI W, 1985, EUR J BIOCHEM, V151, P17, DOI 10.1111/j.1432-1033.1985.tb09063.x; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; GARIEPY J, 1983, FEBS LETT, V160, P1, DOI 10.1016/0014-5793(83)80924-7; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HARTSHOR.DJ, 1968, BIOCHEM BIOPH RES CO, V31, P647, DOI 10.1016/0006-291X(68)90610-4; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; HODGES R S, 1988, Peptide Research, V1, P19; HODGES RS, 1991, HIGH PERFORMANCE LIQ, P773; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; LAN JQ, 1989, BIOCHEMISTRY-US, V28, P7380, DOI 10.1021/bi00444a035; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; MANT CT, 1987, CHROMATOGRAPHIA, V24, P565, DOI 10.1007/BF02688546; NGAI SM, 1992, J BIOL CHEM, V267, P15715; PARKER JMR, 1984, J PROTEIN CHEM, V3, P465, DOI 10.1007/BF01025065; PATO MD, 1981, J BIOL CHEM, V256, P593; PERRY SV, 1973, COLD SPRING HARB SYM, V37, P251, DOI 10.1101/SQB.1973.037.01.035; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; SCHAUB MC, 1969, BIOCHEM J, V115, P993, DOI 10.1042/bj1150993; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SLUPSKY CM, 1992, PROTEIN SCI, V1, P1595, DOI 10.1002/pro.5560011207; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Strynadka NCJ, 1991, CURR OPIN STRUC BIOL, V1, P905, DOI 10.1016/0959-440X(91)90085-8; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; VANEYK JE, 1987, BIOCHEM CELL BIOL, V65, P982; WANG CLA, 1987, J BIOL CHEM, V262, P9636; WANG ZY, 1990, J BIOL CHEM, V265, P4953; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; WILKINSON JM, 1975, BIOCHEM J, V149, P493, DOI 10.1042/bj1490493; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; YAGI K, 1967, BIOCHEM BIOPH RES CO, V29, P331, DOI 10.1016/0006-291X(67)90458-5; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	69	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2165	2172						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294472				2022-12-25	WOS:A1994MR98800093
J	WINITZ, S; GUPTA, SK; QIAN, NX; HEASLEY, LE; NEMENOFF, RA; JOHNSON, GL				WINITZ, S; GUPTA, SK; QIAN, NX; HEASLEY, LE; NEMENOFF, RA; JOHNSON, GL			EXPRESSION OF A MUTANT G(I2) ALPHA-SUBUNIT INHIBITS ATP AND THROMBIN STIMULATION OF CYTOPLASMIC PHOSPHOLIPASE-A(2)-MEDIATED ARACHIDONIC-ACID RELEASE INDEPENDENT OF CA2+ AND MITOGEN-ACTIVATED PROTEIN-KINASE REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GTP-BINDING PROTEINS; SWISS 3T3 CELLS; PROMOTING PHORBOL ESTERS; PHOSPHOLIPASE-C; PERTUSSIS TOXIN; PHOSPHOINOSITIDE HYDROLYSIS; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; RABBIT PLATELETS	The 85-kDa cytoplasmic phospholipase A2 (cPLA2) is the major hormone and growth factor-regulated enzyme that catalyzes release of arachidonic acid in mammalian cells. Activation of cPLA2 requires elevation of intracellular Ca2+ and the phosphorylation of the cPLA2 enzyme by mitogen-activated protein (MAP) kinase. Down-regulation of protein kinase C by phorbol esters or pertussis toxin catalyzed ADP-ribosylation of G(i) proteins inhibits thrombin and ATP receptor-stimulated MAP kinase and arachidonic acid release, indicating that functional protein kinase C and G(i) proteins are required for G protein regulation of arachidonic acid release. A mutant Galpha(i2) subunit having Gly203 mutated to Thr (alpha(i2)G203T) inhibited thrombin and ATP receptor stimulation of arachidonic acid release independent of adenylyl cyclase inhibition, Ca2+ mobilization, and MAP kinase activation. Overexpression of the wild-type alpha(i2) polypeptide or the inactive mutant alpha(i2)G204A (Gly204 mutated to Ala) polypeptide had no effect on thrombin or ATP receptor stimulation of arachidonic acid release. The phenotype observed with expression of the mutant alpha(i2)G203T polypeptide defines a role for G(i2) in the control of cPLA2 activity and subsequent arachidonic acid release in addition to the regulation of intracellular Ca2+ levels and MAP kinase activity.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	JOHNSON, GL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871, R01DK039902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871, DK39902] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAREST R, 1985, BIOCHEM J, V227, P79, DOI 10.1042/bj2270079; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; CURRIE S, 1992, J BIOL CHEM, V267, P6056; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HADLEY JS, 1988, BIOMED ENVIRON MASS, V15, P175, DOI 10.1002/bms.1200150309; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3625; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAJIYAMA Y, 1990, BIOCHEM J, V270, P69, DOI 10.1042/bj2700069; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OSAWA S, 1991, J BIOL CHEM, V266, P4673; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WU DQ, 1992, J BIOL CHEM, V267, P1811; XING MZ, 1992, J BIOL CHEM, V267, P25966; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	52	110	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1889	1895						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294438				2022-12-25	WOS:A1994MR98800053
J	HOEVER, M; CLEMENT, JH; WEDLICH, D; MONTENARH, M; KNOCHEL, W				HOEVER, M; CLEMENT, JH; WEDLICH, D; MONTENARH, M; KNOCHEL, W			OVEREXPRESSION OF WILD-TYPE P53 INTERFERES WITH NORMAL DEVELOPMENT IN XENOPUS-LAEVIS EMBRYOS	ONCOGENE			English	Article							TISSUE-SPECIFIC EXPRESSION; CELL-CYCLE CONTROL; PROTO-ONCOGENE; INSITU HYBRIDIZATION; MOUSE EMBRYOGENESIS; MESSENGER-RNAS; ANTIGEN; LOCALIZATION; EF-1-ALPHA; TRANSITION	We have cloned and sequenced a Xenopus p53 homologue which differs by one amino acid deletion from a previously published Xenopus sequence (Soussi et al., 1987). Transcription analysis revealed that this gene is activated during early oogenesis and that zygotic transcription initiates after midblastula transition. Transcripts are also present in all tested tissues of adult animals. Whole mount in situ hybridization with Xenopus oocytes and embryos revealed, that transcripts are ubiquitously distributed although some accumulation is observed in certain tissues. Microinjection of p53 mRNA into early cleavage stages effectively resulted in overexpression of p53 protein and interfered with normal development. Lethal defects until and during gastrulation and aberrant phenotypes of surviving embryos were probably caused by cleavage arrest or cleavage delay of injected cells with subsequent distortions of cell movements, induction processes and tissue differentiations.	UNIV ULM, BIOCHEM ABT, D-89069 ULM, GERMANY; UNIV SAARLAND, D-66421 HOMBURG, GERMANY	Ulm University; Saarland University			Montenarh, Mathias/AAB-6689-2020	Clement, Joachim H./0000-0002-6601-2456				BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; KASTAN MB, 1991, CANCER RES, V51, P4279; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOHUN TJ, 1989, DEVELOPMENT, V107, P835; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; POTING A, 1990, DIFFERENTIATION, V44, P103; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, CANCER RES, V51, P5232; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; VIZE PD, 1990, DEVELOPMENT, V110, P885; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	41	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					109	120						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302570				2022-12-25	WOS:A1994MW24700014
J	BUTTERS, CA; WILLADSEN, KA; TOBACMAN, LS				BUTTERS, CA; WILLADSEN, KA; TOBACMAN, LS			COOPERATIVE INTERACTIONS BETWEEN ADJACENT TROPONIN-TROPOMYOSIN COMPLEXES MAY BE TRANSMITTED THROUGH THE ACTIN FILAMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RABBIT SKELETAL-MUSCLE; CARDIAC THIN FILAMENT; F-ACTIN; STRIATED-MUSCLE; NONPOLYMERIZABLE TROPOMYOSIN; MYOSIN SUBFRAGMENT-1; ALPHA-TROPOMYOSIN; BINDING; CONTRACTION	Recent analyses of the assembly of thin filaments containing altered forms of troponin (or no troponin) suggested that the strongly cooperative nature of troponin-tropomyosin binding to actin might be primarily caused by indirect interactions involving the actin lattice, rather than by direct contacts between neighboring troponin-tropomyosin molecules. To test this hypothesis, thin filament assembly was examined using either cardiac tropomyosin digested with carboxypeptidase A (cbpTm) or a tropomyosin with defective function at both amino and carboxyl termini (unacetylated cbpTm). Compared to intact troponin-tropomyosin, both troponin-cbpTm and troponin-unacetylated cbpTm had much weaker binding to actin; however, cooperative interactions were only slightly reduced. These data support the implication that the primary source of the cooperativity involves troponin-tropomyosin-promoted conformational changes within the actin polymer. Surprisingly, the effects of tropomyosin amino- and carboxyl-terminal structural defects on troponin-tropomyosin binding to actin were not additive. In the presence of troponin, tropomyosin molecules with either defect had the same diminution in actin affinity as molecules with both defects. Finally, the Ca2+ sensitivity of troponin-tropomyosin binding to actin was increased by alteration of either end of tropomyosin.	UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa; University of Iowa					NHLBI NIH HHS [HL38834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038834, R01HL038834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; CHO YJ, 1990, J BIOL CHEM, V265, P538; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; GRAND RJA, 1976, BIOCHEM J, V159, P633, DOI 10.1042/bj1590633; GREASER ML, 1973, J BIOL CHEM, V248, P2125; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hill T. L., 1985, COOPERATIVITY THEORY; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; INGRAHAM RH, 1984, J BIOL CHEM, V259, P9544; INGRAHAM RH, 1985, BIOCHEMISTRY-US, V24, P5221, DOI 10.1021/bi00340a040; ISHII Y, 1991, J BIOL CHEM, V266, P6894; ISHII Y, 1987, BIOCHEMISTRY-US, V26, P4922, DOI 10.1021/bi00390a005; IZAKOV VY, 1991, CIRC RES, V69, P1171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; LEWIS WG, 1980, J BIOL CHEM, V255, P6854; MAK AS, 1983, J BIOL CHEM, V258, P4330; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MAK AS, 1981, BIOCHEM BIOPH RES CO, V101, P208, DOI 10.1016/S0006-291X(81)80032-0; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; METZGER JM, 1991, J GEN PHYSIOL, V98, P233, DOI 10.1085/jgp.98.2.233; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; PAN BS, 1989, J BIOL CHEM, V264, P8495; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1974, ARCH BIOCHEM BIOPHYS, V162, P436, DOI 10.1016/0003-9861(74)90202-1; SODEK J, 1978, J BIOL CHEM, V253, P1129; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; SZCZESNA D, 1989, BIOL CHEM H-S, V370, P399, DOI 10.1515/bchm3.1989.370.1.399; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TOBACMAN LS, 1987, J BIOL CHEM, V263, P2668; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WALSH TP, 1984, J MOL BIOL, V182, P265; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; ZASEDATELEV AS, 1971, MOL BIOL, V131, P839; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	52	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15565	15570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340383				2022-12-25	WOS:A1993LN30500039
J	FREIJE, JP; BALBIN, M; ABRAHAMSON, M; VELASCO, G; DALBOGE, H; GRUBB, A; LOPEZOTIN, C				FREIJE, JP; BALBIN, M; ABRAHAMSON, M; VELASCO, G; DALBOGE, H; GRUBB, A; LOPEZOTIN, C			HUMAN CYSTATIN-D - CDNA CLONING, CHARACTERIZATION OF THE ESCHERICHIA-COLI EXPRESSED INHIBITOR, AND IDENTIFICATION OF THE NATIVE PROTEIN IN SALIVA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN WHOLE SALIVA; C AMYLOID ANGIOPATHY; AMINO-ACID-SEQUENCE; CATHEPSIN-B; CYSTEINE PROTEINASES; BIOLOGICAL-FLUIDS; GAMMA-TRACE; GENE FAMILY; 3 MEMBERS; PURIFICATION	A cDNA coding for cystatin D, a human member of the cystatin protein family, has been cloned after specific amplification of reverse-transcribed parotid gland RNA. After replacing the segment encoding the putative 20-residue signal peptide with one encoding the Escherichia coli OmpA leader sequence, the cDNA was expressed in E. coli. The isolated recombinant protein exhibited K(i) values of 1.2 nM and >1 muM for papain and cathepsin B, respectively. An antiserum raised against recombinant cystatin D recognized a protein in human saliva with electrophoretical mobility identical to that of the recombinant protein. Immunoenzymatic analysis revealed that this cysteine proteinase inhibitor is present in human saliva and tears at concentrations of 3.8 and 0.5 mg/liter, respectively, while it was not detected in seminal plasma, blood plasma, milk, or cerebrospinal fluid. Cystatin D purified from human saliva by immunosorption displayed a heterogeneous N-terminal end, with sequences starting at residues 5, 7, 9, and 11 of the predicted N-terminal portion of the mature protein. On the basis of structural and functional properties, cystatin D represents a novel cysteine proteinase inhibitor possibly playing a protective role against proteinases present in the oral cavity.	UNIV OVIEDO,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN; UNIV LUND HOSP,DEPT CLIN CHEM,S-22185 LUND,SWEDEN; NOVO NORDISK AS,GENEEXPRESS,DK-2100 COPENHAGEN,DENMARK	University of Oviedo; Lund University; Skane University Hospital; Novo Nordisk			Abrahamson, Magnus/CAG-9507-2022; Velasco, Gloria/AAS-5842-2021; Freije, José M.P./A-6535-2008; Balbín, Milagros/I-4206-2015; Lopez-Otin, Carlos/AAB-2106-2020	Velasco, Gloria/0000-0001-8032-5056; Freije, José M.P./0000-0002-4688-8266; Balbín, Milagros/0000-0001-5325-0407; Lopez-Otin, Carlos/0000-0001-6964-1904; Grubb, Anders/0000-0002-0125-3662				ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ABRAHAMSON M, 1992, HUM GENET, V89, P377; ABRAHAMSON M, 1989, INTRACELLULAR PROTEO, P305; ADAM A, 1985, CLIN CHEM, V31, P423; ALHASHIMI I, 1988, J BIOL CHEM, V263, P9381; BALBIN M, 1993, HUM GENET, V90, P668; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BJORCK L, 1989, NATURE, V337, P385, DOI 10.1038/337385a0; BJORCK L, 1990, J VIROL, V64, P941; BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; FREIJE JP, 1991, J BIOL CHEM, V266, P20538; HALL A, 1992, J ENZYM INHIB, V6, P113, DOI 10.3109/14756369209040742; HAWKE DH, 1987, BIOCHEM BIOPH RES CO, V145, P1248, DOI 10.1016/0006-291X(87)91571-3; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; ISEMURA S, 1987, J BIOCHEM-TOKYO, V102, P693, DOI 10.1093/oxfordjournals.jbchem.a122107; ISEMURA S, 1991, J BIOCHEM, V110, P648, DOI 10.1093/oxfordjournals.jbchem.a123634; ISEMURA S, 1986, FEBS LETT, V198, P145, DOI 10.1016/0014-5793(86)81201-7; ISEMURA S, 1984, J BIOCHEM-TOKYO, V96, P489, DOI 10.1093/oxfordjournals.jbchem.a134861; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY E, 1989, J EXP MED, V169, P1771, DOI 10.1084/jem.169.5.1771; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; LOFBERG H, 1979, SCAND J CLIN LAB INV, V39, P619, DOI 10.3109/00365517909108866; LOFBERG H, 1987, STROKE, V18, P431, DOI 10.1161/01.STR.18.2.431; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; OLAFSSON I, 1990, SCAND J CLIN LAB INV, V50, P85, DOI 10.3109/00365519009091569; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; ORLOWSKI M, 1983, MOL CELL BIOCHEM, V52, P49; PALSDOTTIR A, 1988, LANCET, V2, P603; RAMASUBBU N, 1991, BIOCHEM J, V280, P341, DOI 10.1042/bj2800341; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; SABATINI LM, 1989, J DENT RES, V68, P1138, DOI 10.1177/00220345890680070101; SAITOH E, 1988, BIOL CHEM H-S, V369, P191; SAITOH E, 1991, BIOMED BIOCHIM ACTA, V50, P599; SAITOH E, 1987, GENE, V61, P329, DOI 10.1016/0378-1119(87)90196-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; Sloane B F, 1990, Semin Cancer Biol, V1, P137; TAUGNER R, 1985, HISTOCHEMISTRY, V83, P103, DOI 10.1007/BF00495138; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	56	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15737	15744						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340398				2022-12-25	WOS:A1993LN30500062
J	FUJII, M; HORI, H; MIYAZAKI, G; MORIMOTO, H; YONETANI, T				FUJII, M; HORI, H; MIYAZAKI, G; MORIMOTO, H; YONETANI, T			THE PORPHYRIN-IRON HYBRID HEMOGLOBINS - ABSENCE OF THE FE-HIS BONDS IN ONE TYPE OF SUBUNITS FAVORS A DEOXY-LIKE STRUCTURE WITH LOW-OXYGEN AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PARTIALLY LIGANDED HEMOGLOBIN; PROTOPORPHYRIN-IX; QUATERNARY STRUCTURES; COBALT MYOGLOBINS; ADULT HEMOGLOBIN; CARBON-DIOXIDE; BETA-CHAINS; EQUILIBRIUM; BINDING	Protoporphyrin-protoheme hybrid hemoglobins (Hb), in which the protohemes (Fe) in either the alpha- or beta-subunits were substituted with protoporphyrins IX (PP) alpha(PP)2beta(Fe)2 and alpha(Fe)2beta(PP)2 have been prepared. The structural and functional properties of these hybrid Hbs were investigated by measuring oxygen equilibrium curves and proton nuclear magnetic resonance spectra. The equilibrium constants of the first ligand, K1, observed for alpha(PP)2beta(Fe)2 were much smaller than K1 values of HbA. The effects of pH and inositol hexaphosphate on K1 were substantially diminished. On the other hand, K1 values of alpha(Fe)2beta(PP)2 were similar to those of HbA, including the pH and inositol hexaphosphate effects. The deoxy forms of alpha(PP)2beta(Fe)2 and alpha(Fe)2beta(PP)2 showed exchangeable proton resonances at 11 and 14 parts/million arising from the hydrogen bonds at the alpha1beta2 contact in a deoxy-like structure. In the liganded form, these signals were dependent upon solution conditions. As K1 became larger, the reduction in the intensity of these signals was observed for both liganded forms. The resonance position of E11 Val originating from the beta subunits of alpha(PP)2beta(Fe-CO)2 also varied in accordance with K1. We compare properties of PP-Fe hybrids with those of Co-Fe and Ni-Fe hybrids and conclude that the first oxygen binding to the beta heme may be linked to the metal-proximal His interaction in the a subunits. However, the first oxygen binding to the a heme is linked minimally to the metal-proximal His interaction in the beta subunits but may be correlated instead to the position of E11 Val relative to the porphyrin plane in the beta subunits.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	University of Pennsylvania; Osaka University					NHLBI NIH HHS [HL 14508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014508, R37HL014508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE R, 1969, J MOL BIOL, V42, P351, DOI 10.1016/0022-2836(69)90048-5; CASSOLY R, 1971, EUR J BIOCHEM, V19, P514, DOI 10.1111/j.1432-1033.1971.tb01343.x; COLE SJ, 1971, J AM CHEM SOC, V93, P2153, DOI 10.1021/ja00738a011; DALVIT C, 1985, BIOCHEMISTRY-US, V24, P3398, DOI 10.1021/bi00335a003; ELLFOLK N, 1966, J CHROMATOGR, V25, P373, DOI 10.1016/S0021-9673(01)98255-X; FANELLI AR, 1958, BIOCHIM BIOPHYS ACTA, V30, P608, DOI 10.1016/0006-3002(58)90108-2; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HAYASHI N, 1966, J BIOL CHEM, V241, P79; IKEDASAITO M, 1977, J BIOL CHEM, V252, P620; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; IMAI K, 1980, J MOL BIOL, V138, P635, DOI 10.1016/S0022-2836(80)80021-0; Imai K., 1982, ALLOSTERIC EFFECTS H; INUBUSHI T, 1986, J AM CHEM SOC, V108, P3799, DOI 10.1021/ja00273a040; ISHIMORI K, 1988, BIOCHEMISTRY-US, V27, P4060, DOI 10.1021/bi00411a023; ISHIMORI K, 1992, BIOCHEMISTRY-US, V31, P3256, DOI 10.1021/bi00127a030; ISHIMORI K, 1989, BIOCHEMISTRY-US, V28, P8603, DOI 10.1021/bi00447a050; KIKUCHI G, 1964, BIOCHIM BIOPHYS ACTA, V90, P199, DOI 10.1016/0304-4165(64)90142-4; KILMARTIN JV, 1973, J BIOL CHEM, V248, P7039; KILMARTIN JV, 1971, BIOCHEM J, V124, P31, DOI 10.1042/bj1240031; LAMAR GN, 1979, PORPHYRINS, V4, P129; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1460, DOI 10.1021/bi00704a022; LINDSTROMTR, 1972, BIOCHEMISTRY-US, V11, P1677; LINDSTROMTR, 1973, BIOCHEMISTRY-US, V12, P134; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; LYNCH RE, 1976, J BIOL CHEM, V251, P1015; MAEDA T, 1972, BIOCHEMISTRY-US, V11, P3685, DOI 10.1021/bi00770a004; MATSUKAWA S, 1979, J BIOL CHEM, V254, P2358; MAYER A, 1973, J MOL BIOL, V81, P187, DOI 10.1016/0022-2836(73)90188-5; MIURA S, 1984, BIOCHEMISTRY-US, V23, P2492, DOI 10.1021/bi00306a027; MIURA S, 1982, BIOCHEMISTRY-US, V21, P6280, DOI 10.1021/bi00267a037; NAGAI K, 1977, J MOL BIOL, V111, P41, DOI 10.1016/S0022-2836(77)80130-7; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; NAGAI K, 1982, BIOCHEMISTRY-US, V21, P842, DOI 10.1021/bi00534a005; OGAWA S, 1972, BIOCHEM BIOPH RES CO, V49, P1485, DOI 10.1016/0006-291X(72)90507-4; PARKHURST LJ, 1970, J BIOL CHEM, V245, P4131; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1976, BIOCHEMISTRY-US, V15, P378, DOI 10.1021/bi00647a022; PULSINELLI PD, 1973, P NATL ACAD SCI USA, V270, P3800; RUSSU IM, 1987, BIOCHIM BIOPHYS ACTA, V914, P40, DOI 10.1016/0167-4838(87)90159-2; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; SHIBAYAMA N, 1986, J MOL BIOL, V192, P323, DOI 10.1016/0022-2836(86)90367-0; SHIBAYAMA N, 1987, BIOCHEMISTRY-US, V26, P2194, DOI 10.1021/bi00382a019; SIMOLO K, 1985, J AM CHEM SOC, V107, P2865, DOI 10.1021/ja00296a006; STYNES DV, 1973, J AM CHEM SOC, V95, P1796, DOI 10.1021/ja00787a018; SUGITA Y, 1975, J BIOL CHEM, V250, P1251; SUZUKI T, 1965, BIOCHEM BIOPH RES CO, V19, P691, DOI 10.1016/0006-291X(65)90312-8; TREFFRY A, 1974, BIOCHEM J, V137, P319, DOI 10.1042/bj1370319; TSUBAKI M, 1979, J BIOCHEM-TOKYO, V86, P1029, DOI 10.1093/oxfordjournals.jbchem.a132596; VIGGIANO G, 1979, P NATL ACAD SCI USA, V76, P3673, DOI 10.1073/pnas.76.8.3673; VIGGIANO G, 1978, BIOCHEMISTRY-US, V17, P795, DOI 10.1021/bi00598a007; WATERMAN MR, 1970, J BIOL CHEM, V245, P5847; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493; WINTERHA.KH, 1966, NATURE, V211, P932, DOI 10.1038/211932a0	56	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15386	15393						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340369				2022-12-25	WOS:A1993LN30500014
J	FLINT, DH; EMPTAGE, MH; FINNEGAN, MG; FU, WG; JOHNSON, MK				FLINT, DH; EMPTAGE, MH; FINNEGAN, MG; FU, WG; JOHNSON, MK			THE ROLE AND PROPERTIES OF THE IRON-SULFUR CLUSTER IN ESCHERICHIA-COLI DIHYDROXY-ACID DEHYDRATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; ELECTRON-PARAMAGNETIC-RES; COMPLETE NUCLEOTIDE-SEQUENCE; SPECTROSCOPIC CHARACTERIZATION; AZOTOBACTER-VINELANDII; ACTIVATED ACONITASE; SYNTHETIC ANALOGS; 4FE-4S CLUSTER; PROTEIN; FERREDOXIN	Dihydroxy-acid dehydratase has been purified from Escherichia coli and characterized as a homodimer with a subunit molecular weight of 66,000. The combination of UV visible absorption, EPR, magnetic circular dichroism, and resonance Raman spectroscopies indicates that the native enzyme contains a [4Fe-4S]2+,+ cluster, in contrast to spinach dihydroxy-acid dehydratase which contains a [2Fe-2S]2+,+ cluster (Flint, D. H., and Emptage, M. H. (1988) J. Biol. Chem. 263, 3558-3564). In frozen solution, the reduced [4Fe-4S]+ cluster has a S = 3/2 ground state with minor contributions from forms with S = 1/2 and possibly S = 5/2 ground states. Resonance Raman studies of the [4Fe-4S]2+ cluster in E. coli dihydroxy-acid dehydratase indicate non-cysteinyl coordination of a specific iron, which suggests that it is likely to be directly involved in catalysis as is the case with aconitase (Emptage, M. H., Kent, T. A., Kennedy, M. C., Beinert, H., and Munck, E. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 4674-4678). Dihydroxy-acid dehydratase from E. coli is inactivated by O2 in vitro and in vivo as a result of oxidative degradation of the [4Fe-4S] cluster. Compared to aconitase, the oxidized cluster of E. coli dihydroxy-acid dehydratase appears to be less stable as either a cubic or linear [3Fe-4S] cluster or a [2Fe-2S] cluster. Oxidative degradation appears to lead to a complete breakdown of the Fe-S cluster, and the resulting protein cannot be reactivated with Fe2+ and thiol reducing agents.	UNIV GEORGIA,CTR MET ENZYME STUDIES,ATHENS,GA 30602; UNIV GEORGIA,DEPT CHEM,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	FLINT, DH (corresponding author), DUPONT CO INC,DEPT CENT RES & DEV,WILMINGTON,DE 19880, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033806] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33806] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ABELES RH, 1976, ACCOUNTS CHEM RES, V9, P114, DOI 10.1021/ar50099a006; ARFIN SM, 1969, J BIOL CHEM, V244, P2250; ARMSTRONG FA, 1989, BIOCHEM J, V264, P265, DOI 10.1042/bj2640265; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1978, Methods Enzymol, V54, P435; BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; CARNEY MJ, 1988, J AM CHEM SOC, V110, P6084, DOI 10.1021/ja00226a025; CARNEY MJ, 1989, INORG CHEM, V28, P1497, DOI 10.1021/ic00307a015; CIOFFI EA, 1980, ANAL BIOCHEM, V104, P485, DOI 10.1016/0003-2697(80)90104-9; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; COX JL, 1987, GENE, V56, P185, DOI 10.1016/0378-1119(87)90136-3; CZERNUSZEWICZ RS, 1987, J AM CHEM SOC, V109, P7178, DOI 10.1021/ja00257a045; DREYER JL, 1985, EUR J BIOCHEM, V150, P145, DOI 10.1111/j.1432-1033.1985.tb09000.x; EMPTAGE M H, 1990, P315; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EMPTAGE MH, 1988, ACS SYM SER, V372, P343; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; FEE JA, 1980, BIOCHEM INT, V1, P304; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1988, J BIOL CHEM, V263, P3558; FU WG, 1992, J BIOL CHEM, V267, P16135; FUJ W, 1992, J BIOL CHEM, V267, P15502; GRABOWSKI R, 1991, EUR J BIOCHEM, V199, P89, DOI 10.1111/j.1432-1033.1991.tb16095.x; GRAY JE, 1981, MOL GEN GENET, V183, P428, DOI 10.1007/BF00268761; HAMILTON CL, 1989, J BIOL CHEM, V264, P11605; Hill R. L., 1971, ENZYMES, V5, P539; HILL RK, 1973, J AM CHEM SOC, V95, P7857, DOI 10.1021/ja00804a048; JOHNSON MK, 1988, ACS SYM SER, V372, P326; JOHNSON MK, 1982, IRON SULFUR PROTEINS, P267; KELLY JM, 1986, FEBS LETT, V202, P274, DOI 10.1016/0014-5793(86)80700-1; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; Kiritani K., 1970, METHOD ENZYMOL, V17, P755; KUCHTA RD, 1986, BIOCHEMISTRY-US, V25, P7301, DOI 10.1021/bi00371a009; KUO CF, 1987, J BIOL CHEM, V262, P4724; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LINDAHL PA, 1987, INORG CHEM, V26, P3912, DOI 10.1021/ic00270a018; LOPES JM, 1986, NUCLEIC ACIDS RES, V14, P2779, DOI 10.1093/nar/14.6.2779; MADDEN JF, 1989, BIOCHEMISTRY-US, V28, P5474; MATSUBARA H, 1983, PROTEIN NUCLEIC ACID, P168; MELOCHE HP, 1964, J BIOL CHEM, V239, P3505; MEYER J, 1986, BIOCHEMISTRY-US, V25, P6054, DOI 10.1021/bi00368a033; MYERS JW, 1961, J BIOL CHEM, V236, P1414; ONATE YA, 1989, J BIOL CHEM, V264, P18386; ONATE YA, 1993, IN PRESS BIOCH BIOPH; RICHARDS AJM, 1990, SPECTROCHIM ACTA A, V46, P987, DOI 10.1016/0584-8539(90)80015-Q; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; SCHWEIGER G, 1987, EUR J BIOCHEM, V169, P441, DOI 10.1111/j.1432-1033.1987.tb13631.x; SCOPES RK, 1984, ANAL BIOCHEM, V136, P530, DOI 10.1016/0003-2697(84)90257-4; TELSER J, 1986, J BIOL CHEM, V261, P4840; UZAN M, 1981, MOL GEN GENET, V182, P462, DOI 10.1007/BF00293936	60	127	169	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14732	14742						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325851				2022-12-25	WOS:A1993LL75900033
J	TAKEDA, J; GIDHJAIN, M; XU, LZ; FROGUEL, P; VELHO, G; VAXILLAIRE, M; COHEN, D; SHIMADA, F; MAKINO, H; NISHI, S; STOFFEL, M; VIONNET, N; STCHARLES, R; HARRISON, RW; WEBER, IT; BELL, GI; PILKIS, SJ				TAKEDA, J; GIDHJAIN, M; XU, LZ; FROGUEL, P; VELHO, G; VAXILLAIRE, M; COHEN, D; SHIMADA, F; MAKINO, H; NISHI, S; STOFFEL, M; VIONNET, N; STCHARLES, R; HARRISON, RW; WEBER, IT; BELL, GI; PILKIS, SJ			STRUCTURE-FUNCTION STUDIES OF HUMAN BETA-CELL GLUCOKINASE - ENZYMATIC-PROPERTIES OF A SEQUENCE POLYMORPHISM, MUTATIONS ASSOCIATED WITH DIABETES, AND OTHER SITE-DIRECTED MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXOKINASE-B; CONFORMATION; EXPRESSION; LIVER	Glucokinase plays a key role in the regulation of glucose metabolism in insulin-secreting pancreatic beta-cells and in the liver. Recent studies have shown that mutations in this enzyme can lead to the development of a form of non-insulin-dependent diabetes mellitus that is characterized by an autosomal dominant mode of inheritance and onset during childhood. Here, we report the catalytic properties of five additional missense mutations associated with diabetes (Glu70 --> Lys, Ser131 --> Pro, Ala188 --> Thr, Trp257 --> Arg and Lys414 --> Glu), one polymorphism present in both normal and diabetic subjects (Asp4 --> Asn), and three site-directed mutations (Glu177 --> Lys, Glu256 --> Ala, and Lys414 --> Ala). The Trp257 --> Arg mutation generated an enzyme that had an activity that was less than 0.5% of that for native human beta-cell glucokinase. By contrast, the Glu70 --> Lys, Ser131 --> Pro, Ala188 --> Thr, and Lys414 --> Glu mutations had a V(max) that was 20-100% of normal but a K(m) for glucose that was 8-14-fold greater than the native enzyme. There was no effect of the Asp4 --> Asn polymorphism or the Glu177 --> Lys substitution on glucokinase activity. The Lys414 --> Ala substitution had no effect on V(max) but increased the K(m) for glucose 2-fold and the Glu256 --> Ala substitution caused a approximately 200-fold decrease in V(max). These studies have led to the identification of additional residues involved in glucokinase catalysis and substrate binding.	SUNY, HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,LEVEL 6,RM 140, STONY BROOK, NY 11794 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; CTR ETUD POLYMORPHISM HUMAIN, F-75010 PARIS, FRANCE; CHIBA UNIV, SCH MED, DEPT INTERNAL MED 2, CHIBA 260, JAPAN; HAMAMATSU UNIV SCH MED, DIV INTERNAL MED 2, HAMAMATSU, SHIZUOKA 43132, JAPAN; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; Chiba University; Hamamatsu University School of Medicine; Jefferson University			Velho, Gilberto/Q-6724-2017; FROGUEL, Philippe/O-6799-2017; Vionnet, Nathalie/N-6302-2017	Velho, Gilberto/0000-0001-8811-363X; FROGUEL, Philippe/0000-0003-2972-0784; Harrison, Robert/0000-0003-2449-1214	NIDDK NIH HHS [DK-44840, DK-20595, DK-38354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, P60DK020595, R01DK038354, P01DK044840] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ANDERSON CM, 1978, J MOL BIOL, V123, P1, DOI 10.1016/0022-2836(78)90373-X; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; BARK P, 1992, P NATL ACAD SCI USA, V89, P7290; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; CHEIN CT, 1989, BIOCHEM BIOPH RES CO, V165, P817; FLATHERTY KM, 1990, NATURE, V346, P623; FLATHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; GRANNER DK, 1990, J BIOL CHEM, V265, P16012; HARRISON RW, 1985, THESIS YALE U NEW HA; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KATAGIRI H, 1992, LANCET, V340, P1316, DOI 10.1016/0140-6736(92)92494-Z; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; NISHI S, 1992, DIABETOLOGIA, V35, P743; SAKURA H, 1992, J CLIN ENDOCR METAB, V75, P1571, DOI 10.1210/jc.75.6.1571; SHIMADA F, 1993, IN PRESS DIABETOLOGI, V36; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; STOFFEL M, 1993, IN PRESS DIABETES; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANSCHAFTINGEN E, 1992, ADV ENZYME REGUL, V32, P133; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1	27	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15200	15204						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325892				2022-12-25	WOS:A1993LL75900095
J	WENG, ZG; TAYLOR, JA; TURNER, CE; BRUGGE, JS; SEIDELDUGAN, C				WENG, ZG; TAYLOR, JA; TURNER, CE; BRUGGE, JS; SEIDELDUGAN, C			DETECTION OF SRC HOMOLOGY 3-BINDING PROTEINS, INCLUDING PAXILLIN, IN NORMAL AND V-SRC-TRANSFORMED BALB/C 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; ABL TYROSINE KINASE; SIGNAL TRANSDUCTION; BINDING PROTEIN; C-SRC; CATALYTIC DOMAINS; CELLULAR PROTEINS; FOCAL ADHESIONS; SH3 DOMAINS; PP60C-SRC	The Src homology 3 (SH3) domain, located in the amino-terminal, noncatalytic half of pp60src, is highly conserved among members of the Src family of tyrosine kinases. SH3 domains have also been identified in a variety of proteins otherwise unrelated to protein-tyrosine kinases. The presence of SH3 domains in proteins with diverse functions suggests this domain may be important for directing protein-protein interactions necessary for protein function or cellular localization. To explore possible interactions between the SH3 domain and cellular proteins, we have established conditions for the isolation of proteins that bind in solution to the Src SH3 domain. A 67-amino acid fragment of c-Src containing either the entire glutathione S-transferase-SH3 domain (GST-SH3) or the SH3 domain from the neuronal form of c-Src (GST-SH3+) was expressed as a glutathione S-transferase fusion protein. The GST fusion proteins were incubated with lysates from [S-35]methionine-labeled Balb/c 3T3 cells or v-Src-transformed Balb/c 3T3 cells. We found that GSTSH3, but not wild-type GST, specifically interacted with multiple cellular proteins, whereas GST-SH3+ only weakly associated with a small subset of these proteins. The majority of the SH3-binding proteins were found in particulate and detergent-insoluble cell fractions. Anti-phosphotyrosine immunoblots of the SH3-binding proteins revealed that several of the SH3-binding proteins are phosphorylated on tyrosine in v-Src-transformed cells. In addition, a number of the SH3-binding proteins were phosphorylated on serine and/or threonine in in vitro kinase assays, suggesting that one or more of the SH3-binding proteins has kinase activity. We identified paxillin, a vinculin-binding protein, as one of the Src SH3-binding proteins. This finding strongly supports the hypothesis that SH3 domains may be involved in subcellular localization of proteins to cytoskeleton and/or cellular membranes.	ARIAD PHARMACEUT,26 LANDSDOWNE ST,CAMBRIDGE,MA 02139; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,PHILADELPHIA,PA 19104; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,SYRACUSE,NY 13210	Takeda Pharmaceutical Company Ltd; Takeda Oncology; Howard Hughes Medical Institute; University of Pennsylvania; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL CANCER INSTITUTE [R01CA027951, R37CA027951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047607, R01GM047607] Funding Source: NIH RePORTER; NCI NIH HHS [CA27951] Funding Source: Medline; NIGMS NIH HHS [R01 GM047607, GM47607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BRUGGE JS, 1984, J BIOL CHEM, V259, P4550; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Potts W M, 1988, Oncogene Res, V3, P343; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MK, 1990, J BIOL CHEM, V265, P1837; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	61	229	234	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14956	14963						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325872				2022-12-25	WOS:A1993LL75900064
J	FERREIRA, GC				FERREIRA, GC			MAMMALIAN FERROCHELATASE - OVEREXPRESSION IN ESCHERICHIA-COLI AS A SOLUBLE-PROTEIN, PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIC PROTOPORPHYRIA; MOLECULAR-CLONING; GENE; EXPRESSION; SEQUENCE; DEFECT; MUTANT; DNA	Ferrochelatase (protoheme ferrolyase, EC 4.99.1.1), a membrane bound protein, catalyzes the terminal step of the heme biosynthesis in all living systems. A cDNA encoding the murine ferrochelatase (Taketani, S., Nakahashi, Y., Osumi, T, and Tokunaga, R. (1990) J. Biol. Chem. 265, 19377-19380) has been expressed in Escherichia coli, using the alkaline phosphatase promoter. Ferrochelatase was not only overexpressed in an active form, but more importantly, was produced as a ''soluble protein'' (i.e. associated with the soluble bacterial protein fraction). A simple purification from the ferrochelatase overproducing bacterial strain yielded similar to 50 mg of protein/2-3 liters of bacterial culture. Recombinant ferrochelatase exhibited identical physical and catalytic properties to those of mammalian ferrochelatases. Specifically, the recombinant ferrochelatase has iron and porphyrin as substrates, and N-methylprotoporphyrin and metal ions (e.g. Hg2+ and Mn2+), as strong inhibitors of its enzyme activity. The K-m values are 112.5 mu m for iron and 95 mu m for deuteroporphyrin IX which are in the same range of the K-m values determined for the ferrochelatases isolated from natural sources. This report describes the overexpression of a mammalian ferrochelatase in E. coli, as a soluble protein, and its purification from an overproducing strain. The production of a functional and ''soluble'' ferrochelatase has significance for the pursuit of structural and functional studies of this enzyme.			FERREIRA, GC (corresponding author), UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR,INST BIOMOLEC SCI,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33682, USA.		Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217				Akhtar M., 1991, BIOSYNTHESIS TETRAPY, P67; BOULECHFAR S, 1993, GENOMICS, V16, P645, DOI 10.1006/geno.1993.1242; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; BRENNER DA, 1992, AM J HUM GENET, V50, P1203; CHAN RYY, 1993, BIOCHEM J, V292, P343, DOI 10.1042/bj2920343; CORNISHBOWDEN A, 1981, FUUNDAMENTALS ENZYME, P99; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1983, J BIOL CHEM, V258, P1453; DAILEY HA, 1986, METHOD ENZYMOL, V123, P401; DAILEY HA, 1982, J BIOL CHEM, V257, P4714; ELDRIDGE MG, 1992, PROTEIN SCI, V1, P271; FALK JE, 1964, PORPHYRINS METALLOPO; FERREIRA GC, 1993, J BIOL CHEM, V268, P584; FRUSTACI JM, 1993, J BACTERIOL, V175, P2154, DOI 10.1128/JB.175.7.2154-2156.1993; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; JORDAN PM, 1991, BIOSYNTHESIS TETRAPY, P257; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LABBEBOIS R, 1993, IN PRESS METAL IONS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORIL J, 1991, BIOCHEM BIOPH RES CO, V181, P594, DOI 10.1016/0006-291X(91)91231-Z; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; NAKAHASHI Y, 1990, BIOCHIM BIOPHYS ACTA, V1037, P321, DOI 10.1016/0167-4838(90)90032-B; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P281, DOI 10.1073/pnas.89.1.281; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; NORDMANN Y, 1990, BIOSYNTHESIS HEME CH, P491; PORRA R, 1963, BIOCHEM J, V87, P1181; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAKA JG, 1991, J BIOL CHEM, V266, P24637; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; WANG XH, 1993, BIOCHIM BIOPHYS ACTA, V1181, P198, DOI 10.1016/0925-4439(93)90112-E; WHITCOMBE DM, 1991, GENOMICS, V11, P1152, DOI 10.1016/0888-7543(91)90044-F	38	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4396	4400						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308010				2022-12-25	WOS:A1994MW98900078
J	OH, BH; KANG, CH; DEBONDT, H; KIM, SH; NIKAIDO, K; JOSHI, AK; AMES, GFL				OH, BH; KANG, CH; DEBONDT, H; KIM, SH; NIKAIDO, K; JOSHI, AK; AMES, GFL			THE BACTERIAL PERIPLASMIC HISTIDINE-BINDING PROTEIN - STRUCTURE/FUNCTION ANALYSIS OF THE LIGAND-BINDING SITE AND COMPARISON WITH RELATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TRANSPORT-SYSTEMS; ACTIVE-TRANSPORT; RESOLUTION STRUCTURE; AGROBACTERIUM-TUMEFACIENS; MALTOSE TRANSPORT; ARGININE-BINDING; LYSINE-BINDING; X-RAY	Bacterial periplasmic binding proteins are initial receptors in the process of active transport across cell membranes and/or chemotaxis. Among them, the histidine-binding protein (HisJ) has been extensively studied from the biochemical, physiological, and genetic points of view. The three dimensional crystal structure of the histidine binding protein complexed with histidine has been determined at 2.5-Angstrom resolution by the molecular replacement method using as a probe structure the previously solved lysine liganded structure of the lysine-, arginine-, ornithine binding protein (LAG), which shares 70% sequence identity with HisJ. The structure is bi-lobate; the two lobes, one bigger than the other, are connected by two short strands and are in contact with each other (closed) enclosing the histidine. Charged, polar, and non-polar side chains, as well as the peptide backbone, are involved in tight binding of the histidine. The bound histidine is involved in eight direct hydrogen bonds, six with the bigger lobe and two with the smaller lobe, in one potential water-mediated hydrogen bond with the bigger lobe, as well as in ionic interactions. The HisJ residues surrounding the ligand are the same as the LAO residues interacting with lysine, except for residue 52 which is leucine in HisJ and phenylalanine in LAG. The Leu-52 in HisJ makes a hydrophobic interaction with the imidazole ring of histidine. Of seven mutations affecting the ligand-binding site, five are located in the ligand-binding site, one in a con strand, and one at the domains interface. Based on comparisons among related binding proteins, the specific interactions between the ligands and the respective binding protein residues are predicted for the glutamine-binding protein and the opines-binding protein	LAWRENCE BERKELEY LAB, DEPT CHEM, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, DIV STRUCT BIOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Oh, Byung-Ha/C-2061-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043747] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30725] Funding Source: Medline; NIDDK NIH HHS [DK43747] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1989, J BIOL CHEM, V264, P15739; ADAMS MD, 1991, J BIOL CHEM, V266, P6209; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GFL, 1970, P NATL ACAD SCI USA, V66, P1096, DOI 10.1073/pnas.66.4.1096; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; AMES GFL, 1974, J BIOL CHEM, V249, P634; AMES GFL, 1977, J BACTERIOL, V129, P1289, DOI 10.1128/JB.129.3.1289-1297.1977; AMES GFL, 1990, BACTERIAL ENERGETICS, P225; BENNETT WS, 1984, CRIT REV BIOCH, V15, P290; BINNS AN, 1988, ANNU REV MICROBIOL, V42, P5750; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1991, X PLOR; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DEAN DA, 1990, RES MICROBIOL, V141, P348, DOI 10.1016/0923-2508(90)90010-N; FUGINAGA M, 1987, J APPL CRYSTALLOGR, V21, P273; GOKCEN S, 1992, THESIS U CALIFORNIA; GUYON P, 1980, P NATL ACAD SCI-BIOL, V77, P2693, DOI 10.1073/pnas.77.5.2693; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HUBER R, 1985, MOL REPLACEMENT, P58; JOSHI AK, 1991, BIOTECHNIQUES, V10, P42; KANG CH, 1991, J BIOL CHEM, V266, P23893; KANG CH, 1989, J MOL BIOL, V207, P643, DOI 10.1016/0022-2836(89)90475-0; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KERPPOLA RE, 1990, THESIS U CALIFORNIA; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSTU SG, 1979, J BACTERIOL, V138, P218, DOI 10.1128/JB.138.1.218-234.1979; LEVER JE, 1972, J BIOL CHEM, V247, P4317; LUKAT GS, 1993, J CELL BIOCHEM, V51, P41, DOI 10.1002/jcb.240510109; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; Mowbray S L, 1990, Receptor, V1, P41; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; NOHNO T, 1986, MOL GEN GENET, V205, P260, DOI 10.1007/BF00430437; OH BH, 1993, J BIOL CHEM, V268, P11348; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; POWELL MJD, 1977, MATH PROGRAM, V12, P273; PROSSNITZ E, 1989, THESIS U CALIFORNIA; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; QUIOCHO FA, 1977, J BIOL CHEM, V252, P5142; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHEN QC, 1989, J MOL BIOL, V210, P849, DOI 10.1016/0022-2836(89)90112-5; SHIFRIN S, 1966, J BIOL CHEM, V241, P3424; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; THOMPSON J, 1992, ANNU REV BIOCHEM, V61, P517; TJANDRA N, 1992, J BIOMOL NMR, V2, P149, DOI 10.1007/BF01875526; VALDIVIA RH, 1991, J BACTERIOL, V173, P6398, DOI 10.1128/jb.173.20.6398-6405.1991; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; ZANKER H, 1992, J BACTERIOL, V174, P841, DOI 10.1128/jb.174.3.841-849.1992	59	90	91	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4135	4143						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307974				2022-12-25	WOS:A1994MW98900039
J	PARSELL, DA; KOWAL, AS; LINDQUIST, S				PARSELL, DA; KOWAL, AS; LINDQUIST, S			SACCHAROMYCES-CEREVISIAE HSP104 PROTEIN - PURIFICATION AND CHARACTERIZATION OF ATP-INDUCED STRUCTURAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING; COMPLEX; RING; HYDROLYSIS; MUTATIONS; PARTICLE; SUBUNIT; MEMBER; FAMILY	Heat-shock proteins (hsps) function in a variety of ways to help cells and organisms cope with environmental changes. One class of hsps, the Hsp100 proteins, is especially important for tolerance to a variety of extremely stressful conditions (e.g. high temperatures or high concentrations of ethanol). To begin to characterize the mechanism of action of Hsp100 proteins, we have initiated an in vitro analysis of the Saccharomyces cerevisiae Hsp104 protein. Here, we report the purification and initial structural characterization of the wild-type protein and three variants carrying mutations in the two ATP-binding site consensus elements. As demonstrated by both gel filtration chromatography and by cross-linking studies with glutaraldehyde, Hsp104 forms a homohexameric particle. By electron microscopy, these particles are ring-shaped and reminiscent of proteins in the Hsp60 and TF55/TCP families. In contrast to these other proteins, Hsp104 forms single rings, each containing only six subunits. More strikingly, the assembly and maintenance of Hsp104 particles are dependent upon the presence of adenine nucleotides. Oligomerization appears to primarily depend upon the second of the two ATP-binding sites in the protein.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001777] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01777] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BANEYX F, 1992, J BIOL CHEM, V267, P11637; BRIDGER WA, 1983, CELL ATP, V5; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MIAN IS, 1993, TRENDS BIOCHEM SCI, V18, P125; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; PARSELL DA, 1993, PHILOS T R SOC B, V339, P279, DOI 10.1098/rstb.1993.0026; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SANCHEZ Y, 1993, IN PRESS J BACTERIOL; SCHENA M, 1991, P389; SPIESS E, 1987, ELECT MICROSCOPY MOL, P147; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WOO KM, 1992, J BIOL CHEM, V267, P20429; XIA ZG, 1990, J BIOL CHEM, V265, P6517	40	165	171	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4480	4487						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308017				2022-12-25	WOS:A1994MW98900089
J	MULLIS, KG; KORNFELD, RH				MULLIS, KG; KORNFELD, RH			CHARACTERIZATION AND IMMUNOLOCALIZATION OF BOVINE N-ACETYLGLUCOSAMINE-1-PHOSPHODIESTER ALPHA-N-ACETYLGLUCOSAMINIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; BREFELDIN-A; RECOGNITION MARKER; MEMBRANE-PROTEINS; CIS-GOLGI; PHOSPHORYLATION; CELLS; PURIFICATION; ER; REDISTRIBUTION	N-Acetylglucosamine-1-phosphodiester alpha-N-acetyl-glucosaminidase (phosphodiester alpha-GlcNAcase) has been purified 3,000-fold from bovine liver and its kinetic properties determined as described in the previous report (Mullis, K. G., Huynh, M., and Kornfeld, R. (1993) J. Biol. Chem. 269,1718-1726). This report describes the hydrodynamic and lectin binding properties of phosphodiester alpha-GlcNAcase as well as its intracellular localization. The molecular weight of phosphodiester alpha-GlcNAcase is 204,950, as determined from density gradient centrifugation in D2O and H2O glycerol gradients and gel filtration. Enzymatically active enzyme migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with a molecular weight of 129,000, consistent with native phosphodiester alpha-GlcNAcase being a dimer. The lectin binding properties of phosphodiester alpha-GlcNAcase indicate that it contains sialylated species of both complex type N-linked oligosaccharides and O-linked oligosaccharides. In immunofluorescence studies phosphodiester alpha-GlcNAcase shows a perinuclear, Golgi localization in Vero cells as does the mid-Golgi marker alpha-mannosidase II. After exposure of the Vero cells to brefeldin A, phosphodiester alpha-GlcNAcase assumes an endoplasmic reticulum staining pattern. In contrast, in cells costained with the trans-Golgi marker wheat germ agglutinin, the wheat germ agglutinin marker assumed an endosomal network appearance after exposure to brefeldin A. These findings indicate that phosphodiester alpha-GlcNAcase is normally located within the Golgi stack, separate from the trans-Golgi and trans-Golgi network stained by wheat germ agglutinin.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NCI NIH HHS [CA08759] Funding Source: Medline; NHLBI NIH HHS [T32-HLO7088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; BENYOSEPH Y, 1986, BIOCHEM J, V235, P883, DOI 10.1042/bj2350883; CLARKE S, 1975, J BIOL CHEM, V250, P5459; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GONATAS JO, 1989, J BIOL CHEM, V264, P646; HARLOW E, 1988, ANTIBODIES LABORATOR; HENDRICKS LC, 1991, J BIOL CHEM, V266, P17559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MULLIS KG, 1992, ANAL BIOCHEM, V205, P200, DOI 10.1016/0003-2697(92)90424-6; MULLIS KG, 1993, J BIOL CHEM, V269, P1718; RADONS J, 1990, BIOL CHEM H-S, V371, P567, DOI 10.1515/bchm3.1990.371.2.567; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	24	8	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1727	1733						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294421				2022-12-25	WOS:A1994MR98800031
J	OKUBO, K; KANG, DC; HAMASAKI, N; JENNINGS, ML				OKUBO, K; KANG, DC; HAMASAKI, N; JENNINGS, ML			RED-BLOOD-CELL BAND-3 - LYSINE-539 AND LYSINE-851 REACT WITH THE SAME H2DIDS (4,4'-DIISOTHIOCYANODIHYDROSTILBENE-2,2'-DISULFONIC ACID) MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANES; ANION-TRANSPORT PROTEIN; SITE-DIRECTED MUTAGENESIS; PREDOMINANT TRANSMEMBRANE POLYPEPTIDE; PHOSPHATE BINDING-SITE; CROSS-LINKING; EXCHANGE PROTEIN; XENOPUS-LAEVIS; LOCALIZATION; SEQUENCE	The band 3 protein of the red blood cell membrane catalyzes anion exchange that is inhibited by the stilbenedisulfonate derivative H2DIDS (4,4'-diisothiocyanodihydrostilbene-2,2'-disulfonic acid). There is one H2DIDS binding site per 95,000-Da band 3 polypeptide. The single bound H2DIDS molecule can react covalently with 2 different lysine residues. The 2 lysines that react covalently with H2DIDS have been localized directly by sequencing fragments of human band 3 from cells labeled with [H-3]H2DIDS. The most rapid covalent reaction is with Lys-539, in agreement with site-directed mutagenesis studies. The slower reaction is with Lys-851, which is known to be the primary site of binding of another anion transport inhibitor, pyridoxal phosphate (Kawano et al., 1988). These results indicate that the protein is folded to bring these 2 residues into close enough proximity to react covalently with the same H2DIDS molecule. In addition to defining the residues that react with H2DIDS, these studies have also defined new in situ proteolytic cleavage sites in band 3.	KYUSHU UNIV,SCH MED,DEPT CLIN CHEM & LAB MED,FUKUOKA 812,JAPAN; UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77550	Kyushu University; University of Texas System; University of Texas Medical Branch Galveston	OKUBO, K (corresponding author), FUKUOKA UNIV,SCH MED,DEPT CLIN CHEM & LAB MED,FUKUOKA 81401,JAPAN.				NIGMS NIH HHS [R01 GM 26861] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026861] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL D, 1989, EMBO J, V8, P3601, DOI 10.1002/j.1460-2075.1989.tb08533.x; BARTEL D, 1989, BIOCHIM BIOPHYS ACTA, V985, P355, DOI 10.1016/0005-2736(89)90427-6; BROCK CJ, 1983, BIOCHEM J, V213, P577, DOI 10.1042/bj2130577; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CABANTCHIK ZI, 1975, J BIOL CHEM, V250, P5130; DRICKAMER LK, 1976, J BIOL CHEM, V251, P5115; DRICKAMER LK, 1978, J BIOL CHEM, V253, P7242; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; HAMASAKI N, 1983, EUR J BIOCHEM, V132, P531, DOI 10.1111/j.1432-1033.1983.tb07394.x; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; IDEGUCHI H, 1982, EUR J BIOCHEM, V125, P665, DOI 10.1111/j.1432-1033.1982.tb06734.x; JENNINGS ML, 1985, J BIOL CHEM, V260, P5472; JENNINGS ML, 1984, BIOCHEMISTRY-US, V23, P6432, DOI 10.1021/bi00321a024; JENNINGS ML, 1982, J BIOL CHEM, V257, P7554; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; JENNINGS ML, 1984, J BIOL CHEM, V259, P4652; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JENNINGS ML, 1981, BIOCHEMISTRY-US, V20, P7118, DOI 10.1021/bi00528a011; JENNINGS ML, 1989, ANION TRANSPORT PROT, P59; KAMPMANN L, 1982, J MEMBRANE BIOL, V70, P199, DOI 10.1007/BF01870563; KANG D, 1992, J BIOL CHEM, V267, P19211; KAWANO Y, 1986, J BIOCHEM-TOKYO, V100, P191, DOI 10.1093/oxfordjournals.jbchem.a121692; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KAY MMB, 1991, FASEB J, V5, P109, DOI 10.1096/fasebj.5.1.1991578; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPKE S, 1976, J MEMBRANE BIOL, V29, P147, DOI 10.1007/BF01868957; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; OKUBO K, 1991, J BIOL CHEM, V266, P16420; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; REITHMEIER RAF, 1979, J BIOL CHEM, V254, P3054; STECK TL, 1978, BIOCHEMISTRY-US, V17, P1216, DOI 10.1021/bi00600a013; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOOD PG, 1992, J MEMBRANE BIOL, V127, P139; WOOD PG, 1992, BAND 3 PROTEINS ANIO, P325	42	138	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1918	1926						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294441				2022-12-25	WOS:A1994MR98800057
J	SZALLASI, Z; SMITH, CB; PETTIT, GR; BLUMBERG, PM				SZALLASI, Z; SMITH, CB; PETTIT, GR; BLUMBERG, PM			DIFFERENTIAL REGULATION OF PROTEIN-KINASE-C ISOZYMES BY BRYOSTATIN-1 AND PHORBOL 12-MYRISTATE 13-ACETATE IN NIH 3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EPIDERMAL-CELLS; CARCINOMA-CELLS; ESTER; BINDING; JUN; PHOSPHORYLATION; ACTIVATION; MODULATION; HL-60; AP-1	Bryostatin 1 and phorbol 12-myristate 13-acetate (PMA) are both potent activators of protein kinase C (PKC), although in many systems bryostatin 1 induces only a subset of the responses to PMA and blocks those which it does not induce. We report here that in NIH 3T3 fibroblasts PMA showed similar potencies for translocating PKC isozymes alpha, delta, and epsilon to the Triton X-100-soluble and -insoluble fractions and for the down-regulation of the three isozymes. Bryostatin 1 was slightly more potent than PMA for translocating PKCalpha and was more potent than PMA for down-regulating it. Bryostatin 1 was markedly more potent than PMA for translocating PKCdelta but showed a biphasic dose-response curve for down-regulating this isozyme. 1-10 nm bryostatin 1 down-regulated PKCdelta to a similar extent as PMA; lower (10-100 pm) or, unexpectedly, higher (100 nm to 1 muM) doses of bryostatin 1 caused either no or reduced down-regulation. Moreover, these high (100 nm to 1 muM) doses of bryostatin 1 inhibited the down-regulation of PKCdelta by 1 muM PMA when coapplied. Bryostatin 1 caused translocation of PKCepsilon with slightly higher potency than PKCdelta, but there was no protection of this isozyme at any of the doses examined. Bryostatin 1 induced a long-term increase in c-Jun level. The dose-response curve for bryostatin 1 was biphasic, with maximal induction at 1-10 nM bryostatin 1, coincident with the maximal down-regulation of PKCdelta. We conclude that bryostatin 1 showed substantially different regulation for PKCalpha, PKCdelta, and PKCepsilon, whereas PMA distinguished only weakly between these isozymes.	NCI, CELLULAR CARCINOGENESIS LAB, BETHESDA, MD 20892 USA; ARIZONA STATE UNIV, CANC RES INST, TEMPE, AZ 85287 USA; ARIZONA STATE UNIV, DEPT CHEM, TEMPE, AZ 85287 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe				Szallasi, Zoltan/0000-0001-5395-7509				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BASU A, 1992, CANCER RES, V52, P3119; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BLUMBERG PM, 1992, ALFRED BENZON SYMP S, V33, P273; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DALE IL, 1989, INT J CANCER, V43, P158, DOI 10.1002/ijc.2910430129; DELLAQUILA ML, 1987, CANCER RES, V47, P6006; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KENNEDY MJ, 1992, CANCER RES, V52, P1278; KRAFT AS, 1988, J BIOL CHEM, V263, P8437; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEWIN NE, 1992, BIOCHEM PHARMACOL, V43, P2007, DOI 10.1016/0006-2952(92)90644-X; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; SAKO T, 1987, CANCER RES, V47, P5445; SHARKEY NA, 1985, CANCER RES, V45, P19; SHARKIS SJ, 1989, ANN NY ACAD SCI, V554, P59, DOI 10.1111/j.1749-6632.1989.tb22409.x; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SREDNI B, 1990, IMMUNOLOGY, V70, P473; WARREN BS, 1988, CANCER RES, V48, P5984; WAYS DK, 1992, CANCER RES, V52, P5604	27	237	255	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2118	2124						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294465				2022-12-25	WOS:A1994MR98800086
J	MOSCOW, JA; HE, R; GNARRA, JR; KNUTSEN, T; WENG, YK; ZHAO, WP; WHANGPENG, J; LINEHAN, WM; COWAN, KH				MOSCOW, JA; HE, R; GNARRA, JR; KNUTSEN, T; WENG, YK; ZHAO, WP; WHANGPENG, J; LINEHAN, WM; COWAN, KH			EXAMINATION OF HUMAN TUMORS FOR RHOA MUTATIONS	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; GLUTATHIONE-PEROXIDASE GENE; LUNG-CANCER; SHORT ARM; ADP-RIBOSYLTRANSFERASE; DNA-SEQUENCE; REGION 3P21; CHROMOSOME-3; HETEROZYGOSITY; LOCALIZATION	rhoA encodes a ras-related GTP-binding protein that is thought to play a role in cytoskeletal organization. Recent evidence has suggested both that rhoA could act either as a dominant oncogene, since transfection of both normal and activated who genes confer a transformed phenotype on fibroblast cells in culture, or as a recessive tumor suppressor gene, by virtue, in part, of its chromosomal location at 3p21, a site deleted in many human malignancies. In either case, a role for rhoA in the oncogenesis of human tumors would be supported by the finding of rhoA mutations in tumors. We therefore examined human tumors and cell lines for mutations in the protein coding regions of rhoA by RNAase protection analysis. We first examined the expression of rhoA in renal cell carcinoma cell lines in which 3p21 was heterozygously deleted or retained. We found no evidence for rhoA mutations in these specimens. We also examined RNA from lung, breast, colon or ovarian tumors and also found no evidence of activating rhoA mutations. Furthermore, there was no relation between the level of rhoA mRNA expression and the presence or absence of 3p21 deletions in the renal cell carcinoma specimens. Thus, although rhoA has transforming potential in vitro, there is no evidence that it is activated by mutation in human malignancies, or that it could act as a tumor suppressor gene in tumors in which 3p21 is deleted.	NCI,PEDIAT BRANCH,BETHESDA,MD 20892; NCI,SURG BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MOSCOW, JA (corresponding author), NCI,MED BRANCH,BETHESDA,MD 20892, USA.			Gnarra, James/0000-0002-6369-3110				ANGLARD P, 1992, CANCER RES, V52, P348; ANGLARD P, 1991, CANCER RES, V51, P1071; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CANNIZZARO LA, 1990, GENOMICS, V6, P197, DOI 10.1016/0888-7543(90)90557-B; CARRITT B, 1986, AM J HUM GENET, V38, P428; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DOROSHOW JH, 1990, PHARMACOL THERAPEUT, V47, P359, DOI 10.1016/0163-7258(90)90062-7; DUTRILLAUX B, 1981, HUM GENET, V57, P93; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; FUJIMOTO E, 1988, NUCLEIC ACIDS RES, V16, P10943, DOI 10.1093/nar/16.22.10943; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; KARGER S, 1991, GUIDELINES CANCER CY; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEDUC F, 1989, AM J HUM GENET, V44, P282; MCBRIDE O W, 1988, Biofactors, V1, P285; MIURA Y, 1993, J BIOL CHEM, V268, P510; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MOSCOW JA, 1989, CANCER RES, V49, P1422; MOSCOW JA, IN PRESS; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; OGOROCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1175, DOI 10.1016/0006-291X(89)92344-9; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU M, 1990, ONCOGENE, V5, P185; SZUCS S, 1986, CANCER GENET CYTOGEN, V26, P369; TJIO JH, 1962, STAIN TECHNOL, V37, P17, DOI 10.3109/10520296209114563; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOSHIDA MA, 1986, CANCER RES, V46, P2139; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	47	47	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					189	194						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302578				2022-12-25	WOS:A1994MW24700023
J	TAKAHASHI, K; SUZUKI, K				TAKAHASHI, K; SUZUKI, K			DNA SYNTHESIS-ASSOCIATED NUCLEAR EXCLUSION OF P53 IN NORMAL HUMAN BREAST EPITHELIAL-CELLS IN CULTURE	ONCOGENE			English	Article							TRANSFORMATION-RELATED PROTEIN; MONOCLONAL-ANTIBODIES; 3T3 CELLS; WILD-TYPE; GROWTH; PHOSPHORYLATION; LYMPHOCYTES; ANTIGEN; CYCLE; MOUSE	Immunohistochemical staining using three monoclonal antibodies to p53 revealed that most normal human breast epithelial cells (HBEC) in the exponential growth phase, have p53 located in the nucleus but that some cells have the protein in the cytoplasm. Cytoplasmic staining of p53 with the monoclonal antibody PAb240 was inhibited by the specific oligopeptide, NTFRHSVVVP, that corresponds to the amino acids between 210 and 219 in p53 and which includes the epitope domain for PAb240. It was not inhibited by the control oligopeptide SPFVTVHNVR. Growth arrest of HBEC achieved by EGF depletion resulted in predominant nuclear location of p53 and stimulation of arrested cells with EGF induced transient nuclear exclusion of the protein when the induced DNA synthesis level was maximal. These observations suggest that p53 in normal HBEC becomes inactivated by nuclear exclusion during cellular DNA synthesis.			TAKAHASHI, K (corresponding author), KANAGAWA CANC CTR,RES INST,DEPT BIOCHEM,ASAHI KU,54-2 NAKAO CHO,YOKOHAMA,KANAGAWA 241,JAPAN.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KERN SE, 1991, ONCOGENE, V6, P131; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1992, ONCOGENE, V7, P661; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; STEINMEYER K, 1988, ONCOGENE, V3, P501; SUZUKI K, 1992, BIOCHEM BIOPH RES CO, V183, P1175, DOI 10.1016/S0006-291X(05)80314-6; TAKAHASHI K, 1989, INT J CANCER, V43, P870, DOI 10.1002/ijc.2910430522; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ZHANG W, 1992, ONCOGENE, V7, P1645	31	41	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					183	188						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302577				2022-12-25	WOS:A1994MW24700022
J	METIVIER, C; PIU, F; PFARR, CM; YANIV, M; LOISEAU, L; CASTELLAZZI, M				METIVIER, C; PIU, F; PFARR, CM; YANIV, M; LOISEAU, L; CASTELLAZZI, M			IN-VITRO TRANSFORMING CAPACITIES OF MOUSE C-JUN-JUND CHIMERIC GENES	ONCOGENE			English	Note							TRANSCRIPTIONAL ACTIVATION; EMBRYO FIBROBLASTS; ONCOGENE JUN; V-JUN; FOS; AP-1; PHOSPHORYLATION; DOMAIN; CELLS; DNA	Among the murine Jun family of transcription factors, c-Jun and JunD are closely-related proteins with similar dimerization, DNA binding and transactivating properties. However, when expressed from a self-replicating retroviral RCAS vector, c-jun, but not junD, transforms chick embryo fibroblasts. We attempted to map the regions of c-jun which are important for transformation by constructing hybrids between c-jun and junD. Using common restriction sites, we prepared six different chimeric molecules. All of these c-jun:junD hybrids code for transactivators of AP1-containing promoters. An N-terminal segment of 79 amino acids of c-Jun converts JunD into a strong transforming protein, while other segments of c-Jun contribute to a lesser extent. Contrary to what has been reported with rat embryo fibroblasts, a c-Jun derivative with serines substituted by alanines in positions 63 and 73 still transforms CEFs efficiently.	ECOLE NORMALE SUPER, CNRS,UMR49,BIOL MOLEC & CELLULAIRE LAB, 46 ALLEE ITALIE, F-69364 LYON 07, FRANCE; INST PASTEUR, DEPT BIOTECHNOL,CNRS,URA 1644, UNITE VIRUS ONCOGENES, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Pfarr, Curt/HHD-1410-2022					ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BERGER I, 1991, ONCOGENE, V6, P561; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1991, ONCOGENE, V6, P1623; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1990, New Biologist, V2, P126; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANG-YEN H-F, 1990, New Biologist, V2, P351	38	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2311	2315						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336952				2022-12-25	WOS:A1993LP17100036
J	SHAFQAT, S; TAMARAPPOO, BK; KILBERG, MS; PURANAM, RS; MCNAMARA, JO; GUADANOFERRAZ, A; FREMEAU, RT				SHAFQAT, S; TAMARAPPOO, BK; KILBERG, MS; PURANAM, RS; MCNAMARA, JO; GUADANOFERRAZ, A; FREMEAU, RT			CLONING AND EXPRESSION OF A NOVEL NA+-DEPENDENT NEUTRAL AMINO-ACID TRANSPORTER STRUCTURALLY RELATED TO MAMMALIAN NA+ GLUTAMATE COTRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SYSTEM-ASC; GLYCINE TRANSPORTER; GABA TRANSPORTER; SEQUENCE; HEPATOCYTES; KIDNEY; CDNA; IDENTIFICATION; MECHANISMS	A cDNA has been isolated from human hippocampus that appears to encode a novel Na+-dependent, Cl--independent, neutral amino acid transporter. The putative protein, designated SATT, is 529 amino acids long and exhibits significant amino acid sequence identity (39-44%) with mammalian L-glutamate transporters. Expression of SATT cDNA in HeLa cells induced stereospecific uptake Of L-serine, L-alanine, and L-threonine that was not inhibited by excess (3 mM) 2-(methylamino)-isobutyric acid, a specific substrate for the System A amino acid transporter. SATT expression in HeLa cells did not induce the transport of radiolabeled L-cysteine, L-glutamate, or related dicarboxylates. Northern blot hybridization revealed high levels of SATT mRNA in human skeletal muscle, pancreas, and brain, intermediate levels in heart, and low levels in liver, placenta, lung, and kidney. SATT transport characteristics are similar to the Na+-dependent neutral amino acid transport activity designated System ASC, but important differences are noted. These include: 1) SATT's apparent low expression in ASC-containing tissues such as liver or placenta; 2) the lack of mutual inhibition between serine and cysteine; and 3) the lack of trans-stimulation. SATT may represent one of multiple activities that exhibit System ASC-like transport characteristics in diverse tissues and cell lines.	DUKE UNIV, MED CTR,DEPT PHARMACOL,BOX 3813, 436 NANALINE H DUKE BLDG,RES DR, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED NEUROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, VET AFFAIRS MED CTR, DURHAM, NC 27710 USA; UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	Duke University; Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University System of Florida; University of Florida			Guadaño-Ferraz, Ana/J-7870-2013	Guadaño-Ferraz, Ana/0000-0002-0666-935X; PURANAM, RAM/0000-0003-4383-3849	NIDDK NIH HHS [DK-31580, DK-28374] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028374, R01DK031580] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; COLLARINI EJ, 1987, ANNU REV NUTR, V7, P75, DOI 10.1146/annurev.nu.07.070187.000451; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6054; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HANDLOGTEN ME, 1981, J BIOL CHEM, V256, P7905; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HUNDAL HS, 1989, J PHYSIOL-LONDON, V408, P93, DOI 10.1113/jphysiol.1989.sp017449; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KILBERG MS, 1979, BIOCHEM BIOPH RES CO, V88, P744, DOI 10.1016/0006-291X(79)92110-7; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KONG CT, 1993, J BIOL CHEM, V268, P1509; LIU QR, 1993, J BIOL CHEM, V268, P2106; MANN GE, 1986, BIOCHIM BIOPHYS ACTA, V858, P263, DOI 10.1016/0005-2736(86)90331-7; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLACE B, 1990, J BACTERIOL, V172, P3214, DOI 10.1128/jb.172.6.3214-3220.1990; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	34	195	200	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15351	15355						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340364				2022-12-25	WOS:A1993LN30500008
J	HUGHES, SD; QUAADE, C; JOHNSON, JH; FERBER, S; NEWGARD, CB				HUGHES, SD; QUAADE, C; JOHNSON, JH; FERBER, S; NEWGARD, CB			TRANSFECTION OF ATT-20(INS) CELLS WITH GLUT-2 BUT NOT GLUT-1 CONFERS GLUCOSE-STIMULATED INSULIN-SECRETION - RELATIONSHIP TO GLUCOSE-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; RAT PANCREAS; K+ CHANNELS; B-CELLS; EXPRESSION; TRANSPORTER; ISLETS; GLUCOKINASE; SEQUENCE; LIVER	Glucose is thought to stimulate insulin release from islet beta-cells through generation of metabolic signals. In the current study we have introduced the genes encoding the facilitated glucose transporters known as GLUT-1 and GLUT-2 into AtT-20ins cells to assess their impact on glucose-stimulated insulin release and glucose metabolism. We find that transfection of AtT-20ins cells with GLUT-2, but not GLUT-1, confers glucose-stimulated insulin release in both static incubation and perifusion studies. Cells transfected with GLUT-1 have a K(m) for 3-O-methyl glucose uptake of 4 mM and a V(max) of 5-6 mmol/min/liter cell space. These values are increased compared to untransfected AtT-20ins cells (K(m) = 2 mM; V(max) = 0.5 mmol/min/liter cell space), but are less than observed in GLUT-2-transfected lines (K(m) = 16-17 mM; V(max) = 17-25 mmol/min/liter cell space). Despite these dramatic differences in glucose transport affinity and capacity, the rates of [5-H-3]glucose usage are not different in the control and transfected lines over a range of glucose concentrations from 10 muM to 20 mM. We conclude that the specific effect of GLUT-2 on glucose-stimulated insulin release in AtT-20ins cells is not related to changes in the overall rate of glucose metabolism and may instead involve physical coupling of GLUT-2 with cellular proteins and/or structures involved in glucose signaling.	UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Ferber, Sarah/0000-0003-2764-2786	NIDDK NIH HHS [P01-DK42582] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042582] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P2222, DOI 10.1021/bi00278a025; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; FERBER S, 1991, MOL ENDOCRINOL, V5, P319, DOI 10.1210/mend-5-3-319; FLEISCHER N, 1992, DIABETES, V41, pA5; GERMAN MS, 1991, DIABETES S1, V40, pA163; GHOSH A, 1991, J BIOL CHEM, V266, P22887; GIORDANO E, 1991, J CLIN INVEST, V87, P2178, DOI 10.1172/JCI115251; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KNUDSEN P, 1983, AM J PHYSIOL, V245, pE338, DOI 10.1152/ajpendo.1983.245.4.E338; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P1471, DOI 10.1016/0020-711X(91)90290-4; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NEWGARD CB, 1992, BIO-TECHNOL, V10, P1112, DOI 10.1038/nbt1092-1112; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; TAL M, 1992, J BIOL CHEM, V267, P17241; TAL M, 1992, MOL CELL BIOL, V12, P422, DOI 10.1128/MCB.12.1.422; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VANSCHRAVENDIJK CFH, 1992, J BIOL CHEM, V267, P21344; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WHEELER TJ, 1981, J BIOL CHEM, V252, P5456; WILSON JE, 1984, REGULATION CARBOHYDR, P45; YIN L, 1992, DIABETES, V41, P792	39	149	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15205	15212						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325893				2022-12-25	WOS:A1993LL75900096
J	KNIBBS, RN; AGRWAL, N; WANG, JL; GOLDSTEIN, IJ				KNIBBS, RN; AGRWAL, N; WANG, JL; GOLDSTEIN, IJ			CARBOHYDRATE-BINDING PROTEIN-35 .2. ANALYSIS OF THE INTERACTION OF THE RECOMBINANT POLYPEPTIDE WITH SACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE LECTINS; ENDOGENOUS LECTINS; CULTURED-CELLS; MAC-2 ANTIGEN; IGE; LAMININ; MOUSE; IDENTIFICATION; RECOGNITION; SPECIFICITY	The carbohydrate binding specificity of recombinant carbohydrate-binding protein 35 (rCBP35) has been investigated by quantitative precipitation using a series of glycoproteins and carbohydrate-protein conjugates and by inhibition of precipitation using well defined carbohydrate haptens. Synthetic glycoconjugates and glycoproteins containing terminal nonreducing galactosyl units in beta-linkage were capable of forming a precipitate with rCBP35. If the glycoprotein or glycoconjugate contained terminal Neu5Ac, or galactose in alpha-linkage, precipitate formation was not observed. We also found that murine laminin, which contains polylactosamine structures, reacted more strongly than did bovine fetuin. Using carbohydrate-bovine serum albumin (BSA) glycoconjugates, we found that the tetrasaccharide Galbeta1,4GlcNAcbeta1,3Galbeta1,4-GlcNAc-BSA reacted more strongly than the disaccharide Galbeta1,4GlcNAc-BSA conjugate, suggesting that the binding site accommodates carbohydrate ligands greater in size than a disaccharide. Equilibrium dialysis experiments using [H-3]lactose showed that rCBP35 binds 1 mol (n = 0.84) of lactose/30, 000 g atoms of protein, with an affinity constant of 2.07 x 10(4) M-1. The binding site on the polypeptide appears to contain four subsites that recognize the sequence Galbeta1,4GlcNAcbeta1,Galbeta1,X-. All disaccharides tested that contain a nonreducing beta-galactosyl unit behaved as inhibitors of precipitation at approximately the same concentration, suggesting that the reducing position of the tetrasaccharide does not play an important role in the specific binding to the fourth subsite. The reducing sugar may serve to hold the saccharide in a tunnel like binding pocket since methyl-beta-D-galactoside itself is an extremely poor inhibitor.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University	KNIBBS, RN (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NATIONAL CANCER INSTITUTE [R01CA020424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NCI NIH HHS [CA-20424] Funding Source: Medline; NIGMS NIH HHS [GM-38740, GM-29470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRWAL N, 1992, J BIOL CHEM, V268, P14932; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ANDERSON RL, 1992, TRENDS GLYCOSCI GLYC, V4, P43; ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; BARONDES S, 1988, TRENDS BIOCHEM SCI, V3, P480; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COWLES EA, 1990, J BIOL CHEM, V265, P17706; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FODDY L, 1990, J CELL SCI, V97, P139; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; HARRISON FL, 1991, J CELL SCI, V100, P9; HAYES CE, 1975, J BIOL CHEM, V250, P6837; HSU DK, 1992, J BIOL CHEM, V267, P14167; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; ODA Y, 1991, GENE, V99, P279; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROFF CF, 1983, J BIOL CHEM, V258, P657; ROFF CF, 1983, BIOCHEM J, V211, P625, DOI 10.1042/bj2110625; SATO S, 1992, J BIOL CHEM, V267, P6983; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; WANG J L, 1991, Glycobiology, V1, P243, DOI 10.1093/glycob/1.3.243; WOO HJ, 1990, J BIOL CHEM, V265, P7097	31	87	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14940	14947						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325871				2022-12-25	WOS:A1993LL75900062
J	TURNER, GE; BORKOVICH, KA				TURNER, GE; BORKOVICH, KA			IDENTIFICATION OF A G-PROTEIN ALPHA-SUBUNIT FROM NEUROSPORA-CRASSA THAT IS A MEMBER OF THE G(I) FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM MEMBRANES; BLUE-LIGHT; SIGNAL TRANSDUCTION; PLASMA-MEMBRANES; ADP-RIBOSYLATION; GENE; DIVERSITY; PERTUSSIS; MUTANTS; MOUSE	Heterotrimeric G proteins, consisting of alpha, beta, and gamma subunits, are implicated in major signal transduction pathways controlling a diversity of functions in eukaryotic organisms. In the filamentous fungus Neurospora crassa, G proteins are implicated in the regulation of several environmental responses. As a first step in studying the role of G proteins in these processes, we have cloned the genes for two alpha subunits, gna-1 and gna-2, from Neurospora. The genes are located on different chromosomes and are differentially regulated during asexual development. The encoded proteins (Gna-1 and Gna-2) are the same size as members of the G(i)-alpha family (approximately 40 kDa). The Gna-1 protein sequence is 55% identical overall to members of the G(i) family and contains the consensus sequences for ADP-ribosylation by pertussis toxin and incorporation of myristic acid, which are found in this group. These properties make Gna-1 the first identified microbial alpha subunit to be a member of any class. Furthermore, incubation of a N. crassa plasma membrane fraction with pertussis toxin results in ADP-ribosylation of a protein substrate which is the approximate size of Gna-1. The predicted Gna-2 protein sequence does not share a high degree of sequence identity with the G(i) class. However, the coding region contains at least one intron in a position conserved in the G(i) family. We propose that the G(i) family of alpha subunits is ancient and during evolution may have first appeared in filamentous fungi.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL & MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston								Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BORKOVICH KA, 1991, METHOD ENZYMOL, V200, P205; BOWMAN EJ, 1988, METHOD ENZYMOL, V157, P562; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKER JW, 1990, J GEN MICROBIOL, V136, P1413, DOI 10.1099/00221287-136-7-1413; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ERICKSON JW, 1987, GENE DEV, V1, P419, DOI 10.1101/gad.1.5.419; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HARDING RW, 1983, PLANT PHYSIOL, V72, P996, DOI 10.1104/pp.72.4.996; INNOCENTI FD, 1983, PHOTOCHEM PHOTOBIOL, V37, P49, DOI 10.1111/j.1751-1097.1983.tb04432.x; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KHACHATRIAN L, 1987, BIOCHEM BIOPH RES CO, V149, P975, DOI 10.1016/0006-291X(87)90504-3; KOZAK KR, 1991, BIOCHEM BIOPH RES CO, V179, P1225, DOI 10.1016/0006-291X(91)91703-F; KRITSKY MS, 1982, ARCH MICROBIOL, V133, P206, DOI 10.1007/BF00415002; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; Metzenberg R, 1989, FUNGAL GENET NEWSL, V36, P51; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NAWRATH C, 1990, J PHOTOCH PHOTOBIO B, V4, P261, DOI 10.1016/1011-1344(90)85032-R; OKAICHI K, 1992, MOL BIOL CELL, V3, P735, DOI 10.1091/mbc.3.7.735; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; ORBACH MJ, 1990, J BIOL CHEM, V265, P10981; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; SADHU C, 1992, MOL CELL BIOL, V12, P1977, DOI 10.1128/MCB.12.5.1977; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT ML, 1967, PLANT PHYSIOL, V42, P1504, DOI 10.1104/pp.42.11.1504; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; UI M, 1980, ADP RIBOSYLATING TOX, P45; VANHAASTERT PJM, 1987, EUR J BIOCHEM, V162, P251; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; WEST RE, 1985, J BIOL CHEM, V260, P4428; WILKIE T M, 1991, Methods (Orlando), V2, P32, DOI 10.1016/S1046-2023(05)80123-9; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E	45	97	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14805	14811						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325859				2022-12-25	WOS:A1993LL75900044
J	KAUSHAL, GP; ZENG, YC; ELBEIN, AD				KAUSHAL, GP; ZENG, YC; ELBEIN, AD			BIOSYNTHESIS OF GLUCOSIDASE-II IN SUSPENSION-CULTURED SOYBEAN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; MUNG BEAN SEEDLINGS; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN-BIOSYNTHESIS; MEMBRANE-PROTEINS; PRE-GOLGI; PURIFICATION; REDUCTASE; DEGRADATION; CLEAVAGE	Since antibody against homogeneous mung bean glucosidase II cross-reacted with a 110-kDa protein from cultured soybean cells and also precipitated this activity from extracts of soybean cells, we used this antibody to examine the biosynthesis, turnover, and cellular localization of glucosidase II in soybean cells. Time course studies of [S-35]methionine incorporation into glucosidase II (as well as pulse-chase studies) showed that this enzyme is synthesized as a 110-kDa protein that does not change in size from very early labeling times to those as late as 60 h, indicating the absence of a cleavable signal sequence or extensive modification of the carbohydrate. Furthermore, glucosidase II remained susceptible to digestion by endo-beta-N-acetylglucosaminidase H throughout this time period, and the major oligosaccharide structure was a Man9(GlcNAc)2 with small amounts of Glc1Man9(GlcNAc)2. The half-life of the biosynthesized glucosidase II was about 36 h, and no secretion of this protein occurred. Membranes of gently disrupted cells were separated by sucrose-density gradient centrifugation, and fractions were tested for glucosidase II activity as well as for marker enzymes. The bulk of the glucosidase II activity fractionated with endoplasmic reticulum membranes. Detergent solubility studies with Triton X-114 suggested that glucosidase II did not have a hydrophobic domain and is probably a luminal endoplasmic reticulum protein.			KAUSHAL, GP (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-21800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BARNUN S, 1980, P NATL ACAD SCI-BIOL, V77, P965, DOI 10.1073/pnas.77.2.965; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADA D, 1990, J CELL BIOL, V110, P309, DOI 10.1083/jcb.110.2.309; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; BRISKIN DP, 1987, METHOD ENZYMOL, V148, P542; BROWN DA, 1984, P NATL ACAD SCI-BIOL, V81, P1674, DOI 10.1073/pnas.81.6.1674; BURNS DM, 1982, J BIOL CHEM, V257, P9991; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; Dixon R. A., 1985, PLANT CELL CULTURE P, P1; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GRINNA LS, 1979, J BIOL CHEM, V254, P8814; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HINO Y, 1985, BIOCHEMISTRY-US, V24, P800, DOI 10.1021/bi00324a040; HOHENSCHUTZ LD, 1981, PHYTOCHEMISTRY, V20, P811, DOI 10.1016/0031-9422(81)85181-3; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; KEDERSHA NL, 1985, BIOCHEMISTRY-US, V24, P5960, DOI 10.1021/bi00342a041; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MICHAEL JM, 1980, ARCH BIOCHEM BIOPHYS, V199, P249, DOI 10.1016/0003-9861(80)90278-7; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; OKADA Y, 1982, EUR J BIOCHEM, V122, P393, DOI 10.1111/j.1432-1033.1982.tb05894.x; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POTRYKUS I, 1988, METHODS PLANT MOL BI, P381; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; SAXENA S, 1987, BIOCHEM J, V247, P563, DOI 10.1042/bj2470563; STROUS GJ, 1987, J BIOL CHEM, V262, P3620; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; STURM A, 1987, PLANT PHYSIOL, V85, P741, DOI 10.1104/pp.85.3.741; SZUMILO T, 1985, ANAL BIOCHEM, V151, P32, DOI 10.1016/0003-2697(85)90049-1; SZUMILO T, 1986, ARCH BIOCHEM BIOPHYS, V247, P261, DOI 10.1016/0003-9861(86)90583-7	43	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14536	14542						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314807				2022-12-25	WOS:A1993LJ82500106
J	HARVEY, M; MCARTHUR, MJ; MONTGOMERY, CA; BRADLEY, A; DONEHOWER, LA				HARVEY, M; MCARTHUR, MJ; MONTGOMERY, CA; BRADLEY, A; DONEHOWER, LA			GENETIC BACKGROUND ALTERS THE SPECTRUM OF TUMORS THAT DEVELOP IN P53-DEFICIENT MICE	FASEB JOURNAL			English	Note						P53; TUMOR SUPPRESSOR; P53-DEFICIENT MICE; GENE TARGETING; TUMORIGENESIS	WILD-TYPE P53; CELL-CYCLE CONTROL; ATAXIA-TELANGIECTASIA; SUPPRESSOR GENE; TRANSFORMATION; ONCOGENE; CANCER; MUTATIONS; PROTEIN; MODEL	Using gene targeting in embryonic stem cells, we have generated mice with one or two null p53 germ line alleles. Mice with both p53 alleles inactivated are developmentally normal but highly susceptible to the early development of spontaneous tumors. Initial studies were performed in mice with a mixed inbred genetic background (75% C57BL/6 and 25% 129/Sv) (Donehower et al., Nature (London) 356, 215-221, 1992). To study the effect of genetic background on tumorigenesis in p53-deficient mice, we have put the p53 null allele into a pure 129/Sv background and monitored tumor development. 129/Sv mice with two p53 null alleles developed tumors sooner than the mixed genetic background p53-deficient animals. The most frequently observed tumor in p53 null mice of both genetic backgrounds was a malignant lymphoma. Because the 129/Sv strain has a low incidence of lymphoma, the frequent occurrence of lymphomas in all p53 null mice suggests that this particular tumor type may be a direct result of p53 loss and not a result of a particular genetic background. In addition to malignant lymphomas, the 129/Sv p53-deficient mice showed an increased incidence of aggressive teratocarcinomas (8 of 18 tumor-bearing males), a tumor type rare in virtually all inbred mice except for 129 strains. Thus, it appears that loss of p53 may accelerate a prior tumor predisposition and that genetic background can play a role in mediating both the rate and spectrum of tumor development in these mice.	BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CTR COMPARAT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839				ALTMAN PL, 1979, INBRED GENETICALLY D, P207; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dunn T.B., 1958, PHYSIOPATHOLOGY CANC, P38; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FURMANSKI P, 1982, MOUSE BIOMEDICAL RES, V4, P352; GATTI RA, 1991, ADV CANCER RES, V56, P77; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEVENS LC, 1954, P NATL ACAD SCI USA, V40, P1080, DOI 10.1073/pnas.40.11.1080; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; Stutman O, 1975, Adv Cancer Res, V22, P261; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	35	237	243	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1993	7	10					938	943		10.1096/fasebj.7.10.8344491	http://dx.doi.org/10.1096/fasebj.7.10.8344491			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LQ337	8344491				2022-12-25	WOS:A1993LQ33700018
J	ROGHANI, M; MANSUKHANI, A; DELLERA, P; BELLOSTA, P; BASILICO, C; RIFKIN, DB; MOSCATELLI, D				ROGHANI, M; MANSUKHANI, A; DELLERA, P; BELLOSTA, P; BASILICO, C; RIFKIN, DB; MOSCATELLI, D			HEPARIN INCREASES THE AFFINITY OF BASIC FIBROBLAST GROWTH-FACTOR FOR ITS RECEPTOR BUT IS NOT REQUIRED FOR BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; CAPILLARY ENDOTHELIAL-CELLS; FACTOR FGF RECEPTOR; SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; PROTEOLYTIC DEGRADATION; 3-DIMENSIONAL STRUCTURE; PHOSPHOLIPASE-C; ACIDIC FGF; EXPRESSION	The role of heparin or heparan sulfates in the interaction of basic fibroblast growth factor (bFGF) with its high affinity receptor were investigated using purified extracellular ligand-binding region of FGF receptor-1 (FGFR-1) and intact receptors expressed in a myeloid cell line (32D) that does not express detectable levels of heparan sulfate proteoglycans or in Chinese hamster ovary (CHO) cell mutants defective in heparan sulfate synthesis. The purified extracellular domain of FGFR-1 formed complexes with I-125-bFGF both in the presence or absence of heparin. Intact FGFR-1 expressed in 32D cells also bound the same amount of I-125-bFGF in the presence or absence of heparin when saturating concentrations of bFGF were used. Varying the concentration of I-125-bFGF showed that heparin increased the amount of I-125-bFGF bound at low bFGF concentrations and increased the affinity of bFGF for its receptor by about 3-fold. To eliminate the possibility of alteration of bFGF properties through the chemical modification reactions, bFGF was labeled biosynthetically. The binding of biosynthetically labeled bFGF to FGFR-1 also did not require heparin. When FGFR-1 or FGFR-2 were expressed in mutant CHO cells deficient in heparan sulfate synthesis, the cells also bound I-125-bFGF in the absence of heparin, and the addition of heparin increased the affinity of bFGF for its receptors 2-3-fold. Thus, heparin or heparan sulfate is not required for the binding of bFGF to its receptors but increases the binding affinity to a moderate degree. Finally, the requirement for heparin in signal transduction through the receptor was investigated. Expression of c-fos mRNA was induced by bFGF in 32D cells expressing FGFR-1 to the same extent in the presence or absence of heparin.	NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016; RAYMOND & BEVERLY SACKLER LABS,NEW YORK,NY 10016	New York University; New York University; New York University			Dell'Era, Patrizia/ABD-5848-2020; Dell'Era, Patrizia/N-6964-2019; Dell'Era, Patrizia/G-5294-2010; Bellosta, Paola/AAA-3413-2020	Dell'Era, Patrizia/0000-0001-6682-6321; Bellosta, Paola/0000-0003-1913-5661; Moscatelli, David/0000-0002-4627-4213; Mansukhani, Alka/0000-0003-1020-3242	NATIONAL CANCER INSTITUTE [R01CA042229] Funding Source: NIH RePORTER; NCI NIH HHS [CA34289, CA42229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRESJL, 1992, J BIOL CHEM, V267, P5927; ARMSTRONG E, 1992, CANCER RES, V52, P2004; BASHKIN P, 1992, J CELL PHYSIOL, V151, P126, DOI 10.1002/jcp.1041510117; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GIMENEZGALLEGO G, 1986, BIOCHEM BIOPH RES CO, V135, P541, DOI 10.1016/0006-291X(86)90028-8; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JAYE M, 1987, J BIOL CHEM, V262, P16612; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Linemeyer DL, 1990, GROWTH FACTORS, V3, P287, DOI 10.3109/08977199009003671; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; PRESTA M, 1992, BIOCHEM BIOPH RES CO, V185, P1098, DOI 10.1016/0006-291X(92)91739-D; PRESTRELSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P314, DOI 10.1016/0003-9861(92)90401-H; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Savona C, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000291; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; SQUIRES CH, 1988, J BIOL CHEM, V263, P16297; UHLRICH S, 1986, BIOCHEM BIOPH RES CO, V137, P1205, DOI 10.1016/0006-291X(86)90353-0; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	61	232	240	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3976	3984						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307953				2022-12-25	WOS:A1994MW98900015
J	EDELHOFF, S; AYER, DE; ZERVOS, AS; STEINGRIMSSON, E; JENKINS, NA; COPELAND, NG; EISENMAN, RN; BRENT, R; DISTECHE, CM				EDELHOFF, S; AYER, DE; ZERVOS, AS; STEINGRIMSSON, E; JENKINS, NA; COPELAND, NG; EISENMAN, RN; BRENT, R; DISTECHE, CM			MAPPING OF 2 GENES ENCODING MEMBERS OF A DISTINCT SUBFAMILY OF MAX INTERACTING PROTEINS - MAD TO HUMAN-CHROMOSOME-2 AND MOUSE CHROMOSOME-6, AND MXI1 TO HUMAN-CHROMOSOME-10 AND MOUSE CHROMOSOME-19	ONCOGENE			English	Note							INSITU HYBRIDIZATION; DNA-SEQUENCES; LEUKEMIA; MYC; BINDING	Both the MAD and the MXI1 genes encode basic-helix-loop-helix-leucine zipper (bHLH-Zip) transcription factors which bind Max in vitro, forming a sequence-specific DNA-binding complex similar to the Myc-Max heterodimer. Mad and Myc compete for binding to Max. In addition, Mad has been shown to act as a transcriptional repressor while Myc appears to function as an activator. Mxi1 also appears to lack a transcriptional activation domain. Therefore, Mxi1 and Mad might antagonize Myc function and are candidate tumor suppressor genes. We report here the mapping of the MAD and MXI1 genes in human and mouse by fluorescence in situ hybridization (FISH) and by recombination mapping. The MAD gene was mapped to human chromosome 2 at band p13 by FISH and to mouse chromosome 6 by meiotic mapping. The MXI1 gene was mapped to human chromosome 10 at band q25 and on mouse chromosome 19 at region D by FISH. There was a second site of hybridization on mouse chromosome 2 at region C, which may represent a pseudogene or a related sequence. The mapping results confirm regions of conservation between human chromosome 2p13 and mouse chromosome 6 and between chromosome 10q25 and mouse chromosome 19D. Human chromosomes 2p13 and 10q25 have been involved in specific tumors where the role of Mad and Mxi1 can now he investigated.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Steingrimsson, Eirikur/0000-0001-5826-7486; Ayer, Donald/0000-0002-5595-3269	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, IN PRESS GENES DEV; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; GILLADOGA AD, 1992, ONCOGENE, V7, P1249; Green EL, 1981, GENETICS PROBABILITY, P77; INABA T, 1991, LEUKEMIA, V5, P719; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KRETZNER L, 1992, NATURE, V359, P423; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7841; MERTENS F, 1989, CANCER GENET CYTOGEN, V39, P227, DOI 10.1016/0165-4608(89)90189-1; MOORE KJ, 1992, GENOMICS, V12, P388, DOI 10.1016/0888-7543(92)90389-A; MOYZIS RK, 1987, CHROMOSOMA, V95, P375, DOI 10.1007/BF00333988; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; NEUMANN HPH, 1988, CANCER GENET CYTOGEN, V31, P41, DOI 10.1016/0165-4608(88)90009-X; OCHI H, 1988, JPN J CANCER RES, V79, P1024, DOI 10.1111/j.1349-7006.1988.tb00069.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RICHARDSON AL, 1992, ONCOGENE, V7, P961; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; 1990, CYTOGENET CELL GENET, V55, P1	26	111	111	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					665	668						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290278				2022-12-25	WOS:A1994MW24800036
J	PRASAD, DDK; RAO, VN; LEE, L; REDDY, ESP				PRASAD, DDK; RAO, VN; LEE, L; REDDY, ESP			DIFFERENTIALLY SPLICED ERG-3 PRODUCT FUNCTIONS AS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Note							ETS-RELATED PROTEIN; PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; DNA-BINDING DOMAIN; C-ETS-1 PROTOONCOGENE; C-FOS; GENE FAMILY; FLI-1 GENE; V-ETS	ets oncogene superfamily consists of a family of transcriptional factors that functions as activators and/or repressors. Previously, we have identified a member of this ets superfamily namely erg, ets related gene. erg gene was shown to code for at least two proteins erg-1 and erg-2 because of alternative splicing and alternative usage of initiation codon. In this report we show that erg gene codes for an additional erg variant protein, erg-3 as a result of differential splicing which results in the insertion of 24 amino acids in the coding region of erg-2 protein. RNAase protection analysis revealed that erg-3 transcripts are expressed in a variety of cells. Erg-3 was also found to activate the transcription of the reporter TK-CAT gene linked to er g target sequences suggesting that erg3 codes for a sequence specific transcriptional activator.	JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; NCI,FCRDC,PROGRAM RESOURCES INC,FREDERICK,MD 21702	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA 51083, CA 57157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA057157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P85; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; OHNO T, 1993, IN PRESS CANCER RES; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRASAD DDK, 1992, CANCER RES, V52, P5833; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1990, CANCER RES, V50, P5013; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1990, ONCOGENE, V5, P1761; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	53	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					669	673						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290279				2022-12-25	WOS:A1994MW24800037
J	FERRARA, J; MCCUAIG, K; HENDY, GN; USKOKOVIC, M; WHITE, JH				FERRARA, J; MCCUAIG, K; HENDY, GN; USKOKOVIC, M; WHITE, JH			HIGHLY POTENT TRANSCRIPTIONAL ACTIVATION BY 16-ENE DERIVATIVES OF 1,25-DIHYDROXYVITAMIN-D3 - LACK OF MODULATION BY 9-CIS-RETINOIC ACID OF RESPONSE TO 1,25-DIHYDROXYVITAMIN-D3 OR ITS DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; 9-CIS RETINOIC ACID; MYELOID-LEUKEMIA CELLS; RAT OSTEOCALCIN GENE; THYROID-HORMONE; NUCLEAR-PROTEIN; DIRECT REPEAT; X-RECEPTOR; ELEMENTS; BINDING	Although several studies have been performed on the biological activities of analogs of 1,25-dihydroxyvitamin D3 (1,25-(OH)2 D3) at the whole animal and cellular levels, little work has been done to analyze their transcriptional activation properties. A highly inducible 1,25-(OH)2 D3-responsive promoter composed of three copies of the mouse osteopontin vitamin D3 response element (VDRE3) inserted upstream of a herpes simplex virus thymidine kinase promoter has been constructed, and its transcriptional properties have been analyzed by transient transfection into the monkey kidney cell line COS-7 and the rat osteoblast-like osteosarcoma line ROS 17/2.8. We have studied systematically transcriptional activation by a number of 1,25-(OH)2 D3 analogs, particularly those substituted at positions 16, 23, 26, and 27, sites that are targets for metabolism. Strikingly, except for derivatives that bind the 1,25-(OH)2 D3 receptor (VDR) very weakly, we find no parallel between the potency of action of a derivative as a transcriptional inducer and its affinity for the VDR. Derivatives substituted by multiple bonds at positions 16 and/or 23, although having varying affinities for the VDR, all stimulate transcription more potently than D3, in some cases at 100-fold lower concentrations. The peak transcriptional activity observed varies by only approximately 20% among different active analogs, indicating little difference in the activity of the VDR once bound to ligand. Gel retardation assays with ROS 17/2.8 nuclear extracts suggest that the VDR binds to the mouse osteopontin VDRE predominantly as a heterodimer with retinoid X receptor(s) (RXR(s)). We find that 9-cis-retinoic acid, the cognate ligand for RXRs, does not have a significant effect on the response of the VDRE3 promoter to 1,25-(OH)2 D3 or a number of its derivatives in ROS 17/2.8 or in COS-7 cells, under conditions in which promoters containing retinoid X response elements are activated. This suggests that 9-cis-retinoic acid may not act on the response to 1,25-(OH)2 D3 or its derivatives by directly influencing the transcriptional activity of VDR/RXR heterodimers. This promoter/reporter system should be useful for analyzing the tissue-specific transcriptional activity of 1,25-(OH)2 D3 and its derivatives in any cell type amenable to transient transfection.	MCGILL UNIV,DEPT PHYSIOL,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL H3A 1A1,QUEBEC,CANADA; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110	McGill University; McGill University; Royal Victoria Hospital; Roche Holding			white, john h/N-9782-2013	white, john h/0000-0002-4785-2687				ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; ABE J, 1991, ENDOCRINOLOGY, V129, P832, DOI 10.1210/endo-129-2-832; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BOUILLON R, 1992, J BIOL CHEM, V267, P3044; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CLEMENS TL, 1990, PRINCIPLES PRACTICE, P417; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; DEMAY MB, 1992, MOL ENDOCRINOL, V6, P557, DOI 10.1210/me.6.4.557; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; EISMAN JA, 1986, CELL BIOCHEM FUNCT, V4, P115, DOI 10.1002/cbf.290040207; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; GILL HS, 1984, J MED CHEM, V33, P480; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAQ M, 1993, J CLIN INVEST, V91, P2416, DOI 10.1172/JCI116475; HAUSSLER MR, 1977, NEW ENGL J MED, V297, P974, DOI 10.1056/NEJM197711032971804; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLICK MF, 1971, BIOCHEMISTRY-US, V10, P2799; HOLICK MF, 1981, J INVEST DERMATOL, V76, P51; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; IKEKAWA N, 1983, J STEROID BIOCHEM, V19, P907; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAWSON DEM, 1971, NATURE, V230, P228, DOI 10.1038/230228a0; LAWSON DEM, 1979, VITAMIN D, P167; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MORRISON NA, 1991, J BONE MINER RES, V6, P893; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MUNDY GR, 1989, CALCIUM HOMEOSTASIS; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1971, SCIENCE, V173, P51, DOI 10.1126/science.173.3991.51; PONCHON G, 1969, J CLIN INVEST, V48, P2032, DOI 10.1172/JCI106168; ROODMAN GD, 1985, P NATL ACAD SCI USA, V82, P8213, DOI 10.1073/pnas.82.23.8213; ROSS TK, 1992, P NATL ACAD SCI USA, V89, P256, DOI 10.1073/pnas.89.1.256; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA Y, 1984, ARCH BIOCHEM BIOPHYS, V229, P348, DOI 10.1016/0003-9861(84)90161-9; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USKOKOVIC MR, 1991, VITAMIN D, P139; Wasserman R H, 1974, Vitam Horm, V32, P299; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHOU JY, 1991, BLOOD, V78, P75; ZHOU JY, 1990, P NATL ACAD SCI USA, V87, P3929, DOI 10.1073/pnas.87.10.3929	64	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2971	2981						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300629				2022-12-25	WOS:A1994MV43200088
J	HORIGOME, K; BULLOCK, ED; JOHNSON, EM				HORIGOME, K; BULLOCK, ED; JOHNSON, EM			EFFECTS OF NERVE GROWTH-FACTOR ON RAT PERITONEAL MAST-CELLS - SURVIVAL PROMOTION AND IMMEDIATE-EARLY GENE INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; MESSENGER-RNA; PHEOCHROMOCYTOMA CELLS; HISTAMINE-SECRETION; TRK PROTOONCOGENE; NONNEURONAL CELLS; DE-GRANULATION; KIT LIGAND; C-FOS; FIBROBLASTS	Purified rat peritoneal mast cells in vitro die over a period of 2-6 days in conventional serum-containing medium. As mast cells die, they become pyknotic and undergo DNA fragmentation suggestive of an apoptotic process. Treatment of in vitro mast cells with nerve growth factor (NGF) greatly retards and reduces the death of mast cells (EC50 approximately 1 nM), with no effect on mast cell proliferation. Other neurotrophins have no such effect. NGF also induces the immediate early genes c-fos and NGFI-A with a similar dose dependence. In contrast to the secretagogue activity of NGF, neither the survival-promoting effect nor immediate early gene induction requires lysophosphatidylserine. The ability of NGF to promote mast cell survival is cell density-dependent and appears to be primarily because of induction of the synthesis and/or secretion of an autocrine survival factor by stimulated mast cells. These results suggest that the previously observed effects of NGF on mast cell numbers in vivo may in part be because of enhanced survival and that NGF may be an important mediator of mast cell function in normal and pathological states.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,660 S EUCLID AVE,BOX 8103,ST LOUIS,MO 63110	Washington University (WUSTL)								AGELL N, 1988, P NATL ACAD SCI USA, V85, P3693, DOI 10.1073/pnas.85.11.3693; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; ALOE L, 1988, J NEUROIMMUNOL, V18, P1, DOI 10.1016/0165-5728(88)90129-4; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRUNI A, 1982, FEBS LETT, V138, P190, DOI 10.1016/0014-5793(82)80438-9; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYMAN HN, 1985, IMMUNOL TODAY, V6, P192; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COSTA JJ, 1993, MAST CELL HLTH DIS, P443; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EISEMAN E, 1992, NATURE, V355, P78; FENTON EL, 1970, EXP CELL RES, V59, P383, DOI 10.1016/0014-4827(70)90645-2; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GALLI SJ, 1990, LAB INVEST, V62, P5; GALLI SJ, 1993, AM J PATHOL, V142, P965; GAMBLE HJ, 1961, NATURE, V189, P766, DOI 10.1038/189766a0; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HAMAGUCHI Y, 1987, J EXP MED, V165, P268, DOI 10.1084/jem.165.1.268; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; Hefti F, 1993, Adv Pharmacol, V24, P239, DOI 10.1016/S1054-3589(08)60939-4; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; ISFORT R, 1988, J BIOL CHEM, V263, P19203; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; JOHNSON MD, 1989, ARCH PATHOL LAB MED, V113, P1263; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEEGAN AD, 1991, EMBO J, V10, P3675, DOI 10.1002/j.1460-2075.1991.tb04935.x; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; LEVISCHAFFER F, 1991, IMMUNOLOGY, V72, P174; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MATSUOKA I, 1991, J NEUROSCI, V11, P3165; MAZUREK N, 1986, FEBS LETT, V198, P315, DOI 10.1016/0014-5793(86)80428-8; Meininger C J, 1992, Semin Cancer Biol, V3, P73; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; NIELSEN EH, 1981, CELL TISSUE RES, V216, P635; OLSSON Y, 1971, ACTA NEUROL SCAND, V47, P357, DOI 10.1111/j.1600-0404.1971.tb07490.x; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PRYOR JC, 1992, NEUR ABSTR, V18, P950; RICCARDI V M, 1989, Neurofibromatosis, V2, P292; RICCARDI VM, 1987, ARCH DERMATOL, V123, P1011, DOI 10.1001/archderm.123.8.1011; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHWARTZ LB, 1993, MAST CELL HLTH DIS, P219; SEELDRAYERS PA, 1992, J NEUROIMMUNOL, V35, P239; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SLUTSKY B, 1987, EXP CELL RES, V168, P63, DOI 10.1016/0014-4827(87)90416-2; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; TAKAGI M, 1992, J IMMUNOL, V148, P3446; TAKAGI M, 1989, J EXP MED, V170, P233, DOI 10.1084/jem.170.1.233; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSUJI K, 1990, BLOOD, V75, P421; VALENT P, 1991, Progress in Growth Factor Research, V3, P27, DOI 10.1016/0955-2235(91)90011-R; VIGE X, 1991, MOL PHARMACOL, V40, P186; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	72	134	137	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2695	2702						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300599				2022-12-25	WOS:A1994MV43200052
J	MUELLER, SG; SCHRAW, WP; RICHMOND, A				MUELLER, SG; SCHRAW, WP; RICHMOND, A			MELANOMA GROWTH-STIMULATORY ACTIVITY ENHANCES THE PHOSPHORYLATION OF THE CLASS-II INTERLEUKIN-8 RECEPTOR IN NONHEMATOPOIETIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PEPTIDE-1 INTERLEUKIN-8; COLONY FORMATION INVITRO; HUMAN-NEUTROPHILS; INFLAMMATORY PROTEINS; PROGENITOR CELLS; PLASMA-MEMBRANES; LYMPHOCYTES-T; EXPRESSION; PROLIFERATION; MONOCYTES	The class II IL-8 receptor (IL-8R) binds both melanoma growth stimulatory activity (MGSA) and IL-8 with high affinity. Reverse transcriptase polymerase chain reaction demonstrates that the class II IL-8R mRNA, which has previously been detected only in cells of hematopoietic lineage, is also expressed in non-hematopoietic cell types shown to respond to MGSA or IL-8. To study the signaling mechanism by MGSA through the class II IL-8R in non-hematopoietic cells, this receptor was overexpressed in the 3ASubE human placental and the 293 human kidney cell lines. Membrane preparations of the class II IL-8R expressing 3ASubE transfectants exhibited a 2.3 +/- 0.2-fold increase in GTPgammaS-35 binding, which was sensitive to pertussis toxin, in response to MGSA treatment (0.2 muM). This MGSA response was not observed in cells transfected with the parental expression vector. In vivo phosphorylation studies demonstrated that the class II IL-8R was basally phosphorylated in the untreated transfectants, and MGSA (5 nM) treatment markedly enhanced the phosphorylation of this receptor. The MGSA-induced receptor phosphorylation was both time and concentration dependent and could be mimicked by treatment with the calcium ionophore A23187. Phosphoamino acid analysis indicated that the MGSA-induced receptor phosphorylation was on serine residue(s), suggesting that a serine kinase is activated in response to MGSA binding to the class II IL-8R in non-hematopoietic cells.	VANDERBILT UNIV, DEPT MED DERMATOL, NASHVILLE, TN 37232 USA; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37232 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	MUELLER, SG (corresponding author), VANDERBILT UNIV, DEPT CELL BIOL, NASHVILLE, TN 37232 USA.			RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [CA 34590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA034590, R01CA034590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BACON KB, 1990, BIOCHEM BIOPH RES CO, V169, P1099, DOI 10.1016/0006-291X(90)92008-N; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BORDONI R, 1990, J CELL BIOCHEM, V44, P207, DOI 10.1002/jcb.240440403; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROXMEYER HE, 1990, BLOOD, V76, P1110; BROXMEYER HE, 1989, J EXP MED, V170, P1583, DOI 10.1084/jem.170.5.1583; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CHENG QC, 1992, J IMMUNOL, V148, P451; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; DJEU JY, 1990, J IMMUNOL, V144, P2205; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOON DSB, 1991, CANCER RES, V51, P2002; HORUK R, 1993, J BIOL CHEM, V268, P541; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KRUEGER G, 1990, J INVEST DERMATOL, V94, P545; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE J, 1992, J BIOL CHEM, V267, P16283; LIU JH, 1992, J INFECT DIS, V166, P1089; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RICHMOND A, 1986, J CELL PHYSIOL, V129, P375, DOI 10.1002/jcp.1041290316; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SIBLEY DR, 1984, J BIOL CHEM, V259, P9742; SPRENGER H, 1993, J IMMUNOL, V150, pA126; STRIETER RM, 1992, AM J PATHOL, V141, P1279; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; TUSCHIL A, 1992, J INVEST DERMATOL, V99, P294, DOI 10.1111/1523-1747.ep12616634; UNEMORI EN, 1993, J BIOL CHEM, V268, P1338; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279	47	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1973	1980						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294449				2022-12-25	WOS:A1994MR98800066
J	SWEENEY, HL; STRACESKI, AJ; LEINWAND, LA; TIKUNOV, BA; FAUST, L				SWEENEY, HL; STRACESKI, AJ; LEINWAND, LA; TIKUNOV, BA; FAUST, L			HETEROLOGOUS EXPRESSION OF A CARDIOMYOPATHIC MYOSIN THAT IS DEFECTIVE IN ITS ACTIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEAVY-CHAIN GENE; SKELETAL-MUSCLE; MOLECULAR-BASIS; MUTATIONS; MOTILITY; ASSAY	A point mutation in the heavy chain of cardiac myosin, resulting in replacement of an arginine (Arg) with glutamine (Gln), has been linked to hypertrophic cardiomyopathy in humans (Geisterfer-Lowrance, A. A. T., Kass, S., Tanigawa, G., Vosberg, H.-P., McKenna, W., Seidman, J. G., and Seidman, C. E. (1990) Cell 62, 999-1006). To determine the functional impact of this mutation, baculovirus-driven coexpression of myosin heavy and light chains has been developed. The Arg-403 --> Gln mutation resulted in cardiac myosin with normal ATPase activity in the absence of actin. However, in the presence of actin, ATPase activity was greatly reduced (V(max) decreased > 3.5-fold and K(app) increased >3-fold). In vitro motility was reduced nearly 5-fold by this single amino acid mutation. Thus, Arg-403 likely contributes to an important interaction at the actin interface of myosin. Replacement, of Arg-403 with Gln leads to decreased rate(s) of transition within the actin-myosin crossbridge cycle. In humans, this mutation will result in decreased power output per unit area of cardiac muscle, likely providing a stimulus for hypertrophy.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	SWEENEY, HL (corresponding author), UNIV PENN,SCH MED,DEPT PHYSIOL,37TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.		Sweeney, H Lee/F-1862-2010	LEINWAND, LESLIE/0000-0003-1470-4810				BOTTOMLEY RC, 1975, BIOCHEM J, V149, P365, DOI 10.1042/bj1490365; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GRANDMONTLEBLANC A, 1977, CAN J BIOCHEM CELL B, V55, P949, DOI 10.1139/o77-142; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; HOH JFY, 1976, BIOCHEM J, V157, P87, DOI 10.1042/bj1570087; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MARGOSSIAN SS, 1985, J BIOL CHEM, V260, P3747; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X	25	180	183	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1603	1605						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294404				2022-12-25	WOS:A1994MR98800010
J	CARLESSO, N; GRIFFIN, JD; DRUKER, BJ				CARLESSO, N; GRIFFIN, JD; DRUKER, BJ			USE OF A TEMPERATURE-SENSITIVE MUTANT TO DEFINE THE BIOLOGICAL EFFECTS OF THE P210(BCR-ABL) TYROSINE KINASE ON PROLIFERATION OF A FACTOR-DEPENDENT MURINE MYELOID CELL-LINE	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; MIDDLE-T-ANTIGEN; V-ABL ONCOGENE; BCR-ABL; INTERLEUKIN-3 DEPENDENCE; PHILADELPHIA-CHROMOSOME; INVITRO TRANSFORMATION; HEMATOPOIETIC-CELLS; PROTEIN-KINASE	The Philadelphia chromosome, detected in virtually all cases of chronic myelogenous leukemia, is formed by a reciprocal translocation between chromosomes 9 and 22 that fuses BCR encoded sequences upstream of exon 2 of c-ABL. This oncogene produces a fusion protein, p210(BCR-ABL), in which the ABL tyrosine kinase activity is elevated. This elevated kinase activity is essential for transformation, but the mechanisms involved are unknown. To investigate p210(BCR-ABL) function we constructed a model system in which the tyrosine kinase activity of p210(BCR-ABL) was inducible. Two amino acid substitutions, Arg to His at amino acid 457 and Tyr to His at amino acid 469 of c-abl, modeled on mutations known to render v-src temperature-sensitive for tyrosine kinase activity, were introduced into p210(BCR-ABL). This mutant was characterized in an IL-3 growth factor dependent murine myeloid cell line, 32Dc13. Cell lines expressing the temperature-sensitive mutant remained factor dependent at the non-permissive temperature, but at the permissive temperature displayed a marked reduction in cell death in the absence of growth factor and an exaggerated proliferative response to low levels of IL-3. Both the kinase activity of the mutant and the levels of tyrosine phosphorylated proteins are increased in the temperature-sensitive mutant at the permissive temperature. Further, tyrosine phosphorylation of potential substrates of the p210(BCR-ABL) tyrosine kinase, p120 rasGAP and its associated proteins of p190 and p62, only occurs at the permissive temperature in cells expressing the temperature-sensitive mutant.	DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV TURIN, DEPT EXPTL MED & ONCOL, HEMATOL SECT, TURIN, ITALY; DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Turin; Harvard University; Dana-Farber Cancer Institute				Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [R01CA036167, R37CA036167, K08CA001422] Funding Source: NIH RePORTER; NCI NIH HHS [CA36167, CA01422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNETT MJ, 1989, BONE MARROW TRANSPL, V4, P345; BEDI A, 1992, BLOOD S, V80, pA154; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BROXMEYER HE, 1987, J CLIN INVEST, V79, P721, DOI 10.1172/JCI112877; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DONAHUE RE, 1988, SCIENCE, V241, P1820, DOI 10.1126/science.3051378; DRUKER B, 1992, BLOOD, V79, P2215; DRUKER BJ, 1991, NUCLEIC ACIDS RES, V19, P6855, DOI 10.1093/nar/19.24.6855; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ENGELMAN A, 1987, P NATL ACAD SCI USA, V84, P8021, DOI 10.1073/pnas.84.22.8021; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; EVANS CA, 1993, CANCER RES, V53, P1735; FINCHAM VJ, 1986, J VIROL, V58, P694, DOI 10.1128/JVI.58.2.694-699.1986; Gishizky M L, 1992, Curr Top Microbiol Immunol, V182, P65; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HONMA Y, 1992, LEUKEMIA, V6, P229; HURLEY TR, 1992, J VIROL, V66, P7406, DOI 10.1128/JVI.66.12.7406-7413.1992; KANAKURA Y, 1990, BLOOD, V76, P706; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANEUVILLE P, 1991, ONCOGENE, V6, P275; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATULONIS U, 1993, IN PRESS EXP HEMATOL; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; METCALF D, 1986, BLOOD, V68, P46; MOORE MAS, 1977, CLIN HAEMATOL, V6, P97; NOWELL PC, 1960, SCIENCE, V132, P1497; RISSER R, 1978, J EXP MED, V148, P714, DOI 10.1084/jem.148.3.714; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798	49	85	88	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					149	156						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302574				2022-12-25	WOS:A1994MW24700018
J	CHEN, JY; FUNK, WD; WRIGHT, WE; SHAY, JW; MINNA, JD				CHEN, JY; FUNK, WD; WRIGHT, WE; SHAY, JW; MINNA, JD			HETEROGENEITY OF TRANSCRIPTIONAL ACTIVITY OF MUTANT P53 PROTEINS AND P53 DNA TARGET SEQUENCES	ONCOGENE			English	Article							WILD-TYPE P53; CELL LUNG-CANCER; TUMOR SUPPRESSOR GENE; BINDING PROTEIN; T-ANTIGEN; MUTATIONS; EXPRESSION; CYCLE; INVITRO; GROWTH	Transcriptional activity of p53 was monitored by co-transfection of pCMV expression vectors containing wild-type and mutant p53 cDNAs into the p53-null H1299 lung cancer cells along with luciferase reporter plasmids containing different p53 target sequences in the 5' regulatory region: fragment A of the ribosomal gene cluster (RGC); p53 consensus sequence (p53CON); or a tandemly linked RGC+p53CON sequence. Our results show: (1) wild-type p53 stimulates the transcription of reporter genes with p53CON and RGC in their 5' region while most p53 mutants occurring in human cancers have lost this activity; (2) the R273H mutant retains transcriptional activity for the p53CON sequence but not RGC; (3) some mutants are temperature-sensitive for the transcriptional activity with the p53CON but not the RGC sequence; (4) p53 mutants vary in their ability to inhibit wild-type p53 transactivation but there is no difference between p53CON and RGC sequences; (5) lung cancer cells with endogenous mutant p53 proteins (M246I in H23 cells and R248L in H322 cells) retain transcriptional activity for the p53CON but not the RGC sequence. We conclude that p53 DNA target sequences vary in their response to mutant p53 proteins, and that p53 mutants vary in several transactivation related functions.	UNIV TEXAS,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	CHEN, JY (corresponding author), UNIV TEXAS,SIMMONS CANC CTR,DALLAS,TX 75235, USA.		Chen, Joanne Jeou-Yuan/S-7022-2018; Shay, Jerry W/F-7878-2011					AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODNER SM, 1992, ONCOGENE, V7, P743; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROWER M, 1986, CANCER RES, V46, P798; CARON DFC, 1992, GENE CHROMOSOME CANC, V4, P1; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DAMICO D, 1992, ONCOGENE, V7, P339; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1992, ONCOGENE, V7, P661; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OROURKE RW, 1990, ONCOGENE, V5, P1829; QUINLAN DC, 1992, CANCER RES, V52, P4828; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952	70	165	168	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2159	2166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336941				2022-12-25	WOS:A1993LP17100016
J	ALAM, T; AN, MR; MIFFLIN, RC; HSIEH, CC; GE X; PAPACONSTANTINOU, J				ALAM, T; AN, MR; MIFFLIN, RC; HSIEH, CC; GE, X; PAPACONSTANTINOU, J			TRANSACTIVATION OF THE ALPHA-1-ACID GLYCOPROTEIN GENE ACUTE-PHASE RESPONSIVE ELEMENT BY MULTIPLE ISOFORMS OF C/EBP AND GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; ENRICHED TRANSCRIPTIONAL ACTIVATOR; MOUSE ALBUMIN PROMOTER; DNA-BINDING; NUCLEAR-PROTEIN; 3T3-L1 PREADIPOCYTES; GEL-ELECTROPHORESIS; FACTORS INTERACT; LEUCINE ZIPPER; EXPRESSION	Alpha1-acid glycoprotein (AGP) is a major acute phase protein synthesized primarily by the liver. The AGP gene is transcriptionally activated in hepatocytes during the acute phase response to bacterial lipopolysaccharide. In this study, we analyzed an acute phase responsive element (APRE) located between nucleotide residues -127 to -104 relative to the transcription initiation site of the mouse AGP gene. Binding studies show that several trans-acting factors interact with the APRE. Using monospecific antibodies we demonstrate that three isoforms of the CCAAT/enhancer-binding protein (C/EBP) family, namely C/EBPalpha, C/EBPbeta, and C/EBPdelta, bind to the APRE. Furthermore, with liver nuclear protein from control animals, C/EBPalpha is the predominant form that binds to the APRE, whereas with nuclear proteins from acute phase-induced animals, C/EBPalpha is replaced by C/EBPbeta. The mechanism of activation of the AGP gene during the acute phase response appears to involve an exchange of C/EBPalpha by C/EBPbeta. C/EBPdelta does not play a role in this reaction. Interestingly, the C/EBP binding site of the APRE partially overlaps a functional glucocorticoid responsive element. We present evidence that both purified C/EBPalpha and glucocorticoid receptor bind strongly to the APRE. By site-specific mutation, we have identified the C/EBP and glucocorticoid receptor binding sites in the APRE. These mutants were used in expression vectors to demonstrate that both C/EBP and glucocorticoid receptor are essential for maximal response to interleukin-6 and dexamethasone. These results demonstrate that the APRE is a composite binding site for multiple factors that are responsible for the transcriptional control of the mouse AGP. Finally, functional analyses indicate that C/EBPalpha, C/EBPbeta, and C/EBPdelta are strong transcriptional trans-activators of the AGP APRE in hepatoma cells. These data suggest that the regulatory activity of the C/EBP with the APRE in the liver may require interactions with adjacent proteins.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston			Papaconstantinou, John/E-3312-2010					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, BIOCHEMISTRY-US, V31, P1928, DOI 10.1021/bi00122a005; ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1989, GENETICS BIOCH PHYSL; BENNETT M, 1980, P NATL ACAD SCI-BIOL, V77, P6109, DOI 10.1073/pnas.77.10.6109; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARTER KC, 1989, J BIOL CHEM, V264, P4112; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COOPER R, 1987, BIOCHEMISTRY-US, V26, P5244, DOI 10.1021/bi00391a006; COOPER R, 1986, J BIOL CHEM, V261, P1849; DENTE L, 1987, EMBO J, V6, P2289, DOI 10.1002/j.1460-2075.1987.tb02503.x; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FEY GH, 1987, MOL BIOL MED, V4, P323; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FRIEDMAN MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5421, DOI 10.1073/pnas.80.17.5421; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KUSHNER I, 1989, ANN NY ACAD SCI, V557, P19; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE YM, 1993, MOL CELL BIOL, V13, P432, DOI 10.1128/MCB.13.1.432; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MUELLER CR, 1991, CELL, V65, P915; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PEI DQ, 1990, J VIROL, V64, P1517, DOI 10.1128/JVI.64.4.1517-1522.1990; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; REINKE R, 1985, J BIOL CHEM, V260, P4397; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1990, MOL CELL BIOL, V10, P4389, DOI 10.1128/MCB.10.8.4389; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; TSAI SY, 1990, J BIOL CHEM, V265, P17055; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; YIANGOU M, 1991, BIOCHEMISTRY-US, V30, P3798; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	62	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15681	15688						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340393				2022-12-25	WOS:A1993LN30500055
J	MCCONVILLE, MJ; COLLIDGE, TAC; FERGUSON, MAJ; SCHNEIDER, P				MCCONVILLE, MJ; COLLIDGE, TAC; FERGUSON, MAJ; SCHNEIDER, P			THE GLYCOINOSITOL PHOSPHOLIPIDS OF LEISHMANIA-MEXICANA PROMASTIGOTES - EVIDENCE FOR THE PRESENCE OF 3 DISTINCT PATHWAYS OF GLYCOLIPID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; HUMAN MONONUCLEAR PHAGOCYTES; MAJOR PROMASTIGOTES; GLYCOSYLATED-PHOSPHATIDYLINOSITOLS; STRUCTURAL CHARACTERIZATION; DONOVANI LIPOPHOSPHOGLYCAN; SURFACE GLYCOPROTEIN; VIRULENCE FACTORS; STAGE; IDENTIFICATION	Most macromolecules at the cell surface of parasitic protozoa of the genus Leishmania, including the major surface glycoproteins and a complex lipophosphoglycan (LPG), are attached to the plasma membrane via glycosyl-phosphatidylinositol (GPI) anchors. Free glycoinositol phospholipids (GIPLs) which are not linked to protein or phosphoglycan have also been found. In this study, we show that L. mexicana promastigotes synthesize two distinct GIPL lineages, comprising at least 10 glycolipid species. These structures were characterized using a combination of gas-liquid chromatography-mass spectrometry, methylation linkage analysis, and chemical and exoglycosidase sequencing. The major lineage contains GIPLs with the glycan structures Manalpha1-3Manalpha1-4GlcN (iM2), Manalpha1-6(Manalpha1-3)Manalpha1-4GlcN (iM3), and Manalpha1-2Manalpha1-6(Manalpha1-3)Manalpha1-4GlcN (iM4), which are linked to alkylacyl-PI containing predominantly C16:0 and C18:0 fatty acids and C18:0 alkyl chains (referred to as the hybrid type GIPLs). A proportion of the iM3 and iM4 species (32 and 4%, respectively) are substituted with an ethanolamine-phosphate residue. The location of this residue on the core glucosamine residue was inferred from the results of methylation analyses and alpha-mannosidase digestion. The minor GIPL lineage contains GIPLs with the same glycan sequences as the glycolipid anchor of LPG (referred to as the type-2 GIPLs). The alkylacyl-PI or lyso-alkyl-PI lipid moieties of these GIPLs differ from those of the hybrid type GIPLs and from the main pool of alkylacyl-PI in containing significant levels of C24:0 and C26:0 alkyl chains. The most polar of these GIPLs, LPGp, has the properties expected of a biosynthetic precursor to the LPG, having the structure, [GRAPHICS] Finally, the GPI anchors of the major promastigote proteins were found to contain the glycan sequence Manalpha1-2Manalpha1-6Manalpha1-4GlcN, and an alkylacyl-PI lipid moiety which was highly enriched for C24:0 or C26:0 alkyl chains. These data suggest that L. mexicana promastigotes contain three distinct pathways of GPI biosynthesis. The possibility that the distinct alkyl chain compositions of the different GPI glycolipids reflects the subcellular compartmentalization of different GPI biosynthetic pathways is discussed.			MCCONVILLE, MJ (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.		Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; Schneider, Pascal/0000-0003-0677-9409	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AVILA JL, 1991, J CLIN MICROBIOL, V29, P2305, DOI 10.1128/JCM.29.10.2305-2312.1991; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; BLACKWELL JM, 1985, J EXP MED, V162, P324, DOI 10.1084/jem.162.1.324; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BOUVIER J, 1985, J BIOL CHEM, V260, P5504; BUTIKOFER P, 1992, EUR J BIOCHEM, V208, P677, DOI 10.1111/j.1432-1033.1992.tb17234.x; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DASILVA RP, 1989, J IMMUNOL, V143, P617; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DESCOTEAUX A, 1992, J IMMUNOL, V149, P3008; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FIELD MC, 1991, MOL BIOCHEM PARASIT, V48, P227, DOI 10.1016/0166-6851(91)90118-P; GLASER TA, 1991, MOL BIOCHEM PARASIT, V45, P337, DOI 10.1016/0166-6851(91)90102-C; HIROSE S, 1992, J BIOL CHEM, V267, P16968; ILLG T, 1992, J BIOL CHEM, V267, P6834; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; LEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; MCCONVILLE MJ, 1992, J BIOL CHEM, V267, P5855; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1991, CELL BIOL INT REP, V15, P779, DOI 10.1016/0309-1651(91)90033-F; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; MENON AK, 1990, J BIOL CHEM, V265, P9033; MURRAY PJ, 1989, J IMMUNOL, V143, P4221; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; PREVIATO JO, 1992, J BIOL CHEM, V267, P24279; PUENTES SM, 1990, J IMMUNOL, V145, P4311; ROSEN G, 1988, MOL BIOCHEM PARASIT, V27, P93, DOI 10.1016/0166-6851(88)90028-X; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHNEIDER P, 1993, ANAL BIOCHEM, V210, P106, DOI 10.1006/abio.1993.1158; SCHNEIDER P, 1992, EXP PARASITOL, V75, P196, DOI 10.1016/0014-4894(92)90179-E; SCHNEIDER P, 1993, IN PRESS BIOCH J; SINGH BN, 1988, BIOCHEM BIOPH RES CO, V157, P1239, DOI 10.1016/S0006-291X(88)81007-6; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WASSEF MK, 1985, LIPIDS, V20, P108, DOI 10.1007/BF02534216; WILSON ME, 1986, J IMMUNOL, V136, P4681; WILSON ME, 1988, INFECT IMMUN, V56, P363, DOI 10.1128/IAI.56.2.363-369.1988	51	112	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15595	15604						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340385				2022-12-25	WOS:A1993LN30500043
J	SAITO, K; CROWLEY, JS; MARKEY, SP; HEYES, MP				SAITO, K; CROWLEY, JS; MARKEY, SP; HEYES, MP			A MECHANISM FOR INCREASED QUINOLINIC ACID FORMATION FOLLOWING ACUTE SYSTEMIC IMMUNE STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROSPINAL-FLUID; KYNURENIC ACID; INDOLEAMINE 2,3-DIOXYGENASE; L-TRYPTOPHAN; RAT-BRAIN; 3-HYDROXYANTHRANILIC ACID; NEUROACTIVE KYNURENINES; IMMUNODEFICIENCY VIRUS; INDOLEAMINE-2,3-DIOXYGENASE; QUANTIFICATION	Mechanisms for increased levels of quinolinic acid (QUIN) following systemic immune stimulation were investigated. In gerbils, systemic administration of pokeweed mitogen (PWM) increased plasma and cerebrospinal fluid QUIN levels, while plasma kynurenic acid levels were decreased and cerebrospinal fluid kynurenic acid levels were unchanged. PWM also increased the QUIN concentrations of brain and systemic tissues. In slices of spleen, lung, liver, duodenum, and kidney, PWM caused marked increases in [C-13(6)]QUIN formation from L-[C-13(6)]tryptophan (but not from [C-13(6)anthranilic acid). PWM also increased QUIN excretion in the urine and enhanced the formation and excretion of [C-13(6)]QUIN following an intraperitoneal injection Of L-[C-13(6)]tryptophan. Indoleamine-2,3-dioxygenase activity was increased in the brain, kidney, lung, spleen, and duodenum while hepatic L-tryptophan-2,3-dioxygenase activity was reduced, data consistent with in vitro L-kynurenine formation from L-tryptophan. Kynurenine-3-hydroxylase activity was increased in the duodenum, lung, and spleen, but not in the brain, kidney, or liver. Kynureninase activity was increased in the brain, lung, and duodenum, but not in the spleen, kidney, or liver. 3-Hydroxyanthranilate-3,4-dioxygenase activity was unchanged in the brain, lung, and liver. No change in kynurenine aminotransferase activity was observed in the brain or lung, while liver kynurenine aminotransferase activity was reduced. We conclude that increased activities of kynurenine pathway enzymes in various tissues following systemic immune stimulation, in conjunction with macrophage infiltration of the affected tissue, provide a mechanism to account for increased concentrations of QUIN.			SAITO, K (corresponding author), NIMH, ANALYT BIOCHEM SECT, CLIN SCI LAB, BETHESDA, MD 20892 USA.							ABALLI AJ, 1978, PEDIATR RES, V12, P646, DOI 10.1203/00006450-197805000-00006; BARAN H, 1990, J NEUROCHEM, V55, P738, DOI 10.1111/j.1471-4159.1990.tb04553.x; BENDER DA, 1983, MOL ASPECTS MED, V6, P101, DOI 10.1016/0098-2997(83)90005-5; BESKID M, 1991, EXP PATHOL-JENA, V41, P110, DOI 10.1016/S0232-1513(11)80007-1; CARLIN JM, 1989, EXPERIENTIA, V45, P535, DOI 10.1007/BF01990503; DANGELI F, 1955, J BIOL CHEM, V214, P281; FOSTER AC, 1986, J NEUROCHEM, V47, P23; FUKUI S, 1991, J NEUROCHEM, V56, P2007, DOI 10.1111/j.1471-4159.1991.tb03460.x; HAYCOCK KA, 1992, STATVIEW, P466; HEYES MP, 1992, J NEUROIMMUNOL, V40, P71, DOI 10.1016/0165-5728(92)90214-6; HEYES MP, 1990, J CHROMATOGR-BIOMED, V530, P108, DOI 10.1016/S0378-4347(00)82308-7; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1992, BRAIN RES, V570, P237, DOI 10.1016/0006-8993(92)90587-Y; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1988, BIOMED ENVIRON MASS, V15, P291, DOI 10.1002/bms.1200150509; HEYES MP, 1988, J NEUROCHEM, V51, P1446, DOI 10.1111/j.1471-4159.1988.tb01183.x; HEYES MP, 1988, J CHROMATOGR-BIOMED, V428, P340, DOI 10.1016/S0378-4347(00)83925-0; HEYES MP, 1990, J NEUROCHEM, V55, P338, DOI 10.1111/j.1471-4159.1990.tb08857.x; HIRATA F, 1971, J BIOL CHEM, V246, P7825; KAWAI J, 1988, ENZYME, V39, P181, DOI 10.1159/000469117; LAPIN IP, 1978, J NEURAL TRANSM, V42, P37, DOI 10.1007/BF01262727; LARDY H, 1980, BIOCH MED ASPECTS TR, P199; MARTIN A, 1992, J NEUROPSYCH CLIN N, V4, P270; OKUNO E, 1987, J NEUROCHEM, V49, P771, DOI 10.1111/j.1471-4159.1987.tb00960.x; PERKINS MN, 1983, J PHARMACOL EXP THER, V226, P551; RIOS C, 1991, NEUROCHEM RES, V16, P1139, DOI 10.1007/BF00966592; SAITO K, 1993, BIOCHEM J, V291, P11, DOI 10.1042/bj2910011; SAITO K, 1990, BIOCHEM INT, V20, P71; SAITO K, 1992, NEUROSCIENCE, V51, P25, DOI 10.1016/0306-4522(92)90467-G; SAITO K, 1993, J NEUROCHEM, V60, P180, DOI 10.1111/j.1471-4159.1993.tb05836.x; SAITO K, 1991, LIFE SCI, V49, P527, DOI 10.1016/0024-3205(91)90070-R; SAITO K, 1991, BRAIN RES, V546, P151, DOI 10.1016/0006-8993(91)91171-V; SAITO K, 1991, BRAIN RES, V540, P353, DOI 10.1016/0006-8993(91)90536-5; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SPECIALE C, 1989, NEUROSCI LETT, V104, P345, DOI 10.1016/0304-3940(89)90601-0; STONE TW, 1984, NEUROSCI LETT, V52, P335, DOI 10.1016/0304-3940(84)90184-8; TAKIKAWA O, 1986, J BIOL CHEM, V261, P3648; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; UEDA T, 1978, J BIOCHEM-TOKYO, V84, P687, DOI 10.1093/oxfordjournals.jbchem.a132174; VECSEI L, 1990, BRAIN RES BULL, V25, P623, DOI 10.1016/0361-9230(90)90123-H; WERNER ER, 1988, BIOL CHEM H-S, V369, P337, DOI 10.1515/bchm3.1988.369.1.337; YOSHIDA R, 1986, ARCH BIOCHEM BIOPHYS, V249, P596, DOI 10.1016/0003-9861(86)90038-X	46	167	168	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15496	15503						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340378				2022-12-25	WOS:A1993LN30500029
J	WOODLOCK, TJ; YOUNG, DA; BOAL, TR; LICHTMAN, MA; SEGEL, GB				WOODLOCK, TJ; YOUNG, DA; BOAL, TR; LICHTMAN, MA; SEGEL, GB			PHORBOL ESTER-INDUCED MEMBRANE-PROTEINS IN CHRONIC LEUKEMIC B-LYMPHOCYTES - CANDIDATE PROTEINS FOR THE L-SYSTEM AMINO-ACID TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-CELL LEUKEMIA; SACCHAROMYCES-CEREVISIAE; MULTICOMPONENT ANALYSIS; TRIPHOSPHATASE-ACTIVITY; NUCLEOTIDE-SEQUENCE; KINETIC-PARAMETERS; DIFFERENTIATION; NA+; 5'-NUCLEOTIDASE; ELECTROPHORESIS	Chronic lymphocytic leukemia (CLL) B-lymphocytes have markedly diminished membrane L-system amino acid transport as compared with normal mature B- and T-lymphocytes. L-system functional recovery is induced in CLL B-cells by the maturational agent, 12-O-tetradecanoylphorbol-13-acetate ( TPA). The studies reported here extend the analysis of CLL B-cell maturation by comparing membrane protein expression in untreated and TPA-treated CLL B-cells, with the identification of candidate proteins for the L-system transporter. Cell membrane proteins of resting and TPA-treated CLL B-lymphocytes were studied using ultra-high resolution giant two-dimensional gel electrophoresis. Cellular proteins were metabolically labeled with [S-35]methionine, and, in separate experiments, membrane proteins were photoaffinity labeled with [I-125] iodoazidophenylalanine, an amino acid transported by the L-system and which binds at or near the L-system transport carrier. In a partially purified membrane preparation, approximately 1400 proteins were identified by metabolic labeling. Following TPA treatment for 17 h, 14 new metabolically labeled membrane proteins were identified, and five of these also were labeled by the L-system photoprobe. Photolabeling of four of these proteins was inhibited by an excess of the L-system prototype amino acid, 2-aminobicyclo(2.2.1)heptane-2-carboxylic acid. Given these labeling characteristics, one or more of these four proteins may be related to the L-system amino acid transport carrier.	UNIV ROCHESTER,SCH MED,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT PEDIAT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,ST MARYS HOSP,CTR CANC,SCH MED,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA034691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016177] Funding Source: NIH RePORTER; NCI NIH HHS [CA34691] Funding Source: Medline; NHLBI NIH HHS [HL07152-17] Funding Source: Medline; NIDDK NIH HHS [DK16177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPBELL GS, 1992, J BIOL CHEM, V267, P12496; CARLSSON M, 1989, LEUKEMIA, V3, P593; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1510; FRANCO A, 1989, EUR J IMMUNOL, V19, P1171, DOI 10.1002/eji.1830190703; GALE RP, 1985, ANN INTERN MED, V103, P101, DOI 10.7326/0003-4819-103-1-101; GORDON J, 1984, J IMMUNOL, V132, P541; GRATECOS D, 1982, BIOCHIM BIOPHYS ACTA, V705, P218, DOI 10.1016/0167-4838(82)90181-9; GUY K, 1983, EUR J IMMUNOL, V13, P156, DOI 10.1002/eji.1830130212; HARLOW E, 1988, ANTIBODIES LABORATOR; HO AD, 1986, CANCER, V58, P96, DOI 10.1002/1097-0142(19860701)58:1<96::AID-CNCR2820580117>3.0.CO;2-3; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KORNFELD R, 1974, J BIOL CHEM, V249, P1295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA K, 1977, BLOOD, V50, P683; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LOPES J, 1973, J CLIN INVEST, V52, P1297, DOI 10.1172/JCI107298; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIQUE D, 1973, CANCER RES, V33, P2761; MITSUI H, 1991, IMMUNOL LETT, V27, P105, DOI 10.1016/0165-2478(91)90136-X; NOREN O, 1983, EUR J BIOCHEM, V134, P71, DOI 10.1111/j.1432-1033.1983.tb07532.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSTLUND L, 1986, BLOOD, V67, P152; PARKS DR, 1979, P NATL ACAD SCI USA, V76, P1962, DOI 10.1073/pnas.76.4.1962; RABILLOUD T, 1991, P NATL ACAD SCI USA, V88, P1830, DOI 10.1073/pnas.88.5.1830; RUOHO AE, 1984, MEMBRANES DETERGENTS, P119; SAMUELS BL, 1987, LEUKEMIA, V1, P365; SEGEL GB, 1979, J CELL PHYSIOL, V100, P109, DOI 10.1002/jcp.1041000111; SEGEL GB, 1983, J CELL PHYSIOL, V116, P372, DOI 10.1002/jcp.1041160315; SEGEL GB, 1989, J BIOL CHEM, V264, P16399; SEGEL GB, 1985, J CELL PHYSIOL, V124, P424, DOI 10.1002/jcp.1041240310; SEGEL GB, 1984, J CLIN INVEST, V74, P17, DOI 10.1172/JCI111398; STAROS JV, 1978, BIOCHEMISTRY-US, V17, P3321, DOI 10.1021/bi00609a023; TERNYNCK T, 1974, BLOOD, V43, P789, DOI 10.1182/blood.V43.6.789.789; TOTTERMAN TH, 1980, NATURE, V288, P176, DOI 10.1038/288176a0; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WILLARDGALLO KE, 1984, CLIN CHEM, V30, P2069; WOODLOCK TJ, 1990, J CELL PHYSIOL, V145, P217, DOI 10.1002/jcp.1041450205; WOODLOCK TJ, 1988, J CLIN INVEST, V81, P32, DOI 10.1172/JCI113306; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190	45	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16020	16027						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340423				2022-12-25	WOS:A1993LN30500097
J	YANAGISAWA, S; IZUI, K				YANAGISAWA, S; IZUI, K			MOLECULAR-CLONING OF 2 DNA-BINDING PROTEINS OF MAIZE THAT ARE STRUCTURALLY DIFFERENT BUT INTERACT WITH THE SAME SEQUENCE MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYLASE GENE; NUCLEAR FACTORS INTERACT; TRANSCRIPTION FACTOR; PLANT GENES; TRANSGENIC PLANTS; CDNA CLONE; PROMOTER; EXPRESSION; ENHANCER; ELEMENT	Nuclear extracts from maize leaves have been shown previously to contain a factor, MNF1, that interacts with both the cauliflower mosaic virus 35S promoter and the promoter of the maize gene for phosphoenol-pyruvate carboxylase, which is involved in C4 photosynthesis. We have isolated two cDNA clones encoding proteins (MNB1a and MNB1b), that bind to an MNF1-binding site in a sequence-specific manner, by screening of a maize cDNA expression library with synthetic oligonucleotides. Using various mutated oligonucleotides, we showed that both proteins recognize an AAGG motif at the MNF1-binding site as important bases for binding, as does MNF1 in maize nuclear extracts. However, the binding specificities of MNB1a and MNB1b are similar but not identical to that of MNF1. The deduced amino acid sequences of these proteins are completely different from each other. The basic region of MNB1b exhibits homology to the high mobility group (HMG) box of the vertebrate HMG1 family, whereas MNB1a exhibits no homology to any known proteins. Southern blot analysis of genomic DNA revealed that the cDNA for MNB1a is derived from a multigene family whose members have highly homologous N-terminal basic domain, whereas the gene for MNB1b exhibits only limited homology to a few other genes. These results suggest that the MNF1-binding site on the 35S promoter is a target of multiple DNA-binding proteins.	OSAKA CITY UNIV,FAC SCI,DEPT BIOL,SUMIYOSHI KU,OSAKA 558,JAPAN; KYOTO UNIV,FAC SCI,DEPT CHEM,SAKYO KU,KYOTO 60601,JAPAN	Osaka Metropolitan University; Kyoto University								ALLEN RD, 1989, PLANT CELL, V1, P623, DOI 10.1105/tpc.1.6.623; BENFEY PN, 1989, SCIENCE, V244, P174, DOI 10.1126/science.244.4901.174; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BRUNNER B, 1992, THESIS SWISS FEDERAL; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; DEHESH K, 1992, EMBO J, V11, P4131, DOI 10.1002/j.1460-2075.1992.tb05506.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANG RX, 1989, PLANT CELL, V1, P141, DOI 10.1105/tpc.1.1.141; FROMM H, 1989, PLANT CELL, V1, P977, DOI 10.1105/tpc.1.10.977; GRASSER KD, 1991, NUCLEIC ACIDS RES, V19, P2573, DOI 10.1093/nar/19.10.2573; GRASSER KD, 1990, J BIOL CHEM, V265, P4185; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KAWAMURA T, 1990, J BIOCHEM-TOKYO, V107, P165, DOI 10.1093/oxfordjournals.jbchem.a123002; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; LAM E, 1990, PLANT CELL, V2, P857, DOI 10.1105/tpc.2.9.857; LESSARD PA, 1991, PLANT MOL BIOL, V16, P397, DOI 10.1007/BF00023991; MATSUOKA M, 1991, MOL GEN GENET, V225, P411, DOI 10.1007/BF00261681; MIKAMI K, 1989, NUCLEIC ACIDS RES, V17, P9707, DOI 10.1093/nar/17.23.9707; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHELL JS, 1987, SCIENCE, V237, P1176; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; SCHINDLER U, 1990, EMBO J, V9, P3415, DOI 10.1002/j.1460-2075.1990.tb07549.x; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SIMS TL, 1981, J BIOL CHEM, V256, P8252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; SINGH K, 1990, PLANT CELL, V2, P891, DOI 10.1105/tpc.2.9.891; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TAKATSUJI H, 1992, EMBO J, V11, P241, DOI 10.1002/j.1460-2075.1992.tb05047.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WILLIAMS ME, 1992, PLANT CELL, V4, P485, DOI 10.1105/tpc.4.4.485; YANAGISAWA S, 1989, J BIOCHEM-TOKYO, V106, P982, DOI 10.1093/oxfordjournals.jbchem.a122986; YANAGISAWA S, 1990, MOL GEN GENET, V224, P325, DOI 10.1007/BF00262425; YANAGISAWA S, 1992, PLANT MOL BIOL, V19, P545, DOI 10.1007/BF00026781	43	124	172	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16028	16036						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340424				2022-12-25	WOS:A1993LN30500098
J	COLLINS, MJ; ARCIERO, DM; HOOPER, AB				COLLINS, MJ; ARCIERO, DM; HOOPER, AB			OPTICAL SPECTROPOTENTIOMETRIC RESOLUTION OF THE HEMES OF HYDROXYLAMINE OXIDOREDUCTASE - HEME QUANTITATION AND PH-DEPENDENCE OF E(M)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROSOMONAS-EUROPAEA; REDOX POTENTIOMETRY; RESONANCE SPECTROSCOPY; CYTOCHROME-C; REDUCTION; P-460; P460; SITE	The hemes of hydroxylamine oxidoreductase (HAO) have been analyzed optically by potentiometric titrations using a low volume optically transparent thin layer electrochemical cell. The electrochemical behavior of the HAO monomeric unit has been interpreted by modeling the spectroelectrochemical data at several wavelengths to eight one-electron Nernst sites: seven c-type hemes and one P460 heme. Of the seven c-hemes, six show alpha-bands with absorption maxima at or near 553 nm. One c-heme has an alpha-band absorption maximum at 559 nm. The six c-553 hemes have midpoint potentials at pH 7.0 of +288, -10, -162, -192, -265 and -412 mV versus the normal hydrogen electrode (NHE). The c-559 heme has a midpoint potential (E(m)') at pH 7.0 of +11 mV versus NHE. The midpoint potential of the P460 heme is at -260 mV versus NHE at pH 7.0. In contrast, the midpoint potential for the P460 heme in another protein, cytochrome P460, from the same organism is -402 mV versus NHE at pH 7.0. Midpoint potentials of the c-hemes show little, if any, pH dependence over the range of pH 6-8. In contrast, E(m)' for the P460 heme changes with a slope of -60 mV/pH unit over the same range. Electrochemical isolation of the P460 heme at pH 8.0 led to the discovery of a broad spectroscopic feature centered near 740 nm that was assigned to the oxidized P460 heme. Changes in the spectroelectrochemical behavior of HAO after inactivation by H2O2 was almost exclusively restricted to the P460 heme of HAO. Both the 464-nm absorption band of the reduced P460 heme and the 740-nm band of the oxidized heme were no longer present. For the c-hemes, the only effect seems to be a slight shift in E(m)' for a single c-553 heme from -162 to -135 mV.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; VITERBO COLL,DEPT CHEM,LA CROSSE,WI 54601	University of Minnesota System; University of Minnesota Twin Cities								ANDERSON CW, 1979, ANAL BIOCHEM, V93, P366, DOI 10.1016/S0003-2697(79)80164-5; ANDERSSON KK, 1991, BIOCHEM BIOPH RES CO, V174, P358, DOI 10.1016/0006-291X(91)90528-F; ANDERSSON KK, 1984, J BIOL CHEM, V259, P6833; ARCIERO DM, 1991, BIOCHEMISTRY-US, V30, P11466, DOI 10.1021/bi00112a014; ARCIERO DM, 1991, BIOCHEMISTRY-US, V30, P11459, DOI 10.1021/bi00112a013; ARCIERO DM, 1993, J BIOL CHEM, V266, P14645; COLETTA M, 1991, EUR J BIOCHEM, V202, P1101, DOI 10.1111/j.1432-1033.1991.tb16476.x; ELLIS WR, 1986, BIOCHEMISTRY-US, V25, P161, DOI 10.1021/bi00349a023; ERICKSON RH, 1972, BIOCHIM BIOPHYS ACTA, V275, P231, DOI 10.1016/0005-2728(72)90044-8; HOOPER AB, 1977, BIOCHEMISTRY-US, V16, P455, DOI 10.1021/bi00622a018; HOOPER AB, 1978, BIOCHEMISTRY-US, V17, P2984, DOI 10.1021/bi00608a007; HOOPER AB, 1984, EUR J BIOCHEM, V141, P565, DOI 10.1111/j.1432-1033.1984.tb08230.x; HOOPER AB, 1965, J BIOL CHEM, V240, P4044; LIPSCOMB JD, 1982, BIOCHEMISTRY-US, V21, P3965, DOI 10.1021/bi00260a010; LIPSCOMB JD, 1982, BIOCHEMISTRY-US, V21, P3973, DOI 10.1021/bi00260a011; LOGAN MSP, 1991, THESIS U MINNESOTA S; MILLER DJ, 1984, J GEN MICROBIOL, V130, P3049; NASRI H, 1987, J AM CHEM SOC, V109, P2549, DOI 10.1021/ja00242a069; NUMATA M, 1990, J BIOCHEM, V108, P1016, DOI 10.1093/oxfordjournals.jbchem.a123300; PRINCE RC, 1987, BIOCHEMISTRY-US, V26, P970, DOI 10.1021/bi00377a043; PRINCE RC, 1983, FEBS LETT, V163, P25, DOI 10.1016/0014-5793(83)81154-5; SCHAPPACHER M, 1983, INORG CHIM A-BIOINOR, V78, pL9, DOI 10.1016/S0020-1693(00)86461-0; TERRY KR, 1981, BIOCHEMISTRY-US, V20, P7026, DOI 10.1021/bi00527a039; YAMANAKA T, 1979, J BIOCHEM, V86, P1101, DOI 10.1093/oxfordjournals.jbchem.a132604	24	41	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14655	14662						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325842				2022-12-25	WOS:A1993LL75900022
J	DEANGELIS, PL; PAPACONSTANTINOU, J; WEIGEL, PH				DEANGELIS, PL; PAPACONSTANTINOU, J; WEIGEL, PH			ISOLATION OF A STREPTOCOCCUS-PYOGENES GENE LOCUS THAT DIRECTS HYALURONAN BIOSYNTHESIS IN ACAPSULAR MUTANTS AND IN HETEROLOGOUS BACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; RHEUMATIC-FEVER; CLONING; DNA; INFECTIONS; MINICELLS; PLASMIDS; SYNTHASE; CAPSULE	A contiguous 3-kilobase pair region of DNA was isolated from Group A Streptococcus pyogenes (GAS) that can direct hyaluronic acid (HA) capsule biosynthesis in acapsular mutants as well as heterologous bacteria. The DNA was identified by transposon 916 insertional mutagenesis and subcloned into a plasmid shuttle vector. Mutant acapsular GAS or Enterococcus faecalis containing this plasmid, but not vector alone, displayed a mucoid phenotype on agar plates, possessed a capsule as seen by light microscopy, and produced HA in quantities comparable with wild-type GAS. The polysaccharide was shown to be authentic HA based on its recognition by a specific proteoglycan and its degradation by Streptomyces hyaluronate lyase. Escherichia coli with the complementing plasmid also produced HA but at only 10% of the level made by the above cells. E. coli minicell analysis showed that two proteins, 42 and 45 kDa, are expressed by the functional DNA insert. Deletion analysis of the insert in the minicells revealed that the 42-kDa protein is essential for HA production. This is the first demonstration of reconstitution of HA capsule biosynthesis in vivo.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston			Papaconstantinou, John/E-3312-2010		NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; CLEWELL DB, 1988, J BACTERIOL, V170, P3046, DOI 10.1128/jb.170.7.3046-3052.1988; COLLINS CH, 1976, MICROBIOLOGICAL METH, P110; Dochez AR, 1919, J EXP MED, V30, P179, DOI 10.1084/jem.30.3.179; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; DUNNY GM, 1991, APPL ENVIRON MICROB, V57, P1194, DOI 10.1128/AEM.57.4.1194-1201.1991; EHTESHAM NZ, 1991, BIOTECHNIQUES, V11, P718; GAWRONBURKE C, 1984, J BACTERIOL, V159, P214, DOI 10.1128/JB.159.1.214-221.1984; HAKANSSON S, 1986, ACTA PATH MICRO IM B, V94, P139; KAPLAN EL, 1989, J INFECT DIS, V159, P101, DOI 10.1093/infdis/159.1.101; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; MATSUMURA P, 1977, J BACTERIOL, V132, P996, DOI 10.1128/JB.132.3.996-1002.1977; MEAGHER RB, 1977, CELL, V10, P521, DOI 10.1016/0092-8674(77)90039-3; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; OCONNOR SP, 1987, J INFECT DIS, V156, P495, DOI 10.1093/infdis/156.3.495; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1986, BIOCHEM J, V235, P887, DOI 10.1042/bj2350887; QUINN RW, 1957, BIOCHEM J, V95, P290; ROBERTS IS, 1989, BIOCHEM SOC T, V17, P462, DOI 10.1042/bst0170462; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; TRIEUCUOT P, 1991, GENE, V102, P99, DOI 10.1016/0378-1119(91)90546-N; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317	30	109	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14568	14571						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325836				2022-12-25	WOS:A1993LL75900005
J	MARGULIES, L; SEHGAL, PB				MARGULIES, L; SEHGAL, PB			MODULATION OF THE HUMAN INTERLEUKIN-6 PROMOTER (IL-6) AND TRANSCRIPTION FACTOR-C/EBP BETA (NF-IL6) ACTIVITY BY P53 SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ELEMENT; BREAST-CARCINOMA; BINDING-PROTEIN; NUCLEAR FACTOR; DNA-BINDING; WILD-TYPE; GENE; EXPRESSION; ENHANCER; ACTIVATION	Constitutive up-regulation of interleukin-6 (IL-6) gene expression is observed in many neoplastic cell lines. The contribution of mutations in p53 to the up-regulation of the IL-6 promoter was evaluated in transient transfection experiments. In HeLa cells, wild-type (wt) human or murine p53 preferentially repressed the IL-6 promoter. The p53 mutants Val-135 and Phe-132 up-regulated IL-6 promoter activity in these cells at both 32.5 and 37-degrees-C. The temperature-sensitive Val-135 mutant was not only not inhibitory or ''wt-like'' at the lower temperature, but had gained a transcriptional activator phenotype which was temperature-independent in HeLa cells. The functional DNA target for transcriptional modulation of the IL-6 promoter by p53 species included the multiple cytokine- and second messenger-response element (-173 to -145); point mutations in the transcription factor C/EBPbeta-binding site within the second messenger-response element largely blocked the ability of p53 mutants Val-135 and Phe-132 to up-regulate this promoter. The up-regulation of IL-6 promoter constructs by co-transfection into HeLa cells of a C/EBPbeta constitutive expression vector was blocked in a dominant negative manner by wt p53. In contrast, the p53 mutants Val-135 and Phe-132 further enhanced C/EBPbeta-mediated up-regulation of IL-6 promoter constructs. The modulation of C/EBPbeta function by p53 species provides a basis for the involvement of p53 not only in the regulation of cytokine synthesis but also in the altered responsiveness of tumor cells to cytokines.	NEW YORK MED COLL, DEPT MED, VALHALLA, NY 10595 USA	New York Medical College	MARGULIES, L (corresponding author), NEW YORK MED COLL, DEPT MICROBIOL & IMMUNOL, VALHALLA, NY 10595 USA.				NIAID NIH HHS [AI-16262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1992, CIBA F SYMP, V167, P47; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHEN L, 1988, P NATL ACAD SCI USA, V85, P8037, DOI 10.1073/pnas.85.21.8037; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HIRANO T, 1992, CLIN IMMUNOL IMMUNOP, V62, pS60, DOI 10.1016/0090-1229(92)90042-M; ISSHIKI H, 1991, NEW BIOL, V3, P63; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NATSUKA S, 1992, BLOOD, V79, P460; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAY A, 1989, ANN NY ACAD SCI, V557, P353; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1991, P NATL ACAD SCI USA, V88, P7086, DOI 10.1073/pnas.88.16.7086; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TABIBZADEH SS, 1989, AM J PATHOL, V135, P427; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WIETZERBIN J, 1989, ANN NY ACAD SCI, V557, P162; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	55	113	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15096	15100						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325885				2022-12-25	WOS:A1993LL75900081
J	MCLAREN, RS; ROSS, J				MCLAREN, RS; ROSS, J			INDIVIDUAL PURIFIED CORE AND LINKER HISTONES INDUCE HISTONE-H4 MESSENGER-RNA DESTABILIZATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; GENE-EXPRESSION; DNA-REPLICATION; 3' END; STABILITY; TRANSCRIPTION; ACCUMULATION; DEGRADATION; SEQUENCES; KINETICS	The replication-dependent histone genes encode mRNAs that are expressed during S phase. When DNA synthesis ceases, histone mRNAs are rapidly degraded via the activation of a specific mRNA destabilization process. It has been proposed that this process is autoregulated by histone proteins and is triggered by an increase in the abundance of cytoplasmic histones that accompanies the cessation of DNA synthesis. Consistent with this proposal, all four core histones, in conjunction with cytosol, specifically trigger a 3-4-fold destabilization of polysome-associated histone mRNA in cell-free extracts. Here, we show that each individual purified core histone or purified linker histone H1 can autoregulate (destabilize) histone mRNA in vitro. Three basic polypeptides, protamines, poly-L-lysine, and poly-L-arginine, accelerate an early step in the decay pathway but do not fully autoregulate the mRNA. These data suggest that histones function by overcoming a holdup point at an early step in histone mRNA degradation and that unique properties of histones, aside from their basic domains, are necessary to trigger autoregulation.	UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA23076, CA07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023076, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALTERMAN RBM, 1984, MOL CELL BIOL, V4, P2364; BAUMBACH LL, 1987, BIOCHEMISTRY-US, V26, P6178, DOI 10.1021/bi00393a034; BAUMBACH LL, 1984, BIOCHEMISTRY-US, V23, P1618, DOI 10.1021/bi00303a006; BONNER WM, 1988, BIOCHEMISTRY-US, V27, P6542, DOI 10.1021/bi00417a052; BUTLER WB, 1973, BIOCHIM BIOPHYS ACTA, V294, P481, DOI 10.1016/0005-2787(73)90104-4; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; CROSS SL, 1988, MOL CELL BIOL, V8, P945, DOI 10.1128/MCB.8.2.945; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; GALLWITZ D, 1969, SCIENCE, V163, P1351, DOI 10.1126/science.163.3873.1351; GRUNSTEIN M, 1992, SCI AM, V267, P68, DOI 10.1038/scientificamerican1092-68; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE BJ, 1987, P NATL ACAD SCI USA, V84, P6189, DOI 10.1073/pnas.84.17.6189; LIU TJ, 1989, MOL CELL BIOL, V9, P3499, DOI 10.1128/MCB.9.8.3499; LUSCHER B, 1985, P NATL ACAD SCI USA, V82, P4389, DOI 10.1073/pnas.82.13.4389; LUSCHER B, 1987, EMBO J, V6, P1721, DOI 10.1002/j.1460-2075.1987.tb02423.x; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; MORRIS TD, 1991, MOL CELL BIOL, V11, P544, DOI 10.1128/MCB.11.1.544; OLIVER D, 1974, BIOCHEMISTRY-US, V13, P746, DOI 10.1021/bi00701a017; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PELTZ SW, 1987, MOL CELL BIOL, V7, P4345, DOI 10.1128/MCB.7.12.4345; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1986, MOL CELL BIOL, V6, P4362, DOI 10.1128/MCB.6.12.4362; ROSS J, 1987, J BIOL CHEM, V262, P9374; SARBIAN E, 1985, MOL CELL BIOL, V5, P1279; SCHUMPERLI D, 1986, CELL, V45, P471, DOI 10.1016/0092-8674(86)90277-1; SCHUMPERLI D, 1988, TRENDS GENET, V4, P187, DOI 10.1016/0168-9525(88)90074-1; SENSHU T, 1980, J BIOCHEM-TOKYO, V87, P1659, DOI 10.1093/oxfordjournals.jbchem.a132910; SENSHU T, 1979, J BIOCHEM, V86, P1259, DOI 10.1093/oxfordjournals.jbchem.a132641; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; Smith MM, 1991, CURR OPIN CELL BIOL, V3, P429, DOI 10.1016/0955-0674(91)90070-F; SMITH MM, 1988, J CELL BIOL, V106, P557, DOI 10.1083/jcb.106.3.557; STAUBER C, 1986, EMBO J, V5, P3297, DOI 10.1002/j.1460-2075.1986.tb04643.x; STAUBER C, 1988, NUCLEIC ACIDS RES, V16, P9399, DOI 10.1093/nar/16.20.9399; STEIN GS, 1984, MOL CELL BIOCHEM, V64, P105; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	43	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14637	14644						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325840				2022-12-25	WOS:A1993LL75900020
J	BOWES, AE; SAMAD, AH; JIANG, P; WEAVER, B; MELLORS, A				BOWES, AE; SAMAD, AH; JIANG, P; WEAVER, B; MELLORS, A			THE ACQUISITION OF LYSOPHOSPHATIDYLCHOLINE BY AFRICAN TRYPANOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; BLOOD-STREAM FORMS; ERYTHROCYTE-MEMBRANES; FATTY-ACIDS; BRUCEI; BIOSYNTHESIS; PHOSPHATIDYLCHOLINE; PRECURSORS; IDENTIFICATION	Bloodstream forms of the African trypanosome, Trypanosoma brucei, can acquire substantial amounts of exogenous lysophospholipid. Lysophosphatidylcholine uptake is through a pathway consisting of three enzymes, phospholipase A1, acyl-CoA ligase, and lysophosphatidylcholine: acyl-CoA acyltransferase. The pathway enables the organism to acquire fatty acids and phospholipid head groups such as choline. Radio-labeling and C-13 NMR studies show that two molecules of lysophosphatidylcholine are used to generate one molecule of cellular phosphatidylcholine. The three enzymes are associated with the trypanosomal plasma membrane and are accessible to exogenous substrates. The first enzyme, phospholipase A1, generates free fatty acid from exogenous lysophospholipid, which the second enzyme, a ligase, uses to form acyl-CoA. The fatty acyl-CoA formed by this route is in a separate pool from that derived from exogenous free fatty acid and is used by the third enzyme, acyltransferase, to acylate a second molecule of exogenous lysophospholipid. Acyltransferase is accessible to exogenous and endogenous acyl-CoA. The high activity of this pathway in bloodstream forms, compared with procyclic culture form trypanosomes, suggests that it may play a role in the acquisition of fatty acids for synthesis of the membrane form of the variant surface glycoprotein. Extracellular myristoyllysophosphatidylcholine can be used by trypanosomes as a source of myristate in remodeling the lipid anchor of the variant surface glycoprotein.	UNIV GUELPH,GUELPH WATERLOO CTR GRAD WORK CHEM,DEPT CHEM & BIOCHEM,GUELPH N1G 2W1,ONTARIO,CANADA	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry								BARANY M, 1987, BIOCHIM BIOPHYS ACTA, V923, P339, DOI 10.1016/0304-4165(87)90041-9; BARTANA J, 1971, BIOCHEM J, V122, P353, DOI 10.1042/bj1220353; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COLARD O, 1980, BIOCHIM BIOPHYS ACTA, V618, P88, DOI 10.1016/0005-2760(80)90056-9; CONDREA E, 1967, BIOCHIM BIOPHYS ACTA, V135, P669, DOI 10.1016/0005-2736(67)90097-1; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; CZICHOS J, 1986, EXP PARASITOL, V62, P283, DOI 10.1016/0014-4894(86)90033-0; DISE CA, 1980, J LIPID RES, V21, P292; DIXON H, 1972, COMP BIOCHEM PHYSIOL, V41, P1, DOI 10.1016/0305-0491(72)90002-8; DIXON H, 1970, COMP BIOCHEM PHYSIOL, V33, P111, DOI 10.1016/0010-406X(70)90487-1; DIXON H, 1971, COMP BIOCHEM PHYSIOL, V39, P247, DOI 10.1016/0305-0491(71)90168-4; DOERING TL, 1990, J BIOL CHEM, V265, P611; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; ERBLAND JF, 1965, BIOCHIM BIOPHYS ACTA, V106, P139, DOI 10.1016/0005-2760(65)90102-5; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; GALLO RL, 1984, ARCH BIOCHEM BIOPHYS, V235, P544, DOI 10.1016/0003-9861(84)90228-5; GODFREY D. G., 1958, EXPTL PARASITOL, V7, P255, DOI 10.1016/0014-4894(58)90022-5; Groot P H, 1976, Adv Lipid Res, V14, P75; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; HAMBREY PN, 1981, MOL BIOCHEM PARASIT, V2, P177, DOI 10.1016/0166-6851(81)90098-0; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENON AK, 1990, J BIOL CHEM, V265, P9033; MOLYNEUX DH, 1983, BIOL TRYPANOSOMA LEI, P13; MORAND O, 1985, BIOCHIM BIOPHYS ACTA, V835, P68, DOI 10.1016/0005-2760(85)90031-1; NYE WH, 1961, J CLIN INVEST, V40, P1194, DOI 10.1172/JCI104349; OLIVEIRA MM, 1964, J LIPID RES, V5, P156; OPPERDOES FR, 1982, MOL BIOCHEM PARASIT, V5, P309, DOI 10.1016/0166-6851(82)90038-X; PAIGE LA, 1989, J MED CHEM, V32, P1665, DOI 10.1021/jm00128a001; PORTMAN OW, 1973, BIOCHIM BIOPHYS ACTA, V326, P34, DOI 10.1016/0005-2760(73)90025-8; RENOOIJ W, 1974, BIOCHIM BIOPHYS ACTA, V363, P287, DOI 10.1016/0005-2736(74)90069-8; RENOOIJ W, 1976, EUR J BIOCHEM, V61, P53, DOI 10.1111/j.1432-1033.1976.tb09996.x; RIFKIN MR, 1985, MOL BIOCHEM PARASIT, V15, P245, DOI 10.1016/0166-6851(85)90088-X; ROBERTS MF, 1990, METHOD ENZYMOL, V197, P31; SAGE L, 1981, TROPENMED PARASITOL, V32, P215; SAMAD A, 1988, MOL BIOCHEM PARASIT, V29, P159, DOI 10.1016/0166-6851(88)90071-0; SAVARD JD, 1982, BIOCHIM BIOPHYS ACTA, V711, P40, DOI 10.1016/0005-2760(82)90007-8; SCHMIDT CF, 1977, BIOCHEMISTRY-US, V16, P3948, DOI 10.1021/bi00637a002; SHAPIRO SZ, 1986, EXP PARASITOL, V61, P432, DOI 10.1016/0014-4894(86)90199-2; Shohet S. B, 1970, Biochim. biophys. Acta, V202, P202, DOI 10.1016/0005-2760(70)90237-7; STEIN O, 1967, BIOCHIM BIOPHYS ACTA, V137, P232, DOI 10.1016/0005-2760(67)90099-9; STEIN Y, 1966, BIOCHIM BIOPHYS ACTA, V116, P95, DOI 10.1016/0005-2760(66)90095-6; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1058, DOI 10.1515/bchm2.1971.352.2.1058; TAMURA A, 1985, J BIOCHEM-TOKYO, V97, P353, DOI 10.1093/oxfordjournals.jbchem.a135060; TETLEY L, 1987, J CELL SCI, V87, P363; VIAL HJ, 1982, J PARASITOL, V68, P379, DOI 10.2307/3280946; VOORHEIS HP, 1980, MOL BIOCHEM PARASIT, V1, P177, DOI 10.1016/0166-6851(80)90016-X; WEBSTER P, 1989, EUR J CELL BIOL, V49, P295; ZEISEL SH, 1981, ANNU REV NUTR, V1, P95, DOI 10.1146/annurev.nu.01.070181.000523	59	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13885	13892						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314756				2022-12-25	WOS:A1993LJ82500020
J	SINGERKRUGER, B; FRANK, R; CRAUSAZ, F; RIEZMAN, H				SINGERKRUGER, B; FRANK, R; CRAUSAZ, F; RIEZMAN, H			PARTIAL-PURIFICATION AND CHARACTERIZATION OF EARLY AND LATE ENDOSOMES FROM YEAST - IDENTIFICATION OF 4 NOVEL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR PHEROMONE; RECEPTOR-MEDIATED ENDOCYTOSIS; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; PLASMA-MEMBRANE; KEX2 PROTEASE; GOLGI STACK; STE2 GENE; TRANSPORT; FUSION	Previously (Singer, B., and Riezman, H. (1990) J. Cell Biol. 110, 1911-1922), we provided evidence for the existence of an endocytic intermediate(s) from the yeast Saccharomyces cerevisiae that is responsible for the transport of the pheromone alpha-factor from the plasma membrane to the vacuole. Here we show by kinetic analysis that the endocytic apparatus of yeast is composed of early and late endosomes, similar to what has been found in animal cells. We have developed a three-step isolation procedure to purify early and late endosomes, consisting of differential centrifugation, flotation on a Nycodenz density gradient, and sedimentation density gradient centrifugation on sucrose/D2O. Using internalized S-35-alpha-factor as a marker, the endosomal fractions were substantially enriched over other membranes, except for Golgi elements and a compartment containing binding protein. These contaminants could not be removed by other standard purification methods. We have analyzed the protein composition of our most pure early and late endosome fractions. By two-dimensional gel analysis we identified more than 20 protein spots that are highly enriched in the early/late endosomal fractions. N-terminal protein sequencing resulted in the identification of four novel proteins.	UNIV BASEL, BIOCTR, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND; ZENTRUM MOLEK BIOL HEIDELBERG, W-6900 HEIDELBERG, GERMANY	University of Basel; Ruprecht Karls University Heidelberg				Riezman, Howard/0000-0003-4680-9422				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DULIC V, 1991, METHOD ENZYMOL, V194, P697; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GAUSEPOHL H, 1986, ADV METHODS PROTEIN, P149; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; KREIBICH G, 1973, J CELL BIOL, V58, P436, DOI 10.1083/jcb.58.2.436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; RIEZMAN H, 1992, NATO ASI SERIES H, V62, P467; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104	46	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14376	14386						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314797				2022-12-25	WOS:A1993LJ82500085
J	BRIGLE, KE; SEITHER, RL; WESTIN, EH; GOLDMAN, ID				BRIGLE, KE; SEITHER, RL; WESTIN, EH; GOLDMAN, ID			INCREASED EXPRESSION AND GENOMIC ORGANIZATION OF A FOLATE-BINDING PROTEIN HOMOLOGOUS TO THE HUMAN PLACENTAL ISOFORM IN L1210 MURINE LEUKEMIA-CELL LINES WITH A DEFECTIVE REDUCED FOLATE CARRIER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT CARRIER; KB CELLS; MEMBRANE; METHOTREXATE; RECEPTOR; SEQUENCE; CLONING; CDNA; GENE; DNA	This laboratory previously described an L1210 leukemia cell line (MTX(r)A) selected for resistance to methotrexate by virtue of impaired transport. In this line, the reduced folate carrier had unchanged affinity for methotrexate, was present at the cell surface in usual quantity, but did not deliver drug into the cell, indicative of a functional defect in the translocation process. In this study, we further characterize this cell line along with a subline (F2-MTX(r)A) selected for growth in low levels of folic acid. This subline demonstrates continued high resistance to methotrexate and very low influx of [H-3]methotrexate and 5-[H-3]formyltetrahydrofolate, indicating the persistence of the defect in the reduced folate carrier. Both MTX(r)A and F2-MTX(r)A are shown to overexpresses FBP2, the murine homolog of a folate-binding protein initially isolated from human placenta. Compared with parent L1210 cells, Northern analysis revealed FBP2 expression to be elevated 40 fold in the MTX(r)A line and 500-fold in F2-MTX(r)A. The large increase in FBP2 expression in the F2-MTX(r)A line correlates with a 10-fold increase in [H-3]folic acid membrane surface binding and a 1000-fold decrease in the folic acid growth requirement compared with parental L1210 cells. Also, there are 20- and 500-fold decreases in the 5-formyltetrahydrofolate growth requirement compared with parent L1210 and MTX(r)A cells, respectively. Finally, the genomic organization of the FBP2 locus is presented. The results of Northern analyses using probes specific to FBP2 5'-untranslated sequences or to a splice junction within this region suggest that the up-regulated FBP2-specific message in F2- MTX(r)A utilizes 5'-noncoding se quences distinct from those used in the message encoded in L1210 cell lines with low level FBP2 expression. The MTX(r)A cells provide an example of a line selected for primary resistance to methotrexate that also exhibits concomitant increased expression of a folate-binding protein. Further overexpression of this folate binding protein (which has homology to that initially identified in placenta) provides cells with the ability to meet cellular folate needs in a folate deprived environment.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09340, CA-39807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRIGLE KE, 1992, J BIOL CHEM, V267, P22351; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1994, IN PRESS BIOCH PHARM; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CAVALCANTI F, 1992, CELL BIOCHEM FUNCT, V10, P1, DOI 10.1002/cbf.290100102; CONEY LR, 1991, CANCER RES, V51, P6125; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FRY DW, 1979, J MEMBRANE BIOL, V50, P123, DOI 10.1007/BF01868944; FRY DW, 1982, J MEMBRANE BIOL, V66, P87, DOI 10.1007/BF01868485; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; JANSEN G, 1989, CANCER RES, V49, P1959; JANSEN G, 1989, CANCER RES, V49, P2455; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LICHTENSTEIN NS, 1969, BIOCHIM BIOPHYS ACTA, V193, P456, DOI 10.1016/0005-2736(69)90204-1; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; PAIN ST, 1993, J MOL BIOL, V229, P1175; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1992, BIOCHIM BIOPHYS ACTA, V1131, P91, DOI 10.1016/0167-4781(92)90103-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898	31	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4267	4272						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307991				2022-12-25	WOS:A1994MW98900058
J	MCCARTHY, SA; BICKNELL, R				MCCARTHY, SA; BICKNELL, R			ACTIVIN-A BINDS TO A HETEROTRIMERIC RECEPTOR COMPLEX ON THE VASCULAR ENDOTHELIAL-CELL SURFACE - EVIDENCE FOR A TYPE-3 ACTIVIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ERYTHROID-DIFFERENTIATION FACTOR; SERINE THREONINE KINASE; MONOCLONAL-ANTIBODIES; EXPRESSION CLONING; BETA; IDENTIFICATION; LEUKEMIA; INHIBIN; SYSTEM	The effect of transfection of the type 2 activin receptor, ACTR2, on binding of I-125-activin-A to the surface of bovine aortic endothelial cells (BAEC) was investigated. BAEC transfected either with full-length ACTR2 or with a truncated form of ACTR2 lacking the intracellular kinase domain (ACTR2T) displayed two classes of I-125-activin-A binding sites, one of high affinity (K-d = 250-254 pM) and one of low affinity (K-d = 6.5-16 nM). Affinity labeling of ACTR2-transfected BAEC with I-125-activin-A revealed labeled species of 55, 95, 100, and 160 kDa, all four of which were immunoprecipitated by an anti-ACTR2 monoclonal antibody. Only the 95- and 100-kDa species, however, were immunoprecipitated following denaturation of the affinity-labeled cell lysate with SDS. BAEC transfected with an epitope-tagged form of ACTR2T (ACTR2TMyc) displayed intense 55- and 70-kDa affinity-labeled forms of the truncated receptor, together with a 160-kDa species. As with the full-length receptor, the 160-kDa species associated non-covalently with ACTR2TMyc. These data indicate that, in vascular endothelial cells, ACTR2 forms a high affinity heterotrimeric receptor complex with activin binding proteins characteristic of type 1 and type 3 activin receptors, and that formation of the complex does not require the kinase domain of ACTR2.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,MOLEC ANGIOGENESIS GR,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford			McCarthy, Sarah/HCI-8963-2022	Bicknell, Roy/0000-0002-0941-8919				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, pCH15; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CAMPEN CA, 1988, BIOCHEM BIOPH RES CO, V157, P844, DOI 10.1016/S0006-291X(88)80326-7; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CHIEFETZ S, 1992, J BIOL CHEM, V267, P19027; CHIEFETZ S, 1987, CELL, V48, P409; DEJONG FH, 1988, PHYSIOL REV, V68, P555, DOI 10.1152/physrev.1988.68.2.555; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GROOME N, 1991, HYBRIDOMA, V10, P309, DOI 10.1089/hyb.1991.10.309; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HINO M, 1989, J BIOL CHEM, V264, P10309; KONDO S, 1989, BIOCHEM BIOPH RES CO, V161, P1267, DOI 10.1016/0006-291X(89)91379-X; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCCARTHY SA, 1993, J BIOL CHEM, V268, P23066; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SHAO LE, 1992, BLOOD, V79, P773; SUGINO H, 1988, J BIOL CHEM, V263, P15249; VALE W, 1990, PEPTIDE GROWTH FACTO, P211; WANG XF, 1991, CELL, V67, P796; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	34	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3909	3912						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307945				2022-12-25	WOS:A1994MW98900002
J	YU, L; GOLDBERG, IH; DEDON, PC				YU, L; GOLDBERG, IH; DEDON, PC			ENEDIYNE-MEDIATED DNA-DAMAGE IN NUCLEI IS MODULATED AT THE LEVEL OF THE NUCLEOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PARTICLE; DEOXYRIBONUCLEIC-ACID; ANTITUMOR ANTIBIOTICS; NEOCARZINOSTATIN CHROMOPHORE; CALICHEAMICIN GAMMA-1(I); AFLATOXIN-B1 ADDUCTION; CHROMATIN STRUCTURE; ETHIDIUM-BROMIDE; MINOR-GROOVE; CLEAVAGE	DNA damage in HeLa nuclei and isolated nucleosome core particles has been examined for several members of the enediyne family of antitumor antibiotics: calicheamicin gamma(1)(I) (CAL), esperamicin A(1) (ESP A1), esperamicin C (ESP C), and neocarzinostatin (NCS). In nuclei, both NCS and ESP A1 produced DNA damage limited to the linker region of the nucleosome, while CAL and ESP C, an analog of ESP A1 missing the deoxyfucose-anthranilate moiety, damaged both the core and linker DNA. DNA fragments produced by CAL and ESP C in the nucleosome core occurred with a 10-11-nucleotide periodicity similar to that produced by DNase I, while damage produced by NCS and ESP A1 appeared to be limited to the terminal portions of the core DNA The damage in nuclei is shown to be caused directly by the drugs with little contribution from endogenous factors, such as nucleases and topoisomerases. Features of drug structure that may limit damage to the nucleosome core include the presence of substituents on both sides of the CAL/ESP-type core, and the presence of an intercalating moiety, such as the naphthoate of NCS and possibly the anthranilate of ESP A1.	MIT,DIV TOXICOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School				Dedon, Peter/0000-0003-0011-3067	NCI NIH HHS [CA44257, CA57633] Funding Source: Medline; NIEHS NIH HHS [ES02190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044257, R01CA057633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BECKMANN RP, 1987, BIOCHEMISTRY-US, V26, P5409, DOI 10.1021/bi00391a029; BEERMAN TA, 1983, MOL PHARMACOL, V23, P493; BENNETT RAO, 1993, BIOCHEMISTRY-US, V32, P3188, DOI 10.1021/bi00063a034; CARTWRIGHT IL, 1983, P NATL ACAD SCI-BIOL, V80, P3213, DOI 10.1073/pnas.80.11.3213; CARTWRIGHT IL, 1982, NUCLEIC ACIDS RES, V10, P5835, DOI 10.1093/nar/10.19.5835; CECH T, 1977, CELL, V11, P631, DOI 10.1016/0092-8674(77)90080-0; CHAIRES JB, 1983, BIOCHEMISTRY-US, V22, P284, DOI 10.1021/bi00271a009; CHIN DH, 1986, BIOCHEMISTRY-US, V25, P1009, DOI 10.1021/bi00353a009; CHRISTNER DF, 1992, J AM CHEM SOC, V114, P8763, DOI 10.1021/ja00049a002; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DASGUPTA D, 1985, BIOCHEMISTRY-US, V24, P7049, DOI 10.1021/bi00346a004; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DEDON PC, 1990, J BIOL CHEM, V265, P14713; DEDON PC, 1992, BIOCHEMISTRY-US, V31, P1917, DOI 10.1021/bi00122a004; DEDON PC, 1992, NUCLEIC ACID TARGETE, P475; DING WD, 1991, J AM CHEM SOC, V113, P6617, DOI 10.1021/ja00017a038; DRAK J, 1991, P NATL ACAD SCI USA, V88, P7464, DOI 10.1073/pnas.88.17.7464; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; FEIGON J, 1979, NUCLEIC ACIDS RES, V6, P2327, DOI 10.1093/nar/6.6.2327; GOLDBERG IH, 1991, ACCOUNTS CHEM RES, V24, P191, DOI 10.1021/ar00007a001; GOPALAKRISHNAN S, 1989, BIOCHEMISTRY-US, V28, P726, DOI 10.1021/bi00428a047; HATAYAMA T, 1979, BIOCHIM BIOPHYS ACTA, V563, P59, DOI 10.1016/0005-2787(79)90007-8; HATAYAMA T, 1982, BIOCHEM BIOPH RES CO, V104, P889, DOI 10.1016/0006-291X(82)91332-8; HAWLEY RC, 1989, P NATL ACAD SCI USA, V86, P1105, DOI 10.1073/pnas.86.4.1105; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HEARST JE, 1989, CHEM RES TOXICOL, V2, P69, DOI 10.1021/tx00008a001; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HURLEY I, 1982, BIOCHEMISTRY-US, V21, P4999, DOI 10.1021/bi00263a025; IRVIN TR, 1984, P NATL ACAD SCI-BIOL, V81, P664, DOI 10.1073/pnas.81.3.664; KAPPEN LS, 1993, SCIENCE, V261, P1319, DOI 10.1126/science.8362243; KAPPEN LS, 1987, BIOCHEMISTRY-US, V26, P384, DOI 10.1021/bi00376a008; KAPPEN LS, 1992, P NATL ACAD SCI USA, V89, P6706, DOI 10.1073/pnas.89.15.6706; KAPPEN LS, 1992, BIOCHEMISTRY-US, V31, P9081, DOI 10.1021/bi00152a052; KUO MT, 1978, NATURE, V271, P83, DOI 10.1038/271083a0; KUO MT, 1978, BIOCHIM BIOPHYS ACTA, V518, P186, DOI 10.1016/0005-2787(78)90129-6; LEE MD, 1991, ACCOUNTS CHEM RES, V24, P235, DOI 10.1021/ar00008a003; LEET JE, 1992, J AM CHEM SOC, V114, P7946, DOI 10.1021/ja00046a071; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; LONG BH, 1989, P NATL ACAD SCI USA, V86, P2, DOI 10.1073/pnas.86.1.2; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MCHUGH MM, 1982, BIOCHIM BIOPHYS ACTA, V696, P7, DOI 10.1016/0167-4781(82)90003-3; MCMURRAY CT, 1991, BIOCHEMISTRY-US, V30, P5631, DOI 10.1021/bi00237a001; MCMURRAY CT, 1991, BIOCHEMISTRY-US, V30, P5644, DOI 10.1021/bi00237a002; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; MCMURRAY CT, 1985, BIOCHEMISTRY-US, V24, P7037, DOI 10.1021/bi00346a002; MOORE CW, 1988, CANCER RES, V48, P6837; MOYER R, 1989, J BIOL CHEM, V264, P12226; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; PAOLETTI J, 1977, BIOCHEMISTRY-US, V16, P351, DOI 10.1021/bi00622a002; POVIRK LF, 1985, P NATL ACAD SCI USA, V82, P3182, DOI 10.1073/pnas.82.10.3182; POVIRK LF, 1980, BIOCHEMISTRY-US, V19, P4773, DOI 10.1021/bi00562a009; POVIRK LF, 1979, BIOCHEMISTRY-US, V18, P96, DOI 10.1021/bi00568a015; POVIRK LF, 1988, BIOCHEMISTRY-US, V27, P3850, DOI 10.1021/bi00410a049; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P4007, DOI 10.1021/bi00517a009; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Sambrook J, 1989, MOL CLONING LABORATO; SUGIURA Y, 1989, P NATL ACAD SCI USA, V86, P7672, DOI 10.1073/pnas.86.20.7672; SUGIURA Y, 1990, P NATL ACAD SCI USA, V87, P3831, DOI 10.1073/pnas.87.10.3831; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; UESUGI M, 1993, BIOCHEMISTRY-US, V32, P4622, DOI 10.1021/bi00068a020; van Holde KE., 1989, SPRINGER SERIES MOL; WALKER S, 1992, P NATL ACAD SCI USA, V89, P4608, DOI 10.1073/pnas.89.10.4608; WALKER S, 1993, J AM CHEM SOC, V115, P7954, DOI 10.1021/ja00071a004; WILLIAMS LD, 1988, BIOCHEMISTRY-US, V27, P3004, DOI 10.1021/bi00408a051; WILLIAMS LD, 1988, NUCLEIC ACIDS RES, V16, P11607, DOI 10.1093/nar/16.24.11607; WOLFFE A, 1992, CHROMATIN STRUCTURE; YAGER TD, 1984, J BIOL CHEM, V259, P4212; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; ZEIN N, 1989, SCIENCE, V244, P697, DOI 10.1126/science.2717946; ZEIN N, 1988, SCIENCE, V240, P1198, DOI 10.1126/science.3240341; ZHAO B, 1990, CANCER LETT, V50, P141, DOI 10.1016/0304-3835(90)90244-R	76	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4144	4151						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307975				2022-12-25	WOS:A1994MW98900040
J	LOYER, P; GLAISE, D; CARIOU, S; BAFFET, G; MEIJER, L; GUGUENGUILLOUZO, C				LOYER, P; GLAISE, D; CARIOU, S; BAFFET, G; MEIJER, L; GUGUENGUILLOUZO, C			EXPRESSION AND ACTIVATION OF CDK-1 AND CDK-2 AND CYCLINS IN THE CELL-CYCLE PROGRESSION DURING LIVER-REGENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC2 PROTEIN-KINASE; TRANSCRIPTION FACTOR E2F; XENOPUS EGG EXTRACTS; FISSION YEAST; S-PHASE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; REGULATED EXPRESSION; HISTONE-H1 KINASE	In normal adult liver, hepatocytes are arrested in G0, and they rapidly respond to a mass loss by a definite number of divisions. Thus, taking advantage of the in vivo regenerative capacity of the liver following partial hepatectomy, we have analyzed both expression and activation of p34cdc2 (= cdk1) and p33cdk2 through the cell cycle, particularly during the long lasting G1 phase and in the G1/S transition. While p33cdk2 is constantly expressed during the cell cycle, p34cdc2 is completely absent in resting hepatocytes and remains unexpressed for up to 20 h after partial hepatectomy, a time period corresponding to the G1 phase and G1/S transition, and then accumulates in the S, G2, and M phases. No histone H1 kinase activity is detected during the G1 phase, while two peaks of p34cdc2 kinase activity are observed during the S and M phases and only one peak of p33cdk2 kinase activity in the S phase. p34cdc2 forms complexes with both cyclins A and B while p33cdk2 is associated with cyclin A only. Surprisingly, cyclins E and D1 are present in resting liver and with modest variation throughout the cell cycle. Taken together, our data provide evidence that the pattern of G1-associated proteins in hepatocytes during liver regeneration is distinct from that described in other cell types.	STN BIOL,CNRS,F-29680 ROSCOF,FRANCE	Centre National de la Recherche Scientifique (CNRS)	LOYER, P (corresponding author), HOP PONTCHAILLOU,UNITE RECH HEPATOL,INSERM,U49,F-35033 RENNES,FRANCE.		Baffet, Georges/I-2574-2015; LOYER, Pascal/K-1838-2019; Baffet, Georges/M-1583-2016	LOYER, PASCAL/0000-0002-5656-2673; , laurent/0000-0003-3511-4916				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AKHURST RJ, 1989, DIFFERENTIATION, V40, P36, DOI 10.1111/j.1432-0436.1989.tb00811.x; ANDREWS GK, 1982, J BIOL CHEM, V257, P5148; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AZZI L, 1992, EUR J BIOCHEM, V203, P353, DOI 10.1111/j.1432-1033.1992.tb16557.x; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FABRIKANT JI, 1968, J CELL BIOL, V36, P551, DOI 10.1083/jcb.36.3.551; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRISHAM JW, 1962, CANCER RES, V22, P842; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HADWIGER JA, 1989, MOL CELL BIOL, V9, P6255; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; Higgins GM, 1931, ARCH PATHOL, V12, P186; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P112; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LU XP, 1992, J BIOL CHEM, V267, P2841; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYMONDJEAN M, 1983, BIOCHIM BIOPHYS ACTA, V741, P30, DOI 10.1016/0167-4781(83)90006-4; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON NL, 1986, CANCER RES, V46, P3111; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	73	127	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2491	2500						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300575				2022-12-25	WOS:A1994MV43200025
J	ROBINSON, GLWG; PESHAVARIA, M; HENDERSON, E; SHIEH, SY; TSAI, MJ; TEITELMAN, G; STEIN, R				ROBINSON, GLWG; PESHAVARIA, M; HENDERSON, E; SHIEH, SY; TSAI, MJ; TEITELMAN, G; STEIN, R			EXPRESSION OF THE TRANSACTIVE FACTORS THAT STIMULATE INSULIN CONTROL ELEMENT-MEDIATED ACTIVITY APPEAR TO PRECEDE INSULIN GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; BETA-CELL LINES; II GENE; NEGATIVE REGULATION; ENDOCRINE PANCREAS; RIBONUCLEIC-ACID; ISLET HORMONES; ENHANCER; PROMOTER; MYOD	Cell type-specific expression of the major differentiated products of alpha (glucagon) and beta (insulin) cells are regulated by sequences found within their 5'-flanking region. Specific transcription of the insulin gene appears to be principally controlled by a single cis-acting DNA element, termed the insulin control element (ICE). The ICE activator acts in combination with other positive regulatory factors that interact within this region to generate the correct, cell type-specific expression. In the present study, we show that the ICE activator is not only present but is functionally active in the islet glucagon-producing alpha cell line, alphaTC6. Analysis of the expression of various transfected insulin enhancer expression plasmids demonstrated that the insulin enhancer is active in alphaTC6 cells, although at a lower level than in beta cells. The reduced transcription from these constructs appears to be a consequence of the lack of other essential positive regulator(s). The alphaTC6 cells were also shown to display neuronal-like properties. Since islet cells appear to evolve from an alpha-like precursor cell that transiently expresses neuronal cell markers, these results would indicate that the ICE activator factor is induced before transcription of the insulin gene in the developing islet.	VANDERBILT UNIV,MED CTR,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	Vanderbilt University; Baylor College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center			Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430; Teitelman, Gladys/0000-0003-0687-3032	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BUCCHINI D, 1986, P NATL ACAD SCI USA, V83, P2511, DOI 10.1073/pnas.83.8.2511; CAMPOSORTEGA JA, 1990, ANNU REV GENET, V24, P387; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRAPKIEWICZ NB, 1989, NUCLEIC ACIDS RES, V17, P6651, DOI 10.1093/nar/17.16.6651; CORDLE SR, 1991, MOL CELL BIOL, V11, P2881, DOI 10.1128/MCB.11.5.2881; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DEKRIJGER RR, 1992, DEV BIOL, V153, P368, DOI 10.1016/0012-1606(92)90121-V; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUNNING P, 1983, MOL CELL BIOL, V3, P854; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HEINRICH G, 1984, ENDOCRINOLOGY, V115, P2176, DOI 10.1210/endo-115-6-2176; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LUKINIUS A, 1992, DEV BIOL, V153, P376, DOI 10.1016/0012-1606(92)90122-W; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Peters A., 1991, FINE STRUCTURE NERVO; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SELDEN RF, 1986, NATURE, V321, P525, DOI 10.1038/321525a0; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; TAMKUN MM, 1991, FASEB J, V5, P332; TEITELMAN G, 1990, DEV BIOL, V142, P368, DOI 10.1016/0012-1606(90)90357-O; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VILLAKOMAROFF L, 1978, P NATL ACAD SCI USA, V75, P3727, DOI 10.1073/pnas.75.8.3727; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564	47	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2452	2460						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300572				2022-12-25	WOS:A1994MV43200020
J	BAGAI, S; SARKAR, DP				BAGAI, S; SARKAR, DP			FUSION-MEDIATED MICROINJECTION OF LYSOZYME INTO HEPG2 CELLS THROUGH HEMAGGLUTININ NEURAMINIDASE-DEPLETED SENDAI VIRUS ENVELOPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC ASIALOGLYCOPROTEIN RECEPTOR; ADULT-RAT LIVER; INSULIN MOLECULES; DRUG DELIVERY; PROTEINS; ANTIBODIES; GLYCOPROTEINS; DEGRADATION; LIPOSOMES; VESICLES	The potential of reconstituted Sendai viral envelopes containing only the fusion protein (F-virosomes) was evaluated for a targeted cytosolic delivery of lysozyme to human hepatoblastoma cells (HepG2) in culture. I-125-Lysozyme loaded into F-virosomes was used to monitor its fusion-mediated transfer to the HepG2 cells. Using fusion assay based on the transfer of water soluble probe, we have demonstrated the existence of aqueous connection between F-virosomes and target cells. Target specificity of the F-virosomes was ensured by the strong interaction between terminal 6-galactose moiety of F protein and the asialoglycoprotein receptor on the membrane of HepG2 cells. Incubation of the loaded F-virosomes with cells resulted in fusion-mediated injection, as inferred from the ability of cells to internalize lysozyme in the presence of azide (an inhibitor of the endocytotic process). Binding as well as fusion of the F-virosomes to HepG2 cells was solely mediated by the F protein. Introduction of I-125-lysozyme into the HepG2 cells was confirmed by selective accumulation of acid and antibody-precipitable radioactivity in the cytosolic compartment. The structural integrity of the internalized lysozyme was also assessed. The potential usefulness of F-virosomes with defined specificities as biological carrier for both in vitro and in vivo cytosolic delivery of macromolecules and drugs has been established.	UNIV DELHI S CAMPUS, DEPT BIOCHEM, BENITO JUAREZ ROAD, NEW DELHI 110021, INDIA	University of Delhi				Sarkar, Debi P/0000-0002-8886-8415				Aronson N N Jr, 1974, Methods Enzymol, V31, P90; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAGAI S, 1993, J VIROL, V67, P3312, DOI 10.1128/JVI.67.6.3312-3318.1993; BAGAI S, 1993, FEBS LETT, V326, P183, DOI 10.1016/0014-5793(93)81787-Z; BAGAI S, 1993, IN PRESS BIOCH BIOPH; Bayer E A, 1980, Methods Biochem Anal, V26, P1; BIJSTERBOSCH MK, 1992, MOL PHARMACOL, V41, P404; BLUMENTHAL R, 1991, TRENDS BIOTECHNOL, V9, P41, DOI 10.1016/0167-7799(91)90013-8; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; CITOVSKY V, 1985, J BIOL CHEM, V260, P2072; DASGUPTA P, 1985, BIOCHEM INT, V10, P327; DRAGSTEN PR, 1987, BIOCHIM BIOPHYS ACTA, V926, P270, DOI 10.1016/0304-4165(87)90213-3; ELLENS H, 1989, METHOD CELL BIOL, V31, P155; GITMAN AG, 1984, J BIOL CHEM, V259, P9813; GITMAN AG, 1985, P NATL ACAD SCI USA, V82, P7309, DOI 10.1073/pnas.82.21.7309; GITMAN AG, 1985, BIOCHEMISTRY-US, V24, P2762, DOI 10.1021/bi00332a025; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HSU MC, 1979, VIROLOGY, V95, P476, DOI 10.1016/0042-6822(79)90502-6; HUNTER W, 1978, HDB EXPT IMMUNOLOGY; KALTENBACH JP, 1958, EXP CELL RES, V15, P112, DOI 10.1016/0014-4827(58)90067-3; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANEDA Y, 1989, J BIOL CHEM, V264, P12126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOYTER A, 1984, CIBA F SYMP, V103, P163; LOYTER A, 1991, MEMBRANE FUSION, P731; Markwell M A, 1981, Methods Enzymol, V72, P296; MARKWELL MAK, 1985, P NATL ACAD SCI USA, V82, P978, DOI 10.1073/pnas.82.4.978; NICOLSON GL, 1972, BIOCHIM BIOPHYS ACTA, V266, P543, DOI 10.1016/0005-2736(72)90109-5; NUSSBAUM O, 1984, VIROLOGY, V138, P185, DOI 10.1016/0042-6822(84)90344-1; Okada Y., 1988, TRANSPORT-VILNIUS, P297, DOI [10.1016/S0070-2161(08)60138-0, DOI 10.1016/S0070-2161(08)60138-0]; PERETZ H, 1974, J CELL BIOL, V63, P1, DOI 10.1083/jcb.63.1.1; RECHSTEINER M, 1984, CIBA F SYMP, V103, P181; REDDY R, 1992, J IMMUNOL, V148, P1585; SARKAR DP, 1989, J CELL BIOL, V109, P113, DOI 10.1083/jcb.109.1.113; SARKAR DP, 1988, MEMBRANE BIOCHEM, V7, P231, DOI 10.3109/09687688709029434; SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4; SCHERPHOF GL, 1986, LIPIDS MEMBRANES PAS, P113; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SCHWARTZ AL, 1991, LIVER DISEASES TARGE, P3; SECHOY O, 1989, EXP CELL RES, V185, P122, DOI 10.1016/0014-4827(89)90042-6; SZOKA FC, 1991, MEMBRANE FUSION, P845; TAKENAKA A, 1989, INT J BIOCHEM, V21, P497; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAINSTEIN A, 1984, BIOCHIM BIOPHYS ACTA, V773, P181, DOI 10.1016/0005-2736(84)90081-6; YOSHIMA H, 1981, J BIOL CHEM, V256, P5355	49	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1966	1972						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294448				2022-12-25	WOS:A1994MR98800065
J	KLODOS, I; POST, RL; FORBUSH, B				KLODOS, I; POST, RL; FORBUSH, B			KINETIC HETEROGENEITY OF PHOSPHOENZYME OF NA,K-ATPASE MODELED BY UNMIXED LIPID PHASES - COMPETENCE OF THE PHOSPHOINTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; SENSITIVE PHOSPHORYLATED INTERMEDIATE; PIG-KIDNEY; ATPASE ACTIVITY; NA+/K+-ATPASE; ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; MEMBRANE-VESICLES; OUTER MEDULLA; SODIUM-PUMP	Interconversion of phosphoenzyme resistant to K+ and sensitive to ADP (E1P) and phosphoenzyme resistant to ADP and sensitive to K+ (E2P) was studied in bovine brain and dog and pig kidney. The kinetics of dephosphorylation were observed by chasing phosphoenzyme formed from [P-32]ATP with unlabeled ATP with or without ADP or K+. Phosphorylation in 0.6-1.0 m NaCl produced mostly ADP-sensitive potassium-insensitive E1P. A potassium chase of this phosphoenzyme exposed its rate of conversion to potassium-sensitive ADP-insensitive E2P. At 20-degrees-C the rate constant was approximately 1 s-1. Simultaneous dilution of [NaCl] in the chase to 100 mm increased the constant to approximately 60 s-1, which probably qualifies E1P as an intermediate in Na,K-ATPase activity. Anions inhibited conversion according to a Hofmeister series. Na+ had no specific effect. At 0-degrees-C the rate constant was < 0.4 s-1, but downward jumps in [salt] produced an acceleration to > 1 s-1 for < 3 s followed by a return to the slow rate. The rapid rate would qualify E1P to participate in Na,K-ATPase activity if this rapid state participates in the normal reaction cycle. Phosphorylation in 0.02-0.1 m NaCl produced mostly E2P. Upward jumps in [NaCl] converted E2P to E1P equally rapidly and transiently. Oligomycin and high [salt] cooperated in stabilizing E1P. Jumps in [salt] greatly and transiently increased the rate of conversion of one form of the phosphoenzyme to the other. This extraordinary result required heterogeneous kinetics. A model is proposed based on control of enzyme conformation by changes in separate unmixed phases of the lipid of the membrane.	UNIV PENN, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	University of Pennsylvania; Yale University	KLODOS, I (corresponding author), AARHUS UNIV, INST BIOPHYS, OLE WORMS ALLE 185, DK-8000 AARHUS, DENMARK.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031782] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31782] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; ASTURIAS FJ, 1990, BIOPHYS J, V58, P205, DOI 10.1016/S0006-3495(90)82366-3; BIGELOW DJ, 1992, J BIOL CHEM, V267, P6952; BULTMANN T, 1991, BIOCHEMISTRY-US, V30, P5573, DOI 10.1021/bi00236a033; BURACK WR, 1993, BIOCHEMISTRY-US, V32, P583, DOI 10.1021/bi00053a025; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; FORBUSH B, 1984, ANAL BIOCHEM, V140, P495, DOI 10.1016/0003-2697(84)90200-8; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FORBUSH B, 1991, SOC GEN PHY, V46, P211; FORTES PAG, 1984, J BIOL CHEM, V259, P1176; FROEHLICH JP, 1991, SOC GEN PHY, V46, P227; Glynn I M, 1988, Prog Clin Biol Res, V268A, P435; HARA Y, 1981, J BIOCHEM, V90, P923, DOI 10.1093/oxfordjournals.jbchem.a133580; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hobbs A. S., 1985, SODIUM PUMP, P355; HOBBS AS, 1983, J BIOL CHEM, V258, P8163; HOBBS AS, 1980, J BIOL CHEM, V255, P5724; HOBBS AS, 1983, CURR TOP MEMBR TRANS, V19, P569; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; JENSEN J, 1983, BIOCHIM BIOPHYS ACTA, V731, P282, DOI 10.1016/0005-2736(83)90020-2; JENSEN J, 1992, BIOCHIM BIOPHYS ACTA, V1110, P81, DOI 10.1016/0005-2736(92)90297-Y; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KLODOS I, 1981, BIOCHIM BIOPHYS ACTA, V643, P463, DOI 10.1016/0005-2736(81)90089-4; KLODOS I, 1975, ANAL BIOCHEM, V67, P397, DOI 10.1016/0003-2697(75)90311-5; KLODOS I, 1987, BIOCHIM BIOPHYS ACTA, V897, P302, DOI 10.1016/0005-2736(87)90426-3; Klodos I, 1988, Prog Clin Biol Res, V268A, P315; KLODOS I, 1991, SODIUM PUMP RECENT D, P327; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDH S, 1975, BIOCHIM BIOPHYS ACTA, V391, P448, DOI 10.1016/0005-2744(75)90269-7; MARTIN DW, 1991, J GEN PHYSIOL, V98, P419, DOI 10.1085/jgp.98.2.419; MISRA M, 1990, J STRUCT BIOL, V105, P67, DOI 10.1016/1047-8477(90)90100-Q; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; Norby J G, 1988, Prog Clin Biol Res, V268A, P249; NORBY JG, 1971, BIOCHIM BIOPHYS ACTA, V233, P104, DOI 10.1016/0005-2736(71)90362-2; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; OTTOLENGHI P, 1975, BIOCHEM J, V151, P61, DOI 10.1042/bj1510061; PLESNER L, 1988, BIOCHIM BIOPHYS ACTA, V937, P63, DOI 10.1016/0005-2736(88)90227-1; PLESNER L, 1991, BIOCHIM BIOPHYS ACTA, V1076, P421, DOI 10.1016/0167-4838(91)90486-J; POST RL, 1991, SOC GEN PHY, V46, P201; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; RAYNARD RS, 1991, AM J PHYSIOL, V260, pR916, DOI 10.1152/ajpregu.1991.260.5.R916; SANDERSON PW, 1991, BIOCHIM BIOPHYS ACTA, V1067, P43, DOI 10.1016/0005-2736(91)90024-3; SKRIVER E, 1992, J STRUCT BIOL, V108, P176, DOI 10.1016/1047-8477(92)90017-5; SUZUKI K, 1991, SODIUM PUMP RECENT D, P375; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TANIGUCHI K, 1986, J BIOL CHEM, V261, P3272; TATULIAN SA, 1983, BIOCHIM BIOPHYS ACTA, V736, P189, DOI 10.1016/0005-2736(83)90283-3; WILLIS JS, 1978, AM J PHYSIOL, V235, pC159, DOI 10.1152/ajpcell.1978.235.5.C159; YAMAGUCHI M, 1983, J BIOL CHEM, V258, P5260; YODA A, 1982, MOL PHARMACOL, V22, P693; YODA S, 1986, J BIOL CHEM, V261, P1147; YODA S, 1987, J BIOL CHEM, V262, P103; ZAMPIGHI G, 1984, J CELL BIOL, V98, P1851, DOI 10.1083/jcb.98.5.1851	56	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1734	1743						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294422				2022-12-25	WOS:A1994MR98800032
J	XIE, HY; CLARKE, S				XIE, HY; CLARKE, S			PROTEIN PHOSPHATASE-2A IS REVERSIBLY MODIFIED BY METHYL ESTERIFICATION AT ITS C-TERMINAL LEUCINE RESIDUE IN BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL METHYLATION; SIGNAL TRANSDUCTION; HUMAN-ERYTHROCYTES; METHYLTRANSFERASE; CALMODULIN; KINASES; TYPE-2A; REPAIR	We have recently described a novel protein carboxyl methylation system that results in the reversible modification of a 36-kDa polypeptide component of a 178-kDa protein in the cytosol of a variety of eucaryotic cells. This reaction, catalyzed by a cytosolic 40-kDa methyltransferase, results in the methyl esterification of the alpha-carboxyl group of the C-terminal leucine residue. We have now purified the major methylated 36-kDa polypeptide from bovine brain. N-terminal sequence analysis of a tryptic fragment of this polypeptide revealed identity to the catalytic subunit of protein phosphatase 2A. This enzyme exists in the cell predominantly as a trimeric 151-kDa native species containing the 36-kDa catalytic polypeptide that terminates in a leucine residue. We then fractionated bovine brain cytosolic extracts to separate the major phosphatase isoforms 2A1 and 2A2 and found that both could be methylated by a partially purified preparation of the methyltransferase. A synthetic C-terminal octapeptide based on the sequence of the 36-kDa catalytic subunit is neither a substrate nor an inhibitor of this methyltransferase, suggesting that this enzyme recognizes aspects of the tertiary and/or quaternary structure of the native phosphatase. Because this modification reaction is readily reversible in extracts, it may represent a novel strategy of the cell to modulate the function of this protein phosphatase.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	XIE, HY (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05554] Funding Source: Medline; NIGMS NIH HHS [GM26020] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKLUND PS, 1992, J BIOL CHEM, V267, P18632; BARTEN DM, 1990, LIFE SCI, V47, P81; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; ERICKSON AK, 1992, PREP BIOCHEM, V22, P257, DOI 10.1080/10826069208021375; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GUO H, 1993, J BIOL CHEM, V268, P11193; HRYCYNA CA, 1993, IN PRESS PHARM THER, V60; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; LADINO CA, 1990, MECH AGEING DEV, V55, P123, DOI 10.1016/0047-6374(90)90020-G; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; OCONNOR CM, 1984, J BIOL CHEM, V259, P2570; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; SIEGEL FL, 1985, ARCH BIOCHEM BIOPHYS, V237, P347, DOI 10.1016/0003-9861(85)90286-3; STOCK JB, 1992, J BIOL CHEM, V267, P19753; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; XIE H, 1990, Methods (Orlando), V1, P276, DOI 10.1016/S1046-2023(05)80328-7; XIE HY, 1993, J BIOL CHEM, V268, P13364	31	119	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1981	1984						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294450				2022-12-25	WOS:A1994MR98800067
J	HOGG, D; GUIDOS, C; BAILEY, D; AMENDOLA, A; GROVES, T; DAVIDSON, J; SCHMANDT, R; MILLS, G				HOGG, D; GUIDOS, C; BAILEY, D; AMENDOLA, A; GROVES, T; DAVIDSON, J; SCHMANDT, R; MILLS, G			CELL-CYCLE DEPENDENT REGULATION OF THE PROTEIN-KINASE TTK	ONCOGENE			English	Article							TYROSINE PHOSPHATASE; ACTIVATES P34CDC2; CDC25 PROTEIN; S-PHASE; PHOSPHORYLATION; DEPHOSPHORYLATION; IDENTIFICATION; TRANSITIONS; COMPLEX; G1	TTK is a novel protein kinase detectable in all proliferating human cells and tissues. Expression of the TTK gene is markedly reduced or absent in resting cells and in tissues with a low proliferative index. In view of the apparent association between TTK gene expression and cell proliferation, we examined the regulation of this protein kinase during transit of the cell cycle. We found very low levels of TTK mRNA and protein in starved cells. When cells are induced to enter the cell cycle, levels of TTK mRNA, protein and kinase activity increase at the G1/S phase of the cell cycle and peak in G2/M. TTK mRNA levels, as well as kinase activity, drop sharply in early G1, whereas protein levels are largely maintained. TTK may play a role in cell cycle control.	TORONTO HOSP, DEPT PATHOL, TORONTO M5T 2S8, ON, CANADA; HOSP SICK CHILDREN, DIV IMMUNOL & CANC, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; BASERGA R, 1990, CANCER RES, V50, P6769; Bauer K D, 1990, Methods Cell Biol, V33, P235; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; JOLOMON M, 1993, EMBO J, V12, P3133; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LINDBERG RA, 1993, ONCOGENE, V8, P351; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLS GB, 1992, J BIOL CHEM, V267, P16000; MORIA AO, 1989, CELL, V58, P193; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	44	45	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					89	96						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302607				2022-12-25	WOS:A1994MW24700011
J	WELCH, DR; CHEN, PC; MIELE, ME; MCGARY, CT; BOWER, JM; STANBRIDGE, EJ; WEISSMAN, BE				WELCH, DR; CHEN, PC; MIELE, ME; MCGARY, CT; BOWER, JM; STANBRIDGE, EJ; WEISSMAN, BE			MICROCELL-MEDIATED TRANSFER OF CHROMOSOME-6 INTO METASTATIC HUMAN C8161 MELANOMA-CELLS SUPPRESSES METASTASIS BUT DOES NOT INHIBIT TUMORIGENICITY	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; NM23 GENE; NEGATIVE REGULATION; NUDE-MICE; EXPRESSION; PROGRESSION; CANCER; PHENOTYPE; INVASION; GROWTH	Structural alterations of chromosome 6, including del(6q), are often associated with metastatic melanoma; therefore, we hypothesized that a metastasis-suppressor gene could be coded on human chromosome 6. Highly metastatic C8161 human malignant melanoma cells exhibit chromosomal changes typical of late-stage melanomas. Using microcell-mediated chromosome transfer, a copy of a normal human chromosome 6 was introduced into C8161. Three randomly selected hybrid clones (neo6/C8161.1, neo6/C8161.2 and neo6/C8161.3) were assayed for metastasis in athymic nude mice. All controls - parental C8161 cells, randomly-selected single cell clones, neo-transfected cell clones, neo11/CS161.2 and neo11/C8161.3 - were tumorigenic (270/272 mice) and metastatic (208/272 mice). neo6/C8161 hybrid cells were still tumorigenic (91/93 mice) but were not metastatic (0/195 mice). The presence of the added chromosomes was verified in cultured and tumor cells by amplification of polymorphic (CA), markers using PCR-RFLP. The neo6/C8161 hybrids display growth and morphological patterns of more differentiated cells than C8161. In Northern blot analysis an inverse relationship between metastatic ability and metastasis-suppressor gene, nm23-H1, expression is observed - with clone neo6/C8161.1 expressing the highest level of nm23 transcripts, neo6/C8161.2 and neo6/C8161.3 expressing intermediate levels, and barely detectable levels are seen in C8161. Collectively, these results suggest that a malignant melanoma metastasis-regulatory gene may be located on human chromosome 6. These results further demonstrate that tumorigenicity and metastatic ability are distinct phenotypes.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27514; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27514; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Irvine	WELCH, DR (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PATHOL,DIV EXPTL PATHOL,HERSHEY,PA 17033, USA.				NCI NIH HHS [R01-CA19401, R01-CA44470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044470, R01CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1991, CANCER RES, V51, P4815; ALHADEFF B, 1977, CYTOGENET CELL GENET, V19, P234; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOBROW M, 1974, NATURE, V251, P77, DOI 10.1038/251077a0; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CHAMBERS AF, 1990, INVAS METAST, V10, P225; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; CLARK WH, 1991, CANCER METAST REV, V10, P83, DOI 10.1007/BF00049406; CONWAY K, 1992, CANCER RES, V52, P6487; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1988, SEMIN ONCOL, V15, P541; DRACOPOLI NC, 1992, AM J HUM GENET, V54, pA51; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FLORENES VA, 1992, CANCER RES, V52, P6088; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FOUNTAIN JW, 1992, AM J HUM GENET, V54, pA51; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUAN XY, 1992, GENOMICS, V14, P680, DOI 10.1016/S0888-7543(05)80168-5; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; KJELDSEN L, 1992, BIOCHEM J, V287, P603, DOI 10.1042/bj2870603; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0292-54; LIOTTA LA, 1991, CANCER RES, V51, pS5054; MILLIKIN D, 1991, CANCER RES, V51, P5449; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P4743, DOI 10.1093/nar/16.10.4743; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; NEGRINI M, 1992, CANCER RES, V52, P1297; NICHOLAS CD, 1991, P NATL ACAD SCI USA, V82, P1470; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; NICOLSON GL, 1993, HOSP PRAC, P43; PARMITER AH, 1988, MALIGNANT MELANOMA B, P43; RADINSKY R, 1992, CANCER RES, V52, P5808; Radinsky R, 1991, Semin Cancer Biol, V2, P169; RODECK U, 1991, CANCER METAST REV, V10, P89, DOI 10.1007/BF00049407; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; Sambrook J, 1989, MOL CLONING LABORATO; SANFORD JA, 1987, SOMAT CELL MOLEC GEN, V13, P279, DOI 10.1007/BF01535210; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SCHLATTER B, 1992, P NATL ACAD SCI USA, V89, P9986, DOI 10.1073/pnas.89.21.9986; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; Trent J M, 1989, Carcinog Compr Surv, V11, P165; TRENT JM, 1991, CANCER METAST REV, V10, P103, DOI 10.1007/BF00049408; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TUCK AB, 1990, CLIN EXP METASTAS, V8, P417, DOI 10.1007/BF00058153; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WELCH DR, 1983, INVAS METAST, V3, P65; WELCH DR, 1989, INT J CANCER, V43, P449, DOI 10.1002/ijc.2910430318; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105	63	153	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					255	262						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302587				2022-12-25	WOS:A1994MW24700031
J	SUGINO, K; KUROSAWA, N; NAKAMURA, T; TAKIO, K; SHIMASAKI, S; LING, N; TITANI, K; SUGINO, H				SUGINO, K; KUROSAWA, N; NAKAMURA, T; TAKIO, K; SHIMASAKI, S; LING, N; TITANI, K; SUGINO, H			MOLECULAR HETEROGENEITY OF FOLLISTATIN, AN ACTIVIN-BINDING PROTEIN - HIGHER AFFINITY OF THE CARBOXYL-TERMINAL TRUNCATED FORMS FOR HEPARAN-SULFATE PROTEOGLYCANS ON THE OVARIAN GRANULOSA-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; FOLLICLE-STIMULATING-HORMONE; FSH-RELEASING PROTEIN; PORCINE FOLLISTATIN; XENOPUS-LAEVIS; 2 FORMS; INHIBIN; BETA; EXPRESSION; PITUITARY	Follistatin (FS), an activin-binding protein, is a monomer derived from two polypeptide core sequences of 315 (FS-315) and 288 (FS-288) amino acids originated from alternatively spliced mRNA. To define the structural heterogeneity of native FS, we purified six molecular forms of FS from porcine ovaries. Protein chemical analysis revealed that the structural differences among the six isoforms were caused by truncation of the carboxyl-terminal region and/or the presence of carbohydrate chains, resulting in the formation of FS-315, FS-288, and FS composed of 303 amino acids (FS-303) in various forms of glycosylation on the two potential Asn-linked glycosylation sites. The majority of FS isolated from porcine ovaries was FS-303, which may have been derived from FS-315 by proteolytic cleavage of the 12 COOH-terminal amino acids. All six molecular species have almost the same activin binding activity (K(d) = 540-680 pM). By contrast, the COOH-terminal truncated form, FS-288, showed much higher affinity for the rat granulosa cell surface than FS-303, whereas FS-315 had no affinity. FS-288 bound to heparan sulfate-Sepharose CL-4B, but FS-315 did not, suggesting that the truncated forms of FS bind to heparan sulfate proteoglycans on the cell. COS cells transfected with the FS-288 DNA expressed the FS-288 protein, which adhered to the cell surface, but cells transfected with the FS-315 DNA secreted the expressed protein into the medium, which did not bind to the cell surface. In rat anterior pituitary culture, FS-288 (ED50 = 2 ng/ml) was more potent in suppressing follicle-stimulating hormone release than FS-303 (ED50 = 10 ng/ml) and FS-315 (ED50 = 20 ng/ml). These results suggest that cell-associated FS traps activin more tightly in the matrix, thereby more effectively blocking the activity of activin on heparan sulfate proteoglycans of the cell surface and that cell-associated FS plays an important role in controlling the various actions of activin in a paracrine or autocrine manner.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; WHITTIER INST DIABET & ENDOCRINOL,DEPT MOLEC ENDOCRINOL,LA JOLLA,CA 92037; FUJITA HLTH UNIV,SCH MED,TOYOAKE,AICHI 47011,JAPAN	Tokushima University; RIKEN; Fujita Health University				Kurosawa, Nobuyuki/0000-0002-1548-4541	NICHD NIH HHS [P01-HD-09696] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BILLESTRUP N, 1990, MOL ENDOCRINOL, V4, P356, DOI 10.1210/mend-4-2-356; BROXMEYER HE, 1988, P NATL ACAD SCI USA, V85, P9052, DOI 10.1073/pnas.85.23.9052; ESCH FS, 1987, MOL ENDOCRINOL, V1, P849, DOI 10.1210/mend-1-11-849; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HASEGAWA Y, 1986, ENDOCRINOL JAPON, V33, P645; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HSUEH AJW, 1987, P NATL ACAD SCI USA, V84, P5082, DOI 10.1073/pnas.84.14.5082; HUTCHINSON LA, 1987, BIOCHEM BIOPH RES CO, V146, P1405, DOI 10.1016/0006-291X(87)90806-0; INOUYE S, 1991, BIOCHEM BIOPH RES CO, V179, P352, DOI 10.1016/0006-291X(91)91377-O; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; KITAOKA M, 1988, BIOCHEM BIOPH RES CO, V157, P48, DOI 10.1016/S0006-291X(88)80009-3; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; MURATA M, 1988, BIOCHEM BIOPH RES CO, V151, P230, DOI 10.1016/0006-291X(88)90583-9; NAKAMURA T, 1992, BIOCHIM BIOPHYS ACTA, V1135, P103, DOI 10.1016/0167-4889(92)90173-9; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; ROBERTSON DM, 1987, BIOCHEM BIOPH RES CO, V149, P744, DOI 10.1016/0006-291X(87)90430-X; SAITO S, 1991, BIOCHEM BIOPH RES CO, V176, P413, DOI 10.1016/0006-291X(91)90940-9; SAITO S, 1991, ENDOCRINOL JAPON, V38, P377; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V152, P717, DOI 10.1016/S0006-291X(88)80097-4; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SUGINO H, 1988, BIOCHEM BIOPH RES CO, V153, P281, DOI 10.1016/S0006-291X(88)81219-1; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; XIAO S, 1991, MOL CELL ENDOCRINOL, V79, P99, DOI 10.1016/0303-7207(91)90100-7; YING SY, 1988, ENDOCR REV, V9, P267, DOI 10.1210/edrv-9-2-267; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	44	208	226	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15579	15587						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340384				2022-12-25	WOS:A1993LN30500041
J	CAO, YJ; MAHRENHOLZ, AM; DEPAOLIROACH, AA; ROACH, PJ				CAO, YJ; MAHRENHOLZ, AM; DEPAOLIROACH, AA; ROACH, PJ			CHARACTERIZATION OF RABBIT SKELETAL-MUSCLE GLYCOGENIN - TYROSINE-194 IS ESSENTIAL FOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BIOSYNTHESIS; BIOGENESIS; PRIMER; ANTIBODIES; SYNTHASE; LINKAGE	The biogenesis of glycogen involves a specific initiation event mediated by the initiator protein, glycogenin, which undergoes self-glucosylation to generate an oligosaccharide primer from which the glycogen molecule grows. Rabbit muscle glycogenin was expressed at high levels in Escherichia coli and purified close to homogeneity in a procedure that involved binding to a UDP-agarose affinity column. The resulting protein had subunit molecular weight of 38,000 as judged by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. Analysis of peptide fragments by mass spectroscopy indicated that the recombinant glycogenin was already glucosylated at Tyr-194 and contained from 1 to 8 glucose residues attached. The enzyme was active as a glucosyl transferase and could incorporate a further approximately 5 mol of glucose/mol. The apparent K(m) for the glucosyl donor UDP-glucose was 4.5 muM, and the pH optimum was pH 8. Of a number of nucleotides and related compounds surveyed, UDP and UTP were the most effective inhibitors. There was also a correlation between inhibition and the presence of a pyrophosphate group. Of several oligosaccharides of glucose, only maltose caused significant inhibition. The glucosylation reaction was first order with respect to glycogenin suggesting that it was intramolecular. The efficacy of the purified glycogenin as a substrate for the elongation reaction catalyzed by glycogen synthase was significantly enhanced if glycogenin was first allowed to undergo self-glucosylation. The length of the priming oligosaccharide is thus important for glycogen synthase action. A mutant of glycogenin, in which Tyr-194 was changed to Phe, behaved identically to the wild-type through purification and in particular bound to the UDP-agarose affinity matrix. Despite these indications of the protein's overall structural integrity, it was unable to self-glucosylate. This result indicates that Tyr-194 is necessary for glycogenin function and is consistent with Tyr-194 being the sole site of glucosylation.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	Indiana University System; Indiana University-Purdue University Indianapolis; City of Hope; Beckman Research Institute of City of Hope					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK027221] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; Kennedy L., 1985, MEMBRANES MUSCLE, P65; KRISMAN CR, 1975, EUR J BIOCHEM, V52, P117, DOI 10.1111/j.1432-1033.1975.tb03979.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; LOMAKO J, 1992, CARBOHYD RES, V227, P331, DOI 10.1016/0008-6215(92)85082-B; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759	21	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14687	14693						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325847				2022-12-25	WOS:A1993LL75900027
J	HEIDENREICH, KA; ZEPPELIN, T; ROBINSON, LJ				HEIDENREICH, KA; ZEPPELIN, T; ROBINSON, LJ			INSULIN AND INSULIN-LIKE GROWTH FACTOR-I INDUCE C-FOS EXPRESSION IN POSTMITOTIC NEURONS BY A PROTEIN KINASE-C-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; FETAL CHICK NEURONS; NEURITE FORMATION; MESSENGER-RNA; RAT-BRAIN; ONCOGENE EXPRESSION; RIBONUCLEIC-ACID; HEPATOMA-CELLS; 3T3 CELLS; MOUSE	Recent studies indicate that insulin and insulin-like growth factors regulate development of the nervous system. The signal transduction pathways that mediate the neurotrophic responses to these peptides are largely unknown. The aims of this study were to examine the regulation of c-fos mRNA expression by insulin and insulin-like growth factor I (IGF-I) in postmitotic neurons derived from fetal chick forebrain and to investigate the role of protein kinase C (PKC) in c-fos induction by these growth factors. Cultured neurons were treated with growth factors or other known activators of c-fos gene expression, and then total cellular RNA was isolated and analyzed by Northern analysis using a full-length mouse c-fos cDNA probe. Fetal calf serum, insulin, IGF-I, 12-O-tetradecanoylphorbol (TPA), and cycloheximide induced a 2.2-kilo-base c-fos transcript in neurons. Increased levels of c-fos mRNA were apparent as early as 15 min after the addition of insulin. Levels peaked after 60 min and then remained high up to 180 min. The onset of c-fos induction by IGF-I was similar to insulin; however, the response was more transient. Analyses of dose-response curves indicate that insulin and IGF-I stimulate c-fos expression by interacting with their own receptor type. The decay rate of c-fos mRNA was unaltered by insulin or IGF-I. Pretreatment of neurons with actinomycin D (2 muM) for 5 min prior to the addition of insulin completely blocked the induction of c-fos mRNA. TPA increased c-fos mRNA levels with similar kinetics to that of insulin and IGF-I; however, the attenuation phase more closely paralleled that of insulin. Two inhibitors of PKC, sphingosine and staurosporine, completely blocked the induction of c-fos mRNA by insulin, IGF-I, and TPA. These data indicate that insulin and IGF-I stimulate transcription of the c-fos gene in neurons by a PKC-mediated pathway. Increased AP-1 activity may mediate some of the neurotrophic responses to insulin and IGF-I.	VET AFFAIRS MED CTR, RES SERV, DENVER, CO 80220 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	HEIDENREICH, KA (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, C-236, 4200 E 9TH AVE, DENVER, CO 80262 USA.							AIZENMAN Y, 1986, P NATL ACAD SCI USA, V83, P2263, DOI 10.1073/pnas.83.7.2263; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DICICCOBLOOM E, 1988, P NATL ACAD SCI USA, V85, P4066, DOI 10.1073/pnas.85.11.4066; GOLDSTEIN ME, 1982, J NEUROIMMUNOL, V3, P203, DOI 10.1016/0165-5728(82)90023-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANNUN YA, 1991, METHOD ENZYMOL, V201, P316; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HASELBACHER GK, 1985, P NATL ACAD SCI USA, V82, P2153, DOI 10.1073/pnas.82.7.2153; HAUGUELDEMOUZON S, 1991, MOL ENDOCRINOL, V5, P51, DOI 10.1210/mend-5-1-51; HAVRANKOVA J, 1978, NATURE, V272, P827, DOI 10.1038/272827a0; HAVRANKOVA J, 1978, P NATL ACAD SCI USA, V75, P5737, DOI 10.1073/pnas.75.11.5737; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HEIDENREICH KA, 1989, ENDOCRINOLOGY, V125, P1451, DOI 10.1210/endo-125-3-1451; HEIDENREICH KA, 1988, J NEUROCHEM, V51, P878, DOI 10.1111/j.1471-4159.1988.tb01824.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISHIZUKA T, 1992, END SOC ABSTR, P177; KAPPY M, 1984, J NEUROCHEM, V42, P198, DOI 10.1111/j.1471-4159.1984.tb09717.x; KENNER KA, 1991, ENDOCRINOLOGY, V129, P301, DOI 10.1210/endo-129-1-301; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATSUI M, 1990, ONCOGENE, V5, P249; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; ONG J, 1987, ENDOCRINOLOGY, V120, P353, DOI 10.1210/endo-120-1-353; PURO DG, 1984, SCIENCE, V225, P1170, DOI 10.1126/science.6089343; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RECIOPINTO E, 1984, P NATL ACAD SCI-BIOL, V81, P2562, DOI 10.1073/pnas.81.8.2562; RECIOPINTO E, 1986, J NEUROSCI, V6, P1211; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SARA VR, 1982, ACTA PHYSIOL SCAND, V115, P467, DOI 10.1111/j.1748-1716.1982.tb07105.x; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TAUB R, 1987, J BIOL CHEM, V262, P10893; THOENEN H, 1985, SCIENCE, V229, P238, DOI 10.1126/science.2409599; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON MJ, 1992, DIABETES S1, V44, pA6; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VARON S, 1984, J NEUROSCI, V4, P654; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; XUE ZG, 1988, CELL DIFFER DEV, V25, P1	51	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14663	14670						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325843				2022-12-25	WOS:A1993LL75900023
J	VILE, GF; TYRRELL, RM				VILE, GF; TYRRELL, RM			OXIDATIVE STRESS RESULTING FROM ULTRAVIOLET-A IRRADIATION OF HUMAN SKIN FIBROBLASTS LEADS TO A HEME OXYGENASE-DEPENDENT INCREASE IN FERRITIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; OXIDANT STRESS; HEAT-SHOCK; PROTEIN; LIVER; IRON; CELLS; SUPEROXIDE; INDUCTION; RADICALS	Heme oxygenase-1 mRNA levels increase following exposure of many mammalian cell lines to oxidative stress such as ultraviolet A (UVA) irradiation. Here we demonstrate a 4-fold increase in microsomal heme oxygenase activity and a 40% decrease in microsomal heme content 14 h after treatment of human skin fibroblasts (FEK4) with 250 kJ m-2 of UVA radiation. Paralleling this was a 2-fold increase in ferritin levels that was sustained for at least 46 h after UVA irradiation. Treatment of fibroblasts with the iron chelating agent desferrioxamine, after the UVA-dependent induction of heme oxygenase, prevented the increase in ferritin levels. Treatment of fibroblasts with Sn-protoporphyrin IX (an inhibitor of heme oxygenase) also prevented the effect of UVA radiation on ferritin levels. Thus we conclude that the effect of UVA radiation on ferritin levels is via the heme oxygenase-dependent release of iron from endogenous heme sources. We propose that the increase in ferritin that follows UVA irradiation would decrease intracellular free iron such that iron-catalyzed free radical reactions would be restricted during periods of subsequent oxidative stress.			VILE, GF (corresponding author), SWISS INST EXPTL CANC RES,CH BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.							APPLEGATE LA, 1991, CANCER RES, V51, P974; AUBAILLY M, 1991, PHOTOCHEM PHOTOBIOL, V54, P769, DOI 10.1111/j.1751-1097.1991.tb02088.x; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BAKER MS, 1986, ARCH BIOCHEM BIOPHYS, V246, P581, DOI 10.1016/0003-9861(86)90313-9; BALLA G, 1992, J BIOL CHEM, V267, P18148; Battey, 1986, BASIC METHODS MOL BI; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOLANN BJ, 1990, EUR J BIOCHEM, V193, P899, DOI 10.1111/j.1432-1033.1990.tb19415.x; BORG DC, 1984, ISR J CHEM, V24, P38; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; CUNNINGHAM ML, 1985, PHOTOCHEM PHOTOBIOL, V42, P125, DOI 10.1111/j.1751-1097.1985.tb01549.x; CZOCHRALSKA B, 1984, BIOCHIM BIOPHYS ACTA, V801, P403, DOI 10.1016/0304-4165(84)90145-4; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; ESTABROOK RW, 1967, METHOD ENZYMOL, V10, P212; GRANICK S, 1975, J BIOL CHEM, V250, P9215; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HARRISON PM, 1973, INORGANIC BIOCH, P253; HIWASA T, 1986, CANCER RES, V46, P2474; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; KEYSE SM, 1989, CARCINOGENESIS, V11, P787; KUROSS SA, 1988, BLOOD, V71, P876; KUTTY RK, 1988, ARCH BIOCHEM BIOPHYS, V260, P638, DOI 10.1016/0003-9861(88)90492-4; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; MAINES MD, 1975, J BIOL CHEM, V250, P4171; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MCCORMICK JP, 1976, SCIENCE, V191, P468; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; SHIBAHARA S, 1978, ARCH BIOCHEM BIOPHYS, V188, P243, DOI 10.1016/S0003-9861(78)80006-X; STERRENBERG L, 1984, TOXICOL LETT, V22, P153, DOI 10.1016/0378-4274(84)90059-6; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; TAKETANI S, 1989, FEBS LETT, V245, P173, DOI 10.1016/0014-5793(89)80215-7; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P298, DOI 10.1021/bi00804a016; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003	41	350	356	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14678	14681						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325845				2022-12-25	WOS:A1993LL75900025
J	DEBINSKI, W; PURI, RK; KREITMAN, RJ; PASTAN, I				DEBINSKI, W; PURI, RK; KREITMAN, RJ; PASTAN, I			A WIDE-RANGE OF HUMAN CANCERS EXPRESS INTERLEUKIN-4 (IL4) RECEPTORS THAT CAN BE TARGETED WITH CHIMERIC TOXIN COMPOSED OF IL4 AND PSEUDOMONAS EXOTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION PROTEIN; RECOMBINANT IMMUNOTOXIN; ESCHERICHIA-COLI; ANIMAL TOXICITY; TUMOR-CELLS; CYTOTOXICITY; AERUGINOSA; SEQUENCES; CARCINOMA; DOMAINS	A chimeric toxin has been constructed by fusion of a gene encoding human interleukin 4 (hIL4) to a gene encoding a mutant form of Pseudomonas exotoxin A (PE) which cannot bind to its receptors (PE4E). The chimeric gene was expressed in Escherichia coli where large amounts of the chimeric toxin, hIL4-PE4E, was produced. Purified hIL4-PE4E was very cytotoxic to cancer cell lines of both hematopoietic and solid tumor origin. In the HUT 102 T cell leukemia and Daudi B cell lymphoma cell lines, protein synthesis was inhibited by 50% (ID50) at a hIL4-PE4E concentration of 2 and 7 ng/ml (25 and 86 pM, respectively). hIL4-PE4E was also very cytotoxic to cell lines derived from carcinomas of the colon, breast, stomach, liver, adrenals, and prostate, as well as melanoma and epidermoid carcinoma, indicating that hIL4 receptors are widely expressed on human malignancies. We also found that human phytohemagglutinin- activated peripheral blood lymphocytes were extremely sensitive to hIL4-PE4E with an ID50 of 0.2 ng/ml (2.5 pM). The cytotoxic action of hIL4-PE4E was specific because it was blocked by an excess of hIL4 and not of human interleukin 2. In addition, hIL4-PE4ED553, an enzymatically inactive form of the chimeric toxin, was not cytotoxic. These results suggest that the hIL4 receptor may be a target for therapy in malignant and immunologic disorders using hIL4 chimeric toxin.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BATRA JK, 1989, P NATL ACAD SCI USA, V86, P845; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, J BIOL CHEM, V265, P16306; DEBINSKI W, 1991, MOL CELL BIOL, V11, P1751, DOI 10.1128/MCB.11.3.1751; DEBINSKI W, 1992, J CLIN INVEST, V90, P405, DOI 10.1172/JCI115875; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KREITMAN RJ, 1992, BIOCONJUGATE CHEM, V3, P58, DOI 10.1021/bc00013a009; KREITMAN RJ, 1990, P NATL ACAD SCI USA, V87, P8291, DOI 10.1073/pnas.87.21.8291; KREITMAN RJ, 1992, BLOOD, V79, P1775; LAKKIS F, 1991, EUR J IMMUNOL, V21, P2253, DOI 10.1002/eji.1830210937; LORBERBOUMGALSKI H, 1988, J BIOL CHEM, V263, P18650; LORBERBOUMGALSKI H, 1990, J BIOL CHEM, V265, P16311; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PURI RK, 1991, CANCER RES, V51, P3011; PURI RK, 1993, IN PRESS CANCER INVE; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1990, J BIOL CHEM, V265, P16318; SIEGALL CB, 1991, CANCER RES, V51, P2831; SIEGALL CB, 1990, CANCER RES, V50, P7786; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TUNGEKAR MF, 1991, CANCER RES, V51, P261; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	32	71	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14065	14070						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314773				2022-12-25	WOS:A1993LJ82500044
J	KIRSCH, GE; DREWE, JA; DEBIASI, M; HARTMANN, HA; BROWN, AM				KIRSCH, GE; DREWE, JA; DEBIASI, M; HARTMANN, HA; BROWN, AM			FUNCTIONAL INTERACTIONS BETWEEN K+ PORE RESIDUES LOCATED IN DIFFERENT SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; RAT-BRAIN; BLOCKADE; REGION; AXONS	The aqueous pore (P-region) of homotetrameric voltage-gated K+ channels has been modeled as a radially symmetrical eight-stranded antiparallel beta-barrel to which each of the four subunits contributes equally. This model has hydrogen bonding between residues located on adjacent subunits and predicts that subunit interactions might have functional consequences. Previously we have used point mutations and an electrophysiological assay to detect functional interactions between a pair of residues at positions 369 and 374 in the P-region, but we could not distinguish between intra- and intersubunit interactions. In the present paper, we present evidence for interaction across subunit boundaries after co-injecting two cRNAs encoding subunits differing from each other at either position 369 or 374. Comparison of the phenotypes of homo- and heterotetrameric channels suggests that pore residues residing in adjacent subunits form a closely packed structure which determines both ion conductance and stability of the open state of the channel. Our results are consistent with a structure in which pore residues 369 and 374 are located in close proximity on adjacent antiparallel strands to allow both intra- and intersubunit interactions.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	KIRSCH, GE (corresponding author), BAYLOR COLL MED,DEPT ANESTHESIOL,HOUSTON,TX 77030, USA.		De Biasi, Mariella/M-7646-2017	De Biasi, Mariella/0000-0002-0687-8872	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877, R01NS029473] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37044] Funding Source: Medline; NINDS NIH HHS [NS23877, NS29473] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BOGUSZ S, 1992, PROTEIN ENG, V5, P285, DOI 10.1093/protein/5.4.285; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; DEBIASI M, 1993, PFLUG ARCH EUR J PHY, V422, P354, DOI 10.1007/BF00374291; DREWE JA, 1993, IN PRESS METHODS NEU; DURRELL SR, 1992, BIOPHYS J, V62, P238; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HURST RS, 1992, J BIOL CHEM, V267, P23742; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KIRSCH GE, 1991, AM J PHYSIOL, V261, pC583, DOI 10.1152/ajpcell.1991.261.4.C583; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KIRSCH GE, 1991, FEBS LETT, V278, P55, DOI 10.1016/0014-5793(91)80082-E; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Sambrook J, 1989, MOL CLONING LABORATO; TAGLIALATELA M, 1991, MOL PHARMACOL, V40, P299; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	28	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13799	13804						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314749				2022-12-25	WOS:A1993LJ82500008
J	GOESSLING, LS; MASCOTTI, DP; BHATTACHARYYAPAKRASI, M; GANG, H; THACH, RE				GOESSLING, LS; MASCOTTI, DP; BHATTACHARYYAPAKRASI, M; GANG, H; THACH, RE			IRREVERSIBLE STEPS IN THE FERRITIN SYNTHESIS INDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT BINDING-PROTEIN; IRON-SULFUR CLUSTER; RNA-BINDING; MESSENGER-RNAS; RABBIT LIVER; PURIFICATION; INVITRO; ACONITASE	The ability of cells to re-repress ferritin synthesis after removal of an inducing agent (iron or heme) was investigated. Re-repression was found to be a slow process, requiring approximately 4 (after iron removal) to 10 h (after heme removal) for completion. Desferrioxamine mesylate (Desferal) had only a slight effect on the rate of re-repression, whereas cycloheximide was strongly inhibitory, indicating that new protein synthesis is re quired for re-repression. Re-repression occurred at a slow but significant rate in the presence of both Desferal and cycloheximide. These results indicate that, in the absence of an iron chelator, the induction of ferritin synthesis is essentially irreversible. The kinetics of the previously reported covalent modification of IRE-binding protein (IRE-BP) were then examined, to see whether this phenomenon might account (at least in part) for the irreversibility of induction. It was found that the heme- or iron dependent disappearance of 98-kDa IRE-BP occurred rapidly (within 1 h), and was equally rapidly reversed upon removal of heme after a 1-h exposure. By contrast, after a 4-h exposure to heme, little 98-kDa IRE-BP could be regenerated after heme removal. These results suggest that the slow, irreversible covalent modification of IRE-BP correlates closely over time with the induction of ferritin synthe sis. The covalent modification of IRE-BP depends on cell growth rate, and is most readily detected in rapidly growing cells.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Washington University (WUSTL)			Mascotti, David/G-3594-2012	Mascotti, David/0000-0003-1184-6784	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020484] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20484] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWN PH, 1989, J BIOL CHEM, V264, P13383; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; DANIELSMCQUEEN S, 1992, GENE, V122, P271, DOI 10.1016/0378-1119(92)90215-B; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; GOESSLINGLS, 1992, SCIENCE, V256, P670; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, CELL, V72, P119; KUHN LC, 1991, BRIT J HAEMATOL, V79, P1, DOI 10.1111/j.1365-2141.1991.tb07998.x; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIN JJ, 1990, ENZYME, V44, P59, DOI 10.1159/000468747; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; ROGERS JT, 1992, IRON HUMAN DISEASE, P77; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; TANG CK, 1992, J BIOL CHEM, V267, P24466; THEIL EC, 1990, J BIOL CHEM, V265, P4771; WALDEN WE, 1989, J BIOL CHEM, V264, P13765	19	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4343	4348						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308003				2022-12-25	WOS:A1994MW98900070
J	POSNER, BI; FAURE, R; BURGESS, JW; BEVAN, AP; LACHANCE, D; ZHANGSUN, GY; FANTUS, IG; NG, JB; HALL, DA; LUM, BS; SHAVER, A				POSNER, BI; FAURE, R; BURGESS, JW; BEVAN, AP; LACHANCE, D; ZHANGSUN, GY; FANTUS, IG; NG, JB; HALL, DA; LUM, BS; SHAVER, A			PEROXOVANADIUM COMPOUNDS - A NEW CLASS OF POTENT PHOSPHOTYROSINE PHOSPHATASE INHIBITORS WHICH ARE INSULIN MIMETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; RECEPTOR TYROSINE KINASE; RAT ADIPOCYTES; CRYSTAL-STRUCTURE; DIABETIC RATS; VANADATE TREATMENT; BLOOD-GLUCOSE; V-51; PHOSPHORYLATION; STIMULATION	Twelve peroxovanadium (pV) compounds, each containing an oxo ligand, one or two peroxo anions, and an ancillary ligand in the inner coordination sphere of V, were synthesized, crystallized, and characterized by V-51 NMR as >95% pure. These compounds activated the insulin receptor kinase (IRK) of cultured hepatoma cells, stimulated lipogenesis in adipocytes, and inhibited the in situ dephosphorylation of autophosphorylated IRs and epidermal growth factor receptors of rat liver endosomes. The phosphotyrosine phosphatase inhibitory and IRK activating potencies of these compounds were linearly correlated (r = 0.74; p < 0.003), decayed in parallel in solution, and varied considerably with the ancillary ligands within these compounds. In vivo administration activated rat liver IRK in parallel with its tyrosine phosphorylation. Co-administration of insulin plus pV was markedly synergistic in both respects. pV administration significantly decreased circulating insulin and plasma glucose concentrations; the latter to levels seen after a dose of insulin yielding greater than or equal to 50% occupancy of IRs in vivo. Two compounds (mpV(pic) and mpV(2,6-pdc)) displayed relative specificity as phosphotyrosine phosphatase inhibitors by inhibiting IR dephosphorylation to a significantly greater degree than epidermal growth factor receptor dephosphorylation. Thus, pV compounds are the most potent phosphotyrosine phosphatase inhibitors described to date. Their capacity to activate IRK appears to derive from their phosphotyrosine phosphatase inhibitory activity. Their hypoglycemic action is due to a direct tissue effect.	MCGILL UNIV,DEPT MED,MONTREAL H3A 1A1,PQ,CANADA; MCGILL UNIV,DEPT CHEM,MONTREAL H3A 1A1,PQ,CANADA	McGill University; McGill University	POSNER, BI (corresponding author), ROYAL VICTORIA HOSP,POLYPEPTIDE HORMONE LAB,687 PINE AVE W,ROOM H5 45,MONTREAL H3A 1A1,PQ,CANADA.		Posner, Barry/B-6733-2008	Bevan, Paul/0000-0002-0656-9164				BEGIN D, 1975, INORG CHEM, V14, P1785, DOI 10.1021/ic50150a009; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BLONDEL O, 1989, DIABETOLOGIA, V32, P185, DOI 10.1007/BF00265092; BRICHARD SM, 1988, ENDOCRINOLOGY, V123, P2048, DOI 10.1210/endo-123-4-2048; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; BUTLER A, 1989, J AM CHEM SOC, V111, P2802, DOI 10.1021/ja00190a010; CLARK AS, 1985, BIOCHEM J, V232, P273, DOI 10.1042/bj2320273; CRANS DC, 1990, J AM CHEM SOC, V112, P2901, DOI 10.1021/ja00164a009; DREW RE, 1972, INORG CHEM, V11, P1079, DOI 10.1021/ic50111a033; DREW RE, 1973, INORG CHEM, V12, P829, DOI 10.1021/ic50122a025; DUBYAK GR, 1980, J BIOL CHEM, V255, P5306; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FAURE R, 1992, J BIOL CHEM, V267, P11215; GIL J, 1988, J BIOL CHEM, V263, P1868; HARRISON AT, 1985, J CHEM SOC DALTON, P1173, DOI 10.1039/dt9850001173; HARTKAMP H, 1959, ANGEW CHEM INT EDIT, V71, P553, DOI 10.1002/ange.19590711708; HEATH E, 1981, J CHEM SOC DALTON, P1105, DOI 10.1039/dt9810001105; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; HILL G, 1987, BONE MARROW TRANSPL, V2, P315; HOWARTH OW, 1979, J CHEM SOC DALTON, P1388, DOI 10.1039/dt9790001388; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KADOTA S, 1986, BIOCHEM BIOPH RES CO, V138, P174, DOI 10.1016/0006-291X(86)90262-7; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KHAN MN, 1989, J BIOL CHEM, V264, P12931; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MIMOUN H, 1983, NOUV J CHIM, V7, P467; MIMOUN H, 1983, J AM CHEM SOC, V105, P3101, DOI 10.1021/ja00348a025; QUILITZSCH U, 1979, INORG CHEM, V18, P869, DOI 10.1021/ic50193a069; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SALAPALA J, 1971, J CHEM SOC A, P1132, DOI 10.1039/j19710001132; SHAVER A, 1993, INORG CHEM, V32, P3109, DOI 10.1021/ic00066a024; SHECHTER Y, 1980, NATURE, V284, P556, DOI 10.1038/284556a0; STOMBERG R, 1986, ACTA CHEM SCAND A, V40, P168, DOI 10.3891/acta.chem.scand.40a-0168; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; SVENSSON IB, 1971, ACTA CHEM SCAND, V25, P898, DOI 10.3891/acta.chem.scand.25-0898; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TOLMAN EL, 1979, LIFE SCI, V25, P1159, DOI 10.1016/0024-3205(79)90138-3; TRACEY AS, 1992, J AM CHEM SOC, V114, P3835, DOI 10.1021/ja00036a035; VULETIC N, 1973, J CHEM SOC DALTON, P1137, DOI 10.1039/dt9730001137	40	518	533	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4596	4604						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308031				2022-12-25	WOS:A1994MW98900103
J	HERBERT, JM; LAMARCHE, I; PRABONNAUD, V; DOL, F; GAUTHIER, T				HERBERT, JM; LAMARCHE, I; PRABONNAUD, V; DOL, F; GAUTHIER, T			TISSUE-TYPE PLASMINOGEN-ACTIVATOR IS A POTENT MITOGEN FOR HUMAN AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; PROTEIN KINASE-C; FIBROBLAST GROWTH-FACTOR; RAT CAROTID-ARTERY; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; THROMBIN RECEPTOR; PROLIFERATION; UROKINASE	Tissue-type plasminogen activator (t-PA) is a potent and efficacious mitogen for growth-arrested cultured human aortic smooth muscle cells, stimulating an increase in cell number at 0.3-30 nM concentration. Double-chain t-PA is as efficient as single-chain t-PA in stimulating smooth muscle cell mitogenesis, whereas single-chain urokinase-type plasminogen activator (u-PA) or u-PA and plasmin or plasminogen are ineffective. Plasminogen activator inhibitor-1, Pefabloc-TPA, diisopropyl fluorophosphate or alpha1-anti-trypsin inhibit the mitogenic effect of t-PA for smooth muscle cells in a dose-dependent manner, showing that it is dependent on the enzymatic activity. t-PA activated phosphoinositide turnover in smooth muscle cells through a pertussis toxin-insensitive pathway and stimulated proto-oncogene c-fos and c-jun mRNA levels. These findings indicate that t-PA stimulates vascular human smooth muscle cell proliferation and suggest for the first time that it may contribute to intimal smooth muscle cell proliferation after vascular injury as a result of angioplasty or vascular compromise during atherogenesis.			HERBERT, JM (corresponding author), SANOFI RECH,HEMOBIOL RES DEPT,195 ROUTE ESPAGNE,F-31036 TOULOUSE,FRANCE.							AU YPT, 1992, J BIOL CHEM, V267, P3438; BARON-VAN EVERCOOREN A, 1987, DEV BRAIN RES, V36, P101, DOI 10.1016/0165-3806(87)90068-X; BERK BC, 1991, BIOCHEM J, V274, P799, DOI 10.1042/bj2740799; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Binder B R, 1990, Blood Coagul Fibrinolysis, V1, P717; BJORKERUD S, 1988, CIRC RES, V62, P1011, DOI 10.1161/01.RES.62.5.1011; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1992, CIRC RES, V70, P1128, DOI 10.1161/01.RES.70.6.1128; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DEUEL TF, 1984, J CLIN INVEST, V74, P669, DOI 10.1172/JCI111482; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GOLDSMITH GH, 1981, EXP MOL PATHOL, V35, P257, DOI 10.1016/0014-4800(81)90065-4; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; HERBERT JM, 1992, FEBS LETT, V301, P155, DOI 10.1016/0014-5793(92)81237-G; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KANTHOU C, 1992, FEBS LETT, V314, P143, DOI 10.1016/0014-5793(92)80961-F; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KIRCHHEIMER JC, 1987, THROMB RES, V48, P291, DOI 10.1016/0049-3848(87)90441-5; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KORNER G, 1993, J CELL PHYSIOL, V154, P456, DOI 10.1002/jcp.1041540303; LAMPUGNANI MG, 1990, BLOOD, V76, P1173; LEVIN EG, 1978, THROMB RES, V15, P869; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LIOTTA LA, 1981, CANCER RES, V41, P4629; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MIMURO J, 1987, BLOOD, V70, P721; MOONEN G, 1985, DEV BRAIN RES, V20, P41, DOI 10.1016/0165-3806(85)90085-9; MOORE JP, 1986, J BIOL CHEM, V261, P8158; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PARANJPE M, 1980, LIFE SCI, V26, P1223, DOI 10.1016/0024-3205(80)90067-3; PAUL R, 1987, THROMB RES, V46, P793, DOI 10.1016/0049-3848(87)90071-5; RANBY M, 1982, THROMB RES, V7, P175; REILLY CF, 1991, J BIOL CHEM, V266, P9419; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS RH, 1993, J BIOL CHEM, V268, P5724	48	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3076	3080						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300642				2022-12-25	WOS:A1994MV43200102
J	MARKOVICH, D; BISSIG, M; SORRIBAS, V; HAGENBUCH, B; MEIER, PJ; MURER, H				MARKOVICH, D; BISSIG, M; SORRIBAS, V; HAGENBUCH, B; MEIER, PJ; MURER, H			EXPRESSION OF RAT RENAL SULFATE TRANSPORT-SYSTEMS IN XENOPUS-LAEVIS OOCYTES - FUNCTIONAL-CHARACTERIZATION AND MOLECULAR-IDENTIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; AMINO-ACID-TRANSPORT; RABBIT KIDNEY CORTEX; PROXIMAL TUBULE; BRUSH-BORDER; ANION-EXCHANGE; SPECIFICITY; NA+; CLONING; CDNA	Renal proximal tubular sulfate reabsorption is mediated by brush border membrane Na+/sulfate-cotransport and basolateral Na+-independent sulfate transport. Injection of rat kidney cortex mRNA into Xenopus laevis oocytes induced Na+-dependent as well as Na+-independent sulfate transport. The inhibition pattern of Na+-dependent uptake coincided with that known for the brush border membrane; the inhibition pattern of Na+-independent uptake suggested that this activity could be related to the basolateral cell surface. By Northern blot hybridization of size-fractionated mRNA, we provide evidence that the Na+-dependent uptake is induced by an mRNA species related to a recently cloned cDNA encoding rat renal cortex Na+/SO4 Cotransport (NaSi-1; Markovich, D., Forgo, J., Stange, G., Biber, J., and Murer, H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,8073-8077); the Na+-independent sulfate transport activity seems to be related to an mRNA species encoding a rat liver Na+-independent sulfate transporter (Bissig, M., Hagenbuch, B., Stieger, B., Koller, T., and Meier, P. J. (1994) J. Biol. Chem. 269,3017-3021). Hybrid depletion experiments using antisense oligonucleotides provided further evidence for the association of the expressed transport activities to NaSi-1 and sat-1, respectively.	UNIV ZURICH,INST PHYSIOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND; UNIV HOSP ZURICH,DEPT MED,DIV CLIN PHARMACOL & TOXICOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University Zurich Hospital			Markovich, Daniel/F-7884-2012; Hagenbuch, Bruno/M-5294-2016	Hagenbuch, Bruno/0000-0002-2938-8630; Sorribas, Victor/0000-0003-3457-323X				AHEARN GA, 1984, J MEMBRANE BIOL, V78, P177, DOI 10.1007/BF01925966; BAESTLEIN C, 1986, AM J PHYSIOL, V250, pF226; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BRAZY PC, 1981, AM J PHYSIOL, V241, pF300, DOI 10.1152/ajprenal.1981.241.3.F300; DAVID C, 1992, PFLUG ARCH EUR J PHY, V421, P455, DOI 10.1007/BF00370256; GRINSTEIN S, 1980, AM J PHYSIOL, V238, pF452, DOI 10.1152/ajprenal.1980.238.6.F452; HAGENBUCH B, 1985, PFLUG ARCH EUR J PHY, V405, P202, DOI 10.1007/BF00582561; HIERHOLZER K, 1960, AM J PHYSIOL, V198, P833, DOI 10.1152/ajplegacy.1960.198.4.833; KARNISKI LP, 1987, AM J PHYSIOL, V253, pF513, DOI 10.1152/ajprenal.1987.253.3.F513; KUO SM, 1988, J BIOL CHEM, V263, P9710; LOW I, 1984, AM J PHYSIOL, V246, pF334, DOI 10.1152/ajprenal.1984.246.3.F334; LUECKE H, 1979, Biochemical Journal, V182, P223; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MURER H, 1992, HDB PHYSL 8, V2, P2165; PRITCHARD JB, 1983, P NATL ACAD SCI-BIOL, V80, P2603, DOI 10.1073/pnas.80.9.2603; PRITCHARD JB, 1987, AM J PHYSIOL, V252, pF346, DOI 10.1152/ajprenal.1987.252.2.F346; SCHNEIDER EG, 1984, J BIOL CHEM, V259, P4591; TALOR Z, 1987, EUR J BIOCHEM, V164, P695, DOI 10.1111/j.1432-1033.1987.tb11182.x; TURNER RJ, 1984, AM J PHYSIOL, V247, pF793, DOI 10.1152/ajprenal.1984.247.5.F793; ULLRICH KJ, 1988, AM J PHYSIOL, V254, pF453, DOI 10.1152/ajprenal.1988.254.4.F453; ULLRICH KJ, 1982, PHILOS T ROY SOC B, V299, P549, DOI 10.1098/rstb.1982.0151; ULLRICH KJ, 1985, PFLUG ARCH EUR J PHY, V404, P311, DOI 10.1007/BF00585341; ULLRICH KJ, 1985, PFLUG ARCH EUR J PHY, V404, P300, DOI 10.1007/BF00585339; ULLRICH KJ, 1985, PFLUG ARCH EUR J PHY, V404, P307, DOI 10.1007/BF00585340; ULLRICH KJ, 1984, PFLUG ARCH EUR J PHY, V402, P264, DOI 10.1007/BF00585509; ULLRICH KJ, 1985, PFLUG ARCH EUR J PHY, V404, P293, DOI 10.1007/BF00585338; ULLRICH KJ, 1980, PFLUG ARCH EUR J PHY, V387, P127, DOI 10.1007/BF00584263; WERNER A, 1990, J BIOL CHEM, V265, P12331; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608	35	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3022	3026						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300634				2022-12-25	WOS:A1994MV43200094
J	BUSAM, KJ; GEISER, AG; ROBERTS, AB; SPORN, MB				BUSAM, KJ; GEISER, AG; ROBERTS, AB; SPORN, MB			SYNERGISTIC INCREASE OF PHORBOL ESTER-INDUCED C-FOS MESSENGER-RNA EXPRESSION BY RETINOIC ACID THROUGH STABILIZATION OF THE C-FOS MESSAGE	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION; GROWTH-FACTORS; POSTTRANSCRIPTIONAL REGULATION; COLLAGENASE PRODUCTION; HOMEOBOX GENES; TRANSCRIPTION; INHIBITION; AP-1	Retinoic acid (RA) has been shown to be able to antagonize or synergize with phorbol 12-myristate 13-acetate (PMA). In contrast to its antagonistic effects on PMA-dependent gene expression, no molecular target or mechanism of synergism has been characterized yet. We now report, that RA synergistically enhances the induction of c-fos, but not c-jun mRNA by PMA in cells whose growth was stimulated by RA alone. The responding cells were hybrids of tumor cell lines whose growth and PMA-dependent c-fos mRNA expression remained unaffected by RA. The increase in PMA-dependent c-fos expression required pretreatment of cells with RA for at least 2 - 4 h and was achieved at doses as low as 10(-10) M. Nuclear run-on experiments and transient transfection assays using a chimeric reporter gene construct with sequences from the c-fos promoter indicated that RA did not affect PMA-dependent c-fos transcription. Instead, RA stabilized the c-fos message after induction by PMA as assessed by measuring the half-life of c-fos mRNA in actinomycin D-treated cells. This post-transcriptional regulation provides a mechanism whereby RA can synergistically enhance gene expression by PMA.			BUSAM, KJ (corresponding author), NCI, CHEMOPREVENT LAB, BETHESDA, MD 20892 USA.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BRINCKERHOFF CE, 1980, NEW ENGL J MED, V303, P432, DOI 10.1056/NEJM198008213030805; BRINCKERHOFF CE, 1983, SCIENCE, V221, P756, DOI 10.1126/science.6308759; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DICKER P, 1979, BIOCHEM BIOPH RES CO, V91, P1203, DOI 10.1016/0006-291X(79)91195-1; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEISER AG, 1989, CANCER RES, V49, P1572; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JETTEN AM, 1983, CANCER RES, V43, P68; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MILLER WH, 1990, ONCOGENE, V5, P511; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; RADZIOCH D, 1991, MOL CELL BIOL, V11, P2718, DOI 10.1128/MCB.11.5.2718; REPRESA J, 1990, DEVELOPMENT, V110, P1081; ROBERTS AB, 1984, RETINOIDS, V2, P209; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHRODER EW, 1980, CANCER RES, V40, P3089; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1989, Molecular Reproduction and Development, V1, P107, DOI 10.1002/mrd.1080010205; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; YANGYEN HF, 1991, NEW BIOL, V3, P1206	38	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2267	2273						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336949				2022-12-25	WOS:A1993LP17100029
J	ITO, K; OKADA, Y; ISHIDA, K; MINAMIURA, N				ITO, K; OKADA, Y; ISHIDA, K; MINAMIURA, N			HUMAN SALIVARY ENDO-BETA-N-ACETYLGLUCOSAMINIDASE HS SPECIFIC FOR COMPLEX TYPE SUGAR CHAINS OF GLYCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINIDASE ACTIVITY; PAROTID ALPHA-AMYLASE; RAT-LIVER; FLAVOBACTERIUM-MENINGOSEPTICUM; SUBSTRATE SPECIFICITIES; DIPLOCOCCUS-PNEUMONIAE; CARBOHYDRATE MOIETIES; STREPTOMYCES-GRISEUS; CYTOSOLIC LOCATION; GLYCOSIDASE-F	The enzyme that catalyzed the conversion of human salivary alpha-amylase family A (HSA-A) to family B (HSA-B) was identified. It was partially purified from the precipitate obtained by centrifugation of human saliva at 105,000 x g for 60 min by solubilization with 3[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate and column chromatographies with Sephacryl S-300-HR and hydroxylapatite. The enzyme preparation was practically free from contaminating exoglycosidases and proteases. The enzyme cleaved the N,N'-diacetylchitobiose moiety of the sugar chain of HSA-A, as shown by the isolation of the protein moiety which contained 1 GlcNAc and 1 Fuc residue and the sugar chain (Gal)2(Fuc)1(GlcNAc)2(Man)3(GlcNAc). This enzyme also cleaved the N,N'-diacetylchitobiose moiety of the sugar chain of human transferrin tetraglycopeptide Asn-Tyr-Asn(GlcNAc)2(Man)3(GlcNAc)2-(Gal)2-Lys to yield equimolar amounts of peptide Asn-Tyr-Asn(GlcNAc)Lys and sugar chain (Gal)2(GlcNAc)2-(Man)3(GlcNAc). The enzyme was identified as an endo-beta-N-acetylglucosaminidase. The enzyme acted on HSA-A with desialylated and defucosylated outer chain moieties of the sugar chains at a similar rate as that of native HSA-A. The enzyme activity was reduced to 13 and 5% using HSA-A with the sugar chains whose outer chain moieties lacked Gal and GlcNAc, respectively, from the nonreducing end. The enzyme also acted on human transferrin, calf fetuin, and asparagine oligosaccharides of transferrin and fetuin. On the other hand, the enzyme did not act on ovalbumin, RNase B, Taka-amylase, yeast invertase, and ovalbumin asparagine oligosaccharides. These results indicate that human salivary endo-beta-N-acetylglucosaminidase is specific for complex type sugar chains and can release the sugar chains from native glycoproteins and glycopeptides regardless of the existence of a Fuc residue on the proximal GlcNAc of the N,N'-diacetylchitobiose core of their sugar chains. The source of the enzyme was epithelial cells peeling from the oral cavity epithelium into saliva. The enzyme was thought to be integrated on the surface of the epithelial cell membrane. This enzyme was named endo-beta-N-acetylglucosaminidase HS. Thus, these studies indicate that the properties of the enzyme are distinct from those of known endo-beta-N-acetylglucosaminidase and endo-beta-N-acetylglucosaminidase HS is a novel endo-beta-N-acetylglucosaminidase.			ITO, K (corresponding author), OSAKA CITY UNIV, FAC SCI, DEPT BIOL, 3-3-138 SUGIMOTO, SUMIYOSHI KU, OSAKA 558, JAPAN.							BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BAUSSANT T, 1986, EUR J BIOCHEM, V159, P381, DOI 10.1111/j.1432-1033.1986.tb09879.x; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; Hodge JE, 1962, METHODS CARBOHYDRATE, DOI DOI 10.1371/JOURNAL.PONE.0065418; HOLMES EW, 1979, ANAL BIOCHEM, V93, P167, DOI 10.1016/S0003-2697(79)80060-3; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; IIJIMA Y, 1971, ARCH BIOCHEM BIOPHYS, V145, P50, DOI 10.1016/0003-9861(71)90008-7; ITO K, 1985, J BIOCHEM, V97, P1357, DOI 10.1093/oxfordjournals.jbchem.a135188; ITO K, 1992, J BIOCHEM, V112, P88, DOI 10.1093/oxfordjournals.jbchem.a123871; ITO S, 1975, ARCH BIOCHEM BIOPHYS, V171, P78, DOI 10.1016/0003-9861(75)90009-0; ITO S, 1975, BIOCHEM BIOPH RES CO, V63, P938, DOI 10.1016/0006-291X(75)90659-2; KADOWAKI S, 1991, J BIOCHEM-TOKYO, V110, P17, DOI 10.1093/oxfordjournals.jbchem.a123536; KADOWAKI S, 1990, AGR BIOL CHEM TOKYO, V54, P97, DOI 10.1080/00021369.1990.10869923; KAUFFMAN DL, 1970, ARCH BIOCHEM BIOPHYS, V137, P325, DOI 10.1016/0003-9861(70)90446-7; KELLER PJ, 1971, BIOCHEMISTRY-US, V10, P4867, DOI 10.1021/bi00802a006; KIYOHARA T, 1976, J BIOCHEM, V80, P9, DOI 10.1093/oxfordjournals.jbchem.a131263; KOIDE N, 1974, J BIOL CHEM, V249, P4897; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; MAKINO M, 1966, BIOCHEM BIOPH RES CO, V24, P961, DOI 10.1016/0006-291X(66)90344-5; MURAMATS.T, 1971, J BIOL CHEM, V246, P5534; MURAMATSU T, 1978, J BIOCHEM, V83, P363, DOI 10.1093/oxfordjournals.jbchem.a131922; NEUMANN NP, 1967, BIOCHEMISTRY-US, V6, P468, DOI 10.1021/bi00854a015; PIERCE RJ, 1980, BIOCHEM J, V185, P261, DOI 10.1042/bj1850261; PIERCE RJ, 1979, BIOCHEM J, V180, P673, DOI 10.1042/bj1800673; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PORETZ RD, 1970, BIOCHEMISTRY-US, V9, P2890, DOI 10.1021/bi00816a021; TACHIBANA Y, 1982, ARCH BIOCHEM BIOPHYS, V214, P199, DOI 10.1016/0003-9861(82)90023-6; TACHIBANA Y, 1981, J BIOCHEM-TOKYO, V90, P1291, DOI 10.1093/oxfordjournals.jbchem.a133594; TAI T, 1977, J BIOL CHEM, V252, P6687; TAI T, 1975, J BIOL CHEM, V250, P8569; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TAKAHASHI N, 1981, BIOCHIM BIOPHYS ACTA, V657, P457, DOI 10.1016/0005-2744(81)90331-4; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TARENTINO AL, 1992, J BIOL CHEM, V267, P3868; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TARENTINO AL, 1976, J BIOL CHEM, V251, P6537; TARENTINO AL, 1972, J BIOL CHEM, V247, P2629; TARENTINO AL, 1975, BIOCHEM BIOPH RES CO, V67, P455, DOI 10.1016/0006-291X(75)90337-X; TRIBLE RB, 1991, J BIOL CHEM, V266, P1646; UCHIDA Y, 1974, BIOCHIM BIOPHYS ACTA, V350, P425, DOI 10.1016/0005-2744(74)90517-8; WRIGHT DE, 1964, ARCH ORAL BIOL, V9, P321, DOI 10.1016/0003-9969(64)90064-0; YAMAGUCHI H, 1971, J BIOCHEM, V70, P587, DOI 10.1093/oxfordjournals.jbchem.a129675; YAMAMOTO M, 1991, ARCH BIOCHEM BIOPHYS, V289, P76, DOI 10.1016/0003-9861(91)90444-N; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; YAMASHITA K, 1978, J BIOL CHEM, V253, P3862; YANG FM, 1984, P NATL ACAD SCI-BIOL, V81, P2752, DOI 10.1073/pnas.81.9.2752	53	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16074	16081						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340428				2022-12-25	WOS:A1993LN30500104
J	SUN, Q; HAMPSON, RK; ROTTMAN, FM				SUN, Q; HAMPSON, RK; ROTTMAN, FM			IN-VITRO ANALYSIS OF BOVINE GROWTH-HORMONE PREMESSENGER RNA ALTERNATIVE SPLICING - INVOLVEMENT OF EXON SEQUENCES AND TRANS-ACTING FACTOR(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; SITE SELECTION; BINDING PROTEINS; INFLUENZA-VIRUS; EXPRESSION; COMPLEXES; GENE; REGULATORS; FACTOR-SF2; PRECURSORS	Bovine growth hormone (bGH) pre-mRNA is alternatively spliced, resulting in retention of the last intron (intron D) in a fraction of the cytosolic bGH mRNA. To study the mechanism of this alternative splicing event, we examined the splicing of bGH pre-mRNA in vitro. The splicing of bGH intron D in vitro required a 115-base pair segment of exon 5, reflecting the positive influence of exon sequences observed in transfected cells. No detectable spliceosome complex formation was observed using bGH pre-mRNA containing the 115-base pair deletion in exon 5. The in vitro splicing of the wild type bGH pre-mRNA was inhibited by the addition of RNA containing the 115-nucleotide exon sequence, but not by nonspecific RNAs. UV irradiation of the in vitro splicing reaction resulted in specific cross-linking of a 35-kDa protein(s) to the 115-nucleotide bGH exon sequence. These results suggest that terminal exon sequences are required at an early step of spliceosome complex formation and are consistent with a mechanism in which saturable, trans-acting factor(s) bind to these exon sequences to activate spliceosome complex formation and splicing of bGH intron D.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032770] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32770] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRIS CH, 1989, MOL CELL BIOL, V9, P259, DOI 10.1128/MCB.9.1.259; ALONSOCAPLEN FV, 1991, MOL CELL BIOL, V11, P1092, DOI 10.1128/MCB.11.2.1092; BENNETT M, 1992, MOL CELL BIOL, V12, P3165, DOI 10.1128/MCB.12.7.3165; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; COOKE NE, 1988, J BIOL CHEM, V263, P9001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; ESTES PA, 1992, J BIOL CHEM, V267, P14902; FREYER GA, 1987, J BIOL CHEM, V262, P4267; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; FURDON PJ, 1988, MOL CELL BIOL, V8, P860, DOI 10.1128/MCB.8.2.860; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GORDON DF, 1983, MOL CELL ENDOCRINOL, V33, P81, DOI 10.1016/0303-7207(83)90058-8; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAMPSON RK, 1987, P NATL ACAD SCI USA, V84, P2673, DOI 10.1073/pnas.84.9.2673; KONARSKA MM, 1989, METHOD ENZYMOL, V180, P442; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAMB RA, 1980, CELL, V21, P475, DOI 10.1016/0092-8674(80)90484-5; LUHRMANN R, 1987, STRUCTURE FUNCTION M, P71; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McKeown M, 1990, Genet Eng (N Y), V12, P139; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769	36	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15659	15666						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340391				2022-12-25	WOS:A1993LN30500052
J	HORIGOME, K; PRYOR, JC; BULLOCK, ED; JOHNSON, EM				HORIGOME, K; PRYOR, JC; BULLOCK, ED; JOHNSON, EM			MEDIATOR RELEASE FROM MAST-CELLS BY NERVE GROWTH-FACTOR - NEUROTROPHIN SPECIFICITY AND RECEPTOR MEDIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; TRK PROTOONCOGENE PRODUCT; BIOCHEMICAL-CHARACTERIZATION; BIOLOGICAL-ACTIVITY; MOLECULAR-CLONING; MONONUCLEAR-CELLS; FACTOR FAMILY; NGF RECEPTOR; PC12 CELLS; RAT	Nerve growth factor causes mediator release from rat peritoneal mast cells in the presence of lysophosphatidylserine. We have investigated the neurotrophin and receptor specificity involved in this response. Nerve growth factor produced a dose-dependent release of [C-14]serotonin in the presence of lysophosphatidylserine with an EC50 of approximately 1 nM. Incubation with brain-derived neurotrophic factor and neurotrophin-3 did not produce a response. Northern blot analysis with probes for low affinity nerve growth factor receptor (p75), trkA, trkB, and trkC demonstrated a detectable signal for trkA only. Western blots of trkA immunoprecipitates from mast cell culture lysates, probed with anti-phosphotyrosine antibodies, demonstrated expression of functional TrkA protein. To determine whether p75, trkB, or trkC mRNA was present in amounts below the limit of detection for Northern analysis, a sensitive reverse transcriptase polymerase chain reaction protocol was used; again rat peritoneal mast cells demonstrated only trkA. The predominant form of trkA message expressed in rat peritoneal mast cells was smaller than the neuronal form. An 18-nucleotide exon (coding for 6 amino acids in the extracellular domain) in the neuronal message was not found in the predominant mast cell trkA message. PC12 cells, a rat pheochromocytoma cell line, and dissociated rat sympathetic neurons showed both trkA and p75, but not trkB or trkC. Anterior pituitary expressed both trkB and trkC, but not trkA. To confirm the lack of expression of p75 on mast cells, I-125-nerve growth factor was chemically cross-linked to mast cells or PC12 cells and then immunoprecipitated with a monoclonal antibody specific for p75, 192-IgG; no p75 was detected. Thus, mediator release from rat peritoneal mast cells by nerve growth factor was specific and not a general property of neurotrophins, and the response was modulated through the trkA proto-oncogene. To our knowledge, this is the first description of a bone marrow-derived cell type that expresses trkA at both the mRNA and protein levels. These data provide further evidence that p75 is not necessary for nerve growth factor signal transduction.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,660 S EUCLID AVE,BOX 8103,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024679] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24679] Funding Source: Medline; DS NIH HHS [DS 5 T32 NF07205-10] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DS NIH HHS		ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; ALOE L, 1988, J NEUROIMMUNOL, V18, P1, DOI 10.1016/0165-5728(88)90129-4; BARKER PA, 1992, 4011 SOC NEUR WASH, V18, P948; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRUNI A, 1982, FEBS LETT, V138, P190, DOI 10.1016/0014-5793(82)80438-9; CARROLL SL, 1992, NEURON, V9, P779, DOI 10.1016/0896-6273(92)90040-K; CATTANEO A, 1986, MOL ASPECTS NEUROBIO, P3136; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; GEE AP, 1983, P NATL ACAD SCI-BIOL, V80, P7215, DOI 10.1073/pnas.80.23.7215; HALBOOK F, 1991, NEURON, V6, P845; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON MI, 1983, METHOD ENZYMOL, V103, P334; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORGAN B, 1989, J NEUROSCI RES, V23, P41, DOI 10.1002/jnr.490230106; MORRISON DC, 1974, J IMMUNOL, V12, P573; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; OTTEN U, 1985, EUR J PHARMACOL, V106, P199; PRYOR JC, 1992, 40117 SOC NEUR WASH, V18, P950; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; THORPE LW, 1987, J NEUROSCI RES, V17, P128, DOI 10.1002/jnr.490170206; THORPE LW, 1987, J NEUROSCI RES, V18, P134, DOI 10.1002/jnr.490180120; TOMIOKA M, 1988, J ALLERGY CLIN IMMUN, V82, P599, DOI 10.1016/0091-6749(88)90971-2; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAN Q, 1987, DEV BIOL, V121, P139, DOI 10.1016/0012-1606(87)90147-3; YAN Q, 1991, CLIN SCI, V80, P565, DOI 10.1042/cs0800565; YAN Q, 1990, J NEUROCYTOL, V19, P302, DOI 10.1007/BF01188400	54	205	214	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14881	14887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325866				2022-12-25	WOS:A1993LL75900054
J	KEYOMARSI, K; SAMET, J; MOLNAR, G; PARDEE, AB				KEYOMARSI, K; SAMET, J; MOLNAR, G; PARDEE, AB			THE THYMIDYLATE SYNTHASE INHIBITOR, ICI-D1694, OVERCOMES TRANSLATIONAL DETAINMENT OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-10-PROPARGYL-5,8-DIDEAZAFOLIC ACID; MESSENGER-RNA; COLON-CARCINOMA; BREAST-CANCER; CELL-LINE; CB 3717; ANTIFOLATE; TUMOR; SYNTHETASE; INVIVO	We have investigated the mechanism of inactivation of thymidylate synthase (TS) by ICI D1694 (a folate-based quinazoline) in normal versus tumor-derived human mammary epithelial cells. ICI D1694 is a very potent cytotoxic agent against these cells with IC50 values of 1-2 nM. Its growth inhibitory activity was completely reversed by the addition of thymidine, confirming that TS is its sole target in these cells. Remarkably, TS protein levels rose by 10-40-fold following treatment with ICI D1694, depending on cell type, while TS mRNA levels remained constant. The mechanism appears to be a release of ''detainment'' of TS translation, since addition of cycloheximide, a translational inhibitor, blocked the TS protein levels from rising. But coadministration of 5,6-dichlorobenzimidazole, a transcriptional inhibitor, did not overcome protein accumulation, nor did thymidine which overcomes growth inhibition by ICI D1694. 5,10-Methylenetetrahydrofolate (via folinic acid), however, did block the effects of ICI D1694, showing that the drug has its effect upon both detainment and enzyme inhibition by binding to the folate substrate site of TS. In addition, in the presence of ICI D1694, TS protein was no longer cell cycle-regulated as evident by its constitutive expression in synchronized cells. This accumulation and constitutive expression of TS induced by D1694 should increase drug resistance under a clinical setting. We suggest that an ideal inhibitor of TS would target the TS allosteric site that binds to TS mRNA, responsible for specific translation of the protein, thereby complimenting inactivation of the enzyme.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	KEYOMARSI, K (corresponding author), HARVARD UNIV, SCH MED,DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT,44 BINNEY ST, RM D810B, BOSTON, MA 02115 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [CA08949-02, CA 22427] Funding Source: Medline; NCRR NIH HHS [S07RR05526-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008949, P01CA022427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005526] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALISON DL, 1985, CANCER CHEMOTH PHARM, V14, P265; ARBUCK SG, 1989, CANCER, V63, P1036, DOI 10.1002/1097-0142(19890315)63:6+<1036::AID-CNCR2820631309>3.0.CO;2-K; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVERT AH, 1986, J CLIN ONCOL, V4, P1245, DOI 10.1200/JCO.1986.4.8.1245; CANTWELL BMJ, 1988, EUR J CANCER CLIN ON, V24, P733, DOI 10.1016/0277-5379(88)90307-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU E, 1990, CANCER RES, V50, P5834; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CISNEROS R J, 1988, Drugs of the Future, V13, P859; CLARKE S, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P406; CRISSMAN HA, 1974, SCIENCE, V184, P1297, DOI 10.1126/science.184.4143.1297; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; EINHORN LH, 1989, J CLIN ONCOL, V7, P1377, DOI 10.1200/JCO.1989.7.10.1377; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HARRAP KR, 1989, ADV ENZYME REGUL, V29, P161, DOI 10.1016/0065-2571(89)90099-X; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; JACKMAN A L, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P342; JACKMAN AL, 1991, ADV ENZYME REGUL, V31, P13, DOI 10.1016/0065-2571(91)90006-8; JACKMAN AL, 1990, CANCER RES, V50, P5212; JACKMAN AL, 1991, CANCER RES, V51, P5579; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KAMB A, 1992, BIOCHEMISTRY-US, V31, P9883, DOI 10.1021/bi00156a005; KAMB A, 1992, BIOCHEMISTRY-US, V31, P12876, DOI 10.1021/bi00166a024; KEYOMARSI K, 1988, J BIOL CHEM, V263, P14402; KEYOMARSI K, 1990, J BIOL CHEM, V265, P19163; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KEYOMARSI K, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P330; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; NEWELL DR, 1982, P AM ASSOC CANC RES, V23, P181; PINTER K, 1988, DNA-J MOLEC CELL BIO, V7, P235, DOI 10.1089/dna.1988.7.235; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; RODE W, 1980, J BIOL CHEM, V255, P1305; SPEARS CP, 1982, CANCER RES, V42, P450; STEPHENS T C, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P342; TOMICH PK, 1974, J BIOL CHEM, V249, P7613; VANDERWILT CL, 1992, CANCER RES, V52, P4922; WASHTIEN WL, 1984, MOL PHARMACOL, V25, P171; YIN MB, 1992, CANCER RES, V52, P5900	51	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15142	15149						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325888				2022-12-25	WOS:A1993LL75900087
J	HOU, XY; JOHNSON, AC; ROSNER, MR				HOU, XY; JOHNSON, AC; ROSNER, MR			IDENTIFICATION OF AN EPIDERMAL GROWTH-FACTOR RECEPTOR TRANSCRIPTIONAL REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-BINDING-SITES; DNA-BINDING; STIMULATES TRANSCRIPTION; ENHANCED EXPRESSION; GENE AMPLIFICATION; CARCINOMA-CELLS; PROMOTER; PURIFICATION; ONCOGENE; SEQUENCE	Identification of the factors controlling transcription of the epidermal growth factor (EGF) receptor gene is essential for understanding regulation of the EGF receptor and its overexpression in human carcinomas. In this study, we have identified a 60-base pair (bp) region (-919 to -860) relative to the AUG translation initiation codon in the EGF receptor 5' promoter that functions as a cis-acting EGF receptor transcriptional repressor (ETR). This fragment also acted as a repressor when linked to the thymidine kinase promoter. Gel mobility shift assays demonstrated that trans-acting factors bind to 60- and 19 bp fragments. Competition and chloramphenicol acetyltransferase assays with oligonucleotides containing mutations and deletions in this region indicate that the TTCGAGGG sequence (-877 to -870) is required for binding as well as repressor activity. While the ETR-protected region contains consensus sequences for the E2F binding site, no competition was observed with an E2F binding fragment. However, DNA-protein blot analysis indicates that both the 60- and 19-bp fragments specifically bind a 128-kDa polypeptide in extracts from HeLa or A431 human epidermoid carcinoma cells. These results suggest that a novel transcription factor(s) negatively regulates EGF receptor gene expression through binding to the ETR element.	UNIV CHICAGO, BEN MAY INST, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; NATL CANC INST, MOLEC BIOL LAB, BETHESDA, MD 20892 USA	University of Chicago; University of Chicago; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA 35541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; Cowley GO, 1984, CANCER CELL, V1, P5; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAMOTO T, 1986, CANCER RES, V46, P414; YAN DH, 1991, MOL CELL BIOL, V11, P1875, DOI 10.1128/MCB.11.4.1875; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHAO XY, 1992, MOL CELL BIOL, V12, P2739, DOI 10.1128/MCB.12.6.2739	45	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4307	4312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307997				2022-12-25	WOS:A1994MW98900064
J	TOUGU, K; PENG, H; MARIANS, KJ				TOUGU, K; PENG, H; MARIANS, KJ			IDENTIFICATION OF A DOMAIN OF ESCHERICHIA-COLI PRIMASE REQUIRED FOR FUNCTIONAL INTERACTION WITH THE DNAB HELICASE AT THE REPLICATION FORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; PRIMER SYNTHESIS; PROTEIN ACTION; GENE PRODUCT; PBR322 DNA; T4-61-PROTEIN; T4-41-PROTEIN; MECHANISM; PRIMOSOME	Primase plays a key role in governing the sequence of events required on the lagging strand during a cycle of Okazaki fragment synthesis. To begin to probe the protein-protein interactions necessary for primase function at the replication fork, we have used limited trypsinolysis to separate primase into two functional domains, an N-terminal domain of 49 kDa (p49) and a carboxyl-terminal domain of 16 kDa (p16). p49 retained primase activity in replication assays that utilized bacteriophage M13 DNA carrying the bacteriophage G4 origin of DNA replication as the template, but was inactive during general priming or the conversion of phi X174 single-stranded circular (ss(c))-DNA to the replicative form (RF) and could not support lagging strand DNA synthesis at replication forks reconstituted with the phi X-type primosomal proteins and the DNA polymerase m holoenzyme. On the other hand, p16 inhibited those replication reactions that included the replication fork helicase, DnaB (general priming, phi X174 ss(c) --> RF, and at the replication fork), but had no effect on those that did not (M13Gori ss(c) --> RF). These results demonstrate that p49 defines a domain of primase required for catalytic activity, that p16 defines a domain of primase required for functional interaction with DnaB, and that it is a protein-protein interaction with DnaB that attracts primase to the replication fork.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Cornell University	TOUGU, K (corresponding author), MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5253; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P398; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; GROMPE M, 1991, J BACTERIOL, V173, P1268, DOI 10.1128/jb.173.3.1268-1278.1991; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; Kornberg A., 1992, DNA REPLICATION, P182; LARK KG, 1972, NATURE-NEW BIOL, V240, P237, DOI 10.1038/newbio240237a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1989, J BIOL CHEM, V264, P14531; LIU CC, 1981, J BIOL CHEM, V256, P2821; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; MURAKAMI Y, 1985, J BACTERIOL, V162, P830, DOI 10.1128/JB.162.2.830-832.1985; NORRIS V, 1986, J BACTERIOL, V168, P494, DOI 10.1128/jb.168.2.494-504.1986; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUAN W, 1993, J BIOL CHEM, V268, P8026; SWART JR, 1993, J BIOL CHEM, V268, P12970; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WICKNER S, 1973, P NATL ACAD SCI USA, V70, P1613, DOI 10.1073/pnas.70.5.1613; WRIGHT M, 1973, P NATL ACAD SCI USA, V70, P3120, DOI 10.1073/pnas.70.11.3120; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	36	131	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4675	4682						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308039				2022-12-25	WOS:A1994MW98900114
J	WANG, S; VIK, SB				WANG, S; VIK, SB			SINGLE AMINO-ACID INSERTIONS PROBE THE ALPHA-SUBUNIT OF THE ESCHERICHIA-COLI F(1)F(0)-ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1F0 ATP SYNTHASE; H+-ATPASE; A-SUBUNIT; PROTON TRANSLOCATION; TRANSMEMBRANE TOPOLOGY; PROTEOLIPID SUBUNIT; MEMBRANE-PROTEINS; MUTATIONS; F0F1-ATPASE; F1F0-ATPASE	Single amino acid insertions of alanine or aspartate have been introduced into the a subunit of the F1F0-ATP synthase at seven different sites, after residues 187, 193, 198, 202, 212, 217, and 222. These sites span a highly conserved region of the a subunit, parts of which are thought to be located in transmembrane spanning regions. Alanine insertions have little or no effect on function after positions 187, 193, 198, and 202, indicating that the region spanned by these residues is not essential for function. Alanine insertions after residues 212 and 217 disrupt ATP synthase function without grossly affecting the assembly of the enzyme, while the alanine insertion after residue 222 disrupts both ATP synthase function and assembly. All of the aspartate insertions are deleterious to ATP synthase function, except after residue 198. At the other six sites, aspartate insertions prevent growth on succinate minimal medium, indicating an inability to synthesize ATP. Aspartate insertions after residues 187 and 193 result in a subunits that do not fractionate with membranes, as indicated by immunoblotting. These results support a model of the a subunit in which residues 187-193 and residues 212-222 are part of distinct transmembrane spans, separated by a short extramembrane loop. The results are consistent with an important interaction between residues 212-222 of the a subunit and b or c subunits. General aspects of ''insertion scanning mutagenesis'' are also discussed.	SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275	Southern Methodist University				Vik, Steven/0000-0002-5285-015X	NIGMS NIH HHS [R01 GM040508, GM40508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORBAEK C, 1990, FEBS LETT, V260, P31, DOI 10.1016/0014-5793(90)80058-Q; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CARUTHERS MH, 1987, METHOD ENZYMOL, V154, P287; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HENNIG J, 1986, MOL GEN GENET, V8, P543; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; HOWITT SM, 1990, BIOCHIM BIOPHYS ACTA, V1015, P264, DOI 10.1016/0005-2728(90)90030-8; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; MARTI T, 1992, P NATL ACAD SCI USA, V89, P1219, DOI 10.1073/pnas.89.4.1219; Miller J. H., 1972, EXPT MOL GENETICS, P431; NIEUWENHUIS FJ, 1973, BIOCHIM BIOPHYS ACTA, V325, P62, DOI 10.1016/0005-2728(73)90151-5; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SEBALD W, 1980, P NATL ACAD SCI-BIOL, V77, P785, DOI 10.1073/pnas.77.2.785; SENIOR AE, 1983, BIOCHIM BIOPHYS ACTA, V726, P81, DOI 10.1016/0304-4173(83)90001-0; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SONDEK J, 1990, PROTEINS, V7, P299, DOI 10.1002/prot.340070402; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; VIK SB, 1991, J BACTERIOL, V173, P4544, DOI 10.1128/JB.173.14.4544-4548.1991; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	38	16	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3095	3099						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300644				2022-12-25	WOS:A1994MV43200105
J	DZIARSKI, R; GUPTA, D				DZIARSKI, R; GUPTA, D			HEPARIN, SULFATED HEPARINOIDS, AND LIPOTEICHOIC ACIDS BIND TO THE 70-KDA PEPTIDOGLYCAN LIPOPOLYSACCHARIDE RECEPTOR PROTEIN ON LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRITICAL MICELLE CONCENTRATIONS; PHOTOAFFINITY CROSS-LINKING; MURINE SPLENOCYTES; BACTERIAL LIPOPOLYSACCHARIDE; CHOLESTEROL DEPOSITION; MONOCLONAL-ANTIBODY; DEXTRAN SULFATE; LYMPHOID-CELLS; IDENTIFICATION; BLOOD	The same 70-kDa protein, present on the surface of mouse lymphocytes, served as the predominant binding site for heparin, heparinoids, and bacterial lipoteichoic acids, as well as peptidoglycan and lipopolysaccharides. This conclusion was supported by the following results: (a) all of these compounds photoaffinity cross-linked to one major 70-kDa 6.5-7.0 pI protein that co-migrated on two-dimensional polyacrylamide gel electrophoresis; (b) peptide maps of the 70-kDa proteins digested with chymotrypsin, subtilisin, protease V, or papain yielded the same peptides for heparin-, lipoteichoic acid-, peptidoglycan-, and lipopolysaccharide-binding proteins; (c) cross-linking of peptidoglycan, lipopolysaccharide, lipoteichoic acid, and heparin was competitively inhibited by the same compounds with the same order of potency, i.e. carboxyl-reduced sulfated heparin > peptidoglycan > pentosan polysulfate > heparin > chitin > dextran sulfate > trestatin sulfate > polyanetholesulfonate > fucoidan> beta-cyclodextrin tetradecasulfate > heparan sulfate > carrageenan lambda > lipoteichoic acids > Re-lipopolysaccharide > lipopolysaccharide > lipid A > polygalacturonic acid; and (d) cross-linking of each of these ligands was not inhibited by carboxyl-reduced heparin, dextran, beta-cyclodextrin, trestatin, carrageenan kappa, chondroitin 4-sulfate, chondroitin 6-sulfate, beta-D-glucan, carboxymethylcellulose, levan, alpha-D-mannan, and glycogen. The minimum size of the molecule that bound was 7-9 glycan residues, whereas, di- and trisaccharides did not bind. There was a logarithmic linear relationship between the strength of the binding and the length of the polymer (up to >1500 glycan residues), which indicates an avidity effect of the cooperative binding of one polymeric molecule to several receptor molecules on the cell surface. The 70-kDa receptor, therefore, has a broad, but limited specificity of binding for non-charged (peptidoglycan and chitin), highly negatively charged (heparin and heparinoids), and weakly negatively charged (lipoteichoic acids, lipopolysaccharides, and lipid A) ligands.			DZIARSKI, R (corresponding author), INDIANA UNIV, SCH MED, NW CTR MED EDUC, GARY, IN 46408 USA.				NIAID NIH HHS [AI28797] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028797] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RA, 1986, BIOCHIM BIOPHYS ACTA, V882, P271, DOI 10.1016/0304-4165(86)90248-5; BEACHEY EH, 1977, INFECT IMMUN, V16, P649, DOI 10.1128/IAI.16.2.649-654.1977; BEACHEY EH, 1979, INFECT IMMUN, V23, P618, DOI 10.1128/IAI.23.3.618-625.1979; BHAKDI S, 1991, INFECT IMMUN, V59, P4614, DOI 10.1128/IAI.59.12.4614-4620.1991; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUTLER T, 1977, INFECT IMMUN, V16, P449, DOI 10.1128/IAI.16.2.449-455.1977; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHEN TY, 1990, J IMMUNOL, V145, P8; COURTNEY H, 1981, INFECT IMMUN, V32, P625, DOI 10.1128/IAI.32.2.625-631.1981; COURTNEY HS, 1986, INFECT IMMUN, V51, P414, DOI 10.1128/IAI.51.2.414-418.1986; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DZIARSKI R, 1989, J IMMUNOL, V143, P356; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; DZIARSKI R, 1992, CELL IMMUNOL, V145, P100, DOI 10.1016/0008-8749(92)90316-H; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; DZIARSKI R, 1987, CELL IMMUNOL, V109, P231, DOI 10.1016/0008-8749(87)90307-8; Dziarski R, 1992, J Immunol, V148, P1590; DZIARSKI R, 1993, INT CONGR SER, V1020, P151; EDENS RE, 1992, J PHARM SCI, V81, P823, DOI 10.1002/jps.2600810821; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; FISCHER W, 1983, EUR J BIOCHEM, V133, P523, DOI 10.1111/j.1432-1033.1983.tb07495.x; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; FOMSGAARD A, 1990, J CLIN MICROBIOL, V28, P2627, DOI 10.1128/JCM.28.12.2627-2631.1990; FRANSSON LA, 1985, POLYSACCHARIDES, V3, P337; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GREEN SJ, 1992, J IMMUNOL, V149, P2069; HALLING JL, 1992, INFECT IMMUN, V60, P845, DOI 10.1128/IAI.60.3.845-852.1992; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HU WL, 1990, BIOCHEMISTRY-US, V29, P535, DOI 10.1021/bi00454a030; IWASAKI H, 1989, J BACTERIOL, V171, P424, DOI 10.1128/jb.171.1.424-429.1989; JAQUES LB, 1979, SCIENCE, V206, P528, DOI 10.1126/science.386509; KNAUS HG, 1990, J BIOL CHEM, V265, P11156; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LEI MG, 1988, J IMMUNOL, V141, P996; LEI MG, 1988, J IMMUNOL, V141, P1006; LEI MG, 1991, J IMMUNOL, V147, P1925; LEVY R, 1990, INFECT IMMUN, V58, P566, DOI 10.1128/IAI.58.2.566-568.1990; LINHARDT RJ, 1984, APPL BIOCHEM BIOTECH, V9, P41, DOI 10.1007/BF02798373; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LONCHAMPT MO, 1992, J CARDIOVASC PHARM, V20, pS145, DOI 10.1097/00005344-199204002-00041; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MATHISON JC, 1992, J IMMUNOL, V149, P200; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; MORRISON DC, 1990, J INFECT DIS, V162, P1063, DOI 10.1093/infdis/162.5.1063; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; OFEK I, 1975, J EXP MED, V141, P990, DOI 10.1084/jem.141.5.990; PARISH CR, 1985, CELL IMMUNOL, V91, P201, DOI 10.1016/0008-8749(85)90044-9; PARISH CR, 1988, J IMMUNOL, V141, P3498; QURESHI N, 1988, J BIOL CHEM, V263, P11971; RABIN RL, 1993, J INFECT DIS, V168, P135, DOI 10.1093/infdis/168.1.135; ROEDER DJ, 1989, INFECT IMMUN, V57, P1054, DOI 10.1128/IAI.57.4.1054-1058.1989; RUPLEY JA, 1964, BIOCHIM BIOPHYS ACTA, V83, P245, DOI 10.1016/0926-6526(64)90001-1; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SMITH CIE, 1978, J IMMUNOL, V121, P823; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; TARSITSUK D, 1990, J IMMUNOL, V144, P2665; THURN AL, 1986, J CELL PHYSIOL, V126, P352, DOI 10.1002/jcp.1041260305; TOTH CA, 1992, J LEUKOCYTE BIOL, V51, P466; VANLENTEN BJ, 1986, P NATL ACAD SCI USA, V83, P2704; WESSEL HP, 1990, CARBOHYD RES, V204, P131, DOI 10.1016/0008-6215(90)84028-S; WICKEN AJ, 1986, J BACTERIOL, V166, P72, DOI 10.1128/jb.166.1.72-77.1986; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451	67	28	28	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2100	2110						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294463				2022-12-25	WOS:A1994MR98800084
J	HE, DY; YU, L; YU, CA				HE, DY; YU, L; YU, CA			UBIQUINONE BINDING DOMAINS IN BOVINE HEART MITOCHONDRIAL CYTOCHROME-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; IRON-SULFUR PROTEIN; C REDUCTASE COMPLEX; BEEF-HEART; BC1 COMPLEX; OXIDOREDUCTASE; INHIBITORS; SUBUNIT; RESISTANCE; ANTIMYCIN	Cytochrome b was identified as one of the ubiquinone-binding proteins in bovine heart mitochondrial ubiquinol-cytochrome c reductase by photoaffinity labeling using 3-azido-2-methyl-5-methoxy-6-(3,7-dimethyl[H-3]-octyl)-1,4-benzoquinone ([H-3]azido-Q). The [H-3]azido-Q-labeled cytochrome b protein was purified to homogeneity from the azido-Q-labeled ubiquinol-cytochrome c reductase by a procedure involving Triton X-100 and urea treatment, calcium phosphate column chromatography, acetone precipitation, decanoyl-N-methylglucamide-cholate extraction, and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Purified cytochrome b protein containing 0.5 mol of azido-Q/mol of protein was subjected to reductive carboxymethylation and succinylation prior to digestion by chymotrypsin. Two azido-Q-linked peptides with retention times of 47.1 and 49.0 min were obtained by high performance liquid chromatographic separation. Partial amino-terminal amino acid sequences of these two peptides were determined to be GATVI- and ALVADL-, indicating that these two chymotryptic peptides are from amino residues 142-155 and 326-336. Monospecific polyclonal antibodies against two synthetic ubiquinone-binding peptides, NH2-G-A-T-V-I-T-N-L-L-S-COOH (P-47) and NH2-W-A-L-V-A-D-L-L-T-L-T-W-I-COOH (P-49), were generated in rabbits and purified. Western blotting and enzyme-linked immunosorbent assays showed that the purified antibodies against P-47 reacted with cytochrome b-containing reductases and purified cytochrome b protein. Antibodies against P-47 inhibited activities of succinate-cytochrome c and ubiquinol-cytochrome c reductases only when they were incubated with phospholipid-depleted reductases prior to the replenishment with phospholipid. No inhibition was observed with incubation with phospholipid-containing reductases, indicating that this peptide involved in ubiquinone binding is buried in a phospholipid environment.	OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,NOBLE RES CTR 246,STILLWATER,OK 74078	Oklahoma State University System; Oklahoma State University - Stillwater					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BORCHART U, 1986, FEBS LETT, V200, P81, DOI 10.1016/0014-5793(86)80515-4; BOWYER JR, 1982, FUNCTION QUINONES EN, P365; BRANDT U, 1993, J BIOL CHEM, V268, P8387; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P210; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; DEVRIES S, 1981, J BIOL CHEM, V256, P1996; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GONZALEZHALPHEN D, 1991, J BIOL CHEM, V266, P3870; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HILDRETH JEK, 1982, BIOCHEM J, V207, P363, DOI 10.1042/bj2070363; HOSOKAWA Y, 1989, J BIOL CHEM, V264, P13483; JENNER ER, 1973, Patent No. 3737516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI LB, 1991, BIOCHIM BIOPHYS ACTA, V1057, P215, DOI 10.1016/S0005-2728(05)80104-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRES CAM, 1977, BIOCHIM BIOPHYS ACTA, V462, P531, DOI 10.1016/0005-2728(77)90099-8; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; USUI S, 1990, BIOCHEMISTRY-US, V29, P4618, DOI 10.1021/bi00471a017; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; Voller A., 1980, MANUAL CLIN IMMUNOLO, P359; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1984, J BIOL CHEM, V259, P6318; VONJAGOW G, 1987, ADV MEMBRANE BIOCH B, P155; WAKABAYASHI S, 1980, BIOCHEM BIOPH RES CO, V97, P1548, DOI 10.1016/S0006-291X(80)80042-8; WAKABAYASHI S, 1985, J BIOL CHEM, V260, P337; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; YU CA, 1993, J BIOENERG BIOMEMBR, V25, P259, DOI 10.1007/BF00762587; YU CA, 1983, BIOCHIM BIOPHYS ACTA, V736, P226, DOI 10.1016/0005-2736(83)90288-2; YU CA, 1980, ARCH BIOCHEM BIOPHYS, V204, P59, DOI 10.1016/0003-9861(80)90007-7; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1982, J BIOL CHEM, V257, P2016; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002	41	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2292	2298						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294488				2022-12-25	WOS:A1994MR98800110
J	SWEDER, KS; HANAWALT, PC				SWEDER, KS; HANAWALT, PC			THE COOH TERMINUS OF SUPPRESSOR OF STEM-LOOP (SSL2/RAD25) IN YEAST IS ESSENTIAL FOR OVERALL GENOMIC EXCISION-REPAIR AND TRANSCRIPTION-COUPLED REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; PREFERENTIAL REPAIR; COCKAYNES-SYNDROME; PYRIMIDINE DIMERS; RAD3 PROTEIN; DHFR GENE; HELICASE; HOMOLOG	We examined several yeast strains with different mutations in the essential SSL2 (Suppressor of Stem Loop, also called RAD25) gene for their ability to remove cyclobutane pyrimidine dimers. from expressed genes, and from the genome overall. The SSL2 protein has a high degree of amino acid sequence identity to the protein encoded by the human ERCC3 gene (Gulyas, K. D., and Donahue, T. F. (1992) Cell 69, 1031-0142). The mutant allele SSL2-XP encodes a protein resembling the mutated ERCC3 protein from UV-sensitive human cells belonging to xeroderma pigmentosum complementation group B and Cockayne's syndrome (CS) complementation group C (Weeda, G., van Ham, R. C. A., Vermeulen, W., Bootsma, D., van der Eb, A. J., and Hoeijmakers, J. H. J. (1990) Cell 62, 777-791; Gulyas and Donahue, 1992). The SSL2-XP allele confers UV sensitivity on yeast strain KG119. We found-that the biochemical basis for the UV sensitivity of KG119 is a complete deficiency in the removal of cyclobutane pyrimidine dimers from the overall genome as well as a deficiency in transcription-coupled repair. This is the first analysis of the DNA repair defect responsible for the UV sensitivity of cells carrying the SSL2-XP allele, and it documents the similarity of the defect to that associated with XP-B/CS-C, and the difference between this defect and that in cells belonging to CS complementation groups A and B.			SWEDER, KS (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.		Sweder, Kevin/GSM-7837-2022		NATIONAL CANCER INSTITUTE [R35CA044349] Funding Source: NIH RePORTER; NCI NIH HHS [CA44349] Funding Source: Medline; NIEHS NIH HHS [ES05521-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 1985, DNA REPAIR; BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LEHMANN AR, 1981, DNA REPAIR LABORATOR, V1, P471; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; ROZA L, 1990, CANCER RES, V50, P1905; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SHERMAN F, 1986, LABORATORY COURSE MA; SMERDON MJ, 1990, NUCLEIC ACIDS RES, V18, P2045, DOI 10.1093/nar/18.8.2045; SMITH CA, 1990, ADV MUTAGENESIS RES, V1, P153; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; TERLETH C, 1991, MUTAGENESIS, V6, P103, DOI 10.1093/mutage/6.2.103; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; WEEDA G, 1991, CARCINOGENESIS, V12, P2361, DOI 10.1093/carcin/12.12.2361; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U	26	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1852	1857						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294433				2022-12-25	WOS:A1994MR98800048
J	PAPKOFF, J				PAPKOFF, J			IDENTIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF SECRETED WNT-1 PROTEIN FROM P19 EMBRYONAL CARCINOMA-CELLS INDUCED TO DIFFERENTIATE ALONG THE NEUROECTODERMAL LINEAGE	ONCOGENE			English	Note							MOUSE MAMMARY ONCOGENE; INT-1 PROTOONCOGENE; XENOPUS EMBRYOS; EXPRESSION; DROSOPHILA; PRODUCTS; WINGLESS; REGION; AXIS; RNA	Previous studies have described Wnt-1 protein synthesized by cell lines transfected with Wnt-1 cDNA. This report presents the first identification and biochemical characterization of native Wnt-1 protein, from P19 embryonal carcinoma cells undergoing neuroectodermal differentiation. The data demonstrate that P19 cells efficiently process and secrete glycosylated Wnt-1 protein species of 40kD and 42kD. Similar to recombinant Wnt-1 proteins, native Wnt-1 proteins are associated with the cell surface upon secretion and can be released by suramin treatment of the cells. Non-reducing gel analysis showed that Wnt-1 proteins are secreted as monomers.			PAPKOFF, J (corresponding author), SUGEN INC, 515 GALVESTON DR, REDWOOD CITY, CA 94063 USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STARNAUD R, 1989, ONCOGENE, V4, P1077; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	23	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					313	317						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302595				2022-12-25	WOS:A1994MW24700038
J	BUCKLEY, MF; SWEENEY, KJE; HAMILTON, JA; SINI, RL; MANNING, DL; NICHOLSON, RI; DEFAZIO, A; WATTS, CKW; MUSGROVE, EA; SUTHERLAND, RL				BUCKLEY, MF; SWEENEY, KJE; HAMILTON, JA; SINI, RL; MANNING, DL; NICHOLSON, RI; DEFAZIO, A; WATTS, CKW; MUSGROVE, EA; SUTHERLAND, RL			EXPRESSION AND AMPLIFICATION OF CYCLIN GENES IN HUMAN BREAST-CANCER	ONCOGENE			English	Article							CELL-CYCLE; ESTROGEN-RECEPTOR; CANDIDATE ONCOGENE; PUTATIVE ONCOGENE; CHROMOSOME 11Q13; PROMOTING FACTOR; POOR PROGNOSIS; PROTEIN-KINASE; MESSENGER-RNAS; BCL-1 GENE	Cyclins, the regulatory subunits of cyclin-dependent kinases, play an important role in the control of cellular proliferation. Since dysregulated expression of these genes may contribute to the malignant phenotype the expression and amplification of cyclin A, B1, C, D1, D2, D3 and E genes were studied in 20 breast cancer cell lines. Increased expression of one or more of the cyclin A, B1, D1 or E genes was found in seven cell lines (35%); of these five (25%) showed increased expression of cyclin D1. Overexpression occurred in both the presence and absence of gene amplification. Conversely, amplification did not invariably lead to overexpression. Cyclin D2 expression was lower in breast cancer cell tines than in cultured normal breast epithelial cells. Cyclin D1 expression was further investigated in breast tumour biopsies: 56 of 124 specimens (45%) expressed higher levels of cyclin D1 mRNA than normal breast tissue. These data implicate dysregulated expression of several cyclin genes, particularly cyclin D1, as a potential factor in the pathogenesis of breast cancer.	ST VINCENTS HOSP, GARVAN INST MED RES, DIV CANC BIOL, DARLINGHURST, NSW 2010, AUSTRALIA; UNIV WALES COLL MED, TENOVUS CANC RES CTR, BREAST CANC LAB, CARDIFF CF4 4XX, S GLAM, WALES	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Cardiff University			deFazio, Anna/D-3939-2013; Sutherland, Robert L/A-8378-2008; DeFazio, Anna/O-2385-2019	deFazio, Anna/0000-0003-0057-4744; DeFazio, Anna/0000-0003-0057-4744; buckley, michael/0000-0002-8298-8758				ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1989, ONCOGENE, V4, P89; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; CHAN YL, 1984, J BIOL CHEM, V259, P224; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FAUST JB, 1992, CANCER RES, V52, P2460; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GRAHAM ML, 1989, CANCER RES, V49, P3943; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIS S, 1990, J CLIN PATHOL, V43, P385, DOI 10.1136/jcp.43.5.385; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LISCIA DS, 1989, ONCOGENE, V4, P1219; LOVEKIN C, 1991, BRIT J CANCER, V63, P439, DOI 10.1038/bjc.1991.101; MANNING DL, 1990, CANCER RES, V50, P4098; MANNING DL, 1993, IN PRESS EUR J CANCE; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATTEI MG, 1988, HUM GENET, V78, P96, DOI 10.1007/BF00291245; MEYERS SL, 1990, CANCER RES, V50, P5911; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MUSGROVE EA, UNPUB; NICHOLSON RI, 1991, EUR J CANCER, V27, P908, DOI 10.1016/0277-5379(91)90145-4; NICHOLSON RI, 1993, IN PRESS EUR J CANCE; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ORMANDY CJ, 1992, BIOCHEM BIOPH RES CO, V182, P740, DOI 10.1016/0006-291X(92)91794-Q; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REDDEL RR, 1988, CANCER RES, V48, P4340; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROSENBERG CL, 1991, ONCOGENE, V6, P449; SAMBROOK J, 1908, MOL CLONING LABORATO; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; SUTHERLAND MC, 1991, REGULATORY MECHANISM, P3; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; THEILLET C, 1990, ONCOGENE, V5, P147; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WALKER KJ, 1988, CANCER RES, V48, P6517; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	58	689	704	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2127	2133						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336939				2022-12-25	WOS:A1993LP17100013
J	TORNALETTI, S; ROZEK, D; PFEIFER, GP				TORNALETTI, S; ROZEK, D; PFEIFER, GP			THE DISTRIBUTION OF UV PHOTOPRODUCTS ALONG THE HUMAN P53 GENE AND ITS RELATION TO MUTATIONS IN SKIN-CANCER	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; LIGATION-MEDIATED PCR; TUMOR SUPPRESSOR GENE; XERODERMA PIGMENTOSUM; ESCHERICHIA-COLI; N-RAS; METHYLATION ANALYSIS; PYRIMIDINE DIMERS; 6-4 PHOTOPRODUCTS; MAMMALIAN-CELLS	Mutations in the p53 gene have been found in a large proportion of human skin cancers. These mutations show the same characteristics as mutations induced by UV light in experimental systems. To establish correlations between formation of DNA adducts by a known carcinogen nd incidence of mutations within a specific human gene, we have investigated the formation of UV-induced photoproducts along exons 5-9 of the p53 gene after UV irradiation of human cells. The two major types of DNA photoproducts, cyclobutane pyrimidine dimers and pyrimidine (64) pyrimidone photoproducts [(6-4) photoproducts], were mapped at the DNA sequence level by strand cleavage at the sites of photoproducts. This was followed by ligation-mediated polymerase chain reaction (LMPCR) to amplify gene-specific fragments. In human skin cancers, mutations were most frequently found at codons 151/152, 245, 248, 278 and 286 of the p53 gene. The frequency of UV photoproducts is particularly high at codon 286, which is within a run of 12 adjacent pyrimidines. High levels of both photoproducts were also seen at codons 151 and 278. However, UV-induced DNA adducts are barely detectable at codons 245 and 248, which are mutation hotspots also for internal malignancies. At these positions, the frequency of photoproducts is much lower than at surrounding dipyrimidine sequences. These findings have some implications on molecular mechanisms of mutagenesis in the human genome.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [1RO1ES06070-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBINO AP, 1989, ONCOGENE, V4, P1363; ANATHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BOURRE F, 1987, NUCLEIC ACIDS RES, V15, P8861, DOI 10.1093/nar/15.21.8861; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; CHUMAKOV PM, 1991, GENBANK LOCUS HUMP53; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; GLICKMAN BW, 1986, P NATL ACAD SCI USA, V83, P6945, DOI 10.1073/pnas.83.18.6945; GORDON LK, 1980, J BIOL CHEM, V255, P2047; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONES PA, 1991, CANCER RES, V51, P3617; KEIJZER W, 1989, CANCER RES, V49, P1229; KRESS S, 1992, CANCER RES, V52, P6400; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MOLES JP, 1993, ONCOGENE, V8, P583; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; Pfeifer G P, 1992, PCR Methods Appl, V2, P107; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1993, METHODS MOL BIOL SEL, P153; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADY P, 1992, CANCER RES, V52, P3804; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SHUKLA VK, 1989, ONCOGENE RES, V5, P121; SUAREZ HG, 1989, CANCER RES, V49, P1223; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; TORMANEN VT, 1992, ONCOGENE, V7, P1729; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	54	133	134	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2051	2057						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336934				2022-12-25	WOS:A1993LP17100004
J	BOARD, P; SMITH, S; GREEN, J; COGGAN, M; SUZUKI, T				BOARD, P; SMITH, S; GREEN, J; COGGAN, M; SUZUKI, T			EVIDENCE AGAINST A RELATIONSHIP BETWEEN FATTY-ACID ETHYL-ESTER SYNTHASE AND THE PI-CLASS GLUTATHIONE-S-TRANSFERASE IN HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONOXIDATIVE ETHANOL-METABOLISM; GENETIC-HETEROGENEITY; ESCHERICHIA-COLI; HUMAN-PLACENTA; EXPRESSION; CDNA; IDENTIFICATION; RESOLUTION; MYOCARDIUM; PROTEINS	Recently, Bora et al. (Bora, P. S., Bora, N. S., Wu, X., and Lange, L. G. (1991) J. Biol. Chem. 266,16774-16777) reported the cloning and expression of a human fatty acid ethyl ester synthase III (FAEES-III) cDNA that has only four amino acid substitutions compared with human glutathione S-transferase (GST) GSTP1-1, and, when expressed in MCF-7 cells, the protein has both FAEES and GST activities. By site-directed mutagenesis of a GSTP1 cDNA, we have constructed a clone that encodes the FAEES-III protein described by Bora et al. (1991). The recombinant FAEES-III protein was expressed in Escherichia coli and has been shown to be devoid of FAEES and GST activities. The recombinant FAEES-III protein does not bind to a glutathione agarose affinity matrix, presumably because two of the substituted amino acids, Trp-39 --> Cys and Gln-52 --> Glu, are thought to contribute to the GST glutathione binding site. One of the base substitutions in the FAEES-III cDNA encodes an extra SacI site not found in the GSTPI cDNA. Polymerase chain reaction amplification of human genomic DNA has identified the GSTPI gene, but no DNA from the proposed FAEES gene with a diagnostic SacI site has been detected. Evaluation of the hybridization pattern of HindIII genomic restriction fragments has identified fragments that contain the GSTPI gene and a pseudogene (Board et al. 1992), and there do not appear to be any hybridizing fragments that could contain the FAEEs-III gene. Our results do not provide any evidence in support of a relationship between FAEES-III and GST, and the cDNA reported by Bora et al. (1991) may have resulted from a cloning artifact.			BOARD, P (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MOLEC GENET GRP,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA.							AHMAD H, 1990, ARCH BIOCHEM BIOPHYS, V278, P398, DOI 10.1016/0003-9861(90)90277-6; ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; BOARD P, 1990, PHARMACOL THERAPEUT, V48, P357, DOI 10.1016/0163-7258(90)90054-6; BOARD PG, 1981, AM J HUM GENET, V33, P36; BOARD PG, 1984, ANN HUM GENET, V48, P223, DOI 10.1111/j.1469-1809.1984.tb01018.x; BOARD PG, 1989, ANN HUM GENET, V53, P205, DOI 10.1111/j.1469-1809.1989.tb01786.x; BOARD PG, 1992, GENOMICS, V14, P470, DOI 10.1016/S0888-7543(05)80243-5; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; BORA PS, 1989, J CLIN INVEST, V84, P1942, DOI 10.1172/JCI114382; BORA PS, 1989, P NATL ACAD SCI USA, V86, P4470, DOI 10.1073/pnas.86.12.4470; BORA PS, 1991, J BIOL CHEM, V266, P16774; BORA PS, 1992, BIOCHEM BIOPH RES CO, V184, P706, DOI 10.1016/0006-291X(92)90647-4; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; GUTHENBERG C, 1981, BIOCHIM BIOPHYS ACTA, V661, P255, DOI 10.1016/0005-2744(81)90012-7; Habig W H, 1981, Methods Enzymol, V77, P398; ISENBERG KE, 1992, BIOCHEM BIOPH RES CO, V185, P938, DOI 10.1016/0006-291X(92)91717-5; KANO T, 1987, CANCER RES, V47, P5626; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MOGELSON S, 1984, BIOCHEMISTRY-US, V23, P4075, DOI 10.1021/bi00313a010; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; NISHIHIRA J, 1992, BIOCHEM BIOPH RES CO, V185, P1069, DOI 10.1016/0006-291X(92)91735-9; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA R, 1991, BIOCHEM J, V275, P507, DOI 10.1042/bj2750507; SIMMONS PC, 1977, ANAL BIOCHEM, V82, P334; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; SUZUKI T, 1990, FEBS LETT, V275, P58, DOI 10.1016/0014-5793(90)81438-T; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15655	15658						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340390				2022-12-25	WOS:A1993LN30500051
J	LANIER, SM; IVKOVIC, B; SINGH, I; NEUMEYER, JL; BAKTHAVACHALAM, V				LANIER, SM; IVKOVIC, B; SINGH, I; NEUMEYER, JL; BAKTHAVACHALAM, V			VISUALIZATION OF MULTIPLE IMIDAZOLINE GUANIDINIUM-RECEPTIVE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CLONIDINE-DISPLACING SUBSTANCE; MITOCHONDRIAL OUTER-MEMBRANE; PROTEIN-COUPLED RECEPTORS; ALPHA-2-ADRENERGIC RECEPTOR; BINDING-SITES; VENTROLATERAL MEDULLA; BASOLATERAL MEMBRANES; SIGNAL TRANSDUCTION; RABBIT KIDNEY	Compounds with an imidazoline or guanidinium moiety elicit a variety of stimulatory and inhibitory cell responses in both central and peripheral tissues. Many of these effects are mediated by interaction with alpha-adrenergic receptors, but these molecules also selectively recognize other membrane-bound proteins with high affinity. We used a functionalized derivative of the imidazoline molecule cirazoline to visualize the imidazoline/guanidinium-receptive site (IGRS). 2-[3-Aminophenoxy]methyl imidazoline was radioiodinated and subsequently converted to the arylazide to generate the photoaffinity adduct 2-[3-azido-4-[I-125]iodophenoxy]methyl imidazoline ([I-125]AZIPI). Both 2-[3-amino-4-[I-125]iodophenoxy]methyl imidazoline and [I-125]AZIPI exhibited saturable high affinity binding in rat liver membrane preparations (K(i) = 2-5 nM). In rat liver mitochondrial membranes, [I-125]AZIPI photoincorporates into two peptides with apparent molecular weights of approximately 55,000 and approximately 61,000 as determined by SDS-polyacrylamide gel electrophoresis. The labeling of these two species is blocked by various competing ligands (10 muM) with a potency order expected for an IGRS. The photolabeling of both peptides is blocked by the imidazolines cirazoline and idazoxan or by the guanidinium guanabenz, but it is not altered the alpha2-adrenergic receptor antagonist rauwolscine or by the adrenergic receptor agonist epinephrine. Photoincorporation of [I-125]AZIPI is minimally inhibited by the imidazoline clonidine or by the alpha1-adrenergic receptor antagonist prazosin. However, the guanidinium ligand amiloride exhibits higher affinity for the M(r) = 61,000 peptide as compared with the M(r) = 55,000 peptide, suggesting that the two labeled species differ in their ligand recognition properties. An additional IGRS was identified by photolabeling in membranes prepared from PC-12 pheochromocytoma cells. In PC-12 membranes, [I-125]AZIPI photolabels a major M(r) = approximately 61,000 peptide; the photoincorporation is blocked by cirazoline, guanabenz, and amiloride but not by idazoxan (competing ligands = 10 muM). These data indicate the existence of at least three subtypes of IGRS that differ in their ligand recognition properties, their apparent molecular weight, and their tissue distribution.	MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29425; RES BIOCHEM INT,NATICK,MA 01760	Medical University of South Carolina	LANIER, SM (corresponding author), MED UNIV S CAROLINA,DEPT PHARMACOL,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.			Lanier, Stephen/0000-0002-2740-7607; Neumeyer, John/0000-0003-2287-9864	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM046605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821] Funding Source: NIH RePORTER; NIGMS NIH HHS [R43 GM-46605] Funding Source: Medline; NINDS NIH HHS [R01 NS-24821] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ATLAS D, 1984, EUR J BIOCHEM, V144, P287, DOI 10.1111/j.1432-1033.1984.tb08462.x; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BIDET M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P173, DOI 10.1016/0005-2736(90)90221-9; BOURRE JM, 1982, J NEUROCHEM, V38, P643, DOI 10.1111/j.1471-4159.1982.tb08679.x; BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232; BOUSQUET P, 1986, EUR J PHARMACOL, V124, P167, DOI 10.1016/0014-2999(86)90138-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTIELLO HF, 1989, J BIOL CHEM, V264, P16000; COOPERSTEINE SJ, 1951, J CELL BIOL, V189, P655; COUPRY I, 1987, BIOCHEM BIOPH RES CO, V147, P1055, DOI 10.1016/S0006-291X(87)80177-8; COUPRY I, 1989, J PHARMACOL EXP THER, V252, P293; DHAUNSI GS, 1992, J BIOL CHEM, V267, P6870; DUZIC E, 1992, J BIOL CHEM, V267, P9844; DUZIC E, 1992, J BIOL CHEM, V267, P24045; ERNSBERGER P, 1990, J PHARMACOL EXP THER, V253, P408; ERNSBERGER P, 1987, EUR J PHARMACOL, V134, P1, DOI 10.1016/0014-2999(87)90125-7; FERRIS CD, 1992, J NEUROSCI, V12, P1567; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LACHAUDPETTITI V, 1991, EUR J PHARM-MOLEC PH, V206, P23, DOI 10.1016/0922-4106(91)90142-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGIN D, 1990, MOL PHARMACOL, V37, P876; LANIER SM, 1986, P NATL ACAD SCI USA, V83, P9358, DOI 10.1073/pnas.83.24.9358; LAZO O, 1991, MOL CELL BIOCHEM, V100, P159; LIMON I, 1992, J BIOL CHEM, V267, P21645; MACKINNON AC, 1989, BRIT J PHARMACOL, V98, P1143, DOI 10.1111/j.1476-5381.1989.tb12658.x; MEELEY MP, 1986, LIFE SCI, V38, P1119, DOI 10.1016/0024-3205(86)90248-1; MICHEL MC, 1989, TRENDS PHARMACOL SCI, V10, P342, DOI 10.1016/0165-6147(89)90002-3; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481; PARINI A, 1989, J BIOL CHEM, V264, P11874; PLANT TD, 1991, BRIT J PHARMACOL, V104, P385, DOI 10.1111/j.1476-5381.1991.tb12440.x; REGUNATHAN S, 1991, BIOCHEM PHARMACOL, V42, P2011, DOI 10.1016/0006-2952(91)90602-2; REGUNATHAN S, 1991, MOL PHARMACOL, V40, P884; RUFFOLO RR, 1988, ALPHA 2 ADRENERGIC R, P115; SHULZ A, 1989, N-S ARCH PHARMACOL, V340, P712; TESSON F, 1991, J BIOL CHEM, V266, P155; TIBIRICA E, 1991, J PHARMACOL EXP THER, V256, P606; WANG H, 1992, MOL PHARMACOL, V42, P792; WIKBERG JES, 1990, J NEUROCHEM, V55, P192, DOI 10.1111/j.1471-4159.1990.tb08838.x	41	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16047	16051						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340426				2022-12-25	WOS:A1993LN30500100
J	MURRAY, NR; BAUMGARDNER, GP; BURNS, DJ; FIELDS, AP				MURRAY, NR; BAUMGARDNER, GP; BURNS, DJ; FIELDS, AP			PROTEIN-KINASE-C ISOTYPES IN HUMAN ERYTHROLEUKEMIA (K562) CELL-PROLIFERATION AND DIFFERENTIATION - EVIDENCE THAT BETA-II PROTEIN-KINASE-C IS REQUIRED FOR PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGENIC RESPONSE; PHORBOL ESTERS; GROWTH-FACTOR; LAMIN-C; ALPHA; ACTIVATION; EXPRESSION; ISOZYMES; PKC; PHOSPHORYLATION	The human erythroleukemia (K562) cell line undergoes megakaryocytic differentiation and cessation of proliferation when treated with phorbol myristate acetate (PMA). To investigate the role of individual protein kinase C (PKC) isotypes in these events, we have assessed PKC isotype expression during leukemic proliferation and PMA-induced differentiation. Immunoblot analysis using isotype-specific antibodies demonstrates that proliferating K562 cells express the alpha, beta(II), and zeta PKC isotypes. PMA-induced differentiation and cytostasis lead to a decrease in beta(II) PKC and increases in alpha and zeta PKC levels. The role of the alpha and beta(II), PKC isotypes was further assessed in cells overexpressing these isotypes. K562 cells overexpressing human alpha PKC grew more slowly and were more sensitive to the cytostatic effects of PMA than control cells, whereas cells overexpressing beta(II) PKC were less sensitive to PMA. PMA-induced cytostasis is reversed upon removal of PMA. Resumption of proliferation is accompanied by reexpression of beta(II) PKC to near control levels, whereas alpha and zeta PKC levels remain elevated for several days after removal of PMA. Proliferation of PMA-withdrawn cells can be partially inhibited by antisense beta(II), PKC oligodeoxyribonucleotide. Growth inhibition is dose-dependent, specific for beta(II) PKC-directed antisense oligonucleotide, and associated with significant inhibition of beta(II) PKC levels indicating that beta(II) PKC is essential for K562 cell proliferation. Sodium butyrate, which unlike PMA induces megakaryocytic differentiation without cytostasis, causes increases in both alpha and beta(II) PKC levels. These data demonstrate that beta(II) PKC is required for K562 cell proliferation, whereas alpha PKC is involved in megakaryocytic differentiation.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, 2119 ABINGTON RD, CLEVELAND, OH 44106 USA; SPHINX PHARMACEUT INC, DURHAM, NC 27717 USA	Case Western Reserve University					NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043186] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56869] Funding Source: Medline; NIGMS NIH HHS [GM-43186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BALAZOVICH KJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P247, DOI 10.1016/0167-4889(87)90141-8; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BARR LF, 1991, CANCER RES, V51, P5514; BECKMAN BS, 1992, EXP HEMATOL, V20, P324; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIARUGI V, 1990, BIOCHEM BIOPH RES CO, V173, P528, DOI 10.1016/S0006-291X(05)80066-X; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; FRIEDMAN DL, 1988, J BIOL CHEM, V263, P1103; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1992, J BIOL CHEM, V267, P21816; MASONGARCIA M, 1990, BIOCHEM BIOPH RES CO, V168, P490, DOI 10.1016/0006-291X(90)92348-4; MCBAIN JA, 1988, CARCINOGENESIS, V9, P123, DOI 10.1093/carcin/9.1.123; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MINANA MD, 1991, FEBS LETT, V284, P60, DOI 10.1016/0014-5793(91)80761-Q; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SPANGLER R, 1992, BLOOD, V79, P52; TABILIO A, 1983, CANCER RES, V43, P4569; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	43	208	217	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15847	15853						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340409				2022-12-25	WOS:A1993LN30500076
J	NAGAYA, T; JAMESON, JL				NAGAYA, T; JAMESON, JL			THYROID-HORMONE RECEPTOR DIMERIZATION IS REQUIRED FOR DOMINANT-NEGATIVE INHIBITION BY MUTATIONS THAT CAUSE THYROID-HORMONE RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; RAT GROWTH-HORMONE; GENERALIZED RESISTANCE; RESPONSE ELEMENTS; AUXILIARY PROTEIN; BETA GENE; TRANSCRIPTIONAL ACTIVITY; MAMMALIAN-CELLS; DNA-BINDING	The syndrome of thyroid hormone resistance (THR) is caused by multiple distinct mutations of the ligand-binding domain of the thyroid hormone beta receptor. Although the mutant receptors are transcriptionally inactive, they inhibit normal receptor function in a dominant negative manner to cause hormone resistance. Because most of the naturally occurring mutations are clustered within two areas that lie on either side of a putative dimerization region, we hypothesized that receptor dimerization was important for dominant negative inhibition. In gel mobility shift assays, two THR mutants (G345R and P453H) formed homodimers as well as heterodimers with the the retinoic acid X receptor alpha. In contrast, an artificial mutation (L428R) in one of the hydrophobic heptad repeats of the putative receptor dimerization domain impaired heterodimerization with retoinoic acid X receptor alpha without altering the formation of homodimers. Double mutants containing either of the THR mutations along with the dimerization mutation formed homodimers but not heterodimers, reflecting the properties of the dimerization mutant alone. In transient expression assays using positively (TRETKLuc) or negatively (TSHalphaLuc) regulated reporter genes, the dominant negative activity of the THR mutants was eliminated by the addition of the dimerization mutation. These results support a mechanism for dominant negative activity by THR mutants in which functionally inactive heterodimers bind to DNA to inhibit access by normal receptors.	MASSACHUSETTS GEN HOSP,THYROID UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Jameson, James/0000-0001-9538-4059	NICHD NIH HHS [HD 28138] Funding Source: Medline; NIDDK NIH HHS [DK 42144] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042144] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS M, 1992, CLIN ENDOCRINOL, V36, P281, DOI 10.1111/j.1365-2265.1992.tb01444.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BIGLER J, 1992, MOL CELL BIOL, V12, P2406, DOI 10.1128/MCB.12.5.2406; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; KATZ D, 1992, MOL ENDOCRINOL, V6, P805, DOI 10.1210/me.6.5.805; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MAGNER JA, 1986, J ENDOCRINOL INVEST, V9, P459, DOI 10.1007/BF03346968; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCPHAUL MJ, 1991, FASEB J, V5, P2910, DOI 10.1096/fasebj.5.14.1752359; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MIXSON AJ, 1992, J CLIN ENDOCR METAB, V75, P1039, DOI 10.1210/jc.75.4.1039; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; REFETOFF S, 1967, J CLIN ENDOCR METAB, V27, P279, DOI 10.1210/jcem-27-2-279; REFETOFF S, 1982, AM J PHYSIOL, V243, P88; REFETOFF S, 1992, ENDOCRINOLOGIST, V2, P261; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SASAKI S, 1992, MOL CELL ENDOCRINOL, V84, P159, DOI 10.1016/0303-7207(92)90026-3; SELMI S, 1991, J BIOL CHEM, V266, P11589; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P712, DOI 10.1210/jc.74.4.712; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P49, DOI 10.1210/jc.74.1.49; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; USALA SJ, 1991, TRENDS ENDOCRIN MET, V2, P140, DOI 10.1016/1043-2760(91)90004-7; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WEISS RE, 1992, ANNU REV MED, V43, P363, DOI 10.1146/annurev.med.43.1.363; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	48	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15766	15771						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340402				2022-12-25	WOS:A1993LN30500066
J	TAKAGI, J; FUJISAWA, T; USUI, T; AOYAMA, T; SAITO, Y				TAKAGI, J; FUJISAWA, T; USUI, T; AOYAMA, T; SAITO, Y			A SINGLE-CHAIN 19-KDA FRAGMENT FROM BOVINE THROMBOSPONDIN BINDS TO TYPE-V COLLAGEN AND HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; PLATELET THROMBOSPONDIN; CELL ATTACHMENT; MATRIX PROTEINS; I REPEATS; PROPOLYPEPTIDE; ADHESION; GLYCOPROTEIN; PROPERDIN; DOMAIN	Location of the type V collagen-binding domain within bovine thrombospondin (TSP) was investigated by using fragments of reduced and alkylated TSP. A fragment of relative molecular mass (19 kDa) was isolated, which inhibited binding of I-125-TSP to type V collagen in a solid-phase binding assay. A direct binding assay using the I-125-labeled fragment confirmed that the fragment actually bound to collagen. The fragment retained specificity for the native structure of type V collagen like the intact TSP molecule. Its binding to the collagen, however, was not inhibited by Ca2+ in contrast to intact TSP. Amino acid sequence analysis of the 19-kDa fragment suggested that this fragment corresponded to Val333-Lys412, a part of the stalklike region in the human TSP primary structure. It was found that the fragment also bound well to heparin in a specific and saturable manner and, furthermore, binding to type V collagen was inhibited by soluble heparin. Removal of the N-linked sugar chain from this fragment resulted in a 14-kDa fragment. The deglycosylated fragment retained the ability to bind to type V collagen as well as heparin. These results suggest that a type V collagen-binding site is present in the 80-residue portion of bovine TSP (Val333-Lys412) and is likely to be identical or lie very close to a heparin-binding site, which exists in the type I repeat structure.	TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL,DEPT BIOL SCI,OOKAYAMA, MEGURO KU, TOKYO 152, JAPAN	Tokyo Institute of Technology								BACONBAGULEY T, 1987, J BIOL CHEM, V262, P1927; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; DIXIT VM, 1984, J BIOL CHEM, V259, P100; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FUJISAWA T, 1991, EUR J BIOCHEM, V196, P673, DOI 10.1111/j.1432-1033.1991.tb15864.x; FUNAHASHI M, 1982, ANAL BIOCHEM, V126, P414, DOI 10.1016/0003-2697(82)90537-1; GALVIN NJ, 1987, J CELL BIOL, V104, P1413, DOI 10.1083/jcb.104.5.1413; GAY S, 1985, J IMMUNOL, V135, P1097; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LAWLER J, 1986, ANN NY ACAD SCI, V485, P273, DOI 10.1111/j.1749-6632.1986.tb34589.x; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1986, BLOOD, V67, P1197; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, CELL MEMBRANES METHO, V3, P55; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; MARGOSSIAN SS, 1981, J BIOL CHEM, V256, P7495; MUMBY SM, 1984, J CELL BIOL, V98, P646, DOI 10.1083/jcb.98.2.646; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; TAKAGI J, 1989, J BIOL CHEM, V264, P10425; TAKAGI J, 1992, BIOCHEMISTRY-US, V31, P8530, DOI 10.1021/bi00151a021; TAKAGI J, 1991, J BIOL CHEM, V266, P5575; TAKAGI J, 1989, J BIOL CHEM, V264, P6017; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TUSZYNSKI GP, 1987, SCIENCE, V236, P1570, DOI 10.1126/science.2438772; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; USUI T, 1992, EUR J BIOCHEM, V205, P363, DOI 10.1111/j.1432-1033.1992.tb16788.x; YAOI Y, 1991, EXP CELL RES, V194, P180, DOI 10.1016/0014-4827(91)90351-T; YAOI Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P139, DOI 10.1016/0304-4165(90)90108-9	45	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15544	15549						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340381				2022-12-25	WOS:A1993LN30500036
J	HILLARP, A; PARDOMANUEL, F; RUIZ, RR; DECORDOBA, SR; DAHLBACK, B				HILLARP, A; PARDOMANUEL, F; RUIZ, RR; DECORDOBA, SR; DAHLBACK, B			THE HUMAN C4B-BINDING PROTEIN BETA-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; HUMAN C4-BINDING PROTEIN; COMPLEMENT FACTOR-H; CLASSICAL PATHWAY; C3B INACTIVATOR; ALPHA-CHAIN; COMPONENT; PLASMA; C4B; ACTIVATION	Human complement component C4b-binding protein (C4BP) is composed of seven alpha-chains and one beta-chain. The alpha- and beta-chains are homologous and both contain multiple copies of short consensus repeats (SCR) and in addition carboxyl-terminal non-repeat regions. Each of the alpha-chains contains a binding site for C4b, whereas the beta-chain binds protein S, a vitamin K-dependent protein involved in the regulation of blood coagulation. The alpha- and beta-chain genes are closely linked in the regulators of complement activation gene cluster on the long arm of human chromosome 1, band 1q32. The human beta-chain gene which has now been characterized was found to span more than 10 kilobases of DNA. The presence of at least two different beta-chain gene transcripts was suggested by the isolation of two new cDNA clones which contained different sequences in their extended 5'-untranslated regions. Northern blot analysis demonstrated that the two clones represented distinct beta-chain mRNAs with different 5' end sequences. One class of beta-chain mRNA (denoted A19) was found to be encoded by six exons and primer extension, and Sl nuclease protection assays revealed multiple closely spaced transcription start sites for this mRNA class. Its 5'-untranslated region and signal peptide was encoded by the first exon. The second class of mRNA (denoted A12) had a different transcription start site and its 5'-untranslated region was derived from at least three exons out of which the last one was formed by utilization of an acceptor splice site within the first A19 exon. Exons encoding the mature beta-chain and the 3'-untranslated region were common to both classes of mRNA. The beta-chain contains three SCRs, out of which the first and second are encoded by individual exons, whereas two exons encode the third SCR. The exon encoding the carboxyl-terminal part of the third SCR also encodes 14 amino acids of the non-repeat region. The last exon encodes the remaining 46 carboxyl-terminal amino acids and the entire 3'-untranslated region. The elucidation of the organization of the beta-chain gene provides insight into the sophisticated molecular structure of C4BP and a basis for future structural and functional studies.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; CTR INVEST BIOL,UNIDAD INMUNOL,E-28006 MADRID,SPAIN	Lund University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			de Cordoba, Santiago Rodriguez/K-6727-2014; ramos-ruiz, ricardo/Q-2237-2016	de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; ramos-ruiz, ricardo/0000-0002-6331-9786; Dahlback, Bjorn/0000-0003-1546-0328				ANDERSSON A, 1990, SOMAT CELL MOLEC GEN, V16, P493, DOI 10.1007/BF01233199; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARNUM SR, 1989, BIOCHEMISTRY-US, V28, P8312, DOI 10.1021/bi00447a008; BARNUM SR, 1990, COMPLEMENT INFLAMMAT, V7, P71, DOI 10.1159/000463131; BERTINA RM, 1985, THROMB HAEMOSTASIS, V53, P268; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BORA NS, 1989, J EXP MED, V169, P597, DOI 10.1084/jem.169.2.597; BRAATEN DC, 1988, NUCLEIC ACIDS RES, V16, P865, DOI 10.1093/nar/16.3.865; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; COMP PC, 1986, BLOOD, V67, P504; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DECORDOBA SR, 1991, J EXP MED, V173, P1073, DOI 10.1084/jem.173.5.1073; DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJISAKU A, 1989, J BIOL CHEM, V264, P2118; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; Maniatis T, 1989, DECONTAMINATION DILU; NAGASAWA S, 1980, J IMMUNOL, V125, P578; PARDOMANUEL F, 1990, P NATL ACAD SCI USA, V87, P4529, DOI 10.1073/pnas.87.12.4529; PERLINO E, 1987, EMBO J, V6, P2767, DOI 10.1002/j.1460-2075.1987.tb02571.x; POST T W, 1989, FASEB Journal, V3, pA368; POST TW, 1990, J IMMUNOL, V144, P740; REYCAMPOS J, 1990, GENOMICS, V7, P644, DOI 10.1016/0888-7543(90)90213-E; REYCAMPOS J, 1988, J EXP MED, V167, P664, DOI 10.1084/jem.167.2.664; REYCAMPOS J, 1987, J EXP MED, V166, P246, DOI 10.1084/jem.166.1.246; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; VELASCO E, 1992, HUM MOL GENET, V1, P552, DOI 10.1093/hmg/1.7.552-a; VIK DP, 1988, J BIOL CHEM, V263, P16720; WALKER FJ, 1984, J BIOL CHEM, V259, P335; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WONG WW, 1989, J EXP MED, V169, P847, DOI 10.1084/jem.169.3.847	45	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15017	15023						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325877				2022-12-25	WOS:A1993LL75900071
J	KOTULA, L; DESILVA, TM; SPEICHER, DW; CURTIS, PJ				KOTULA, L; DESILVA, TM; SPEICHER, DW; CURTIS, PJ			FUNCTIONAL-CHARACTERIZATION OF RECOMBINANT HUMAN RED-CELL ALPHA-SPECTRIN POLYPEPTIDES CONTAINING THE TETRAMER BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; BETA-SPECTRIN; HEREDITARY ELLIPTOCYTOSIS; MOLECULAR DEFECT; SELF-ASSOCIATION; MUTATION; DOMAIN; CHAIN; PYROPOIKILOCYTOSIS; SKELETON	Spectrin, a heterodimer composed of alpha and beta subunits, interacts with itself head-to-head to form tetramers in the erythrocyte membrane cytoskeleton. The NH2-terminal region of alpha-spectrin, encompassing the alphaI 80-kDa domain, was expressed in Escherichia coli. In addition to the correctly initiated polypeptide, four smaller polypeptides were produced by initiation at internal codons. Only the full-length polypeptide was able to bind to spectrin dimers, beta monomers, and to a recombinant polypeptide containing the COOH terminus of beta-spectrin. The head-to-head interaction with beta-spectrin was also retained by a recombinant polypeptide containing the NH2-terminal 158 amino acids of the alpha subunit. Deletion of the first 27 or 49 NH2-terminal amino acids abolished binding of this polypeptide to the beta monomer. The phasing used to design these recombinant polypeptides was based on a conformational model recently refined by Speicher et al. (Speicher, D. W., DeSilva, T. M., Speicher, K. D., Ursitti, J. A., Hembach, P., and Weglarz, L. (1993) J. Biol. Chem. 268, 4227-4235), where the structural unit begins and terminates around residue 30 of the repeat unit. The binding properties, mobility on gel filtration, and circular dichroism data of the recombinant polypeptides indicated that most polypeptides were able to assume their native conformation.	WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute				Kotula, Leszek/0000-0002-7977-7124	NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033884, R01HL038794] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10815] Funding Source: Medline; NHLBI NIH HHS [HL 38794, HL 33884] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; EBER SW, 1988, J CLIN INVEST, V81, P523, DOI 10.1172/JCI113350; GALLAGHER PG, 1991, J BIOL CHEM, V266, P15154; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KNOWLES WJ, 1983, J CLIN INVEST, V71, P1867, DOI 10.1172/JCI110942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1982, J CLIN INVEST, V70, P1019, DOI 10.1172/JCI110689; Maniatis T., 1982, MOL CLONING; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; PALEK J, 1990, SEMIN HEMATOL, V27, P290; POTHIER B, 1990, BLOOD, V75, P2061; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SPEICHER DW, 1983, J BIOL CHEM, V258, P4938; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; TSE WT, 1991, BLOOD, V78, P517; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YOON SH, 1991, J BIOL CHEM, V266, P8490; YURCHENCO PD, 1982, J BIOL CHEM, V257, P9102	27	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14788	14793						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325856				2022-12-25	WOS:A1993LL75900041
J	CLAUSMEYER, S; KLOSGEN, RB; HERRMANN, RG				CLAUSMEYER, S; KLOSGEN, RB; HERRMANN, RG			PROTEIN IMPORT INTO CHLOROPLASTS - THE HYDROPHILIC LUMENAL PROTEINS EXHIBIT UNEXPECTED IMPORT AND SORTING SPECIFICITIES IN SPITE OF STRUCTURALLY CONSERVED TRANSIT PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; CHLOROPHYLL A/B-PROTEIN; OUTER ENVELOPE MEMBRANE; THYLAKOID MEMBRANE; SMALL SUBUNIT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; NUCLEOTIDE-SEQUENCE; PRECURSOR PROTEINS; PEA-CHLOROPLASTS; FOREIGN PROTEIN	Plastocyanin and the 16-, 23-, and 33-kDa polypeptides of the oxygen-evolving complex associated with photosystem II are hydrophilic, nuclear encoded components of the photosynthetic machinery that are all located in the lumen of thylakoid membranes. All four proteins are therefore imported into chloroplasts and, in addition, translocated across the thylakoid membrane. They share functionally equivalent, bipartite transit peptides, which are removed in two steps during or after import into the organelle and translocation across the thylakoid membrane, respectively. The transit peptides lack any homology at the sequence level but possess remarkably similar predicted secondary structures. We have studied the targeting potential of the authentic precursor molecules and all possible chimeric combinations generated by a specific, commonly applicable cassette system, which facilitates codon-correct reciprocal exchanges of transit peptides and mature parts. An unexpected specificity of import and sorting processes was found. All constructs can be imported into the organelle, though with greatly differing efficiency. On the other hand, the lumen-targeting parts are essential but not in all cases sufficient for correct intraorganellar routing. This implies that translocation across the thylakoid membrane appears not to depend merely on simple interactions of charged or hydrophobic regions between protein and membrane but requires an additional quality of information that includes the functional co-evolution of a transit peptide with its mature protein. Signaling and sorting appear to be essential at almost every step of the entire process for proper traffic regulation since distinct steps can be impaired (rate-limiting or arrested) in the individual combinations: the transfer across the envelope membranes (e.g. 16/PC) and the interaction with (e.g. 16/33) or the translocation across the thylakoid membrane (e.g. 33/23).	UNIV MUNICH,INST BOT,MENZINGER STR 67,W-8000 MUNICH 19,GERMANY	University of Munich								ANDERSSON B, 1984, BIOCHIM BIOPHYS ACTA, V766, P21, DOI 10.1016/0005-2728(84)90212-3; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BARTLING D, 1990, BOT MAG TOKYO, V2, P119; CAI D, 1993, PLANT J, V3, P383, DOI 10.1046/j.1365-313X.1993.t01-21-00999.x; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHUA NH, 1977, J CELL BIOL, V74, P441, DOI 10.1083/jcb.74.2.441; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1992, J BIOL CHEM, V267, P2688; COHEN Y, 1992, EMBO J, V11, P79, DOI 10.1002/j.1460-2075.1992.tb05030.x; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEBOER D, 1991, EMBO J, V10, P2765, DOI 10.1002/j.1460-2075.1991.tb07825.x; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; HAEHNEL W, 1986, ENCY PLANT PHYSL, P547; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; Herrmann R. G., 1991, Plant molecular biology 2. Proceedings of a NATO Advanced Study Institute, 14-23 May 1990, Elmau, Germany., P411; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; KARLINNEUMANN GA, 1986, EMBO J, V5, P9, DOI 10.1002/j.1460-2075.1986.tb04170.x; KEEGSTR AK, 1992, CELL ORGANELLES, P353; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIRWIN PM, 1988, J BIOL CHEM, V263, P18123; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KOTELCHU.D, 1968, P NATL ACAD SCI USA, V61, P1163, DOI 10.1073/pnas.61.4.1163; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MEADOWS JW, 1989, FEBS LETT, V253, P244, DOI 10.1016/0014-5793(89)80968-8; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; NAGANO K, 1973, J MOL BIOL, V75, P401, DOI 10.1016/0022-2836(73)90030-2; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; OSTREM JA, 1989, J BIOL CHEM, V264, P3662; REISS B, 1987, MOL GEN GENET, V209, P116, DOI 10.1007/BF00329845; ROBSON B, 1971, J MOL BIOL, V58, P237, DOI 10.1016/0022-2836(71)90243-9; ROTHER C, 1986, CURR GENET, V11, P171, DOI 10.1007/BF00420603; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1989, MOL GEN GENET, V216, P178, DOI 10.1007/BF00332249; THEG SM, 1989, J BIOL CHEM, V264, P6730; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591; VALENTIN K, 1993, MOL GEN GENET, V236, P245, DOI 10.1007/BF00277119; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1991, PLANT MOL BIOL REP, V9, P104; WASMANN CC, 1988, J BIOL CHEM, V263, P617; WASMANN CC, 1986, MOL GEN GENET, V205, P446, DOI 10.1007/BF00338081; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; WESTHOFF P, 1985, PLANT MOL BIOL, V4, P137, DOI 10.1007/BF02418761	63	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13869	13876						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314754				2022-12-25	WOS:A1993LJ82500018
J	THISSEN, JA; CASEY, PJ				THISSEN, JA; CASEY, PJ			MICROSOMAL-MEMBRANES CONTAIN A HIGH-AFFINITY BINDING-SITE FOR PRENYLATED PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE BRAIN; ALPHA-SUBUNITS; BETA-GAMMA; PROTEINS	Prenylation and subsequent processing of many proteins involved in cellular signaling serves to direct and/or anchor these proteins to specific membranes in the cell. One major class of prenylated proteins contains the so-called CAAX motif, such proteins contain a cysteine residue fourth from the COOH terminus. After addition of the isoprenoid to this cysteine residue by specific cytosolic protein prenyltransferases, the proteins are subject to further processing by enzymes associated with microsomal membranes. This suggests that newly prenylated proteins are initially directed to a microsomal membrane compartment for completion of their processing. Using a radiolabeled, prenylated peptide as a ligand, we have identified a specific, high affinity binding site or receptor on microsomal membranes. This receptor is both protease- and heat-sensitive and exhibits saturable binding of the prenylated peptide with a K(D) of 30 nM. Competition analysis indicates that both geranylgeranylated and farnesylated, but not myristoylated, peptides bind to this receptor. A fully processed prenylated protein also does not compete, indicating a role for the three terminal residues of the prenylated peptide in receptor recognition. This receptor may serve to direct newly prenylated proteins to a microsomal compartment for completion of processing prior to trafficking to their final destination in the cell.	DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309				ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1992, J LIPID RES, V33, P1731; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; ENTENMAN C, 1957, METHOD ENZYMOL, V3, P299, DOI 10.1016/S0076-6879(57)03395-9; Fleischer S, 1974, Methods Enzymol, V31, P6; GODDARD C, 1989, J BIOL CHEM, V264, P15173; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; MA YT, 1992, BIOCHEMISTRY-US, V31, P11772, DOI 10.1021/bi00162a014; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	21	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13780	13783						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314746				2022-12-25	WOS:A1993LJ82500005
J	WADA, N; CHOU, JY				WADA, N; CHOU, JY			CHARACTERIZATION OF UPSTREAM ACTIVATION ELEMENTS ESSENTIAL FOR THE EXPRESSION OF GERM-CELL ALKALINE-PHOSPHATASE IN HUMAN CHORIOCARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; BINDING-FACTOR; DNA-BINDING; CACCC-BOX; SEQUENCE; PROMOTER; SP1; PHOSPHATIDYLINOSITOL; TRANSFECTION	Expression of the germ cell alkaline phosphatase is a highly regulated process tied to malignant transformation of the human placenta. Human choriocarcinoma cells (malignant trophoblasts) express primarily the germ cell alkaline phosphatase gene and only low or nondetectable levels of the placental alkaline phosphatase normally found in the human placenta. Here, we show that nucleotides -156 to -1 region relative to the gene transcription start site (+1) contain cis-acting DNA elements that direct germ cell alkaline phosphatase expression in choriocarcinoma cells. Within the minimal activator region, at least three nuclear protein-binding sites, I (-63/-44), II (-87/-67), and III (-136/-103), were identified by DNase I footprinting analysis. All three sites are GC-rich. Sites I and II contain a sequence known to bind the transcription factor AP-2; the AP-2 site in site II overlaps a consensus motif for the transcription factor Sp1. Gel retardation experiments showed that similar nuclear protein factor(s) in JEG-3 choriocarcinoma cells bind to all three sites, with highest affinity to sites I and II. Site-directed mutagenesis that prevents binding of nuclear proteins to either site I or II, or both sites I and II, resulted in the loss of factor binding and reduced activator activity. The germ cell alkaline phosphatase promoter that contains an intact binding site III but altered sites I and II had little activator activity, suggesting that protein-protein interaction is important for germ cell alkaline phosphatase gene activation.	NICHHD,HUMAN GENET BRANCH,BLDG 10,RM 9S242,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								CHANG CH, 1980, CANCER RES, V40, P1506; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENG G, 1992, CANCER RES, V52, P3378; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOELLGAST GJ, 1982, HUMAN ALKALINE PHOSP, P25; FISHMAN L, 1976, CANCER RES, V36, P2268; FISHMAN WH, 1987, ADV CANCER RES, V48, P1, DOI 10.1016/S0065-230X(08)60689-2; FISHMAN WH, 1968, CANCER RES, V28, P150; FORDIS CM, 1986, METHOD ENZYMOL, V151, P382; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GOLDSTEIN DJ, 1982, CLIN CHIM ACTA, V125, P63, DOI 10.1016/0009-8981(82)90046-8; GUMUCIO DL, 1991, BLOOD, V78, P1853; HARRIS H, 1981, HARVEY LECT, V76, P95; HENTHORN PS, 1988, J BIOL CHEM, V263, P12011; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KNOLL BJ, 1988, J BIOL CHEM, V263, P12020; KNOLL BJ, 1987, GENE, V60, P267, DOI 10.1016/0378-1119(87)90235-6; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; LANGE PH, 1982, CANCER RES, V42, P3244; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P4299, DOI 10.1093/nar/16.10.4299; MARTIN D, 1987, ANN HUM GENET, V51, P145, DOI 10.1111/j.1469-1809.1987.tb01056.x; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MILLAN JL, 1988, P NATL ACAD SCI USA, V85, P3024, DOI 10.1073/pnas.85.9.3024; NAKAYAMA T, 1970, CLIN CHIM ACTA, V30, P543; NOVAK ER, 1979, GYNECOLOGIC OBSTETRI, P476; OGATA S, 1988, J BIOL CHEM, V263, P10489; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PATTILLO RA, 1968, CANCER RES, V28, P1231; POVINELLI CM, 1991, PLACENTA, V12, P663, DOI 10.1016/0143-4004(91)90500-F; SAKIYAMA T, 1978, ARCH BIOCHEM BIOPHYS, V191, P782, DOI 10.1016/0003-9861(78)90420-4; SAKIYAMA T, 1979, J BIOL CHEM, V254, P935; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; STIGBRAND T, 1982, ISOZYMES-CURR T BIOL, V6, P93; WAHREN B, 1979, INT J CANCER, V24, P749, DOI 10.1002/ijc.2910240608; WATANABE S, 1989, J BIOL CHEM, V264, P12611; WATANABE T, 1991, J BIOL CHEM, V266, P21174; WEISS MJ, 1988, J BIOL CHEM, V263, P12002; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670	49	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14003	14010						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314767				2022-12-25	WOS:A1993LJ82500036
J	GERBER, NC; SLIGAR, SG				GERBER, NC; SLIGAR, SG			A ROLE FOR ASP-251 IN CYTOCHROME P-450CAM OXYGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; REDUCED PUTIDAREDOXIN; SINGLE TURNOVER; BINDING; SUBSTRATE; COMPLEX; HYDROXYLATION; PEROXIDASES	We have mutated Asp-251, Thr-252, and Lys-178 in cytochrome P-450cam and studied their effect on steady-state P-450cam catalysis. The mutation of Asp-251 to Asn, which dramatically slows the reaction rate, affects a pH-dependent step in the reaction cycle. By examining the individual steps in the reaction cycle, we have determined that the effect of the D251N mutation occurs after dioxygen binding. Furthermore, our results suggest that the rate-limiting step of the D251N reaction cycle is the O-O bond scission event and that this residue also plays a crucial role in O-O bond scission in wild-type P-450cam. Based on homology with other P-450 enzymes and previous mutagenesis investigations, this role may be common to other P-450 systems, and we suggest a mechanism that is consistent with the effects of these mutations on enzyme activity.	UNIV ILLINOIS, DEPT CHEM, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031756, R01GM033775, R37GM031756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31756, GM33775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS WM, 1987, J AM CHEM SOC, V109, P3754, DOI 10.1021/ja00246a038; ATKINS WM, 1988, BIOCHEMISTRY-US, V27, P1610, DOI 10.1021/bi00405a033; BOWRY VW, 1991, J AM CHEM SOC, V113, P5699, DOI 10.1021/ja00015a025; BREWER CB, 1988, J BIOL CHEM, V263, P791; BREWER CB, 1986, ARCH BIOCHEM BIOPHYS, V249, P515, DOI 10.1016/0003-9861(86)90029-9; DAVIES MD, 1992, BIOCHEMISTRY-US, V31, P11383, DOI 10.1021/bi00161a016; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; EISENSTEIN L, 1977, BIOCHEM BIOPH RES CO, V77, P1377, DOI 10.1016/S0006-291X(77)80131-9; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; GROVES JT, 1976, J AM CHEM SOC, V98, P859, DOI 10.1021/ja00419a049; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Gunsalus I C, 1978, Methods Enzymol, V52, P166; GUNSALUS IC, 1973, IRON SULFUR PROTEINS, P151; HEDEGAARD J, 1965, J BIOL CHEM, V240, P4038; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ISHIGOOKA M, 1992, BIOCHEMISTRY-US, V31, P1528, DOI 10.1021/bi00120a033; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; LOEW GH, 1980, J AM CHEM SOC, V102, P3655, DOI 10.1021/ja00530a073; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PEDERSON TC, 1977, MICROSOMES DRUG OXID, P275; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RODGERS KK, 1991, J MOL BIOL, V221, P1453, DOI 10.1016/0022-2836(91)90945-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; SHIMADA H, 1990, INT S OXYGENASES OXY; SHIMADA H, 1993, 2ND INT S CYT P450 M; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157; TSUBAKI M, 1989, BIOCHEMISTRY-US, V28, P9777, DOI 10.1021/bi00451a035; WAGNER GC, 1983, FEBS LETT, V156, P244, DOI 10.1016/0014-5793(83)80505-5; YONETANI T, 1966, J BIOL CHEM, V241, P3240; YU CA, 1974, J BIOL CHEM, V249, P102; ZHOU D, 1992, J BIOL CHEM, V267, P762	46	171	171	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4260	4266						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307990				2022-12-25	WOS:A1994MW98900057
J	HALLAK, H; BRASS, LF; MANNING, DR				HALLAK, H; BRASS, LF; MANNING, DR			FAILURE TO MYRISTOYLATE THE ALPHA-SUBUNIT OF G(Z) IS CORRELATED WITH AN INHIBITION OF PALMITOYLATION AND MEMBRANE ATTACHMENT, BUT HAS NO AFFECT ON PHOSPHORYLATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; PERTUSSIS TOXIN; PLASMA-MEMBRANE; HUMAN-PLATELETS; RAS PROTEINS; CELLS; ASSOCIATION; GZ; SUBSTRATE; SITE	The alpha subunit of the GTP-binding regulatory protein G(z) has been shown to be a substrate for N-myristoylation, palmitoylation, and protein kinase C-catalyzed phosphorylation. In the present study, we used an NH2-terminal Gly --> Ala mutation to examine the relevance of myristoylation to phosphorylation and anchorage. 293 cells were transfected with cDNA encoding the normal or mutant form of alpha(z). Normal alpha(z) was myristoylated and stably anchored, as assessed by biosynthetic labeling and sedimentation with membrane following cell lysis. The mutant form of alpha(z) was not myristoylated and was found predominantly (70-90%) in the cytosol. These distributions were corroborated by immunofluorescence microscopy. Thus, the NH2-terminal glycine of alpha(z) appears critical for both myristoylation and anchorage. The effects of the Gly --> Ala mutation, however, were not confined to these two events. Significantly, the mutation also prevented palmitoylation, which presumably occurs at Cys(3) in the normal subunit. Therefore, it cannot be concluded that myristoylation alone is sufficient for anchorage. The protein kinase C-catalyzed phosphorylation of alpha(z) was demonstrated previously to occur near to the NH2 terminus, raising the possibility of an effect of phosphorylation on anchorage or, conversely, an effect of myristoylation and/or palmitoylation on phosphorylation. The phosphorylation induced in 293 cells with phorbol 12-myristate 13-acetate, however, had little impact on anchorage. Moreover, the mutant (and thus cytosolic) form of alpha(z) was as good a substrate for phosphorylation as the normal subunit. The fact that myristoylation occurs in cells containing alpha(z) normally, as well as the fact that phosphorylation does not influence anchorage, was confirmed with mouse anterior pituitary AtT-20 and rat basophilic RBL-2H3 cells. These results demonstrate: 1) that mutagenesis of the glycine needed for myristoylation of alpha(z) also inhibits palmitoylation, 2) that the resultant lack of myristoylation and/or palmitoylation does not support anchorage, and 3) that neither myristoylation, palmitoylation, nor anchorage is required for phosphorylation.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [HL45181] Funding Source: Medline; NIGMS NIH HHS [GM34781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM034781] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BERGER M, 1985, FEBS LETT, V187, P289, DOI 10.1016/0014-5793(85)81261-8; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HIDE M, 1991, MOL PHARMACOL, V40, P473; HINTON DR, 1990, J NEUROSCI, V10, P2763; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PARKER EM, 1991, J BIOL CHEM, V266, P519; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WILLIAMS AG, 1990, BLOOD, V76, P721; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	40	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4571	4576						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308028				2022-12-25	WOS:A1994MW98900100
J	LEGOFF, P; MONTANO, MR; SCHODIN, DJ; KATZENELLENBOGEN, BS				LEGOFF, P; MONTANO, MR; SCHODIN, DJ; KATZENELLENBOGEN, BS			PHOSPHORYLATION OF THE HUMAN ESTROGEN-RECEPTOR - IDENTIFICATION OF HORMONE-REGULATED SITES AND EXAMINATION OF THEIR INFLUENCE ON TRANSCRIPTIONAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; DEPENDENT PROTEIN-KINASE; GROWTH FACTOR-I; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTORS; RESPONSIVE ELEMENT; DOWN-REGULATION; DNA-BINDING; ACTIVATION; ANTIESTROGEN	We have used a transient transfection system with a cytomegalovirus-based vector expressing high levels of biologically active human estrogen receptor (ER) in COS-1 cells to study the phosphorylation of human ER and to identify major hormone-regulated phosphorylation sites. The features of phosphorylation of the wildtype ER were very similar to those previously observed for the endogenous ER in uterine cells: The ER exhibited a basal level of phosphorylation which was increased similar to 3-4-fold by estrogen (estradiol) and by antiestrogens (hydroxytamoxifen and ICI164,384), and phosphorylation was increased to an almost similar extent by activation of either protein kinase A or C signal transduction pathways with cholera toxin plus isobutyl methylxanthine (CT+IBMX) or phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), respectively. Phosphoamino acid analysis revealed that the phosphorylation occurred exclusively on serine residues in all cases. Tryptic phosphopeptide analysis of ER, using a two-dimensional peptide mapping procedure, revealed similar patterns for ER in cells treated with estradiol, antiestrogens or TPA; with CT+IBMX treatment, the same phosphopeptides were seen, but the relative phosphorylation of the different ER phosphotryptic peptides differed. In ER deleted of the NH2-terminal A and B (A/B) domains, estrogen and antiestrogen-stimulated phosphorylations were abolished, while the phosphorylation induced by CT+IBMX was maintained. This suggests that sites of phosphorylation enhanced by estradiol and antiestrogen, but not those induced by CT+IBMX, are located in the A/B domain. These results were further confirmed by comparing the tryptic phosphopeptide patterns of wild-type and A/B-deleted receptor upon estradiol and CT+IBMX treatments, and then by site directed mutagenesis, by substituting alanines for the serine residues in the AIS domain (Ser(104), Ser(106), Ser(118), Ser(154), and Ser(167)) involved in known protein kinase consensus sequences. Comparison of the tryptic phosphopeptide patterns of wild-type ER and these mutant ERs allowed us to identify serine 104 and/or serine 106 and serine 118, all three being part of a serine-proline moth, the preferred substrate of proline-directed protein kinase, as major ER phosphorylation sites. When tested with two estrogen responsive reporter gene constructs in several cell types, the mutant S104A, S106A, S118A showed a similar to 40% reduction in transactivation activity in response to E(2), while the mutants S118A and S104A, S106A alone showed a similar to 15% decrease in transactivation. Our studies identify several serines in the NH2-terminal portion of the human ER as being major hormone-regulated phosphorylation sites. The location of these sites in one of the two transactivation domains of the ER is consistent with their modulatory effects on transcriptional activity of the human ER.	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, URBANA, IL 61801 USA; UNIV ILLINOIS, COLL MED, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			LE GOFF, PASCALE/K-1842-2015	LE GOFF, PASCALE/0000-0002-3931-2197	NCI NIH HHS [CA18119, CA51482] Funding Source: Medline; NICHD NIH HHS [T32 HD7028] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007028] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA018119, R01CA051482, R01CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; AURICCHIO F, 1989, J STEROID BIOCHEM, V32, P613, DOI 10.1016/0022-4731(89)90397-X; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DENTON RR, 1992, J BIOL CHEM, V267, P7263; ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HALL FL, 1991, J BIOL CHEM, V266, P17430; Ham J, 1989, CURR OPIN CELL BIOL, V1, P503, DOI 10.1016/0955-0674(89)90012-4; HOECK W, 1989, J BIOL CHEM, V264, P14396; IMAKADO S, 1991, J BIOCHEM-TOKYO, V109, P684, DOI 10.1093/oxfordjournals.jbchem.a123441; KATZENELLENBOGE.BS, 1983, J STEROID BIOCHEM, V18, P59; KATZENELLENBOGEN BS, 1985, BREAST CANCER RES TR, V5, P231, DOI 10.1007/BF01806018; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEGOFF P, 1992, ENDOCRINOLOGY S, V130; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MONSMA FJ, 1984, ENDOCRINOLOGY, V115, P143, DOI 10.1210/endo-115-1-143; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; REESE JC, 1991, J BIOL CHEM, V266, P10880; SHERIDAN PL, 1988, MOL ENDOCRINOL, V2, P1329, DOI 10.1210/mend-2-12-1329; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WASHBURN T, 1991, MOL ENDOCRINOL, V5, P235, DOI 10.1210/mend-5-2-235; WILKINSON JM, 1986, PRACTICAL PROTEIN CH, P122; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647	42	375	381	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4458	4466						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308015				2022-12-25	WOS:A1994MW98900086
J	LUTSENKO, S; KAPLAN, JH				LUTSENKO, S; KAPLAN, JH			MOLECULAR EVENTS IN CLOSE PROXIMITY TO THE MEMBRANE-ASSOCIATED WITH THE BINDING OF LIGANDS TO THE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; OUTER MEDULLA; (NA,K)-ATPASE; OCCLUSION; PROTEINS; KIDNEY; NA+,K+-ATPASE; DIGESTION; CLEAVAGE; SEQUENCE	The membrane-bound fraction of purified Na,K-ATPase was characterized following extensive proteolytic digestion in the presence of various physiological ligands which stabilize different conformational states of the sodium pump. There are distinctive conformational changes of the protein which are revealed by amino-terminal amino acid sequence analysis of the digests following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The changes in cleavage patterns result from alterations in domain-domain interactions of the protein. We provide evidence in the alpha-subunit for (i) tight interaction between part of the cytoplasmic ATP binding domain and the membrane-bound portion of the protein; (ii) involvement of the cytoplasmic loop between M2 and M3 in structural rearrangements upon phosphorylation or ion binding; (iii) generation of the same digested products when either ouabain or potassium (rubidium) is present. Similarly, evidence is provided for conformational sensitivity of the extracellular domain of the beta-subunit. The position of the tryptic cleavage point in the beta-subunit is altered depending on whether the alpha-subunit is phosphorylated or whether rubidium ions are occluded. Based upon the conformationally dependent patterns of exposure and protection of different tryptic cleavage sites in the alpha- and beta-subunits we propose a model for intraprotein interactions within the alpha-subunit and between alpha- and beta-subunits following the binding of physiological ligands to the Na,K-ATPase.	UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Kaplan, Jack/0000-0002-7048-6574	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; DZHANDZHUGAZYAN KN, 1988, NAPLUS KPLUS PUMP, V268, P181; ELLISDAVIES GCR, 1993, J BIOL CHEM, V268, P11622; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KAPLAN JH, 1985, ANNU REV PHYSIOL, V47, P535, DOI 10.1146/annurev.ph.47.030185.002535; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KIRLEY TL, 1991, J BIOL CHEM, V266, P19953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1992, ANN NY ACAD SCI, V671, P147, DOI 10.1111/j.1749-6632.1992.tb43792.x; LUTSENKO S, 1993, BIOPHYS J, V64, pA331; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MODYANOV NN, 1990, SODIUM PUMP, P99; NICHOLAS RA, 1984, BIOCHEMISTRY-US, V23, P888, DOI 10.1021/bi00300a015; OHTA T, 1986, FEBS LETT, V204, P297, DOI 10.1016/0014-5793(86)80832-8; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x	32	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4555	4564						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308026				2022-12-25	WOS:A1994MW98900098
J	RAGONE, R; COLONNA, G				RAGONE, R; COLONNA, G			ENTHALPY-ENTROPY BALANCE AND CONVERGENCE TEMPERATURES IN PROTEIN UNFOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLAR HEAT-CAPACITY; HYDROPHOBIC INTERACTION; GLOBULAR-PROTEINS; HYDRATION; THERMODYNAMICS; STABILITY; WATER	We find that isoenthalpic and isoentropic temperatures characterizing the unfolding of small globular proteins are linked by a simple relationship, which takes into account the occurrence of common values of specific unfolding enthalpy and entropy changes. The difference between these temperatures implies that the hydration effect favors protein folding over a quite large range of temperatures.			RAGONE, R (corresponding author), UNIV NAPLES 2, DEPT BIOCHEM & BIOPHYS, VIA COSTANTINOPOLI 16, I-80138 NAPLES, ITALY.		Colonna, Giovanni/AAY-3568-2021	Colonna, Giovanni/0000-0002-0473-1455				BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BALDWIN RL, 1992, P NATL ACAD SCI USA, V89, P7110, DOI 10.1073/pnas.89.15.7110; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Creighton TE, 1991, CURR OPIN STRUC BIOL, V1, P5, DOI 10.1016/0959-440X(91)90004-D; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOIG AJ, 1992, BIOCHEMISTRY-US, V31, P9371, DOI 10.1021/bi00154a007; FU L, 1992, P NATL ACAD SCI USA, V89, P9335, DOI 10.1073/pnas.89.19.9335; GILL SJ, 1985, J PHYS CHEM-US, V89, P3758, DOI 10.1021/j100263a034; LEE B, 1991, P NATL ACAD SCI USA, V88, P5154, DOI 10.1073/pnas.88.12.5154; MAKHATADZE GI, 1990, J MOL BIOL, V213, P375, DOI 10.1016/S0022-2836(05)80197-4; MULLER N, 1992, TRENDS BIOCHEM SCI, V17, P459, DOI 10.1016/0968-0004(92)90488-U; MULLER N, 1990, ACCOUNTS CHEM RES, V23, P23, DOI 10.1021/ar00169a005; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; MURPHY KP, 1991, J MOL BIOL, V222, P699, DOI 10.1016/0022-2836(91)90506-2; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1990, SCIENCE, V250, P298; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1992, J MOL BIOL, V224, P715, DOI 10.1016/0022-2836(92)90555-X; PRIVALOV PL, 1990, J MOL BIOL, V213, P385, DOI 10.1016/S0022-2836(05)80198-6; RAGONE R, 1993, STUD ORG CHEM, V47, P451; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009	22	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4047	4049						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307961				2022-12-25	WOS:A1994MW98900025
J	WELLS, GB; MUSTAFI, D; MAKINEN, MW				WELLS, GB; MUSTAFI, D; MAKINEN, MW			STRUCTURE AT THE ACTIVE-SITE OF AN ACYLENZYME OF ALPHA-CHYMOTRYPSIN AND IMPLICATIONS FOR THE CATALYTIC MECHANISM - AN ELECTRON-NUCLEAR DOUBLE-RESONANCE STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-PARAMETERS; LABELED AMINO-ACIDS; FROZEN-SOLUTIONS; STEREOELECTRONIC CONTROL; CARBOXYPEPTIDASE-A; SUBZERO TEMPERATURES; COMPUTER-GRAPHICS; SERINE PROTEASES; SPIN-LABELS; HYDROLYSIS	The structure of the acylenzyme intermediate in the hydrolysis of the specific spin-label ester substrate methyl N-(2,2,5,5-tetramethyl-1-oxypyrrolinyl-3-carbon-yl)-L-tryptophanate and its fluoro analogs catalyzed by alpha-chymotrypsin (EC 3.4.21.1) has been determined by electron nuclear double resonance (ENDOR) and molecular modeling methods. By a combination of kinetic and cryoenzymology methods, we have established conditions to stabilize the spin-labeled acylenzyme reaction intermediate. Proton ENDOR features specific for the substrate were assigned on the basis of specific deuteration. From the observed ENDOR shifts for pro tons and fluorines that correspond to principal hyperfine coupling components, the dipolar hyperfine coupling contributions were calculated to estimate electron-nucleus distances. With these dipolar separations as constraints, conformations of the substrate both free in solution and in the active site of alpha-chymotrypsin were determined by molecular graphics analysis. Comparison of the conformation of the bound substrate to that of the free substrate showed that formation of the acylenzyme requires significant torsional alteration in substrate structure. The structural relationships between active site residues and the substrate in its ENDOR-assigned conformation are examined with respect to the requirements of stereoelectronic rules for formation and breakdown of the acylenzyme species.	UNIV CHICAGO,CUMMINGS LIFE SCI CTR,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago			Wells, Gregg/AAU-7798-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281, R01GM021900] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 07281, GM 21900] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BENDER M L, 1973, Critical Reviews in Biochemistry, V1, P149, DOI 10.3109/10409237309102546; BENDER ML, 1965, ANNU REV BIOCHEM, V34, P49, DOI 10.1146/annurev.bi.34.070165.000405; BENDER ML, 1964, J AM CHEM SOC, V86, P3697, DOI 10.1021/ja01072a019; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; BIZZOZERO SA, 1981, BIOORG CHEM, V10, P46, DOI 10.1016/0045-2068(81)90042-0; BIZZOZERO SA, 1975, FEBS LETT, V59, P105, DOI 10.1016/0014-5793(75)80351-6; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; BRANDT KG, 1967, J BIOL CHEM, V242, P3973; CARTWRIGHT SJ, 1981, CRC CRIT REV BIOCH, V11, P145; CHURG AK, 1978, REV SCI INSTRUM, V49, P212, DOI 10.1063/1.1135368; COTRAIT PM, 1974, ACTA CRYSTALLOGR B, V30, P510; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; DESLONGCHAMPS P, 1975, TETRAHEDRON, V31, P2463, DOI 10.1016/0040-4020(75)80257-2; Deslongchamps P, 1983, STEREOELECTRONIC EFF, P54; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; DOUZOU P, 1977, CRYOBIOCHEMISTRY, P286; FINK AL, 1973, BIOCHEMISTRY-US, V12, P1736, DOI 10.1021/bi00733a012; FINK AL, 1979, BIOCHEM J, V181, P733, DOI 10.1042/bj1810733; FINK AL, 1973, ARCH BIOCHEM BIOPHYS, V155, P473, DOI 10.1016/0003-9861(73)90139-2; FRIEDEN C, 1993, TRENDS BIOCHEM SCI, V18, P56; GORENSTEIN DG, 1984, BIOPHYS J, V46, P749, DOI 10.1016/S0006-3495(84)84073-4; GREENSTEIN JP, 1984, CHEM AMINO ACIDS, V3, P2344; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; IIJIMA H, 1987, PROTEINS, V2, P330, DOI 10.1002/prot.340020408; INGLES DW, 1968, BIOCHEM J, V108, P561, DOI 10.1042/bj1080561; JOELA H, 1991, J PHYS CHEM-US, V95, P9135, DOI 10.1021/j100176a021; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KUNUGI S, 1979, J AM CHEM SOC, V101, P3640, DOI 10.1021/ja00507a034; KUNUGI S, 1978, ARCH BIOCHEM BIOPHYS, V189, P298, DOI 10.1016/0003-9861(78)90216-3; KUO LC, 1983, J MOL BIOL, V163, P63, DOI 10.1016/0022-2836(83)90030-X; Lambert J. B., 1971, TOP STEREOCHEM, P19; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEHN JM, 1980, J AM CHEM SOC, V102, P1347, DOI 10.1021/ja00524a019; LIENHARD GE, 1971, COLD SPRING HARB SYM, V36, P45, DOI 10.1101/SQB.1972.036.01.009; LUMRY R, 1971, J PHYS CHEM-US, V75, P1387, DOI 10.1021/j100680a007; MAKINEN MW, 1989, J MOL BIOL, V207, P201, DOI 10.1016/0022-2836(89)90451-8; MAKINEN MW, 1977, ANNU REV BIOPHYS BIO, V6, P301, DOI 10.1146/annurev.bb.06.060177.001505; MARET W, 1991, J BIOL CHEM, V266, P20636; MATTHEWS BW, 1967, NATURE, V214, P652, DOI 10.1038/214652a0; MCCONN J, 1971, J BIOL CHEM, V246, P2918; MUSTAFI D, 1990, J AM CHEM SOC, V112, P2558, DOI 10.1021/ja00163a012; MUSTAFI D, 1990, BIOPOLYMERS, V29, P45, DOI 10.1002/bip.360290108; MUSTAFI D, 1991, J MAGN RESON, V91, P497, DOI 10.1016/0022-2364(91)90376-5; MUSTAFI D, 1994, J BIOL CHEM, V269, P4587; MUSTAFI D, 1993, J AM CHEM SOC, V115, P3674, DOI 10.1021/ja00062a037; MUSTAFI D, 1990, FREE RADICAL RES COM, V10, P95, DOI 10.3109/10715769009145938; MUSTAFI D, 1988, INORG CHEM, V27, P3360, DOI 10.1021/ic00292a020; NARUTO S, 1985, J AM CHEM SOC, V107, P5262, DOI 10.1021/ja00304a037; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PETKOV D, 1978, BIOCHIM BIOPHYS ACTA, V527, P131, DOI 10.1016/0005-2744(78)90262-0; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; Rozantsev E.G., 1970, FREE NITROXYL RADICA, P203; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; SEGAL DM, 1971, COLD SPRING HARB SYM, V36, P85, DOI 10.1101/SQB.1972.036.01.014; SEGAL DM, 1971, BIOCHEMISTRY-US, V10, P3728; STEITZ TA, 1969, J MOL BIOL, V46, P337, DOI 10.1016/0022-2836(69)90426-4; Tipton K F, 1979, Methods Enzymol, V63, P183; TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6; TURLEY JW, 1972, ACTA CRYSTALL B-STRU, VB 28, P1641, DOI 10.1107/S0567740872004765; VALLEE BL, 1968, P NATL ACAD SCI USA, V59, P498, DOI 10.1073/pnas.59.2.498; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; WELLS GB, 1988, J AM CHEM SOC, V110, P6343, DOI 10.1021/ja00227a012; WELLS GB, 1990, J AM CHEM SOC, V112, P2566, DOI 10.1021/ja00163a013; WELLS GB, 1987, THESIS U CHICAGO; WILLIAMS RJP, 1971, COLD SPRING HARB SYM, V36, P53, DOI 10.1101/SQB.1972.036.01.010; YIM MB, 1986, J MAGN RESON, V70, P89, DOI 10.1016/0022-2364(86)90365-3; ZERNER B, 1964, J AM CHEM SOC, V86, P3674, DOI 10.1021/ja01072a016	72	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4577	4586						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308029				2022-12-25	WOS:A1994MW98900101
J	CHEN, J; ENGLE, SJ; SEILHAMER, JJ; TISCHFIELD, JA				CHEN, J; ENGLE, SJ; SEILHAMER, JJ; TISCHFIELD, JA			CLONING AND RECOMBINANT EXPRESSION OF A NOVEL HUMAN LOW-MOLECULAR-WEIGHT CA2+-DEPENDENT PHOSPHOLIPASE-A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEMBRANE-ASSOCIATED PHOSPHOLIPASE-A2; RAT PLATELET PHOSPHOLIPASE-A2; PANCREATIC PHOSPHOLIPASE-A2; SUBCELLULAR-LOCALIZATION; HAMSTER HEART; PURIFICATION; SEQUENCE; FORMS; LUNG; PHOSPHATIDYLCHOLINE	Extensive biochemical studies of phospholipase A2s (PLA2s) over the last two decades indicate that there are likely to be several distinct PLA2 genes in mammals. Here we report the cloning of a 1-kilobase pair cDNA encoding a novel human low molecular weight PLA2. The cDNA appears to encode a 118-amino acid mature peptide (M(r) = 13,592) preceded by a 20-residue prepeptide. The deduced amino acid sequence encodes a protein that lacks one of the seven disulfide bridges found in similar PLA2s and, therefore, represents a class of enzymes distinct from the mammalian group I and group II enzymes. An RNA blot hybridized with the cDNA exhibited a putative 1.2-kilobase pair transcript in heart and, less abundantly, in lung, as well as multiple putative transcripts in placenta. When the cDNA was expressed using an Epstein-Barr virus-based vector in human 293s cells, PLA2 activity accumulated in the culture medium. Conditioned medium optimally hydrolyzed the phospholipids of [1-C-14]oleate-labeled Escherichia coli at neutral to alkaline pH with 10 mM or greater Ca2+. In assays done with individual substrates, L-alpha-1-palmitoyl-2-oleoyl phosphatidylcholine was more efficiently hydrolyzed than L-alpha-1-palmitoyl-2-arachidonyl phosphatidylcholine, L-alpha-1-palmitoyl-2-arachidonyl phosphatidylethanolamine, or L-alpha-1-stearoyl-2-arachidonyl phosphatidylinositol.	INDIANA UNIV, SCH MED,DEPT MED & MOLEC GENET,IB130, 975 W WALNUT ST, INDIANAPOLIS, IN 46202 USA; INCYTE PHARMACEUT INC, PALO ALTO, CA 94304 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Incyte			Chen, Ju/E-5579-2011	Tischfield, Jay/0000-0003-3217-8287				AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; BENNETT CF, 1990, BIOCHIM BIOPHYS ACTA, V1047, P271, DOI 10.1016/0005-2760(90)90526-4; CAO YZ, 1987, J BIOL CHEM, V262, P16927; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; Dennis EA, 1983, ENZYMES, P307; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; FRANSON RC, 1982, LUNG, V160, P275, DOI 10.1007/BF02719301; HEINRIKSON RL, 1991, METHOD ENZYMOL, V197, P201; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HEVALAINEN TJ, 1993, INFLAMMATION, V17, P453; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; Johnson L K, 1990, Adv Exp Med Biol, V275, P17; JORDAN LM, 1992, J CHROMATOGR, V597, P299, DOI 10.1016/0021-9673(92)80124-D; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUSUNOKI C, 1990, BIOCHIM BIOPHYS ACTA, V1087, P95, DOI 10.1016/0167-4781(90)90127-N; LINDAHL M, 1989, BIOCHIM BIOPHYS ACTA, V1005, P282, DOI 10.1016/0005-2760(89)90050-7; MALFERTHEINER P, 1989, KLIN WOCHENSCHR, V67, P183, DOI 10.1007/BF01711350; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; NALBONE G, 1985, J LIPID RES, V26, P104; ONO T, 1988, J BIOL CHEM, V263, P5732; PRUZANSKI W, 1990, ADV EXP MED BIOL, V279, P239; RORDORF G, 1991, J NEUROSCI, V11, P1829; SEILHAMER JJ, 1989, J BIOCHEM, V106, P38, DOI 10.1093/oxfordjournals.jbchem.a122815; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; TAM SW, 1984, CAN J BIOCHEM CELL B, V62, P1269, DOI 10.1139/o84-161; UHL W, 1990, J TRAUMA, V30, P1285, DOI 10.1097/00005373-199010000-00015; VADAS P, 1986, LAB INVEST, V55, P391	30	213	217	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2365	2368						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300559				2022-12-25	WOS:A1994MV43200005
J	WALKER, P; MUNOZ, M; MARTINEZ, R; PEITSCH, MC				WALKER, P; MUNOZ, M; MARTINEZ, R; PEITSCH, MC			ACIDIC RESIDUES IN EXTRACELLULAR LOOPS OF THE HUMAN-Y1 NEUROPEPTIDE-Y RECEPTOR ARE ESSENTIAL FOR LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PANCREATIC-POLYPEPTIDE; PEPTIDE-YY; G-PROTEIN; AGONIST; IDENTIFICATION; MUTAGENESIS; DYNAMICS; CLONING; BRAIN	To investigate whether negatively charged residues of the human Y1 neuropeptide Y (NPY) receptor are required for ligand binding, a series of mutants were constructed in which aspartic acid and glutamic acid residues present in putative extracellular domains of the Y1 receptor were systematically replaced by alanines. The mutant cDNAs were transiently expressed in HeLa cells using a vaccinia virus-derived expression system, and their ability to bind NPY was evaluated. The level of expression of mutants unable to bind NPY was also tested immunologically. In addition, the ability of the mutant proteins to be recruited to the cell surface was assessed by confocal microscopy. Substitution of aspartic acids and glutamic acids of the N-terminal first extracellular domain had no effect on binding. On the other hand, substitution of acidic residues present in the second, third, and fourth extracellular loops resulted in proteins unable to bind I-125-NPY. These results demonstrate that the extracellular loops of the human Y1 NPY receptor are essential portions of its ligand binding domain.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND	University of Lausanne	WALKER, P (corresponding author), CHU VAUDOIS,DIV HYPERTENS,CH-1011 LAUSANNE,SWITZERLAND.		Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X				ALLEN J, 1987, P NATL ACAD SCI USA, V84, P2532, DOI 10.1073/pnas.84.8.2532; BALASUBRAMANIAM A, 1990, PEPTIDES, V11, P545, DOI 10.1016/0196-9781(90)90057-C; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BECK A, 1989, FEBS LETT, V244, P119, DOI 10.1016/0014-5793(89)81175-5; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BLUNDELL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4175, DOI 10.1073/pnas.78.7.4175; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAHL SG, 1991, P NATL ACAD SCI USA, V88, P8111, DOI 10.1073/pnas.88.18.8111; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HACKENTHAL E, 1987, AM J PHYSIOL, V252, pF543, DOI 10.1152/ajprenal.1987.252.3.F543; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HILBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; KASSIS S, 1987, J BIOL CHEM, V262, P3429; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIRBY DA, 1993, J MED CHEM, V36, P385, DOI 10.1021/jm00055a010; KRAUSE J, 1992, MOL PHARMACOL, V41, P817; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEHMANN J, 1990, DRUG DEVELOP RES, V19, P329, DOI 10.1002/ddr.430190402; MACKERELL AD, 1988, J COMPUT AID MOL DES, V2, P55, DOI 10.1007/BF01532053; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; PETTERSSON M, 1987, CELL TISSUE RES, V248, P43, DOI 10.1007/BF01239960; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; STANLEY BG, 1986, PEPTIDES, V7, P1189; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; UNDEN A, 1984, EUR J BIOCHEM, V145, P525, DOI 10.1111/j.1432-1033.1984.tb08588.x; WAEBER B, 1988, AM J HYPERTENS, V1, P193, DOI 10.1093/ajh/1.2.193; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WALKER P, 1991, TRENDS PHARMACOL SCI, V12, P111, DOI 10.1016/0165-6147(91)90518-W; WALKER P, 1992, MOL CELL ENDOCRINOL, V91, P107	42	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2863	2869						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300621				2022-12-25	WOS:A1994MV43200075
J	XU, PX; FUKUTA, M; TAKIYA, S; MATSUNO, K; XU, X; SUZUKI, Y				XU, PX; FUKUTA, M; TAKIYA, S; MATSUNO, K; XU, X; SUZUKI, Y			PROMOTER OF THE POU-M1/SGF-3 GENE INVOLVED IN THE EXPRESSION OF BOMBYX SILK GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU-DOMAIN; TRANSCRIPTION FACTOR; FIBROIN GENE; DNA-BINDING; CELL IDENTITY; STEM-CELLS; INVITRO; DROSOPHILA; PIT-1; SITES	To characterize the transcription regulation of the POU-M1/SGF-3 gene, we have cloned a genomic DNA fragment encompassing the whole coding region and its flanking sequences. This gene does not contain any intron. The 5'-flanking region of the gene contains several interesting motifs, such as homeodomain-binding motifs, sequences resembling the transcriptional factor Sp1-binding site, and TGTTT motifs, but lacks some of the typical transcriptional regulatory sequences, such as TATA and CCAAT boxes. Transcriptional analysis of a series of deletion mutants of the gene in the nuclear extracts prepared from the middle silk gland of 2-day-old fifth instar larvae revealed the presence of multiple cis-regulatory elements located both upstream and downstream of the initiation site. One of these elements, the homeodomain-binding element, was identified to mediate negative regulation. By mobility shift assay using the POU-M1 specific antibodies, we found that this negative element interacts with the POU-M1/SGF-3. Transcription analysis in vitro using templates mutagenized in the PB region and one of the POU-M1 antibodies indicated that the PB region is an autoregulatory element responsible for SGF-3-dependent transcriptional repression.	NATL INST BASIC BIOL, MYODAIJI, OKAZAKI, AICHI 444, JAPAN; GRAD UNIV ADV STUDIES, OKAZAKI 444, JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan			Takiya, Shigeharu/A-6439-2012					AKAM M, 1987, DEVELOPMENT, V101, P1; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELSONLTZ HP, 1990, GENE DEV, V4, P43; Favaloro J, 1980, Methods Enzymol, V65, P718; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FUKUTA M, 1993, J BIOL CHEM, V268, P19471; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HIROSE S, 1982, P NATL ACAD SCI-BIOL, V79, P7258, DOI 10.1073/pnas.79.23.7258; HIROSE S, 1985, J BIOL CHEM, V260, P557; HUI CC, 1990, J MOL BIOL, V213, P651, DOI 10.1016/S0022-2836(05)80253-0; HUI CC, 1992, P NATL ACAD SCI USA, V89, P167, DOI 10.1073/pnas.89.1.167; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MATHIS DJ, 1981, NATURE, V290, P310, DOI 10.1038/290310a0; MATSUNO K, 1990, NUCLEIC ACIDS RES, V18, P1853, DOI 10.1093/nar/18.7.1853; MATSUNO K, 1989, J BIOL CHEM, V264, P18707; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PERKINS KK, 1988, GENE DEV, V2, P1615, DOI 10.1101/gad.2.12a.1615; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; Shenk T, 1981, Curr Top Microbiol Immunol, V93, P25; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; SUZUKI Y, 1986, P NATL ACAD SCI USA, V83, P9522, DOI 10.1073/pnas.83.24.9522; Suzuki Y., 1990, MOL INSECT SCI, P83; TAKIYA S, 1990, EMBO J, V9, P489, DOI 10.1002/j.1460-2075.1990.tb08135.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	47	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2733	2742						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300605				2022-12-25	WOS:A1994MV43200058
J	JOUNEAUX, C; MALLAT, A; SERRADEILLEGAL, C; GOLDSMITH, P; HANOUNE, J; LOTERSZTAJN, S				JOUNEAUX, C; MALLAT, A; SERRADEILLEGAL, C; GOLDSMITH, P; HANOUNE, J; LOTERSZTAJN, S			COUPLING OF ENDOTHELIN B-RECEPTORS TO THE CALCIUM-PUMP AND PHOSPHOLIPASE-C VIA GS AND GQ IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEIN; BETA-GAMMA-SUBUNITS; SIGNAL TRANSDUCTION; GUANINE-NUCLEOTIDE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA-MEMBRANES; ADENYLYL CYCLASE; ALPHA-SUBUNITS; CA-2+ PUMP; ACTIVATION	We have demonstrated in liver from male rats that both endothelin A (ET(A)) and ET(B) receptors coexist in equal proportion and that ET(A) receptors mediate a calcium-dependent activation of glycogenolysis. We describe here a sex difference in endothelin action in hepatocytes because, in female rats, 80% of the ET receptors are of ET(B) type and, accordingly, activation of glycogenolysis is an ET(B)-mediated process (EC50 = 0.03 pm). ET- 1 stimulation of glycogenolysis in female rats was consecutive to activation of phosphatidylinositol 4,5-bisphosphate hydrolysis (EC50 = 0.03 pm) and to inhibition of the calcium extrusion pump (IC50 = 0.03 pm) in plasma membranes, with ET-1 almost-equal-to sarafotoxin S6C almost-equal-to ET-3. Endothelin regulation of each effector was potentiated by GTPgammaS. ET-1 did not stimulate adenylyl cyclase activity. To identify the nature of the guanine nucleotide regulatory proteins (G protein(s)) coupling ET(B) receptors to each effector, we used antibodies against the COOH terminus of different G protein alpha subunits. Antibodies reactive with Gsalpha (RM) blocked ET-1 inhibition of the calcium pump, while they did not affect ET-1 stimulation of phospholipase C. Antibodies reactive with Gqalpha (QL) dose-dependently antagonized stimulation of phospholipase C by ET-1 and vasopressin, without affecting ET-1 inhibition of the calcium pump. Antibodies reactive with Gi1alpha/Gi2alpha (AS) had no effect on either system. We conclude that the calcium signal provoked by endothelins in hepatocyte is not only consecutive to activation of phospholipase C but also to inhibition of the plasma membrane calcium pump, each effector being coupled to ET(B) receptors by different G proteins, Gq, and Gs.	SANOFI RECH,BIOCHIM EXPLORATOIRE,F-31036 TOULOUSE,FRANCE; NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BETHESDA,MD 20892	Sanofi-Aventis; Sanofi France; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	JOUNEAUX, C (corresponding author), HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE.		Lotersztajn, Sophie/K-9160-2017	lotersztajn, Sophie/0000-0002-0053-7807				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; EGUCHI S, 1993, ENDOCRINOLOGY, V132, P524, DOI 10.1210/en.132.2.524; EMORI T, 1991, BIOCHEM BIOPH RES CO, V174, P228, DOI 10.1016/0006-291X(91)90510-E; GANDHI CR, 1992, BIOCHEM J, V287, P897, DOI 10.1042/bj2870897; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JHON DY, 1993, J BIOL CHEM, V268, P6654; JOUNEAUX C, 1993, J BIOL CHEM, V268, P2368; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LITOSCH I, 1989, BIOCHEM J, V261, P325, DOI 10.1042/bj2610325; LOTERSZTAJN S, 1990, J BIOL CHEM, V265, P9876; LOTERSZTAJN S, 1992, J BIOL CHEM, V267, P2375; LOTERSZTAJN S, 1990, TRANSMEMBRANE SIGNAL; MACRAE AD, 1992, TRENDS ENDOCRIN MET, V3, P153, DOI 10.1016/1043-2760(92)90164-V; MALLAT A, 1987, NATURE, V325, P620, DOI 10.1038/325620a0; MARIN P, 1991, J NEUROCHEM, V56, P1270, DOI 10.1111/j.1471-4159.1991.tb11421.x; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MCKENZIE RC, 1990, BIOCHEM J, V266, P817; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHUBERT B, 1989, SCIENCE, V245, P804; SERRADEILLEGAL C, 1991, J CLIN INVEST, V87, P133, DOI 10.1172/JCI114962; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SHETTY SS, 1993, BIOCHEM BIOPH RES CO, V191, P459, DOI 10.1006/bbrc.1993.1240; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SOKOLOVSKY M, 1991, TRENDS BIOCHEM SCI, V16, P261, DOI 10.1016/0968-0004(91)90100-A; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; STUDER RK, 1982, J BIOL CHEM, V257, P7987; TAKUWA Y, 1990, J CLIN INVEST, V85, P653, DOI 10.1172/JCI114488; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VIGNE P, 1990, J BIOL CHEM, V265, P6782; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	43	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1845	1851						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294432				2022-12-25	WOS:A1994MR98800047
J	PAANANEN, K; KOVANEN, PT				PAANANEN, K; KOVANEN, PT			PROTEOLYSIS AND FUSION OF LOW-DENSITY-LIPOPROTEIN PARTICLES INDEPENDENTLY STRENGTHEN THEIR BINDING TO EXOCYTOSED MAST-CELL GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; APOLIPOPROTEIN B-100; HEPARIN-BINDING; ATHEROSCLEROTIC LESIONS; ARTERIAL PROTEOGLYCANS; PERITONEAL-MACROPHAGES; MEDIATED UPTAKE; RABBIT AORTAS; DEGRADATION; IDENTIFICATION	Contact between low density lipoproteins (LDL) and exocytosed mast cell granules, the ''granule remnants,'' leads to binding of LDL to the granule remnants via ionic interactions between the apolipoprotein B-100 (apoB-100) component of LDL and the heparin proteoglycan component of the granule remnants. Upon incubation at 37-degrees-C, the heparin proteoglycan-bound apoB-100 is progressively proteolyzed by remnant chymase and carboxypeptidase A, which are also bound to the heparin proteoglycans. Thereupon, the LDL particles fuse, and their binding to the granule remnants strengthens, as defined by the decreased ability of NaCl to release LDL from the remnants. We now have examined separately the effects of proteolysis and fusion on LDL binding. Proteolysis without fusion was induced by lowering the incubation temperature to 15-degrees-C, and proteolysis-independent fusion was induced by treating granule remnant-bound LDL with sphingomyelinase in the presence of protease inhibitors. It was found that degradation of the heparin proteoglycan-bound apoB-100, even without accompanying particle fusion, increased the strength of LDL binding to the granule remnants, suggesting exposure of buried heparin binding regions of apoB-100. When such proteolyzed LDL particles were allowed to fuse, the strength of their binding to the granule remnants increased still further, probably because of an increase in the number of apoB-100 fragments in the enlarged particles. Proteolysis-independent fusion, induced by sphingomyelinase treatment of granule remnant-bound LDL, also increased the strength of binding. The results show that proteolytic degradation and fusion, the two modifications of granule remnant-bound LDL subsequent to action by chymase and carboxypeptidase A of the granule remnants, represent two separate mechanisms by which LDL particles become tightly bound to the heparin proteoglycans of exocytosed mast cell granules. Since the formation of an atheroma, the hallmark of atherosclerosis, is characterized by accumulation in the proteoglycan matrix of the arterial intima of extracellular lipid droplets resembling the fused LDL particles on the granule remnant surfaces, the modifications of LDL described in this study may provide a clue to the actual processes by which the lipid droplets are anchored to the arterial intima.	WIHURI RES INST, KALLIOLINNANTIE 4, SF-00140 HELSINKI, FINLAND	Wihuri Research Institute			Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				BAGGIOLINI M, 1982, INT ARCH ALLER A IMM, V67, P219, DOI 10.1159/000233022; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMEJO G, 1991, BIOCHIM BIOPHYS ACTA, V1096, P253, DOI 10.1016/0925-4439(91)90013-Y; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CARDIN AD, 1986, BIOCHEMISTRY-US, V25, P5258, DOI 10.1021/bi00366a041; CHAO FF, 1988, AM J PATHOL, V131, P73; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN SH, 1986, J BIOL CHEM, V261, P2918; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1975, SCIENCE, V190, P392, DOI 10.1126/science.170681; FRANK JS, 1989, J LIPID RES, V30, P967; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; GUYTON JR, 1989, AM J PATHOL, V134, P705; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P644, DOI 10.1161/01.ATV.5.6.644; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIROSE N, 1987, BIOCHEMISTRY-US, V26, P5505, DOI 10.1021/bi00391a044; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1987, EXP MOL PATHOL, V46, P331, DOI 10.1016/0014-4800(87)90054-2; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KOKKONEN JO, 1985, J BIOL CHEM, V260, P4756; KOKKONEN JO, 1987, BIOCHEM J, V241, P583, DOI 10.1042/bj2410583; KOKKONEN JO, 1989, ATHEROSCLEROSIS, V79, P213, DOI 10.1016/0021-9150(89)90126-3; KOVANEN PT, 1991, J BIOL CHEM, V266, P4430; KOVANEN PT, 1991, ANN MED, V23, P551, DOI 10.3109/07853899109150517; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; LINDAHL U, 1979, BIOCHEM J, V182, P189, DOI 10.1042/bj1820189; LINDSTEDT KA, 1992, J LIPID RES, V33, P65; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; VIJAYAGOPAL P, 1981, J BIOL CHEM, V256, P8234; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WOODBURY RG, 1981, METHOD ENZYMOL, V80, P588; XU XX, 1991, J BIOL CHEM, V266, P24849; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YURT RW, 1977, J BIOL CHEM, V252, P518	44	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2023	2031						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294453				2022-12-25	WOS:A1994MR98800073
J	BOND, JA; WYLLIE, FS; ROWSON, J; RADULESCU, A; WYNFORDTHOMAS, D				BOND, JA; WYLLIE, FS; ROWSON, J; RADULESCU, A; WYNFORDTHOMAS, D			IN-VITRO RECONSTRUCTION OF TUMOR INITIATION IN A HUMAN EPITHELIUM	ONCOGENE			English	Article							RET ONCOGENE ACTIVATION; COLORECTAL TUMORIGENESIS; THYROID-TUMORS; RAS ONCOGENE; MUTATIONS OCCUR; HIGH-FREQUENCY; CELL-LINE; PAPILLARY; CARCINOMAS; MARKERS	Knowledge of tumour initiation in human epithelia is limited by sample availability and difficulty in experimental manipulation of human cells. The thyroid is a useful model since, in addition to multiple tumour stages, it presents two distinct 'pathways' of tumorigenesis: 'follicular' tumours, in which vas oncogene mutations occur at high frequency and 'papillary' tumours, associated with ret (or trk) activation. We have used these observations to reconstruct early thyroid tumorigenesis, using amphotropic retroviral vectors. When introduced into normal thyroid epithelial cells, mutant vas induces self-limiting growth of well-demarcated, differentiated colonies - a phenotype consistent with follicular adenoma. Activated ret on the other hand induces smaller, poorly demarcated colonies with a morphology consistent with early papillary tumours. Mutant p53 - which occurs only in the latest stages of thyroid cancer - was without effect. Our results provide the first direct experimental evidence in a human epithelium for alternative initiating oncogenes and their determination of the subsequent 'direction' of tumour development.	UNIV WALES COLL CARDIFF,COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL RES GRP,CARDIFF,S GLAM CF4 4XN,WALES	Cardiff University								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BONGARZONE I, 1989, ONCOGENE, V4, P1457; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Hedinger, 2012, HISTOLOGICAL TYPING; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ITO T, 1992, CANCER RES, V52, P1369; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SCHRODER S, 1985, AM J SURG PATHOL, V9, P619, DOI 10.1097/00000478-198509000-00001; SHEPARD TH, 1968, GEN COMP ENDOCR, V10, P174, DOI 10.1016/0016-6480(68)90024-5; SUAREZ HG, 1990, ONCOGENE, V5, P565; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WILLIAMS DW, 1989, THYROID TUMOURS MOL, P57; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; WRIGHT PA, 1993, J PATH S, V169, P230; WYNFORDTHOMAS D, 1991, J PATHOL, V165, P187, DOI 10.1002/path.1711650302	32	81	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					281	290						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302590				2022-12-25	WOS:A1994MW24700034
J	VERDERAME, MF; VARMUS, HE				VERDERAME, MF; VARMUS, HE			HIGHLY CONSERVED AMINO-ACIDS IN THE SH2 AND CATALYTIC DOMAINS OF V-SRC ARE ALTERED IN NATURALLY-OCCURRING, TRANSFORMATION-DEFECTIVE ALLELES	ONCOGENE			English	Article							TERMINAL REGULATORY DOMAIN; TYROSINE PROTEIN-KINASES; C-ABL; ONCOGENIC ACTIVATION; CELL-TRANSFORMATION; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; POINT MUTATIONS; SARCOMA-VIRUS; PP60C-SRC	We have identified 11 novel point mutations that abolish the transforming capacity of the oncogene v-src. These transformation-defective alleles were originally identified in morphologically flat subclones of rat cells transformed by wild type v-src. Nine of the mutations affect amino acid residues that are highly conserved in the catalytic domain of pp60(v-src) and completely abolish kinase activity. The other 2 mutations alter conserved residues in the SH2 domain (Phe-172 replaced with Val in one case [F172V] and Leu-186 replaced with Phe in the other [L186F]), drastically reducing, but not eliminating, kinase activity. The enzymatic and transforming functions of one of the SH2 mutants, L186F are host dependent; the mutant protein is active in chicken cells, but inactive in rat cells, as previously observed for some other SH2 mutants. These results are interpreted in relation to the recently described three-dimensional structures of SH2 domains and of the catalytic domain of a protein kinase. In addition, they support a role for the SH2 domain in the regulation of kinase activity.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	VERDERAME, MF (corresponding author), PENN STATE UNIV, COLL MED, DEPT MICROBIOL & IMMUNOL, HERSHEY, PA 17033 USA.			Verderame, Michael F./0000-0001-7046-0879	NATIONAL CANCER INSTITUTE [R01CA052791, R35CA039832] Funding Source: NIH RePORTER; NCI NIH HHS [CA52791, CA39832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LIEBL EC, 1993, VIROLOGY, V195, P265, DOI 10.1006/viro.1993.1371; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1990, ONCOGENE, V5, P1437; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7	40	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					175	182						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302576				2022-12-25	WOS:A1994MW24700021
J	TVERBERG, LA; RUSSO, AF				TVERBERG, LA; RUSSO, AF			REGULATION OF THE CALCITONIN CALCITONIN-GENE-RELATED PEPTIDE GENE BY CELL-SPECIFIC SYNERGY BETWEEN HELIX-LOOP-HELIX AND OCTAMER-BINDING TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY-THYROID CARCINOMA; IMMUNOGLOBULIN GENES; NUCLEAR FACTOR; DNA-SEQUENCE; FACTOR OTF-1; E-BOX; ENHANCER; EXPRESSION; PROTEIN; ACTIVATION	The calcitonin/calcitonin gene-related peptide (CGRP) gene is transcribed in thyroid C-cells and a subset of neurons. We have localized sequences required for cell-specific enhancement of calcitonin/CGRP transcription in rat thyroid C-cell lines. An 18-base pair element approximately 1 kilobase pair up-stream of the transcriptional start site stimulated expression of a luciferase reporter gene 50-fold in 44-2C C-cells. There was less than 2-fold stimulation in HeLa and Rat-1 cells, which do not express the endogenous calcitonin/CGRP gene. The enhancer contains potential binding sites for helix-loop-helix (HLH) and octamer transcription factors based on sequence homologies. The functional significance of these sites was shown by point mutations in the HLH and octamer motifs and by separation of the two motifs, all of which decreased enhancer activity greater than 10-fold. The involvement of HLH proteins was further shown by co-expression of the mammalian achaete-scute homologue-1 HLH protein, which activated the enhancer severalfold in HeLa cells. Electrophoretic mobility shift analyses revealed several DNA-protein complexes containing HLH and octamer-binding proteins. One octamer-binding complex (OB1) most likely contains the ubiquitous Oct-1 protein, whereas a second complex (OB2) was cell-specific. In contrast to OB1, OB2 had lower affinity for a consensus octamer motif, and its DNA binding was not affected by addition of antiserum that recognizes Oct-1 and Oct-2 proteins. In addition, we observed a large complex that appears to contain both an HLH protein and OB2. These results demonstrate that calcitonin/CGRP enhancer activity is controlled by a cell-specific synergistic activation involving HLH and octamer-binding factors.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa				Russo, Andrew/0000-0002-8156-5649	NICHD NIH HHS [HD25969] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALL DW, 1992, NUCLEIC ACIDS RES, V20, P117, DOI 10.1093/nar/20.1.117; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; DEBUSTROS A, 1986, J BIOL CHEM, V261, P8036; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSZYNSKI M, 1983, J BIOL CHEM, V258, P1678; NAVEHMANY T, 1988, J CLIN INVEST, V81, P270, DOI 10.1172/JCI113305; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PELEG S, 1990, MOL ENDOCRINOL, V4, P1750, DOI 10.1210/mend-4-11-1750; PETTERSSON M, 1990, J MOL BIOL, V214, P373, DOI 10.1016/0022-2836(90)90187-Q; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; RUSSO AF, 1992, MOL ENDOCRINOL, V6, P207, DOI 10.1210/me.6.2.207; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STOLARSKYFREDMAN L, 1990, MOL ENDOCRINOL, V4, P497, DOI 10.1210/mend-4-3-497; TVERBERG LA, 1992, J BIOL CHEM, V267, P17567; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; ZELEZNIKLE NJ, 1992, J BIOL CHEM, V267, P7677	47	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15965	15973						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340417				2022-12-25	WOS:A1993LN30500091
J	ZHAO, GP; SOMERVILLE, RL				ZHAO, GP; SOMERVILLE, RL			A SINGLE AMINO-ACID SWITCH WITHIN THE HINGE REGION OF THE TRYPTOPHAN SYNTHASE BETA-SUBUNIT OF ESCHERICHIA-COLI THAT LEADS TO DIMINISHED ASSOCIATION WITH ALPHA-SUBUNIT AND ARRESTED CONVERSION OF ESII TO PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; L-SERINE; SYNTHETASE; MECHANISM; COMPLEX; BINDING; INDOLE; INACTIVATION; REPLICATION; PROTEIN	The trpB8 mutation of Escherichia coli causes a major conformational change within the beta subunit of tryptophan synthase. The basis of this effect is a replacement of glycine 281 by arginine within a structurally important ''hinge'' region. The mutant subunit, beta(B8), is catalytically active only under certain conditions, both in vivo and in vitro. Physiologically, the availability of wild type alpha subunit is the most important determinant of catalytic proficiency (Zhao, G.-P., and Somerville, R. L. (1992) J. Biol. Chem. 267, 526-541; Zhao, G.-P., and Somerville, R. L. (1993) J. Biol. Chem. 268, 14912-14920). Through enzyme activity titration experiments it was shown that the alpha subunit of tryptophan synthase dramatically stimulates catalysis by the beta2(B8) mutant enzyme. However, by size exclusion high performance liquid chromatography, the stability of the alpha.beta2(B8) complex was markedly reduced in comparison with wild type. The alpha-mediated stimulation of catalysis by the beta2(B8) mutant enzyme was enhanced by polyethylene glycol, a volume excluder. By absorption spectroscopy, it was shown that catalysis by the beta(B8) mutant protein is blocked in at least one step after the formation of a particular Schiff base intermediate (ESII). Either the alpha subunit or ammonium ion was able to overcome this block. The microenvironment of the ESII catalytic intermediate was examined by fluorescence spectroscopy. The data are consistent with a less hydrophobic environment for ESII in the beta2(B8) mutant protein than in the wild type protein. These lines of evidence not only support a conformational switch model of open versus closed states within the beta subunit during the catalytic cycle but also suggest a functional role for the hinge region in the process of conformational switching.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [GM22131] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022131] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI O, 1974, J BIOL CHEM, V249, P7756; AHMED SA, 1991, J BIOL CHEM, V266, P21548; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BARTHOLMES P, 1976, BIOCHEMISTRY-US, V15, P4712, DOI 10.1021/bi00666a027; BARTHOLMES P, 1979, EUR J BIOCHEM, V95, P323, DOI 10.1111/j.1432-1033.1979.tb12968.x; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; CREIGHTON TE, 1970, METHODS ENZYMOLOGY A, V17, P365, DOI DOI 10.1021/ACS.BIOCHEM.8B00167; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; Friedrich P., 1984, SUPRAMOLECULAR ENZYM; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; HATANAKA M, 1962, ARCH BIOCHEM BIOPHYS, V97, P596, DOI 10.1016/0003-9861(62)90129-7; HENNING U, 1962, J BIOL CHEM, V237, P1523; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JACKSON DA, 1969, J BIOL CHEM, V244, P4526; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1984, DYNAMICS BIOCH SYSTE, P115; MATCHETT WH, 1974, J BIOL CHEM, V249, P4041; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1970, J BIOL CHEM, V245, P6016; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; MILES EW, 1985, PYRIDOXAL PHOSPHATE, P253; MURRYBRELIER A, 1990, J BIOL CHEM, V265, P7987; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; REGNIER FE, 1983, METHOD ENZYMOL, V91, P137; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; WILSON DA, 1965, J BIOL CHEM, V240, P4801; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YANOFSKY C, 1989, BIOCHIM BIOPHYS ACTA, V1000, P133, DOI 10.1016/S0006-3002(89)80013-7; YANOFSKY C, 1987, BIOESSAYS, V6, P133, DOI 10.1002/bies.950060309; YANOFSKY C, 1960, BACTERIOL REV, V24, P221, DOI 10.1128/MMBR.24.2.221-245.1960; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029; ZHAO GP, 1993, J BIOL CHEM, V268, P14912; ZHAO GP, 1992, J BIOL CHEM, V267, P526; ZHAO GP, 1987, FASEB J, V46, P1938	45	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14921	14931						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325869				2022-12-25	WOS:A1993LL75900060
J	CARTER, ME; GULICK, T; RAISHER, BD; CAIRA, T; LADIAS, JAA; MOORE, DD; KELLY, DP				CARTER, ME; GULICK, T; RAISHER, BD; CAIRA, T; LADIAS, JAA; MOORE, DD; KELLY, DP			HEPATOCYTE NUCLEAR FACTOR-IV ACTIVATES MEDIUM-CHAIN ACYL-COA DEHYDROGENASE GENE-TRANSCRIPTION BY INTERACTING WITH A COMPLEX REGULATORY ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; TISSUE; DEFICIENCY; EXPRESSION; MEMBER; ALPHA-1-ANTITRYPSIN; TRANSTHYRETIN; EFFICIENCY; PROTEINS	We have recently identified a complex transcriptional regulatory element in the medium chain acyl-CoA dehydrogenase (MCAD) gene promoter region that confers response to retinoids through interaction with receptors for all-trans-retinoic acid (RARs) and 9-cis-retinoic acid (RXRs) (Raisher, B. D., Gulick, T., Zhang, Z., Strauss, A. W., Moore, D. D., and Kelly, D. P. (1992) J. Biol. Chem. 267, 20264-20269). We examined the interaction of this element (RARE(MCAD)) with hepatocyte nuclear factor-4 (HNF-4), an orphan receptor with a tissue expression pattern similar to that of MCAD. Electrophoretic mobility shift assays and cotransfection experiments showed that HNF-4 binds with high affinity to RARE(MCAD) to activate transcription by an RXR-independent mechanism. Mutational analysis revealed that the MCAD HNF-4 response element consists of an imperfect direct repeat homologous to the consensus sequence for binding to the thyroid receptor/RAR/RXR subgroup of receptors and that distinct sequence requirements dictate HNF-4 binding and transactivation. Mobility shift assays with anti-HNF-4 antiserum demonstrated that the MCAD HNF-4 response element binds endogenous rat liver HNF-4 supporting its role in the regulation of MCAD gene expression in vivo. Thus, HNF-4 activates MCAD gene transcription via a complex regulatory element, the architecture of which carries important implications for the structure of HNF-4 response elements in general.	WASHINGTON UNIV, DEPT MED, ST LOUIS, MO 63130 USA; WASHINGTON UNIV, DEPT PEDIAT, ST LOUIS, MO 63130 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT MED, BOSTON, MA 02215 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Kelly, Daniel/ABG-2056-2021		NIDDK NIH HHS [DK45416] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045416, R29DK045416] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUSIBEL FM, 1992, CURRENT PROTOCOLS MO, V2; Beinert H., 1963, ENZYMES, P447; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DURAN M, 1986, PEDIATRICS, V78, P1052; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STANLEY CA, 1990, PROG CLIN BIOL RES, V321, P291; STANLEY CA, 1983, PEDIATR RES, V17, P872; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TREEM WR, 1986, HEPATOLOGY, V6, P1270, DOI 10.1002/hep.1840060608; UEMSONO K, 1991, CELL, V65, P1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHANG ZF, 1992, BIOCHEMISTRY-US, V31, P81, DOI 10.1021/bi00116a013	40	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13805	13810						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314750				2022-12-25	WOS:A1993LJ82500009
J	LARNER, JM; PAHUJA, SL; SHACKLETON, CH; MCMURRAY, WJ; GIORDANO, G; HOCHBERG, RB				LARNER, JM; PAHUJA, SL; SHACKLETON, CH; MCMURRAY, WJ; GIORDANO, G; HOCHBERG, RB			THE ISOLATION AND CHARACTERIZATION OF ESTRADIOL-FATTY ACID-ESTERS IN HUMAN OVARIAN FOLLICULAR-FLUID - IDENTIFICATION OF AN ENDOGENOUS LONG-LIVED AND POTENT FAMILY OF ESTROGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOIDAL DERIVATIVES; HUMAN-PLASMA; PREGNENOLONE; BIOSYNTHESIS; RAT; CORTICOSTERONE; METABOLISM; ESTRIOL; TISSUES	The estradiol-fatty acid esters are highly potent and long-lived estrogens that were first isolated and identified from in vitro biosynthetic experiments (Mellon-Nussbaum S., Ponticorvo, L., Schatz, F., and Hochberg, R. B. (1982) J. Biol. Chem. 257, 5678-5684). Other studies have indicated that these esters exist endogenously, but the evidence is indirect, resting solely on the presence of a nonpolar saponifiable metabolite. Although there are similar reports of other naturally occurring fatty acid esters of biologically active steroid hormones, likewise, none has been isolated and characterized. In this study we have found that follicular fluid from the ovaries of women stimulated with gonadotrophins contains relatively large amounts of a nonpolar saponifiable derivative of estradiol (approximately 10(-7) M), which we presumed to be fatty acid esters. Using a combination of chromatographic techniques we isolated these estradiol metabolites and identified them by mass spectral analysis. They are a mixture of five different estradiol-17 fatty acid esters, The amount of each present was determined by separating the esters by reversed phase high performance liquid chromatography and then quantifying each peak by radioimmunoassay and UV absorption. The esters of estradiol are predominantly unsaturated, with linoleate the most abundant comprising 43% of the total. The other esters are: palmitate (20%), arachidonate (19%), oleate (14%), and stearate (4%). Thus these studies conclusively demonstrate the existence of these unusually powerful estrogens.	YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,MASS SPECT FACIL,333 CEDAR ST,NEW HAVEN,CT 06510; CHILDRENS HOSP OAKLAND RES INST,OAKLAND,CA 94609; YALE UNIV,SCH MED,CTR COMPREHENS CANC,NEW HAVEN,CT 06510	Yale University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Yale University					NCI NIH HHS [CA-29591] Funding Source: Medline; NCRR NIH HHS [RR06515] Funding Source: Medline; NIDDK NIH HHS [DK-34400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034400] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADDO S B, 1989, Steroids, V54, P257, DOI 10.1016/0039-128X(89)90001-9; ADDO SB, 1990, STEROIDS, V55, P492; ALBERT DH, 1980, J BIOL CHEM, V255, P618; BISCHOF P, 1974, EXPERIENTIA, V30, P1101, DOI 10.1007/BF01939032; COUTURE J, 1990, J STEROID BIOCH S, V36, P134; HOCHBERG R, 1979, J STEROID BIOCHEM, V11, P1333, DOI 10.1016/0022-4731(79)90103-1; HOCHBERG RB, 1977, P NATL ACAD SCI USA, V74, P941, DOI 10.1073/pnas.74.3.941; HOCHBERG RB, 1991, NEW BIOL STEROID HOR, P31; JANOCKO L, 1983, SCIENCE, V222, P1334, DOI 10.1126/science.6419346; JONES DL, 1985, J STEROID BIOCHEM, V22, P243, DOI 10.1016/0022-4731(85)90119-0; LARNER JM, 1992, J CLIN ENDOCR METAB, V75, P195, DOI 10.1210/jc.75.1.195; LARNER JM, 1985, ENDOCRINOLOGY, V117, P1209, DOI 10.1210/endo-117-3-1209; LARNER JM, 1985, J STEROID BIOCHEM, V22, P407, DOI 10.1016/0022-4731(85)90446-7; LARNER JM, 1992, STEROIDS, V57, P475; LESZCZYNSKI DE, 1989, BIOCHIM BIOPHYS ACTA, V1014, P90, DOI 10.1016/0167-4889(89)90245-0; MACLUSKY NJ, 1989, ENDOCRINOLOGY, V124, P318, DOI 10.1210/endo-124-1-318; MARGRAF HARRY W., 1963, STEROIDS, V2, P155, DOI 10.1016/S0039-128X(63)80020-3; MELLONNUSSBAUM S, 1980, J BIOL CHEM, V255, P5566; MELLONNUSSBAUM S, 1979, J BIOL CHEM, V254, P2500; MELLONNUSSBAUM SH, 1982, J BIOL CHEM, V257, P5678; PAHUJA SL, 1991, J BIOL CHEM, V266, P7410; PAHUJA SL, 1989, J BIOL CHEM, V264, P3216; PARIS A, 1989, J CHROMATOGR-BIOMED, V493, P367, DOI 10.1016/S0378-4347(00)82743-7; PARIS A, 1989, J STEROID BIOCHEM, V33, P465, DOI 10.1016/0022-4731(89)90338-5; PEARLMAN WH, 1985, J BIOL CHEM, V260, P5296; RAJU U, 1985, J CLIN ENDOCR METAB, V60, P940, DOI 10.1210/jcem-60-5-940; ROY R, 1989, Steroids, V54, P385, DOI 10.1016/0039-128X(89)90052-4; ROY R, 1989, J STEROID BIOCHEM, V33, P257, DOI 10.1016/0022-4731(89)90302-6; ROY R, 1991, BIOCHEM BIOPH RES CO, V179, P1576, DOI 10.1016/0006-291X(91)91753-Y; SCHATZ F, 1981, ENDOCRINOLOGY, V109, P697; WEICHSELBAUM TE, 1960, J CLIN ENDOCR METAB, V20, P1341, DOI 10.1210/jcem-20-10-1341; WEINBAUER GF, 1990, ACTA ENDOCRINOL-COP, V4, P432; ZIELINSKI JE, 1991, J STEROID BIOCHEM, V38, P399, DOI 10.1016/0960-0760(91)90327-2	33	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13893	13899						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314757				2022-12-25	WOS:A1993LJ82500021
J	BERMEJO, B; REMACHA, M; ORTIZREYES, B; SANTOS, C; BALLESTA, JPG				BERMEJO, B; REMACHA, M; ORTIZREYES, B; SANTOS, C; BALLESTA, JPG			EFFECT OF ACIDIC RIBOSOMAL PHOSPHOPROTEIN MESSENGER-RNA 5'-UNTRANSLATED REGION ON GENE-EXPRESSION AND PROTEIN ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; EXCESS PROTEIN; YEAST; PROMOTER; CDNA; PHOSPHORYLATION; TRANSFORMATION; DEPLETION	Constructions were made from genes encoding ribosomal acidic phosphoproteins YP1 beta(L44') and YP2 beta(L45) from Saccharomyces cerevisiae in which different parts of the 5'-untransiated regions were included. The constructs were inserted into centromeric plasmids under the control of the GAL1 promoter and expressed in yeast strains in which the genes coding for each acidic protein family, P1 and P2, had been disrupted. Deletions in the 5' region of the two genes have been found to oppositely affect their expression. Deletion of most of this region strongly stimulates the expression of YP2 beta(L45), increasing the translation efficiency of the mRNA, and generating a 6-fold excess of protein in the cell. A similar deletion in the rpYP1 beta gene represses the expression of the protein, reducing drastically the amount of the mRNA in the cell. The overexpression of rpYP2 beta affects the cell growth by inhibiting protein synthesis at the level of initiation. Reduction of the YP2 beta(L45) overproduction by growing in controlled concentrations of glucose abolishes the inhibitory effect. The excess protein, probably as a high molecular weight complex, apparently interferes with the joining of the 60 S subunit to the initiation complex generating the accumulation of polysome half-mers. In addition, the results indicate the existence of a regulatory mechanism by which each one of the two acidic proteins controls the expression of the other polypeptide. YP1 beta(L44') represses the expression of YP2 beta(L45), while this protein stimulates the expression of YP1 beta(L44').	CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,E-28049 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid			Remacha, Miguel/G-1250-2016; Santos, Cruz/ABG-3054-2020	Santos, Cruz/0000-0001-5164-5050				ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; BALLESTA JPG, 1993, PROTEIN SYNTHESIS TA, P67; BOZZONI I, 1984, J MOL BIOL, V180, P987, DOI 10.1016/0022-2836(84)90267-5; BROT N, 1972, BIOCHEM BIOPH RES CO, V49, P673, DOI 10.1016/0006-291X(72)90464-0; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CITRON BA, 1984, J BACTERIOL, V158, P269, DOI 10.1128/JB.158.1.269-278.1984; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; ELBARADI TTAL, 1986, CURR GENET, V10, P733, DOI 10.1007/BF00405095; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; FRIED HM, 1985, MOL CELL BIOL, V5, P99, DOI 10.1128/MCB.5.1.99; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; ISONO S, 1981, MOL GEN GENET, V183, P473, DOI 10.1007/BF00268767; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JUANVIDALES F, 1984, BIOCHEMISTRY-US, V23, P390; KIM CH, 1983, J MOL BIOL, V165, P79, DOI 10.1016/S0022-2836(83)80243-5; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAAKMAN LS, 1991, BIOCHIM BIOPHYS ACTA, V1090, P204, DOI 10.1016/0167-4781(91)90102-R; KRUISWIJK T, 1978, EUR J BIOCHEM, V83, P245, DOI 10.1111/j.1432-1033.1978.tb12089.x; LUCIOLI A, 1988, MOL CELL BIOL, V8, P4792, DOI 10.1128/MCB.8.11.4792; MAGER WH, 1991, MOL CELL BIOCHEM, V104, P181; MAICAS E, 1988, MOL CELL BIOL, V8, P169, DOI 10.1128/MCB.8.1.169; MITSUI K, 1988, J BIOCHEM-TOKYO, V104, P908, DOI 10.1093/oxfordjournals.jbchem.a122581; Moller W., 1986, STRUCTURE FUNCTION G, P309; MORRISSEY JJ, 1975, BIOCHEM BIOPH RES CO, V65, P293, DOI 10.1016/S0006-291X(75)80092-1; NAM HG, 1986, MOL CELL BIOL, V6, P1535, DOI 10.1128/MCB.6.5.1535; NARANDA T, 1993, J BIOL CHEM, V268, P2451; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; RAMAGOPAL S, 1976, EUR J BIOCHEM, V69, P289, DOI 10.1111/j.1432-1033.1976.tb10885.x; REMACHA M, 1990, MOL CELL BIOL, V10, P2182, DOI 10.1128/MCB.10.5.2182; REMACHA M, 1992, J BIOL CHEM, V267, P12061; REMACHA M, 1988, J BIOL CHEM, V263, P9094; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANCHEZMADRID F, 1981, EUR J BIOCHEM, V114, P609, DOI 10.1111/j.1432-1033.1981.tb05187.x; SANDERMANN J, 1979, FEBS LETT, V107, P343, DOI 10.1016/0014-5793(79)80404-4; SANTOS C, 1993, BIOCHEMISTRY-US, V32, P4231, DOI 10.1021/bi00067a010; SCHIJMAN AG, 1992, NUCLEIC ACIDS RES, V20, P2894, DOI 10.1093/nar/20.11.2894; SCHIJMAN AG, 1990, NUCLEIC ACIDS RES, V18, P3399, DOI 10.1093/nar/18.11.3399; Sherman F., 1983, METHODS YEAST GENETI; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; TSAY YF, 1988, GENE DEV, V2, P664, DOI 10.1101/gad.2.6.664; VANAGTHOVEN A, 1978, EUR J BIOCHEM, V91, P553; VAZQUEZ MP, 1992, NUCLEIC ACIDS RES, V20, P2893, DOI 10.1093/nar/20.11.2893; VAZQUEZ MP, 1992, NUCLEIC ACIDS RES, V20, P2894; VILELLA MD, 1991, EUR J BIOCHEM, V196, P407, DOI 10.1111/j.1432-1033.1991.tb15831.x; WARNER JR, 1985, MOL CELL BIOL, V5, P1512, DOI 10.1128/MCB.5.6.1512; WARNER JR, 1977, CELL, V11, P201, DOI 10.1016/0092-8674(77)90331-2; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M	56	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3968	3975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307952				2022-12-25	WOS:A1994MW98900014
J	COPPEE, JY; BRASSEUR, G; BRIVETCHEVILLOTTE, P; COLSON, AM				COPPEE, JY; BRASSEUR, G; BRIVETCHEVILLOTTE, P; COLSON, AM			NONNATIVE INTRAGENIC REVERSIONS SELECTED FROM SACCHAROMYCES-CEREVISIAE CYTOCHROME B-DEFICIENT MUTANTS - STRUCTURAL AND FUNCTIONAL FEATURES OF THE CATALYTIC CENTER N-DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOCYTOCHROME-B; MITOCHONDRIAL MUTANTS; FRAMESHIFT MUTATIONS; YEAST MITOCHONDRIA; COMPLEX-III; WILD-TYPE; GENE; REVERTANTS; ANTIMYCIN; SUPPRESSORS	A total of 110 revertants have been isolated from two well characterized cytochrome b deficient (mit(-)) mutants. The mit(-) mutations are located in an extramembranous loop linking the transmembrane alpha-helices IV and V of cytochrome b which has been postulated to be part of the catalytic center Q(N) and therefore is assumed to be essential for the functioning of the bc(1) complex. The molecular bases of the reversions were identified by sequencing the cytochrome b mRNAs. This allowed us to identify seven new structures of cytochrome b which are more or less compatible with its catalytic activity. The secondary mutations occurred either at the level of the original site mutation or at adjacent positions (region 204-208 of the polypeptide chain), or even at a distance of more than 150 amino acids (position 30) suggesting topological interaction between these two areas. All the revertants recovered cytochrome contents and phosphorylation efficiencies similar to the wild type ones, albeit differences appeared in their specific growth rates and NADH respirations. The failure in bc(1) complex functioning induced by the mutation S206L and its restoration by non native reversions are tentatively explained.	UNIV CATHOLIQUE LOUVAIN,DEPT BIOL,GENET MICROBIENNE LAB,UNITE GENET,B-1348 LOUVAIN,BELGIUM; LAB CHIM BACTERIENNE,UNITE METAB ENERGET,F-13275 MARSEILLE 9,FRANCE	Universite Catholique Louvain; UDICE-French Research Universities; Aix-Marseille Universite								BRASSEUR G, 1993, BIOCHEM SOC T, V22, pS60; BRIQUET M, 1981, EUR J BIOCHEM, V117, P333, DOI 10.1111/j.1432-1033.1981.tb06342.x; BRIVETCHEVILLOTTE P, 1989, FEBS LETT, V255, P5, DOI 10.1016/0014-5793(89)81050-6; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHEVILLOTTEBRIVET P, 1983, EUR J BIOCHEM, V129, P653; CHEVILLOTTEBRIVET P, 1987, BIOCHIMIE, V69, P25, DOI 10.1016/0300-9084(87)90268-9; CHEVILLOTTEBRIVET P, 1980, EUR J BIOCHEM, V111, P161; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P211, DOI 10.1007/BF00762583; COLSON AM, 1992, BIOCHIM BIOPHYS ACTA, V1101, P157; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DIRAGO JP, 1990, J BIOL CHEM, V265, P15750; DIRAGO JP, 1990, J BIOL CHEM, V265, P3332; FOX TD, 1980, NATURE, V288, P60, DOI 10.1038/288060a0; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; HAID A, 1979, EUR J BIOCHEM, V94, P451, DOI 10.1111/j.1432-1033.1979.tb12913.x; JACQ C, 1980, ORG EXPRESSION MITOC, P139; KOTYLAK Z, 1977, GENETICS BIOGENESIS, P83; KRUSZEWSKA A, 1984, CURR GENET, V9, P1, DOI 10.1007/BF00396198; LAZOWSKA J, 1989, J MOL BIOL, V205, P275, DOI 10.1016/0022-2836(89)90341-0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MEUNIERLEMESLE D, 1980, EUR J BIOCHEM, V111, P151; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; PRATJE E, 1977, MOL GEN GENET, V152, P167, DOI 10.1007/BF00268814; RICH PR, 1991, BIOSCIENCE REP, V11, P539, DOI 10.1007/BF01130217; TRON T, 1990, CURR GENET, V18, P413, DOI 10.1007/BF00309910; TRON T, 1991, FEBS LETT, V278, P26, DOI 10.1016/0014-5793(91)80075-E; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990	30	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4221	4226						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307985				2022-12-25	WOS:A1994MW98900051
J	KANAYA, E; ANAGUCHI, H; KIKUCHI, M				KANAYA, E; ANAGUCHI, H; KIKUCHI, M			INVOLVEMENT OF 2 SULFUR-ATOMS OF PROTEIN DISULFIDE-ISOMERASE AND ONE SULFUR ATOM OF THE DSBA/PPFA PROTEIN IN THE OXIDATION OF MUTANT HUMAN LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; ACTIVE-SITE; THIOREDOXIN; IDENTIFICATION; ISOMERIZATION; RIBONUCLEASE; REACTIVITY; RESOLUTION; CATALYSIS	Protein disulfide isomerase (PDI) and the DsbA/PpfA protein catalyze the oxidation of mutant human lysozyme, L79CC81A, which has two native disulfide bonds, Cys(6)-Cys(128) and Cys(30)-Cys(116), a non-native Cys(79)-Cys(95), and 2 free cysteine residues at positions 65 and 77. Oxidation of L79CC81A (R-form) yielded two isomers, L79CC81A-a (A-form) with tandem-linked Cys(65)-Cys(77) and Cys(79)-Cys(95), and L79CC81A-b (B-form) with crosslinked Cys(65)-Cys(79) and Cys(77)-Cys(95) (Kanaya, E., Ishihara, It., Tsunasawa, S., Nokihara, K., and Kikuchi, M. (1993) Biochem. J. 292, 469-476). PDI mainly enhanced the formation of the A- form in the absence of oxidized glutathione (GSSG); however, as the concentration of GSSG increased, it markedly accelerated the formation of the B-form. In contrast, the DspA/PpfA protein mainly enhanced the formation of the A-form, regardless of the presence or absence of GSSG. These results and the presumed spatial locations of Cys(65), Cys(77), and Cys(79)-Cys(95) in the R-form suggest that 1 of the half-cystine residues in the active site of PDI and the DsbA/PpfA protein can react with 1 of the 2 free Cys residues of the R-form. The dependence on GSSG of the B-form formation with PDI can be explained by the formation of two transient in termolecular disulfide bonds between PDI and the R-form and the attack of GSSG by the resultant thiolate anion of Cys(79) or Cys(95). The independence of the reac tion with the DsbA/PpfA protein from GSSG can be explained by the formation of one transient intermolecular disulfide bond. The possible formation of the two transient intermolecular disulfide bonds involving two sulfur atoms of PDI and 2 cysteine or half cystine residues of the substrate could explain the high isomerase activity of PDI.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN									AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HAYANO T, 1993, FEBS LETT, V328, P203, DOI 10.1016/0014-5793(93)80993-5; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KANAYA E, 1993, BIOCHEM J, V292, P469, DOI 10.1042/bj2920469; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KIKUCHI M, 1988, P NATL ACAD SCI USA, V85, P9411, DOI 10.1073/pnas.85.24.9411; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; VUORI K, 1992, J BIOL CHEM, V267, P7211	29	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4273	4278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307992				2022-12-25	WOS:A1994MW98900059
J	KURUMIZAKA, H; IKAWA, S; IKEYA, T; OGAWA, T; SHIBATA, T				KURUMIZAKA, H; IKAWA, S; IKEYA, T; OGAWA, T; SHIBATA, T			A CHIMERIC RECA PROTEIN EXHIBITS ALTERED DOUBLE-STRANDED DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED CIRCULAR DNA; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; DUPLEX DNA; BRANCH MIGRATION; COMPLEX; EXCHANGE; MOLECULES; RENATURATION; INHIBITION	RecAc38 protein, a chimeric RecA protein of Escherichia coli and Pseudomonas aeruginosa, is proficient in the renaturation from complementary single strands. However, RecAc38 protein showed a significant deficiency in promoting homologous pairing of single-stranded DNA and double-stranded DNA. RecAc38 protein was able to remove the secondary structure of single-stranded DNA, the first step of homologous pairing, at a slightly reduced rate. RecAc38 protein-single-stranded DNA-complex (presynaptic complex) was found to be deficient in the sequence-independent binding to double-stranded DNA which is a step in the search for the homology. On the other hand, once unwinding was initiated, RecAc38 protein was able to propagate the unwinding of the double helix at the same extent as wild-type Rec-A protein. These defects and the proficiency of RecAc38 protein are explained by a model showing that RecA protein has three distinct DNA strand-binding sites (a site for the primary binding to single-stranded DNA, a site for the binding to a strand of second single- or double-stranded DNA, and a site required for the binding to the other strand of the double-stranded DNA) and that RecAc38 protein has a defect in the third site.	INST PHYS & CHEM RES, CELLULAR & MOLEC BIOL LAB, WAKO, SAITAMA 35101, JAPAN; OSAKA UNIV, FAC SCI, DEPT BIOL, TOYONAKA, OSAKA 560, JAPAN; SAITAMA UNIV, GRAD SCH SCI & ENGN, URAWA, SAITAMA 338, JAPAN	RIKEN; Osaka University; Saitama University				Kurumizaka, Hitoshi/0000-0001-7412-3722				ARAI N, 1992, NUCLEIC ACIDS RES, V20, P3679, DOI 10.1093/nar/20.14.3679; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; CAZENAVE C, 1983, EMBO J, V2, P2247, DOI 10.1002/j.1460-2075.1983.tb01730.x; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; CHOW SA, 1988, J BIOL CHEM, V263, P200; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; CUNNINGHAM RP, 1979, NATURE, V281, P191, DOI 10.1038/281191a0; CUNNINGHAM RP, 1979, NATURE, V282, P426, DOI 10.1038/282426a0; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; ENGLUND PT, 1969, J BIOL CHEM, V244, P3038; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GONDA DK, 1983, CELL, V34, P647, DOI 10.1016/0092-8674(83)90397-5; HORII T, 1991, BIOCHIMIE, V73, P177, DOI 10.1016/0300-9084(91)90200-K; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; IKAWA S, 1989, J BIOL CHEM, V264, P21167; IWABUCHI MA, 1983, J BIOL CHEM, V258, P2394; KAHN R, 1984, J BIOL CHEM, V259, P7495; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOWALCZYKOWSKI SC, 1989, J MOL BIOL, V207, P719, DOI 10.1016/0022-2836(89)90239-8; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; NORDEN B, 1990, J MOL BIOL, V216, P223, DOI 10.1016/S0022-2836(05)80311-0; OGAWA T, 1979, COLD SPRING HARB SYM, V43, P909, DOI 10.1101/SQB.1979.043.01.099; OGAWA T, 1992, J MOL BIOL, V226, P651, DOI 10.1016/0022-2836(92)90622-Q; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; PUGH BF, 1987, J BIOL CHEM, V262, P1326; PUGH BF, 1987, J BIOL CHEM, V262, P1337; RADDING CM, 1982, COLD SPRING HARB SYM, V47, P821, DOI 10.1101/SQB.1983.047.01.094; ROBERTS JW, 1979, COLD SPRING HARB SYM, V43, P917, DOI 10.1101/SQB.1979.043.01.100; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHIBATA T, 1984, COLD SPRING HARB SYM, V49, P541, DOI 10.1101/SQB.1984.049.01.061; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P5100, DOI 10.1073/pnas.76.10.5100; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; SHIBATA T, 1981, J BIOL CHEM, V256, P7565; SHIBATA T, 1982, J BIOL CHEM, V257, P370; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; WABIKO H, 1983, EUR J BIOCHEM, V137, P263, DOI 10.1111/j.1432-1033.1983.tb07824.x; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WU AM, 1983, P NATL ACAD SCI-BIOL, V80, P1256, DOI 10.1073/pnas.80.5.1256	51	15	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3068	3075						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300641				2022-12-25	WOS:A1994MV43200101
J	LEPLEY, RA; FITZPATRICK, FA				LEPLEY, RA; FITZPATRICK, FA			IRREVERSIBLE INACTIVATION OF 5-LIPOXYGENASE BY LEUKOTRIENE-A(4) CHARACTERIZATION OF PRODUCT INACTIVATION WITH PURIFIED ENZYME AND INTACT LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; HUMAN-NEUTROPHILS; BIOSYNTHESIS INHIBITOR; SOYBEAN LIPOXYGENASE; MEMBRANE ASSOCIATION; CELLS; TRANSLOCATION; PURIFICATION; HYDROLASE; SYNTHASE	We report that leukotriene A4, the electrophilic product of 5-lipoxygenase catalysis, irreversibly inactivates the enzyme. Leukotriene A4 inhibits 5-hydroxyeicosatetraenoic acid formation by human neutrophils and differentiated granulocytic HL-60 cells in a concentration-dependent manner with IC50 values = 22.4 +/- 2.5 and 29.0 +/- 8.0 muM, respectively. Recovery of cellular enzymatic activity is negligible (<6%) following inactivation. Leukotriene A4 inactivates cellular 5-lipoxygenase without inhibiting its translocation from the cytosol to the membrane, suggesting that it impairs catalysis without impairing formation of the complex between 5-lipoxygenase and its membrane-associated activating protein. Consistent with this, leukotriene A4 inactivates purified 5-lipoxygenase from human neutrophils, via saturable, pseudo first-order kinetics with a rate constant, k(i) = 0.14 min-1 and a dissociation constant, K(i) = 2.1 +/- 0.7 muM. Purified 5-lipoxygenase incubated with [H-3]arachidonic acid incorporated a radiolabeled species that was not removed by electrophoresis under reduced denaturing conditions. Preincubation with leukotriene A4 diminished the incorporation of radiolabeled material, consistent with irreversible modification of 5-lipoxygenase by its metastable product, leukotriene A4. This unusual product inactivation mechanism may contribute to the decline in 5-lipoxygenase activity observed during catalysis.			LEPLEY, RA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,DENVER,CO 80262, USA.				NHLBI NIH HHS [HLB PO1 34303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHARONY D, 1987, PROSTAGLANDINS, V33, P85, DOI 10.1016/0090-6980(87)90307-8; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; CHARLESON S, 1992, MOL PHARMACOL, V41, P873; CHO KS, 1969, BIOCHEMISTRY-US, V8, P2827; COFFEY M, 1992, J BIOL CHEM, V267, P570; DENIS D, 1991, J BIOL CHEM, V266, P5072; EVANS JF, 1985, J BIOL CHEM, V260, P966; EVANS JF, 1992, FEBS LETT, V297, P139, DOI 10.1016/0014-5793(92)80345-H; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GOETZE AM, 1985, PROSTAGLANDINS, V29, P689, DOI 10.1016/0090-6980(85)90130-3; HARTEL B, 1982, EUR J BIOCHEM, V126, P353; HILGER RA, 1992, IMMUNOLOGY, V77, P408; JONES DA, 1991, J BIOL CHEM, V266, P23510; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; KIM MR, 1989, BIOCHEM BIOPH RES CO, V164, P1384, DOI 10.1016/0006-291X(89)91823-8; KITZ R, 1962, J BIOL CHEM, V237, P3245; LECOMTE M, 1990, J BIOL CHEM, V265, P5178; LUNDBERG U, 1981, FEBS LETT, V126, P127, DOI 10.1016/0014-5793(81)81050-2; MAAS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2884, DOI 10.1073/pnas.80.10.2884; MULLIEZ E, 1987, BIOCHIM BIOPHYS ACTA, V916, P13, DOI 10.1016/0167-4838(87)90205-6; NARUMIYA S, 1981, J BIOL CHEM, V256, P9583; ORNING L, 1992, J BIOL CHEM, V267, P22733; PRESCOTT SM, 1984, J BIOL CHEM, V259, P7615; RAPAPORT S, 1984, EUR J BIOCHEM, V139, P573; RAPAPORT SM, 1979, EUR J BIOCHEM, V96, P545; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; SMITH WL, 1972, J BIOL CHEM, V247, P1038; SOK DE, 1989, BIOCHEM BIOPH RES CO, V162, P1357, DOI 10.1016/0006-291X(89)90823-1; SUN FF, 1984, BIOCHIM BIOPHYS ACTA, V794, P56, DOI 10.1016/0005-2760(84)90297-2; TAYLOR L, 1983, J BIOL CHEM, V258, P6855; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; WISEMAN JS, 1989, BIOCHEMISTRY-US, V28, P2106, DOI 10.1021/bi00431a021; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; YOUNG SK, 1990, AM J RESP CELL MOL, V2, P523, DOI 10.1165/ajrcmb/2.6.523	40	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2627	2631						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300592				2022-12-25	WOS:A1994MV43200043
J	PODLASEK, CA; SERIANNI, AS				PODLASEK, CA; SERIANNI, AS			F-19 AND C-13 NMR-STUDIES OF POLYOL METABOLISM IN FREEZE-TOLERANT PUPAE OF HYALOPHORA-CECROPIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; GALL FLY LARVA; EUROSTA-SOLIDAGINIS; INVIVO; GLYCEROL; 3-DEOXY-3-FLUORO-D-GLUCOSE; CRYOPROTECTANTS; MONOSACCHARIDES; YEAST; COLD	Sorbitol biosynthesis and regulation in freeze tolerant pupae of Hyalophora cecropia have been investigated as a function of temperature by F-19 and C-13 nuclear magnetic resonance (NMR) spectroscopy using several C-13-labeled and/or fluorine-substituted carbohydrates. 3-Deoxy-3-fluoro-D-glucose (3DFG) was metabolized to 3-deoxy-3-fluoro-D-sorbitol (3DFS), 3-deoxy-3-fluoro-D-fructose (3DFF), and 3-deoxy-3-fluoro-D-gluconic acid (3DFGA), indicating that the enzymes required for sorbitol biosynthesis and metabolism are active in H. cecropia at warm (22-degrees-C) and cold (4 and -10-degrees-C) temperatures. Two additional metabolites were produced when pupae were injected with either 3DFG, 3DFS, 3DFF, or 3-deoxy-3-fluoro-D-mannose (3DFM). One of these was identified as 3-deoxy-3-fluoro-D-mannitol (3DFML) by C-13 NMR using [1-C-13]3DFM and [1-C-13]3DFG as metabolic probes. H. cecropia pupae injected with D-glucose labeled with C-13 at C-1, C-2, or C-3 and subsequently analyzed by C-13 NMR clearly demonstrated the ability to generate sorbitol and fructose. In contrast, gas chromatography/mass spectrometric analysis of hemolymph failed to detect sorbitol in pupae reared under natural conditions (i.e. in the absence of injected enriched sugars). Thus, although H. cecropia pupae have the enzymic machinery to biosynthesize sorbitol, they do not appear to accumulate high steady-state concentrations of this polyol over the temperature range studied. The specificity of the enzymes involved in alditol biosynthesis in H. cecropia was examined by C-13 NMR with a wide range of aldoses enriched with C-13 at C-1. Pupae were capable of converting these sugars to their corresponding [1-C-13]alditols, indicating that nonspecific dehydrogenase(s), in addition to aldose reductase, is(are) involved in polyol biosynthesis in H. cecropia pupae.	UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA	University of Notre Dame					NIGMS NIH HHS [GM 33791] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033791] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGBANYO MY, 1983, THESIS U WINDSOR WIN; ANGELOTTI T, 1987, J AM CHEM SOC, V109, P4464, DOI 10.1021/ja00249a007; ANGYAL SJ, 1979, CARBOHYD RES, V73, P9, DOI 10.1016/S0008-6215(00)85471-3; Asahina E, 1966, LOW TEMP SCI B, V24, P25; BERKOWITZ BA, 1990, J BIOL CHEM, V265, P12417; BESSELL EM, 1973, BIOCHEM J, V131, P83, DOI 10.1042/bj1310083; BESSELL EM, 1972, BIOCHEM J, V128, P199, DOI 10.1042/bj1280199; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; BUCHANAN GW, 1983, CAN J BIOCHEM CELL B, V61, P1260, DOI 10.1139/o83-162; CROWE JH, 1983, ARCH BIOCHEM BIOPHYS, V220, P477, DOI 10.1016/0003-9861(83)90438-1; CSUK R, 1988, ADV CARBOHYD CHEM BI, V46, P73, DOI 10.1016/S0065-2318(08)60165-1; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOSTER AB, 1972, METHODS CARBOHYDR CH, V6, P197; HAYES ML, 1982, J AM CHEM SOC, V104, P6760; Hochachka P.W., 1984, BIOCHEMICAL ADAPTATI, P355; KENT PW, 1971, TETRAHEDRON, V27, P3887, DOI 10.1016/S0040-4020(01)98250-X; KUKAL O, 1989, J COMP PHYSIOL B, V158, P661, DOI 10.1007/BF00693004; KUKAL O, 1988, J COMP PHYSIOL B, V158, P175, DOI 10.1007/BF01075831; KWEE IL, 1987, J NEUROCHEM, V49, P428, DOI 10.1111/j.1471-4159.1987.tb02883.x; PERLIN AS, 1956, CAN J CHEM, V34, P541, DOI 10.1139/v56-075; PODLASEK CA, 1992, 29TH SOC CRY M ITH, P136; RASMUSSEN JR, 1983, CARBOHYD RES, V116, P21, DOI 10.1016/S0008-6215(00)90949-2; ROMASCHIN A, 1977, CAN J BIOCHEM CELL B, V55, P369, DOI 10.1139/o77-051; RUDOLPH AS, 1985, CRYOBIOLOGY, V22, P367, DOI 10.1016/0011-2240(85)90184-1; SERIANNI AS, 1990, J CARBOHYD CHEM, V9, P513, DOI 10.1080/07328309008543851; STOREY KB, 1988, PHYSIOL REV, V68, P27, DOI 10.1152/physrev.1988.68.1.27; STOREY KB, 1984, EUR J BIOCHEM, V142, P591, DOI 10.1111/j.1432-1033.1984.tb08327.x; STOREY KB, 1981, J COMP PHYSIOL, V144, P183, DOI 10.1007/BF00802756; STORY JM, 1983, J COMP PHYSIOL, V149, P495, DOI 10.1007/BF00690008; THOMPSON SN, 1988, INSECT BIOCHEM, V18, P21, DOI 10.1016/0020-1790(88)90032-7; ZIEGLER R, 1975, NATURE, V254, P622, DOI 10.1038/254622a0; ZIEGLER R, 1985, NATURWISSENSCHAFTEN, V72, P206, DOI 10.1007/BF01195764	32	2	2	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2521	2528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300579				2022-12-25	WOS:A1994MV43200029
J	NIGAM, SK; GOLDBERG, AL; HO, S; ROHDE, MF; BUSH, KT; SHERMAN, MY				NIGAM, SK; GOLDBERG, AL; HO, S; ROHDE, MF; BUSH, KT; SHERMAN, MY			A SET OF ENDOPLASMIC-RETICULUM PROTEINS POSSESSING PROPERTIES OF MOLECULAR CHAPERONES INCLUDES CA2+-BINDING PROTEINS AND MEMBERS OF THE THIOREDOXIN SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; GLUCOSE-REGULATED PROTEINS; DISULFIDE ISOMERASE; SUBCELLULAR-DISTRIBUTION; HEAT-SHOCK; RAT-LIVER; T-CELL; ERP72; GENE; IDENTIFICATION	The major proteins in the lumen of the endoplasmic reticulum (ER) are thought to function in Ca2+ sequestration or as ''molecular chaperones' in the folding and assembly of membrane or secreted proteins. Based on the ability of many chaperones to bind selectively to unfolded proteins and to dissociate from them upon ATP hydrolysis, we developed an affinity chromatography method to isolate proteins with these characteristics from pancreatic or liver ER. Seven ER proteins bound selectively to denatured protein columns and were specifically eluted by ATP (10(-6) M) but not by a nonhydrolyzable ATP analog. These proteins were identified with antibodies and microsequencing as the ER chaperone BiP (grp78), grp94, calreticulin, a novel 46-kDa protein that binds azido-ATP, as well as three members of the thioredoxin superfamily: protein-disulfide isomerase, ERp72, and a previously reported 50-kDa protein (p50). This set of seven proteins bound to and was eluted with ATP from a variety of denatured proteins, including histone, gelatin, a fetoprotein, thyroglobulin, lysozyme, casein, and IgG. The release of grp94, protein-disulfide isomerase, ERp72, calreticulin, and p50 was stimulated by Ca2+ in the presence of ATP. These proteins thus appear to function as Ca2+-dependent chaperones, which may account for the Ca2+ and ATP requirement for protein folding in the ER.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, 25 SHATTUCK ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV RENAL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Amgen					NIDDK NIH HHS [R01 DK44503-01A1] Funding Source: Medline; NIGMS NIH HHS [R01 GM46147] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CHAUDHURI MM, 1992, BIOCHEM J, V281, P645, DOI 10.1042/bj2810645; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LU XJ, 1992, BIOCHEMISTRY-US, V31, P4205, DOI 10.1021/bi00132a008; LYTTON J, 1992, Current Opinion in Cell Biology, V4, P220, DOI 10.1016/0955-0674(92)90036-C; MACER DRJ, 1988, J CELL SCI, V91, P61; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MICHALAK M, 1992, BIOCH J, V285; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; NIGAM SK, 1990, P NATL ACAD SCI USA, V87, P1296, DOI 10.1073/pnas.87.4.1296; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PETER F, 1992, J BIOL CHEM, V267, P10631; PORUCHYNSKY MS, 1991, J CELL BIOL, V114, P651, DOI 10.1083/jcb.114.4.651; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TASANEN K, 1992, J BIOL CHEM, V267, P11513; VAN PN, 1989, J BIOL CHEM, V264, P17494; WADA I, 1991, J BIOL CHEM, V266, P19599; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006	39	259	265	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1744	1749						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294423				2022-12-25	WOS:A1994MR98800033
J	ROBERTSON, DL; HILTON, S; WONG, KR; KOEPKE, A; BUCKLEY, JT				ROBERTSON, DL; HILTON, S; WONG, KR; KOEPKE, A; BUCKLEY, JT			INFLUENCE OF ACTIVE-SITE AND TYROSINE MODIFICATION ON THE SECRETION AND ACTIVITY OF THE AEROMONAS-HYDROPHILA LIPASE ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; SUBSTRATE-SPECIFICITY; PURIFICATION; PHOSPHOLIPASE-A2; SALMONICIDA; ACTIVATION; EXPRESSION; MECHANISM; AEROLYSIN	Aeromonas sp. secrete a lipase/acyltransferase that shares several properties with the mammalian plasma enzyme lecithin:cholesterol acyltransferase. Reaction of the enzyme with tetranitromethane led to modification of 2 tyrosines and a nearly 80% decline in enzyme activity. Replacing Tyr230 with Phe altered the activity of the enzyme in the same way as did treatment with tetranitromethane. Unlike the wild type enzyme, which preferentially hydrolyzes the 2-position acyl chain of phosphatidylcholine, the Y230F mutant enzyme did not discriminate between the 1- and 2-positions of the phospholipid. Tyr230 may be necessary to correctly position phospholipid substrates at the active site. Several amino acids around the active site Ser16 of the lipase were also changed. Replacing Ser18 with Gly; bringing the enzyme' s sequence into line with the ''lipase consensus sequence,'' resulted in reduced secretion of the protein and complete loss of activity. Changing this serine to Val led to an inactive protein that was not secreted at all. Substituting Phe'' in the hydrophobic region of the consensus sequence with Ser also prevented secretion, although the mutant protein appeared to be active. The Aeromonas lipase may represent a distinct group of lipolytic enzymes which have a novel active site structure.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,POB 3055,VICTORIA V8W 3P6,BC,CANADA; MAX PLANCK INST MOLEK NEUROENDOKRINOL,W-3400 GOTTINGEN,GERMANY	University of Victoria; Max Planck Society								ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; ARON L, 1978, J BIOL CHEM, V253, P7220; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BUCKLEY JT, 1983, BIOCHEMISTRY-US, V22, P5490, DOI 10.1021/bi00293a006; BUCKLEY JT, 1982, J BIOL CHEM, V257, P3320; BUCKLEY JT, 1982, BIOCHEMISTRY-US, V21, P6699, DOI 10.1021/bi00269a013; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; CHO HS, 1993, J BIOL CHEM, V268, P9238; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GREEN MJ, 1990, BIOCHEMISTRY-US, V29, P2177, DOI 10.1021/bi00460a031; HILTON S, 1990, BIOCHEMISTRY-US, V29, P9072, DOI 10.1021/bi00490a026; HILTON S, 1991, J BIOL CHEM, V266, P997; KUIPERS OP, 1990, BIOCHEMISTRY-US, V29, P6094, DOI 10.1021/bi00477a029; KUIPERS OP, 1989, PROTEIN ENG, V2, P467, DOI 10.1093/protein/2.6.467; MILLER JH, 1972, EXPT MOL GENETICS, P341; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ROBERTSON DL, 1992, BIOCHEMISTRY-US, V31, P4974, DOI 10.1021/bi00136a009; Sambrook J, 1989, MOL CLONING LABORATO; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; SUBBAIAH PV, 1985, J BIOL CHEM, V260, P5308; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1990, CURRENT PROTOCOLS MO, P1621; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANOORT MG, 1989, BIOCHEMISTRY-US, V28, P9278, DOI 10.1021/bi00450a007; WONG KR, 1989, J BACTERIOL, V171, P2523, DOI 10.1128/jb.171.5.2523-2527.1989	33	25	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2146	2150						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294469				2022-12-25	WOS:A1994MR98800090
J	GRAEF, E; CASELMANN, WH; WELLS, J; KOSHY, R				GRAEF, E; CASELMANN, WH; WELLS, J; KOSHY, R			INSERTIONAL ACTIVATION OF MEVALONATE KINASE BY HEPATITIS-B VIRUS-DNA IN A HUMAN HEPATOMA-CELL LINE	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; INBORN ERROR; ACIDURIA; GENE; BIOSYNTHESIS; CHOLESTEROL; INTEGRATION; P21RAS	Insertional mutagenesis of growth related genes by hepatitis B virus (HBV) DNA is presumed to play a role in hepatocarcinogenesis. Here, we report on insertional activation of the mevalonate kinase (MK) gene in the human hepatoma cell line PLC/PRF/5, Integration of HBV DNA dissociated the promoter and upstream regulatory elements of the gene from its coding sequences. This led to the over-expression of hybrid transcripts arising from an HBV promoter and the consequent over-production of functionally active mevalonate kinase. MK phosphorylates mevalonate, a major intermediate in the branched cholesterol/isoprenoid biosynthetic pathway. Isoprenylation is crucial to the functions of cellular proteins related to growth control, including the proto-oncogene ras. As the enzymes of these biosynthetic pathways are regulated at multiple points by negative feedback, both transcriptionally and at the protein level, the results discussed here support the idea that aberrant growth could result from deregulated overexpression of MK and, perhaps, other enzymes in the cholesterol pathway. These results invoke novel mechanisms by which cell transformation might occur.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,W-8000 MUNICH,GERMANY; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,CAMBS,ENGLAND	Imperial College London; Max Planck Society; University of Munich; University of Cambridge								BARBU V, 1990, ONCOGENE, V5, P1077; BERGER R, 1985, CLIN CHIM ACTA, V152, P219, DOI 10.1016/0009-8981(85)90195-0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CATTANEO R, 1984, EMBO J, V3, P2191, DOI 10.1002/j.1460-2075.1984.tb02113.x; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOCH S, 1984, NUCLEIC ACIDS RES, V12, P6871, DOI 10.1093/nar/12.17.6871; KOSHY R, 1992, REV MED VIROL, V2, P131, DOI 10.1002/rmv.1980020303; OU J, 1985, P NATL ACAD SCI USA, V82, P83, DOI 10.1073/pnas.82.1.83; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; QUESNEYHUNEEUS V, 1983, J BIOL CHEM, V258, P378; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; ZHANG XK, 1992, BIOCHEM BIOPH RES CO, V188, P344, DOI 10.1016/0006-291X(92)92391-A	24	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					81	87						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302606				2022-12-25	WOS:A1994MW24700010
J	JOLLY, KW; MALKIN, D; DOUGLASS, EC; BROWN, TF; SINCLAIR, AE; LOOK, AT				JOLLY, KW; MALKIN, D; DOUGLASS, EC; BROWN, TF; SINCLAIR, AE; LOOK, AT			SPLICE-SITE MUTATION OF THE P53 GENE IN A FAMILY WITH HEREDITARY BREAST-OVARIAN CANCER	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; SINGLE BASE SUBSTITUTIONS; LI-FRAUMENI SYNDROME; GEL-ELECTROPHORESIS; GERMLINE MUTATIONS; PRONE FAMILY; DNA; NEOPLASMS; P53-GENE; JUNCTION	Germline mutations within evolutionary conserved exons of the p53 gene predispose to tumor development in several familial cancer syndromes. We now report identification of a novel p53 mutation affecting the splice acceptor site of exon 6 in the germline DNA of a family with hereditary breast-ovarian cancer. This splice-site mutation, which results in omission of exon 6 and creates a frame-shift and premature stop codon in transcripts from the mutant allele, was found in seven family members-four of whom have developed breast, ovarian or choroid plexus tumors before age 35. Our finding suggests the need to examine the entire p53 gene for frame-shift, and nonsense (as well as missense) mutations in families with early-onset hereditary breast and breast-ovarian cancers not linked to the BRCA1 gene on chromosome 17q. We propose that the term 'p53 familial cancer syndrome' be applied to dusters of tumors in families with documented germline p53 mutations, regardless of the histopathologic findings or pattern of tumor development.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; HOSP SICK CHILDREN, DEPT PEDIAT, DIV ONCOL, TORONTO M5G 1X8, ON, CANADA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)					NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-23099, CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORRESEN AL, 1992, CANCER RES, V52, P3234; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; Bunn HF, 1986, HEMOGLOBIN MOL GENET; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2658, DOI 10.1002/1097-0142(19901215)66:12<2658::AID-CNCR2820661232>3.0.CO;2-C; GITSCHIER J, 1991, THROMB HAEMOSTASIS, V66, P37; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; JENKINS JR, 1988, ONCOGENE HDB, P403; KING MC, 1992, NAT GENET, V2, P89, DOI 10.1038/ng1092-89; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LAW JC, 1991, CANCER RES, V51, P6385; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1988, CANCER RES, V48, P5381; LIVINGSTON D, 1992, CANCER RES, V52, P3246; LYNCH HT, 1978, CANCER-AM CANCER SOC, V41, P1543, DOI 10.1002/1097-0142(197804)41:4<1543::AID-CNCR2820410444>3.0.CO;2-Y; LYNCH HT, 1984, CANCER GENET CYTOGEN, V13, P43, DOI 10.1016/0165-4608(84)90087-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MONTENARH M, 1992, ONCOGENE, V7, P1673; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NAROD SA, 1991, LANCET, V338, P82; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PUISIEUX A, 1991, CANCER RES, V51, P6185; REES DJG, 1985, NATURE, V316, P643, DOI 10.1038/316643a0; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	40	82	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					97	102						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302608				2022-12-25	WOS:A1994MW24700012
J	CHEN, SC; REDENIUS, D; YOUNG, JC; SCHWARTZ, RC				CHEN, SC; REDENIUS, D; YOUNG, JC; SCHWARTZ, RC			SYNERGY OF IL-7 AND V-HA-RAS IN THE IN-VITRO NEOPLASTIC PROGRESSION OF MURINE PRE-B CELLS	ONCOGENE			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; INOSITOL PHOSPHOLIPID TURNOVER; LEUKEMIA-VIRUS; LYMPHOID-CELLS; INTERLEUKIN-7; CONSTRUCTION; EXPRESSION; ONCOGENES; GROWTH; DIFFERENTIATION	A recombinant retrovirus expressing IL-7 was super-infected into a murine pre-B cell line previously infected with a retrovirus expressing v-Ha-ras. Populations of cells polyclonal for integration of the IL-7 virus and independent of IL-7 for growth were generated. These cells were highly tumorigenic. Similarly, co-infection of murine bone marrow with retroviruses expressing IL-7 and v-Ha-ras generated a pre-B lymphoid outgrowth that was tumorigenic. While IL-7 and v-Ha-ras expression are not individually sufficient to induce tumorigenicity, their co-expression yields highly tumorigenic pre-B lymphoid cell lines. IL-7 expression may be equivalent to v-myc expression for synergy with v-H-ras in the neoplastic transformation of murine pre-B cells.	MICHIGAN STATE UNIV,DEPT MIKROBIOL,E LANSING,MI 48824; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	Michigan State University; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R29CA045360] Funding Source: NIH RePORTER; NCI NIH HHS [CA45360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHANG JM, 1989, BLOOD, V73, P1487; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEEKER TC, 1990, BLOOD, V76, P285; MORRISSEY PJ, 1989, J EXP MED, V169, P707, DOI 10.1084/jem.169.3.707; MUIRHEAD M, 1990, INT J CELL CLONING, V8, P392, DOI 10.1002/stem.5530080643; MUIRHEAD M, 1992, LYMPHOKINE CYTOK RES, V11, P167; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OVERELL RW, 1991, MOL CELL BIOL, V11, P1590, DOI 10.1128/MCB.11.3.1590; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; ROIFMAN CM, 1992, J IMMUNOL, V148, P1136; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHWARTZ RC, 1986, CURR TOP MICROBIOL, V132, P75; SCHWARTZ RC, 1981, J IMMUNOL, V126, P2104; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SCHWARTZ RC, 1988, MUTAT RES, V195, P245, DOI 10.1016/0165-1110(88)90003-6; SEIDMAN JG, 1978, NATURE, V276, P790, DOI 10.1038/276790a0; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WHITLOCK CA, 1983, CELL, V32, P903, DOI 10.1016/0092-8674(83)90075-2; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WONG PMC, 1989, MOL CELL BIOL, V9, P797; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	31	4	4	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2119	2125						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336938				2022-12-25	WOS:A1993LP17100012
J	SARKAR, S; GILMORE, TD				SARKAR, S; GILMORE, TD			TRANSFORMATION BY THE VREL ONCOPROTEIN REQUIRES SEQUENCES CARBOXY-TERMINAL TO THE REL HOMOLOGY DOMAIN	ONCOGENE			English	Article							NF-KAPPA-B; CHICKEN-EMBRYO FIBROBLASTS; VIRUS-STRAIN-T; V-REL; C-REL; RETICULOENDOTHELIOSIS VIRUS; SPLEEN-CELLS; TRANSCRIPTIONAL ACTIVATOR; ONCOGENIC TRANSFORMATION; CELLULAR PROTEINS	The vRel oncoprotein of the avian Rev-T retrovirus is a member of the Rel/NF-kappaB family of transcription factors. The highly conserved amino-terminal Rel Homology (RH) domain in these proteins is required for DNA binding, protein-protein interactions and nuclear localization, and many mutations within this domain abolish transformation by vRel. We demonstrate here that overexpression of the vRel RH domain alone is insufficient to induce transformation of chicken spleen cells, indicating that sequences from the nonconserved carboxy terminus are necessary for the vRel transforming function. Thererfore, we constructed and assayed several vRel mutants with deletions of carboxy-terminal sequences. These mutant vRel proteins did not transform spleen cells with equal efficiency, even though they were functionally similar by several other criteria. Our results demonstrate that there are two regions (aa 389 to 432 and aa 437 to 503) within the carboxy-terminal half of vRel that are important for transformation: mutant vRel proteins containing the RH domain and one or both of these carboxy-terminal regions can transform at roughly wild-type levels. Analysis of Gal4 fusion proteins containing carboxy-terminal sequences from the vRel mutants indicated that there is a correlation between the ability of these mutant proteins to transform avian spleen cells and their ability to activate transcription. These observations suggest that vRel induces malignant transformation by directly altering gene expression.	BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215	Boston University					NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GARSON K, 1990, ONCOGENE, V5, P1431; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	44	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2245	2252						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336947				2022-12-25	WOS:A1993LP17100026
J	SAKAMAKI, K; WANG, HM; MIYAJIMA, I; KITAMURA, T; TODOKORO, K; HARADA, N; MIYAJIMA, A				SAKAMAKI, K; WANG, HM; MIYAJIMA, I; KITAMURA, T; TODOKORO, K; HARADA, N; MIYAJIMA, A			LIGAND-DEPENDENT ACTIVATION OF CHIMERIC RECEPTORS WITH THE CYTOPLASMIC DOMAIN OF THE INTERLEUKIN-3 RECEPTOR BETA-SUBUNIT (BETA-IL3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN TYROSINE PHOSPHORYLATION; GROWTH SIGNAL TRANSDUCTION; MURINE ERYTHROPOIETIN RECEPTOR; HUMAN IL-2 RECEPTOR; T-CELL LINE; GM-CSF; EXPRESSION CLONING; HORMONE RECEPTOR; ESSENTIAL REGION	Beta(IL3) (formerly known as AIC2A), a beta subunit of the murine interleukin-3 receptor (IL-3R), is not only required for formation of the high affinity receptor but is also important for signal transduction. To examine the function of beta(IL3) in signal transduction, we constructed several chimeric receptors consisting of the intracellular portion of beta(IL3) and the extracellular portion of other members of the cytokine receptor super-family, i.e. the human interleukin-2 receptor beta chain (hIL-2Rbeta), the human interleukin-4 receptor (hIL-4R), and the murine erythropoietin receptor (mEpoR). These chimeric receptors and normal cytokine receptors were expressed in an IL-3-dependent murine proB cell line, Ba/F3, and an IL-2-dependent murine T cell line, CTLL2. Regardless of the origin of the extracellular domain, these chimeric receptors were functional in Ba/F3 cells; they stimulated proliferation and induced tyrosine phosphorylation in response to the cytokine corresponding to the extracellular domain. However, the response of transfectants expressing chimeric receptors was similar to, but not identical with, the response of Ba/F3 cells to mIL-3. We present evidence that the IL-4R and EpoR probably have an additional component which is involved in signal transduction.	DNAX RES INST MOLEC & CELLULAR BIOL INC, MOLEC & CELLULAR BIOL RES INST, DEPT MOLEC BIOL, PALO ALTO, CA 94304 USA; DNAX RES INST MOLEC & CELLULAR BIOL INC, MOLEC & CELLULAR BIOL RES INST, DEPT IMMUNOL, PALO ALTO, CA 94304 USA; RIKEN TSUKUBA LIFE SCI CTR, KOHYADAI, TSUKUBA, JAPAN	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; RIKEN			Kitamura, Toshio/AAA-2071-2021	Sakamaki, Kazuhiro/0000-0002-7072-9628				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ARIMA N, 1992, J IMMUNOL, V149, P83; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V186, P1236, DOI 10.1016/S0006-291X(05)81538-4; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DURONIO V, 1992, J BIOL CHEM, V267, P21856; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HARADA N, 1992, J BIOL CHEM, V267, P22752; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HULI J, 1989, J IMMUNOL, V142, P800; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JUBINSKY PT, 1993, BLOOD, V81, P587; KANAKURA Y, 1991, BLOOD, V77, P243; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1992, BLOOD, V80, P84; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MIYAJIMA A, 1992, INT J CELL CLONING, V10, P126, DOI 10.1002/stem.5530100302; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; SABE H, 1991, INT IMMUNOL, V3, P1137, DOI 10.1093/intimm/3.11.1137; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHOWERS MO, 1992, BLOOD, V80, P3070; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; YAMAMURA Y, 1992, EMBO J, V11, P4909, DOI 10.1002/j.1460-2075.1992.tb05597.x; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	54	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15833	15839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340408				2022-12-25	WOS:A1993LN30500074
J	SUGIURA, N; SAKURAI, K; HORI, Y; KARASAWA, K; SUZUKI, S; KIMATA, K				SUGIURA, N; SAKURAI, K; HORI, Y; KARASAWA, K; SUZUKI, S; KIMATA, K			PREPARATION OF LIPID-DERIVATIZED GLYCOSAMINOGLYCANS TO PROBE A REGULATORY FUNCTION OF THE CARBOHYDRATE MOIETIES OF PROTEOGLYCANS IN CELL-MATRIX INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN-MEDIATED ADHESION; CHONDROITIN-SULFATE; MONOCLONAL-ANTIBODY; COLLAGEN SUBSTRATA; FIBROBLASTS; ATTACHMENT; CARTILAGE; CHAINS; SUGARS	We have shown previously that chondroitin sulfate, but not heparan sulfate/heparin, linked to either natural core proteins or serum albumin interferes with cell-to-substrate adhesion, provided that the external proteoglycans are topologically immobilized on plastic plates. In order to study the roles of glycosaminoglycan chains (GAGs) as recognition structure, a new assay system is now developed which involves the conversion of free GAGs to reactive lactone derivatives selectively modified at the reducing end. The modified GAGs can be coupled to the amino group of phosphatidylethanolamine (PE) for use as probes on either plastic plates or cell surfaces. Incubation of GAG-PE solutions in polystyrene plates results in a time- and dose-dependent increase of the density of the GAG chains noncovalently immobilized onto the plates. No immobilization is detected with any of the GAG-PE samples that have been treated with phospholipase D. A M(r) 30,000 chondroitin sulfate conjugate to PE (CS-PE), when immobilized onto a fibronectin-coated well for 2 h at an initial concentration of 0.06 mug/100 mul/well, inhibits the adhesion of baby hamster kidney (BHK) cells to the substratum by approximately 50%, whereas heparin-, heparan sulfate-, hyaluronic acid-, and dermatan sulfate-PE do not. The effect of CS-PE is abolished by treating the CS-PE-coated plates with chondroitinase ABC. A similar level of inhibition by CS-PE is found when the RGD-containing 120-kDa fragment of fibronectin is used in place of fibronectin. CS-PE in soluble form, once exposed to BHK cells in suspension, can be associated with the cell surfaces, thereby exerting some inhibitory effects on cell-to-substrate adhesion. On a per mol basis, however, the activity of cell-associated CS-PE is far lower than that of substrate-associated CS-PE. Together the results indicate that our GAG-PEs offer useful tools for probing regulatory function of the GAG moieties of proteoglycans and further support the hypothesis that the inhibitory regulation of cell-to-matrix adhesion by large chondroitin sulfate proteoglycans is caused by an interaction between the cell surface and the chondroitin sulfate chains topologically immobilized on extracellular matrices.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN; SEIKAGAKU CORP,TOKYO RES INST,TOKYO 207,JAPAN	Aichi Medical University; Seikagaku Corporation								AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOREL E, 1952, HELV CHIM ACTA, V35, P115, DOI 10.1002/hlca.19520350116; BRENNAN MJ, 1983, CANCER RES, V43, P4302; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; Humphries M.J., 1991, RECEPTORS EXTRACELLU, P195; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; JALKANEN M, 1991, RECEPTORS EXTRACELLU, P1; KATO M, 1987, J BIOL CHEM, V262, P7180; LEE YC, 1992, TRENDS GLYCOSCI GLYC, V4, P251; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; OGAMO A, 1982, CARBOHYD RES, V105, P69, DOI 10.1016/S0008-6215(00)81855-8; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; RICH AM, 1981, NATURE, V293, P224, DOI 10.1038/293224a0; ROLLINS BJ, 1979, BIOCHEMISTRY-US, V18, P441; ROSEMAN S, 1991, TRENDS GLYCOSCI GLYC, V3, P438; ROSENBERG LC, 1986, CIBA F SYMP, V124, P47; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; RUOSLAHTI E, 1991, CELL BIOL EXTRACELLU; RYU EK, 1979, J LIPID RES, V20, P561; SANANTONIO JD, 1992, J CELL PHYSIOL, V150, P8; SHIOZAWA S, 1992, ANN RHEUM DIS, V51, P869, DOI 10.1136/ard.51.7.869; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; Sugiura Nobuo, 1992, Cell Structure and Function, V17, P510; SUZUKI S, 1991, PURE APPL CHEM, V63, P545, DOI 10.1351/pac199163040545; TAKAGAKI K, 1990, J BIOCHEM BIOPH METH, V21, P209, DOI 10.1016/0165-022X(90)90014-4; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; TANG PW, 1985, BIOCHEM BIOPH RES CO, V132, P474, DOI 10.1016/0006-291X(85)91158-1; UENO Y, 1988, CHEM PHARM BULL, V36, P4971; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMADA KM, 1981, IMMUNOCHEMISTRY EXTR, P111; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012	36	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15779	15787						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340404				2022-12-25	WOS:A1993LN30500068
J	WILSON, AL; MALTESE, WA				WILSON, AL; MALTESE, WA			ISOPRENYLATION OF RAB1B IS IMPAIRED BY MUTATIONS IN ITS EFFECTOR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING-PROTEINS; VESICULAR TRANSPORT; MOLECULAR-CLONING; SMG P25A; FARNESYLTRANSFERASE; SEQUENCE; GERANYLGERANYLTRANSFERASE; CYSTEINE; SUBUNIT; FAMILY	Low molecular mass GTP-binding proteins encoded by the Rab gene family are posttranslationally modified by a specific geranylgeranyltransferase (GGTase II), which catalyzes the thioether linkage of geranylgeranyl isoprenoids to cysteines within one of the following carboxyl-terminal sequence motifs: GGCC, CXC, CCSN. Short peptides containing these sequences are poor substrates for isoprenylation in vitro, suggesting that structural domains remote from the carboxyl terminus are required for interactions between Rab proteins and GGTase II. To begin to define these domains, deletions and point mutations were created within the Rab1B gene, and the ability of the mutant translation products to undergo isoprenylation was evaluated in reticulocyte lysates. Deletion of amino acids 2-9 diminished but did not eliminate isoprenylation of Rab1B, suggesting that the extreme amino-terminal region is not absolutely required for interaction with GGTase II. Longer deletions in the amino-terminal region, which probably disrupt the overall conformation of Rab1B, completely prevented isoprenylation. Site-directed mutations predicted to lie in the amino-terminal variable region (Y5N), the beta3 strand (Q60E), and Loop 7 (A110D) of the Rab1B structure did not reduce isoprenylation. However, two mutations (I41N, D44N) in the effector domain, which appears to mediate interactions with proteins that stimulate GTP hydrolysis or GDP dissociation, essentially abolished the ability of Rab1B to undergo isoprenylation. These findings imply that the effector domain plays a key role in the isoprenylation of Rab proteins, either by serving as a prenyltransferase binding site or by facilitating interactions with accessory proteins that allow Rab1B to assume a specific guanine nucleotide-dependent conformation that is recognized by GGTase II.	WEIS CTR RES,GEISINGER CLIN,100 N ACAD AVE,DANVILLE,PA 17822						NCI NIH HHS [CA34569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BUCCI C, 1991, BIOTECH CELL REG, V4, P103; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Higuchi R., 1989, PCR TECHNOLOGY, P61; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VIELH E, 1989, NUCLEIC ACIDS RES, V17, P1770, DOI 10.1093/nar/17.4.1770; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	38	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14561	14564						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325834				2022-12-25	WOS:A1993LL75900003
J	CAMEJO, G; FAGER, G; ROSENGREN, B; HURTCAMEJO, E; BONDJERS, G				CAMEJO, G; FAGER, G; ROSENGREN, B; HURTCAMEJO, E; BONDJERS, G			BINDING OF LOW-DENSITY LIPOPROTEINS BY PROTEOGLYCANS SYNTHESIZED BY PROLIFERATING AND QUIESCENT HUMAN ARTERIAL SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE; GROWTH-FACTOR; ATHEROSCLEROSIS; ACCUMULATION; TISSUE; ATHEROGENESIS; MACROPHAGES; APO-B-100; CULTURE; HEPARIN	Chondroitin sulfate-rich proteoglycans secreted by arterial intima smooth muscle cells appear involved in low density lipoprotein entrapment and modification. Hypothetically, such a process may contribute to atherogenesis. We compared composition and size of those proteoglycans synthesized by proliferating and resting human arterial smooth muscle cells for which low density lipoprotein had affinity. Lipoprotein-binding proteoglycans secreted by proliferating cells were larger than those of resting cells (M(r) = 1.1 x 10(6) versus 0.8 x 10(6)). This was primarily caused by increased M(r) of the chondroitin sulfate chains (6 x 10(4) versus 3.5 x 10(4)). The glycosaminoglycan chains of the proteoglycans from both cells were made of more than 90% chondroitin 6-sulfate and chondroitin 4-sulfate in a 6:4 ratio. Affinity chromatography indicated that low density lipoprotein had a higher affinity with the proteoglycans synthesized by proliferating cells than those from resting cells. Measured with gel mobility shift assay, the apparent affinity constant of low density lipoproteins for proteoglycans from proliferating cells was 3-fold higher than that for proteoglycans from resting cells. This increased affinity appeared related to the higher relative proportion of proteoglycans with longer glycosaminoglycan chains secreted by the proliferating cells than those secreted by the resting cells.	GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT HEART & LUNG DIS,WALLENBERG LAB,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg	CAMEJO, G (corresponding author), ASTRA HASSLE,PRECLIN RES LABS,DEPT BIOCHEM,S-43183 MOLNDAL,SWEDEN.							ALAVI MZ, 1992, ATHEROSCLEROSIS, V95, P59, DOI 10.1016/0021-9150(92)90176-H; ALVES CS, 1988, ATHEROSCLEROSIS, V73, P113, DOI 10.1016/0021-9150(88)90032-9; BERENSON GS, 1984, EXP MOL PATHOL, V41, P267, DOI 10.1016/0014-4800(84)90043-1; BIHARIVARGA M, 1964, J ATHEROSCLER RES, V4, P106, DOI 10.1016/S0368-1319(64)80020-X; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CHEN JK, 1991, IN VITRO CELL DEV B, V27, P6; EDWARDS IJ, 1988, J BIOL CHEM, V263, P9612; FABER M, 1949, ARCH PATHOL, V48, P342; FAGER G, 1992, IN VITRO CELL DEV-AN, V28A, P176; FAGER G, 1992, IN VITRO CELL DEV-AN, V28A, P168; FAGER G, 1988, EXP CELL RES, V176, P319, DOI 10.1016/0014-4827(88)90334-5; GOLDBERG RL, 1990, CONNECT TISSUE RES, V24, P265, DOI 10.3109/03008209009152154; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1983, ARTERY, V12, P104; HOFF HF, 1986, ATHEROSCLEROSIS, V61, P231, DOI 10.1016/0021-9150(86)90143-7; HOLLANDER W, 1976, EXP MOL PATHOL, V25, P106, DOI 10.1016/0014-4800(76)90021-6; HOLLMANN J, 1986, EXP CELL RES, V167, P484, DOI 10.1016/0014-4827(86)90188-6; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; HURTCAMEJO E, 1990, J LIPID RES, V31, P43; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; OLSSON U, 1991, BIOCHIM BIOPHYS ACTA, V1097, P37, DOI 10.1016/0925-4439(91)90021-Z; REZVIN A, 1989, BIOTECHNIQUES, V7, P346; ROSENFELD ME, 1992, ARTERIOSCLER THROMB, V12, P985, DOI 10.1161/01.ATV.12.8.985; ROSS R, 1991, TRENDS CARDIOVAS MED, V1, P277, DOI 10.1016/1050-1738(91)90043-E; SCHMIDT A, 1990, EUR J CELL BIOL, V52, P229; SCHONHERR E, 1991, J BIOL CHEM, V266, P1740; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SRINIVASAN SR, 1989, BIOCHIM BIOPHYS ACTA, V1006, P159, DOI 10.1016/0005-2760(89)90190-2; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; VIJAYAGOPAL P, 1992, BIOCHIM BIOPHYS ACTA, V1135, P129, DOI 10.1016/0167-4889(92)90128-X; WAGNER WD, 1988, ARTERIOSCLEROSIS, V6, P407; WIGHT TN, 1986, CIBA F SYMP, V124, P241; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; YLAHERTTUALA S, 1991, ANN MED, V23, P561, DOI 10.3109/07853899109150518	38	137	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14131	14137						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314779				2022-12-25	WOS:A1993LJ82500053
J	CHEN, JW; YANG, SH; JAYARAM, M				CHEN, JW; YANG, SH; JAYARAM, M			TESTS FOR THE FRACTIONAL ACTIVE-SITE MODEL IN FLP SITE-SPECIFIC RECOMBINATION - ASSEMBLY OF A FUNCTIONAL RECOMBINATION COMPLEX IN HALF-SITE AND FULL-SITE STRAND TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGIONAL SIMILARITIES; SUBSTRATE RECOGNITION; CIRCLE PLASMID; MUTANTS; DNA; PROTEIN; MECHANISM; MUTATIONS; TARGET; BENDS	The Arg191-His305-Arg308 (the RHR triad) and Tyr343 of Flp site-specific recombinase correspond to the invariant tetrad residues of the integrase family of proteins. Flp mutants altered at these positions are blocked at the strand cleavage or the strand exchange step of recombination. Hybrid half-site-recombinase complexes formed by step-arrest mutants of Flp have revealed that an Flp monomer occupying a half-site does not cleave that half-site but rather cleaves a half-site occupied by a second Flp monomer. This trans-DNA cleavage is neatly accommodated by a model in which an Flp active site is assembled by contribution of amino acid residues from at least two protein monomers. Using a combination of wild type Flp, single, double, and triple step-arrest Flp mutants, critical predictions of the fractional active-site model have been verified. First, a wild type monomer paired with an RHR triad Tyr343 double mutant is a catalytically inactive combination. Second, each pairwise combination of a single, double, or triple RHR mutant with Flp(Y343F) yields approximately equivalent levels of catalytic complementation. Half-site to half-site and half-site to full-site crosses suggest that execution of a strand transfer event within a half-site and between a half-site and a full site requires dimeric and tetrameric Flp configurations, respectively.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ANDREWS BJ, 1986, MOL CELL BIOL, V11, P4497; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHEN JW, 1991, J MOL BIOL, V218, P107, DOI 10.1016/0022-2836(91)90877-9; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CHEN JW, 1992, J MOL BIOL, V69, P647; EVANS BR, 1990, J BIOL CHEM, V265, P18504; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Maniatis T., 1982, MOL CLONING; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; PRASAD PV, 1986, MOL CELL BIOL, V6, P4329, DOI 10.1128/MCB.6.12.4329; QIAN XH, 1990, J BIOL CHEM, V265, P21779; QIAN XH, 1992, J BIOL CHEM, V267, P7794; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SERRE MC, 1992, J MOL BIOL, V225, P643, DOI 10.1016/0022-2836(92)90391-V; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	23	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14417	14425						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314800				2022-12-25	WOS:A1993LJ82500091
J	MACFARLANE, DE; MANZEL, L				MACFARLANE, DE; MANZEL, L			ACTIVATION OF BETA-ISOZYME OF PROTEIN-KINASE-C (PKC-BETA) IS NECESSARY AND SUFFICIENT FOR PHORBOL ESTER-INDUCED DIFFERENTIATION OF HL-60 PROMYELOCYTES - STUDIES WITH PKC-BETA-DEFECTIVE PET MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; GENE-EXPRESSION; LEUKEMIA-CELLS; RETINOIC ACID; HETEROGENEITY; INDUCTION; RESISTANT; MULTIPLE; DIESTER; FAMILY	12-O-Tetradecanoylphorbol-13-acetate (TPA) induces growth arrest and differentiation of a number of leukemia cell lines including HL-60 human promyelocytic leukemia. We investigated the involvement of protein kinase C (PKC) isotypes in phorbol ester-induced differentiation using the phorbol ester tolerant PET mutant of HL-60 cells, which (in contrast to the parent phorbol ester-sensitive (wild-type) S variant of HL-60 cells) does not growth-arrest, become adherent, or undergo apoptosis when exposed to TPA (Macfarlane, D. E., Gailani, D., and Vann, K. (1988) Br. J. Haematol. 68, 291-302). In comparison to S cells, we found that proliferating PET cells markedly underexpress mRNA for PKC beta, but do express PKC alpha and PKC delta. The PKC beta-selective activator 12-deoxyphorbol 13-phenylacetate 20-acetate induces growth arrest, adherence, surface expression of CD11a, and apoptosis in S cells, but not in PET cells. Expression of PKC beta in PET cells can be restored by exposing them to dihydroxyvitamin D-3, and this treatment restores the ability of subsequently added 12-deoxyphorbol 13-phenylacetate 20-acetate or TPA to induce immediate cell adherence and growth arrest of PET cells. These data led us to conclude that activation of PKC beta is both necessary and sufficient for phorbol ester-induced growth arrest and adherence in these myeloid cells.	UNIV IOWA,IOWA CITY,IA 52242	University of Iowa	MACFARLANE, DE (corresponding author), VET ADM MED CTR,DEPT MED,IOWA CITY,IA 52242, USA.			Macfarlane, Donald/0000-0001-8785-5690				AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; CHOMCZYNSKI PA, 1991, CURRENT PROTOCOLS S, V14; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; GAILANI D, 1989, CANCER RES, V49, P5329; GALLAGHER R, 1979, BLOOD, V54, P713; HOOPER WC, 1989, BIOCHIM BIOPHYS ACTA, V1013, P47, DOI 10.1016/0167-4889(89)90126-2; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P293; KELLEHER D, 1992, FEBS LETT, V301, P310, DOI 10.1016/0014-5793(92)80264-H; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KORETZKY GA, 1989, J IMMUNOL, V143, P1692; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; MACFARLANE DE, 1988, BRIT J HAEMATOL, V68, P291, DOI 10.1111/j.1365-2141.1988.tb04205.x; MACFARLANE DE, 1994, IN PRESS LEUKEMIA BA; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SPIVAK JL, 1990, MOL BIOL HAEMATOPOIE, P420; TANAKA Y, 1992, J BIOCHEM-TOKYO, V111, P265, DOI 10.1093/oxfordjournals.jbchem.a123747; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	31	146	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4327	4331						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308000				2022-12-25	WOS:A1994MW98900067
J	TAKEDA, A; MAIZEL, AL; KITAMURA, K; OHTA, T; KIMURA, S				TAKEDA, A; MAIZEL, AL; KITAMURA, K; OHTA, T; KIMURA, S			MOLECULAR-CLONING OF THE CD45-ASSOCIATED 30-KDA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CD45 PHOSPHOTYROSINE PHOSPHATASE; CELL ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; T-CELLS; KINASE; ACTIVATION; PHOSPHORYLATION; EXPRESSION; ANTIBODIES	CD45, a leukocyte-specific transmembrane protein tyrosine phosphatase, mediates signal transduction pathways critical for immune responses. However, the mechanism of CD45-mediated signal transduction and the identity of CD45-associated proteins have remained unclear. A CD45-associated 30-kDa phosphorylated protein (CD45-AP) was purified by virtue of its specific association with CD45, and its mouse cDNA was cloned by using the internal amino acid sequence information. In vitro translated CD45-AP bound specifically to CD45. CD45-AP appears to be leukocyte-specific and shares no significant homology with presently known sequences. The predicted sequence contains no consensus tyrosine phosphorylation sites or conserved sequences of GTP-binding proteins. CD45-AP may act as an adapter molecule for CD45-mediated signal transduction.	NCI, MOLEC CARCINOGENESIS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAKEDA, A (corresponding author), BROWN UNIV, ROGER WILLIAMS, MED CTR, DEPT PATHOL, 825 CHALKSTONE AVE, PROVIDENCE, RI 02908 USA.			Ohta, Tomohiko/0000-0002-9700-7342	NATIONAL CANCER INSTITUTE [P30CA013943, R37CA045148] Funding Source: NIH RePORTER; NCI NIH HHS [CA 45148, P30 CA13943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIKES M, 1973, J NATL CANCER I, V50, P347, DOI 10.1093/jnci/50.2.347; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; ELLINGTON A, 1993, CURRENT PROTOCOLS MO, V2; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LESLEY J, 1984, CELL IMMUNOL, V83, P14, DOI 10.1016/0008-8749(84)90220-X; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1990, SCIENCE, V250, P676, DOI 10.1126/science.2146743; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835	32	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2357	2360						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300558				2022-12-25	WOS:A1994MV43200003
J	LITTLE, RG; KELNER, DN; LIM, E; BURKE, DJ; CONLON, PJ				LITTLE, RG; KELNER, DN; LIM, E; BURKE, DJ; CONLON, PJ			FUNCTIONAL DOMAINS OF RECOMBINANT BACTERICIDAL PERMEABILITY-INCREASING PROTEIN (RBPI(23))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; LIPID-A; ANTIBACTERIAL PEPTIDES; BOVINE BRAIN; POLYMYXIN-B; BINDING; PURIFICATION; ENDOTOXIN; FRAGMENT; LIPOPOLYSACCHARIDES	The 23-kDa recombinant amino-terminal bactericidal/permeability increasing protein fragment (rBPI22) has all of the antibacterial and antiendotoxin properties of the holoprotein. In the current studies, we have identified multiple active domains within rBPI23 with chemical and proteolytic cleavage fragments and with synthetic overlapping peptides. We also demonstrate a novel, high affinity heparin binding property for rBPI23, in addition to its established bactericidal and lipopolysaccharide binding properties. Cleavage fragments and synthetic, overlapping peptides of rBPI23 were analyzed for inhibition of the lipopolysaccharide-induced Limulus amebocyte lysate reaction, for bactericidal activity, and for heparin binding. Three separate, active domains were identified in amino acid regions 17-45, 65-99, and 142-169. A single synthetic peptide (85-99) was bactericidal. These results indicate that rBPI23 is comprised of three separate functional domains which contribute to the high affinity interaction of rBPI23 with Gram-negative bacteria. The individual activity of each domain and the cooperative interaction among domains provide the basis for developing rBPI23 analogues with increased biologic efficacy.	XOMA CORP,DEPT ANALYT BIOCHEM,BERKELEY,CA 94710		LITTLE, RG (corresponding author), XOMA CORP,DEPT IMMUNOL,2910 7TH ST,BERKELEY,CA 94710, USA.							BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BJORK I, 1992, J BIOL CHEM, V267, P1976; BOMAN HG, 1989, FEBS LETT, V259, P103, DOI 10.1016/0014-5793(89)81505-4; BRADE L, 1987, INFECT IMMUN, V55, P2636, DOI 10.1128/IAI.55.11.2636-2644.1987; BRAY AM, 1991, J ORG CHEM, V56, P6659, DOI 10.1021/jo00023a035; BURD RS, 1992, IMMUNOTHERAPY GRAM N, P21; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DANNER RL, 1989, ANTIMICROB AGENTS CH, V33, P1428, DOI 10.1128/AAC.33.9.1428; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; ELSBACH P, 1988, INFLAMMATION BASIC P, P603; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; KINI RM, 1989, INT J PEPT PROT RES, V34, P277; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MARRA MN, 1990, J IMMUNOL, V144, P662; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; OOI CE, 1987, J BIOL CHEM, V262, P14891; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RUSTICI A, 1993, SCIENCE, V259, P361, DOI 10.1126/science.8420003; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; THOMAS KA, 1984, P NATL ACAD SCI-BIOL, V81, P357, DOI 10.1073/pnas.81.2.357; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; WEISS J, 1982, ADV EXP MED BIOL, V141, P129; WEISS J, 1984, J IMMUNOL, V132, P3109; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; WEISS J, 1978, J BIOL CHEM, V253, P2664; YAYON A, 1991, MOL CELL BIOL, V12, P240; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	42	108	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1865	1872						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294435				2022-12-25	WOS:A1994MR98800050
J	THOMALE, J; HOCHLEITNER, K; RAJEWSKY, MF				THOMALE, J; HOCHLEITNER, K; RAJEWSKY, MF			DIFFERENTIAL FORMATION AND REPAIR OF THE MUTAGENIC DNA ALKYLATION PRODUCT O6-ETHYLGUANINE IN TRANSCRIBED AND NONTRANSCRIBED GENES OF THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYL-N-NITROSOUREA; TRANSCRIPTIONALLY ACTIVE DNA; NUCLEOTIDE EXCISION REPAIR; COMPLEMENTATION GROUP-C; ALKALI-LABILE SITES; SELECTIVE REPAIR; BRAIN DNA; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ESCHERICHIA-COLI; HUMAN-CELLS	Intragenomic differences regarding the formation and repair of carcinogen-DNA adducts influence gene-specific mutational patterns and the cellular risk of malignant conversion. Using a newly developed, monoclonal antibody-based immunoaffinity method (Hochleitner, K., Thomale, J., Nikitin, A. Y., and Rajewsky, M. F. (1991) Nucleic Acids Res. 19, 4467-4472), it has become possible to quantitate the mutagenic DNA alkylation product O6-ethylguanine (O6-EtGua) at the level of single-copy genes. We have analyzed the formation and repair kinetics of O6-EtGua in DNA in relation to the transcriptional activity of selected genes in two isogenic rat hepatoma cell lines (Fao and H5) exposed to N-ethyl-N-nitrosourea. Whereas the frequency of O6-EtGua initially formed in the inactive immunoglobulin E gene was indistinguishable from the value for bulk DNA, the initial O6-EtGua/guanine molar ratio in the transcribed beta-actin gene was nearly three times higher. The overall elimination rates of O6-EtGua were the same for bulk DNA and the IgE gene sequence, i.e. rapid in Fao cells (68% removed within 20 min) and four times slower in H5 cells. Preferential repair was found in the transcribed gene: during the initial phase of elimination, the half-life of O6-EtGua in the beta-actin gene was three times shorter than in the IgE gene in Fao cells (5 versus 15 min) and 12 times shorter in H5 cells (20 min versus 4 h).	UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,HUFELAND STR 55,D-45122 ESSEN,GERMANY	University of Duisburg Essen								BHANOT OS, 1992, NUCLEIC ACIDS RES, V20, P587, DOI 10.1093/nar/20.3.587; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BRONSTEIN SM, 1992, CANCER RES, V52, P2008; COX R, 1979, CANCER RES, V39, P2675; DESCHATRETTE J, 1979, SOMAT CELL GENET, V5, P697, DOI 10.1007/BF01542636; DOLAN ME, 1991, CARCINOGENESIS, V12, P2305, DOI 10.1093/carcin/12.12.2305; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; FREI JV, 1975, CHEM-BIOL INTERACT, V10, P413, DOI 10.1016/0009-2797(75)90072-1; GEORGIADIS P, 1991, CANCER RES, V51, P5843; GOTH R, 1974, P NATL ACAD SCI USA, V71, P639, DOI 10.1073/pnas.71.3.639; HO L, 1989, MOL CELL BIOL, V9, P1594, DOI 10.1128/MCB.9.4.1594; HOCHLEITNER K, 1991, NUCLEIC ACIDS RES, V19, P4467, DOI 10.1093/nar/19.16.4467; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUH N, 1986, CARCINOGENESIS, V7, P435, DOI 10.1093/carcin/7.3.435; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LEDOUX SP, 1991, CANCER RES, V51, P775; LEDOUX SP, 1990, J BIOL CHEM, V265, P14875; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; LU SJ, 1992, P NATL ACAD SCI USA, V89, P1001, DOI 10.1073/pnas.89.3.1001; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MILLIGAN JR, 1988, BIOCHEM BIOPH RES CO, V155, P14, DOI 10.1016/S0006-291X(88)81042-8; MULLER R, 1983, CANCER RES, V43, P2897; NEHLS P, 1985, MUTAT RES, V150, P13, DOI 10.1016/0027-5107(85)90096-X; NEHLS P, 1984, EMBO J, V3, P327, DOI 10.1002/j.1460-2075.1984.tb01806.x; NEHLS P, 1984, J CANCER RES CLIN, V108, P23, DOI 10.1007/BF00390969; NEHLS P, 1985, CANCER RES, V45, P1378; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OKUMOTO DS, 1987, NUCLEIC ACIDS RES, V15, P10021, DOI 10.1093/nar/15.23.10021; PALOMBO F, 1992, J MOL BIOL, V223, P587, DOI 10.1016/0022-2836(92)90974-O; PEGG AE, 1982, P NATL ACAD SCI-BIOL, V79, P5162, DOI 10.1073/pnas.79.17.5162; PERERA FP, 1992, NATURE, V360, P256, DOI 10.1038/360256a0; RAJEWSKY MF, 1977, ORIGINS HUMAN CANCER, P709; RAJEWSKY MF, 1980, CARCINOGENESIS FUNDA, P207; RAJEWSKY MF, 1987, MOL MECHANISMS CARCI, P131; RICHARDSON FC, 1989, J BIOL CHEM, V264, P838; RICHARDSON KK, 1983, NUCLEIC ACIDS RES, V11, P8809, DOI 10.1093/nar/11.24.8809; RYAN AJ, 1986, CARCINOGENESIS, V7, P1497, DOI 10.1093/carcin/7.9.1497; SAMSON L, 1988, EMBO J, V7, P2261, DOI 10.1002/j.1460-2075.1988.tb03066.x; SATOH MS, 1988, J BIOL CHEM, V263, P6854; SENDOWSKI K, 1991, MUTAT RES, V250, P153, DOI 10.1016/0027-5107(91)90171-J; SINGER B, 1986, CANCER RES, V46, P4879; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; SMITH CA, 1990, ADV MUTAGENESIS RES, V1, P153; STEEN ML, 1984, J MOL BIOL, V177, P19, DOI 10.1016/0022-2836(84)90055-X; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; SWENBERG JA, 1984, P NATL ACAD SCI-BIOL, V81, P1692, DOI 10.1073/pnas.81.6.1692; TEO IA, 1983, CARCINOGENESIS, V4, P1075, DOI 10.1093/carcin/4.8.1075; TERLETH C, 1991, MUTAGENESIS, V6, P103, DOI 10.1093/mutage/6.2.103; THOMALE J, 1990, P NATL ACAD SCI USA, V87, P9883, DOI 10.1073/pnas.87.24.9883; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VONHOFE E, 1992, P NATL ACAD SCI USA, V89, P11199, DOI 10.1073/pnas.89.23.11199	52	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1681	1686						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294414				2022-12-25	WOS:A1994MR98800024
J	LERHUN, Y; DUTHU, A; EHRHART, JC; MICHIELS, F; MAY, E; MAY, P				LERHUN, Y; DUTHU, A; EHRHART, JC; MICHIELS, F; MAY, E; MAY, P			DIRECTIONAL SELECTION ASSOCIATED WITH CLONAL EXPANSION OF P53 MUTANT-CELLS DURING NEOPLASTIC DEVELOPMENT OF CARCINOGEN-TREATED RAT EMBRYO LUNG EPITHELIAL-CELLS	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; HEAT-SHOCK PROTEINS; SV40-TRANSFORMED CELLS; SUPPRESSOR GENE; CYCLE CONTROL; TRANSFORMATION; MUTATIONS; ONCOGENE; SEQUENCE	In this study, rat embryo lung organ cultures were exposed to benzo[a]pyrene (B[a]P). After carcinogen-treatment the cells were dissociated and an epithelial cell line (BP) was developed from the primary cell culture derived from the carcinogen-treated explants. Investigations were performed on the sequential changes occurring in the course of neoplastic progression of BP cells and in the tumor cells that arose in vivo from implanted BP cells. During the neoplastic progression a mutation was shown to occur in p53 gene at codon 130 (AAG > AGG; Lys > Arg) in a single cell which expanded and gave rise to a predominant subpopulation. This mutational event was already detected at passage 14 but was probably not a direct consequence of a specific alteration caused by the carcinogen in the target cell. This mutation was retained through the subsequent progressional steps first as a heterozygous mutation, then converted to a homozygous state. From passage 18 on, it was possible in BP cell. cultures to detect foci of larger morphologically distinct cells emerging on a background of cells maintaining the original morphology. These foci were shown to derive from a single cell carrying the p53 mutation in a homozygous state. During the neoplastic progression the mutant p53 allele frequency steadily increased and this mutant allele eventually came to predominate completely in the late stages of the neoplastic progression, including in the transplantation-induced tumors. The pattern of a directional selection for mutant p53 gene towards fixation is probably applicable to a wide range of human malignancies and may reflect the particular importance of this gene for tumorigenesis.	IRSC,ONCOL MOLEC LAB,CNRS,F-94801 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTKOVA J, 1993, EUR J CANCER, V29A, P881, DOI 10.1016/S0959-8049(05)80431-9; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; EHRHART JC, 1988, ONCOGENE, V3, P595; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUJIMOTO K, 1992, CANCER RES, V52, P1393; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JONES PA, 1991, CANCER RES, V51, P3617; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLEBERG SL, 1992, MOL CARCINOGEN, V6, P159, DOI 10.1002/mc.2940060211; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAKINO H, 1992, P NATL ACAD SCI USA, V89, P4850, DOI 10.1073/pnas.89.11.4850; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MERCER WE, 1990, ONCOGENE, V5, P973; MICHIELS F, 1981, CARCINOGENESIS, V2, P885, DOI 10.1093/carcin/2.9.885; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROTHFELS KH, 1958, STAIN TECHNOL, V33, P73, DOI 10.3109/10520295809111827; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1993, CARCINOGENESIS, V14, P503, DOI 10.1093/carcin/14.3.503; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STURZBECHER HW, 1990, ONCOGENE, V5, P795; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	63	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					263	271						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302588				2022-12-25	WOS:A1994MW24700032
J	TONISSEN, KF; KRIEG, PA				TONISSEN, KF; KRIEG, PA			ANALYSIS OF A VARIANT MAX SEQUENCE EXPRESSED IN XENOPUS-LAEVIS	ONCOGENE			English	Article							C-MYC; DNA-BINDING; RAS COTRANSFORMATION; TRANSCRIPTION; PROTEIN; REQUIRES; ONCOGENE; CELLS; FORMS	Max is a small helix-loop-helix protein which forms heterodimers with members of the Myc protein family. Myc/Max heterodimers exhibit sequence-specific DNA binding with much greater affinity than Myc homodimers. The Xenopus laevis homologue of Max, XMax, is shorter than the equivalent mammalian protein. This difference results from the deletion of a 24 amino acid sequence located near the C-terminus of the protein. Xenopus max transcripts undergo alternative splicing. In addition to the 27 base alternatively spliced sequence (exon A) previously detected in mice and humans, some Xmax transcripts also contain an 81 base sequence (exon B) at a second site within the coding sequence. Although exon B insertion alters part of the leucine zipper protein/protein interaction domain, the resulting XMax protein retains the ability to form stable heterodimers with both c-Myc acid N-Myc. Xmax mRNA is present at approximately constant levels during early development. This contrasts with the rapidly changing levels of c-myc and N-myc mRNA in the embryo and has implications for regulation of gene expression during differentiation. All four alternatively spliced forms of Xmax mRNA are present during development and in all adult tissue examined.	UNIV TEXAS,CTR DEV BIOL,DEPT ZOOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin			Tonissen, Kathryn F/E-9424-2010	Tonissen, Kathryn F/0000-0002-1018-2798	NICHD NIH HHS [HD25179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025179] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Battey, 1986, BASIC METHODS MOL BI; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DEAN M, 1986, J BIOL CHEM, V261, P9161; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; GERHART JG, 1980, MECHANISMS REGULATIN, P133; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HOURDRY J, 1988, DEVELOPMENT, V104, P631; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VASTRIK I, 1993, ONCOGENE, V8, P503; VIZE PD, 1990, DEVELOPMENT, V110, P885	30	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					33	38						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302600				2022-12-25	WOS:A1994MW24700005
J	DINIZ, MRV; PAINE, MJI; DINIZ, CR; THEAKSTON, RDG; CRAMPTON, JM				DINIZ, MRV; PAINE, MJI; DINIZ, CR; THEAKSTON, RDG; CRAMPTON, JM			SEQUENCE OF THE CDNA CODING FOR THE LETHAL NEUROTOXIN TX1 FROM THE BRAZILIAN ARMED SPIDER PHONEUTRIA-NIGRIVENTER PREDICTS THE SYNTHESIS AND PROCESSING OF A PREPROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FUNNEL-WEB SPIDER; AGELENOPSIS-APERTA; VENOM; PURIFICATION; ACID; PRECURSORS; PEPTIDES	A cDNA library was constructed from the venom glands of the Brazilian ''armed'' spider, Phoneutria nigriventer, and a clone coding for Tx1, a lethal toxin, was identified and sequenced. The sequence data derived from this cDNA clone combined with the previously determined amino acid sequence predict that Tx1 is initially synthesized as a preprotoxin. Four segments (comprising the signal sequence, a short, 15-amino acid, glutamate-rich sequence, the functional toxin, and 2 glycine residues) can be distinguished. The structure of the preprotoxin and the proposed processing steps required to form the mature Tx1 toxin show similarities with the synthesis and processing of omega-agatoxin IA.	CTR PESQUISA & DESENVOLVIMENTO,FDN EZEQUIEL DIAS,BR-30510-10 BELO HORIZON,MG,BRAZIL		DINIZ, MRV (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,WOLFSON UNIT MOLEC GENET,PEMBROKE PL,LIVERPOOL L3 5QA,ENGLAND.		Paine, Mark John Ingraham/O-7450-2019	Paine, Mark John Ingraham/0000-0003-2061-7713	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS ME, 1990, J BIOL CHEM, V265, P861; BARRIO AVALINO, 1955, ACTA PHYSIOL LATINOAMER, V5, P132; BOUCHIER C, 1991, BIOCHIM BIOPHYS ACTA, V1088, P401, DOI 10.1016/0167-4781(91)90132-6; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; BRAZIL V, 1925, MEM I BUTANTAN, V2, P1; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDEIRO MD, 1993, TOXICON, V31, P35, DOI 10.1016/0041-0101(93)90354-L; CORDEIRO MD, 1992, FEBS LETT, V310, P153, DOI 10.1016/0014-5793(92)81318-G; DINIZ CARLOS R., 1963, AN ACAD BRASIL CIENC, V35, P283; DINIZ CR, 1990, FEBS LETT, V263, P251, DOI 10.1016/0014-5793(90)81386-3; ENTWISTLE ID, 1982, TOXICON, V20, P1059, DOI 10.1016/0041-0101(82)90108-8; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; FAZZAL A, 1989, FEBS LETT, V257, P260; FONTANA MD, 1985, BRAZ J MED BIOL RES, V18, P557; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; Kreil G, 1980, Ann N Y Acad Sci, V343, P338, DOI 10.1111/j.1749-6632.1980.tb47262.x; LUCAS S, 1988, TOXICON, V26, P759, DOI 10.1016/0041-0101(88)90317-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELLHAM HRB, 1976, EUR J BIOCHEM, V67, P247; RESENDE C, 1991, TOXICON, V29, P1225; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS AD, 1992, J BIOL CHEM, V267, P20701; SCHEMBERG S, 1971, VENOMOUS ANIMALS THE, P217; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; STAPLETON A, 1990, J BIOL CHEM, V265, P2054	29	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15340	15342						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340362				2022-12-25	WOS:A1993LN30500005
J	SAXENA, U; FERGUSON, E; BISGAIER, CL				SAXENA, U; FERGUSON, E; BISGAIER, CL			APOLIPOPROTEIN-E MODULATES LOW-DENSITY-LIPOPROTEIN RETENTION BY LIPOPROTEIN-LIPASE ANCHORED TO THE SUBENDOTHELIAL MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER PROTEIN-DEFICIENCY; CHOLESTEROL-FED RABBITS; ESTER TRANSFER ACTIVITY; SMOOTH-MUSCLE CELLS; PLASMA-LIPOPROTEINS; ATHEROSCLEROTIC LESIONS; A-I; PHOSPHOLIPID LIPOSOMES; COLLAGEN COMPLEXES; MOUSE MACROPHAGES	Lipoprotein lipase (lipase), a key enzyme in lipoprotein triglyceride metabolism, has been shown to markedly increase low density lipoprotein (LDL) retention by subendothelial matrix. In the present study we assessed the role that lipoprotein and matrix components play in retention of LDL by lipase anchored to the subendothelial matrix. Lipase addition to subendothelial matrix increased LDL retention by 66-fold. Scatchard analysis of LDL binding to lipase-containing matrix yielded an association constant of 12 nm. Exogenous addition of the matrix components, heparan sulfate and dermatan sulfate (i.e. chondroitin sulfate B), reduced LDL retention by greater than 90%. These glycosaminoglycans (GAGs) also reduced lipolytic activity associated with the matrix, suggesting that lipase was released from its binding sites on the matrix. In contrast, other matrix components (collagen, fibronectin, vitronectin, and chondroitin sulfate A) neither affected LDL release nor matrix lipolytic activity. Thus, heparan sulfate and dermatan sulfate function to anchor lipase to the subendothelial cell matrix. The effects of apolipoprotein E (apoE) and apoA-I were also examined. Preincubation of the subendothelial matrix with apoE, followed by washing, did not affect subsequent lipase binding to the matrix nor its ability to retain LDL. However, the direct addition of apoE alone or in combination with phospholipid liposomes decreased lipase-mediated LDL retention in a concentration-dependent fashion. Addition of apoA-I had no effect. Thus, in these studies apoE functions to displace LDL bound to lipase, but not lipase anchored to the matrix. To further examine the physiologic implications of this process, we assessed the ability of human apoE-rich and apoE-poor high density lipoproteins (HDL) to displace LDL from matrix-anchored lipase. ApoE-rich HDL reduced LDL retention dramatically (86% at 2.5 mug/ml). In contrast, apoE-poor HDL, at the highest concentration evaluated (400 mug/ml), decreased LDL retention by only 32%. Overall, these data suggest apoE and specifically apoE-containing HDL reduce the lipase-mediated retention of LDL by subendothelial matrix. This observation, in part could explain the protective effects of apoE and apoE-containing HDL against atherosclerosis.			SAXENA, U (corresponding author), WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT PHARMACOL, ANN ARBOR, MI 48105 USA.							BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BARTER PJ, 1978, BIOCHIM BIOPHYS ACTA, V531, P233, DOI 10.1016/0005-2760(78)90147-9; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BISGAIER CL, 1991, J LIPID RES, V32, P21; BISGAIER CL, 1989, J BIOL CHEM, V264, P862; BOCAN TMA, 1988, ARTERIOSCLEROSIS, V8, P499, DOI 10.1161/01.ATV.8.5.499; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CAMEJO G, 1985, BIOMED BIOCHIM ACTA, V44, P389; CHAJEKSHAUL T, 1990, BIOCHIM BIOPHYS ACTA, V1042, P168, DOI 10.1016/0005-2760(90)90003-G; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CLARK AB, 1985, J BIOL CHEM, V260, P4778; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DORY L, 1991, J LIPID RES, V32, P783; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EDWARDS IJ, 1990, AM J PATHOL, V136, P609; FALCONE DJ, 1988, ARTERIOSCLEROSIS, V8, P263, DOI 10.1161/01.ATV.8.3.263; FALCONE DJ, 1984, J CELL BIOL, V99, P1266, DOI 10.1083/jcb.99.4.1266; FOGELMAN AM, 1988, J CELL SCI, P135; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUYTON JR, 1992, AM J PATHOL, V141, P925; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1975, CIRC RES, V37, P72, DOI 10.1161/01.RES.37.1.72; HOUGH GP, 1990, EUR HEART J, V11, P62, DOI 10.1093/eurheartj/11.suppl_E.62; HURTCAMEJO E, 1990, ARTERIOSCLEROSIS, V10, pA783; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; JACKSON RL, 1985, FEBS LETT, V190, P297, DOI 10.1016/0014-5793(85)81304-1; JOHANSSON J, 1991, ARTERIOSCLER THROMB, V11, P174, DOI 10.1161/01.ATV.11.1.174; KOIZUMI J, 1985, ATHEROSCLEROSIS, V58, P175, DOI 10.1016/0021-9150(85)90064-4; KOIZUMI J, 1991, ATHEROSCLEROSIS, V90, P189, DOI 10.1016/0021-9150(91)90114-I; KUROSAKA D, 1991, ATHEROSCLEROSIS, V88, P15, DOI 10.1016/0021-9150(91)90252-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1977, J LIPID RES, V18, P314; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; OSCHRY Y, 1982, J LIPID RES, V23, P1099; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RADHAKRISHNAMUR.B, 1982, GLYCOCONJUGATES, V4, P265; RADHAKRISHNAMURTHY B, 1990, EUR HEART J, V11, P148, DOI 10.1093/eurheartj/11.suppl_E.148; RIFICI VA, 1984, J BIOL CHEM, V259, P3814; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONFELD G, 1974, J CLIN INVEST, V54, P236, DOI 10.1172/JCI107758; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; SRINIVAS.SR, 1972, ATHEROSCLEROSIS, V16, P95, DOI 10.1016/0021-9150(72)90012-3; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WILLIAMS KJ, 1987, J CLIN INVEST, V79, P1466, DOI 10.1172/JCI112975; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WISSLER RW, 1954, AMA ARCH PATHOL, V57, P333; YAMADA N, 1992, J CLIN INVEST, V89, P706, DOI 10.1172/JCI115639; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	66	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14812	14819						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325860				2022-12-25	WOS:A1993LL75900045
J	YANG, BH; LEJOHN, HB				YANG, BH; LEJOHN, HB			NADP(+)-ACTIVABLE, NAB(+)-SPECIFIC GLUTAMATE-DEHYDROGENASE - PURIFICATION AND IMMUNOLOGICAL ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; IMMUNODETECTION; MECHANISM; PROTEINS	An NAD(+)-specific glutamate dehydrogenase (NAD-GDH) that is inducible by L-glutamine was isolated from Achlya klebsiana and purified to electrophoretic homogeneity. The enzyme is only partially active in vitro unless NADP(+) (an activator) is present in both its oxidative deamination and reductive amination reactions. This type of enzyme was reported (LeJohn, H. B. (1971) Nature 231, 164-168) to be widespread among the amorphous group of algae-related fungi classified as Oomycota. The enzyme retained its dependence on NADP(+) at all stages of its purification. NADP(+) decreased the K-m of substrates 3-fold and increased the V-max 4-fold. M(r) of the undenatured enzyme was 480,000, and, denatured, only a single subunit of M(r), 120,000 was seen. A polyclonal antibody raised in rabbit against purified enzyme subunit excised from SDS-polyacrylamide gel electrophoresis gels immunoprecipitated the M(r) 120,000 polypeptide, the undenatured enzyme, and a physically distinct polypeptide of M(r), 74,000. The antibody, purified against the M(r) 120,000 enzyme subunit as anchored antigen on Sepharose, still immunoprecipitated the M(r) 74,000 polypeptide. The M(r) 74,000 polypeptide was found to be a subunit of a M(r) 220,000 native protein.	UNIV MANITOBA, DEPT MICROBIOL, WINNIPEG R3T 2N2, MB, CANADA; MANITOBA INST CELL BIOL, WINNIPEG R3E 0V9, MB, CANADA; UNIV MANITOBA, FAC MED, DEPT HUMAN GENET, WINNIPEG R3E 0W3, MB, CANADA	University of Manitoba; University of Manitoba								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAZIN H, 1906, METHOD ENZYMOL, V121, P638; CAMERON LE, 1972, J BIOL CHEM, V247, P4729; CHOMCZYNSKI P, 1977, ANAL BIOCHEM, V132, P156; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; Dewald B, 1974, Methods Enzymol, V32, P82; DEWET JR, 1984, DNA-J MOLEC CELL BIO, V3, P437, DOI 10.1089/dna.1.1984.3.437; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; KAPOOR M, 1993, BIOCHEM CELL BIOL, V71, P205, DOI 10.1139/o93-032; LEJOHN HB, 1971, NATURE, V231, P164, DOI 10.1038/231164a0; LEJOHN HB, 1994, J BIOL CHEM, V269, P4523; LEJOHN HB, 1994, J BIOL CHEM, V269, P4513; LEJOHN HB, 1970, J BIOL CHEM, V245, P3890; LEJOHN HB, 1975, EVOL BIOL, V7, P79; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER SM, 1990, J BACTERIOL, V172, P4927, DOI 10.1128/jb.172.9.4927-4935.1990; PALMITER RD, 1971, J BIOL CHEM, V246, P724; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; STEVENSON RM, 1971, J BIOL CHEM, V246, P2127; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCUROVA I, 1989, J GEN MICROBIOL, V135, P3311; WEBER K, 1969, J BIOL CHEM, V244, P4406; YANG B, 1992, THESIS U MANITOBA	27	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4506	4512						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308020				2022-12-25	WOS:A1994MW98900092
J	ISHIHARA, H; ASANO, T; TSUKUDA, K; KATAGIRI, H; INUKAI, K; ANAI, M; KIKUCHI, M; YAZAKI, Y; MIYAZAKI, J; OKA, Y				ISHIHARA, H; ASANO, T; TSUKUDA, K; KATAGIRI, H; INUKAI, K; ANAI, M; KIKUCHI, M; YAZAKI, Y; MIYAZAKI, J; OKA, Y			OVEREXPRESSION OF HEXOKINASE-I BUT NOT GLUT1 GLUCOSE-TRANSPORTER ALTERS CONCENTRATION-DEPENDENCE OF GLUCOSE-STIMULATED INSULIN-SECRETION IN PANCREATIC BETA-CELL LINE MIN6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC HYPERGLYCEMIA; NONSENSE MUTATION; GLUCOKINASE GENE; TRANSGENIC MICE; RAT-BRAIN; EXPRESSION; METABOLISM; ISLETS; MOUSE; LIVER	The recently established pancreatic beta-cell line MIN6 retains the ability to secrete insulin in response to physiological glucose concentrations. To investigate the role of glucose transport and phosphorylation in glucose-stimulated insulin secretion by beta-cells, MIN6 cells were stably transfected with a rabbit GLUT1 glucose transporter cDNA or a rat hexokinase I cDNA cloned in an expression vector. Overexpression of GLUT1 increased 3-O-methylglucose uptake, but did not alter either glucose utilization or glucose-stimulated insulin secretion. In contrast, clones overexpressing hexokinase I exhibited enhanced glucose-stimulated insulin secretion at glucose concentrations below 10 mM with a concomitant increase in glucose utilization. Maximal insulin secretion as well as the maximal rate of glucose utilization were not altered in these clones. Insulin secretion stimulated by 2-ketoisocaproate, a non-glucose secretagogue, was not affected by hexokinase I expression. These results strongly suggest that the glucose phosphorylating step, but not glucose transport step, regulates glucose-stimulated insulin secretion by modulating the glycolytic rate in the beta-cell.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT DIS RELATED GENE REGULAT RES SANDOZ,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST ADULT DIS,SHINJUKU KU,TOKYO 160,JAPAN	University of Tokyo; Novartis; Sandoz; University of Tokyo; Asahi Life Foundation			Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X				ARORA KK, 1990, J BIOL CHEM, V265, P6481; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; GRIFFIN LD, 1992, BIOCHIM BIOPHYS ACTA, V1129, P309, DOI 10.1016/0167-4781(92)90508-W; HAMAGUCHI K, 1991, DIABETES, V40, P842, DOI 10.2337/diabetes.40.7.842; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KATAGIRI H, 1992, LANCET, V340, P1316, DOI 10.1016/0140-6736(92)92494-Z; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MORITA Y, 1992, BIOCHEM BIOPH RES CO, V188, P8, DOI 10.1016/0006-291X(92)92342-U; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; ORCI L, 1990, J CLIN INVEST, V86, P1615, DOI 10.1172/JCI114883; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; SALAS J, 1965, J BIOL CHEM, V240, P1014; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; TAL M, 1992, P NATL ACAD SCI USA, V89, P5744, DOI 10.1073/pnas.89.13.5744; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WHITESELL RR, 1991, BIOCHEMISTRY-US, V30, P11560, DOI 10.1021/bi00113a011; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	32	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3081	3087						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300643				2022-12-25	WOS:A1994MV43200103
J	LIU, J; MATHIAS, S; YANG, ZH; KOLESNICK, RN				LIU, J; MATHIAS, S; YANG, ZH; KOLESNICK, RN			RENATURATION AND TUMOR-NECROSIS-FACTOR-ALPHA STIMULATION OF A 97-KDA CERAMIDE-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SENSITIVE METHOD; CELLS; SPHINGOMYELINASE; PHOSPHORYLATION; DIFFERENTIATION; SPHINGOSINE; MECHANISM; PATHWAY	Recent investigations identified a new signal transduction pathway, termed the sphingomyelin pathway, which may mediate the action of tumor necrosis factor (TNF)alpha and interleukin-1beta (Mathias, S., Younes, A., Kan, C., Orlow, I., Joseph, C., and Kolesnick, R. N. (1993) Science 259, 519-522). This pathway is initiated by hydrolysis of sphingomyelin to ceramide by a neutral sphingomyelinase and stimulation of a ceramide-activated Ser/Thr protein kinase. Recent investigations demonstrated that kinase activity is proline-directed, recognizing substrates in which the phosphoacceptor site is followed by a proline residue. Until now, the kinase has been defined only as a membrane-bound activity capable of phosphorylating a peptide derived from the sequence surrounding Thr669 of the epidermal growth factor receptor. In the present studies, the kinase was quantitatively extracted from membrane with detergent and separated from protein kinase C by anion-exchange chromatography and isoelectric focusing. Ceramide-activated protein kinase was resolved as an exclusively membrane-bound, 97-kDa protein with a pI of 7.05. Kinase activity toward the epidermal growth factor receptor peptide co-purified with activity toward a generic proline-directed substrate, myelin basic protein. Kinase activity was reconstituted by a denaturation-renaturation procedure and demonstrated activity toward self (autophosphorylation) and exogenous substrate (myelin basic protein). Autophosphorylation occurred exclusively on serine residues. These activities were enhanced to 7-fold of control by ceramide and TNFalpha. These investigations provide additional evidence for a role for ceramide-activated protein kinase in signal transduction for TNFalpha.	MEM SLOAN KETTERING CANC CTR, SIGNAL TRANSDUCT LAB, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA-42385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIM MY, 1991, J BIOL CHEM, V266, P484; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Trautschold I., 1963, METHODS ENZYMATIC AN, P543; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997	24	205	213	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3047	3052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300638				2022-12-25	WOS:A1994MV43200098
J	SCHUMANN, MA; RAFFIN, TA				SCHUMANN, MA; RAFFIN, TA			ACTIVATION OF A VOLTAGE-DEPENDENT CHLORIDE CURRENT IN HUMAN NEUTROPHILS BY PHORBOL 12-MYRISTATE 13-ACETATE AND FORMYL-METHIONYL-LEUCYL-PHENYLALANINE - THE ROLE OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CALCIUM; MYRISTATE ACETATE; ION CHANNELS; CA-2+; CELLS; HETEROGENEITY; LYMPHOCYTES; CONDUCTANCE; EXOCYTOSIS; TRANSPORT	Calcium-activated, voltage-independent Cl- currents have been demonstrated in human neutrophils (Krause, K.-H., and Welsh, M. J. (1990) J. Clin. Invest. 85,491-498). The activation is mediated by calcium/calmodulin-dependent protein kinase and not by protein kinase C (PKC) (Schumann, M., Gardner, A. P., and Raffin, T. A. (1993) J. Biol. Chem. 268, 2134-2140). It is not known whether there are Ca2+-independent, voltage-dependent Cl- currents in these cells. Using K+-free solutions and patch-clamp recordings from human neutrophils, we separated the whole cell Cl- current. Base-line Cl- currents of unstimulated cells were small and displayed time and voltage independence; some showed voltage dependence. With a Ca2+-free pipette solution, bath-administered 1 muM phorbol 12-myristate 13-acetate (PMA) or 0.1 muM N-formyl-methionyl-leucyl-phenylalanine (fMLP) for 10 s induced augmented Cl- currents with voltage- and time-dependent outwardly rectifying properties. The threshold voltage of tail Cl- current activation was -69 mV. With a pipette solution containing 0.1 mm Ca2+, bath-administered 0.1 muM fMLP, 1 muM PMA, or 1 muM Ca2+ ionophore A23187 for 30 s induced augmented Cl- currents with voltage-independent properties. With intracellular application of 5 muM PKC inhibitor PKC(19-36), voltage-dependent Cl- currents were no longer activated by PMA or fMLP. Similar application of 5 muM PKC noninhibitory analog [Glu27]PKC(19-36) did not block PMA (or fMLP)-induced Cl- currents. These results indicate that, in addition to Ca2+-activated Cl- currents, human neutrophils have voltage-dependent Cl- currents which are regulated by PKC.	STANFORD UNIV,MED CTR,SCH MED,DIV PULM & CRIT CARE MED,STANFORD,CA 94305	Stanford University					NHLBI NIH HHS [HL455330] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLOCK ML, 1990, SCIENCE, V247, P1090, DOI 10.1126/science.2309122; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DAVIES EV, 1991, IMMUNOLOGY, V73, P228; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; DIVIRGILIO F, 1985, BIOCHEM J, V229, P361, DOI 10.1042/bj2290361; EGGLETON P, 1992, J LEUKOCYTE BIOL, V51, P617, DOI 10.1002/jlb.51.6.617; GAY JC, 1990, J LEUKOCYTE BIOL, V47, P49, DOI 10.1002/jlb.47.1.49; GRAY LS, 1986, J IMMUNOL, V136, P3032; GRINSTEIN S, 1989, PHYSIOL REV, V69, P417, DOI 10.1152/physrev.1989.69.2.417; GRINSTEIN S, 1992, AM J PHYSIOL, V263, pC78, DOI 10.1152/ajpcell.1992.263.1.C78; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELFMAN DM, 1983, BIOCHEM BIOPH RES CO, V111, P847, DOI 10.1016/0006-291X(83)91376-1; HOGG JC, 1987, PHYSIOL REV, V67, P1249, DOI 10.1152/physrev.1987.67.4.1249; HUANG CK, 1989, MEMBRANE BIOCHEM, V8, P61, DOI 10.3109/09687688909082261; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KORCHAK HM, 1984, J BIOL CHEM, V259, P4076; KORCHAK HM, 1980, P NATL ACAD SCI-BIOL, V77, P2721, DOI 10.1073/pnas.77.5.2721; KRAUSE KH, 1990, J CLIN INVEST, V85, P491, DOI 10.1172/JCI114464; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; LEW PD, 1990, AM REV RESPIR DIS, V141, P5127; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARKERT M, 1988, J LAB CLIN MED, V111, P577; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; MERRITT JE, 1993, BIOCHEM J, V289, P919, DOI 10.1042/bj2890919; MYERS JB, 1990, AM J PHYSIOL, V259, pC531, DOI 10.1152/ajpcell.1990.259.4.C531; NASMITH PE, 1987, J BIOL CHEM, V262, P13558; NISHIHIRA J, 1985, J IMMUNOL, V135, P3439; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ROSOFF PM, 1988, J BIOL CHEM, V263, P19535; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SCHUMANN MA, 1992, BIOCHEM BIOPH RES CO, V185, P531, DOI 10.1016/0006-291X(92)91657-C; SCHUMANN MA, 1993, J BIOL CHEM, V268, P2134; SCHWARZE W, 1984, PFLUG ARCH EUR J PHY, V402, P281, DOI 10.1007/BF00585511; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SIMCHOWITZ L, 1986, J GEN PHYSIOL, V88, P167, DOI 10.1085/jgp.88.2.167; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; SUZUKI Y, 1980, J CLIN INVEST, V66, P1409, DOI 10.1172/JCI109994; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0	46	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2389	2398						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300564				2022-12-25	WOS:A1994MV43200011
J	THOMPSON, SA; HIGASHIYAMA, S; WOOD, K; POLLITT, NS; DAMM, D; MCENROE, G; GARRICK, B; ASHTON, N; LAU, K; HANCOCK, N; KLAGSBRUN, M; ABRAHAM, JA				THOMPSON, SA; HIGASHIYAMA, S; WOOD, K; POLLITT, NS; DAMM, D; MCENROE, G; GARRICK, B; ASHTON, N; LAU, K; HANCOCK, N; KLAGSBRUN, M; ABRAHAM, JA			CHARACTERIZATION OF SEQUENCES WITHIN HEPARIN-BINDING EGF-LIKE GROWTH-FACTOR THAT MEDIATE INTERACTION WITH HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; FIBROBLAST GROWTH; ESCHERICHIA-COLI; FACTOR FAMILY; CELL-SURFACE; SULFATE; IDENTIFICATION; PROTEIN; CONSTRUCTION; EXPRESSION	Heparin-binding (HB) epidermal growth factor (EGF)-like growth factor (HB-EGF), a member of the EGF protein family, is a potent mitogen for fibroblasts, smooth muscle cells, and keratinocytes that was initially identified as a secreted product of macrophage-like cells. HB-EGF and EGF appear to act on target cells utilizing the same receptor, but HB-EGF is distinguishable from EGF by its strong affinity for heparin. To facilitate studies of structure-function relationships in HB-EGF, a bacterial recombinant expression system was established that produced biologically active HB-EGF with the expected disulfide bonding pattern. Mutagenesis and protease digestion studies of the recombinant HB-EGF, coupled with heparin-binding analyses of synthetic peptides, indicated that the sequences within HB-EGF mediating its interaction with heparin are located primarily in a stretch of 21 amino acids characterized by a high content of lysine and arginine residues. Most of this heparin-binding domain lies in an amino-terminal region of HB-EGF that has no counterpart in EGF, but a portion of the 21-residue sequence extends into the EGF-like region of HB-EGF. In addition, the mutagenesis and synthetic peptide studies indicated that sequences in HB-EGF lying outside of the 21-residue stretch can also influence the interaction with heparin. Finally, a synthetic peptide derived from the 21-residue stretch was found to compete with HB-EGF for binding to Chinese hamster ovary cells, suggesting that the heparin-binding sequences in HB-EGF may also mediate the interaction of this factor with cell surface heparan sulfate proteoglycan.	SCIOS NOVA INC, 2450 BAYSHORE PKWY, Mountain View, CA 94043 USA; CHILDRENS HOSP MED CTR, DEPT SURG RES, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Scios; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R44GM046166, R43GM046166, R01GM047397] Funding Source: NIH RePORTER; NCI NIH HHS [CA37392] Funding Source: Medline; NIGMS NIH HHS [GM46166-01, GM47397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BENNETT GN, 1978, J MOL BIOL, V121, P113, DOI 10.1016/S0022-2836(78)80001-1; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; Besner GE, 1992, GROWTH FACTORS, V7, P289, DOI 10.3109/08977199209046411; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLOSE TJ, 1982, GENE, V20, P305, DOI 10.1016/0378-1119(82)90048-8; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, IN VITRO CELL DEV-AN, V28A, P218; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KAMBER B, 1980, HELV CHIM ACTA, V63, P899, DOI 10.1002/hlca.19800630418; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MESRI EA, 1993, J BIOL CHEM, V268, P4853; Miller J. H., 1972, EXPT MOL GENETICS, P431; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAVAGE CR, 1973, J BIOL CHEM, V248, P7669; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHIPLEY GD, 1984, CANCER RES, V44, P710; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WINKLER ME, 1986, J BIOL CHEM, V261, P3838; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	47	145	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2541	2549						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300582				2022-12-25	WOS:A1994MV43200032
J	HONDA, Z; TAKANO, T; GOTOH, Y; NISHIDA, E; ITO, K; SHIMIZU, T				HONDA, Z; TAKANO, T; GOTOH, Y; NISHIDA, E; ITO, K; SHIMIZU, T			TRANSFECTED PLATELET-ACTIVATING-FACTOR RECEPTOR ACTIVATES MITOGEN-ACTIVATED PROTEIN (MAP) KINASE AND MAP KINASE KINASE IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA PC12 CELLS; SIGNAL TRANSDUCTION; TYROSINE KINASE; GENE-EXPRESSION; PHOSPHORYLATION; RAS; FIBROBLASTS; INSULIN; CASCADE	The platelet-activating factor (PAF) was seen to potently activate mitogen-activated protein (MAP) kinase and MAP kinase kinase through the cloned guinea pig PAF receptor stably expressed in Chinese hamster ovary (CHO) cells. Both 42- and 44-kDa MAP kinases were activated and tyrosine-phosphorylated in response to PAF. The PAF receptor also triggered the production of inositol phosphates and the release of arachidonic acid and inhibited cyclic AMP accumulation. Differential inhibitory effects of pertussis toxin (PTX) on these signals suggested that the PAF receptor couples to both PTX-sensitive and -insensitive G proteins in CHO cells. MAP kinase and MAP kinase kinase activations were partially regulated by PTX-sensitive G proteins. The PAF receptor did not trigger any detectable increase in the GTP form of Ras under the conditions in which the human insulin receptor expressed in the same parent CHO cells potently increased the level. Since these agonists induced comparable MAP kinase activations through cognate receptors, Ras seems to play different roles in MAP kinase activation by the two different classes of receptors. The activation of MAP kinase by the cloned PAF receptor may explain part of the mechanisms underlying PAF-induced differentiation and proliferation in non-inflammatory cells.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,7-3-1 BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,SAKYO KU,KYOTO 60601,JAPAN	University of Tokyo; University of Tokyo; Kyoto University								AHN NG, 1990, J BIOL CHEM, V265, P11495; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BATZER NL, 1993, NATURE, V363, P85; BEHRENS TW, 1990, INT J IMMUNOPHARMACO, V12, P175, DOI 10.1016/0192-0561(90)90051-N; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COBB MH, 1983, J BIOL CHEM, V258, P2472; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DHAR A, 1991, J BIOL CHEM, V266, P18797; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANAHAN DJ, 1987, ANN REV BIOCH, V55, P69; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HWANG SB, 1988, J BIOL CHEM, V263, P3225; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KORNECKI E, 1988, SCIENCE, V260, P315; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEPRINCE C, 1991, LIPIDS, V26, P1204, DOI 10.1007/BF02536532; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEQUINTO SP, 1989, J NEUROSCI RES, V24, P558; SETH A, 1991, J BIOL CHEM, V266, P23521; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SHIMIZU T, 1992, BIOCHEM PHARMACOL, V44, P1001; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SNYDER F, 1987, PLATELET ACTIVATING; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1991, J BIOL CHEM, V266, P24793; ULLRICH A, 1986, COLD SPRING HARB SYM, V51, P713, DOI 10.1101/SQB.1986.051.01.084; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	76	162	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2307	2315						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294489				2022-12-25	WOS:A1994MR98800112
J	LIU, YC; MATTHEWS, KS				LIU, YC; MATTHEWS, KS			TRP REPRESSOR MUTATIONS ALTER DNA COMPLEX STOICHIOMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; TRYPTOPHAN-SPECIFIC PERMEASE; GAMMA-DELTA RESOLVASE; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; OPERATOR DNA; BINDING; APOREPRESSOR; GENE; EXPRESSION	We have examined the interaction of a series of mutant trp repressors with various operator DNA sequences using gel retardation. Binding to 40 base pairs (bp) TrpEDCBA operator yielded patterns distinct from the wild-type protein for superrepressors EK13, EK18, and EK49, with a protein-DNA complex of higher stoichiometry (three dimers/operator) than observed for wild-type repressor (two dimers/operator). This higher stoichiometry complex may contribute to the enhanced binding affinity and higher protein-operator stability observed for the superrepressors. In contrast, DN46 displayed the same complexes characteristic of the wild-type protein, although the complex of a single dimer with operator was more prominent in the DN46 binding pattern than wild-type despite higher apparent affinity of this protein for TrpEDCBA operator than wild-type protein. The binding of AV77 was indistinguishable from the wild-type protein. Similar patterns to that found for TrpEDCBA were also observed for the 40-bp aroH operator and symmetrized derivatives of TrpEDCBA for these superrepressors. Binding of EK13, EK18, and EK49 superrepressors to half-site DNAs, composed of 20 bp of TrpEDCBA sequence coupled with 20 bp of lac operator sequence, yielded 2:1 complex as the primary product with no detectable 3:1 complex; thus, two half-sites appear to be required for generation of the 3:1 complex. Mutation in the tryptophan-binding site can also generate higher order complexes with TrpEDCBA DNA as demonstrated by the binding of VA58; the presence of 3:1 complex with this protein was also dependent on the presence of two half-sites. In addition to effects of sequence changes in the protein, the ligand employed can influence the binding pattern, as demonstrated for EK49 and VA58 using 5-methyl-tryptophan; the 3:1 complex is produced more prominently and at lower protein concentration for both mutants. It is apparent from these data that binding of the trp repressor to DNA is influenced by the operator sequence, the nature of the corepressor, as well as interactions (perhaps involving the N-terminal regions) that occur within and between the dimeric structure of this protein.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH CH, 1989, BIOCHEMISTRY-US, V28, P3875, DOI 10.1021/bi00435a037; ARVIDSON DN, 1991, GENETICS, V128, P29; ARVIDSON DN, 1993, J BIOL CHEM, V268, P4362; ARVIDSON DN, 1986, J BIOL CHEM, V261, P238; BASS S, 1987, GENE DEV, V1, P565, DOI 10.1101/gad.1.6.565; BENHAR I, 1993, CELL, V72, P121, DOI 10.1016/0092-8674(93)90056-V; BENHAR I, 1992, MOL MICROBIOL, V6, P2777, DOI 10.1111/j.1365-2958.1992.tb01457.x; BENNETT GN, 1978, J MOL BIOL, V121, P179, DOI 10.1016/S0022-2836(78)80004-7; CAREY J, 1989, J BIOL CHEM, V264, P1941; CAREY J, 1991, J BIOL CHEM, V266, P24509; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; FERNANDO T, 1992, BIOCHEMISTRY-US, V31, P3429, DOI 10.1021/bi00128a018; GRADDIS TJ, 1988, PROTEINS, V4, P173, DOI 10.1002/prot.340040304; GROVE CL, 1987, J BACTERIOL, V169, P2158, DOI 10.1128/jb.169.5.2158-2164.1987; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HE JJ, 1990, J BIOL CHEM, V265, P731; HEATWOLE VM, 1991, J BACTERIOL, V173, P3601, DOI 10.1128/jb.173.11.3601-3604.1991; HEATWOLE VM, 1992, J BACTERIOL, V174, P331, DOI 10.1128/jb.174.1.331-335.1992; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; HURLBURT BK, 1992, NUCLEIC ACIDS RES, V20, P337, DOI 10.1093/nar/20.2.337; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KLIG LS, 1988, J BIOL CHEM, V263, P243; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LEPECQ JB, 1966, ANAL BIOCHEM, V17, P100, DOI 10.1016/0003-2697(66)90012-1; LIU YC, 1993, J BIOL CHEM, V268, P23239; LIU YC, 1991, THESIS RICE U HOUSTO; Maniatis T., 1982, MOL CLONING; MARMORSTEIN RQ, 1991, BIOCHEMISTRY-US, V30, P1141, DOI 10.1021/bi00218a036; MARMORSTEIN RQ, 1987, J BIOL CHEM, V262, P4922; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; Sambrook J., 1989, MOL CLONING; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SUTTON CL, 1993, BIOCHEMISTRY-US, V32, P4225, DOI 10.1021/bi00067a009; WICK KL, 1991, J BIOL CHEM, V266, P6106; YANG WP, 1993, P NATL ACAD SCI USA, V90, P5796, DOI 10.1073/pnas.90.12.5796; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	44	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1692	1698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294416				2022-12-25	WOS:A1994MR98800026
J	LU, Q; LUDUENA, RF				LU, Q; LUDUENA, RF			IN-VITRO ANALYSIS OF MICROTUBULE ASSEMBLY OF ISOTYPICALLY PURE TUBULIN DIMERS - INTRINSIC DIFFERENCES IN THE ASSEMBLY PROPERTIES OF ALPHA-BETA-II, ALPHA-BETA-III, AND ALPHA-BETA-IV TUBULIN DIMERS IN THE ABSENCE OF MICROTUBULE-ASSOCIATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BRAIN TUBULIN; BOVINE BRAIN; COLCHICINE BINDING; MASS-SPECTROMETRY; PORCINE BRAIN; ISOTYPE; CHLAMYDOMONAS; PURIFICATION; EXPRESSION	Microtubule assembly of different beta tubulin isotypes in the presence of 4 m glycerol and 6 mm magnesium ion demonstrates significantly different characteristics. alphabetaII and alphabetaIV assembled faster and to a greater extent than did unfractionated phosphocellulose-purified tubulin (PC-tubulin). Microtubule assembly from alphabetaIII showed a distinctive delay in nucleation, proceeded at a slower rate than those of the other beta tubulin isotypes, and had the highest critical concentration. However, treatment of beta tubulin isotypes with subtilisin to remove the C-terminal domain of the tubulin dimer abolished these differences in microtubule assembly pattern and enhanced self-assembly. The kinetic analysis of microtubule elongation of different beta tubulin isotypes also showed significant differences. Elongation of alphabetaIII from microtubule seeds had a lower apparent K(alpha) and a lower apparent K(d) than did alphabetaII and alphabetaIV. The dynamic behaviors of different beta tubulin isotypes were qualitatively similar to each other and fit the dynamic instability model. However, microtubules formed from alphabetaIII appeared to be less dynamic than microtubules formed from other beta tubulin isotypes. Our results suggest that the betaIII isotype might have a different conformation than do the other beta tubulin isotypes. The distinctive nucleation and elongation behaviors of the alphabetaIII dimers demonstrated in vitro may have a significant influence on microtubule functions in vivo.			LU, Q (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NCI NIH HHS [CA26376] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIZAWA H, 1989, J BIOL CHEM, V264, P5885; ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; ALLEN C, 1974, J MOL BIOL, V90, P381, DOI 10.1016/0022-2836(74)90381-7; Avila J, 1990, MICROTUBULE PROTEINS, V1st; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BANERJEE A, 1992, J BIOL CHEM, V267, P13335; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BARRA HS, 1974, BIOCHEM BIOPH RES CO, V60, P1384, DOI 10.1016/0006-291X(74)90351-9; BINDER LI, 1975, P NATL ACAD SCI USA, V72, P1122, DOI 10.1073/pnas.72.3.1122; Dustin P., 1984, MICROTUBULES; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; HAVERCROFT JC, 1984, J CELL BIOL, V99, P1927, DOI 10.1083/jcb.99.6.1927; HERZOG W, 1977, P NATL ACAD SCI USA, V74, P1860, DOI 10.1073/pnas.74.5.1860; HIMES RH, 1976, P NATL ACAD SCI USA, V73, P4397, DOI 10.1073/pnas.73.12.4397; JOHNSON KA, 1977, J MOL BIOL, V117, P1, DOI 10.1016/0022-2836(77)90020-1; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; KRISTOFFERSON D, 1986, J CELL BIOL, V102, P1007, DOI 10.1083/jcb.102.3.1007; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; LOBERT S, 1992, ARCH BIOCHEM BIOPHYS, V296, P152, DOI 10.1016/0003-9861(92)90557-D; LOBERT S, 1993, CELL MOTIL CYTOSKEL, V25, P285; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU Q, 1991, Journal of Cell Biology, V115, p38A; LU Q, 1992, MOL BIOL CELL, V3, pA168; LUDUENA RF, 1982, BIOCHEMISTRY-US, V21, P4787, DOI 10.1021/bi00262a041; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MONTEIRO MJ, 1988, J MOL BIOL, V199, P439, DOI 10.1016/0022-2836(88)90616-X; PEYROT V, 1900, ARCH BICOH BIOPHYS, V279, P328; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; RAYBIN D, 1975, BIOCHEM BIOPH RES CO, V65, P1088, DOI 10.1016/S0006-291X(75)80497-9; ROTHWELL SW, 1986, J CELL BIOL, V102, P619, DOI 10.1083/jcb.102.2.619; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SERRANO L, 1985, EUR J BIOCHEM, V153, P595, DOI 10.1111/j.1432-1033.1985.tb09342.x; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; ZHU NZ, 1992, MOL BIOL CELL, V3, pA50	43	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2041	2047						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294455				2022-12-25	WOS:A1994MR98800075
J	MIKI, T; MIKI, M; ORII, Y				MIKI, T; MIKI, M; ORII, Y			MEMBRANE POTENTIAL-LINKED REVERSED ELECTRON-TRANSFER IN THE BEEF-HEART CYTOCHROME-BC(1) COMPLEX RECONSTITUTED INTO POTASSIUM-LOADED PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS PROTON TRANSLOCATION; RESPIRATORY-CHAIN; C REDUCTASE; Q-CYCLE; UBIQUINOL; OXIDASE; OXIDOREDUCTASE; MITOCHONDRIA; DICYCLOHEXYLCARBODIIMIDE; ORGANIZATION	The cytochrome bc1 complex purified from beef heart mitochondria was incorporated into potassium (K+)-loaded phospholipid vesicles by a cholate dialysis method to study the reverse reaction of electron transfer in the complex. The reduction of cytochrome b in the presence of sodium ascorbate was observed on addition of valinomycin to the K+-loaded proteoliposomes in a medium containing no external KCl; it was followed by the gradual oxidation. Nigericin accelerated the reoxidation of reduced cytochrome b, indicating that a K+ diffusion potential (negative inside) induced the reduction of cytochrome b. The extent of the cytochrome b reduction depended on the magnitude of the diffusion potential across the liposomal membranes, and its maximal reduction was attained at more than 210 mV of the diffusion potential. It was cytochrome b562 that was reduced during the establishment of the K+ diffusion potential in the presence of ascorbate, and about 90% of cytochrome b562 was estimated to be reduced. Antimycin A and myxothiazol inhibited the diffusion potential-induced reduction of cytochrome b562, and ubiquinone was proved to be essential for the reversed electron transfer. The K+ diffusion potential also induced the partial reduction of cytochrome b566 when cytochrome b562 had previously been reduced with ascorbate plus tetramethyl-p-phenylenediamine. These results were interpreted well based on the Q cycle scheme which assumed the energy-dependent reduction of ubiquinone at center o. Dicyclohexylcarbodiimide, which did not perturb the ability of proteoliposomes to generate the K+ diffusion potential, inhibited the energy-dependent reduction of cytochrome b562 without a significant loss in the catalytic activity of the complex. The half-inhibition was brought about by 200, mol of dicyclohexylcarbodiimide/mol of cytochrome c1. These results strongly suggest the coupling of a proton flow with the reversed electron transfer in the bc1 complex.	KYOTO UNIV,FAC MED,DEPT PUBL HLTH,YOSHIDAKONOE CHO,SAKYO KU,KYOTO 606,JAPAN; KINKI UNIV,FAC MED,DEPT HYG,SAYAMA,OSAKA 589,JAPAN	Kyoto University; Kindai University (Kinki University)								BEATTIE DS, 1982, J BIOL CHEM, V257, P14746; BRASSEUR R, 1988, J BIOL CHEM, V263, P12571; CASEY RP, 1979, BIOCHEM BIOPH RES CO, V87, P1044, DOI 10.1016/S0006-291X(79)80013-3; CATTELL KJ, 1971, BIOCHEM J, V125, P169, DOI 10.1042/bj1250169; DRACHEV LA, 1989, BIOCHIM BIOPHYS ACTA, V973, P189, DOI 10.1016/S0005-2728(89)80421-9; ESPOSTI MD, 1983, BIOCHIM BIOPHYS ACTA, V725, P349, DOI 10.1016/0005-2728(83)90209-8; FLATMARK T, 1973, BIOCHIM BIOPHYS ACTA, V325, P16, DOI 10.1016/0005-2728(73)90146-1; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; GOPHER A, 1980, J BIOENERG BIOMEMBR, V12, P349, DOI 10.1007/BF00748764; GUTWENIGER H, 1977, BIOCHIM BIOPHYS ACTA, V459, P216, DOI 10.1016/0005-2728(77)90023-8; HINKLE PC, 1967, J BIOL CHEM, V242, P5169; KONSTANTINOV AA, 1990, BIOCHIM BIOPHYS ACTA, V1018, P138, DOI 10.1016/0005-2728(90)90234-U; KONSTANTINOV AA, 1981, CHEMIOSMOTIC PROTON, P123; LEUNG KH, 1975, J BIOL CHEM, V250, P8467; LOWRY OH, 1951, J BIOL CHEM, V262, P8677; MIKI T, 1987, J BIOCHEM-TOKYO, V102, P199, DOI 10.1093/oxfordjournals.jbchem.a122033; MIKI T, 1986, J BIOCHEM-TOKYO, V100, P735, DOI 10.1093/oxfordjournals.jbchem.a121766; MIKI T, 1986, J BIOL CHEM, V261, P3915; MIKI T, 1990, BIOCHEMISTRY-US, V30, P230; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; Nelson B D, 1978, Methods Enzymol, V53, P80; OHNISHI T, 1989, J BIOL CHEM, V264, P735; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; RIESKE JS, 1971, ARCH BIOCHEM BIOPHYS, V145, P179, DOI 10.1016/0003-9861(71)90025-7; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SATO N, 1971, BIOCHIM BIOPHYS ACTA, V253, P88, DOI 10.1016/0005-2728(71)90236-2; SEMENOV AY, 1993, FEBS LETT, V321, P1, DOI 10.1016/0014-5793(93)80608-W; Slater E C, 1970, Nature, V226, P1248, DOI 10.1038/2261248a0; SLATER EC, 1973, OXIDASE RELATED REDO, V2, P823; SONE N, 1977, J BIOCHEM-TOKYO, V81, P519, DOI 10.1093/oxfordjournals.jbchem.a131485; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; TSAI AL, 1987, J BIOL CHEM, V262, P8677; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; WANG YD, 1991, ARCH BIOCHEM BIOPHYS, V291, P363, DOI 10.1016/0003-9861(91)90147-B; WIKSTROM MK, 1973, BIOCHIM BIOPHYS ACTA, V301, P155; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1980, BIOCHEMISTRY-US, V19, P5715, DOI 10.1021/bi00566a008	38	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1827	1833						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294431				2022-12-25	WOS:A1994MR98800044
J	HAINAUT, P; HALL, A; MILNER, J				HAINAUT, P; HALL, A; MILNER, J			ANALYSIS OF P53 QUATERNARY STRUCTURE IN RELATION TO SEQUENCE-SPECIFIC DNA-BINDING	ONCOGENE			English	Article							TUMOR SUPPRESSOR PROTEIN; WILD-TYPE; MUTANT P53; CELL-CYCLE; GENE-EXPRESSION; CONFORMATION; FORMS; TRANSFORMATION; TRANSCRIPTION; PROLIFERATION	Quaternary interactions of p53 influence its tertiary structure which, in turn, is critical for sequence-specific DNA binding and tumour suppressor function. Given its regulatory potential we have sought to define the quaternary structure of p53 involved in sequence-specific DNA binding. Double stranded DNA [5'-GGACATGCCCG GGCATGTCC-3'; Funk et al. (1992) Mol. Cell. Biol., 12, 2866-2871] was used to test p53 binding capacity in vitro. The p53 protein was translated in vitro and size fractionated prior to the DNA binding reaction. Two independent DNA binding assays were employed. The first detected electromobility shift of P-32-labelled DNA and was carried out in the presence of PAb421, which stabilises and supershifts p53-DNA complexes. The second detected S-35-labelled p53 bound to biotinylated target DNA in the absence of PAb421. Sequence-specific DNA binding was found to be a property of full length, oligomeric p53. Greatest binding activity involved tetramers and/or higher molecular weight forms of p53, minimal binding was observed for dimers. This size profile was unaffected by PAb421 and it therefore seems unlikely that PAb421 dissociates high molecular weight forms of p53 into dimers. We conclude that high molecular weight forms of p53 are the most effective structures for sequence-specific DNA binding in vitro; these structures may represent tetramers and/or heterogeneous complexes of p53 with other proteins.	UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK			Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P1266; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALAZONETIS TD, 1993, EMBO J, V12, P1221; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MEDCALF EA, 1993, IN PRESS ONCOGENE; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIVAS CI, 1992, BLOOD, V79, P1982; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TRUANT R, 1993, J BIOL CHEM, V268, P2284; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1992, ONCOGENE, V7, P1039	48	41	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					299	303						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302593				2022-12-25	WOS:A1994MW24700036
J	BETZEL, C; SINGH, TP; VISANJI, M; PETERS, K; FITTKAU, S; SAENGER, W; WILSON, KS				BETZEL, C; SINGH, TP; VISANJI, M; PETERS, K; FITTKAU, S; SAENGER, W; WILSON, KS			STRUCTURE OF THE COMPLEX OF PROTEINASE-K WITH A SUBSTRATE-ANALOG HEXAPEPTIDE INHIBITOR AT 2.2-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY; 3-DIMENSIONAL STRUCTURE; CHLOROMETHYL KETONE; ACTIVE-SITE; SUBTILISIN; TRYPSIN; REFINEMENT; MECHANISM; GEOMETRY	The crystal structure of a transition state/product complex formed by the interaction between proteinase K and the substrate analogue N-Ac-L-Pro-L-Ala-L-Pro-L-Phe-D-Ala-L-Ala-NH2 has been determined at a resolution of 2.2 angstrom and refined to an R-factor of 0.165 for 12,725 reflections. The inhibitor forms a stable complex through a series of hydrogen bonds with protein atoms and water molecules. The inhibitor is hydrolyzed between Phe4I and D-Ala5I (I indicates inhibitor). The two fragments are separated by a distance of 3.07 angstrom between the carbonyl carbon and the main chain nitrogen. Both fragments remain bound to the protein. The N-terminal fragment occupies subsites S5 to S1, whereas the C-terminal part is bound in S1' and S2', the first time that electron density for a substrate analogue has been observed in the P1' and P2' sites of a subtilisin-like enzyme. The flexible segments of the substrate recognition sites Gly100-Tyr104 and Ser132-Gly136 move appreciably to accommodate the inhibitor. Biochemical results indicate an inhibition by this specifically designed peptide of 95%.	ALL INDIA INST MED SCI,DEPT BIOPHYS,NEW DELHI 110029,INDIA; MARTIN LUTHER UNIV HALLE WITTENBERG,INST PHYSIOL CHEM,O-4020 HALLE,GERMANY; FREE UNIV BERLIN,INST KRISTALLOG,W-1000 BERLIN 33,GERMANY	All India Institute of Medical Sciences (AIIMS) New Delhi; Martin Luther University Halle Wittenberg; Free University of Berlin	BETZEL, C (corresponding author), DESY,EUROPEAN MOLEC BIOL LAB,NOTKESTR 85,W-2000 HAMBURG 52,GERMANY.		Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019; Wilson, Keith/0000-0002-3581-2194				ARGAWAL RC, 1978, ACTA CRYSTALLOGR A, V34, P791; BAUER CA, 1976, BIOCHIM BIOPHYS ACTA, V438, P495, DOI 10.1016/0005-2744(76)90265-5; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BETZEL C, 1986, FEBS LETT, V197, P105, DOI 10.1016/0014-5793(86)80307-6; BETZEL C, 1988, PROTEINS, V4, P157, DOI 10.1002/prot.340040302; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; BROMME D, 1986, ARCH BIOCHEM BIOPHYS, V244, P439, DOI 10.1016/0003-9861(86)90611-9; DRENTH J, 1972, EUR J BIOCHEM, V26, P177, DOI 10.1111/j.1432-1033.1972.tb01754.x; HENDRICKSON WA, 1981, INT S BIOMOLECULAR S, P43; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; JONES TA, 1983, COMPUTATIONAL CRYSTA, P303; KOSSIAKOFF AA, 1980, NATURE, V288, P414, DOI 10.1038/288414a0; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MACHIN PA, 1983, DARESBURY LABORATORY, V10, P3; MOULT J, 1985, J MOL BIOL, V182, P555, DOI 10.1016/0022-2836(85)90241-4; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; SCHLECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157; THOMPSON RC, 1973, BIOCHEMISTRY-US, V12, P57, DOI 10.1021/bi00725a011; WOLF WM, 1991, J BIOL CHEM, V266, P17695; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0	23	44	44	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15854	15858						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340410				2022-12-25	WOS:A1993LN30500077
J	HOCKENSMITH, JW; KUBASEK, WL; VORACHEK, WR; VONHIPPEL, PH				HOCKENSMITH, JW; KUBASEK, WL; VORACHEK, WR; VONHIPPEL, PH			LASER CROSS-LINKING OF PROTEINS TO NUCLEIC-ACIDS .1. EXAMINING PHYSICAL PARAMETERS OF PROTEIN-NUCLEIC ACID COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; BACTERIOPHAGE T4-GENE 32-PROTEIN; DNA-REPLICATION SYSTEM; GENE 32 PROTEIN; PHOTOCHEMICAL ADDITION; AMINO-ACIDS; DEOXYRIBONUCLEIC-ACID; MELTING PROTEINS; BINDING-PROTEIN; TRANSCRIPTION	Pulsed laser cross-linking results in efficient and rapid formation of covalent bonds between proteins and the nucleic acids to which they are bound, creating a ''snapshot'' of the protein-nucleic acid equilibrium existing at the moment of irradiation. The ''frozen'' equilibrium allows the determination of protein-nucleic acid binding constants, confirming both theoretical predictions and experimental determinations by standard physical chemical methods. Laser cross-linking results accurately reflect the alteration of protein-nucleic acid interactions induced by traditional methods such as increasing the salt concentration or by the addition of a nucleic acid that competes for binding of the protein. Thus this technique is very useful for the study of the association of proteins and protein complexes with nucleic acids under environmental conditions at which the reactions are not amenable to study by traditional physical chemical methods. In this paper we continue our calibration of the method, focusing primarily on interactions with single-stranded DNA-binding proteins and describe techniques for measuring quantitative interactions between nucleic acid constructs and single-protein or multiprotein complexes. Laser cross-linking can also provide direct evidence that binding correlates with functional activity.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon; University of Oregon; University of Oregon	HOCKENSMITH, JW (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,BOX 440,CHARLOTTESVILLE,VA 22908, USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015792, T32GM007759, R01GM029158, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792, GM-07759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BITTNER M, 1979, J BIOL CHEM, V254, P9565; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; DIZDAROGLU M, 1985, INT J RADIAT BIOL, V47, P63, DOI 10.1080/09553008514550091; DOLEJSI MK, 1988, THESIS U OREGON; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; FLORY J, 1982, CELL, V28, P747, DOI 10.1016/0092-8674(82)90054-X; FODOR SPA, 1986, J RAMAN SPECTROSC, V17, P471, DOI 10.1002/jrs.1250170609; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15721; HUANG WM, 1972, J BIOL CHEM, V247, P3139; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P5346, DOI 10.1021/bi00521a040; KUBASEK WL, 1993, IN PRESS PHOTOCHEM P; Maxam A M, 1980, Methods Enzymol, V65, P499; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MESNER LD, 1992, P NATL ACAD SCI USA, V89, P2521, DOI 10.1073/pnas.89.7.2521; MOROWITZ HJ, 1950, SCIENCE, V111, P229; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NIKOGOSYAN DN, 1990, INT J RADIAT BIOL, V57, P233, DOI 10.1080/09553009014552411; NOSSAL NG, 1974, J BIOL CHEM, V249, P5668; REEVE AE, 1980, PHOTOCHEM PHOTOBIOL, V31, P297, DOI 10.1111/j.1751-1097.1980.tb02544.x; REEVE AE, 1980, PHOTOCHEM PHOTOBIOL, V31, P413, DOI 10.1111/j.1751-1097.1980.tb02561.x; SCHOTT HN, 1974, BIOCHEM BIOPH RES CO, V59, P1112, DOI 10.1016/S0006-291X(74)80093-8; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SETLOW P, 1972, J BIOL CHEM, V247, P232; SHETLAR MD, 1984, PHOTOCHEM PHOTOBIOL, V39, P135, DOI 10.1111/j.1751-1097.1984.tb03418.x; SHETLAR MD, 1984, PHOTOCHEM PHOTOBIOL, V39, P125, DOI 10.1111/j.1751-1097.1984.tb03417.x; SHETLAR MD, 1984, PHOTOCHEM PHOTOBIOL, V39, P141, DOI 10.1111/j.1751-1097.1984.tb03419.x; SMITH KC, 1969, BIOCHEM BIOPH RES CO, V34, P354, DOI 10.1016/0006-291X(69)90840-7; SMITH KC, 1968, BIOCHEMISTRY-US, V7, P1033, DOI 10.1021/bi00843a023; WAHL AF, 1983, J BACTERIOL, V155, P922, DOI 10.1128/JB.155.2.922-925.1983	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15712	15720						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340395				2022-12-25	WOS:A1993LN30500059
J	AGRWAL, N; SUN, Q; WANG, SY; WANG, JL				AGRWAL, N; SUN, Q; WANG, SY; WANG, JL			CARBOHYDRATE-BINDING PROTEIN-35 .1. PROPERTIES OF THE RECOMBINANT POLYPEPTIDE AND THE INDIVIDUALITY OF THE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDOGENOUS LECTINS; CULTURED-CELLS; MOLECULAR-CLONING; 3T3 FIBROBLASTS; MAC-2 ANTIGEN; IGE; GALACTOSE; IDENTIFICATION; LOCALIZATION	The cDNA clone for carbohydrate-binding protein 35 (CBP35) was engineered into the bacterial expression vector pIN III ompA2, which directs the secretion of the expressed protein into the periplasmic space. Recombinant CBP35 was purified from this system, at a level of approximately 50 mg/liter of bacterial culture. Digestion of recombinant CBP35 with collagenase D, followed by purification using saccharide-specific affinity chromatography yielded a M(r) approximately 16,000 polypeptide, corresponding to the COOH-terminal domain (residues 118-264) of the CBP35 polypeptide. This indicates that the COOH-terminal half of CBP35 contains the carbohydrate recognition domain, consistent with its sequence homology to other S-type lectins. The NH2-terminal domain (residues 1-137) was derived by site-directed mutagenesis of the cDNA, in which stop codons are inserted in place of Gly138 and Gly139, and expression of the mutant cDNA in the same pIN III ompA2 system. The purified NH2-terminal domain failed to bind to saccharide-specific affinity resins. Differential scanning calorimetry of rCBP35 and its individual domains yielded transition temperatures of approximately 39 and approximately 56-degrees-C for the NH2- and COOH-terminal domains, respectively. Lactose binding by the COOH-terminal domain shifted the transition temperature to 65-degrees-C, whereas sucrose failed to yield the same effect. These results suggest that the individual domains of the CBP35 polypeptide are folded independently.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM-38740, GM-27203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRWAL N, 1989, J BIOL CHEM, V264, P17236; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; Bjerrum O. J., 1986, ANAL ELECTROPHORESIS; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CRITTENDEN SL, 1984, MOL CELL BIOL, V4, P1252, DOI 10.1128/MCB.4.7.1252; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EDGE V, 1985, BIOCHEMISTRY-US, V24, P5899, DOI 10.1021/bi00342a032; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HO MK, 1982, J IMMUNOL, V128, P1221; HSU DK, 1992, J BIOL CHEM, V267, P14167; JIA SH, 1988, J BIOL CHEM, V263, P6009; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; MANLY SP, 1985, BIOCHEMISTRY-US, V24, P3842, DOI 10.1021/bi00336a004; MILLER EJ, 1971, BIOCHEMISTRY-US, V10, P1652, DOI 10.1021/bi00785a024; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; ODA Y, 1991, GENE, V99, P279; RAZ A, 1991, CANCER RES, V51, P2173; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROFF CF, 1983, J BIOL CHEM, V258, P657; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; TAKAGI H, 1988, BIO-TECHNOL, V6, P948, DOI 10.1038/nbt0888-948; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VILLAR E, 1985, J BIOL CHEM, V260, P2245; WANG J L, 1991, Glycobiology, V1, P243, DOI 10.1093/glycob/1.3.243; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V276, P510, DOI 10.1016/0003-9861(90)90752-K; WRAY W, 1981, ANAL BIOCHEM, V48, P617	37	106	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14932	14939						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325870				2022-12-25	WOS:A1993LL75900061
J	RADOMINSKA, A; LITTLE, J; PYREK, JS; DRAKE, RR; IGARI, Y; FOURNELGIGLEUX, S; MAGDALOU, J; BURCHELL, B; ELBEIN, AD; SIEST, G; LESTER, R				RADOMINSKA, A; LITTLE, J; PYREK, JS; DRAKE, RR; IGARI, Y; FOURNELGIGLEUX, S; MAGDALOU, J; BURCHELL, B; ELBEIN, AD; SIEST, G; LESTER, R			A NOVEL UDP-GLC-SPECIFIC GLUCOSYLTRANSFERASE CATALYZING THE BIOSYNTHESIS OF 6-O-GLUCOSIDES OF BILE-ACIDS IN HUMAN LIVER-MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN LENGTH; RAT-LIVER; HYODEOXYCHOLIC-ACID; DOLICHYL PHOSPHOGLUCOSE; GLUCURONOSYLTRANSFERASE; GLUCURONIDATION; BILIRUBIN; GLUCURONYLTRANSFERASE; EXPRESSION; PURIFICATION	Two active site-directed photoaffinity analogs, 5-[beta-P-32]azido-UDP-glucuronic acid and 5-[beta-P-32]azido-UDP-glucose, were used for the characterization of UDP-sugar-utilizing enzymes in human liver microsomes. Both compounds were recognized by human microsomal proteins: major photolabeled bands of 50-56 kDa were detected. Both photoincorporations were competitively decreased by increasing concentrations of either UDP-Glc or UDP-GlcUA, indicating a high affinity for both nucleotides. The patterns of photoaffinity labeling in the 50-56-kDa range by the two probes were significantly different, indicating the presence of different UDP-GlcUA- and UDP-Glc-specific enzymes of similar molecular mass. The presence of a UDP-Glc-dependent transferase was confirmed by the identification of an enzymatic activity catalyzing the formation of glucosides of the 6alpha-hydroxylated bile acid hyodeoxycholic acid (3alpha,6alpha-diOH (HDCA)) in the presence of UDP-Glc. The specific activity of 1.5-3.2 nmol/min/mg of protein was similar to that of 6alpha-glucuronidation of HDCA. The apparent K(m) for UDP-Glc estimated with HDCA was 280 muM, and the formation of HDCA glucosides was strongly inhibited by UDP-GlcUA (apparent K(i) = 7 muM). Evidence is presented that HDCA-specific UDP-glucuronosyltransferase clone UGT2B4) expressed in V79 cells is not involved in glucosidation of HDCA and is not photolabeled with 5-[beta-P-32]azido-UDP-Glc. Rigorous structure identification of the biosynthetic product proved that HDCA was glucosidated at the 6-position. Thus, this UDP-Glc-dependent activity catalyzing the biosynthesis of 6-O-glucosides of 6alpha-hydroxylated bile acids represents a new pathway in the metabolism of these bile acids.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; UNIV KENTUCKY,COLL PHARM,LEXINGTON,KY 40536; CTR MED,F-54000 NANCY,FRANCE; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT BIOCHEM MED,DUNDEE DD1 9SY,SCOTLAND	University of Arkansas System; University of Arkansas Medical Sciences; University of Kentucky; University of Dundee	RADOMINSKA, A (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT INTERNAL MED,DIV GASTROENTEROL,4301 W MARKHAM,SLOT 567-1,LITTLE ROCK,AR 72205, USA.			SIEST, Gerard/0000-0002-3001-760X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014198] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038678] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-08238] Funding Source: Medline; NICHD NIH HHS [HD-14198] Funding Source: Medline; NIDDK NIH HHS [DK-38678] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACK P, 1976, H-S Z PHYSIOL CHEM, V357, P213, DOI 10.1515/bchm2.1976.357.1.213; BANERJEE DK, 1989, J BIOL CHEM, V264, P2024; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BARNES S, 1989, J LIPID RES, V30, P529; BURCHELL B, 1984, BIOCHEM J, V223, P461, DOI 10.1042/bj2230461; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; DRAKE RR, 1992, J BIOL CHEM, V267, P11360; DRAKE RR, 1991, J BIOL CHEM, V266, P23257; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; Dutton G.F., 1980, GLUCURONIDATION DRUG; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FEVERY J, 1971, BIOCHEM J, V125, P803, DOI 10.1042/bj1250803; FOURNELGIGLEUX S, 1991, MOL PHARMACOL, V39, P177; FOURNELGIGLEUX S, 1989, FEBS LETT, V243, P119, DOI 10.1016/0014-5793(89)80111-5; GESSNER T, 1973, BIOCHEM J, V132, P249, DOI 10.1042/bj1320249; IRSHAID YM, 1987, MOL PHARMACOL, V31, P27; JACKSON MR, 1987, BIOCHEM J, V242, P581, DOI 10.1042/bj2420581; JOHNSON MR, 1991, J BIOL CHEM, V266, P10227; KIRKPATRICK RB, 1984, J BIOL CHEM, V259, P6179; LABOW RS, 1972, BIOCHEM J, V128, P491, DOI 10.1042/bj1280491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAGDALOU J, 1982, J BIOL CHEM, V257, P13624; MARSCHALL HU, 1987, BIOCHIM BIOPHYS ACTA, V921, P392, DOI 10.1016/0005-2760(87)90041-5; MARSCHALL HU, 1987, FEBS LETT, V213, P411, DOI 10.1016/0014-5793(87)81532-6; MATERN H, 1989, BIOCHIM BIOPHYS ACTA, V1004, P67, DOI 10.1016/0005-2760(89)90214-2; MATERN H, 1987, BIOCHIM BIOPHYS ACTA, V921, P1, DOI 10.1016/0005-2760(87)90163-9; MATERN H, 1991, EUR J BIOCHEM, V200, P393, DOI 10.1111/j.1432-1033.1991.tb16197.x; MATERN H, 1984, P NATL ACAD SCI-BIOL, V81, P7036, DOI 10.1073/pnas.81.22.7036; MATERN H, 1982, J BIOL CHEM, V257, P7422; PALMER RH, 1967, P NATL ACAD SCI USA, V58, P1047, DOI 10.1073/pnas.58.3.1047; PARQUET M, 1988, EUR J BIOCHEM, V171, P329, DOI 10.1111/j.1432-1033.1988.tb13794.x; RADOMINSKA A, 1988, J LIPID RES, V29, P501; RADOMINSKA A, 1990, BIOCHEM J, V272, P597, DOI 10.1042/bj2720597; RADOMINSKAPYREK A, 1987, J CLIN INVEST, V80, P234, DOI 10.1172/JCI113053; RADOMINSKAPYREK A, 1986, J LIPID RES, V27, P89; RADOMINSKAPYREK A, 1986, J LIPID RES, V27, P102; RITTER JK, 1990, J BIOL CHEM, V265, P7900; Rothstein A, 1980, Ann N Y Acad Sci, V358, P1, DOI 10.1111/j.1749-6632.1980.tb15381.x; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANSTAPEL F, 1988, ARCH BIOCHEM BIOPHYS, V263, P216, DOI 10.1016/0003-9861(88)90630-3; VANSTAPEL F, 1987, J BIOL CHEM, V262, P4616; WONG KP, 1971, BIOCHEM J, V125, P929, DOI 10.1042/bj1250929a; ZIMNIAK P, 1988, J LIPID RES, V29, P183; ZOCCOLI MA, 1982, J BIOL CHEM, V257, P3919	47	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15127	15135						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325887				2022-12-25	WOS:A1993LL75900085
J	SALVUCCI, ME; RAJAGOPALAN, K; SIEVERT, G; HALEY, BE; WATT, DS				SALVUCCI, ME; RAJAGOPALAN, K; SIEVERT, G; HALEY, BE; WATT, DS			PHOTOAFFINITY-LABELING OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE ACTIVASE WITH ATP GAMMA-BENZOPHENONE - IDENTIFICATION OF THE ATP GAMMA-PHOSPHATE BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; RUBISCO ACTIVASE; ADENYLATE KINASE; ESCHERICHIA-COLI; SITES; 1,5-BISPHOSPHATE; 5'-TRIPHOSPHATE; HYDROLYSIS; EXPRESSION; F1-ATPASE	The phosphate-binding domain of the ATP-binding site of tobacco Rubisco (ribulose-1,5-bisphosphate carboxylase/oxygenase) activase was elucidated by photoaffinity labeling with a monoanhydride of ADP with N-(4-(benzoyl)phenylmethyl)phosphoramide ([gamma-P-32] ATPgammaBP). Covalent incorporation of [gamma-P-32]ATPgammaBP into the 42-kDa Rubisco activase subunit was dependent upon irradiation with ultraviolet light. Photolabeling of Rubisco activase with ATPgammaBP exhibited saturation kinetics; the apparent K(d) for photolabeling was 5 muM. Two lines of evidence showed that ATPgammaBP modified Rubisco activase at the ATP-binding domain. First, physiological concentrations of ATP and ADP afforded complete protection against photolabeling of Rubisco activase by ATPgammaBP. Second, photolysis of Rubisco activase in the presence of ATPgammaBP decreased both the ATPase and the Rubisco activating activities. Inactivation of enzyme activity was dependent on ATPgammaBP concentration and could be prevented by including ADP during photolabeling. The region of Rubisco activase that was modified by ATPgammaBP was identified by isolating photolabeled peptides. Sequence analysis showed that ATPgammaBP modified Rubisco activase in two distinct regions; one region, S117-A136, is adjacent to the P-loop and the other region, V223-T234, exhibits homology to a region of adenylate kinase that ligates the essential metal ion. Photolabeling of these two regions of Rubisco activase was consistent with modification of the ATP gamma-phosphate-binding domain of Rubisco activase with ATPgammaBP.	UNIV KENTUCKY,DEPT CHEM,LEXINGTON,KY 40546; UNIV KENTUCKY,DEPT MED CHEM,LEXINGTON,KY 40546; UNIV KENTUCKY,DEPT AGRON,LEXINGTON,KY 40546	University of Kentucky; University of Kentucky; University of Kentucky	SALVUCCI, ME (corresponding author), UNIV KENTUCKY,USDA ARS,107-A ANIM PATHOL BLDG,LEXINGTON,KY 40546, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; BAR-ZVI D, 1992, Journal of Biological Chemistry, V267, P11029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUAN H, 1988, J BIOL CHEM, V263, P13003; COLMAN RF, 1990, ENZYMES, V19, P283; CRAFTSBRANDNER SJ, 1991, PLANTA, V183, P300, DOI 10.1007/BF00197802; DOUKAS MA, 1992, BIOCONJUGATE CHEM, V3, P484, DOI 10.1021/bc00018a004; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; GALARDY RE, 1974, J BIOL CHEM, V249, P3510; GUTTERIDGE S, 1986, NATURE, V324, P274, DOI 10.1038/324274a0; JORDAN DB, 1983, J BIOL CHEM, V258, P3752; KORANGY F, 1992, J BIOL CHEM, V267, P1727; LILLEY RM, 1990, PLANT PHYSIOL, V94, P245, DOI 10.1104/pp.94.1.245; MAHMOOD R, 1987, J BIOL CHEM, V262, P14479; MIZIORKO HM, 1990, J BIOL CHEM, V265, P3642; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PERCHOROWICZ JT, 1981, P NATL ACAD SCI-BIOL, V78, P2985, DOI 10.1073/pnas.78.5.2985; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; RAJAGOPALAN K, 1993, J BIOL CHEM, V268, P14230; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; ROBINSON SP, 1989, ARCH BIOCHEM BIOPHYS, V268, P93, DOI 10.1016/0003-9861(89)90568-7; ROBINSON SP, 1988, PLANT PHYSIOL, V88, P1008, DOI 10.1104/pp.88.4.1008; SALVUCCI ME, 1992, ARCH BIOCHEM BIOPHYS, V298, P688, DOI 10.1016/0003-9861(92)90467-B; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SALVUCCI ME, 1985, PHOTOSYNTH RES, V7, P197; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHEN JB, 1991, J BIOL CHEM, V266, P8963; TAGAYA M, 1987, J BIOL CHEM, V262, P8257; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; Turro NJ., 1965, MODERN MOL PHOTOCHEM; WANG ZY, 1991, BIOCHIM BIOPHYS ACTA, V1079, P263, DOI 10.1016/0167-4838(91)90067-A; WANG ZY, 1992, PLANT PHYSIOL, V100, P1858, DOI 10.1104/pp.100.4.1858; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; YAN HG, 1991, BIOCHEMISTRY-US, V30, P5539, DOI 10.1021/bi00236a029; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; ZHU GH, 1991, PLANT PHYSIOL, V97, P1354, DOI 10.1104/pp.97.4.1354	39	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14239	14244						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314787				2022-12-25	WOS:A1993LJ82500067
J	SINNETTSMITH, J; ZACHARY, I; VALVERDE, AM; ROZENGURT, E				SINNETTSMITH, J; ZACHARY, I; VALVERDE, AM; ROZENGURT, E			BOMBESIN STIMULATION OF P125 FOCAL ADHESION KINASE TYROSINE PHOSPHORYLATION - ROLE OF PROTEIN-KINASE-C, CA2+ MOBILIZATION, AND THE ACTIN CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; HETEROLOGOUS MITOGENIC DESENSITIZATION; RAPIDLY STIMULATE; SIGNAL TRANSDUCTION; ENDOTHELIN RECEPTOR; PHOSPHOLIPASE-C; PHORBOL ESTERS; GROWTH-FACTOR; EARLY EVENTS; VASOPRESSIN	Activation of protein kinase C (PKC) in quiescent Swiss 3T3 cells using either the tumor promoter phorbol 12,13-dibutyrate (PDB) or diacylglycerols increased the tyrosine phosphorylation of p125 focal adhesion kinase (p125FAK) by 3.8-fold. PDB stimulation of p125FAK tyrosine phosphorylation was detected within 1 min and reached a maximum within 5 min, considerably slower than PDB stimulation of 80K/MARCKS phosphorylation which was maximal within 1 min. In sharp contrast, bombesin-induced tyrosine phosphorylation of p125FAK reached a maximum (8-fold stimulation) within 1 min after addition of the peptide and occurred with a half-maximal effect of 0.08 nM, 6-fold lower than the half-maximal effect of bombesin on 80K/MARCKS phosphorylation. Down-regulation of PKC by prolonged treatment with PDB blocked the effect of PDB on p125FAK tyrosine phosphorylation but had no effect on the response to bombesin. A selective inhibitor of PKC, GF 109203X, markedly inhibited the stimulation of p125FAK tyrosine phosphorylation by PDB but had little effect on the response to bombesin, vasopressin, and endothelin. Bombesin stimulation of tyrosine phosphorylation could also be dissociated from mobilization of Ca2+ from intracellular stores. Depletion of the intracellular Ca2+ pool by treatment with the tumor promoter thapsigargin completely blocked the ability of bombesin to transiently increase the cytosolic Ca2+ concentration but had no effect on bombesin stimulation of p125FAK tyrosine phosphorylation. In contrast, cytochalasin D, an agent which selectively disrupts the network of actin microfilaments, completely inhibited bombesin- and PDB-induced p125FAK tyrosine phosphorylation. Within the same concentration range (0.3-2 muM), the drug had no effect on other early events stimulated by bombesin, including Ca2+ mobilization and activation of PKC. These findings demonstrate that neither the PKC nor Ca2+ pathways are responsible for the rapid stimulation of p125FAK tyrosine phosphorylation by neuropeptide growth factors. Furthermore, the integrity of the actin cytoskeleton is essential for the effects of both PDB and bombesin.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANN REV CELL BIOL, V7, P337; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; COLLINS MKL, 1983, P NATL ACAD SCI-BIOL, V80, P1924, DOI 10.1073/pnas.80.7.1924; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; FORCE T, 1991, J BIOL CHEM, V266, P6650; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MIURA Y, 1993, J BIOL CHEM, V268, P510; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1986, J CELL PHYSIOL, V129, P124, DOI 10.1002/jcp.1041290117; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	56	280	281	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14261	14268						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314789				2022-12-25	WOS:A1993LJ82500071
J	HEMRIC, ME; TRACY, PB; HAEBERLE, JR				HEMRIC, ME; TRACY, PB; HAEBERLE, JR			CALDESMON ENHANCES THE BINDING OF MYOSIN TO THE CYTOSKELETON DURING PLATELET ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PROTEIN-KINASE-C; LIGHT CHAIN KINASE; NONMUSCLE CALDESMON; ATPASE ACTIVITY; HEAVY-MEROMYOSIN; BLOOD-PLATELETS; SHAPE CHANGE; F-ACTIN; PHOSPHORYLATION	Activation of platelets with physiological agents results in distinct cellular events such as shape change, cell aggregation, granule secretion, and clot retraction. Translocation of soluble cytoplasmic myosin to the actin cytoskeleton occurs during activation and may be involved in some of these physiological responses. Phosphorylation of the 20,000-dalton myosin light chain occurs in parallel with myosin translocation; however, exceptions to this correlation have been reported. The present study tests the hypothesis that the actin- and myosin-binding protein, caldesmon, is required for this enhanced binding of myosin to the actin cytoskeleton. Caldesmon, a putative regulatory protein found in nonmuscle and smooth muscle cells, binds actin and myosin simultaneously to form an actin-caldesmon myosin complex and ''tethers'' myosin to actin in a manner that promotes, rather than inhibits, translocation of actin filaments relative to myosin. In this study, we demonstrated that a purified myosin-binding fragment of caldesmon competitively blocks caldesmon dependent tethering in an in vitro motility assay and that this effect is prevented by phosphorylating the fragment. More importantly, we demonstrated that the unphosphorylated, but not the phosphorylated, fragment displaces myosin from the cytoskeleton of activated platelets; this suggests that caldesmon enhances the binding of myosin to the cytoskeleton during platelet activation.	UNIV VERMONT, COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, BURLINGTON, VT 05405 USA; UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA	University of Vermont; University of Vermont					NHLBI NIH HHS [HL28001] Funding Source: Medline; NIAMS NIH HHS [AR08164, AR40259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040259, F32AR008164] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADAM LP, 1993, BIOPHYS J, V64, pA122; BRASS LF, 1985, J BIOL CHEM, V260, P5172; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1991, J MUSCLE RES CELL M, V12, P372, DOI 10.1007/BF01738592; BURGOYNE RD, 1986, NATURE, V319, P68, DOI 10.1038/319068a0; COX AC, 1984, J CELL BIOL, V98, P8, DOI 10.1083/jcb.98.1.8; CROSBIE R, 1991, J BIOL CHEM, V266, P20001; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; FOX JEB, 1982, J BIOL CHEM, V257, P4120; HAEBERLE JR, 1992, J BIOL CHEM, V267, P23001; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1993, J BIOL CHEM, V268, P15305; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HETTASCH JM, 1991, J BIOL CHEM, V266, P11876; HIGASHIHARA M, 1991, BLOOD, V78, P3224; HOLMSEN H, 1979, ANNU REV MED, V30, P119, DOI 10.1146/annurev.me.30.020179.001003; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P11242, DOI 10.1021/bi00503a013; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU FWM, 1993, BIOPHYS J, V64, pA29; MUSTARD JF, 1989, METHOD ENZYMOL, V169, P3; NACHMIAS VT, 1987, J CELL BIOL, V105, P1761, DOI 10.1083/jcb.105.4.1761; NGAI PK, 1985, BIOCHEM BIOPH RES CO, V127, P533, DOI 10.1016/S0006-291X(85)80192-3; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; NOVY RE, 1991, J BIOL CHEM, V266, P16917; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PERSECHINI A, 1981, SCIENCE, V213, P1383, DOI 10.1126/science.6455737; PHO DB, 1986, FEBS LETT, V202, P117, DOI 10.1016/0014-5793(86)80660-3; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WALKER G, 1989, J BIOL CHEM, V264, P496; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	45	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4125	4128						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307972				2022-12-25	WOS:A1994MW98900037
J	MIKI, J; KUSUKI, H; TSUGUMI, S; KANAZAWA, H				MIKI, J; KUSUKI, H; TSUGUMI, S; KANAZAWA, H			AMINO-ACID REPLACEMENTS AT BINDING-SITES OF MONOCLONAL-ANTIBODY IN THE F1-ATPASE BETA-SUBUNIT FROM ESCHERICHIA-COLI CAUSED ALTERED SUBUNIT INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-SEQUENCE; H+-ATPASE; SYNTHASE; TRANSFORMATION; F1-ATPASE; CLONING; F0F1; DNA	The monoclonal antibodies (mAb), beta 12 and beta 31, against the beta subunit of Escherichia coli F-1-ATPase (Miki, J., Matsuda, T., Kariya, H., Ohmori, H., Tsuchiya, T, Futai, M., and Kanazawa, H. (1992) Arch, Biochem. Biophys. 294, 373-381) recognize the amino-terminal portion of the maximal 104 residues, that are not exposed to the surface of the F-1-ATPase. To identify the epitope residues within these 104 residues, we introduced random mutations in the region, and clones without binding activity to the mAb, beta 12 and beta 31, were screened. beta subunits defective in binding with mAb beta 12 or beta 31 had amino acid replacements at residues 26, 40, 52, 71, and 74 or at residues 40, 41, 43, 44, 46, and 52, respectively. These residues could be part of the epitope and are possibly located close together. We tested the effects of the mutations on oxidative phosphorylation-dependent growth by introducing expression plasmids of the beta subunit gene with the point mutations into the beta-less mutant, JP17. The alpha and beta subunits were missing from the JP17 membranes, and both subunits were assembled functionally after expression of the beta subunit was induced by introducing the expression plasmid. The replacement of Leu-40 by Pro caused the amounts of the a and p subunits on the membranes to be reduced less than 20% of the amounts in wild type. The replacement of Glu-41 by Lys caused a loss of the alpha subunit on the membranes, without any decrease in the beta subunit. These results indicated that the mutation of Leu-40 to Pro affects the essential role of the beta subunit in the assembly of the alpha and beta subunits on the membranes and that the mutation of Glu-41 to Lys partly affects it. The amino-terminal region of the beta subunit, in particular its ternary structure, including residues 40 and 41, plays an important role in the molecular assembly of the alpha and beta subunits on the membranes.	OKAYAMA UNIV,FAC ENGN SCI,DEPT BIOTECHNOL,OKAYAMA,JAPAN	Okayama University								BERUS KI, 1965, J MOL BIOL, V11, P476; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; KANAZAWA H, 1980, J BIOCHEM-TOKYO, V88, P695, DOI 10.1093/oxfordjournals.jbchem.a133022; KANAZAWA H, 1982, BIOCHEM BIOPH RES CO, V105, P1257, DOI 10.1016/0006-291X(82)90922-6; KANAZAWA H, 1980, P NATL ACAD SCI-BIOL, V77, P7005, DOI 10.1073/pnas.77.12.7005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MIKI J, 1992, ARCH BIOCHEM BIOPHYS, V294, P373, DOI 10.1016/0003-9861(92)90698-V; NOUMI T, 1986, J BIOL CHEM, V261, P7070; NOUMI T, 1987, J BIOL CHEM, V262, P14978; OHTA S, 1986, J BIOCHEM-TOKYO, V99, P135, DOI 10.1093/oxfordjournals.jbchem.a135452; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X	22	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4227	4232						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307986				2022-12-25	WOS:A1994MW98900052
J	MONTERO, M; GARCIASANCHO, J; ALVAREZ, J				MONTERO, M; GARCIASANCHO, J; ALVAREZ, J			PHOSPHORYLATION DOWN-REGULATES THE STORE-OPERATED CA2+ ENTRY PATHWAY OF HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PROTEIN-PHOSPHORYLATION; RESPIRATORY-BURST; NADPH OXIDASE; OKADAIC ACID; INTRACELLULAR CALCIUM; ACTIVATION; PHOSPHATASES; PHOSPHOPROTEIN; TRANSLOCATION	We have reported previously that the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) inhibits transiently Ca2+ entry through the plasma membrane Ca2+ pathway activated by emptying the intracellular Ca2+ stores (Montero, M., Garcia-Sancho, J., and Alvarez, J. (1993) J. Biol. Chem. 268, 13055-13061). We show here that calyculin A and okadaic acid, inhibitors of protein phosphatases 1 and 2A, prevent the spontaneous reversion of the fMLP-induced inhibition of the entry of Ca2+ and Mn2+ (used as a Ca2+ surrogate), leading to a permanently inhibited Ca2+ entry pathway. At high concentrations or long incubation times the phosphatase inhibitors were even able to inhibit the store-operated Ca2+ entry pathway (SOCP) in the absence of fMLP. Inhibition of SOCP by phorbol dibutyrate, which is not reversible, was not modified by phosphatase inhibitors. These results provide additional support for the view that fMLP inhibits SOCP through phosphorylation of either the SOCP protein or a regulatory protein and indicate that dephosphorylation mediated by protein phosphatases 1 and/or 2A restores the activity of SOCP after inhibition by fMLP. The time course of the inhibition of SOCP by fMLP was similar to the one reported previously for the transient fMLP-induced phosphorylation of a 47-kDa protein involved in the generation of respiratory burst, which was similarly affected by the phosphatase inhibitors.	UNIV VALLADOLID,FAC MED,DEPT BIOQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN	Universidad de Valladolid			Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014; Garcia-Sancho, Javier/K-2975-2014	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521; Garcia-Sancho, Javier/0000-0003-4573-7930				BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BERLIN RD, 1993, CELL CALCIUM, V14, P379, DOI 10.1016/0143-4160(93)90042-5; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DING JB, 1992, J BIOL CHEM, V267, P6442; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; GARCIA RC, 1992, BIOCHEM J, V286, P687, DOI 10.1042/bj2860687; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEYWORTH PG, 1986, BIOCHEM J, V239, P723, DOI 10.1042/bj2390723; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; MONTERO M, 1993, J BIOL CHEM, V268, P13055; OHTSUKA T, 1990, J BIOL CHEM, V265, P15418; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318	23	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3963	3967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307951				2022-12-25	WOS:A1994MW98900013
J	MCLEOD, RS; ZHAO, Y; SELBY, SL; WESTERLUND, J; YAO, ZM				MCLEOD, RS; ZHAO, Y; SELBY, SL; WESTERLUND, J; YAO, ZM			CARBOXYL-TERMINAL TRUNCATION IMPAIRS LIPID RECRUITMENT BY APOLIPOPROTEIN-B100 BUT DOES NOT AFFECT SECRETION OF THE TRUNCATED APOLIPOPROTEIN-B-CONTAINING LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; HEP G2 CELLS; MESSENGER-RNA; RAT-LIVER; FAMILIAL HYPOBETALIPOPROTEINEMIA; TRIGLYCERIDE-RICH; STOP CODON; EXPRESSION; IDENTIFICATION; INTESTINE	Human apolipoprotein (apo) B plays an obligatory role in the assembly and secretion of hepatic triglycerde-rich lipoproteins. Investigation of the truncated human apoB variants associated with hypobetalipoproteinemia has suggested that both size and secretion of apoB-containing lipoproteins may be reduced by carboxyl-terminal truncation. To examine the role of the carboxyl terminus of apoB in the assembly and secretion of hepatic lipoproteins, we have generated rat hepatoma McA-RH7777 cells that synthesize and secrete the full-length human apoB100 and the truncated forms B94, B88, B80, B72, and B60. In the resulting lipoproteins, particle density was inversely related to the logarithm of apoB length, ranging from 1.019 g/ml for apoB100 to 1.06 g/ml for B60. Furthermore, particle diameter (as determined by non-denaturing gel electrophoresis) was directly correlated with apoB length, ranging from 21.4 nm for apoB100 to 17.7 nm for B60. The relationship between apoB length and particle geometry was best defined by a linear correlation between length and core volume; a 10% decrease in apoB length resulted in an approximately 13% decrease in core volume. These observations, which are in agreement with the observations of aberrant lipoproteins in hypobetalipoproteinemia, suggest that lipid recruitment by apoB is progressively reduced by carboxyl-terminal truncation. However, pulse-chase studies indicated that carboxyl-terminal truncation did not impair apoB secretion. The recombinant human apoB forms were secreted as efficiently as endogenous rat apoB100; approximately 20% of total newly synthesized apoB72, B80, or B100 was secreted at the end of the chase. Intracellular degradation of newly synthesized apoB was observed for both the truncated human and the endogenous rat proteins. These data suggest that the low apoB levels in hypobetalipoproteinemia might not be caused by impaired secretion of the truncated apoB proteins.	UNIV ALBERTA,HERITAGE MED RES CTR 328,LIPID & LIPOPROT RES GRP,EDMONTON TG2 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T22 2S2,AB,CANADA	University of Alberta; University of Alberta			McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569				ANDERSON DW, 1977, BIOCHIM BIOPHYS ACTA, V493, P55, DOI 10.1016/0005-2795(77)90259-8; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHATTERTON JE, 1991, J BIOL CHEM, V266, P5955; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; ELOVSON J, 1992, CIRCULATION, V86, P692; FARESE RV, 1992, J LIPID RES, V33, P569; FAZIO S, 1992, J BIOL CHEM, V267, P6941; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRUEL ES, 1992, J LIPID RES, V33, P1037; LINTON MF, 1993, J LIPID RES, V34, P521; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MARCEL YL, 1987, ARTERIOSCLEROSIS, V7, P166, DOI 10.1161/01.ATV.7.2.166; PARHOFER KG, 1990, J LIPID RES, V31, P2001; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PULLINGER CR, 1992, J LIPID RES, V33, P699; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPRING DJ, 1992, J LIPID RES, V33, P233; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; TENNYSON GE, 1989, P NATL ACAD SCI USA, V86, P500, DOI 10.1073/pnas.86.2.500; WELTY FK, 1991, J CLIN INVEST, V87, P1748, DOI 10.1172/JCI115193; YAO ZM, 1993, ARTERIOSCLER THROMB, V13, P1476, DOI 10.1161/01.ATV.13.10.1476; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1992, J BIOL CHEM, V267, P1175; YOUNG SG, 1987, J BIOL CHEM, V262, P16604; YOUNG SG, 1990, J CLIN INVEST, V85, P933, DOI 10.1172/JCI114522; YOUNG SG, 1990, CIRCULATION, V80, P219	39	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2852	2862						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300620				2022-12-25	WOS:A1994MV43200074
J	QUEST, AFG; BARDES, ESG; BELL, RM				QUEST, AFG; BARDES, ESG; BELL, RM			A PHORBOL ESTER BINDING DOMAIN OF PROTEIN KINASE-C-GAMMA - DELETION ANALYSIS OF THE CYS2 DOMAIN DEFINES A MINIMAL 43-AMINO ACID PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY DOMAIN; DILUTE-SOLUTION; ACTIVATION; EXPRESSION; FAMILY; ZINC; PURIFICATION; RECEPTOR; PHOSPHATIDYLSERINE; DIACYLGLYCEROL	Cysteine-rich regions of protein kinase C (PKC) are critical for the lipid-dependent regulation of activity and are implicated in the coordination of zinc. A glutathione S-transferase fusion protein containing the second cysteine-rich region, Cys2, of PKCgamma with bound zinc with a stoichiometry of 1.8 +/- 0.1 mol of zinc/mol of protein. Deletion analysis within this cysteine-rich region defined amino acids essential for zinc coordination. An NH2-terminal histidine (His102) and a COOH-terminal cysteine (Cys151) were both critical for the coordination of distinct zinc atoms. Both represent the ultimate residues of a 50-amino acid consensus motif with six conserved cysteines and two conserved histidines present in the cysteine-rich regions of all PKC isoforms. Removal of histidine His102 abolished phorbol ester binding, while deletion of cysteine Cys151 did not. Deletion of valine (Val147) greatly diminished phorbol ester binding, which was completely lost only when valine (Val144) was also deleted. No significant further reduction in zinc stoichiometry below one resulted even when three COOH-terminal conserved cysteines (Cys151, Cys143, and Cys135) and a conserved histidine (His140) were deleted. These results are consistent with a model in which two zinc atoms are tetracoordinated per cysteine-rich region in two independent coordination spheres that are not functionally equivalent. These analyses determine a minimal peptide (residues 102-144) of 43 amino acids capable of [H-3]PDBu binding.	DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,POB 3711,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38737] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKITA Y, 1990, J BIOL CHEM, V265, P354; BELL RM, 1991, J BIOL CHEM, V266, P4661; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; BURNS DJ, 1992, PROTEIN KINASE C CUR, P25; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; EBLING JG, 1985, P NATL ACAD SCI USA, V82, P815; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUBBARD SR, 1991, SCIENCE, V254, P1776; JEFFREY AM, 1986, P NATL ACAD SCI USA, V83, P241, DOI 10.1073/pnas.83.2.241; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MURUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; ORR JW, 1992, J BIOL CHEM, V267, P15263; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RANDO RR, 1988, FASEB J, V2, P2348, DOI 10.1096/fasebj.2.8.3282960; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; TAKAI Y, 1979, J BIOCHEM-TOKYO, V86, P575, DOI 10.1093/oxfordjournals.jbchem.a132557; TAKAI Y, 1979, J BIOL CHEM, V254, P3962; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENDER PA, 1986, P NATL ACAD SCI USA, V83, P4214, DOI 10.1073/pnas.83.12.4214; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119	43	118	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2961	2970						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300628				2022-12-25	WOS:A1994MV43200087
J	KALFA, TA; THULL, JD; BUTKOWSKI, RJ; CHARONIS, AS				KALFA, TA; THULL, JD; BUTKOWSKI, RJ; CHARONIS, AS			TUBULOINTERSTITIAL NEPHRITIS ANTIGEN INTERACTS WITH LAMININ AND TYPE-IV COLLAGEN AND PROMOTES CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANES; BINDING-SITES; DOMAINS; FORMS	Tubulointerstitial nephritis (TIN) antigen has been recently identified as a novel basement membrane macromolecule. It consists of a single chain of 58 kDa and exhibits a restricted distribution. The interaction between TIN antigen and laminin or type IV collagen has been studied using solid-phase binding assays and found to be for both macromolecules specific, saturable, and with an affinity in the low micromolar range. In similar assays, TIN antigen did not interact with heparin. In turbidimetry assays, it was found that the presence of TIN antigen did not affect the polymerization of type IV collagen but had a concentration-dependent inhibitory effect on laminin polymerization and on preformed laminin polymers. TIN antigen was able to promote adhesion of epithelial cells derived from kidney tubules and of endothelial cells derived from aorta. The data suggest that TIN antigen may be a macromolecule of importance both for basement membrane ultrastructure and cellular adhesion.	UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 609 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities				Kalfa, Theodosia/0000-0002-0426-9686; Charonis, Aristidis/0000-0001-9956-732X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043569, R01DK036007] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43569, DK 36007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BUTKOWSKI RJ, 1990, J BIOL CHEM, V265, P21091; BUTKOWSKI RJ, 1991, KIDNEY INT, V40, P838, DOI 10.1038/ki.1991.283; CARLSSON R, 1981, P NATL ACAD SCI-BIOL, V78, P2403, DOI 10.1073/pnas.78.4.2403; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119	15	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1654	1659						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294412				2022-12-25	WOS:A1994MR98800020
J	LAI, K; MCGRAW, P				LAI, K; MCGRAW, P			DUAL CONTROL OF INOSITOL TRANSPORT IN SACCHAROMYCES-CEREVISIAE BY IRREVERSIBLE INACTIVATION OF PERMEASE AND REGULATION OF PERMEASE SYNTHESIS BY INO2, INO4, AND OPI1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; PHOSPHATIDYLSERINE SYNTHASE; COORDINATE REGULATION; STRUCTURAL GENE; YEAST; MEMBRANE; PROTEIN; TRANSFORMATION; ENCODES	Uptake of inositol by Saccharomyces cerevisiae is regulated through transcriptional control of the gene that encodes the major inositol permease, ITR1 (Nikawa, J., Tsukagoshi, Y., and Yamashita, S. (1991) J. Biol. Chem. 266, 11184-11191). ITR1 mRNA abundance decreases when cells are transferred from medium without inositol to medium with inositol. Here we demonstrate that the mechanism of transcriptional regulation of ITR1 is through the action of the INO2, INO4 and OPI1 genes. INO2 and INO4 are required for derepressed levels of ITR1 mRNA, and OPI1 is necessary for repression of transcript levels in response to inositol. The INO2, INO4, and OPI1 genes thus coordinate uptake of inositol to endogenous inositol biosynthesis and to phospholipid biosynthesis. Repression of transcription of ITR1 also requires ongoing synthesis of phosphatidylcholine, defining an additional link between synthesis of phospholipids and regulation of inositol uptake. Analysis showed that the INO1 gene, encoding a key enzyme in the inositol biosynthetic pathway, responded to decreases in permease activity with a graduated increase in the level of INO1 mRNA. We also found that, in addition to the transcriptional regulation, inositol permease activity is regulated by irreversible inactivation. Inactivation of the ITR1 permease occurs in response to the presence of inositol and involves a change in the functional half-life of the protein.	UNIV MARYLAND, DEPT BIOL SCI, BALTIMORE CTY CAMPUS, CATONSVILLE, MD 21228 USA	University System of Maryland; University of Maryland Baltimore County								AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BISSON LF, 1983, P NATL ACAD SCI-BIOL, V80, P1730, DOI 10.1073/pnas.80.6.1730; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; FRUEN BR, 1991, FEBS LETT, V295, P43, DOI 10.1016/0014-5793(91)81380-Q; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GREENBERG ML, 1982, GENETICS, V100, P19; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1987, J BACTERIOL, V169, P3276, DOI 10.1128/jb.169.7.3276-3280.1987; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOEWY BS, 1985, THESIS A EINSTEIN CO; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MCGRAW P, 1989, GENETICS, V122, P317; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULLER HJ, 1992, NUCLEIC ACIDS RES, V20, P5955, DOI 10.1093/nar/20.22.5955; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; WHITE MJ, 1991, J BIOL CHEM, V266, P863; WINEGRAD AI, 1987, DIABETES, V36, P396, DOI 10.2337/diab.36.3.396	34	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2245	2251						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294482				2022-12-25	WOS:A1994MR98800103
J	LOVEC, H; SEWING, A; LUCIBELLO, FC; MULLER, R; MOROY, T				LOVEC, H; SEWING, A; LUCIBELLO, FC; MULLER, R; MOROY, T			ONCOGENIC ACTIVITY OF CYCLIN D1 REVEALED THROUGH COOPERATION WITH HA-RAS - LINK BETWEEN CELL-CYCLE CONTROL AND MALIGNANT TRANSFORMATION	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; EXPRESSION; CARCINOMAS; BCL-1	Circumstantial evidence implicates the putative cell cycle regulator cyclin D1 in the process of malignant transformation. Overexpression of cyclin D1 is observed in mammary carcinomas as a result of gene amplification and in parathyroid adenomas and centrocytic B-cell lymphomas as a consequence of chromosomal rearrangements and juxtaposition of the cyclin D1 gene to strong transcriptional control elements. These findings suggest that deregulation of cyclin D1 expression may contribute to malignant transformation in these tumours. To date, however, an oncogenic potential of cyclin D1 has not been demonstrated and the mechanism of its oncogenic activation remains obscure although overexpression of the wild-type protein is likely. We report here that the overexpression of cyclin D1 induces transformation in primary rat embryo fibroblasts in cooperation with activated Ha-uas. Cyclin D1/Ha-ras transformed cells are immortalized, show anchorage independence and give rise to fibrosarcomas in nude mice. Our data directly demonstrate that cyclin D1 is a proto-oncogene that can be activated by transcriptional deregulation. Its previously demonstrated ability to interact with putative cell cycle regulators suggests that cyclin D1 defines a new class of proto-oncogenes.	PHILIPPS UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Moroy, Tarik/D-9923-2011; Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1992, CANCER RES, V52, P2980; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; ROSENBERG CL, 1993, ONCOGENE, V8, P519; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHUURING E, 1992, ONCOGENE, V7, P355; SEWING A, 1993, J CELL SCI, V104, P545; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	253	262	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					323	326						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302597				2022-12-25	WOS:A1994MW24700040
J	MATZ, JM; BLAKE, MJ; SAARI, JT; BODE, AM				MATZ, JM; BLAKE, MJ; SAARI, JT; BODE, AM			DIETARY COPPER DEFICIENCY REDUCES HEAT-SHOCK PROTEIN EXPRESSION IN CARDIOVASCULAR TISSUES	FASEB JOURNAL			English	Note						METABOLIC STRESSORS; CATECHOLAMINE METABOLISM; CARDIAC MITOCHONDRIA	CARDIAC-HYPERTROPHY; MESSENGER-RNAS; RATS; MITOCHONDRIAL; STRESS; IRON; ENLARGEMENT; MEMBRANE; COMPLEX; LIVER	Dietary copper deficiency impairs cardiovascular function by depression of catecholamine metabolism, and alteration of the structure and function of cardiac mitochondria. Heat shock proteins (HSPs) are a group of cellular homeostatic proteins that are induced in vascular tissue by catecholaminergic transmission after exposure to stress. We investigated the effects of dietary copper deficiency on the induction and accumulation of HSPs in several cardiovascular tissues. Stress-induced levels of aortic HSP70 mRNA were reduced in copper-deficient (CuD) rats when compared with copper-adequate (CuA) controls. Cocaine-induced HSP70 mRNA accumulation was not different between CuA and CuD rats, suggesting that reduced HSP70 levels in restrained CuD animals may result from altered catecholaminergic neurotransmission. The level of HSP60 mRNA was specifically reduced in the atria of CuD rats, which may be associated with altered mitochondrial structure and function. These results describe a novel relationship between dietary copper deficiency and the expression of highly conserved cellular stress response proteins. Loss of these essential homeostatic proteins in vascular tissue may contribute to the impairment of cardiovascular function known to accompany copper deficiency.	UNIV N DAKOTA,SCH MED,DEPT PHYSIOL,BOX 9001,GRAND FORKS,ND 58202; UNIV N DAKOTA,SCH MED,DEPT PHARMACOL & TOXICOL,GRAND FORKS,ND 58202; USDA ARS,GRAND FORKS HUMAN NUTR RES CTR,GRAND FORKS,ND 58202	University of North Dakota Grand Forks; University of North Dakota Grand Forks; United States Department of Agriculture (USDA)					NIDDK NIH HHS [DK44439] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044439] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANG D, 1991, J BIOL CHEM, V266, P24233; BENNETTS H. W., 1948, AUSTRALIAN VET JOUR, V24, P237, DOI 10.1111/j.1751-0813.1948.tb04683.x; BLAKE MJ, 1990, J BIOL CHEM, V265, P15275; BLAKE MJ, 1993, IN PRESS J PHARM EXP; BODE AM, 1992, J NUTR BIOCHEM, V3, P668, DOI 10.1016/0955-2863(92)90088-Z; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CURRIE RW, 1991, BIOCHEM CELL BIOL, V69, P375, DOI 10.1139/o91-057; DALLMAN PR, 1970, BLOOD-J HEMATOL, V35, P496, DOI 10.1182/blood.V35.4.496.496; DELCAYRE C, 1988, J CLIN INVEST, V82, P460, DOI 10.1172/JCI113619; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN S, 1965, J BIOL CHEM, V240, pPC552; GOODMAN JR, 1970, PEDIATR RES, V4, P244, DOI 10.1203/00006450-197005000-00003; GRAY RE, 1990, FEBS LETT, V265, P265; GUBLER CJ, 1957, J BIOL CHEM, V224, P553; HOWARD G, 1986, MOL CELL BIOCHEM, V69, P155; JOHNSON WT, 1987, J NUTR, V117, P1085, DOI 10.1093/jn/117.6.1085; KELLY WA, 1974, EXP MOL PATHOL, V20, P40, DOI 10.1016/0014-4800(74)90042-2; KITANO S, 1980, CIRC RES, V46, P681, DOI 10.1161/01.RES.46.5.681; KLEVAY LM, 1991, PHYSIOL BEHAV, V49, P309, DOI 10.1016/0031-9384(91)90048-S; KLEVAY LM, 1993, P SOC EXP BIOL MED, V203, P214, DOI 10.3181/00379727-203-43594; KNOWLTON AA, 1991, J CLIN INVEST, V88, P2018, DOI 10.1172/JCI115529; KOHANE DS, 1990, AM J PHYSIOL, V258, pH1699, DOI 10.1152/ajpheart.1990.258.6.H1699; LAI YK, 1986, BIOCHEM BIOPH RES CO, V135, P857, DOI 10.1016/0006-291X(86)91007-7; LUIS AM, 1990, J BIOL CHEM, V265, P7713; MEDEIROS DM, 1993, BIOL TRACE ELEM RES, V36, P271, DOI 10.1007/BF02783961; MEDEIROS DM, 1991, J NUTR, V121, P815, DOI 10.1093/jn/121.6.815; MEHTA HB, 1988, CIRC RES, V63, P512, DOI 10.1161/01.RES.63.3.512; MORIMOTO R I, 1990, P1; NIELSEN FH, 1982, BIOL TRACE ELEM RES, V4, P125, DOI 10.1007/BF02783253; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PROHASKA JR, 1990, J NUTR BIOCHEM, V1, P149, DOI 10.1016/0955-2863(90)90015-D; PROHASKA JR, 1982, J NUTR, V112, P2142; SEIDEL KE, 1991, J NUTR, V121, P474, DOI 10.1093/jn/121.4.474; SHIELDS GS, 1962, AM J PATHOL, V41, P603; TINKER D, 1985, PHYSIOL REV, V65, P607, DOI 10.1152/physrev.1985.65.3.607; UDELSMAN R, 1993, J CLIN INVEST, V91, P465, DOI 10.1172/JCI116224; UDELSMAN R, 1991, SURGERY, V110, P1125; VIESTENZ KE, 1982, AM J CLIN NUTR, V35, P258, DOI 10.1093/ajcn/35.2.258; [No title captured]	41	19	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1994	8	1					97	102		10.1096/fasebj.8.1.8299895	http://dx.doi.org/10.1096/fasebj.8.1.8299895			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MV282	8299895				2022-12-25	WOS:A1994MV28200014
J	NUREKI, O; KOHNO, T; SAKAMOTO, K; MIYAZAWA, T; YOKOYAMA, S				NUREKI, O; KOHNO, T; SAKAMOTO, K; MIYAZAWA, T; YOKOYAMA, S			CHEMICAL MODIFICATION AND MUTAGENESIS STUDIES ON ZINC-BINDING OF AMINOACYL-TRANSFER RNA-SYNTHETASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS HB8; ISOLEUCYL-TRANSFER-RNA; TRANSCRIPTION FACTOR-IIIA; ASPARTYL-TRANSFER RNA; VALYL-TRANSFER-RNA; ESCHERICHIA-COLI; EXTREME THERMOPHILE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE	Thermus thermophilus methionyl-tRNA synthetase consists of two identical subunits with a potential Zn2+-binding sequence of Cys-X2-Cys-X13-Cys-X2-His (Nureki, O., Muramatsu, T., Suzuki, K., Kohda, D., Matsuzawa, H., Ohta, T. Miyazawa, T., and Yokoyama, S. (1991) J. Biol. Chem. 266, 3268-3277). Upon chemical modification of the 3 Cys residues of T. thermophilus MetRS with sodium p-(hydroxymercuri)phenylsulfonate, one Zn2+ ion was released from one subunit of the molecule, as monitored with 4-(2-pyridylazo)resorcinol. Site-directed mutagenesis of Cys and His residues in the Zn2+-binding sequence reduced the aminoacylation activity; the k(cat) value was markedly decreased, and the K(m) values for L-methionine and tRNA(f)Met were increased. Similarly, Cys modification released two Zn2+ ions from T. thermophilus and Escherichia coli isoleucyl-tRNA synthetases and E. coli threonyl-tRNA synthetase, which have Zn2+-binding motifs, and impaired their activities. By contrast, three other aminoacyl-tRNA synthetases that lack Zn2+-binding motif neither released Zn2+ ion nor lost their activities upon Cys modification. These results indicate that the Zn2+-binding sequences are important for catalysis and recognition in the aminoacylation reactions of a subgroup of aminoacyl-tRNA synthetases.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN	University of Tokyo			Sakamoto, Kensaku/N-7496-2015; Yokoyama, Shigeyuki/N-6911-2015	Sakamoto, Kensaku/0000-0003-2866-5031; Yokoyama, Shigeyuki/0000-0003-3133-7338				AVALOS J, 1991, FEBS LETT, V286, P176, DOI 10.1016/0014-5793(91)80968-9; BARSTOW DA, 1986, GENE, V46, P37, DOI 10.1016/0378-1119(86)90164-2; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BRETON R, 1986, J BIOL CHEM, V261, P610; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CHANG PK, 1990, J BIOL CHEM, V265, P20898; CRUZEN ME, 1991, J BIOL CHEM, V266, P9919; CSANK C, 1992, J BIOL CHEM, V267, P4592; DARDEL F, 1984, J BACTERIOL, V160, P1115, DOI 10.1128/JB.160.3.1115-1122.1984; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1989, NUCLEIC ACIDS RES, V17, P5725, DOI 10.1093/nar/17.14.5725; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FASIOLO F, 1985, J BIOL CHEM, V260, P5571; FETT R, 1991, J BIOL CHEM, V266, P1448; GAMPEL A, 1989, P NATL ACAD SCI USA, V86, P6023, DOI 10.1073/pnas.86.16.6023; GIEDROC DP, 1986, BIOCHEMISTRY-US, V25, P4969, DOI 10.1021/bi00365a037; HALL CV, 1982, J BIOL CHEM, V257, P6132; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HERBERT CJ, 1988, MOL GEN GENET, V213, P297, DOI 10.1007/BF00339595; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1990, BIOCHEMISTRY-US, V29, P8190, DOI 10.1021/bi00487a029; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; HUNT JB, 1984, J BIOL CHEM, V259, P4793; HUNT JB, 1986, ANAL BIOCHEM, V146, P150; JACOBSON GR, 1973, ENZYMES, V9, P225; KAWAKAMI M, 1985, FEBS LETT, V185, P162, DOI 10.1016/0014-5793(85)80762-6; KISSELEV LL, 1981, EUR J BIOCHEM, V120, P511, DOI 10.1111/j.1432-1033.1981.tb05729.x; KOHDA D, 1987, J BIOL CHEM, V262, P558; KOHDA D, 1984, FEBS LETT, V174, P20, DOI 10.1016/0014-5793(84)81069-8; LIU J, 1992, ANN ASS CAN FR AV SC, V60, P26; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; MAYAUX JF, 1982, EUR J BIOCHEM, V128, P41; MAYAUX JF, 1981, BIOCHEMISTRY-US, V20, P4647, DOI 10.1021/bi00519a020; MAYAUX JF, 1983, P NATL ACAD SCI-BIOL, V80, P6152, DOI 10.1073/pnas.80.20.6152; MECHULAM Y, 1985, J BACTERIOL, V163, P787, DOI 10.1128/JB.163.2.787-791.1985; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P2635, DOI 10.1021/bi00224a011; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P6970, DOI 10.1021/bi00242a023; MILLER WT, 1992, P NATL ACAD SCI USA, V89, P2032, DOI 10.1073/pnas.89.6.2032; NUREKI O, 1992, EUR J BIOCHEM, V204, P465, DOI 10.1111/j.1432-1033.1992.tb16656.x; NUREKI O, 1991, J BIOL CHEM, V266, P3268; PAPE LK, 1985, NUCLEIC ACIDS RES, V13, P6171, DOI 10.1093/nar/13.17.6171; PLUMBRIDGE JA, 1982, J BACTERIOL, V152, P650; POSORSKE LH, 1979, BIOCHIM BIOPHYS ACTA, V576, P128, DOI 10.1016/0005-2795(79)90491-4; PUTNEY SD, 1981, SCIENCE, V213, P1497, DOI 10.1126/science.7025207; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SHANG ZG, 1989, BIOCHEMISTRY-US, V28, P9790, DOI 10.1021/bi00451a037; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; TZAGOLOFF A, 1988, J BIOL CHEM, V263, P850; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WALTER P, 1983, P NATL ACAD SCI-BIOL, V80, P2437, DOI 10.1073/pnas.80.9.2437; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679	58	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15368	15373						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340367				2022-12-25	WOS:A1993LN30500011
J	STEINBECK, MJ; KHAN, AU; KARNOVSKY, MJ				STEINBECK, MJ; KHAN, AU; KARNOVSKY, MJ			EXTRACELLULAR PRODUCTION OF SINGLET OXYGEN BY STIMULATED MACROPHAGES QUANTIFIED USING 9,10-DIPHENYLANTHRACENE AND PERYLENE IN A POLYSTYRENE FILM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-GENERATING SYSTEM; MOLECULAR-OXYGEN; HYDROGEN-PEROXIDE; XANTHINE-OXIDASE; BACTERICIDAL ACTIVITY; LIPID PEROXIDATION; MOUSE MACROPHAGES; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; H+-ATPASE	The extracellular production of singlet oxygen (O2(1DELTA(g)) by stimulated macrophages was measured using a modification of our quantitative method initially developed to measure the intracellular production of O2(1DELTA(g)) by neutrophils (Steinbeck, M. J., Khan, A. U., and Karnovsky, M. J. (1992) J. Biol. Chem. 267, 13425-13433). Glass coverslips were coated with the specific chemical trap for O2(1DELTA(g)), 9,10-diphenylanthracene (DPA) and perylene, which is an internal standard, in a methylene chloride solution containing 0.3 mg/ml polystyrene. On evaporation, the polystyrene formed an even coating of DPA and perylene over the surface of a glass coverslip (PDP film). Unstimulated macrophages or macrophages stimulated with 4beta-phorbol 12-myristate 13-acetate (PMA) or formyl-methionyl-leucyl-phenylalanine (fMLP) were then added to the PDP film in a darkened room and incubated at 37-degrees-C for 30 min in a humidified 5% CO2 atmosphere. Both unstimulated and stimulated cells adhered to the PDP film in approximately equivalent numbers. Only stimulated cells produced measurable amounts of O2(1DELTA(g)) in a dose-dependent response to either PMA or fMLP. The production of O2(1DELTA(g)) by macrophages stimulated with PMA was maximal in response to 25 ng, 17.8 +/- 1.3 nmol Of O2(1DELTA(g))/approximately 1.00 x 10(6) cells. The maximal response for fMLP was at a concentration of 1 muM, 18.4 +/- 1.0 nmol Of O2(1DELTA(g))/approximately 1.00 x 10(6) cells. The specific detection of O2(1DELTA(g)) by this method was confirmed by thermally releasing O2(1DELTA(g)) from the DPA-O2(1DELTA(g)) reaction product, DPA-endoperoxide, regenerating the original DPA compound. Production of O2(1DELTA(g)) by the stimulated cells was inhibited 80-89% by the addition of 60-120 mug of superoxide dismutase, an enzyme that converts superoxide to hydrogen peroxide and ground state molecular oxygen or 79-84% with the addition of 2 mM histidine, an avid quencher Of O2(1DELTA(g)). Neither of these additions interfered with adhesion of the cells to the PDP film. The ability of superoxide dismutase to inhibit the production of O2(1DELTA(g)) suggested that O2(1DELTA(g)) was produced via a superoxide-dependent route. The ability of an oxidase to produce O2(1DELTA(g)) secondary to superoxide production was substantiated further using a xanthine oxidase-acetaldehyde system. Purified xanthine oxidase produced both superoxide and O2(1DELTA(g)), and their production was inhibited by the addition of superoxide dismutase. The production Of O2(1DELTA(g)) by this system was also verified by thermally reversing the reaction. With the use of the PDP film, we have modified our original method for the intracellular detection Of O2(1DELTA(g)) and have demonstrated that extracellular production of O2(1DELTA(g)) by stimulated macrophages can be quantified and appears to be generated via a superoxide-dependent pathway.			STEINBECK, MJ (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,BLDG D2,RM 442,200 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008507] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08507] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALLEN RC, 1972, BIOCHEM BIOPH RES CO, V47, P679, DOI 10.1016/0006-291X(72)90545-1; ARNESON RM, 1970, ARCH BIOCHEM BIOPHYS, V136, P352, DOI 10.1016/0003-9861(70)90205-5; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BABIOR GL, 1981, J CLIN INVEST, V67, P1724, DOI 10.1172/JCI110210; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BADWEY JA, 1983, J CELL PHYSIOL, V115, P208, DOI 10.1002/jcp.1041150216; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; BROWNE RJ, 1965, CAN J CHEMISTRY, V43, P2915, DOI 10.1139/v65-402; CLARK RA, 1987, J BIOL CHEM, V262, P4065; COHEN HJ, 1978, J CLIN INVEST, V61, P1081, DOI 10.1172/JCI109007; COREY EJ, 1987, BIOCHEM BIOPH RES CO, V145, P842, DOI 10.1016/0006-291X(87)91041-2; COREY EJ, 1964, J AM CHEM SOC, V86, P3881, DOI 10.1021/ja01072a062; FOOTE CS, 1964, J AM CHEM SOC, V86, P3879, DOI 10.1021/ja01072a060; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; FRIMER AA, 1985, SINGLET O2, V1; GOLDSTEIN IM, 1977, J CLIN INVEST, V59, P249, DOI 10.1172/JCI108635; GREEN TR, 1980, BIOCHEM BIOPH RES CO, V94, P262, DOI 10.1016/S0006-291X(80)80215-4; GREENWALD RA, 1991, SEMIN ARTHRITIS RHEU, V20, P219, DOI 10.1016/0049-0172(91)90018-U; GUIRAUD HJ, 1906, J AM CHEM SOC, V98, P1984; HELD AM, 1978, J AM CHEM SOC, V100, P5732, DOI 10.1021/ja00486a025; HODGSON EK, 1976, ARCH BIOCHEM BIOPHYS, V172, P202, DOI 10.1016/0003-9861(76)90067-9; IYER GYN, 1963, CAN J BIOCHEM PHYS, V41, P427; JOHNSTON RB, 1978, J EXP MED, V148, P115; KANOFSKY JR, 1988, J BIOL CHEM, V263, P9692; KELLOGG EW, 1975, J BIOL CHEM, V250, P8812; KELLOGG EW, 1977, J BIOL CHEM, V252, P6721; KHAN AU, 1976, J PHYS CHEM-US, V80, P2219, DOI 10.1021/j100561a018; KHAN AU, 1981, J AM CHEM SOC, V103, P6516, DOI 10.1021/ja00411a051; KHAN AU, 1977, J AM CHEM SOC, V99, P370, DOI 10.1021/ja00444a010; KHAN AU, 1963, J CHEM PHYS, V39, P2105, DOI 10.1063/1.1734588; KHAN AU, 1970, J AM CHEM SOC, V92, P3293, DOI 10.1021/ja00714a010; KHAN AU, 1970, SCIENCE, V168, P476, DOI 10.1126/science.168.3930.476; KING MM, 1975, J BIOL CHEM, V250, P6496; KRINSKY NI, 1974, SCIENCE, V186, P363, DOI 10.1126/science.186.4161.363; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MERKEL PB, 1972, J AM CHEM SOC, V94, P7244, DOI 10.1021/ja00776a003; MURRAY HW, 1980, J EXP MED, V152, P1596, DOI 10.1084/jem.152.6.1596; NAGANO T, 1985, PHOTOCHEM PHOTOBIOL, V41, P31; NATHAN CF, 1977, J EXP MED, V146, P1648, DOI 10.1084/jem.146.6.1648; PAUL B, 1968, BIOCHIM BIOPHYS ACTA, V156, P168, DOI 10.1016/0304-4165(68)90116-5; ROSEN H, 1977, J BIOL CHEM, V252, P4803; ROSEN H, 1979, J EXP MED, V149, P27, DOI 10.1084/jem.149.1.27; ROSEN H, 1978, CLIN RES, V26, P404; ROSENTHAL I, 1975, ISRAEL J CHEM, V13, P86; ROSSI F, 1964, EXPERIENTIA, V20, P21, DOI 10.1007/BF02146019; SINGH A, 1978, PHOTOCHEM PHOTOBIOL, V28, P4; SINGH A, 1978, PHOTOCHEM PHOTOBIOL, V28, P5; SOBERMAN RJ, 1981, LYMPHOKINES, V3, P11; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TAKAYAMA K, 1977, BIOCHEM BIOPH RES CO, V75, P1052, DOI 10.1016/0006-291X(77)91488-7; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; TAUBER AI, 1977, J CLIN INVEST, V60, P374, DOI 10.1172/JCI108786; TOMITA M, 1969, BIOCHEMISTRY-US, V8, P5149, DOI 10.1021/bi00840a069; TURRO NJ, 1981, J AM CHEM SOC, V103, P7218, DOI 10.1021/ja00414a029; WASSERMA.HH, 1972, J AM CHEM SOC, V94, P4991, DOI 10.1021/ja00769a034; Wilson T, 1970, Photophysiology, V5, P49	59	123	131	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15649	15654						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340389				2022-12-25	WOS:A1993LN30500050
J	STROM, MS; BERGMAN, P; LORY, S				STROM, MS; BERGMAN, P; LORY, S			IDENTIFICATION OF ACTIVE-SITE CYSTEINES IN THE CONSERVED DOMAIN OF PILD, THE BIFUNCTIONAL TYPE-IV PILIN LEADER PEPTIDASE N-METHYLTRANSFERASE OF PSEUDOMONAS-AERUGINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR PROTEIN SECRETION; ESCHERICHIA-COLI; CHER METHYLTRANSFERASE; PULLULANASE SECRETION; KLEBSIELLA-OXYTOCA; PREPILIN PEPTIDASE; MOLECULAR-CLONING; BINDING-SITE; SEQUENCE; GENE	PilD is a bifunctional enzyme responsible for cleavage of the leader peptides from the precursors of the type IV pilin and four proteins with type IV pilin-like amino termini that are required for extracellular protein secretion in Pseudomonas aeruginosa. Following cleavage, PilD also catalyzes the second major post-translational modification of these proteins, namely the N-methylation of the amino-terminal phenylalanine residues of the mature polypeptides. In this report, we demonstrate that the enzymatic activities of PilD involve cysteine residues that lie within a cytoplasmic domain that shows a high degree of similarity to other proteins postulated to perform the same function in other bacterial species. Both activities are reduced in the presence of sulfhydryl-reactive reagents such as N-ethylmaleimide and p-chloromercuribenzoate. Mutagenesis of pilD resulting in specific amino acid substitutions in all of the Cys residues in PilD show that the 4 conserved cysteines in the cytoplasmic domain are required for full peptidase activity in vivo and for complete peptidase and methyltransferase activities in vitro. Conversely, substitution for a Cys residue in a membrane spanning domain had no effect on PilD activities in vivo or in vitro. Evidence suggests that the peptidase and methyltransferase sites of PilD are adjacent, with the Cys residues in the cytoplasmic domain important for methyl donor binding, as prior reaction of PilD with the S-adenosyl-L-methionine analogue sinefungin afforded complete protection of peptidase activity from inactivation with N-ethylmaleimide.							NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021451, R37AI021451] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21451] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLY M, 1992, MOL MICROBIOL, V6, P1121, DOI 10.1111/j.1365-2958.1992.tb01550.x; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DUFOUR E, 1988, BIOCHIMIE, V70, P1335, DOI 10.1016/0300-9084(88)90004-1; DUPUY B, 1991, J BACTERIOL, V173, P7589, DOI 10.1128/jb.173.23.7589-7598.1991; DUPUY B, 1992, MOL MICROBIOL, V6, P1887, DOI 10.1111/j.1365-2958.1992.tb01361.x; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GREENE PJ, 1981, J BIOL CHEM, V256, P2143; ISHIMOTO KS, 1992, J BACTERIOL, V174, P3514, DOI 10.1128/JB.174.11.3514-3521.1992; KAUFMAN MR, 1991, GENE DEV, V5, P1834, DOI 10.1101/gad.5.10.1834; KOGA T, 1993, INFECT IMMUN, V61, P1371, DOI 10.1128/IAI.61.4.1371-1377.1993; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUER P, 1993, MOL MICROBIOL, V8, P357, DOI 10.1111/j.1365-2958.1993.tb01579.x; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MARRS CF, 1985, J BACTERIOL, V163, P132, DOI 10.1128/JB.163.1.132-139.1985; MCKERN NM, 1983, FEBS LETT, V164, P149, DOI 10.1016/0014-5793(83)80039-8; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; Miller JH., 1972, EXPT MOL GENETICS; MOHAN S, 1989, J BACTERIOL, V171, P6043, DOI 10.1128/jb.171.11.6043-6051.1989; NUNN D, 1990, J BACTERIOL, V172, P2911, DOI 10.1128/jb.172.6.2911-2919.1990; NUNN DN, 1991, P NATL ACAD SCI USA, V88, P3281, DOI 10.1073/pnas.88.8.3281; NUNN DN, 1992, P NATL ACAD SCI USA, V89, P47, DOI 10.1073/pnas.89.1.47; PAN T, 1989, P NATL ACAD SCI USA, V86, P3145, DOI 10.1073/pnas.86.9.3145; PASLOSKE BL, 1988, MOL MICROBIOL, V2, P489, DOI 10.1111/j.1365-2958.1988.tb00055.x; PUGSLEY AP, 1992, MOL MICROBIOL, V6, P751, DOI 10.1111/j.1365-2958.1992.tb01525.x; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P365, DOI 10.1111/j.1365-2958.1990.tb00604.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAW CE, 1990, INFECT IMMUN, V58, P3042, DOI 10.1128/IAI.58.9.3042-3049.1990; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; Stock A, 1988, Adv Exp Med Biol, V231, P387; STROM MS, 1992, J BACTERIOL, V174, P7345, DOI 10.1128/jb.174.22.7345-7351.1992; STROM MS, 1991, J BIOL CHEM, V266, P1656; STROM MS, 1991, J BACTERIOL, V173, P1175, DOI 10.1128/jb.173.3.1175-1180.1991; STROM MS, 1987, J BACTERIOL, V169, P3181, DOI 10.1128/jb.169.7.3181-3188.1987; STROM MS, 1993, P NATL ACAD SCI USA, V90, P2404, DOI 10.1073/pnas.90.6.2404; SUBBARAMAIAH K, 1991, J BIOL CHEM, V266, P19023; SUBBARAMAIAH K, 1992, J BIOL CHEM, V267, P8636; TONJUM T, 1991, J GEN MICROBIOL, V137, P2483, DOI 10.1099/00221287-137-10-2483; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	44	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15788	15794						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340405				2022-12-25	WOS:A1993LN30500069
J	DMITRIEV, O; DECKERSHEBESTREIT, G; ALTENDORF, K				DMITRIEV, O; DECKERSHEBESTREIT, G; ALTENDORF, K			ATP SYNTHESIS ENERGIZED BY DELTA-PNA AND DELTA-PHI IN PROTEOLIPOSOMES CONTAINING THE F(0)F(1)-ATPASE FROM PROPIONIGENIUM-MODESTUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-REDUCING BACTERIA; DECOMPOSE FATTY-ACIDS; ESCHERICHIA-COLI; ADENOSINE-TRIPHOSPHATASE; BETA-SUBUNIT; GEN-NOV; SYNTHASE; ENZYME; ION; RECONSTITUTION	After incorporation of the purified Na+-translocating F0F1-ATPase from Propionigenium modestum into preformed phospholipid vesicles the synthesis of ATP from ADP and inorganic phosphate could be observed under conditions where a valinomycin-mediated K+ diffusion potential (DELTAphi) and/or a Na+ concentration gradient (DELTApNa) were imposed. This reaction was not inhibited by the protonophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP). Furthermore, the DELTApNa-driven ATP synthesis was stimulated by FCCP. In contrast, the addition of the Na+/H+ antiporter monensin or of the F0F1 inhibitors N,N-dicyclohexylcarbodiimide and venturicidin abolished the synthesis of ATP completely. Finally, DELTApNa alone was able to elicit ATP synthesis, when a Na+ concentration gradient of sufficient magnitude was applied. In this case ATP synthesis occurred above a threshold level of approximately 120 mV and, furthermore, DELTAphi and DELTApNa appear to be equivalent as driving forces for this process. Therefore, the data provide firm evidence for the concept that DELTAmu''Na+ is the primary driving force for the synthesis of ATP in P. modestum.	UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,ARBEITSGRP MIKROBIOL,BARBARASTR 11,W-4500 OSNABRUCK,GERMANY	University Osnabruck			Dmitriev, Oleg/AAB-7830-2019					ARNOLD A, 1976, ANAL BIOCHEM, V71, P209, DOI 10.1016/0003-2697(76)90029-4; BOKRANZ M, 1985, BIOCHIM BIOPHYS ACTA, V810, P332, DOI 10.1016/0005-2728(85)90218-X; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DIMROTH P, 1992, BIOCHIM BIOPHYS ACTA, V1101, P236, DOI 10.1016/S0005-2728(05)80029-5; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRIEDL P, 1979, EUR J BIOCHEM, V100, P175, DOI 10.1111/j.1432-1033.1979.tb02046.x; HEISE R, 1992, EUR J BIOCHEM, V206, P553, DOI 10.1111/j.1432-1033.1992.tb16959.x; HILPERT W, 1984, EMBO J, V3, P1665, DOI 10.1002/j.1460-2075.1984.tb02030.x; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; JUNESCH U, 1985, BIOCHIM BIOPHYS ACTA, V809, P429, DOI 10.1016/0005-2728(85)90194-X; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; JUNESCH U, 1991, FEBS LETT, V294, P275, DOI 10.1016/0014-5793(91)81447-G; KIMMICH GA, 1975, ANAL BIOCHEM, V69, P187, DOI 10.1016/0003-2697(75)90580-1; KLUGE C, 1992, BIOCHEMISTRY-US, V31, P12665, DOI 10.1021/bi00165a017; LAUBINGER W, 1987, EUR J BIOCHEM, V168, P475, DOI 10.1111/j.1432-1033.1987.tb13441.x; LAUBINGER W, 1990, BIOCHEMISTRY-US, V29, P5458, DOI 10.1021/bi00475a008; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; Linnett P E, 1979, Methods Enzymol, V55, P472; MATSUNOYAGI A, 1993, J BIOL CHEM, V268, P1539; SCHMIDT G, 1987, BIOCHIM BIOPHYS ACTA, V890, P392, DOI 10.1016/0005-2728(87)90168-X; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SLOOTEN L, 1989, BIOCHIM BIOPHYS ACTA, V975, P148, DOI 10.1016/S0005-2728(89)80213-0; SONE N, 1977, J BIOCHEM-TOKYO, V82, P1751, DOI 10.1093/oxfordjournals.jbchem.a131873; SONE N, 1977, J BIOL CHEM, V252, P2956; TAKEDA K, 1985, J BIOCHEM-TOKYO, V97, P1401, DOI 10.1093/oxfordjournals.jbchem.a135194; WIDDEL F, 1983, ARCH MICROBIOL, V134, P286, DOI 10.1007/BF00407804; WIDDEL F, 1981, ARCH MICROBIOL, V129, P395, DOI 10.1007/BF00406470; WIDDEL F, 1980, THESIS U GOTTINGEN G	31	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14776	14780						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325855				2022-12-25	WOS:A1993LL75900039
J	HARRIS, DE; WARSHAW, DM				HARRIS, DE; WARSHAW, DM			SMOOTH AND SKELETAL-MUSCLE MYOSIN BOTH EXHIBIT LOW DUTY CYCLES AT ZERO LOAD IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE KINESIN MOLECULES; ACTIN-FILAMENTS; SLIDING MOVEMENT; VELOCITY; MICROTUBULES; TROPOMYOSIN; TRANSPORT; MOTION	Smooth muscle's stress equals that of skeletal muscle with less myosin. Thus, under isometric conditions, smooth muscle myosin may spend a greater fraction of its cycle time attached to actin in a high force state (i.e. higher duty cycle). If so, then smooth muscle myosin may also have a higher duty cycle under unloaded conditions. To test this, we used an in vitro motility assay in which fluorescently labeled actin filaments move freely over a sparsely coated (5-100 mug/ml) myosin surface. Actin filament velocity (V) was a function of the number of cross-bridges capable of interacting with an actin filament (N) and the duty cycle (f), V = (a x V(max)) x (1 - (1 - f)N) (Uyeda et al., 1990; Harada et al., 1990). N was estimated from the myosin density on the motility surface and the actin filament length. Data for V versus N were fit to the above equation to predict f. The duty cycle of smooth muscle myosin (4.0 +/- 0.7%) was not significantly different from that of skeletal muscle myosin (3.8 +/- 0.5%) in agreement with values estimated by Uyeda et al. (1990) for skeletal muscle myosin under unloaded conditions. The duty cycles of smooth and skeletal muscle myosin may still differ under isometric conditions.			HARRIS, DE (corresponding author), UNIV VERMONT, DEPT MOLEC PHYSIOL & BIOPHYS, BURLINGTON, VT 05405 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034872] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45161] Funding Source: Medline; NIAMS NIH HHS [AR34872] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FINER J, 1992, PHYSIOLOGIST, V35, P87; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HARRIS DE, 1990, J GEN PHYSIOL, V96, P581, DOI 10.1085/jgp.96.3.581; HIGUCHI H, 1991, NATURE, V352, P353; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; MILLER RH, 1985, J CELL BIOL, V101, P2181, DOI 10.1083/jcb.101.6.2181; MURPHY RA, 1974, J GEN PHYSIOL, V64, P691, DOI 10.1085/jgp.64.6.691; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; SPUDICH JA, 1990, NATURE, V348, P284, DOI 10.1038/348284a0; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOYOSHIMA YY, 1989, NATURE, V341, P154, DOI 10.1038/341154a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VANBUREN P, 1993, BIOPHYS J, V64, pA230; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0	35	138	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14764	14768						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325853				2022-12-25	WOS:A1993LL75900037
J	IWATA, M; WIGHT, TN; CARLSON, SS				IWATA, M; WIGHT, TN; CARLSON, SS			A BRAIN EXTRACELLULAR-MATRIX PROTEOGLYCAN FORMS AGGREGATES WITH HYALURONAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SMOOTH-MUSCLE CELLS; ELECTRON-MICROSCOPIC CHARACTERIZATION; CARTILAGE PROTEOGLYCANS; PROTEINS; VERSICAN; BINDING; NERVE; CORE	Unlike many tissues, the adult central nervous system extracellular matrix (ECM) has few known components. Previously, we characterized a large chondroitin sulfate proteoglycan, pgT1, from adult rat brain which has the properties of a general brain ECM component and is immunologically distinct from aggrecan and versican (Iwata, M., and Carlson, S. S. (1993) J. Neurosci. 13, 195-207). In this study we demonstrate that pgT1 binds hyaluronan with relatively high affinity. The pgT1 preparation isolated from rat brain aggregates in non-denaturing conditions. This aggregation is abolished by incubation of pgT1 with Streptomyces hyaluronidase. Examination of these aggregates by electron microscope reveals a structure in which an average of 18 subunits arise laterally from opposite sides of an elongated 350-nm filament. These pgT1 aggregates resemble the proteoglycan aggregates in cartilage which are composed of aggrecan and hyaluronan. Using affinity coelectrophoresis, we measure a dissociation constant (K(d)) of 0.9 +/- 0.2 nM for the interaction of pgT1 and hyaluronan. These new findings, combined with the general distribution of pgT1 in brain, suggest that pgT1/hyaluronan aggregates are an extended general structure of the brain extracellular matrix network.	UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SJ-40,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 18645] Funding Source: Medline; NINDS NIH HHS [NS22367] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; ATKINS EDT, 1974, POLYMER, V15, P263, DOI 10.1016/0032-3861(74)90122-0; AXELSSON I, 1983, J BIOL CHEM, V238, P8915; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BUCKWALTER JA, 1983, J BONE JOINT SURG AM, V65, P958, DOI 10.2106/00004623-198365070-00011; BUCKWALTER JA, 1982, J BIOL CHEM, V257, P9830; BURNETTE WN, 1981, ANAL BIOCHEM, V122, P364; CARLSON SS, 1987, J CELL BIOL, V105, P3075, DOI 10.1083/jcb.105.6.3075; CHANG Y, 1983, J BIOL CHEM, V258, P5679; CLELAND RL, 1977, J BIOL CHEM, V252, P420; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; GORDON CN, 1968, BIOCHIM BIOPHYS ACTA, V155, P305, DOI 10.1016/0005-2787(68)90363-8; HAMAI A, 1989, AGR BIOL CHEM TOKYO, V53, P2163, DOI 10.1080/00021369.1989.10869625; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDINGHAM TE, 1976, BIOCHEM J, V157, P127, DOI 10.1042/bj1570127; HASCALL GK, 1980, J ULTRA MOL STRUCT R, V70, P369, DOI 10.1016/S0022-5320(80)80019-0; HASCALL VC, 1988, ISI ATLAS-BIOCHEM, V1, P189; HEINEGARD D, 1978, BIOCHEM J, V175, P913, DOI 10.1042/bj1750913; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; IOZZO R V, 1982, Journal of Biological Chemistry, V257, P11135; IWATA M, 1993, J NEUROSCI, V13, P195; IWATA M, 1991, J BIOL CHEM, V266, P323; KIMURA JH, 1978, J BIOL CHEM, V253, P4721; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; MARGOLIS RU, 1967, BIOCHIM BIOPHYS ACTA, V141, P91, DOI 10.1016/0304-4165(67)90248-6; PAULSSON M, 1987, COLLAGEN REL RES, V7, P443; PECHAK DG, 1985, J CELL BIOL, V100, P1767, DOI 10.1083/jcb.100.5.1767; PERIDES G, 1992, J BIOL CHEM, V267, P23883; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; ROSENBERG L, 1975, J BIOL CHEM, V250, P1877; ROSENBERG L, 1970, J BIOL CHEM, V245, P4123; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; THYBERG J, 1975, BIOCHEM J, V151, P157, DOI 10.1042/bj1510157; UNDERHILL CB, 1989, CIBA FDN S, V143, P87; VOGEL H, 1992, J NEUROCYTOL, V21, P363, DOI 10.1007/BF01191704; WETLAUFER DB, 1973, ANNU REV BIOCHEM, V42, P135, DOI 10.1146/annurev.bi.42.070173.001031; Wight T. N., 1991, CELL BIOL EXTRACELLU; WIGHT TN, 1983, J CELL BIOL, V96, P167, DOI 10.1083/jcb.96.1.167; ZAREMBA S, 1989, NEURON, V2, P1207, DOI 10.1016/0896-6273(89)90305-X; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	46	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15061	15069						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325882				2022-12-25	WOS:A1993LL75900077
J	CRAXTON, A; ERNEUX, C; SHEARS, SB				CRAXTON, A; ERNEUX, C; SHEARS, SB			INOSITOL 1,4,5,6-TETRAKISPHOSPHATE IS PHOSPHORYLATED IN RAT-LIVER BY A 3-KINASE THAT IS DISTINCT FROM INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; CELLS; METABOLISM; PHOSPHATES; TETRAKISPHOSPHATES; 3,4,5,6-TETRAKISPHOSPHATE; PENTAKISPHOSPHATE; EXPRESSION; RECEPTOR; ENZYMES	Liver homogenates phosphorylated inositol 1,4,5,6-tetrakisphosphate exclusively to inositol 1,3,4,5,6-pentakisphosphate. Approximately 30% of this phosphorylating activity was associated with the particulate fraction of the cell, in contrast to the inositol 3,4,5,6 tetrakisphosphate 1-kinase, which was 90% soluble. This soluble 1-kinase activity was resolved from the soluble activity that phosphorylated inositol 1,4,5,6 tetrakisphosphate by an-ion-exchange chromatography. The two phosphorylating activities were also found to be differentially inhibited by inositol 1,3,4-trisphosphate (IC50 for 3-kinase > 100 mu m; IC50 for 1-kinase < 1 mu M). Thus, we have demonstrated that inositol 1,4,5,6-tetrakisphosphate is phos phorylated directly by a 3-kinase, -and inositol 3,4,5,6 tetrakisphosphate is not an obligatory intermediate, in contrast to one previous model (Oliver, K. G., Putney, J. W., Jr., Obie, J. F., and Shears, S. B. (1992) J. Biol, Chem. 267, 21528-21534). Inositol 1,4,5,6-tetrakisphosphate 3-kinase was inhibited by inositol 1,3,4,6-tetrakisphosphate (IC50, 1 mu M). Soluble inositol 1,4,5,6-tetrakisphosphate 3-kinase and inositol 1,4,5-trisphosphate 3-kinase were resolved by anion exchange chromatography. Furthermore, cDNA clones of two isozymes of inositol 1,4,5-trisphosphate 3-kinase from rat and human brain did not phosphorylate inositol 1,4,5,6-tetrakisphosphate. Thus, these two 3-kinase activities are performed by distinct enzymes.	FREE UNIV BRUSSELS,SCH MED,INST INTERDISCIPLINARY RES,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	CRAXTON, A (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709, USA.		Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916				ALI N, 1993, J BIOL CHEM, V268, P6161; BALLA T, 1989, J BIOL CHEM, V264, P9386; BARKER CJ, 1992, BIOCHEM J, V286, P469, DOI 10.1042/bj2860469; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; ERNEUX C, 1991, TRENDS PHARMACOL SCI, V12, P174, DOI 10.1016/0165-6147(91)90539-5; IRVINE RF, 1992, BIOCHEM J, V281, P261, DOI 10.1042/bj2810261; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MCCONNELL FM, 1991, BIOCHEM J, V280, P323, DOI 10.1042/bj2800323; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; SAFRANY ST, 1991, FEBS LETT, V278, P252, DOI 10.1016/0014-5793(91)80128-P; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018	24	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4337	4342						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308002				2022-12-25	WOS:A1994MW98900069
J	GOLDBERG, MA; SCHNEIDER, TJ				GOLDBERG, MA; SCHNEIDER, TJ			SIMILARITIES BETWEEN THE OXYGEN-SENSING MECHANISMS REGULATING THE EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ERYTHROPOIETIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MITOGEN; PERMEABILITY FACTOR; MESSENGER-RNA; FACTOR FAMILY; GENE; HYPOXIA; PROTEIN; ENHANCER; CHEMORECEPTORS; ACCUMULATION	The ability to adapt successfully to periods of relative hypoxia is crucial to the survival of all higher life forms. Several genes have previously been identified which are up-regulated in response to hypoxia; these include the genes encoding erythropoietin (Epo), platelet derived growth factor B chain, endothelin, interleukin-1 alpha, ornithine decarboxylase, and vascular endothelial growth factor (VEGF). However, the molecular mechanisms by which hypoxia is sensed remain enigmatic. In addition, it is unknown whether the genes mentioned share a common oxygen-sensing signal transduction pathway. In this report we demonstrate multiple similarities between the oxygen-sensing mechanisms regulating the expression of VEGF and Epo. The expression of both mRNAs is significantly up-regulated by hypoxia and cobalt chloride (CoCl2), and the half-life of both mRNAs is markedly prolonged by cycloheximide. In addition, hypoxic induction of both Epo and VEGF is inhibited by carbon monoxide. As part of our investigation into the signal transduction pathway responsible for the hypoxia and cobalt induction of these genes, we discovered that the expression of members of the jun and fos protooncogene families is also up-regulated early after exposure to either of these stimuli. These findings provide support for the hypothesis that the mechanism(s) by which hypoxia is sensed at a molecular level may be highly conserved and tightly regulated.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	GOLDBERG, MA (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, 221 LONGWOOD AVE, LMRC 222, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045098] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45098] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKER H, 1989, ANNU REV PHYSIOL, V51, P835, DOI 10.1146/annurev.physiol.51.1.835; ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; BECK I, 1993, BLOOD, V82, P704; BECK I, 1991, J BIOL CHEM, V266, P15563; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BONDURANT MC, 1986, MOL CELL BIOL, V6, P2731, DOI 10.1128/MCB.6.7.2731; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; COBURN RF, 1979, PREV MED, V8, P310, DOI 10.1016/0091-7435(79)90008-2; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DIGIULIO C, 1990, J APPL PHYSIOL, V68, P1844, DOI 10.1152/jappl.1990.68.5.1844; ERSLEV AJ, 1987, J LAB CLIN MED, V109, P429; FAQUIN WC, 1993, EXP HEMATOL, V21, P420; FAQUIN WC, 1992, BLOOD, V79, P1987; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDWASSER E, 1958, BLOOD, V13, P55, DOI 10.1182/blood.V13.1.55.55; HEISTAD DD, 1980, CIRCULATION, V61, P463, DOI 10.1161/01.CIR.61.3.463; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KRANTZ SB, 1991, BLOOD, V77, P419; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; LONGO LD, 1993, P NATL ACAD SCI USA, V90, P692, DOI 10.1073/pnas.90.2.692; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; Sambrook J, 1989, MOL CLONING LABORATO; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STRYER L, 1988, BIOCHEMISTRY-US, P313; SUNDERMAN FW, 1982, YALE J BIOL MED, V55, P123; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VOELKEL NF, 1986, AM REV RESPIR DIS, V133, P1186; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	53	554	581	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4355	4359						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308005				2022-12-25	WOS:A1994MW98900072
J	LI, YY; INOUYE, M				LI, YY; INOUYE, M			AUTOPROCESSING OF PROTHIOLSUBTILISIN-E IN WHICH ACTIVE-SITE SERINE-221 IS ALTERED TO CYSTEINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PRO-SEQUENCE; SUBTILISIN-E; INTRAMOLECULAR CHAPERONE; DENATURED SUBTILISIN; PROTEASE; PEPTIDE; POLYMERASE; EXPRESSION; INVITRO	Subtilisin, an extracellular serine protease from Bacillus subtilis, requires the amino-terminal propeptide of 77 amino acid residues for the formation of the active enzyme. The propeptide is cleaved upon completion of folding. Serine 221 at the active center was substituted with cysteine, and the mutant enzyme (prothiolsubtilisin) was expressed in Escherichia coli under the control of a T7 promoter. Prothiolsubtilisin, which was produced as inclusion bodies, was dissolved in 6 M guanidine HC1 and purified to near homogeneity in the presence of 5 M urea. The purified protein was renatured by stepwise dialysis. In spite of the mutation at the active center, the propeptide was found to be autoprocessed with similar to-60-80% efficiency. However, protease activity could not be detected in the final product by the spectrophotometric assay. Moreover, the cleaved propeptide remained tightly bound to thiolsubtilisin without being digested, as evident by SDS polyacrylamide gel electrophoresis. The amino terminal sequence of the processed thiolsubtilisin was determined and proved that the propeptide was cleaved at a site identical to that of wildtype prosubtilisin. The processed thiolsubtilisin was also found to contain one free SH group/molecule. These results unambiguously demonstrate that the processing of prosubtilisin occurs by an intramolecular autoprocessing mechanism.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BOYER HW, 1968, ARCH BIOCHEM BIOPHYS, V128, P442, DOI 10.1016/0003-9861(68)90050-7; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LERNER CG, 1990, J BIOL CHEM, V265, P20085; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; Maniatis T., 1982, MOL CLONING; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; NECT KE, 1966, P NATL ACAD SCI USA, V56, P1606; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; OHTA Y, 1990, MOL MICROBIOL, V4, P295, DOI 10.1111/j.1365-2958.1990.tb00596.x; PHILIPP M, 1983, MOL CELL BIOCHEM, V51, P5, DOI 10.1007/BF00215583; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WITHER JR, 1991, P NATL ACAD SCI USA, V88, P9330; WONG SL, 1986, J BIOL CHEM, V261, P176; ZHU X, 1992, LIFE SCI ADV, V11, P35; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	29	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4169	4174						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307978				2022-12-25	WOS:A1994MW98900043
J	OKAZAKI, T; BIELAWSKA, A; DOMAE, N; BELL, RM; HANNUN, YA				OKAZAKI, T; BIELAWSKA, A; DOMAE, N; BELL, RM; HANNUN, YA			CHARACTERISTICS AND PARTIAL-PURIFICATION OF A NOVEL CYTOSOLIC, MAGNESIUM-INDEPENDENT, NEUTRAL SPHINGOMYELINASE ACTIVATED IN THE EARLY SIGNAL-TRANSDUCTION OF 1-ALPHA,25-DIHYDROXYVITAMIN D-3-INDUCED HL-60 CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; INHIBITION; MECHANISM; TURNOVER	Treatment of HL-60 cells with 1 alpha,25-dihydroxyvitamin D-3 induces activation of a neutral sphingomyelinase (SMase), resulting in a decrease in sphingomyelin (SM) levels and an increase in ceramide levels in a proposed ''sphingomyelin cycle'' of cell regulation (Okazaki, T, Bell, R., and Hannun, Y. (1989) J. Biol. Chem 264, 19076-19080). Cell-permeable synthetic ceramides induce HL-60 cell differentiation toward a monocytic lineage without conversion to sphingosine, suggesting that ceramide is a lipid mediator of cell differentiation (Okazaki, T., Bielawska, A., Bell, R., and Hannun, Y. (1990) J. Biol. Chem. 265, 15823-15831). In this study, we investigated a novel SMase that was activated 2-2.5 h after treatment of cells with 1 alpha,25-dihydroxyvitamin D-3. The activated SMase was localized to the cytosolic fraction. It was inhibited by copper, ferric iron, and zinc and showed optimal activity at pH 7.5. A mixed micellar assay was developed for the enzyme, with optimal activity achieved at 12 mol % SM in Triton X-100 mixed micelles and at 20 mol % SM in deoxycholate micelles. The activity was modestly enhanced by phosphatidic acid, phosphatidylserine, or phosphatidylinositol, but not by other major phospholipids. Purification was performed by chromatography on DEAE anion-exchange, Q-Sepharose Fast Flow, hydroxylapatite, sphingosylphosphocholine affinity, and Superose 12 gel filtration columns. Two peaks of activity with molecular masses of 45 and 95 kDa were resolved by gel filtration chromatography on Superose 12. The specific activities of the purified 45- and 95-kDa enzymes were 2780 and 2790 nmol/mg/h, respectively. These data identify a novel cytosolic, magnesium-independent, neutral SMase(s) that is activated during cell differentiation.	DUKE UNIV,DEPT MED,DURHAM,NC 27710; DUKE UNIV,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University	OKAZAKI, T (corresponding author), OSAKA DENT UNIV,DEPT MED,CYUOU KU,1-5-17 OTEMAE,OSAKA,OSAKA 540,JAPAN.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020205, R37DK020205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20205] Funding Source: Medline; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNHOLZ Y, 1966, J BIOL CHEM, V241, P3731; Brady R. O., 1983, METABOLIC BASIS INHE, P831; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIRSHFELD D, 1975, ARCH BIOCHEM BIOPHYS, V167, P186, DOI 10.1016/0003-9861(75)90455-5; JONES CS, 1981, BIOCHEM J, V195, P373, DOI 10.1042/bj1950373; KIM MY, 1991, J BIOL CHEM, V266, P484; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEHLHORN IE, 1988, BIOCHIM BIOPHYS ACTA, V939, P151, DOI 10.1016/0005-2736(88)90056-9; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V176, P339, DOI 10.1016/0005-2760(69)90192-1; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15822; RAO BG, 1976, J LIPID RES, V17, P506; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1058, DOI 10.1515/bchm2.1971.352.2.1058; WONG P, 1991, J BIOL CHEM, V266, P14877; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	27	191	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4070	4077						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307965				2022-12-25	WOS:A1994MW98900029
J	SAVAGE, TJ; HATCH, MW; CROTEAU, R				SAVAGE, TJ; HATCH, MW; CROTEAU, R			MONOTERPENE SYNTHASES OF PINUS-CONTORTA AND RELATED CONIFERS - A NEW CLASS OF TERPENOID CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAGE SALVIA-OFFICINALIS; ESSENTIAL HISTIDINE RESIDUE; SODIUM DODECYL-SULFATE; MENTHA-X-PIPERITA; GERANYL PYROPHOSPHATE; PARTIAL-PURIFICATION; SESQUITERPENE CYCLASE; GLANDULAR TRICHOMES; NERYL PYROPHOSPHATE; 4S-LIMONENE SYNTHASE	A cell-free extract from the xylem of lodgepole pine (Pinus contorta) catalyzes the conversion of [1-H-3(1)]geranyl pyrophosphate to a variety of moneterpene olefins found in lodgepole pine oleoresin. This monoterpene synthase activity is similar to previously described terpenoid cyclases from grand fir (Abies grandis) and other higher plants in molecular mass (67 +/- 2 kDa as estimated by size exclusion chromatography), K-m for geranyl pyrophosphate (7.8 +/- 1.9 mu M), and isoelectric point (4.75 +/- 0.2 as determined by isoelectric focusing), but the cyclases from both lodgepole pine and grand fir are unlike previously characterized terpenoid cyclases from angiosperms and fungi, in that they have an alkaline pH optimum (pH 7.8), are activated by K+, Rb+, Cs+, or NH4+ (Li+ and Na+ are not effective), require either Mn2+ or Fe2+ as divalent metal ion cofactors (Mg2+ is not effective), and are not protected by the substratemetal ion complex against inhibition by the histidine-directed reagent diethyl pyrocarbonate. Chromatography of the pine xylem extracts on a quaternary amino anion-exchange resin results in the separation of four similar, but distinct, multiple product monoterpene synthases that produce sabinene, beta-phellandrene, 3-carene, and beta-pinene as the principal components, respectively. The major cyclase (phellandrene synthase) was subsequently purified by hydroxyapatite chromatography and electrophoresis. V8 proteolysis provided a peptide map significantly different from that obtained with limonene synthase from spearmint (Mentha spicata), and limited NH2-terminal sequencing of the phellandrene synthase fragments revealed no significant similarity to the deduced amino acid sequence of the angiosperm limonene synthase, the only monoterpene cyclase to be cloned and sequenced thus far. Furthermore, polyclonal antibodies raised against the angiosperm limonene synthase did not detectably cross react with any proteins in extracts from either lodgepole pine or grand fir by immunoblotting analysis. In addition to these structural differences between cyclases from conifers and herbaceous angiosperms, the unusual pH optimum, mono- and divalent metal ion requirement, and reactivity toward histidine carbethoxylation indicate that monoterpene cyclases isolated from conifers may also have a different complement of active-site amino acid residues involved in substrate binding and catalysis than those of terpenoid cyclases previously isolated from angiosperms.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031354, R01GM031354] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31354] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO WR, 1991, ARCH BIOCHEM BIOPHYS, V286, P511, DOI 10.1016/0003-9861(91)90073-R; ALONSO WR, 1993, ARCH BIOCHEM BIOPHYS, V301, P58, DOI 10.1006/abbi.1993.1114; ALONSO WR, 1992, J BIOL CHEM, V267, P7582; BERNARDDAGAN C, 1982, PHYSIOL VEG, V20, P775; Bienfait H. F., 1983, Metals and micronutrients: uptake and utilization by plants, P111; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1987, ARCH BIOCHEM BIOPHYS, V254, P421, DOI 10.1016/0003-9861(87)90120-2; Capozzi G., 1974, CHEM THIOL GROUP 2; CHAYET L, 1977, ARCH BIOCHEM BIOPHYS, V180, P318, DOI 10.1016/0003-9861(77)90044-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLBY SM, 1993, J BIOL CHEM, V268, P23016; CROTEAU R, 1989, J BIOL CHEM, V264, P15309; CROTEAU R, 1977, PLANT PHYSIOL, V59, P519, DOI 10.1104/pp.59.3.519; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1981, PLANT PHYSIOL, V67, P820, DOI 10.1104/pp.67.4.820; CROTEAU R, 1976, ARCH BIOCHEM BIOPHYS, V176, P734, DOI 10.1016/0003-9861(76)90217-4; CROTEAU R, 1989, J BIOL CHEM, V264, P2075; CROTEAU R, 1988, J BIOL CHEM, V263, P10063; CROTEAU R, 1979, ARCH BIOCHEM BIOPHYS, V198, P512, DOI 10.1016/0003-9861(79)90526-5; CROTEAU R, 1977, ARCH BIOCHEM BIOPHYS, V179, P257, DOI 10.1016/0003-9861(77)90110-2; CROTEAU R, 1990, ARCH BIOCHEM BIOPHYS, V277, P374, DOI 10.1016/0003-9861(90)90593-N; CROTEAU R, 1980, ARCH BIOCHEM BIOPHYS, V200, P534, DOI 10.1016/0003-9861(80)90385-9; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; CROTEAU RB, 1990, J CHROMATOGR, V500, P349, DOI 10.1016/S0021-9673(00)96076-X; CROTEAU RB, 1987, BIOCHEMISTRY-US, V26, P5383, DOI 10.1021/bi00391a025; DEHAL SS, 1988, ARCH BIOCHEM BIOPHYS, V261, P346, DOI 10.1016/0003-9861(88)90350-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUEBER MT, 1978, PLANT PHYSIOL, V62, P598, DOI 10.1104/pp.62.4.598; FAHN A, 1979, SECRETORY TISSUES PL, P176; FERSHT A, 1985, ENZYME STRUCTURE MEC, P405; FROST RG, 1977, PLANT PHYSIOL, V59, P22, DOI 10.1104/pp.59.1.22; GAMBLIEL H, 1984, J BIOL CHEM, V259, P740; GAMBLIEL H, 1982, J BIOL CHEM, V257, P2335; GERSHENZON J, 1991, RECENT ADV PHYTOCHEM, V25, P347; Gershenzon J., 1992, HERBIVORES THEIR INT, VVolume 1, P165; GIJZEN M, 1992, ARCH BIOCHEM BIOPHYS, V294, P670, DOI 10.1016/0003-9861(92)90740-N; HALLAHAN TW, 1988, ARCH BIOCHEM BIOPHYS, V264, P618, DOI 10.1016/0003-9861(88)90328-1; HOHN TM, 1986, ARCH BIOCHEM BIOPHYS, V251, P756, DOI 10.1016/0003-9861(86)90386-3; HOHN TM, 1989, ARCH BIOCHEM BIOPHYS, V272, P137, DOI 10.1016/0003-9861(89)90204-X; JOVIN TM, 1973, ANN NY ACAD SCI, V209, P477, DOI 10.1111/j.1749-6632.1973.tb47551.x; KING HL, 1977, BIOCHEMISTRY-US, V16, P3815, DOI 10.1021/bi00636a015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P38, DOI 10.1104/pp.96.1.38; LEWINSOHN E, 1992, ARCH BIOCHEM BIOPHYS, V293, P167, DOI 10.1016/0003-9861(92)90380-F; MCCASKILL D, 1992, PLANTA, V187, P445, DOI 10.1007/BF00199962; MUNCK SL, 1990, ARCH BIOCHEM BIOPHYS, V282, P58, DOI 10.1016/0003-9861(90)90086-E; Penhallow D.P, 1907, MANUAL N AM GYMNOSPE MANUAL N AM GYMNOSPE; POULOSE AJ, 1978, ARCH BIOCHEM BIOPHYS, V191, P400, DOI 10.1016/0003-9861(78)90104-2; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V296, P49, DOI 10.1016/0003-9861(92)90543-6; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; ROBARDS AW, 1968, PLANTA, V82, P179, DOI 10.1007/BF01305721; ROBINSON DR, 1970, BIOCHEMISTRY-US, V9, P80, DOI 10.1021/bi00803a011; ROJAS MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P389, DOI 10.1016/0003-9861(83)90535-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SECKBACH J, 1972, J ULTRA MOL STRUCT R, V39, P65, DOI 10.1016/S0022-5320(72)80007-8; Suelter C., 1974, METAL IONS BIOL SYST, V3, P201; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; VOGELI U, 1990, PLANT PHYSIOL, V93, P182, DOI 10.1104/pp.93.1.182; WAGSCHAL K, 1991, TETRAHEDRON, V47, P5933, DOI 10.1016/S0040-4020(01)86486-3; WERKER E, 1969, Botanical Journal of the Linnean Society, V62, P379, DOI 10.1111/j.1095-8339.1969.tb01974.x; WERKER E, 1968, NATURE, V218, P388, DOI 10.1038/218388a0; WHITE EE, 1983, PHYTOCHEMISTRY, V22, P1399, DOI 10.1016/S0031-9422(00)84022-4; WOODING FBP, 1965, J ULTRA MOL STRUCT R, V13, P233, DOI 10.1016/S0022-5320(65)80072-7; ZAVARIN E, 1970, PHYTOCHEMISTRY, V9, P1049, DOI 10.1016/S0031-9422(00)85225-5	68	62	68	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4012	4020						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307957				2022-12-25	WOS:A1994MW98900020
J	STOLL, LL; DENNING, GM; KASNER, NA; HUNNINGHAKE, GW				STOLL, LL; DENNING, GM; KASNER, NA; HUNNINGHAKE, GW			PLATELET-ACTIVATING-FACTOR MAY STIMULATE BOTH RECEPTOR-DEPENDENT AND RECEPTOR-INDEPENDENT INCREASES IN [CA2+] IN HUMAN AIRWAY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; FUTURE CLINICAL IMPLICATIONS; CYTOSOLIC FREE CALCIUM; SIGNAL TRANSDUCTION; FACTOR PAF; LINKED DIGLYCERIDES; ANTAGONISTS; PATHWAYS; ASTHMA	Platelet-activating factor (PAF) is a potent mediator which produces a wide range of biological responses by binding to specific, high affinity receptors on the target cell surface. In addition, we and others have observed cellular responses to PAF which are not receptor-mediated. We report here that in HBE-16 human bronchial epithelial cells, PAF produces a biphasic increase in [Ca2+](i) consisting of a rapid initial increase due to release from intracellular stores followed by a gradual, sustained phase caused by influx of extracellular Ca2+. Under certain conditions, the PAF receptor antagonist L-659,989 completely blocks the release of Ca2+ from intracellular stores, suggesting a complete block of the receptor-mediated response. Under these same conditions, a residual influx of extracellular Ca2+ is observed, suggesting a possible receptor-independent response. HBE-16 cells partially metabolize PAF to 1-O-alkyl-2 acetyl-sn-glycerol (AAG), a bioactive diacylglycerol analog. Moreover, AAG stimulates Ca2+ influx in these cells; the response to AAG is at least 100-fold more potent than that to PAF. Taken together, these results suggest that PAF may stimulate Ca2+ influx in HBE-16 cells through a receptor-independent pathway mediated by AAG. Thus these studies suggest a previ ously unrecognized dual-pathway regulatory mechanism for PAF in the airway.	UNIV IOWA, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA	University of Iowa	STOLL, LL (corresponding author), UNIV IOWA, DEPT ANESTHESIA, 2-317 BSB, IOWA CITY, IA 52242 USA.							BARNES PJ, 1991, ANN NY ACAD SCI, V629, P193; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BERDEL WE, 1987, ANTICANCER RES, V7, P1181; BLANK ML, 1984, BIOCHEM BIOPH RES CO, V118, P344, DOI 10.1016/0006-291X(84)91107-0; BROCK TA, 1986, AM J PHYSIOL, V250, P1086, DOI 10.1152/ajpheart.1986.250.6.H1086; BUCKLEY TL, 1989, EUR J PHARMACOL, V163, P275, DOI 10.1016/0014-2999(89)90196-9; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DEMPSEY EC, 1990, J CELL PHYSIOL, V144, P159, DOI 10.1002/jcp.1041440121; DUBOURDIEU DJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P326, DOI 10.1016/0167-4889(90)90104-L; FORD DA, 1989, J BIOL CHEM, V264, P13818; GANDHI CR, 1990, J BIOL CHEM, V265, P18234; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIRAFUJI M, 1992, JPN J PHARMACOL, V58, P231, DOI 10.1254/jjp.58.231; HOSFORD D, 1990, CRIT REV THER DRUG, V7, P261; HWANG SB, 1988, J PHARMACOL EXP THER, V246, P534; KESTER M, 1987, FASEB J, V1, P215, DOI 10.1096/fasebj.1.3.2442057; KOLTAI M, 1991, DRUGS, V42, P174, DOI 10.2165/00003495-199142020-00002; KOLTAI M, 1991, DRUGS, V42, P9, DOI 10.2165/00003495-199142010-00002; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; MULDOON LL, 1990, CELL REGUL, V1, P379, DOI 10.1091/mbc.1.4.379; PAGE CP, 1988, J ALLERGY CLIN IMMUN, V81, P144, DOI 10.1016/0091-6749(88)90233-3; PALMER S, 1986, BIOCHEM J, V238, P491, DOI 10.1042/bj2380491; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REDONDO JM, 1988, J BIOL CHEM, V263, P17467; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SMITH IL, 1992, BLOOD COAGUL FIBRIN, V3, P759, DOI 10.1097/00001721-199212000-00009; SMITH LJ, 1991, AM REV RESPIR DIS, V143, pS100, DOI 10.1164/ajrccm/143.5_Pt_2.S100; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; STOLL LL, 1989, J CELL PHYSIOL, V139, P253, DOI 10.1002/jcp.1041390206; STOLL LL, 1989, CELL REGUL, V1, P13, DOI 10.1091/mbc.1.1.13; STOLL LL, 1987, J CELL PHYSIOL, V133, P103, DOI 10.1002/jcp.1041330113; STOLL LL, 1991, J CELL SCI, V100, P145; TAN WC, 1992, AM REV RESPIR DIS, V146, P916, DOI 10.1164/ajrccm/146.4.916; VOELKEL NF, 1986, PROSTAGLANDINS, V32, P359, DOI 10.1016/0090-6980(86)90005-5; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319	36	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4254	4259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307989				2022-12-25	WOS:A1994MW98900056
J	WENNSTROM, S; SIEGBAHN, A; YOKOTE, K; ARVIDSSON, AK; HELDIN, CH; MORI, S; CLAESSONWELSH, L				WENNSTROM, S; SIEGBAHN, A; YOKOTE, K; ARVIDSSON, AK; HELDIN, CH; MORI, S; CLAESSONWELSH, L			MEMBRANE RUFFLING AND CHEMOTAXIS TRANSDUCED BY THE PDGF BETA-RECEPTOR REQUIRE THE BINDING-SITE FOR PHOSPHATIDYLINOSITOL 3' KINASE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE CELLS; MIDDLE T-ANTIGEN; B-TYPE RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SH3 DOMAINS; EXPRESSION CLONING; INDUCED ACTIVATION	Activation of the platelet-derived growth factor (PDGF) beta-receptor results in motility responses in the forms of membrane ruffling and chemotaxis. Porcine aortic endothelial cells expressing the PDGF beta-receptor or a chimeric fibroblast growth factor (FGF) receptor, in which the endogenous kinase insert was replaced with the corresponding region from the PDGF beta-receptor, migrated efficiently towards a concentration gradient of PDGF-BB and bFGF, respectively, and exhibited both pronounced edge ruffling and circular membrane ruffling in response to ligand-stimulation. The wildtype FGF receptor-1 showed weak or no response in these assays. Further analyses were conducted on mutant receptors, in which tyrosine residues that can serve as autophosphorylation sites and thereby mediate interactions with specific signal transduction molecules, were changed to phenylalanine residues. Each one of the analysed mutants were mitogenically active, however, a mutant in which Tyr740 and Tyr751 were replaced failed to mediate ruffling and chemotaxis. These two residues are implicated in the binding of phosphatidylinositol 3' kinase. The notion that this enzyme is involved in PDGF beta-receptor-induced cell motility is furthermore supported by the finding that another mutant, in which Met743 and Met754 were replaced, and which failed to interact with phosphatidylinositol 3' kinase, was also unable to mediate motility responses.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; UNIV HOSP UPPSALA,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital				Claesson-Welsh, Lena/0000-0003-4275-2000				ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ARVIDSSON AK, 1992, CELL GROWTH DIFFER, V3, P881; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLAESSONWELSH L, 1993, BIOL PLATELET DERIVE, V5, P31; COOPER J, 1993, BIOL PLATELET DERIVE, V5, P44; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOSANG M, 1989, J CELL PHYSIOL, V140, P558, DOI 10.1002/jcp.1041400322; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; LAROSE L, 1993, ONCOGENE, V8, P2493; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHOFIELD PN, 1992, FEBS LETT, V298, P154, DOI 10.1016/0014-5793(92)80044-H; SENIOR RM, 1983, J CELL BIOL, V96, P382, DOI 10.1083/jcb.96.2.382; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VALIUS B, 1993, CELL, V73, P321; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WESTERMARK B, 1985, J CELL PHYSIOL, V124, P43, DOI 10.1002/jcp.1041240108; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	81	307	307	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					651	660						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290276				2022-12-25	WOS:A1994MW24800034
J	BOIX, E; NOGUES, MV; SCHEIN, CH; BENNER, SA; CUCHILLO, CM				BOIX, E; NOGUES, MV; SCHEIN, CH; BENNER, SA; CUCHILLO, CM			REVERSE TRANSPHOSPHORYLATION BY RIBONUCLEASE-A NEEDS AN INTACT P(2)-BINDING SITE - POINT MUTATIONS AT LYS-7 AND ARG-10 ALTER THE CATALYTIC PROPERTIES OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; ESCHERICHIA-COLI; ACTIVE-SITE; CRYSTAL-STRUCTURE; C-PEPTIDE; BINDING; ACID; RESIDUES; SUBSTITUTION; MUTAGENESIS	Bovine pancreatic ribonuclease A interacts with RNA along multiple binding subsites that essentially recognize the negatively charged phosphates of the substrate. This work gives additional strong support to the existence of the postulated phosphate-binding subsite p2 (Pares, X., Llorens, R., Arus, C., and Cuchillo, C. M. (1980) Eur. J. Biochem. 105, 571-579) and confirms the central role of Lys-7 and Arg-10 in establishing an electrostatic interaction with a phosphate group of the substrate. The effects of charge elimination by Lys-7 --> Gln (K7Q) and/or Arg-10 --> Gln (R10Q) substitutions in catalytic and ligand-binding properties of ribonuclease A have been studied. The values of K(m) for cytidine 2',3'-cyclic phosphate and cytidylyl-3',5'-adenosine are not altered but are significantly increased for poly(C). In all cases, k(cat) values are lower. Synthetic activity, i.e. the reversion of the transphosphorylation reaction, is reduced for K7Q and R10Q mutants and is practically abolished in the double mutant. Finally, the extent of the reaction of the mutants with 6-chloropurine-9-beta-D-ribofuranosyl 5'-monophosphate indicates that the phosphate ionic interaction in P2 is weakened. Thus, p2 modification alters both the catalytic efficiency and the extent of the processes in which an interaction of the phosphate group of the substrate or ligand with the p2-binding subsite is involved.	UNIV AUTONOMA BARCELONA, FAC CIENCIAS, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN; UNIV AUTONOMA BARCELONA, INST BIOL FONAMENTAL VICENT VILLAR PALASI, E-08193 BARCELONA, SPAIN; SWISS FED INST TECHNOL, ORGAN CHEM LAB, CH-8092 ZURICH, SWITZERLAND; SWISS FED INST TECHNOL, DEPT PHARM, CH-8092 ZURICH, SWITZERLAND	Autonomous University of Barcelona; University of Barcelona; Autonomous University of Barcelona; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich			Boix, Ester/B-9038-2012; Schein, Catherine H/A-1426-2012; Nogues, M. Victoria/H-6100-2015	Boix, Ester/0000-0003-1790-2142; Nogues, M. Victoria/0000-0002-7104-0961; Schein, Catherine/0000-0002-8290-2109				ALONSO J, 1986, ARCH BIOCHEM BIOPHYS, V246, P681, DOI 10.1016/0003-9861(86)90324-3; ARUS C, 1981, BIOCHIM BIOPHYS ACTA, V660, P117, DOI 10.1016/0005-2744(81)90116-9; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BIRDSALL DL, 1992, J BIOL CHEM, V267, P22230; Blackburn P, 1982, ENZYMES, VXV, P317; BORKAKOTI N, 1983, EUR J BIOCHEM, V132, P89, DOI 10.1111/j.1432-1033.1983.tb07329.x; BRUNGER AT, 1985, P NATL ACAD SCI USA, V82, P8458, DOI 10.1073/pnas.82.24.8458; DAY AG, 1992, BIOCHEMISTRY-US, V31, P6390, DOI 10.1021/bi00143a005; DELLORENS R, 1989, PROTEIN ENG, V2, P417, DOI 10.1093/protein/2.6.417; FILIPPI B, 1987, MACROMOLECULAR BIORE, P147; GEORGALIS Y, 1992, J BIOL CHEM, V267, P10323; GUASCH A, 1989, J CHROMATOGR, V473, P281, DOI 10.1016/S0021-9673(00)91311-6; IRIE M, 1986, J BIOCHEM-TOKYO, V100, P1057, DOI 10.1093/oxfordjournals.jbchem.a121785; IRIE M, 1984, J BIOCHEM-TOKYO, V95, P751, DOI 10.1093/oxfordjournals.jbchem.a134666; ISOBE K, 1986, J BIOCHEM BIOPH METH, V12, P299, DOI 10.1016/0165-022X(86)90066-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON A, 1986, J MOL BIOL, V189, P305, DOI 10.1016/0022-2836(86)90512-7; MOSSAKOWSKA DE, 1989, BIOCHEMISTRY-US, V28, P3843, DOI 10.1021/bi00435a033; NAMBIAR KP, 1987, EUR J BIOCHEM, V163, P67, DOI 10.1111/j.1432-1033.1987.tb10737.x; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; OSTERMAN HL, 1979, BIOCHEMISTRY-US, V18, P1984, DOI 10.1021/bi00577a021; PARES X, 1991, ESSAYS BIOCHEM, V26, P89; PARES X, 1980, EUR J BIOCHEM, V105, P571, DOI 10.1111/j.1432-1033.1980.tb04534.x; PFLUMM MN, 1969, J BIOL CHEM, V244, P3973; RIBO M, 1991, STRUCTURE, MECHANISM AND FUNCTION OF RIBONUCLEASES, P157; RICHARDS FM, 1971, ENZYMES, V4, P647; RICHARDSON RM, 1988, BIOCHIM BIOPHYS ACTA, V953, P70, DOI 10.1016/0167-4838(88)90010-6; RICHARDSON RM, 1990, BIOCHEM J, V267, P593, DOI 10.1042/bj2670593; RINK H, 1984, NUCLEIC ACIDS RES, V12, P6369, DOI 10.1093/nar/12.16.6369; SCHEIN CH, 1992, BIOCHEM J, V283, P137, DOI 10.1042/bj2830137; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V24, P229, DOI 10.1016/0006-3002(57)90186-5; STREHLOW KG, 1989, BIOCHEMISTRY-US, V28, P2130, DOI 10.1021/bi00431a025; STRICKLA.EH, 1972, BIOCHEMISTRY-US, V11, P3465, DOI 10.1021/bi00768a022; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; WLODAWER A, 1984, BIOL MACROMOL, P393; YAMANE K, 1988, J BIOL CHEM, V263, P19690	38	71	71	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2529	2534						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300580				2022-12-25	WOS:A1994MV43200030
J	FERNANDEZ, JA; GRIFFIN, JH				FERNANDEZ, JA; GRIFFIN, JH			A PROTEIN-S BINDING-SITE ON C4B-BINDING PROTEIN INVOLVES BETA-CHAIN RESIDUES 31-45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; IDENTIFICATION; COMPLEX; SUBUNIT; PLASMA; FORMS	C4b-binding protein (C4BP) down-regulates the anticoagulant cofactor activity of protein S in the protein C pathway since free protein S but not the protein S:C4BP complex is anticoagulantly active. To identify beta chain residues responsible for binding protein S, synthetic overlapping pentadecapeptides covering the entire 1-235 sequence were tested as inhibitors of complex formation. The peptide comprising residues 31-45 (VCIKGYHLVGKKTLF) from the first short consensus repeat domain inhibited the binding of C4BP to protein S with half-maximal inhibition at 20-45 muM, and studies suggested the sequence of YxLVG was crucial. Peptide beta(31-45) specifically inhibited the APC cofactor activity of purified protein S in Xa-1-stage coagulation assays with 50% inhibition at 15 muM peptide. Peptide beta(31-45) and related peptides such as beta(34-42) inhibited the binding of protein S to an antipeptide monoclonal antibody made against residues 420-434 of protein S (monoclonal antibody LJ-56). Polyclonal anti-beta(31-45) peptide antibodies inhibited complex formation. Dose-dependent binding studies showed that protein S bound directly to immobilized peptide beta(31-45). These results show that residues 31-45 of the C4BP beta chain provide a binding site for protein S, and they suggest that the C4BP beta chain residues 34-42 are located near residues 420-434 of protein S in the protein S:C4BP complex.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-21544] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHUNG LP, 1985, MOL IMMUNOL, V22, P427, DOI 10.1016/0161-5890(85)90127-0; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; FERNANDEZ JA, 1993, J BIOL CHEM, V268, P16788; GRIFFIN JH, 1992, BLOOD, V79, P3203; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; HESSING M, 1993, FEBS LETT, V317, P228, DOI 10.1016/0014-5793(93)81281-4; HESSING M, 1990, THROMB HAEMOSTASIS, V64, P245; HILLARP A, 1987, J BIOL CHEM, V262, P11300; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; HILLARP A, 1988, J BIOL CHEM, V263, P12759; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; NELSON RM, 1991, BIOCHEMISTRY-US, V30, P2384, DOI 10.1021/bi00223a013; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHWARZ HP, 1987, THROMB HAEMOSTASIS, V56, P382; SUZUKI K, 1988, J BIOL CHEM, V263, P17034; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357	22	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2535	2540						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300581				2022-12-25	WOS:A1994MV43200031
J	JI, ZS; FAZIO, S; LEE, YL; MAHLEY, RW				JI, ZS; FAZIO, S; LEE, YL; MAHLEY, RW			SECRETION-CAPTURE ROLE FOR APOLIPOPROTEIN-E IN REMNANT LIPOPROTEIN METABOLISM INVOLVING CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; CHOLESTEROL TRANSPORT; CHYLOMICRON REMNANTS; CULTURED-CELLS; MACROPHAGES; E3-LEIDEN; BINDING; HEPARINASE; CLEARANCE	To determine the impact of enhanced apolipoprotein (apo) E secretion on the mechanism of remnant lipoprotein uptake, rat hepatoma cells (McA-RH7777) were stably transfected with normal human apoE3 or receptor binding-defective apoE-Leiden. After a 2-h incubation, the human apoE secreted from the transfected hepatocytes was 10-12 times greater than the endogenous rat apoE. The apoE3-transfected cells bound and internalized rabbit beta-very low density lipoproteins (beta-VLDL) to a much greater degree than did apoE-Leiden-transfected cells and nontransfected cells. The apoE3-secreting cells displayed a 2-3.5-fold enhancement of cell-associated beta-VLDL compared to either the apoE-Leiden-transfected or nontransfected cells. Fluorescently labeled beta-VLDL were observed to concentrate within intracellular granules of the apoE3-transfected cells, presumably within endosomes and lysosomes. Furthermore, electron microscopy revealed that the apoE3-secreting cells displayed abundant beta-VLDL and chylomicron remnants on their cell surfaces and microvilli, in contrast to non-transfected or apoE-Leiden-secreting cells. Electron microscopy also revealed an abundance of chylomicron remnants within intracellular vesicles and multivesicular bodies of apoE3-transfected hepatocytes. Heparinase treatment (3 units/ml) completely abolished the increased association of beta-VLDL with apoE3-transfected cells but did not affect the limited association of beta-VLDL with apoE-Leiden-transfected or nontransfected cells. We established that the apoE3-enriched beta-VLDL were bound to cell surface heparan sulfate proteoglycans, as was the newly synthesized and secreted apoE3 (approximately 12% of the total secreted apoE3 was released by heparinase and suramin; 4% by heparin). In addition, reisolation of beta-VLDL by fast performance liquid chromatography after their incubation with exogenous apoE3, with medium from apoE3-secreting cells, or with the apoE3-secreting cells themselves revealed that the particles were enriched in apoE3 and displayed enhanced binding. These results suggest a secretion-capture role for apoE and indicate an important role for heparan sulfate proteoglycans on the cell surface for remnant lipoprotein metabolism.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, CARDIOVASC RES INST, POB 419100, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNON R, 1991, BIOCHIM BIOPHYS ACTA, V1085, P336, DOI 10.1016/0005-2760(91)90138-8; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FAZIO S, 1992, J BIOL CHEM, V267, P6941; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAVEKES L, 1986, HUM GENET, V73, P157, DOI 10.1007/BF00291607; HIXSON JE, 1990, J LIPID RES, V31, P545; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; JI ZS, 1993, J BIOL CHEM, V268, P10160; KHAN MY, 1991, ANAL BIOCHEM, V196, P373; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LILLYSTAUDERMAN M, 1993, J LIPID RES, V34, P190; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MOKUNO H, 1991, BIOCHIM BIOPHYS ACTA, V1082, P63; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; OWENS RT, 1991, ARTERIOSCLER THROMB, V11, P1752, DOI 10.1161/01.ATV.11.6.1752; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SHIMANO H, 1991, BIOCHIM BIOPHYS ACTA, V1086, P245, DOI 10.1016/0005-2760(91)90166-F; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEISGRABER KH, 1988, BIOCHEM BIOPH RES CO, V157, P1212, DOI 10.1016/S0006-291X(88)81003-9; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; YANG VC, 1985, J BIOL CHEM, V260, P1849	41	198	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2764	2772						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300609				2022-12-25	WOS:A1994MV43200062
J	JEONG, S; STEIN, A				JEONG, S; STEIN, A			DNA-SEQUENCE AFFECTS NUCLEOSOME ORDERING ON REPLICATING PLASMIDS IN TRANSFECTED COS-1 CELLS AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CHROMATIN STRUCTURE; GENE-EXPRESSION; SV40 DNA; REGION; TRANSCRIPTION; MINICHROMOSOMES; ORIGIN; ENCAPSIDATION; INITIATION	Nucleosome ordering on a variety of replicating plasmids, assembled into chromatin in transfected COS-1 cells, was studied by micrococcal nuclease digestion of isolated nuclei. Generally, no more than three well defined multiples of a unit nucleosome repeat, which resembled the first three bands of the (187 +/- 5 base pair (bp)) cellular chromatin ladder, could be detected in constructs that contained a near-minimal SV40 replication origin. In contrast, constructs that additionally contained the SV40 early region exhibited significantly more regular nucleosome arrangements. In some cases, eight to nine multiples of a 203 +/- 5-bp repeat could be resolved. The presence of the SV40 early region was necessary for physiological nucleosome alignment over the SV40 late and ori regions, or onto adjacent pBR327 DNA. In an in vitro chromatin assembly system, using purified chicken erythrocyte histones plus polyglutamic acid, a portion of SV40 DNA became packaged into a highly ordered 200 +/- 5-bp nucleosome array, which encompassed the early region and extended for about 2800 bp. The data suggest that in the cell nucleus, nucleosome ordering on SV40 DNA might spread from sequences in the early region, close to where transcription terminates, probably as a consequence of histone H1-nucleosome interactions.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Jeong, Shinwu/0000-0002-4847-813X	NIGMS NIH HHS [GM48341] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048341] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1980, P NATL ACAD SCI-BIOL, V77, P885, DOI 10.1073/pnas.77.2.885; AMBROSE C, 1986, P NATL ACAD SCI USA, V83, P3287, DOI 10.1073/pnas.83.10.3287; AMBROSE C, 1990, J MOL BIOL, V214, P875, DOI 10.1016/0022-2836(90)90342-J; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BLASQUEZ V, 1986, J MOL BIOL, V191, P97, DOI 10.1016/0022-2836(86)90425-0; BLASQUEZ V, 1985, THESIS PURDUE U W LA; BLASQUEZ V, 1987, MOL ASPECTS PAPOVAVI, P219; CARTWRIGHT IL, 1988, ARCHITECTURE EUKARYO, P283; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; COCAPRADOS M, 1982, J VIROL, V44, P603, DOI 10.1128/JVI.44.2.603-609.1982; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; JEONG SW, 1991, J MOL BIOL, V222, P1131, DOI 10.1016/0022-2836(91)90597-Y; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; LAUDERDALE JD, 1993, BIOCHEMISTRY-US, V32, P489, DOI 10.1021/bi00053a013; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LOHR D, 1975, SCIENCE, V188, P165, DOI 10.1126/science.1090006; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; OPPENHEIM A, 1992, J VIROL, V66, P5320, DOI 10.1128/JVI.66.9.5320-5328.1992; OPPENHEIM A, 1989, GENE, V77, P79, DOI 10.1016/0378-1119(89)90361-2; PIENTA K J, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P355; POLJAK LG, 1987, BIOCHEMISTRY-US, V26, P295, DOI 10.1021/bi00375a041; POMMIER Y, 1990, J VIROL, V64, P419, DOI 10.1128/JVI.64.1.419-423.1990; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSE SM, 1984, J BIOL CHEM, V259, P8534; ROSL F, 1991, MOL CARCINOGEN, V4, P248, DOI 10.1002/mc.2940040312; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Sambrook J, 1989, MOL CLONING LABORATO; SARAGOSTI S, 1980, CELL, V20, P65, DOI 10.1016/0092-8674(80)90235-4; SHELTON ER, 1978, J MOL BIOL, V125, P491, DOI 10.1016/0022-2836(78)90312-1; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBERON X, 1980, GENE, V9, P287, DOI 10.1016/0378-1119(90)90328-O; STEIN A, 1989, METHOD ENZYMOL, V170, P585; STEIN A, 1987, J BIOL CHEM, V262, P3872; van Holde KE., 1989, SPRINGER SERIES MOL; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	48	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2197	2205						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294476				2022-12-25	WOS:A1994MR98800097
J	JUNKER, J; SOMMER, JR; SAR, M; MEISSNER, G				JUNKER, J; SOMMER, JR; SAR, M; MEISSNER, G			EXTENDED JUNCTIONAL SARCOPLASMIC-RETICULUM OF AVIAN CARDIAC-MUSCLE CONTAINS FUNCTIONAL RYANODINE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELEASE CHANNEL COMPLEX; SKELETAL-MUSCLE; CALCIUM RELEASE; CA-2+; VESICLES; CHARGE; PROBE; CDNA	The ryanodine receptor (RYR)/Ca2+ release channel of avian cardiac muscle was localized by immunocytochemical techniques and biochemically characterized using isolated membrane and receptor protein fractions. Monoclonal antibody C3-33 raised against the canine cardiac RYR bound to the junctional sarcoplasmic reticulum of pigeon and finch hearts, both at peripheral couplings and at extended junctional sarcoplasmic reticulum (EJSR). Immunoblots of sarcoplasmic reticulum vesicles from pigeon and finch hearts showed this antibody recognized a single high molecular weight protein, which co-migrated with the canine M(r) 565,000 RYR/Ca2+ release channel polypeptide. The pigeon heart RYR bound [H-3]ryanodine with high affinity in a Ca2+-dependent manner, comparable to the canine cardiac RYR. Purification of the pigeon RYR yielded a 30 S protein complex, which bound the maximum calculated amount of [H-3]ryanodine ((440 +/- 60) pmol/mg protein), assuming one high affinity site/tetrameric 30 S RYR comprised of M(r) 565,000 polypeptides. Autoradiography of isolated finch cardiac myocytes indicated [H-3]ryanodine binding throughout the cells. These results suggest that avian heart contains a single population of RYRs, and thereby support the hypothesis that avian EJSR contains functional calcium release channels which, because of the absence of transverse tubules, can be located micrometers away from the surface membrane in avian heart.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; CAMPBELL UNIV,SCH PHARM,BULES CREEK,NC 27506; DUKE UNIV,DEPT PATHOL,DURHAM,NC 27710; VET ADM MED CTR,DURHAM,NC 27705; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; Campbell University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL 12486] Funding Source: Medline; NIAMS NIH HHS [AR 18687] Funding Source: Medline; NINDS NIH HHS [NS 17479] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL012486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018687, R37AR018687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017479] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BENDUKIDZE Z, 1985, BASIC RES CARDIOL S1, V80, P513; BOSSEN EH, 1978, TISSUE CELL, V10, P773, DOI 10.1016/0040-8166(78)90062-9; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CHU A, 1990, MOL PHARMACOL, V37, P735; DOLBER PC, 1984, J ULTRA MOL STRUCT R, V87, P190, DOI 10.1016/S0022-5320(84)80078-7; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; GYORKE S, 1992, J PHYSIOL-LONDON, V457, P195; INUI M, 1987, J BIOL CHEM, V262, P15637; JORGENSEN AO, 1988, CIRC RES, V63, P1060, DOI 10.1161/01.RES.63.6.1060; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; JUNKER J, 1992, FASEB J, V6, pA1240; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LAI FA, 1989, J BIOL CHEM, V264, P16776; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NOWYCKY MC, 1993, BIOPHYS J, V64, P77, DOI 10.1016/S0006-3495(93)81342-0; OTSU K, 1990, J BIOL CHEM, V265, P13472; RARDON DP, 1989, CIRC RES, V64, P779, DOI 10.1161/01.RES.64.4.779; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SAR M, 1985, TECHNIQUES IMMUNOCYT, V3, P43; SCHNEIDER MF, 1981, ANNU REV PHYSIOL, V43, P507, DOI 10.1146/annurev.ph.43.030181.002451; Sommer J.R., 1979, HDB PHYSL 2, VVolume 1, P113; SOMMER JR, 1968, J CELL BIOL, V36, P497, DOI 10.1083/jcb.36.3.497; SOMMER JR, 1969, Z ZELLFORSCH MIK ANA, V98, P437, DOI 10.1007/BF00346685; SOMMER JR, 1991, ACTA PHYSIOL SCAND, V142, P5; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; Stumpf W E, 1975, Methods Enzymol, V36, P135	38	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1627	1634						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294409				2022-12-25	WOS:A1994MR98800016
J	NOLTA, KV; STECK, TL				NOLTA, KV; STECK, TL			ISOLATION AND INITIAL CHARACTERIZATION OF THE BIPARTITE CONTRACTILE VACUOLE COMPLEX FROM DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; LOCALIZATION; MEMBRANE; ASSOCIATION; ACIDOSOMES; PARAMECIUM; MYOSIN; ATPASE	The contractile vacuole complex serves to excrete excess cytosolic water from protists. In the amoeba, Dictyostelium discoideum, the organelle had a bipartite morphology: a large main vacuole (bladder) marked by lumenal alkaline phosphatase was surrounded by numerous satellite vacuoles (spongiomes). Bladders and spongiomes have now been purified for the first time. The spongiome membranes had a high density of surface projections identified as catalytically-active vacuolar proton pumps (V-H+-ATPase). Spongiomes were resolved from the pump-poor bladders by immunogold buoyant density shift with antibodies to the V-H+-ATPase; they contained little protein other than this pump. It appears that, following homogenization, most of the spongiome dissociated from bladders and populated the proton pump-rich membrane fraction called acidosomes. Isolated bladders were enriched >40-fold in alkaline phosphatase and phosphodiesterase, the activities of which were >85% latent. Bladders depleted of spongiomes bore several distinctive polypeptides; they also had an excess of the basepieces of the proton pump over the catalytic heads. Bladder membranes were also lipid-rich and had a distinctive lipid composition. We conclude that the contractile vacuole system in Dictyostelium is a complex of discrete, separable bladder and spongiome membranes. The V-H+-ATPase in the spongiome may catalyze the primary energy transduction step for pumping water out of the cytoplasm.	UNIV CALIF LOS ANGELES,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183, R01GM047282] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42086] Funding Source: Medline; NIGMS NIH HHS [GM07183, R01GM47282] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON S, 1974, J CELL SCI, V4, P1; AKBARIEH M, 1988, J PROTOZOOL, V35, P99, DOI 10.1111/j.1550-7408.1988.tb04085.x; ALLEN RD, 1990, J CELL SCI, V96, P469; ALLEN RD, 1988, J PROTOZOOL, V35, P63, DOI 10.1111/j.1550-7408.1988.tb04078.x; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BOWERS B, 1973, J CELL BIOL, V59, P784, DOI 10.1083/jcb.59.3.784; BOWERS B, 1968, J CELL BIOL, V39, P95, DOI 10.1083/jcb.39.1.95; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECHASTELLIER C, 1978, J ULTRA MOL STRUCT R, V62, P220, DOI 10.1016/S0022-5320(78)80019-7; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; GILKES NR, 1977, BIOCHIM BIOPHYS ACTA, V464, P142, DOI 10.1016/0005-2736(77)90377-7; GINGELL D, 1982, J CELL SCI, V54, P287; GLOMP I, 1985, HISTOCHEMISTRY, V83, P251, DOI 10.1007/BF00953993; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; HEYWOOD P, 1978, J CELL SCI, V31, P213; KANE PM, 1992, J EXP BIOL, V172, P93; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHARD JM, 1992, J BIOL CHEM, V267, P1896; LINDER JC, 1979, J CELL BIOL, V83, P371, DOI 10.1083/jcb.83.2.371; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; MCKANNA JA, 1976, J ULTRA MOL STRUCT R, V54, P1, DOI 10.1016/S0022-5320(76)80002-0; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NOLTA KV, 1993, J CELL SCI, V105, P849; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; PADH H, 1991, J BIOL CHEM, V266, P12123; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; PATTERSON DJ, 1980, BIOL REV, V55, P1, DOI 10.1111/j.1469-185X.1980.tb00686.x; PRUSCH RD, 1970, J CELL BIOL, V46, P431, DOI 10.1083/jcb.46.2.431; QUIVIGER B, 1978, J ULTRA MOL STRUCT R, V62, P228, DOI 10.1016/S0022-5320(78)80020-3; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RIDDICK DH, 1968, AM J PHYSIOL, V215, P736, DOI 10.1152/ajplegacy.1968.215.3.736; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; ZEUTHEN T, 1992, BIOCHIM BIOPHYS ACTA, V1113, P229, DOI 10.1016/0304-4157(92)90040-H; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	36	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2225	2233						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294479				2022-12-25	WOS:A1994MR98800100
J	VAELLO, ML; RUIZGOMEZ, A; LERMA, J; MAYOR, F				VAELLO, ML; RUIZGOMEZ, A; LERMA, J; MAYOR, F			MODULATION OF INHIBITORY GLYCINE RECEPTORS BY PHOSPHORYLATION BY PROTEIN-KINASE-C AND CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; NICOTINIC ACETYLCHOLINE-RECEPTOR; MOUSE SPINAL-CORD; FUNCTIONAL EXPRESSION; CHLORIDE CHANNELS; PRIMARY CULTURES; BETA-SUBUNIT; MUSCLE-CELLS; RAT-BRAIN; VARIANTS	Recent evidence has suggested a role for phosphorylation in the regulation of ligand-gated ion channels. We have recently shown (Ruiz-Gomez, A., Vaello, M., Valdivieso, F., and Mayor, F., Jr. (1991) J. Biol. Chem. 266, 559-566) that the inhibitory glycine receptor (GlyR) alpha subunit is phosphorylated in vitro by protein kinase C (PKC). In this report we further show that alpha subunits of the GlyR can also be phosphorylated by cAMP-dependent protein kinase (PKA) in an in vitro assay. Moreover, incubation of intact rat spinal cord neurons with specific PKC or PKA activators leads to increased phosphorylation of the GlyR alpha subunits, strongly suggesting a physiological role in its functional modulation. The role of protein phosphorylation in modulating GlyR channels was explored in Xenopus oocytes injected with poly (A)+ mRNA isolated from nervous tissue. The treatment of oocytes with phorbol esters or dibutyryl cAMP resulted in a decrease of an enhancement, respectively, of glycine-evoked currents. Our results show that the GlyR can be phosphorylated in vivo in response to activation of either PKC or PKA with opposite functional consequences, suggesting that neurotransmitters affecting the activity of such kinases could profoundly alter glycine-mediated neuronal signaling and modulate synaptic efficacy.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC SEVERO OCHOA, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Ruiz-Gómez, Ana/H-2092-2015; Ruiz-Gomez, Ana/ABF-3079-2021; Mayor, Federico/N-7644-2016; Lerma, Juan/G-7907-2015	Ruiz-Gómez, Ana/0000-0002-1646-3072; Lerma, Juan/0000-0001-7838-5199; Mayor Menendez, Federico/0000-0003-1434-8449				Aprison MH, 1978, ADV NEUROCHEM, V3, P203; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; CLARK EA, 1991, J NEUROCHEM, V57, P802, DOI 10.1111/j.1471-4159.1991.tb08222.x; GARCIACALVO M, 1989, BIOCHEMISTRY-US, V28, P6405, DOI 10.1021/bi00441a037; GOMEZ AR, 1989, BIOCHEM BIOPH RES CO, V160, P374, DOI 10.1016/0006-291X(89)91666-5; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HOCH W, 1989, NEURON, V3, P339, DOI 10.1016/0896-6273(89)90258-4; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JOHNSTON ME, 1989, J NEUROCHEM, V52, P75, DOI 10.1111/j.1471-4159.1989.tb10900.x; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; KUHSE J, 1990, J BIOL CHEM, V265, P22317; LAI Y, 1990, J BIOL CHEM, V265, P20839; LANGOSCH D, 1992, FEBS LETT, V298, P113, DOI 10.1016/0014-5793(92)80034-E; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LERMA J, 1989, P NATL ACAD SCI USA, V86, P1708, DOI 10.1073/pnas.86.5.1708; LOTAN I, 1990, FEBS LETT, V267, P25, DOI 10.1016/0014-5793(90)80279-R; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; MILES K, 1987, P NATL ACAD SCI USA, V84, P6591, DOI 10.1073/pnas.84.18.6591; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PILLER V, 1989, J BIOL CHEM, V264, P18824; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132, DOI 10.1152/jn.1977.40.5.1132; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROSS A, 1988, J CELL BIOL, V107, P1139, DOI 10.1083/jcb.107.3.1139; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; RUIZGOMEZ A, 1990, BIOCHEMISTRY-US, V29, P7033, DOI 10.1021/bi00482a012; RUIZGOMEZ A, 1991, J BIOL CHEM, V266, P559; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SONG Y, 1990, NATURE, V348, P242, DOI 10.1038/348242a0; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; VAELLO ML, 1992, BIOCHEM BIOPH RES CO, V188, P813, DOI 10.1016/0006-291X(92)91129-E; VITORICA J, 1988, J NEUROSCI, V8, P615; WAGNER K, 1991, J BIOL CHEM, V266, P23784; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377	44	106	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2002	2008						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294452				2022-12-25	WOS:A1994MR98800070
J	CIARDIELLO, F; TORTORA, G; BIANCO, C; SELVAM, MP; BASOLO, F; FONTANINI, G; PACIFICO, F; NORMANNO, N; BRANDT, R; PERSICO, MG; SALOMON, DS; BIANCO, AR				CIARDIELLO, F; TORTORA, G; BIANCO, C; SELVAM, MP; BASOLO, F; FONTANINI, G; PACIFICO, F; NORMANNO, N; BRANDT, R; PERSICO, MG; SALOMON, DS; BIANCO, AR			INHIBITION OF CRIPTO EXPRESSION AND TUMORIGENICITY IN HUMAN COLON-CANCER CELLS BY ANTISENSE RNA AND OLIGODEOXYNUCLEOTIDES	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; MAMMARY EPITHELIAL-CELLS; C-HA-RAS; INVITRO TRANSFORMATION; COLORECTAL TUMORS; LINES; PROLIFERATION; GENE; OLIGONUCLEOTIDES; AMPHIREGULIN	CRIPTO is an epidermal growth factor-related gene expressed in a majority of human colorectal tumors. To assess the role of CRIPTO in the growth control of human colon cancer, we have treated human colon carcinoma GEO and CBS cells, that possess high levels of CRIPTO, and WIDR colon cancer cells, that are negative for CRIPTO expression, with two antisense phosphorothioate oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. Both antisense oligodeoxynucleotides significantly reduced endogenous CRIPTO protein levels and inhibited GEO and CBS cell growth in monolayer and in semisolid medium, whereas they did not affect WIDR cell growth. In addition, GEO, CBS and WIDR cells were infected with a recombinant retroviral vector containing the hygromycin-resistance gene and a 900 bp EcoRI-EcoRI coding fragment of the human CRIPTO cDNA oriented in the 3' to 5' direction. GEO and CBS CRIPTO antisense infectants exhibited a 60 to 70% reduction in CRIPTO protein expression, in monolayer growth and in soft agar cloning efficiency as compared to parental noninfected cells. In contrast, infection of WIDR cells with the CRIPTO antisense retrovirus did not alter their growth. Finally, GEO CRIPTO antisense infectants formed tumors in nude mice that were significantly smaller and had a larger latency period as compared to noninfected GEO cells.	US FDA,DIV TRANSFUS SCI,BETHESDA,MD 20892; UNIV PISA,FAC MED & CHIRURG,IST ANAT & ISTOL PATOL,I-56100 PISA,ITALY; CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY; NCI,TUMOR IMMUNOL & BIOL LAB,TUMOR GROWTH FACTOR SECT,BETHESDA,MD 20892	US Food & Drug Administration (FDA); University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CIARDIELLO, F (corresponding author), UNIV NAPOLI FEDERICO II,FAC MED & CHIRURG,CATTEDRA ONCOL MED,I-80131 NAPLES,ITALY.		Normanno, Nicola/AAT-1107-2021; Fontanini, Gabriella/O-7636-2015	Fontanini, Gabriella/0000-0003-1957-2052; Normanno, Nicola/0000-0002-7158-2605; Pacifico, Francesco Maria/0000-0001-9563-3596; Tortora, Giampaolo/0000-0002-1378-4962; BASOLO, FULVIO/0000-0003-1657-5020				ANZANO MA, 1989, CANCER RES, V49, P2898; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; CALABRETTA B, 1991, CANCER RES, V51, P4505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; CIARDIELLO F, 1993, INT J CANCER, V54, P952, DOI 10.1002/ijc.2910540615; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CLARKE R, 1992, J NATL CANCER I, V84, P1506, DOI 10.1093/jnci/84.19.1506; COFFEY RJ, 1987, CANCER RES, V47, P4590; DOLNICK BJ, 1991, CANCER INVEST, V9, P185, DOI 10.3109/07357909109044229; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FONTANINI G, 1992, AM J PATHOL, V141, P1285; GRAY GD, 1993, CANCER RES, V53, P577; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; LAHM H, 1992, BRIT J CANCER, V65, P341, DOI 10.1038/bjc.1992.69; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORONI MC, 1992, J BIOL CHEM, V267, P2714; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; MULDER KM, 1989, CELL MOL BIOL COLON, P46; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; RASCHELLA G, 1992, CANCER RES, V52, P4221; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; STEIN CA, 1988, CANCER RES, V48, P2659; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; Todaro G J, 1990, Semin Cancer Biol, V1, P257; TRICOLI JV, 1986, CANCER RES, V46, P6169; TROOJAN J, 1992, P NATL ACAD SCI USA, V89, P4874; VALDEZ BC, 1992, CANCER RES, V52, P5681; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P325; WATKINS LF, 1991, INT J CANCER, V47, P455, DOI 10.1002/ijc.2910470325; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	42	69	80	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					291	298						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302592				2022-12-25	WOS:A1994MW24700035
J	DICKINSON, CJ; DAUGHERTY, D; GUO, YJ; STADLER, B; FINNISS, S; YAMADA, T				DICKINSON, CJ; DAUGHERTY, D; GUO, YJ; STADLER, B; FINNISS, S; YAMADA, T			SUBSTRATE-SPECIFICITY OF THE GASTRIN-AMIDATING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HYDROXYGLYCINE INTERMEDIATE; N-C LYASE; HUMAN GALANIN; D-ALANINE; HYDROXYLATING MONOOXYGENASE; PORCINE PITUITARY; MOLECULAR-CLONING; PEPTIDE AMIDES; MESSENGER-RNA; 2 ENZYMES	As is the case with many other peptide hormones of the brain and gut, gastrin requires a carboxyl-terminal amide moiety for optimal biological activity. In the structure of progastrin, the carboxyl-terminal Phe of gastrin is followed by the sequence Gly93-Arg94-Arg95, which must be processed sequentially by an endoprotease, a carboxypeptidase, and an amidating enzyme to produce amidated bioactive gastrin. To examine the molecular determinants of peptide amidation in vivo, we mutated the wild-type Gly93 residue of progastrin to Ala93 and Ser93 and expressed the three progastrin DNAs in GH3 and MTC 6-23 endocrine cell lines. Although substantial quantities of amidated gastrin were seen in cells expressing wild-type progastrin, replacement of Gly93 With Ala93 completely abolished production of amidated gastrin when the cells were incubated in standard medium containing only L-alanine. In a similar fashion, cells expressing [Ser93]progastrin also demonstrated no production of amidated gastrin. When cells expressing [Ala93]- or [Ser93]progastrin were incubated in the presence of 1 mg/ml D-alanine or D-serine, respectively, a small but consistent amount of amidated gastrin production was detected (< 1% of wild type). These data lead us to conclude that the amidating enzyme has a rigid substrate specificity for a glycine-extended precursor. Furthermore, this in vivo substrate specificity confirms the importance of the pro-S-alpha-hydrogen of the carboxyl-terminal glycine for enzyme-substrate recognition.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	DICKINSON, CJ (corresponding author), UNIV MICHIGAN,MED CTR,DEPT PEDIAT,C6105 MIB,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001903, P30DK034933, R01DK034306] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-34306, K08-DK-01903, P30-DK-34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERSANI M, 1991, FEBS LETT, V283, P189, DOI 10.1016/0014-5793(91)80585-Q; BOEL E, 1983, P NATL ACAD SCI-BIOL, V80, P2866, DOI 10.1073/pnas.80.10.2866; BRADBURY AF, 1983, BIOCHEM BIOPH RES CO, V112, P372, DOI 10.1016/0006-291X(83)91473-0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUGHERTY D, 1989, PHYSIOL REV, V69, P482, DOI 10.1152/physrev.1989.69.2.482; DAUGHERTY DF, 1991, AM J PHYSIOL, V260, pG783, DOI 10.1152/ajpgi.1991.260.5.G783; DICKINSON C, 1989, HDB PHYSL NEUROENDOC, P63; DICKINSON CJ, 1991, J BIOL CHEM, V266, P334; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EVANS HF, 1991, ENDOCRINOLOGY, V129, P1682, DOI 10.1210/endo-129-3-1682; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORY H, 1964, NATURE, V204, P931, DOI 10.1038/204931a0; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P306; IWASAKI Y, 1991, EUR J BIOCHEM, V201, P551, DOI 10.1111/j.1432-1033.1991.tb16314.x; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KAWAHARA T, 1992, J CHEM SOC CHEM COMM, P625, DOI 10.1039/c39920000625; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACEY JC, 1988, P NATL ACAD SCI USA, V85, P4996, DOI 10.1073/pnas.85.14.4996; LANDYMORELIM AEN, 1983, BIOCHEM BIOPH RES CO, V117, P289, DOI 10.1016/0006-291X(83)91573-5; MARINO LR, 1991, J BIOL CHEM, V266, P6133; MATSUMOTO M, 1987, AM J PHYSIOL, V252, pG315, DOI 10.1152/ajpgi.1987.252.3.G315; MCKNIGHT GL, 1992, DIABETES, V41, P82, DOI 10.2337/diabetes.41.1.82; MERKLER DJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P192, DOI 10.1016/0003-9861(91)90461-Q; MOR A, 1991, J BIOL CHEM, V266, P6264; MOR A, 1990, BIOCHEM BIOPH RES CO, V170, P30, DOI 10.1016/0006-291X(90)91236-L; RAMER SE, 1988, J AM CHEM SOC, V110, P8526, DOI 10.1021/ja00233a032; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; ROKAEUS A, 1986, P NATL ACAD SCI USA, V83, P6287, DOI 10.1073/pnas.83.17.6287; ROSENQUIST GL, 1980, GASTROINTESTINAL HOR, P769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT WE, 1991, P NATL ACAD SCI USA, V88, P11435, DOI 10.1073/pnas.88.24.11435; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; SUZUKI K, 1990, EMBO J, V9, P4259, DOI 10.1002/j.1460-2075.1990.tb07874.x; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAKEUCHI T, 1991, J BIOL CHEM, V266, P17409; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; VRONTAKIS ME, 1987, J BIOL CHEM, V262, P16755; YAMANE T, 1981, BIOCHEMISTRY-US, V20, P7059, DOI 10.1021/bi00528a001; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088; ZEYTINOGLU FN, 1980, ENDOCRINOLOGY, V107, P509, DOI 10.1210/endo-107-2-509	46	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15929	15934						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340416				2022-12-25	WOS:A1993LN30500086
J	LOMAS, DA; FINCH, JT; SEYAMA, K; NUKIWA, T; CARRELL, RW				LOMAS, DA; FINCH, JT; SEYAMA, K; NUKIWA, T; CARRELL, RW			ALPHA-1-ANTITRYPSIN S(IIYAMA) (SER(53)-]PHE) - FURTHER EVIDENCE FOR INTRACELLULAR LOOP-SHEET POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN ALPHA-1-PROTEINASE INHIBITOR; DEFICIENCY ALLELE; LIVER; VARIANT; MMALTON; PROTEINS; DISEASE	Antitrypsin S(iiyama) is a rare example of the deficiency variants of antitrypsin that accumulate in the endoplasmic reticulum of the hepatocyte. The common example is Z antitrypsin, which has a mutation (Glu342 --> Lys) at the junction of the head of the fifth strand of the A sheet and the base of the reactive center loop. It was previously shown that Z antitrypsin spontaneously polymerizes due to the insertion of the reactive center loop of one molecule into the A sheet of a second. The mutation in antitrypsin S(iiyama)(Ser53 --> Phe) affects a residue that provides a ridge for the sliding movement that opens the A sheet, and it had been predicted that this would result in the same type of loop-sheet polymerization observed with the Z variant. We confirm this here and show that virtually all the plasma antitrypsin in a homozygote for the S(iiyama) variant was polymerized due to non-covalent bonding with a loss of accessibility of the reactive center loop. The common basis of the polymerization of Z and S(iiyama) antitrypsin is supported by identical findings on electron microscopy. Taken together these results confirm that loop-sheet polymerization is a general mechanism and as such is likely to be responsible for the intracellular inclusions associated with liver pathology.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; JUNTENDO UNIV,SCH MED,DEPT RESP MED,BUNKYO KU,TOKYO 113,JAPAN	MRC Laboratory Molecular Biology; Juntendo University	LOMAS, DA (corresponding author), UNIV CAMBRIDGE,DEPT HAEMATOL,CAMBRIDGE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CURIEL DT, 1989, J BIOL CHEM, V264, P13938; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; FABBRETTI G, 1992, LIVER, V12, P296; FRAIZER GC, 1989, AM J HUM GENET, V44, P894; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GRAHAM A, 1989, HUM GENET, V84, P55, DOI 10.1007/BF00210671; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1993, J BIOL CHEM, V268, P516; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MATSUNAGA E, 1990, AM J HUM GENET, V46, P602; ROBERTS EA, 1984, AM J CLIN PATHOL, V82, P424, DOI 10.1093/ajcp/82.4.424; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVIS J, 1981, METHOD ENZYMOL, V80, P754; YOSHIDA A, 1976, P NATL ACAD SCI USA, V73, P1324, DOI 10.1073/pnas.73.4.1324	19	184	190	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15333	15335						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340361				2022-12-25	WOS:A1993LN30500003
J	MOON, C; PRESTON, GM; GRIFFIN, CA; JABS, EW; AGRE, P				MOON, C; PRESTON, GM; GRIFFIN, CA; JABS, EW; AGRE, P			THE HUMAN AQUAPORIN-CHIP GENE - STRUCTURE, ORGANIZATION, AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; TRANSMEMBRANE CHANNEL PROTEINS; INTEGRAL MEMBRANE-PROTEIN; LENS FIBER MEMBRANE; ESCHERICHIA-COLI; GLYCEROL FACILITATOR; INSITU HYBRIDIZATION; NUCLEOTIDE-SEQUENCE; SOYBEAN NODULIN-26; WATER CHANNELS	Aquaporin-CHIP is the first known molecular water channel. Originally identified in red cells and renal tubules, transcripts and proteins related to AQP-CHIP are also expressed in diverse epithelia with distinct developmental patterns. Northern analyses of RNA from several tissues revealed transcripts of 3.1 kilobases and other sizes. The nucleotide sequences of human kidney AQP-CHIP cDNAs are identical to the human bone marrow AQP-CHIP cDNA. The 17-kilobase human AQP-CHIP structural gene was isolated, and restriction maps were constructed and partially sequenced. The TATA consensus sequence is located 87 bp 5' to the translation initiation site, and sequences surrounding the polyadenylation consensus were determined. Four exons were identified corresponding to amino acids 1-128, 129-183, 184-2 10, and 211-269, separated by introns of 9.6, 0.43, and 0.80 kilobases. Genomic Southern analyses indicated the existence of a single AQP-CHIP gene which was located at human chromosome 7p14 by in situ hybridization. Sequence comparisons of AQP-CHIP and cDNAs of similar proteins from diverse species suggested a common evolutionary origin. At least three of these proteins are now known to function as membrane water pores and are referred to as the ''Aquaporins.'' These genomic AQP-CHIP DNA sequences should permit molecular characterization of the complex patterns of AQP-CHIP expression.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED & CELL BIOL ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT & MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, CTR MED GENET, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Jabs, Ethylin/0000-0001-8983-5466	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R01HL048268, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA009012] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIAAA NIH HHS [AA09012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AGRE P, 1993, IN PRESS AM J PHYSL; BAKER ME, 1990, CELL, V60, P185, DOI 10.1016/0092-8674(90)90731-S; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; DENKER BM, 1988, J BIOL CHEM, V263, P15634; EHRING GR, 1990, J GEN PHYSIOL, V96, P631, DOI 10.1085/jgp.96.3.631; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MAUREL C, 1993, IN PRESS EMBO J; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P4378; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1993, IN PRESS P NATL ACAD; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PISANO MM, 1991, GENOMICS, V11, P981; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; Sambrook J, 1989, MOL CLONING LABORATO; SANDAL NN, 1988, NUCLEIC ACIDS RES, V16, P9347, DOI 10.1093/nar/16.19.9347; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANAELST L, 1991, EMBO J, V10, P2095, DOI 10.1002/j.1460-2075.1991.tb07742.x; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	36	104	112	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15772	15778						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340403				2022-12-25	WOS:A1993LN30500067
J	BEDALE, WA; INMAN, RB; COX, MM				BEDALE, WA; INMAN, RB; COX, MM			A REVERSE DNA STRAND EXCHANGE MEDIATED BY RECA PROTEIN AND EXONUCLEASE-I - THE GENERATION OF APPARENT DNA STRAND BREAKS BY RECA PROTEIN IS EXPLAINED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENETIC-RECOMBINATION; DEOXYRIBONUCLEIC-ACID; UNWINDING PROTEIN; BRANCH MIGRATION; BINDING-PROTEIN; 3-STRANDED DNA; M13 VECTORS; PURIFICATION; COMPLEXES	The combined action of exonuclease I and recA protein leads to a kind of reverse DNA strand exchange in which joint molecules formed on the ''wrong'' or distal end of a linear duplex in the presence of ATP are stabilized by exonuclease I degradation of the displaced (+) strand. Continued pairing and degradation of the displaced strand leads to strand exchange that appears to progress with a polarity opposite that of the normal recA protein promoted reaction (i. e. 3'-5' with respect to the (+) strand). However, in contrast to the normal 5'-3' strand exchange, the displaced strand is completely degraded in the process. When the linear duplex DNA substrate has a heterologous region at the 5' (proximal) end, the major product (described in a previous study (Bedale, W. A., Inman, R. B., and Cox, M. M. (1991) J. Biol. Chem. 266, 6499-6510)) is a circular duplex DNA molecule with a double-stranded tail whose length corresponds closely to the heterologous segment of the substrate. The origin of this product is here shown to be the result of the exonuclease activity of exonuclease I (either added exogenously or present as a trace contaminant of recA protein or SSB protein preparations), as opposed to endonucleolytic or mechanical breakage. The levels of exonuclease I required to generate these products are sufficiently low that they are undetected by assays for exonuclease contamination in recA protein preparations. These results demonstrate that the interplay of recA protein with other enzymes can have a profound effect on both the mechanism and outcome of recA protein-promoted DNA strand exchange. They also demonstrate that the (+) strand of the duplex DNA substrate is at least transiently displaced in recA protein-mediated pairing even when joint molecules are limited to the distal end.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Bedale, Wendy/0000-0002-0122-4255	NIGMS NIH HHS [GM32335, T32-GM07215, GM14711] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335, U01GM032335, R01GM014711, T32GM007215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; BEDALE WA, 1991, J BIOL CHEM, V266, P6499; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CHASE JW, 1974, J BIOL CHEM, V249, P4545; CHASE JW, 1981, GENE AMPLIFICATION A, P147; Cox M M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 2, P803; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1987, DNA REPLICATION RECO, P597; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FREITAG N, 1988, J BIOL CHEM, V263, P19525; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JWANG BR, 1992, P NATL ACAD SCI USA, V89, P7596, DOI 10.1073/pnas.89.16.7596; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; MOLINEUX IJ, 1974, J BIOL CHEM, V249, P6090; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PHILLIPS GJ, 1988, J BACTERIOL, V170, P2089, DOI 10.1128/jb.170.5.2089-2094.1988; PRASHER DC, 1983, J BIOL CHEM, V258, P6340; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RAO BJ, 1991, BIOCHIMIE, V73, P363, DOI 10.1016/0300-9084(91)90102-7; RAO BJ, 1993, IN PRESS J MOL BIOL; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; Sambrook J, 1989, MOL CLONING LABORATO; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; STASIAK A, 1992, MOL MICROBIOL, V6, P3267, DOI 10.1111/j.1365-2958.1992.tb02194.x; VALES LD, 1982, J BIOL CHEM, V257, P8799; WALCZAK CE, 1993, CELL MOTIL CYTOSKEL, V24, P17, DOI 10.1002/cm.970240103; WEISS B, 1981, ENZYMES, V14, P203; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149	50	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15004	15016						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325876				2022-12-25	WOS:A1993LL75900070
J	BOCKHOLT, SM; BURRIDGE, K				BOCKHOLT, SM; BURRIDGE, K			CELL SPREADING ON EXTRACELLULAR-MATRIX PROTEINS INDUCES TYROSINE PHOSPHORYLATION OF TENSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROUS-SARCOMA VIRUS; FOCAL ADHESIONS; TRANSFORMING PROTEIN; VINCULIN; TALIN; PAXILLIN	A small number of proteins becomes tyrosine-phosphorylated in response to integrin-mediated cell adhesion to extracellular matrix proteins. Previous work has identified two of these tyrosine-phosphorylated proteins as the focal adhesion kinase and paxillin. Here we identify a third focal adhesion protein, tensin, that becomes tyrosine-phosphorylated during cell adhesion to extracellular matrix proteins. The tyrosine phosphorylation of tensin does not occur when cells adhere to plastic or polylysine and is blocked when microfilament assembly and cell spreading are inhibited with cytochalasin D. In addition, we show that other focal adhesion proteins such as talin and vinculin do not become tyrosine-phosphorylated under the same conditions of cell spreading on extracellular matrix proteins.			BOCKHOLT, SM (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CB 7090,214 TAYLOR HALL,CHAPEL HILL,NC 27599, USA.							BOCKHOLT SM, 1992, EXP CELL RES, V203, P39, DOI 10.1016/0014-4827(92)90037-9; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; OTEY C, 1990, HYBRIDOMA, V9, P57, DOI 10.1089/hyb.1990.9.57; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WILKINS JA, 1987, J CELL BIOL, V105, pA103	24	250	250	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14565	14567						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325835				2022-12-25	WOS:A1993LL75900004
J	SKURAT, AV; CAO, YJ; ROACH, PJ				SKURAT, AV; CAO, YJ; ROACH, PJ			GLUCOSE CONTROL OF RABBIT SKELETAL-MUSCLE GLYCOGENIN EXPRESSED IN COS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; SYNTHASE; BIOGENESIS; PRIMER; DNA; BIOSYNTHESIS; INITIATION; ANTIBODIES; SEQUENCE; CLONING	Glycogenin is a self-glucosylating protein involved in the initiation of glycogen synthesis. Rabbit skeletal muscle glycogenin, transiently expressed in COS cells, was found exclusively in the low speed supernatant fraction, with M(r) 37-38,000. The protein was capable of self-glucosylation and was, if suitably primed, an effective substrate for glycogen synthase. Rabbit muscle glycogen synthase was similarly expressed, to a level 7-10-fold over the endogenous activity. Most of the expressed protein was found in the low speed pellet fraction. However, when co-expressed with glycogenin, a significant increase in the proportion of glycogen synthase in the soluble fraction was observed. Therefore, glycogenin interacts with glycogen synthase in the cell and redistributes the synthase to the soluble fraction. Co-expression of an inactive form of glycogenin did not affect glycogen synthase localization. The expressed glycogenin could be detected as two distinguishable species, differing slightly in electrophoretic mobility, depending on the glucose concentration of the cell culture medium. At 25 mM glucose, a form of M(r) 38,000 was observed; however, upon transfer to 5 mM glucose, it converted to a species of slightly lower M(r). The M(r) of the 38,000-dalton species could be also be reduced by treatment of the cell extract with a-amylase. It was additionally found that the 38,000-dalton glycogenin was a much more effective glycogen synthase substrate than the lower M(r) species. These results, therefore, raise the possibility of a novel mechanism for the control of glycogen metabolism in which glucose levels would regulate the glucosylation state of glycogenin, which in turn would determine glycogenin's efficacy as a substrate for elongation by glycogen synthase.			SKURAT, AV (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202, USA.				NIDDK NIH HHS [DK27221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027221, R37DK027221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD Z, 1986, ARCH BIOCHEM BIOPHYS, V250, P329, DOI 10.1016/0003-9861(86)90734-4; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARMSTRONG DJ, 1989, ARCH BIOCHEM BIOPHYS, V275, P16, DOI 10.1016/0003-9861(89)90344-5; BAI G, 1990, J BIOL CHEM, V265, P7843; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROWN NE, 1971, BIOCHIM BIOPHYS ACTA, V242, P69, DOI 10.1016/0005-2744(71)90088-X; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; Cohen P., 1986, ENZYMES, VXVII, P461; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FRIEDMAN DL, 1963, BIOCHEMISTRY-US, V2, P669, DOI 10.1021/bi00904a009; Kennedy L., 1985, MEMBRANES MUSCLE, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE RD, 1989, BIOCHEM INT, V18, P961; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; LOMAKO J, 1992, CARBOHYD RES, V227, P331, DOI 10.1016/0008-6215(92)85082-B; Maniatis T., 1982, MOL CLONING; NIMMO HG, 1976, EUR J BIOCHEM, V68, P21, DOI 10.1111/j.1432-1033.1976.tb10761.x; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P487; Roach P. J., 1986, ENZYMES, VXVII, P499; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14701	14707						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325849				2022-12-25	WOS:A1993LL75900029
J	PASTORINO, JG; SNYDER, JW; SERRONI, A; HOEK, JB; FARBER, JL				PASTORINO, JG; SNYDER, JW; SERRONI, A; HOEK, JB; FARBER, JL			CYCLOSPORINE AND CARNITINE PREVENT THE ANOXIC DEATH OF CULTURED-HEPATOCYTES BY INHIBITING THE MITOCHONDRIAL PERMEABILITY TRANSITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PERMEABILITY; LIVER-MITOCHONDRIA; INORGANIC-PHOSPHATE; HEART-MITOCHONDRIA; OXIDATIVE STRESS; DYSFUNCTION; MECHANISMS; NUCLEOTIDES; REVERSAL; CALCIUM	Cyclosporin A (CyA) and L-carnitine (LC) prevented the killing of cultured hepatocytes by anoxia and rotenone but not by cyanide. Neither CyA nor LC affected the rate or extent of the loss of the mitochondrial membrane potential or the rate or extent of the depletion of ATP. Atractyloside blocked the ability of both CyA and LC to protect, and D-carnitine antagonized the effect of LC but not that of CyA. Cell killing by cyanide was prevented when the phospholipase A2 inhibitor butacaine was added together with CyA. Butacaine by itself had no effect on cell killing. In a swelling assay with isolated rat liver mitochondria having a low calcium content, phenylarsine oxide or palmitoyl-CoA induced the inner membrane permeability transition when electron transport was inhibited by rotenone or cyanide. CyA prevented the permeability transition with rotenone but not with cyanide, and atractyloside reversed the effect of CyA. LC prevented the permeability transition occurring with palmitoyl-CoA plus rotenone but not with palmitoyl-CoA plus cyanide. Atractyloside and D-carnitine antagonized the protective effect of LC. Inhibition of the cyanide-dependent permeability transition in isolated liver mitochondria required the presence of both CyA and butacaine. These data document the close correlation between the effect of CyA and LC on the response of cultured hepatocytes to inhibition of mitochondrial electron transport and their ability to prevent the permeability transition in isolated mitochondria. It is concluded that the ability of CyA and LC to protect cultured hepatocytes is a consequence of their ability to prevent the mitochondrial permeability transition, indicating that this event is likely to be causally linked to the genesis of irreversible injury. Thus, cell death with anoxia or inhibitors of electron transport is related to a mitochondrial alteration by a mechanism that is independent of the maintenance of a membrane potential or cellular stores of ATP.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,RM 251,JEFFERSON ALUMNI HALL,PHILADELPHIA,PA 19107	Jefferson University				Hoek, Jan/0000-0001-7127-4218	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07186] Funding Source: Medline; NIDDK NIH HHS [DK38305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; FARBER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312, DOI 10.1016/0003-9861(81)90459-8; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HOEK JB, 1980, J BIOL CHEM, V255, P1458; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; IBRAVBOA UC, 1989, BIOCHEM BIOPH RES CO, V161, P619; KANE AB, 1985, AM J PHYSIOL, V249, pC256, DOI 10.1152/ajpcell.1985.249.3.C256; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V270, P672, DOI 10.1016/0003-9861(89)90550-X; MITTNACHT S, 1981, J BIOL CHEM, V256, P3199; MITTNACHT S, 1979, J BIOL CHEM, V254, P9871; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; SAKAIDA I, 1992, AM J PHYSIOL, V263, pC684, DOI 10.1152/ajpcell.1992.263.3.C684; SCHMID PC, 1981, J LIPID RES, V22, P882; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SNYDER JW, 1990, ARCH BIOCHEM BIOPHYS, V276, P132, DOI 10.1016/0003-9861(90)90019-U; SNYDER JW, 1993, AM J PHYSIOL, V264, pC709, DOI 10.1152/ajpcell.1993.264.3.C709; THOMSON AW, 1990, IMMUNOL TODAY, V11, P35; TONINELLO A, 1983, BIOCHEM BIOPH RES CO, V111, P792, DOI 10.1016/0006-291X(83)91368-2; WALAJTYSRHODE E, 1992, J BIOL CHEM, V267, P370	28	301	303	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13791	13798						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314748				2022-12-25	WOS:A1993LJ82500007
J	VALERA, A; RODRIGUEZGIL, JE; YUN, JS; MCGRANE, MM; HANSON, RW; BOSCH, F				VALERA, A; RODRIGUEZGIL, JE; YUN, JS; MCGRANE, MM; HANSON, RW; BOSCH, F			GLUCOSE-METABOLISM IN TRANSGENIC MICE CONTAINING A CHIMERIC P-ENOLPYRUVATE CARBOXYKINASE BOVINE GROWTH-HORMONE GENE	FASEB JOURNAL			English	Note						BOVINE GROWTH HORMONE; P-ENOLPYRUVATE CARBOXYKINASE PROMOTER; TRANSGENIC MICE; GLUCOSE METABOLISM; GENE EXPRESSION	TYROSINE AMINOTRANSFERASE GENE; PROMOTER-REGULATORY REGION; HEPATIC GLYCOGEN-SYNTHASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; RAT-LIVER; FACTOR-I; PROTEIN-KINASE; MESSENGER-RNA; INSULIN; ACTIVATION	Transgenic mice, containing the chimeric gene obtained by linking the promoter-regulatory region of P-enolpyruvate carboxykinase (PEPCK) gene to the bovine growth hormone structural gene (bGH), were used to investigate the long-term effects of bGH on glucose metabolism. Expression of the PEPCK/bGH gene was markedly enhanced by feeding a diet high in protein and inhibited by a high carbohydrate diet. All transgenic mice had normal levels of blood glucose but were hyperinsulinemic, indicating that they were insulin resistant. The glycogen synthase activity ratios in the muscle and liver of transgenic mice were lower than noted for control animals, and remained unchanged in liver after feeding a standard high carbohydrate or a high protein diet. Similar effects were detected in the activity of glycogen phosphorylase, except that a high carbohydrate diet activated this enzyme in the liver. The activation of glycogen phosphorylase in both muscle and liver correlated with the expression of their genes. These animals had a significant content of glycogen and glucose 6-phosphate, which was related to the levels of glucokinase mRNA in the liver. The concentration of fructose 2,6-bisphosphate in the liver of all fed transgenic mice was lower than noted in livers from fed animals. In addition, a decrease in the hepatic expression of the endogenous genes for PEPCK, tyrosine aminotransferase (TAT), and the glucose transporter GLUT-2 was observed and directly correlated with the expression of bGH. Thus, bGH can control glucose metabolism in vivo, at least in part, by modifying the expression of several genes coding for proteins of importance in carbohydrate metabolism. Taken together, these results indicate a state of insulin resistance caused by chronic exposure of the animals to an elevated concentration of bGH.	AUTONOMOUS UNIV BARCELONA, SCH VET MED, DEPT BIOCHEM, E-08193 BARCELONA, SPAIN; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; OHIO UNIV, EDISON ANIM BIOTECHNOL CTR, ATHENS, OH 45701 USA; AUTONOMOUS UNIV BARCELONA, SCH VET MED, DEPT MOLEC BIOL, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona; Case Western Reserve University; University System of Ohio; Ohio University; Autonomous University of Barcelona			Rodriguez-Gil, Joan E./F-8748-2016	Rodriguez-Gil, Joan E./0000-0002-1112-9884; BOSCH, FATIMA/0000-0002-7705-5515	NIDDK NIH HHS [DK-24451, DK-21859] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021859, R01DK021859] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAK JF, 1991, AM J PHYSIOL, V260, pE736, DOI 10.1152/ajpendo.1991.260.5.E736; BAXTER RC, 1980, ENDOCRINOLOGY, V107, P1176, DOI 10.1210/endo-107-4-1176; BECK P, 1965, J LAB CLIN MED, V66, P366; BEHRINGER RR, 1990, ENDOCRINOLOGY, V127, P1033, DOI 10.1210/endo-127-3-1033; CAMERON CM, 1987, ENDOCRINOLOGY, V120, P1568, DOI 10.1210/endo-120-4-1568; CHISTIANSEN JS, 1991, ACTA ENDOCRINOL-COP, V125, P7; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; CIUDAD CJ, 1981, FEBS LETT, V129, P123, DOI 10.1016/0014-5793(81)80771-5; COATS WS, 1991, J BIOL CHEM, V266, P16113; CRETTAZ M, 1988, BIOCHEMISTRY-US, V27, P495, DOI 10.1021/bi00401a071; DANFORTH WH, 1965, J BIOL CHEM, V240, P588; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DOUGLAS RG, 1990, BRIT J SURG, V77, P785, DOI 10.1002/bjs.1800770722; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; HANSEN I, 1986, AM J PHYSIOL, V250, pE269, DOI 10.1152/ajpendo.1986.250.3.E269; HASHIMOTO S, 1984, P NATL ACAD SCI-BIOL, V81, P6637, DOI 10.1073/pnas.81.21.6637; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JOHNSON RM, 1990, ENDOCRINOLOGY, V127, P2099, DOI 10.1210/endo-127-5-2099; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LEE KL, 1986, ARCH BIOCHEM BIOPHYS, V248, P597, DOI 10.1016/0003-9861(86)90513-8; LESAGE C, 1991, J PEDIATR-US, V119, P29, DOI 10.1016/S0022-3476(05)81034-0; Li CH, 1944, SCIENCE, V99, P183, DOI 10.1126/science.99.2566.183; LI CH, 1945, J BIOL CHEM, V159, P353; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Maniatis T, 1989, MOL CLONING; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; MILLER TB, 1973, J BIOL CHEM, V248, P3483; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; NAKANO K, 1986, FEBS LETT, V204, P283, DOI 10.1016/0014-5793(86)80829-8; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; NIELSEN JH, 1982, ENDOCRINOLOGY, V110, P600, DOI 10.1210/endo-110-2-600; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OKA Y, 1990, DIABETES, V39, P441, DOI 10.2337/diabetes.39.4.441; PERET J, 1976, J NUTR, V106, P103, DOI 10.1093/jn/106.1.103; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; POSTELVINAY MC, 1990, HORM METAB RES, V22, P7, DOI 10.1055/s-2007-1004837; POSTELVINAY MC, 1982, MOL CELL ENDOCRINOL, V28, P657, DOI 10.1016/0303-7207(82)90153-8; PRESS M, 1988, DIABETES METAB REV, V4, P391, DOI 10.1002/dmr.5610040406; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; RABINOVITCH A, 1983, DIABETES, V32, P307, DOI 10.2337/diabetes.32.4.307; ROACH PJ, 1977, FEBS LETT, V80, P95, DOI 10.1016/0014-5793(77)80414-6; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SCHERER G, 1982, P NATL ACAD SCI-BIOL, V79, P7205, DOI 10.1073/pnas.79.23.7205; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; SMAL J, 1987, BIOCHEM BIOPH RES CO, V147, P1232, DOI 10.1016/S0006-291X(87)80202-4; SONENBERG M, 1954, ENDOCRINOLOGY, V55, P709; STEWART TA, 1992, ENDOCRINOLOGY, V130, P405, DOI 10.1210/en.130.1.405; SWENNE I, 1987, DIABETES, V36, P288, DOI 10.2337/diabetes.36.3.288; THOMAS AP, 1985, J BIOL CHEM, V260, P5963; UHING RJ, 1981, FEBS LETT, V134, P185, DOI 10.1016/0014-5793(81)80598-4; VANDEWERVE G, 1977, BIOCHEM J, V162, P135, DOI 10.1042/bj1620135; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; WAGNER TE, 1981, P NATL ACAD SCI-BIOL, V78, P6376, DOI 10.1073/pnas.78.10.6376; WALKER J, 1989, J CLIN ENDOCR METAB, V69, P253, DOI 10.1210/jcem-69-2-253; WANG P, 1972, ANAL BIOCHEM, V47, P495, DOI 10.1016/0003-2697(72)90143-1; WITTERS LA, 1978, BIOCHEMISTRY-US, V17, P406, DOI 10.1021/bi00596a004; WOYCHIK RP, 1982, NUCLEIC ACIDS RES, V10, P7197, DOI 10.1093/nar/10.22.7197; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	80	41	43	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1993	7	9					791	800		10.1096/fasebj.7.9.8330686	http://dx.doi.org/10.1096/fasebj.7.9.8330686			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LK430	8330686				2022-12-25	WOS:A1993LK43000012
J	KANG, HA; HERSHEY, JWB				KANG, HA; HERSHEY, JWB			EFFECT OF INITIATION-FACTOR EIF-5A DEPLETION ON PROTEIN-SYNTHESIS AND PROLIFERATION OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPUSINE-CONTAINING PROTEIN; FACTOR 4D; TRANSLATION; PURIFICATION; YEAST; REPRESSION; MUTATIONS	Eukaryotic translation initiation factor eIF-5A (formerly eIF-4D) is thought to function in protein synthesis by promoting synthesis of the first peptide bond because it stimulates methionyl-puromycin formation in vitro. eIF-5A is encoded by two genes (TIF51A and TIF51B) in Saccharomyces cerevisiae; the protein and its hypusine modification are essential for cell viability. To analyze the factor's function in vivo, we expressed from the repressible GAL promoter a functional but unstable eIF-5A fusion protein (R-eIF-5A) with an NH2-terminal arginine which is subject to rapid turnover through the NH2-terminal end rule proteolytic pathway. When the conditional mutant strain is shifted from galactose to glucose medium, the rapid disappearance of R-eIF-5A protein occurs within one generation, causing an immediate inhibition of cell growth. However, eIF-5A-depleted cells synthesize protein at about 70% of the wild type rate and exhibit only a slight change in polysome profiles reflecting a subtle defect in a late step of translation initiation. These results suggest that the activity of eIF-5A may not be absolutely essential for general protein synthesis. Rather, eIF-5A may be selectively required for translation of certain mRNAs and/or may be involved in some other aspect of cell metabolism.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BENNE R, 1978, J BIOL CHEM, V253, P3070; BLUM S, 1989, P NATL ACAD SCI USA, V86, P6043, DOI 10.1073/pnas.86.16.6043; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; DUNCAN RF, 1986, J BIOL CHEM, V261, P2903; GORDON ED, 1987, J BIOL CHEM, V262, P16590; GORDON ED, 1987, J BIOL CHEM, V262, P16585; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HERSHEY JWB, 1990, BIOCHIM BIOPHYS ACTA, V1050, P160, DOI 10.1016/0167-4781(90)90159-Y; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KANG HA, 1992, MOL GEN GENET, V233, P487, DOI 10.1007/BF00265449; KANG HA, 1993, J BIOL CHEM, V268, P14750; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; METHA KD, 1990, J BIOL CHEM, V265, P8802; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PARK MH, 1984, J BIOL CHEM, V259, P2123; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; Sherman F., 1986, METHODS YEAST GENETI; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; STRUHL K, 1979, PNATL ACAD SCI US, V76, P503; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THOMAS A, 1979, EUR J BIOCHEM, V98, P329, DOI 10.1111/j.1432-1033.1979.tb13192.x; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	36	264	290	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3934	3940						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307948				2022-12-25	WOS:A1994MW98900008
J	MCLEAN, BG; GREENE, EA; ZAMBRYSKI, PC				MCLEAN, BG; GREENE, EA; ZAMBRYSKI, PC			MUTANTS OF AGROBACTERIUM VIRA THAT ACTIVATE VIR GENE-EXPRESSION IN THE ABSENCE OF THE INDUCER ACETOSYRINGONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMEFACIENS VIRULENCE GENES; T-DNA TRANSFER; TRANSCRIPTIONAL ACTIVATOR; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; BINDING-PROTEIN; OMPR; PHOSPHORYLATION; OSMOREGULATION; MECHANISM	In the presence of inducer molecules produced by wounded plants, the VirA/VirG two-component positive regulatory system of Agrobacterium tumefaciens initiates transcription of virulence genes required for crown gall tumor formation. Exactly how this system enables the bacterium to respond to an environmental signal is not known, but phosphorylation of VirA and VirG plays a role. To analyze further the function of VirA, we chemically mutagenized the virA gene. Two mutants that activate vir transcription without the plant inducer acetosyringone were found; these mutants alter VirA function by distinct mechanisms. One mutant functions entirely independently of acetosyringone, whereas the activity of the second mutant is enhanced by acetosyringone. Both mutants function best at acid pH, but respond differently to specific monosaccharides that stimulate induction by wild-type VirA. Both mutant phenotypes are dominant over wild-type VirA, and both need the conserved histidine at the autophosphorylation site for strong inducer-independent vir transcription.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,111 KOSHLAND HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014124] Funding Source: NIH RePORTER; NIGMS NIH HHS [F-32-GM14124] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ANKENBAUER RG, 1990, J BACTERIOL, V172, P6442, DOI 10.1128/jb.172.11.6442-6446.1990; ANKENBAUER RG, 1991, MOL PLANT MICROBE IN, V4, P400, DOI 10.1094/MPMI-4-400; AOYAMA T, 1990, FEBS LETT, V263, P1, DOI 10.1016/0014-5793(90)80691-B; BINNS AN, 1988, ANNU REV MICROBIOL, V42, P575, DOI 10.1146/annurev.mi.42.100188.003043; CANGELOSI GA, 1990, P NATL ACAD SCI USA, V87, P6708, DOI 10.1073/pnas.87.17.6708; CHANG CH, 1992, J BACTERIOL, V174, P7033, DOI 10.1128/JB.174.21.7033-7039.1992; HAN DC, 1992, J BACTERIOL, V174, P7040, DOI 10.1128/JB.174.21.7040-7043.1992; HESS KM, 1991, P NATL ACAD SCI USA, V88, P7854, DOI 10.1073/pnas.88.17.7854; HUANG MW, 1990, J BACTERIOL, V172, P1814, DOI 10.1128/jb.172.4.1814-1822.1990; HUANG Y, 1990, J BACTERIOL, V172, P1142, DOI 10.1128/jb.172.2.1142-1144.1990; JIN SG, 1993, MOL MICROBIOL, V7, P555, DOI 10.1111/j.1365-2958.1993.tb01146.x; JIN SG, 1990, J BACTERIOL, V172, P4945, DOI 10.1128/jb.172.9.4945-4950.1990; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; JIN SG, 1990, J BACTERIOL, V172, P531, DOI 10.1128/jb.172.2.531-537.1990; JOUANIN L, 1985, MOL GEN GENET, V201, P370, DOI 10.1007/BF00331325; KANAMARU K, 1989, J BIOL CHEM, V264, P21633; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; LEE KH, 1992, P NATL ACAD SCI USA, V89, P8666, DOI 10.1073/pnas.89.18.8666; LEROUX B, 1987, EMBO J, V6, P849, DOI 10.1002/j.1460-2075.1987.tb04830.x; MELCHERS LS, 1989, EMBO J, V8, P1919, DOI 10.1002/j.1460-2075.1989.tb03595.x; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PAZOUR GJ, 1990, J BACTERIOL, V172, P1241, DOI 10.1128/jb.172.3.1241-1249.1990; PAZOUR GJ, 1992, J BACTERIOL, V174, P4169, DOI 10.1128/jb.174.12.4169-4174.1992; PAZOUR GJ, 1990, NUCLEIC ACIDS RES, V18, P6909, DOI 10.1093/nar/18.23.6909; PAZOUR GJ, 1991, P NATL ACAD SCI USA, V88, P6941, DOI 10.1073/pnas.88.16.6941; POWELL BS, 1990, MOL MICROBIOL, V4, P2159, DOI 10.1111/j.1365-2958.1990.tb00577.x; ROITSCH T, 1990, J BACTERIOL, V172, P6054, DOI 10.1128/jb.172.10.6054-6060.1990; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SHIMODA N, 1990, P NATL ACAD SCI USA, V87, P6684, DOI 10.1073/pnas.87.17.6684; STACHEL SE, 1986, P NATL ACAD SCI USA, V83, P379, DOI 10.1073/pnas.83.2.379; STACHEL SE, 1985, NATURE, V318, P624, DOI 10.1038/318624a0; STACHEL SE, 1986, CELL, V46, P325, DOI 10.1016/0092-8674(86)90653-7; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; WINANS SC, 1989, J BACTERIOL, V171, P1616, DOI 10.1128/jb.171.3.1616-1622.1989; WINANS SC, 1986, P NATL ACAD SCI USA, V83, P8278, DOI 10.1073/pnas.83.21.8278; WINANS SC, 1992, MICROBIOL REV, V56, P12, DOI 10.1128/MMBR.56.1.12-31.1992; WINANS SC, 1988, J BACTERIOL, V170, P4047, DOI 10.1128/jb.170.9.4047-4054.1988; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	43	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2645	2651						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300595				2022-12-25	WOS:A1994MV43200046
J	ROBERTS, SB; RIPELLINO, JA; INGALLS, KM; ROBAKIS, NK; FELSENSTEIN, KM				ROBERTS, SB; RIPELLINO, JA; INGALLS, KM; ROBAKIS, NK; FELSENSTEIN, KM			NON-AMYLOIDOGENIC CLEAVAGE OF THE BETA-AMYLOID PRECURSOR PROTEIN BY AN INTEGRAL MEMBRANE METALLOENDOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; CULTURED-CELLS; APP-SECRETASE; GENE; MUTATION; PEPTIDE; IDENTIFICATION; PHOSPHORYLATION; SEQUENCE; ENZYME	The beta-amyloid precursor protein (beta-APP) is a membrane spanning glycoprotein. The small beta-protein domain within the precursor is presumed to be the source of amyloid found in plaques characteristic of Alzheimer's disease. The amino terminus of beta-APP is released from cells by cleavages that produce both potentially amyloidogenic and nonamyloidogenic fragments of the carboxyl terminus. We developed a cell free system that imposes specificity and co-localization to characterize the proteolytic activity that cleaves the precursor within the beta-protein domain. A reporter protein containing the carboxyl-terminal 105 amino acids of beta-APP provided a specific substrate for cleavage at Lys16 of the beta-protein. The protease inhibitor profile and solubility characteristics of the activity demonstrate the cleavage is produced by an integral membrane metalloendopeptidase.	CUNY MT SINAI SCH MED,DEPT PSYCHIAT,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	ROBERTS, SB (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,CNS DRUG DISCOVERY,DEPT BIOPHYS & MOLEC BIOL,5 RES PKWY,WALLINGFORD,CT 06492, USA.		Robakis, Nikolaos/AAA-1838-2021					ALLSOP D, 1991, BRAIN RES, V551, P1, DOI 10.1016/0006-8993(91)90905-B; ANDERSON JP, 1992, J NEUROCHEM, V59, P2328; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FERNANDEZMADRID I, 1991, ANN NEUROL, V30, P730, DOI 10.1002/ana.410300516; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P690; GOLDGABER D, 1987, SCIENCE, V235, P8778; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOJIMA S, 1992, FEBS LETT, V304, P57, DOI 10.1016/0014-5793(92)80588-8; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MCDERMOTT JR, 1991, BIOCHEM BIOPH RES CO, V179, P1148, DOI 10.1016/0006-291X(91)91691-5; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; POWERS JC, 1986, RES MONOGRAPHS CELL, V12, P219; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1991, BIOCHEMISTRY-US, V30, P10795, DOI 10.1021/bi00108a027; TAGAWA K, 1991, BIOCHEM BIOPH RES CO, V177, P377, DOI 10.1016/0006-291X(91)91994-N; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	31	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					3111	3116						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300647				2022-12-25	WOS:A1994MV43200108
J	TAMORI, Y; HASHIRAMOTO, M; CLARK, AE; MORI, H; MURAOKA, A; KADOWAKI, T; HOLMAN, GD; KASUGA, M				TAMORI, Y; HASHIRAMOTO, M; CLARK, AE; MORI, H; MURAOKA, A; KADOWAKI, T; HOLMAN, GD; KASUGA, M			SUBSTITUTION AT PRO(385) OF GLUT1 PERTURBS THE GLUCOSE-TRANSPORT FUNCTION BY REDUCING CONFORMATIONAL FLEXIBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE; PROTEOLYTIC DISSECTION; PROLINE RESIDUES; PROTEIN; BINDING; MUTAGENESIS; RESOLUTION; KINETICS; CARRIER; HELICES	The mammalian glucose transporter, GLUT1, is capable of alternating between two conformations which expose either an outward- or inward-facing ligand binding site. The possibility that these conformational changes are related to the presence of prolines and glycines in transmembrane region 10 was investigated by site-directed mutagenesis. Chinese hamster ovary clones which were transfected with Pro385 --> Ile and Pro385 --> glycine mutations of GLUT1 were shown, by Western blotting and cell surface carbohydrate labeling, to have expression levels which were comparable with the wild type. The transport activity was markedly reduced as a result of the Pro385 --> isoleucine but not in the Pro385 --> glycine mutation. The loss of transport activity in the Pro385 --> isoleucine clone was associated with loss of labeling by the exofacial photoaffinity ligand, 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine (ATB-BMPA), but there was no loss in labeling by the inside site-directed ligand cytochalasin B. These results suggest that the transporter cannot adopt the outward-directed conformation in the Pro385 --> isoleucine clone. By contrast, the glycine substitution for proline at this position resulted in a retention of the ligand binding properties at both inside and outside sites. We suggest a putative mode of operation of the transporter which involves conformational flexibility about the prolines in transmembrane segment 10 such that helices 11 and 12 can alternately either pack against the outside (ATB-BMPA binding) site in helices 7, 8, and 9 or against the inner (cytochalasin B binding) site at the base of transmembrane segment 10.	KOBE UNIV, SCH MED,DEPT INTERNAL MED 3,7-5-1 KUSUNOKI CHO, CHUO KU, KOBE 650, JAPAN; UNIV BATH, DEPT BIOCHEM, BATH BA2 7AY, AVON, ENGLAND; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	Kobe University; University of Bath; University of Tokyo				Holman, Geoffrey/0000-0001-7045-1358				ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; APPLEMAN JR, 1985, J BIOL CHEM, V260, P4575; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; BLANDL CY, 1986, P NATL ACAD SCI USA, V83, P917; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHIN JJ, 1987, P NATL ACAD SCI USA, V84, P4113, DOI 10.1073/pnas.84.12.4113; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CONSLER TG, 1991, BIOCHEMISTRY-US, V30, P1291, DOI 10.1021/bi00219a019; DAVIDSEN AF, 1992, MORIOND AST, P125; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; GIBBS AF, 1988, BIOCHEM J, V256, P421, DOI 10.1042/bj2560421; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; KING APJ, 1991, BIOCHEMISTRY-US, V30, P11546, DOI 10.1021/bi00113a009; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAY JM, 1989, J MEMBRANE BIOL, V106, P227; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P227; PAWAGI AB, 1990, BIOCHEMISTRY-US, V29, P950, DOI 10.1021/bi00456a015; VILSEN B, 1989, J BIOL CHEM, V264, P21024; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WALMSLEY AR, 1987, BIOCHIM BIOPHYS ACTA, V901, P229, DOI 10.1016/0005-2736(87)90119-2; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001	32	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2982	2986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300630				2022-12-25	WOS:A1994MV43200089
J	CREMERS, FPM; ARMSTRONG, SA; SEABRA, MC; BROWN, MS; GOLDSTEIN, JL				CREMERS, FPM; ARMSTRONG, SA; SEABRA, MC; BROWN, MS; GOLDSTEIN, JL			REP-2, A RAB ESCORT PROTEIN ENCODED BY THE CHOROIDEREMIA-LIKE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYL TRANSFERASE; BINDING; CLONING; ENZYME; FAMILY; YPT1	Rab escort proteins (REPs) bind to newly synthesized Rab proteins and remain bound during and after the attachment of a geranylgeranyl (GG) group by the catalytic component of the Rab GG transferase. Transfer of the GG group is absolutely dependent on the participation of a REP. REP-1, the first characterized REP, is produced by a gene on the X chromosome that is defective in patients with choroideremia, a form of retinal degeneration. Cremers et al. (Cremers, F. P. M., Molloy, C. M., van de Pol, D. J. R., van den Hurk, J. A. J. M., Bach, I., Geurts van Kessel, A. H. M., and Ropers, H.-H. (1992) Hum. Mol. Genet. 1, 71-75) isolated a related gene designated choroideremia-like, which encodes a protein that closely resembles REP-1. In the current studies, we produced REP-1 and REP-2 by recombinant DNA methods and showed that both proteins were approximately equal in facilitating the attachment of GG groups to several Rab proteins, including Rab1A, Rab5A, and Rab6. However, REP-2 was only 25% as active as REP-1 in supporting GG attachment to Rab3A and Rab3D. The low activity toward Rab3A was increased to that of Rab1A when the COOH-terminal 12 amino acids of Rab3A were replaced with the corresponding residues of Rab1A. We suggest that REP-2 substitutes for the absent function of REP-1 in nonretinal cells of patients with choroideremia, thus preventing cellular dysfunction throughout the body. In the retina, REP-2 may be only partially effective, leading eventually to retinal degeneration and blindness.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Seabra, Miguel C/M-3280-2013; Cremers, Frans/A-5625-2014; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; Cremers, Frans/0000-0002-4954-5592; 	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; GUAN K, 1992, ANAL BIOCHEM, V192, P262; Heckenlively JR, 1988, RETINITIS PIGMENTOSA, P176; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; Sambrook J, 1989, MOL CLONING LABORATO; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	30	161	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2111	2117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294464				2022-12-25	WOS:A1994MR98800085
J	INUZUKA, M; ISHIKAWA, H; KUMAR, S; GELINAS, C; ITO, Y				INUZUKA, M; ISHIKAWA, H; KUMAR, S; GELINAS, C; ITO, Y			THE VIRAL AND CELLULAR REL ONCOPROTEINS INDUCE THE DIFFERENTIATION OF P19 EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							CHICKEN SPLEEN-CELLS; NF-KAPPA-B; V-REL; RETICULOENDOTHELIOSIS VIRUS; C-JUN; PROTEINS; EXPRESSION; ONCOGENE; F9; TRANSFORMATION	Rel proteins have been implicated in the differentiation and transformation of lymphoid cells. Despite their significant sequence homology to the Drosophila Dorsal morphogen, a functional role for Rel proteins in early development has yet to be established. Here we show that expression of the v- or c-rel genes in P19 embryonal carcinoma (EC) cells leads to drastic morphological changes accompanied by the expression of several differentiation-specific antigens. In contrast, v-Rel mutants defective for DNA-binding as well as those lacking the F9 cell-specific transcription activation region of v-Rel were equally unable to promote P19 cell differentiation. Our results demonstrate that transcriptional activation by Rel proteins correlates with Rel-induced differentiation of EC cells, and raise the intriguing possibility that Rel proteins may play an important role in early developmental processes.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Kyoto University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center								ADAMSON ED, 1984, DIFFERENTIATION, V27, P152, DOI 10.1111/j.1432-0436.1984.tb01421.x; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRAVO R, 1988, QUANT BIOL, P901; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Graham C.F, 1977, CONCEPTS MAMMALIAN E, P315; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISHIKAWA H, 1993, IN PRESS ONCOGENE; KAHAN B, 1983, CELL PROLIFERAT, V10, P131; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T, 1989, DECONTAMINATION DILU; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SHIBUYA T, 1982, CANCER RES, V42, P2722; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	33	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					133	140						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302572				2022-12-25	WOS:A1994MW24700016
J	TAKAISHI, K; SASAKI, T; KATO, M; YAMOCHI, W; KURODA, S; NAKAMURA, T; TAKEICHI, M; TAKAI, Y				TAKAISHI, K; SASAKI, T; KATO, M; YAMOCHI, W; KURODA, S; NAKAMURA, T; TAKEICHI, M; TAKAI, Y			INVOLVEMENT OF RHO-P21 SMALL GTP-BINDING PROTEIN AND ITS REGULATOR IN THE HGF-INDUCED CELL MOTILITY	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN CYTOSOL; SCATTER FACTOR; GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; FACTOR RECEPTOR; PARTIAL-PURIFICATION; MET PROTOONCOGENE; EXCHANGE PROTEINS	Hepatocyte growth factor (HGF) induced motility of cultured mouse keratinocytes (308R cells). This HGF-induced cell motility was inhibited by microinjection of either rho GDI, an inhibitory GDP/GTP exchange protein for rho p21 small GTP-binding protein, or a botulinum exoenzyme C3 which is known to selectively impair the function of who p21 by ADP-ribosylating its effector domain. The rho GDI action was prevented by comicroinjection with the guanosine 5'-(3-O-thio)triphosphate (GTP gamma S)-bound active form of rhoA p21, and the C3 action was prevented by comicroinjection with a rhoA p21 mutant (rhoA(Ile41) p21) which is resistant to the C3 action. The HGF-induced cell motility was not inhibited by microinjection of a dominant negative rac1 p21 mutant (rac1(Asn17) p21) or a dominant negative Ki-ras p21 mutant (Ki-ras(Asn17) p21). Microinjection of the GTP gamma S-bound form of rac1 p21 or a dominant active Ki-ras p21 mutant (Ki-ras(Val12) p21) did not induce cell motility. These results indicate that both rho p21 and who GDI, but neither rac p21 nor ras p21, are involved in the HGF-induced cell motility. However, microinjection of the GTP gamma S-bound form of rhoA p21 alone did not induce cell motility in the absence of HGF, suggesting that activation of who p21 is necessary but not sufficient for the HGF-induced cell motility. The HGF-induced cell motility was mimicked by 12-O-tetradecanoylphorbol-13-acetate, a protein kinase C-activating phorbol ester, but not by Ca2+ ionophore. The phorbol ester-induced cell motility was also inhibited by microinjection of rho GDI or C3. These results indicate that both rho p21 and rho GDI are also involved in the phorbol ester-induced cell motility.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA,OSAKA 565,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO,KYOTO 606,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kobe University; Osaka University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			Takeichi, Masatoshi/G-5903-2012; KURODA, SHINYA/G-4961-2014	Takeichi, Masatoshi/0000-0002-9931-3378; 				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; FURLONG RA, 1991, J CELL SCI, V100, P173; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; KURODA S, 1992, BIOCHEM BIOPH RES CO, V185, P473, DOI 10.1016/S0006-291X(05)81009-5; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1992, J BIOL CHEM, V267, P20921; MORIISHI K, 1991, J BACTERIOL, V173, P6025, DOI 10.1128/jb.173.19.6025-6029.1991; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; OSADA S, 1992, FEBS LETT, V297, P271, DOI 10.1016/0014-5793(92)80554-T; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J, 1989, MOL CLONING LABORATO; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; WATABE M, 1993, CELL STRUCT FUNCT, V18, P111; Weber K, 1972, Methods Enzymol, V26, P3; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0	59	195	198	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					273	279						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302589				2022-12-25	WOS:A1994MW24700033
J	WELSH, M; MARES, J; KARLSSON, T; LAVERGNE, C; BREANT, B; CLAESSONWELSH, L				WELSH, M; MARES, J; KARLSSON, T; LAVERGNE, C; BREANT, B; CLAESSONWELSH, L			SHB IS A UBIQUITOUSLY EXPRESSED SRC HOMOLOGY-2 PROTEIN	ONCOGENE			English	Article							TYROSINE KINASE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PDGF RECEPTOR; CDNA CLONING; ACTIVATION; ONCOGENE; INSULIN; DOMAIN; SEQUENCES	To identify serum-inducible genes in the insulin-producing cell line beta TC-1, a library subtraction screening procedure was performed on serum-deprived (G(0)) and serum-restimulated (G(1)) insulin-producing beta TC-1 cells. A cDNA containing a motif with strong homology to Src homology 2 (SH2) domains was found using this procedure and called Shb. The Shb cDNA contains two methionine codons in its N-terminus and thus may code for two proteins of 67 and 56 kDa, each with one SH2 domain in its C-terminus. No other structural similarity to proteins with catalytic activity could be detected, suggesting that Shb is a so called adaptor. Shb contains the proline-rich sequence PPPGPGR between the two proposed initiator methionines which resembles a sequence for binding to Src homology 3 (SH3) domains. A second proline-rich sequence was detected after the second methionine codon. The Shb cDNA hybridized to a similar or identical mRNA of 3.1 kb expressed in mouse brain, liver, kidney, heart, NIH3T3 fibroblasts and beta TC-1 cells. Western blot analysis of the same tissues using an antiserum directed against a synthetic peptide corresponding to a part of the SH2 domain of Shb, revealed reactivity with two proteins of 56 and 67 kDa. In addition, a third reactive component of 40 kDa was detected in most tissues. Transfection and transient expression of the Shb cDNA in COS-1 cells yielded increased expression of the 67, 56 and 40 kDa proteins. Transfection and stable expression of the Shb cDNA in pig aortic endothelial cells showed increased expression primarily of the 67 kDa protein. A fusion protein consisting of the SH2 domain of Shb linked to glutathione S-transferase showed increased binding to glycoproteins of cells stimulated with platelet-derived growth factor (PDGF-BB). Furthermore, the autophosphorylated PDGF beta-receptor but not the autophosphorylated epidermal growth factor (EGF) receptor bound specifically to immobilized fusion protein. It is concluded that Shb is a novel SH2-containing protein with proline-rich domains and therefore probably involved in the signal-transduction of some ligand-activated tyrosine kinase receptors.	CHARLES UNIV, INST BIOL & MED GENET, PRAGUE, CZECH REPUBLIC; HOP ST ANTOINE, INSERM, U55, F-75571 PARIS, FRANCE; UPPSALA UNIV, LUDWIG INST CANC RES, UPPSALA, SWEDEN	Charles University Prague; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ludwig Institute for Cancer Research; Uppsala University	WELSH, M (corresponding author), UPPSALA UNIV, DEPT MED CELL BIOL, UPPSALA, SWEDEN.		Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755; Claesson-Welsh, Lena/0000-0003-4275-2000				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BREANT B, 1990, DIABETOLOGIA, V33, P586, DOI 10.1007/BF00400201; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1993, IN PRESS PROG GROWTH; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Hellerstrom C, 1985, DIABETIC PANCREAS, P53; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; OIE HK, 1983, ENDOCRINOLOGY, V112, P1070, DOI 10.1210/endo-112-3-1070; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sambrook J, 1989, MOL CLONING LABORATO; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1984, CELL, V36, P349; WELSH M, 1993, DIABETES METAB REV, V9, P25, DOI 10.1002/dmr.5610090104; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	66	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					19	27						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302579				2022-12-25	WOS:A1994MW24700003
J	ARONDEL, V; BENNING, C; SOMERVILLE, CR				ARONDEL, V; BENNING, C; SOMERVILLE, CR			ISOLATION AND FUNCTIONAL EXPRESSION IN ESCHERICHIA-COLI OF A GENE ENCODING PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE (EC-2.1.1.17) FROM RHODOBACTER-SPHAEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; RAT-LIVER; PURIFICATION; YEAST; METHYLATION; PATHWAY; CLONING; PROTEIN	Phosphatidylcholine is a major component of membranes in most eukaryotes, but it is found only in a small number of bacteria, where it is synthesized by N-methylation of phosphatidylethanolamine. In yeast and other fungi the methylation of phosphatidylethanolamine to phosphatidylcholine proceeds in two steps: the methylation of phosphatidylethanolamine by phosphatidylethanolamine methyltransferase followed by the methylation of monomethylphosphatidylethanolamine by phospholipid methyltransferase. Here we describe the isolation of two allelic phosphatidylcholine-deficient mutants of Rhodobacter sphaeroides which are unable to methylate phosphatidylethanolamine, monomethylphosphatidylethanolamine, or dimethylphosphatidylethanolamine. A DNA fragment containing a gene designated pmtA, which encodes a 22.9-kDa protein, was found to complement both mutants. Expression of this gene in Escherichia coli, which normally lacks phosphatidylcholine or methylated derivatives of phosphatidylethanolamine, resulted in the formation of phosphatidylcholine. A protein extract derived from the E. coli strain expressing the pmtA gene was able to convert phosphatidylethanolamine, mono- and dimethylphosphatidylethanolamine into phosphatidylcholine. Based on these data we conclude that the product of the pmtA gene catalyzes a sequence of three chemically distinct, methylation reactions beginning with phosphatidylethanolamine and leading to the formation of phosphatidylcholine in R. sphaeroides.			ARONDEL, V (corresponding author), MICHIGAN STATE UNIV,DEPT ENERGY,PLANT RES LAB,E LANSING,MI 48824, USA.		Benning, Christoph/Y-2528-2019; Somerville, Christopher R/A-4048-2009	Benning, Christoph/0000-0001-8585-3667; Somerville, Christopher R/0000-0003-4647-0094				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BENNING C, 1992, J BACTERIOL, V174, P6479, DOI 10.1128/JB.174.20.6479-6487.1992; BENNING C, 1992, J BACTERIOL, V174, P2352, DOI 10.1128/JB.174.7.2352-2360.1992; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIN BD, 1984, J BIOL CHEM, V259, P942; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CRONAN JE, 1972, BIOCHIM BIOPHYS ACTA, V265, P25, DOI 10.1016/0304-4157(72)90018-4; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GUREVITZ M, 1985, P NATL ACAD SCI USA, V82, P6546, DOI 10.1073/pnas.82.19.6546; JENSEN NJ, 1988, MASS SPECTROM REV, V7, P41, DOI 10.1002/mas.1280070103; JOHNSTON NC, 1983, J GEN MICROBIOL, V129, P1075; KANESHIRO T, 1964, J BIOL CHEM, V239, P1705; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V2, P1190; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; OGAWA H, 1983, ARCH BIOCHEM BIOPHYS, V226, P265, DOI 10.1016/0003-9861(83)90293-X; PIERCE JW, 1982, METHOD ENZYMOL, V89, P47; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; Sambrook J, 1989, MOL CLONING LABORATO; SCARBOROUGH GA, 1967, J BIOL CHEM, V242, P238; SILVER BL, 1985, PHYSICAL CHEM MEMBRA, P57; SISTROM WR, 1962, J GEN MICROBIOL, V28, P607, DOI 10.1099/00221287-28-4-607; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAHARA Y, 1986, AGR BIOL CHEM TOKYO, V50, P257, DOI 10.1080/00021369.1986.10867372; van Niel CB, 1944, BACTERIOL REV, V8, P1; Vance D E, 1981, Methods Enzymol, V71 Pt C, P581; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; Wilkinson S., 1988, MICROBIAL LIPIDS; YAZDI MA, 1990, J GEN MICROBIOL, V136, P1335, DOI 10.1099/00221287-136-7-1335	34	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16002	16008						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340421				2022-12-25	WOS:A1993LN30500095
J	PASCHAL, BM; HOLZBAUR, ELF; PFISTER, KK; CLARK, S; MEYER, DI; VALLEE, RB				PASCHAL, BM; HOLZBAUR, ELF; PFISTER, KK; CLARK, S; MEYER, DI; VALLEE, RB			CHARACTERIZATION OF A 50-KDA POLYPEPTIDE IN CYTOPLASMIC DYNEIN PREPARATIONS REVEALS A COMPLEX WITH P150(GLUED) AND A NOVEL ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; IDENTIFICATION; TRANSPORT; INVITRO; BRAIN; GENE; 1C	Earlier work identified a series of accessory polypeptides of 150, 74, 59, 57, 55, 53, 50, and 45 kDa copurifying with cytoplasmic dynein. In the present study immunoprecipitation of the 50-kDa polypeptide from bovine brain cytosol with a specific monoclonal antibody revealed coprecipitating components of 150, 135, 62, and 45 kDa, which were completely distinct from the polypeptides immunoprecipated using an antibody to the well established 74-kDa cytoplasmic dynein subunit. The 150- and 135-kDa polypeptides reacted with an antibody to p150Glued, the mammalian homologue of the Drosophila Glued gene. N-terminal microsequencing of tryptic peptides of the major 45-kDa component of the complex revealed it to be the alpha-isoform of centractin, a novel form of actin. Immunoblotting of sucrose gradient-fractionated brain cytosol revealed p150Glued, p50, and centractin to cosediment exclusively at 20 S. Immunofluorescence microscopy using antibody to p150Glued revealed centrosomal staining, which was abolished by microtubule depolymerization. Together these results reveal the 50-kDa polypeptide to be part of a cytosolic complex distinct from cytoplasmic dynein. However, the immunolocalization data indicate an association with microtubule minus ends, suggesting a possible interaction with cytoplasmic dynein in the cell.	WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA; UNIV PENN, SCH VET MED, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT ANAT & CELL BIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	Worcester Foundation for Biomedical Research; University of Pennsylvania; University of Virginia; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047434, R01GM047434, R01GM026701] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47434, GM26701] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; GAREN SH, 1983, DEV BIOL, V96, P445, DOI 10.1016/0012-1606(83)90182-3; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOLZBAUR ELF, 1989, J CELL BIOL, V109, P157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; LIN SXH, 1992, J CELL SCI, V101, P125; MEYYEROWITZ EM, 1983, DEV BIOL, V62, P112; MITCHELL DR, 1991, J CELL BIOL, V113, P835, DOI 10.1083/jcb.113.4.835; NEELY MD, 1988, J CELL BIOL, V107, P1767, DOI 10.1083/jcb.107.5.1767; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vallee R, 1991, Trends Cell Biol, V1, P25, DOI 10.1016/0962-8924(91)90066-I; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; [No title captured]	27	120	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15318	15323						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325901				2022-12-25	WOS:A1993LL75900111
J	AKSAMIT, RR; BACKLUND, PS; MOOS, M; CARYK, T; GOMI, T; OGAWA, H; FUJIOKA, M; CANTONI, GL				AKSAMIT, RR; BACKLUND, PS; MOOS, M; CARYK, T; GOMI, T; OGAWA, H; FUJIOKA, M; CANTONI, GL			THE ROLE OF CYSTEINE-78 IN FLUOROSULFONYLBENZOYLADENOSINE INACTIVATION OF RAT-LIVER S-ADENOSYLHOMOCYSTEINE HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-HOMOCYSTEINE HYDROLASE; AMINO-ACID SEQUENCE; SITE-DIRECTED MUTAGENESIS; DICTYOSTELIUM-DISCOIDEUM; COENZYME BINDING; CDNA SEQUENCE; PROTEINS; PURIFICATION; RESIDUES; ENZYME	Inactivation of rat liver S-adenosylhomocysteine hydrolase by the site-directed reagent 5'-p-fluorosulfonyl-benzoyladenosine (FSBA) is associated with the formation of a disulfide bond between Cys-78 and Cys-112 (Takata, Y., and Fujioka, M. (1984) Biochemistry 23, 4357-4362; Gomi, T., Ogawa,H., and Fujioka, M. (1986) J. Biol. Chem. 261, 13422-13425). To characterize the inactivation mechanism more precisely, the properties of four hydrolase proteins mutated at Cys-78 or Cys-112 were compared to those of the wild-type enzyme. When Cys-78 was mutated to either a serine or an alanine, proteins with greatly reduced enzymatic activity were obtained, large effects on kinetic constants were observed, and enzymatic activity was not affected by incubation with FSBA. When Cys-112 was mutated to either a serine or an alanine, the activity was similar to the wild-type protein, only small changes in the kinetic constants were observed, and the enzyme was inactivated more rapidly upon incubation with FSBA. FSBA inactivation of the C112A mutant protein was accompanied by the formation of a disulfide between Cys-78 and Cys-52. The data indicate that FSBA initially reacts with Cys-78 and that Cys-78 has an important role in the structure of the enzyme.	US FDA, CTR BIOL EVALUAT & RES, DEV BIOL LAB, BETHESDA, MD 20892 USA; TOYAMA MED & PHARMACEUT UNIV, FAC MED, DEPT BIOCHEM, SUGITANI, TOYAMA 93001, JAPAN	US Food & Drug Administration (FDA); University of Toyama	AKSAMIT, RR (corresponding author), NIMH, GEN & COMPARAT BIOCHEM LAB, BLDG 36, RM 3D06, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Moos, Malcolm C/F-3673-2011	Moos, Malcolm C/0000-0002-9575-9938				ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; Borchardt R. T., 1986, BIOL METHYLATION DRU, P227; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; COULL J M, 1990, Journal of Protein Chemistry, V9, P259; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; DELAHABA G, 1959, J BIOL CHEM, V234, P603; DELAHABA G, 1986, BIOCHEMISTRY-US, V25, P8337, DOI 10.1021/bi00373a031; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOSKELAND SO, 1982, BIOCHIM BIOPHYS ACTA, V708, P185, DOI 10.1016/0167-4838(82)90219-9; FUJIOKA M, 1981, J BIOL CHEM, V256, P1631; GOMI T, 1986, J BIOL CHEM, V261, P3422; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GOMI T, 1989, J BIOL CHEM, V264, P16138; GOMI T, 1990, J BIOL CHEM, V265, P16102; GURANOWSKI A, 1977, EUR J BIOCHEM, V80, P517, DOI 10.1111/j.1432-1033.1977.tb11907.x; HENDERSON DM, 1992, MOL BIOCHEM PARASIT, V53, P169, DOI 10.1016/0166-6851(92)90019-G; HOHMAN RJ, 1984, ARCH BIOCHEM BIOPHYS, V233, P785, DOI 10.1016/0003-9861(84)90507-1; KASIR J, 1988, BIOCHEM BIOPH RES CO, V153, P359, DOI 10.1016/S0006-291X(88)81231-2; KAWALLECK P, 1992, P NATL ACAD SCI USA, V89, P4713, DOI 10.1073/pnas.89.10.4713; KIM IK, 1983, ARCH BIOCHEM BIOPHYS, V226, P65, DOI 10.1016/0003-9861(83)90271-0; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOS M, 1988, J BIOL CHEM, V263, P6005; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POTTER MD, 1992, J BIOL CHEM, V267, P2023; PRASAD SS, 1993, GENOME, V36, P57, DOI 10.1139/g93-008; RICHARDS HH, 1978, J BIOL CHEM, V253, P4476; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEBESTOVA L, 1984, COLLECT CZECH CHEM C, V49, P1543, DOI 10.1135/cccc19841543; SGANGA MW, 1992, P NATL ACAD SCI USA, V89, P6328, DOI 10.1073/pnas.89.14.6328; SHIMIZU S, 1984, EUR J BIOCHEM, V141, P385, DOI 10.1111/j.1432-1033.1984.tb08203.x; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; TAKATA Y, 1984, BIOCHEMISTRY-US, V23, P4357, DOI 10.1021/bi00314a017; TAKATA Y, 1991, BIOCHEM J, V277, P399, DOI 10.1042/bj2770399; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	43	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4084	4091						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307967				2022-12-25	WOS:A1994MW98900031
J	MORROW, JD; MINTON, TA; MUKUNDAN, CR; CAMPBELL, MD; ZACKERT, WE; DANIEL, VC; BADR, KF; BLAIR, IA; ROBERTS, LJ				MORROW, JD; MINTON, TA; MUKUNDAN, CR; CAMPBELL, MD; ZACKERT, WE; DANIEL, VC; BADR, KF; BLAIR, IA; ROBERTS, LJ			FREE RADICAL-INDUCED GENERATION OF ISOPROSTANES IN-VIVO - EVIDENCE FOR THE FORMATION OF D-RING AND E-RING ISOPROSTANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; FAST-ATOM-BOMBARDMENT; MASS-SPECTROMETRY; PROSTAGLANDINS; PHOSPHOLIPIDS; SERIES; NONCYCLOOXYGENASE; INVIVO; RATS	We recently reported the discovery that a series of novel prostaglandin (PG)F-2-like compounds (F-2-isoprostanes) are produced in vivo independent of the cyclooxygenase as products of free radical-catalyzed lipid peroxidation. F-2-isoprostanes are initially formed in situ from arachidonic acid esterified to phospholipids and then released preformed. We have now investigated whether PGD(2)/E(2)-like isoprostanes are also produced by rearrangement of the PGG(2)-like intermediates involved in isoprostane formation. Using a variety of approaches utilizing mass spectrometry, compelling evidence was obtained for the presence of D-2/E(2)-isoprostane-containing phosphospholipids in the liver (85 +/- 33 ng/g of liver) and free D-2/E(2)-isoprostanes in the circulation (215 +/- 90 pg/ml) of rats treated with CCl4 to induce lipid peroxidation. In untreated rats, levels of D-2/E(2)-isoprostanes esterified in liver phospholipids were much lower (0.90 +/- 0.10 ng/g), and free compounds could not be detected in the circulation (<5 pg/ml). Interestingly, one of the E(2)-isoprostanes that would be expected to be formed in abundance, 8-epi-PGE(2), was found to be a potent renal vasoconstrictor, and these effects could be abrogated by SQ29548, a thromboxane receptor antagonist. Further understanding of the biological consequences of the for mation of these novel compounds and factors that influence their formation may provide valuable insights into the pathophysiology of oxidant injury.	VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; EMORY UNIV, DEPT MED, DIV NEPHROL, ATLANTA, GA 30033 USA; VET AFFAIRS MED CTR, ATLANTA, GA 30033 USA	Vanderbilt University; Vanderbilt University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System			Blair, Ian A/B-3320-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, R37GM042056] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39261] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM42056] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AWAD JA, 1993, J BIOL CHEM, V268, P4161; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; BURK RF, 1979, TOXICOL APPL PHARM, V50, P467, DOI 10.1016/0041-008X(79)90400-9; DUNN MJ, 1977, AM J PHYSIOL, V233, pF169, DOI 10.1152/ajprenal.1977.233.3.F169; ELLINGSON JS, 1987, J LIPID RES, V28, P1016; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HANRAS C, 1991, J AM OIL CHEM SOC, V68, P804, DOI 10.1007/BF02660591; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HUGHES H, 1983, ANAL BIOCHEM, V130, P431, DOI 10.1016/0003-2697(83)90612-7; JACKSON EK, 1989, J PHARMACOL EXP THER, V250, P9; JENSEN NJ, 1986, LIPIDS, V21, P580, DOI 10.1007/BF02534056; KAYGANICHHARRISON KA, 1993, J LIPID RES, V34, P1229; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; MORROW JD, 1993, IN PRESS BIOCH BIOPH; OCONNOR DE, 1981, J AM CHEM SOC, V103, P223, DOI 10.1021/ja00391a056; PACEASCIAK C, 1971, J CHROMATOGR, V56, P129, DOI 10.1016/S0021-9673(00)97786-0; PACEASCIAK CR, 1989, ADV PROSTAGLANDIN TH, V18, P251; PARSONS WG, 1988, J IMMUNOL, V141, P2413; RADIN NS, 1969, METHOD ENZYMOL, V14, P245; ROBERTS LJ, 1987, CRC HDB EICOSANOIDS, V1, P233; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; TABER DF, 1992, J ORG CHEM, V57, P441, DOI 10.1021/jo00028a012; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; WENDELBORN DF, 1990, METHOD ENZYMOL, V187, P51; ZIRROLLI JA, 1990, J AM SOC MASS SPECTR, V1, P325, DOI 10.1016/1044-0305(90)85009-B	31	285	288	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4317	4326						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307999				2022-12-25	WOS:A1994MW98900066
J	KRAMARCY, NR; VIDAL, A; FROEHNER, SC; SEALOCK, R				KRAMARCY, NR; VIDAL, A; FROEHNER, SC; SEALOCK, R			ASSOCIATION OF UTROPHIN AND MULTIPLE DYSTROPHIN SHORT FORMS WITH THE MAMMALIAN-M(R) 58,000 DYSTROPHIN-ASSOCIATED PROTEIN (SYNTROPHIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; CULTURED XENOPUS MUSCLE; SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTIONS; GLYCOPROTEIN COMPLEX; NONMUSCLE TISSUES; ELECTRIC TISSUE; CYSTEINE-RICH; 58K PROTEIN; LOCALIZATION	Electric tissue syntrophin, originally described as an M(r) 58,000 postsynaptic protein having homologs in mammalian muscle, was previously shown to associate with dystrophin in Triton extracts of Torpedo postsynaptic membranes. It also associates with the Torpedo M(r) 87,000 postsynaptic protein (87K), the core of which is a superdomain homologous to the cysteine-rich (CR) and COOH-terminal (CT) domains of human dystrophin. Using immunoaffinity purifications from various rat tissues and immunoblotting, we find that syntrophin associates with dystrophin, utrophin (the chromosome 6-encoded dystrophin homolog formerly known as dystrophin-related protein), multiple proteins which are cross-reactive with 87K, and two subfamilies of 71K-like proteins (CRCT-containing proteins encoded by the dystrophin gene under the control of an alternative promoter in intron 62). One 71K subfamily retains the dystrophin COOH-terminal sequence; the other has an alternative COOH-terminal sequence caused by deletion of the penultimate exon by alternative splicing. The relative masses of the members of the subfamilies suggest they arise by alternative splicing at other previously described sites within CT. These results establish that syntrophin is a general ligand for the CRCT domain in mammalian dystrophin and its homologs. They also reveal a greater diversity in 71K proteins than has previously been apparent.			KRAMARCY, NR (corresponding author), UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599, USA.		Vidal, Adriana/AAG-8944-2021		FIC NIH HHS [1-F05-TW04733] Funding Source: Medline; NINDS NIH HHS [NS14871, NS15293] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015293, R01NS014871] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; BIES RD, 1992, NUCLEIC ACIDS RES, V20, P1725, DOI 10.1093/nar/20.7.1725; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; BLOCH RJ, 1991, J CELL BIOL, V115, P435, DOI 10.1083/jcb.115.2.435; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHEN Q, 1990, J CELL BIOL, V110, P2061, DOI 10.1083/jcb.110.6.2061; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FARDEAU M, 1990, CR ACAD SCI III-VIE, V311, P197; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; HELLIWELL TR, 1992, AM J HUM GENET, V50, P508; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1991, ANN NEUROL, V30, P605, DOI 10.1002/ana.410300414; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KIM TW, 1992, P NATL ACAD SCI USA, V89, P11642, DOI 10.1073/pnas.89.23.11642; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KRAMARCY NR, 1990, FEBS LETT, V274, P171, DOI 10.1016/0014-5793(90)81356-S; LANSMAN JB, 1991, J MUSCLE RES CELL M, V12, P409, DOI 10.1007/BF01738325; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LEMAIRE C, 1988, EMBO J, V7, P4157, DOI 10.1002/j.1460-2075.1988.tb03311.x; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIDOV HGW, 1993, NEUROSCIENCE, V54, P167, DOI 10.1016/0306-4522(93)90392-S; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MILNER RE, 1992, BIOCHEM J, V288, P1037, DOI 10.1042/bj2881037; NGUYEN TM, 1992, BIOCHEM J, V288, P663, DOI 10.1042/bj2880663; NICHOLSON LVB, 1990, ACTA NEUROPATHOL, V80, P239, DOI 10.1007/BF00294640; NICHOLSON LVB, 1992, ACTA NEUROL SCAND, V86, P8, DOI 10.1111/j.1600-0404.1992.tb08046.x; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PENG HB, 1992, J CELL SCI, V103, P551; RAPAPORT D, 1992, DIFFERENTIATION, V49, P187, DOI 10.1111/j.1432-0436.1992.tb00666.x; RECAN D, 1992, J CLIN INVEST, V89, P712, DOI 10.1172/JCI115640; SATO O, 1992, J BIOCHEM-TOKYO, V112, P631, DOI 10.1093/oxfordjournals.jbchem.a123951; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SHIMIZU T, 1989, BIOMED RES-TOKYO, V10, P405, DOI 10.2220/biomedres.10.405; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WAGNER KR, 1993, IN PRESS J NEUROCHEM; YEADON JE, 1991, J CELL BIOL, V115, P1069, DOI 10.1083/jcb.115.4.1069; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	58	155	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2870	2876						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300622				2022-12-25	WOS:A1994MV43200076
J	PORTEU, F; HIEBLOT, C				PORTEU, F; HIEBLOT, C			TUMOR-NECROSIS-FACTOR INDUCES A SELECTIVE SHEDDING OF ITS P75-RECEPTOR FROM HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; NF-KAPPA-B; FACTOR-BINDING-PROTEIN; CELL-SURFACE; MOLECULAR-CLONING; SOLUBLE FORM; MONOCLONAL-ANTIBODIES; LIGAND-BINDING; I TNF; EXPRESSION	The effect of tumor necrosis factor alpha (TNF) on the expression of its specific receptors (p55 TNF-R and p75 TNF-R) on the surface of human neutrophils (PMN) and mononuclear cells (MNC) was investigated and compared to the effect of various agonists. PMN and-MNC express both p55 and p75 TNF-R on their membranes. Within minutes of incubation with chemotactic factors or calcium ionophore A23187, both types of TNF-R were down-regulated from the surface on both cell populations. At the same time, soluble forms of these TNF-R appeared in supernatants, in amounts proportional to the extent of down-regulation induced by each stimulus, suggesting that shedding is the major mechanism leading to loss of p55 and p75 TNF-R upon activation with these agonists. Likewise, TNF induced 60-80% and 73-90% decreases in PMN surface p55 TNF-R and p75 TNF-R, respectively. However, modulation of the two types of TNF-R by TNF proceeded through different mechanisms. TNF induced a selective shedding of the p75 TNF-R since, by both enzyme-linked immunosorbent assay and Western blot analysis, only the p75 TNF-R was detected in supernatants of cells stimulated with TNF. Down-modulation of surface p55 TNF-R most probably resulted from TNF-induced receptor internalization, since I-125-TNF bound to PMN p55 TNF-R was rapidly internalized with a t1/2 = 5 min and preincubation of PMN with TNF inhibited by 68 +/- 6% the release of p55 TNF-R triggered upon subsequent treatment with A23187. The apparently unique property of TNF to induce a differential modulation of the two types of TNF-R at the surface of PMN and MNC might play an important role in the control of peripheral blood cell responses to TNF.			PORTEU, F (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U90,161 RUE SEVRES,F-75743 PARIS 15,FRANCE.		PORTEU, Françoise/I-8445-2016	PORTEU, Françoise/0000-0002-2403-4163				ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROUCKAERT P, 1992, LYMPHOKINE CYTOK RES, V11, P193; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GEHR G, 1992, J IMMUNOL, V149, P911; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KALTHOFF H, 1993, J BIOL CHEM, V268, P2762; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRUPPA G, 1992, J IMMUNOL, V148, P3152; KULL FC, 1981, CANCER RES, V41, P4885; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MOSSALAYI MD, 1990, J EXP MED, V171, P959, DOI 10.1084/jem.171.3.959; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NAUME B, 1991, J IMMUNOL, V146, P3045; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PEETRE C, 1988, EUR J HAEMATOL, V41, P414; PENNICA D, 1993, BIOCHEMISTRY-US, V32, P3131, DOI 10.1021/bi00063a027; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PORTEU F, 1992, J LEUKOCYTE BIOL, V52, P122, DOI 10.1002/jlb.52.1.122; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHALABY MR, 1985, J IMMUNOL, V135, P2069; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO M, 1987, J BIOCHEM-TOKYO, V102, P1571, DOI 10.1093/oxfordjournals.jbchem.a122206; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VANOSTADE X, 1993, NATURE, V361, P266; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WATANABE N, 1989, CANCER IMMUNOL IMMUN, V28, P157; WINZEN R, 1993, J IMMUNOL, V150, P4346; WINZEN R, 1992, J IMMUNOL, V148, P3454; WONG GHW, 1992, J IMMUNOL, V149, P3350; YOSHIE O, 1986, J BIOCHEM-TOKYO, V100, P531, DOI 10.1093/oxfordjournals.jbchem.a121744	61	98	100	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2834	2840						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300617				2022-12-25	WOS:A1994MV43200071
J	GRACE, ME; NEWMAN, KM; SCHEINKER, V; BERGFUSSMAN, A; GRABOWSKI, GA				GRACE, ME; NEWMAN, KM; SCHEINKER, V; BERGFUSSMAN, A; GRABOWSKI, GA			ANALYSIS OF HUMAN ACID BETA-GLUCOSIDASE BY SITE-DIRECTED MUTAGENESIS AND HETEROLOGOUS EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE TYPE-1; HUMAN GLUCOCEREBROSIDASE GENE; BINDING-SITES; ACTIVE-SITE; MONOCLONAL-ANTIBODIES; CATALYTIC ACTIVITY; HETEROGENEITY; MUTATIONS; FIBROBLASTS; INVESTIGATE	Structure/function relationships of acid beta-glucosidase, the enzyme deficient in Gaucher disease, were evaluated by characterizing the proteins expressed from cDNAs encoding normal and mutant enzymes. Twenty-two Gaucher disease mutations or created mutations were expressed in Spodoptera frugiperda (Sf9) cells and analyzed for catalytic properties, stability, inhibitor binding, and modifier interactions. Many Gaucher disease mutations encoded highly disruptive amino acid substitutions (e.g. P289L and D409V) and produced severely compromised proteins with very reduced activity (k(cat) < 1% of normal) and/or stability. Six mutant enzymes had sufficient catalytic activity (k(cat) approximately 5-30% of normal) for extensive studies. The highly conservative substitutions, i.e. F216Y or S364T and V394L, led to severe, but selective, abnormalities of enzyme stability or large decreases in catalytic activity, respectively. The T323I, N370S, and V394L enzymes interacted abnormally with active site-directed inhibitors and localized these residues to the glycon binding region. Selected mutant enzymes were poorly activated by phosphatidylserine (V394L, L444P, and R463C) or by saposin C (L444P and T323I), indicating that the enzyme sites for interaction with these activators were within the carboxyl one-third of the enzyme. Substitutions of Ser, Glu, and/or Gly at residues Asp-443 and/or Asp-445 demonstrated important steric roles for these residues in the active site, but neither is the catalytic nucleophile. Together with previous studies, the present analyses provide an insight into the pathogenesis of Gaucher disease and the functional organization of acid beta-glucosidase.	CHILDRENS HOSP MED CTR, DIV HUMAN GENET, 3333 BURNET AVE, CINCINNATI, OH 45229 USA; CUNY MT SINAI SCH MED, DEPT MED & MOLEC GENET, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PEDIAT, NEW YORK, NY 10029 USA	Cincinnati Children's Hospital Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIDDK NIH HHS [DK 36729] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AERTS JMFG, 1987, EUR J BIOCHEM, V163, P583, DOI 10.1111/j.1432-1033.1987.tb10907.x; AGMON V, 1993, IN PRESS BIOCH BIOPH; BARNEVELD RA, 1983, HUM GENET, V64, P227, DOI 10.1007/BF00279398; BERENT SL, 1981, ARCH BIOCHEM BIOPHYS, V208, P248, DOI 10.1016/0003-9861(81)90147-8; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; BERGMANN JE, 1989, AM J HUM GENET, V44, P741; BEUTELR E, 1994, IN PRESS METABOLIC B; BEUTLER E, 1990, ANN HUM GENET, V54, P149, DOI 10.1111/j.1469-1809.1990.tb00371.x; BEUTLER E, 1993, GENOMICS, V15, P203, DOI 10.1006/geno.1993.1035; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CONZELMANN E, 1984, DEV NEUROSCI-BASEL, V6, P58, DOI 10.1159/000112332; DAHL N, 1990, AM J HUM GENET, V47, P275; Devine E A, 1982, Prog Clin Biol Res, V95, P511; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; DINUR T, 1984, ANAL BIOCHEM, V136, P223, DOI 10.1016/0003-2697(84)90329-4; DINUR T, 1986, ENZYMES LIPID METABO, V2, P289; ERICKSON AH, 1985, J BIOL CHEM, V260, P4319; EYAL N, 1990, GENE, V96, P277, DOI 10.1016/0378-1119(90)90264-R; EYAL N, 1991, HUM GENET, V87, P328; FABBRO D, 1987, AM J HUM GENET, V40, P15; FABBRO D, 1991, J BIOL CHEM, V266, P15021; GATT S, 1966, J BIOL CHEM, V241, P3724; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GRABOWSKI GA, 1984, ARCH BIOCHEM BIOPHYS, V231, P144, DOI 10.1016/0003-9861(84)90371-0; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GRABOWSKI GA, 1989, ENZYME, V41, P131, DOI 10.1159/000469068; GRABOWSKI GA, 1985, AM J MED GENET, V21, P529, DOI 10.1002/ajmg.1320210316; GRABOWSKI GA, 1986, J BIOL CHEM, V261, P8263; GRACE ME, 1990, BIOCHEM BIOPH RES CO, V168, P771, DOI 10.1016/0006-291X(90)92388-G; GRACE ME, 1990, J BIOL CHEM, V265, P6827; GRACE ME, 1991, AM J HUM GENET, V49, P646; GRAVES PN, 1988, DNA-J MOLEC CELL BIO, V7, P521, DOI 10.1089/dna.1.1988.7.521; GREENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1039, P12, DOI 10.1016/0167-4838(90)90220-A; HE GS, 1992, AM J HUM GENET, V51, P810; He Guo-Shun, 1992, Human Mutation, V1, P423, DOI 10.1002/humu.1380010513; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; Institute of Gaucher Disease, 2020, EP GAUCH DIS; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; LATHAM T, 1990, AM J HUM GENET, V47, P79; LATHAM TE, 1991, DNA CELL BIOL, V10, P15, DOI 10.1089/dna.1991.10.15; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MATTHEWS REF, 1982, 4TH INT COMM TAX VIR; MUELLER OT, 1979, J BIOL CHEM, V254, P3521; OHASHI T, 1991, J BIOL CHEM, V266, P3661; ONEILL RR, 1989, P NATL ACAD SCI USA, V86, P5049, DOI 10.1073/pnas.86.13.5049; OSIECKINEWMAN K, 1987, BIOCHIM BIOPHYS ACTA, V915, P87, DOI 10.1016/0167-4838(87)90128-2; OSIECKINEWMAN K, 1988, ENZYME, V40, P173, DOI 10.1159/000469161; OSIECKINEWMAN KM, 1986, ENZYME, V35, P147, DOI 10.1159/000469336; OSIECKINEWMAN KO, 1987, THESIS CITY U NEW YO; PATTERSON MC, 1993, NEUROLOGY, V43, P1993, DOI 10.1212/WNL.43.10.1993; REIDHAAROLSON JF, 1990, BIOCHEMISTRY-US, V29, P7563, DOI 10.1021/bi00485a004; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SANO A, 1988, J BIOL CHEM, V263, P19597; SIBILLE A, 1993, AM J HUM GENET, V52, P1094; SORGE J, 1985, P NATL ACAD SCI USA, V82, P7289, DOI 10.1073/pnas.82.21.7289; Summers M.D., 1987, TEXAS AGR EXPT STATI; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THEOPHILUS B, 1989, AM J HUM GENET, V45, P212; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TRIMBUR DE, 1992, J BIOL CHEM, V267, P10248; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; WIGDERSON M, 1989, AM J HUM GENET, V44, P365; WILLEMSEN R, 1987, J NEUROL, V234, P44, DOI 10.1007/BF00314009; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1990, J CLIN INVEST, V85, P219, DOI 10.1172/JCI114415	72	118	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2283	2291						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294487				2022-12-25	WOS:A1994MR98800109
J	KUBISESKI, TJ; GREEN, NC; BORHANI, DW; FLYNN, TG				KUBISESKI, TJ; GREEN, NC; BORHANI, DW; FLYNN, TG			STUDIES ON PIG ALDOSE REDUCTASE - IDENTIFICATION OF AN ESSENTIAL ARGININE IN THE PRIMARY AND TERTIARY STRUCTURE OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALDEHYDE REDUCTASE; CRYSTAL-STRUCTURE; BINDING; LENS; MUSCLE; KIDNEY; SUPERFAMILY; EXPRESSION; MECHANISM	Reaction of pig muscle aldose reductase with phenylglyoxal resulted in the chemical modification of 2 arginine residues with accompanying loss of catalytic activity. The amino acid sequences of radioactive peptides resulting from the reaction of aldose reductase with [C-14]phenylglyoxal followed by tryptic digestion and high performance liquid chromatography separation allowed identification of the modified arginine residues as R268 and R293. In the presence of the coenzyme NADP+, R268 is protected from modification by phenylglyoxal, while R293 becomes hyper-reactive. Phenylglyoxal modification of aldose reductase is slowed 3-fold by the presence of the coenzyme analog ADPRP; however, both arginines are still modified. These chemical modification results are in complete accord with the previously determined crystal structures of human and porcine aldose reductase complexed with NADPH, NADP+, and ADPRP. These structures indicate that R268 is located at the adenosine binding site, salt bridged to the 2'-phosphate group of NADP(H) and ADPRP. Arginine 293 is near the surface of the enzyme and is part of the C-terminal loop. In the apoenzyme or the ADPRP complex, R293 is partially protected by loop 7; upon binding NADP(H), loop 7 folds down over the co-enzyme, thus exposing R293 to solvent. Our modification studies provide further evidence of the conformational change that occurs during the aldose reductase catalytic cycle.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; BIOCRYST PHARMACEUT INC,BIRMINGHAM,AL 35244	Queens University - Canada				Borhani, David/0000-0002-8486-8792; Kubiseski, Terrance/0000-0001-9388-8608	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK044789] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44789] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; BOHREN KM, 1993, ENZYMOLOGY MOL BIOL, V328, P267; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANLANT G, 1981, EUR J BIOCHEM, V116, P505, DOI 10.1111/j.1432-1033.1981.tb05365.x; BRANLANT G, 1982, EUR J BIOCHEM, V129, P99, DOI 10.1111/j.1432-1033.1982.tb07026.x; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CHANG GG, 1981, BIOCHIM BIOPHYS ACTA, V660, P341, DOI 10.1016/0005-2744(81)90179-0; CROMLISH JA, 1983, J BIOL CHEM, V258, P3583; DAVIDSON WS, 1979, J BIOL CHEM, V254, P3724; DIXON M, 1979, ENZYMES, P374; DOUGHTY CC, 1982, BIOCHIM BIOPHYS ACTA, V708, P358, DOI 10.1016/0167-4838(82)90449-6; FLYNN TG, 1986, METABOLISM, V35, P105, DOI 10.1016/0026-0495(86)90197-6; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9936, DOI 10.1021/bi00494a026; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; HALDER AB, 1985, OPHTHALMIC RES, V17, P185, DOI 10.1159/000265372; HYNDMAN DJ, 1986, THESIS QUEENS U KING; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; KUBISESKI TJ, 1993, ENZYMOLOGY MOL BIOL, V4, P259; LIU S, 1989, ARCH BIOCHEM BIOPHYS, V275, P112, DOI 10.1016/0003-9861(89)90355-X; MORJANA NA, 1989, J BIOL CHEM, V264, P2912; PENEFSKY SH, 1971, METHOD ENZYMOL, V56, P527; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; PETRASH JM, 1993, ENZYMOLOGY MOL BIOL, V4, P289; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TARLE I, 1993, J BIOL CHEM, V268, P25687; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P10912; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098	32	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2183	2188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294474				2022-12-25	WOS:A1994MR98800095
J	KUSUKAWA, J; RAMACHANDRA, M; NAKANO, R; PADMANABHAN, R				KUSUKAWA, J; RAMACHANDRA, M; NAKANO, R; PADMANABHAN, R			PHOSPHORYLATION-DEPENDENT INTERACTION OF ADENOVIRUS PRETERMINAL PROTEIN WITH THE VIRAL ORIGIN OF DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; RECOMBINANT VACCINIA VIRUS; NUCLEAR FACTOR-III; CASEIN KINASE-II; TERMINAL PROTEIN; BINDING PROTEIN; POLYMERASE-ALPHA; CELL-CYCLE; INSECT CELLS; HELA-CELLS	Adenovirus preterminal protein (pTP) exists as a heterodimer with the viral DNA polymerase (AdPol) and becomes covalently linked to a dCMP residue during initiation of DNA replication. The in vivo phosphorylation of pTP could he demonstrated when pTP is overproduced using recombinant vaccinia viruses, or by a large scale metabolic labeling of adenovirus 2 (Ad2)-infected HeLa cells. Phosphoserine was the only phosphoamino acid obtained by acid hydrolysis of P-32-labeled pTP immunoprecipitated from metabolically labeled HeLa cells infected with either Ad2 or recombinant vaccinia virus. Tryptic peptide maps of pTP expressed using recombinant vaccinia virus system in HeLa cells revealed that phosphorylation of pTP occurred on multiple sites. Dephosphorylation of pTP with calf intestinal alkaline phosphatase resulted in a significant decrease in its activity in the in vitro DNA replication initiation assays. Further characterization of the phosphatase-treated pTP indicated that although dephosphorylation did not affect its interaction with AdPol, the specific recognition of the DNA replication origin by pTP was significantly reduced as determined by gel electrophoresis-based DNA mobility shift assays.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 3901 RAINBOW BLVD, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center				Ramachandra, Murali/0000-0003-4039-1491	NCI NIH HHS [CA33099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; BINGER MH, 1982, J VIROL, V42, P488, DOI 10.1128/JVI.42.2.488-501.1982; BOSHER J, 1990, New Biologist, V2, P1083; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHALLBERG MD, 1981, J VIROL, V38, P272, DOI 10.1128/JVI.38.1.272-277.1981; CHALLBERG MD, 1980, P NATL ACAD SCI-BIOL, V77, P5105, DOI 10.1073/pnas.77.9.5105; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; CHEN M, 1990, J BIOL CHEM, V265, P18634; CHEN M, 1989, P NATL ACAD SCI USA, V86, P6116, DOI 10.1073/pnas.86.16.6116; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOBBS L, 1990, VIROLOGY, V178, P43, DOI 10.1016/0042-6822(90)90377-4; DONALDSON RW, 1987, P NATL ACAD SCI USA, V84, P759, DOI 10.1073/pnas.84.3.759; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DUCEMAN BW, 1980, BIOCHEM J, V190, P781, DOI 10.1042/bj1900781; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ENOMOTO T, 1981, P NATL ACAD SCI-BIOL, V78, P6779, DOI 10.1073/pnas.78.11.6779; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Green M, 1979, Methods Enzymol, V58, P425; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; HOSS A, 1990, J VIROL, V64, P4799; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JENG YH, 1977, J VIROL, V22, P402, DOI 10.1128/JVI.22.2.402-411.1977; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JOUNG I, 1992, J VIROL, V66, P5788, DOI 10.1128/JVI.66.10.5788-5796.1992; KENNY MK, 1988, J BIOL CHEM, V263, P9809; KLEIN H, 1979, J BIOL CHEM, V254, P1051; KRANIAS EG, 1977, J BIOL CHEM, V252, P6750; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LICHY JH, 1982, P NATL ACAD SCI-BIOL, V79, P5225, DOI 10.1073/pnas.79.17.5225; LINNE T, 1980, EUR J BIOCHEM, V103, P259, DOI 10.1111/j.1432-1033.1980.tb04310.x; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORIN N, 1989, J VIROL, V63, P5228, DOI 10.1128/JVI.63.12.5228-5237.1989; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NAKANO R, 1991, GENE, V105, P173, DOI 10.1016/0378-1119(91)90148-5; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; PRONK R, 1993, NUCLEIC ACIDS RES, V21, P2293, DOI 10.1093/nar/21.10.2293; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PRUIJN GJM, 1987, EMBO J, V6, P3771, DOI 10.1002/j.1460-2075.1987.tb02712.x; RAMACHANDRA M, 1993, J BIOL CHEM, V268, P17448; RAMACHANDRA M, 1993, J BIOL CHEM, V268, P442; REKOSH DMK, 1977, CELL, V11, P283, DOI 10.1016/0092-8674(77)90045-9; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RONINSON I, 1980, BIOCHEM BIOPH RES CO, V94, P398, DOI 10.1016/S0006-291X(80)80234-8; ROOVERS DJ, 1993, J VIROL, V67, P265, DOI 10.1128/JVI.67.1.265-276.1993; ROSE KM, 1979, J BIOL CHEM, V254, P256; SASAGURI Y, 1987, VIROLOGY, V160, P389, DOI 10.1016/0042-6822(87)90010-9; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHU LM, 1987, VIROLOGY, V161, P520, DOI 10.1016/0042-6822(87)90146-2; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1981, CELL, V23, P497, DOI 10.1016/0092-8674(81)90145-8; STILLMAN BW, 1979, VIROLOGY, V93, P69, DOI 10.1016/0042-6822(79)90276-9; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; TAMANOI F, 1982, P NATL ACAD SCI-BIOL, V79, P2221, DOI 10.1073/pnas.79.7.2221; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; Vishwanatha J K, 1989, Cancer Commun, V1, P345; WATSON CJ, 1990, NUCLEIC ACIDS RES, V18, P1167, DOI 10.1093/nar/18.5.1167; WIDES RJ, 1987, MOL CELL BIOL, V7, P864, DOI 10.1128/MCB.7.2.864; ZHAO LJ, 1991, NEW BIOL, V3, P1074; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0; ZHAO LJ, 1991, GENE, V100, P147, DOI 10.1016/0378-1119(91)90360-N	82	8	8	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2189	2196						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294475				2022-12-25	WOS:A1994MR98800096
J	PULVERER, BJ; FISHER, C; VOUSDEN, K; LITTLEWOOD, T; EVAN, G; WOODGETT, JR				PULVERER, BJ; FISHER, C; VOUSDEN, K; LITTLEWOOD, T; EVAN, G; WOODGETT, JR			SITE-SPECIFIC MODULATION OF C-MYC COTRANSFORMATION BY RESIDUES PHOSPHORYLATED IN-VIVO	ONCOGENE			English	Article							CASEIN KINASE-II; GLYCOGEN-SYNTHASE KINASE-3-BETA; HUMAN NEUROBLASTOMA-CELLS; CELLULAR GENE-EXPRESSION; DNA-BINDING ACTIVITY; PROTEIN-KINASE; ACTIVATES TRANSCRIPTION; NUCLEAR-LOCALIZATION; NUCLEOTIDE-SEQUENCE; RAPID INDUCTION	c-Myc is a nuclear phosphoprotein which binds DNA as a heterodimer with Max. We have identified two in vivo phosphorylation sites, Thr58 and Ser62, within a domain highly conserved among all Myc family members. Thr58 is mutated in several viral forms of the protein and constitutes a mutational hot-spot in Burkitt's lymphoma. Members of the GSK-3 and MAP kinase families, but not CKII, specifically phosphorylated these sites in vitro. The effect of these phosphorylation sites on Myc function was assessed by cotransformation of primary rat embryo fibroblasts with Pas. Mutagenesis of Thr58 to alanine potentiated focus formation, whereas substitution of Ser62 severely inhibited transformation. Mutation of both residues restored wild-type activity. These data suggest acute, post-translational modulation of Myc via phosphorylation of a conserved region previously implicated in transactivation, transformation and autorepression.	ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Imperial College London; Ludwig Institute for Cancer Research; Cancer Research UK			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BISTER K, 1980, J VIROL, V36, P617, DOI 10.1128/JVI.36.2.617-621.1980; BISTER K, 1987, ONCOGENE, V1, P97; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CROUCH DH, 1990, ONCOGENE, V5, P683; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOODE N, 1992, J BIOL CHEM, V267, P16878; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HAMANN U, 1991, ONCOGENE, V6, P1745; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Ingvarsson S, 1990, Semin Cancer Biol, V1, P359; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUO K, 1990, ONCOGENE, V5, P921; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MEEK DW, 1992, BIOCHEM J, V287, P1; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOORE JP, 1987, ONCOGENE RES, V2, P65; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAMAKRISHNA S, 1989, BIOCHEMISTRY-US, V28, P856, DOI 10.1021/bi00428a067; RAMAKRISHNA S, 1988, J BIOL CHEM, V263, P12677; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SAKSELA K, 1992, ONCOGENE, V7, P347; SCHWEINFEST CW, 1988, MOL CELL BIOL, V8, P3080, DOI 10.1128/MCB.8.8.3080; SETH A, 1991, J BIOL CHEM, V266, P23521; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1989, ONCOGENE, V4, P285; WATERS CM, 1991, ONCOGENE, V6, P797; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WOODGETT JR, 1989, ANAL BIOCHEM, V180, P237, DOI 10.1016/0003-2697(89)90423-5; WOODGETT JR, 1992, NEURONAL CELL LINES, P133; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	83	207	210	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					59	70						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302604				2022-12-25	WOS:A1994MW24700008
J	SACHSE, R; MURAKAMI, Y; SHIRAISHI, M; HAYASHI, K; SEKIYA, T				SACHSE, R; MURAKAMI, Y; SHIRAISHI, M; HAYASHI, K; SEKIYA, T			DNA ABERRATIONS AT THE RETINOBLASTOMA GENE LOCUS IN HUMAN SQUAMOUS-CELL CARCINOMAS OF THE LUNG	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; SEQUENCE POLYMORPHISMS; PROTEIN EXPRESSION; POINT MUTATIONS; HUMAN GENOME; SHORT ARM; RB GENE; HETEROZYGOSITY	We detected DNA aberrations at the RB locus in surgical specimens of human primary non-small cell lung carcinoma by single-strand conformation polymorphism analysis of polymerase chain reaction products amplified from regions of exons 2 to 27 including parts of the flanking intron sequences. Detection of nucleotide sequence polymorphism revealed loss of heterozygosity in six of eight informative cases among 13 squamous cell carcinomas analysed. In two of the six cases, mutations in the remaining allele were detected. In 25 adenocarcinomas analysed, no loss of heterozygosity was observed in 16 informative cases and a point mutation was detected in one of the uniformative cases. In one of three adenosquamous carcinomas analysed, a point mutation was detected and one adenoid cystic carcinoma analysed showed allelic loss of the RB gene. Our results indicated that loss of heterozygosity at the RB locus is frequent in squamous cell carcinomas of the lung,:but not in adenocarcinomas. In the squamous cell carcinomas with allelic loss, mutations of the RB gene in the remaining alleles were found in one third of the tumors.	NATL CANC CTR,RES INST,DIV ONCOGENE,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								BARKER D, 1982, CYTOGENET CELL GENET, V32, P253; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORG A, 1992, CANCER RES, V52, P2991; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CAIRNS P, 1991, ONCOGENE, V6, P2305; COOPER DN, 1984, HUM GENET, V66, P1, DOI 10.1007/BF00275182; COOPER DN, 1985, HUM GENET, V69, P201, DOI 10.1007/BF00293024; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HAYASHI K, 1992, GENET ANAL-BIOMOL E, V9, P73, DOI 10.1016/1050-3862(92)90001-L; HENSEL CH, 1990, CANCER RES, V50, P3067; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISHIKAWA J, 1991, CANCER RES, V51, P5736; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KISHIMOTO Y, 1992, HUM GENET, V88, P487, DOI 10.1007/BF00219333; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MASHIYAMA S, 1991, TECHNIQUE, V2, P304; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MORI N, 1990, ONCOGENE, V5, P1713; MORI N, 1989, CANCER RES, V49, P5130; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Nei M., 1987, MOL EVOLUTIONARY GEN; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REISSMANN PT, 1993, ONCOGENE, V8, P1913; REISSMANN PT, 1989, ONCOGENE, V4, P839; SACHSE R, 1992, JPN J CANCER RES, V83, P1299, DOI 10.1111/j.1349-7006.1992.tb02762.x; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VARLEY JM, 1989, ONCOGENE, V4, P725; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; XU HJ, 1991, CANCER RES, V51, P2735; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOYAMA S, 1992, CANCER RES, V52, P873	52	31	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					39	47						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302602				2022-12-25	WOS:A1994MW24700006
J	KARRAN, P; MACPHERSON, P; CECCOTTI, S; DOGLIOTTI, E; GRIFFIN, S; BIGNAMI, M				KARRAN, P; MACPHERSON, P; CECCOTTI, S; DOGLIOTTI, E; GRIFFIN, S; BIGNAMI, M			O(6)-METHYLGUANINE RESIDUES ELICIT DNA-REPAIR SYNTHESIS BY HUMAN CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; ESCHERICHIA-COLI; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; EXCISION REPAIR; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; 3-METHYLADENINE-DNA GLYCOSYLASE; REPLICATION INVITRO; ALKYLATING-AGENTS; INITIATION; DEFICIENT	We have investigated the processing of O6-methylguanine (O6-MeGua) in plasmid DNA by extracts of human cells defective in O6-MeGua-DNA methyltransferase. Cell extracts of HeLaMR cells performed viral T antigen-independent DNA synthesis on plasmids that had been treated with low concentrations of methylating agents. The in vitro DNA synthesis was non-semiconservative and depended on the presence of O6-MeGua in the substrate. The involvement of DNA polymerase delta or epsilon and proliferating cell nuclear antigen but not single-strand binding protein was indicated by partial fractionation, inhibitor, and antibody studies. Processing of O6-MeGua is not via the UV nucleotide excision repair pathway since additional component(s) are apparently required to perform repair synthesis on the methylated substrate. This is the first direct demonstration of DNA repair synthesis provoked by O6-MeGua in DNA. Since O6-MeGua is not excised from DNA by Mex- cells, it represents a novel type of processing of the methylated base that may be involved in its cytotoxicity.	IST SUPER SANITA,COMPARAT TOXICOL & ECOTOXICOL LAB,I-00161 ROME,ITALY	Istituto Superiore di Sanita (ISS)	KARRAN, P (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,ENGLAND.							ALADJEM MI, 1992, MUTAT RES, V276, P339, DOI 10.1016/0165-1110(92)90020-A; AU KG, 1992, J BIOL CHEM, V267, P12142; BASU AK, 1988, CHEM RES TOXICOL, V1, P1, DOI 10.1021/tx00001a001; BIGGERSTAFF M, 1992, J BIOL CHEM, V267, P6879; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DAY RS, 1987, J CELL SCI S, V6, P333; DECKER RS, 1986, MOL CELL BIOL, V6, P3815, DOI 10.1128/MCB.6.11.3815; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; GALLAGHER PE, 1982, BIOCHEMISTRY-US, V21, P6404, DOI 10.1021/bi00268a013; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HARRIS AL, 1983, CANCER RES, V43, P3247; KAINA B, 1991, CARCINOGENESIS, V12, P1857; KALAMEGHAM R, 1988, CARCINOGENESIS, V9, P1749, DOI 10.1093/carcin/9.10.1749; KARRAN P, 1980, J MOL BIOL, V140, P101, DOI 10.1016/0022-2836(80)90358-7; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; LAWLEY PD, 1984, ACS MONOGR SER, V182, P25; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; Lindahl T, 1975, MOL MECHANISMS REPAI, P31; LJUNGQUIST S, 1977, J BIOL CHEM, V252, P2808; MAGEE TR, 1992, EMBO J, V11, P4219, DOI 10.1002/j.1460-2075.1992.tb05516.x; MATTERN MR, 1981, CARCINOGENESIS, V2, P1215, DOI 10.1093/carcin/2.11.1215; PEGG AE, 1990, CANCER RES, V50, P6119; ROSA S, 1991, NUCLEIC ACIDS RES, V19, P5569, DOI 10.1093/nar/19.20.5569; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; SCUDIERO DA, 1984, CANCER RES, V44, P961; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; Singer B., 1983, MOL BIOL MUTAGENS CA; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; ULLAH S, 1992, BIOCHEMISTRY-US, V31, P7998; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WU ZN, 1992, CANCER RES, V52, P32; ZHUKOVSKAYA N, 1992, NUCLEIC ACIDS RES, V20, P6081, DOI 10.1093/nar/20.22.6081	47	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15878	15886						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340413				2022-12-25	WOS:A1993LN30500080
J	WILSON, ME; PAETZ, KE; RAMAMOORTHY, R; DONELSON, JE				WILSON, ME; PAETZ, KE; RAMAMOORTHY, R; DONELSON, JE			THE EFFECT OF ONGOING PROTEIN-SYNTHESIS ON THE STEADY-STATE LEVELS OF GP63 RNAS IN LEISHMANIA-CHAGASI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE MESSENGER-RNA; 3' UNTRANSLATED REGION; AU-RICH SEQUENCES; C-MYC; SURFACE GLYCOPROTEIN; TRYPANOSOMA-BRUCEI; STABILITY INVITRO; TUBULIN GENES; DONOVANI; PROMASTIGOTES	G63, the major surface glycoprotein of Leishmania chagasi promastigotes, increases 11-fold in amount as promastigotes grow from logarithmic to stationary phase. Transcripts from three different classes of gp63 genes are differentially expressed during this development (Ramamoorthy, R., Donelson, J. E., Paetz, K. E., Maybodi, M., Roberts, S. P., and Wilson, M. E. (1992) J. Biol. Chem. 267, 1888-1895). We studied the effect of protein synthesis inhibitors on gp63 mRNAs. The steady state level of log class gp63 RNA, expressed primarily in logarithmic phase promastigotes, increased 16.5-fold after incubation in cycloheximide. A similar increase in log gp63 RNAs was caused by inhibitors that block different steps in translation. In contrast, the levels of stationary class gp63 RNA, expressed in stationary phase parasites, and constitutive class gp63 RNA, expressed throughout promastigote growth, increased only 2.3- and 1.5-fold, respectively. The latter was not statistically significant. Nuclear run-on assays showed that the cycloheximide effect was not due to an increased rate of transcription. However, the t1/2 Of log RNAs was prolonged 6.5-fold after incubation in cycloheximide, in contrast to a 1.7-fold increase in the t1/2 of ATPase RNA, suggesting that cycloheximide specifically stabilizes log gp63 mRNAs. Thus, a highly labile negative regulatory protein, such as an RNase, may specifically target log gp63 RNAs for degradation.	UNIV IOWA,DEPT MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; VET ADM MED CTR,IOWA CITY,IA 52240; HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute			Donelson, John E/F-5795-2010	Wilson, Mary/0000-0001-8680-7275	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032135, R29AI030126] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI32135, R29 AI30126] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALTUS MS, 1991, J BIOL CHEM, V266, P21190; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; COX GS, 1990, J BIOL CHEM, V265, P13190; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DORN PL, 1991, MOL BIOCHEM PARASIT, V44, P133, DOI 10.1016/0166-6851(91)90229-Y; ENGLUND PT, 1982, ANNU REV BIOCHEM, V51, P695, DOI 10.1146/annurev.bi.51.070182.003403; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MEADE JC, 1989, MOL BIOCHEM PARASIT, V33, P81, DOI 10.1016/0166-6851(89)90045-5; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PEARSON RD, 1980, J IMMUNOL, V125, P2195; PELTZ SW, 1987, MOL CELL BIOL, V7, P4345, DOI 10.1128/MCB.7.12.4345; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO SZ, 1982, ANAL BIOCHEM, V127, P112, DOI 10.1016/0003-2697(82)90152-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPITHILL TW, 1987, MOL BIOCHEM PARASIT, V24, P23, DOI 10.1016/0166-6851(87)90112-5; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VAZQUEZ D, 1979, RIBOSOMES STRUCTURE, P847; WILSON ME, 1984, INFECT IMMUN, V46, P128, DOI 10.1128/IAI.46.1.128-134.1984; WILSON ME, 1988, J IMMUNOL, V141, P265; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	43	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15731	15736						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340397				2022-12-25	WOS:A1993LN30500061
J	VYAS, K; RAJARATHNAM, K; YU, LP; EMERSON, SD; LAMAR, GN; KRISHNAMOORTHI, R; MIZUKAMI, H				VYAS, K; RAJARATHNAM, K; YU, LP; EMERSON, SD; LAMAR, GN; KRISHNAMOORTHI, R; MIZUKAMI, H			H-1-NMR INVESTIGATION OF THE HEME CAVITY OF ELEPHANT (E7 GLN) MET-CYANO-MYOGLOBIN - EVIDENCE FOR A B-HELIX PHENYLALANINE INTERACTION WITH BOUND LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; NUCLEAR MAGNETIC-RESONANCE; DISTAL SIDE; ELECTRONIC-STRUCTURE; 2-DIMENSIONAL NMR; CARBON-MONOXIDE; MODEL COMPOUNDS; ASSIGNMENT; PROTEINS; BINDING	A combination of one- and two-dimensional NMR experiments has been used to identify and spatially locate the heme pocket residues in the paramagnetic, low spin, met-cyano complex of elephant myoglobin. In addition to assigning resonances of the conserved residues, we have also assigned Gln64(E7) and an aromatic ring designated Phe(A) whose side chain is inserted into the heme pocket, as found earlier for elephant carbonmonoxy-myoglobin and oxy-myoglobin (Yu, L. P., La Mar, G. N., and Mizukami, H. (1990) Biochemistry 29, 2578-2585). The assigned conserved proximal side residues (Leu89(F4), Ala90(F5), His93(F8), His97(FG3), Ile99(FG5), Leu104(G5), Phe138(H15), and Tyr146(H23)) and conserved distal side residues (Phe43(CD1), Thr67(E10), Val68(E11), and Ala71(E14)) in elephant met-cyano-myoglobin are found to have orientations similar to those in sperm whale met-cyano-myoglobin. The observed dipolar connectivities and dipolar shift pattern for the substituted Gln64(E7) place the Gln in the heme pocket oriented toward the iron, as found for His64(E7). The conserved structural elements demand that the inserted Phe(A) originate from the B-helix (i.e. Phe27 or Phe33). Dipolar contacts between the inserted Phe(A) and the conserved residues Phe43(CD1), Val68(E11), Ile107(G8), and Gln64(E7), place Phe(A) in the position occupied by the B10 residue in sperm whale myoglobin (Mb), with the larger size of the Phe(A) side chain as compared to the replaced Leu being accommodated by the vacancy that occurs in sperm whale Mb. The paramagnetic induced relaxation places Phe(A) in van der Waals contact with the bound ligand. Hence we conclude that the B10 position of elephant Mb is occupied by a Phe, and this substitution relative to sperm whale Mb is responsible for the low autoxidation rate and low reduction potential of elephant Mb. A reduced autoxidation rate has been reported for a sperm whale synthetic point mutant Leu29(B10) --> Phe (Carver, T. E., Brantley, R. E., Jr., Singleton, E. W., Arduini, R. M., Quillin, M. L., Phillips, G. N., and Olson, J. S. (1992) J. Biol. Chem. 267, 14443-14450). The published sequence of elephant Mb places B-helix Phe residues at position 27(B8) and 33(B14), but a Phe at neither of these positions can account for the observed NMR properties. Since a large proportion of the substitutions in elephant relative to sperm whale Mb, and some of the least conservative, occur in the B-helix, neither a structurally perturbed B-helix nor an error in the sequence can be discounted.	UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616; WAYNE STATE UNIV,DEPT BIOL SCI,DETROIT,MI 48202	University of California System; University of California Davis; Wayne State University				Yu, Liping/0000-0003-3536-6427	NHLBI NIH HHS [HL 16087] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016087, R37HL016087] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BARTNICKI DE, 1983, J BIOL CHEM, V258, P1599; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BELLELLI A, 1990, J BIOL CHEM, V265, P18898; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BRUNORI M, 1992, J BIOL CHEM, V267, P2258; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; COOKE RM, 1987, EUR J BIOCHEM, V166, P399, DOI 10.1111/j.1432-1033.1987.tb13529.x; CUTNELL JD, 1981, J AM CHEM SOC, V103, P3567, DOI 10.1021/ja00402a053; DALVIT C, 1987, J MOL BIOL, V194, P313, DOI 10.1016/0022-2836(87)90378-0; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, P235; DENE H, 1980, PROC R SOC SER B-BIO, V207, P111, DOI 10.1098/rspb.1980.0016; EMERSON SD, 1988, J AM CHEM SOC, V110, P4176, DOI 10.1021/ja00221a013; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; HANSON JC, 1981, J MOL BIOL, V153, P117, DOI 10.1016/0022-2836(81)90530-1; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KERR EA, 1985, J BIOL CHEM, V260, P8360; KRISHNAMOORTHI R, 1984, J BIOL CHEM, V259, P8826; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMAR GN, 1986, J AM CHEM SOC, V108, P5568, DOI 10.1021/ja00278a033; LECOMTE JTJ, 1986, EUR BIOPHYS J BIOPHY, V13, P373, DOI 10.1007/BF00265673; LECOMTE JTJ, 1987, J AM CHEM SOC, V109, P7219, DOI 10.1021/ja00257a068; MAGDE D, 1985, P SOC PHOTO-OPT INST, V533, P2, DOI 10.1117/12.946532; MAYER A, 1974, J MOL BIOL, V86, P749, DOI 10.1016/0022-2836(74)90351-9; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; QIN J, 1992, J BIOMOL NMR, V2, P597, DOI 10.1007/BF02192849; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; RAJARATHNAM K, 1992, J AM CHEM SOC, V114, P9048, DOI 10.1021/ja00049a042; RAJARATHNAM K, 1993, IN PRESS BIOCHEMISTR, V32; RAJARATHNAM K, 1992, THESIS U CALIFORNIA; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROMEROHERRERA AE, 1981, J MOL EVOL, V17, P140, DOI 10.1007/BF01733907; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SHULMAN RG, 1971, J MOL BIOL, V57, P93, DOI 10.1016/0022-2836(71)90121-5; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUZUKI T, 1987, BIOCHIM BIOPHYS ACTA, V914, P170, DOI 10.1016/0167-4838(87)90060-4; SUZUKI T, 1988, ZOOL SCI, V5, P69; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; VAINSHTEIN BK, 1977, DOKL AKAD NAUK SSSR, V223, P238; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; YU LP, 1990, BIOCHEMISTRY-US, V29, P2578, DOI 10.1021/bi00462a021; YU LPP, 1990, J AM CHEM SOC, V112, P9527, DOI 10.1021/ja00182a012; [No title captured]	49	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14826	14835						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325862				2022-12-25	WOS:A1993LL75900047
J	LANGE, Y; STREBEL, F; STECK, TL				LANGE, Y; STREBEL, F; STECK, TL			ROLE OF THE PLASMA-MEMBRANE IN CHOLESTEROL ESTERIFICATION IN RAT HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; CULTURED HUMAN-FIBROBLASTS; LEYDIG TUMOR-CELLS; ACYLTRANSFERASE; METABOLISM; COA; MACROPHAGES; ZYMOSTEROL; TRANSPORT; MOVEMENT	The source of the cholesterol used for ester synthesis by cultured rat hepatoma cells was examined. The activities synthesizing and esterifying cholesterol codistributed with RNA at a high buoyant density, presumably in the rough endoplasmic reticulum (RER). Cholesterol mass was undetectable in the RER, and the transfer of cholesterol synthesized in the RER to the cell surface was more than 100 times greater than was its esterification. Similarly, essentially all of the cholesterol liberated from ingested intracellular lipoproteins was recovered at the cell surface. The plasma membranes, which contained approximately 87% of cell cholesterol, provided >100 times more cholesterol for esterification in the RER than did nascent cholesterol. The supply of cholesterol was rate-limiting for esterification in cell homogenates. Prior oxidation of plasma membrane cholesterol in intact cells reduced the acyl-CoA:chlosterol acyltransferase activity in isolates proportionately. Finally, cholesterol in hepatoma plasma membranes was a far better substrate for in vitro esterification than was that in fibroblast plasma membranes, red blood cell ghosts, or liposomes. We conclude that the level of saturation of acyl-CoA:cholesterol acyltransferase, controlled principally through the bidirectional movement of the substrate between plasma membranes and RER, plays a major role in the regulation of cholesterol esterification.	RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT BIOCHEM,CHICAGO,IL 60612; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Rush University; University of Chicago	LANGE, Y (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.		Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028448, R55HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILLHEIMER JT, 1981, ANAL BIOCHEM, V111, P331, DOI 10.1016/0003-2697(81)90570-4; BRAESAMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1976, J BIOL CHEM, V251, P3277; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KAPLAN MR, 1985, J CELL BIOL, V101, P466; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1991, J LIPID RES, V32, P329; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; NAGY L, 1990, BIOCHEM J, V271, P809, DOI 10.1042/bj2710809; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1974, LIPIDS, V9, P526, DOI 10.1007/BF02532500; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STECK TL, 1988, J BIOL CHEM, V263, P13023; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1988, J BIOL CHEM, V263, P1266; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WIRTZ KWA, 1990, EXPERIENTIA, V46, P592, DOI 10.1007/BF01939698; XU XX, 1991, J BIOL CHEM, V266, P17040	30	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13838	13843						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314752				2022-12-25	WOS:A1993LJ82500014
J	BARKALOW, FJ; SCHWARZBAUER, JE				BARKALOW, FJ; SCHWARZBAUER, JE			INTERACTIONS BETWEEN FIBRONECTIN AND CHONDROITIN SULFATE ARE MODULATED BY MOLECULAR CONTEXT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; CELL-SUBSTRATE ADHESION; PLASMA FIBRONECTIN; PROTEOLYTIC FRAGMENTS; III MODULE; PROTEOGLYCAN; MATRIX; GLYCOSAMINOGLYCANS; IDENTIFICATION; LOCALIZATION	Interactions between fibronectin (FN) and glycosaminoglycans are essential for extracellular matrix morphology and cell adhesion. One of the most abundant glycosaminoglycans is chondroitin sulfate, and here we show that recombinant FNs (deminectins (DN)) containing the carboxyl-terminal cell, heparin, and fibrin domains bind specifically to chondroitin sulfate in affinity chromatography assays. Using a panel of mutant DNs, important determinants for chondroitin sulfate binding have been localized to repeats III13 and III14 within the heparin domain. In particular, mutation of an arginine pair in repeat III13 to neutral residues ablated binding to chondroitin sulfate as we previously reported for heparin (Barkalow, F.J.B., and Schwarzbauer, J.E. (1991) J. Biol. Chen. 266, 7812-7818). These results, in combination with the ability of heparin and chondroitin sulfate to compete for binding to DNs, demonstrate that these two glycosaminoglycans interact with similar or overlapping sites in FN. One important difference between FN interactions with heparin and chondroitin sulfate is that, while FN and DNs bound equally to heparin, FN bound less efficiently than DNs to chondroitin sulfate. Reduced binding to chondroitin sulfate was also observed with a larger recombinant FN lacking internal repeats III1-7 indicating that the amino-terminal region acts to limit binding to the carboxyl-terminal domain. Our results demonstrate that interactions between FN and chondroitin sulfate are modulated by molecular context.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University				Schwarzbauer, Jean/0000-0003-1012-7593	NCI NIH HHS [CA-09253, CA-44627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA009253, R01CA044627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BELLOSTA P, 1993, J CELL BIOL, V121, P705, DOI 10.1083/jcb.121.3.705; BENECKY MJ, 1988, BIOCHEMISTRY-US, V27, P7565, DOI 10.1021/bi00419a058; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRENNAN MJ, 1983, CANCER RES, V43, P4302; DANISHEFSKY I, 1976, THROMB RES, V8, P131, DOI 10.1016/0049-3848(76)90256-5; GOLD LI, 1983, BIOCHEMISTRY-US, V22, P4113, DOI 10.1021/bi00286a019; HAYASHI M, 1980, J BIOL CHEM, V255, P17; Hynes RO, 1990, FIBRONECTINS; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; IZZARD CS, 1986, EXP CELL RES, V165, P320, DOI 10.1016/0014-4827(86)90586-0; JALKANEN M, 1991, RECEPTORS EXTRACELLU, P1; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MINGUELL JJ, 1992, EXP CELL RES, V201, P200, DOI 10.1016/0014-4827(92)90364-E; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; NOVOKHATNY V, 1992, J MOL BIOL, V227, P1182, DOI 10.1016/0022-2836(92)90530-W; PERKINS ME, 1979, CELL, V16, P944; PERRIS R, 1987, J CELL BIOL, V105, P2511, DOI 10.1083/jcb.105.6.2511; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P4359; SEKIGUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P2661, DOI 10.1073/pnas.77.5.2661; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1992, J CELL SCI, V101, P277; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012	41	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3957	3962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307950				2022-12-25	WOS:A1994MW98900012
J	VANDERBEND, RL; DEWIDT, J; HILKMANN, H; VANBLITTERSWIJK, WJ				VANDERBEND, RL; DEWIDT, J; HILKMANN, H; VANBLITTERSWIJK, WJ			DIACYLGLYCEROL KINASE IN RECEPTOR-STIMULATED CELLS CONVERTS ITS SUBSTRATE IN A TOPOLOGICALLY RESTRICTED MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; PHOSPHATIDIC-ACID; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHOLIPID-METABOLISM; INDUCED TRANSLOCATION; HUMAN FIBROBLASTS; HUMAN-PLATELETS; RAT-BRAIN; PHOSPHORYLATION	The regulation of diacylglycerol (DG) kinase activity was studied in fibroblasts and Jurkat T cells. We questioned whether enzyme activity only depends on substrate availability or whether it requires receptor stimulation. To this end, we raised DG levels up to 15-fold by treatment of cells with bacterial phosphatidylinositol-specific phospholipase C (PLC). In detergent cell lysates, DG kinase was readily capable of converting this surplus of DG to phosphatidic acid (PA), but in intact cells the enzyme remained inactive. Stimulation of fibroblasts with bradykinin or endothelin and Jurkat cells with anti CDS resulted in DG kinase-mediated formation of PA, but its level was unaffected by PLC pretreatment. Likewise, in streptolysin O-permeabilized fibroblasts, where bradykinin stimulation in the presence of [gamma-P-32]ATP and guanosine 5'-O-(thiotriphosphate) generates [P-32]PA exclusively via DG kinase, PLC pretreatment did not affect the amount of [P-32]PA formed. We conclude that DG kinase acts on DG generated by receptor stimulation, but not on DG generated by exogenous PLC. We propose a model in which DG kinase physically associates with endogenous PLC. Within this complex, receptor-induced DG would then be transmitted (''channeled'') from endogenous PLC to the active site of DG kinase, whereas excess DG generated randomly in the plasma membrane by bacterial PLC is inaccessible to this catalytic site.	NETHERLANDS CANC INST, DIV CELLULAR BIOCHEM, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P9378, DOI 10.1073/pnas.83.24.9378; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COCKROFT S, 1987, J CELL BIOL, V105, P339; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HAMILTON JG, 1988, LIPIDS, V23, P1146, DOI 10.1007/BF02535281; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KATO M, 1990, J BIOL CHEM, V265, P794; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MAY WS, 1986, P NATL ACAD SCI USA, V83, P1281, DOI 10.1073/pnas.83.5.1281; MUIR JG, 1986, BIOCHIM BIOPHYS ACTA, V885, P176, DOI 10.1016/0167-4889(86)90086-8; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SOLING HD, 1989, J BIOL CHEM, V264, P10643; STRATHOPOULOS VM, 1990, BIOCHEM J, V272, P569; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBLITTERSWIJK WJ, 1993, EMBO J, V12, P2655, DOI 10.1002/j.1460-2075.1993.tb05926.x; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANLIER RAW, 1987, EUR J IMMUNOL, V17, P1599, DOI 10.1002/eji.1830171112; YADA Y, 1990, J BIOL CHEM, V265, P19237	36	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4098	4102						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307969				2022-12-25	WOS:A1994MW98900033
J	WIENTZEK, M; KAY, CM; OIKAWA, K; RYAN, RO				WIENTZEK, M; KAY, CM; OIKAWA, K; RYAN, RO			BINDING OF INSECT APOLIPOPHORIN-III TO DIMYRISTOYLPHOSPHATIDYLCHOLINE VESICLES - EVIDENCE FOR A CONFORMATIONAL CHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; MANDUCA-SEXTA; SECONDARY STRUCTURE; LIPID TRANSPORT; PURIFICATION; PHOSPHATIDYLCHOLINE; INTERCONVERSIONS; RECOMBINANTS; COMPLEXES	Apolipophorin-III (apoLp-III), a hemolymph protein of Manduca sexta, can reversibly associate with the surface of lipoprotein particles. In order to examine the lipid-associated form of apoLp-III, the present studies investigate the structure and properties of apoLp-III complexes with dimyristoylphosphatidylcholine (DMPC). Association of apoLp-III with DMPC vesicles results in the formation of uniform discs with an average diameter and width of 18.5 +/- 2.0 nm and 4.8 +/- 0.8 nm, respectively, as determined by electron microscopy. ApoLp-III.DMPC complexes analyzed by pore limiting native gradient PAGE demonstrated that a single major species of complex was formed within a wide range of lipid to protein molar ratios (DMPC:apoLp-III; 13:1 to 360:1). Flotation equilibrium experiments, conducted in an analytical ultracentrifuge, confirmed that only one species of apoLp-III DMPC complex was formed at an initial lipid to protein molar ratio of 67:1, with an apparent molecular mass of 642,000. Complexes cross-linked with dimethyl suberimidate indicate that there are a maximum of 6 apoLp-III molecules per disc. Circular dichroism experiments revealed that apoLp-III becomes essentially completely a-helical on formation of apoLp-III DMPC complexes. Compared to apoLp-III in the lipid-free state, apoLp-III DMPC complexes were relatively resistant to denaturation by guanidine HCl, displaying denaturation transitions with midpoints at 2.2 and 3.7 M guanidine HCl, respectively. The fluorescence excitation and emission spectra of apoLp-III DMPC complexes demonstrate a large enhancement of tyrosine fluorescence as compared to the lipid-free state, suggesting that a conformational change occurs when apoLp-III associates with a lipid surface. Denaturation of apoLp-III in the complex by guanidine HCl resulted in a tyrosine fluorescence level similar to that of lipid-free apoLp-III in the presence of guanidine HCl. The tyrosine-induced fluorescence of the complex was quenched with both Cs+ (K-q = 0.573 M(-1)) and KI (K-q = 0.376 M(-1)). The results presented in this study indicate that the conformation of apoLp-III is stabilized when complexed with phospholipids and suggest that tyrosine fluorescence provides a sensitive method to detect M. sexta apoLp-III interaction with lipid surfaces. Based on the data obtained, together with the length of ru-helices derived from the x-ray crystal structure of Locusta migratoria apoLp-III, we propose a model for the interaction of apoLp-III with phospholipid.	UNIV ALBERTA,DEPT BIOCHEM,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,PROT STRUCTURE & FUNCT GRP,MED RES COUNCIL,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta								Atkinson D, 1980, Ann N Y Acad Sci, V348, P284, DOI 10.1111/j.1749-6632.1980.tb21308.x; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; CHERVENKA CH, 1969, MANUAL ANAL ULTRACEN; COLE KD, 1987, J BIOL CHEM, V262, P11794; DEMEL RA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P151, DOI 10.1016/0005-2760(92)90091-9; EISINGER J, 1969, BIOCHEMISTRY-US, V8, P3902, DOI 10.1021/bi00838a004; FORTE T, 1974, BIOCHIM BIOPHYS ACTA, V337, P169, DOI 10.1016/0005-2760(74)90199-4; FORTE TM, 1971, BIOCHIM BIOPHYS ACTA, V248, P381, DOI 10.1016/0005-2760(71)90026-9; GWYNNE J, 1975, J BIOL CHEM, V250, P2269; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HOLDEN HM, 1988, J BIOL CHEM, V263, P3960; HOMER RB, 1976, BIOCHIM BIOPHYS ACTA, V434, P297, DOI 10.1016/0005-2795(76)90222-1; JONAS A, 1993, J BIOL CHEM, V268, P1596; JONAS A, 1989, J BIOL CHEM, V264, P4818; Jonas A., 1992, STRUCTURE FUNCTION A, P217; Kahlon T S, 1986, Methods Enzymol, V129, P26; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; KAWOOYA JK, 1984, J BIOL CHEM, V259, P733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINS L, 1992, STRUCTURE FUNCTION A, P251; NELSON CA, 1974, ANAL BIOCHEM, V59, P69, DOI 10.1016/0003-2697(74)90010-4; Pownall H. J., 1987, PLASMA LIPOPROTEINS, P95; PRASAD SV, 1986, J BIOL CHEM, V261, P558; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; REIJNGOUD DJ, 1982, BIOCHEMISTRY-US, V21, P2969, DOI 10.1021/bi00541a026; RIFICI VA, 1985, BIOCHIM BIOPHYS ACTA, V834, P205, DOI 10.1016/0005-2760(85)90157-2; RYAN RO, 1985, J BIOL CHEM, V260, P782; RYAN RO, 1990, J LIPID RES, V31, P1725; RYAN RO, 1993, J BIOL CHEM, V268, P1525; RYAN RO, 1986, J BIOL CHEM, V261, P563; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; SEGREST JP, 1992, J LIPID RES, V33, P141; SHAPIRO JP, 1988, ANNU REV ENTOMOL, V33, P297, DOI 10.1146/annurev.en.33.010188.001501; SHAPIRO JP, 1983, BIOCHEM BIOPH RES CO, V115, P924, DOI 10.1016/S0006-291X(83)80023-0; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; SWANEY JB, 1980, J BIOL CHEM, V255, P877; TAJIMA S, 1982, J BIOCHEM-TOKYO, V91, P1273, DOI 10.1093/oxfordjournals.jbchem.a133812; TALL AR, 1977, J BIOL CHEM, V252, P4701; VANDERHORST DJ, 1988, J BIOL CHEM, V263, P2027; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; WEINBERG RB, 1990, J BIOL CHEM, V265, P8081; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WELLS MA, 1985, INSECT BIOCHEM, V15, P565, DOI 10.1016/0020-1790(85)90116-7; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WLODAWER A, 1979, FEBS LETT, V104, P231, DOI 10.1016/0014-5793(79)80821-2; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P3942, DOI 10.1021/bi00066a014	49	96	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4605	4612						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308032				2022-12-25	WOS:A1994MW98900104
J	ZIEGLER, M; XIAO, R; PENEFSKY, HS				ZIEGLER, M; XIAO, R; PENEFSKY, HS			CLOSE PROXIMITY OF CYS(64) AND CYS(140) IN THE DELTA-SUBUNIT OF ESCHERICHIA-COLI F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-SEQUENCE; EXCIMER FLUORESCENCE; SPECTRAL PROPERTIES; SYNTHASE; F1; PROTEINS; COMPLEX; OPERON	The delta subunit of the F-1-ATPase from Escherichia coli contains 2 cysteine residues, one at position 64 and the second at position 140 of the amino acid sequence. These residues were specifically labeled with sulfhydryl reagents in this study without labeling other -SH groups in the enzyme. Modification of Cys(140) by maleimides such as N-ethylmaleimide or fluorescein maleimide resulted in a reconstitutively active enzyme that was indistinguishable from the native protein. Labeling of Cys(64) with Or without concomitant labeling of Cys(140) resulted in a reconstitutively inactive enzyme. The ATPase activity of either form of the labeled enzyme was unaffected. However, labeling of Cys(64) was accompanied by dissociation of the delta subunit from the enzyme. These observations suggest a role for the microenvironment of Cys(64) in interactions of the delta subunit with other subunits in the enzyme. Two types of evidence support the conclusion that the 2 cysteine residues of the delta subunit are in close proximity. First, incorporation of pyrene maleimide into both delta cysteines led to excimer formation. Second, incubation of F-1 with 5,5'-dithiobis(2-nitrobenzoic acid) resulted in quantitative formation of a disulfide bond between Cys(64) and Cys(140), presumably via disulfide interchange. The enzyme containing the internally cross-linked delta subunit exhibited an undiminished ability to support proton pumping when reconstituted into F-1-depleted membrane vesicles. The presence of 2 closely apposed cysteinyl residues in the delta subunit of the native enzyme places constraints on the type of structure that may be proposed for the subunit.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center				Ziegler, Mathias/0000-0001-6961-2396	NIGMS NIH HHS [GM21737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; BRAGG PD, 1973, ARCH BIOCHEM BIOPHYS, V159, P664, DOI 10.1016/0003-9861(73)90505-5; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; COX GB, 1970, BIOCHEM J, V117, P551, DOI 10.1042/bj1170551; DUSZYNSKI J, 1988, BIOCHEMISTRY-US, V27, P6288, DOI 10.1021/bi00417a014; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P3919, DOI 10.1093/nar/9.16.3919; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; KINNUNEN PKJ, 1993, FLUORESCENCE SPECTRO, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUMPER L., 1965, ADVANCE ENZYMOL, V27, P199; MABUCHI K, 1981, BIOCHEM BIOPH RES CO, V102, P172, DOI 10.1016/0006-291X(81)91504-7; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; NIELSEN J, 1981, MOL GEN GENET, V184, P33, DOI 10.1007/BF00271191; PENEFSKY H, 1991, ADV ENZYMOL REL AREA, V64, P173; Penefsky H S, 1979, Methods Enzymol, V56, P527; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; SEN AC, 1990, J BIOL CHEM, V265, P14277; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WISE JG, 1990, J BIOL CHEM, V265, P10403	33	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4233	4239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307987				2022-12-25	WOS:A1994MW98900053
J	ARKHAMMAR, P; JUNTTIBERGGREN, L; LARSSON, O; WELSH, M; NANBERG, E; SJOHOLM, A; KOHLER, M; BERGGREN, PO				ARKHAMMAR, P; JUNTTIBERGGREN, L; LARSSON, O; WELSH, M; NANBERG, E; SJOHOLM, A; KOHLER, M; BERGGREN, PO			PROTEIN-KINASE-C MODULATES THE INSULIN SECRETORY PROCESS BY MAINTAINING A PROPER FUNCTION OF THE BETA-CELL VOLTAGE-ACTIVATED CA2+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CA-2+ CONCENTRATION; RAT PANCREATIC-ISLETS; PHORBOL ESTER; SIGNAL TRANSDUCTION; PHOSPHOINOSITIDE HYDROLYSIS; INOSITOL TRISPHOSPHATE; CYTOPLASMIC CA-2+; K+ CHANNELS; LINE RINM5F; GLUCOSE	In the present study an attempt was made to further elucidate the molecular mechanisms whereby protein kinase C (PKC) modulates the beta-cell stimulus-secretion coupling. Regulation of Ca2+ channel activity, [Ca2+]i, and insulin release were investigated in both normal pancreatic mouse beta-cells and in similar beta-cells deprived of PKC activity. [Ca2+]i was measured with the intracellular fluorescent Ca2+ indicator fura-2 and the Ca2+ channel activity was estimated by the whole cell configuration of the patch-clamp technique. To reveal the various isoenzymes of PKC present in the mouse beta-cell, proteins were separated by one-dimensional gel electrophoresis and Western blotting was performed. The production of inositol phosphates was measured by ion-exchange chromatography and insulin release was measured radioimmunologically. Acute stimulation with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate resulted in suppression of both the carbamylcholine-induced increase in [Ca2+]i and production of inositol 1,4,5-trisphosphate. Under these conditions the increase in [Ca2+]i in response to glucose was similar to that found in control cells. When beta-cells were deprived of PKC, by exposure to 200 nM 12-O-tetradecanoylphorbol-13-acetate for 24-48 h, there was an enhanced response to carbamylcholine. This response constituted increases in both the [Ca2+]i signal and production of inositol 1,4,5-trisphosphate. Interestingly, cells with down-regulated PKC activity responded more slowly to glucose stimulation, when comparing the initial increase in [Ca2+]i, than control cells. On the other hand, the maximal increase in [Ca2+]i was similar whether or not PKC was present. Moreover, PKC down-regulated cells exhibited a significant reduction of maximal whole cell Ca2+ currents, a finding that may explain the altered kinetics with regard to the [Ca2+]i increase in response to the sugar. Both the alpha and beta1 forms of the PKC isoenzymes were present in the mouse beta-cell and were also subjected to PKC down-regulation. Hence, either of these isoenzymes or both may be involved in the modulation of phospholipase C and Ca2+ channel activity. Since insulin release under physiological conditions is critically dependent on Ca2+-influx through the voltage-gated L-type Ca2+ channels, the kinetics of hormone release was expected to demonstrate a similar delay as that of the [Ca2+]i increase. Although not as pronounced, such a delay was indeed also observed in the onset of insulin release. There was, however, no effect on the total amounts of hormone released. The present study confirms that PKC has multiple roles and thereby interacts at different sites in the complex series of events constituting the beta-cell signal-transduction pathway. It is suggested that PKC may be tonically active and effective in the maintenance of the phosphorylation state of the voltage-gated L-type Ca2+ channel, enabling an appropriate function of this channel in the insulin secretory process.	KAROLINSKA INST, KAROLINSKA HOSP,ROLF LUFT CTR DIABET RES, DEPT ENDOCRINOL,BOX 60500, S-10401 STOCKHOLM 60, SWEDEN; UNIV UPPSALA, CTR BIOMED, DEPT MED CELL BIOL, S-75123 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, DEPT PATHOL, S-75185 UPPSALA, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Uppsala University; Uppsala University; Uppsala University Hospital			Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755; Berggren, Per-Olof/0000-0001-8991-413X				AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; ARKHAMMAR P, 1990, BIOCHEM J, V265, P203, DOI 10.1042/bj2650203; ARKHAMMAR P, 1989, BIOCHEM BIOPH RES CO, V159, P223, DOI 10.1016/0006-291X(89)92426-1; ARKHAMMAR P, 1986, BIOCHIM BIOPHYS ACTA, V887, P236, DOI 10.1016/0167-4889(86)90060-1; ASHCROFT FM, 1988, J PHYSIOL-LONDON, V400, P501, DOI 10.1113/jphysiol.1988.sp017134; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BARROWMAN MM, 1986, FEBS LETT, V201, P137, DOI 10.1016/0014-5793(86)80586-5; BERGGREN PO, 1989, BIOCHEM BIOPH RES CO, V165, P416, DOI 10.1016/0006-291X(89)91086-3; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BEST L, 1983, BIOCHEM BIOPH RES CO, V116, P9, DOI 10.1016/0006-291X(83)90373-X; DIVIRGILIO F, 1986, J BIOL CHEM, V261, P32; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; EFENDIC S, 1993, J INT MED, V229, P9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HELLMAN B, 1975, ENDOCRINOLOGY, V97, P392, DOI 10.1210/endo-97-2-392; HII CST, 1987, BIOCHEM J, V246, P489, DOI 10.1042/bj2460489; KANATSUNA T, 1981, DIABETES, V30, P231, DOI 10.2337/diabetes.30.3.231; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KINDMARK H, 1992, FEBS LETT, V303, P85, DOI 10.1016/0014-5793(92)80483-W; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LI GD, 1990, BIOCHEM J, V272, P637, DOI 10.1042/bj2720637; Martell A. E., 1974, CRITICAL STABILITY C, V2; MONACO ME, 1988, BIOCHEM BIOPH RES CO, V151, P717, DOI 10.1016/S0006-291X(88)80339-5; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PETERSEN OH, 1990, NATURE, V344, P300, DOI 10.1038/344300c0; PFEILSCHIFTER J, 1989, BIOCHEM J, V262, P285, DOI 10.1042/bj2620285; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; RICKARD JE, 1985, BIOCHEM J, V231, P623, DOI 10.1042/bj2310623; RORSMAN P, 1986, AM J PHYSIOL, V251, pC912, DOI 10.1152/ajpcell.1986.251.6.C912; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; Smith RM, 1974, CRITICAL STABILITY C, V1-6; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; VELASCO JM, 1989, Q J EXP PHYSIOL CMS, V74, P367, DOI 10.1113/expphysiol.1989.sp003280; VELASCO JM, 1988, FEBS LETT, V231, P366, DOI 10.1016/0014-5793(88)80851-2; VICENTINI LM, 1988, FEBS LETT, V228, P346, DOI 10.1016/0014-5793(88)80029-2; WELSH N, 1991, AUTOIMMUNITY, V9, P33, DOI 10.3109/08916939108997121; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YADA T, 1989, J BIOL CHEM, V264, P2455; ZAWALICH W, 1983, BIOCHEM BIOPH RES CO, V117, P448, DOI 10.1016/0006-291X(83)91221-4; ZAWALICH W, 1987, DIABETES, V36, P426, DOI 10.2337/diabetes.36.4.426	55	91	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2743	2749						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300606				2022-12-25	WOS:A1994MV43200059
J	PEDRON, T; GIRARD, R; TURCO, SJ; CHABY, R				PEDRON, T; GIRARD, R; TURCO, SJ; CHABY, R			PHOSPHATIDYLINOSITOL-ANCHORED MOLECULES AND INDUCIBLE LIPOPOLYSACCHARIDE-BINDING SITES OF HUMAN AND MOUSE BONE-MARROW CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A; LEISHMANIA-DONOVANI; HUMAN MONOCYTES; MACROPHAGES; BACTERIAL; LIPOPHOSPHOGLYCAN; DIFFERENTIATION; ENDOTOXIN; RECEPTOR; RELEASE	We have previously established that lipopolysaccharide (LPS) induces the expression of new specific LPS-binding sites (LpsR) in mouse bone marrow cells (BMC). We now show that exposure of human BMC to LPS elicits the production of both CD14 molecules (detectable with monoclonal antibody My4) and LpsR (detectable with fluorescein isothiocyanate-LPS). Pretreatment of stimulated human BMC with My4 inhibited the binding of fluorescein isothiocyanate-LPS. The stimulation of human BMC, but not mouse BMC, required the presence of serum. Other characteristics of mouse and human BMC examined were very similar. Their inducible LpsR interacted with the lipid moieties of LPS and Leishmania donovani lipophosphoglycan and with a soluble preparation of peptidoglycan. Moreover, mouse and human LpsR were susceptible to treatment with a phosphatidylinositol-specific phospholipase C (PI-PLC), thus suggesting that both are PI-anchored CD14 molecules. Neither LpsR appeared able to interact with a synthetic LPS antagonist (compound PPDm2) structurally related to the lipid region of LPS. However, PPDm2 blocked LPS-induced expression of LpsR in both BMC. Furthermore, in both species, pretreatment of BMC with PI-PLC did not prevent the cells from expressing LpsR in response to LPS. The results support the hypothesis that the elicited LpsR of mouse and human BMC is an inducible form of CD14, whereas the putative ''signaling LPS receptor'' of these cells is not CD14 or any other PI-anchored molecule.	UNIV PARIS 11,CNRS,URA 1116,EQUIPE ENDOTOXINES,BATIMENT 432,F-91405 ORSAY,FRANCE; INST PASTEUR,CNRS,URA 359,UNITE IMMUNOPHYSIOL MOLEC,F-75724 PARIS 15,FRANCE; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Kentucky								ADAM A, 1972, P NATL ACAD SCI USA, V69, P851, DOI 10.1073/pnas.69.4.851; ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; BALL ED, 1984, J CLIN INVEST, V73, P1072, DOI 10.1172/JCI111292; BRIGHAM KL, 1974, J CLIN INVEST, V54, P792, DOI 10.1172/JCI107819; BUCKINGH.RB, 1972, J CLIN INVEST, V51, P1186, DOI 10.1172/JCI106912; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CHABY R, 1993, IN PRESS J IMMUNOL; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; COUTURIER C, 1991, J IMMUNOL, V147, P1899; DASILVA RP, 1989, J IMMUNOL, V143, P617; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; FEIST W, 1989, IMMUNOBIOLOGY, V179, P293, DOI 10.1016/S0171-2985(89)80036-1; FERRERO E, 1993, P NATL ACAD SCI USA, V90, P2380, DOI 10.1073/pnas.90.6.2380; GIRARD R, 1993, J IMMUNOL, V150, P4504; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; GOYERT SM, 1986, J IMMUNOL, V137, P3909; GREISMAN SE, 1969, P SOC EXP BIOL MED, V131, P1154, DOI 10.3181/00379727-131-34059; HAMMERLING U, 1976, P NATL ACAD SCI USA, V73, P2008, DOI 10.1073/pnas.73.6.2008; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAZIOT A, 1988, J IMMUNOL, V141, P547; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HINSHAW LB, 1977, SURG GYNECOL OBSTET, V145, P1; JORDAN MM, 1964, P SOC EXP BIOL MED, V115, P455; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEI MG, 1988, J IMMUNOL, V141, P996; LOPPNOW H, 1986, EUR J IMMUNOL, V16, P1263, DOI 10.1002/eji.1830161013; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; Morrison D C, 1979, Adv Immunol, V28, P293; MUNN DH, 1990, BLOOD, V75, P2042; NASU N, 1991, INT IMMUNOL, V3, P205, DOI 10.1093/intimm/3.2.205; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PEDRON T, 1992, INT IMMUNOL, V4, P533, DOI 10.1093/intimm/4.4.533; PORATH J, 1967, NATURE, V215, P1491, DOI 10.1038/2151491a0; RUCO LP, 1978, J IMMUNOL, V121, P2035; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; STUTZ PL, 1990, CELLULAR MOL ASPECTS, P129; TAHRIJOUTI MA, 1990, MOL IMMUNOL, V27, P763, DOI 10.1016/0161-5890(90)90085-E; TAHRIJOUTI MA, 1990, MOL IMMUNOL, V27, P751, DOI 10.1016/0161-5890(90)90084-D; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Tracey K J, 1990, Adv Surg, V23, P21; ULMER AJ, 1992, INFECT IMMUN, V60, P5145, DOI 10.1128/IAI.60.12.5145-5152.1992; WEERSINK AJL, 1993, J IMMUNOL, V150, P253; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; WILSON ME, 1986, J IMMUNOL, V136, P4681; WORTHEN GS, 1988, J IMMUNOL, V140, P3553; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	50	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2426	2432						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300569				2022-12-25	WOS:A1994MV43200016
J	TURNBOW, MA; KELLER, SR; RICE, KM; GARNER, CW				TURNBOW, MA; KELLER, SR; RICE, KM; GARNER, CW			DEXAMETHASONE DOWN-REGULATION OF INSULIN-RECEPTOR SUBSTRATE-1 IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; PROTEIN; PHOSPHORYLATION; RESISTANCE; BINDING; CELLS; RAT	Insulin resistance resulting from prolonged exposure of intact animals or cultured cells to glucocorticoids is often attributed to postreceptor signaling defects. To better understand the specific effects of glucocorticoids on insulin signaling, we have characterized the effect of dexamethasone on the expression of an insulin signaling intermediate, the insulin receptor substrate-1 (IRS-1) in 3T3-L1 adipocytes. Addition of dexamethasone resulted in a 40-70% decline in steady-state IRS-1 protein over 24-48 h of treatment. Dexamethasone did not significantly change the degradation rate of IRS-1 protein but decreased the net rate of amino acid incorporation into IRS-1 by 87%. Between 1 and 2.5 h of treatment with dexamethasone, actinomycin D, or both drugs given simultaneously, the concentration of IRS-1 mRNA declined with a half-life of 0.7-1.0 h. However, after 4 h of dexamethasone treatment, IRS-1 mRNA concentrations stabilized at approximately 35% of the control level. The dexamethasone-induced decline in IRS-1 protein could be prevented by simultaneous administration of the glucocorticoid antagonist mifepristone, RU38486. These results suggest that in 3T3-L1 adipocytes the loss of IRS-1 protein after dexamethasone treatment can be accounted for chiefly by inhibition of the synthesis of IRS-1 mRNA.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College	TURNBOW, MA (corresponding author), TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,3601 4TH ST,LUBBOCK,TX 79430, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU DT, 1990, BIOCHEM SOC T, V18, P1247, DOI 10.1042/bst0181247; FROST SC, 1985, J BIOL CHEM, V260, P2646; GARVEY WT, 1989, ENDOCRINOLOGY, V124, P2063, DOI 10.1210/endo-124-5-2063; GRUNFELD C, 1981, ENDOCRINOLOGY, V109, P1723, DOI 10.1210/endo-109-5-1723; GUILLAUMEGENTIL C, 1990, ENDOCRINOLOGY, V126, P1873, DOI 10.1210/endo-126-4-1873; HOECK W, 1989, J BIOL CHEM, V264, P14396; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLER SR, 1991, J BIOL CHEM, V266, P12817; LAZAR G, 1986, BIOCHEM BIOPH RES CO, V134, P44, DOI 10.1016/0006-291X(86)90524-3; OLEFSKY JM, 1975, J CLIN INVEST, V56, P1499, DOI 10.1172/JCI108231; RICE KM, 1992, J BIOL CHEM, V267, P10163; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TURNBOW MA, 1993, BIOTECHNIQUES, V15, P267; VANPUTTEN JPM, 1985, DIABETOLOGIA, V28, P445, DOI 10.1007/BF00280889; WAJNGOT A, 1992, P NATL ACAD SCI USA, V89, P6035, DOI 10.1073/pnas.89.13.6035; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	19	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2516	2520						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300578				2022-12-25	WOS:A1994MV43200028
J	HIASA, H; DIGATE, RJ; MARIANS, KJ				HIASA, H; DIGATE, RJ; MARIANS, KJ			DECATENATING ACTIVITY OF ESCHERICHIA-COLI DNA GYRASE AND TOPOISOMERASE-I AND TOPOISOMERASE-III DURING ORIC AND PBR322 DNA-REPLICATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ORIGIN; GENE; CHROMOSOME; ENZYME; TRANSCRIPTION; PURIFICATION; MECHANISM; SEQUENCES; CLONING	oriC and pBR322 DNA replication, reconstituted with purified replication proteins, has been used to study the functional activities of Escherichia coli topoisomerase I, DNA gyrase, and topoisomerase III during the final stages of DNA replication. In the oriC system, DNA gyrase-catalyzed decatenation of daughter DNA molecules was very inefficient, whereas topoisomerase III could catalyze complete decatenation. In the pBR322 DNA replication system, almost all the daughter DNA molecules could be decatenated by DNA gyrase alone in the absence of salt. Decatenation by DNA gyrase in the pBR322 system was completely inhibited, without a concomitant inhibition of DNA synthesis, by the addition of physiological concentrations of salt. Topoisomerase III, however, could decatenate all of the daughter DNA molecules in the pBR322 system, even in the presence of high concentrations of salt. A similar effect could not be observed in the oriC system, because the addition of salt inhibited DNA synthesis. Topoisomerase I was incapable of catalyzing decatenation under any conditions examined in either the oriC or pBR322 replication system. The addition of topoisomerase I to the replication systems resulted only in an inhibition of DNA synthesis.	UNIV MARYLAND, SCH PHARM, DEPT BIOMED CHEM, BALTIMORE, MD 21201 USA; UNIV MARYLAND, INST MED BIOTECHNOL, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR, MOLEC BIOL PROGRAM, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558, R29GM048445, R01GM048445] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48445, GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BOHK HJ, 1983, GENE, V24, P265; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DRLICA K, 1978, J MOL BIOL, V120, P145, DOI 10.1016/0022-2836(78)90061-X; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; ITOH T, 1979, COLD SPRING HARB SYM, V43, P409, DOI 10.1101/SQB.1979.043.01.047; KAGUNI JM, 1982, NATURE, V296, P623, DOI 10.1038/296623a0; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; ORR E, 1979, MOL GEN GENET, V177, P103, DOI 10.1007/BF00267259; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, IN PRESS J BIOL CHEM; RICHEY B, 1987, J BIOL CHEM, V262, P7157; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TOMIZAWA JI, 1974, P NATL ACAD SCI USA, V71, P2260, DOI 10.1073/pnas.71.6.2260; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; WANG JC, 1983, NUCLEIC ACIDS RES, V11, P1773, DOI 10.1093/nar/11.6.1773; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU CA, 1992, J BIOL CHEM, V267, P4030; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	39	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2093	2099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294462				2022-12-25	WOS:A1994MR98800083
J	LONGATI, P; BARDELLI, A; PONZETTO, C; NALDINI, L; COMOGLIO, PM				LONGATI, P; BARDELLI, A; PONZETTO, C; NALDINI, L; COMOGLIO, PM			TYROSINES(1234-1235) ARE CRITICAL FOR ACTIVATION OF THE TYROSINE KINASE ENCODED BY THE MET PROTOONCOGENE (HGF RECEPTOR)	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; SIGNAL TRANSDUCTION; SCATTER FACTOR; SH2 DOMAINS; CELL-LINE; AUTOPHOSPHORYLATION	The tyrosine kinase encoded by the MET proto-oncogene (p190(MET)) is the receptor for Hepatocyte Growth Factor/Scatter Factor (HGF/SF). Previous work has shown that autophosphorylation of p190(MET) enhances its enzymatic activity and that the major phosphorylation site is Tyr(1235), located in the catalytic domain. This residue is part of a 'three tyrosine' motif, including Tyr(1230), Tyr(1234), and Tyr(1235), conserved in several other receptor kinases. We studied the role of these tyrosines in the positive regulation of the p190(MET) kinase by site-directed mutagenesis. Substitution of either Tyr(1235) Or Tyr(1234) with phenylalanine severely reduced the in vitro kinase activity toward exogenous substrates. Kinetic experiments showed that the residual activity of these mutants could still be enhanced by autophosphorylation. Phosphopeptide mapping indicated that, in the absence of Tyr(1235), Tyr(1234) is phosphorylated. Only the replacement of both Tyr(1234) and Tyr(1235) yielded a mutant which completely lost the ability to be activated by autophosphorylation. In stable transfectants expressing the HGF/SF receptor with single substitution of either Tyr(1234) Or Tyr(1235) the response to HGF/SF was impaired. The ligand did not induce tyrosine phosphorylation of the receptor nor stimulated chemotaxis. These data show that Tyr(1234) and Tyr(1235) are critical for the activation of the HGF/SF receptor kinase both in vitro and in response to the ligand in intact cells.	UNIV TORINO,SCH MED,DEPT BIOMED SCI & OCOL,I-10126 TURIN,ITALY	University of Turin			Naldini, Luigi/E-9083-2012; BARDELLI, Alberto/J-9721-2018	BARDELLI, Alberto/0000-0003-1647-5070				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1992, ONCOGENE, V7, P3; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAYNE DM, EMBO J, V4, P885; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE FM, 1988, J BIOL CHEM, V263, P2629	44	203	206	1	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					49	57						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302603				2022-12-25	WOS:A1994MW24700007
J	MAENZ, DD; CHENU, C; BERTELOOT, A				MAENZ, DD; CHENU, C; BERTELOOT, A			HETEROTROPIC EFFECTS OF DIPOLAR AMINO-ACIDS ON THE ACTIVITY OF THE ANIONIC AMINO-ACID-TRANSPORT SYSTEM-X(AG)(-) IN RABBIT JEJUNAL BRUSH-BORDER MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID FILTRATION APPARATUS; SMALL-INTESTINE; COTRANSPORT; GLUTAMATE; NUTRITION; SYSTEM; K+	D-Aspartic acid was used as a specific substrate to evaluate the effects of dipolar amino acids on the high affinity anionic amino acid transport system X(AG)- in rabbit jejunal brush-border membrane vesicles. At pH 6, increasing L-phenylalanine concentrations caused a saturable activation of 0.05 mM D-aspartic acid uptake (K(a) = 2.4 mM), and a saturating concentration of effector increased the V(max) of transport (2.6-fold) without any significant effect on the K(m). At pH 8, however, a complex activation/inhibition curve was obtained with increasing L-phenylalanine concentrations, and a saturating concentration of effector increased both the V(max) (1.5-fold) and K(m) (2.1-fold) for transport. Increasing concentrations of L-valine, L-isoleucine, L-methionine, and L-threonine also showed complex activation/inhibition curves of D-aspartic acid uptake at both pH 6 and 8. The maximum level of activation, the plateau reached at saturating concentrations, and the concentration of effector producing either maximum activation or inhibition were, however, different at these two pH values. By using an optimum concentratiOn of 10 mM L-valine at pH 6, the absence of trans-activation and of further activation by a cis-gradient of effector could be demonstrated. These results suggest that two allosteric sites directly accessible from the external medium are responsible for the heterotropic activation of intestinal system X(AG)- by dipolar amino acids and that, under physiological conditions, such effects might compensate for the lack of specificity of the neutral brush-border system.	UNIV MONTREAL,FAC MED,DEPT PHYSIOL,MEMBRANE TRANSPORT RES GRP,CP 6128,SUCCURSALE A,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal								ADIBI SA, 1973, J CLIN INVEST, V52, P1586, DOI 10.1172/JCI107335; BELIVEAU R, 1990, BIOCHEM J, V268, P195, DOI 10.1042/bj2680195; BERTELOOT A, 1986, BIOCHIM BIOPHYS ACTA, V861, P447, DOI 10.1016/0005-2736(86)90453-0; BERTELOOT A, 1984, BIOCHIM BIOPHYS ACTA, V775, P129, DOI 10.1016/0005-2736(84)90163-9; BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BERTELOOT A, 1991, J MEMBRANE BIOL, V122, P111, DOI 10.1007/BF01872635; BERTELOOT A, 1990, COMP PHYSL, V7, P130; BOTTS DJ, 1958, FARADAY T SOC, V54, P593; CHENU C, 1993, J MEMBRANE BIOL, V132, P95; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTENSEN HN, 1982, PHYSIOL REV, V62, P1193, DOI 10.1152/physrev.1982.62.4.1193; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CORCELLI A, 1983, BIOCHIM BIOPHYS ACTA, V732, P24, DOI 10.1016/0005-2736(83)90182-7; CORCELLI A, 1982, BIOCHIM BIOPHYS ACTA, V689, P97, DOI 10.1016/0005-2736(82)90193-6; HARIG JM, 1987, BIOCHIM BIOPHYS ACTA, V903, P358, DOI 10.1016/0005-2736(87)90226-4; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; LAWLESS K, 1987, AM J PHYSIOL, V253, pG637, DOI 10.1152/ajpgi.1987.253.5.G637; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; MAENZ DD, 1991, BIOCHIM BIOPHYS ACTA, V1069, P250, DOI 10.1016/0005-2736(91)90132-R; MAKOWSKE M, 1982, J BIOL CHEM, V257, P4635; MAKOWSKE M, 1982, J BIOL CHEM, V257, P5663; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; MUNCK BG, 1980, J MEMBRANE BIOL, V53, P45, DOI 10.1007/BF01871171; RAJENDRAN VM, 1987, AM J PHYSIOL, V252, pG33, DOI 10.1152/ajpgi.1987.252.1.G33; ROBINSON J. W. L., 1964, GASTROENTEROLOGIA [BASEL], V101, P330; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; WINGROVE TG, 1987, AM J PHYSIOL, V252, pC105, DOI 10.1152/ajpcell.1987.252.1.C105	28	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15361	15367						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340366				2022-12-25	WOS:A1993LN30500010
J	MERRILL, GA; BUTLER, M; HOROWITZ, PM				MERRILL, GA; BUTLER, M; HOROWITZ, PM			LIMITED TRYPTIC DIGESTION NEAR THE AMINO-TERMINUS OF BOVINE LIVER RHODANESE PRODUCES ACTIVE ELECTROPHORETIC VARIANTS WITH ALTERED REFOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMS; PROTEINS; ENZYME	When the enzyme rhodanese was partially digested by immobilized trypsin, it retained greater than 50% of its original activity although less than 10% of the undigested enzyme remained. The predominant daughter species were two 31-kDa polypeptides whose amino termini corresponded to either residue 44 or 45 of the enzyme's sequence. Following digestion, charged species were isolated by ion exchange chromatography. Denaturing electrophoresis revealed that a 4-kDa peptide remained associated with the 31-kDa fragment. This 4-kDa peptide appears to correspond to the amino-terminal 45 residues of rhodanese. Further proteolysis gave a 2.5-kDa peptide that dissociated under non-denaturing conditions without apparent change in migration of the 31-kDa fragment on SDS gels. Refolding of undigested, urea-denatured rhodanese restored much of its activity. Similar treatment of rhodanese following limited tryptic digestion resulted in no regain of activity. Refolding of a mixture of intact and digested rhodanese resulted in regain of activity appropriate for the amount of intact rhodanese in the sample, indicating that clipped rhodanese does not inhibit refolding of intact rhodanese. It is concluded that portions of the amino terminus of rhodanese are important in the enzyme's folding, but are not essential for the enzyme's sulfurtransferase activity.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,CTR DEV & APPLICAT BIOANALYT METHODS,SAN ANTONIO,TX 78284; BROOKE ARMY MED CTR,DEPT CLIN INVEST,FT SAM HOUSTON,TX 78234	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; San Antonio Military Medical Center; United States Department of Defense; United States Army					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1988, BIOCHIM BIOPHYS ACTA, V956, P30, DOI 10.1016/0167-4838(88)90294-4; ALEXANDER K, 1986, J BIOL CHEM, V262, P6595; BLUMENTHAL KM, 1971, J BIOL CHEM, V246, P2430; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; CANNELLA C, 1981, EUR J BIOCHEM, V119, P491, DOI 10.1111/j.1432-1033.1981.tb05634.x; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; HOROWITZ P, 1983, J BIOL CHEM, V258, P1614; HOROWITZ PM, 1987, J BIOL CHEM, V262, P14544; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; KRATZIN HD, 1989, ANAL BIOCHEM, V183, P1, DOI 10.1016/0003-2697(89)90161-9; Kurzban G P, 1991, Protein Expr Purif, V2, P379, DOI 10.1016/1046-5928(91)90097-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1993, J PROTEIN CHEM, V12, P65, DOI 10.1007/BF01024916; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MERRILL GA, 1992, J PROTEIN CHEM, V11, P193, DOI 10.1007/BF01025225; MILLER D, 1990, J BIOL CHEM, V266, P4686; OGATA K, 1989, J BIOL CHEM, V264, P2718; PLOEGMAN JH, 1978, J MOL BIOL, V123, P557, DOI 10.1016/0022-2836(78)90207-3; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STEVEN PF, 1986, ANAL BIOCHEM, V155, P83; TANDON S, 1986, J BIOL CHEM, V261, P5615; TRUMPOWER BL, 1974, BIOCHEM BIOPH RES CO, V57, P532, DOI 10.1016/0006-291X(74)90965-6	26	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15611	15620						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340386				2022-12-25	WOS:A1993LN30500045
J	SINGHAL, RK; WILSON, SH				SINGHAL, RK; WILSON, SH			SHORT GAP-FILLING SYNTHESIS BY DNA POLYMERASE-BETA IS PROCESSIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASE; PERMEABLE HUMAN-FIBROBLASTS; REPAIR SYNTHESIS; ESCHERICHIA-COLI; EXCISION REPAIR; HUMAN-CELLS; IDENTIFICATION; ALPHA; INHIBITORS; EXPRESSION	Mammalian DNA polymerase beta (beta-pol) is considered to be part of the DNA repair machinery. However, there have been conceptual problems with this idea because beta-pol does not completely fill some gapped substrates, and unlike other DNA polymerases, beta-pol adds just one dNMP for each cycle of binding to the DNA substrate, incorporation, and product release (distributive synthesis). To examine the questions of complete gap filling and gap recognition by beta-pol, we designed template-primer substrates with a range of gap sizes from 1 to 53 template residues between the 3'-OH primer and a downstream polynucleotide. M13mp18(+) single-stranded DNA was used as template, and synthetic deoxyoligonucleotides were used as primers and downstream polynucleotides. We find that beta-pol can completely fill gaps and that the gap-filling activity on substrates with gaps of up to 6 nucleotides is highly processive rather than distributive; processive synthesis to fill a gap strictly required 5'-phosphate on the 5'-moiety of the gap. Similar specificity for filling short gaps was not observed with other DNA polymerases. These results on substrate specificity and the mechanism of beta-pol suggest distinct requirements for the role of beta-pol in vivo.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BARIL EF, 1971, BIOCHEMISTRY-US, V10, P1981, DOI 10.1021/bi00787a004; CHANG LMS, 1975, J MOL BIOL, V93, P219, DOI 10.1016/0022-2836(75)90129-1; CHANG LMS, 1973, J BIOL CHEM, V248, P3789; CHANG LMS, 1972, BIOCHEMISTRY-US, V11, P1264, DOI 10.1021/bi00757a023; DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DRESLER SL, 1983, J BIOL CHEM, V258, P9990; FRY M, 1986, ANIMAL CELL DNA POLY, P135; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; MATSUKAGE A, 1974, P NATL ACAD SCI USA, V71, P578, DOI 10.1073/pnas.71.2.578; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MILLER MR, 1982, J BIOL CHEM, V257, P204; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; RANDAHL H, 1988, J BIOL CHEM, V263, P12228; SIEDLECKI JA, 1980, NUCLEIC ACIDS RES, V8, P361, DOI 10.1093/nar/8.2.361; SMITH CA, 1984, BIOCHEMISTRY-US, V23, P1383, DOI 10.1021/bi00302a008; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3407; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	26	221	225	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15906	15911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340415				2022-12-25	WOS:A1993LN30500083
J	KOHRI, K; NOMURA, S; KITAMURA, Y; NAGATA, T; YOSHIOKA, K; IGUCHI, M; YAMATE, T; UMEKAWA, T; SUZUKI, Y; SINOHARA, H; KURITA, T				KOHRI, K; NOMURA, S; KITAMURA, Y; NAGATA, T; YOSHIOKA, K; IGUCHI, M; YAMATE, T; UMEKAWA, T; SUZUKI, Y; SINOHARA, H; KURITA, T			STRUCTURE AND EXPRESSION OF THE MESSENGER-RNA ENCODING URINARY STONE PROTEIN (OSTEOPONTIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED PHOSPHOPROTEIN-I; MINERALIZED-TISSUE FORMATION; BONE SIALOPROTEIN; RAT BONE; NEOPLASTIC TRANSFORMATION; DEVELOPMENTAL EXPRESSION; FIBROBLAST ATTACHMENT; KIDNEY; MATRIX; CELLS	The chemical nature of urinary stone protein is poorly understood. We have sequenced a cDNA of urinary calcium oxalate stone protein extracted with EDTA. cDNA sequences showed complete identity between urinary stone protein and human osteopontin. Osteopontin protein was detected by staining with Stains-All, which specifically stains phosphoproteins, and by digestion with the highly specific protease thrombin, demonstrating that urinary calcium oxalate stones consist of osteopontin protein. We used a technique of in situ hybridization to detect osteopontin mRNA in the kidney. In control rats, distal tubular cells were sporadically positive, and proximal tubular cells and glomeruli were negative for osteopontin mRNA. A rat model of stone formation was induced with glyoxylic acid. In stone-forming rats, staining of distal tubular cells was remarkably increased, but proximal tubular cells and glomeruli were still negative. Immunostaining for the osteopontin protein also revealed that epithelial cells of distal tubules were weakly positive in control rats and significantly increased in stone-forming rats, although proximal tubular cells and glomeruli were negative. Northern blot analysis showed a significant increase of osteopontin mRNA in stone-forming rats in proportion to the dosage and the duration of the stone-inducing drugs. These results show that osteopontin in the kidney is presumably involved in urinary stone formation as the stone matrix.	KINKI UNIV, SCH MED, DEPT BIOCHEM, SAYAMA, OSAKA 589, JAPAN; KINKI UNIV, SCH MED, DEPT PEDIAT, SAYAMA, OSAKA 589, JAPAN; OSAKA UNIV, SCH MED, DEPT PATHOL, SUITA, OSAKA 565, JAPAN; UNIV TOKUSHIMA, SCH DENT, DEPT PERIODONTOL & ENDODONTOL, TOKUSHIMA 770, JAPAN	Kindai University (Kinki University); Kindai University (Kinki University); Osaka University; Tokushima University	KOHRI, K (corresponding author), KINKI UNIV, SCH MED, DEPT UROL, SAYAMA, OSAKA 589, JAPAN.							BOYCE WH, 1968, AM J MED, V45, P673, DOI 10.1016/0002-9343(68)90203-9; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CHANG PL, 1991, CANCER RES, V51, P2144; DOMENICUCCI C, 1988, BIOCHEM J, V253, P139, DOI 10.1042/bj2530139; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GOLDBERG HA, 1988, COLLAGEN REL RES, V8, P187; HIENZSCH E, 1979, UROL RES, V7, P223; KEUTEL H. J., 1964, INVEST UROL, V2, P115; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KING JS, 1957, P SOC EXP BIOL MED, V95, P183, DOI 10.3181/00379727-95-23161; KING JS, 1959, ARCH BIOCHEM BIOPHYS, V82, P455, DOI 10.1016/0003-9861(59)90142-0; KOHRI K, 1992, BIOCHEM BIOPH RES CO, V184, P859, DOI 10.1016/0006-291X(92)90669-C; KRUMLAUF R, 1987, DEVELOPMENT, V99, P603; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LIAN JB, 1977, J CLIN INVEST, V59, P1151, DOI 10.1172/JCI108739; MARK MP, 1987, J HISTOCHEM CYTOCHEM, V35, P707, DOI 10.1177/35.7.3295029; MARK MP, 1988, CELL TISSUE RES, V251, P23, DOI 10.1007/BF00215443; MOORE S, 1975, BRIT J UROL, V47, P489, DOI 10.1111/j.1464-410X.1975.tb06244.x; NAGATA T, 1991, BIOCHEM J, V274, P513, DOI 10.1042/bj2740513; NAGATA T, 1989, BIOCHEM BIOPH RES CO, V165, P234, DOI 10.1016/0006-291X(89)91059-0; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1988, CANCER RES, V48, P5770; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SINGH K, 1990, J BIOL CHEM, V265, P18696; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; SOMERMAN MJ, 1988, CALCIFIED TISSUE INT, V43, P50, DOI 10.1007/BF02555169; SPECTOR AR, 1976, INVEST UROL, V13, P387; SWANSON GJ, 1989, HEARING RES, V41, P169, DOI 10.1016/0378-5955(89)90008-7; VERMEULEN CW, 1968, AM J MED, V45, P684, DOI 10.1016/0002-9343(68)90204-0; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; YOSHIDA O, 1990, UROL INT, V45, P104, DOI 10.1159/000281680; YOSHIOKA K, 1985, AM J PATHOL, V121, P156; ZHANG R, 1990, J BIOL CHEM, V265, P15375	39	227	230	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15180	15184						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325891				2022-12-25	WOS:A1993LL75900092
J	TAMURA, K; TANIMOTO, K; ISHII, M; MURAKAMI, K; FUKAMIZU, A				TAMURA, K; TANIMOTO, K; ISHII, M; MURAKAMI, K; FUKAMIZU, A			PROXIMAL AND CORE DNA ELEMENTS ARE REQUIRED FOR EFFICIENT ANGIOTENSINOGEN PROMOTER ACTIVATION DURING ADIPOGENIC DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; BLOOD-PRESSURE REGULATION; 3T3-L1 PREADIPOCYTES; GENE-EXPRESSION; MOLECULAR-BIOLOGY; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTION; CELLS; C/EBP	Angiotensinogen is abundantly expressed in adipose tissue as well as in liver where it is mainly produced. To address the mechanism of this adipogenic expression, promoter regions of the mouse angiotensinogen gene are fused to the chloramphenicol acetyltransferase reporter gene and stably transfected into 3T3-L1 preadipocytes. Promoter activity correlates well with an increase of mRNA levels during adipogenic differentiation, thereby demonstrating that the induction is primarily due to transcriptional activation. Deletion analysis indicates that the proximal promoter region from -96 to +22 is able to mediate the chloramphenicol acetyltransferase induction and identifies two transcriptionally active regions: AGE1 (position -399 to -139) and AGE2 (position -96 to -52). Heterologous promoter assay reveals that AGE1 behaves with a constitutive enhancer-like property and that AGE2 functions as a differentiation-inducible activator. Gel shift experiments show that AGE2 specifically binds a novel factor (AGF2), which is induced upon differentiation. Furthermore, a constitutive factor (AGF3) binds to the core promoter region including the exon 1 (from -6 to +22, AGE3). Mutations within either AGE2 or AGE3 that disrupt nuclear factors binding in vitro dramatically reduced the chloramphenicol acetyltransferase activation in the native promoter context. These results suggest that both AGE2 and AGE3 are necessary for mediating efficient activation of the mouse angiotensinogen promoter during adipogenic differentiation.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED,KANAGAWA 236,JAPAN	University of Tsukuba; Yokohama City University			fukamizu, akiyoshi/J-5350-2012; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Tanimoto, Keiji/0000-0003-1971-6546				BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAMPBELL DJ, 1987, J CLIN INVEST, V79, P1, DOI 10.1172/JCI112768; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHENEVAL D, 1991, P NATL ACAD SCI USA, V88, P8465, DOI 10.1073/pnas.88.19.8465; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DANESCH U, 1992, J BIOL CHEM, V267, P7185; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FERRARIO CM, 1990, J CARDIOVASC PHARM, V15, pS1, DOI 10.1097/00005344-199000153-00001; FREDERICH RC, 1992, HYPERTENSION, V19, P339, DOI 10.1161/01.HYP.19.4.339; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GOMEZ RA, 1988, ENDOCRINOLOGY, V123, P2298, DOI 10.1210/endo-123-5-2298; GOMEZ RA, 1990, PEDIATR NEPHROL, V4, P421, DOI 10.1007/BF00862529; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KALINYAK JE, 1991, J ENDOCRINOL INVEST, V14, P647, DOI 10.1007/BF03347886; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KRIEGER JE, 1991, HYPERTENSION, V18, P3; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROCCHINI AP, 1991, HYPERTENSION, V17, P837, DOI 10.1161/01.HYP.17.6.837; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SAYE J, 1990, HYPERTENSION, V15, P867, DOI 10.1161/01.HYP.15.6.867; SAYE JA, 1989, AM J PHYSIOL, V256, pC448, DOI 10.1152/ajpcell.1989.256.2.C448; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P7895, DOI 10.1073/pnas.89.17.7895; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAMURA K, 1992, JPN HEART J, V33, P113; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P3617, DOI 10.1093/nar/20.14.3617; TEWKSBURY DA, 1990, HYPERTENSION PATHOPH, V1, P1197; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879	58	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15024	15032						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325878				2022-12-25	WOS:A1993LL75900072
J	SU, K; STOLLER, T; ROCCO, J; ZEMSKY, J; GREEN, R				SU, K; STOLLER, T; ROCCO, J; ZEMSKY, J; GREEN, R			PRE-GOLGI DEGRADATION OF YEAST PREPRO-ALPHA-FACTOR EXPRESSED IN A MAMMALIAN-CELL - INFLUENCE OF CELL-TYPE-SPECIFIC OLIGOSACCHARIDE PROCESSING ON INTRACELLULAR FATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ANTIGEN RECEPTOR CHAINS; SACCHAROMYCES-CEREVISIAE; BREFELDIN-A; PROTEIN-DEGRADATION; SECRETORY GLYCOPROTEINS; FOREIGN PROTEINS; FACTOR PRECURSOR; GLYCOSYLATION; COMPLEX	We demonstrate that expression of yeast prepro-alpha-factor in GH3 rat pituitary cells results in its degradation in an endoplasmic reticulum (ER) or early Golgi compartment, suggesting that this wild-type prohormone is recognized as abnormal or misfolded in the context of a mammalian ER. In GH3 cells, as in yeast, the nascent polypeptide is efficiently targeted to the ER, where it undergoes cleavage of its amino-terminal signal peptide and core glycosylation to form glycosylated pro-alpha-factor (gpalphaf). Subsequently, however, this species disappears from cells with a half-time of 25-30 min (including a 10-20-min lag), and no alpha-factor-or proregion-derived products can be detected. Localization of the degradative process to the ER is suggested by its occurrence in the presence of brefeldin A or chloroquine and by the endoglycosidase H susceptibility of the substrate. We present evidence that Asn-linked oligosaccharide processing, which differs in extent between yeast and mammalian cells, may be an important factor in determining degradation in this heterologous circumstance. When GH3 cells are treated with deoxymannojirimycin, an inhibitor of ER alpha-mannosidases, gpalphaf is essentially stable, suggesting that trimming of core oligosaccharides below Man8 (a process that does not occur in yeast) strongly promotes proteolysis. Inhibition of ER glucosidase activity by treatment with deoxynojirimycin, by contrast, considerably accelerates the disappearance of gpalphaf (t1/2 = 8-10 min). These data indicate that cell type-specific post-translational modifications of a secretory glycoprotein can substantially modify its recognition by the mammalian ER degradative apparatus.	CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,BRONX,NY 10461	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine								AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BAUSE E, 1986, BIOSCIENCE REP, V6, P827, DOI 10.1007/BF01117106; BERGH MLE, 1987, P NATL ACAD SCI USA, V84, P3570, DOI 10.1073/pnas.84.11.3570; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; BISCHOFF J, 1986, J BIOL CHEM, V261, P4768; BITTER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5330, DOI 10.1073/pnas.81.17.5330; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIL G, 1985, CELL, V41, P241; GREEN R, 1986, J BIOL CHEM, V261, P7558; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STOCKERT RJ, 1983, HEPATOLOGY, V3, P750; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TRIMBLE RJ, 1992, GUIDEBOOK SECRETORY; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WATERS MG, 1988, J BIOL CHEM, V263, P6209; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	48	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14301	14309						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	8314793				2022-12-25	WOS:A1993LJ82500076
J	BIERHUIZEN, MFA; MAEMURA, K; FUKUDA, M				BIERHUIZEN, MFA; MAEMURA, K; FUKUDA, M			EXPRESSION OF A DIFFERENTIATION ANTIGEN AND POLY-N-ACETYLLACTOSAMINYL O-GLYCANS DIRECTED BY A CLONED CORE 2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; HAMSTER-KIDNEY CELLS; MAJOR SIALOGLYCOPROTEIN; LINKED OLIGOSACCHARIDES; SIALYL-LEX; SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODY; HUMAN LEUKOSIALIN; SIALOPHORIN CD43; LEUKEMIA-CELLS	Chinese hamster ovary (CHO) cells do not contain detectable amounts of core 2 beta-1,6-N-acetylglucosaminyl-transferase, C2GnT, and thus lack various modifications in their branched O-linked oligosaccharides. In the pre-sent study, the O-linked oligosaccharides and the occurrence of a differentiation antigen were analyzed in CHO cells stably transfected with cDNA encoding human leukosialin alone (CHO-leu) or with cDNAs encoding both leukosialin and C2GnT (CHO-leu.C2GnT). The analysis of O-glycans, released from [H-3]glucosamine labeled cells, revealed that CHO-leu cells synthesize O-glycans with a Gal beta 1-->3GalNAc backbone, whereas CHO-leu C2GnT cells synthesize in addition O-glycans with a Gal beta 1-->3(Gal beta 1-->4GlcNAc beta 1-->6)GalNAc backbone. Moreover, CHO-leu C2GnT cells express poly-N-acetyllactosaminyl extensions from the GlcNAc beta 1-->6 branch in O-glycans, while CHO-leu cells express no detectable amount of poly-N-acetyllactosaminyl O-glycans. It was also demonstrated that leukosialin in CHO-leu C2GnT cells is recognized by the T305 monoclonal antibody, while the same antibody did not react at all with CHO-leu cells. In addition, the transient expression cloning scheme using the T305 monoclonal antibody as a selectin marker and COS-1 cells, which endogenously express C2GnT as recipient cells, resulted in the isolation of cDNA encoding leukosialin. These results indicate that C2GnT determines the expression of poly-N-acetyllactosamines in O-glycans and together with leukosialin, an onco-differentiation antigen recognized by the T305 antibody.	LA JOLLA CANC RES FDN,CANC RES CTR,GLYOCBIOL PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA33000, CA33895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA033000, R01CA033000, R01CA033895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BERG EL, 1991, J BIOL CHEM, V266; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; DYER MJS, 1981, J EXP MED, V154, P1164, DOI 10.1084/jem.154.4.1164; FEINBERG AP, 1983, ANAL BIOCHEM, V12, P6; FOX RI, 1983, J IMMUNOL, V131, P762; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1993, SEMIN HEMATOL, V30, P138; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GULLEY ML, 1988, J IMMUNOL, V140, P3751; HESSION C, 1989, P NATL ACAD SCI USA, V87, P3743; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KUDO S, 1991, J BIOL CHEM, V266, P8483; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; NATHAN C, 1993, J CELL BIOL, V122, P243, DOI 10.1083/jcb.122.1.243; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PAULSON JC, 1982, J BIOL CHEM, V257; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIERCE M, 1986, J BIOL CHEM, V261, P772; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; PILLER V, 1989, J BIOL CHEM, V264, P18824; PILLER V, 1990, J BIOL CHEM, V265, P9264; REMOLD-O'DONNELL E, 1990, Immunodeficiency Reviews, V2, P151; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SADLER JE, 1979, J BIOL CHEM, V254, P2112; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH O, 1991, BLOOD, V77, P1491; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCHMID K, 1992, P NATL ACAD SCI USA, V89, P663, DOI 10.1073/pnas.89.2.663; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SMITH DF, 1990, J BIOL CHEM, V265, P6225; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	59	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4473	4479						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8308016				2022-12-25	WOS:A1994MW98900088
J	ZHU, GH; SPREITZER, RJ				ZHU, GH; SPREITZER, RJ			DIRECTED MUTAGENESIS OF CHLOROPLAST RIBULOSEBISPHOSPHATE CARBOXYLASE/OXYGENASE - SUBSTITUTIONS AT LARGE SUBUNIT ASPARAGINE-123 AND SERINE-379 DECREASE CO2/O-2 SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; CHLAMYDOMONAS-REINHARDII; ACTIVE-SITE; 1,5-DIPHOSPHATE CARBOXYLASE; OXYGENASE; MUTANT; DNA; 1,5-BISPHOSPHATE	Chloroplast-encoded large subunits of ribulose-1,5-bisphosphate carboxylase/oxygenase (EC 4.1.1.39) are insoluble when separated from the holoenzyme or expressed in Escherichia coli, limiting directed mutagenesis to prokaryotic enzymes. In the present study, we performed directed mutagenesis and chloroplast transformation with the large subunit gene of Chlamydomonas reinhardtii. Two separate mutations were created that are known to influence the CO2/O-2 specificity of prokaryotic enzymes. The asparagine 123 to glycine and serine 379 to alanine substitutions gave rise to photosynthesis-deficient mutants that synthesize normal levels of holoenzyme. The V-max for carboxylation was reduced more than 95% and the K-m(CO2) was increased more than 3-fold for both mutant enzymes. K-m(O-2) was slightly reduced for the glycine 123 enzyme, but increased more than 5-fold for the alanine 379 enzyme. CO2/O-2 specificity factors for both enzymes are decreased by more than 70%. K-m values for ribulose 1,5-bisphosphate are not significantly affected, but binding affinities for the transition-state analog 2-carboxy-D-arabinitol 1,5 bisphosphate are reduced. The changes brought about by these substitutions in the eukaryotic large subunit are different from the changes observed in prokaryotic enzymes.			ZHU, GH (corresponding author), UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68583, USA.							ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BOYNTONJE, 1993, METHOD ENZYMOL, V217, P510; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Z, 1988, P NATL ACAD SCI USA, V85, P4696, DOI 10.1073/pnas.85.13.4696; CHEN Z, 1991, PLANTA, V83, P597; CHEN ZX, 1992, PHOTOSYNTH RES, V31, P157, DOI 10.1007/BF00028792; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; CHENE P, 1992, J MOL BIOL, V225, P891, DOI 10.1016/0022-2836(92)90408-C; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DAY AG, 1993, BIOCHEMISTRY-US, V32, P1940, DOI 10.1021/bi00059a009; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; GATENBY AA, 1984, EUR J BIOCHEM, V144, P361, DOI 10.1111/j.1432-1033.1984.tb08472.x; GUTTERIDGE S, 1993, J BIOL CHEM, V268, P7818; HARPEL MR, 1992, J BIOL CHEM, V267, P6475; HARPEL MR, 1991, J BIOL CHEM, V266, P24734; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; KINDLE KL, 1991, P NATL ACAD SCI USA, V88, P1721, DOI 10.1073/pnas.88.5.1721; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LEE GJ, 1992, BIOCHEMISTRY-US, V31, P2304, DOI 10.1021/bi00123a014; NEWMAN SM, 1991, MOL GEN GENET, V230, P65, DOI 10.1007/BF00290652; NEWMAN SM, 1990, GENETICS, V126, P875; OGREN WL, 1984, ANNU REV PLANT PHYS, V35, P415, DOI 10.1146/annurev.pp.35.060184.002215; PARRY MAJ, 1992, PLANTA, V187, P109, DOI 10.1007/BF00201631; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; SOPER TS, 1992, J BIOL CHEM, V267, P8452; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; TABITA FR, 1974, J BIOL CHEM, V249, P3459; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WURTZ EA, 1979, MOL GEN GENET, V170, P235, DOI 10.1007/BF00267056; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU WZ, 1992, P NATL ACAD SCI USA, V89, P3904, DOI 10.1073/pnas.89.9.3904; ZHU GH, 1990, PLANT PHYSIOL, V93, P244, DOI 10.1104/pp.93.1.244	46	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3952	3956						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	8307949				2022-12-25	WOS:A1994MW98900011
J	LEE, JSC; EDELMAN, AM				LEE, JSC; EDELMAN, AM			A PROTEIN ACTIVATOR OF CA2+-CALMODULIN-DEPENDENT PROTEIN KINASE-IA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; RAT-BRAIN; AUTOPHOSPHORYLATION; PURIFICATION; CALCIUM; PHOSPHORYLATION; BINDING; IB	A protein activator of Ca2+-calmodulin-dependent protein kinase la (CaM kinase Ia) was purified to near homogeneity from pig brain. In the final step of purification, sucrose density gradient centrifugation, CaM kinase la activating activity correlated with the presence of a approximately 52-kDa protein band detected by SDS-polyacrylamide gel electrophoresis. Comparison of this value with estimations of its molecular mass under nondenaturing conditions indicated that CaM kinase Ia activator is a slightly asymmetric monomer. After removal of endogenous CaM kinase la activator, the activity of CaM kinase la was 2% of its activity in the presence of a maximally stimulating concentration (15 nM) of the purified activator. In its activated state, CaM kinase Ia retained complete dependence of its activity upon Ca2+-CaM. The activation of CaM kinase la was rapid (t1/2 < 1 min) and required the combined presence of CaM kinase Ia activation Ca2+-CaM, and MgATP. Similarly, in addition to MgATP, the phosphorylation of CaM kinase Ia required CaM kinase la activator and Ca2+-CaM. CaM kinase la activator was capable of Ca2+-dependent binding to CaM-Sepharose. The requirement of the combined presence of CaM kinase la activator, Ca2+-CaM, and MgATP for both the activation and phosphorylation of CaM kinase la is discussed in terms of potential mechanisms for CaM kinase la activation.	SUNY BUFFALO,DEPT PHARMACOL & THERAPEUT,102 FARBER HALL,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NINDS NIH HHS [NS24738] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024738, R01NS024738] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell A.K, 1983, INTRACELLULAR CALCIU; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDELMAN AM, 1992, MOL BRAIN RES, V14, P27, DOI 10.1016/0169-328X(92)90006-W; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; KENNEDY MB, 1987, CALCIUM CELL FUNCTIO, V7, P62; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; MOEREMANS M, 1985, ANAL BIOCHEM, V145, P315, DOI 10.1016/0003-2697(85)90368-9; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NARIN AC, 1985, ANNU REV BIOCHEM, V54, P931; Pickett-Gies CA., 1986, ENZYMES, V17, P395; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Sherman M R, 1975, Methods Enzymol, V36, P211; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STULL JT, 1986, ENZYMES, V17, P113; TEO TS, 1973, J BIOL CHEM, V248, P588; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WORTHINGTON CC, 1988, WORTHINGTON MANUAL E; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	34	86	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2158	2164						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294471				2022-12-25	WOS:A1994MR98800092
J	OTTESON, EW; WELCH, WH; KOZEL, TR				OTTESON, EW; WELCH, WH; KOZEL, TR			PROTEIN-POLYSACCHARIDE INTERACTIONS - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE CAPSULAR POLYSACCHARIDE OF CRYPTOCOCCUS-NEOFORMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTYPE-A; 3-DIMENSIONAL STRUCTURE; ENZYMATIC AMPLIFICATION; HYPERVARIABLE REGIONS; ANTIGEN COMPLEX; FLUORESCENCE; BINDING; SPECTROSCOPY; DNA; GLUCURONOXYLOMANNAN	Monoclonal antibodies that react with the capsular polysaccharide, termed glucuronoxylomannan (GXM), of Cryptococcus neoformans have potential roles in the diagnosis, monitoring of disease progress, and immunotherapy of cryptococcosis. Monoclonal antibody 439 reacts with cryptococcal GXM of all four serotypes. A molecular model of the Fab fragment of monoclonal antibody 439 was constructed from the amino acid sequence and a template antibody molecule, Fab 4-4-20. A tryptophan is present on the surface between light chain CDR3 and heavy chain CDR3 in the putative binding site. This tryptophan residue proved to be a reporter group, and a fluorescence study of Fab 439 was performed to analyze the interaction between cryptococcal GXM and Fab 439. Binding of the polysaccharide enhanced the intrinsic fluorescence and caused a blue shift in the emission maximum, indicating that the environment of a tryptophan changes from a polar to less polar environment. This is consistent with the loss of water from the binding site caused by the binding of antigen. This interpretation was confirmed by acrylamide quenching, which showed that 1 less tryptophan was exposed to solvent in the Fab-GXM complex than in free Fab. Fluorescence titration was used to determine binding and dissociation constants (K(D)). The apparent K(D) values for serotypes A-C were approximately the same; the K(D) for serotype D GXM was 5-11-fold greater. De-O-acetylation of serotype A GXM produced a 31-fold increase in the K(D), indicating that the O-acetyl groups are important, but not essential, for binding. Carboxyl groups appear to be essential for strong binding because the K(D) for carboxyl-reduced GXM was so large that it could not be determined.	UNIV NEVADA,DEPT MICROBIOL,RENO,NV 89557; UNIV NEVADA,DEPT BIOCHEM,RENO,NV 89557; UNIV NEVADA,CELL & MOLEC BIOL PROGRAM,RENO,NV 89557	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno					NIAID NIH HHS [AI31696, AI14209] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014209, U01AI031696, R01AI014209] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOLA EE, 1987, PROTEIN DATA BANK CR, P107; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHATTACHARJEE AK, 1979, MOL IMMUNOL, V16, P531, DOI 10.1016/0161-5890(79)90081-6; BHATTACHARJEE AK, 1981, CARBOHYD RES, V95, P237, DOI 10.1016/S0008-6215(00)85580-9; BHATTACHARJEE AK, 1979, CARBOHYD RES, V73, P183, DOI 10.1016/S0008-6215(00)85488-9; BHATTACHARJEE AK, 1980, CARBOHYD RES, V82, P103, DOI 10.1016/S0008-6215(00)85524-X; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLOOMFIELD N, 1963, P SOC EXP BIOL MED, V114, P64, DOI 10.3181/00379727-114-28586; CASADEVALL A, 1992, J IMMUNOL METHODS, V154, P27, DOI 10.1016/0022-1759(92)90209-C; CHERNIAK R, 1988, CARBOHYD RES, V172, P113, DOI 10.1016/S0008-6215(00)90846-2; CHERNIAK R, 1980, MOL IMMUNOL, V17, P1025, DOI 10.1016/0161-5890(80)90096-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COULTER A, 1983, J IMMUNOL METHODS, V59, P199, DOI 10.1016/0022-1759(83)90031-5; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DIAMOND RD, 1974, ANN INTERN MED, V80, P176, DOI 10.7326/0003-4819-80-2-176; DIVITA G, 1991, BIOCHEMISTRY-US, V30, P3256, DOI 10.1021/bi00227a013; DROMER F, 1987, INFECT IMMUN, V55, P749, DOI 10.1128/IAI.55.3.749-752.1987; ECKERT TF, 1987, INFECT IMMUN, V55, P1895, DOI 10.1128/IAI.55.8.1895-1899.1987; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EFTINK MR, 1987, BIOCHIM BIOPHYS ACTA, V916, P343, DOI 10.1016/0167-4838(87)90179-8; EVANS EE, 1953, J BACTERIOL, V65, P571, DOI 10.1128/JB.65.5.571-577.1953; Fersht AR., 1977, ENZYME STRUCTURE MEC; GADE W, 1991, J CLIN MICROBIOL, V29, P1616, DOI 10.1128/JCM.29.8.1616-1619.1991; GHIRON CA, 1990, BIOCHIM BIOPHYS ACTA, V1041, P311, DOI 10.1016/0167-4838(90)90290-V; GLAUDEMANS CPG, 1971, METHODS CARBOHYDR CH, V3, P145; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; JOLLEY ME, 1974, CARBOHYD RES, V33, P377, DOI 10.1016/S0008-6215(00)82819-0; JONES KN, 1965, METHODS CARBOHYDR CH, V5, P445; Kabat EA, 1992, SEQUENCES PROTEINS I; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; KOZEL TR, 1982, J IMMUNOL, V129, P1675; KOZEL TR, 1988, J IMMUNOL METHODS, V107, P53, DOI 10.1016/0022-1759(88)90008-7; KOZEL TR, 1984, INFECT IMMUN, V43, P879, DOI 10.1128/IAI.43.3.879-886.1984; Kwon-Chung K.J., 1992, MED MYCOL; LADOKHIN AS, 1991, BIOCHEMISTRY-US, V30, P10200, DOI 10.1021/bi00106a018; LAWS WR, 1992, METHOD ENZYMOL, V210, P448; MELHUISH WH, 1961, J PHYS CHEM-US, V65, P229, DOI 10.1021/j100820a009; MUKHERJEE J, 1992, INFECT IMMUN, V60, P4534, DOI 10.1128/IAI.60.11.4534-4541.1992; MUKHERJEE J, 1993, J EXP MED, V177, P1105, DOI 10.1084/jem.177.4.1105; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; NASHED EM, 1990, J BIOL CHEM, V265, P20699; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1988, P NATL ACAD SCI USA, V85, P6885, DOI 10.1073/pnas.85.18.6885; PIGAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P106, DOI 10.1016/0167-4838(90)90108-R; RAYCHAUDHURI G, 1985, MOL IMMUNOL, V22, P1009, DOI 10.1016/0161-5890(85)90104-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANFORD JE, 1990, INFECT IMMUN, V58, P1919, DOI 10.1128/IAI.58.6.1919-1923.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELIK RM, 1987, AIDS, V1, P175; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SPIROPULU C, 1989, INFECT IMMUN, V57, P3240, DOI 10.1128/IAI.57.10.3240-3242.1989; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; TAYLOR RL, 1972, BIOCHEMISTRY-US, V11, P1383, DOI 10.1021/bi00758a009; TURNER SH, 1992, CARBOHYD RES, V233, P205, DOI 10.1016/S0008-6215(00)90932-7; VALENZUELA CF, 1992, J BIOL CHEM, V267, P8238; WILSON DE, 1968, P SOC EXP BIOL MED, V127, P820, DOI 10.3181/00379727-127-32812	62	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1858	1864						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294434				2022-12-25	WOS:A1994MR98800049
J	SANCHEZ, A; ROBBINS, J				SANCHEZ, A; ROBBINS, J			UNPROCESSED MYOGENIN TRANSCRIPTS ACCUMULATE DURING MOUSE EMBRYOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE REGULATORY GENE; BINDING PROTEINS; EXPRESSION; DIFFERENTIATION; MYOD; MYC; RNA; INACTIVATION; NEUROGENESIS; MYOBLASTS	The gene myogenin encodes a helix-loop-helix protein whose function is critical to the integrity of the mammalian myogenic cascade. In vitro, the expression of this gene immediately precedes terminal differentiation, as measured by the synthesis of those proteins that make up the contractile apparatus. However, during mammalian development, expression of myogenin and the appearance of sarcomeres are separated by at least 1 week. The observation that early embryos (10.5 days post coitum) do not possess myogenin protein despite the fact that transcripts are detected (Cusella-De Angelis et al. (1992) J. Cell Biol. 116, 1243-1255), suggests the possibility of post-transcriptional regulation. Using polymerase chain reaction and in situ analyses, we report here that the mouse embryo accumulates a significant pool of unprocessed myogenin RNA in the developing somites (10.5 days post coitum). These results indicate that post-transcriptional regulation of myogenin may occur at the RNA processing level.	CHILDRENS HOSP RES FDN,DEPT PEDIAT,DIV MOLEC CARDIOVASC BIOL,TCHRF,RM 3057,3333 BURNET AVE,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046826, P01HL022619, P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22619, HL41496, HL46826] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSONI S, 1991, DEVELOPMENT, V112, P1041; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CRONMILLER C, 1994, MOL GENETICS SEX DET, P171; CUSELLADEANGELIS MG, 1992, J CELL BIOL, V116, P1243, DOI 10.1083/jcb.116.5.1243; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HORABIN JI, 1993, MOL CELL BIOL, V13, P1408, DOI 10.1128/MCB.13.3.1408; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Rugh R, 1990, MOUSE; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	31	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1587	1590						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294401				2022-12-25	WOS:A1994MR98800006
J	KURATA, WE; LAU, AF				KURATA, WE; LAU, AF			P130(GAG-FPS) DISRUPTS GAP JUNCTIONAL COMMUNICATION AND INDUCES PHOSPHORYLATION OF CONNEXIN43 IN A MANNER SIMILAR TO THAT OF PP60(V-SRC)	ONCOGENE			English	Note							FUJINAMI SARCOMA-VIRUS; TYROSINE PROTEIN-KINASES; TO-CELL COMMUNICATION; SRC GENE-PRODUCT; PHORBOL ESTER; MAP KINASE; V-SRC; GROWTH; INHIBITION; PHOSPHOTYROSINE	The pp60v-src tyrosine kinase disrupts gap junctional communication in transformed fibroblasts and induces the phosphorylation of the gap junction protein, connexin43, on tyrosine. We report here that the p130(gag-fps) tyrosine kinase also profoundly disrupted gap junctional communication and markedly increased the phosphorylation of connexin43 which appeared to result from an accumulation of phosphotyrosine and phosphoserine. The disruption of gap junctional communication by pp60(v-src) and p130(gag-fps) did not appear to result from the gross alteration of gap junction plaques. Furthermore, two-dimensional phosphotryptic peptide mapping showed that the v-Src and V-Fps kinases stimulated the phosphorylation of multiple connexin43 peptides which contained phosphotyrosine and/or phosphoserine. Phosphotyrosine was detected in two connexin43 phosphotryptic peptides from v-src-transformed cells which suggested that more than one connexin43 tyrosine site may be recognized by pp60(v-src) in fibroblasts. The apparent higher levels of phosphoserine-containing connexin43 peptides in the oncogene-transformed cells pointed to the possibility that pp60(v-src) and p130(gag-fps) may also modulate connexin43 function through mechanism(s) involving the activation of signaling serine kinases. Taken together, these results suggested that connexin43 is a common target of the v-Src and v-Fps tyrosine kinase oncoproteins.	UNIV HAWAII, CANC RES CTR, MOLEC CARCINOGENESIS PROGRAM, HONOLULU, HI 96813 USA	Cancer Research Center of Hawaii; University of Hawaii System					NCI NIH HHS [CA-52098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P207, DOI 10.1007/BF01871630; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; CAVENEY S, 1985, ANNU REV PHYSIOL, V47, P319; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; GARFIELD RE, 1988, OXFORD REV REPROD B, V10, P436; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KUFFLER SW, 1976, NEURON BRAIN CELLULA, P154; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAU AF, 1986, VIROLOGY, V151, P86, DOI 10.1016/0042-6822(86)90106-6; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; LOEWENSTEIN WR, 1987, CELL, V48, P725, DOI 10.1016/0092-8674(87)90067-5; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; OH SY, 1991, BIOCHIM BIOPHYS ACTA, V1094, P243, DOI 10.1016/0167-4889(91)90016-Q; PAGE E, 1986, HEART CARDIOVASCULAR, P573; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; YOUNG JDE, 1987, CELL, V48, P733, DOI 10.1016/0092-8674(87)90071-7	41	60	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					329	335						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302599				2022-12-25	WOS:A1994MW24700042
J	RHYU, MG; PARK, WS; MELTZER, SJ				RHYU, MG; PARK, WS; MELTZER, SJ			MICROSATELLITE INSTABILITY OCCURS FREQUENTLY IN HUMAN GASTRIC-CARCINOMA	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; APC GENE; COLORECTAL TUMORIGENESIS; MUTATIONS OCCUR; CANCER; DELETIONS; REPEAT	Microsatellites are short repeated oligonucleotide sequences found throughout the human genome. Microsatellite instability has been reported in hereditary and sporadic colorectal carcinomas. Since gastric carcinoma shares numerous molecular abnormalities with colon cancer, we evaluated 52 gastric adenocarcinomas and adjacent dysplastic tissues for microsatellite instability at five chromosomal loci. Instability at one or more loci was observed in 16 (31%) of the 52 tumors, but in only two dysplastic tissues adjacent to their respective tumors. These results demonstrate that microsatellite instability is not limited to colorectal carcinoma, but also occurs frequently in another cancer, that of the stomach. It is probably a late event, developing only rarely in premalignant dysplastic lesions.	DEPT VET AFFAIRS,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21201; UNIV MARYLAND HOSP,BALTIMORE,MD 21201; CATHOLIC UNIV SEOUL,COLL MED,DEPT PATHOL,SEOUL,SOUTH KOREA	University System of Maryland; University of Maryland Baltimore; Catholic University of Korea								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SJ, 1990, CANCER RES, V50, P7717; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; GUSELLA JF, 1993, NEW ENGL J MED, V329, P571, DOI 10.1056/NEJM199308193290811; HORII A, 1992, CANCER RES, V52, P3231; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAERVI O, 1951, ACTA PATHOL MIC SC, V29, P26; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEISTER I, 1990, CANCER RES, V50, P7232; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MELTZER SJ, 1990, CANCER RES, V50, P3627; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RENAULT B, 1993, CANCER RES, V53, P2614; SANO T, 1991, CANCER RES, V51, P2926; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBER JL, 1989, AM J HUM GENET, V44, P388	23	221	227	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					29	32						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302591				2022-12-25	WOS:A1994MW24700004
J	GUPTA, K; COPELAND, NG; GILBERT, DJ; JENKINS, NA; GRAY, DA				GUPTA, K; COPELAND, NG; GILBERT, DJ; JENKINS, NA; GRAY, DA			UNP, A MOUSE GENE-RELATED TO THE TRE ONCOGENE	ONCOGENE			English	Note							LINKAGE MAP; CLONING; SEQUENCES; REGION; CDNA; ADENOVIRUS-E1A; TRANSLATION; CARCINOMA; DELETION; PROTEIN	We have cloned cDNAs from a novel gene designated Unp. Unp cDNAs contain a large open reading frame that would encode a protein of 89 kDa. The predicted protein contains a putative nuclear localization signal, as well as consensus sequences for binding to the retinoblastoma gene product. The latter elements are contained within a region having strong similarity to the human tre oncogene. We have localized the Unp gene to mouse chromosome 9 in a region of homology with human chromosome 3p. This region has been implicated in a number of human malignancies.	UNIV OTTAWA,DEPT BIOCHEM,451 SMYTH RD,OTTAWA K1H 8M5,ONTARIO,CANADA; NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702; UNIV OTTAWA,DEPT MED,OTTAWA K1H 8M5,ONTARIO,CANADA	University of Ottawa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Ottawa			/U-3554-2018	/0000-0002-8634-4984	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; Green EL, 1981, GENETICS PROBABILITY, P77; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUEBNER K, 1988, ONCOGENE, V3, P449; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KINGSLEY DM, 1989, GENETICS, V123, P165; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	24	65	70	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2307	2310						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336951				2022-12-25	WOS:A1993LP17100035
J	OBRIG, TG; LOUISE, CB; LINGWOOD, CA; BOYD, B; BARLEYMALONEY, L; DANIEL, TO				OBRIG, TG; LOUISE, CB; LINGWOOD, CA; BOYD, B; BARLEYMALONEY, L; DANIEL, TO			ENDOTHELIAL HETEROGENEITY IN SHIGA TOXIN RECEPTORS AND RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC-UREMIC SYNDROME; TUMOR-NECROSIS-FACTOR; ESCHERICHIA-COLI; GLYCOLIPID GLOBOTRIOSYLCERAMIDE; SHIGELLA TOXIN; CELLS INVITRO; GLOBOTRIAOSYLCERAMIDE; IDENTIFICATION; LIPOPOLYSACCHARIDE; PATHOGENESIS	This study addresses the basis for regional microvascular susceptibility to bacterial toxins implicated in hemolytic uremic syndrome. The results indicate a relationship between the degree of Shiga toxin sensitivity of human endothelial cells from different sources and the amount of globotriaosylceramide (Gb3) glycosphingolipid receptor for Shiga toxin expressed by these cells. Cell viability and protein synthesis of renal endothelial cells were reduced to 50% by 1 pM Shiga toxin, while umbilical vein cells were not affected by >1 nM toxin. Similarly, basal levels of Gb3 were approximately 50 times higher in renal endothelial cells than in the umbilical endothelial cells. Pre-exposure of umbilical endothelial cells to tumor necrosis factor-alpha or bacterial lipopolysaccharide increased Gb3 content 4-6-fold coincident with increases in sensitivity to cytotoxic and protein synthesis inhibitory effects of Shiga toxin. Lipopolysaccharide induction of both Gb3 and sensitivity to Shiga toxin cytotoxic action in umbilical endothelial cells was dependent on the structure of lipopolysaccharide. Neither tumor necrosis factor-alpha nor lipopolysaccharide altered the Shiga toxin sensitivity or the Gb3 content of renal endothelial cells. These data indicate that differential endothelial expression of glycolipid receptors for Shiga toxins may be responsible for localized involvement of the kidney in hemolytic uremic syndrome.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV NEPHROL,MCN 53223,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; HOSP SICK CHILDREN,DEPT MICROBIOL,TORONTO M5G 1X8,ONTARIO,CANADA	Vanderbilt University; Vanderbilt University; University of Rochester; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI024431, R01AI024431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, R01DK038517] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24431] Funding Source: Medline; NIDDK NIH HHS [P50-DK39261, R01-DK38517] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BITZAN M, 1991, J PEDIATR-US, V119, P380, DOI 10.1016/S0022-3476(05)82049-9; BOYD B, 1989, NEPHRON, V51, P207, DOI 10.1159/000185286; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; HABIB R, 1992, HEMOLYTIC UREMIC SYN, P315; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; KAPLAN BS, 1990, PEDIATR NEPHROL, V4, P276, DOI 10.1007/BF00857676; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; KOSTER F, 1978, NEW ENGL J MED, V298, P927, DOI 10.1056/NEJM197804272981702; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; LINGWOOD CA, 1993, IN PRESS ADV LIPID R, V25; LOUISE CB, 1992, INFECT IMMUN, V60, P1536, DOI 10.1128/IAI.60.4.1536-1543.1992; LOUISE CB, 1991, INFECT IMMUN, V59, P4173, DOI 10.1128/IAI.59.11.4173-4179.1991; NAIKI M, 1974, BIOCHEM BIOPH RES CO, V60, P1105, DOI 10.1016/0006-291X(74)90426-4; OBRIG TG, 1988, INFECT IMMUN, V56, P2373, DOI 10.1128/IAI.56.9.2373-2378.1988; OBRIG TG, 1987, BIOCHEM J, V244, P287, DOI 10.1042/bj2440287; Obrig TG, 1992, HEMOLYTIC UREMIC SYN, P405; PUDYMAITIS A, 1991, ARCH BIOCHEM BIOPHYS, V286, P448, DOI 10.1016/0003-9861(91)90064-P; REISBIG R, 1981, J BIOL CHEM, V256, P8739; RICHARDSON SE, 1988, HUM PATHOL, V19, P1102, DOI 10.1016/S0046-8177(88)80093-5; RIDDELL RR, FOOD CHEM TOXICOL, V24, P469; SAKAKIBARA N, 1991, CANCER LETT, V57, P187, DOI 10.1016/0304-3835(91)90155-B; SAMUEL JE, 1990, INFECT IMMUN, V58, P611, DOI 10.1128/IAI.58.3.611-618.1990; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; TESH VL, 1991, J INFECT DIS, V164, P344, DOI 10.1093/infdis/164.2.344; VANDEKAR NCAJ, 1992, BLOOD, V80, P2755; WADDELL T, 1990, P NATL ACAD SCI USA, V87, P7898, DOI 10.1073/pnas.87.20.7898; WADDELL T, 1988, BIOCHEM BIOPH RES CO, V152, P674, DOI 10.1016/S0006-291X(88)80091-3; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P3959, DOI 10.1128/IAI.58.12.3959-3965.1990; WOJTA J, 1989, J BIOL CHEM, V264, P2846; Zoja C., 1992, HEMOLYTIC UREMIC SYN, P389	34	250	258	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15484	15488						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340376				2022-12-25	WOS:A1993LN30500027
J	WANG, K; BOHREN, KM; GABBAY, KH				WANG, K; BOHREN, KM; GABBAY, KH			CHARACTERIZATION OF THE HUMAN ALDOSE REDUCTASE GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE VAS-DEFERENS; DIABETIC COMPLICATIONS; TRANSCRIPTION FACTORS; MEDULLARY CELLS; BINDING-PROTEIN; DNA-REPLICATION; EXPRESSION; SORBITOL; SEQUENCE; CLONING	The promoter region of the human aldose reductase gene has been identified upstream of the translation start ATG codon. The promoter contains a TATA box, a CCAAT promoter element, and three Sp1 protein binding consensus sequences upstream of the capsite. A 640-base pair insert spanning +31 to -609 directs expression of the reporter gene chloramphenicol acetyltransferase in an orientation-specific manner in transfected Hep G2 cells. The promoter activity remained constant with deletions from base pairs -609 to -186. The TATA and the CCAAT consensus sequences show significant promoter activity, whereas the three Sp1 binding consensus sequences, individually, have no significant promoter activity. A GA-rich region (-186 to -146) contains two CGGAAA/G motifs, which show promoter activity and interaction with Hep G2 nuclear extract and GA-binding proteins (GABPalpha and GABPbeta1) as shown by mobility shift assays and DNase I footprinting. Similar cis-elements in herpes simplex virus type 1 interact with rat liver GABP and the viral VP16 protein to mediate the induction of immediate early viral genes. A GC-rich region (87 to -31) is identified by mobility shift assay, and a consensus sequence of an androgen response element is present at -396 to -382. The human aldose reductase promoter, thus, has regulatory response elements that may be important during early development and puberty. These regulatory elements may play a significant role in the development of certain diabetic complications.	BAYLOR COLL MED,DIABET RES CTR,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	WANG, K (corresponding author), BAYLOR COLL MED,DIABET RES CTR,DEPT PEDIAT,HOUSTON,TX 77030, USA.			Bohren, Kurt/0000-0002-3183-4118	NIDDK NIH HHS [DK-39044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; BAGNASCO SM, 1988, AM J PHYSIOL, V254, pC788, DOI 10.1152/ajpcell.1988.254.6.C788; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, 1991 US JAP ALD RED; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DVORNIK D, 1973, SCIENCE, V182, P1146, DOI 10.1126/science.182.4117.1146; DVORNIK D, 1987, ALDOSE REDUCTASE INH, P153; GABBAY KH, 1966, SCIENCE, V151, P209, DOI 10.1126/science.151.3707.209; GABBAY KH, 1968, DIABETES, V17, P239, DOI 10.2337/diab.17.5.239; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GRAHAM A, 1991, J BIOL CHEM, V266, P6872; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Higuchi R., 1989, PCR TECHNOLOGY, P61; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KINOSHITA JH, 1979, METABOLISM, V28, P462, DOI 10.1016/0026-0495(79)90057-X; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; PAILHOUX E, 1992, J STEROID BIOCHEM, V42, P561, DOI 10.1016/0960-0760(92)90445-O; PAILHOUX EA, 1990, J BIOL CHEM, V265, P19932; PEEK R, 1992, DEV BIOL, V152, P152, DOI 10.1016/0012-1606(92)90165-D; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHWARTZ GJ, 1992, J CLIN INVEST, V90, P1275, DOI 10.1172/JCI115991; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614	41	70	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					16052	16058						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340427				2022-12-25	WOS:A1993LN30500101
J	ZENZIEGREGORY, B; SHERIDAN, P; JONES, KA; SMALE, ST				ZENZIEGREGORY, B; SHERIDAN, P; JONES, KA; SMALE, ST			HIV-1 CORE PROMOTER LACKS A SIMPLE INITIATOR ELEMENT BUT CONTAINS A BIPARTITE ACTIVATOR AT THE TRANSCRIPTION START SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TAT GENE-PRODUCT; MESSENGER-RNA; MUTATIONAL ANALYSIS; TRANS-ACTIVATION; EXPRESSION; SEQUENCES; PROTEINS; CELLS	The human immunodeficiency virus type 1 (HIV-1) core promoter region, extending approximately from nucleotides -40 to +80 relative to the transcription start site, contains a complex array of putative regulatory elements, including a TATA box, an initiator element, an element between the TATA box and start site, binding sites for LBP/UBP, the TAR element, and others. However, because of this elaborate architecture, the precise boundaries and functional roles for the individual regulatory elements have not been defined. To facilitate a detailed analysis of the HIV-1 core promoter, we employed in vitro transcription assays to identify the simplest control elements that activate RNA synthesis in the context of a synthetic, heterologous promoter. Because mutations at the start site previously were shown to diminish transcription, we anticipated finding an initiator as a basic regulator. However, we have demonstrated that the HIV-1 core promoter lacks an initiator that is functionally analogous to those found in the terminal transferase and adenovirus major late promoters. In its place, we identified two elements between -6 and +30, both of which appear to be necessary for significant transcriptional activation. Unlike a strong initiator, the activity of these elements was dependent on the presence of a TATA box and on their position relative to TATA. We have called the region containing these two elements the HIV-1 SSR to distinguish it from the simple transcriptional initiator elements found in other genes.	UNIV CALIF LOS ANGELES,SCH MED,HOWARD HUGHES MED INST,INST MOLEC BIOL,MACDONALD RES LABS 5748,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Salk Institute					NIDDK NIH HHS [DK-43726] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043726, R01DK043726] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KLIEWER S, 1989, J VIROL, V63, P4616, DOI 10.1128/JVI.63.11.4616-4625.1989; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LU YC, 1989, J VIROL, V63, P4115, DOI 10.1128/JVI.63.9.4115-4119.1989; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	34	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15823	15832						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	8340407				2022-12-25	WOS:A1993LN30500073
J	BASSE, CW; FATH, A; BOLLER, T				BASSE, CW; FATH, A; BOLLER, T			HIGH-AFFINITY BINDING OF GLYCOPEPTIDE ELICITOR TO TOMATO CELLS AND MICROSOMAL-MEMBRANES AND DISPLACEMENT BY SPECIFIC GLYCAN SUPPRESSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOYBEAN GLYCINE-MAX; ETHYLENE BIOSYNTHESIS; PLANT-CELLS; TRANSDUCTION; FRACTIONS; INVITRO; SIGNAL; INVIVO	We have previously isolated glycopeptides derived from yeast invertase that acted as highly potent elicitors in suspension-cultured tomato cells, inducing ethylene biosynthesis and phenylalanine ammonia-lyase activity, and we have found that the high mannose oligosaccharides released from the pure glycopeptide elicitors by endo-beta-N-acetylglucosaminidase H acted as suppressors of elicitor activity (Basse, C. W., Bock, K., and Boller, T. (1992) J. Biol. Chem. 267, 10258-10265). One of the elicitor-active glycopeptides (gp 8c) was labeled with t-butoxycarbonyl-L-[S-35]methionine and purified by reversed phase high performance liquid chromatography resulting in a specific radioactivity of the derivative of about 900 Ci/mmol. This radiolabeled glycopeptide showed specific, saturable, and reversible binding to whole tomato cells under conditions in which cells are responsive to elicitors as well as to microsomal membranes derived from these cells. Ligand saturation experiments, performed with microsomal membranes, gave a dissociation constant (K(d)) of 3.3 nm as determined by Scatchard analysis. Various glycopeptide elicitors and preparations from yeast invertase were compared with respect to their abilities to compete for binding of S-35-labeled gp 8c to tomato membranes and to induce ethylene biosynthesis in tomato cells. These studies revealed a high degree of correlation between elicitor activities in vivo and displacement activities in vitro. In both tests, a high activity depended on the presence of glycan side chains consisting of more than 8 mannosyl residues. The high mannose oligosaccharides that acted as suppressors of elicitor activity in vivo competed for binding of the labeled elicitor also. The suppressor-active glycan Man11GlcNAc and the elicitor-active gp 8c exhibited very similar displacement activities, and the inhibitory constant (K(i)) of the glycan Man11GlcNAc was very similar to the K(d) value calculated for S-35-labeled gp 8c, indicating that the glycopeptide elicitors and the glycan suppressors derived from these elicitors competed with similar affinities for the same binding site. The suppressor-inactive glycan Man8GlcNAc had a 200-fold lower capacity to compete for binding of S-35-labeled gp 8c to tomato membranes compared with the suppressor-active glycan Man11GlcNAc. Our results demonstrate the existence of a specific elicitor binding site in tomato cell membranes and suggest that glycopeptides and glycans act as agonists and antagonists for induction of the stress response, respectively, by competing for this binding site.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Boller, Thomas/G-3500-2012	Boller, Thomas/0000-0001-6768-7503				BASSE CW, 1992, J BIOL CHEM, V267, P10258; BASSE CW, 1992, PLANT PHYSIOL, V98, P1239, DOI 10.1104/pp.98.4.1239; BOLLER T, 1990, POLYAMINES ETHYLENE, P138; Boller T., 1986, PLANT PROTEOLYTIC EN, V2, P67; Boller T., 1991, PLANT HORMONE ETHYLE; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; COSIO EG, 1992, EUR J BIOCHEM, V204, P1115, DOI 10.1111/j.1432-1033.1992.tb16736.x; COSIO EG, 1990, FEBS LETT, V271, P223, DOI 10.1016/0014-5793(90)80411-B; COSIO EG, 1988, EUR J BIOCHEM, V175, P309, DOI 10.1111/j.1432-1033.1988.tb14198.x; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EBEL J, 1992, PLANT GENE RES GENES, P183; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FELIX G, 1991, PLANT PHYSIOL, V97, P19, DOI 10.1104/pp.97.1.19; GALLAGHER SR, 1982, PLANT PHYSIOL, V70, P1335, DOI 10.1104/pp.70.5.1335; GROSSKOPF DG, 1990, FEBS LETT, V275, P177, DOI 10.1016/0014-5793(90)81466-2; HORN MA, 1989, PLANT CELL, V1, P1003, DOI 10.1105/tpc.1.10.1003; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; RODRIGO I, 1991, PLANT PHYSIOL, V95, P616, DOI 10.1104/pp.95.2.616; SCHEEL D, 1990, Z NATURFORSCH C, V45, P569; SCHMIDT WE, 1987, P NATL ACAD SCI USA, V84, P4117, DOI 10.1073/pnas.84.12.4117; SHARON N, 1989, LECTINS; SPANU P, 1990, PLANT PHYSIOL, V93, P1482, DOI 10.1104/pp.93.4.1482; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; VERA P, 1989, PHYSIOL MOL PLANT P, V34, P323, DOI 10.1016/0885-5765(89)90029-5; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103	29	100	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14724	14731						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325850				2022-12-25	WOS:A1993LL75900032
J	BERGFUSSMAN, A; GRACE, ME; IOANNOU, Y; GRABOWSKI, GA				BERGFUSSMAN, A; GRACE, ME; IOANNOU, Y; GRABOWSKI, GA			HUMAN ACID BETA-GLUCOSIDASE - N-GLYCOSYLATION SITE OCCUPANCY AND THE EFFECT OF GLYCOSYLATION ON ENZYMATIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; GAUCHER DISEASE TYPE-1; DIRECTED MUTAGENESIS; GENETIC-HETEROGENEITY; CULTURED FIBROBLASTS; CATALYTIC ACTIVITY; BINDING-SITES; GLUCOCEREBROSIDASE; SEQUENCE; DNA	The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme. Each N-glycosylation consensus sequence [Asn-Xaa-(Ser/Thr)] was obliterated by individually substituting glutamine (Q) for asparagine (N). By expression of the normal and mutated cDNAs in insect (Sf9) and COS-1 cells and subsequent immunoblotting with anti-human acid beta-glucosidase antibodies, the four sequons at Asn-19, Asn-59, Asn-146, and Asn-270 were shown to be glycosylated in either source. The sequon at Asn-462 was never occupied. The mutant enzymes N59Q, N146Q, and N270Q were catalytically active and had normal interactions with active site-directed inhibitors as well as with the activators, phosphatidylserine and saposin C. Of the occupied sequons, N-glycosylation of the first was critical to the synthesis of a catalytically active enzyme. Alteration of this sequon, Asn-19-Ala-20-Thr-21, by the substitutions N19Q, N19D, N19E, or T21G led to a lack of glycosylation at this site. Enzymes containing N19Q, N19E, or T21G had significant decreases (3- to 60-fold) in intrinsic enzyme activity. The N19D enzyme had nearly normal catalytic activity and had enhanced activation by phosphatidylserine. These results show that sequon occupancy as well as steric effects at residue 19 are important for the development of an active conformer of this enzyme. This is the first example of a lysosomal hydrolase that requires sequon occupancy for the synthesis of a catalytically active	CHILDRENS HOSP MED CTR,DIV HUMAN GENET,ELLAND & BETHESDA AVE,CINCINNATI,OH 45229; CUNY MT SINAI SCH MED,DEPT PEDIAT,DIV MED & MOLEC GENET,NEW YORK,NY 10029	Cincinnati Children's Hospital Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCRR NIH HHS [RR-71] Funding Source: Medline; NIDDK NIH HHS [DK 36729] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGMANN JE, 1989, AM J HUM GENET, V44, P741; BEUTLER E, 1985, AM J HUM GENET, V37, P1062; BEUTLER E, 1993, METABOLIC BASIS INHE; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; DINUR T, 1984, ANAL BIOCHEM, V136, P223, DOI 10.1016/0003-2697(84)90329-4; DOEBBER TW, 1982, J BIOL CHEM, V257, P2193; ERICKSON AH, 1985, J BIOL CHEM, V260, P4319; FABBRO D, 1987, AM J HUM GENET, V40, P15; FABBRO D, 1991, J BIOL CHEM, V266, P15021; FALLET S, 1992, PEDIATR RES, V31, P496, DOI 10.1203/00006450-199205000-00018; GINNS EI, 1982, P NATL ACAD SCI-BIOL, V79, P5607, DOI 10.1073/pnas.79.18.5607; GLEW RH, 1988, LAB INVEST, V58, P5; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GRABOWSKI GA, 1984, ANAL BIOCHEM, V141, P267, DOI 10.1016/0003-2697(84)90456-1; GRABOWSKI GA, 1985, AM J MED GENET, V21, P529, DOI 10.1002/ajmg.1320210316; GRACE ME, 1990, BIOCHEM BIOPH RES CO, V168, P771, DOI 10.1016/0006-291X(90)92388-G; GRACE ME, 1990, J BIOL CHEM, V265, P6827; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; Martin B M, 1989, Adv Pediatr, V36, P277; OHASHI T, 1991, J BIOL CHEM, V266, P3661; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OSIECKINEWMAN K, 1988, ENZYME, V40, P173, DOI 10.1159/000469161; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; SAMBROOK J, 1988, MOL CLONING LABORATO; SANO A, 1988, J BIOL CHEM, V263, P19597; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P1224; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; TAKASAKI S, 1984, J BIOL CHEM, V259, P112; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VANWEELY S, 1991, BIOCHIM BIOPHYS ACTA, V1096, P301, DOI 10.1016/0925-4439(91)90066-I; WEINREB NJ, 1968, BIOCHIM BIOPHYS ACTA, V159, P141, DOI 10.1016/0005-2744(68)90251-9; WITTWER AJ, 1989, BIOCHEMISTRY-US, V28, P7662, DOI 10.1021/bi00445a022; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	41	87	107	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14861	14866						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325864				2022-12-25	WOS:A1993LL75900051
J	HIDALGO, C; JORQUERA, J; TAPIA, V; DONOSO, P				HIDALGO, C; JORQUERA, J; TAPIA, V; DONOSO, P			TRIADS AND TRANSVERSE TUBULES ISOLATED FROM SKELETAL-MUSCLE CONTAIN HIGH-LEVELS OF INOSITOL 1,4,5-TRISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL FOOT PROTEIN; SARCOPLASMIC-RETICULUM; CALCIUM CHANNELS; RABBIT SKELETAL; FROG; TRISPHOSPHATE; MEMBRANES; RELEASE; FIBERS; 1,3,4,5-TETRAKISPHOSPHATE	We measured the content of inositol 1,4,5-trisphosphate in sarcoplasmic reticulum, transverse tubules, and triads isolated from frog skeletal muscle, as well as in triads isolated from rabbit skeletal muscle. We found that acid extracts of both transverse tubules and triads contained significant amounts of inositol 1,4,5-trisphosphate, in the range of 300-400 pmol/mg of protein as determined by a radioreceptor assay, whereas no detectable amounts were found in sarcoplasmic reticulum vesicles. The identity of inositol 1,4,5-trisphosphate in the extracts was confirmed by comigration with [H-3]inositol 1,4,5-trisphosphate on polyethyleneimine-cellulose plates, and by phosphorylation to inositol 1,3,4,5-tetrakisphosphate using the inositol 1,4,5-trisphosphate 3-kinase present in muscle extracts. These findings may have important physiological implications. First, the results indicate that the muscle plasma membrane regions differentiated as transverse tubules contain high amounts of inositol 1,4,5-trisphosphate, suggesting that they might possess a high density of binding sites for this compound. Second, since inositol 1,4,5-trisphosphate has been proposed as a chemical transmitter in excitation-contraction coupling in skeletal muscle, our finding that this second messenger is present in high density at the site of coupling may contribute to the understanding of its role in this process.	UNIV CHILE,FAC MED,DEPT FISIOL & BIOFIS,SANTIAGO,CHILE	Universidad de Chile	HIDALGO, C (corresponding author), CTR ESTUDIOS CIENT SANTIAGO,CASILLA 16443,SANTIAGO 9,CHILE.		HIDALGO, Cecilia/H-7107-2013					BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P976, DOI 10.1016/0006-291X(89)92204-3; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CARRASCO MA, 1993, BIOPHYS J, V64, pA154; DEWAARD M, 1992, NEURON, V9, P497, DOI 10.1016/0896-6273(92)90187-I; DONALDSON SK, 1988, P NATL ACAD SCI USA, V85, P5749, DOI 10.1073/pnas.85.15.5749; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FOSTER PS, 1989, LANCET, V2, P124, DOI 10.1016/S0140-6736(89)90182-7; HANNON JD, 1992, J MUSCLE RES CELL M, V13, P447, DOI 10.1007/BF01738039; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HIDALGO C, 1986, FEBS LETT, V202, P69, DOI 10.1016/0014-5793(86)80651-2; HIDALGO C, 1986, BIOCHIM BIOPHYS ACTA, V855, P79, DOI 10.1016/0005-2736(86)90191-4; HIDALGO C, 1989, J BIOENERG BIOMEMBR, V21, P267, DOI 10.1007/BF00812072; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; JAIMOVICH E, 1991, J MUSCLE RES CELL M, V12, P316, DOI 10.1007/BF01738586; JAIMOVICH E, 1986, BIOCHIM BIOPHYS ACTA, V855, P89, DOI 10.1016/0005-2736(86)90192-6; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JR, 1991, CELL CALCIUM, V12, P543, DOI 10.1016/0143-4160(91)90074-O; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAYR GW, 1991, BIOCHEM J, V280, P631, DOI 10.1042/bj2800631; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; PETERSEN OH, 1992, NEW PHYSL, V7, P193; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROJAS C, 1990, PFLUG ARCH EUR J PHY, V416, P296, DOI 10.1007/BF00392066; SCHOLZ J, 1991, LANCET, V337, P1361, DOI 10.1016/0140-6736(91)93052-B; SPENCER CEL, 1990, METHODS INOSITIDE RE, P39; Stephens L. R., 1990, METHODS INOSITIDE RE, P9; SUAREZISLA BA, 1991, J PHYSIOL-LONDON, V441, P575, DOI 10.1113/jphysiol.1991.sp018768; THEIBERT AB, 1990, BIOCHEM J, V267, P441, DOI 10.1042/bj2670441; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; VALDIVIA C, 1992, BIOPHYS J, V61, P1184, DOI 10.1016/S0006-3495(92)81927-6; VARSANYI M, 1986, BIOCHEM BIOPH RES CO, V138, P1395, DOI 10.1016/S0006-291X(86)80438-7; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; VILVEN J, 1988, NATURE, V336, P587, DOI 10.1038/336587a0; VOLPE P, 1985, NATURE, V316, P347, DOI 10.1038/316347a0	39	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15111	15117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325886				2022-12-25	WOS:A1993LL75900083
J	LOW, PS; RATHINAVELU, P; HARRISON, ML				LOW, PS; RATHINAVELU, P; HARRISON, ML			REGULATION OF GLYCOLYSIS VIA REVERSIBLE ENZYME BINDING TO THE MEMBRANE-PROTEIN, BAND-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ERYTHROCYTE-MEMBRANES; TYROSINE PHOSPHORYLATION; BLOOD-CELL; ASSOCIATION; ALDOLASE; PHOSPHOFRUCTOKINASE; SITE; ATP	Most metabolic pathways are regulated by feedback inhibition/activation or by covalent modification of a regulatory enzyme. In erythrocytes, however, we demonstrate that glycolysis can be modulated over 30-fold by controlling the availability of glycolytic enzyme binding sites at the extreme N terminus of the anion transporter, band 3. Direct obstruction of these inhibitory sites by anti-peptide Fab's against residues 1-15 of band 3 promotes an approximately 3-fold increase in the rate of lactate production. In contrast, enrichment of the erythrocyte cytoplasm with the band 3 peptide against which the above antibodies were raised results in a more than 10-fold decrease in the rate of lactate accumulation. Control peptides and their derived antipeptide antibodies corresponding to other sequences of band 3 or glycophorin were found to have no effect on lactate production. Analysis of changes in glycolytic intermediates during Fab treatments suggests that hexokinase may be one enzyme that is modulated by association with band 3. We conclude that the extreme N terminus of band 3 can bind and inhibit glycolytic enzymes in vivo and that it probably participates in control of red cell glycolysis.	PURDUE UNIV,DEPT MEDICINAL CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	LOW, PS (corresponding author), PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907, USA.			Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM40983] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040983] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DP, 1988, THESIS PURDUE U, P15; ARESE P, 1977, ACTA BIOL MED GER, V36, P481; BERGMEYER HU, 1965, METHODS ENZYMATIC AN; Beutler E, 1982, GLUTATHIONE RED CELL, V3 rd; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; DURRIEU C, 1987, ARCH BIOCHEM BIOPHYS, V252, P32, DOI 10.1016/0003-9861(87)90005-1; FOSSEL ET, 1978, BIOCHIM BIOPHYS ACTA, V510, P99, DOI 10.1016/0005-2736(78)90133-5; FUNDER J, 1967, ACTA PHYSIOL SCAND, V71, P113, DOI 10.1111/j.1748-1716.1967.tb03716.x; HARRIS SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P306, DOI 10.1016/0167-4838(90)90242-8; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HIGASHI T, 1979, J BIOL CHEM, V254, P9542; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1987, J BIOL CHEM, V262, P4592; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARETZKI D, 1989, TRENDS BIOCHEM SCI, V14, P93, DOI 10.1016/0968-0004(89)90128-X; MASTERS CJ, 1981, CRC CR REV BIOCH MOL, V11, P105, DOI 10.3109/10409238109108700; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; MISHRA RK, 1969, J MEMBRANE BIOL, V1, P214, DOI 10.1007/BF01869782; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; OVADI J, 1988, TRENDS BIOCHEM SCI, V13, P486, DOI 10.1016/0968-0004(88)90237-X; PROVERBIO F, 1977, J GEN PHYSIOL, V69, P605, DOI 10.1085/jgp.69.5.605; ROGALSKI AA, 1989, J BIOL CHEM, V264, P6438; SOLTI M, 1976, MOL CELL BIOCHEM, V10, P145, DOI 10.1007/BF01731685; SRERE PA, 1990, TRENDS BIOCHEM SCI, V15, P411, DOI 10.1016/0968-0004(90)90273-E; STECK TL, 1974, J CELL BIOL, V62, P1, DOI 10.1083/jcb.62.1.1; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; TSAI IH, 1982, J BIOL CHEM, V257, P1438; WALSH JL, 1987, BIOCHIM BIOPHYS ACTA, V952, P83; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	33	157	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14627	14631						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325839				2022-12-25	WOS:A1993LL75900018
J	RAO, KS; PRAKASH, V				RAO, KS; PRAKASH, V			INTERACTION OF SODIUM DODECYL-SULFATE WITH MULTISUBUNIT PROTEINS - A CASE-STUDY WITH CARMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED CARTHAMUS-TINCTORIUS; CIRCULAR-DICHROISM; COMPLEXES; CONFORMATION; DISSOCIATION; FRACTION; BOVINE	Sodium dodecyl sulfate (SDS) dissociates the multimeric protein, carmin, into its monomers (2 S) at low concentration. Dissociation begins at and above 1.6 mm SDS concentration and reaches 50% at 5 mM SDS concentration. Denaturation occurs above 5 mM SDS concentration. The dissociation step involves binding of 540 +/- 50 mol of SDS/mol of protein with an association constant, K(a) of 6.90 +/- 0.35 x 10(2) M-1. The interaction reflects a DELTAG0 = -4.0 +/- 0.1 kcal mol-1. In the denaturation step, the K(a) has the same value, and the gamma value is nearly 2-fold higher. Dissociation of carmin thus begins only above a binding of 0.60 g of SDS/g of protein. Analysis of the binding data at 37-degrees-C indicates a maximum of 1030 +/- 90 mol of SDS bound/mol of protein, which is equivalent to 1.14 +/- 0.10 g of SDS/g of protein. Upon denaturation, the alpha-helix content of the protein increases from 4 to 15%. Kinetically, the denaturation process consists of a two-step process (a fast and a slow step). The first order rate constants for these steps are 89.6 +/- 8.1 and 15.8 +/- 1.5 min-1, respectively, at 6.3 mM SDS concentration. The processes of dissociation and denaturation occur sequentially. Dissociation of the protein is reversible, whereas the process of denaturation is only partially reversible as reflected by sedimentation velocity and conformational analysis. These data are taken as a model for general understanding of the dissociation and/or denaturation processes, which could be either sequential or simultaneous in multimeric proteins.	CENT FOOD TECHNOL RES INST, DEPT PROT TECHNOL, MYSORE 570013, KARNATAKA, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food Technological Research Institute (CFTRI)								BRADBURY JH, 1970, PHYSICAL PRINCIPLE B, P99; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Donovan J W, 1973, Methods Enzymol, V27, P525; Hiromi K., 1979, KINETICS FAST ENZYME; HUNT AH, 1973, BIOCHEMISTRY-US, V12, P4435, DOI 10.1021/bi00746a021; JIRGENSONS B, 1966, J BIOL CHEM, V241, P4855; JIRGENSONS B, 1982, J PROTEIN CHEM, V1, P71; JONES MN, 1982, BIOCHEM J, V203, P285, DOI 10.1042/bj2030285; JONES MN, 1982, BIOPOLYMERS, V21, P1435, DOI 10.1002/bip.360210712; KLOTZ IM, 1975, PROTEINS, V1, P294; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHA TS, 1986, NAHRUNG, V30, P833; LATHA TS, 1984, J AGR FOOD CHEM, V32, P1412, DOI 10.1021/jf00126a048; LUNDAHL P, 1986, BIOCHIM BIOPHYS ACTA, V873, P20, DOI 10.1016/0167-4838(86)90184-6; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; MUKERJEE P, 1956, ANAL CHEM, V28, P870, DOI 10.1021/ac60113a026; NOZAKI Y, 1974, J BIOL CHEM, V249, P4452; PITTRIVE.R, 1968, BIOCHEM J, V109, P825, DOI 10.1042/bj1090825; PRAKASH V, 1986, CRC CR REV BIOCH MOL, V20, P265, DOI 10.3109/10409238609083736; PRAKASH V, 1988, J BIOSCIENCE, V13, P171, DOI 10.1007/BF02903099; PRAKASH V, 1980, INT J PEPT PROT RES, V15, P305; PRAKASH V, 1976, INT J PEPT PROT RES, V8, P385; PRAKASH V, 1986, INT J PEPT PROT RES, V28, P192; RAJENDRAN S, 1988, J PROTEIN CHEM, V7, P689, DOI 10.1007/BF01025578; RAO KS, 1989, J PROTEIN CHEM, V8, P529; RAY A, 1966, BIOCHEMISTRY-US, V5, P2606, DOI 10.1021/bi00872a019; REYNOLDS JA, 1967, BIOCHEMISTRY-US, V6, P937, DOI 10.1021/bi00855a038; REYNOLDS JA, 1970, P NATL ACAD SCI USA, V66, P1002, DOI 10.1073/pnas.66.3.1002; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P75; SHIRAHAMA K, 1974, J BIOCHEM, V75, P309, DOI 10.1093/oxfordjournals.jbchem.a130398; STEINHAR.J, 1973, BIOCHEMISTRY-US, V12, P1789, DOI 10.1021/bi00733a020; SURESHCHANDRA BR, 1987, J AGR FOOD CHEM, V35, P244, DOI 10.1021/jf00074a019; TAKEDA K, 1990, J PROTEIN CHEM, V9, P573, DOI 10.1007/BF01025010; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TEALE FWJ, 1957, BIOCHEM J, V65, P476, DOI 10.1042/bj0650476; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; VANHOLDE KE, 1971, PHYSICAL BIOCH, P51; WEBER K, 1969, J BIOL CHEM, V244, P4406; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; ZIRWER D, 1989, NAHRUNG, V33, P929, DOI 10.1002/food.19890331004	41	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14769	14775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	8325854				2022-12-25	WOS:A1993LL75900038
